<SEC-DOCUMENT>0001023024-24-000026.txt : 20240229
<SEC-HEADER>0001023024-24-000026.hdr.sgml : 20240229
<ACCEPTANCE-DATETIME>20240229072242
ACCESSION NUMBER:		0001023024-24-000026
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		118
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240229
DATE AS OF CHANGE:		20240229

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANI PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001023024
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				582301143
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31812
		FILM NUMBER:		24698869

	BUSINESS ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623
		BUSINESS PHONE:		2186343500

	MAIL ADDRESS:	
		STREET 1:		210 MAIN STREET WEST
		CITY:			BAUDETTE
		STATE:			MN
		ZIP:			56623

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOSANTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19991228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEN ABRAHAM TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19991027
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>anip-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:anip="http://www.anipharmaceuticals.com/20231231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>anip-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001023024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">false</ix:nonNumeric><ix:nonNumeric contextRef="c-66" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" id="f-537">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="c-134" name="anip:RestrictionPeriodForSharesIssuedInBusinessCombination" id="f-663">P3M</ix:nonNumeric><ix:nonNumeric contextRef="c-195" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-851">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="c-204" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-862">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="c-14" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-900">http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-901">http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</ix:nonNumeric><ix:nonNumeric contextRef="c-285" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-1089">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-1206">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-1208">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-1209">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-1214">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-1216">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="f-1222">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-1361">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1363">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-395" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1510">270</ix:nonNumeric><ix:nonNumeric contextRef="c-398" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1511">293</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="anip-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">anip:OakvilleOntarioFormerManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="facility"><xbrli:measure>anip:facility</xbrli:measure></xbrli:unit><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:CranfordPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>anip:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfGenericPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfGenericPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfGenericPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfBrandedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfBrandedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfBrandedPharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfRareDiseasePharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfRareDiseasePharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfRareDiseasePharmaceuticalProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfContractManufacturedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:FourCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="anip:InterestPeriodAxis">anip:OneMonthDurationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="anip:InterestPeriodAxis">anip:ThreeMonthDurationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="anip:InterestPeriodAxis">anip:SixMonthDurationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-19</xbrli:startDate><xbrli:endDate>2021-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanAndDelayedDrawTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanAndDelayedDrawTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">anip:OneSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:BiosantePharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-01-01</xbrli:startDate><xbrli:endDate>2013-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:WellSpringPharmaServicesIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:MarketingAndDistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:MarketingAndDistributionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:NonCompeteAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:NonCompeteAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AlvogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-21</xbrli:startDate><xbrli:endDate>2022-07-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-22</xbrli:startDate><xbrli:endDate>2024-02-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="anip:PaymentTypeAxis">anip:ProjectBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="anip:PaymentTypeAxis">anip:ProductDevelopmentBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">anip:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="anip:PaymentTypeAxis">anip:ProductDevelopmentBasedMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AlvogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-27</xbrli:startDate><xbrli:endDate>2023-12-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductIntellectualPropertyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AlvogenIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="intangibleasset"><xbrli:measure>anip:intangibleAsset</xbrli:measure></xbrli:unit><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredPipelineProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AkornHoldingCompanyPipelineProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AkornHoldingCompanyPipelineProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AkornHoldingCompanyPipelineProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredCommercialProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredApprovedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredFiledProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredNDAIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>anip:vote</xbrli:measure></xbrli:unit><xbrli:unit id="tradingday"><xbrli:measure>anip:tradingDay</xbrli:measure></xbrli:unit><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-27</xbrli:startDate><xbrli:endDate>2022-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-23</xbrli:startDate><xbrli:endDate>2023-05-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:EmployeesAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:EmployeesAndConsultantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:MarketPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:MarketPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">anip:ANICanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">anip:ANICanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operatinglease"><xbrli:measure>anip:operatingLease</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>anip:product</xbrli:measure></xbrli:unit><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:ContractCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:ContractCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:ContractCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-03</xbrli:startDate><xbrli:endDate>2020-12-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plaintiff"><xbrli:measure>anip:plaintiff</xbrli:measure></xbrli:unit><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="manufacturer"><xbrli:measure>anip:manufacturer</xbrli:measure></xbrli:unit><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:AzurityPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-15</xbrli:startDate><xbrli:endDate>2022-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-20</xbrli:startDate><xbrli:endDate>2020-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>anip:claim</xbrli:measure></xbrli:unit><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-08</xbrli:startDate><xbrli:endDate>2021-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:NovitiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:CortrophinGelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:CortrophinGelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-08</xbrli:startDate><xbrli:endDate>2021-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="founder"><xbrli:measure>anip:founder</xbrli:measure></xbrli:unit><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:EsjayPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:EsjayPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:EsjayPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:Mr.ShanmugamAndEsjayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:ChaliPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-12</xbrli:startDate><xbrli:endDate>2023-12-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:Mr.ShanmugamAndEsjayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:ChaliPropertiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-29</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:GenericsEstablishedBrandsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:GenericsEstablishedBrandsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:GenericsEstablishedBrandsAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:RareDiseaseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-14</xbrli:startDate><xbrli:endDate>2024-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-14</xbrli:startDate><xbrli:endDate>2024-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-14</xbrli:startDate><xbrli:endDate>2024-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NewEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-15</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-15</xbrli:startDate><xbrli:endDate>2024-02-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">anip:CGOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">anip:CGOncologyInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.MuthusamyShanmugamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.MuthusamyShanmugamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.MuthusamyShanmugamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.ChadGassertMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.ChadGassertMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001023024</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.ChadGassertMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4bc95b424f3d46babd419bb800693000_1"></div><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:2.209%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"/><td style="width:2.700%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.000%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period from _______ to _______.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-31812</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ANI PHARMACEUTICALS, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">58-2301143</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">210 Main Street West</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Baudette</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Minnesota</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">56623</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">218</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">634-3500</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock</ix:nonNumeric>, par value $0.0001 per share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ANIP</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:3pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">x</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">o</ix:nonNumeric></span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the registrant as of June 30, 2023 was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="6" id="f-29">824.2</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> (based upon the last reported sale price of $53.83 per share on June 30, 2023, on The Nasdaq Global Market).</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of February&#160;22, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">21,068,122</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ares of common stock and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">10,864</ix:nonFraction> shares of Class C Special stock of the registrant were outstanding.</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-bottom:3pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the definitive proxy statement for the registrant&#8217;s 2024 annual meeting of stockholders to be filed within 120 days after the end of the period covered by this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:30pt;margin-top:24pt;text-align:center"><span><br/></span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December 31, 2023</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:76.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_16">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_16">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_19">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_19">13</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_22">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_22">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_1099511628359">I</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_1099511628359">tem 1C. </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_1099511628359">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_1099511628359">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_25">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_25">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_28">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_28">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_31">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_31">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_37">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_37">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_40">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_40">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_43">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_43">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_70">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_70">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_70">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_73">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_73">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_73">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_145">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_145">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_145">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_148">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_148">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_148">116</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_151">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_151">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_151">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_154">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_154">Disclosures Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_154">117</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_157">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_160">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_160">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_160">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_163">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_163">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_163">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_166">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_166">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_166">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_169">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_169">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_169">118</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_172">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_172">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_172">118</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_175">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_178">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_178">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_178">119</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_181">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_181">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_181">124</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_184">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#i4bc95b424f3d46babd419bb800693000_184">125</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this annual report, references to &#8220;ANI Pharmaceuticals,&#8221; &#8220;ANI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer, unless the context requires otherwise, to ANI Pharmaceuticals, Inc., a Delaware corporation, and its consolidated subsidiaries. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K and certain information incorporated herein by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such statements include, but are not limited to, statements about future operations, strategies and growth potential, the revenue potential (licensing, royalty and sales) of products we sell, development timelines, expected timeframe for submission of new drug applications, abbreviated new drug applications, or supplemental new drug applications to the U.S. Food and Drug Administration (the &#8220;FDA&#8221;), pipeline or potential markets for our products, selling and marketing strategies and associated costs to support the sales of Purified Cortrophin&#174; Gel (Repository Corticotropin Injection USP) (&#8220;Cortrophin Gel&#8221;), impact of accounting principles, litigation expenses, liquidity and capital resources, the impact of the novel coronavirus (&#8220;COVID-19&#8221;) global pandemic on our business, and other statements that are not historical in nature, particularly those that utilize terminology such as &#8220;anticipates,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;future,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;continue,&#8221; other words of similar meaning, derivations of such words, and the use of future dates. Such forward-looking statements are based on the reasonable beliefs of our management as well as assumptions made by and information currently available to our management. Readers should not put undue reliance on these forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified; therefore, our actual results may differ materially from those described in any forward-looking statements. Factors that might cause such a difference include, but are not limited to, those discussed in our periodic reports filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including those discussed in the &#8220;Risk Factors&#8221; section in Part I, Item 1A.of this Annual Report on Form 10-K, and the following factors: </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cortrophin Gel is our first rare disease pharmaceutical product. To the extent we are not able to continue to achieve commercial success with this product, including expanding the market and gaining market share, our business, financial condition, and results of operations will be negatively impacted;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our approved products, including Cortrophin Gel, may not achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquisitions and investments could disrupt our business and harm our financial position and operating results;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the limited number of suppliers for our active pharmaceutical ingredients (&#8220;API&#8221;) could result in lengthy delays in production if we need to change suppliers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or failure in obtaining and maintaining approvals by the FDA of the products we sell;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in policy or actions that may be taken by the FDA and other regulatory agencies, including drug recalls;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products at levels that will allow us to achieve profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to develop, license or acquire, and commercialize new products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of competition we face and the legal, regulatory and/or legislative strategies employed by our competitors to prevent or delay competition from generic alternatives to branded products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property rights;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of legislative or regulatory reform on the pricing for pharmaceutical products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of any litigation to which we are, or may become, a party;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability, and that of our suppliers, development partners, and manufacturing partners, to comply with laws, regulations and standards that govern or affect the pharmaceutical and biotechnology industries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain the services of our key executives and other personnel; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we experience difficulties closing a sale transaction with a buyer for the plant and property resulting from the closure of our Oakville, Ontario manufacturing plant; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general business and economic conditions, such as inflationary pressures, geopolitical conditions including, but not limited to, the conflict between Russia and the Ukraine, the conflict between Israel and Gaza, conflicts related to the attacks on cargo ships in the Red Sea, and the effects and duration of outbreaks of public health emergencies, such as COVID-19.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apexicon&#174;, Cortenema&#174;, Purified Cortrophin&#174; Gel, Inderal&#174; LA, Inderal&#174; XL, InnoPran XL&#174;, Lithobid&#174;, Reglan&#174;, Vancocin&#174;, and Veregen&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are registered trademarks subject to trademark protection and are owned by ANI Pharmaceuticals, Inc. and its consolidated subsidiaries. Cortrophin-Zinc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a trademark owned by ANI Pharmaceuticals, Inc. and its consolidated subsidiaries pending registration. Atacand&#174; and Atacand HCT&#174; are the property of AstraZeneca AB and are licensed to ANI Pharmaceuticals, Inc. for U.S. sales of those products. Arimidex&#174; and Casodex&#174; are the property of AstraZeneca UK Limited and are licensed to ANI Pharmaceuticals, Inc. for U.S. sales of those products. Oxistat&#174; is the property of Fougera Pharmaceuticals Inc. and licensed to ANI Pharmaceuticals, Inc. for U.S. sales of Oxistat&#174; Lotion. Pandel&#174; is property of Taisho Pharmaceutical Co, Ltd. and licensed to ANI Pharmaceuticals for U.S. sales of Pandel&#174; creme.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i4bc95b424f3d46babd419bb800693000_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, &#8220;ANI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The team is focused on delivering growth by scaling up the Rare Disease business through the successful launch of its lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. The Company's three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (&#8220;Novitium&#8221;) in November 2021. The Company has fully completed the transition of the products manufactured or packaged in Oakville to one of the three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement for the purchase and sale of the Oakville, Ontario manufacturing facility. However, during December 3023, the agreement was mutually terminated. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">see Note 19. Subsequent Events, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">port on Form 10-K). </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, through a public offering, the Company completed the issuance and sale of 2,183,545 shares of ANI common stock, resul</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ting in net proceeds after issuance costs of $80.6 million. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a commercial portfo</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lio of 116 pro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ducts with a wide variety of indications and a robust portfolio of pipeline products as of December&#160;31, 2023. This portfolio is the result of internal research and development, acquisitions of businesses, acquisitions of Abbreviated New Drug Applications (&#8220;ANDAs&#8221;), New Drug Applications (&#8220;NDAs&#8221;), product rights, and entry into agreements to obtain the distribution rights for various products..</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to build a sustainable and growing biopharmaceutical company serving patients in need and creating long-term value for our investors. Our overall strategy is enabled by an empowered, collaborative, and purposeful team with a high performance-orientation, Serving Patients, Improving Lives. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth strategy is driven by the following key growth drivers:</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Building a successful Rare Disease platform</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have spent significant time, effort and resources in establishing our Rare Disease platform. We acquired the NDAs for Cortrophin Gel and Cortrophin-Zinc in January 2016 and executed long-term supply agreements with a supplier of our primary raw material for corticotrophin API, a supplier of corticotrophin API with whom we have advanced the manufacture of commercial scale batches of API, and a Cortrophin Gel fill/finish contract manufacturer. During the second quarter of 2021, we submitted a Supplemental New Drug Application (&#8220;sNDA&#8221;) to the FDA.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, the FDA approved the Company&#8217;s sNDA for Purified Cortrophin Gel (Repository Corticotropin Injection USP) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (&#8220;MS&#8221;) and rheumatoid arthritis (&#8220;RA&#8221;), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (&#8220;ACTH&#8221;), also known as purified corticotropin.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, we invested significantly in leadership, expertise and infrastructure in the areas of commercialization of rare disease therapies and developed a launch strategy and commercial plan for this product. During this timeframe, we hired a significant number of new employees and assembled and trained our Rare Disease field force. On January 24, 2022, we announced the commercial launch of Cortrophin Gel in the U.S as our foundational Rare Disease asset. On October 2, 2023, we announced FDA approval and commercial availability of a 1-mLvial of Cortrophin Gel, appropriate for adjunctive treatment of certain patients with acute gouty arthritis flares. We continued to invest in our Rare Disease team and support investments in Cortrophin Gel during 2023. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to expand our rare disease business through a combination of organic growth, as described above, and through acquisition. While we continue to execute against our strategic initiatives that we believe will result in long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to expand our existing capabilities.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strengthening our Generics, Established Brands, and Other segment through continued investment in our generic research and development capability and increased focus on niche opportunities</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown our generics business through a combination of market share gains on existing products and new product launches. We have also successfully acquired numerous ANDAs through business and asset acquisitions. Our most recent business acquisition was Novitium, including its portfolio of commercial and pipeline generic products, manufacturing and development facilities and expert workforce. The Novitium acquisition significantly increased our generic pharmaceutical research and development and manufacturing capabilities. We have begun to increase our focus on niche lower competition opportunities such as injectables, Paragraph IV, and competitive generic therapy ("CGT") designation filings. Additionally, we will continue to seek opportunities to enhance our capabilities through strategic partnerships and acquisitions of assets and businesses. During 2022, we completed an asset acquisition of four ANDAs from Oakrum Pharma, including two that were commercial at the time of acquisition. During the second quarter of 2023, we acquired two ANDAs and one pipeline product from the Cha</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates. During the third quarter of 202</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3, we acquired an ANDA and registered patents and pending patent applications from Slayback Pharma Limited Liability Company. During the fourth quarter of 2023, we completed two additional asset acquisitions in which we acquired an ANDA from PAI Pharma LLC for one product, and also product rights for a separate product from Alvogen, Inc., which we plan to launch commercially in early 2024.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown our established brand product offerings through acquisition. We have acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. We are innovating in our go-to-market strategy through creative partnerships. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Generic Product Development Considerations</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider a variety of criteria in determining which products to develop. These criteria include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Formulation Complexity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our development and manufacturing capabilities enable us to manufacture pharmaceuticals that are differentiated  and include high potency, modified release, combination, and hormonal products. This ability to manufacture a variety of differentiated products is a competitive strength that we intend to leverage in selecting products to develop and commercialize.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Market Size.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When determining whether to develop or acquire an individual product, we review the current and expected market size for that product. and competitive environment. We endeavor to pursue products with sufficient market size to enable us to enter the market with a strong likelihood of being able to price our products both competitively and at a profit.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Profit Potential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In determining the potential profit of a product, we forecast our anticipated market share, pricing, competitive environment  and the estimated cost to manufacture the products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We generally seek to develop and manufacture products at our own manufacturing plants to  ensure quality control of our products, supply chain reliability and to more closely control the economic inputs and outputs of our products. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Competition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> When determining whether to develop or acquire a product, we research existing and expected competition. We seek to develop products for which we can obtain sufficient market share and may decline to develop a product if we anticipate significant competition. Our manufacturing facilities provide a means of entering niche markets, such as hormone therapies, in which fewer generic companies typically compete.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Generic Therapy</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA Reauthorization Act of 2017 (&#8220;FDARA&#8221;) created a new pathway by which FDA may, at the request of the applicant, designate a drug with &#8220;inadequate generic competition&#8221; as a competitive generic therapy (&#8220;CGT&#8221;). At the request of the applicant, the FDA may also expedite the review of an ANDA for a drug designated as a CGT. Under the CGT pathway, the FDA provides a statutory provision for a 180-day exclusivity period for certain first to market applicants whose ANDA received a CGT designation. Our Novitium subsidiary has developed a strong track record of obtaining CGT approvals and we expect to continue to develop generic drugs under the CGT pathway.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A complete list of our generic and branded pharmaceutical products and descriptions is posted on our website, www.anipharmaceuticals.com. </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing, Suppliers, and Raw Materials</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require a supply of quality raw materials, including API, and components to manufacture and package our pharmaceutical products. In order to manufacture certain of our products deemed controlled substances, we must submit a request to the DEA for a quota to purchase the amount of API needed for manufacture. Without approved quotas from the DEA, we would not be able to purchase these ingredients from our suppliers.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source the raw materials for our products from both domestic and international suppliers, which we carefully select. Generally, we qualify only a single source of API for use in each product due to the cost and time required to validate and qualify a second source of supply. Any change in one of our API suppliers must usually be approved through a Prior Approval Supplement (&#8220;PAS&#8221;) by the FDA. The process of obtaining an approval of such a PAS can require between four and 18 months. While we also generally qualify a single source for non-API raw materials, the process required to qualify an alternative source of a non-API raw material is typically much less rigorous. If we were to change the supplier of a raw material for a product, the cost for the material could be greater than the amount we paid with the previous supplier. Changes in suppliers are rare but could occur as a result of a supplier&#8217;s business failing, an issue arising from an FDA inspection, or failure to maintain our required standards of quality. As a result, we selectively choose suppliers based on various factors including quality, reliability of supply, and long-term financial stability. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the APIs for our drug products, including those that are marketed without approved NDAs or ANDAs, are sourced from international suppliers. From time to time, we have experienced temporary disruptions in the supply of certain of such imported API due to FDA inspections and customs delays. In addition, certain of our products are manufactured, packaged, or manufactured and packaged by third parties.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry in the U.S. is highly regulated by multiple U.S. government agencies, such as the FDA, the DEA, and the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;). As a result, we are subject to extensive and complex rules and regulations, which are subject to revision from time to time. While we have experience with these regulations, there can be no assurance that we will be able to fully comply with all applicable regulations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Branded and Generic Pharmaceutical Products</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All prescription pharmaceutical products distributed in the U.S., whether branded or generic, must be approved by the FDA. All applications for FDA approval must contain information relating to product formulation, raw material suppliers, stability, manufacturing processes, packaging, labeling, and quality control. Information to support the bioequivalence of generic drug products or the safety and effectiveness of new drug products for their intended use is also required to be submitted. There are generally two types of applications used for obtaining FDA approval of new products:</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Drug Application (&#8220;NDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;An NDA is filed when approval is sought to market a newly developed branded product and, in certain instances, for a new dosage form, a new delivery system, or a new indication for an approved drug. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Abbreviated New Drug Application (&#8220;ANDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;An ANDA is filed when approval is sought to market a generic equivalent of a drug approved under an NDA. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ANDA development process is generally less time-consuming and less complex than the NDA development process. It typically does not require new preclinical and clinical studies, because it relies on the studies establishing safety and efficacy conducted for the branded drug approved through the NDA process. The ANDA process, however, typically requires one or more bioequivalence studies to show that the ANDA drug is bioequivalent to the previously approved reference listed drug (&#8220;RLD&#8221;).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Act&#8221;) provides that generic drugs may enter the market after the approval of an ANDA, which requires (1) that bioequivalence to the branded product be demonstrated through clinical studies, and (2) either the expiration, invalidation or circumvention of any patents or the end of any other relevant market exclusivity periods related to the branded drug.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, generic products generally provide a safe, effective, and cost-efficient alternative to users of branded products. Growth in the generic pharmaceutical industry has been driven by the increased market acceptance of generic drugs, as well as the number of branded drugs for which patent terms and/or other market exclusivities have expired.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic products are generally commercialized after the expiration of patent protection for the branded product and after the end of a period of non-patent market exclusivity. In addition to patent exclusivity, the holder of the NDA may be entitled to a period of non-patent market exclusivity, during which the FDA cannot approve an application for a generic product. Also, if the NDA is a new chemical entity (&#8220;NCE&#8221;), the FDA may not approve an ANDA for a generic product for up to five years following approval of the NDA for the NCE. If an NDA is not an NCE, but the holder of the NDA conducted clinical trials essential to approval of the NDA or a supplement thereto, the FDA may not approve a generic equivalent to the NDA for three years. Certain other periods of exclusivity may be available if the branded drug is indicated for treatment of a rare disease or is studied for pediatric indications.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain FDA approval of NDAs and ANDAs, our manufacturing procedures and operations must conform to FDA requirements and guidelines, generally referred to as &#8220;cGMP.&#8221; The requirements for FDA approval encompass all aspects of the production process, including validation and recordkeeping, the standards around which are continuously changing and evolving. As a result, we must consistently monitor and comply with these changes.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our facilities, procedures, operations, and testing of products are subject to periodic inspection by the FDA, the DEA, and other authorities. In addition, the FDA conducts pre-approval and post-approval reviews and plant inspections to determine whether our systems and processes are in compliance with cGMP and other FDA regulations. Our suppliers are subject to similar regulations and periodic inspections.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Post-approval Requirements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After FDA approval of an NDA or ANDA product is obtained, there are many post-approval requirements that must be met. These include registering the manufacturing establishment and listing the product with the FDA, reporting and keeping records of any adverse reactions or production problems, providing updated safety and efficacy information to the agency, and complying with advertising and promotional labeling regulations. Additionally, FDA may approve an NDA with post-marketing study requirements, meaning that additional clinical trials must be conducted after approval in order to further monitor the drug&#8217;s safety and efficacy.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has the authority to require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. A REMS may include, but is not limited to, elements such as medication guides, patient package inserts, communication plans to educate healthcare providers of the product's risks, patient registries, or limitations on who can prescribe or dispense it. A REMS imposes numerous compliance obligations on the NDA and ANDA manufacturers. We currently participate in the Opioid Analgesic REMS for our Oxycodone Hydrochloride Oral Solution, Oxycodone Capsules and Levorphanol Tartrate Tablets commercial products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the marketing, labeling, advertising, and promotion of products that are placed on the market. Manufacturers must adhere to strict guidelines when promoting their products; all statements regarding a product must be consistent with its approved labeling and truthful in nature. Additionally, manufacturers may only promote their product for approved indications outlined by the FDA. Physicians may prescribe drugs or biologics off-label but manufacturers cannot promote such uses unless they have been previously authorized by the FDA. All claims made about a product should also be adequately substantiated with evidence of both benefits and risks associated with use in order to ensure fair balance between them.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Prescription Drug Marketing Act (&#8220;PDMA&#8221;) regulates the distribution of a manufacturer&#8217;s prescription drug samples and requires a compliance program governing the storage, security, distribution and recordkeeping of samples, as well as monitoring for loss or theft. The Drug Supply Chain Security Act (&#8220;DSCSA&#8221;) requires manufacturers and their trading partners, such as repackagers, wholesale distributors, dispensers, and third-party logistics providers, to implement product tracking and tracing technology at the package level to identify and trace certain prescription drugs as they are distributed in the United States. ANI started manufacturing serialization-compliant products in November 2018. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">"Risk Factors &#8213; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal, state, and local laws and regulations, and complying with these may cause us to incur significant additional costs."</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Substances</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DEA regulates certain drug products containing controlled substances, pursuant to the U.S. Controlled Substances Act (&#8220;CSA&#8221;). Certain of our products contain significant components that are classified as controlled substances. CSA and DEA regulations impose specific requirements on manufacturers and other entities that handle these substances including registration, recordkeeping, reporting, storage, security, and distribution. Recordkeeping requirements include accounting for the amount of product received, manufactured, stored, and distributed. Companies handling controlled substances also are required to maintain adequate security and to report suspicious orders, thefts, and significant losses. The DEA periodically inspects facilities for compliance with the CSA and its regulations. Failure to comply with current and future regulations of the DEA could lead to a variety of sanctions, including revocation or denial of renewal of DEA registrations, injunctions, or civil or criminal penalties.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we must submit a request to the DEA for a quota to purchase the amount of API needed to manufacture certain of our products deemed controlled substances. Without approved quotas from the DEA, we would not be able to purchase these ingredients from our suppliers. As a result, we are dependent upon the DEA to approve quotas large enough to support our continued manufacture of our controlled substances at commercial level. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8213; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are entirely dependent on periodic approval by the DEA for the supply of the API needed to manufacture our controlled substances. An inability to obtain such approvals would reduce or eliminate our revenues for our controlled substances, and could have a material adverse effect on our business, financial position, and operating results. In addition, we are subject to strict regulation by the DEA and are subject to sanctions if we are unable to comply with related regulatory requirements.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unapproved Products</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three of our products, EEMT, Opium Tincture, and Thyroid Tablets, are marketed without approved NDAs or ANDAs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rth quarter of 2023, we acquired product rights for Hyoscyamine, a product without approved NDAs, which we plan to launch commercially in early 2024. The FDA's policy with respect to the continued marketing of unapproved products appears in the FDA's September 2011 Compliance Policy Guide Sec. 440.100 titled &#8220;Marketed New Drugs without Approved NDAs or ANDAs.&#8221; Under this policy, the FDA has stated that it will follow a risk-based approach with regard to enforcement against marketing of unapproved products. The FDA evaluates whether to initiate enforcement action on a case-by-case basis, but gives higher priority to enforcement action against products in certain categories, such as those with potential </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">safety risks or that lack evidence of effectiveness. We continue to believe that, so long as we comply with applicable manufacturing standards, the FDA will continue to operate on a risk-based approach and will not take action against us. However, we can offer no assurance that the FDA will continue to follow this approach or that it will not take a contrary position with any individual product or group of products. See </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8220;Risk Factors &#8211; </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three products, which together comprised less than 10% of our total revenue in 2023, are marketed without approved NDAs or ANDAs and we can offer no assurances that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA will not require us to either seek approval for these products or withdraw them from the market. In either case, our business, financial position, and operating results could be materially adversely affected.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid/Medicare</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid and Medicare, both of which are U.S. federal health care programs administered by CMS, are major payors of pharmaceutical products, including those we produce.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid is administered by the states and jointly funded by the federal and state governments. Its focus is on low-income populations. State drug coverage policies under Medicaid may vary significantly state by state. The Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;), as amended by the Health Care and Education and Reconciliation Act of 2010, together known as the Affordable Care Act (&#8220;ACA&#8221;), originally required states to expand their Medicaid programs to individuals with incomes up to 138% of the federal poverty level. Although the United States Supreme Court in 2011 made the Medicaid expansion optional, many states have expanded their Medicaid programs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA also made changes to Medicaid law that has negatively impacted our business. Pharmaceutical manufacturers that want their drug products covered by state Medicaid programs must enter into a rebate agreement with CMS and pa</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y rebates to state Medicaid agencies on utilization of their drugs dispensed to Medicaid beneficiaries. The ACA raised the rebate percentages for both generic and branded pharmaceuticals effective January 1, 2010. The basic rebate is currently 13% of the average manufacturer price for sales of Medicaid-reimbursed products marketed under ANDAs. Sales of Medicaid-reimbursed products marketed under NDAs require manufacturers to rebate the greater of 23.1% of the average manu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facturer price or the difference between the average manufacturer price and the &#8220;best price&#8221; (as defined in the Medicaid statute) during a specific period. In addition, there is an additional rebate if the average manufacturer price of the drug is rising faster than inflation. Since passage of ACA in 2010, Medicaid rebates have been capped at average manufacturer price per unit.  However, beginning January 1, 2024 pursuant to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Rescue Plan of 2021 Medicaid rebates will no longer be capped at average manufacturer price. As a result we could end up paying substantially higher Medicaid rebates on certain products. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in a Proposed Rule released in May 2023 CMS proposed changing how &#8220;best price&#8221; is determined.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If enacted it would require a manufacturer to aggregate any and all discounts and rebates to best price eligible customers when determining best price rather than considering only discounts and rebates to each best price eligible customer individually.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If finalized, we could end up owing additional rebates on Medicaid utilization of our branded products to the states.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is run by the federal government and is largely focused on the elderly and disabled. The Medicare Modernization Act of 2003 (&#8220;MMA&#8221;) created Medicare Part D to provide voluntary prescription drug coverage for Medicare beneficiaries. The MMA has increased coverage of pharmaceuticals, which has benefited the pharmaceutical industry for both brands and generic drugs. The ACA made some changes to Part D to make it easier for Medicare beneficiaries to obtain drugs, such as reducing coinsurance amounts. The ACA also required pharmaceutical companies to provide discounts to Medicare Part D beneficiaries for the cost of branded prescription drugs. The ACA created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, or BBA, effective as of 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Under the Medicare Coverage Gap Discount Program, any pharmaceutical product marketed under an NDA, regardless of whether the product is marketed as a &#8220;generic,&#8221; is subject to the discount requirement. Certain of our products, while marketed as &#8220;generics,&#8221; are sold under approved NDAs and, therefore, are subject to the discount requirement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 ("IRA"), was signed into law by President Biden on August 16, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA brings sweeping changes to Medicare coverage and reimbursement for prescription drugs that could negatively impact us and other pharmaceutical manufacturers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of note, beginning January 1, 2025 the IRA alters the current structure of the Medicare Part D standard benefit by eliminating the coverage gap.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA reduces a beneficiary&#8217;s out-of-pocket maximum to $2,000 beginning in 2025. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existing coverage gap discount program for pharmaceutical manufacturers will be replaced by a new manufacturer discount program effective in 2025. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the new program, manufacturers will provide a 10 percent discount off the negotiated price for applicable drugs (branded drugs and biologics manufactured by companies that have Part D discount agreements) after the deductible is satisfied through the catastrophic phase of the benefit. In the catastrophic phase, manufacturers will provide a 20 percent discount off negotiated price.  Any pharmaceutical product marketed under an NDA, regardless of whether the product is marketed as a &#8220;generic,&#8221; is subject to the manufacturer discount requirement.  This could increase discounts due on Medicare Part D utilization of our drug products.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to restructuring the Medicare Part D benefit, under the IRA the CMS will </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">negotiate directly with manufacturers the price that Medicare will pay for certain high-cost drugs via establishment of the Drug Price Negotiation Program (or the "Program"). The Program will apply to drugs administered or dispensed under both Medicare Parts B and D, although for the first two years of the Program, only Medicare Part D qualifying drugs will be impacted. The Program officially began in 2023 with CMS selecting 10 drugs for direct price negotiation from a list of drugs representing the highest Medicare Part D spend. The newly negotiated prices for the first tranche of Part D drugs will not be applicable until 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a manufacturer of a selected drug does not negotiate a Maximum Fair Price ("MFP")v with the CMS, the manufacturer must pay an excise  tax of 65 to 95 percent of Medicare utilization based on the prior year. Manufacturers that agree on an MFP, but do not honor it, will be subject to civil monetary penalties equal to 10 times the amount of the product dispensed or administered that year, as well as the difference between the reimbursed price and the MFP. Even if a manufacturer&#8217;s drug is not selected for negotiation under the Program, its Medicare coverage could be impacted as a drug with a MFP automatically receives placement on Part D plan formularies and could usurp coverage of another therapeutic alternative in the same class of drugs as the general rule is that Medicare Part D plan formularies have at least 2 drugs per each therapeutic class outside of the 6 protected classes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While none of our drug products have currently been selected for negotiation, we continue to monitor the process for potential impact to our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Program and resulting excise tax have been challenged as unconstitutional in various lawsuits including cases brought by the National Infusion Center Association, Global Colon Cancer Association, and Pharmaceutical Research and Manufacturers of America. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that the Program and resulting excise tax are struck down as unconstitutional, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Medicare Part D marketplace could be disturbed by insurers exiting the Medicare Part D market and premiums increasing.  If this occurs, it could negatively impact reimbursement and coverage for our self-administered drugs.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, the IRA imposed additional rebates on manufacturers including ANI to the extent certain drug pricing metrics are rising faster than inflation.  These new inflation rebates are similar to those imposed on manufacturers under Medicaid and could result in additional rebates due from us on Medicare utilization of our products. Inflation rebates are accruing on Medicare Part D utilization from October 1, 2022 and on Medicare Part B utilization of drugs from January 1, 2023 forward though the CMS has deferred collection of such rebates until 2025.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our products are covered by Medicaid and Medicare. Our reporting and payment obligations under the Medicaid rebate program and other governmental purchasing and rebate programs are complex and may involve subjective decisions. Any determination that we have failed to comply with those obligations could subject us to penalties and sanctions, and we could be subject to federal or state false claims litigation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing.  Certain states have formed Prescription Drug Affordability Boards that have the authority to set reimbursement and/or drug pricing in the state.  We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments and/or third party payors or purchasing customers in certain states  pay for health care products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents, Trademarks, and Licenses</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own the trademark names for most of our branded products, including Apexicon, Cortenema, Purified Cortrophin Gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan, Vancocin, and Veregen. We license the trademark names for Atacand, Atacand HCT, Arimidex, Casodex, Oxistat, and Pandel. With the exception of a license for patent technology for Inderal XL, InnoPran XL, and Veregen, we do not license any patents associated with these products. Further, patent protection and market exclusivity for these branded products have expired, with the exception of the Veregen product, which has three patents. One patent expired in 2022 and the remaining two patents expire in 2025 and 2026. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herefore, we consider the trademark names to be of material value and we act to protect these rights from infringement. However, our business is not dependent upon any single trademark. Trademark protection continues in some countries as long as used, and in other countries, as long as registered. Registration is for fixed terms and may be renewed indefinitely. We believe that sales of our branded products have benefited and will continue to benefit from the value of the product name.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recently acquired certain patents and patent applications relating to baclofen and a patent was granted on our hydrochlorothiazide product. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Distribution Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to selling products under our own NDAs and ANDAs, we enter into marketing and distribution agreements with third parties in which we sell products under ANDAs or NDAs owned or licensed by these third parties. These products are sold under our own label.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customers</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ur customers purchase and distribute our products. Our customers include major national wholesalers. Our products are sold by major retail pharmacy chains, distributors, national mail order houses, as well as group purchasing organizations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, the wholesale distributor network for pharmaceutical products has been subject to increasing consolidation, which has increased the concentration of our wholesale customers. In addition, the number of retail market chains and, in particular, the number of independent drug stores and small chains, has decreased as retail consolidation has occurred, also increasing the concentration of our retail custom</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ers. As a result of this trend toward consolidation, a smaller number of companies each control a larger share of pharmaceutical distribution channels. For the year ended December&#160;31, 2023, approximately 70% of our net revenues were attributable to four customers. For the years ended December 31, 2022 and 2021, three customers, togeth</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">er accounted for approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 59% and 68% of our ne</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t revenues, respectively. In addition, as noted below, our customers also distribute our products. The loss of any of these customers, including in their role as distributors, could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to strategic partnerships between wholesalers and pharmacy chains, we have experienced, and expect to continue to experience, increases in net sales to the wholesalers, with corresponding decreases in net sales to the pharmacy chains.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the rare disease business there is a limited distribution network and a select group of specialty pharmacies which can dispense product to appropriate patients. We contract and engage with the largest health insurance payers across the appropriate channels and classes of trade. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with industry practice, we maintain a return policy that allows customers to return product within a specified period prior to and subsequent to the expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date to up to one year after its expiration date. See &#8220;Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#8212;Critical Accounting Estimates&#8221; for a discussion of our accruals for chargebacks, rebates, returns, and other allowances.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sales, Marketing, and Distribution</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We market, sell, and distribute our products in the United States. Our products are distributed through the following channels:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Wholesalers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We conduct business with the three major wholesalers in the United States: Cencora, Inc., Cardinal Health, and McKesson.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Retail Market Chains</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We conduct business with all the major retail chains in the United States which includes CVS, Rite Aid, Kroger, Walmart, and Walgreens.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Distributors and Mail Order Pharmacies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have contracts with several major distributors and mail order pharmacies in the United States, including Anda, Smith Drug Company, Morris Dickson, CVS Caremark, Centerwell, and ExpressScripts.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Group Purchasing Organizations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have contracts with group purchasing organizations in the United States, such as ClarusONE, Walgreens Boots Alliance Development Group, Red Oak Sourcing, Econdisc, Optisource, Rx Sourcing Strategies, The Premier Group, Topco, The Buyer&#8217;s Consortium, Managed Health Care Associates Inc., Asembia, Premier Inc, and Kaiser Permanente.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Specialty Pharmacies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In our Rare Disease segment we contract with specialty pharmacies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Hospitals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In our Rare Disease segment we contract with certain hospital systems.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products face limited competition due to complexities in formulation, active pharmaceutical ingredient sourcing, materials handling and manufacturing, and regulatory hurdles. Nevertheless, we compete with numerous other pharmaceutical companies, including large, global pharmaceutical manufacturers capable of addressing these complexities and hurdles with respect to products that we currently produce and products that are in our pipeline. In addition, our products are subject to competition from other generic products and non-prescription alternative therapies.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our established brand pharmaceutical products currently face competition from generic products and we expect them to continue to face competition from generic products in the future. In order to launch a generic product, a manufacturer must apply to the FDA for an ANDA showing that the generic product is therapeutically equivalent to the RLD. (See &#8220;Government Regulation.&#8221;)</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary means of competition among generic drug manufacturers are pricing, contract terms, service levels, and reliability. To compete effectively, we seek to consistently produce high-quality, reliable, and effective products. We also establish active working relationships with each of our customers, continually gather important market information in order to respond successfully to requests for proposals, maintain sufficient inventories to assure high service levels, and work to reduce product costs by sourcing and qualifying alternative suppliers whenever possible.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, the pharmaceutical industry has experienced significant consolidation, particularly in distribution channels and among generic and brand drug companies.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The wholesale distributor network for pharmaceutical products has been subject to increasing consolidation, which has increased the concentration of our wholesale customers. In addition, the number of retail market chains and, in particular, the number of independent drug stores and small chains, has decreased as retail consolidation has occurred, also increasing the concentration of our retail customers. As a result of this trend toward consolidation, a smaller number of companies each control a larger share of pharmaceutical distribution channels, which results in pricing pressure on our business and can result in a shift in sales to our competitors.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, consolidation among pharmaceutical companies has created opportunities by reducing the number of competitors. However, as competitors grow larger through consolidation, so do their resources. Larger competitors may be able to aggressively decrease prices in order to gain market share on certain products and may have resources that would allow them to market their products more effectively to potential customers.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales can also be impacted by new studies that indicate that a competitor&#8217;s product has greater efficacy than one of our products. If competitors introduce new products with therapeutic or cost advantages, our products can be subject to progressive price reductions and/or decreased volume of sales.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Principal competitors for the pharmaceutical market in which we do business include, but are not limited to, Amneal Pharmaceuticals, Inc., Apotex Inc., Aurobindo Pharma, Camber Pharmaceuticals Inc., Hikma Pharmaceuticals plc, Lupin Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Rising Pharmaceuticals, Inc., Strides Pharma Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals USA, Inc.,  Viatris Inc., and Zydus Pharmaceuticals USA.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product liability litigation represents an inherent risk to all firms in the pharmaceutical industry. We utilize traditional third-party insu</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rance policies with regard to our product liability claims. Such insurance coverage at any given time reflects current market conditions, including cost and availability, when the policy is written.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 2024, we have 642 employees, of which 569 are located in the United States, including Puerto Rico, 1 is located in Canada, and 72 are located in India. As of January 2023, we had 600 employees, of which 496 are located in the United States, including Puerto Rico, 48 located in Canada, and 56 are located in India. We occasionally use a small number of part-time and consultant resources to meet our operational needs a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd our turnover is in line with similar businesses in our industry and locations. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Our Purpose and Core Values</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our human capital management strategy is guided by our purpose and core values. Our purpose is Serving Patients, Improving Lives. Our core values are Patient First, Teamwork, Innovation, Integrity &amp; Compliance, Accountability &amp; Transparency, and Commitment to Excellence. We believe that our purpose and core values provide clarity, a shared language, and ultimately create what is distinctive about our company and our culture. We are motivated to bring our best to ANI every day by the patients we serve, the people we work with, the direct impact we have on the work, and the learning, growth and development opportunities we provide.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Culture, Engagement, and Diversity, Equity, and Inclusion</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that attracting, retaining, and promoting engagement for talented employees is critical to the success of our business, and we take pride in our values, culture, and communities. We are committed to creating a diverse, equitable, and inclusive work environment within all levels of the business. As of the end of 2023, approximately 41% of our workforce identified as female and approximately 59% identified as male. In the same period, approximately 45% of our workforce identified as a person of color or indigenous person, with approximately 55% identifying as white.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we do not tolerate discrimination or harassment on the basis of gender, race, or ethnicity, or the use of child or forced labor. We value employee input, and conduct focus groups and survey employees on specific topics (e.g. approximately 25% of our employees participated in a benefits satisfaction survey in 2023). We offer ongoing training and career development to all employees, both through curriculum developed internally, and through external resources (e.g. LinkedIn Learning). Together, we own our culture and participate in ongoing open dialogue as we strive for continued growth. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At ANI, we believe that no one should go without medicines that they need. In December 2022, we formed the ANI Rare Disease Patient Assistance Program, Inc. (&#8220;ANI PAP&#8221;) for the purpose of providing certain medicine for free to patients in the United States who do not have prescription drug or health insurance coverage and who, without assistance, cannot afford their medicine.  In addition, ANI has provided patient-related financial support to nonprofit organizations that are aligned with ANI&#8217;s mission to address unmet needs. Our charitable contributions support initiatives and programs that advance medical care or patient care within the Company's therapeutic areas of focus.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Total Rewards</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI&#8217;s Total Rewards Philosophy is grounded in pay for performance and seeks to provide compensation and benefits that are competitive within the pharmaceuticals industry, as well as competitive with local employers for jobs of a cross-industry nature. We pay fair and competitive salaries, short-term incentives, and long-term incentives that are informed by external market rates and internal equity. We recognize and reward employee performance, productivity, and alignment with ANI&#8217;s Core Values. We believe that a holistic rewards strategy should also go beyond compensation and benefits to consider elements such as wellness and recognition. We support flexible and remote working arrangements throughout the business. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Health and Safety Management and Training</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to the safety and health of our employees, patient-customers, and the public. It is critical within our mission to ensure we keep our employees and customers safe while accomplishing our business goals. ANI has established a health and safety program with a focus on continuous improvement and employee engagement. ANI personnel are encouraged to take corrective actions where appropriate and to communicate concerns to management with a &#8220;see something, say something&#8221; approach. We recognize and reward personnel for contributing to the safety system within our working environment. The overall program continually evolves to reflect regulatory changes and compliance standard industry best practices. As part of onboarding new employees, we provide health and safety training and periodic training programs to maintain and improve employee awareness of safety issues. The goal of the safety training programs is to ensure that our staff are well informed on the subject matters and have the appropriate tools to make sound health and safety decisions in our day-to-day operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Environmental Stewardship and Sustainability</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI is committed to Serving Patients, Improving Lives, both directly though our high-quality products, and through our environmental stewardship and sustainability practices. We strive to minimize waste and emissions, promote reuse and recycling, and conserve resources. We continue to increase our efforts and have formed an Environmental, Social, and Governance ("ESG") Steering Committee to oversee cross-functional initiatives. The ESG Steering Committee reports to our Board of Directors through our Nominating and Governance Committee and is committed to providing progress updates at least twice per year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file annual, quarterly and current reports, proxy statements and other information required by the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), with the Securities and Exchange Commission (&#8220;SEC&#8221;). We make available free of charge on our website (www.anipharmaceuticals.com) our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements and any amendments to those filings as soon as reasonably practicable after such material is electronically filed with or furnished to the SEC. Also posted on our website in the &#8220;Investors &#8211; Corporate Governance&#8221; section are our Corporate Governance Guidelines, Code of Ethics and the charters for the Audit and Finance, Compensation, and Nominating and Corporate Governance Committees. Information on, or accessible through, our website is not a part of, and is not incorporated into, this report or any other SEC filing. Copies of our SEC filings or corporate governance materials are available without charge upon written request to Investor Relations, c/o ANI Pharmaceuticals, Inc., 210 Main Street West, Baudette, Minnesota, 56623.</span></div><div id="i4bc95b424f3d46babd419bb800693000_19"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing in our common stock involves a high degree of risk. You should carefully consider all information in this Annual Rep</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ort on Form 10-K prior to investing in our common stock. These risks are discussed more fully in the section titled &#8220;Risk Factors.&#8221; These risks and uncertainties include, but are not limited to, the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cortrophin Gel is our first rare disease pharmaceutical product. To the extent we are not able to continue to achieve commercial success with this product, including expanding the market and gaining market share, our business, financial condition, and results of operations will be negatively impacted;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approved products, including Cortrophin Gel, may not achieve commercialization at levels of market acceptance that will continue to allow us to achieve profitability;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisitions and investments could disrupt our business and harm our financial position and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The limited number of suppliers for our API could result in lengthy delays in production if we need to change suppliers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Several of the products we have acquired cannot be manufactured in our facilities and we must secure and maintain qualified and compliant contract manufacturers. Noncompliance by these contract manufacturers or our inability to find qualified contract manufacturers could result in us being unable to commercialize these products; Several of our products are manufactured and/or packaged by third parties, which we cannot control and could result in us being unable to market and distribute products;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are subject to United States federal and state laws related to healthcare fraud and abuse and health information privacy and security, and the failure to comply with such laws may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The continuing trend toward consolidation of customer groups that could result in declines in the sales volume and prices of our products, and increased fees charged by customers; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmaceutical product quality standards are steadily increasing on all products, and if we cannot meet these standards, we may be required to discontinue marketing and/or recall products from the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal and state false claims litigation brought against us by private individuals and the government could result in civil and criminal penalties, damages, fines and other related actions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The use of legal, regulatory, and legislative strategies by competitors could result in increased costs to develop and market our products, delay new product introductions and reduce profit potential;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party payer actions may prevent us from effectively marketing our products or cause us to decrease pricing;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Continuing studies of our products could produce results that could have a negative impact on our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Healthcare reform legislation could have a material adverse effect on our business, financial position, and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Barriers in achieving anticipated revenue growth and profitability could have a material adverse effect on our business, financial position, and operating results;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not achieve the anticipated benefits from our acquisition of Novitium Pharma LLC (&#8220;Novitium&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The obligations and liabilities of Novitium, some of which may be unanticipated or unknown, may be greater than we have anticipated, which may diminish the value of Novitium to us;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Public health outbreaks, epidemics, or pandemics (such as COVID-19) have adversely affected and may in the future adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Food and Drug Administration (&#8220;FDA&#8221;) does not provide guidance on safety labeling for products that are marketed without approved New Drug Applications (&#8220;NDAs&#8221;) or Abbreviated New Drug Applications (&#8220;ANDAs&#8221;), which could increase our potential liability with respect to failure-to-warn claims for these products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Four of our products are marketed without approved NDAs or ANDAs and we can offer no assurances that the FDA will not require us to either seek approval for these products or withdraw them from the market. In either case, our business, financial position, and operating results could be materially adversely affected;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the Drug Enforcement Administration (&#8220;DEA&#8221;) does not approve supply of the API we need to manufacture our controlled substances, we may be unable to manufacture controlled substances, which would eliminate our revenue on these products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Medicaid rebate accruals have increased and continue to increase due to our acquisitions and subsequent sales of branded products and authorized generics of branded products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our accruals for the Medicare Coverage Gap Discount Program have increased due to growth and acquisitions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face vigorous competition from other pharmaceutical manufacturers that threatens the commercial acceptance and pricing of our products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We expect to spend a significant amount of resources on research and development efforts, and such efforts may not result in marketable products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Production at any or all of our three current manufacturing facilities could be interrupted, which could cause us to fail to deliver product on a timely basis;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third parties to assist with our clinical studies. If these parties do not perform or are non-compliant, it could negatively impact the clinical trial and potential of regulatory approval; Further, we may be required to audit or redo previously completed trials or recall already-approved commercial products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inability to protect our intellectual property in the U.S. and foreign countries could negatively affect sales of our branded products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the exception of patents on a limited number of products we do not own or license any material patents associated with the majority of our products, and our ability to protect and control unpatented trade secrets, know-how, and other technological innovation is limited;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success is largely dependent upon certain key employees, including members of our senior management, the loss of whom could adversely affect our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology could harm our ability to operate the business effectively;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are involved in and may become involved in legal proceedings from time to time, which may result in substantial losses, government enforcement actions, damage to our business and reputation, and place a strain on our internal resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are susceptible to product liability claims that may not be covered by insurance, which, if successful, could require us to pay substantial sums;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our policies regarding returns, allowances and chargebacks, and marketing programs adopted by wholesalers may reduce revenues in future fiscal periods;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Making interest and principal payments under our Credit Agreement with Truist requires a significant amount of cash;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We previously identified material weaknesses in our internal control over financial reporting, and the failure to maintain an effective system of internal controls and procedures may cause investors to lose confidence in our financial reporting;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our Credit Facility contains restrictive and financial covenants and if are not in compliance with these covenants, our outstanding indebtedness under this facility could be accelerated and the lenders could terminate their commitments under the facility; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional funds by issuing additional equity securities may cause dilution to our current stockholders. Raising additional funds by entering into additional credit or other borrowing facilities or issuing debt may subject us to covenants and other requirements that may restrict our operations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations in an international market subject us to additional regulatory oversight both in the international market and in the U.S., as well as, social, and political uncertainties, which could cause a material adverse effect on our business, financial position, and operating results; and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations, including those resulting from our acquisition of Novitium and its international operations, will subject us to political and economic risks, increase our exposure to potential liability under anti-corruption, trade protection, tax, and other laws and regulations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are significant factors known to us that could materially harm our business, financial position, or operating results or could cause our actual results to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statement made in this report. The risks described are not the only risks facing us. Additional risks and uncertainties not currently known to us, or that we currently deem to be immaterial, also may adversely affect our business, financial position, and operating results. If any of these risks actually occur, our business, financial position, and operating results could suffer significantly. As a result, the market price of our common stock could decline and investors could lose all or part of their investment.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Business</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cortrophin Gel is our first rare disease pharmaceutical product. To the extent our ongoing and continuing efforts to commercialize this product are unsuccessful, our business, financial condition and results of operations will be negatively impacted.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, we received approval from the FDA for our Cortrophin Gel product for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (&#8220;MS&#8221;) and rheumatoid arthritis (&#8220;RA&#8221;), in addition to excess urinary protein due to nephrotic syndrome. We have devoted significant time and money over the past eight years to the development of this product since we acquired the rights to the product in 2016. We have invested and continue to invest significantly in the commercialization of this product in the U.S, including building out a sales force and developing a patient support program, with a full-scale launch in January 2022. In October 2023, we announced FDA approval and commercial availability of a 1-mLvial of Cortrophin Gel, appropriate for adjunctive treatment of certain patients with acute gouty arthritis flares. The ability for us to generate significant net product revenues from our Cortrophin Gel products will depend upon our ability to successfully sell the product and numerous other factors, including:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully establishing and maintaining effective sales, marketing, and distribution systems in jurisdictions in which Cortrophin Gel is approved for sale&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully establishing and maintaining manufacturing capabilities with our third-party suppliers and CMOs and manufacturing adequate commercial quantities of Cortrophin Gel at acceptable cost and quality levels, including maintaining current good manufacturing practice (&#8220;cGMP&#8221;) and quality systems regulation standards required by various regulatory agencies&#894; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broad acceptance of Cortrophin Gel by physicians, patients, and gaining market access share in the healthcare community&#894; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the acceptance of pricing and placement of Cortrophin Gel on payers&#8217; formularies and the associated tiers&#894; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with the only other competitor that has an approved adrenocorticotropic hormone (&#8220;ACTH&#8221;) therapy product on the market, as well as other products that are in development or may be developed in the future as a treatment option&#894;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continued demonstration of safety and efficacy of Cortrophin Gel in comparison to competing products or treatment options&#894; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with ongoing regulatory obligations and continued regulatory review which may result in significant additional expense and may require labeling changes based on new safety information, post-market studies or clinical trials to evaluate safety risks related to the use of Cortrophin Gel; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining, maintaining, enforcing, and defending intellectual property rights and claims.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors, we could experience an inability to successfully commercialize Cortrophin Gel, which would negatively impact our business, financial condition and results of operations. In addition, sales of Cortrophin Gel could be negatively affected by discovery of previously unknown problems with the product, such as adverse events of unanticipated severity or frequency, problems with the facilities where the product is manufactured, or imposition of restrictions on Cortrophin Gel, including requiring withdrawal of the product from the market, by a regulatory agency if it disagrees with the promotion, marketing, or labeling of the product.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are continuing to develop our marketing and sales organization to support Cortrophin Gel and have limited experience in marketing prescription rare disease drug products. If we are unable to  continue to develop marketing and sales capabilities for Cortrophin Gel, our business will suffer.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first established our rare disease sales, marketing or distribution capabilities in 2021 and have limited institutional experience in marketing rare disease products. We intend to continue to develop an in-house marketing organization and sales force, which will require significant expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future acquisitions and investments could disrupt our business and harm our financial position and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth will depend, in part, on our continued ability to develop, commercialize, and expand our products, including in response to changing regulatory and competitive pressures. In some circumstances, we have and may continue to grow our business through the acquisition of complementary businesses and technologies rather than through internal development. The identification of suitable acquisition candidates or products can be difficult, time-consuming, and costly, and we may not be able to successfully complete or successfully execute strategies for identified acquisitions. The risks faced in connection with acquisitions include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management time and focus from operating our business to addressing acquisition and/or product integration challenges;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coordination of research and development and sales and marketing functions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retention of key employees from the acquired company;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integration of the acquired company&#8217;s accounting information, management, human resources, and other administrative systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to implement or improve controls, procedures, and policies at a business that prior to the acquisition may have lacked effective controls, procedures and policies;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties relating to integrating the acquired business;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liability for activities of the acquired company and/or products before the acquisition, including patent infringement claims, violations of laws, commercial disputes, tax liabilities and other known and unknown liabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated write-offs or charges; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation or other claims in connection with the acquired company or product, including claims from product users, former stockholders, or other third parties.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any acquisition that we may undertake, our failure to address these risks or other problems encountered in connection with any acquisitions and investments could cause us to fail to realize the anticipated benefits of these acquisitions or investments, cause us to incur unanticipated liabilities, and harm our business generally. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on a limited number of suppliers for API. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. We may experience lengthy delays if we need to change an API supplier, which could have a material impact on business and results of operations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to manufacture and distribute products is dependent, in part, upon ingredients and components supplied by others, including entities based outside the U.S. During the year ended December&#160;31, 2023, no single vendor represented at least 10% of inventory purchases. During the year ended December 31, 2022, we purchased approximately 19% of our inventory from one supplier. During the year ended December 31, 2021, no single vendor represented at least 10% of inventory purchases. Any disruption in the supply of these ingredients or components or any problems in their quality could materially affect our ability to manufacture and distribute our products and could result in legal liabilities that could materially affect our ability to realize profits or otherwise harm our business, financial, and operating results. Virtually all of our generic contracts for the supply of pharmaceutical products to customers contain "failure to supply" clauses. Under these clauses, if we are unable to supply the requested quantity of product within a certain period after receipt of a customer&#8217;s purchase order, the customer is entitled to procure a substitute product elsewhere and we must reimburse the customer for the difference between our contract price and the price the customer was forced to pay to procure the substitute product. Therefore, our ability to source sufficient quantities of API for manufacturing is critical. We source the raw materials for our products from both domestic and international suppliers. Generally, we qualify only a single source of API for use in each product due to the cost and time required to validate and qualify a second source of supply. Any change in one of our API suppliers must usually be approved through a Prior Approval Supplement (&#8220;PAS&#8221;) by the FDA. The process of obtaining an approval of such a PAS can require between four and 18 months. While we also generally qualify a single source for non-API raw materials, the process required to qualify an alternative source of a non-API raw material is typically much less rigorous. If we were to change the supplier of a raw material for a product, the cost for the material could be greater than the amount we paid with the previous supplier. Changes in suppliers are rare but could occur as a result of a supplier&#8217;s business failing, an issue arising from an FDA inspection, or failure to maintain our required standards of quality. As a result, we carefully select suppliers, based on various factors including quality, reliability of supply, and long-term financial stability. Certain of the APIs for our drug products, including those that are marketed without approved NDAs or ANDAs, are sourced from international suppliers. From time to time, we have experienced temporary disruptions in the supply of certain of such imported API due to FDA inspections. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Several of the products we have acquired cannot be manufactured in our facilities and are manufactured and/or packaged by third parties, which we cannot control. If we are unable to secure or maintain qualified contract manufacturers for those products or if a contract manufacturer fails to comply with federal, state, and local laws and regulations, our business, financial position, and operating results could be materially, adversely affected.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have acquired, and may continue to acquire, a variety of products that we seek to commercialize. Some of these products, including injectables, softgel capsules, and Purified Cortrophin Gel, are products that we cannot currently manufacture in our facilities. As a result, we may seek partners to contract manufacture the products on our behalf, and we rely on third parties to manufacture and/or package many of our products. Like our company, these firms must comply with cGMPs and other federal, state, and local laws and regulations regarding pharmaceutical manufacturing. Noncompliance by those firms may result in warning letters, fines, product recalls, and partial or total suspension of production and distribution. If we are unable to find qualified contract manufacturers or if a contract manufacturer fails to comply with federal, state, and local laws and regulations, we may be unable to commercialize these products, which could have a material adverse effect on our business, financial position, and operating results, including an impairment of the acquired product.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our reliance on third party manufacturers to continue to increase in the future as we receive approvals for new products to be manufactured through our collaborative arrangements, and as we seek additional growth opportunities outside of the capabilities of our current manufacturing facilities. If we are unable to secure third-party manufacturers for these products on commercially acceptable terms, we may not be able to market and distribute such products at a profit. Any delays or difficulties with third-party manufacturers could adversely affect the marketing and distribution of these products, or future products, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to United States federal and state laws related to healthcare fraud and abuse and health information privacy and security, and the failure to comply with such laws may adversely affect our business.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our products are eligible for reimbursement under federal and state health care programs such as Medicaid, Medicare, TRICARE, and/or state pharmaceutical assistance programs, and as a result, certain U.S. federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&#8217; rights are, and will be, applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The domestic and foreign laws that may affect our ability to operate include, but are not limited to: (i) the U.S. Anti-Kickback Statute, which applies to our marketing and research practices, educational programs, pricing policies and relationships with healthcare providers or other entities, by prohibiting, among other things, soliciting, receiving, offering or paying remuneration, directly or indirectly, as a means of inducing, or in exchange for, either the referral of an individual or the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs; (ii) U.S. federal civil and criminal false claims laws and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to Medicare, Medicaid or other federal healthcare program payers that are false or fraudulent; (iii) new federal criminal statutes that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; (iv) the U.S. Physician Payments Sunshine Act, which among other things, requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually information related to certain &#8220;payments or other transfers of value&#8221; made to physicians, physician assistants, advanced practice nurses and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members, and similar state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; (v) the government pricing rules applicable to the Medicare and Medicaid programs, the 340B Drug Pricing Program, the U.S. Department of Veterans Affairs program, the TRICARE program, and state price transparency reporting laws; and (vi) state and foreign law equivalents of each of the above U.S. laws, such as anti-kickback and false claims laws which may apply to items or services. Defense of litigation claims and government investigations can be costly, time-consuming, and distract management, and it is possible that we could incur judgments, settlements, deferred or non-prosecution agreements, or corporate integrity agreements that would require us to change the way we operate our business. We are committed to conducting the sales and marketing of our products in compliance with the healthcare fraud and abuse laws, but certain applicable laws may impose liability even in the absence of specific intent to defraud. Furthermore, should there be ambiguity, a governmental authority may take a position contrary to a position we have taken, or should an employee violate these laws without our knowledge, a governmental authority may impose civil and/or criminal sanctions.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any adverse outcome in these types of actions, or the imposition of penalties or sanctions for failing to comply with fraud and abuse laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows. Some of the statutes and regulations that govern our activities, such as federal and state anti-kickback and false claims laws, are broad in scope, and while exemptions and safe harbors protecting certain common activities exist, they are often narrowly drawn and construed by the courts. While we manage our business activities to comply with these statutory provisions, due to their breadth, complexity and, in certain cases, uncertainty of application, it is possible that our activities could be subject to challenge by various government agencies. In particular, the FDA, the DOJ, the Office of Inspector General at the U.S. Department of Health and Human Services, and other agencies have increased their enforcement activities with respect to the manufacturing, sales, marketing, research and similar activities of pharmaceutical companies in recent years, and many pharmaceutical companies have been subject to government investigations related to these practices. A determination that we are in violation of these and/or other government regulations and legal requirements may result in civil damages and penalties, criminal fines and prosecution, administrative remedies, the recall of products, the total or partial suspension of manufacturing and/or distribution activities, seizure of products, injunctions, whistleblower lawsuits, failure to obtain approval of pending product applications, withdrawal of existing product approvals, exclusion from participation in government healthcare programs and other sanctions.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these types of investigations or enforcement actions could affect our ability to commercially distribute our products and could materially and adversely affect our business, financial condition, results of operations and cash flows.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to certain privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies, contractual obligations and failure to comply with such requirements, as well as any breach of unsecured identifiable personal information protected by law, could subject us to significant costs, fines, penalties (civil and criminal), and civil litigation which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As regulatory focus on privacy issues continues to increase, and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. In addition, the interpretation and application of consumer, health-related, and data protection laws are often uncertain, contradictory, and in flux, which complicates compliance efforts.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our anticipated revenue growth and profitability, if achieved, is dependent upon our ability to develop, license or acquire, and commercialize new products on a timely basis in relation to our competitors&#8217; product introductions, and to address all regulatory requirements applicable to the development and commercialization of new products. Our failure to do so successfully could impair our growth strategy and plans and could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future revenues and profitability are dependent upon our ability to successfully develop, license or acquire, and commercialize pharmaceutical products in a timely manner. Product development is inherently risky and time-consuming. Likewise, product licensing involves inherent risks, including uncertainties due to matters that may affect the achievement of milestones, as well as the possibility of contractual disagreements with regard to the supply of product meeting specifications and terms such as license scope or termination rights. The development and commercialization process also requires substantial time, effort, and financial resources. Additionally, we have entered profit-sharing or royalty arrangements with third parties in which we sell products under ANDAs or NDAs owned or licensed by these third parties. Under these agreements, we pay these third parties a specified percentage of the gross profit earned on sales of the products, and such percentages in certain cases increase as additional gross profit is earned. Any increases in these percentages would impact our future profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in commercializing products on a timely basis, if at all, which could adversely affect our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA must approve any new prescription product before it can be marketed in the U.S. The process of obtaining regulatory approval to manufacture and market branded and generic pharmaceutical products is rigorous, time consuming, costly, and largely unpredictable. We may be unable to obtain requisite approvals on a timely basis for branded or generic products that we may develop, license, or acquire. Moreover, if we obtain regulatory approval for a drug, we may be limited with respect to the indicated uses and delivery methods for which the drug may be marketed, which in turn could restrict the potential market for the drug. Also, for products pending approval, we may obtain raw materials or produce batches of inventory. In the event that regulatory approval is denied or delayed, we could be exposed to the risk of any such inventory becoming obsolete. The timing and cost of obtaining regulatory approvals could adversely affect our product introduction plans, business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval process for generic pharmaceutical products often results in the FDA granting simultaneous final approval to a number of generic pharmaceutical products at the time a patent claim for a corresponding branded product or other market exclusivity expires. This often forces a generic firm to face immediate competition when it introduces a generic product into the market. Additionally, further generic approvals often continue to be granted for a given product subsequent to the initial launch of the generic product. These circumstances generally result in significantly lower prices, as well as reduced margins, for generic products compared to branded products. New generic market entrants generally cause continued price and margin erosion over the generic product life cycle. As a result, we could be unable to grow or maintain market share with respect to our generic pharmaceutical products, which could have a material adverse effect on our ability to market that product profitably and on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, if we are unable to address all regulatory requirements applicable to the development and commercialization of new products in a timely manner, our product introduction plans, business, financial position, and operating results could be materially adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates and monitors all promotion and advertising of prescription drugs after approval. All promotion must be consistent with the conditions of approval and submitted to the agency. Failure to adhere to FDA promotional requirements can result in enforcement letters, warning letters, changes to existing promotional material, and corrective notices to healthcare professionals. Promotion of a prescription drug for uses not approved by the FDA can have serious consequences and result in lawsuits by private parties, state governments and the federal government, significant civil and criminal penalties, and compliance agreements that require a company to change current practices and prevent unlawful activity in the future.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our branded products may become subject to increased generic competition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our branded products have not been patent-protected for several years and no longer have market exclusivity. As a result, they face competition from lower priced generic products which may reduce and limit the sales of our mature brand products. Additionally, increased focus by the FDA on approval of generic products may accelerate this trend. If generic products are substituted for these branded products, our revenue from these products will decrease, which could have an adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Medicaid rebate accruals have increased and continue to increase due to our acquisitions and subsequent sales of branded products and authorized generics of branded products, and the estimates on which our accruals are based are subject to change. Any such change could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicaid rebate accruals have increased significantly due to our acquisitions and subsequent sales of branded products and authorized generics of branded products. We accrue for these rebates at the time of sale based on our estimates of the amount of our product that will be prescribed to Medicaid beneficiaries. The resulting accruals are significant, and as Medicaid utilization trends change, we may need to change our estimates accordingly. We cannot guarantee that actual results will not differ from our estimates. In addition, the Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;) included a significant expansion of state Medicaid programs. As more individuals become eligible for coverage under these programs, Medicaid utilization of our products could increase, resulting in a corresponding increase in our rebate payments. Increases in Medicaid rebate payments could decrease our revenues from product sales, which in turn could adversely affect our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our accruals for the Medicare Coverage Gap Discount Program have increased due to growth and acquisitions. Any such change could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accruals for the rebates under the Medicare Coverage Gap Discount Program have increased due to growth and acquisitions. We accrue for these rebates at the time of sale based on our estimates of the amount of product that will be prescribed to patients in the Medicare Coverage Gap Discount program, which is primarily for the benefit of persons aged 65 years and over. As we acquire and launch additional products, many of which, are often used by patients in the 65 and older age range, our estimates of these rebates have grown. Increases in Medicare Coverage Gap Discount rebates, and legislative changes to the Medicare Coverage Gap Discount Program, could decrease our revenues from product sales, which in turn could adversely affect our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into distribution agreements under which we market products under ANDAs and NDAs owned by third parties. Any changes to these agreements could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into several distribution agreements to market and distribute products under our own label that are sold under ANDAs and NDAs owned by third parties, over which we have no control. Generally, the responsibility for maintaining the ANDAs and NDAs lies with these third parties. If any regulatory issues were to arise with the underlying ANDA or NDA for one of these products, we could be required to discontinue sales of the product, which could have an adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face vigorous competition from other pharmaceutical manufacturers that may adversely impact commercial acceptance and pricing of our products. If we are unable to successfully compete, such competition could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The generic pharmaceutical industry is highly competitive. We face intense competition from U.S. and foreign manufacturers, many of whom are significantly larger than us and operate in lower cost geographies. Our competitors may be able to develop products and processes competitive with or superior to ours for many reasons, including but not limited to the possibility that they may have:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater financial resources;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proprietary processes or delivery systems;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger research and development and marketing staffs;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger production capabilities;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more products; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">access to lower cost wages; or</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">more experience in developing new drugs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of our significant competitors, due to one or more of these and other factors, could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approved products may not achieve commercialization at levels of market acceptance that allow us to achieve profitability, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to develop, license, or acquire products that we can commercialize at levels of market acceptance that would allow us to recoup our costs, grow market share, and achieve profitability. Even if we are able to obtain regulatory approvals for our pharmaceutical products, if we fail to predict accurately demand for such products, our business, financial position, and operating results could be adversely affected. Levels of market acceptance for our products could be impacted by several factors, including but not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of alternative products from our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our products&#8217; pricing relative to that of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our marketing effectiveness relative to that of our competitors;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">timing of our market entry;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to market our products effectively to the retail level; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products by government and private formularies.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these factors are outside of our control and, if any arise, our profitability, business, financial position, and operating results could be materially adversely affected.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have entered into several collaborative arrangements that may not result in marketable products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into several collaborative arrangements to develop generic products for us to market in the U.S. We can offer no assurances that these arrangements will result in additional approved products, or that we will be able to market the products at a profit. In addition, any expenses related to clinical trials, or additional studies required by the FDA, that we may incur in connection with these collaborative arrangements may negatively affect our business, financial position, and operating results. Specifically:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials could be more costly than we anticipate;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulation development could take longer and be more costly than we expect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to obtain specialized equipment in order to manufacture products on a commercial scale; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be subject to milestone payments to collaborative partners, the timing of which we may be unable to predict.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We expect to spend a significant amount of resources on research and development efforts, and such efforts may not result in marketable products. Failure to successfully introduce products into the market could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct research and development primarily to enable us to manufacture and market approved products in accordance with applicable regulations. Research and development is expensive and time-consuming. As we seek to develop new products, or re-commercialize products that were previously approved, our research expenses will increase, potentially significantly, and we cannot be certain that we will recover our investment in a product, even if that product is commercialized. If we spend significant resources on research and development efforts and are not able to introduce new products, our business, financial position, and operating results may be materially adversely affected.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We produce the majority of our products in three manufacturing facilities. Production at any or all of these facilities could be interrupted, which could cause us to fail to deliver sufficient product to customers on a timely basis and have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal manufacturing operations are currently based in three fa</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cilities. We have transitioned the products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites, and we are seeking to find potential buyers for the Oakville site. While these three remaining facilities are sufficient for our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current needs, the facilities are highly specialized and any damage to or need for replacement of all or any significant function of our facilities could be very costly and time-consuming and could impair or prohibit production and shipping. A significant disruption at any of the facilities, even on a short-term basis, whether due to a labor strike, adverse quality or compliance observation, vandalism, natural disaster, fire, storm or other environmental damage, or other events could impair our ability to produce and ship products on a timely basis and, among other consequences, could subject us to &#8220;failure to supply&#8221; claims from our customers, as discussed below. Although we believe we carry commercially reasonable business interruption and liability insurance, we might suffer losses because of business interruptions that exceed the coverage available under our insurance policies or for which we do not have coverage. Any of these events could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virtually all our contracts for the supply o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f generic products to our customers contain "failure to supply" clauses which require us to reimburse the customer for the difference between our contract price and the price the customer was forced to pay to procure the substitute product in the event we failed to deliver the requested quantity within a specified period of time. This difference can be substantial because of the much higher spot price at which the customer must cover its requirements and can be far in excess of the revenue that we would otherwise have received on the sale of our own product. Therefore, our ability to produce and ship a sufficient quantity of product on a consistent basis is critical. Failure to deliver products could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to assist with our clinical studies. If these third parties do not perform as required or expected, or if they are not in compliance with FDA rules and regulations, our clinical studies may be extended, delayed or terminated, or may need to be repeated, and we may not be able to obtain regulatory approval for or commercialize the products being tested in such studies. Further, we may be required to audit or redo previously completed trials or recall already-approved commercial products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties, such as medical institutions, clinical investigators, and contract laboratories, to assist with our clinical studies. We are responsible for confirming that our studies are conducted in accordance with applicable regulations and that each of our clinical studies is conducted in accordance with our general investigational plan and protocol. The FDA requires us to comply with regulations and standards, commonly referred to as good clinical practices for conducting, monitoring, recording, and reporting the results of clinical studies, to assure that data and reported results are accurate and that the clinical study participants are adequately protected. Our reliance on these third parties does not relieve us of these responsibilities. If the third parties assisting us with our clinical studies do not perform their contractual duties or obligations, do not meet expected deadlines, fail to comply with the FDA&#8217;s good clinical practice regulations, do not adhere to our protocols or otherwise fail to generate reliable clinical data, we may need to enter into new arrangements with alternative third parties and our clinical studies may be extended, delayed or terminated or may need to be repeated, and we may not be able to obtain regulatory approval for or commercialize the products being tested in such studies. For our already-approved commercial products, we may be required to audit or redo previously completed trials or recall our products from the market, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">With the exception of patents or patent applications related to Veregen, baclofen, and hydrochlorothiazide products, we do not own or license any material patents associated with our products, and our ability to protect and control unpatented trade secrets, know-how, and other technological innovation is limited.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the branded pharmaceutical business relies upon patent protection to ensure market exclusivity for the life of the patent. Except for licenses for patent technology for Veregen, and ownership of patents and patent applications relating to our baclofen and hydrochlorothiazide products, we do not own or license any material patents associated with our products and therefore do not enjoy the same level of intellectual property protection with respect to such products as would a pharmaceutical manufacturer that markets a patented product. We have limited ability to protect and control trade secrets, know-how, and other technological innovation, all of which are unpatented. Others independently may develop similar or better proprietary information and techniques and disclose them publicly. In addition, others may gain access to our trade secrets, and we may not be able to protect our rights to our unpatented trade secrets. In addition, confidentiality agreements and other measures may not provide protection for our trade secrets in the event of unauthorized use or disclosure of such information. Failure to protect and control such trade secrets, know-how and innovation could harm the value of our trade secrets, know-how and other technological innovation, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inability to protect our intellectual property in the U.S. and foreign countries could negatively affect sales of our branded products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own the trademark names for most of our branded pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ducts, including, Apexicon, Cortenema, Purified Cortrophin Gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan, Vancocin, and Veregen. We license the trademark names for Atacand, Atacand HCT, Arimidex, Casodex, Oxistat, and Pandel. W</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hile we will seek to protect those trademarks through timely renewal in applicable jurisdictions, we may not be able to renew our trademarks in a timely manner or to prevent third parties from using our trademarks, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success is largely dependent upon certain key employees, including members of our senior management team, the loss of whom could adversely affect our operations. Competition for talent is intense, especially in northern Minnesota, where the population is small. If we cannot attract and retain qualified personnel, the growth and success of our business could be adversely affected.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon the efforts of certain key employees, including members of our senior management team. We have employment arrangements in place with our executive and other officers, but none of these executive and other officers are bound legally to remain employed with ANI for any specific term. We do not have key person life insurance policies covering our executive and other officers or any of our other employees. If key individuals were to leave ANI, our business could be affected adversely if suitable replacement personnel are not recruited quickly. Competition for personnel is intense in certain localities in which we operate, specifically northern Minnesota, where two of our three current manufacturing facilities are located, is small, and as a result, there is a limited number of qualified personnel available in all functional areas, which could make it difficult to retain and attract the qualified personnel necessary for the development and growth of our business. If we were unable to attract and retain qualified personnel, our business, financial position, and operating results could be materially adversely affected.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely significantly on information technology and any failure, inadequacy, interruption, or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate the business effectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely significantly on our information technology and manufacturing infrastructure to effectively manage and maintain inventory and financial reports, manufacture and ship products, and invoice customers in a timely manner. While we have invested in the protection of data and information technology, any failure, accidents, inadequacy, or interruption of that infrastructure or security lapse of that technology, including cybersecurity incidents, could harm our ability to operate our business effectively. Our ability to manage and maintain inventory and financial reports, manufacture and ship products, and invoice customers timely depends significantly on our general ledger, our contracted electronic data interface system, and other information systems. Cybersecurity attacks in particular are evolving and include, but are not limited to, malicious software, attempts to gain unauthorized access to data and other electronic security breaches that could lead to disruptions in systems, misappropriation of confidential or otherwise protected information and corruption of data. Cybersecurity incidents resulting in the failure of our information systems to operate effectively or to integrate with other systems, or a breach in security or other unauthorized access of these systems, may affect our ability to manage and maintain inventory and financial reports, and result in delays in product fulfillment and reduced efficiency of operations. A breach in security, unauthorized access resulting in misappropriation, theft, or sabotage with respect to proprietary and confidential information, including research or clinical data, could require significant capital investments to remediate any such failure, problem or breach, all of which could adversely affect our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are currently involved in and may from time to time become involved in legal proceedings, some of which may result in substantial losses, government enforcement actions, damage to our business and reputation, and place a strain on our internal resources.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in and in the future may become involved in legal proceedings in the ordinary course of our business, as a party or non-party witness, with both private parties and certain government agencies. We may incur substantial time and expenses participating in these types of lawsuits and investigations, which could also divert management&#8217;s attention from ongoing business concerns and normal operations. In addition, these matters and any other substantial litigation may result in verdicts against us or government enforcement actions, which may include significant monetary awards, and preventing the manufacture, marketing and sale of our products. Any dispute resolved unfavorably, could have a material adverse effect on our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">business, financial position, and operating results. For a description of legal proceedings which are currently pending, see Note 15. Commitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">port on Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are susceptible to product liability claims that may not be covered by insurance, which, if successful, could require us to pay substantial sums.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like all pharmaceutical companies, we face the risk of loss resulting from, and the adverse publicity associated with, product liability lawsuits, whether or not such claims are valid. We likely cannot avoid such claims. Unanticipated side effects or unfavorable publicity concerning any of our products or product candidates would likely have an adverse effect on our ability to achieve acceptance by prescribing physicians, managed care providers, pharmacies and other retailers, customers, patients and clinical trial participants. Even unsuccessful product liability claims could require us to spend money on litigation, divert management&#8217;s time, damage our reputation and impair the marketability of our products. In addition, although we believe that we have adequate product liability insurance coverage, we cannot be certain that our insurance will, in fact, be sufficient to cover such claims or that we will be able to obtain or maintain adequate insurance coverage in the future at acceptable prices. A successful product liability claim that is excluded from coverage or exceeds our policy limits could require us to pay substantial sums. Additionally, insurance coverage for product liability may become prohibitively expensive in the future or may not be available at all, and as a result, we may not be able to maintain adequate product liability insurance coverage to mitigate the risk of large claims, or we may be required to maintain a larger self-insured retention that we would otherwise choose.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currency fluctuations and changes in exchange rates could have a material adverse effect on our business, fina</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ncial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our transactions are denominated in a foreign currency, the Indian rupee. Because we engage in certain transactions in a foreign currency, we are subject to the effects of exchange rate fluctuations. If the U.S. dollar depreciates against the Indian rupee, the expenses we recognize from Indian-denominated transactions made by our Indian subsidiary could be translated at an unfavorable rate, leading to foreign exchange losses. Foreign exchange gains or losses as a result of exchange rate fluctuations in any given period could harm our operating results and negatively impact our financial position and results of operati</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ons.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not achieve the anticipated benefits from our acquisition of Novitium, which could have a material adverse effect on our business, financial position, and operating results. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, the Company completed its previously announced acquisition (the &#8220;Acquisition&#8221;) of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021 (the &#8220;Merger Agreement&#8221;), by and among the Company, Novitium, Nile Merger Sub LLC, a Delaware limited liability company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and certain other parties, with Novitium becoming a wholly owned subsidiary of ANI. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize the potential benefits from the Acquisition that we or the market expects. Risks associated with the Acquisition include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to effectively manage our expanded operations, which were materially increased by the Acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management&#8217;s attention, the disruption or interruption of, or the loss of momentum in, the businesses of ANI and Novitium or inconsistencies in standards, controls, procedures, and policies, any of which could adversely affect our ability to maintain relationships with customers, partners, and employees or our ability to achieve the anticipated benefits of the acquisition;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of key employees; and </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to maintain relationships with third parties, including Novitium&#8217;s and our pre-existing customers, which relationships may be affected by customer preferences or public attitudes about the Acquisition. Any adverse changes in these relationships could adversely affect our business, financial condition, and results of operations.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The obligations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> liabilities of Novitium, some of which may be unanticipated or unknown, may be greater than we have anticipated, which may diminish the value of Novitium to us.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novitium&#8217;s obligations and liabilities, some of which may not have been disclosed to us or may not be reflected or reserved for in Novitium&#8217;s historical financial statements, may be greater than we have anticipated. The obligations and liabilities of Novitium could have a material adverse effect on Novitium&#8217;s business or Novitium&#8217;s value to us or on our business, financial condition, or results of operations. Under the Merger Agreement relating to the Novitium acquisition, we have only limited indemnification with respect to obligations or liabilities of Novitium, whether known or unknown. In addition, even in cases where we are able to obtain indemnification, we may discover liabilities greater than the contractual limits or the financial resources of the indemnifying party. In the event that we are responsible for liabilities substantially in excess of any amounts recovered through rights to indemnification or alternative remedies that might be available to us, or any applicable insurance, we could suffer severe consequences that would substantially reduce our earnings and cash flows or otherwise materially and adversely affect our business, financial condition, or results of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Industry</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) have adversely affected and may in the future adversely affect our business.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic previously adversely affected us in the years ended December 31, 2021 and 2020, and the COVID-19 pandemic or other actual or threatened public health outbreaks, epidemics, or pandemics may in the future adversely affect, among other things, the economic and financial markets and labor resources of the countries in which we operate; our manufacturing and supply chain operations, research and development efforts, commercial operations and sales force, administrative personnel, third-party service providers, and business partners and customers; and the demand for our products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such disruptions in our operations could materially adversely impact our business, prospects, operating results, and financial condition. To the extent a public health outbreak, epidemic, or pandemic adversely affects our business, prospects, operating results, or financial condition, it may also have the effect of heightening many of the other risks described in this "Risk Factors" section.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing trend toward consolidation of customer groups could result in declines in the sales volume and prices of our products, and increased fees charged by customers, each of which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidation and the formation of strategic partnerships among and between wholesale distributors, chain drug stores, and group purchasing organizations has resulted in a smaller number of companies, each controlling a larger share of pharmaceutical distribution channels. For example, our net revenues are concentrated among four customers representing </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 31%, 13%, 13%, and 12% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of net revenues, respectively, during the year ended December&#160;31, 2023. As of December&#160;31, 2023, accounts receivable from these four customers was approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our accounts receivable, net. Drug wholesalers and retail pharmacy chains, which represent an essential part of the distribution chain for generic pharmaceutical products, have undergone, and are continuing to undergo, significant consolidation. This consolidation may result in declines in our sales volumes if a customer is consolidated into another company that purchases products from a competitor. In addition, the consolidation of drug wholesalers and retail pharmacy chains could result in these groups gaining additional purchasing leverage and consequently increasing the product pricing pressures facing our business and enabling those groups to charge us increased fees. Additionally, the emergence of large buying groups representing independent retail pharmacies and the prevalence and influence of managed care organizations and similar institutions potentially enable those groups to extract price discounts on our products. The result of these developments or the loss of our relationship with one or more of these wholesalers, may have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our reporting and payment obligations under the Medicaid rebate program and other governmental purchasing and rebate programs are complex and may involve subjective decisions. Any determination that we have failed to comply with those obligations could subject us to penalties and sanctions, which could adversely affect our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations regarding reporting and payment obligations with respect to Medicaid rebates and other governmental programs are complex. Because our processes for these calculations and the judgments involved in making these calculations involve subjective decisions and complex methodologies, these calculations are subject to the risk of errors. Our calculations and methodologies are subject to review and challenge by governmental agencies, and it is possible that such reviews could result in changes. Any determination by governmental agencies that we have failed to comply with our reporting and payment obligations could subject us to penalties and sanctions, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Three products, which tog</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ether comprised less than 10% of ou</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">r total revenue in 2023, are marketed without approved NDAs or Abbreviated New Drug Applications (&#8220;ANDAs&#8221;) and we can offer no assurances that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) will not require us to either seek approval for these products or withdraw them from the market. In either case, our business, financial position, and operating results could be materially adversely affected.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three products, Esterified Estrogen with Methyltestosterone (&#8220;EEMT&#8221;), Opium Tincture, and Thyroid Tablets are marketed without approved NDAs or ANDAs. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company obtained the rights to Hyoscyamine, a product without approved NDAs or ANDAs, on of December 27, 2023. During 2023 the Company recorded only contract manufacturing revenues for Hyoscyamine (see further discussion in Note 15. Commitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K). We plan to launch Hyoscyamine commercially in early 2024.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA's policy with respect to the continued marketing of unapproved products appears in the FDA's September 2011 Compliance Policy Guide Sec. 440.100 titled &#8220;Marketed New Drugs without Approved NDAs or ANDAs.&#8221; Under this policy, the FDA has stated that it will follow a risk-based approach with regard to enforcement against marketing of unapproved products. The FDA evaluates whether to initiate enforcement action on a case-by-case basis, but gives higher priority to enforcement action against products in certain categories, such as those with potential safety risks or that lack evidence of effectiveness. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that, so long as we comply with applicable manufacturing standards, the FDA will continue to operate on a risk-based approach and will not take action against us. However, we can offer no assurance that the FDA will continue to follow this approach or that it will not take a contrary position with any individual product or group of products. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our EEMT products are related to an outstanding Notice of Opportunity for Hearing on estrogen-androgen products. The hearing relates to the FDA's intent to reclassify certain estrogen-androgen combination drugs as lacking substantial evidence of their effectiveness for the treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogen alone. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA were to move away from the risk-based approach to enforcement against marketing of unapproved products, we may be required to seek FDA approval for these products or withdraw such products from the market. If we decide to withdraw the products from the market, our net revenues for generic pharmaceutical products would decline materially, and if we decide to seek FDA approval, we would face increased expenses and might need to suspend sales of the products until such approval was obtained, and there are no assurances that we would receive such approval.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Imported API are subject to inspection by the FDA and the FDA can refuse to permit the importation of API for use in products that are marketed without approved NDAs or ANDAs. We are dependent on imported API to make certain of our products. If the FDA detained or refused to allow the importation of such API, our revenues from certain of our products would be reduced or eliminated and our business, financial position, and operating results could be materially adversely affected.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source some of the API for our products, including those that are marketed without approved NDAs or ANDAs, from international suppliers. From time to time, due to FDA inspections, we have experienced temporary disruptions in the supply of imported API. Any prolonged disruption in the supply of imported API could materially affect our ability to manufacture and distribute our products, reduce or eliminate our revenues, and have a material adverse effect on our business, financial position, and operating results. In addition, as regulatory fees and compliance oversight of API manufacturers increase, this could result in certain companies discontinuing their supply of API to us, which would materially affect our ability to manufacture our products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA does not provide guidance on safety labeling for products that are marketed without approved NDAs or ANDAs. As a result, we are dependent on our internal post-approval drug safety surveillance program to identify necessary safety-related changes to the labels for EEMT, Opium Tincture, and Thyroid Tablets, and Hyoscyamine.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product labels contain important safety information including Black Box warnings, contraindications, dosing and administration, adverse reactions, drug interactions, use in specific populations such as pregnant women, pediatric, and geriatric patients, and other warnings and precautions. Pharmaceutical manufacturers may change product labels when post-approval drug safety surveillance programs identify previously unknown side-effects, drug interactions, and other risks. Manufacturers may also change product labels after conducting post-approval clinical studies and may receive or seek guidance from the FDA regarding updating safety labeling information. However, the FDA does not provide guidance on labeling for products that are marketed without approved NDAs or ANDAs. As a result, we are dependent on our internal post-approval drug safety surveillance program to identify necessary safety-related changes to the labels for EEMT, Opium Tincture, Thyroid Tablets, and Hyoscyamine. Additionally, because the FDA does not review and approve labeling for the products without approved NDAs or ANDAs, it would be difficult to make a claim for preemption due to the FDA&#8217;s approval of the labeling and this could increase our potential liability with respect to failure-to-warn claims for these products. Such claims, even if successfully defended, could have an adverse impact on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are entirely dependent on periodic approval by the DEA for the supply of the API needed to manufacture our controlled substances. An inability to obtain such approvals would reduce or eliminate our revenues for our controlled substances, and could have a material adverse effect on our business, financial position, and operating results. In addition, we are subject to strict regulation by the DEA and are subject to sanctions if we are unable to comply with related regulatory requirements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DEA regulates products containing controlled substances, such as opiates, pursuant to the U.S. Controlled Substances Act (&#8220;CSA&#8221;). The CSA and DEA regulations impose specific requirements on manufacturers and other entities that handle these substances including registration, recordkeeping, reporting, storage, security, and distribution. Recordkeeping requirements include accounting for the amount of product received, manufactured, stored, and distributed. Companies handling controlled substances also are required to maintain adequate security and to report suspicious orders, thefts and significant losses. The DEA periodically inspects facilities for compliance with the CSA and its regulations. Failure to comply with current and future regulations of the DEA could lead to a variety of sanctions, including revocation or denial of renewal of DEA registrations, injunctions, or civil or criminal penalties.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, each year, we must submit a request to the DEA for a procurement quota in order to purchase the amount of API needed to manufacture our Schedule II controlled substances. Without approved procurement quotas from the DEA, we would not be able to purchase these ingredients from our suppliers. As a result, we are entirely dependent upon the DEA to approve, on an annual basis, a quota of API that is sufficiently large to support our plans for the continued manufacture of our controlled substances at commercial levels. In 2017, the DEA announced that the administration would decrease the total quotas approved for Schedule II opioid painkillers. In 2018, the DEA decreased quotas approved for Schedule II opioid painkillers. The DEA continues to closely monitor quotas of certain opioids and as a result there may be a reduction from what was requested; however, firms may file an application for a quota adjustment at any time during the calendar year. If the DEA does not approve our requested procurement quotas, we may be unable to obtain sufficient API to manufacture these products at levels required by our customers, which could have an adverse impact on our business, financial position, and operating results. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products are subject to regulatory and quality standards and guidelines set forth by FDA and other governmental agencies. Changes or developments in such standards and guidelines may affect the ability of our products to meet such standards, including with respect to already approved products. If our products are not able to meet these standards, we may be required to discontinue marketing and/or recall such products from the market.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes or developments in regulatory and quality standards and guidelines set forth by FDA, such as criteria for residual solvents, periodic guidance from the FDA regarding testing for impurities, such as nitrosamines, in our products, and updated U.S. Pharmacopeial Convention (&#8220;USP&#8221;) Reference Standards may impact our ability to sell certain drug products. The USP is a scientific nonprofit organization that sets standards for the identity, strength, quality, and purity of medicines, food ingredients, and dietary supplements manufactured, distributed, and consumed worldwide. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical products approved prior to the implementation of new or revised quality standards, including those produced or sold by us, may not meet these standards, which could require us to discontinue marketing and/or recall such products from the market, either of which could adversely affect our business, financial position, and operating results. In addition, results of periodic testing we conduct on our products may indicate the presence of substances at levels greater than those deemed acceptable under FDA or other standards, which could potentially require a recall of the product. For example, during the fourth quarter of 2019, testing of the API used in our ranitidine drug product, as well as testing of the drug product itself, indicated a level of a nitrosamine impurity called N-nitrosdimethylamine (&#8220;NDMA&#8221;) above acceptable thresholds. NDMA is classified as a probable human carcinogen. Appco Pharma, LLC, with whom we had partnered to develop and market the product, initiated a voluntary recall, and we elected to exit the market for Ranitidine in 2019. For a description of legal proceedings which are currently pending relating to ranitidine, see Note 15. Commitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December of 2021, the FDA issued an information request to all manufacturers of propranolol products, including Inderal LA (Propranolol ER) currently being marketed by ANI in the United States to evaluate their product for the presence and level of a nitrosamine impurity known as N-nitroso-propranolol (&#8220;NNP&#8221;), which is distinct from NDMA. We undertook a review and analysis of NNP, working with testing and toxicology experts, and communicated with the FDA on the scientific bases for establishing appropriate acceptable daily intake for NNP and the appropriate approach for propranolol products in the U.S. On August 4, 2023, the FDA issued final guidance on acceptable intake limits for nitrosamine drug substance-related impurities (NDSRIs), with recommended limits for propranolol products of 1500 mg/day. Based on this guidance, we were able to continue sales of the product to our customers. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to federal and state false claims litigation brought by private individuals and the government.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to state and federal laws that govern the submission of claims for reimbursement. The Federal False Claims Act (&#8220;FFCA&#8221;), also known as Qui Tam, imposes civil liability and criminal fines on individuals or entities that knowingly submit, or cause to be submitted, false or fraudulent claims for payment to the government. Violations of the FFCA and other similar laws may result in criminal fines, imprisonment, and civil penalties for each false claim submitted and exclusion from federally funded health care programs, including Medicare and Medicaid. The FFCA also allows private individuals to bring a suit on behalf of the government against an individual or entity for violations of the FFCA. These suits, also known as Qui Tam actions, may be brought, with only a few exceptions, by any private citizen who has material information of a false claim that has not yet been previously disclosed. These suits have increased significantly in recent years because the FFCA allows an individual to share in any amounts paid to the federal government from a successful Qui Tam action. If our past or present operations are found to be in violation of any of such laws or other applicable governmental regulations, we may be subject to civil and criminal penalties, damages, fines, exclusion from federal health care programs, and/or the curtailment or restructuring of our operations, any of which could materially adversely affect our business, financial position, and operating results. Actions brought against ANI for violations of these laws, even if successfully defended, could also have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The use of legal, regulatory, and legislative strategies by competitors, both branded and generic, including "authorized generics," citizen&#8217;s petitions, and legislative proposals, may increase the costs to develop and market our generic products, could delay or prevent new product introductions, and could significantly reduce our profit potential. These factors could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors, both branded and generic, often pursue legal, regulatory, and/or legislative strategies to prevent or delay competition from generic alternatives to branded products. These strategies include, but are not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entering into agreements whereby other generic companies will begin to market an authorized generic, a generic equivalent of a branded product, at the same time generic competition initially enters the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">launching a generic version of their own branded product at the same time generic competition initially enters the market;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">filing citizen petitions with the FDA or other regulatory bodies, including timing the filings so as to thwart generic competition by causing delays of generic product approvals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking to establish regulatory and legal obstacles that would make it more difficult to demonstrate bioequivalence or meet other approval requirements;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiating legislative and regulatory efforts to limit the substitution of generic versions of branded pharmaceuticals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">filing suits for patent infringement that may delay regulatory approval of generic products;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introducing "next-generation" products prior to the expiration of market exclusivity for the reference product, which often materially reduces the demand for the first generic product;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining extensions of market exclusivity by conducting clinical trials of branded drugs in pediatric populations or by other potential methods;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">persuading regulatory bodies to withdraw the approval of branded name drugs for which the patents are about to expire, thus allowing the branded company to obtain new patented products serving as substitutes for the products withdrawn; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seeking to obtain new patents on drugs for which patent protection is about to expire.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot compete with such strategies, our business, financial position, and operating results could be adversely impacted.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party payers deny coverage, substitute another company&#8217;s product for our product, or offer inadequate levels of reimbursement, we may not be able to market our products effectively or we may be required to offer our products at prices lower than anticipated.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payers are increasingly challenging the prices charged for medical products and services. For example, third-party payers may deny coverage, choose to provide coverage for a competitor&#8217;s bioequivalent product rather than our product, or offer limited reimbursement if they determine that a prescribed product has not received appropriate clearances from the FDA, is not used in accordance with cost-effective treatment methods as determined by the third-party payer, or is experimental, unnecessary, or inappropriate. Prices also could be driven down by health maintenance organizations that control or significantly influence purchases of healthcare services and products. If third-party payers deny coverage or limit reimbursement, we may not be able to market our products effectively or we may be required to offer our products at prices lower than anticipated.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to federal, state, and local laws and regulations, and complying with these may cause us to incur significant additional costs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pharmaceutical industry is subject to regulation by various federal authorities, including the FDA, the DEA, and state governmental authorities. Federal and state statutes and regulations govern or influence the testing, manufacturing, packing, labeling, storing, record keeping, safety, approval, advertising, promotion, sale, and distribution of our products. Noncompliance with applicable legal and regulatory requirements can have a broad range of consequences, including warning letters, fines, seizure of products, product recalls, total or partial suspension of production and distribution, refusal to approve NDAs or other applications or revocation of approvals previously granted, withdrawal of product from marketing, injunctions, withdrawal of licenses or registrations necessary to conduct business, disqualification from supply contracts with the government, civil penalties, debarment, and criminal prosecution.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All U.S. facilities where prescription drugs are manufactured, tested, packaged, stored, or distributed must comply with FDA current good manufacturing practices (&#8220;cGMPs&#8221;). All of our products are manufactured, tested, packaged, stored, and distributed according to cGMP regulations. The FDA performs periodic audits to ensure that our facilities remain in compliance with all applicable regulations. If it finds violations of cGMP, the FDA could make its concerns public and could impose sanctions including, among others, fines, product recalls, total or partial suspension of production and/or distribution, suspension of the FDA&#8217;s review of product applications, injunctions, and civil or criminal prosecution. If imposed, enforcement actions could have a material adverse effect on our business, financial position, and operating results. Under certain circumstances, the FDA also has the authority to revoke previously granted drug approvals. Although we have internal compliance programs in place that we believe are adequate, the FDA may conclude that these programs do not meet regulatory standards. If compliance is deemed deficient in any significant way, it could have a material adverse effect on our business.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government has enacted the Federal Drug Supply Chain Security Act ("DSCSA") that requires development of an electronic pedigree to track and trace each prescription drug at the salable unit level through the distribution system, which will be effective incrementally over a 10-year period. All prescription pharmaceutical products distributed in the U.S. must be serialized with unique product identifiers. ANI started manufacturing serialization-compliant products in November 2018. The DSCSA establishes national traceability standards requiring drugs to be labeled and tracked at the bottle level, preempts state drug pedigree requirements, and requires all supply-chain stakeholders to participate in an electronic, interoperable prescription drug traceability system by November 2023. In August 2023, however, the FDA established a one-year stabilization period to allow trading partners to implement, troubleshoot and mature their electronic interoperable systems. The FDA expects trading partners to use this stabilization period, which expires on November 27, 2024, to build and validate interoperable systems and processes, manage products and data, and ensure continuity of the supply chain and product availability to patients. Additionally, certain of our largest customer are requiring earlier compliance with the DSCSA, despite the stabilization period enacted by the FDA. Compliance with DSCSA and future U.S. federal or state electronic pedigree requirements may increase the Company&#8217;s operational expenses and impose significant administrative burdens. In addition, if we are unable to comply with DSCSA as of the required dates, we could face penalties or be unable to sell our products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, product development, and manufacturing activities involve the controlled use of hazardous materials, and we may incur significant costs in complying with numerous laws and regulations. We are subject to laws and regulations enforced by the FDA, the DEA, and other regulatory statutes including the Occupational Safety and Health Act (&#8220;OSHA&#8221;), the Environmental Protection Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, and other current and potential federal, state, local, and foreign laws and regulations governing the use, manufacture, storage, handling, and disposal of our products, materials used to develop and manufacture such products, and resulting waste products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot completely eliminate the risk of contamination or injury, by accident or as the result of intentional acts, from these materials. In the event of an accident, we could be held liable for any damages that result, and any resulting liability could exceed our resources. We may also incur significant costs in complying with environmental laws and regulations in the future. We are also subject to laws generally applicable to businesses, including but not limited to, federal, state, and local regulations relating to wage and hour matters, employee classification, mandatory healthcare benefits, unlawful workplace discrimination, and whistle-blowing. Any actual or alleged failure to comply with any regulation applicable to our business or any whistle-blowing claim, even if without merit, could result in costly litigation, regulatory action or otherwise harm our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations in an international market subject us to additional regulatory oversight both in the international market and in the U.S., as well as, social, and political uncertainties, which could cause a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks associated with having assets and operations located in a foreign jurisdiction, including our operations in India. Our operations in India may be adversely affected by general economic conditions and economic and fiscal policy, including changes in exchange rates and controls, interest rates and taxation policies, and increased government regulation, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, involvement in a war or other military action or international acts of terrorism may cause significant disruption to commerce throughout the world. To the extent that such disruptions result in (i) delays or cancellations of customer orders, (ii) a general decrease in consumer spending on healthcare technology, (iii) our inability to effectively market and distribute our products internationally (iv) our inability to timely engage with and collect payment from our customers or (v) our inability to access capital markets, our business and results of operations could be materially and adversely affected. For example, in response to the continued conflict between Russia and Ukraine, the United States has imposed and may further impose, and other countries may additionally impose, broad sanctions or other restrictive actions against governmental and other entities in Russia. Additionally, further escalation of geopolitical tensions, such as the conflict in Israel and Gaza and the surrounding areas, and conflicts related to the attacks on cargo ships in the Red Sea, could have a broader impact that extends into other markets where we do business. We are unable to predict whether acts of international terrorism or the involvement in a war or other military actions by the United States and/or the countries in which we sell or distribute our products will result in any long-term commercial disruptions or if such involvement or responses will have any long-term material adverse effect on our business, results of operations, or financial condition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Continuing studies of our products could produce negative results, which could require us to implement risk management programs, or discontinue product marketing. In addition, ongoing post-approval drug safety surveillance of our products could result in the submission of adverse event reports to the FDA.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Studies of the proper utilization, safety, and efficacy of pharmaceutical products are being conducted by the industry, government agencies, and others on a continuous basis. Such studies, which increasingly employ sophisticated methods and techniques, can call into question the utilization, safety, and efficacy of current and previously marketed products, including those that we produce. In addition, we are required by the FDA to submit reports of adverse events involving the use of our products. In some cases, studies and safety surveillance programs have resulted, and in the future may result, in the one or more of the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product label changes including FDA-mandated Black Box warnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk management programs such as patient registries;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced product sales due to concerns among patients and physicians; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">discontinuance of product marketing.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These situations, should they occur with respect to any of our products, could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform and changes in pharmaceutical pricing, reimbursement and coverage, by governmental authorities and third-party payors may materially affect our business, financial position and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, there have been numerous initiatives on the federal and state levels for comprehensive reforms affecting the payment for, the availability of, and reimbursement for healthcare services in the U.S. generally and prescription drug coverage, reimbursement and pricing specifically, and it is likely that federal and state legislatures will continue to advocate change to the healthcare system generally and to prescription drug coverage, reimbursement and pricing specifically.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the federal level, the American Rescue Plan Act eliminated the cap on Medicaid Drug Rebate Program rebates beginning January 1, 2024. As such, we could end up owing additional rebates to state Medicaid programs related to utilization of our drug products negatively impacting profitability. States continue to look for ways to save on Medicaid spend specifically related to prescription drugs. As such, states are increasingly expanding or change supplemental rebates programs to secure additional rebates from manufacturers in exchange for drug coverage and to limit coverage of certain drugs for certain Medicaid patients or to all Medicaid patients. To the extent the Centers for Medicare &amp; Medicaid Services entertains waivers to federal requirements under the Medicaid program to allow states Medicaid programs such flexibility, coverage of and payment for our drugs utilized by Medicaid beneficiaries could be negatively impacted. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Passage of the Inflation Reduction Act ("IRA")  has brought sweeping change to Medicare coverage of and reimbursement for prescription drugs. Most notably, CMS is able to directly negotiate the reimbursement for certain prescription drugs reimbursed under Medicare Part D or B to be effective for the 2026 plan year. If a manufacturer&#8217;s drug is selected for negotiation, the manufacturer must negotiate a Maximum Fair Price with CMS or be liable for an excise tax of 65 to 95 percent of Medicare utilization based on the prior year. While no ANI drugs have currently been selected for negotiation, ANI continues to evaluate the implications of direct negotiation on its products in the future and potential repercussions of competitive products being selected for direct negotiation. In addition, as previously noted, there are numerous legal challenges to the direct negotiation provisions of the IRA. If any of those challenges are successful, this could change the current competitive landscape for manufacturers generally and may change the dynamics of the Medicare Part D marketplace potentially resulting in increased premiums, fewer Part D plans and sponsors and increased pressure on manufacturers to offer formulary placement rebates and additional price concessions. In addition, under the IRA the Part D benefit design with be altered and the coverage gap discount program replaced by a new manufacturer discount program  pursuant to which manufacturers will provide a 10 percent discount off the negotiated price for applicable drugs (branded drugs and biologics manufactured by companies that have Part D discount agreements) after the deductible is satisfied through the catastrophic phase of the benefit. In the catastrophic phase, manufacturers will provide a 20 percent discount off negotiated price. Any pharmaceutical product marketed under an NDA, regardless of whether the product is marketed as a &#8220;generic,&#8221; is subject to the manufacturer discount requirement. This could increase discounts due on Medicare Part D utilization of our drug products.  Lastly, the IRA imposed additional rebates on manufacturers including ANI to the extent certain drug pricing metrics are rising faster than inflation. These new inflation rebates are similar to those imposed on manufacturers under Medicaid and could result in additional rebates due from us on Medicare utilization of our products</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain U.S. states have implemented statutes aimed at prescription drug price transparency and some of those laws would permit state run boards or agencies to cap reimbursement for certain prescription drugs in the states. Such laws could negatively impact our financial performance and could result in us terminating distribution of certain products in certain states or regions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflationary pressures are currently being experienced and may continue to exist in the U.S. and key worldwide mark</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ets. The rate of inflation may significantly increase input costs for our products and, given the competitive nature of the generic and rare disease markets in which we compete, we may not be able to pass those costs on to our customers.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Accounting, Tax, and SEC Rules and Regulations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have increased exposure to tax liabilities, including foreign tax liabilities.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to, or potentially subject to, income taxes as well as non-income based taxes in various U.S. jurisdictions, Canada, and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> India. Significant judgment is required in determining our international provision for income taxes and other tax liabilities. Changes in tax laws or tax rulings may have a significantly adverse impact on our effective tax rate. In addition, we have potential tax exposures resulting from the varying application of statutes, regulations, and interpretations, which include exposures on intercompany terms of cross-border arrangements between our U.S. operations and our Indian subsidiary in relation to various aspects of our business, including research and development services, tech transfers, and contract manufacturing. Tax authorities in various jurisdictions may disagree with, and subsequently challenge, the amount of profits taxed in such jurisdictions; such challenges may result in increased tax liability, including accrued interest and penalties, which would cause our tax expense to increase and which could have a material adverse effect on our business, financial position and results of operations and our ability to satisfy our debt obligations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations in an international market subject us to additional regulatory oversight both in the international market and in the U.S., as well as, social, and political uncertainties, which could cause a material adverse effect on our business, financial position, and operating results.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to certain risks associated with having assets and operations located in a foreign jurisdiction, including our operations in India. Our operations in India may be adversely affected by general economic conditions and economic and fiscal policy, including changes in exchange rates and controls, interest rates and taxation policies, and increased government regulation, which could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, involvement in a war or other military action or international acts of terrorism may cause significant disruption to commerce throughout the world. To the extent that such disruptions result in (i) delays or cancellations of customer orders, (ii) a general decrease in consumer spending on healthcare technology, (iii) our inability to effectively market and distribute our products internationally (iv) our inability to timely engage with and collect payment from our customers or (v) our inability to access capital markets, our business and results of operations could be materially and adversely affected. For example, in response to the continued conflict between Russia and Ukraine, the United States has imposed and may further impose, and other countries may additionally impose, broad sanctions or other restrictive actions against governmental and other entities in Russia. Additionally, further escalation of geopolitical tensions, such as the conflict in Israel and Gaza and the surrounding areas, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and conflicts related to the attacks on cargo ships in the Red Sea, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">could have a broader impact that extends into other markets where we do business. We are unable to predict whether acts of international terrorism or the involvement in a war or other military actions by the United States and/or the countries in which we sell or distribute our products will result in any long-term commercial disruptions or if such involvement or responses will have any long-term material adverse effect on our business, results of operations, or financial condition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our expanded international operations from the Novitium acquisition increased our exposure to potential liability under anti-corruption, trade protection, tax, and other laws and regulations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Foreign Corrupt Practices Act and other anti-corruption laws and regulations (&#8220;Anti-Corruption Laws&#8221;) prohibit corrupt payments by our employees, vendors, or agents. From time to time, we receive inquiries from authorities in the U.S. and elsewhere about our business activities outside of the U.S. and our compliance with Anti-Corruption Laws. While we devote substantial resources to our  compliance programs and have implemented policies, training, and internal controls designed to reduce the risk of corrupt payments, our employees, vendors or agents may violate our policies and with the acquisition of Novitium, our expanded international operations would significantly increase our exposure to potential liability. Our failure to comply with Anti-Corruption Laws could result in significant fines and penalties, criminal sanctions against us, our officers or our employees, prohibitions on the conduct of our business, and damage to our reputation. Operations outside of the U.S. may be affected by changes in trade production laws, policies, and measures, and other regulatory requirements affecting trade and investment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Indian foreign tax regulations. Such regulations may not be clear, not consistently applied and subject to sudden change, particularly with regard to international transfer pricing. Our earnings could be reduced by changes to such tax regulations or changing interpretation of such tax regulations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The international nature of Novitium&#8217;s operations (including those of its Indian subsidiary Novitium Labs Private Limited) will subject us to political and economic risks that could adversely affect our business, results of operations, or financial condition.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks presented by international operations include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on ownership or participation in local enterprises;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price controls, exchange controls, and limitations on repatriation of earnings;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">transportation delays and interruptions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the application of additional legal, regulatory and taxation regimes to our operations;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political, social, and economic instability and disruptions in applicable regions, including as a result of war, such as the conflict between Russia and the Ukraine, the conflict between Israel and Gaza, and conflicts related to the attacks on cargo ships in the Red Sea;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acts of terrorism;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government embargoes or foreign trade restrictions;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of duties and tariffs and other trade barriers;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">import and export controls;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">labor unrest and current and changing regulatory environments;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign current exchange and interest rates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing multi-national operations; </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations on our ability to enforce legal rights and remedies. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully manage these and other risks associated with managing the expansion of our business to the jurisdictions in which Novitium operates, including India, the risks could have a material adverse effect on our business, results of operations, or financial condition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with applicable transfer pricing and similar regulations could have a material adverse effect on our financial position and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to complex transfer pricing and other tax regulations in the United States and India designed to ensure that appropriate levels of income are reported as earned and are taxed in the appropriate taxing jurisdictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that we are in substantial compliance with all applicable regulations and restrictions, we are subject to the risk that governmental authorities could audit our transfer pricing and related practices and assert that additional taxes are owed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event that such audits or assessments are concluded adversely against us, we may or may not be able to offset or mitigate the consolidated effect of any such assessments.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in estimates regarding the fair value of goodwill or intangible assets may result in an adverse impact to our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We test goodwill for impairment annually, or more frequently if changes in circumstances indicate that the carrying amount of goodwill might not be recoverable. Judgment is used in determining when these events and circumstances arise. We perform our annual assessment of goodwill based on our two reporting units. If we determine that the carrying value of our assets may not be recoverable, we assess, using judgment and estimates, the fair value of our assets and to determine the amount of any impairment loss, if any. Changes in judgments and estimates may result in the recognition of an impairment loss, which could have a material negative impact on our business, financial position, and operating results. While our testing in fiscal 2023 did not result in an impairment charge related to goodwill, there can be no assurances that our goodwill will not be impaired in the future.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our material definite-lived intangible assets consist of ANDAs for previously marketed generic products, NDAs and product rights for our branded products, product rights related to certain generic products, and a non-compete agreement. These assets are being amortized over their useful lives of seven to 10 years. For these definite-lived intangible assets, we perform an impairment analysis when events or circumstances indicate that the carrying value of the assets may not be recoverable. An impairment loss is recognized if, based on our impairment analysis, the carrying amount of the asset is not recoverable and its carrying amount exceeds its fair value. Any significant change in market conditions, estimates or judgments used to determine expected future cash flows that indicate a reduction in carrying value may give rise to impairment in the period that the change becomes known. An impairment charge could have a material negative impact on our business, financial position, and operating results. No impairment losses were recognized in the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our management is required to devote substantial time to comply with public company regulations. If we are unable to comply with these regulations, investors could lose confidence in us, which could have a material adverse effect on our stock price, business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are required to comply with significant legal, accounting, and other requirements, and as a result, we incur significant regulatory compliance-related expenses. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act as well as rules implemented by the SEC and The Nasdaq Stock Market, impose various requirements on public companies, including those related to corporate governance practices. Our management and other personnel devote a substantial amount of time to these requirements. Some members of management do not have significant experience in addressing these requirements. Moreover, these rules and regulations have increased our legal and financial compliance costs relative to those of previous years and make some activities more time consuming and costly.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Sarbanes-Oxley Act requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluation and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. The Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) provides a framework for companies to assess and improve their internal control systems. Our compliance with these requirements has required that we incur substantial accounting and related expenses and expend significant management efforts. Moreover, if we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, are unable to assert that our internal controls over financial reporting are effective, or identify deficiencies that are deemed to be material weaknesses, investors could lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline and we could be subject to sanctions or investigations by The Nasdaq Stock Market, the SEC, or other regulatory authorities, which would require additional financial and management resources and could damage our reputation. Further, if we identify any material weaknesses or deficiencies that aggregate to a material weakness in our internal controls, we will have to implement appropriate changes to these controls, which may require specific compliance training for our directors, officers and employees, require the hiring of additional finance, accounting, legal and other personnel, entail substantial costs to modify our existing accounting systems and take a significant period of time to complete. Such changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a timely basis, could increase our operating costs and could materially impair our ability to operate our business. Any of these events could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We previously identified material weaknesses in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls, any of which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we identified material weaknesses related to ineffective control environment at our Novitium subsidiary, subsequent to the acquisition of Novitium in November 2021, and information technology general controls (&#8220;ITGCs&#8221;) in the areas of user access over certain information technology systems that support our financial reporting processes. These material weaknesses continued into 2023 and were fully remediated as of December 31, 2023. For a detailed summary of these material weaknesses, including our remediation steps, please refer to Item 9A. - Controls and Procedures. As of December 31, 2023 management has concluded that the Company&#8217;s internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain effective internal control over financial reporting or disclosure controls and procedures, our ability to record, process, and report financial information accurately and to prepare financial statements within required time periods could be adversely affected, which could subject us to litigation, investigations, or penalties; negatively affect our liquidity, our access to capital markets, perceptions of our creditworthiness, our ability to complete acquisitions, our ability to maintain compliance with covenants under our debt instruments or derivative arrangements regarding the timely filing of periodic reports, or investor confidence in our financial reporting, any of which may divert management resources or cause our stock price to decline. Further, remediation of a material weakness does not provide assurance that our remediation or other controls will continue to operate properly or remain adequate.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our policies regarding returns, allowances and chargebacks, and marketing programs adopted by wholesalers may reduce revenues in future fiscal periods.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, like other generic drug manufacturers, have agreements with customers allowing chargebacks, product returns, administrative fees, and other rebates. Under many of these arrangements, we may match lower prices offered to customers by competitors. If we choose to lower our prices, we generally give the customer a credit on the products that the customer is holding in inventory, which could reduce sales revenue for the period the credit is provided. Like our competitors, we also give credits for chargebacks to wholesalers with whom we have contracts for their sales to hospitals, group purchasing organizations, pharmacies, or other customers. A chargeback is the difference between the price at which we invoice the wholesaler and the price that the wholesaler&#8217;s end-customer pays for a product. Although we establish reserves based on prior experience and our best estimates of the impact that these policies may have in subsequent periods, we cannot ensure that our reserves are adequate or that actual product returns, allowances, and chargebacks will not exceed our estimates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Debt</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Making interest and principal payments under our Credit Facility consisting of $300.0 million term loan and a $40.0 million revolving credit facility, requires a significant amount of cash.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the completion of the Novitium acquisition, we entered into a $300.0 million term loan and a $40.0 million revolving credit facility. The Credit Facility, which is secured by all our assets and the assets of our subsidiaries, was used to finance the cash consideration of the acquisition of Novitium and terminate and repay our previous senior credit facilities. In order to service the debt we incur under this facility, we will require a significant amount of cash. Our ability to make scheduled payments of principal and interest depends on our future performance, which is subject to economic, financial, competitive, and other factors beyond our control. Our business may not continue to generate cash flow from operations in the future sufficient to service our debt. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt, or obtaining additional debt or equity financing on terms that may not be favorable to us or available to us at all. Our ability to refinance any such debt will depend on the capital markets and our financial condition at that time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default under our current or future indebtedness. Any event of default or inability to otherwise satisfy our obligations could have a material adverse effect on our future operating results and financial condition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Credit Agreement contains restrictive and financial covenants and if we are not in compliance with these covenants, our outstanding indebtedness under this facility could be accelerated and the lenders could terminate their commitments under the facility.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary covenants that require maintenance of a leverage ratio at or below specified thresholds and restricts our ability to make certain distributions with respect to our capital stock, prepay other debt, make certain investments, encumber our assets, incur additional indebtedness, make capital expenditures, engage in certain business combinations, transfer, lease or dispose of our assets, alter the character of our business in any material respect or undertake various other corporate activities. Therefore, as a practical matter, these covenants restrict our ability to engage in or benefit from such activities. In addition, we pledged our assets in order to secure our repayment obligations under the Credit Agreement. This pledge may reduce our operating flexibility because it restricts our ability to dispose of our assets or engage in other transactions that may be beneficial to us.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to comply with the covenants in the Credit Agreement, we will be in default, which could result in the acceleration of our outstanding indebtedness and termination of funding commitments by the lenders. If such an acceleration occurs, we may not be able to repay our debt and we may not be able to borrow sufficient additional funds to refinance our debt, which would have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in the method of determining London Interbank Offered Rate ("LIBOR"), or the replacement of LIBOR with an alternative reference rate, such as SOFR, may adversely affect interest expense related to outstanding debt.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2023, we amended our Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement. SOFR will be applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and will replace all LIBOR terms. We have no other material financing agreements that use LIBOR as an interest index. There is no guarantee that the transition from LIBOR to SOFR will not result in financial market disruptions, significant increases in benchmark rates, or borrowing costs to borrowers. While we will continue to use SOFR, certain factors may impact SOFR, including factors causing SOFR to cease to exist, new methods of calculating SOFR to be established, or the use of alternative reference rates. These consequences are not entirely predictable and could have an adverse impact on our financing costs and our results of operations. As such, the future of SOFR at this time remains uncertain. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to our Common</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Stock</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders, directors, and executive officers own a significant percentage of our stock and will be able to exercise meaningful influence over our business.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current principal stockholders, directors, and executive officers beneficially own approximately 13% of our outstanding capital stock entitled to vote as of December&#160;31, 2023. As a result, these stockholders, if acting together, would be able to influence or control matters requiring approval by our stockholders, including the election of directors and the approval of mergers, acquisitions, or other extraordinary transactions. They may also have interests that differ from stockholders generally and may vote in a way with which other stockholders disagree and which may be adverse to their interests. This concentration of ownership may have the effect of delaying, preventing, or deterring a change of control of ANI, could deprive stockholders of an opportunity to receive a premium for their common stock as part of a sale of ANI, and might ultimately affect the market price of our common stock.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds by issuing additional equity securities may cause dilution to our current stockholders. Raising additional funds by entering into additional credit or other borrowing facilities or issuing debt may subject us to covenants and other requirements that may restrict our operations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to raise additional funds through the issuance of equity or equity-linked securities. If we were to raise funds through the issuance of equity or equity-linked securities, the percentage ownership of our stockholders could be diluted, potentially significantly, and these newly issued securities may have rights, preferences, or privileges senior to those of our existing stockholders. In addition, the issuance of any equity securities could be at a discount to the then-prevailing market price of our common stock. </span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we require new debt financing, there is no assurance that such a transaction will be available on terms acceptable to us, or at all. In addition, we could be subject to onerous repayment terms or covenants that restrict our ability to operate our business and make distributions to our stockholders. These restrictive covenants may include limitations on additional borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends, redeem our stock, or make investments. We can offer no assurance that any equity or debt financing transaction will be available on terms acceptable to us, or at all.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and Delaware law could discourage or prevent a takeover, even if such a transaction would be beneficial to our stockholders.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire ANI, even if doing so would be beneficial to our stockholders. These provisions include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing the issuance of &#8220;blank check&#8221; preferred shares that could be issued by our board of directors to increase the number of outstanding shares and thwart a takeover attempt;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibiting cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice provisions and information submission requirements in connection with stockholder proposals and director nominations that may prevent or hinder any attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">as a Delaware corporation, we are also subject to provisions of Delaware law, including Section 203 of the Delaware General Corporation law, which prevents certain stockholders holding more than 15% of our outstanding common stock from engaging in certain business combinations without approval of the holders of at least two-thirds of our outstanding common stock not held by such 15% or greater stockholder.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our certificate of incorporation and bylaws or Delaware law that has the effect of delaying, preventing, or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use a variety of estimates, judgments, and assumptions in preparing our consolidated financial statements. Estimates, judgments, and assumptions are inherently subject to change, and any such changes could result in corresponding changes to the amounts of assets, liabilities, revenues, expenses, and income. Any such changes could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) requires us to make estimates, judgments, and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the period. There are inherent uncertainties involved in estimates, judgments and assumptions, and any changes in estimates, judgments and assumptions used could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the consolidated financial statements included in the periodic reports filed with the SEC, estimates, judgments, and assumptions are used for, but not limited to, revenue recognition, allowance for credit losses, accruals for chargebacks, rebates, returns and other allowances, allowance for inventory obsolescence, stock-based compensation, valuation of financial instruments and intangible assets, allowances for contingencies and litigation, deferred tax assets and liabilities, deferred tax valuation allowance, contingent consideration, and the depreciable lives of fixed and intangible assets. Actual results could differ from those estimates. Estimates, judgments, and assumptions are inherently subject to change in the future, and any such changes could result in corresponding changes to the amounts of assets, liabilities, revenues, expenses, and income. Any such changes could have a material adverse effect on our business, financial position, and operating results.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock has been volatile, and an investment in our common stock could decline in value.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock has increased and decreased significantly and is likely to continue to fluctuate in the future. From time to time, the securities of small capitalization pharmaceutical companies, including ANI, experience significant market price fluctuations, often unrelated to these companies&#8217; operating performance. In particular, the market price of our common stock may fluctuate significantly due to a variety of factors, including, but not limited to, regulatory or legal developments with respect to our industry, variations in our financial results or those of companies that are perceived to be similar to us, and rumors or new announcements by third parties, many of which are beyond our control and that may not be related to our operating performance.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the occurrence of any of the risks described in this report or in subsequent reports we file with the SEC could have a material adverse impact on the market price of our common stock. Securities class action litigation is sometimes brought against a company following periods of volatility in the market price of its securities or for other reasons. Securities litigation, whether with or without merit, could result in substantial costs and divert management&#8217;s attention and resources, which could harm our business, financial position, and operating results, as well as the market price of our common stock.</span></div><div id="i4bc95b424f3d46babd419bb800693000_22"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4bc95b424f3d46babd419bb800693000_1099511628359"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk management and strategy</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a comprehensive process for identifying, assessing and managing material risks arising from cybersecurity threats, and have integrated these into our overall risk management processes. Our senior leadership team, along with representatives from our information technology, legal, human resources and finance departments, are responsible for developing the Company&#8217;s overall risk management program and are also responsible for executing our cybersecurity policies. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are establishing a formal written information security policy and incident response policy which outlines the methods for assessing, identifying, and managing risks related to the Company. We&#8217;ve developed a robust cybersecurity program which includes multiple security layers. We understand the importance of a strong cybersecurity framework and have hired external security consultants to assess, audit, and monitor its security controls and events. We also ensure that third-party service providers have the ability to implement and maintain appropriate security measures in connection with their work with us, and to promptly report any suspected breach of its security measures that may affect our company. In addition, we maintain a cybersecurity insurance policy. Our business strategy, results of operations and financial condition have not been materially affected by risks from cybersecurity threats.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors, with delegation to the audit committee, as appropriate, retains oversight of the Company&#8217;s cybersecurity risks. The senior leadership team provides periodic reports to our board of directors, as well as the Chief Executive Officer and audit committee as necessary. In addition, we have contracted with certified security experts that act as an extension of the internal information technology team for all security related items. These communications include potential risks facing the Company, assessments and evaluations of our cybersecurity environment, results of internal controls testing, and reports on our on-going initiatives to strengthen our cybersecurity framework. </span></div><div id="i4bc95b424f3d46babd419bb800693000_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate offices are located at 210 Main Street West, Baudette, Minnesota 56623. The facility, which we own, includes oral solid dose, powder and liquid manufacturing and packaging, warehouse facilities, analytical, stability, and microbiological laboratory space, and employee office and mechanical space. We own a manufacturing facility that includes oral solid dose manufacturing and packaging for pharmaceutical products that must be manufactured in a fully contained environment, warehouse facilities, and employee office and mechanical space, also located in Baudette, Minnesota. We own a cold storage facility located in Baudette, Minnesota. In addition, we own a facility in East Windsor, New Jersey, which includes manufacturing, warehousing, laboratory, product development, and employee office space, which was acquired as part of the acquisition of Novitium in November 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ceased operations at our subsidiary, ANI Pharmaceuticals Canada, Inc., a wholly owned subsidiary of the Company located in Oakville, Ontario, Canada as of March 31, 2023. This action is part of ongoing initiatives to capture operational synergies following our acquisition of Novitium. We have fully completed the transition of the products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., entered into an agreement for the sale of the Oakville, Ontario manufacturing facility. On December 22, 2023, the agreement was terminated by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of <ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-37">19.2</ix:nonFraction> million Canadian Dollars, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-38">14.2</ix:nonFraction> million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">see Note 19. Subsequent Events, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">port on Form 10-K). </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease spaces for warehouse and packaging activities in East Windsor, New Jersey, and for research and development activities in Chennai, India. In September 2022, we entered into a lease for office space in Princeton, New Jersey, which includes certain employees in our corporate, legal, human resources, business functions, and rare disease operations. The leases will expire between 2025 and 2028. During 2023, we have expanded our East Windsor, New Jersey facility to accommodate additional laboratory, product development, and employee office space.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider our leased and owned properties suitable and adequate for our current and foreseeable needs.</span></div><div id="i4bc95b424f3d46babd419bb800693000_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our legal proceedings are dis</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cussed in Note 15. Com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K.</span></div><div id="i4bc95b424f3d46babd419bb800693000_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i4bc95b424f3d46babd419bb800693000_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Market under the symbol &#8220;ANIP.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholder Information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;22, 2024, there were approximatel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y 264 shar</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eholders of record of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our common stock, which does not include stockholders that beneficially own shares held in a &#8220;nominee&#8221; or in &#8220;street&#8221; name, and six holders of record of Class C stock.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We do not anticipate paying any cash dividends on our common stock in the foreseeable future. Our shares of Series A convertible preferred stock (the &#8220;PIPE Shares&#8221;), accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to our common stock. To date, we have paid all preferred stock dividends in cash. We currently intend to retain all remaining available funds and any future earnings to fund the development and growth of our business. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average Price<br/>Paid per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total Number of<br/>Shares Purchased as<br/>Part of Publicly<br/>Announced Plans or <br/>Programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum Number (or<br/>approximate dollar<br/>value) of Shares<br/>&#160;that may yet be<br/>Purchased Under the<br/>Plans or Programs</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October 1 - October 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November 1 - November 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,528</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 1 - December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,865</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,393</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52.56&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:2.94pt">Shares purchased during the period were transferred to the Company from employees in satisfaction of minimum tax withholding obligations associated with the vesting of restricted stock awards during the period.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below compares the five-year cumulative total stockholder return on our common stock, the Nasdaq Stock Market (US) Index, and the S&amp;P 600 Pharmaceuticals, Biotechnology &amp; Life Sciences Index, assuming the investment of $100.00 on December 31, 2018, with dividends being reinvested. The stock price performance in the graph below is not necessarily indicative of future price performance.</span></div><div style="margin-top:12pt;text-indent:18pt"><img src="anip-20231231_g1.jpg" alt="Graph in JPEG.jpg" style="height:338px;margin-bottom:5pt;vertical-align:text-bottom;width:636px"/></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Reserved</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Please read the following discussion in conjunction with Item 1A. (&#8220;Risk Factors&#8221;) and our audited consolidated financial statements included elsewhere in this Annual Report on Form 10-K. Some of the statements in the following discussion are forward-looking statements. See the discussion about forward-looking statements on page 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This section of this Form 10-K generally discusses 2023 and 2022 items and year-to-year comparisons between 2023 and 2022. Discussions of 2021 items and year-to-year comparisons between 2022 and 2021 that are not included in this Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of the</span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">, filed with the SEC on March </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1023024/000102302423000005/anip-20221231x10k.htm">2023</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div id="i4bc95b424f3d46babd419bb800693000_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Overview</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, &#8220;ANI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. We own and operate three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. We ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium Pharma LLC (&#8220;Novitium&#8221;) in November 2021. We have fully completed the transition of the products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with a potential buyer for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of <ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-39">19.2</ix:nonFraction> million Canadian Dollars, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-40">14.2</ix:nonFraction> million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">see Note 19. Subsequent Events, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">port on Form 10-K). </span></div><div id="i4bc95b424f3d46babd419bb800693000_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to build a sustainable and growing biopharmaceutical company serving patients in need and creating long-term value for our investors. Our growth strategy is driven by the following key growth drivers:</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Building a successful Rare Disease platform</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have spent significant time, effort and resources in establishing our Rare Disease platform. We acquired the NDAs for Cortrophin Gel and Cortrophin-Zinc in January 2016 and executed long-term supply agreements with a supplier of our primary raw material for corticotrophin API, a supplier of corticotrophin API with whom we have advanced the manufacture of commercial scale batches of API, and a Cortrophin Gel fill/finish contract manufacturer. During the second quarter of 2021, we submitted a Supplemental New Drug Application (&#8220;sNDA&#8221;) to the FDA.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 29, 2021, the FDA approved the Company&#8217;s sNDA for Purified Cortrophin Gel (Repository Corticotropin Injection USP) for the treatment of certain chronic autoimmune disorders, including acute exacerbations of multiple sclerosis (&#8220;MS&#8221;) and rheumatoid arthritis (&#8220;RA&#8221;), in addition to excess urinary protein due to nephrotic syndrome. Cortrophin Gel is an adrenocorticotropic hormone (&#8220;ACTH&#8221;), also known as purified corticotropin.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, we invested significantly in leadership, expertise and infrastructure in the areas of commercialization of rare disease therapies and developed a launch strategy and commercial plan for this product. During this timeframe, we hired a significant number of new employees and assembled and trained our Rare Disease field force. On January 24, 2022, we announced the commercial launch of Cortrophin Gel in the U.S as our foundational Rare Disease asset. On October 2, 2023, we announced FDA approval and commercial availability of a 1-mLvial of Cortrophin Gel, appropriate for adjunctive treatment of certain patients with acute gouty arthritis flares. As a result of the build out of our Rare Disease team, our expenditures in support of these efforts were significantly higher in 2022 as compared to the prior year, and we continued to invest behind Cortrophin Gel and our Rare Disease platform in 2023. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to expand our rare disease business, through a combination of organic growth, as described above, and acquisition. While we continue to execute against our strategic initiatives that we believe will result in the long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to expand our existing capabilities.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strengthening our Generics, Established Brands, and Other segment through continued investment in our generic research and development capability and increased focus on niche opportunities</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown our generics business through a combination of market share gains on existing products and new product launches. We have also successfully acquired numerous ANDAs through business and asset acquisitions. Our most recent business acquisition was Novitium, including its portfolio of commercial and pipeline generic products, manufacturing and development facilities and expert workforce. The Novitium acquisition significantly increased our generic pharmaceutical research and development and manufacturing capabiliti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es. We have begun to increase our focus on niche lower competition opportunities such as injectables, Paragraph IV, and competitive generic therapy ("CGT") designation filings. Additionally, we will continue to seek opportunities to enhance our capab</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilities through strategic partnerships and acquisitions of assets and businesses. During 2022, we completed an asset acquisition of four ANDAs from Oakrum Pharma, including two that were co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mmercial at the time of acquisition. During the second quarter of 2023, we acquired two ANDAs and one pipeline product from the Chapter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates. During the third quarter of 2023, we acquired an ANDA and registered patents and pending patent applications from Slayback Pharma Limited Liability Company. During the fourth quarter of 2023, we acquired additional ANDAs and product rights for two products.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have grown our established brand product offerings through acquisition. We have acquired the NDAs for and market Atacand, Atacand HCT, Arimidex, Casodex, Lithobid, Vancocin, Inderal LA, Inderal XL, InnoPran XL, Oxistat, Veregen, and Pandel. We are innovating in our go-to-market strategy through creative partnerships. </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our overall strategy is enabled by an empowered, collaborative, and purposeful team with a high performance-orientation. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Generic Product Development Considerations</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider a variety of criteria in determining which products to develop: These criteria include:</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Formulation Complexity</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our development and manufacturing capabilities enable us to manufacture pharmaceuticals that are differentiated  and include high potency, modified release, combination, and hormonal products. This ability to manufacture a variety of differentiated products is a competitive strength that we intend to leverage in selecting products to develop and commercialize.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Market Size and Patient Need</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. When determining whether to develop or acquire an individual product, we review the current and expected market size for that product. and competitive environment. We endeavor to pursue products with sufficient market size to enable us to enter the market with a strong likelihood of serving patients in need and thus being able to price our products both competitively and at a profit.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Profit Potential.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In determining the potential profit of a product, we forecast our anticipated market share, pricing, competitive environment and the estimated cost to manufacture the products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Manufacturing. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally seek to develop and manufacture products at our own manufacturing plants to  ensure quality control of our products, supply chain reliability and to more closely control the economic inputs and outputs of our products. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Competition. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When determining whether to develop or acquire a product, we research existing and expected competition. We seek to develop products for which we can obtain sufficient market share and may decline to develop a product if we anticipate significant competition. Our manufacturing facilities provide a means of entering niche markets, such as hormone therapies, in which fewer generic companies typically compete.</span></div><div id="i4bc95b424f3d46babd419bb800693000_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal 2023 Developments</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Election of Directors</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 21, 2023, the Board of Directors of ANI (the &#8220;Board&#8221;), appointed Matthew Leonard to serve on the Board as a director with a term expiring at the Company&#8217;s 2024 annual meeting of stockholders. Mr. Leonard serves as a member of the Audit and Finance Committee and member of the Nominating and Corporate Governance Committee. On August 22, 2023, Dr. David B. Nash, M.D. informed the Board of his decision not to seek reelection as a director on the Board at the Company&#8217;s 2024 Annual Meeting of Stockholders (the &#8220;2024 Annual Meeting&#8221;). Dr. Nash will continue to serve for the remainder of his term as a director until the 2024 Annual Meeting. Dr. Nash has served as a member of the Company&#8217;s Board since May 2018 and has served as Chair of the Nominating and Corporate Governance Committee and as a Member of the Audit and Finance Committee.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offering</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hrough a public offering, we completed the issuance and sale of 2,183,545 shares of ANI common stock, resulting</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in net proceeds after issuance costs of $80.6 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds are being used to in-license, acquire or invest in additional businesses, technologies, products or assets, to fund our commercialization efforts, including, but not limited to, sales and marketing and consulting expenses related thereto, and for general corporate purposes. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Update</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following our acquisition of Novitium in November 2021. We have fully completed the transition of the products manufactured or packaged in Oakville to one of our three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with a potential buyer for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">see Note 19. Subsequent Events, in the notes to the consolidated financial statements in Part II, Item 8 of this Annual Re</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">port on Form 10-K). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Products Launches</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to our website at www.anipharmaceuticals.com for information on the products, including indications/treatments.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impacts to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> results of operations, including to net revenues, operating expenses, interest and other expense, net, and income taxes are described below.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our results of operations for the periods indicated:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,785&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,286&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,318&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration fair value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Income (Loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,971&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,283)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (Loss) Before Expense (Benefit) for Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62,665)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,769)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Income (Loss)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,779&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,896)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth, for the periods indicated, items in our consolidated statements of operations as a percentage of net revenues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration fair value adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Income (Loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (Loss) Before Expense (Benefit) for Income Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Income (Loss)</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div id="i4bc95b424f3d46babd419bb800693000_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations for the Years Ended December 31, 2023 and 2022</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Revenues</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Generics, Established Brands, and Other Segment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Established brand pharmaceutical products, royalties, and other pharmaceutical services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, established brands, and other segment total net revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274,699&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rare Disease Segment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare disease pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">169.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">170,431&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive substantially all of our revenues from sales of generic, rare disease, and established brand pharmaceutical products, royalties on net sales of certain products, and other pharmaceutical services. Many of our established brand products as well as our generic products face competition from generic products and we expect them to continue to face competition from generic products in the future. The primary means of competition among generic manufacturers are pricing, contract terms, service levels, and reliability. Increased competition generally results in decreased average selling prices of generic and brand products over time. In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to strategic partnerships between wholesalers and pharmacy chains, we have experienced, and expect to continue to experience, increases in net sales to the wholesalers, with corresponding decreases in net sales to the pharmacy chains.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues for the year ended December&#160;31, 2023 were $486.8 million compared to $316.4 million for the same period in 2022, an increase of $170.4 million, or 53.9%, primarily as a result of the following factors:</span></div><div style="margin-top:12pt;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Net revenues for generic pharmaceutical products were $269.4 million during the year ended December&#160;31, 2023, an increase of 28.2%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> compared to $210.1 million for the same period in 2022, driven by increased volumes on the base business, increased volumes from the inclusion of 2022 launches in 2023 and 2023 new product launches. From a product perspective, the increase was principally driven by revenues from year over year increases in products such as Acebutolol, Colestipol, Digoxin, Famotidine, Fluoxetine, Levocarnitine, Mixed Amphetamine Salts Extended Release, Misoprostol, Nitrofurantoin, Pyrazinamide, Thyroid, Tolterodine, Tranexamic Acid, Trimethorpim, and various other products tempered by a decrease in revenues of Cholestyramine, Fenofibrate, Mesalamine, Nicardipine, Oxybutynin Chloride, Paliperidone Extended Release, and Prazosin, among others. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net revenues for branded pharmaceutical products, royalties, and other pharmaceutical services were $105.3 million during the year ended December&#160;31, 2023, an increase of 63.0% compared to $64.6 million for the same period in 2022, driven by a net increase in volume.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Net revenues of rare disease pharmaceutical products, which consists entirely of sales of Purified Cortrophin Gel, were </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$112.1 million during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, which represents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an increase of $70.4 million from $41.7 million for the sam</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This increase was driven by increased volume in this second year of launch (product was launched in late January 2022).</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, within our Generic, established brand, and other segment in the current year period, we were successful in supplying incremental volume in markets that were experiencing supply chain disruptions for competing products. Generally, when opportunities for volume and revenue upside related to our products arise in the marketplace, there is no assurance as to how long these favorable market conditions may persist.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales (Excluding Depreciation and Amortization)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:53.376%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.101%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.459%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.466%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (excluding depreciation and amortization)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">181,513&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138,785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of sales consists of direct labor, including manufacturing and packaging, active and inactive pharmaceutical ingredients, freight costs, packaging components, and royalties payable related to profit-sharing arrangements. Cost of sales does not include depreciation and amortization expense, which is reported as a separate component of operating expenses on our consolidated statements of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the year ended December&#160;31, 2023, cost of sales increased to $181.5 million from $138.8 million for the same period in 2022, an increase of $42.7 million or 30.8%. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The increase is primarily due to a significant increase in sales volumes of generic and rare disease pharmaceutical products and a net increase in sales of products that bear a royalty payable, including Purified Cortrophin Gel. During the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, we recognized $5.3 million in cost of sales representing the excess of fair value over cost for inventory acquired in acquisitions and subsequently sold during the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. There are no comparable expenses in the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cost of sales, as a percentage of net revenues, decreased from 42.2% to 37.3% for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, compared to the same period in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The decrease was primarily due to the non-recurrence of $5.3 million expense recognized in the year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, related to the excess of fair value over cost for inventory acquired in a business combination, as well as the increased sales of Established brand pharmaceutical products, royalties, and other pharmaceutical services products and Cortrophin Gel coupled with increased generic volumes with a mix shift in higher margin products.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended December&#160;31, 2023, no single vendor represented at least 10% of inventory purchases. During the year ended December 31, 2022, we purc</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">hased 19% of our inventory from one supplier.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Operating Expenses</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,318&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,968&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">161,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59,791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration fair value adjustment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,332)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,547)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(80.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset impairment charge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(100.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">258,332&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">212,883&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45,449&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, other operating expenses increased to $258.3 million from $212.9 million for the same period in 2022, an increase of $45.4 million, or 21.3%, primarily as a result of the following factors:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Research and development expenses increased from $22.3 million to $34.3 million, an increase of 53.6%,  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">primarily due to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expenses related to a 505(b)(2) filing for one product of approximately $1.6 million, expenses related to ANDA filings, and</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a higher level of activity associated with ongoing and new projects in the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> ended December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Selling, general, and administrative expenses increased from $124.0 million to $161.7 million, an increase of 30.4%, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to increased employment related costs, Rare Disease sales and marketing costs, legal expenses, as well as an overall increase in activities required to support the growth of our business. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Depreciation and amortization expense was $59.8 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million for the year ended December&#160;31, 2023, compared to $57.0 million for the same period in 2022, an increase of  $2.8 million. The increase is primarily due to an increase in amortization expense related to intangible assets acquired during 2023, and amortization of IPR&amp;D which commenced during the year ended December&#160;31, 2023.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized a loss of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.4 million and loss of $3.8 million in the year ended December&#160;31, 2023 and 2022, respectively, for the contingent consideration fair value adjustment. The change in the fair value adjustment is primarily related to changes in the anticipated cash flows, specifically extending the timeframe over which cash flows will be generated by the products, offset by the passage of time (i.e., moving closer to the anticipated payment date of the consideration), an increase to the probability of payment for the product development-based milestone payments, and by fluctuations in the discount rates utilized throughout the year.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized restructuring activities of $1.1 million of expense in the year ended December&#160;31, 2023, in relation </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the closure of our Oakville, Ontario, Canada facility. Costs included severance and other employee benefits costs of $0.2 million, and $0.7 million of accelerated depreciation costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized restructuring activities of $5.7 million of expense in the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> year ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022, in relation to the closure of our Oakville, Ontario, Canada facility. Costs included $2.1 million in termination benefits, $3.1 million in fixed asset impairments and accelerated depreciation, and $0.4 million of other costs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We recognized an impairment charge of $0.1 million in the year ended December 31, 2022, in relation to an ANDA asset. No impairm</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent charges were recognized in the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Expense, net</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,940)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,052)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(829)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(123.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,099)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,382)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">283&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we recognized total other expense, net of $27.1 million versus total other expense of $27.4 million for the same period in 2022, a decrease of $0.3 million. Interest expense, net for the year ended December&#160;31, 2023 and 2022 consisted primarily of interest expense on borrowings under our Term Facility, amortization of deferred debt issuance costs, dividend income earned on our money market funds, the effects of the interest rate swap, and interest earned on cash balances. The decrease in interest expense is due to dividend income earned on our money market funds, income from our interest rate swap, and increased interest income earned on higher cash balances, offset by an increased borrowing rate on the Term Facility and an increase in amortization of finance fees. For the year ended December&#160;31, 2023, there was $0.6 million of interest capitalized into construction in progress, compared to less than $0.1 million of interest capitalized for the year ended December 31, 2022, representing an offset to interest expense. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense (Benefit)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.748%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended <br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,093&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,769)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(107.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incom</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e tax expense (benef</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">it) consists of current and deferred components, which include changes in our deferred tax assets, our deferred tax liabilities, and our valuation allowance. See Note 14. Income Taxes, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K for further information.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, we recognized an income tax expense of approximately $1.1 million. The Company's effective tax rate was 5.5% after discrete items for the year ended December&#160;31, 2023. The effective tax rate differed from the federal statutory rate of 21% primarily due to the recognition of the U.S. federal research and development credit, permanent differences, and stock based compensation. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, we recognized an income tax benefit of $(14.8) million, an effective benefit rate of 23.6% of consolidated pre-tax losses reported in the period, as well as the net effects of certain discrete items occurring in 2022 which impact our income tax provision in the period in which they occur. There were no material discrete items occurring during the year ended December 31, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table highlights selected liquidity and working capital information from our consolidated balance sheets.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">162,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">165,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets held for sale</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">519,816&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">344,261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt, net of deferred financing costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation and related expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued government rebates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Returned goods reserve</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,678&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,606&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99,439&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had $221.1 million in unrestricted cash and cash equivalents. On December 31, 2022, we had $48.2 million in unrestricted cash and cash equivalents. In 2023 and 2022, we invested in leadership, expertise, and infrastructure in the areas of commercialization of rare disease therapies, and in 2022 began to commercialize our Cortrophin Gel product. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on expanding our business and product pipeline through collaborations, and also through acquisitions of products and companies. We are continually evaluating potential asset acquisitions and business combinations. To finance such acquisitions, we might raise additional equity capital, incur additional debt, or both.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital ratio, defined as total current assets divided by total current liabilities, is 3.6 as of December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe that our financial resources, consisting of net current working capital of approximately $374.3 million, anticipated future operating revenue and corresponding collections from customers, and our Credit Facility, under which $40.0 million remains available for borrowing as of December&#160;31, 2023, will be sufficient to enable us to meet our working capital requirements and debt obligations for at least the next 12 months. If our assumptions underlying estimated revenue and expenses are wrong, or if our cash requirements change materially as a result of shifts in our business or strategy, we could require additional financing. If we are not able to continue to be profitable in future years or are not able to continue to generate cash from operations as anticipated and additional capital is needed to support operations, we may be unable to obtain such financing, or obtain it on favorable terms, in which case we may be required to curtail development of new products, limit expansion of operations, or accept financing terms that are not as attractive as desired.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidation among wholesale distributors, chain drug stores, and group purchasing organizations has resulted in a smaller number of companies each controlling a larger share of pharmaceutical distribution channels. Our net revenues were concentrated among four customers representing 31%, 13%, 13%, and 12% of net revenues during the year ended December&#160;31, 2023. As of December&#160;31, 2023 accounts receivable from these four customers totaled approximately 81% of accounts receivable, net. Our net revenues were concentrated among three customers representing 26%, 18%, and 15% of net revenues during the year ended December 31, 2022. As a result, negotiated payment terms with these customers have a material impact on our liquidity and working capital.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Our Cortrophin Gel product accounted for approximately 23% and 13% of our net revenues in  2023 and 2022, respectively. We pay to Merck Sharpe &amp; Dohme B.V. ("Merck") quarterly contingent consideration in the form of a perpetual, tiered royalty expressed as a percentage of Cortrophin Gel net sales. During the initial two years of commercialization (2022 and 2023) this royalty approximated 10% of net sales. We currently anticipate the blended Merck royalty rate to be in the upper teens in 2024. In the case of significant revenue growth beyond 2024, we anticipate the blended rate may reach the low 20 percent range.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Financing</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company, as borrower, entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the &#8220;Term Facility&#8221;) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the &#8220;Revolving Facility,&#8221; and together with the Term Facility, the &#8220;Credit Facility&#8221;). The Term Facility proceeds were used to finance the cash portion of the consideration under the Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility has a subjective acceleration clause in case of a material adverse effect.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility permits both base rate borrowings (&#8220;ABR Loans&#8221;) and Eurodollar rate borrowings (&#8220;Eurodollar Loans&#8221;), plus a spread of (a) 5.00% above the base rate in the case of ABR Loans under the Term Facility and 6.00% above the SOFR Rate (or alternate benchmark rate as defined in the Credit Agreement) in the case of SOFR loans under the Term Facility and (b) 3.75% above the base rate in the case of ABR Loans under the Revolving Facility and 4.75% above the SOFR Rate (as defined in the Credit Facility) in the case of loans under the Revolving Facility. Amendment No. 1 also includes the addition of a credit spread adjustment of 0.11448% for an interest period of one-month duration, 0.26161% for a three-month duration, and 0.42826% for a six-month duration, in addition to SOFR and the applicable margin, as noted above. There were no other changes or modifications to the Credit Agreement.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility has a subjective acceleration clause in case of a material adverse effect. The Term Facility includes a repayment schedule, pursuant to which $750 thousand of the loan will be paid in quarterly installments during the 12 months ending December 31, 2024. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $3.0 million of principal of the loan was recorded as current borrowings, net of deferred financing costs, in the consolidated balance sheet. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had not drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Financing</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 2023, through a public offering, we completed the issuance and sale of 2,183,545 shares of ANI common stock, resulting in net proceeds after issuance costs of $80.6 million. Th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e proceeds are intended to be used to in-license, acquire or invest in additional businesses, technologies, products or assets, to fund our commercialization efforts, including, but not limited to, sales and marketing and consulting expenses related thereto, and for general corporate purposes. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Uses of Cash</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary cash requirements are to fund operations, including Purified Cortrophin Gel commercialization efforts, research and development programs and collaborations, to support general and administrative activities, to purchase equipment and machinery to expand our manufacturing capabilities as our product lines grow, and to expand our business and product pipeline through acquisitions of products and companies. We are continually evaluating potential asset acquisitions and business combinations. Our future capital requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product mix and pricing for product sales and contract manufacturing; </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing and payment terms with customers; </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of raw materials and payment terms with suppliers; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">capital expenditures and equipment purchases to support product launches; and </span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business and product acquisitions. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, we completed our previously announced acquisition of all of the interests of Novitium pursuant to the terms of the Agreement and Plan of Merger (the &#8220;Merger Agreement&#8221;), dated as of March 8, 2021, for cash consideration, 2,466,654 restricted shares of our common stock valued at $91.2 million based on our closing stock price of $43.54 on the date of closing and discounted for lack of marketability due to restrictions on shares, and up to $46.5 million in additional contingent consideration. Additionally, we agreed to pay certain debts of Novitium in the amount of $8.5 million, which we deemed to be paid in consummation of the transaction closing, and not assumed liabilities, and thus were included as additional cash consideration. This acquisition was accounted for as a business combination. The contingent consideration is based on the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products that are launched in the future. As of the closing of the acquisition, the contingent consideration had a fair value of $30.8 million. Refer to Note 10 for changes in contingent consideration and changes in fair value. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration including cash, restricted shares and contingent consideration was valued at $206.5 million.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entry into the Credit Facility, on November 19, 2021, we terminated our existing Amended and Restated Credit Agreement, dated as of December 27, 2018 (the &#8220;Prior Credit Agreement&#8221;), among the Company, as borrower, and Citizens Bank with other lenders. In connection with the termination of the Prior Credit Agreement, on November 19, 2021, we used borrowings under the Credit Facility to prepay the full amount of indebtedness under the Prior Credit Agreement, and to pay related accrued and unpaid interest, legal fees, and expenses. We made a reacquisition payment of $200.1 million, representing the remaining principal balance on the debt of $200.1 million plus certain legal fees.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discussion of Cash Flows</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net cash and cash equivalents provided by (used in) operating activities, investing activities, and financing activities for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,203)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,511)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,738)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Operations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by operating activities was $119.0 million for the year ended December&#160;31, 2023, compared to $31.2 million used in operating activities during the same period in 2022, a change of $150.2 million. The increase was driven by net income in the current year period due to increased sales and gross profit and the non-recurrence of significant utilization of cash during the initial launch period of Cortrophin Gel in 2022, as well as other net changes in our assets and liabilities.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing Activities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash used in investing activities for the year ended December&#160;31, 2023 was $18.5 million, principally due to $8.9 million of capital expenditures and consideration paid for asset acquisitions of ANDAs and other product rights from Akorn Holding Company, Slayback Pharma Limited Liability Company, and Alvogen, Inc. totaling $9.6 million. Net cash used in investing activities for the year ended December 31, 2022 was $15.7 million, principally due to $8.9 million of capital expenditures and the consideration paid for asset acquisitions of intangible assets totaling $7.6 million, partially offset by $0.8 million of proceeds from the sale of long-lived assets during the period.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by (Used in) Financing Activities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by financing activities was $67.4 million for the year ended December&#160;31, 2023, principally due to $80.6 million in net proceeds from the May 2023 public offering and $9.0 million from proceeds from stock option exercises and ESPP purchases. This is offset by cash used in financing activities related to $12.5 million to Company Members of Novitium, $3.0 million maturity payments on the Term Facility, $5.0 million of treasury stock purchased in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">relation to restricted stock vests, and $1.6 million convertible preferred stock dividends paid. Net cash used in financing activities for the year ended December 31, 2022 was $5.1 million, principally due to the $3.0 million maturity payments on the Term Facility, $2.0 million of treasury stock purchased in relation to restricted stock vests, and $1.6 million convertible preferred stock dividends paid.</span></div><div id="i4bc95b424f3d46babd419bb800693000_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe our available cash and cash equivalents along with our ability to generate operating cash flow and continued access to debt markets are sufficient to fund existing and planned cash requirements. Our contractual obligations and commitments as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> are comprised of principal payments on debt, interest payments on debt, operating leases, purchase obligations, dividends, and contingent consideration.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our largest contractual obligation relates to our principal payments on our interest payments on our debt. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the principal amount of our Term Facility was $294.0 million. The interest rate on our Term Facility is currently 1-month SOFR plus 6.00% per annum, plus a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">credit spread adjustment of 0.11448% for an interest period of one-month duration, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subject to a 0.75% floor. The interest rate under the Term Facility as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.46%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. See Note 5, Indebtedness, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K for additional information and timing on our principal payments on debt. We also have an interest rate swap used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility. Under the swap agreement, ANI pays the counterparty a fixed rate of 2.26% and receives variable 1-month SOFR, subject to a 0.75% floor, on the outstanding notional value. As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the notional value of the interest rate swap was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$139.4 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. See Note 6, Derivative Financial Instruments and Hedging Activity, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K for additional information.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operating leases are for facilities and office equipment. As leases expire, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> do not anticipate difficulty in negotiating renewals or finding other satisfactory space if the premise becomes unavailable. See Note 15, Co</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mmitments and Contingencies, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K for additional discussion and timing of payments related to these operating lease obligations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our convertible preferred stock (&#8220;PIPE Shares&#8221;) accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind. Dividends are payable until the preferred stock is converted, either at the option of the PIPE investor, at any time, or the option of ANI, beginning two years after the November 19, 2021 issuance provided ANI&#8217;s stock price reaches a certain lev</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">el. See Note 11, Mezz</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anine and Stockholders&#8217; Equity, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K for additional discussion of dividends. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration of the Novitium acquisition included $46.5 million in contingent future earn-out payments. The contingent consideration is based on the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future. Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021, on December 12, 2023, the Company paid $12.5&#160;million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Agreement and Plan of Merger, of Novitium for the achievement of the "ANDA Filing Earn-Out," as defined in the Agreement. On February 22, 2024, the Company paid $12.5&#160;million to Novitium related to the achievement of the milestone, see Note 2 and Note 10, Business Combination and Fair Value, respectively, in the notes to the consolidated financial statements in Part II, Item 8. of this Annual Report on Form 10-K for additional information on our contingent consideration.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenditures in support of our commercial launch of Cortrophin, including costs related to service contracts and increased headcount.</span></div><div id="i4bc95b424f3d46babd419bb800693000_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and related disclosures in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) and the Company&#8217;s discussion and analysis of its financial condition and operating results require the Company&#8217;s management to make judgments, assumptions and estimates that affect the amounts reported. Our significant accounting policies are discussed in Note 1, "Description of Business and Summary of Significant Accounting Policies" of the Notes to the consolidated financial statements in Part II, Item 8. of this Form 10-K describes the significant accounting policies and methods used in the preparation of the Company's consolidated financial statements. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">apparent from other sources. Actual results could differ from those estimates. Due to the estimation processes involved, the following summarized accounting policies and their application are considered to be critical to understanding our business operations, financial condition, and operating results.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when our obligations under the terms of our contracts with customers are satisfied, which generally occurs when control of the products we sell is transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our gross product revenue is subject to a variety of deductions, which are estimated and recorded in the same period that the revenue is recognized, and primarily represent chargebacks, rebates, prompt payment (cash) discounts, Medicaid and other government pricing programs, price protection and shelf stock adjustments, sales returns, and other potential adjustments. Those deductions represent estimates of rebates and discounts related to gross sales for the reporting period and, as such, knowledge and judgment of market conditions and practice are required when estimating the impact of these revenue deductions on gross sales for a reporting period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, our changes of estimates reflecting actual results or updated expectations have not been material to our overall business. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by program, type of customer and geographic location. However, estimates associated with governmental allowances, Medicaid and other performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results were not consistent with our estimates, we could be exposed to losses or gains that could be material, as changes to chargeback estimates could cause an increase or decrease in revenue recognized during the year and increase or decrease accounts receivable. If there were a 1% change in the chargeback estimates throughout the year, our net revenues would be affected by $5.9 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results were not consistent with our estimates as related to government rebates, we could be exposed to losses or gains that could be material, as changes to government rebate estimates could cause an increase or decrease in revenue recognized during the year and decrease or increase the government rebate reserve. If there were a 10% change in the government rebate estimates throughout the year, our net revenues would be affected by $2.4 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results were not consistent with our estimates, we could be exposed to losses or gains that could be material, as changes to returns estimates could cause an increase or decrease in revenue recognized during the year and decrease or increase the returned goods reserve. If there were a 10% change in the returns estimates throughout the year, our net revenues would be affected by $1.8 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative Fees and Other Rebates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If actual results were not consistent with our estimates, we could be exposed to losses or gains that could be material, as changes to these estimates could cause an increase or decrease in revenue recognized during the year and increase or decrease accounts receivable. If there were a 10% change in the administrative fees estimates throughout the year, our net revenues would be affected by $5.6 million for the year ended December&#160;31, 2023.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If customers do not take 100% of available discounts as we estimate, we could need to re-adjust our methodology for calculating the prompt payment discount reserve. If there were a 10% decrease in the prompt payment discounts estimates throughout the year, our net revenues would increase by $2.3 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Goodwill and Intangible Assets</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate goodwill to reporting units based on the reporting unit expected to benefit from the business combination. We evaluate our reporting units on an annual basis and, if necessary, reassign goodwill using a relative fair value allocation approach. Goodwill is tested for impairment at the reporting unit level (operating segment or one level below an operating segment) on an annual basis (October 31) and between annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Application of the goodwill impairment test requires judgment, including the identification of reporting units, assignment of assets and liabilities to reporting units, assignment of goodwill to reporting units, and determination of the fair value of each reporting unit. The estimates used to calculate the fair value of a reporting unit change from year to year based on operating results, market conditions, and other factors. Changes in these estimates and assumptions could materially affect the determination of fair value and goodwill impairment for each reporting unit. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of goodwill at December&#160;31, 2023 was $28.2 million. As part of the Novitium acquisition on November 19, 2021, we acquired goodwill of $24.6 million. We believe it is unlikely that there will be a material change in the future estimates or assumptions used to test for impairment losses on goodwill. However, if actual results are not consistent with our estimates or assumptions, we could be exposed to an impairment charge that could be material.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Impairments of Long-Lived Assets </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review our long-lived assets, including intangible assets with finite lives, for recoverability whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. We evaluate assets for potential impairment by comparing estimated future undiscounted net cash flows to the carrying amount of the asset. If the carrying amount of the assets exceeds the estimated future undiscounted cash flows, impairment is measured based on the difference between the carrying amount of the assets and fair value which is generally an expected present value cash flow technique. Our policy in determining whether an impairment indicator exists comprises measurable operating performance criteria as well as other qualitative measures. Events giving rise to impairment are an inherent risk in the pharmaceutical industry and cannot be predicted. Factors that we consider in deciding when to perform an impairment review include significant under-performance of a product in relation to expectations, significant negative industry or economic trends, and significant changes or planned changes in our use of the assets. If our assumptions are not correct, there could be an impairment loss in subsequent periods or, in the case of a change in the estimated useful life of the asset, a change in amortization expense.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset&#8217;s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. We consider many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to the discount rate, terminal growth rates, general economic conditions, our outlook and market </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance of our industry and recent and forecasted financial performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of our contingent consideration was $24.0 million and $35.1 million at December&#160;31, 2023 and 2022, respectively. The fair value of contingent consideration is remeasured to the estimated fair value each reporting period with the change recognized as an operating expense in our consolidated statements of operations. Changes in fair value can result from changes in assumptions such as discount rates, probabilities or estimates of revenue and profits, and probability of achieving regulatory milestones, as well as the passage of time. These changes resulted in charges of $1.4 million and $3.8 million during the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#8217;s requisite service period. Awards may also be issued in the form of Performance Stock Units (&#8220;PSUs&#8221;) to certain employees of the Company. PSUs represent the right to receive an amount of cash, a number of shares of common stock or a combination of both, contingent upon the achievement of specified performance and market objectives during a specified performance period. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of our stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation and ESPP expense included in our consolidated statements of operations:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,036&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,316&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">910&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,652&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,599&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,489&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#8217;s requisite service period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of our stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates could affect compensation expense within individual periods. If there were to be a 10% change in our stock-based compensation expense for the year, our Income (Loss) Before Expense (Benefit) for Income Taxes would be affected by $2.1 million for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact to the consolidated financial statements. We are subject to taxation in various U.S. jurisdictions, Canada, and India and remain subject to examination by taxing jurisdictions for the years 1998 and all subsequent periods due to the availability of net operating loss carryforwards. To the extent we are required to pay amounts in excess of our established liability, our effective income tax rate in a given financial statement period could be materially affected. An unfavorable tax settlement generally would require use of our cash and may result in an increase in our effective income tax rate in the period of resolution.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider potential tax effects resulting from discontinued operations and gains and losses included in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and record intra-period tax allocations, when those effects are deemed material. Our effective income tax rate is also affected by changes in tax law, our level of earnings, and the results of tax audits.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the judgments and estimates discussed herein are reasonable, actual results could differ, and we may be exposed to losses or gains that could be material.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal and Other Contingencies </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcomes of legal proceedings and claims brought against us are subject to significant uncertainty. An estimated loss from a loss contingency such as a legal proceeding or claim is accrued by a charge to income if it is probable that an asset has been impaired or a liability has been incurred and the amount of the loss can be reasonably estimated. In determining whether a loss should be accrued we evaluate, among other factors, the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of loss. Changes in these factors could materially impact our consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on recent accounti</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng standards, see Note 1, "Description of Business and Summary of Significant Accounting Policies" of the Notes to the consolidated financial statements in Part II, Item 8. of this Form 10-K.</span></div><div id="i4bc95b424f3d46babd419bb800693000_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market risks include interest rate risk, equity risk, foreign currency exchange rate risk, commodity price risk, and other relevant market rate or price risks. Of these risks, interest rate risk, equity risk, and foreign currency exchange rate risk could have a significant impact on our results of operations.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 19, 2021, we entered into the Credit Agreement, which is secured by substantially all of the personal property and certain material real property owned by ANI and our wholly-owned domestic subsidiaries, and obligations under the Credit Agreement are guaranteed by certain of our wholly-owned domestic subsidiaries.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility proceeds were used to finance a portion of the consideration for the Novitium acquisition, repay our existing credit facility, and pay fees, costs and expenses incurred in connection with the acquisition. Proceeds from the Revolving Facility are expected to be used, subject to certain limitations, for working capital and other general corporate purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Facility matures on the six-year anniversary of November 19, 2021 (the &#8220;Closing Date&#8221;) and the Revolving Facility matures on the five-year anniversary of the Closing Date.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains usual and customary representations and warranties of the parties for credit facilities of this type, subject to customary exceptions and materiality standards. In addition, we are required to maintain, a total net leverage ratio not to exceed 4.75:1.00 and, solely with respect to the Revolving Facility, (a) during the period beginning on October 1, 2022 and ended on September 30, 2023, a total net leverage ratio not to exceed 4.50:1.00 and (b) for all periods thereafter, a total net leverage ratio not to exceed 4.25:1.00.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement also contains certain customary covenants and events of default, as well as, in the event of an occurrence of an event of default under the Credit Agreement, customary remedies for the lenders, including the acceleration of any amounts outstanding under the Credit Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Amendment No. 1</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement (&#8220;Amendment No. 1&#8221;). SOFR will be applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and will replace all LIBOR terms. Amendment No. 1 also includes the addition of a credit spread adjustment of 0.11448% for an interest period of one-month duration, 0.26161% for a three-month duration, and 0.42826% for a six-month duration, in addition to SOFR and the applicable margin, as noted above. There were no other changes or modifications to the Credit Agreement. The Company has applied the optional expedients in ASC 848, Reference Rate Reform, and elected to treat the change in the benchmark interest rate to SOFR as a continuation of the existing Credit Agreement and account for the change prospectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, we entered into an interest rate swap with Citizens Bank, N.A. to manage our exposure to changes in LIBOR-based interest rates underlying total borrowings under term facilities related to our Prior Credit Agreement. The interest rate swap matures in December 2026. Concurrent with the termination of the Prior Credit Agreement and entry into the Credit Facility with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on November 19, 2021 was novated and is now with Truist Bank and is used to manage changes in LIBOR-based interest rates underlying a portion of the borrowing under the Term Facility. The notional value of the swap was $139.4 million and $151.5 million at December&#160;31, 2023 and 2022, respectively. We are exposed to interest rate risk on the unhedged portion of our Term Facility and if interest rates increased or decreased by 1%, interest expense would have increased or decreased by approximately $1.6 million. If our Revolving Facility were fully drawn and interest rates increased or decreased by 1%, interest expense would have increased or decreased by approximately $0.4 million. The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. As a result of the interest rate swap, our exposure to interest rate volatility is minimized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with changes in interest rates. The returns from certain of our cash and cash equivalents will vary as short-term interest rates change. A 100 basis-point adverse movement (decrease) in short-term interest rates would decrease the interest income earned on our cash balance in the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by approximately $2.2 million.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with foreign currency exchange rate risks as we remeasure certain Indian rupee-denominated transactions from our Indian subsidiary from the  Indian-rupee to the U.S. dollar. Changes in exchange rates can positively or negatively impact our revenue, income, assets, liabilities, and equity. Currency exchange rates did not have a material impact on our revenue, income, assets, liabilities, or equity during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div id="i4bc95b424f3d46babd419bb800693000_76"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI Pharmaceuticals, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of ANI Pharmaceuticals, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023 and 2022, and the related consolidated statements of operations, comprehensive income (loss), mezzanine equity and stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2023 and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December 31,</span><span style="color:#00b050;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;), and our report dated February 29, 2024 expressed an unqualified opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Basis for Opinion </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Evaluation of Certain Assumptions impacting the Chargeback Accrual</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 2 to the consolidated financial statements, the Company records certain variable consideration including discounts, which are estimated at the time of sale generally using the expected value method. Amounts accrued for chargebacks as of December 31, 2023, are approximately $84.2 million and are evaluated on a quarterly basis. Management&#8217;s estimate of chargebacks is based on the inventory levels in the distribution channel as provided by wholesalers, as well as the actual average selling price for each product which is impacted by changes in customer mix, changes in negotiated terms with customers, changes in the volume of off-contract purchases, and changes in the wholesaler acquisition cost, in order to estimate the expected provision.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal consideration for our determination that performing procedures relating to the chargeback reserve is a critical audit matter is that there was a significant judgment required by management with respect to measure uncertainty, as the calculation of the chargeback reserve includes assumptions such as average selling price, purchasing trends of distributors and historical product sales used to predict future sales. This in turn led to a high degree of auditor judgment, subjectivity and effort in applying the procedures related to those assumption.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included assessing the design and testing the effectiveness of controls relating to the chargeback reserve, including management&#8217;s control over the assumptions used to estimate the corresponding accruals. We recalculated the chargeback accrual for a selection of products, based on a combination of Company internal data, historical accrual by recalculating the accrual using our independent assumptions. We evaluated the Company&#8217;s ability to accurately estimate the accrual for chargebacks by comparing historically recorded accruals to the actual amount that was ultimately claimed by the wholesalers. We analyzed year over year trends in the reserve in comparison with revenue trends to further evaluate reasonableness of the estimate and consistency with expectations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ EisnerAmper LLP</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2013.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EISNERAMPER LLP</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philadelphia, Pennsylvania</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and Stockholders of</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI Pharmaceuticals, Inc.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Internal Control over Financial Reporting </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited ANI Pharmaceuticals, Inc. and Subsidiaries (the &#8220;Company&#8221;) internal control over financial reporting as of December 31, 2023 based on criteria established in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as December 31, 2023, based on criteria established in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control - Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">2013</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) issued by COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of ANI Pharmaceuticals, Inc. and Subsidiaries as of December 31, 2023 and 2022, and the related consolidated statements of operations, comprehensive income (loss), mezzanine equity and stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended December 31, 2023 and the related notes and our report dated February 29, 2024 expressed an unqualified opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.  Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances.  We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">An entity&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. An entity&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the entity; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the entity are being made only in accordance with authorizations of management and directors of the entity; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the entity&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ EisnerAmper LLP</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EISNERAMPER LLP</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Philadelphia, Pennsylvania</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 29, 2024</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Current Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-41">221,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-42">48,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-44">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accounts receivable, net of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-45">97,262</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-46">161,052</ix:nonFraction> of adjustments for chargebacks and other allowances at December&#160;31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">162,079</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">165,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-49">111,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-50">105,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="anip:PrepaidIncomeTaxesNet" format="ixt:fixed-zero" scale="3" id="f-51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="anip:PrepaidIncomeTaxesNet" format="ixt:num-dot-decimal" scale="3" id="f-52">3,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">8,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">8,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">17,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">8,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total Current Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">519,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">344,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Non-current Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-59">44,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-60">43,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Deferred tax assets, net of deferred tax liabilities and valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-61">90,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-62">81,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-63">209,009</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-64">251,635</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-65">28,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-66">28,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Derivatives and other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">12,072</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">11,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-69">904,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-70">760,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Current Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Current debt, net of deferred financing costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-71">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-72">850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">36,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">29,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">16,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">9,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accrued compensation and related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">23,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">10,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accrued government rebates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="anip:AccruedGovernmentRebates" format="ixt:num-dot-decimal" scale="3" id="f-79">12,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="anip:AccruedGovernmentRebates" format="ixt:num-dot-decimal" scale="3" id="f-80">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Income taxes payable </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-81">8,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:fixed-zero" scale="3" id="f-82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Returned goods reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="anip:ReturnedGoodsReserve" format="ixt:num-dot-decimal" scale="3" id="f-83">29,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="anip:ReturnedGoodsReserve" format="ixt:num-dot-decimal" scale="3" id="f-84">33,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Current contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">12,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accrued expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-87">5,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-88">5,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total Current Liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-89">145,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-90">99,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Non-current Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Non-current debt, net of deferred financing costs and current component</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">284,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">285,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Non-current contingent consideration, net of current </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-93">11,718</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-94">35,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">4,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">1,381</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total Liabilities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-97">446,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-98">421,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Commitments and Contingencies (Note 15)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-99"></ix:nonFraction>&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-7" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-100"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Mezzanine Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Convertible Preferred Stock, Series A, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-101"><ix:nonFraction unitRef="usdPerShare" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="f-102">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-103"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-104">1,666,667</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-106"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-107"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-108">25,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-109">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-110">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Common Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-111"><ix:nonFraction unitRef="usdPerShare" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-112">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-113"><ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-114">33,333,334</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-115">20,730,896</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-10" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-116">20,466,953</ix:nonFraction> outstanding at December&#160;31, 2023; <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-117">17,643,497</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-118">17,494,466</ix:nonFraction> shares outstanding at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-119">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-120">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Class C Special Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-121"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-122">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-123"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-124">781,281</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-125"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-126"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-127"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-128">10,864</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and 2022  respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="anip:ClassCSpecialStockValue" format="ixt:fixed-zero" scale="3" id="f-129">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="anip:ClassCSpecialStockValue" format="ixt:fixed-zero" scale="3" id="f-130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Preferred Stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-131"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-132">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-133"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-134">1,666,667</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-135"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-136"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="f-137"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockSharesIssued" scale="0" id="f-138">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Treasury stock, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-141">263,943</ix:nonFraction> shares of common stock, at cost, at December&#160;31, 2023 and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="0" id="f-142">149,031</ix:nonFraction> shares of common stock, at cost, at December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-143">10,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-144">5,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-145">514,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-146">403,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-147">80,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-148">97,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Accumulated other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-149">8,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-150">12,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total Stockholders&#8217; Equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">432,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">313,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">Total Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-153">904,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-154">760,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_82"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-155">486,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-156">316,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-157">216,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales (excluding depreciation and amortization)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-158">181,513</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-159">138,785</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-160">100,610</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-161">34,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-162">22,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-163">11,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-164">161,697</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-165">124,044</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-166">84,294</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-167">59,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-168">56,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-169">47,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration fair value adjustment</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-170">1,426</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="f-171">3,758</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="f-172">500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal settlement expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="f-173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="3" id="f-174">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:num-dot-decimal" scale="3" id="f-175">8,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purified Cortrophin Gel pre-launch charges</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:CortrophinPreLaunchCharges" format="ixt:fixed-zero" scale="3" id="f-176">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="anip:CortrophinPreLaunchCharges" format="ixt:fixed-zero" scale="3" id="f-177">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="anip:CortrophinPreLaunchCharges" scale="3" id="f-178">780</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-179">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="3" id="f-180">5,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="3" id="f-181">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible asset impairment charge</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="3" id="f-182">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="3" id="f-183">112</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="3" id="f-184">2,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Operating Expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-185">439,845</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-186">351,668</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-187">255,929</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating Income (Loss)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-188">46,971</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-189">35,283</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-190">39,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Expense, net</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-191">26,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-192">28,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-193">11,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (expense) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-194">159</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-195">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-196">4,343</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (Loss) Before Expense (Benefit) for Income Taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">19,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">62,665</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-199">56,058</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 11.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense (benefit)</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-200">1,093</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-201">14,769</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-202">13,455</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Income (Loss)</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">18,779</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">47,896</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-205">42,603</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends on Series A Convertible Preferred Stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" format="ixt:num-dot-decimal" scale="3" id="f-206">1,625</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" format="ixt:num-dot-decimal" scale="3" id="f-207">1,625</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="f-208">190</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net Income (Loss) Available to Common Shareholders</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-209">17,154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-210">49,521</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-211">42,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Income (Loss) Per Share:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic Income (Loss) Per Share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-212">0.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-213">3.05</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-214">3.40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted Income (Loss) Per Share</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-215">0.85</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-216">3.05</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-217">3.40</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic Weighted-Average Shares Outstanding</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-218">18,001</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-219">16,260</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-220">12,596</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-221">18,194</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-222">16,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-223">12,596</ix:nonFraction></span></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-224">18,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">47,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">42,603</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-227">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-228">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-229">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Loss) gain on interest rate swap</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-230">3,355</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-231">15,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="3" id="f-232">8,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-233">3,311</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-234">15,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-235">8,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total comprehensive income (loss), net of tax</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-236">15,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-237">32,673</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-238">34,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Mezzanine Equity and Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Years Ended December&#160;31, 2023, 2022, and 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Mezzanine Equity<br/>Series A Convertible<br/>Preferred<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Mezzanine Equity<br/>Series A Convertible<br/>Preferred Stock<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common<br/>Stock<br/>Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Common<br/>Stock<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Class C<br/>Special<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Treasury<br/>Stock<br/>Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Treasury<br/>Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated Other<br/>Comprehensive<br/>(Loss) Gain<br/>Net of Tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Total<br/>Mezzanine Equity<br/>and Stockholders'<br/>Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Balance, December 31, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-239">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-240">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-241">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-242">12,430</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-243">214,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="f-244">76</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-245">2,246</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-246">11,437</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-247">4,972</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="anip:StockholdersEquityAttributableToParentAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-248">195,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-249">10,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-250">10,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Treasury Stock Purchases for Restricted Stock Vests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-251">28</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="f-252">889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="3" id="f-253">889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Common Shares upon Stock Option and ESPP Exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-254">56</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-255">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-256">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Restricted Stock Awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-257">541</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Awards Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-258">81</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="f-259">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-260">21</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="f-261">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Common Stock for Novitium Acquisition</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-262">2,467</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-263">91,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-264">91,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Common Stock in Public Offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-265">1,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-266">69,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-267">69,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dividends on Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="f-268">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="f-269">190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-270">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-271">25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-272">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-273">8,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-274">8,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-275">42,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-276">42,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Balance, December 31, 2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-277">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="f-278">25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-279">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-280">16,913</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-281">387,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="f-282">83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-283">3,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-284">3,055</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-285">47,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="anip:StockholdersEquityAttributableToParentAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-286">358,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-287">14,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-288">14,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Treasury Stock Purchases for Restricted Stock Vests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-289">66</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-290">1,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-291">1,959</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Common Shares upon Stock Option and ESPP Exercise</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-292">52</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-293">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-294">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Restricted Stock Awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-295">748</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Awards Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-296">69</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dividends on Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-297">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-298">1,625</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-299">15,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-300">15,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-301">47,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-302">47,896</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Balance, December 31, 2022</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-303">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="f-304">25</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-305">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-306">17,644</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-307">403,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="f-308">149</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-309">5,094</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-310">12,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-311">97,286</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="anip:StockholdersEquityAttributableToParentAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-312">338,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based Compensation Expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-313">20,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-314">20,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Treasury Stock Purchases for Restricted Stock Vests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-315">115</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-316">4,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-317">4,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Common Shares upon Stock Option and ESPP Exercise</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-318">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-319">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-320">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Restricted Stock Awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-321">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Performance Stock Units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-322">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.244%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted Stock Awards and Performance Stock Units Forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-323">83</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="f-324">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" scale="3" id="f-325">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Issuance of Common Stock in Public Offering, net of offering costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-326">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-327">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-328">80,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-329">80,556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Dividends on Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-330">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-331">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-332">3,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-333">3,311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-334">18,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-335">18,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Balance, December 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-336">24,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="f-337">25</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-338">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-339">20,731</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-340">514,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-3" name="us-gaap:TreasuryStockCommonShares" scale="3" id="f-341">264</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-342">10,081</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-343">8,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-344">80,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="anip:StockholdersEquityAttributableToParentAndTemporaryEquity" format="ixt:num-dot-decimal" scale="3" id="f-345">457,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span><br/></span></div><div style="margin-top:7pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_91"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash Flows From Operating Activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-346">18,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-347">47,896</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-348">42,603</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-349">20,652</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-350">14,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-351">10,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-352">11,740</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-353">15,253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" format="ixt:num-dot-decimal" scale="3" id="f-354">16,754</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-355">59,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-356">59,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-357">47,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquired in-process research and development ("IPR&amp;D")</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:AcquiredInProcessReserachAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="anip:AcquiredInProcessReserachAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-359">1,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="anip:AcquiredInProcessReserachAndDevelopmentExpense" format="ixt:fixed-zero" scale="3" id="f-360">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:num-dot-decimal" scale="3" id="f-361">1,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="3" id="f-362">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" format="ixt:fixed-zero" scale="3" id="f-363">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Non-cash interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-364">3,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-365">3,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-366">2,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Contingent consideration fair value adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" format="ixt:num-dot-decimal" scale="3" id="f-367">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" format="ixt:num-dot-decimal" scale="3" id="f-368">4,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" scale="3" id="f-369">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Loss on extinguishment of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-372">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AssetImpairmentCharges" scale="3" id="f-374">574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="f-375">2,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Gain on sale of ANDAs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" id="f-377">750</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-378">1,822</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities, net of acquisition (2021):</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-379">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-380">36,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-381">5,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-382">5,841</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-383">23,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-384">3,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="f-385">9,015</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-386">798</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="f-387">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-388">7,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-389">5,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-390">10,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accrued royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:IncreaseDecreaseInRoyaltyPayable" format="ixt:num-dot-decimal" scale="3" id="f-391">6,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="anip:IncreaseDecreaseInRoyaltyPayable" format="ixt:num-dot-decimal" scale="3" id="f-392">3,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="anip:IncreaseDecreaseInRoyaltyPayable" scale="3" id="f-393">267</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Current income taxes payable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-394">11,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxes" scale="3" id="f-395">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-396">7,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accrued government rebates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:IncreaseDecreaseAccruedGovernmentRebates" format="ixt:num-dot-decimal" scale="3" id="f-397">1,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="anip:IncreaseDecreaseAccruedGovernmentRebates" format="ixt:num-dot-decimal" scale="3" id="f-398">5,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="anip:IncreaseDecreaseAccruedGovernmentRebates" format="ixt:num-dot-decimal" scale="3" id="f-399">3,078</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Returned goods reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="anip:IncreaseDecreaseInReturnedGoodsReserve" format="ixt:num-dot-decimal" scale="3" id="f-400">3,722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="anip:IncreaseDecreaseInReturnedGoodsReserve" format="ixt:num-dot-decimal" scale="3" id="f-401">2,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="anip:IncreaseDecreaseInReturnedGoodsReserve" format="ixt:num-dot-decimal" scale="3" id="f-402">6,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Accrued expenses, accrued compensation, and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-403">12,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" scale="3" id="f-404">905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" format="ixt:num-dot-decimal" scale="3" id="f-405">3,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Cash and Cash Equivalents Provided by (Used in) Operating Activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-406">118,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-407">31,203</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-408">3,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash Flows From Investing Activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of Novitium Pharma LLC, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-409">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="f-410">33</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-411">84,494</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of product rights, IPR&amp;D, and other related assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-412">9,643</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-413">7,579</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-414">21,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-415">8,868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-416">8,876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-417">2,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from the sale of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="f-419">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-420">2,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Cash and Cash Equivalents Used in Investing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-421">18,511</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-422">15,738</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-423">105,483</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash Flows From Financing Activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from public offering, net of transaction expenses&#160;&#160;&#160;&#160;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-424">80,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-425">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-426">69,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payments on contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-427">12,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="0" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payments on Term Loan and Delayed Draw Term Loan agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfOtherLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-432">10,862</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Payments on borrowings under credit agreements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-433">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-434">3,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfDebt" format="ixt:fixed-zero" scale="3" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Borrowings under Prior Revolver agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromLongTermLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-438">24,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Repayment of Prior Credit Facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-439">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RepaymentsOfLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-441">200,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Borrowings under the Credit Facility, net of issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:num-dot-decimal" scale="3" id="f-444">286,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from issuance of convertible preferred stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" format="ixt:num-dot-decimal" scale="3" id="f-447">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Series A convertible preferred stock dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-448">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-449">1,625</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsOfDividends" scale="3" id="f-450">190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Proceeds from stock option exercises and ESPP purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-451">8,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-452">1,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-453">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Treasury stock purchases for restricted stock vests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-454">4,987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-455">1,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="f-456">890</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Cash and Cash Equivalents Provided by (Used in) Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-457">67,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-458">5,126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-459">194,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net Change in Cash and Cash Equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-460">167,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-461">52,067</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-462">92,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents, beginning of year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-463">53,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-464">105,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-465">12,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-466">221,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-467">53,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-468">105,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Reconciliation of cash, cash equivalents, and restricted cash, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-469">48,228</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-470">100,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-471">7,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-472">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-473">5,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-474">5,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash, beginning of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-475">53,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-476">105,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-477">12,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Reconciliation of cash, cash equivalents, and restricted cash, end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-478">221,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-479">48,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-480">100,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="3" id="f-481">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-482">5,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:RestrictedCashCurrent" format="ixt:num-dot-decimal" scale="3" id="f-483">5,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash, cash equivalents, and restricted cash, end of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-484">221,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-485">53,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-486">105,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Supplemental disclosure for cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash paid for interest, net of amounts capitalized</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-487">31,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-488">21,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-489">9,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-490">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="f-491">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-492">10,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-493">4,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Supplemental non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value of contingent consideration in a business combination</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" format="ixt:fixed-zero" scale="3" id="f-497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="3" id="f-498">30,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Fair value of equity issued as consideration in a business combination</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="f-499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:fixed-zero" scale="3" id="f-500">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="3" id="f-501">91,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Acquisition of product rights included in accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="3" id="f-503">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Property and equipment purchased and included in accounts payable</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-505">328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-506">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-507">152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_94"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div><span><br/></span></div><div id="i4bc95b424f3d46babd419bb800693000_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="f-508" continuedAt="f-508-1" escape="true">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-508-1" continuedAt="f-508-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Business</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, &#8220;ANI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The team is focused on delivering growth by scaling up the Rare Disease business through the successful launch of its lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. The Company owns and operates <ix:nonFraction unitRef="facility" contextRef="c-6" decimals="INF" name="anip:NumberOfPharmaceuticalManufacturingFacilities" format="ixt-sec:numwordsen" scale="0" id="f-509">three</ix:nonFraction> pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at the Oakville, Ontario, manufacturing facility as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium Pharma LLC (&#8220;Novitium&#8221;) in November 2021. The Company has fully completed the transition of the products manufactured or packaged at Oakville to one of the three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of <ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-510">19.2</ix:nonFraction> million Canadian Dollars, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-511">14.2</ix:nonFraction> million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (Note 19).</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-512" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-513" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-514" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. Unless otherwise noted, all references to &#8220;$&#8221; or &#8220;dollar&#8221; refer to the U.S. dollar. The Company&#8217;s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders&#8217; equity accounts, intercompany, and fixed assets, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders&#8217; equity within accumulated other comprehensive income (loss), net of tax.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-2" continuedAt="f-508-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-515" continuedAt="f-515-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-515-1">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In the consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and potential adjustments, income tax expense or benefit, deferred taxes and valuation allowance, stock-based compensation, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" id="f-516" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Activities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the consolidated statements of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-517" continuedAt="f-517-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Revenue is recognized using the following steps:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price, including the identification and estimation of variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when we satisfy a performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives its revenues primarily from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold is transferred to the customer. Generally, the Company does not incur incremental costs to obtain contracts that would otherwise not have been incurred. The Company has not identified any agreements or arrangement that would qualify as a significant financing component.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-3" continuedAt="f-508-4"><ix:continuation id="f-517-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Distribution Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may enter into marketing and distribution agreements with third parties in which products are sold under Abbreviated New Drug Applications (&#8220;ANDAs&#8221;) or New Drug Applications (&#8220;NDAs&#8221;) owned or licensed by third parties. These products are sold under the ANI label. The Company controls the products sold under these marketing and distribution agreements and therefore are the principal for sales under each of these marketing and distribution agreements. As a result, revenue is recognized on a gross basis when control has passed to the customer and the performance obligation has been satisfied. Under these agreements, the Company pays third parties a specified percentage of the gross profit earned on sales of the products. These profit-sharing percentages are recognized in cost of sales in the consolidated statements of operations and are accrued in accrued royalties in the consolidated balance sheets until payment has occurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Product Sales Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing arrangements consist of agreements in which pharmaceutical products are manufactured by the Company on behalf of a third party. The performance obligation is to manufacture and provide pharmaceutical products to customers, typically pharmaceutical companies. The products are sold at predetermined standalone selling prices and the performance obligation is considered to be satisfied when control of the product is transferred to the customer. Control is transferred to the customer when the product leaves the shipping dock to be shipped to the customer, as  contract manufactured pharmaceutical products are sold on an FOB shipping point basis and the inventory risk and risk of ownership passes to the customer at that time. Payment terms for these sales are generally fewer than two months. Typically, there are no material returns for contract manufactured products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties from Licensing Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into licensing agreements, under which the Company licenses to the seller the right to sell the acquired products. Because these royalties are sales-based, the Company recognizes the revenue when the underlying sales occur, based on sales and gross profit information received from the sellers. The Company may enter into agreements which include profit-sharing percentages on gross profits. The profit-sharing percentages are recorded in cost of sales in the consolidated statements of operations when the associated revenue is recognized and are recorded in accrued royalties in the consolidated balance sheets when the associated revenue is recognized and until payment has occurred.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-518" continuedAt="f-518-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with original maturities of three months or less from the date of purchase are classified as cash equivalents. Cash and cash equivalents consist of cash deposited in checking accounts, time deposits with maturities of less than three months, and money market accounts with maturities of three months or less at the date of purchase. Cash and cash equivalents include cash on-hand and money market funds which invest exclusively in high-quality, short-term securities that are issued or guaranteed by the U.S. government. Due to the short-term maturity of the funds invested in the money market accounts, the carrying amounts are a reasonable estimate of fair value. All interest bearing and non-interest bearing accounts are guaranteed by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="anip:FDICGuaranteedAmount" format="ixt:num-dot-decimal" scale="3" id="f-519">250</ix:nonFraction> thousand. The majority of the Company's cash balances are in excess of FDIC coverage, which the Company considers to be a normal business risk.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-518-1">Restricted cash at December 31, 2022, represented $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-5" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="6" id="f-520">5.0</ix:nonFraction> million of funds held in a bank account owned by the Company to be used to pay for future milestones related to the purchase of  the rights, title, and interest in the NDA for Inderal LA, as well as certain documentation, trademark rights, and finished goods from Cranford Pharmaceuticals, LLC in April 2016. This amount was was released from restricted cash during the first quarter of the year ended December&#160;31, 2023.</ix:continuation> </span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-4" continuedAt="f-508-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-521" continuedAt="f-521-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-521-1">The Company extends credit to customers on an unsecured basis. Expected credit losses are measured at amortized cost, including trade and unbilled receivables, on a collective basis, based on their similar risk characteristics. Expected credits losses are based on historical credit loss experience, review of the current aging or status of accounts receivable and current and forward-looking views from an economic and industry perspective. Receivables are written off when it is determined that amounts are uncollectible. The allowance for credit losses was immaterial as of December&#160;31, 2023 and 2022.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-522" continuedAt="f-522-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-522-1">Inventories consist of raw materials, packaging materials, work-in-progress, and finished goods. Inventories are stated at the lower of standard cost or net realizable value. The Company periodically reviews and adjusts standard costs, which generally approximate weighted average cost.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-523" continuedAt="f-523-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are charged to expense as incurred. <ix:nonNumeric contextRef="c-1" name="anip:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" id="f-524" continuedAt="f-524-1" escape="true">Depreciation is recorded on a straight-line basis over estimated useful lives as follows:</ix:nonNumeric></span></div><ix:continuation id="f-524-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.297%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-60" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-525">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-61" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-526">40</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of asset's useful life or remaining life of lease </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-62" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-527">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-63" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-528">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of multiple projects, primarily related to new equipment and expansion of laboratory and manufacturing facilities to expand manufacturing capability as product lines grow. Construction in progress includes the cost of construction and other direct costs attributable to the construction, along with capitalized interest. Depreciation is not recorded on construction in progress until such time as the assets are placed in service.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-523-1">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-529"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-530"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="3" id="f-531">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment loss related to property and equipment was recognized during the years ended December&#160;31, 2023, 2022, and 2021. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-532" continuedAt="f-532-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets Held-for-Sale </span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><ix:continuation id="f-532-1" continuedAt="f-532-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-532-2">. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria.</ix:continuation> As of December&#160;31, 2023 and 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="f-533"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="f-534">8.0</ix:nonFraction></ix:nonFraction> million of assets held for sale were recorded on the consolidated balance sheets. See Note 4 to the consolidated financial statements for additional information. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-5" continuedAt="f-508-6"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-535" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the Company does not separate lease and non-lease components of contracts. There are no material residual guarantees associated with any of the Company&#8217;s leases, and there are no significant restrictions or covenants included in the Company&#8217;s lease agreements. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. As of December&#160;31, 2023 and 2022, the Company did not have any finance leases.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="f-536" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The definite-lived ANDAs, NDAs and product rights, marketing and distribution rights, customer relationships, and non-compete agreement are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from <span style="-sec-ix-hidden:f-537">seven</span> to <ix:nonNumeric contextRef="c-67" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:durwordsen" id="f-538">ten years</ix:nonNumeric>, based on the straight-line amortization method. In the case of certain NDA and product rights, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Management reviews definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. During the year ended December&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="6" id="f-539">no</ix:nonFraction> impairment charges were recognized on intangible assets.. During the year ended December&#160;31, 2022, the Company recognized a full impairment of a definite-lived ANDA asset with a remaining carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="f-540">0.1</ix:nonFraction> million. During the year ended December&#160;31, 2021, the Company recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-541">2.4</ix:nonFraction> million related to a definite-lived ANDA intangible asset. No events or circumstances arose in 2023, 2022, or 2021 that indicated that the carrying value of any of the other definite-lived intangible assets may not be recoverable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets other than goodwill include in-process research and development (&#8220;IPR&amp;D&#8221;) projects. IPR&amp;D intangible assets represent the fair value of technology acquired in a business combination for which the technology projects are incomplete but have substance. When an IPR&amp;D project is completed (generally upon receipt of regulatory approval), the asset is then accounted for as a definite-lived intangible asset. Indefinite-lived intangibles are tested for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying amount of the asset might not be recoverable. Judgment is used in determining when these events and circumstances arise. No events or circumstances arose in 2023 that indicated that the carrying value of any of the indefinite-lived intangible assets may not be recoverable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-542" continuedAt="f-542-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost, using the purchase method of accounting, and is related to past business combinations with BioSante Pharmaceuticals, Inc., WellSpring, and Novitium. Goodwill is not amortized, but is subject to periodic review for impairment. The Company is organized in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-543">two</ix:nonFraction> operating segments, and <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-544">two</ix:nonFraction> reporting units, and has determined that goodwill resides in one reporting unit, Generics, Established Brands, and Other.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-6" continuedAt="f-508-7"><ix:continuation id="f-542-1" continuedAt="f-542-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews goodwill for impairment on a reporting unit basis annually, on October 31, and whenever events or changes in circumstances indicate the carrying value of goodwill might not be recoverable. Under the authoritative guidance issued by the FASB, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company&#8217;s financial condition and results of operations. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-542-2">The Company assessed the assets qualitatively, and concluded it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit is greater than its carrying value as of October 31, 2023 and 2022, and therefore no quantitative testing for impairment was required.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-545"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-546"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="3" id="f-547">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment loss related to goodwill was recognized in the years ended December&#160;31, 2023, 2022, and 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-548" continuedAt="f-548-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Arrangements </span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-548-1">The Company may enter into collaborative arrangements with various commercial partners to further business opportunities. In collaborative arrangements revenues and costs generated by collaborative arrangements may be presented on a gross or net basis depending on the specific facts of the collaborative arrangement.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-549" continuedAt="f-549-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-549-1">Research and development ("R&amp;D") activities are expensed as incurred. R&amp;D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-550" continuedAt="f-550-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock options and restricted stock awards, which are awarded in exchange for employee and non-employee director services. From time to time, the Company may grant awards through an inducement grant outside of the incentive plan to induce prospective employees to accept employment with the Company. These grants are made pursuant to inducement grants outside of the shareholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock awards is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#8217;s requisite service period and classified where the underlying salaries are classified. Forfeitures are accounted for as they occur. Excess tax benefits or tax deficiencies are recognized as a component of the current period provision for income taxes.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards may also be issued in the form of Performance Stock Units (&#8220;PSUs&#8221;) to certain employees of the Company. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted vest over a <ix:nonNumeric contextRef="c-68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-551">three-year</ix:nonNumeric> performance period. Currently, the PSU&#8217;s vesting is contingent upon the Company meeting certain total shareholder return (&#8220;TSR&#8221;) levels as compared to a select peer group over the over <ix:nonNumeric contextRef="c-68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-552">three years</ix:nonNumeric>, and contingent upon the Company meeting certain adjusted non-GAAP year-on-year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings before interest, income taxes, depreciation, and amortization (&#8220;EBITDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates over the vesting term. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-7" continuedAt="f-508-8"><ix:continuation id="f-550-1"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also administers an Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The estimated fair value of stock-based compensation awards are recognized and classified in the expense where the underlying salaries are classified. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of the Company's stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-553" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in various U.S. jurisdictions, Canada, and India, and all of our income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into an interest rate swap agreement (Note 6) designated as a cash flow hedge designed to manage exposure to changes in SOFR-interest rate underlying our variable rate debt. Due to the effective nature of the hedge, the initial fair value of the hedge and subsequent changes in the fair value of the hedge are recognized in other comprehensive income (loss) in the consolidated balance sheets. Income taxes are allocated to the hedge component of other comprehensive income (loss) based on appropriate intra-period tax allocations when those effects are deemed material.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives" id="f-554" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedge Accounting</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate swaps to hedge exposure to interest rate risk, as well as benefit from favorable conditions. The Company recognizes all derivative instruments as either assets or liabilities at fair value. For all of the Company&#8217;s derivative positions that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivatives is reported as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on derivatives representing any ineffective component of the hedge are recognized in current earnings. All of the Company&#8217;s cash flow hedges have been deemed effective as of December&#160;31, 2023 for both accounting and tax purposes. The Company has elected hedge accounting for both U.S. GAAP and tax purposes. The Company maintains formal documentation through a periodic memo and accounting analysis that cover what is being hedged, how it is being hedged, hedge effectiveness, the nature of the risk being hedged, among other required analyses. Company policy further includes a quarterly probability analysis covering hedge effectiveness.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-508-8" continuedAt="f-508-9"><ix:nonNumeric contextRef="c-1" name="us-gaap:ContingentLiabilityReserveEstimatePolicy" id="f-555" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the acquisition agreement between ANI and Novitium Pharma LLC include the potential payment of future consideration that is contingent upon the achievement of certain regulatory and financial performance milestones. At the acquisition date, contingent consideration is recorded at fair value based on the additional consideration expected to be transferred, which is based on the estimate of probability-weighted future cash flows as discounted to present value. Significant inputs used in the measurement of the fair value include discount rates, probabilities of achievement of regulatory-based milestones and payments, and projected revenues and gross profits. The discount rates are derived using accepted valuation methodologies. The probability of achievement of regulatory milestones is based on historical and projected success rates. The projected revenues and gross profits are based on internal forecasts and long-term plans. The contingent consideration is remeasured each reporting period using Level 3 inputs. Changes in fair value, which incorporate changes in assumptions and the passage of time, are recognized as an operating expense in the consolidated statements of operations. As payments are not expected to be made shortly after the acquisition, any future payment of contingent consideration will be reported as a financing cash flow for amounts paid up to the acquisition-date fair value of the consideration, and as an operating cash outflow for any amounts in excess of the acquisition-date fair value in our consolidated statement of cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-556" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets include certain financial instruments (primarily cash and cash equivalents, prepaid expenses, accounts receivable, accounts payable, accrued expenses, and other current liabilities) that are carried at cost and that approximate fair values as of December&#160;31, 2023, 2022 due to their short term nature. See Note 10 for additional information regarding fair value.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-557" continuedAt="f-557-1" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-557-1" continuedAt="f-557-2"><ix:continuation id="f-508-9" continuedAt="f-508-10"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on the consolidated financial statements.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. </span></div></ix:continuation></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-557-2"><ix:continuation id="f-508-10">In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company&#8217;s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.</ix:continuation></ix:continuation> </span></div><div id="i4bc95b424f3d46babd419bb800693000_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-558" continuedAt="f-558-1" escape="true">REVENUE RECOGNITION AND RELATED ALLOWANCES </ix:nonNumeric></span></div><ix:continuation id="f-558-1" continuedAt="f-558-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products we sell is transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-559" continuedAt="f-559-1" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All revenue recognized in the accompanying consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products and Services</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-560">269,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-561">210,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-562">143,571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-563">105,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-564">64,578</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-565">72,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of rare disease pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-566">112,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-567">41,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-569">486,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-570">316,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-571">216,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-558-2" continuedAt="f-558-3"><ix:continuation id="f-559-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timing of Revenue Recognition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations transferred at a point in time</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-572">486,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-573">313,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-574">214,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations transferred over time</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-575">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-576">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-577">1,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-578">486,816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-579">316,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-580">216,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the years ended December&#160;31, 2023 or 2022, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. As of December&#160;31, 2023, there were no contract assets recorded which were related to revenue recognized based on percentage of completion but not yet billed. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an increase of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="f-581">4.1</ix:nonFraction> million of net revenue from performance obligations satisfied in prior periods during the year ended December&#160;31, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisting primarily of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023 and 2022, the Company recognized less than $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-582"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="f-583">0.1</ix:nonFraction></ix:nonFraction> million of revenue that was included in deferred revenue as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-584">6.3</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million, which consists of firm orders for contract manufactured products. We will recognize revenue for these performance obligations as they are satisfied, which is anticipated within <ix:nonNumeric contextRef="c-84" name="us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" format="ixt-sec:durwordsen" id="f-585">six months</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks, primarily from wholesalers, result from arrangements with indirect customers establishing prices for products which the indirect customer purchases through a wholesaler. Alternatively, the Company may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, the Company provides a chargeback credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler&#8217;s invoice price, typically Wholesale Acquisition Cost (&#8220;WAC&#8221;).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period chargebacks claimed by wholesalers are analyzed to determine the actual average selling price (&#8220;ASP&#8221;) for each product. This calculation is performed by product by wholesaler. ASPs can be affected by several factors such as:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in customer mix</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in negotiated terms with customers</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in the volume of off-contract purchases</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in WAC</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As necessary, ASPs are adjusted based on anticipated changes in the factors above.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between ASP and WAC is recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets, at the time revenue is recognized from the product sale. The Company continually monitors chargeback activity and adjusts ASPs when the Company believes that actual selling prices will differ from current ASPs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-558-3" continuedAt="f-558-4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates reserve consists of estimated payments due to governmental agencies for utilization of our products by beneficiaries under such governmental programs. The two largest government programs are Medicaid and Medicare.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the Medicaid Drug Rebate Program and pays rebates to the states related on Medicaid beneficiary utilization of the Company's products. Medicaid rebates are billed 60-90 days of the end of the quarter in which the product was dispensed to a Medicaid beneficiary. Medicaid rebate amounts per product unit are established by law, based on the Average Manufacturer Price (&#8220;AMP&#8221;), which is reported on a monthly and quarterly basis, and, in the case of branded products, best price, which is reported on a quarterly basis. Medicaid reserves are based on expected claims from state Medicaid programs. Estimates for expected claims are driven by patient usage, sales mix, calculated AMP or best price, as well as inventory in the distribution channel that will be subject to a Medicaid rebate. As a result of the delay between selling the products, dispensing the products and rebate billing, the Medicaid rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the products are also covered under Medicare. ANI participates in the Coverage Gap Discount Program in order for its branded drugs to be covered by Medicare Part D and must provide a rebate for any products sold under NDAs dispensed to Medicare Part D beneficiaries while the beneficiaries are in the Coverage Gap phase of the benefit. This applies to all products sold under NDAs, regardless of whether the products are marketed as branded or generic. Estimates for these discounts are based on historical experience with Medicare rebates for products. Medicare rebates are billed quarterly for drugs dispensed to Medicare beneficiaries in the prior quarter, which is typically 120 days after the product is shipped. As a result of the delay between selling the products, dispensing the products and rebate billing, Medicare rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to Medicare Part D participants.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate the adequacy of the government rebate reserves, reserves are reviewed on a quarterly basis against actual claims data to ensure the liability is fairly stated. The Company continually monitors the government rebate reserve and adjusts estimates if it is expected that actual government rebates may differ from established accruals. Accruals for government rebates are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to accrued government rebates in the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A returns policy is in place that allows customers to return product within a specified period prior to and subsequent to the expiration date. Generally, product may be returned for a period beginning <ix:nonNumeric contextRef="c-66" name="anip:ProductReturnPeriod" format="ixt-sec:durwordsen" id="f-586">six months</ix:nonNumeric> prior to its expiration date to up to <ix:nonNumeric contextRef="c-67" name="anip:ProductReturnPeriod" format="ixt-sec:durwordsen" id="f-587">one year</ix:nonNumeric> after its expiration date. Product returns are settled through the issuance of a credit to the customer. The estimate for returns is based upon historical experience with actual returns. While such experience has allowed for reasonable estimation in the past, history may not always be an accurate indicator of future returns. We continually monitor estimates for returns and make adjustments when it is expected that actual product returns may differ from the established accruals. Accruals for returns are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to the return goods reserve in the consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-558-4" continuedAt="f-558-5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative Fees and Other Rebates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative fees or rebates are offered to wholesalers, group purchasing organizations, and indirect customers. Fees and rebates are accrued, by product by wholesaler, at the time of sale based on contracted rates and ASPs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate the adequacy of the administrative fee accruals, on-hand inventory counts are obtained from the wholesalers. The Company continually monitors administrative fee activity and adjust accruals when it is expected that actual administrative fees may differ from the accruals. Accruals for administrative fees and other rebates are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales discounts may be granted to customers for prompt payment. The reserve for prompt payment discounts is based on invoices outstanding. Based on past experience, it is assumed that all available discounts will be taken. Accruals for prompt payment discounts are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="anip:ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" id="f-588" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.086%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accruals for Chargebacks, Returns, and Other Allowances</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government<br/>Rebates</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Administrative<br/>Fees and Other<br/>Rebates</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Prompt<br/>Payment<br/>Discounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-589">94,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-590">5,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-591">35,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-592">13,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-593">4,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals/Adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-594">642,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-595">20,657</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-596">23,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-597">42,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-598">21,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits Taken Against Reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-599">587,913</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-600">15,277</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-601">25,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-602">45,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-603">19,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022 (1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-604">148,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-605">10,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-606">33,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-607">9,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-608">6,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-609">586,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-610">23,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-611">18,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-612">55,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesAdjustments" format="ixt:num-dot-decimal" scale="3" id="f-613">22,932</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits Taken Against Reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-614">650,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-615">22,619</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-616">22,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-617">53,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-618">24,555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023 (1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-619">84,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-620">12,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-621">29,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-622">11,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-623">4,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Returns are included in returned goods reserve in the consolidated balance sheets. Government Rebates are included in accrued government rebates in the consolidated balance sheets.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Concentration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023 four customers accounted for 10% or more of net revenues. During the years ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, three customers accounted for 10% or more of net revenues. As of December&#160;31, 2023, accounts receivable from these customers totaled <ix:nonFraction unitRef="number" contextRef="c-110" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-624">81</ix:nonFraction>% of accounts receivable, net.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-625" escape="true"><ix:continuation id="f-558-5"><div style="margin-top:12pt;padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The four customers represent the total percentage of net revenues as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-111" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-626">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-627">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-113" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-628">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-629">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-115" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-630">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-631">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-632">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-633">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-634">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-635">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-121" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-636">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" format="ixt:fixed-zero" scale="-2" id="f-637">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation></ix:nonNumeric><div id="i4bc95b424f3d46babd419bb800693000_1099511628377"></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-638" continuedAt="f-638-1" escape="true">BUSINESS COMBINATION</ix:nonNumeric></span></div><ix:continuation id="f-638-1" continuedAt="f-638-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company acquired all of the interests of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021. This acquisition was accounted for as a business combination. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration consisted of cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-639">88.1</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-640">2,466,654</ix:nonFraction> restricted shares of common stock valued at $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-641">91.2</ix:nonFraction> million, and up to $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-642">46.5</ix:nonFraction> million in additional contingent consideration. Additionally, the Company agreed to pay certain debts of Novitium in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:num-dot-decimal" scale="6" id="f-643">8.5</ix:nonFraction> million. The contingent consideration is based on the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a <ix:nonNumeric contextRef="c-123" name="anip:RestrictionPeriodForSharesIssuedInBusinessCombination" format="ixt-sec:durmonth" id="f-644">24</ix:nonNumeric>-month period, regulatory filings completed during this <ix:nonNumeric contextRef="c-123" name="anip:RestrictionPeriodForSharesIssuedInBusinessCombination" format="ixt-sec:durmonth" id="f-645">24</ix:nonNumeric>-month period, and a percentage of net profits on certain products that are launched in the future. As of the acquisition date, the contingent consideration had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-646">30.8</ix:nonFraction> million. Total consideration including cash, restricted shares and contingent consideration, net of cash acquired of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="6" id="f-647">12.1</ix:nonFraction>&#160;million was $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-648">206.5</ix:nonFraction> million at the date of purchase.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-649">24.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-650">35.1</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10 for changes in contingent consideration and changes in fair value.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration was funded in part by borrowings under the cr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">edit facility (Note 5) and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through issuance of convertible  preferred stock sha</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the &#8220;PIPE Investor&#8221;), pursuant to which the PIPE Investor agreed to purchase, <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-651">25,000</ix:nonFraction> shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Series A Convertible Preferred Stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="INF" name="us-gaap:TemporaryEquityRedemptionPricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-652">1,000</ix:nonFraction> per share and an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-653">25.0</ix:nonFraction> million on November 19, 2021 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Note 11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he acquisition of Novitium was completed due to its proven track record of being a research and development growth engine capable of fueling sustainable growth, to expand the research and development pipeline via niche opportunities, to enhance the contract development and manufacturing organization (&#8220;CDMO&#8221;) business and U.S. based manufacturing capacity, and to diversify the Company's revenue base.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets were recorded at their estimated fair value. In valuing acquired assets and liabilities, fair value estimates were based primarily on future expected cash flows, market rate assumptions for contractual obligations, and appropriate discount rates. In connection with the acquisition, $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-654">46.9</ix:nonFraction> million of indefinite-lived in-process research and development intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-655">67.4</ix:nonFraction> million of acquired ANDA intangible assets, $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-656">24.9</ix:nonFraction> million of customer relationship intangible assets, and goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-657">24.6</ix:nonFraction>&#160;million was recognized. Goodwill is considered an indefinite-lived asset and relates primarily to intangible assets that do not qualify for separate recognition, such as the assembled workforce and synergies between the entities. Goodwill established as a result of the acquisition is tax deductible in the U.S. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novitium operations generated $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-658">149.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" format="ixt:num-dot-decimal" scale="6" id="f-659">90.3</ix:nonFraction> million of revenue during the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Costs</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the acquisition, approximately $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-660">9.4</ix:nonFraction> million in transaction costs were expensed during the year ended 2022 as selling, general, and administrative expense in the consolidated statement of operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-638-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Shares</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novitium acquisition consideration included <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-661">2,466,654</ix:nonFraction> restricted shares, which were valued at $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="6" id="f-662">91.2</ix:nonFraction> million. These shares contained restrictions on their transfer for periods from <span style="-sec-ix-hidden:f-663">three</span> to <ix:nonNumeric contextRef="c-135" name="anip:RestrictionPeriodForSharesIssuedInBusinessCombination" format="ixt-sec:durwordsen" id="f-664">twenty-four months</ix:nonNumeric> following the completion of the acquisition. A Finnerty model was used to value the restricted shares. It includes inputs of not readily observable market data, which are Level 3 inputs. These unobservable inputs include ANI stock volatility with a range of <ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-665">65</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-137" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-666">71</ix:nonFraction>%, and the discounted lack of marketability with a range of <ix:nonFraction unitRef="number" contextRef="c-138" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-667">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-139" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-668">21.5</ix:nonFraction>% depending on the length of restriction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro Forma Consolidated Financial Information (unaudited)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" id="f-669" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma consolidated financial information summarizes the results of operations for the periods indicated as if the Novitium acquisition had been completed as of January 1, 2020.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:BusinessAcquisitionsProFormaRevenue" format="ixt:num-dot-decimal" scale="3" id="f-670">272,888</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-671">31,740</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_103"></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-672" continuedAt="f-672-1" escape="true">RESTRUCTURING </ix:nonNumeric></span></div><ix:continuation id="f-672-1"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023 the Compan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Company's <ix:nonFraction unitRef="facility" contextRef="c-6" decimals="INF" name="anip:NumberOfPharmaceuticalManufacturingFacilities" format="ixt-sec:numwordsen" scale="0" id="f-673">three</ix:nonFraction> U.S.-based manufacturing sites. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, restructuring activities resulted in expenses of $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-674">1.1</ix:nonFraction> million. This included $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-675">0.2</ix:nonFraction> million of severance and other employee benefit costs and $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-676">0.7</ix:nonFraction> million of asset-related impairment and accelerated depreciation costs, and $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-677">0.2</ix:nonFraction> million for other miscellaneous other costs. As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-678">0.1</ix:nonFraction> million of the severance and other employee benefits are unpaid and accrued. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, restructuring activities resulted in expenses of $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-679">5.7</ix:nonFraction>&#160;million. This included $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-680">2.1</ix:nonFraction>&#160;million of severance and other employee benefit costs and $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-681">3.1</ix:nonFraction>&#160;million of asset-related impairment and accelerated depreciation costs, and $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-682">0.4</ix:nonFraction>&#160;million for other miscellaneous other costs. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-149" decimals="INF" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:fixed-zero" scale="0" id="f-683">no</ix:nonFraction> restructuring expenses incurred for the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are recorded as restructuring activities, an operating item, in the accompanying consolidated statements of operations. Certain of the severance and other employee benefit costs contain a service requirement, and as such, are being accrued over time as they are earned. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the exit of the Canadian facility, the Company has determined that the land and building at the Oakville, Ontario, Canada plant will be sold together and met the criteria to be classified as held for sale as of March 31, 2023. The land and building have a net carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="f-684">8.0</ix:nonFraction> million, which is presented as assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the accompanying consolidated balance sheets as of December 31, 2023. These assets are part of the Generics, Established Brands, and Other segment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with a potential buyer for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of <ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-685">19.2</ix:nonFraction> million Canadian Dollars, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-686">14.2</ix:nonFraction> million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (Note 19).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_106"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-687" continuedAt="f-687-1" escape="true">INDEBTEDNESS</ix:nonNumeric></span></div><ix:continuation id="f-687-1" continuedAt="f-687-2"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company, as borrower, entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-688">300.0</ix:nonFraction> million (the &#8220;Term Facility&#8221;) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-689">40.0</ix:nonFraction> million, which may be used for revolving credit loans, swingline loans and letters of credit (the &#8220;Revolving Facility,&#8221; and together with the Term Facility, the &#8220;Credit Facility&#8221;). The Term Facility proceeds were used to finance the cash portion of the consideration under the Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility has a subjective acceleration clause in case of a material adverse effect. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement (&#8220;Amendment No. 1&#8221;). SOFR will be applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and replaced all LIBOR terms.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility permits both base rate borrowings (&#8220;ABR Loans&#8221;) and Eurodollar rate borrowings (&#8220;Eurodollar Loans&#8221;), plus a spread of (a) <ix:nonFraction unitRef="number" contextRef="c-152" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-690">5.00</ix:nonFraction>% above the base rate in the case of ABR Loans under the Term Facility and <ix:nonFraction unitRef="number" contextRef="c-153" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-691">6.00</ix:nonFraction>% above the SOFR Rate (or alternate benchmark rate as defined in the Credit Agreement) in the case of SOFR loans under the Term Facility and (b) <ix:nonFraction unitRef="number" contextRef="c-154" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-692">3.75</ix:nonFraction>% above the base rate in the case of ABR Loans under the Revolving Facility and <ix:nonFraction unitRef="number" contextRef="c-155" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-693">4.75</ix:nonFraction>% above the SOFR Rate (as defined in the Credit Facility) in the case of loans under the Revolving Facility. Amendment No. 1 also includes the addition of a credit spread adjustment of <ix:nonFraction unitRef="number" contextRef="c-156" decimals="7" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-694">0.11448</ix:nonFraction>% for an interest period of one-month duration, <ix:nonFraction unitRef="number" contextRef="c-157" decimals="7" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-695">0.26161</ix:nonFraction>% for a three-month duration, and <ix:nonFraction unitRef="number" contextRef="c-158" decimals="7" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-696">0.42826</ix:nonFraction>% for a six-month duration, in addition to SOFR and the applicable margin, as noted above. There were no other changes or modifications to the Credit Agreement. The Company has applied the optional expedients in ASC 848, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and elected to treat the change in the benchmark interest rate to SOFR as a continuation of the existing Credit Agreement and account for the change prospectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate under the Term Facility was <ix:nonFraction unitRef="number" contextRef="c-159" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-697">11.46</ix:nonFraction>% at December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="INF" name="us-gaap:ProceedsFromLinesOfCredit" scale="0" id="f-698">0</ix:nonFraction> drawn on the Revolving Facility and $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-699">40.0</ix:nonFraction> million remained available for borrowing subject to certain conditions.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-700">14.0</ix:nonFraction> million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of <ix:nonFraction unitRef="number" contextRef="c-163" decimals="3" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="f-701">0.5</ix:nonFraction>% per annum on any unused portion of the Revolving Facility.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.&#8217;s and its principal domestic subsidiary&#8217;s assets and any future domestic subsidiary guarantors&#8217; assets. The Credit Facility is subject to customary financial and nonfinancial covenants. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-702" continuedAt="f-702-1" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the current and non-current components of the Term Facility as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current borrowing on debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="anip:LongTermDebtGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-703">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="anip:LongTermDebtGrossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-704">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-705">2,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-706">2,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt, net of deferred financing costs </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-707">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-708">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-687-2"><ix:continuation id="f-702-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current borrowing on debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="anip:LongTermDebtGrossNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-709">291,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="anip:LongTermDebtGrossNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-710">294,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-711">6,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="3" id="f-712">8,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current debt, net of deferred financing costs and current component</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-713">284,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-714">285,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, outstanding principal was $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="f-715">294.0</ix:nonFraction> million on the Term Facility. Of the $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="f-716">0.6</ix:nonFraction> million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" format="ixt:num-dot-decimal" scale="6" id="f-717">0.4</ix:nonFraction> million is included in other non-current assets in the consolidated balance sheets, and $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="f-718">0.2</ix:nonFraction> million is included in prepaid expenses and other current assets in the consolidated balance sheets. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-719" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturity of the Term Facility is as follows for the years ending December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"/><td style="width:62.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-720">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-721">3,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-722">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-723">285,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-724">294,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock" id="f-725" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of total interest expense related to the Term Facility recognized in the accompanying consolidated statements of operations for the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-726">30,692</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-727">26,150</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseDebtExcludingAmortization" format="ixt:num-dot-decimal" scale="3" id="f-728">11,129</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance fees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-729">2,364</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-730">2,363</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="f-731">914</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" scale="3" id="f-732">587</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" scale="3" id="f-733">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestCostsCapitalizedAdjustment" scale="3" id="f-734">98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-735">32,469</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-736">28,418</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-737">11,945</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_109"></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-738" continuedAt="f-738-1" escape="true">DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY</ix:nonNumeric></span></div><ix:continuation id="f-738-1" continuedAt="f-738-2"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage exposure to changes in LIBOR-based interest rates (or alternate benchmark rate as defined in the Credit Agreement) underlying total borrowings under term facilities related to the Prior Credit Agreement. The interest rate swap matures in December 2026. Concurrent with the termination of the Prior Credit Agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-739">168.6</ix:nonFraction> million at origin on November 19, 2021 was novated and Truist Bank became the new counterparty. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described further below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap provides an effective fixed interest rate of <ix:nonFraction unitRef="number" contextRef="c-167" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-740">2.26</ix:nonFraction>% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. The notional amount of the interest rate swap was $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-741">139.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-742">151.5</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively, and decreased quarterly by approximately $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="anip:DerivativeLiabilityDecreaseInNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-743">4.0</ix:nonFraction> million until December 2023, after which it remains static until maturity in December 2026. As of December&#160;31, 2023, the fair value of the interest rate swap asset was recorded in other non-current assets in the consolidated balance sheets was $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-744">6.2</ix:nonFraction> million. As of December&#160;31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-745">8.9</ix:nonFraction> million was recorded in accumulated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-738-2"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the change in fair value of the interest rate swaps was a loss of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-746">3.7</ix:nonFraction> million. During the year ended December&#160;31, 2023, losses on the interest rate swap of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="f-747">3.4</ix:nonFraction> million were recorded in other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of tax. Di</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fferences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the years ended December&#160;31, 2023 and 2022, $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-748">2.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-749">2.3</ix:nonFraction> million, respectively, of interest expense was recognized in relation to the interest rate swaps. Included in these amounts for the years ended December&#160;31, 2023 and 2022 are reclassifications out of accumulated other comprehensive income (loss) of $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="6" id="f-750"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:num-dot-decimal" scale="6" id="f-751">2.8</ix:nonFraction></ix:nonFraction> million in expense, related to terminated and de-designated cash flow hedges. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the amendment of the Credit Agreement (Note 5), the Company&#8217;s derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform, hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Company's consolidated financial statements.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_112"></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-752" continuedAt="f-752-1" escape="true">INVENTORIES</ix:nonNumeric></span></div><ix:continuation id="f-752-1" continuedAt="f-752-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-753" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the Company's inventory by asset class as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-754">62,237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="f-755">67,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Packaging materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies" format="ixt:num-dot-decimal" scale="3" id="f-756">9,617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies" format="ixt:num-dot-decimal" scale="3" id="f-757">7,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-758">3,144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="f-759">1,889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-760">36,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="3" id="f-761">28,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-762">111,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="f-763">105,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vendor Concentration</span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><ix:continuation id="f-752-2" continuedAt="f-752-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials are sourced for products, including API, from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. As a result, we are dependent upon current vendors to supply reliably the API required for on-going product manufacturing. During the year ended December&#160;31, 2023, no single vendor represented at least 10% of invent</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ory purchases. During th</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-752-3">e year ended December&#160;31, 2022, the Company purchased approximately <ix:nonFraction unitRef="number" contextRef="c-172" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-764">19</ix:nonFraction>% of inventory from one supplier. During the year ended December&#160;31, 2021, no single vendor represented at least 10% of inventory purchases.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_115"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-765" continuedAt="f-765-1" escape="true">PROPERTY AND EQUIPMENT, NET</ix:nonNumeric></span></div><ix:continuation id="f-765-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-766" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s gross property and equipment by major asset class and accumulated depreciation as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-767">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-768">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-769">17,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-770">16,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-771">50,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-772">53,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-773">7,692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-774">4,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-775">77,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-776">75,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-777">32,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-778">32,712</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-779">44,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-780">43,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2023, 2022, and 2021 totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-781">7.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-782">7.4</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="f-783">5.5</ix:nonFraction> million, respectively. During the years ended December&#160;31, 2023, 2022, and 2021 there was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="f-784">0.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="f-785">0.1</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:InterestCostsCapitalized" scale="6" id="f-786">0.1</ix:nonFraction> million, respectively, of interest capitalized into construction in progress, respectively.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_118"></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-787" continuedAt="f-787-1" escape="true">GOODWILL AND INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-787-1" continuedAt="f-787-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2013 merger with BioSante Pharmaceuticals, Inc. (&#8220;BioSante&#8221;), the Company recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-788">1.8</ix:nonFraction> million. As a result of the acquisition of WellSpring Pharma Services Inc., the Company recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-789">1.7</ix:nonFraction> million in 2018. From the acquisition of Novitium in 2021, the Company recorded goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-790">24.6</ix:nonFraction>&#160;million. As of December 31, 2023, the Company had <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-791">two</ix:nonFraction> operating segments, which were also deemed the Company's <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-792">two</ix:nonFraction> reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in the Generics, Established Brands, and Other reporting unit.reporting unit.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually, at October 31st, or more frequently if a triggering event occurs between impairment testing dates. The Company&#8217;s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is &#8220;more likely than not&#8221; that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of the reporting unit to its respective carrying value, including its goodwill. If it is determined that it is &#8220;not likely&#8221; that the fair value of the reporting unit is less than its carrying value, then no further testing is required. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the qualitative assessments performed by the Company, it was determined that it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit was greater than its carrying value as of October 31, 2023, and therefore no impairment charges have been recognized, and no quantitative testing was required.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the qualitative impairment analysis performed at October 31, 2023, there were no events or changes in circumstances that would have reduced the fair value of the reporting unit below its carrying value from October 31, 2023 to December&#160;31, 2023. <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-793"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-794"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-795"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-796">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment loss was recognized during the years ended December&#160;31, 2023, 2022, and 2021, and the balance of goodwill was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-797"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-798">28.2</ix:nonFraction></ix:nonFraction> million as of December&#160;31, 2023 and 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-787-2" continuedAt="f-787-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-799" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net definite-lived intangible assets and net indefinite-lived intangible assets other than goodwill are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.175%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Amortization<br/>Period(1)</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definite-Lived Intangible Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired ANDA intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-800">209,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-801">100,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-802">109,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-803">195,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-804">75,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-805">120,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-183" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-806">5.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NDAs and product rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-807">244,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-808">184,861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-809">60,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-810">242,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-811">162,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-812">80,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-185" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-813">3.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketing and distribution rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-814">17,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-815">14,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-816">2,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-817">17,157</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-818">13,309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-819">3,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-187" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-820">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-compete agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-821">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-822">624</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="3" id="f-823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-824">624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-825">602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-826">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-827">24,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-828">7,707</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-829">17,193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-830">24,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-831">4,150</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-832">20,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-191" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-833">4.8</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Definite-Lived Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-834">497,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-835">308,123</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-836">189,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-837">480,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-838">255,855</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-839">225,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-840">4.5</ix:nonNumeric> years</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-841">19,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-842">19,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-843">26,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-844">26,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Intangible Assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-845">517,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-846">308,123</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-847">209,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-848">507,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-849">255,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-850">251,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average amortization period as of December 31, 2023.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (&#8220;ANDAs&#8221;), New Drug Applications (&#8220;NDAs&#8221;) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from <span style="-sec-ix-hidden:f-851">seven</span> to <ix:nonNumeric contextRef="c-196" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-852">ten years</ix:nonNumeric> years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment annually, or when events or changes in circumstances indicate that these asset might be impaired.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets other than goodwill include primarily IPR&amp;D projects. IPR&amp;D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&amp;D project is completed (generally upon receipt of regulatory approval), then the IPR&amp;D will be accounted for as a definite-lived intangible asset.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, definite-lived intangibles increased approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-853">16.4</ix:nonFraction>&#160;million, which includes $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" sign="-" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-854"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-855">6.8</ix:nonFraction></ix:nonFraction> million which was reclassified from indefinite-lived IPR&amp;D to acquired ANDA intangible assets upon completion of projects and launch of related products, and the Company added approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-856">9.6</ix:nonFraction>&#160;million of intangible assets, comprised of $<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-857">7.1</ix:nonFraction>&#160;million of ANDA intangible assets related to asset acquisitions with Slayback Pharma Limited Liability Company and Akorn Holding Company, $<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-858">2.0</ix:nonFraction>&#160;million in product rights related to the transaction with Alvogen, Inc., and other asset acquisitions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, approximately $<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-859"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" sign="-" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-860">20.3</ix:nonFraction></ix:nonFraction> million was reclassified from indefinite-lived IPR&amp;D to acquired ANDA intangible assets upon completion of projects and launch of related products. The Company added $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-861">7.2</ix:nonFraction> million in ANDA intangible assets related to the July&#160;21, 2022 transaction with Oakrum Pharma, LLC (Note 10). These assets will be amortized over a <span style="-sec-ix-hidden:f-862">seven</span>-year useful life. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-787-3"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for definite-lived intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-863">52.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-864">49.5</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-865">41.8</ix:nonFraction> million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. Refer to Note 10 for more details on acquired definite-lived and indefinite-lived intangible assets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="f-866" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense is as follows for the years ending December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-867">50,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-868">47,128</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-869">33,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-870">24,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-871">17,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-872">15,502</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-873">189,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization expense is an estimate. Actual amounts of amortization expense may differ due to timing of regulatory approvals related to IPR&amp;D assets, additional intangible assets acquired, impairment of intangible assets, and other events.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets and definite-lived intangibles when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31, 2023. The Company performed qualitative assessments to determine whether it was more likely than not that the assets were impaired in order to determine the necessity of performing a quantitative impairment test, under which management would calculate the asset&#8217;s fair value. When performing the qualitative assessments, the Company evaluated events and circumstances that would affect the significant inputs used to determine the fair value of the assets. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the assessments of the aforementioned factors, it was determined that it was more likely than not that the fair value of assets are greater than their carrying amount as of October 31, 2023, and therefore no quantitative testing for impairment was required.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the qualitative impairment analysis performed at October 31, 2023, there were no events or changes in circumstances that would have reduced the fair value of the indefinite or definite-lived intangible assets below their carrying values from October 31, 2023 to December&#160;31, 2023. <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-874">No</ix:nonFraction> impairment loss was recognized during the year ended December&#160;31, 2023. During the years ended December 31, 2022 and 2021, impairment losses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-875">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-876">2.4</ix:nonFraction> million, respectively, were recognized in relation to ANDA assets.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_121"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-877" continuedAt="f-877-1" escape="true">FAIR VALUE</ix:nonNumeric></span></div><ix:continuation id="f-877-1" continuedAt="f-877-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the funds. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to the Company, the carrying values of these borrowings approximated their fair values at December&#160;31, 2023 and 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-877-2" continuedAt="f-877-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Money market funds are readily convertible into cash and the net asset value of each fund on the last day of the reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of December 31, 2023 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-878">191.8</ix:nonFraction>&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swap</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve. The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 5, the fair value of the interest rate swap was a $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-879">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:InterestRateDerivativeLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-880">8.8</ix:nonFraction>&#160;million at December&#160;31, 2023 and 2022, respectively, and was classified as a non-current asset.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Novitium, the Company may pay up to $<ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-881">46.5</ix:nonFraction> million in additional consideration related to the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a <ix:nonNumeric contextRef="c-206" name="anip:BusinessCombinationContingentConsiderationArrangementsPeriod" format="ixt-sec:durwordsen" id="f-882">24-month</ix:nonNumeric> period, regulatory filings completed during this <ix:nonNumeric contextRef="c-206" name="anip:BusinessCombinationContingentConsiderationArrangementsPeriod" format="ixt-sec:durwordsen" id="f-883">24-month</ix:nonNumeric> period, and a percentage of net profits on certain products that are launched in the future.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discounted cash flow method used to value this contingent consideration includes inputs of not readily observable market data, which are Level 3 inputs. As of the November&#160;19, 2021 acquisition date, the contingent consideration had a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-884">30.8</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021, on December 12, 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-885">12.5</ix:nonFraction>&#160;million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Agreement and Plan of Merger, as the holders of Novitium ownership interests, for the achievement of the "ANDA Filing Earn-Out," as defined in the Agreement (Note 17). Furthermore, on February 22, 2024, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="f-886">12.5</ix:nonFraction> million to Company Members of Novitium upon the achievement of the "Gross Profit Earn-Out," as defined in the Agreement (Note 19).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was approximately $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-887">24.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-888">35.1</ix:nonFraction> million as of December&#160;31, 2023 and 2022, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the consolidated balance sheets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-889" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payment Type</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assumptions</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profit-based milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability-weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-211" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-890">12</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025-2035</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product development-based milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability-weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-212" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-891">12.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-213" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-892">100</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-877-3" continuedAt="f-877-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-893" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in contingent consideration balances classified as Level 3 balances for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-894">35,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-895">31,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="anip:FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" format="ixt:fixed-zero" scale="3" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="anip:FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" scale="3" id="f-897">300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of ANDA filing earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:num-dot-decimal" scale="3" id="f-898">12,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" format="ixt:fixed-zero" scale="3" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-900"><span style="-sec-ix-hidden:f-901">Change in fair value</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-902">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:num-dot-decimal" scale="3" id="f-903">3,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-904">23,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="f-905">35,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent value rights (&#8220;CVRs&#8221;), which were granted coincident with the merger with BioSante expired during June 2023, were considered contingent consideration and were classified as liabilities, and there were no payments made pursuant to the terms of the CVR agreement. The Company determined that the fair value of the CVRs was immaterial as of December 31, 2022, and also determined that the changes in such fair value were immaterial for the years ended December 31, 2022, and 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-906" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents financial assets and liabilities accounted for at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, by level within the fair value hierarchy:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.475%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)<br/>Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value at <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Fund</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-907">191,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-908">191,841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-909">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-910">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-911">6,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-912">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-913">6,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-915">23,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-917">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-918">23,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value at <br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-919">8,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:num-dot-decimal" scale="3" id="f-921">8,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:InterestRateDerivativeAssetsAtFairValue" format="ixt:fixed-zero" scale="3" id="f-922">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-923">35,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="3" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="f-926">35,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no financial assets and liabilities that are measured at fair value on a non-recurring basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no non-financial assets and liabilities that are measured at fair value on a recurring basis.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-877-4" continuedAt="f-877-5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, ROU assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis. During the year ended December&#160;31, 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-226" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt-sec:numwordsen" scale="6" id="f-927">no</ix:nonFraction> impairment charges recognized related to non-financial assets and liabilities measured at fair value on a non-recurring basis. During the year ended December&#160;31, 2022, the Company recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="f-928">0.1</ix:nonFraction> million related to a definite-lived ANDA intangible asset. There were no other fair value impairments recognized in the years ended December&#160;31, 2023 and 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired Non-Financial Assets Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the Company acquired from Alvogen, Inc. the rights to certain pharmaceutical products for total cash consideration of $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-929">2.0</ix:nonFraction>&#160;million (Note 8), which we plan to launch commercially in early 2024. The transaction was accounted for as an asset acquisition and there were no transaction costs directly related to the acquisition. Intangible assets amounted to $<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="f-930">2.0</ix:nonFraction>&#160;million as NDAs and product rights. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The intangible asset will be amortized in full over its useful life of <ix:nonNumeric contextRef="c-229" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-931">seven years</ix:nonNumeric> and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2023.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 14, 2023, the Company acquired <ix:nonFraction unitRef="intangibleasset" contextRef="c-230" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-932">one</ix:nonFraction> ANDA and registered patents and pending patent applications from Slayback Pharma Limited </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability Company for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-933">3.0</ix:nonFraction> million (Note 9). The Company also acquired an NDA which has yet to be filed. The transaction was funded from cash on hand. The transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. Intangible assets amounted to $<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="f-934">2.8</ix:nonFraction> million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDA will be amortized in full over its useful life of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-230" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-935">seven years</ix:nonNumeric></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-936">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment loss was recognized for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of fiscal 2023, the Company acquired <ix:nonFraction unitRef="intangibleasset" contextRef="c-233" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-937">two</ix:nonFraction> ANDAs and <ix:nonFraction unitRef="intangibleasset" contextRef="c-234" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-938">one</ix:nonFraction> pipeline product from the Chapter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="f-939">4.8</ix:nonFraction> million. The transaction was funded from cash on hand. This transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. The product portfolio included <ix:nonFraction unitRef="intangibleasset" contextRef="c-233" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-940">two</ix:nonFraction> commercial products and <ix:nonFraction unitRef="intangibleasset" contextRef="c-234" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-941">one</ix:nonFraction> pipeline product. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" scale="6" id="f-942">4.3</ix:nonFraction> million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDAs will be amortized in full over its useful life of <ix:nonNumeric contextRef="c-236" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-943">seven years</ix:nonNumeric> and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023, and therefore <ix:nonFraction unitRef="usd" contextRef="c-237" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-944">no</ix:nonFraction> impairment loss was recognized for the year ended December&#160;31, 2023.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-877-5"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;21, 2022, we acquired <ix:nonFraction unitRef="intangibleasset" contextRef="c-238" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-945">four</ix:nonFraction> ANDAs from Oakrum Pharma, LLC for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-946">8.0</ix:nonFraction> million plus an immaterial amount for the purchase of finished goods inventory. The transaction was funded from cash on hand. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. The product portfolio included <ix:nonFraction unitRef="intangibleasset" contextRef="c-239" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-947">one</ix:nonFraction> commercial product, <ix:nonFraction unitRef="intangibleasset" contextRef="c-240" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-948">one</ix:nonFraction> approved product with a launch completed in September and <ix:nonFraction unitRef="intangibleasset" contextRef="c-241" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-949">two</ix:nonFraction> filed products, with approval pending. We recognized $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-950">7.2</ix:nonFraction> million as acquired ANDA intangible assets and $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-951">1.2</ix:nonFraction> million as research and development expense because certain of the generic products have significant remaining work required in order to be commercialized and the products do not have an alternative future use. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. We used the present value of the estimated cash flows related to the products, using a discount rate of <ix:nonFraction unitRef="number" contextRef="c-242" decimals="INF" name="anip:IntangibleAssetMeasurementInput" scale="0" id="f-952">13</ix:nonFraction>% to determine the fair value of the acquired intangible assets and in-process research and development. The inventory acquired was immaterial. Contingent liabilities are accrued when they are both estimable and probable. We accrued $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="f-953">0.2</ix:nonFraction> million in contingent payments due to a third party upon the launch of a product completed in September. This was accrued and recorded in the fair value of acquired intangible assets as it was probable at the acquisition date and has been paid in 2022. The ANDAs will be amortized in full over its useful life of <ix:nonNumeric contextRef="c-243" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-954">seven years</ix:nonNumeric> and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023, and therefore <ix:nonFraction unitRef="usd" contextRef="c-244" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="6" id="f-955">no</ix:nonFraction> impairment loss was recognized for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we acquired <ix:nonFraction unitRef="intangibleasset" contextRef="c-245" decimals="INF" name="anip:NumberOfIntangibleAssetsAcquired" format="ixt-sec:numwordsen" scale="0" id="f-956">three</ix:nonFraction> NDAs and an ANDA and certain related inventories from Sandoz, Inc. for total consideration of $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-957">20.7</ix:nonFraction> million. We also incurred and paid $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:PaymentsForFees" format="ixt:num-dot-decimal" scale="6" id="f-958">0.4</ix:nonFraction> million in transaction costs directly related to the acquisition. The acquisition was funded via borrowings under our Revolver. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. We recognized $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-959">11.4</ix:nonFraction> million as acquired intangible assets and $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-960">9.7</ix:nonFraction> million of inventory at fair value, including $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="6" id="f-961">0.6</ix:nonFraction> million of API, $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:OtherInventoryDemo" format="ixt:num-dot-decimal" scale="6" id="f-962">1.0</ix:nonFraction> million of sample inventory, and $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:InventoryFinishedGoods" format="ixt:num-dot-decimal" scale="6" id="f-963">8.1</ix:nonFraction> million in finished goods inventory. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the fair value of the intangible assets, we used the present value of the estimated cash flows related to the product rights using a discount rate of <ix:nonFraction unitRef="number" contextRef="c-248" decimals="0" name="anip:IntangibleAssetMeasurementInput" scale="0" id="f-964">10</ix:nonFraction>%, which are level 3 unobservable inputs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the inventory was determined based on the estimated selling price to be generated from the finished goods, less costs to sell, including a reasonable margin, which are level 3 unobservable inputs. The intangible assets are being amortized in full over a useful life of <ix:nonNumeric contextRef="c-247" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-965">seven years</ix:nonNumeric> and are tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023 and therefore <ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-966"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-967">no</ix:nonFraction></ix:nonFraction> impairment loss was recognized for the years ended December&#160;31, 2022 and 2023.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_124"></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-968" continuedAt="f-968-1" escape="true">MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-968-1" continuedAt="f-968-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized shares</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-969"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-970">33.3</ix:nonFraction></ix:nonFraction> million shares of common stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-44" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-971"><ix:nonFraction unitRef="usdPerShare" contextRef="c-54" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-972">0.0001</ix:nonFraction></ix:nonFraction> per share, <ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-973"><ix:nonFraction unitRef="shares" contextRef="c-252" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-974">0.8</ix:nonFraction></ix:nonFraction> million shares of class C special stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-251" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-975"><ix:nonFraction unitRef="usdPerShare" contextRef="c-252" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-976">0.0001</ix:nonFraction></ix:nonFraction> per share, and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-977"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-978">1.7</ix:nonFraction></ix:nonFraction> million shares of undesignated preferred stock with a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-979"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-980">0.0001</ix:nonFraction></ix:nonFraction> per share at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-981">20.7</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-982">20.5</ix:nonFraction>&#160;million shares of common stock issued and outstanding as of December&#160;31, 2023, respectively, and <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-5" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-983">17.6</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="f-984">17.5</ix:nonFraction>&#160;million shares of common stock issued and outstanding as of December&#160;31, 2022, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offering</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, through a public offering, the Company completed the issuance and sale of <ix:nonFraction unitRef="shares" contextRef="c-253" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-985">2,183,545</ix:nonFraction> shares of ANI common stock, resulting in net proceeds after issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-986">80.6</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-987">1.5</ix:nonFraction>&#160;million shares related to a public offering of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock and <ix:nonFraction unitRef="shares" contextRef="c-254" decimals="-5" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" format="ixt:num-dot-decimal" scale="6" id="f-988">2.5</ix:nonFraction>&#160;million shares as consideration for the acquisition of Novitium.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-968-2" continuedAt="f-968-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class C Special Stock</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="c-252" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-989"><ix:nonFraction unitRef="shares" contextRef="c-252" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-990"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-991"><ix:nonFraction unitRef="shares" contextRef="c-251" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-992">11</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;thousand shares of class C special stock issued and outstanding as of December&#160;31, 2023 and 2022. Each share of class C special stock entitles its holder to <ix:nonFraction unitRef="vote" contextRef="c-252" decimals="INF" name="anip:CommonStockNumberOfVotesPerShare" format="ixt-sec:numwordsen" scale="0" id="f-993">one</ix:nonFraction> vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for <ix:nonFraction unitRef="number" contextRef="c-6" decimals="INF" name="anip:CommonStockConvertibleConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-994">one</ix:nonFraction> share of the Company's common stock, at an exchange price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-252" decimals="2" name="anip:CommonStockConversionPrice" scale="0" id="f-995">90.00</ix:nonFraction> per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of the Company's assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PIPE Shares</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the &#8220;PIPE Investor&#8221;), pursuant to which the PIPE Investor agreed to purchase, <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-996">25,000</ix:nonFraction> shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Series A Convertible Preferred Stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="INF" name="us-gaap:TemporaryEquityRedemptionPricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-997">1,000</ix:nonFraction> per share and an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-998">25.0</ix:nonFraction> million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> control. The Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-999">0.2</ix:nonFraction> million in issuance costs associated with the transaction.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PIPE Shares accrue dividends at <ix:nonFraction unitRef="number" contextRef="c-127" decimals="4" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="f-1000">6.50</ix:nonFraction>% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to the Company's common stock. The PIPE Shares are convertible into the Company's common shares at the conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="f-1001">41.47</ix:nonFraction> (i) beginning <ix:nonNumeric contextRef="c-127" name="anip:PreferredStockConvertibleMinimumPeriodOfConversion" format="ixt-sec:durwordsen" id="f-1002">two years</ix:nonNumeric> years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the Company's common stock for any <ix:nonFraction unitRef="tradingday" contextRef="c-128" decimals="INF" name="anip:ThresholdNumberOfTradingDays" scale="0" id="f-1003">20</ix:nonFraction> trading days out of <ix:nonFraction unitRef="tradingday" contextRef="c-128" decimals="INF" name="anip:NumberOfConsecutiveTradingDays" scale="0" id="f-1004">30</ix:nonFraction> consecutive trading days exceeds <ix:nonFraction unitRef="number" contextRef="c-128" decimals="INF" name="anip:PercentageOfConversionPrice" scale="-2" id="f-1005">170</ix:nonFraction>% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of December&#160;31, 2023, the PIPE shares are currently convertible into a maximum of <ix:nonFraction unitRef="shares" contextRef="c-255" decimals="INF" name="us-gaap:PreferredStockConvertibleSharesIssuable" format="ixt:num-dot-decimal" scale="0" id="f-1006">602,901</ix:nonFraction> shares of the Company's common stock.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Company's common stock, the greater of (i) the PIPE Shares&#8217; purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock. The PIPE Shares will have voting rights, voting as one series with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &#8220;Certificate&#8221;) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares&#8217; purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the holder of the PIPE Shares would have received if it had converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-968-3">There were <ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1007"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1008">25,000</ix:nonFraction></ix:nonFraction> shares of Series A convertible preferred stock outstanding as of December&#160;31, 2023 and 2022.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_1099511628349"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1009" continuedAt="f-1009-1" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="f-1009-1" continuedAt="f-1009-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings (loss) per share by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under our ESPP, and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1010" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share for the years ended December&#160;31, 2023, 2022, and 2021 are calculated for basic and diluted earnings (loss) per share as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) available to common shareholders </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1011">17,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1012">49,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="f-1013">42,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1014">17,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1015">49,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1016">42,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:num-dot-decimal" scale="3" id="f-1017">1,679</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1018">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" format="ixt:fixed-zero" scale="3" id="f-1019">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1020">1,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1021">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" format="ixt:fixed-zero" scale="3" id="f-1022">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) available to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1023">15,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:UndistributedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1024">49,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:UndistributedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-1025">42,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarningsDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1026">15,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:UndistributedEarningsDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1027">49,521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:UndistributedEarningsDiluted" format="ixt:num-dot-decimal" scale="3" id="f-1028">42,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1029">18,001</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1030">16,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1031">12,596</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1032">18,001</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1033">16,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1034">12,596</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of stock options, ESPP, and performance stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-1035">193</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1036">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-1037">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1038">18,194</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1039">16,260</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1040">12,596</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1041">0.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1042">3.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1043">3.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1044">0.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-14" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1045">3.05</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-15" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1046">3.40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><ix:continuation id="f-1009-2" continuedAt="f-1009-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings (loss) per share, were <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1047">2.4</ix:nonFraction> million, <ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1048">2.6</ix:nonFraction> million, and <ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-1049">1.7</ix:nonFraction> million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. For the years ended December 31, 2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because the Company reported a net loss</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1009-3">.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_127"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1050" continuedAt="f-1050-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-1050-1" continuedAt="f-1050-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 ESPP. As of December 31, 2023 there are <ix:nonFraction unitRef="shares" contextRef="c-256" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1051">0.1</ix:nonFraction>&#160;million shares of common stock available for issuance under the ESPP. Under the ESPP, participants can purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="c-257" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-1052">15</ix:nonFraction>% discount. The Company issued <ix:nonFraction unitRef="shares" contextRef="c-257" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1053">38</ix:nonFraction>&#160;thousand, <ix:nonFraction unitRef="shares" contextRef="c-258" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1054">29</ix:nonFraction>&#160;thousand, and <ix:nonFraction unitRef="shares" contextRef="c-259" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1055">14</ix:nonFraction>&#160;thousand shares in the years ended December&#160;31, 2023, 2022, and 2021, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1056" continuedAt="f-1056-1" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in the consolidated statements of operations:</span></div></ix:nonNumeric><div style="margin-top:12pt"><ix:continuation id="f-1056-1" continuedAt="f-1056-2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1057">360</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1058">222</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1059">87</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1060">60</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1061">50</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1062">15</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1063">47</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1064">41</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1065">21</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1066">467</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1067">313</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1068">123</ix:nonFraction></span></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Incentive Plan <br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity-based service awards are granted under the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the &#8220;2022 Plan&#8221;), which was approved by the Company's stockholders at the 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) held on April 27, 2022. Prior to this approval, the Company granted equity-based incentive awards under the Sixth Amended and Restated 2008 Stock Incentive Plan (the &#8220;2008 Plan&#8221;), which was renamed, amended and restated to the 2022 Plan. The 2022 Plan, among other things, increased the number of shares reserved for issuance thereunder by <ix:nonFraction unitRef="shares" contextRef="c-269" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1069">1,150,000</ix:nonFraction> shares. As of December&#160;31, 2023, <ix:nonFraction unitRef="shares" contextRef="c-270" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="f-1070">1.1</ix:nonFraction>&#160;million shares of common stock were available for issuance under the 2022 Plan. On May 23, 2023, the Company&#8217;s stockholders approved an amendment to the 2022 Plan (such amendment, the &#8220;2023 Stock Plan Amendment&#8221;). Subject to adjustment, the 2023 Stock Plan Amendment increased the number of shares reserved for issuance under the 2022 Plan by <ix:nonFraction unitRef="shares" contextRef="c-271" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1071">750,000</ix:nonFraction> shares.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may grant stock options to employees through an inducement grant outside of the 2022 Plan to induce prospective employees to accept employment with us (the &#8220;Inducement Grants&#8221;). The options are granted at an exercise price equal to the fair market value of a share of the common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of the stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of equity-based service awards are measured based on the grant-date fair value of the award. The cost is recognized ratably over the period during which an employee is required to provide service in exchange for the award or the requisite service period. Stock-based compensation expense is recognized ratably over the vesting periods of the awards.</span></div><ix:continuation id="f-1056-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense incurred for stock options, restricted stock awards, performance-based restricted stock units, and Inducement Grants and included in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1072">18,676</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1073">13,094</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1074">9,818</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1075">863</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1076">710</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1077">543</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1078">646</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1079">482</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1080">5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1081">20,185</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1082">14,286</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1083">10,366</ix:nonFraction></span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1050-2" continuedAt="f-1050-3"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1084">3.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1085">1.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1086">1.0</ix:nonFraction> million were recognized for stock-based compensation-related tax deductions in the 2023, 2022, and 2021 consolidated statements of operations, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options granted to employees and consultants generally vest over a period of <ix:nonNumeric contextRef="c-284" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1087">four years</ix:nonNumeric> and have <ix:nonNumeric contextRef="c-284" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1088">10-year</ix:nonNumeric> contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of <span style="-sec-ix-hidden:f-1089">one</span> to <ix:nonNumeric contextRef="c-286" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1090">four years</ix:nonNumeric> and have <ix:nonNumeric contextRef="c-287" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1091">10-year</ix:nonNumeric> contractual terms. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1092" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, 2022, and 2021, the fair value of each option grant was estimated using the Black-Scholes option-pricing model, using the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-288" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1093">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-289" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1094">5.50</ix:nonNumeric> - <ix:nonNumeric contextRef="c-290" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1095">6.25</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-291" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1096">5.50</ix:nonNumeric> - <ix:nonNumeric contextRef="c-292" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1097">6.25</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-288" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1098">4.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-289" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1099">1.71</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-290" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1100">2.83</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1101">0.68</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1102">1.39</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-288" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1103">49.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-289" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1104">48.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-290" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1105">50.0</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-291" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1106">48.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-292" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1107">49.5</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-288" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1108">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-293" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1109">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-294" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1110">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the simplified method to estimate the expected option life of options. The risk-free interest rate used is the yield on a U.S. Treasury note as of the grant date with a maturity equal to the estimated life of the option. The calculated estimated volatility rate is based on ANI's historical stock price. The Company has not issued a cash dividend on the common shares in the past nor does the Company have any current plans to do so in the future; therefore, an expected dividend yield of <ix:nonFraction unitRef="number" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-1111">zero</ix:nonFraction> was used.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1050-3" continuedAt="f-1050-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-1112" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2022 Plan and Inducement Grants during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.023%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-295" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1113">936</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-295" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1114">48.44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-296" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1115">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="f-1116">372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-294" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1117">168</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1118">33.09</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1119">15.71</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-294" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1120">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1121">40.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-1122">552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-294" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1123">19</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1124">59.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-294" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-1125">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-294" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1126">55.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-297" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1127">988</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-297" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1128">45.56</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-294" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1129">6.6</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1130">6,786</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-293" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1131">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-293" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1132">34.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-293" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1133">16.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-293" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1134">23</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-293" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1135">30.03</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-1136">153</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-293" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1137">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-293" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1138">36.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-293" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-1139">47</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-293" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1140">55.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-298" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1141">907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-298" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1142">45.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-293" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1143">5.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1144">3,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-288" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1145">3</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1146">41.84</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1147">22.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-288" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1148">189</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1149">44.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1150">2,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-288" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-1151">21</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1152">33.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-288" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-1153">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-288" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1154">55.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="f-1155">689</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-299" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1156">46.05</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-288" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1157">4.9</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1158">8,370</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-299" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="f-1159">580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-299" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1160">48.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-288" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1161">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1162">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1163">1.6</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options granted under the 2022 Plan and Inducement Grant. The cost is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-288" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1164">1.1</ix:nonNumeric> years. During the year ended December&#160;31, 2023, ANI received $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1165">8.3</ix:nonFraction> million in cash from the exercise of stock options and recorded approximately $<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1166">0.2</ix:nonFraction> million tax provision related to these exercises. During the year ended December&#160;31, 2022, ANI received $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1167">0.7</ix:nonFraction> million in cash from the exercise of stock options and recorded a $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-1168">0.1</ix:nonFraction> million tax provision related to these exercises. During the year ended December&#160;31, 2021, ANI received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="6" id="f-1169">1.7</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash from the exercise of stock options and recorded a $<ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" scale="6" id="f-1170">0.1</ix:nonFraction> million tax provision related to these exercises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards (&#8220;RSAs&#8221;) granted to employees generally vest over a period of <ix:nonNumeric contextRef="c-300" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1171">four years</ix:nonNumeric>. RSAs granted to non-officer directors generally vest over a period of <ix:nonNumeric contextRef="c-301" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1172">one year</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock delivered to employees and directors will be unrestricted upon vesting. During the vesting period, the recipient of the restricted stock has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of the Company's stock on the date of grant.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1050-4" continuedAt="f-1050-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-1173" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSA activity under the Plan during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Term<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-302" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1174">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-302" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1175">48.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-303" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1176">2.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-304" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1177">541</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1178">33.02</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-304" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1179">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1180">48.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-304" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1181">61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-304" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1182">48.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-305" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1183">707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-305" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1184">36.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-304" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1185">2.8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-306" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1186">748</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1187">32.76</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-306" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1188">245</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1189">36.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-306" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1190">69</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-306" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1191">38.08</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-307" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1192">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-307" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1193">33.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-306" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1194">2.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-308" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1195">674</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1196">43.30</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-308" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1197">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1198">34.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-308" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1199">81</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-308" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1200">38.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-309" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="f-1201">1,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-309" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1202">38.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-308" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1203">2.4</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-1204">41.5</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total unrecognized compensation cost related to non-vested RSAs granted under the Plan, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-308" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1205">2.4</ix:nonNumeric> years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards may also be issued in the form of PSUs. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a <span style="-sec-ix-hidden:f-1206">three</span>-year performance period. On February 28, 2023, as part of the Company's equity compensation program, PSUs were granted to certain executives. Of these PSUs, <ix:nonFraction unitRef="number" contextRef="c-311" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" scale="-2" id="f-1207">50</ix:nonFraction>% were market performance-based restricted stock units (&#8220;MPRSUs&#8221;), vesting of which is contingent upon the Company meeting certain total shareholder return (&#8220;TSR&#8221;) levels as compared to a select peer group over the over <span style="-sec-ix-hidden:f-1208">three</span> years starting January 1, 2023. The MPRSUs are also subject to the recipient&#8217;s continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the <span style="-sec-ix-hidden:f-1209">three</span>-year period and have a maximum potential to vest at <ix:nonFraction unitRef="number" contextRef="c-311" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" scale="-2" id="f-1210">200</ix:nonFraction>% (<ix:nonFraction unitRef="shares" contextRef="c-311" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" format="ixt:num-dot-decimal" scale="0" id="f-1211">85,099</ix:nonFraction> shares) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-312" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1212">68.65</ix:nonFraction> and was calculated using a Monte Carlo simulation model. These MPRSUs are included at <ix:nonFraction unitRef="number" contextRef="c-311" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" scale="-2" id="f-1213">100</ix:nonFraction>% of the estimate number of shares at the end of the <span style="-sec-ix-hidden:f-1214">three</span>-year performance period and are reflected under &#8220;Granted&#8221; in the table below.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="number" contextRef="c-313" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" scale="-2" id="f-1215">50</ix:nonFraction>% of the PSUs were performance based restricted stock units (&#8220;PRSUs&#8221;), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over <span style="-sec-ix-hidden:f-1216">three</span> years starting January 1, 2023. The PRSUs are also subject to the recipient&#8217;s continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the <ix:nonNumeric contextRef="c-310" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1217">three-year</ix:nonNumeric> period and have a maximum potential to vest at <ix:nonFraction unitRef="number" contextRef="c-313" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" scale="-2" id="f-1218">200</ix:nonFraction>% (<ix:nonFraction unitRef="shares" contextRef="c-313" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" format="ixt:num-dot-decimal" scale="0" id="f-1219">85,099</ix:nonFraction> shares) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-310" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1220">41.84</ix:nonFraction> based on the closing price of the stock on the date of grant. These PRSUs are included at <ix:nonFraction unitRef="number" contextRef="c-313" decimals="INF" name="anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" scale="-2" id="f-1221">100</ix:nonFraction>% of the estimated number of shares at the end of the <span style="-sec-ix-hidden:f-1222">three</span>-year performance period and are reflected under &#8220;Granted&#8221; in the table below.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1050-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" id="f-1223" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PSU activity under the Plan during the years ended December&#160;31, 2023 and 2022 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Term<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-314" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="3" id="f-1224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-314" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1226">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1227">41.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:fixed-zero" scale="3" id="f-1228">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="f-1229">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="shares" contextRef="c-68" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-1230">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-68" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1231">41.84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-315" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1232">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-315" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1233">41.84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-68" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="f-1234">2.0</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-1235">2.5</ix:nonFraction> million of total unrecognized compensation cost related to non-vested PSUs granted under the Plan, which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-68" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1236">2.0</ix:nonNumeric> years.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1237" continuedAt="f-1237-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-1237-1" continuedAt="f-1237-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2018, ANI Pharmaceuticals Canada Inc. (&#8220;ANI Canada&#8221;) acquired all the issued and outstanding equity interests of WellSpring in a non-taxable transaction. Following the consummation of the transaction, WellSpring was merged into ANI Canada. For U.S. Federal and state income tax purposes, ANI Canada is not part of ANI&#8217;s consolidated group; rather, ANI Canada is subject to income taxes only in Canada and solely based on its stand-alone operations. The foreign current and foreign deferred provisions (benefits) below represent the Company's tax provision (benefit) from the Canadian and Indian taxing jurisdictions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to establish a valuation allowance is required to be established for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Projected future taxable income and tax planning strategies in making this assessment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the consolidated valuation allowance was $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1238">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-1239">0.4</ix:nonFraction>&#160;million, respectively, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1240" continuedAt="f-1240-1" escape="true">expense (benefit) for income taxes consists of the following for the years ended December 31:</ix:nonNumeric></span></div><ix:continuation id="f-1240-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1241">9,117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="f-1242">152</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1243">1,296</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1244">3,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1245">249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1246">1,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1247">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1248">66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1249">691</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1250">12,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1251">467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1252">3,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax benefit</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1253">7,601</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1254">13,382</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1255">12,163</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1256">3,946</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1257">1,722</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1258">5,122</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-1259">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-1260">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="f-1261">336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1262">11,576</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1263">15,232</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1264">16,949</ix:nonFraction>)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="f-1265">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="f-1266">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" id="f-1267">187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expense (benefit) for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1268">1,093</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1269">14,769</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1270">13,455</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1237-2" continuedAt="f-1237-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1271" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between expected income tax expense (benefit) from applying U.S. Federal statutory tax rates to the pre-tax income (loss) and actual income tax expense (benefit) relates primarily to the effect of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1272">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1273">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1274">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of Federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1275">4.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1276">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1277">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1278">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1279">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1280">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1281">0.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:fixed-zero" scale="-2" id="f-1282">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-1283">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1284">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1285">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1286">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1287">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1288">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1289">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in state apportionment factors, state and foreign rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" scale="-2" id="f-1290">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" scale="-2" id="f-1291">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" scale="-2" id="f-1292">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and experimentation and charitable credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1293">19.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1294">1.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1295">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer pricing and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1296">2.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1297">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1298">2.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1299">5.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-14" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1300">23.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-15" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1301">24.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1302" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Deferred income tax assets and liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals and advances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1303">12,470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1304">9,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1305">6,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1306">6,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for chargebacks and returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" format="ixt:num-dot-decimal" scale="3" id="f-1307">17,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" format="ixt:num-dot-decimal" scale="3" id="f-1308">15,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-1309">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInventory" format="ixt:num-dot-decimal" scale="3" id="f-1310">5,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1311">40,193</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1312">33,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1313">2,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1314">5,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1315">11,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1316">4,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1317">7,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1318">11,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1319">102,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1320">91,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1321">5,658</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1322">5,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1323">5,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1324">4,298</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1325">11,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1326">10,074</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-1327">438</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-1328">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of deferred tax liabilities and valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1329">90,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1330">81,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, U.S. federal net operating loss carryforwards were approximately $<ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1331">8.0</ix:nonFraction> million, all of which arose as a result of the 2013 merger with BioSante Pharmaceuticals, Inc. Net operating loss carryforwards related to the 2013 merger, if not used, expire in annual increments through 2033 and are limited on an annual basis as prescribed by Section 382 of the U.S. Internal Revenue Code; and the current annual limitation is approximately $<ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="anip:OperatingLossCarryforwardsAnnualLimitationsOnUse" format="ixt:num-dot-decimal" scale="6" id="f-1332">0.8</ix:nonFraction> million per year. Additionally, as of December&#160;31, 2023, there were total net operating losses in various states of approximately $<ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1333">13.0</ix:nonFraction>&#160;million which begin to expire through 2042, and in Canada of $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-1334">1.0</ix:nonFraction> million that expire through 2038. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1237-3"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous jurisdictions in the U.S., Canada, and India. Significant judgment is required in evaluating the tax positions and determining the provision for income taxes. Liabilities are established for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These liabilities are established when it is believed that certain positions might be challenged despite the belief that our tax return positions are fully supportable. These liabilities are adjusted in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of changes to the liability that is considered appropriate. There were no material uncertain income tax positions identified as of December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income tax audits in all jurisdictions for which tax returns are filed. Tax audits by their nature are often complex and can require several years to complete. All of the Company's income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_133"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsDisclosureTextBlock" id="f-1335" continuedAt="f-1335-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-1335-1" continuedAt="f-1335-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All existing leases as of December&#160;31, 2023 are classified as operating leases. As of December&#160;31, 2023, there are <ix:nonFraction unitRef="operatinglease" contextRef="c-6" decimals="INF" name="anip:NumberOfOperatingLeases" scale="0" id="f-1336">14</ix:nonFraction> operating leases for facilities and office equipment with remaining terms expiring from 2025 through 2028 and a weighted average remaining lease terms of <ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1337">3.9</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-7" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1338">2.6</ix:nonNumeric> years, as of December 31, 2023 and 2022, respectively. During April 2023, the Company entered into a lease agreement for additional warehouse space in East Windsor, New Jersey. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Company's square footage and also extended the termination date to December 2028. Many of the operating leases have fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the balance sheet, and the Company does not separate lease and non-lease components of contracts. The Company&#8217;s lease agreements do not provide for determination of the interest rate implicit in the lease. Therefore, the Company used a benchmark approach to derive an appropriate incremental borrowing rate. The Company&#8217;s incremental borrowing rate is the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived an incremental borrowing rate, which was used to discount its lease liabilities. The weighted average incremental borrowing rates as of December 31, 2023 and 2022 is <ix:nonFraction unitRef="number" contextRef="c-6" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1339">8.12</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-7" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1340">3.99</ix:nonFraction>%, respectively. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any finance leases, any sublease arrangements, or any leases where the Company is considered the lessor.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1341" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense consisted of the following for the years ended December 31:</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"/><td style="width:59.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.676%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.676%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1342">2,031</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-1343">701</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-1344">240</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-1345">221</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1.37pt 0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-1346">236</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-1347">48</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1348">2,252</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-1349">937</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-1350">288</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1335-2" continuedAt="f-1335-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1351" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the lease liabilities recorded on the Consolidated Balance Sheet as of December 31, 2023:</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"/><td style="width:85.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.203%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1352">1,967</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1353">1,610</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1354">1,290</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1355">1,289</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-1356">506</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-1357">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1358">6,662</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: effects of discounting </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-1359">990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1360">5,672</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1361">Less: current lease liability, included in accrued expenses and other</span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1362">1,561</ix:nonFraction>)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1363">Non-current lease liability, included in other non-current liabilities</span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1364">4,111</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (&#8220;DEA&#8221;), the Food and Drug Administration (&#8220;FDA&#8221;), the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), the Central Drugs Standard Control Organization (&#8220;CDSCO&#8221;), The Narcotics Control Bureau (&#8220;NCB&#8221;), and India&#8217;s Ministry of Health and Family Welfare (&#8220;MoHFW&#8221;). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANI's products. The DEA and NCB maintain oversight over products that are considered controlled substances. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unapproved Products</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="product" contextRef="c-6" decimals="INF" name="anip:NumberOfProductsMarketed" format="ixt-sec:numwordsen" scale="0" id="f-1365">Three</ix:nonFraction> products, Esterified Estrogen with Methyltestosterone (&#8220;EEMT&#8221;), Opium Tincture, Thyroid Tablets, and are marketed without approved NDAs or ANDAs. During the years ended December&#160;31, 2023, 2022, and 2021, net revenues for Esterified Estrogen with Methyltestosterone (&#8220;EEMT&#8221;), Opium Tincture and Thyroid Tablets products totaled $<ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1366">22.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1367">14.2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1368">16.2</ix:nonFraction> million, respectively. The Company obtained the rights to Hyoscyamine, a product without an approved NDA as of December 27, 2023, which we plan to launch commercially in early 2024 (see further discussion below).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA's policy with respect to the continued marketing of unapproved products appears in the FDA's September 2011 Compliance Policy Guide Sec. 440.100 titled &#8220;Marketed New Drugs without Approved NDAs or ANDAs.&#8221; Under this policy, the FDA has stated that it will follow a risk-based approach with regard to enforcement against marketing of unapproved products. The FDA evaluates whether to initiate enforcement action on a case-by-case basis, but gives higher priority to enforcement action against products in certain categories, such as those with potential safety risks or that lack evidence of effectiveness. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that, so long as we comply with applicable manufacturing standards, the FDA will continue to operate on a risk-based approach and will not take action against us. However, we can offer no assurance that the FDA will continue to follow this approach or that it will not take a contrary position with any individual product or group of products. If the FDA were to move away from the risk-based approach to enforcement against marketing of unapproved products, we may be required to seek FDA approval for these products or withdraw such products from the market. If we decide to withdraw the products from the market, net revenues for generic pharmaceutical products would decline materially, and if we decide to seek FDA approval, we would face increased expenses and might need to suspend sales of the products until such approval was obtained, and there are no assurances that we would receive such approval.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1335-3" continuedAt="f-1335-4"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One group of products that the Company manufactured on behalf of a contract customer, Hyoscyamine, was marketed by that customer without an approved NDA. Contract manufacturing revenues for Hyoscyamine, for the years ended December&#160;31, 2023, 2022, and 2021 were $<ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1369">1.9</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1370">2.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-1371">2.4</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. On December 27, 2023 the Company purchased the intellectual property and product rights to Hyoscamine from Alvogen, Inc. (Note 10).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal proceedings </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved, and from time to time may become involved, in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees for litigation-related matters are expensed as incurred and included in the consolidated statements of operations under the selling, general, and administrative expense line item. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1335-4" continuedAt="f-1335-5"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Litigation </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, <ix:nonFraction unitRef="plaintiff" contextRef="c-327" decimals="INF" name="us-gaap:LossContingencyNumberOfPlaintiffs" format="ixt-sec:numwordsen" scale="0" id="f-1372">six</ix:nonFraction> individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with <ix:nonFraction unitRef="manufacturer" contextRef="c-328" decimals="0" name="anip:LossContingencyNumberOfManufacturers" format="ixt-sec:numwordsen" scale="0" id="f-1373">seven</ix:nonFraction> potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company&#8217;s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys&#8217; fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York as In re Bystolic Antitrust Litigation, Case No. 20-cv-005735 (LJL). On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendants&#8217; motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit.  Oral arguments were held on December 6, 2023 and a decision from the court is pending. ANI continues to dispute any liability in this matter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2021, Azurity Pharmaceuticals, Inc. (&#8220;Azurity&#8221;) filed a complaint in the United States District Court for the District of Minnesota against ANI, asserting that ANI&#8217;s vancomycin hydrochloride oral solution drug product infringes U.S. Patent No. 10,688,046. The complaint sought injunctive relief, damages, including lost profits and/or royalty, treble damages, and attorneys&#8217; fee and costs. On February 15, 2022, the Company entered into a settlement agreement with Azurity to resolve all claims related to this action. Under the terms of the agreement, Azurity granted ANI a non-exclusive, non-transferable, non-sublicensable, royalty-bearing license under its patents to sell ANI product in the United States and dismissed the action with prejudice. In exchange, ANI paid Azurity $<ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-1374">1.9</ix:nonFraction>&#160;million of royalties from past sales and will pay Azurity a royalty equal to <ix:nonFraction unitRef="number" contextRef="c-329" decimals="2" name="anip:RoyaltyOnFutureSalesPercent" scale="-2" id="f-1375">20</ix:nonFraction>% of gross margin of sales of the ANI product for a contractually defined term.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2021, United Therapeutics Corp. and Supernus Pharmaceuticals, Inc. (&#8220;UTC/Supernus&#8221;) filed a complaint in the United States District Court for the District of Delaware against ANI, asserting that ANI&#8217;s proposed Treprostinil extended release drug product, which is subject to ANI&#8217;s Abbreviated New Drug Application No. 215667, infringes U.S. Patent Nos. 7,417,070, 7,544,713, 8,252,839, 8,349,892, 8,410,169, 8,747,897, 9,050,311, 9,278,901, 9,393,203, 9,422,223, 9,593,066 and 9,604,901 (&#8220;the Asserted Patents&#8221;). The complaint sought injunctive relief</span><span style="color:#353535;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attorneys' fee and costs. On May 26, 2022, the parties&#8217; respective claims and counterclaims were dismissed pursuant to a confidential settlement agreement.</span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1335-5"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, Azurity filed a complaint in the United States District Court for the District of New Jersey against Novitium, seeking a declaratory judgment that Novitium&#8217;s manufacture, use, sale, importation and/or offer to sell Bionpharma Inc.&#8217;s (&#8220;Bionpharma&#8221;) enalapril maleate oral solution drug product (the &#8220;Product&#8221;) would infringe U.S. Patents Nos. 11,040,023 and 11,141,405 (the &#8220;Novitium Action&#8221;). The complaint sought injunctive relief, and an award of Azurity&#8217;s costs and expenses. On October 12, 2022, Bionpharma filed a motion in the New Jersey court to intervene on Novitium&#8217;s behalf in the litigation and on October 14, 2022, Novitium and Bionpharma jointly moved to transfer venue to the District of Delaware. Transfer was granted on January 20, 2023. On March 27, 2023, the transferred Novitium Action (assigned Delaware Civil Action No. 23-163-MSG) was consolidated with the Delaware Third Wave Suits against Bionpharma (Civil Action Nos. 21-1286-MSG, 21-1455-MSG), which include Azurity&#8217;s infringement claims against Bionpharma involving the same patents asserted in the Novitium Action, as well as Bionpharma&#8217;s antitrust claims against Azurity. On August 3, 2023, Azurity filed an amended complaint against Novitium seeking damages for supplying Bionpharma's ANDA product. On November 14, 2023, the court dismissed all of Azurity's claims against Novitium with prejudice and dismissed Novitium as a party from the Delaware Third Wave Suits. Bionpharma has agreed to indemnify Novitium under the terms of its manufacturing and supply agreement for any damages, costs, and expenses relating to actual or alleged infringement of intellectual property rights or sale of the Product by Bionpharma. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2023, Orphalan SA ("Orphalan") filed a complaint in the United States District Court for the District of Delaware against Novitium, asserting that Novitium's proposed triethylenetetramine tetrachloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218493, infringes U.S. Patent Nos. 10,988,436 and 11,072,577.  The complaint seeks damages, injunctive relief, attorneys' fees and costs. On December 1, 2023, Orphalan voluntarily dismissed the action without prejudice. Novitium disputes any liability in this matter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2023, Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS filed a compliant in the United States District Court for the District of Delaware against Novitium and certain other defendants named in the complaint, asserting, among other things, that Novitium's proposed pitolisant hydrochloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218495, infringes U.S. Patent Nos 8,207,197, 8,354,430 and 8,486,947.  The complaint seeks damages, injunctive relief, attorneys' fees and costs.  Novitium disputes any liability in this matter.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ranitidine Related Litigation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July 2020, ANI and Novitium were served with a complaint brought in the First Judicial Court, County of Santa Fe, State of New Mexico by the Office of the Attorney General of the State of New Mexico against manufacturers and sellers of ranitidine products. The complaint asserted a public nuisance claim and a negligence claim against the generic ranitidine manufacturer defendants, including ANI and Novitium. As damages for the nuisance claim, New Mexico asked that the defendants fund this medical monitoring program.  With respect to the nuisance claim, New Mexico asserted that it paid for ranitidine products through state-funded insurance and health-care programs. On April 16, 2021, New Mexico filed an amended complaint in the New Mexico First Judicial District Court in Santa Fe County. It did not name ANI in the amended complaint, effectively voluntarily dismissing ANI from the action. Novitium was named as a defendant in the amended complaint. On September 1, 2023, the court entered an order dismissing Novitium without prejudice.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Federal Court Personal Injury Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In June 2020, ANI was served with a personal injury complaint in the case of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Koepsel v. Boehringer Ingelheim Pharmaceuticals, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No. 20-MD-2924, Case No. 9:20-cv-80882-RLR, filed in the United States District Court for Southern District of Florida, in which the plaintiff alleges that he developed kidney cancer in 2018 as a result of taking over the counter medication containing ranitidine. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Koepsel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action was filed within the existing multi-district litigation concerning ranitidine-containing drugs pending in the Southern District of Florida, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In re Zantac MDL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 20 MDL 2924 (the "MDL"). A Master Personal Injury Complaint (&#8220;MPIC&#8221;) in that MDL that was filed on June 22, 2020 also named ANI and Novitium as defendants. ANI was dismissed from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Koepsel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case on August 21, 2020 and was dismissed from the MPIC on September 8, 2020. On December&#160;31, 2020, after ANI was dismissed, the district court dismissed the MPIC claims against generic manufacturer defendants partially with prejudice and partially with leave to replead. The failure to warn and design defect claims were dismissed with prejudice on preemption grounds. An Amended MPIC was filed on February 8, 2021, which did not name ANI but did name Novitium. By opinion dated July 8, 2021, the district court dismissed all claims against the generic manufacturer defendants with prejudice on preemption grounds.  In addition, by opinion and order dated December 6, 2022, the district court granted the brand manufacturer defendants&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> motion to exclude the plaintiffs&#8217; expert testimony on general causation for the &#8220;designated cancers&#8221; that the plaintiffs&#8217; leadership team claimed to be caused by ranitidine. The district court also granted the brand manufacturer defendants&#8217; motion for summary judgment because the plaintiffs had failed to produce admissible primary evidence of general causation. The plaintiffs have appealed to the Eleventh Circuit Court of Appeals. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI and Novitium were named in other individual personal injury complaints filed in the MDL in which plaintiffs allege that they developed cancer after taking prescription and over the counter medication containing ranitidine. ANI was served with complaints in <ix:nonFraction unitRef="claim" contextRef="c-330" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1376">five</ix:nonFraction> of those additional cases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cooper v. Boehringer Ingelheim Pharmaceuticals, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No. 20-MD-2924, Case No. 9:20-cv-81130-RLR (served September 30, 2020), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lineberry v. Amneal Pharmaceuticals, LLC, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No. 20-MD-2924, Case No. 9:20-cv-81079-RLR (served August 20, 2020), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lovette v. Amneal Pharmaceuticals, LLC, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No. 20-MD-2924, Case No. 9:20-cv-81040-RLR (served August 26, 2020), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hightower v. Pfizer, et al,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> MDL No. 20-MD-2924, Case No. 9-20-cv-82214-RLR (served December 16, 2020) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bird v. Boehringer Ingelheim Pharmaceuticals, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MDL No. 20-MD-2924, Case No. 9-20-cv-80837-RLR (served December 30, 2020). Each of the plaintiffs in the <ix:nonFraction unitRef="claim" contextRef="c-330" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1377">five</ix:nonFraction> pending cases alleges a cancer diagnosis prior to the time that ANI sold ranitidine, and ANI informally sought dismissal from these cases on that basis. ANI was voluntarily dismissed from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cooper</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lineberry</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lovette</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions on November 20, 2020, from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bird</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action on March 15, 2021, and from the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hightower</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> action on March 29, 2021. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the district court&#8217;s July&#160;8, 2021 preemption decision, Novitium had been named in <ix:nonFraction unitRef="claim" contextRef="c-331" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="f-1378">158</ix:nonFraction> short form complaints filed by claimants in the MDL. Those complaints were effectively dismissed with prejudice with the MPIC on July 8, 2021. Counsel for the plaintiffs have been notified that Novitium did not sell an over the counter ranitidine product and sold a generic prescription ranitidine product for a limited period of time, from December 2018 until September 2019 and Novitium&#8217;s product was voluntarily recalled in October 2019. Out of the <ix:nonFraction unitRef="claim" contextRef="c-331" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="f-1379">158</ix:nonFraction> short form complaints, approximately 114 plaintiffs either were diagnosed with cancer before Novitium began manufacturing the product, only took over the counter ranitidine, or took ranitidine before Novitium began manufacturing it. Two of those 114 plaintiffs dismissed Novitium from their short form complaints. In light of the Court&#8217;s dismissal of all claims with prejudice, Novitium has not pursued dismissal of the short form complaints against it at this time. Following the district court&#8217;s </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision, plaintiffs began filing additional short form complaints in the MDL. Novitium currently is named as a defendant in more than <ix:nonFraction unitRef="claim" contextRef="c-332" decimals="-2" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="f-1380">700</ix:nonFraction> short form complaints. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The plaintiffs have taken multiple appeals from decisions issued by the district court in the MDL to the Eleventh Circuit. On September 8, 2023, the Eleventh Circuit remanded a subset of the MDL appeals back to the district court for entry of final judgments pursuant to Rule 58. The defendants filed a motion with the Eleventh Circuit to remand a similarly situated appeal for similar entry of a final judgment. In addition, the defendants are seeking a stay from the Eleventh Circuit of all non-remanded related appeals in order to have all of the related appeals decided together. The district court has entered final judgments and the appeals are now pending before the Eleventh Circuit.</span></div><div style="margin-top:10pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI and Novitium dispute any liability in these matters.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Court Personal Injury Litigation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Illinois. On February 3, 2022, a complaint was filed in Cook County, Illinois, naming Novitium as a defendant. The complaint incorrectly identifies Novitium as a &#8220;repackager.&#8221; The case is styled Ross v. Boehringer Ingelheim Pharmaceuticals, Inc., et. al. The complaint asserts claims of strict liability/failure to warn, strict liability/design defect, negligent failure to warn, negligent product design, general negligence, negligent misrepresentation, breach of express and implied warranties, and unjust enrichment. The plaintiff alleges that he was diagnosed with prostate cancer in 2017, before Novitium began selling generic ranitidine products, and that he took over the counter ranitidine that he purchased at Walgreens from 2008 to 2019. At this point, the allegations show that the plaintiff&#8217;s alleged cancer injury could not have come from a Novitium product. The Ross action was consolidated with the coordinated proceedings in Illinois, which have been dismissed, as discussed below.</span></div><div style="margin-top:1pt;padding-left:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, the Keller Postman law firm commenced <ix:nonFraction unitRef="claim" contextRef="c-333" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1381">six</ix:nonFraction> multi-plaintiff actions in Illinois state court naming generic ranitidine manufacturers, including ANI and/or Novitium, as defendants. Those cases are: (1) Jodee Gillespie v. Walgreen Co., et. al., Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 2022LA001007 (naming both Novitium and ANI); (2) John Jackson v. Walgreen Co., et. al., Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 2022LA001012 (naming Novitium); (3) Ayesha Salahuddin v. Walgreen Co., et. al., Circuit Court of the Twentieth Judicial Circuit, St. Clair County, Illinois, Case No. 22LA0709 (naming Novitium); (4) Lashanda McGruder v. Walgreen Co., et. al., Circuit Court of the Third Judicial Circuit, Madison County, Illinois, Case No. 22LA0710 (naming both Novitium and ANI); (5) Richard Devriendt v. Walgreen Co., et. al., Circuit Court of Cook County, Illinois, Case No. 2022L007429 (naming Novitium); (6) Anthony Stigger v. Walgreen Co., et. al., Circuit Court of Cook County, Illinois, Case No. 2022L007396 (naming both Novitium and ANI). The complaints allege causes of action for failure to warn, design defect, general negligence, loss of consortium and wrongful death. Pursuant to an Order of the Illinois Supreme Court dated October 25, 2022, the pending ranitidine personal injury actions in Illinois have been consolidated in Cook County for coordinated pre-trial proceedings. Plaintiffs filed a master long-form complaint on March 9, 2023 naming Novitium as a defendant. ANI is not named as a defendant. The Keller Postman firm has confirmed that its clients are no longer pursuing claims against ANI. When the court ruled the cases needed to be re-filed as single-plaintiff cases, Novitium was never served. The counts in the master complaint include strict liability for failure to warn/design defects, general negligence, negligent misrepresentation, negligent storage and transport, apparent manufacturer liability, common law fraud, unjust enrichment, civil conspiracy, and breach of express and implied warranties. The complaint further alleges violations of the Illinois Consumer Fraud Act. Pursuant to the court&#8217;s standing order, the generic defendants filed a motion to dismiss pursuant to IL 2-615 (failure to state a claim on the face of the complaint) on April 13, 2023, claiming preemption by federal law. On August 10, 2023, the court dismissed all claims against the generic defendants, including Novitium, with prejudice on preemption grounds.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">California. In August and September 2022, the Keller Postman law firm commenced <ix:nonFraction unitRef="claim" contextRef="c-334" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1382">seven</ix:nonFraction> multi-plaintiff actions in California state court, Alameda County, naming generic ranitidine manufacturers, including ANI and/or Novitium, as defendants. Those cases are: (1) Carlos Ascencio v. ANI Pharmaceuticals, et. al., Superior Court of California, County of Alameda, Case. No. 22CV016230 (naming both Novitium and ANI); (2) Andre Lebeau v. Actavis Mid Atlantic, LLC et. al., Superior Court of California, County of Alameda, Case No. 22CV016448 (naming Novitium); (3) Roque Torres v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016338 (naming both Novitium and ANI); (4) Deborah Hinds v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016123 (naming both Novitium and ANI); (5) Mark Cruz v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016338 (naming both Novitium and ANI); (6) Bent Olsen v. ANI Pharmaceuticals, Inc., et. al., Superior Court of California, County of Alameda, Case No. 22CV016402 (naming both Novitium and ANI); (7) John Norman v. Actavis Mid Atlantic, LLC, et. al., Superior Court of California, County of Alameda, Case No. 22CV018334 (naming Novitium). The complaints allege causes of action for failure to warn, design defect, general negligence, loss of consortium and wrongful death. By stipulation and order dated December 28, 2022, the cases were transferred to an existing civil case coordination docket for pretrial proceedings (JCCP) pending in Alameda County. On January 19, 2023, the court ordered that counsel for the plaintiffs must dismiss the individual plaintiffs (other than the first-named plaintiff) from each of the multi-plaintiff complaints and that each of the dismissed plaintiffs must re-file their claims in a single plaintiff complaint.  On September 21, 2023, the plaintiff leadership filed a master complaint in the JCCP. The master complaint does not name any generic defendants. However, the short form complaints allow individual plaintiffs to name "other defendants," leaving open the option for individual plaintiffs to name generic manufacturers as defendants. The master complaint alleges strict liability (design defect and failure to warn), negligent failure to warn, and general negligence. In December 2023, the Keller Postman firm filed approximately <ix:nonFraction unitRef="claim" contextRef="c-335" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="f-1383">200</ix:nonFraction> individual plaintiff short form complaints in the JCCP that name generic defendants. Novitium is named in <ix:nonFraction unitRef="claim" contextRef="c-336" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" scale="0" id="f-1384">28</ix:nonFraction> of the short form complaints which reference the allegations for the master complaint. ANI is not named. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pennsylvania. In September 2022, <ix:nonFraction unitRef="claim" contextRef="c-337" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1385">two</ix:nonFraction> single-plaintiff complaints were filed in Pennsylvania state court, Philadelphia County, naming Novitium as a defendant: (1) William Titus v. Glaxo SmithKline LLC, et. al., Court of Common Pleas, Philadelphia County, Pennsylvania, Case No. 220902548; and (2) Jodi Woodard v. Ajanta Pharma USA, Inc., et. al., Court of Common Pleas, Philadelphia County, Pennsylvania, Case No. 220902329. These complaints allege causes of action for negligence, failure to warn, negligent storage and transportation, breach of express and implied warranties, negligent misrepresentation, and fraud. On February 16, 2023, the Pennsylvania plaintiffs filed a consolidated long-form complaint against the generic defendants, Plaintiffs v. Actavis, et. al. Civil Action No. 1364. The long-form complaint names Novitium as a defendant. The long form complaint asserts causes of action for negligence, failure to warn, negligent storage and transportation, breach of express warranties, breach of implied warranties, negligent misrepresentation, fraud, strict products liability, wrongful death and survivor actions, and loss of consortium. The complaint includes a prayer for punitive damages. The generic defendants filed their preliminary objections to Plaintiffs&#8217; consolidated long-form generic complaint on March 20, 2023. The court sustained the generics&#8217; objection that plaintiffs&#8217; failure to warn/design defect claims were preempted by federal law; therefore, all allegations related to failure to warn/design defects are dismissed. The court also sustained the generics&#8217; preliminary objections relating to the counts of strict liability-design defect and breach of implied warranty to the extent Pennsylvania substantive law applies. The court noted the substantive law of another state may not conflict with federal law, and, further, strict liability and breach of implied warranty causes of action of another state may apply in individual cases. This is a determination that can only be made after short form complaints are filed. It is the generics&#8217; position that the court&#8217;s ruling on the preliminary orders effectively dismissed the generics from the case unless and until a non-resident plaintiff names a generic in a short form complaint. Out of an abundance of caution, however, the generics, including Novitium, all filed answers to the long form complaint in June 2023. In January 2024, plaintiffs filed short form complaints naming generic defendants, including Novitium in one complaint, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Titus</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI and Novitium dispute any liability in these matters.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Industry Related Matters</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about September 20, 2017, the Company and certain of its employees were served with search warrants and/or grand jury subpoenas to produce documents and possibly testify relating to a federal investigation of the generic pharmaceutical industry. We have been cooperating and intend to continue cooperating with the investigation. However, no assurance can be given as to the timing or outcome of the investigation.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_136"></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="anip:CortrophinPreLaunchChargesTextBlock" id="f-1386" continuedAt="f-1386-1" escape="true">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</ix:nonNumeric></span></div><ix:continuation id="f-1386-1"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company acquired the right, title and interest in the NDAs for Cortrophin Gel and Cortrophin-Zinc. Subsequently, the Company assembled a Cortrophin Gel re-commercialization team of scientists, executed a long-term supply agreement with a supplier of pig pituitary glands, our primary raw material for corticotrophin API, executed a long-term supply agreement with an API manufacturer, with whom ANI has advanced the manufacture of corticotropin API via manufacture of commercial-scale batches, and executed a long-term commercial supply agreement with a current good manufacturing practice (&#8220;cGMP&#8221;) aseptic fill contract manufacturer.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter 2019, all purchases of material, including pig pituitary glands and API, related to the re-commercialization efforts were consumed in research and development activities and recognized as research and development expense in the period in which they were incurred. In the third quarter of 2019, the purchase of materials commenced that were intended to be used commercially in anticipation of FDA approval of Cortrophin Gel and the resultant product launch. The FDA granted approval of the sNDA of this product on October 29, 2021. Prior to FDA approval, under U.S. GAAP, the Company was prohibited from capitalizing these pre-launch purchases of materials as inventory, and accordingly, they were charged to expense in the period in which they were incurred. Subsequent to approval, these purchases are recorded as inventory at net realizable value. During the year ended December 31, 2021, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="anip:CortrophinPreLaunchCharges" scale="6" id="f-1387">0.8</ix:nonFraction> million of charges for the purchase of materials. Other charges were incurred directly related to the Cortrophin pre-launch commercialization efforts, including, but not limited to, sales and marketing and consulting expenses. During the year ended December 31, 2021, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1388"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1389">14.0</ix:nonFraction></ix:nonFraction> million of these charges, which are included on the consolidated statements of operations as a selling, general, and administrative expense. There were no comparable expenses in 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i4bc95b424f3d46babd419bb800693000_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 17. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-1390" continuedAt="f-1390-1" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><ix:continuation id="f-1390-1" continuedAt="f-1390-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which  <ix:nonFraction unitRef="shares" contextRef="c-340" decimals="INF" name="anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-1391">25,000</ix:nonFraction> shares were purchased for $<ix:nonFraction unitRef="usdPerShare" contextRef="c-341" decimals="INF" name="us-gaap:TemporaryEquityRedemptionPricePerShare" format="ixt:num-dot-decimal" scale="0" id="f-1392">1,000</ix:nonFraction> per share and an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-1393">25.0</ix:nonFraction> million on November 19, 2021. The Chairman of the Company's board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Novitium, the Company entered into employment agreements with the <ix:nonFraction unitRef="founder" contextRef="c-6" decimals="INF" name="anip:NumberOfExecutiveFounders" format="ixt-sec:numwordsen" scale="0" id="f-1394">two</ix:nonFraction> executives and founders of Novitium, Muthusamy Shanmugam, Head of R&amp;D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company's board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (&#8220;Scitus&#8221;), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC (&#8220;SS Pharma&#8221;), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited (&#8220;Nuray&#8221;), which manufactures and supplies API to Novitium, and a majority interest in Esjay Pharma LLC (&#8220;Esjay&#8221;), which provided research and development and facilities consulting services through September 30, 2022. Mr. Gassert holds a minority interest in Scitus. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="f-1395" continuedAt="f-1395-1" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of payments to related parties is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scitus Pharma Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1396">3,646</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1397">2,075</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:fixed-zero" scale="3" id="f-1398">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SS Pharma LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1399">8,235</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1400">3,669</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:fixed-zero" scale="3" id="f-1401">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esjay Pharma LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:fixed-zero" scale="3" id="f-1402">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="3" id="f-1403">101</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="3" id="f-1404">25</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nuray Chemical Private Limited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:fixed-zero" scale="3" id="f-1405">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1406">1,110</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="3" id="f-1407">365</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1408">11,881</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" format="ixt:num-dot-decimal" scale="3" id="f-1409">6,955</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="0" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="3" id="f-1410">390</ix:nonFraction></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div></ix:nonNumeric><div style="padding-left:18pt"><ix:continuation id="f-1395-1" continuedAt="f-1395-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1395-2">Includes payments during the period from November 19, 2021 to December 31, 2021, subsequent to the acquisition of Novitium.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1390-2" continuedAt="f-1390-3"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the outstanding balances due to Scitus and SS Pharma were $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1411">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1412">0.6</ix:nonFraction>&#160;million, respectively. There was <ix:nonFraction unitRef="usd" contextRef="c-359" decimals="INF" name="us-gaap:AccountsPayableCurrent" format="ixt:fixed-zero" scale="0" id="f-1413">no</ix:nonFraction> outstanding balance due to Nuray or Esjay at December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2023, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1414">12.5</ix:nonFraction>&#160;million of cash consideration to the Company Members of Novitium for the achievement of the "ANDA Filing Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $<ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1415">6.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1416">1.9</ix:nonFraction>&#160;million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1390-3">On February 22, 2024, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="f-1417">12.5</ix:nonFraction> million of cash consideration to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $<ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1418">6.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-1419">1.9</ix:nonFraction>&#160;million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.</ix:continuation> </span></div><div id="i4bc95b424f3d46babd419bb800693000_142"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1420" continuedAt="f-1420-1" escape="true">SEGMENT REPORTING</ix:nonNumeric></span></div><ix:continuation id="f-1420-1" continuedAt="f-1420-2"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity&#8217;s chief operating decision maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. Prior to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on this definition, the Company was organized as <ix:nonFraction unitRef="segment" contextRef="c-364" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1421">one</ix:nonFraction> operating and reporting segment. Prior period segment disclosures have been recast for the new segment presentation. Effective in the first quarter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and prospectively, in conjunction with the principal completion of the buildout of infrastructure in the areas of commercialization of rare disease therapies and the launch of Cortrophin Gel, it was determined that the Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1422">two</ix:nonFraction> operating segments as follows:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Generics, Established Brands, and Other</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rare Disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM evaluates the performance of the Company as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1423">two</ix:nonFraction> operating segments based on revenues and EBITDA, exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not manage assets of the Company by operating segment and the CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:continuation id="f-1420-2" continuedAt="f-1420-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-1424" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information by reportable segment, including historical information that has been retroactively re-cast to reflect <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1425">two</ix:nonFraction> reporting segments, is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, Established Brands, and Other</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1426">374,699</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1427">274,699</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1428">216,136</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1429">112,117</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1430">41,686</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-1431">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1432">486,816</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1433">316,385</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1434">216,136</ix:nonFraction></span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment earnings (loss) before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) and reconciliation to income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, Established Brands, and Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-3" name="anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1435">152,990</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-3" name="anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1436">78,958</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1437">63,418</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Disease</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" name="anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1438">12,498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-3" sign="-" name="anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1439">18,348</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-3" sign="-" name="anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1440">18,571</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" sign="-" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1441">59,791</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" sign="-" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1442">56,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" sign="-" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1443">47,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate and other unallocated expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1444">58,726</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1445">38,920</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" sign="-" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1446">37,388</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating income (loss)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1447">46,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1448">35,283</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1449">39,793</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1450">26,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1451">28,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="f-1452">11,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1453">159</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-1454">670</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-1455">4,343</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before expense (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1456">19,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1457">62,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1458">56,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.27pt">Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our consolidated statement of operations.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations are located in the United States and India. The Company has ceased operations at the Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="f-1459" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table depicts the Company&#8217;s revenue by geographic operations during the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Location of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1460">486,251</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1461">312,427</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1462">211,893</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-1463">565</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1464">3,958</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1465">4,243</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1466">486,816</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1467">316,385</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-1468">216,136</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:90pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANI Pharmaceuticals, Inc. and Subsidiaries</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to the Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the years ended December&#160;31, 2023, 2022, and 2021</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-1469" escape="true"><ix:continuation id="f-1420-3"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table depicts the Company&#8217;s property and equipment, net according to geographic location as of:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.113%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1470">43,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1471">40,343</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:fixed-zero" scale="3" id="f-1472">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1473">1,856</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1474">1,430</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1475">1,047</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1476">44,593</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1477">43,246</ix:nonFraction></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts as of December&#160;31, 2023 and 2022 exclude the land and building at the Canada facility, which are classified as held for sale as of December&#160;31, 2023 and 2022. These assets have a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1478"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1479">8.0</ix:nonFraction></ix:nonFraction> million.</span></div></ix:continuation></ix:nonNumeric><div id="i4bc95b424f3d46babd419bb800693000_1099511628367"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1480" continuedAt="f-1480-1" escape="true">SUBSEQUENT EVENTS </ix:nonNumeric></span></div><ix:continuation id="f-1480-1" continuedAt="f-1480-2"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2024, the Company granted RSA and PSU awards to officers and employees of the Company under the 2022 Plan. The Company granted <ix:nonFraction unitRef="shares" contextRef="c-387" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1481">525,729</ix:nonFraction> RSAs to employees and officers of the Company. These RSAs vest over <ix:nonNumeric contextRef="c-387" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1482">four years</ix:nonNumeric>. The Company granted <ix:nonFraction unitRef="shares" contextRef="c-388" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1483">73,588</ix:nonFraction> PSUs to employees and officers of the Company (<ix:nonFraction unitRef="shares" contextRef="c-389" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1484">66,433</ix:nonFraction> to officers of the Company). PSU performance will be measured over <ix:nonNumeric contextRef="c-388" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-1485">three years</ix:nonNumeric> from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. PSUs granted to date vest over a <ix:nonNumeric contextRef="c-388" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1486">three-year</ix:nonNumeric> performance period. Additionally, on February 15, 2024, the Company granted <ix:nonFraction unitRef="shares" contextRef="c-390" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1487">13,054</ix:nonFraction> RSAs to new employees of the Company, which will vest over <ix:nonNumeric contextRef="c-391" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1488">four years</ix:nonNumeric>.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2024, ANI Pharmaceuticals Canada, Inc. and 1540700 Ontario Limited entered into an agreement of purchase and sale for the Oakville, Ontario manufacturing facility for a purchase price of <ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1489">19.2</ix:nonFraction> million Canadian Dollars, or approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="6" id="f-1490">14.2</ix:nonFraction> million US Dollars, based on the current exchange rate. The first and second deposits, each amounting to approximately <ix:nonFraction unitRef="cad" contextRef="c-5" decimals="-5" name="anip:DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" format="ixt:num-dot-decimal" scale="6" id="f-1491">1.0</ix:nonFraction> million Canadian Dollars or approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="anip:DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" format="ixt:num-dot-decimal" scale="6" id="f-1492">0.7</ix:nonFraction> million US Dollars, based on the current exchange rate, were received on February 20, 2024, and February 27, 2024, respectively. The remaining balance of the purchase price, less deposits, will be paid upon closing, which is expected to occur by the end of March 2024. The closing of the transaction is subject to customary termination conditions, including the buyer&#8217;s right to terminate the agreement if the property is materially damaged prior to the closing.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2024, the Company paid $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="f-1493">12.5</ix:nonFraction> million to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2010, ANI, formerly Biosante, entered into an assignment and technology transfer agreement and stock subscription agreement (collectively the "CG Agreement") with CG Oncology, Inc. formerly, Cold Genesys, Inc. (&#8220;CG Oncology&#8221;), pursuant to which the Company sold to CG Oncology exclusive, worldwide rights to develop and commercialize BioSante&#8217;s oncolytic virus technology. The technology includes a replication-competent adenovirus that has completed clinical trials for treatment of superficial bladder cancer. Under the terms of the CG Agreement, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d an equity investment in CG Oncology, an upfront cash payment and the right to receive future royalty payments. Historically, this equity investment was recorded at cost and as of December 31, 2023, this equity investment was valued at <ix:nonFraction unitRef="usd" contextRef="c-392" decimals="INF" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt-sec:numwordsen" id="f-1494">zero</ix:nonFraction>. On January 24, 2024, CG Oncology completed their Initial Public Offering, at an offering price of $<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="0" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" id="f-1495">19.00</ix:nonFraction> per share. The Company currently holds <ix:nonFraction unitRef="shares" contextRef="c-392" decimals="0" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" id="f-1496">219,925</ix:nonFraction> shares of common stock in CG Oncology. As of February 27, 2024 these shares are valued at approximately $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:InvestmentOwnedAtFairValue" format="ixt:num-dot-decimal" scale="6" id="f-1497">10.2</ix:nonFraction>&#160;million. </span></div></ix:continuation><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1480-2">On February 28, 2024, CG Oncology disputed the Company's rights to receive royalties. The dispute is unresolved at this time.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_145"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i4bc95b424f3d46babd419bb800693000_148"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disclosure controls and procedures are controls and other procedures that are designed to ensure information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, we recognize that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 154-15(e) under the Exchange Act), as of December 31, 2023. Based on this evaluation, our principal executive officer and principal financial officers concluded that our disclosure controls and procedures were effective as of December 31, 2023.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over our financial reporting. Internal control over financial reporting is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act as a process designed by, or under the supervision of, a company&#8217;s principal executive and principal financial officers and effected by a company&#8217;s board of directors, management, and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. Our internal control over financial reporting includes those policies and procedures that:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of our assets</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures are being made only in accordance with authorizations of management and directors</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.15pt">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of assets that could have a material effect on our consolidated financial statements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) in Internal Control &#8212; Integrated Framework (2013). Based on this assessment, management has concluded that, as of December 31, 2023, our internal control over financial reporting is effective. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has concluded that the Consolidated Financial Statements included in this Annual Report on Form 10-K present fairly, in all material respects, the Company&#8217;s financial position, results of operations and cash flows for the periods disclosed in conformity with U.S. GAAP.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Item 9A. Controls and Procedures in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, we identified material weaknesses related to an ineffective control environment at our Novitium subsidiary, and information technology general controls (&#8220;ITGCs&#8221;) in the areas of user access over certain information technology systems that support our financial reporting processes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we determined that the designed internal controls were not operating effectively in Novitium related processes including (i) purchase to pay (purchasing, accounts payable, and cash disbursements); (ii) manufacturing and inventory; (iii) human resources/payroll; (iv) financial statement close; and (v) information technology related controls, as well as overall ITGC related to user access which were not operating effectively to adequately restrict user access to our network and financial applications and data, and therefore did not reduce the risk of a material error occurring and going undetected in our financial statements to an acceptable level giving rise to the material weaknesses. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December 31, 2023, we implemented our material weakness remediation plan that included: (i) refining and completing our plan to incorporate procure to pay cycle into the overall company controls; (ii) review and revise control documentation for controls at our Novitium subsidiary; (iii) ensure Novitium processes and controls have adequate resources to properly perform identified controls including hiring of additional resources with the requisite skills to consistently perform control procedures without material exception; (iv) implement one ERP system for the entire company to support the internal control structure; and (v) ensure all personnel are properly trained as to the importance of and specifics over the internal controls for which they are responsible, including consistent, repeatable performance of such controls. We completed our testing of the operating effectiveness of the implemented controls and found them to be effective. As a result, we have concluded the material weaknesses have been remediated as of December 31, 2023. Our independent registered public accounting firm, EisnerAmper LLP, has issued an attestation report on the effectiveness of our internal control over financial reporting, which is included in Item 8. Financial Statements and Supplementary Data of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i4bc95b424f3d46babd419bb800693000_151"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Oakville Sale </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement (the &#8220;Agreement&#8221;) with Mastercom Inc. for the purchase and sale of the Company's Oakville, Ontario former manufacturing facility at a total purchase price of approximately 17.9 million Canadian dollars, or approximately $13.0 million US Dollars based on the current exchange rate, subject to certain market adjustments. On December 22, 2023, the Agreement was terminated by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trading Arrangements </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our directors and officers (as defined in Exchange Act Rule 16a-1(f)) may from time to time enter into plans or other arrangements for the purchase or sale of our shares that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act.</span></div><ix:nonNumeric contextRef="c-394" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1498" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On <ix:nonNumeric contextRef="c-395" name="ecd:TrdArrAdoptionDate" id="f-1499">November 27, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="c-395" name="ecd:TrdArrIndName" id="f-1500">Mr. Muthusamy Shanmugam</ix:nonNumeric>, <ix:nonNumeric contextRef="c-395" name="ecd:TrdArrIndTitle" id="f-1501">Head of R&amp;D and COO</ix:nonNumeric> of NJ Operations, <ix:nonNumeric contextRef="c-395" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1502">adopted</ix:nonNumeric> a trading arrangement for the sale of securities of the Company&#8217;s common stock (a &#8220;Rule 10b5-1 Trading Plan&#8221;) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Shanmugam's Rule 10b5-1 Trading Plan, which has a term from March 4, 2024 through November 29, 2024, provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-396" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1503">400,000</ix:nonFraction> shares of common stock pursuant to the terms of the plan.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-397" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1504" escape="true">On <ix:nonNumeric contextRef="c-398" name="ecd:TrdArrAdoptionDate" id="f-1505">December 12, 2023</ix:nonNumeric>, <ix:nonNumeric contextRef="c-398" name="ecd:TrdArrIndName" id="f-1506">Mr. Chad Gassert</ix:nonNumeric>, <ix:nonNumeric contextRef="c-398" name="ecd:TrdArrIndTitle" id="f-1507">Sr. Vice President, Corporate Development and Strategy</ix:nonNumeric>, <ix:nonNumeric contextRef="c-398" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1508">adopted</ix:nonNumeric> a trading arrangement for the sale of securities of the Company&#8217;s common stock (a &#8220;Rule 10b5-1 Trading Plan&#8221;) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Gassert's Rule 10b5-1 Trading Plan, which will terminate September 30, 2024, provides for the sale of up to <ix:nonFraction unitRef="shares" contextRef="c-399" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1509">100,000</ix:nonFraction> shares of common stock pursuant to the terms of the plan.</ix:nonNumeric> </span></div><div id="i4bc95b424f3d46babd419bb800693000_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_157"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i4bc95b424f3d46babd419bb800693000_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers, and Corporate Governance</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The text of our Code of Ethics, which applies to our principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions, is posted on our website, www.anipharmaceuticals.com, under the &#8220;Governance&#8221; subsection of the &#8220;Investors&#8221; section of the site. We will disclose on our website amendments to, and, if any are granted, waivers of, our Code of Ethics for our principal executive officer, principal financial officer, or principal accounting officer, controller, or persons performing similar functions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to our directors will be set forth under the caption &#8220;Election of Directors&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to our executive officers will be set forth under the caption &#8220;Executive Officers of the Company&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent required, information required by this item with respect to compliance with Section 16(a) of the Exchange Act will be set forth under the caption &#8220;Delinquent Section 16(a) Reports&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to our audit committee, our audit committee financial expert, and any material changes to the way in which our security holders may recommend nominees to our Board of Directors will be set forth under the caption &#8220;Corporate Governance&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div id="i4bc95b424f3d46babd419bb800693000_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. Executive Compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to executive compensation will be set forth under the caption &#8220;Executive Compensation&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div id="i4bc95b424f3d46babd419bb800693000_166"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to security ownership of certain beneficial owners and management will be set forth under the captions &#8220;Security Ownership of Certain Beneficial Owners&#8221; and &#8220;Security Ownership of Directors and Executive Officers&#8221; and information relating to our equity compensation plans will be set forth under &#8220;Equity Compensation Plan Information&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div id="i4bc95b424f3d46babd419bb800693000_169"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to certain relationships and related transactions and director independence will be set forth under the captions &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Corporate Governance&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div id="i4bc95b424f3d46babd419bb800693000_172"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-1512">EisnerAmper LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-1513">Philadelphia, Pennsylvania</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-1514">274</ix:nonNumeric>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by this item with respect to principal accounting fees and services will be set forth under the caption &#8220;Ratification of Selection of Independent Registered Public Accountants&#8221; in our definitive proxy statement for our 2024 annual meeting, to be filed with the SEC pursuant to Regulation 14A no later than 120 days after the close of our fiscal year, and is incorporated herein by reference.</span></div><div id="i4bc95b424f3d46babd419bb800693000_175"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV.</span></div><div id="i4bc95b424f3d46babd419bb800693000_178"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits and Financial Statement Schedules</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Documents filed as part of this report on Form 10-K:</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Financial Statements:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets of the Registrant as of December 31, 2023 and 2022, the related consolidated statements of operations, statements of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, changes in stockholders&#8217; equity, and cash flows for each of the years ended December 31, 2023, 2022, and 2021, the footnotes thereto, and the reports of EisnerAmper LLP, independent registered public accounting firm, are filed herewith.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.78pt">Financial Statement Schedules:</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because they are not applicable or the required information is included in the consolidated financial statements or notes thereto.</span></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.91pt">Exhibits</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits included or incorporated by reference herein: see Exhibit Index on page 120.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ANI PHARMACEUTICALS, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE YEAR ENDED DECEMBER 31, 2023</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Method of Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465913029065/a13-10024_1ex2d1.htm">Amended and Restated Agreement and Plan of Merger, dated as of April 12, 2013, by and among BioSante Pharmaceuticals, Inc., ANI Merger Sub, Inc. and ANIP Acquisition Company (1)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 2.1 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on April 12, 2013 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465921033875/tm219108d2_ex2-1.htm">Agreement and Plan of Merger dated March 8, 2021 by and among ANI Pharmaceuticals, Inc., Nile Merger Sub LLC, Novitium Pharma LLC, Esjay LLC, Chali Properties, LLC, Chad Gassert, Muthusamy Shanmugam and Thorappadi Vijayaraj and Shareholder Representative Services LLC as the representative of the Company Members</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 9, 2021 (File No. 001-31812)</span></div><div><span><br/></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420413044160/v349735_ex3-1.htm">Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of July 17, 2013, Certificate of Amendment of the Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc., dated as of June 1, 2012, and Restated Certificate of Incorporation of BioSante Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 3.1 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2013 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465923029038/tm238560d1_ex3-1.htm">Second Amended and Restated Bylaws of ANI Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 3.1 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on March 6, 2023 (File No. 001-31812)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_ex3-1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock of the Company, effective as of November 19, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 3.1 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on November 26, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302421000007/anip-20201231ex418bc77a4.htm">Description of Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 4.1 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2020 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_ex4-1.htm">Registration Rights Schedule to the Merger Agreement, effective as of November 19, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 4.1 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on November 26, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465920005962/tm205553d1_ex10-4.htm">Employment Agreement, entered into by the Company and James G. Marken</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.4 to ANI&#8217;s Current Report on Form 8-K filed January 22, 2020 (File No. 001-31812)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.2*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465920005962/tm205553d1_ex10-2.htm">Employment Agreement, entered into by the Company and Stephen P. Carey</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.2 to ANI&#8217;s Current Report on Form 8-K filed January 22, 2020 (File No. 001-31812)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.3*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465920089648/tm2026323d1_ex10-1.htm">Employment Agreement between Nikhil Lalwani and ANI Pharmaceuticals, Inc., dated July 24, 2020</a></span><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Current Report on Form 8-K filed August 3, 2020 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Method of Filing</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.4*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_ex10-3.htm">Employment Agreement between Muthusamy Shanmugam and the Company, dated as of March 8, 2021 and effective as of November 19, 2021.</a></span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.3 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on November 26, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.5*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex1026e26af.htm">Employment Agreement between and Christopher Mutz and the Company, dated February 10, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.26 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.6*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex10272894a.htm">Employment Agreement between Ori Gutwerg and the Company, dated January 18, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.27 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.7*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex102897c72.htm">Employment Agreement between Chad Gassert and the Company, dated March 8, 2021.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.28 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000017/anip-20220630xex10d1.htm">Employment Agreement between Meredith Cook and the Company, dated June 21, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000021/anip-20220930xex10.htm">Employment Agreement between Krista Davis and ANI Pharmaceuticals, Inc. dated July 14, 2022.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2022 (File No. 001-31812)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm">Amendment No. </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm"> to Asset Purchase Agreement</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm">, dated as of July 10, 2015, Teva Pharm</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm">aceuticals, Inc. and</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm">ANI Pharmaceuticals, Inc</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-1.htm">.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015 (File No. 001-31812)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.11</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420415062504/v421880_ex10-2.htm">Asset Purchase Agreement, dated as of September 18, 2015, between Merck Sharp &amp; Dohme B.V. and ANI Pharmaceuticals, Inc. (2)</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.2 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2015 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.12</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420416099268/v437620_ex10-2.htm">Asset Purchase Agreement between Cranford Pharmaceuticals, LLC and ANI Pharmaceuticals, Inc. (2)</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.2 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.13</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420418011197/tv484825_ex10-25.htm">Asset Purchase Agreement between AstraZeneca AB, AstraZeneca UK Limited, and ANI Pharmaceuticals, Inc. (2)</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.25 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.14</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465920025744/tm205343d1_ex10-24.htm">Asset Purchase Agreement between Amerigen Pharmaceuticals LTD. and ANI Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.24 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.15</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465921143748/tm2133555d1_ex10-1.htm">Credit Agreement, dated as of November 19, 2021 by and among the Company, certain of the Company&#8217;s subsidiaries, as guarantors, Truist Bank, as Administrative Agent and other parties party thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on November 26, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Method of Filing</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.16</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465921033875/tm219108d2_ex10-2.htm">Equity Commitment and Investment Agreement, dated as of March 8, 2021, by and between the Company and Ampersand 2020 Limited Partnership</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.2 to ANI&#8217;s Current Report on Form 8-K as filed with the Securities and Exchange Commission on March 9, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.17</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex1024bb055.htm">Sublicense Agreement, dated as of October 30, 2009, by and between ANIP Acquisition Company, d/b/a ANI Pharmaceuticals, Inc., and Jazz Pharmaceuticals, Inc. (2)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.24 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.18</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000004/anip-20211231ex1025113ac.htm">Master Product Development and Collaboration Agreement, dated as of July 11, 2011, by and among ANIP Acquisition Company d/b/a ANI Pharmaceuticals, Inc. and RiconPharma LLC (2)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.25 to ANI&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.19</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000008/anip-20220331ex10114ef8b.htm">Asset Purchase Agreement between Cranford Pharmaceuticals, LLC and ANI Pharmaceuticals, Inc. (2)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302422000008/anip-20220331ex1026cf953.htm">Asset Purchase Agreement between Holmdel Pharmaceuticals, LP and ANI Pharmaceuticals, Inc. (2)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.2 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2022 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.21*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420416094232/v436561_def14a.htm">A</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000114420416094232/v436561_def14a.htm">NI Pharmaceuticals, Inc. 2016 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Appendix A to ANI&#8217;s Definitive Proxy Statement on Schedule 14A filed with the Commission on April 14, 2016</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.22*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465922038151/tm223557-1_def14a.htm">ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference Appendix A to ANI Pharmaceuticals, Inc.&#8217;s definitive proxy statement dated March 25, 2022 filed with the Securities and Exchange Commission on March 25, 2022 (File No. 001-31812).</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.23*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465923074187/tm2318293d1_ex10-1.htm">Amendment No. 2023-1 to ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (including form of Performance Stock Unit Award Agreement)</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI's Form S-8 filed on June 23. 2023 (File No. 001-31812)</span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.24*</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-2023x1231xexx1024.htm">Amendment No. 2024-2 to ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.25*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465922038151/tm223557-1_def14a.htm">Form of Restricted Stock Grant Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Appendix A to ANI&#8217;s Definitive Proxy Statement for the 2022 Virtual Annual Meeting filed on March 25, 2022 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.26*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465922038151/tm223557-1_def14a.htm">Form of Stock Option Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Appendix A to ANI&#8217;s Definitive Proxy Statement for the 2022 Virtual Annual Meeting filed on March 25, 2022 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302420000008/anip-20200930ex1020d6792.htm">Inducement Stock Option Award Agreement, effective as of September 8, 2020, between ANI Pharmaceuticals, Inc. and Nikhil Lalwani</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.2 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2020 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.172%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Method of Filing</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.28*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465922028128/tm227815d1_ex10-1.htm">ANI Pharmaceuticals, Inc. Executive Incentive Bonus Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Current Report on Form 8-K filed on February 28, 2022 (File No. 001-31812)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.29</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000102302423000043/anip-20230930x10qxexx101.htm">Amendment No. 1 to the Credit Agreement, dated as of July 3, 2023 by and among the Company, and Truist Bank, as Administrative Agent.</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 10.1 to ANI&#8217;s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 (File No. 001-31812)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1023024/000110465923059829/tm2315239d4_ex1-1.htm">Underwriting Agreement, dated May 11, 2023, by and between ANI Pharmaceuticals, Inc. and Guggenheim Securities, LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated by reference to Exhibit 1.1 to ANI&#8217;s Current Report on Form 8-K filed on May 12, 2023 (File No. 001-31812)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-2023x1231xexx1031.htm">Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc. </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.32</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx1032.htm">Amendment to Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc. </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.33</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx1033.htm">Notice of Termination of Purchase and Sale Agreement between ANI Pharmaceuticals Canada Inc. and Mastercom Inc. </a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.34</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx1034.htm">Form of Indemnification Agreement</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx21.htm">List of subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-2023x1231xexx231.htm">Consent of EisnerAmper LLP</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx311.htm">Certification of Chief Executive Officer Pursuant to SEC Rule 13a-14</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx312.htm">Certification of Chief Financial Officer Pursuant to SEC Rule 13a-14</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx971.htm">A</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx971.htm">NI Pharmaceuticals, Inc. Amended and Restated Clawback Pol</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="anip-20231231xexx971.htm">icy</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information from this annual report on Form 10-K for the fiscal year ended December&#160;31, 2023, formatted in Inline XBRL: (i) the audited consolidated Balance Sheets, (ii) the audited consolidated Statements of Operations, (iii) the audited consolidated Statements of Comprehensive Income, (iv) the audited consolidated Statements of Mezzanine Equity and Stockholders&#8217; Equity; (v) the audited consolidated Statements of Cash Flows, and (vi) Notes to consolidated Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cover page from the Company Annual Report on Form 10-K for the year ended December&#160;31, 2023 formatted in inline XBRL (included in Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) All exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. ANI will furnish the omitted exhibits to the SEC upon request by the SEC.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Confidential treatment has been granted with respect to redacted portions of this document or certain information has been omitted from this exhibit in accordance with Regulation S-K Item 601(b)(10)(iv). The Company agrees to furnish supplementally a copy of any omitted information to the Securities and Exchange Commission upon its request.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Management contract or compensatory plan or arrangement required to be filed as an exhibit to this Annual Report on Form 10-K pursuant to Item 15(a).</span></div><div id="i4bc95b424f3d46babd419bb800693000_181"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">124</span></div></div></div><div id="i4bc95b424f3d46babd419bb800693000_184"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.702%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">ANI PHARMACEUTICALS, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Nikhil Lalwani</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nikhil Lalwani</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(principal executive officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: February&#160;29, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:2.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.699%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.702%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Stephen P. Carey</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stephen P. Carey</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Senior Vice President, Finance and</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(principal financial and accounting officer)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Date: February&#160;29, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pursuant to the requirements the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-top:10pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i4bc95b424f3d46babd419bb800693000_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.832%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Capacity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Date</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Nikhil Lalwani</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director, President, and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Chief Executive Officer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(principal executive officer)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Nikhil Lalwani</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Stephen P. Carey</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Senior Vice President, Finance and<br/>Chief Financial Officer<br/>(principal financial and accounting officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stephen P. Carey</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Muthusamy Shanmugam</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director, Head of Research and Development and Chief Operating Officer of New Jersey Operations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Muthusamy Shanmugam</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Patrick D. Walsh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director and Chairman of the Board of<br/>Directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patrick D. Walsh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Thomas J. Haughey</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thomas J. Haughey</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ David B. Nash, M.D., M.B.A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">David B. Nash, M.D., M.B.A.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Matthew J. Leonard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Matthew J. Leonard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Jeanne Thoma</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Jeanne Thoma</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Antonio Pera</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Antonio Pera</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">/s/ Renee Tannenbaum</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">February 29, 2024</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Renee Tannenbaum</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">126</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>anip-2023x1231xexx1024.htm
<DESCRIPTION>EX-10.24
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i4163e037aadd4f00a8f61d56ab81a137_35"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.24</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AMENDMENT NO. 2024-2 TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED 2022 STOCK INCENTIVE PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 5, 2024</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, ANI Pharmaceuticals, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), maintains the Company&#8217;s Amended and Restated 2022 Stock Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) for the benefit of eligible employees of the Company and subsidiaries, non-employee members of the Board, and other service providers who perform services for the Company or its subsidiaries&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the Company desires to amend the Plan (i) to more closely align the Cause definition in the Plan with the definitions in the Executive Employment Agreements, (ii) to clarify that in the event of the Committee determines a Participant has committed any action constituting Cause, only the unvested portion of an Incentive Award is subject to forfeiture, (iii) to remove the discretion of the Company to defer the exercise of any Option, the vesting of any Restricted Stock Award or payment of any Stock Unit Award, Performance Award or Stock Bonus pending determination of Cause, and (iv) to align with Company policy or applicable requirements of law to determine the extent of any disgorgement or forfeiture of Incentive Awards in the event of a breach by a Participant of the terms of any employment, consulting, confidentiality or non-compete agreement entered into with the Company&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NOW, THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, in accordance with the foregoing and subject to approval of the Company&#8217;s stockholders, the Plan shall be, and hereby is, amended as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                1.             Section 2.3 of the Plan is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;2.3                         &#8220;Cause&#8221; means &#8220;cause&#8221; as defined in any employment or other agreement or policy applicable to the Participant, or if no such agreement or policy exists, will mean (i) any crime involving dishonesty, fraud, misrepresentation, embezzlement or deliberate injury or attempted injury, in each case related to the Company or any Subsidiary, (ii) any unlawful or criminal activity of a serious nature, (iii) any intentional and deliberate breach of a duty or duties that, individually or in the aggregate, are material in relation to the Participant&#8217;s overall duties, or (iv) any material breach of any employment, service, confidentiality, non-compete or non-solicitation agreement entered into with the Company or any Subsidiary.&#8221; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                2.             Section 12.4 of the Plan is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;12.4                      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Effects of Actions Constituting Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Notwithstanding anything in the Plan to the contrary, in the event that a Participant is determined by the Committee, acting in its sole discretion, to have committed any action which would constitute Cause as defined in Section 2.3 of the Plan, irrespective of whether such action or the Committee&#8217;s determination occurs before or after termination of such Participant&#8217;s employment with the Company or any Subsidiary, all rights of the Participant under the Plan and any agreements evidencing an Incentive Award then held by the Participant shall terminate and any unvested portion of the Incentive Award be forfeited without notice of any kind.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                3.             Section 12.6 of the Plan is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;12.6                      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Breach of Employment, Consulting, Confidentiality or Non-Compete Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Notwithstanding anything in the Plan or in any Incentive Award granted hereunder to the contrary and in addition to the rights of the Committee under Section 12.4 of the Plan, the Committee in its sole discretion may cancel, rescind, withhold or otherwise limit or restrict any Incentive Award at any time in the event that a Participant materially breaches the terms of any employment, consulting, confidentiality or non-compete agreement entered into with the Company or any Subsidiary (including an employment, consulting, confidentiality or non-compete agreement made in connection with the grant of an Incentive Award), whether such breach occurs before or after termination of such Participant&#8217;s employment or other service with the Company or any Subsidiary, to the extent disgorgement or forfeiture of the Incentive Award or any amounts received under the Incentive Award is required under a policy of the Company or any successor, or its or their subsidiaries, adopted to comply with applicable requirements of law (including Section 10D of the Securities Exchange Act of 1934, as amended) or of any applicable stock exchange.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.             Except as modified herein, all provisions of the Plan shall remain in full force and effect.</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Signature Page Follows</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.24</font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the undersigned has executed this Amendment No. 2024-2 to the Company&#8217;s Amended and Restated 2022 Stock Incentive Plan as of the date first set forth above.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">                                                                                             ANI PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">&#47;s&#47;Nikhil Lalwani                 </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                                                                                                 Name&#58;  Nikhil Lalwani</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">                                                                                                 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;    President &#38; CEO</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>3
<FILENAME>anip-2023x1231xexx1031.htm
<DESCRIPTION>EX-10.31
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i87630bcd0d6043aa84e961207f89fea6_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div><font><br></font></div><div style="text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">THIS AGREEMENT OF PURCHASE AND SALE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">made this</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> 23 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">day of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> November</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> 2023</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BETWEEN&#58;</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ANI PHARMACEUTICALS CANADA INC.</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Vendor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;)</font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OF THE FIRST PART</font></div><div><font><br></font></div><div style="text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">- and -</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MASTERCOM INC.</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;)</font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OF THE SECOND PART</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">WHEREAS </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Vendor is the owner of the Property and has agreed to sell, transfer, assign, set over and convey the Property to the Purchaser and the Purchaser has agreed to purchase, acquire and assume the Property from the Vendor on the terms and conditions set forth in this Agreement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:40.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, in consideration of the mutual covenants and agreements set forth in this Agreement and the sum of Ten ($10.00) Dollars paid by each of the Vendor and the Purchaser to the other and for good and other valuable consideration (the receipt and sufficiency of which is hereby acknowledged), the parties hereto covenant and agree as follows&#58;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:195pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%">ARTICLE 1 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration:underline">INTERPRETATION</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:11.07pt">Definitions</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The terms defined herein shall have, for all purposes of this Agreement, the following meaning, unless the context expressly or by necessary implication otherwise requires&#58;</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the adjustments to the Purchase Price provided for and determined pursuant to Section 3.3.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:218%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8221; has the meaning set out in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:218%">Business Corporations Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">(Ontario). &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:218%">Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8221; means Cresa Toronto Inc., Brokerage.</font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means this Agreement of Purchase and Sale and the Schedules attached hereto as amended from time to time.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">As Is</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; has the meaning given to it in Section 6.3.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Assumed Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; has the meaning given to it in Section 4.5.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; includes any international, national, federal, provincial, state, territorial, regional, municipal or local government, governmental or regulatory agency, commission, bureau, authority, service, office, Crown corporation, ministry, department, or similar organization, court, board, administrative panel, tribunal or dispute settlement panel, whether domestic or foreign, and any other entity with the power to enact or enforce laws.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Building</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the existing approximately 101,111 square feet industrial building and all other buildings and improvements presently located on the Lands.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means a day other than a Saturday or Sunday on which chartered banks in the City of Toronto are normally open for the transaction of business.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chattels</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means equipment, furniture, chattels and other items which constitute personal property owned by the Vendor which are located on the Lands.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means all claims, suits, proceedings, losses, damages, penalties, judgments, costs, expenses, fines, disbursements, interest, demands and actions of any nature or any kind whatsoever, including all</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">legal fees on a substantial indemnity basis and other professional fees and disbursements in connection therewith.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Closing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the closing of the transaction contemplated by this Agreement, including without limitation the payment of the Purchase Price and the delivery of the Closing Documents on the Closing Date.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Closing Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means twenty (20) Business Days after waiver of the Purchaser Due Diligence Condition referred to in Section 4.2 or such earlier date as the parties agree upon in writing.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Closing Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the agreements, instruments and other documents to be delivered by the Vendor to the Purchaser or the Purchaser's Solicitors pursuant to Section 5.1 and the agreements, instruments and other documents to be delivered by the Purchaser to the Vendor or the Vendor's Solicitors pursuant to Section 5.2.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the Warranties (if any) and all existing contracts and agreements material to the ongoing operation of the Property to which the Vendor is bound with respect to ongoing operation, maintenance, repair, cleaning, security, fire protection, and servicing of the Property.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Damages</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any losses, liabilities, damages, costs, obligations, liabilities, demands, fines, penalties, assessments, judgment, Claims and expenses of whatsoever kind or nature, direct or indirect, including, without limitation, legal fees and disbursements.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Data Room</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the virtual data room created and maintained by the Agent on behalf of the Vendor containing the Vendor&#8217;s Due Diligence Deliveries and other material relating to the Property.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:218%">Delivery Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8221; means 5&#58;00 p.m. on the third Business Day after the execution of this Agreement. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:218%">Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8221; means collectively, the First Deposit and Second Deposit.</font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Due Diligence Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means Twenty (20) Business Days after the date of execution of this Agreement, or such other date as the parties agree upon in writing.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means all personnel employed by Vendor in connection with its former business conducted at the Building.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Environmental Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any statute, law (including any principle of the common law), regulation, by- law, ordinance, code, tickets, notices, standards, guidelines, criteria, policies, directives, and approvals (in each case having the force of law), licences and permits issued, promulgated or administered by any applicable Authority or any court of competent jurisdiction relating to environmental, health and safety matters and&#47;or regulating the remediation, clean-up, decommissioning or disposal of Hazardous Substances in effect as of the date of this Agreement, including, but not limited to, the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Environmental Protection Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Ontario).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fixtures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means all fixtures and building systems owned by the Vendor included in or permanently affixed to the Building, including, without limitation, the heating, air-conditioning, ventilating, plumbing and electrical systems, sprinklers, alarm and security systems, boilers, compressors, substations, transformers, and other mechanical and building systems and similar improvements in or upon the Lands used in the operation thereof owned by the Vendor.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Hazardous Substances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any substance or material that is prohibited, controlled, otherwise regulated by any Authority or is toxic or hazardous in fact, including, without limitation, contaminants, pollutants, asbestos, lead, urea formaldehyde foam insulation, volatile organic compounds, polychlorinated by-phenyls, hydrocarbon products, any substances or materials containing components of the foregoing or derivatives thereof, radioactive substances, dangerous or hazardous substances or materials, controlled products, hazardous wastes and any other substances or materials defined as contaminants or pollutants under Environmental Laws, including any replacements or amendments of such laws from time to time.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lands</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means the lands in the Town of Oakville, in the Province of Ontario, known municipally as 400 Iroquois Shore Road, Oakville, Ontario, as more particularly described in Schedule &#8220;A&#8221; attached hereto.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#8220;Law&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">means any law, statute, regulation, bylaw, ordinance, rule, instrument, code, order, common law, judgment, decree or other requirement or rule of law of any Authority and any standard, guideline, criteria, policy, directive or approval having the force of law.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Legal Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any litigation, action, suit, investigation, hearing, claim, complaint, arbitration, mediation, investigation, mediation, charge, demand, audit or other proceeding.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means a charge, mortgage, lien, security interest or similar encumbrance which secures payment of monies or performance of an obligation.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Order</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any order, directive, field order, notice of requirement or similar instrument issued by any Authority.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Encumbrances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">any registered restrictions or covenants that run with the land registered as of the date of this Agreement provided same do not materially impair the present use of the Property&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any municipal agreements and agreements with publicly regulated utilities affecting the Property as of the date of this Agreement providing such have been complied with, or security has been posted to ensure compliance and completion, as evidenced by a letter from the relevant municipality or regulated utility&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">any minor easements for the supply of domestic utility or telephone services to the Property or adjacent properties which do not materially impair the present use of the Property registered as of the date of this Agreement&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any easements for drainage, storm or sanitary sewers, public utility lines, telephone lines, cable television lines or other services which do not materially impair the present use of the Property registered as of the date of this Agreement&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the matters set out in Schedule &#8220;B&#8221;, provided same have been complied with in all material respects, or security has been posted to ensure compliance and performance of any material future obligations thereunder.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means an individual, corporation, company, limited liability company, body corporate, partnership, joint venture, unincorporated organization, trust, association or other entity.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;Phase II ESA Diligence Date&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the date referred to in Section 4.2.3.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Possession and&#47;or Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;, where such phrase is used in this Agreement, means the ability of the Vendor to acquire the requested items only if they are either in the possession of the Vendor or are otherwise readily available to the Vendor and provided that the Vendor shall not incur any material cost in obtaining the applicable items.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;Property&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means collectively, the Lands, Building, Chattels and Fixtures.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Purchase Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means Seventeen Million Eight Hundred Fifty Thousand ($17,850,000.00) Dollars.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Purchaser&#8217;s Solicitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means such firm or firms of solicitors as are appointed by the Purchaser from time to time and written notice of which is provided to the Vendor.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; has the meaning given to it under Environmental Laws including, without limitation, any release, spill, leak, pumping, pouring, emission, emptying, discharge, injection, escape, leaching, disposal, dumping, deposit, spraying, burial, abandonment, incineration, seepage or placement of any Hazardous Substances.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Survey</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means a real property report prepared and signed by an Ontario Land Surveyor.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Third Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any Person who is not a party to this Agreement and expressly includes a prior or subsequent owner, tenant, licensee or other occupant of the Property and any owner, tenant, licensee or other occupant from time to time of any real property adjacent to or in the vicinity of the Property.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:218%">Third Party Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8221; means any Legal Proceeding that is instituted or asserted by a Third Party. &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:218%">Vendor&#8217;s Due Diligence Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">&#8221; has the meaning ascribed to it in Section 2.4.</font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vendor's Solicitors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means Dentons Canada LLP, or such other firm or firms of solicitors as are appointed by the Vendor from time to time and written notice of which is provided to the Purchaser.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means any existing warranties and guarantees relating to the Property, to the extent the same exist as of Closing and are assignable without consent of a Third Party.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Work Orders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; means all outstanding work orders, deficiency notices, and orders to comply issued by any Authority with respect to the Property, but shall exclude any open files and incomplete permit applications where such work was not proceeded with by Vendor or a predecessor in title of the Vendor.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.2 Schedules</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">The following Schedules are attached to and form part of this Agreement&#58; Schedule &#8220;A - Lands</font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">Schedule &#8220;B - Permitted Encumbrances Schedule &#8220;C -Vendor&#8217;s Due Diligence Deliveries</font></div><div style="text-align:center;text-indent:136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ARTICLE 2</font></div><div style="text-align:center;text-indent:136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">AGREEMENT OF PURCHASE AND SALE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.1 Agreement of Purchase and Sale</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor hereby agrees to sell, transfer, assign, set over and convey the Property to the Purchaser and the Purchaser hereby agrees to purchase, acquire and assume the Property at the Purchase Price on and subject to the terms and conditions of this Agreement. The transaction provided for in this Agreement shall be completed on the Closing Date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.2 Authorizations</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor shall deliver to the Purchaser, on or before the Delivery Date, authorizations to Authorities in a form acceptable to the Purchaser, acting reasonably, necessary to permit the Purchaser to obtain information from their files about the Property, expressly not including permission to conduct any inspection of the Property.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.3 Statement of Adjustments</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As soon as reasonably possible, and not later than five (5) Business Days prior to Closing, the Vendor shall deliver a preliminary statement of adjustments to the Purchaser and, on Closing, a final statement of adjustments.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.4 Documentation for Inspection</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor shall, on or before the Delivery Date, provide in electronic form by access to the Data Room granted to the authorized representative(s) of the Purchaser, copies of the documents listed in Schedule &#8220;C&#8221; which are not privileged or subject to a confidentiality agreement binding the Vendor and which are in the Vendor's Possession and&#47;or Control (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vendor&#8217;s Due Diligence Deliveries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;). The Purchaser acknowledges and agrees that any information made available to the Purchaser or provided or to be provided by or on behalf of the Vendor with respect to the Property was obtained from a variety of sources and that the Vendor makes no representations as to the accuracy or completeness of such information. The Purchaser shall be entitled to make copies or cause copies to be made of all such documents, subject to the terms of this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.5 Access</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt;text-decoration:underline">Inspections</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Until the Due Diligence Date or the Phase II ESA Diligence Date, if applicable, the Purchaser and its agents and employees shall, upon at least two (2) Business Days prior written notice, have reasonable access to the Property during normal business hours and in the company of a representative of the Vendor, if requested by the Vendor, for the purpose of making any inspections, tests, studies, surveys and investigations of the Property that the Purchaser considers to be necessary or desirable, subject to paragraph</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b. of this section.</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">         b.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Repair of Damage</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser may not conduct inspections or tests which require physical interference with the Property such as drilling, excavation, destruction or disturbance of components of the Building without the prior written consent of Vendor, provided that the Vendor shall have the right to have any such work conducted by Purchaser under the supervision of a competent and experienced engineer or similar professional consultant, and after approval by Vendor of the location and scope of work proposed, and further provided that the Vendor shall obtain satisfactory evidence of the drilling contractor&#8217;s third party liability and professional negligence insurance. The Purchaser agrees to repair forthwith any damage to the Property arising from such access at the Purchaser's expense and shall indemnify and hold the Vendor harmless from and against any and all Third Party Claims and other losses, damages, claims, costs (including, without limitation, legal costs on a substantial indemnity basis) or liabilities in respect of physical injury or damage that may be suffered or incurred by the Vendor arising from or in respect of the Purchaser's access and testing activities. This indemnity will survive the termination of this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2.6 Confidentiality</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser shall keep in strict confidence all environmental and other information obtained with respect to the Property pursuant to this Agreement (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) until such time as the transaction contemplated by this Agreement is completed, provided that the Purchaser shall be entitled to disclose any and all Confidential Information to its legal counsel, investors, lenders and professional advisors provided the Purchaser agrees to instruct those parties to comply with the provisions of this Section. The Purchaser shall not use any Confidential Information for any purposes not related to this transaction. If the transaction contemplated by this Agreement is not completed for any reason, the Purchaser shall promptly either deliver all such Confidential Information to the Vendor at Vendor's request or certify that it has destroyed or deleted all such Confidential Information, including all electronic copies of the Purchaser's notes and due diligence material obtained by Purchaser in respect to the Property, whether or not such was included in the Vendor&#8217;s Due Diligence Deliveries.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:194.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%">ARTICLE 3 </font></div><div style="text-align:center;text-indent:194.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration:underline">PURCHASE PRICE</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.1 Method of Payment of Purchase Price</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Purchase Price shall be paid and satisfied by the Purchaser as follows&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the sum of Five Hundred Thousand ($500,000.00) Dollars (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">First Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) by wire transfer payable to the Vendor&#8217;s Solicitors in trust within two (2) Business Days after the execution of this Agreement, to be held in trust as a deposit pending the completion or other termination of the transaction contemplated by this Agreement and to be credited on the Closing Date on account of the Purchase Price&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the sum of Seven Hundred and Fifty Thousand ($750,000.00) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Second Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) by wire transfer payable to the Vendor&#8217;s Solicitors in trust within two (2) Business Days after the waiver or satisfaction of the Purchaser's due diligence conditions set out in Section 4.2 of this Agreement, to be held in trust as a deposit pending the completion or other termination of the transaction contemplated by this Agreement and to be credited on the Closing Date on account of the Purchase Price&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the balance, subject to the Adjustments, shall be paid on the Closing Date by the Purchaser to the Vendor, or as the Vendor directs, by wire transfer through the Canadian Payment Association Large Value Transfer System.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.2 Deposit</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Deposit, when received, shall be held by the Vendor&#8217;s Solicitors in trust in a non-interest bearing account pending the earlier of&#58; (a) the satisfactory completion and closing of the transaction contemplated by this Agreement&#59; and (b) the termination of this Agreement. The Deposit shall be credited against the Purchase Price on Closing. If the transaction contemplated by this Agreement is not completed as a result of termination pursuant to Section 4.2 or the default by the Vendor, the Deposit (or such portion of it as has been delivered by the Purchaser) shall be returned to the Purchaser forthwith without interest or deduction. If the transaction contemplated by this Agreement is not completed as a result of the default of the Purchaser, the Deposit shall be forfeited to the Vendor, without prejudice to the Vendor&#8217;s legal rights against the Purchaser for all damages, losses, costs and expenses incurred by the Vendor as a result of such default.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.3 Adjustments</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Adjustments shall be made as of the Closing Date. The Vendor shall be responsible for all income and expenses for the period ending on the day prior to the Closing Date.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The adjustments (herein referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) shall include all rental income, operating costs, realty taxes, local improvement rates and charges, water and assessment rates, amounts payable or paid in respect of any Assumed Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and other adjustments established by the usual practice for the purchase and sale of a commercial in the Greater Toronto Area. A draft of the statement of Adjustments shall be provided to Purchaser no later than two Business Days prior to Closing. In the event that the Vendor has appealed or otherwise applied for a reduction of realty taxes and has not yet received a final decision in connection with such appeal or application, or if the Vendor is entitled to receive any refund, rebate or other amount with respect to realty taxes which has not been paid as of the Closing then all such reductions, rebates and&#47;or refunds for the period up to Closing shall be the property of the Vendor, even if received after Closing or paid to the Purchaser, but shall not be adjusted for on Closing. If such reduction, rebate or refund is received by the Purchaser (whether as a payment or as a credit against amounts payable or otherwise) then the Purchaser shall hold such amounts in trust for the Vendor and promptly account to and pay them over to the Vendor. If the Vendor receives any such reduction, rebate or refund that relates to the period following Closing, the Vendor shall hold such amounts in trust for the Purchaser and promptly account to and pay them over to the Purchaser. In addition, the Adjustments shall include the other matters referred to in this Agreement which are stated to be the subject of adjustment and shall exclude the other matters in this Agreement which are stated not to be the subject of adjustment.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.4 Harmonized Sales Tax</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With respect to harmonized sales tax (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">HST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) payable pursuant to Part IX of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Excise Tax Act Canada</font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), the parties covenant and agree as follows&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">subject to clause (b) below, the Purchaser shall pay to the Vendor on Closing all HST payable as a result of this transaction in accordance with the Act, and the Vendor shall remit such HST to the Receiver General for Canada when and to the extent required by the Act&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">notwithstanding clause (a), the Vendor shall not collect the HST from the Purchaser in this transaction if the Purchaser is registered under the Act, and in that event the Purchaser shall file returns and remit such HST to the government when and to the extent required by the Act&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the Purchaser shall indemnify the Vendor and hold the Vendor harmless from any liability of the Vendor under the Act arising due to any breach of the obligations of the Purchaser set out in this Section or arising under the Act, together with all loss, costs and expenses resulting from such breach&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the Purchaser shall provide a copy of its HST registration number under the Act and a certificate of a senior officer of the Purchaser on Closing confirming that such registration is, to the best of his or her knowledge, in full force and effect&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the Vendor's and Purchaser's obligations under this Section 3.4 shall survive Closing.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:213.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%">ARTICLE 4 </font></div><div style="text-align:center;text-indent:213.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration:underline">CONDITIONS PRECEDENT</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.1 Conditions of the Vendor</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The obligation of the Vendor to complete the transaction contemplated by this Agreement on Closing shall be subject to the following conditions&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt;text-decoration:underline">Performance of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On the Closing Date, all of the terms, covenants and conditions of this Agreement to be complied with or performed by the Purchaser shall have been complied with or performed in all material respects at the times contemplated herein&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt;text-decoration:underline">Closing Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On the Closing Date, the Purchaser shall have delivered all required closing documents, duly executed&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On the Closing Date, the representations and warranties of the Purchaser set out in Section 6.2 shall be true and accurate in all material respects with the same effect as if made on and as of the Closing Date.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conditions set out in this Section are for the sole benefit of the Vendor and may be waived in whole or in part by the Vendor, in its sole discretion acting reasonably, by written notice to the Purchaser. Completion of this transaction shall deem satisfaction by the Vendor of the conditions set out herein.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.2 Due Diligence Termination Rights of the Purchaser</font></div><div><font><br></font></div><div style="padding-left:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.2.1 Phase I ESA</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The obligation of the Purchaser to complete the purchase of the Property on the Closing Date is subject to the condition precedent that on or before the Due Diligence Date the Purchaser has satisfied itself in its sole and unfettered discretion with respect to the environmental condition of the Property, including but not limited to obtaining a current Phase I environmental assessment report of the Property completed by a reputable and experienced environmental consultant (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase I ESA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) at Purchaser&#8217;s expense. In the event that the Phase I ESA does not conclude that there are risks of non-compliance of the Property with Environmental Laws and does not recommend that a Phase II ESA be conducted, the Purchaser shall have no right to terminate this Agreement for non-fulfillment of the condition set out in this section and this condition shall be deemed to have been irrevocably waived. The Purchaser shall provide a true copy of the Phase I ESA to the Vendor forthwith after it is obtained by Purchaser and in any event prior to giving any Notice of termination under this Section 4.2.1.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Phase I ESA concludes that there are risks of non-compliance of the Property with Environmental Laws and recommends that a Phase II ESA be conducted, the Purchaser shall have the right by Notice given on or before the Due Diligence Date to terminate this Agreement and in that case this Agreement shall be terminated, both parties hereto shall be released from all of their respective liabilities and obligations under this Agreement (other than those liabilities and obligations which are expressly stated to survive the termination of this Agreement) and the First Deposit shall be returned without deduction or set off to the Purchaser. For further certainty, and without limiting the generality of the foregoing, the Vendor acknowledges and agrees that it shall be estopped from challenging the Purchaser's right to terminate this Agreement pursuant to this Section 4.2.1 on the basis that the Purchaser's discretion hereunder was exercised unreasonably. In the event that the Purchaser does not give such Notice on or before the Due Diligence Date and Section 4.2.3 does not apply, the Purchaser shall have no further right to terminate this Agreement under this Section and this condition shall be irrevocably deemed to have been waived.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.2.2 Financing</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The obligation of the Purchaser to complete the purchase of the Property on the Closing Date is subject to the condition precedent that on or before the Due Diligence Date the Purchaser has satisfied itself in its sole and unfettered discretion with respect to the availability of financing to complete the transaction, on terms satisfactory to the Purchaser.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Purchaser is unable to obtain financing to complete the transaction on terms satisfactory to Purchaser, the Purchaser shall have the right by Notice given on or before the Due Diligence Date to terminate this Agreement and in that case this Agreement shall be terminated, both parties hereto shall be released from all of their respective liabilities and obligations under this Agreement (other than those liabilities and obligations which are expressly stated to survive the termination of this Agreement) and the First Deposit shall be returned without deduction or set off to the Purchaser. For further certainty, and without limiting the generality of the foregoing, the Vendor acknowledges and agrees that it shall be estopped from challenging the Purchaser's right to terminate this Agreement pursuant to this Paragraph on the basis that the Purchaser's discretion hereunder was exercised unreasonably. In the event that the Purchaser does not give a Notice of termination pursuant to this Section 4.2.2 on or before the Due Diligence Date, the Purchaser shall have no further right to terminate this Agreement pursuant to this Section 4.2.2 and this condition shall be irrevocably deemed to have been waived.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.2.3 Phase II ESA Diligence Date</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Purchaser has not given a Notice to terminate this Agreement pursuant to either Sections 4.2.1 and 4.2.2, and has obtained a Phase I ESA which concluded that there are risks of non-compliance of the Property with Environmental Laws and recommends that a Phase II ESA be conducted, then the Purchaser shall have an additional period of twenty (20) Business Days from the Due Diligence Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase II ESA Diligence Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) in order to conduct a phase II environmental assessment report of the Property </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(&#8220;Phase II ESA&#8221;), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">such right to be exercised by Notice in writing to the Vendor given on or before the Due Diligence Date. The Purchaser shall provide the Vendor with a true copy of the Phase II ESA forthwith after it is obtained by the Purchaser and in any event prior to giving any Notice of termination under this Section 4.2.3.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Phase II ESA concludes that there is non-compliance of the Property with Environmental Laws or recommends further testing, investigations or remediation of the Property, the Purchaser shall have the right by Notice given on or before the Phase II ESA Diligence Date to terminate this Agreement and in that case this Agreement shall be terminated, both parties hereto shall be released from all of their respective liabilities and obligations under this Agreement (other than those liabilities and obligations which are expressly stated to survive the termination of this Agreement) and the First Deposit shall be returned without deduction or set off to the Purchaser. In the event that the Purchaser does not give such Notice to terminate on or before the Phase II ESA Diligence Date, the Purchaser shall have no further right to terminate this Agreement under this Section 4.2.3 and this condition shall be irrevocably deemed to have been waived.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For greater certainty, if the Purchaser exercises the right under this Section 4.2.3 to conduct a Phase II ESA the Due Diligence Date in respect of all other rights and obligations of the Purchaser shall not be extended.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.3 Additional Conditions of the Purchaser</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The obligation of the Purchaser to complete the transaction contemplated by this Agreement on Closing shall be subject to the following conditions&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt;text-decoration:underline">Performance of Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. On the Closing Date, all of the terms, covenants and conditions of this Agreement to be complied with or performed by the Vendor shall have been complied with or performed in all material respects at the times contemplated herein&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt;text-decoration:underline">Closing Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. On the Closing Date, the Vendor shall have delivered all required closing documents, duly executed&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt;text-decoration:underline">Representations and Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. On the Closing Date, the representations and warranties of the Vendor set out in Section 6.1, shall be true and accurate in all material respects with the same effect as if made on and as of the Closing Date.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The conditions set out in this Section are for the sole benefit of the Purchaser and may be waived in whole or in part by the Purchaser, in its sole discretion acting reasonably, by written notice to the Purchaser. Completion of this transaction shall deem satisfaction by the Purchaser of the conditions set out herein.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.4 Title</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser shall be allowed until the Due Diligence Date to investigate title to the Property and to satisfy itself that the title is free and clear from all Liens and other encumbrances other than Permitted Encumbrances and there are no existing Work Orders. If, by the Due Diligence Date, the Purchaser has made any valid objection to title or the Vendor is advised by the Purchaser of any outstanding Work Orders, which objections have been made in writing to the Vendor and which the Vendor is unable to remove, remedy or satisfy on or before Closing, and which the Purchaser will not waive, then this Agreement, notwithstanding any intermediate acts or negotiations in respect of such objections, shall be at an end and the Deposit shall be returned to the Purchaser without deduction or set off. Except for any objections so made or any matter that goes to the root of title, the Purchaser shall be deemed to have accepted title to the Property.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If a registerable discharge of any Lien affecting the Property and held by a chartered bank, trust company, life insurance company or other institutional lender is not available at Closing then the Vendor shall provide a statement issued by such lender confirming that on payment of an amount not exceeding the Purchase Price it will discharge such Lien, and the personal undertaking of the Vendor's Solicitors to deliver such payment forthwith to such lender together with any interest owing to the date of such payment and register such discharge as soon as possible after Closing, which the Purchaser shall accept as a satisfactory answer to any requisition requiring registration of such discharge.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.5 Contracts</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser shall advise the Vendor by notice in writing no later than the Due Diligence Date whether it wishes to assume any Contracts at Closing, provided that in no event shall the Purchaser be entitled to assume any Contract requiring the consent of a Third Party to assign to the Purchaser, which Contract the Vendor may at its option assign if such consent is available or terminate at the Vendor&#8217;s cost. Subject to the Vendor obtaining any necessary consent from a Third Party to such Contract, the Purchaser agrees that it shall assume on, from and after Closing only those Contracts which the Purchaser confirms in writing to the Vendor that it wishes to assume by notice delivered to the Vendor on or before the Due Diligence Date (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Assumed Contracts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;). The Vendor shall be responsible for the performance and payment of all of the Vendor's obligations and covenants in the Assumed Contracts prior to the day of Closing and shall terminate and be responsible for payment of all costs and expenses to terminate all Contracts not assumed by the Purchaser, as herein provided for. The Vendor shall indemnify and save the Purchaser harmless for any Claims, costs, losses, expenses and liabilities which Purchaser suffers by reason of the Vendor's breach of any obligations and covenants in Assumed Contracts prior to Closing. The Purchaser shall assume and be responsible for the performance and payment of all of the Vendor's obligations and covenants in the Assumed Contracts from and after the day of such assignment, shall indemnify and save the Vendor harmless for any Claims, costs, losses, expenses and liabilities which it suffers by reason of the Purchaser's breach of the obligations and covenants in such Assumed Contracts, and shall use commercially reasonable efforts to obtain a release of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Vendor from any such obligations and covenants in the Assumed Contracts as soon as possible after such assignment by the Vendor to the Purchaser.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:213.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%">ARTICLE 5</font></div><div style="text-align:center;text-indent:213.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration:underline">CLOSING DOCUMENTS</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.1 Vendor's Closing Documents</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On or before Closing, subject to the provisions of this Agreement, the Vendor shall execute or cause to be executed and shall deliver or cause to be delivered to the Purchaser's Solicitors the following&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">a registerable Transfer&#47;Deed of Land conveying title to the Property to the Purchaser&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">the final statement of Adjustments&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">a certificate of the Vendor confirming that the Vendor is not a non-resident of Canada pursuant to Section 116 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Tax Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Canada)&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">a direction by the Vendor for payment of the balance of the Purchase Price due on Closing, if payable to a person other than the Vendor&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">an undertaking by the Vendor to readjust all items on the statement of Adjustments&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.17pt">a certificate executed by a senior officer of the Vendor on behalf of the Vendor and without personal liability setting out that each of the Vendor's representations and warranties contained in this Agreement are true as at Closing&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">the assignment of Assumed Contracts, if any&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">notice to Third Parties to Assumed Contracts re&#58; assignment&#59; if any&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt">registrable discharges of all encumbrances which are not Permitted Encumbrances, provided that the personal undertaking of the Vendor&#8217;s Solicitor shall be acceptable with respect to certain Liens in accordance with Section 4.4 above&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.73pt">a duplicate key and other access codes and devices to the Building&#59; and</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">all other conveyances and other documents which the Purchaser reasonably requires and which the Purchaser has requested the Vendor to deliver by written notice provided to the Vendor not less than five (5) Business Days prior to Closing, to give effect to the proper transfer, assignment and conveyance of the Property by the Vendor to the Purchaser free and clear of all encumbrances other than Permitted Encumbrances.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All documentation shall be in form and substance acceptable to the Purchaser and the Vendor acting reasonably and in good faith.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.2 Purchaser's Closing Documents</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">By the Closing Date, subject to the terms and conditions of this Agreement, the Purchaser shall execute or cause to be executed and shall deliver or cause to be delivered to the Vendor's Solicitors the following&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">the balance of the Purchase Price, subject to Adjustments&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">a certificate executed by a senior officer of the Purchaser and without personal liability setting out that each of the Purchaser's representations and warranties contained in this Agreement are true and accurate in all materials respects as at Closing&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">the Purchaser's undertaking to readjust all items on the statement of Adjustments&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">the registration number of the Purchaser and&#47;or the transferee of the Property for purposes of HST, a certificate of the Purchaser's senior officer confirming such HST registration is in full force and effect, and an indemnity with respect to any amount owing on account of HST as provided in Section 3.4&#59;</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">the assignment and assumption of Assumed Contracts, if applicable&#59; and</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.17pt">all other conveyances and other documents which the Vendor reasonably requires and which the Vendor has requested the Purchaser to deliver by written notice provided to the Purchaser not less than five (5) Business Days prior to Closing, to give effect to the proper transfer, assignment and conveyance of the Property by the Vendor to the Purchaser free and clear of all encumbrances other than Permitted Encumbrances.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All documentation shall be in form and substance acceptable to the Purchaser and the Vendor acting reasonably and in good faith.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.3 Closing Date</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If the Closing Date would otherwise fall on a Saturday, Sunday or a statutory holiday, the Closing Date shall take place on the day next Business Day following such date that is not a Saturday, Sunday or a statutory holiday.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.4 Registration and Other Costs</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor and the Purchaser shall be responsible for the costs of the Vendor's Solicitors and the Purchaser's Solicitors, respectively, in respect of this transaction. The Vendor shall be responsible for and shall pay for all registration fees payable in connection with the registration of discharges of any Liens and other encumbrances which the Vendor is required to discharge hereunder. The Purchaser shall be responsible for all land transfer tax and costs of registration of any other documents.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.5 Closing Arrangements</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Agreement shall be completed by 5&#58;00 p.m. on the Closing Date at the offices of the Vendor's Solicitors in Toronto, Ontario. The Teraview electronic registration system (hereinafter referred to as &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TERS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) is operative in the land titles office in which the Property is registered. The parties agree that the following provisions shall apply.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor's Solicitors and the Purchaser's Solicitors shall be authorized TERS users and shall be in good standing with the Law Society of Upper Canada. The parties hereto shall authorize their respective solicitors to enter into a document registration agreement in the form provided by the Vendor's Solicitors and acceptable to the Purchaser&#8217;s Solicitors, acting reasonably.(hereafter referred to as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Document Registration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The delivery and exchange of Closing Documents and the Purchase Price and the release thereof to the Vendor and the Purchaser, as the case may be&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">may not, at the Vendor's Solicitors' and the Purchasers' Solicitors' discretion, occur contemporaneously with the registration of the transfer (and other registerable documentation)&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">shall be governed by the Document Registration Agreement, pursuant to which the solicitor receiving any documents and funds will be required to hold same in escrow, and will not be entitled to release same except in strict accordance with the provisions of the Document Registration Agreement.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:213.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%">ARTICLE 6 </font></div><div style="text-align:center;text-indent:213.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.1 Vendor's Representations and Warranties</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor represents, warrants and covenants to and with the Purchaser, which representations, warranties and covenants are relied upon by the Purchaser, that as of the date of this Agreement and on Closing&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the Vendor is a body corporate existing in good standing under the laws of Nova Scotia, with authority and capacity to enter into this Agreement and to carry out the transaction contemplated hereby&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the Vendor has the power and authority and capacity to own the Property and to enter into and fulfill its obligations under this Agreement and the Closing Documents delivered pursuant thereto&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the Vendor was not at the time this Agreement was entered into and will not be on Closing a non-resident pursuant to section 116 of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Income Tax Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Canada)&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the transactions contemplated by this Agreement have been duly and validly authorized by all requisite proceedings of the Vendor, this Agreement constitutes and all other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="padding-left:108pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">documents and agreements to be delivered by the Vendor pursuant to this Agreement shall constitute legal, valid and binding obligations of the Vendor enforceable against the Vendor in accordance with their terms&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">neither the execution of this Agreement nor its performance by the Vendor will result in a breach of any term or provision or constitute a default under the constating documents or by-laws of the Vendor or any agreement to which the Vendor is a party or by which it is bound&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">the Vendor has no Employees engaged in working at the Building.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.2 Purchaser's Representations and Warranties</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser represents, warrants and covenants to and with the Vendor, which representations, warranties and covenants are relied upon by the Vendor, that as of the date of this Agreement and on Closing&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the Purchaser is a body corporate existing in good standing under the laws of &#91;NTD- Purchaser to advise&#93; with authority and capacity to accept this Agreement and to carry out the transaction contemplated hereby&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the transactions contemplated by this Agreement have been duly and validly authorized by all requisite proceedings of the Purchaser, this Agreement constitutes and all other documents and agreements to be delivered by the Purchaser pursuant to this Agreement shall constitute legal, valid and binding obligations of the Purchaser enforceable against the Purchaser in accordance with their terms&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">neither the execution of this Agreement nor its performance by the Purchaser will result in any breach of any term or provision or constitute a default under the constating documents or by-laws of the Purchaser or any agreement to which Purchase is a party or by which it is bound&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the Purchaser has the power and authority to fulfill its obligations under this Agreement and any other Closing Documents delivered pursuant thereto.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6.3 As-Is Purchase</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser acknowledges that it has been afforded an adequate opportunity to inspect the Property and satisfy itself with respect to the physical and environmental condition and all other aspects of the Property, and has not been induced to enter into this Agreement by, or otherwise relied on, the Vendor's Due Diligence Deliveries or any representations, warranties (other than those set out in this Agreement) or other information provided by or on behalf of the Vendor or the Agent (written or oral) concerning the physical or environmental condition of the Property. The Purchaser acknowledges that the Property is being sold by the Vendor and accepted by the Purchaser on an &#8220;as is where is&#8221; basis. Without limiting the generality of the foregoing, the Purchaser acknowledges that the Vendor makes no representations, warranties or covenants with respect to&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">title to and the physical aspects of the Building, Chattels or Fixtures&#59; the existence of any Work Orders&#59; the environmental condition of the Property&#59; the accuracy and completeness of the Vendor's Due Diligence Deliveries including any environmental site assessments and the contents thereof&#59; or any other matter whatsoever affecting the Property, including any warranties of fitness for a particular purpose or use or warranties of merchantability with respect to any Fixtures or Chattels&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">the value, quality, state of repair, or lack of repair, of the Property and any components thereof&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the existence of and the rights of any Third Party or Authorities to commence any Third Party Claim or other action or issue any Order in respect to the Property&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">compliance with any land use, zoning or other Laws affecting any part of the Property&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">the presence or absence of Hazardous Substances at, on, in, under, within, adjacent to or Released at any time from the Property&#59; and</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">any other issue or matter whatsoever concerning or relating to the condition of the Property.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.4 Chattels</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser and Vendor acknowledge and agree that the Vendor shall have no obligation to remove any Chattels now located at the Property at any time prior to or by the Closing, and the Purchaser shall automatically assume sole ownership and responsibility for same, all on the same basis as set out in Section</font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.3 of this Agreement without adjustment to the Purchase Price.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:207.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARTICLE 7</font></div><div style="text-align:center;text-indent:207.55pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">COVENANTS</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.1        Vacant Possession</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Vendor shall deliver vacant possession of the Property on Closing, subject to Section 6.4.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ARTICLE 8</font></div><div style="text-align:center;text-indent:136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">SURVIVAL AND INDEMNIFICATION</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.1 Survival of Representations, Warranties and Covenants</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to the terms of this Section 8.1, the representations, warranties and covenants of each party contained in this Agreement will not merge on and will survive the Closing notwithstanding the Closing or any investigation or knowledge acquired by or on behalf of the other party, for the time periods set out in this Agreement&#59; provided that the rights of both parties to enforce any representation, warranty or covenant in a Closing Document shall survive Closing for the period set out in such Closing Document, if applicable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.2 Indemnification by the Vendor</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to Section 8.4 and Section 8.5, the Vendor shall indemnify and save the Purchaser and its officers, directors, and employees (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Purchaser's Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) fully harmless against, and will reimburse each of them for, any Damages suffered by or asserted against the Purchaser's Indemnified Parties, directly or indirectly, arising from, in connection with or related to&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">any incorrectness in or breach of any representation or warranty of the Vendor contained in this Agreement&#59; and</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any breach or non-fulfilment of any covenant or obligation on the part of the Vendor contained in this Agreement or in any Closing Document.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights to indemnification of the Purchaser's Indemnified Parties under this Section 8.2 will apply notwithstanding the Closing.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.3 Indemnification by the Purchaser</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Subject to Section 8.4 and Section 8.5, the Purchaser shall indemnify and save the Vendor and its officers, directors and employees (collectively the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vendor's Indemnified Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) fully harmless against, and will reimburse each of them for, any Damages suffered by or asserted against the Vendor's Indemnified Parties arising from, in connection with or related to&#58;</font></div><div><font><br></font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">any incorrectness in or breach of any representation or warranty of the Purchaser contained in this Agreement&#59; and</font></div><div style="padding-left:108pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any breach or non-fulfilment of any covenant or obligation on the part of the Purchaser contained in this Agreement or in any Closing Document.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The rights to indemnification of the Vendor's Indemnified Parties under this Section 8.3 will apply notwithstanding the Closing.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.4 Limitations on Amount of Indemnification</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor shall have no liability to the Purchaser&#8217;s Indemnified Parties for any amount in excess of Five Hundred Thousand ($500,000) Dollars and the Purchaser shall have no liability to the Vendor&#8217;s Indemnified Parties under this Article for any amount in excess of Five Hundred Thousand ($500,000) Dollars.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.5 Time Limits for Claims for Indemnification</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor has no obligation to make any payment for Damages in respect of a Claim (for indemnification or otherwise) under Section 8.2 unless written notice of that claim is delivered to the Vendor within twelve</font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(12) months after the Closing Date. The Vendor will have no liability with respect to any of the foregoing matters or any other representation, warranty or covenant made by the Vendor in this Agreement after the expiry of the applicable time period specified in this Section 8.5, except for claims for which written notice has been given under this Agreement at or prior to the end of the applicable time period.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser has no obligation to make any payment for damages in respect of a Claim (for indemnification or otherwise) under Section 8.3 unless notice of that claim is delivered to the Purchaser within twelve (12) months after the Closing Date. The Purchaser will have no liability with respect to any of the foregoing matters or any other representation, warranty or covenant made by the Purchaser in this Agreement, after the expiry of the applicable time period specified in this Section 8.5 except for claims for which written notice has been given under this Agreement at or prior to the end of the applicable time period.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:213.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARTICLE 9 </font></div><div style="text-align:center;text-indent:213.1pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">OPERATION UNTIL CLOSING</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.1        Damage Before Closing</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The interest of the Vendor in and to the Property shall be at the risk of the Vendor until Closing. If any loss or damage to the Building in excess of Five Million Dollars ($5,000,000) (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">material loss</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) occurs before that time, the Purchaser, at its sole option, by notice given within ten (10) Business Days after disclosure to the Purchaser by the Vendor of the occurrence of such material loss and the extent of insurance coverage available and any deductibles in insurance coverage for such material loss, or two Business Days prior to the Closing Date (whichever first occurs) may terminate this Agreement by notice in writing to the Vendor, in which case this Agreement shall be terminated, null and void and of no further force or effect whatsoever and the Deposit shall be refunded without interest or deduction, or the Purchaser may elect to complete the agreement of purchase and sale constituted upon the execution of this Agreement, in which event the Purchaser shall be entitled to the net proceeds of insurance in respect of the loss or damage after any deductible, if, as and when received by the Vendor, together with a credit on the closing statement of adjustments equal to the amount of the insurance deductible. If no notice is delivered by the Purchaser within the time set out in this Section 9.1, it shall be deemed to have elected to proceed with the agreement of purchase and sale. If a loss or damage occurs which is not a material loss, neither the Purchaser and the Vendor shall have any right to terminate this Agreement pursuant to this Section and the Vendor shall assign to the Purchaser the proceeds of any applicable insurance net of any deductible amounts.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:210.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARTICLE 10 </font></div><div style="text-align:center;text-indent:210.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">AGENT COMMISSION</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">10.1      Agent's Commission</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor covenants and agrees to be solely responsible for and pay any real estate commissions or amounts due and owing to the Agent resulting from the sale of the Property to the Purchaser and shall instruct the Agent to pay any cooperating broker any fees owing with respect to the transaction from amounts payable to the Agent, as agreed between the Broker and the co-operating broker.</font></div><div><font><br></font></div><div style="text-align:center;text-indent:210.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%">ARTICLE 11 </font></div><div style="text-align:center;text-indent:210.35pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:116%;text-decoration:underline">GENERAL</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.1 Gender and Name</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Words importing the singular include the plural and vice versa. Words importing gender include all genders.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.2 Captions and Table of Contents</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The captions, headings and table of contents contained herein are for reference only and in no way affect this Agreement or its interpretation.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.3 Obligations as Covenants</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each agreement and obligations of any of the parties hereto in this Agreement, even though not expressed as a covenant is considered for all purposes to be a covenant.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.4 Applicable Law</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Agreement shall be construed and enforced in accordance with the laws of the Province of Ontario and the laws of Canada applicable thereto and shall be treated in all respects as an Ontario contract.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.5 Currency</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All references to currency in this Agreement shall be deemed to be references to Canadian dollars. All cheques to be tendered shall be drawn from one of the major Canadian Chartered Banks.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.6 Amendment of Agreement</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No supplement, modification or waiver or termination of this Agreement shall be binding unless executed in writing by the parties hereto in the same manner as the execution of this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.7 Time of the Essence</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Time shall be of the essence of this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.8 Further Assurances</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each of the parties hereto shall from time to time hereafter and upon any reasonable request of the other, execute and deliver, make or cause to be made all such further acts, deeds, assurances and things as may be required or necessary to more effectually implement and carry out the true intent and meaning of this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.9 Entire Agreement</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Agreement and any agreements, instruments and other documents herein contemplated to be entered into between, by or including the parties hereto constitute the entire agreement between the parties hereto pertaining to the agreement of purchase and sale provided for herein and supersede all prior agreement, understandings, negotiations and discussions, whether oral or written, with respect thereto. There are no other warranties or representations and no other agreements between the parties hereto in connection with the agreement of purchase and sale provided for herein, except as specifically set forth in this Agreement or the Schedules attached hereto.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.10 Waiver</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions (whether or not similar) nor shall any waiver constitute a continuing waiver unless otherwise expressed or provided.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.11 Solicitors and Agents and Tender</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any notice, approval, waiver, agreement, instrument, document or communication permitted, required or contemplated in this Agreement may be given or delivered and accepted or received by the Purchaser's Solicitors on behalf of the Purchaser and by the Vendor's Solicitors on behalf of the Vendor and any tender of Closing Documents and the balance of the Purchase Price may be made upon the Vendor's Solicitors and the Purchaser's Solicitors, as the case may be.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.12 Assignment</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of the covenants and agreements contained in this Agreement shall be binding upon the parties and their respective successors and assigns and shall enure to the benefit of and be enforceable by the parties and their successors and permitted assigns pursuant to the terms and conditions of this Agreement. After payment of the Deposit and waiver of the Due Diligence Condition, the Purchaser shall have the right to assign this Agreement to an Affiliate with written notice to the Vendor given no later than five (5) Business Days prior to Closing, and upon the assignee entering into an assumption agreement with the Vendor pursuant to which such assignee shall assume all of the covenants and obligations of the Purchaser hereunder and the Purchaser shall acknowledge that it shall remain liable for performance of the covenants and obligations under this Agreement notwithstanding such assignment.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.13 Notice</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any notice, demand, approval, consent, information, agreement, offer, payment, request or other communication (hereinafter referred to as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221;) to be given under or in connection with this Agreement shall be in writing and shall be given by personal delivery or by telecopier or other electronic communication which results in a written or printed notice being given, addressed or sent as set out below or to such other address or electronic number as may from time to time be the subject of Notice&#58;</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vendor&#58;</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c&#47;o ANI Pharmaceuticals Inc. </font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">210 Main Street West </font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Baudette MN 56623</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">United States of America</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Attention&#58; Chad Gassert, Senior Vice-President, Head of Business Development </font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Email&#58; Chad.Gassert&#64;anipharmaceuticals.com</font></div><div style="padding-left:36pt;text-indent:41pt"><font><br></font></div><div style="padding-left:36pt;text-indent:41pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:252%">With a copy to its solicitors (which shall not constitute Notice)&#58; DENTONS CANADA LLP</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">77 King Street West</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Suite 400, Toronto Dominion Centre </font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Toronto, Ontario M5K OA1 </font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Attention&#58; Paul D. Shantz</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Email&#58; paul.shantz&#64;dentons.com</font></div><div><font><br></font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:218%">Facsimile No.&#58; 416-863-4592 Purchaser&#58; Mastercom Inc.</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c&#47;o CBRE Limited</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1235 North Service Road</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Suite 101, Oakville, ON L6M 2W2</font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attention&#58; Elliot Goldspink, Senior Vice President </font></div><div style="text-indent:77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Email&#58; Elliot.goldspink&#64;cbre.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any Notice, if personally delivered, shall be deemed to have been validly and effectively given and received on the Business Day of such delivery and if sent by telecopier or other electronic communication with confirmation of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">transmission, shall be deemed to have been validly and effectively given and received on the Business Day next following the day it was received.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.14 No Registration of Agreement</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser shall not register this Agreement or any caution, caveat, certificate of pending litigation, or other form of notice against title to the Lands. If the Purchaser registers this Agreement or notice thereof against title to the Lands in contravention of this Section, the Purchaser agrees that the Vendor shall be entitled to equitable relief to cause the removal of such registration, in addition to any other rights and remedies.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.15 Planning Act</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">This Agreement is subject to the express condition that it is to be effective only if the subdivision and part lot control provisions of the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Planning Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Ontario) are complied with. The Vendor covenants to proceed diligently at its expense to obtain any necessary consent on or before the Closing Date and will advise the Purchaser that it has obtained the necessary consent in final form under the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Planning Act </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(Ontario) for the conveyance of the Property.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.16 Announcements</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Neither party shall issue any media release or similar notification concerning this Agreement prior to Closing without the prior written consent of the other party and its approval of the form of such notification&#59; notwithstanding the foregoing, the parties acknowledge that the Vendor shall be entitled to make and file certain reports, forms, announcements and other notifications with applicable Authorities and other Third Parties as required by securities and other Laws without consent or notice to the Purchaser.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.17 Data Verification</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to its acknowledgement in Section 6.3, the Purchaser hereby acknowledges that to the extent that this Agreement has been executed by the Purchaser based on information which has been made available through the Due Diligence Deliveries and Agent&#8217;s marketing materials or electronic marketing programs, and from other information sources, all such information may not be completely accurate or reliable. The Purchaser hereby acknowledges that it has taken such steps as it considers necessary and appropriate to investigate and verify the accuracy and reliability of all such information provided through the Vendor, the Agent and from other information sources.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.18 Legal Advice</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Purchaser and Vendor hereby acknowledge being advised by CBRE, Brokerage, (the &#34;Purchaser&#8217;s Broker&#34;) prior to signing this Agreement, to seek legal advice on the terms and conditions of this Agreement.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.19 Irrevocable&#47;Date of Agreement</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Vendor has executed and delivered a copy of this Agreement to the Purchaser which shall constitute an offer to sell on the terms set out herein which shall be irrevocable by the PVeunrcdhoarser until 6&#58;00 p.m. EST on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">November 7, 2023 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">after which time, if not accepted and a copy executed by Purchaser is delivered to the Vendor or the Agent such offer shall be null and void and of no further force or effect. Upon acceptance and delivery of an executed copy of this Agreement by Purchaser the date of such delivery shall be deemed to be the date of execution referred to in this Agreement and the Due Diligence Date and all other dates provided in this Agreement shall be calculated accordingly.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:53.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The remainder of this page is intentionally left blank. Execution page to follow</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-indent:5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-indent:5pt"><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">IN WITNESS WHEREOF </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the parties thereto have executed this Agreement under seal as evidenced by their properly authorized officers in that behalf as of the day and year first above written.</font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ANI PHARMACEUTICALS CANADA INC.</font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%">Per&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:108%;text-decoration:underline"> &#47;s&#47; Nikhi Lalwani                                          </font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58; Nikhil Lalwani </font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58; President &#38;CEO</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Per&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;text-decoration:underline"> &#47;s&#47; Stephen P. Carey                                   </font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name Stephen P. Carey</font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58; CFO</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">I&#47;we have the authority to bind the Corporation.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MASTERCOM INC.</font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Per&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%;text-decoration:underline"> &#47;s&#47; Omar Nouelaty                                       </font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:91%">Name&#58; Omar Nouelaty</font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></div><div><font><br></font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Per&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">                                                                  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Name&#58;</font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Title&#58;</font></div><div style="text-indent:221.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I&#47;we have the authority to bind the Corporation.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div><font><br></font></div><div style="text-align:center;text-indent:136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SCHEDULE &#8220;A&#8221;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:136.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LEGAL DESCRIPTION OF THE PROPERTY</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PT OF LOT 6 PLAN M14 BEING PTS 5, 6 &#38; 7 ON PL 20R20380&#59; SUBJECT TO AN EASEMENT OVER PT 6 PL 20R20380 IN FAVOUR OF PT OF LOT 6 PLAN M14 BEING PTS 2 &#38; 3 ON PL 20R20380 AS IN HR1338842&#59; TOWN OF OAKVILLE.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PIN 24883-0036 (LT)</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PART OF LOT 7, PLAN M14, DESIGNATED AS PARTS 9 &#38; 10, PLAN 20R20380&#59; SUBJECT TO AN EASEMENT OVER PT 9 ON PL 20R20380 IN FAVOUR OF PT OF LT 6 PL M14 BEING PTS 2 &#38; 3 ON PL 20R20380 AS IN HR1338842&#59; TOWN OF OAKVILLE.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PIN 24883-0033 (LT)</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">General</font></div><div><font><br></font></div><div style="text-indent:40.84pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:166%">SCHEDULE &#8220;B&#8221; PERMITTED ENCUMBRANCES</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">liens for realty taxes (which term includes charges, rates and assessments) for amounts the payment of which is not yet due or delinquent&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">permits, reservations, covenants, right of access, easements, rights of way, restrictions, building schemes, licenses, restrictive covenants and servitudes, and other similar rights in land (including, without limitation, licenses, easements, rights of way, servitudes and rights in the nature of easements for walkways, sidewalks, public ways, sewers, drains, gas, soil, steam and water mains or pipelines, electrical lights and power, telephone, television and cable conduits, poles, wires or cables) granted to, reserved or taken by any Person, in each case provided the same are complied with in all material respects&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">title defects or irregularities which do not, in the aggregate, materially impair the use, or marketability of the Property&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any rights of expropriation, access or use, or any other right conferred or reserved by or in any statute of Canada or the Province of Ontario&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any minor encroachments of improvements on adjoining lands onto any portion of the Property&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any subdivision agreements, site plan control agreements, development agreements or other similar agreements with an Authority or public or private utility provided the same have been complied with in all material respects&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any subsisting restrictions, exceptions, reservations, limitation, provisos and conditions (including, without limitation, royalties, reservation of mines, mineral rights and timber rights, access to navigable waters and similar rights) expressed in any original grants from the Crown and any statutory limitations, exceptions, reservations and qualifications, provided that the same are complied with in all material respects&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any zoning, land use and building restrictions, by-laws, regulations and ordinances of Authorities, including municipal by-laws and regulations, airport zoning regulations, restrictive covenants and other land use limitations, public or private, by-laws and regulations and other restrictions as to the use of the Property, provided the same are complied with in all material respects.</font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Specific</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Instrument No. HR179746, registered on February 21, 2003, being an Application to Change Name-Owners.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Instrument No. HR1338842, registered on February 24, 2016, being a Transfer of Easement in favour of 2467459 Ontario Inc.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Instrument No. HR1338861, registered on February 24, 2016, being a Notice in favour of The Corporation of the Town of Oakville.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Instrument No. HR1520622, registered on January 25, 2018, being a Land Registrar&#8217;s Order.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.31</font></div></div><div style="text-align:center;text-indent:136.8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SCHEDULE &#8220;C&#8221;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:136.8pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">DUE DILIGENCE DELIVERIES</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Provided the items below are within the Vendor&#8217;s Possession and&#47;or Control, the Vendor will deliver the following to the Purchaser, and at no cost to the Purchaser, copies of the following&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">Realty tax bills, assessment notices and any realty tax appeals for the calendar years 2022 and 2023&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">b.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Warranties in effect for the Building systems, including the roof, if any&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">c.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">any existing Environmental Site Assessments for the Property and Building condition reports&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">any Survey of the Property&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">e.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:11.07pt">As built plans for any existing build-outs at the Property&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.17pt">Contracts&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">g.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">Property operating statements for 2022 and to date for 2023&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">h.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.5pt">List and copies of all invoices for capital expenditures made at the Property in 2022 and to date for 2023.</font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:23pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.32
<SEQUENCE>4
<FILENAME>anip-20231231xexx1032.htm
<DESCRIPTION>EX-10.32
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i136ef25aac5e4d1389dfc0b7feb2a986_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.32</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">AMENDMENT TO AGREEMENT OF PURCHASE AND SALE</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">THIS AMENDMENT </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">dated as of November 21, 2023.</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">BETWEEN&#58;</font></div><div><font><br></font></div><div style="text-align:center;text-indent:102.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ANI PHARMACEUTICALS CANADA INC.</font></div><div style="text-align:center;text-indent:102.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Vendor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#34;)</font></div><div><font><br></font></div><div style="text-align:center;text-indent:102.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">- and -</font></div><div><font><br></font></div><div style="text-align:center;text-indent:102.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MASTERCOM INC.</font></div><div style="text-align:center;text-indent:102.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(the &#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Purchaser</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#34;)</font></div><div><font><br></font></div><div style="text-indent:5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:8.28pt">the Vendor and the Purchaser entered into an agreement of purchase and sale dated as of November 6, 2023, and which was fully executed by the parties on November 7, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Purchase Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;) whereby the Vendor agreed to sell and the Purchaser agreed to purchase the Property subject to and in accordance with the terms and conditions of the Purchase Agreement&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:8.84pt">the Purchaser failed to pay the First Deposit in the amount of $500,000.00 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Original First Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8221;) to the Vendor&#8217;s Solicitors in trust within 2 Business Days after execution of the Purchase Agreement&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:8.84pt">the parties have agreed to amend the Purchase Agreement as set out herein.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">NOW THEREFORE </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">in consideration of the mutual covenants and agreements set forth in this Amending Agreement and the sum of Two ($2.00) Dollars now paid by each of the parties to the other and for other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged) the parties hereto covenant and agree as follows&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">Capitalized terms used in this Amendment and not otherwise defined shall have the meanings ascribed thereto in the Purchase Agreement.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">In lieu of the Original First Deposit, the parties hereby agree that the Purchaser shall pay on or before November 21, 2023 the sum of One Hundred Thousand ($100,000.00) Dollars by wire transfer payable to the Vendor&#8217;s Solicitors in trust, to be held in trust as a deposit pending the completion or other termination of the transaction contemplated by the Purchase Agreement and to be credited on the Closing Date on account of the Purchase Price. For clarity, the parties acknowledge that any reference to the &#8220;First Deposit&#8221; in the Purchase Agreement shall be read to mean the foregoing sum of $100,000.00, including the reference in Section 3.1(a).</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">The parties hereby acknowledge and agree that the Purchase Agreement is amended by deleting Section 3.1(b) of the Purchase Agreement, and replacing it with the following&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8220;(b) the sum of One Million One Hundred and Fifty Thousand ($1,150,000.00) Dollars (the  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Second Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8221;) by wire transfer payable to the Vendor&#8217;s Solicitors in trust within two (2) Business Days after the Due Diligence Date unless the Purchaser gives Notice that it is terminating the Purchase Agreement due to the failure to satisfy the Purchaser's financing condition set out in Section 4.2.2 of this Agreement, to be held in trust as a deposit pending the completion or other termination of the transaction contemplated by this Agreement and to be credited on the Closing Date on account of the Purchase Price&#59; and&#8221;.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">The parties hereby acknowledge that the &#8220;Due Diligence Date&#8221; under the Purchase Agreement shall be deemed to be December 6, 2023.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">Except as expressly amended by this Amendment, all other terms of the Purchase Agreement shall remain binding on the parties and the parties agree that this Amendment will from the date hereof, be read and construed along with the Purchase Agreement and be treated as part thereof and for such purposes and so far as may be necessary to effectuate these presents, the Purchase Agreement will be regarded as being </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.32</font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">hereby amended, and the Purchase Agreement as so amended together with all terms and conditions thereof will remain in full force and effect and time will remain of the essence.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">This Amendment shall be governed by and construed in accordance with the laws of the Province of Ontario and the laws of Canada applicable thereto.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">This Amendment shall enure to the benefit of and be binding upon the successors and permitted assigns of the parties, as applicable.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:10.5pt">This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which taken together shall be deemed to constitute one and the same instrument. Counterparts may be executed either in original or electronic form and the parties adopt any signatures received by electronic transmission as original signatures of the parties.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#91;Signature Page Follows&#93;</font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="text-align:center;text-indent:180.9pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.32</font></div></div><div style="text-indent:5.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF the parties hereto have duly executed this Amendment as of the date first above written.</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ANI PHARMACEUTICALS CANADA INC.</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> &#47;s&#47; Nikhil Lalwani</font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58; Nikhil Lalwani </font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58; President &#38; CEO</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> &#47;s&#47; Stephen P. Carey</font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58; Stephen P. Carey</font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Title&#58; Vice President &#38; CFO</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I&#47;We have authority to bind the Corporation.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">MASTERCOM INC.</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"> &#47;s&#47; Omar Nouelaty</font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58; Omar Nouelaty</font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Per&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                                              </font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58; &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;</font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></div><div><font><br></font></div><div style="text-indent:248.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I&#47;We have authority to bind the Corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.33
<SEQUENCE>5
<FILENAME>anip-20231231xexx1033.htm
<DESCRIPTION>EX-10.33
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ie1d64a1d47ef48ae89a996c3c57073ba_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.33</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notice of Termination</font></div><div style="text-indent:176.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Agreement of Purchase and Sale - Commercial</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.907%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:5.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:81%">SELLER,</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:6.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:81%">ANI PHARMACEUTICALS CANADA INC.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">and</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.15pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BUYER,</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:6.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">MASTERCOM INC.</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.15pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BROKERAGES,</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:6.05pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CRESA TORONTO, BROKERAGE</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:51.3pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CBRE LIMITED, BROKERAGE</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:6.3pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Listing Brokerage)</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:49.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Co-operating Brokerage)</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.65pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the Sale of</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:6.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">400 Iroquois Shore Road, Oakville. ON</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:5.1pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">dated the</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:6.15pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6th day of November. 2023</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-indent:15.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">We. the Buyer and the Seller in the above noted transaction hereby acknowledge that the above described transaction is terminated and release each other and the Brokerage in the proposed transaction, from all liabilities, covenants, obligations, claims and sum of money arising out of the above Agreement of Purchase and Sale - Commercial, together with any rights and causes of action that each party may have had against the other and&#47;or the Brokerage, and we direct the deposit holder to disburse the deposit of&#58;</font></div><div><font><br></font></div><div style="text-indent:15.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:101%">One Hundred Thousand Canadian Dollars ($CDN) $100,000.00</font></div><div><font><br></font></div><div style="text-indent:15.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Payable to&#58; Amara Construction Inc. </font></div><div><font><br></font></div><div><font><br></font></div><div style="text-indent:15.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:80%">BUYER&#58;                                                               MASTERCOM INC.</font></div><div style="text-indent:240.9pt"><font><br></font></div><div style="text-indent:240.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%;text-decoration:underline">Per&#58; &#47;s&#47; Omar Nouelaty</font></div><div style="text-indent:240.9pt"><font><br></font></div><div style="text-indent:240.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">Name&#58; Omar Nouelaty, A.S.O.</font></div><div><font><br></font></div><div style="text-indent:240.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">I have authority to bind the company</font></div><div><font><br></font></div><div style="text-indent:241pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></div><div style="text-indent:240.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I have authority to bind the company</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RECEIPT ACKNOWLEDGED AT 4&#58;30 A.M. P.M. this 22</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">nd</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> day of December 2023 by&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Print Name&#58; ANI Pharmaceuticals Canada Inc. </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Signature&#58; &#47;s&#47; Chad Gassert</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.34
<SEQUENCE>6
<FILENAME>anip-20231231xexx1034.htm
<DESCRIPTION>EX-10.34
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i883f9726dcd0403dbc11b4b32b0d5455_35"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FORM OF INDEMNIFICATION AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">THIS INDEMNIFICATION AGREEMENT, made and executed this __ day of ________, 202_, by and between ANI Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;), and ____________, an individual resident of the State of ________ (the &#8220;Indemnitee&#8221;). </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, the Company is aware that, in order to induce highly competent persons to serve the Company as directors or officers or in other capacities, the Company must provide such persons with adequate protection through insurance and indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the Company&#59; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, the Company recognizes that the increasing difficulty in obtaining directors&#8217; and officers&#8217; liability insurance, the increases in the cost of such insurance and the general reductions in the coverage of such insurance have increased the difficulty of attracting and retaining such persons&#59; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, the Board of Directors of the Company has determined that it is essential to the best interests of the Company&#8217;s stockholders that the Company act to assure such persons that there will be increased certainty of such protection in the future&#59; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify such persons to the fullest extent permitted by applicable law so that they will continue to serve the Company free from undue concern that they will not be so indemnified&#59; and </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">WHEREAS, the Indemnitee is willing to serve, continue to serve, and take on additional service for or on behalf of the Company or any of its direct or indirect subsidiaries on the condition that he&#47;she be so indemnified. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">NOW, THEREFORE, in consideration of the premises and the mutual promises and covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Indemnitee do hereby agree as follows&#58; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Service by the Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The Indemnitee agrees to serve and&#47;or continue to serve as a director, officer, employee or other agent of the Company faithfully and will discharge his&#47;her duties and responsibilities to the best of his&#47;her ability so long as the Indemnitee is duly elected or qualified in accordance with the provisions of the Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate&#8221;), and Bylaws, as amended (the &#8220;Bylaws&#8221;) of the Company and the General Corporation Law of the State of Delaware, as amended (the &#8220;DGCL&#8221;), or until his&#47;her earlier death, resignation or removal. The Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or other obligation imposed by operation by law), in which event the Company shall have no obligation under this Agreement to continue to retain the Indemnitee in any such position. Nothing in this Agreement shall confer upon the Indemnitee the right to continue in the employ of the Company or as a director of the Company or affect the right of the Company to terminate the Indemnitee&#8217;s employment or service at any time in the sole discretion of the Company, with or without cause, subject to any contract rights of the Indemnitee created or existing otherwise than under this Agreement. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The Company shall indemnify the Indemnitee against all Expenses (as defined below), judgments, fines and amounts paid in settlement actually and reasonably incurred by the Indemnitee as provided in this Agreement to the fullest extent permitted by the Certificate, Bylaws and DGCL or other applicable law in effect on the date of this Agreement and to any greater extent that applicable law may in the future from time to time permit. Without diminishing the scope of the indemnification provided by this Section 2, the rights of indemnification of the Indemnitee provided hereunder shall include, but shall not be limited to, those rights hereinafter set forth, except that no indemnification shall be paid to the Indemnitee&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;on account of any action, suit or proceeding in which judgment is rendered against the Indemnitee for disgorgement of profits made from the purchase or sale by the Indemnitee of securities of the Company pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or similar provisions of any federal, state or local statutory law&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;on account of conduct of the Indemnitee which is finally adjudged by a court of competent jurisdiction to have been knowingly fraudulent or to constitute willful misconduct&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                </font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;in any circumstance where such indemnification is expressly prohibited by applicable law&#59; </font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)           with respect to liability for which payment is actually made to the Indemnitee under a valid and collectible insurance policy of the Company or under a valid and enforceable indemnity clause, Bylaw or agreement (other than this Agreement) of the Company, except in respect of any liability in excess of payment under such insurance, clause, Bylaw or agreement&#59; </font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)       if a final decision by a court having jurisdiction in the matter shall determine that such indemnification is not lawful (and, in this respect, both the Company and the Indemnitee have been advised that it is the position of the Securities and Exchange Commission that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable, and that claims for indemnification should be submitted to the appropriate court for adjudication)&#59; or </font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font><br></font></div><div style="padding-left:9pt;text-align:justify;text-indent:40.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)            in connection with any action, suit or proceeding by the Indemnitee against the Company or any of its direct or indirect subsidiaries or the directors, officers, employees or other Indemnitees of the Company or any of its direct or indirect subsidiaries, (i) unless such indemnification is expressly required to be made by law, (ii) unless the proceeding was authorized by the Board of Directors of the Company, (iii) unless such indemnification is provided by the Company, in its sole discretion, pursuant to the powers vested in the Company under applicable law, or (iv) except as provided in Sections 11 and 13 hereof. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Actions or Proceedings Other Than an Action by or in the Right of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The Indemnitee shall be entitled to the indemnification rights provided in this Section 3 if the Indemnitee was or is a party or witness or is threatened to be a party or witness to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative in nature, other than an action by or in the right of the Company, by reason of the fact that the Indemnitee is or was a director, officer, employee, agent or fiduciary of the Company, or any of its direct or indirect subsidiaries, or is or was serving at the request of the Company, or any of its direct or indirect subsidiaries, as a director, officer, employee, agent or fiduciary of any other entity, including, but not limited to, another corporation, partnership, limited liability company, employee benefit plan, joint venture, trust or other enterprise, or by reason of any act or omission by him&#47;her in such capacity. Pursuant to this Section 3, the Indemnitee shall be indemnified against all Expenses, judgments, penalties (including excise and similar taxes), fines and amounts paid in settlement which were actually and reasonably incurred by the Indemnitee in connection with such action, suit or proceeding (including, but not limited to, the investigation, defense or appeal thereof), if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his&#47;her conduct was unlawful. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Actions by or in the Right of the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The Indemnitee shall be entitled to the indemnification rights provided in this Section 4 if the Indemnitee was or is a party or witness or is threatened to be made a party or witness to any threatened, pending or completed action, suit or proceeding brought by or in the right of the Company to procure a judgment in its favor by reason of the fact that the Indemnitee is or was a director, officer, employee, agent or fiduciary of the Company, or any of its direct or indirect subsidiaries, or is or was serving at the request of the Company, or any of its direct or indirect subsidiaries, as a director, officer, employee, agent or fiduciary of another entity, including, but not limited to, another corporation, partnership, limited liability company, employee benefit plan, joint venture, trust or other enterprise, or by reason of any act or omission by him&#47;her in any such capacity. Pursuant to this Section 4, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by him&#47;her in connection with the defense or settlement of such action, suit or proceeding (including, but not limited to the investigation, defense or appeal thereof), if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company&#59; provided however, that no such indemnification shall be made in respect of any claim, issue, or matter as to which the Indemnitee shall have been adjudged to be liable to the Company, unless and only to the extent that the Court of Chancery of the State of Delaware or the court in which such action, suit or proceeding was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, the Indemnitee is fairly and reasonably entitled to be indemnified against such Expenses actually and reasonably incurred by him&#47;her which such court shall deem proper. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Good Faith Definition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   For purposes of this Agreement, the Indemnitee shall be deemed to have acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Company, or, with respect to any criminal action or proceeding to have had no reasonable cause to believe the Indemnitee&#8217;s conduct was unlawful, if such action was based on (i) the records or books of the account of the Company or other enterprise, including financial statements&#59; (ii) information supplied to the Indemnitee by the officers of the Company or other enterprise in the course of their duties&#59; (iii) the advice of legal counsel for the Company or other enterprise&#59; or (iv) information or records given in reports made to the Company or other enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Company or other enterprise. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Indemnification for Expenses of Successful Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   Notwithstanding the other provisions of this Agreement, to the extent that the Indemnitee has served on behalf of the Company, or any of its direct or indirect subsidiaries, as a witness or other participant in any class action or proceeding, or has been successful, on the merits or otherwise, in defense of any action, suit or proceeding referred to in Section 3 and 4 hereof, or in defense of any claim, issue or matter therein, including, but not limited to, the dismissal of any action without prejudice, the Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee in connection therewith, regardless of whether or not the Indemnitee has met the applicable standards of Section 3 or 4 and without any determination pursuant to Section 8. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Partial Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If the Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of the Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by the Indemnitee in connection with the investigation, defense, appeal or settlement of such suit, action, investigation or proceeding described in Section 3 or 4 hereof, but is not entitled to indemnification for the total amount thereof, the Company shall nevertheless indemnify the Indemnitee for the portion of such Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by the Indemnitee to which the Indemnitee is entitled. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Procedure for Determination of Entitlement to Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (a)           To obtain indemnification under this Agreement, the Indemnitee shall submit to the Company a written request, including documentation and information which is reasonably available to the Indemnitee and is reasonably necessary to determine whether and to what extent the Indemnitee is entitled to indemnification. The Secretary of the Company shall, promptly upon receipt of a request for indemnification, advise the Board of Directors in writing that the Indemnitee has requested indemnification. Any Expenses incurred by the Indemnitee in connection with the Indemnitee&#8217;s request for indemnification hereunder shall be borne by the Company. The Company hereby indemnifies and agrees to hold the Indemnitee harmless for any Expenses incurred by the Indemnitee under the immediately preceding sentence irrespective of the outcome of the determination of the Indemnitee&#8217;s entitlement to indemnification. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (b)           Upon written request by the Indemnitee for indemnification pursuant to Section 3 or 4 hereof, the entitlement of the Indemnitee to indemnification pursuant to the terms of this Agreement shall be determined by the following person or persons, who shall be empowered to make such determination&#58; (i) if a Change in Control (as hereinafter defined) shall have occurred, by Independent Counsel (as hereinafter defined) (unless the Indemnitee shall request in writing that such determination be made by the Board of Directors (or a committee thereof) in the manner provided for in clause (ii) of this Section 8(b)) in a written opinion to the Board of Directors, a copy of which shall be delivered to the Indemnitee&#59; or (ii) if a Change in Control shall not have occurred, (A)(1) by the Board of Directors of the Company, by a majority vote of Disinterested Directors (as hereinafter defined) even though less than a quorum, or (2) by a committee of Disinterested Directors designated by majority vote of Disinterested Directors, even though less than a quorum, or (B) if there are no such Disinterested Directors or, even if there are such Disinterested Directors, if the Board of Directors, by the majority vote of Disinterested Directors, so directs, by Independent Counsel in a written opinion to the Board of Directors, a copy of which shall be delivered to the Indemnitee. Such Independent Counsel shall be selected by the Board of Directors and approved by the Indemnitee. Upon failure of the Board of Directors to so select, or upon failure of the Indemnitee to so approve, such Independent Counsel shall be selected by the Chancellor of the State of Delaware or such other person as the Chancellor shall designate to make such selection. Such determination of entitlement to indemnification shall be made not later than 45 days after receipt by the Company of a written request for indemnification. If the person making such determination shall determine that the Indemnitee is entitled to indemnification as to part (but not all) of the application for indemnification, such person shall reasonably prorate such part of indemnification among such claims, issues or matters. If it is so determined that the Indemnitee is entitled to indemnification, payment to the Indemnitee shall be made within ten days after such determination. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Presumptions and Effect of Certain Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (a)        In making a determination with respect to entitlement to indemnification, the Indemnitee shall be presumed to be entitled to indemnification hereunder and the Company shall have the burden of proof in the making of any determination contrary to such presumption. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (b)           If the Board of Directors, or such other person or persons empowered pursuant to Section 8 to make the determination of whether the Indemnitee is entitled to indemnification, shall have failed to make a determination as to entitlement to indemnification within 45 days after receipt by the Company of such request, the requisite determination of entitlement to indemnification shall be deemed to have been made and the Indemnitee shall be absolutely entitled to such indemnification, absent actual and material fraud in the request for indemnification or a prohibition of indemnification under applicable law. The termination of any action, suit, investigation or proceeding described in Section 3 or 4 hereof by judgment, order, settlement or conviction, or upon a plea of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">nolo contendere </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or its equivalent, shall not, of itself&#58; (i) create a presumption that the Indemnitee did not act in good faith and in a manner which he&#47;she reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, that the Indemnitee has reasonable cause to believe that the Indemnitee&#8217;s conduct was unlawful&#59; or (ii) otherwise adversely affect the rights of the Indemnitee to indemnification, except as may be provided herein. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Advancement of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   All reasonable Expenses actually incurred by the Indemnitee in connection with any threatened or pending action, suit or proceeding shall be paid by the Company in advance of the final disposition of such action, suit or proceeding, if so requested by the Indemnitee, within 20 days after the receipt by the Company of a statement or statements from the Indemnitee requesting such advance or advances. The Indemnitee may submit such statements from time to time. The Indemnitee&#8217;s entitlement to such Expenses shall include those incurred in connection with any proceeding by the Indemnitee seeking an adjudication or award in arbitration pursuant to this Agreement. Such statement or statements shall reasonably evidence the Expenses incurred by the Indemnitee in connection therewith and shall include or be accompanied by a written affirmation by the Indemnitee of the Indemnitee&#8217;s good faith belief that the Indemnitee has met the standard of conduct necessary for indemnification under this Agreement and an undertaking by or on behalf of the Indemnitee to repay such amount if it is ultimately determined that the Indemnitee is not entitled to be indemnified against such Expenses by the Company pursuant to this Agreement or otherwise. Each written undertaking to pay amounts advanced must be an unlimited general obligation but need not be secured, and shall be accepted without reference to financial ability to make repayment. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">11.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Remedies of the Indemnitee in Cases of Determination not to Indemnify or to Advance Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   In the event that a determination is made that the Indemnitee is not entitled to indemnification hereunder or if the payment has not been timely made following a determination of entitlement to indemnification pursuant to Sections 8 and 9, or if Expenses are not advanced pursuant to Section 10, the Indemnitee shall be entitled to a final adjudication in an appropriate court of the State of Delaware or any other court of competent jurisdiction of the Indemnitee&#8217;s entitlement to such indemnification or advance. Alternatively, the Indemnitee may, at the Indemnitee&#8217;s option, seek an award in arbitration to be conducted by a single arbitrator pursuant to the rules of the American Arbitration Association, such award to be made within 60 days following the filing of the demand for arbitration. The Company shall not oppose the Indemnitee&#8217;s right to seek any such adjudication or award in arbitration or any other claim. Such judicial proceeding or arbitration shall be made </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">de novo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and the Indemnitee shall not be prejudiced by reason of a determination (if so made) that the Indemnitee is not entitled to indemnification. If a determination is made or deemed to have been made pursuant to the terms of Section 8 or Section 9 hereof that the Indemnitee is entitled to indemnification, the Company shall be bound by such determination and shall be precluded from asserting that such determination has not been made or that the procedure by which such determination was made is not valid, binding and enforceable. The Company further agrees to stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement and is precluded from making any assertions to the contrary. If the court or arbitrator shall determine that the Indemnitee is entitled to any indemnification hereunder, the Company shall pay all reasonable Expenses actually incurred by the Indemnitee in connection with such adjudication or award in arbitration (including, but not limited to, any appellate proceedings). </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Notification and Defense of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   Promptly after receipt by the Indemnitee of notice of the commencement of any action, suit or proceeding, the Indemnitee will, if a claim in respect thereof is to be made against the Company under this Agreement, notify the Company in writing of the commencement thereof&#59; but the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">omission to so notify the Company will not relieve the Company from any liability that it may have to the Indemnitee otherwise than under this Agreement or otherwise, except to the extent that the Company may suffer material prejudice by reason of such failure. Notwithstanding any other provision of this Agreement, with respect to any such action, suit or proceeding as to which the Indemnitee gives notice to the Company of the commencement thereof&#58; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">             (a)           The Company will be entitled to participate therein at its own expense. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">           (b)          Except as otherwise provided in this Section 12(b), to the extent that it may wish, the Company, jointly with any other indemnifying party similarly notified, shall be entitled to assume the defense thereof with counsel reasonably satisfactory to the Indemnitee. After notice from the Company to the Indemnitee of its election to so assume the defense thereof, the Company shall not be liable to the Indemnitee under this Agreement for any legal or other Expenses subsequently incurred by the Indemnitee in connection with the defense thereof other than reasonable costs of investigation or as otherwise provided below. The Indemnitee shall have the right to employ the Indemnitee&#8217;s own counsel in such action or lawsuit, but the fees and Expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of the Indemnitee unless (i) the employment of counsel by the Indemnitee has been authorized by the Company, (ii) the Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and the Indemnitee in the conduct of the defense of such action and such determination by the Indemnitee shall be supported by an opinion of counsel, which opinion shall be reasonably acceptable to the Company, or (iii) the Company shall not in fact have employed counsel to assume the defense of the action, in each of which cases the fees and Expenses of counsel shall be at the expense of the Company. The Company shall not be entitled to assume the defense of any action, suit or proceeding brought by or on behalf of the Company or as to which the Indemnitee shall have reached the conclusion provided for in clause (ii) above. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (c)           The Company shall not be liable to indemnify the Indemnitee under this Agreement for any amounts paid in settlement of any action, suit or proceeding effected without its written consent, which consent shall not be unreasonably withheld. The Company shall not be required to obtain the consent of the Indemnitee to settle any action, suit or proceeding which the Company has undertaken to defend if the Company assumes full and sole responsibility for such settlement and such settlement grants the Indemnitee a complete and unqualified release in respect of any potential liability. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (d)           If, at the time of the receipt of a notice of a claim pursuant to this Section 12, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of the policies.</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">13.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Other Right to Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The indemnification and advancement of Expenses provided by this Agreement are cumulative, and not exclusive, and are in addition to any other rights to which the Indemnitee may now or in the future be entitled under any provision of the Bylaws or Certificate of the Company, any vote of stockholders or Disinterested Directors, any provision of law or otherwise. Except as required by applicable law, the Company shall not adopt any amendment to its Bylaws or Certificate the effect of which would be to deny, diminish or encumber the Indemnitee&#8217;s right to indemnification under this Agreement. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Director and Officer Liability Insurance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Company shall maintain directors&#8217; and officers&#8217; liability insurance for so long as the Indemnitee&#8217;s services are covered hereunder, provided and to the extent that such insurance is available on a commercially reasonable basis. In the event the Company maintains directors&#8217; and officers&#8217; liability insurance, the Indemnitee shall be named as an insured in such manner as to provide the Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company&#8217;s officers or directors. However, the Company agrees that the provisions hereof shall remain in effect regardless of whether liability or other insurance coverage is at any time obtained or retained by the Company, except that any payments made to, or on behalf of, the Indemnitee under an insurance policy shall reduce the obligations of the Company hereunder. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Spousal Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The Company will indemnify the Indemnitee&#8217;s spouse to whom the Indemnitee is legally married at any time the Indemnitee is covered under the indemnification provided in this Agreement (even if the Indemnitee did not remain married to him or her during the entire period of coverage) against any pending or threatened action, suit, proceeding or investigation for the same period, to the same extent and subject to the same </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">standards, limitations, obligations and conditions under which the Indemnitee is provided indemnification herein, if the Indemnitee&#8217;s spouse (or former spouse) becomes involved in a pending or threatened action, suit, proceeding or investigation solely by reason of his or her status as the Indemnitee&#8217;s spouse, including, without limitation, any pending or threatened action, suit, proceeding or investigation that seeks damages recoverable from marital community property, jointly-owned property or property purported to have been transferred from the Indemnitee to his&#47;her spouse (or former spouse). The Indemnitee&#8217;s spouse or former spouse also may be entitled to advancement of Expenses to the same extent that the Indemnitee is entitled to advancement of Expenses herein. The Company may maintain insurance to cover its obligation hereunder with respect to the Indemnitee&#8217;s spouse (or former spouse) or set aside assets in a trust or escrow fund for that purpose. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Intent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   This Agreement is intended to be broader than any statutory indemnification rights applicable in the State of Delaware and shall be in addition to any other rights the Indemnitee may have under the Company&#8217;s Certificate, Bylaws, applicable law or otherwise. To the extent that a change in applicable law (whether by statute or judicial decision) permits greater indemnification by agreement than would be afforded currently under the Company&#8217;s Certificate, Bylaws, applicable law or this Agreement, it is the intent of the parties that the Indemnitee enjoy by this Agreement the greater benefits so afforded by such change. In the event of any change in applicable law, statute or rule which narrows the right of a Delaware corporation to indemnify a member of its Board of Directors or an officer, employee, agent or fiduciary, such change, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement, shall have no effect on this Agreement or the parties&#8217; rights and obligations hereunder. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Attorney&#8217;s Fees and Other Expenses to Enforce Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   In the event that the Indemnitee is subject to or intervenes in any action, suit or proceeding in which the validity or enforceability of this Agreement is at issue or seeks an adjudication or award in arbitration to enforce the Indemnitee&#8217;s rights under, or to recover damages for breach of, this Agreement the Indemnitee, if he&#47;she prevails in whole or in part in such action, shall be entitled to recover from the Company and shall be indemnified by the Company against any actual expenses for attorneys&#8217; fees and disbursements reasonably incurred by the Indemnitee. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The provisions of this Agreement shall cover claims, actions, suits or proceedings whether now pending or hereafter commenced and shall be retroactive to cover acts or omissions or alleged acts or omissions which heretofore have taken place. The Company shall be liable under this Agreement, pursuant to Sections 3 and 4 hereof, for all acts of the Indemnitee while serving as a director and&#47;or officer, notwithstanding the termination of the Indemnitee&#8217;s service, if such act was performed or omitted to be performed during the term of the Indemnitee&#8217;s service to the Company. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">19.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Duration of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   This Agreement shall survive and continue even though the Indemnitee may have terminated his&#47;her service as a director, officer, employee, agent or fiduciary of the Company or as a director, officer, employee, agent or fiduciary of any other entity, including, but not limited to another corporation, partnership, limited liability company, employee benefit plan, joint venture, trust or other enterprise or by reason of any act or omission by the Indemnitee in any such capacity. This Agreement shall be binding upon the Company and its successors and assigns, including, without limitation, any corporation or other entity which may have acquired all or substantially all of the Company&#8217;s assets or business or into which the Company may be consolidated or merged, and shall inure to the benefit of the Indemnitee and his&#47;her spouse, successors, assigns, heirs, devisees, executors, administrators or other legal representations. The Company shall require any successor or assignee (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and&#47;or assets of the Company, by written agreement in form and substance reasonably satisfactory to the Company and the Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession or assignment had taken place. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Disclosure of Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   Except as expressly required by any Federal or state securities laws or other Federal or state law, neither party shall disclose any payments under this Agreement unless prior approval of the other party is obtained. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   If any provision or provisions of this Agreement shall be held invalid, illegal or unenforceable for any reason whatsoever, (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, but not limited to, all portions of any Sections of this Agreement containing any such provision held to be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (b) to the fullest extent possible, the provisions of this Agreement (including, but not limited to, all portions of any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">paragraph of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that are not themselves invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifest by the provision held invalid, illegal or unenforceable. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">22.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   This Agreement may be executed by one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought shall be required to be produced to evidence the existence of this Agreement. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">23.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Captions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   The captions and headings used in this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">24.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  For purposes of this Agreement&#58; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (a)           &#8220;Change in Control&#8221; shall mean the occurrence of any one of the following&#58; </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)          the sale, lease, exchange or other transfer, directly or indirectly, of substantially all of the assets of the Company (in one transaction or in a series of related transactions) to a person or entity that is not controlled by the Company&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)         the approval by the stockholders of the Company of any plan or proposal for the liquidation or dissolution of the Company&#59;</font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)        any person becomes after the effective date of this Agreement the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of (A) 20% or more, but not 50% or more, of the combined voting power of the Company&#8217;s outstanding securities ordinarily having the right to vote at elections of directors, unless the transaction resulting in such ownership has been approved in advance by the Continuity Directors, or (B) 50% or more of the combined voting power of the Company&#8217;s outstanding securities ordinarily having the right to vote at elections of directors (regardless of any approval by the Continuity Directors)&#59; </font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                             </font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)        a merger or consolidation to which the Company is a party if the stockholders of the Company immediately prior to effective date of such merger or consolidation have &#8220;beneficial ownership&#8221; (as defined in Rule 13d-3 under the Exchange Act), immediately following the effective date of such merger or consolidation, of securities of the surviving corporation representing (A) more than 50%, but less than 80%, of the combined voting power of the surviving corporation&#8217;s then outstanding securities ordinarily having the right to vote at elections of directors, unless such merger or consolidation has been approved in advance by the Continuity Directors, or (B) 50% or less of the combined voting power of the surviving corporation&#8217;s then outstanding securities ordinarily having the right to vote at elections of directors (regardless of any approval by the Continuity Directors)&#59;</font></div><div style="text-align:justify;text-indent:81pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                            </font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(v)         the Continuity Directors cease for any reason to constitute at least a majority of the Board&#59; or </font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(vi) any other change in control of the Company of a nature that would be required to be reported pursuant to Section 13 or 15(d) of the Exchange Act, whether or not the Company is then subject to such reporting requirement. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">            (b)           &#8220;Continuity Directors&#8221; shall mean any individuals who are members of the Board on the effective date of this Agreement and any individual who subsequently becomes a member of the Board whose election, or nomination for election by the Company&#8217;s stockholders, was approved by a vote of at least a majority of the Continuity Directors (either by specific vote or by approval of the Company&#8217;s proxy statement in which such individual is named as a nominee for director without objection to such nomination). </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (c)           &#8220;Disinterested Director&#8221; shall mean a director of the Company who is not or was not a party to the action, suit, investigation or proceeding in respect of which indemnification is being sought by the Indemnitee.</font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                (d)           &#8220;Expenses&#8221; shall include all attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating or being or preparing to be a witness in any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative in nature. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">              (e)           &#8220;Independent Counsel&#8221; shall mean a law firm or a member of a law firm that neither is presently nor in the past five years has been retained to represent (i) the Company or the Indemnitee in any matter material to either such party or (ii) any other party to the action, suit, investigation or proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or the Indemnitee in an action to determine the Indemnitee&#8217;s right to indemnification under this Agreement. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">25.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Entire Agreement, Modification and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  This Agreement constitutes the entire agreement and understanding of the parties hereto regarding the subject matter hereof, and no supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver. No supplement, modification or amendment of this Agreement shall limit or restrict any right of the Indemnitee under this Agreement in respect of any act or omission of the Indemnitee prior to the effective date of such supplement, modification or amendment unless expressly provided therein. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.   All notices, requests, demands or other communications hereunder shall be in writing and shall be deemed to have been duly given if (a) delivered by hand with receipt acknowledged by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail, return receipt requested with postage prepaid, on the date shown on the return receipt, (c) sent by a recognized next-day courier service on the first business day following the date of dispatch or (d) delivered by facsimile transmission on the date shown on the facsimile machine report&#58; </font></div><div><font><br></font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)    If to the Indemnitee, to&#58; </font></div><div><font><br></font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        ________________</font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        ________________</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">________________</font></div><div><font><br></font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)   If to the Company, to&#58;</font></div><div><font><br></font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        ANI Pharmaceuticals, Inc.</font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        210 Main Street West</font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        Baudette, MN  56623</font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        Attn&#58; General Counsel</font></div><div style="text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">        Email&#58; legaldept&#64;anipharmaceuticals.com</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or to such other address as may be furnished to the Indemnitee by the Company or to the Company by the Indemnitee, as the case may be. </font></div><div style="text-align:justify;text-indent:18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27.          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The parties hereto agree that this Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, applied without giving effect to any conflicts-of-law principles. </font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#91;Signature Page Follows&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 10.34</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written. </font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.012%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ANI PHARMACEUTICALS, INC.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">_______________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">INDEMNITEE&#58;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">_______________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>anip-20231231xexx21.htm
<DESCRIPTION>EX-21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i713ee01b19f245e797c3269b74f0f5e2_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Exhibit 21</font></div><div><font><br></font></div></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ANI PHARMACEUTICALS, INC.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a list of subsidiaries of ANI Pharmaceuticals, Inc., omitting subsidiaries which, considered in the aggregate as a single subsidiary, would not constitute a significant subsidiary, as of December 31, 2023&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.138%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Jurisdiction of Incorporation or Organization</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ANIP Acquisition Company</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ANI Pharmaceuticals Canada Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Canada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novitium Pharma, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New Castle Pharma LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Novitium Labs Private Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New Castle Pharma Real Estate LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ANI Rare Disease Patient Assistance Program, Inc. </font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Delaware</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>anip-2023x1231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="iab781682822a4dcdbbeca978c6ccbb01_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Exhibit 23.1</font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements of ANI Pharmaceuticals, Inc. on Form S-3 (Nos. 333-239771 and 333-261731) and Form S-8 (Nos. 333-196518, 333-214416, 333-218120, 333-250892, 333-260662, 333-264511, and 333-272860) of our reports dated February 29, 2024, on our audits of the financial statements as of December 31, 2023 and 2022 and for each of the years in the three-year period ended December 31, 2023, and the effectiveness of ANI Pharmaceuticals, Inc. and Subsidiaries&#8217; internal control over financial reporting as of December 31, 2023, which reports are included in this Annual Report on Form 10-K to be filed on or about February 29, 2024. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47; EisnerAmper LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">EISNERAMPER LLP</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Philadelphia, Pennsylvania</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 29, 2024</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>anip-20231231xexx311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i303c8fcf693d46749139e72cf0fd9b5c_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Nikhil Lalwani, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of ANI Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.417%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;29, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Nikhil Lalwani</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nikhil Lalwani</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>anip-20231231xexx312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i9db352e5728b435b9d393203836b4f52_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;padding-left:13.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Stephen P. Carey, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this Annual Report on Form 10-K of ANI Pharmaceuticals, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:40.5pt;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.41pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:72pt;text-indent:-31.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.84pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February&#160;29, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Stephen P. Carey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stephen P. Carey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Vice President, Finance and Chief Financial Officer</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>anip-20231231xexx321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i92203c2f5c784357ae808e9afcab8558_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report on Form 10-K of ANI Pharmaceuticals, Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2023 (the &#8220;Report&#8221;) as filed with the Securities and Exchange Commission on the date hereof, the undersigned Chief Executive Officer and Chief Financial Officer of the Company hereby certify that, to such officer&#8217;s knowledge&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is provided solely pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dated&#58; February&#160;29, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Nikhil Lalwani</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Nikhil Lalwani</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal executive officer)</font></td></tr></table></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Dated&#58; February&#160;29, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#47;s&#47; Stephen P. Carey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Stephen P. Carey</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Senior Vice President, Finance and</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal financial and accounting officer)</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.1
<SEQUENCE>12
<FILENAME>anip-20231231xexx971.htm
<DESCRIPTION>EX-97.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i269e3a37ebe7439bbcee2f43f6b248e7_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 97.1</font></div></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:193%">ANI PHARMACEUTICALS, INC. AMENDED AND RESTATED CLAWBACK POLICY</font></div><div style="text-align:center"><font><br></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:193%">I.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:193%;padding-left:28.97pt">Purpose.</font></div><div style="text-indent:47pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The Bo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">ard of Directors (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) of ANI Pharmaceuticals, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) based upon the recommendation of its Compensation Committee (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), has adopted this Compensation Recoupment Policy (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;) in order to implement a mandatory clawback policy in the event of a Restatement in compliance with the Applicable Rules. Any capitalized terms used, but not immediately defined, in this Policy have the meanings set forth in</font></div><div style="text-indent:47pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Section </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">VIII.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%">II. Administration.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Policy shall be administered by the Committee, which shall make all determinations with respect to this Policy in its sole discretion&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">that this Policy shall be interpreted in a manner consistent with the requirements of the Applicable Rules. Notwithstanding the foregoing, subject to the Applicable Rules, the Board may assume any or all powers and authority of the Committee with respect to this Policy, in which case references to the Committee shall be deemed to include the Board, as applicable.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">III. Recovery on a Restatement.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event that the Company is required to prepare a Restatement, the Company shall reasonably promptly recover from an Executive Officer the amount of any erroneously awarded Incentive-Based Compensation that is Received by such Executive Officer during the Recovery Period. The amount of erroneously Received Incentive-Based Compensation will be the excess of the Incentive-Based Compensation Received by the Executive Officer (whether in cash or shares) based on the erroneous data in the original financial statements over the Incentive-Based Compensation (whether in cash or in shares) that would have been Received by the Executive Officer had such Incentive-Based Compensation been based on the restated results, without respect to any tax liabilities incurred or paid by the Executive Officer.</font></div><div><font><br></font></div><div style="text-indent:46.9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Recovery of any erroneously awarded compensation under this Policy is not dependent on fraud or misconduct by any Executive Officer in connection with a Restatement.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Without limiting the foregoing, for Incentive-Based Compensation based on the Company&#8217;s stock price or total shareholder return, where the amount of erroneously awarded compensation is not subject to mathematical recalculation directly from the information in the Restatement, (i) the amount shall be based on the Company&#8217;s reasonable estimate of the effect of the Restatement on the stock price or total shareholder return upon which the Incentive-Based Compensation was Received and (ii) the Company shall maintain documentation of the determination of that reasonable estimate and provide such estimate to the Regulators as required by the Applicable Rules.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition to the foregoing, in the event that an Executive Officer fails to repay or reimburse erroneously awarded compensation that is subject to recovery, the Committee may require an Executive Officer to reimburse the Company for any and all expenses reasonably incurred (including legal fees) by the Company in recovering erroneously awarded compensation under this Policy.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">IV. Coverage and Application.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Policy covers all persons who are Executive Officers at any time during the Recovery Period for which Incentive-Based Compensation is Received or during the performance period applicable to such Incentive-Based Compensation. Incentive-Based Compensation shall not be recovered under this Policy to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 97.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">the extent Received by any person before the date the person served as an Executive Officer. Subsequent changes in an Executive Officer&#8217;s employment status, including retirement or termination of employment, do not affect the Company&#8217;s right to recover Incentive-Based Compensation pursuant to this Policy.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This Policy shall apply to Incentive-Based Compensation that is Received by any Executive Officer on or after the Effective Date and that results from attainment of a Financial Reporting Measure based on or derived from financial information for any fiscal period ending on or after the Effective Date. For the avoidance of doubt, this will include Incentive-Based Compensation that may have been approved, awarded, or granted to an Executive Officer on or before the Effective Date if such Incentive-Based Compensation is Received after the Effective Date.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">V. Exceptions to Policy.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">No recovery of Incentive-Based Compensation shall be required if any of the following conditions are met and the Committee determines that, on such basis, recovery would be impracticable&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.37pt">the direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%">provided </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">that prior to making a determination that it would be impracticable to recover any Incentive-Based Compensation based on the expense of enforcement, the Company shall (i) have made a reasonable attempt to recover the Incentive-Based Compensation, (ii) have documented such reasonable attempts to recover, and (iii) provide the documentation to the Regulators as required by the Applicable Rules&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.75pt">recovery would violate home country law where that law was adopted prior to November 28, 2022&#59; or</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.37pt">recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;), and U.S. Treasury regulations promulgated thereunder.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">VI. Methods of Recovery.</font></div><div><font><br></font></div><div style="text-indent:46.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the event of a Clawback Event, subject to applicable law, the Committee may take any such actions as it deems necessary or appropriate, including, without limitation&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">the reduction or cancellation of any Incentive-Based Compensation in the form of vested or unvested equity or equity-based awards that have not been distributed or otherwise settled prior to the date of determination&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the recovery of any Incentive-Based Compensation that was previously paid to the Executive Officer&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">the recovery of any gain realized on the vesting, exercise, settlement, sale, transfer, or other disposition of any Incentive-Based Compensation in the form of equity or equity- based awards&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">the offset, withholding, or elimination of any amount that could be paid or awarded to the Executive Officer after the date of determination&#59;</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">the recoupment of any amount in respect of Incentive-Based Compensation contributed to a plan that takes into account Incentive-Based Compensation (excluding certain tax- qualified plans, but including long-term disability, life insurance, supplemental executive retirement plans and deferred compensation plans, in each case to the extent permitted by applicable law, including Section 409A of the Code) and any earnings accrued to date on any such amount&#59; and</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.59pt">the taking of any other remedial and recovery action permitted by law, as determined by the Committee.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 97.1</font></div></div><div style="text-indent:47pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In addition, the Committee may authorize legal action for breach of fiduciary duty or other violation of law and take such other actions to enforce the Executive Officer&#8217;s obligations to the Company as the Committee deems appropriate.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">VII. Miscellaneous.</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.37pt">Effectiveness of this Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. This Policy is adopted as of December 1, 2023, with retroactive effectiveness as of October 2, 2023 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9.75pt">Public Disclosure</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company shall make all required disclosures and filings with the Regulators with respect to this Policy in accordance with the requirements of the Applicable Rules, and any other requirements applicable to the Company, including any disclosures required in connection with SEC filings.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.37pt">Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Before the Company takes action to seek recovery of compensation pursuant to this Policy against an Executive Officer, the Company shall take commercially reasonable steps to provide such individual with advance written notice of such clawback&#59; provided that this notice requirement shall not in any way delay the reasonably prompt recovery of any erroneously awarded Incentive-Based Compensation.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9.75pt">No Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company shall not indemnify any current or former Executive Officer against the loss of erroneously awarded compensation and shall not pay or reimburse any Executive Officer for premiums incurred or paid for any insurance policy to fund such Executive Officer&#8217;s potential recovery obligations.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:10.37pt">No Substitution of Rights&#59; Non-Exhaustive Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. Any right of recoupment under this Policy is in addition to, and not in lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant to (i) any equity or equity-based incentive compensation plan or any successor plan thereto, or any other incentive plan of the Company or any of its subsidiaries or affiliates or (ii) the terms of any similar policy or provision in any employment agreement, compensation agreement or arrangement, or similar agreement and any other legal remedies available to the Company. In addition to recovery of compensation as provided for in this Policy, the Company may take any and all other actions as it deems necessary, appropriate and in the Company&#8217;s best interest in connection with a Clawback Event, including termination of an Executive Officer&#8217;s employment and initiating legal action against an Executive Officer, and nothing in this Policy limits the Company&#8217;s rights to take any such or other appropriate actions.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:11.59pt">Governing Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. This Policy and all determinations made and actions taken pursuant hereto, to the extent not otherwise governed by mandatory provisions of the Applicable Rules, shall be governed by and construed in accordance with the laws of Delaware without regard to choice of law principles. If any provision of this Policy shall be held illegal or invalid for any reason, such illegality or invalidity shall not affect the remaining parts of this Policy, but this Policy shall be construed and enforced as if the illegal or invalid provision had never been included in this Policy.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:112%;padding-left:9.75pt">Amendment&#59; Termination&#59; Sunset</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. This Policy amends and restates and replaces in all respects the Amended and Restated Clawback Policy adopted by the Board effective April 7, 2023. The Board, based upon the recommendation of the Committee, may amend this Policy at any time for any reason, subject to any limitations under the Applicable Rules. Unless otherwise required by applicable law, this Policy shall no longer be effective from and after the date that the Company no longer has a class of securities publicly listed on a U.S. national securities exchange or is otherwise not subject to the Applicable Rules.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:112%">VIII. Defined Terms.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Exhibit 97.1</font></div></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Applicable Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means Section 10D of the Exchange Act and Rule 10D-1 promulgated thereunder, Listing Rule 5608 of the Listing Rules of Nasdaq, and any other national stock exchange rules that the Company is or may become subject to.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Clawback Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means a required recoupment of Incentive-Based Compensation in the event of a Restatement under the Applicable Rules.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Securities Exchange Act of 1934, as amended.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Executive Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means each officer of the Company who is the Company&#8217;s president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice president of the Company in charge of a principal business unit, division or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar significant policy-making functions for the Company, as determined under 17 CFR &#167;229.401(b).</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:10.37pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Financial Reporting Measures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means (i) measures that are determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements, and any measures that are derived wholly or in part from such measures, (ii) the Company&#8217;s stock price, and (iii) total shareholder return in respect of the Company. A &#8220;Financial Reporting Measure&#8221; need not be presented within the financial statements or included in a filing with the SEC.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">f.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:11.59pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means any compensation that is granted, earned, or vested, based wholly or in part upon the attainment of a Financial Reporting Measure. Incentive-Based Compensation does not include, among other forms of compensation, equity awards that vest exclusively upon completion of a specified employment period, without any performance condition, and bonus awards that are discretionary or based on subjective goals or goals unrelated to Financial Reporting Measures.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Nasdaq</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the Nasdaq Stock Market LLC.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">h.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Received</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; &#8211; Incentive-Based Compensation is deemed &#8220;Received&#8221; for the purposes of this Policy in the Company&#8217;s fiscal period during which the Financial Reporting Measure applicable to the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">i.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Recovery Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the three completed fiscal years immediately preceding the date on which the Company is required to prepare a Restatement, which date is the earlier of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare a Restatement or (ii) a date that a court, regulator, or other legally authorized body directs the Company to prepare a Restatement.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">j.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Regulators</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means, as applicable, the SEC and Nasdaq.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">k.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:9.75pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">Restatement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means that the Company is required to prepare an accounting restatement due to a material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements (i) that is material to the previously issued financial statements, or (ii) that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period.</font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">l.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;padding-left:12.2pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration:underline">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">&#8221; means the U.S. Securities and Exchange Commission.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>anip-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d1b0d374-59d3-494d-ab57-0327414dd086,g:e2d69e39-7080-477b-8655-fce353fd237f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:anip="http://www.anipharmaceuticals.com/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.anipharmaceuticals.com/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anip-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anip-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anip-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="anip-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.anipharmaceuticals.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.anipharmaceuticals.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000009 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONANDRELATEDALLOWANCES" roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES">
        <link:definition>0000010 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATION" roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION">
        <link:definition>0000011 - Disclosure - BUSINESS COMBINATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURING" roleURI="http://www.anipharmaceuticals.com/role/RESTRUCTURING">
        <link:definition>0000012 - Disclosure - RESTRUCTURING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESS" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESS">
        <link:definition>0000013 - Disclosure - INDEBTEDNESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY" roleURI="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY">
        <link:definition>0000014 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://www.anipharmaceuticals.com/role/INVENTORIES">
        <link:definition>0000015 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNET" roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET">
        <link:definition>0000016 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETS" roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS">
        <link:definition>0000017 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUE" roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUE">
        <link:definition>0000018 - Disclosure - FAIR VALUE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MEZZANINEANDSTOCKHOLDERSEQUITY" roleURI="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY">
        <link:definition>0000019 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>0000020 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>0000021 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXES">
        <link:definition>0000022 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PURIFIEDCORTROPHINGELPRELAUNCHCHARGES" roleURI="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES">
        <link:definition>0000024 - Disclosure - PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>0000025 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTING" roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTING">
        <link:definition>0000026 - Disclosure - SEGMENT REPORTING</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS">
        <link:definition>0000027 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - . DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>9954472 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONANDRELATEDALLOWANCESTables" roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables">
        <link:definition>9954473 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONTables" roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONTables">
        <link:definition>9954474 - Disclosure - BUSINESS COMBINATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSTables" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables">
        <link:definition>9954475 - Disclosure - INDEBTEDNESS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESTables">
        <link:definition>9954476 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETTables">
        <link:definition>9954477 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSTables" roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables">
        <link:definition>9954478 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUETables" roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUETables">
        <link:definition>9954479 - Disclosure - FAIR VALUE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>9954480 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>9954481 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESTables">
        <link:definition>9954482 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESTables" roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables">
        <link:definition>9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSTables" roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables">
        <link:definition>9954484 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGTables" roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables">
        <link:definition>9954485 - Disclosure - SEGMENT REPORTING (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails">
        <link:definition>9954486 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails" roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails">
        <link:definition>9954487 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE and Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails">
        <link:definition>9954488 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails">
        <link:definition>9954489 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails">
        <link:definition>9954490 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails">
        <link:definition>9954491 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails">
        <link:definition>9954492 - Disclosure - BUSINESS COMBINATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSCOMBINATIONProFormaDetails" roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails">
        <link:definition>9954493 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGDetails" roleURI="http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails">
        <link:definition>9954494 - Disclosure - RESTRUCTURING (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSCreditfacilityDetails" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails">
        <link:definition>9954495 - Disclosure - INDEBTEDNESS - Credit facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSFacilitycomponentsDetails" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails">
        <link:definition>9954496 - Disclosure - INDEBTEDNESS - Facility components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSOutstandingDetails" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails">
        <link:definition>9954497 - Disclosure - INDEBTEDNESS - Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSCreditfacilitymaturityDetails" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails">
        <link:definition>9954498 - Disclosure - INDEBTEDNESS - Credit facility maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INDEBTEDNESSInterestDetails" roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails">
        <link:definition>9954499 - Disclosure - INDEBTEDNESS - Interest (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" roleURI="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails">
        <link:definition>9954500 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESScheduleofinventoryDetails" roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails">
        <link:definition>9954501 - Disclosure - INVENTORIES - Schedule of inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails">
        <link:definition>9954502 - Disclosure - INVENTORIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails">
        <link:definition>9954503 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>9954504 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails">
        <link:definition>9954505 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSComponentsDetails" roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails">
        <link:definition>9954506 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLANDINTANGIBLEASSETSAmortizationDetails" roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails">
        <link:definition>9954507 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUENarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails">
        <link:definition>9954508 - Disclosure - FAIR VALUE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUELevel3Details" roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details">
        <link:definition>9954509 - Disclosure - FAIR VALUE - Level 3 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEHierarchyDetails" roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails">
        <link:definition>9954510 - Disclosure - FAIR VALUE - Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEAcquiredDetails" roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails">
        <link:definition>9954511 - Disclosure - FAIR VALUE - Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MEZZANINEANDSTOCKHOLDERSEQUITYDetails" roleURI="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails">
        <link:definition>9954512 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>9954513 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>9954514 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONExpenseDetails" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails">
        <link:definition>9954515 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONFairvalueoptionsDetails" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails">
        <link:definition>9954516 - Disclosure - STOCK-BASED COMPENSATION - Fair value options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONStockoptionactivityDetails" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails">
        <link:definition>9954517 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONRSAactivityDetails" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails">
        <link:definition>9954518 - Disclosure - STOCK-BASED COMPENSATION - RSA activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails" roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails">
        <link:definition>9954519 - Disclosure - STOCK-BASED COMPENSATION - Performance shares activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>9954520 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESProvisionDetails" roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails">
        <link:definition>9954521 - Disclosure - INCOME TAXES - Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESEffectiverateDetails" roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails">
        <link:definition>9954522 - Disclosure - INCOME TAXES - Effective rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredtaxDetails" roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails">
        <link:definition>9954523 - Disclosure - INCOME TAXES - Deferred tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>9954524 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails" roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails">
        <link:definition>9954525 - Disclosure - COMMITMENTS AND CONTINGENCIES - Leases expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESLeasematurityDetails" roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails">
        <link:definition>9954526 - Disclosure - COMMITMENTS AND CONTINGENCIES - Lease maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails" roleURI="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails">
        <link:definition>9954527 - Disclosure - PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSNarrativeDetails" roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails">
        <link:definition>9954528 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails" roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails">
        <link:definition>9954529 - Disclosure - RELATED PARTY TRANSACTIONS - Schedule of related parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGRevenueDetails" roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails">
        <link:definition>9954530 - Disclosure - SEGMENT REPORTING - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SEGMENTREPORTINGGeographicDetails" roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails">
        <link:definition>9954531 - Disclosure - SEGMENT REPORTING - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>9954532 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="anip_AcquiredAndaIntangibleAssetsMember" abstract="true" name="AcquiredAndaIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_RestrictionPeriodForSharesIssuedInBusinessCombination" abstract="false" name="RestrictionPeriodForSharesIssuedInBusinessCombination" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anip_ScitusPharmaServicesMember" abstract="true" name="ScitusPharmaServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_NurayChemicalPrivateLimitedMember" abstract="true" name="NurayChemicalPrivateLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SalesOfContractManufacturedProductsMember" abstract="true" name="SalesOfContractManufacturedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CustomerTwoMember" abstract="true" name="CustomerTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_InterestPeriodAxis" abstract="true" name="InterestPeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="anip_NonCompeteAgreementMember" abstract="true" name="NonCompeteAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_AcquiredFiledProductsMember" abstract="true" name="AcquiredFiledProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_FourCustomersMember" abstract="true" name="FourCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" abstract="false" name="IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="anip_CortrophinGelMember" abstract="true" name="CortrophinGelMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ChargebacksMember" abstract="true" name="ChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ReservesForCashDiscountMember" abstract="true" name="ReservesForCashDiscountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_PaymentTypeDomain" abstract="true" name="PaymentTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_ReturnedGoodsReserve" abstract="false" name="ReturnedGoodsReserve" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" abstract="true" name="SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_CommonStockNumberOfVotesPerShare" abstract="false" name="CommonStockNumberOfVotesPerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" abstract="false" name="OperatingLossCarryforwardsAnnualLimitationsOnUse" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="anip_ThreeMonthDurationMember" abstract="true" name="ThreeMonthDurationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_MarketPerformanceBasedRestrictedStockUnitsMember" abstract="true" name="MarketPerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_RareDiseaseMember" abstract="true" name="RareDiseaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_EsjayPharmaLlcMember" abstract="true" name="EsjayPharmaLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_PaymentTypeAxis" abstract="true" name="PaymentTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="anip_DerivativeLiabilityDecreaseInNotionalAmount" abstract="false" name="DerivativeLiabilityDecreaseInNotionalAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" abstract="false" name="EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="anip_CGOncologyInc.Member" abstract="true" name="CGOncologyInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_AdministrativeFeesAndOtherRebatesMember" abstract="true" name="AdministrativeFeesAndOtherRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_NumberOfOperatingLeases" abstract="false" name="NumberOfOperatingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_UnapprovedProductsMember" abstract="true" name="UnapprovedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SalesOfBrandedPharmaceuticalProductsMember" abstract="true" name="SalesOfBrandedPharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_AkornHoldingCompanyPipelineProductMember" abstract="true" name="AkornHoldingCompanyPipelineProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ProductIntellectualPropertyMember" abstract="true" name="ProductIntellectualPropertyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_OakvilleOntarioFormerManufacturingFacilityMember" abstract="true" name="OakvilleOntarioFormerManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="anip_AcquiredInProcessReserachAndDevelopmentExpense" abstract="false" name="AcquiredInProcessReserachAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_CranfordPharmaceuticalsMember" abstract="true" name="CranfordPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" abstract="false" name="EarningsLossBeforeInterestTaxesDepreciationAndAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_NumberOfProductsMarketed" abstract="false" name="NumberOfProductsMarketed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_PercentageOfConversionPrice" abstract="false" name="PercentageOfConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="anip_ProductRightMember" abstract="true" name="ProductRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_ProjectBasedMilestonePaymentsMember" abstract="true" name="ProjectBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_NumberOfConsecutiveTradingDays" abstract="false" name="NumberOfConsecutiveTradingDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" abstract="false" name="ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="anip_MeasurementInputProbabilityOfPaymentMember" abstract="true" name="MeasurementInputProbabilityOfPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CortrophinPreLaunchChargesTextBlock" abstract="false" name="CortrophinPreLaunchChargesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="anip_NewEmployeesMember" abstract="true" name="NewEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="anip_BusinessCombinationContingentConsiderationArrangementsPeriod" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anip_OneSupplierMember" abstract="true" name="OneSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CommonStockConvertibleConversionRatio" abstract="false" name="CommonStockConvertibleConversionRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="anip_AzurityPharmaceuticalsMember" abstract="true" name="AzurityPharmaceuticalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_Mr.MuthusamyShanmugamMember" abstract="true" name="Mr.MuthusamyShanmugamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_RoyaltyOnFutureSalesPercent" abstract="false" name="RoyaltyOnFutureSalesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="anip_ClassCSpecialStockValue" abstract="false" name="ClassCSpecialStockValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_InterestPeriodDomain" abstract="true" name="InterestPeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_BiosantePharmaceuticalsIncMember" abstract="true" name="BiosantePharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_NovitiumPharmaMember" abstract="true" name="NovitiumPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" abstract="true" name="ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" abstract="false" name="FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_IncreaseDecreaseInRoyaltyPayable" abstract="false" name="IncreaseDecreaseInRoyaltyPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="anip_ANICanadaMember" abstract="true" name="ANICanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_AccruedGovernmentRebates" abstract="false" name="AccruedGovernmentRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_PerformanceBasedRestrictedStockUnitsMember" abstract="true" name="PerformanceBasedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" abstract="true" name="SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_NumberOfPharmaceuticalManufacturingFacilities" abstract="false" name="NumberOfPharmaceuticalManufacturingFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_ProductDevelopmentBasedMilestonePaymentsMember" abstract="true" name="ProductDevelopmentBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="anip_AcquiredApprovedProductMember" abstract="true" name="AcquiredApprovedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_TermLoanAndDelayedDrawTermLoanMember" abstract="true" name="TermLoanAndDelayedDrawTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CortrophinPreLaunchChargesAbstract" abstract="true" name="CortrophinPreLaunchChargesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="anip_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_OakrumPharmaMember" abstract="true" name="OakrumPharmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_OakvilleOntarioCanadaMember" abstract="true" name="OakvilleOntarioCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_WellSpringPharmaServicesIncMember" abstract="true" name="WellSpringPharmaServicesIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_StockIncentivePlanMember" abstract="true" name="StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CustomerOneMember" abstract="true" name="CustomerOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_AllowancesForSalesReturnsMember" abstract="true" name="AllowancesForSalesReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_NumberOfExecutiveFounders" abstract="false" name="NumberOfExecutiveFounders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_IncreaseDecreaseInReturnedGoodsReserve" abstract="false" name="IncreaseDecreaseInReturnedGoodsReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_TermLoanMember" abstract="true" name="TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SalesOfRareDiseasePharmaceuticalProductsMember" abstract="true" name="SalesOfRareDiseasePharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SalesOfGenericPharmaceuticalProductsMember" abstract="true" name="SalesOfGenericPharmaceuticalProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="anip_ContractCustomerMember" abstract="true" name="ContractCustomerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SsPharmaLlcMember" abstract="true" name="SsPharmaLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CortrophinPreLaunchCharges" abstract="false" name="CortrophinPreLaunchCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_Mr.ChadGassertMember" abstract="true" name="Mr.ChadGassertMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_NumberOfIntangibleAssetsAcquired" abstract="false" name="NumberOfIntangibleAssetsAcquired" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_LongTermDebtGrossCurrent" abstract="false" name="LongTermDebtGrossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_ChaliPropertiesLLCMember" abstract="true" name="ChaliPropertiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_IncreaseDecreaseAccruedGovernmentRebates" abstract="false" name="IncreaseDecreaseAccruedGovernmentRebates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_PrepaidIncomeTaxesNet" abstract="false" name="PrepaidIncomeTaxesNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_ThresholdNumberOfTradingDays" abstract="false" name="ThresholdNumberOfTradingDays" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_PreferredStockConvertibleMinimumPeriodOfConversion" abstract="false" name="PreferredStockConvertibleMinimumPeriodOfConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anip_CustomerFourMember" abstract="true" name="CustomerFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_FDICGuaranteedAmount" abstract="false" name="FDICGuaranteedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_ProductRightsMember" abstract="true" name="ProductRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" abstract="false" name="ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="anip_AcquiredPipelineProductMember" abstract="true" name="AcquiredPipelineProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_CustomerThreeMember" abstract="true" name="CustomerThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_OneMonthDurationMember" abstract="true" name="OneMonthDurationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" abstract="true" name="EmployeeStockPurchasePlanTwoThousandAndSixteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ProductReturnPeriod" abstract="false" name="ProductReturnPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="anip_SandozIncMember" abstract="true" name="SandozIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_CommonStockConversionPrice" abstract="false" name="CommonStockConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="anip_AcquiredNDAIntangibleAssetsMember" abstract="true" name="AcquiredNDAIntangibleAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_Mr.ShanmugamAndEsjayMember" abstract="true" name="Mr.ShanmugamAndEsjayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_LongTermDebtGrossNonCurrent" abstract="false" name="LongTermDebtGrossNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_AcquiredCommercialProductMember" abstract="true" name="AcquiredCommercialProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_LossContingencyNumberOfManufacturers" abstract="false" name="LossContingencyNumberOfManufacturers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="anip_GovernmentRebatesMember" abstract="true" name="GovernmentRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_NovitiumMember" abstract="true" name="NovitiumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_MarketingAndDistributionRightsMember" abstract="true" name="MarketingAndDistributionRightsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_AlvogenIncMember" abstract="true" name="AlvogenIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_PrivateInvestmentInPublicEquityMember" abstract="true" name="PrivateInvestmentInPublicEquityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_SixMonthDurationMember" abstract="true" name="SixMonthDurationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="anip_StockholdersEquityAttributableToParentAndTemporaryEquity" abstract="false" name="StockholdersEquityAttributableToParentAndTemporaryEquity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="anip_NonEmployeeDirectorStockOptionMember" abstract="true" name="NonEmployeeDirectorStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_EmployeesAndConsultantsMember" abstract="true" name="EmployeesAndConsultantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_ClassCSpecialStockMember" abstract="true" name="ClassCSpecialStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="anip_GenericsEstablishedBrandsAndOtherMember" abstract="true" name="GenericsEstablishedBrandsAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>anip-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d1b0d374-59d3-494d-ab57-0327414dd086,g:e2d69e39-7080-477b-8655-fce353fd237f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5e4c8303-ae31-4664-8a67-3c742e472e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:to="loc_us-gaap_AssetsCurrent_5e4c8303-ae31-4664-8a67-3c742e472e7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_63928fa8-9787-4e08-a6ca-c2a05225cc44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_63928fa8-9787-4e08-a6ca-c2a05225cc44" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_0265d4b7-7e8a-405a-9a9a-ea288a1d3da0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_0265d4b7-7e8a-405a-9a9a-ea288a1d3da0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_56dc8900-4c8b-46c5-bdee-ed84895c3c53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_56dc8900-4c8b-46c5-bdee-ed84895c3c53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_47401662-b8f3-4b45-b9a7-25ee95ca7e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:to="loc_us-gaap_Goodwill_47401662-b8f3-4b45-b9a7-25ee95ca7e0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c481518f-9763-4fc2-b24b-a00dd06c19ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_dcc37ae2-188e-46e2-8d38-4cd2a40dbeb9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c481518f-9763-4fc2-b24b-a00dd06c19ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c423bcbb-0e34-495f-9dd5-b8c06f9059f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a37a0ae3-3ae2-45d9-8898-ec48b5050667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c423bcbb-0e34-495f-9dd5-b8c06f9059f3" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a37a0ae3-3ae2-45d9-8898-ec48b5050667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_421400f4-3b80-4078-898c-a5954106e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c423bcbb-0e34-495f-9dd5-b8c06f9059f3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_421400f4-3b80-4078-898c-a5954106e6fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aee556ba-0567-485c-9af4-bb535a923d09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c423bcbb-0e34-495f-9dd5-b8c06f9059f3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aee556ba-0567-485c-9af4-bb535a923d09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_163ef1bd-b4d4-40b2-ad71-071c96907e38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c423bcbb-0e34-495f-9dd5-b8c06f9059f3" xlink:to="loc_us-gaap_LiabilitiesCurrent_163ef1bd-b4d4-40b2-ad71-071c96907e38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4f22bec-7206-406c-995e-494a87374667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_3f5ba040-34d3-4eb2-9937-6ebce5d3d1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4f22bec-7206-406c-995e-494a87374667" xlink:to="loc_us-gaap_Liabilities_3f5ba040-34d3-4eb2-9937-6ebce5d3d1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9777ef3f-872a-45fa-b0e6-4ac152f43c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4f22bec-7206-406c-995e-494a87374667" xlink:to="loc_us-gaap_StockholdersEquity_9777ef3f-872a-45fa-b0e6-4ac152f43c0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_01ae423f-3df9-4fed-a2da-74ac8096cd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d4f22bec-7206-406c-995e-494a87374667" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_01ae423f-3df9-4fed-a2da-74ac8096cd48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_02fc3288-b0a2-43db-9927-35fbb766c657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_AccountsPayableCurrent_02fc3288-b0a2-43db-9927-35fbb766c657" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_d79ece16-c824-4368-8db2-ad859b31287e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_d79ece16-c824-4368-8db2-ad859b31287e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d95bb7c3-c584-4a82-bb12-561d9cc03cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_LongTermDebtCurrent_d95bb7c3-c584-4a82-bb12-561d9cc03cbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AccruedGovernmentRebates_3791eaac-8850-48b0-81df-d2019c4dc8cd" xlink:href="anip-20231231.xsd#anip_AccruedGovernmentRebates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_anip_AccruedGovernmentRebates_3791eaac-8850-48b0-81df-d2019c4dc8cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_940f8aeb-d0e3-477c-b454-215f9d947f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_TaxesPayableCurrent_940f8aeb-d0e3-477c-b454-215f9d947f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_976a4f90-ec9b-401f-92dd-e1c5e4a07aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_976a4f90-ec9b-401f-92dd-e1c5e4a07aa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReturnedGoodsReserve_810ad857-8612-4dae-847d-9e20a2bbb912" xlink:href="anip-20231231.xsd#anip_ReturnedGoodsReserve"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_anip_ReturnedGoodsReserve_810ad857-8612-4dae-847d-9e20a2bbb912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_eff00371-371f-494b-9d4b-7bfa16a9667e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_eff00371-371f-494b-9d4b-7bfa16a9667e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8af9b3c1-0bb9-4cf0-93c6-bd815689386c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d345784-9562-4156-b5e3-05c12fcd6c24" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_8af9b3c1-0bb9-4cf0-93c6-bd815689386c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_39d411ac-04f8-423c-8b49-e434fb335833" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_us-gaap_CommonStockValue_39d411ac-04f8-423c-8b49-e434fb335833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockValue_4dfb60c8-05c3-4838-a94b-36d7a81663d0" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_anip_ClassCSpecialStockValue_4dfb60c8-05c3-4838-a94b-36d7a81663d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5fc79c43-51e7-41b9-af19-7871b8634c09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_us-gaap_PreferredStockValue_5fc79c43-51e7-41b9-af19-7871b8634c09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_1b99ef63-8f03-4cc2-902d-6094c2c70214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_us-gaap_TreasuryStockCommonValue_1b99ef63-8f03-4cc2-902d-6094c2c70214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_143e4512-24ce-451c-8f77-0258873e30b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_us-gaap_AdditionalPaidInCapital_143e4512-24ce-451c-8f77-0258873e30b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1cbc144-b1b7-48b3-a865-50b8a8edbedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a1cbc144-b1b7-48b3-a865-50b8a8edbedd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8805893a-1dfc-4f7d-8666-08d8bf8500f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_74063fe4-4431-46c6-9447-d993d02b8cbc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8805893a-1dfc-4f7d-8666-08d8bf8500f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49249732-1694-414d-b20f-18ebb11623c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_49249732-1694-414d-b20f-18ebb11623c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_72772c35-5f69-460e-85c0-8f4c2e50dba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_us-gaap_RestrictedCashCurrent_72772c35-5f69-460e-85c0-8f4c2e50dba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d6a575b7-1199-4be3-a15f-176e83fc9849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d6a575b7-1199-4be3-a15f-176e83fc9849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c7e54feb-e858-4902-8dc5-00d0325daefa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_us-gaap_InventoryNet_c7e54feb-e858-4902-8dc5-00d0325daefa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_5babe554-6f31-48cc-89fb-a6dde79f3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_5babe554-6f31-48cc-89fb-a6dde79f3bb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_df1620c1-3e10-4ce1-ad2b-374590fd1b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_df1620c1-3e10-4ce1-ad2b-374590fd1b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrepaidIncomeTaxesNet_0f3e9ab1-cfff-4dbe-9a3c-c8167b0690a5" xlink:href="anip-20231231.xsd#anip_PrepaidIncomeTaxesNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_9da09480-100c-4dcb-b42e-2750c1f301c9" xlink:to="loc_anip_PrepaidIncomeTaxesNet_0f3e9ab1-cfff-4dbe-9a3c-c8167b0690a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e2c3e7d6-7da7-45b9-a1ba-6efb337bb204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f2285d3f-834e-4b07-b7a6-c26f02b5294a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e2c3e7d6-7da7-45b9-a1ba-6efb337bb204" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f2285d3f-834e-4b07-b7a6-c26f02b5294a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7e90c759-bcbb-4367-b19c-6ac57b4c2afd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e2c3e7d6-7da7-45b9-a1ba-6efb337bb204" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7e90c759-bcbb-4367-b19c-6ac57b4c2afd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_781a8a63-4e4b-42a3-bbcd-9bda374fd02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_7a7ebd18-ef81-4ab5-b24c-cf365e8629dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_781a8a63-4e4b-42a3-bbcd-9bda374fd02d" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_7a7ebd18-ef81-4ab5-b24c-cf365e8629dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d57668aa-04cf-4662-8e7a-f6312b6210c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_781a8a63-4e4b-42a3-bbcd-9bda374fd02d" xlink:to="loc_us-gaap_NetIncomeLoss_d57668aa-04cf-4662-8e7a-f6312b6210c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_923c9e07-0317-4687-b4a4-456905aaa5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_923c9e07-0317-4687-b4a4-456905aaa5c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_45357a22-2a5e-4a0f-b713-603ee092d57f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_45357a22-2a5e-4a0f-b713-603ee092d57f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_01f4173a-94e3-48ac-b207-769608877c90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_01f4173a-94e3-48ac-b207-769608877c90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_e295b233-dab9-4d0f-8c4a-be1164b1ea39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_DepreciationAndAmortization_e295b233-dab9-4d0f-8c4a-be1164b1ea39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_728f24b8-2c5e-4363-ae7b-4ddb1ae442e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_728f24b8-2c5e-4363-ae7b-4ddb1ae442e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_d4e31213-aa45-4dff-b96a-00eba2ec7b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_d4e31213-aa45-4dff-b96a-00eba2ec7b31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchCharges_fb6fd904-6504-498a-ac16-dcd98cc7d87a" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchCharges"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_anip_CortrophinPreLaunchCharges_fb6fd904-6504-498a-ac16-dcd98cc7d87a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f9a081a9-a007-4c4c-8793-2e467a35d7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_f9a081a9-a007-4c4c-8793-2e467a35d7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2aee065a-6c4e-45d3-bd3c-bfc6fff039f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_cf81d117-5e0f-47eb-ba49-252d5a927c85" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_2aee065a-6c4e-45d3-bd3c-bfc6fff039f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_adf89a14-c002-46a3-9d4f-b507fa212827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_504d0fd8-2ef7-47de-8608-84162c790f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_adf89a14-c002-46a3-9d4f-b507fa212827" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_504d0fd8-2ef7-47de-8608-84162c790f5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_11172a8d-8a7c-499b-b1ae-eafe3c66b194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_adf89a14-c002-46a3-9d4f-b507fa212827" xlink:to="loc_us-gaap_CostsAndExpenses_11172a8d-8a7c-499b-b1ae-eafe3c66b194" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f377836a-e57c-4a48-af80-e7f9283d3d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_34567e96-22da-42cd-bc63-cf4c307283db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f377836a-e57c-4a48-af80-e7f9283d3d7b" xlink:to="loc_us-gaap_OperatingIncomeLoss_34567e96-22da-42cd-bc63-cf4c307283db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5615bfca-c41f-4b7b-a67a-a73534a65cf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f377836a-e57c-4a48-af80-e7f9283d3d7b" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5615bfca-c41f-4b7b-a67a-a73534a65cf3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_0e0e8928-8820-473d-8b10-b4f569d93693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f377836a-e57c-4a48-af80-e7f9283d3d7b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_0e0e8928-8820-473d-8b10-b4f569d93693" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81f0d605-3b02-4992-942e-8ea70dd5c85e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_451510fc-66e7-4b62-a195-1137d38a9b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81f0d605-3b02-4992-942e-8ea70dd5c85e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_451510fc-66e7-4b62-a195-1137d38a9b1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c4d735fa-37fd-4cd9-a6af-c223ef175d91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_81f0d605-3b02-4992-942e-8ea70dd5c85e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_c4d735fa-37fd-4cd9-a6af-c223ef175d91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe10d5e4-63f3-4a46-a078-bf8838ff9a24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a025a811-91bb-4293-9fc7-f38d58c1f8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe10d5e4-63f3-4a46-a078-bf8838ff9a24" xlink:to="loc_us-gaap_NetIncomeLoss_a025a811-91bb-4293-9fc7-f38d58c1f8e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_07c891bb-5984-4960-bc0a-eac9ecf09f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fe10d5e4-63f3-4a46-a078-bf8838ff9a24" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_07c891bb-5984-4960-bc0a-eac9ecf09f35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d32c71d-495f-4449-83e3-ef5bdea22442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ec11f25-d95b-488d-8388-918f9790ae50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d32c71d-495f-4449-83e3-ef5bdea22442" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6ec11f25-d95b-488d-8388-918f9790ae50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62ea94c4-539e-4245-ad6d-2589bef878ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d32c71d-495f-4449-83e3-ef5bdea22442" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_62ea94c4-539e-4245-ad6d-2589bef878ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c85d9626-3189-4a23-87a6-5180cc15b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9d32c71d-495f-4449-83e3-ef5bdea22442" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c85d9626-3189-4a23-87a6-5180cc15b32e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4eeaa66-a0b3-48da-b8eb-fbad84673d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f6324f63-7d1e-40c8-8c23-7294bb9829cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4eeaa66-a0b3-48da-b8eb-fbad84673d97" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_f6324f63-7d1e-40c8-8c23-7294bb9829cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_efd1cdf6-3d15-4d0c-bd02-56faa48e6ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4eeaa66-a0b3-48da-b8eb-fbad84673d97" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_efd1cdf6-3d15-4d0c-bd02-56faa48e6ee0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a5132ce-251a-4e69-872d-a47b9de03d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4eeaa66-a0b3-48da-b8eb-fbad84673d97" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3a5132ce-251a-4e69-872d-a47b9de03d3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b66dfe55-8356-444e-9cc2-037dbe332759" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c4eeaa66-a0b3-48da-b8eb-fbad84673d97" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_b66dfe55-8356-444e-9cc2-037dbe332759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_7ee0271f-8f2b-40aa-bd92-b431545226ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_ShareBasedCompensation_7ee0271f-8f2b-40aa-bd92-b431545226ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_65ee20d7-738d-4d3f-bba7-2f3925669767" xlink:href="anip-20231231.xsd#anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_65ee20d7-738d-4d3f-bba7-2f3925669767" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f82363ab-bfc1-4d56-9ecf-1af0bca2022f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_f82363ab-bfc1-4d56-9ecf-1af0bca2022f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_535f509e-0347-49fc-897a-b9c63f31331a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_535f509e-0347-49fc-897a-b9c63f31331a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_a5a63eb8-ea3a-4c5c-9ab5-fcf22702ea92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_AssetImpairmentCharges_a5a63eb8-ea3a-4c5c-9ab5-fcf22702ea92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredInProcessReserachAndDevelopmentExpense_6123980f-ca46-4610-a17d-802b423193e2" xlink:href="anip-20231231.xsd#anip_AcquiredInProcessReserachAndDevelopmentExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_anip_AcquiredInProcessReserachAndDevelopmentExpense_6123980f-ca46-4610-a17d-802b423193e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_efe7ea86-801d-4628-bd39-9733a9ec01ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_efe7ea86-801d-4628-bd39-9733a9ec01ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_79da8c52-8df3-410f-962b-4e3aeefd1028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_79da8c52-8df3-410f-962b-4e3aeefd1028" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_bc60c2ca-dbc9-43c5-ba26-cf0dc3e467f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_bc60c2ca-dbc9-43c5-ba26-cf0dc3e467f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f4b44ff3-f506-4182-b072-1b470f3dcce9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_f4b44ff3-f506-4182-b072-1b470f3dcce9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseInRoyaltyPayable_3e343a7e-b418-47f9-94d6-819898d1171d" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseInRoyaltyPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_anip_IncreaseDecreaseInRoyaltyPayable_3e343a7e-b418-47f9-94d6-819898d1171d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_752310fc-2daf-46dc-b60e-d1ba0f6b7cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_752310fc-2daf-46dc-b60e-d1ba0f6b7cd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseAccruedGovernmentRebates_b96fa015-7044-414f-bc74-2ebf7eb3b5e8" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseAccruedGovernmentRebates"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_anip_IncreaseDecreaseAccruedGovernmentRebates_b96fa015-7044-414f-bc74-2ebf7eb3b5e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseInReturnedGoodsReserve_49cc2e61-209d-4604-a7e4-25dbf7158a63" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseInReturnedGoodsReserve"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_anip_IncreaseDecreaseInReturnedGoodsReserve_49cc2e61-209d-4604-a7e4-25dbf7158a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_3e0bbe11-bc76-4a77-b553-968bfbd0e1cb" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_3e0bbe11-bc76-4a77-b553-968bfbd0e1cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_beab7521-3629-40ef-9c3e-2c68026de431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_beab7521-3629-40ef-9c3e-2c68026de431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac6decef-e464-4c0f-9691-3c5e71ca5c03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_ac6decef-e464-4c0f-9691-3c5e71ca5c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b0aa187b-64f1-40e2-bcc5-5498694616f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_ProfitLoss_b0aa187b-64f1-40e2-bcc5-5498694616f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_3f46d3f2-be1d-4319-bacd-9fb4974f4504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_3f46d3f2-be1d-4319-bacd-9fb4974f4504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_878b3a54-8435-4a43-906e-246dc6b52042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_fa064afe-2dc2-49b9-a951-23578a583268" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_878b3a54-8435-4a43-906e-246dc6b52042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_92e191ec-06e9-40e3-8541-2758bb56fcfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_92e191ec-06e9-40e3-8541-2758bb56fcfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_611e28cf-2518-4833-9920-5ec7e248911f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_611e28cf-2518-4833-9920-5ec7e248911f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_4efc6c6d-4858-4de3-ae9a-8633328ce8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_4efc6c6d-4858-4de3-ae9a-8633328ce8ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_e591fd12-033a-4de6-8078-860b61bf2490" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_PaymentsOfDividends_e591fd12-033a-4de6-8078-860b61bf2490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_db3a04b9-c63c-43fe-bdfb-d815f47ad61d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_db3a04b9-c63c-43fe-bdfb-d815f47ad61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7ac72c5-18e1-4e59-8893-a9328ba86153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e7ac72c5-18e1-4e59-8893-a9328ba86153" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_342bf80e-0f32-4bbc-90d6-f3a6b60a37c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_342bf80e-0f32-4bbc-90d6-f3a6b60a37c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_59157391-cfbc-466e-acac-0757a29675fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_59157391-cfbc-466e-acac-0757a29675fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_2a0aebc8-339d-456e-8257-64e133742921" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_2a0aebc8-339d-456e-8257-64e133742921" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_6c06a1d4-4ed7-4ba7-af07-9e150ea34665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_RepaymentsOfDebt_6c06a1d4-4ed7-4ba7-af07-9e150ea34665" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_002b7951-3ccb-4315-8479-f4b62ff2af8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1125e101-52c8-48b1-90c8-f6b7002dfaa8" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_002b7951-3ccb-4315-8479-f4b62ff2af8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41830cd7-d4d4-4e37-9901-ed05fd2f07c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ade30edb-1423-4860-9c8c-fb45bf392844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41830cd7-d4d4-4e37-9901-ed05fd2f07c5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ade30edb-1423-4860-9c8c-fb45bf392844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_67fca621-3d3d-4f9d-a9dd-e4b6e33642c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41830cd7-d4d4-4e37-9901-ed05fd2f07c5" xlink:to="loc_us-gaap_RestrictedCashCurrent_67fca621-3d3d-4f9d-a9dd-e4b6e33642c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSFacilitycomponentsDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_63961029-ff9a-46bf-a1f6-ffcf53f3936c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossNonCurrent_0eb2548e-e0e6-493f-b57c-6e323afef58a" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossNonCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_63961029-ff9a-46bf-a1f6-ffcf53f3936c" xlink:to="loc_anip_LongTermDebtGrossNonCurrent_0eb2548e-e0e6-493f-b57c-6e323afef58a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_0eba574f-7112-4d21-b9bf-6e918b8b4937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_63961029-ff9a-46bf-a1f6-ffcf53f3936c" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_0eba574f-7112-4d21-b9bf-6e918b8b4937" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_f593ba43-a3a0-4d33-aae2-f9e9e10f5b01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_12107c2e-91d0-45ab-a8ed-70abc015a43d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtCurrent_f593ba43-a3a0-4d33-aae2-f9e9e10f5b01" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_12107c2e-91d0-45ab-a8ed-70abc015a43d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossCurrent_a945423b-9cb9-411b-8d1b-02c5072ba9d0" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtCurrent_f593ba43-a3a0-4d33-aae2-f9e9e10f5b01" xlink:to="loc_anip_LongTermDebtGrossCurrent_a945423b-9cb9-411b-8d1b-02c5072ba9d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSOutstandingDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_09e13526-d54f-4306-b3e9-404d79c2acb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_de268640-c1ac-4378-a06b-df1a035e73d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_09e13526-d54f-4306-b3e9-404d79c2acb1" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_de268640-c1ac-4378-a06b-df1a035e73d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_731792e3-18e1-441e-b543-5ef2d221286e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_09e13526-d54f-4306-b3e9-404d79c2acb1" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_731792e3-18e1-441e-b543-5ef2d221286e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSCreditfacilitymaturityDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9cb64dcc-7c11-43e5-b048-e5a8465155dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4b0df2fa-8165-4d87-8642-1432ebb894d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9cb64dcc-7c11-43e5-b048-e5a8465155dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4b0df2fa-8165-4d87-8642-1432ebb894d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e745b612-3300-4bea-8405-a58671f1092a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9cb64dcc-7c11-43e5-b048-e5a8465155dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_e745b612-3300-4bea-8405-a58671f1092a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_53533159-521a-4ab4-ba80-da184510b42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9cb64dcc-7c11-43e5-b048-e5a8465155dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_53533159-521a-4ab4-ba80-da184510b42b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e733583b-bebb-4f4e-aa06-366ea84db1a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9cb64dcc-7c11-43e5-b048-e5a8465155dd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e733583b-bebb-4f4e-aa06-366ea84db1a0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSInterestDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_5d574978-9f65-484e-88b4-df222207bc74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8b11e812-3932-4412-ae0c-5529a83b0d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_5d574978-9f65-484e-88b4-df222207bc74" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_8b11e812-3932-4412-ae0c-5529a83b0d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_255e667d-6892-49d0-86f3-413bf5dbb667" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_5d574978-9f65-484e-88b4-df222207bc74" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_255e667d-6892-49d0-86f3-413bf5dbb667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment_c5283ede-2e80-49bc-8ded-d57e8f56d620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestExpenseDebt_5d574978-9f65-484e-88b4-df222207bc74" xlink:to="loc_us-gaap_InterestCostsCapitalizedAdjustment_c5283ede-2e80-49bc-8ded-d57e8f56d620" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INVENTORIESScheduleofinventoryDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_edf9c67d-0919-42ff-bd34-b659090a9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_563acb1d-3ac5-4547-b3dc-efb0a4ff077a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_edf9c67d-0919-42ff-bd34-b659090a9a5b" xlink:to="loc_us-gaap_InventoryRawMaterials_563acb1d-3ac5-4547-b3dc-efb0a4ff077a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_8c645133-644c-4c01-89bd-c4fdaa0bad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_edf9c67d-0919-42ff-bd34-b659090a9a5b" xlink:to="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_8c645133-644c-4c01-89bd-c4fdaa0bad2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_ae0709c0-acaf-4a81-8bea-598b10624458" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_edf9c67d-0919-42ff-bd34-b659090a9a5b" xlink:to="loc_us-gaap_InventoryWorkInProcess_ae0709c0-acaf-4a81-8bea-598b10624458" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_be94012d-11d1-4b42-880a-4089744a84d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_edf9c67d-0919-42ff-bd34-b659090a9a5b" xlink:to="loc_us-gaap_InventoryFinishedGoods_be94012d-11d1-4b42-880a-4089744a84d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7c39a140-ba84-4eb6-8258-413e0d857623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6baac77b-676e-4aef-9cb1-2efdd9b44990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7c39a140-ba84-4eb6-8258-413e0d857623" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6baac77b-676e-4aef-9cb1-2efdd9b44990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1c158bb3-ae13-44ec-94f3-f4a99175bccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_7c39a140-ba84-4eb6-8258-413e0d857623" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1c158bb3-ae13-44ec-94f3-f4a99175bccf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_38603921-6923-4ac2-acf6-550b54c70a05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_38603921-6923-4ac2-acf6-550b54c70a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cb6f10b3-6fa2-458b-8a07-6a73fabef9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_cb6f10b3-6fa2-458b-8a07-6a73fabef9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9c8300bc-0eae-4f8b-98e5-4e379083bff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9c8300bc-0eae-4f8b-98e5-4e379083bff4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9536f111-3dc3-47de-84e5-9ad0505fc071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9536f111-3dc3-47de-84e5-9ad0505fc071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_43a69744-29ff-4a8b-bbeb-c698a7b8ef0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_43a69744-29ff-4a8b-bbeb-c698a7b8ef0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_67802692-1059-4c32-82b9-26c2b6339eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_409e2ca1-2d8c-4193-84e3-33ad96148b5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_67802692-1059-4c32-82b9-26c2b6339eaf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_170e055b-2ca2-440d-8afc-34734283d1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_605d6d98-844c-4250-a591-8df28333bcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_170e055b-2ca2-440d-8afc-34734283d1fd" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_605d6d98-844c-4250-a591-8df28333bcba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ff13eb7a-b292-4051-a7ef-d28ae3370c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_170e055b-2ca2-440d-8afc-34734283d1fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ff13eb7a-b292-4051-a7ef-d28ae3370c7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings_7ce0f8e9-7783-40d5-bd59-47d9add7263f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarnings"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_20f23d89-e9d5-4cf4-bd3a-b9d1db2c04c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UndistributedEarnings_7ce0f8e9-7783-40d5-bd59-47d9add7263f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_20f23d89-e9d5-4cf4-bd3a-b9d1db2c04c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4b42492-042f-44b5-8b6c-d45f96e78c48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UndistributedEarnings_7ce0f8e9-7783-40d5-bd59-47d9add7263f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_a4b42492-042f-44b5-8b6c-d45f96e78c48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsDiluted_32b1239f-a73a-4ae7-bd52-9b17ccb8380f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf3da605-2563-42d9-8de7-efc005f08773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UndistributedEarningsDiluted_32b1239f-a73a-4ae7-bd52-9b17ccb8380f" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_cf3da605-2563-42d9-8de7-efc005f08773" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_ba4e275b-d959-4503-bfc3-af31d9c58968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UndistributedEarningsDiluted_32b1239f-a73a-4ae7-bd52-9b17ccb8380f" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_ba4e275b-d959-4503-bfc3-af31d9c58968" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESProvisionDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f22720ae-dc38-40e4-8f95-a4fa2d4be50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_90b3b403-0188-4d89-9c57-18b75aad909d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f22720ae-dc38-40e4-8f95-a4fa2d4be50c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_90b3b403-0188-4d89-9c57-18b75aad909d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3692cbce-649e-4299-b709-7fc0c56f3e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f22720ae-dc38-40e4-8f95-a4fa2d4be50c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_3692cbce-649e-4299-b709-7fc0c56f3e40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7266b047-d680-4167-a994-ba2f8c79c75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_f22720ae-dc38-40e4-8f95-a4fa2d4be50c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_7266b047-d680-4167-a994-ba2f8c79c75b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f428b1d9-e916-4260-9fd2-48c5b2b39814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c72c24fb-ddd3-403e-a770-9572ab5b7524" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f428b1d9-e916-4260-9fd2-48c5b2b39814" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_c72c24fb-ddd3-403e-a770-9572ab5b7524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b3167428-65b8-43e5-b092-ac697132ade4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f428b1d9-e916-4260-9fd2-48c5b2b39814" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_b3167428-65b8-43e5-b092-ac697132ade4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_eb34e8ff-a359-49bd-9103-30e62ae49193" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f428b1d9-e916-4260-9fd2-48c5b2b39814" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_eb34e8ff-a359-49bd-9103-30e62ae49193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_95134039-e2aa-45a8-b850-639a72c3b3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2fc413e0-5730-4e00-ae42-06ef11354bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95134039-e2aa-45a8-b850-639a72c3b3b2" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_2fc413e0-5730-4e00-ae42-06ef11354bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8669f45d-0d96-4d9f-b6bb-c9eff29ba46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95134039-e2aa-45a8-b850-639a72c3b3b2" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8669f45d-0d96-4d9f-b6bb-c9eff29ba46f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e4acd60-3b43-4c12-9ec9-9ddeada38379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_95134039-e2aa-45a8-b850-639a72c3b3b2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_7e4acd60-3b43-4c12-9ec9-9ddeada38379" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESEffectiverateDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_99196e22-54e6-4768-9612-f447e56e47df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_99196e22-54e6-4768-9612-f447e56e47df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_28f82bd7-b27b-42c1-ac6a-4ba56fc8bedb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_28f82bd7-b27b-42c1-ac6a-4ba56fc8bedb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_130f04da-e353-449f-a29e-d76be4fefd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_130f04da-e353-449f-a29e-d76be4fefd1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5beb60e6-e6d3-4633-8846-abbba23af8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_5beb60e6-e6d3-4633-8846-abbba23af8f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_58dc10d1-d32c-44aa-b3c6-88f15d27f121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_58dc10d1-d32c-44aa-b3c6-88f15d27f121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_865255f7-49d1-47cb-a4c8-66687c1fcb42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_865255f7-49d1-47cb-a4c8-66687c1fcb42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b6661f26-0273-4c57-bba5-0dcfface1d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_b6661f26-0273-4c57-bba5-0dcfface1d80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_58d03e75-14ba-4241-876b-a4220e95d21b" xlink:href="anip-20231231.xsd#anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_58d03e75-14ba-4241-876b-a4220e95d21b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7f479e93-d1df-4e4c-8d79-c0f5ff695f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_2892a09e-3d56-4c41-a945-a9a7b40b9dff" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_7f479e93-d1df-4e4c-8d79-c0f5ff695f60" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESDeferredtaxDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8fe25147-24b9-4ba0-b6ee-80ef8a4e0a7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f1fbb7c2-ce60-450d-a51d-7487d7170fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8fe25147-24b9-4ba0-b6ee-80ef8a4e0a7e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_f1fbb7c2-ce60-450d-a51d-7487d7170fe3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_91c03119-5c23-4f1c-9ed9-14ef4cbf68aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_8fe25147-24b9-4ba0-b6ee-80ef8a4e0a7e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_91c03119-5c23-4f1c-9ed9-14ef4cbf68aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8bf79aa-3308-472f-bfa1-207476132059" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e3ab1377-e46d-49b7-811d-502a3bfa4934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8bf79aa-3308-472f-bfa1-207476132059" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e3ab1377-e46d-49b7-811d-502a3bfa4934" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_fddff5f5-51fc-45fa-ac26-92f1298be886" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8bf79aa-3308-472f-bfa1-207476132059" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_fddff5f5-51fc-45fa-ac26-92f1298be886" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0a2c8ee1-146d-445a-9414-a17e42042ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b8bf79aa-3308-472f-bfa1-207476132059" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0a2c8ee1-146d-445a-9414-a17e42042ab3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_bea22101-e215-4026-970b-baef343964f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_bea22101-e215-4026-970b-baef343964f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8f74d6e7-8eb4-44f2-93bf-a72fa8fbf922" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_8f74d6e7-8eb4-44f2-93bf-a72fa8fbf922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_42f539aa-c90e-4796-9480-dac074ee8146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_42f539aa-c90e-4796-9480-dac074ee8146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_014d0b3d-9882-4391-a61d-863ea5c81ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_014d0b3d-9882-4391-a61d-863ea5c81ea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2f76d7bb-08e9-4d36-b0bd-8602942aa6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_2f76d7bb-08e9-4d36-b0bd-8602942aa6ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_69d3932d-9689-4385-8a8b-ff7037608fcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_69d3932d-9689-4385-8a8b-ff7037608fcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_0879c81f-f5e7-4a83-b9b5-833f4320a093" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_0879c81f-f5e7-4a83-b9b5-833f4320a093" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_32904a0f-4bf8-4845-8ed5-b129f4817c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_4b8eaa8f-1797-4a51-8563-fedc5913ac19" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_32904a0f-4bf8-4845-8ed5-b129f4817c32" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0ba82a21-cca0-47ae-96e5-27812033e34e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d95e8fc8-379b-4618-8127-b3e943a6dea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0ba82a21-cca0-47ae-96e5-27812033e34e" xlink:to="loc_us-gaap_OperatingLeaseCost_d95e8fc8-379b-4618-8127-b3e943a6dea3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_15902f28-0111-4a20-9ff9-b04f22717e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0ba82a21-cca0-47ae-96e5-27812033e34e" xlink:to="loc_us-gaap_VariableLeaseCost_15902f28-0111-4a20-9ff9-b04f22717e6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESLeasematurityDetails"/>
  <link:calculationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d15dc1d9-76aa-42cd-8315-012ca06dc71d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_37c7bc7d-8cbd-411c-95f1-6f3e55903481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d15dc1d9-76aa-42cd-8315-012ca06dc71d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_37c7bc7d-8cbd-411c-95f1-6f3e55903481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ced57625-1821-4764-a675-cf974e8eaab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_d15dc1d9-76aa-42cd-8315-012ca06dc71d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ced57625-1821-4764-a675-cf974e8eaab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0fbad3e1-3837-44c7-a1c1-643522674ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0fbad3e1-3837-44c7-a1c1-643522674ebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45aa1f6b-ee4c-4daf-8729-2bef3a8bef62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45aa1f6b-ee4c-4daf-8729-2bef3a8bef62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb4f0e7a-2bd4-45fb-b313-0a90c1d8c579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb4f0e7a-2bd4-45fb-b313-0a90c1d8c579" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6b7d38a5-5494-46ed-8598-50ae1cb4d0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6b7d38a5-5494-46ed-8598-50ae1cb4d0a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2bdcc0fb-8275-4935-8337-48e2d1ee098a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_2bdcc0fb-8275-4935-8337-48e2d1ee098a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2158086e-687c-47c2-8408-c1abbda65e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7d325834-bf91-4cb2-b546-d67879c6cfbc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_2158086e-687c-47c2-8408-c1abbda65e74" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>anip-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d1b0d374-59d3-494d-ab57-0327414dd086,g:e2d69e39-7080-477b-8655-fce353fd237f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/Cover" xlink:type="simple" xlink:href="anip-20231231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:to="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_731f53a7-8f81-4ae4-8e5d-b833eb74970d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:to="loc_us-gaap_ClassOfStockDomain_731f53a7-8f81-4ae4-8e5d-b833eb74970d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:to="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e98298d-c48d-4e0e-b8c9-cc4d59d113b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:to="loc_us-gaap_CommonStockMember_8e98298d-c48d-4e0e-b8c9-cc4d59d113b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember_1457264f-4a59-417a-bd6a-c8c08038087e" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:to="loc_anip_ClassCSpecialStockMember_1457264f-4a59-417a-bd6a-c8c08038087e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7633835a-7a97-4237-bda5-ae13d8c3bb5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentType_7633835a-7a97-4237-bda5-ae13d8c3bb5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_68901fcc-3a6b-4b44-b604-71cc8fff4e96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentAnnualReport_68901fcc-3a6b-4b44-b604-71cc8fff4e96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5f72dd08-2974-4c95-bf6b-a6884bbee9a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentPeriodEndDate_5f72dd08-2974-4c95-bf6b-a6884bbee9a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_06b56987-ec19-4d86-9236-6120adf15182" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_CurrentFiscalYearEndDate_06b56987-ec19-4d86-9236-6120adf15182" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_efb9ceff-76e0-4798-8f3f-4018b011c79e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentTransitionReport_efb9ceff-76e0-4798-8f3f-4018b011c79e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a2207cab-51ee-44d8-a369-084820392316" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityFileNumber_a2207cab-51ee-44d8-a369-084820392316" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e721569a-40e8-44e9-9e89-f5a012181443" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityRegistrantName_e721569a-40e8-44e9-9e89-f5a012181443" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_29c7276a-216f-4685-8e1e-36a1157ce2d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_29c7276a-216f-4685-8e1e-36a1157ce2d1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bd39d53f-1e68-4636-8fa5-0dfea534100f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityTaxIdentificationNumber_bd39d53f-1e68-4636-8fa5-0dfea534100f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d91d1ffc-9f83-4042-9c6a-d6df634005b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressAddressLine1_d91d1ffc-9f83-4042-9c6a-d6df634005b7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cbabc82e-15ee-4316-881e-b23338765c0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressCityOrTown_cbabc82e-15ee-4316-881e-b23338765c0f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_76c695ca-fc1c-4e1e-a5e5-fc6307475bf2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressStateOrProvince_76c695ca-fc1c-4e1e-a5e5-fc6307475bf2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4fc4b31-6e05-424b-98d0-f5b03a00867b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressPostalZipCode_e4fc4b31-6e05-424b-98d0-f5b03a00867b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_24eb42d3-e7c2-4a22-b2db-d6ef2df9c75d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_CityAreaCode_24eb42d3-e7c2-4a22-b2db-d6ef2df9c75d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d6b9c97a-e388-4664-9dfc-ef76b935ece7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_LocalPhoneNumber_d6b9c97a-e388-4664-9dfc-ef76b935ece7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_349cd44a-c46a-45bb-9013-92e694221d67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_Security12bTitle_349cd44a-c46a-45bb-9013-92e694221d67" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0d73a968-bfae-472d-883c-0f694532f20b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_TradingSymbol_0d73a968-bfae-472d-883c-0f694532f20b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d709b8e1-b95d-4f40-8a4f-9f8608f38563" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_SecurityExchangeName_d709b8e1-b95d-4f40-8a4f-9f8608f38563" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0c02d1d0-1cdb-4ea9-8f27-cf6d539b2c8f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0c02d1d0-1cdb-4ea9-8f27-cf6d539b2c8f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_313f8494-d5a2-4ce5-917a-4104a9d52cdc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityVoluntaryFilers_313f8494-d5a2-4ce5-917a-4104a9d52cdc" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d787eb0b-1996-435c-bf3f-dc81101d1f2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityCurrentReportingStatus_d787eb0b-1996-435c-bf3f-dc81101d1f2b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bab73da7-4040-40e0-90c1-6518c3da1ce7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityInteractiveDataCurrent_bab73da7-4040-40e0-90c1-6518c3da1ce7" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fdec23a7-6ef3-46b0-9857-a1a36fd3628e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityFilerCategory_fdec23a7-6ef3-46b0-9857-a1a36fd3628e" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_119fe90e-2dbf-4708-a58f-81221bedd4cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntitySmallBusiness_119fe90e-2dbf-4708-a58f-81221bedd4cd" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_46c8b779-0a1f-49c0-9d02-0b42569b65b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityEmergingGrowthCompany_46c8b779-0a1f-49c0-9d02-0b42569b65b5" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_210914e5-52d8-411e-81d1-0de64a65047d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_IcfrAuditorAttestationFlag_210914e5-52d8-411e-81d1-0de64a65047d" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_1b15ad2d-e3a3-473d-b093-5bf3d9ea869e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_1b15ad2d-e3a3-473d-b093-5bf3d9ea869e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4c09b97c-ae3b-48ea-854e-3081e9510628" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityShellCompany_4c09b97c-ae3b-48ea-854e-3081e9510628" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_65f52cc7-bbe9-4161-99d3-86b8be0f9580" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityPublicFloat_65f52cc7-bbe9-4161-99d3-86b8be0f9580" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cb9f8d50-a884-4a4a-a2a6-26eef4bb0ec3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cb9f8d50-a884-4a4a-a2a6-26eef4bb0ec3" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ad34dde1-f3a3-4488-9268-91f42abb1837" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ad34dde1-f3a3-4488-9268-91f42abb1837" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a04f9c67-e138-4cba-8a51-f136075e6938" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityCentralIndexKey_a04f9c67-e138-4cba-8a51-f136075e6938" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b075134f-4638-4d45-8e06-4c529b75d1a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentFiscalYearFocus_b075134f-4638-4d45-8e06-4c529b75d1a1" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0b9d044c-60cc-456e-a325-8b5c827545ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0b9d044c-60cc-456e-a325-8b5c827545ac" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c3d38b5-92e0-446e-9814-d8a3e5a18a6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_AmendmentFlag_5c3d38b5-92e0-446e-9814-d8a3e5a18a6c" xlink:type="arc" order="34"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2feade9f-c091-456f-a875-16616bed70c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:to="loc_us-gaap_ClassOfStockDomain_2feade9f-c091-456f-a875-16616bed70c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:to="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_c98bf152-e06a-40ce-a04a-86e5c279eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_c98bf152-e06a-40ce-a04a-86e5c279eeb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_12bfbc3a-297d-4932-abf8-ae892e33964d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:to="loc_us-gaap_CommonStockMember_12bfbc3a-297d-4932-abf8-ae892e33964d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember_93176bf1-7668-415a-b45d-d3eee227f9b8" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:to="loc_anip_ClassCSpecialStockMember_93176bf1-7668-415a-b45d-d3eee227f9b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_245c0726-7af0-4283-b9c2-f36ade8829db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_245c0726-7af0-4283-b9c2-f36ade8829db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_21924c78-7804-4ac8-8877-07c0019dc2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_21924c78-7804-4ac8-8877-07c0019dc2e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bcf01180-9ed1-4e77-b371-8a28c1eb183b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bcf01180-9ed1-4e77-b371-8a28c1eb183b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_45e88cb5-483b-43ed-a427-d5dd4fbd223b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_45e88cb5-483b-43ed-a427-d5dd4fbd223b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0ab3ffb6-6144-49eb-a70a-b08362d507a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0ab3ffb6-6144-49eb-a70a-b08362d507a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dfc389b6-e3cd-4ed5-960d-f8d1f08c8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dfc389b6-e3cd-4ed5-960d-f8d1f08c8c58" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c9e64092-a815-4ff9-8997-713f535fd2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c9e64092-a815-4ff9-8997-713f535fd2c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1547f95d-afc8-4be8-a6a3-828a4010a5da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockSharesIssued_1547f95d-afc8-4be8-a6a3-828a4010a5da" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d1e4243f-b6c4-42ca-bab3-f2e04a9e8a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d1e4243f-b6c4-42ca-bab3-f2e04a9e8a48" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fba1d852-3f1d-435c-8af6-2473ef5c8e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fba1d852-3f1d-435c-8af6-2473ef5c8e66" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f54f4773-f15c-463a-81d8-3439718c28a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f54f4773-f15c-463a-81d8-3439718c28a5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4942ddc0-f8da-402b-b500-5750ed2115e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4942ddc0-f8da-402b-b500-5750ed2115e5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_46ece8dd-11b9-44fb-b907-48d9e336ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_46ece8dd-11b9-44fb-b907-48d9e336ee81" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_22b1fdf4-b639-49b3-a61f-93b451edc043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_22b1fdf4-b639-49b3-a61f-93b451edc043" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:to="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2f21a035-86a8-48a8-9311-740327a1568f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:to="loc_us-gaap_EquityComponentDomain_2f21a035-86a8-48a8-9311-740327a1568f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:to="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5085cbfa-fbf7-4a7b-a28e-183eb661e903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_CommonStockMember_5085cbfa-fbf7-4a7b-a28e-183eb661e903" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_131c9916-519b-41b4-b0bd-acea68c5e387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_131c9916-519b-41b4-b0bd-acea68c5e387" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_c2991fc9-7828-4bc0-851d-53cf705f396c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_TreasuryStockCommonMember_c2991fc9-7828-4bc0-851d-53cf705f396c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8ae68cf-aa99-416b-ac9c-21235649c421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8ae68cf-aa99-416b-ac9c-21235649c421" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40fc31bb-b0db-49d1-88da-eb88b00b7890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_RetainedEarningsMember_40fc31bb-b0db-49d1-88da-eb88b00b7890" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b0623933-7bbd-4317-8edf-214944a9b04d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b0623933-7bbd-4317-8edf-214944a9b04d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee14dafa-ad3f-4c72-80db-e5595d5a1a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee14dafa-ad3f-4c72-80db-e5595d5a1a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_16cce125-1191-43cd-a4a1-33177a31de7e" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee14dafa-ad3f-4c72-80db-e5595d5a1a53" xlink:to="loc_anip_NovitiumMember_16cce125-1191-43cd-a4a1-33177a31de7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:to="loc_us-gaap_ClassOfStockDomain_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef103636-a01d-4088-93be-4276ce84f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:to="loc_us-gaap_ClassOfStockDomain_ef103636-a01d-4088-93be-4276ce84f87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_baf31196-2187-48b5-9c6a-af97feb1660a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ef103636-a01d-4088-93be-4276ce84f87e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_baf31196-2187-48b5-9c6a-af97feb1660a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5e92355d-dec8-4e57-8419-74fb1e65a243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5e92355d-dec8-4e57-8419-74fb1e65a243" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_02f3d6e4-ffbf-4118-ae96-626b2a4eb593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_02f3d6e4-ffbf-4118-ae96-626b2a4eb593" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_50abc0b4-6890-418d-90ab-29a147ce00e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_50abc0b4-6890-418d-90ab-29a147ce00e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_04c9ab56-972d-4f9c-852d-a0302abb6207" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_04c9ab56-972d-4f9c-852d-a0302abb6207" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d1d65ad7-b91d-40fd-91ae-dcb52606951e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4d12fe81-770a-4fc1-b355-b680179924d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_144e2997-10d3-420e-afbd-f80041c6ad5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockholdersEquity_144e2997-10d3-420e-afbd-f80041c6ad5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4a3acfc0-d736-4e6e-b163-79fbdbde7549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_CommonStockSharesIssued_4a3acfc0-d736-4e6e-b163-79fbdbde7549" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0a881b89-c6f1-4c4a-9bcb-a1585ece481c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0a881b89-c6f1-4c4a-9bcb-a1585ece481c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_d483670d-0b95-42c0-b3b8-dc6feed6eff4" xlink:href="anip-20231231.xsd#anip_StockholdersEquityAttributableToParentAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_d483670d-0b95-42c0-b3b8-dc6feed6eff4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3ab9c74-4e31-4ef5-b633-c9151155fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3ab9c74-4e31-4ef5-b633-c9151155fdb5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_360bd319-632b-4c78-895b-b5dcdc7bc737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_360bd319-632b-4c78-895b-b5dcdc7bc737" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3a976360-e47e-4cd9-86ba-98dff1cb0039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3a976360-e47e-4cd9-86ba-98dff1cb0039" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_328a99f1-1a84-449b-a3cd-79c3e4e0ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_328a99f1-1a84-449b-a3cd-79c3e4e0ba6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cdfdb4ce-1f92-43eb-a06a-bbae5272974d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cdfdb4ce-1f92-43eb-a06a-bbae5272974d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0851cfcf-4322-444f-953a-e0a3020fb4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0851cfcf-4322-444f-953a-e0a3020fb4d9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f976152-aa95-4a6a-847c-3e942921a400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f976152-aa95-4a6a-847c-3e942921a400" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_66648f42-795a-45a7-9609-a3e945a97def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_66648f42-795a-45a7-9609-a3e945a97def" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_5bcc6285-faaf-42a6-9190-d54f3bc52d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_5bcc6285-faaf-42a6-9190-d54f3bc52d7a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fd983111-6a62-44e5-854e-9f2b71ecfdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fd983111-6a62-44e5-854e-9f2b71ecfdc5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b79bd9eb-8135-41de-b0b9-83f72d5fe5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b79bd9eb-8135-41de-b0b9-83f72d5fe5e6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_a6b8f16b-9404-49a6-9b78-2b25752446a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_DividendsPreferredStock_a6b8f16b-9404-49a6-9b78-2b25752446a1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_6acacf8b-7a5e-4324-9338-f4130420c04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23d9451b-98b8-4c63-885c-d77960bdd094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23d9451b-98b8-4c63-885c-d77960bdd094" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1865799e-8dd1-4db4-9b7a-ecc997047cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_NetIncomeLoss_1865799e-8dd1-4db4-9b7a-ecc997047cde" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8257af2f-c74d-4acb-a0a2-e58f597c6629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8cb5bb3b-620e-40fc-9689-1d2bd6cf95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_aaac7101-e0ba-4819-b59a-5af8bd8fdb94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_10698695-51b1-4d57-9a0e-bdf78b76f551" xlink:href="anip-20231231.xsd#anip_StockholdersEquityAttributableToParentAndTemporaryEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ec1d2cc-dd2d-41b6-bb7c-9f630955cd93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ec1d2cc-dd2d-41b6-bb7c-9f630955cd93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CranfordPharmaceuticalsMember_b0edc85e-9118-4253-8919-49b088f4ac89" xlink:href="anip-20231231.xsd#anip_CranfordPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ec1d2cc-dd2d-41b6-bb7c-9f630955cd93" xlink:to="loc_anip_CranfordPharmaceuticalsMember_b0edc85e-9118-4253-8919-49b088f4ac89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d8cdfea8-dfd3-45dc-a687-e69d8b013a03_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:to="loc_srt_SegmentGeographicalDomain_d8cdfea8-dfd3-45dc-a687-e69d8b013a03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9071080a-ee2d-43bb-95b6-5b1aaae4cf30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:to="loc_srt_SegmentGeographicalDomain_9071080a-ee2d-43bb-95b6-5b1aaae4cf30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_130a3401-8778-47d9-93cb-b09aebdd259e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9071080a-ee2d-43bb-95b6-5b1aaae4cf30" xlink:to="loc_country_CA_130a3401-8778-47d9-93cb-b09aebdd259e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6b28ccd4-96be-4b55-9124-fc4674904868_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:to="loc_srt_RangeMember_6b28ccd4-96be-4b55-9124-fc4674904868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:to="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_edbb4607-57be-40b2-9d0f-728c4783c14d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:to="loc_srt_MinimumMember_edbb4607-57be-40b2-9d0f-728c4783c14d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f34b3bfd-a042-46c0-9fc7-99fcb541378d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:to="loc_srt_MaximumMember_f34b3bfd-a042-46c0-9fc7-99fcb541378d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46b797e0-9ec4-4ee8-adf0-0e4fa348af06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_46b797e0-9ec4-4ee8-adf0-0e4fa348af06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f33ebc-6dc9-49a0-9f41-73c07fac46ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f33ebc-6dc9-49a0-9f41-73c07fac46ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d6d89e3c-d932-44d2-938d-d371558f797d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f33ebc-6dc9-49a0-9f41-73c07fac46ed" xlink:to="loc_us-gaap_PerformanceSharesMember_d6d89e3c-d932-44d2-938d-d371558f797d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_606f2321-6787-4aa0-b05d-1a2c35e27dec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_606f2321-6787-4aa0-b05d-1a2c35e27dec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e8e41289-156c-471f-b49f-9fa0c57a48e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e8e41289-156c-471f-b49f-9fa0c57a48e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_7604964f-48ed-4e2c-9f2d-6e46fb4dabfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e8e41289-156c-471f-b49f-9fa0c57a48e2" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_7604964f-48ed-4e2c-9f2d-6e46fb4dabfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dfc4192a-b691-47ea-9afd-81b8f76eccef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_dfc4192a-b691-47ea-9afd-81b8f76eccef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74165042-448c-4d27-80e8-66046b1c5f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74165042-448c-4d27-80e8-66046b1c5f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_eef49a22-a457-4f3f-a7bb-7624131508f6" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74165042-448c-4d27-80e8-66046b1c5f88" xlink:to="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_eef49a22-a457-4f3f-a7bb-7624131508f6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_97d2f6e7-2bbf-49fb-af17-024f9d01af68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_97d2f6e7-2bbf-49fb-af17-024f9d01af68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_573dc865-98ef-4f7f-b8e5-333f38882239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_573dc865-98ef-4f7f-b8e5-333f38882239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e802eb9-a301-46d3-b813-d48cb2d19cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_573dc865-98ef-4f7f-b8e5-333f38882239" xlink:to="loc_us-gaap_SubsequentEventMember_0e802eb9-a301-46d3-b813-d48cb2d19cd3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a9c2bd4e-ec01-43b8-ba72-dd2b98cda57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a9c2bd4e-ec01-43b8-ba72-dd2b98cda57e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_7581ae96-9645-4c42-b60e-b5444d1a27f9" xlink:href="anip-20231231.xsd#anip_NumberOfPharmaceuticalManufacturingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_7581ae96-9645-4c42-b60e-b5444d1a27f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FDICGuaranteedAmount_a3923e49-89f2-4a95-9ba0-577a138c1157" xlink:href="anip-20231231.xsd#anip_FDICGuaranteedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_anip_FDICGuaranteedAmount_a3923e49-89f2-4a95-9ba0-577a138c1157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_2f9126e1-0f1d-418a-9abe-ab564378e6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_EscrowDeposit_2f9126e1-0f1d-418a-9abe-ab564378e6cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79e4e3c7-d535-44c7-91b9-1249a0ffe897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79e4e3c7-d535-44c7-91b9-1249a0ffe897" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_16af8f3d-2b6c-4f59-9304-b412b6448e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_16af8f3d-2b6c-4f59-9304-b412b6448e24" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_18d9851c-a39b-458c-bc76-93f20028d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_18d9851c-a39b-458c-bc76-93f20028d67d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dced7c7e-eb31-4ef0-ab23-b3f5b8a5e428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dced7c7e-eb31-4ef0-ab23-b3f5b8a5e428" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cd5703f7-b41c-4f19-bfe3-035796ec9479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cd5703f7-b41c-4f19-bfe3-035796ec9479" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c70441aa-4997-42b1-a79f-286e12590602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_NumberOfReportableSegments_c70441aa-4997-42b1-a79f-286e12590602" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5c756cfa-de47-4adc-9e44-39905e2de745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5c756cfa-de47-4adc-9e44-39905e2de745" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82218df4-564e-482d-8270-22881d183741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82218df4-564e-482d-8270-22881d183741" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_72709fdd-62eb-4cc0-84a3-0d0121edfce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_72709fdd-62eb-4cc0-84a3-0d0121edfce1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae88e88a-9442-4662-9631-b02dbd4d7b2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ae88e88a-9442-4662-9631-b02dbd4d7b2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_5ebc9110-6496-4fca-ad5b-5d4dd5e96ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_5ebc9110-6496-4fca-ad5b-5d4dd5e96ee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_626411a8-2801-41e8-9511-52ba5c0faf05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_626411a8-2801-41e8-9511-52ba5c0faf05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:to="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6fdc75d1-4c0b-4c23-8920-3070911994ee_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:to="loc_srt_RangeMember_6fdc75d1-4c0b-4c23-8920-3070911994ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:to="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_892d404f-b204-44c6-8eee-b18d72adbce0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:to="loc_srt_MinimumMember_892d404f-b204-44c6-8eee-b18d72adbce0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d6f8bf1d-a4bd-410b-b3e1-08307882cf81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:to="loc_srt_MaximumMember_d6f8bf1d-a4bd-410b-b3e1-08307882cf81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_165398e0-0c77-4679-b148-5edd4419307c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_72709fdd-62eb-4cc0-84a3-0d0121edfce1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_165398e0-0c77-4679-b148-5edd4419307c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bb85542e-1670-47db-825f-b3aae861d736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb85542e-1670-47db-825f-b3aae861d736" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:to="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50191bf7-dc9a-4c8b-bef3-daa07309f009_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:to="loc_srt_ProductsAndServicesDomain_50191bf7-dc9a-4c8b-bef3-daa07309f009_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:to="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfGenericPharmaceuticalProductsMember_64950bb1-cd55-43d4-baad-25f7b7bfcee7" xlink:href="anip-20231231.xsd#anip_SalesOfGenericPharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:to="loc_anip_SalesOfGenericPharmaceuticalProductsMember_64950bb1-cd55-43d4-baad-25f7b7bfcee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfBrandedPharmaceuticalProductsMember_57399684-6175-4975-af8e-8d025268ba9f" xlink:href="anip-20231231.xsd#anip_SalesOfBrandedPharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:to="loc_anip_SalesOfBrandedPharmaceuticalProductsMember_57399684-6175-4975-af8e-8d025268ba9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfRareDiseasePharmaceuticalProductsMember_85ba06f4-7b94-4136-9ffe-dff11a677c95" xlink:href="anip-20231231.xsd#anip_SalesOfRareDiseasePharmaceuticalProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:to="loc_anip_SalesOfRareDiseasePharmaceuticalProductsMember_85ba06f4-7b94-4136-9ffe-dff11a677c95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78afa478-8aa8-40a8-a1e2-1242ed92675c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb85542e-1670-47db-825f-b3aae861d736" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78afa478-8aa8-40a8-a1e2-1242ed92675c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_35b8123a-ddb7-4c78-98c8-ba930a5a7c56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_35b8123a-ddb7-4c78-98c8-ba930a5a7c56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_fee51494-ff73-4aa0-84e6-19c0b97decc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_fee51494-ff73-4aa0-84e6-19c0b97decc1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_a25727ef-4c9c-48bd-936a-7cca12ca24b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:to="loc_us-gaap_TransferredOverTimeMember_a25727ef-4c9c-48bd-936a-7cca12ca24b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_515a8116-774e-4067-b7e0-1253a1bebbff_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:to="loc_srt_ProductsAndServicesDomain_515a8116-774e-4067-b7e0-1253a1bebbff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41737d15-ba85-4893-be91-6963179392d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:to="loc_srt_ProductsAndServicesDomain_41737d15-ba85-4893-be91-6963179392d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfContractManufacturedProductsMember_57948cac-bb79-426c-b83f-0965370133db" xlink:href="anip-20231231.xsd#anip_SalesOfContractManufacturedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_41737d15-ba85-4893-be91-6963179392d2" xlink:to="loc_anip_SalesOfContractManufacturedProductsMember_57948cac-bb79-426c-b83f-0965370133db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_688837c2-a287-439c-a915-fe529021fda6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:to="loc_srt_RangeMember_688837c2-a287-439c-a915-fe529021fda6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:to="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37bc3bf8-59aa-4cd8-9486-4cd2869b3dda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:to="loc_srt_MinimumMember_37bc3bf8-59aa-4cd8-9486-4cd2869b3dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12627ece-5d0d-4c91-84ad-a3a6918b797b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:to="loc_srt_MaximumMember_12627ece-5d0d-4c91-84ad-a3a6918b797b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65d6890a-0de6-4471-93c6-0d124ac6c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65d6890a-0de6-4471-93c6-0d124ac6c36a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_babca258-1a90-4161-b1a4-d3bd4fff8847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_babca258-1a90-4161-b1a4-d3bd4fff8847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea81bdca-8ab4-4cdf-9920-16427f83fa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea81bdca-8ab4-4cdf-9920-16427f83fa0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3c8cbd3d-b10f-4139-b835-0f92bec18e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3c8cbd3d-b10f-4139-b835-0f92bec18e74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_816dc9bb-0061-45ab-9cf8-0819e62d23f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_816dc9bb-0061-45ab-9cf8-0819e62d23f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductReturnPeriod_3e2533f1-3be5-4a5b-8b0c-227859ec3e92" xlink:href="anip-20231231.xsd#anip_ProductReturnPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_anip_ProductReturnPeriod_3e2533f1-3be5-4a5b-8b0c-227859ec3e92" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5452ca85-a721-4bf7-938b-0b10686eee3e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5452ca85-a721-4bf7-938b-0b10686eee3e" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ChargebacksMember_b6b58bf7-a607-4969-8486-862702133aa6" xlink:href="anip-20231231.xsd#anip_ChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_ChargebacksMember_b6b58bf7-a607-4969-8486-862702133aa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_GovernmentRebatesMember_f343b85f-a432-4b36-a983-c23ee1a7a0d4" xlink:href="anip-20231231.xsd#anip_GovernmentRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_GovernmentRebatesMember_f343b85f-a432-4b36-a983-c23ee1a7a0d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AllowancesForSalesReturnsMember_e541c46f-8421-445d-9c1c-41437c5edf60" xlink:href="anip-20231231.xsd#anip_AllowancesForSalesReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_AllowancesForSalesReturnsMember_e541c46f-8421-445d-9c1c-41437c5edf60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AdministrativeFeesAndOtherRebatesMember_ad9a58e7-31fd-4b9c-b226-60b3924c5592" xlink:href="anip-20231231.xsd#anip_AdministrativeFeesAndOtherRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_AdministrativeFeesAndOtherRebatesMember_ad9a58e7-31fd-4b9c-b226-60b3924c5592" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReservesForCashDiscountMember_be041355-f7d9-401a-828a-90631e59cefa" xlink:href="anip-20231231.xsd#anip_ReservesForCashDiscountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_ReservesForCashDiscountMember_be041355-f7d9-401a-828a-90631e59cefa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5452ca85-a721-4bf7-938b-0b10686eee3e" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7ab77625-ea2e-4204-8be2-84383d782fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7ab77625-ea2e-4204-8be2-84383d782fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_6b711662-80df-4ab3-9b97-061553607a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_6b711662-80df-4ab3-9b97-061553607a50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_769bcf8b-1871-4829-9f40-a0df69f99d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_769bcf8b-1871-4829-9f40-a0df69f99d18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1bb11b17-f128-4a16-b7fc-68f631856fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_c4f1e4f5-ae62-4007-a7aa-6a7af74456d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c4f1e4f5-ae62-4007-a7aa-6a7af74456d8" xlink:to="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_258ed4e7-f886-4d06-8bfa-4f1de6bbbb69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_258ed4e7-f886-4d06-8bfa-4f1de6bbbb69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_08eb71d9-972b-451e-9dbb-693639c9ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_258ed4e7-f886-4d06-8bfa-4f1de6bbbb69" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_08eb71d9-972b-451e-9dbb-693639c9ab47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fbda167c-a9eb-4ba7-b28d-2ea65462434a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_fbda167c-a9eb-4ba7-b28d-2ea65462434a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b5a9df6e-3ebd-4cd7-967e-4dbe416f8497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:to="loc_us-gaap_AccountsReceivableMember_b5a9df6e-3ebd-4cd7-967e-4dbe416f8497" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_e185f189-85f1-4ab4-ab89-66e455a2988b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_e185f189-85f1-4ab4-ab89-66e455a2988b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1d3a45af-1743-43fa-ad5e-1149ca15b023_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:to="loc_srt_NameOfMajorCustomerDomain_1d3a45af-1743-43fa-ad5e-1149ca15b023_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4e017aa5-f7b3-479a-8c83-feb10ef0420e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:to="loc_srt_NameOfMajorCustomerDomain_4e017aa5-f7b3-479a-8c83-feb10ef0420e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:href="anip-20231231.xsd#anip_FourCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4e017aa5-f7b3-479a-8c83-feb10ef0420e" xlink:to="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerOneMember_3c91b782-e0a2-4e4d-906e-a6f371cb4a66" xlink:href="anip-20231231.xsd#anip_CustomerOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerOneMember_3c91b782-e0a2-4e4d-906e-a6f371cb4a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerTwoMember_e6c95076-ced6-4ae7-a452-25ffdc646044" xlink:href="anip-20231231.xsd#anip_CustomerTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerTwoMember_e6c95076-ced6-4ae7-a452-25ffdc646044" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerThreeMember_25b91997-c70a-42c4-ab0e-b9604692e766" xlink:href="anip-20231231.xsd#anip_CustomerThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerThreeMember_25b91997-c70a-42c4-ab0e-b9604692e766" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerFourMember_3788118c-343e-4b02-9e0b-61c19a24cb99" xlink:href="anip-20231231.xsd#anip_CustomerFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerFourMember_3788118c-343e-4b02-9e0b-61c19a24cb99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_608ba863-e10b-44b1-8641-cf6d60625dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c4f1e4f5-ae62-4007-a7aa-6a7af74456d8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_608ba863-e10b-44b1-8641-cf6d60625dea" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da754b2-c683-4b09-8960-f8c386c90eac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8da754b2-c683-4b09-8960-f8c386c90eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_161a3aed-ca3a-41cf-8932-3cc5834ca2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_161a3aed-ca3a-41cf-8932-3cc5834ca2fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_5099f2b7-bb2f-47e1-bf3e-f7138b1c3f1c" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_161a3aed-ca3a-41cf-8932-3cc5834ca2fa" xlink:to="loc_anip_NovitiumMember_5099f2b7-bb2f-47e1-bf3e-f7138b1c3f1c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_02e26c51-9701-49a9-b069-a1f323b31ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_02e26c51-9701-49a9-b069-a1f323b31ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ac63c999-9f82-4403-bc03-2a158e49fdca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_02e26c51-9701-49a9-b069-a1f323b31ab6" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ac63c999-9f82-4403-bc03-2a158e49fdca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43bba64d-26e0-470d-84f6-882a01cdb9c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_43bba64d-26e0-470d-84f6-882a01cdb9c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_7ec8cdd1-c3a1-4966-b173-067ae5424591" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_7ec8cdd1-c3a1-4966-b173-067ae5424591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_99f87572-0bb6-4157-9103-a55e058b7678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:to="loc_us-gaap_CustomerRelationshipsMember_99f87572-0bb6-4157-9103-a55e058b7678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05b17ec1-709d-4ba5-a19b-62a47999df36_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:to="loc_srt_RangeMember_05b17ec1-709d-4ba5-a19b-62a47999df36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:to="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbe74118-15d0-4201-a897-9fab1ebe7ec4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:to="loc_srt_MinimumMember_dbe74118-15d0-4201-a897-9fab1ebe7ec4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_761c39cf-a099-453d-9dae-62841cade46f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:to="loc_srt_MaximumMember_761c39cf-a099-453d-9dae-62841cade46f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_c9a1369b-e317-4647-9453-5d18bb699c74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_c9a1369b-e317-4647-9453-5d18bb699c74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_cd8b6397-43e8-412d-8c36-cb5dd4213bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_cd8b6397-43e8-412d-8c36-cb5dd4213bf4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_181f1c31-719d-4064-b061-b5f445cb3121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_181f1c31-719d-4064-b061-b5f445cb3121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_220f9e9a-c2f5-4f52-af58-c07259c2e880_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:to="loc_us-gaap_ClassOfStockDomain_220f9e9a-c2f5-4f52-af58-c07259c2e880_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d40a2a11-2315-4937-9644-fb3dea0c0f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:to="loc_us-gaap_ClassOfStockDomain_d40a2a11-2315-4937-9644-fb3dea0c0f00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_e5169f62-72e1-4126-9f77-acaa34d2f75a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d40a2a11-2315-4937-9644-fb3dea0c0f00" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_e5169f62-72e1-4126-9f77-acaa34d2f75a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25909c6b-9307-4822-9840-7e0cdac596f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_25909c6b-9307-4822-9840-7e0cdac596f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99ecd5a9-131d-4bf1-a91a-7d4b4d62d420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99ecd5a9-131d-4bf1-a91a-7d4b4d62d420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember_9b70a89a-657b-4529-b51d-12edee14ab07" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99ecd5a9-131d-4bf1-a91a-7d4b4d62d420" xlink:to="loc_anip_PrivateInvestmentInPublicEquityMember_9b70a89a-657b-4529-b51d-12edee14ab07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a48f3125-aa0c-4129-a511-e902bcc632a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a48f3125-aa0c-4129-a511-e902bcc632a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_06b6856e-10b9-4a57-947e-34220118c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_06b6856e-10b9-4a57-947e-34220118c92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_90f327bc-f78e-42be-a955-69adc00d1e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_90f327bc-f78e-42be-a955-69adc00d1e64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4c506779-b9e8-44e8-9240-45dc4653a5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4c506779-b9e8-44e8-9240-45dc4653a5f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4205b3da-aaef-44c1-b27c-d5f81bfb2829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4205b3da-aaef-44c1-b27c-d5f81bfb2829" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_ebca76b1-31aa-4a92-a7e1-b7fbce07a32d" xlink:href="anip-20231231.xsd#anip_RestrictionPeriodForSharesIssuedInBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_ebca76b1-31aa-4a92-a7e1-b7fbce07a32d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3de54d0c-745a-412f-839f-78630c7104b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3de54d0c-745a-412f-839f-78630c7104b6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_dfc4cc5f-54b8-47b2-94f2-c1b2d3dfb21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_dfc4cc5f-54b8-47b2-94f2-c1b2d3dfb21b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3c73b207-7081-40e0-bd3c-321bfff167cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3c73b207-7081-40e0-bd3c-321bfff167cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bd676c8d-75ce-4f58-aa79-87857d6286d0" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bd676c8d-75ce-4f58-aa79-87857d6286d0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_ac590fee-7849-489c-949e-a2bf0ede791e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_ac590fee-7849-489c-949e-a2bf0ede791e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2244bab4-322a-4fe3-923e-12334e5d26b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2244bab4-322a-4fe3-923e-12334e5d26b5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2dab98d0-edcc-4bad-a3cc-65c275fa98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2dab98d0-edcc-4bad-a3cc-65c275fa98ef" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_20dfb66b-51a3-4327-bba5-f6350de68949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_Goodwill_20dfb66b-51a3-4327-bba5-f6350de68949" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_6e2964fb-de85-48b8-a8b4-77cea53c595a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_6e2964fb-de85-48b8-a8b4-77cea53c595a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a89bf62b-2b6b-46b8-ada7-cbf54806d32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a89bf62b-2b6b-46b8-ada7-cbf54806d32f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78c9ea40-b61a-466b-8102-deaea7e56eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78c9ea40-b61a-466b-8102-deaea7e56eb0" xlink:type="arc" order="16"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#RESTRUCTURINGDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a8ff64ec-becb-4dd5-9f33-d125f15c0699_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:to="loc_us-gaap_RestructuringPlanDomain_a8ff64ec-becb-4dd5-9f33-d125f15c0699_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ad4b3f30-3841-485c-b0b4-11661eca0db5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:to="loc_us-gaap_RestructuringPlanDomain_ad4b3f30-3841-485c-b0b4-11661eca0db5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioCanadaMember_8a3a0d94-8adc-4f54-ab1f-2e4506389d4c" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_ad4b3f30-3841-485c-b0b4-11661eca0db5" xlink:to="loc_anip_OakvilleOntarioCanadaMember_8a3a0d94-8adc-4f54-ab1f-2e4506389d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_14a35e72-95ca-4115-8640-fab052847fc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_14a35e72-95ca-4115-8640-fab052847fc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_57b0859b-3fdf-4d6f-a203-ea3d320eca51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_57b0859b-3fdf-4d6f-a203-ea3d320eca51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_40b178f9-22af-4f47-8072-bda1585063a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityClosingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:to="loc_us-gaap_FacilityClosingMember_40b178f9-22af-4f47-8072-bda1585063a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_be73dc07-508c-430e-9b61-91e0aa32f1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:to="loc_us-gaap_OtherRestructuringMember_be73dc07-508c-430e-9b61-91e0aa32f1dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1266e0e4-e1fd-4568-b662-dc1ebe5b4900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1266e0e4-e1fd-4568-b662-dc1ebe5b4900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_9748e04c-10c7-40f3-8124-d0bd859829dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1266e0e4-e1fd-4568-b662-dc1ebe5b4900" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_9748e04c-10c7-40f3-8124-d0bd859829dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d943f5a9-fe14-44a9-ab62-ebc20396c0e4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_d943f5a9-fe14-44a9-ab62-ebc20396c0e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_904dde36-a391-417e-bb1c-4b994947e2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_904dde36-a391-417e-bb1c-4b994947e2bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_e9e60ea7-6a95-45cf-8aed-57e4e69a94e8" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_904dde36-a391-417e-bb1c-4b994947e2bf" xlink:to="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_e9e60ea7-6a95-45cf-8aed-57e4e69a94e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4279d57b-8da4-4708-8aa4-667f09e868d2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4279d57b-8da4-4708-8aa4-667f09e868d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ac0177fa-5333-4f28-8e32-95cdf232aa13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ac0177fa-5333-4f28-8e32-95cdf232aa13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_89e62995-9ccc-457b-8fda-66b6833cece1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ac0177fa-5333-4f28-8e32-95cdf232aa13" xlink:to="loc_us-gaap_SubsequentEventMember_89e62995-9ccc-457b-8fda-66b6833cece1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_1d560025-b451-47f1-a6ac-f87fe2356d39" xlink:href="anip-20231231.xsd#anip_NumberOfPharmaceuticalManufacturingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_1d560025-b451-47f1-a6ac-f87fe2356d39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_5e0b28c4-b1d8-428b-b654-46445bbbee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_5e0b28c4-b1d8-428b-b654-46445bbbee6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5dc15d1a-d9f5-442f-903d-b631a96df653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_RestructuringReserve_5dc15d1a-d9f5-442f-903d-b631a96df653" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_96eca771-c850-4c58-8171-9b549ba4a12c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_96eca771-c850-4c58-8171-9b549ba4a12c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ebb3025a-d173-46f8-94e4-2e4994b0ee83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ebb3025a-d173-46f8-94e4-2e4994b0ee83" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSCreditfacilityDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_99957c66-5e58-4359-98ce-d7ce93fc3da7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:to="loc_us-gaap_CreditFacilityDomain_99957c66-5e58-4359-98ce-d7ce93fc3da7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d48a7ada-390c-4af1-810f-30e28b3999e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:to="loc_us-gaap_CreditFacilityDomain_d48a7ada-390c-4af1-810f-30e28b3999e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CreditAgreementMember_003c4fc4-9e59-4969-bf0f-8b169f5af355" xlink:href="anip-20231231.xsd#anip_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_d48a7ada-390c-4af1-810f-30e28b3999e0" xlink:to="loc_anip_CreditAgreementMember_003c4fc4-9e59-4969-bf0f-8b169f5af355" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af95506c-50df-42cc-bbc0-b82e5c4d06c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af95506c-50df-42cc-bbc0-b82e5c4d06c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember_45cede8c-e89a-4c7b-a576-4fd36ee5500e" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:to="loc_anip_TermLoanMember_45cede8c-e89a-4c7b-a576-4fd36ee5500e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d82374a7-a6d9-4ce8-914e-3abbd02bcd57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:to="loc_us-gaap_LineOfCreditMember_d82374a7-a6d9-4ce8-914e-3abbd02bcd57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_05bd7712-107d-4d14-8e3e-25f81d3aa3e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:to="loc_us-gaap_VariableRateDomain_05bd7712-107d-4d14-8e3e-25f81d3aa3e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:to="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_f6f76174-9ce1-476d-9dc1-e6e2e17fefdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:to="loc_us-gaap_BaseRateMember_f6f76174-9ce1-476d-9dc1-e6e2e17fefdb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e4c6b496-cd7b-483a-8852-d0fde21c3c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e4c6b496-cd7b-483a-8852-d0fde21c3c32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:href="anip-20231231.xsd#anip_InterestPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodDomain_2210edfe-aae4-41a0-a98b-607b37a04cd0_default" xlink:href="anip-20231231.xsd#anip_InterestPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:to="loc_anip_InterestPeriodDomain_2210edfe-aae4-41a0-a98b-607b37a04cd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:href="anip-20231231.xsd#anip_InterestPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:to="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OneMonthDurationMember_7ac07820-da8b-42e3-b8d6-dfb6da151d32" xlink:href="anip-20231231.xsd#anip_OneMonthDurationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:to="loc_anip_OneMonthDurationMember_7ac07820-da8b-42e3-b8d6-dfb6da151d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ThreeMonthDurationMember_6906fcc8-333f-484b-994c-9e4dc5a53790" xlink:href="anip-20231231.xsd#anip_ThreeMonthDurationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:to="loc_anip_ThreeMonthDurationMember_6906fcc8-333f-484b-994c-9e4dc5a53790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SixMonthDurationMember_193ef41d-52c9-4b13-a282-fedde69d641e" xlink:href="anip-20231231.xsd#anip_SixMonthDurationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:to="loc_anip_SixMonthDurationMember_193ef41d-52c9-4b13-a282-fedde69d641e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6744e28c-b572-4761-85d1-f863585a40d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6744e28c-b572-4761-85d1-f863585a40d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba5d58e8-1ef4-4d29-9973-b22fda27ad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba5d58e8-1ef4-4d29-9973-b22fda27ad0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_91501366-5300-4ed3-9b42-7b918134c697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_91501366-5300-4ed3-9b42-7b918134c697" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_0ede7cc1-6d56-4f71-abb4-fea8d759662d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_0ede7cc1-6d56-4f71-abb4-fea8d759662d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e574d9dd-2392-4c4a-8e43-8a0ee77fcbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e574d9dd-2392-4c4a-8e43-8a0ee77fcbd6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_218977a9-9acf-4398-8e86-64c659946cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_218977a9-9acf-4398-8e86-64c659946cbe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0a14d984-d261-4923-9c07-85af419a00df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0a14d984-d261-4923-9c07-85af419a00df" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSFacilitycomponentsDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b0da18fc-97ef-4c4c-b3f9-7925b4dbf590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b0da18fc-97ef-4c4c-b3f9-7925b4dbf590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanAndDelayedDrawTermLoanMember_6c02af7d-b610-4e9d-8ad9-e445bf36c8aa" xlink:href="anip-20231231.xsd#anip_TermLoanAndDelayedDrawTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0da18fc-97ef-4c4c-b3f9-7925b4dbf590" xlink:to="loc_anip_TermLoanAndDelayedDrawTermLoanMember_6c02af7d-b610-4e9d-8ad9-e445bf36c8aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossCurrent_a4f4260c-a1b0-4510-94f5-ef00d519a393" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_anip_LongTermDebtGrossCurrent_a4f4260c-a1b0-4510-94f5-ef00d519a393" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_8391f9e0-7833-4e43-b1ab-a7a3f01aa563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_8391f9e0-7833-4e43-b1ab-a7a3f01aa563" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_eea79871-c529-4c0d-a723-bd0ff97ce6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_LongTermDebtCurrent_eea79871-c529-4c0d-a723-bd0ff97ce6b7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossNonCurrent_00c8e968-8b34-4ada-8c71-79a5d1eca570" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossNonCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_anip_LongTermDebtGrossNonCurrent_00c8e968-8b34-4ada-8c71-79a5d1eca570" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_15414dd2-8e42-4c65-a305-ede57a41897a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_15414dd2-8e42-4c65-a305-ede57a41897a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8ccb8f89-17ab-4f1a-8539-39aa54b53ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8ccb8f89-17ab-4f1a-8539-39aa54b53ad3" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:to="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_acf5688c-fd99-4304-8102-18b9d4038bd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:to="loc_us-gaap_CreditFacilityDomain_acf5688c-fd99-4304-8102-18b9d4038bd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_66e7e748-5d79-4787-9890-aa02dda4106c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:to="loc_us-gaap_CreditFacilityDomain_66e7e748-5d79-4787-9890-aa02dda4106c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CreditAgreementMember_5c4aab12-d033-41fd-9d3d-911f6b26fcdc" xlink:href="anip-20231231.xsd#anip_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_66e7e748-5d79-4787-9890-aa02dda4106c" xlink:to="loc_anip_CreditAgreementMember_5c4aab12-d033-41fd-9d3d-911f6b26fcdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember_015e2fa8-98ba-457c-933f-6ab81d242a9b" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:to="loc_anip_TermLoanMember_015e2fa8-98ba-457c-933f-6ab81d242a9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0c850f49-9407-43fb-8827-585b6cf5b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:to="loc_us-gaap_LineOfCreditMember_0c850f49-9407-43fb-8827-585b6cf5b1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c6e1ed99-8b36-41eb-9876-a0f05ae0eaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c6e1ed99-8b36-41eb-9876-a0f05ae0eaf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_719d08ce-d6b2-4dda-9701-989a40e4c4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_719d08ce-d6b2-4dda-9701-989a40e4c4ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d56899bf-2318-4a72-ad3f-174c2b3075a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d56899bf-2318-4a72-ad3f-174c2b3075a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_9e2a24f2-2b15-4f58-a9d2-a6ff2dbb2439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_9e2a24f2-2b15-4f58-a9d2-a6ff2dbb2439" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSCreditfacilitymaturityDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_45b72556-a185-48c2-be6b-8712b5a76ede_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_45b72556-a185-48c2-be6b-8712b5a76ede_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b672654-86c8-415d-a2bb-6a62f804ce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b672654-86c8-415d-a2bb-6a62f804ce3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember_944079b7-8102-411f-97e1-65f3a242decb" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b672654-86c8-415d-a2bb-6a62f804ce3d" xlink:to="loc_anip_TermLoanMember_944079b7-8102-411f-97e1-65f3a242decb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_476e4a7c-3ebc-4886-b9d5-6a9e0e74fb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_476e4a7c-3ebc-4886-b9d5-6a9e0e74fb1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_af60c782-d5f5-4251-a4dc-9c4177703f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_af60c782-d5f5-4251-a4dc-9c4177703f65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_53255070-1669-46ed-8fe6-29961197c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_53255070-1669-46ed-8fe6-29961197c4ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cb485fa3-58c4-4ca8-9a8b-d3ce24718707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cb485fa3-58c4-4ca8-9a8b-d3ce24718707" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_178cecb9-39f1-4c5d-8c0e-0064733c6878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebt_178cecb9-39f1-4c5d-8c0e-0064733c6878" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b27861f2-6a21-4c7e-b279-8710460b50ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b27861f2-6a21-4c7e-b279-8710460b50ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_da16c517-a975-4a43-a3a2-7f7dd2d0bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_da16c517-a975-4a43-a3a2-7f7dd2d0bec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1aed65f3-d14b-4ca6-a9d0-09195b01a31e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_da16c517-a975-4a43-a3a2-7f7dd2d0bec8" xlink:to="loc_us-gaap_InterestRateSwapMember_1aed65f3-d14b-4ca6-a9d0-09195b01a31e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_568cb419-629b-4783-bf9a-779defb78021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_568cb419-629b-4783-bf9a-779defb78021" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2de8f3c9-df77-4fcc-927d-a4abfdc79e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2de8f3c9-df77-4fcc-927d-a4abfdc79e6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_DerivativeLiabilityDecreaseInNotionalAmount_c5580cbc-9df0-475c-a9a4-13cfe1086186" xlink:href="anip-20231231.xsd#anip_DerivativeLiabilityDecreaseInNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_anip_DerivativeLiabilityDecreaseInNotionalAmount_c5580cbc-9df0-475c-a9a4-13cfe1086186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ba863a30-cf16-446f-a423-9c896226e2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ba863a30-cf16-446f-a423-9c896226e2b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_941ab6c2-ad41-478a-a923-f73fb9dae73d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_941ab6c2-ad41-478a-a923-f73fb9dae73d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_447aa99b-08f5-471b-b0e8-01b1c987483a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_447aa99b-08f5-471b-b0e8-01b1c987483a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_18a61cc6-8b9b-43e3-85ce-e54d2a052a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_18a61cc6-8b9b-43e3-85ce-e54d2a052a6b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94d2457d-9eb4-4350-a821-d67dced8d5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_InterestExpense_94d2457d-9eb4-4350-a821-d67dced8d5fa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7b9a39cc-fc27-4d9e-a0fb-ad375e1bebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7b9a39cc-fc27-4d9e-a0fb-ad375e1bebdb" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INVENTORIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_ab6c7d33-4570-45e0-8c79-2c119dca5ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_ab6c7d33-4570-45e0-8c79-2c119dca5ae5" xlink:to="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a5d74b86-0a95-4818-a2eb-b049c4bcb426_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a5d74b86-0a95-4818-a2eb-b049c4bcb426_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44c1f1ad-2aba-4e1e-8937-2a3fa0308b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44c1f1ad-2aba-4e1e-8937-2a3fa0308b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsTotalMember_0ecd8162-b3c9-42fe-a74d-0cfe975c8c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44c1f1ad-2aba-4e1e-8937-2a3fa0308b5e" xlink:to="loc_us-gaap_CostOfGoodsTotalMember_0ecd8162-b3c9-42fe-a74d-0cfe975c8c8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_38306443-4611-458c-8cc4-950796eb736a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_38306443-4611-458c-8cc4-950796eb736a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4267184a-d3d9-4709-bb15-6b00d75c013a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4267184a-d3d9-4709-bb15-6b00d75c013a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_c2374688-1dbe-43a5-9166-072ec862a82e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4267184a-d3d9-4709-bb15-6b00d75c013a" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_c2374688-1dbe-43a5-9166-072ec862a82e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_4a0eb83c-dc90-4805-a8bb-d15516db2737_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_4a0eb83c-dc90-4805-a8bb-d15516db2737_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_7d606843-10a8-455a-9aed-d6cfd315d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_7d606843-10a8-455a-9aed-d6cfd315d4e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OneSupplierMember_10f1851c-961d-43b4-870c-4afe1a747650" xlink:href="anip-20231231.xsd#anip_OneSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_7d606843-10a8-455a-9aed-d6cfd315d4e6" xlink:to="loc_anip_OneSupplierMember_10f1851c-961d-43b4-870c-4afe1a747650" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2785d5c7-00f5-43f3-9ed9-4fad9fe0a048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_ab6c7d33-4570-45e0-8c79-2c119dca5ae5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2785d5c7-00f5-43f3-9ed9-4fad9fe0a048" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b738aec-87cc-41ef-bd11-01e17c41877c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_4b738aec-87cc-41ef-bd11-01e17c41877c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_156cd700-ce22-4484-8d85-00781f15c238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_LandMember_156cd700-ce22-4484-8d85-00781f15c238" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_207cc2ed-58fd-440d-b602-c8efa4abc866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_BuildingMember_207cc2ed-58fd-440d-b602-c8efa4abc866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_5bb3ed5a-ae61-4da5-97c1-58d44da3a4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_5bb3ed5a-ae61-4da5-97c1-58d44da3a4fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_3c8dd0b9-8e97-4b67-8465-83278647b623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_ConstructionInProgressMember_3c8dd0b9-8e97-4b67-8465-83278647b623" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_83beb6c8-08c7-44e4-b1e3-b143d42d38df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_83beb6c8-08c7-44e4-b1e3-b143d42d38df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27470205-96dd-41ec-a692-ef41cfa6aee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27470205-96dd-41ec-a692-ef41cfa6aee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_34bbdbdc-b01d-483b-807d-ffd0cec61fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_34bbdbdc-b01d-483b-807d-ffd0cec61fdd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9bc388e-f4cf-4ba2-a483-44230992be17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e9bc388e-f4cf-4ba2-a483-44230992be17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BiosantePharmaceuticalsIncMember_95687d34-2492-40dc-a8db-afdefc3ac504" xlink:href="anip-20231231.xsd#anip_BiosantePharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:to="loc_anip_BiosantePharmaceuticalsIncMember_95687d34-2492-40dc-a8db-afdefc3ac504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_WellSpringPharmaServicesIncMember_aefcf68c-7ca4-4da9-9173-1f743a091524" xlink:href="anip-20231231.xsd#anip_WellSpringPharmaServicesIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:to="loc_anip_WellSpringPharmaServicesIncMember_aefcf68c-7ca4-4da9-9173-1f743a091524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_e4adb901-68e4-4b05-9cc5-d91e029b6ea0" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:to="loc_anip_NovitiumMember_e4adb901-68e4-4b05-9cc5-d91e029b6ea0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_5a702227-f42a-4d6a-a5c4-51aeb46b5179" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_5a702227-f42a-4d6a-a5c4-51aeb46b5179" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductRightMember_a6e33a9b-7c57-4e63-9c2b-d27ee1dd614e" xlink:href="anip-20231231.xsd#anip_ProductRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:to="loc_anip_ProductRightMember_a6e33a9b-7c57-4e63-9c2b-d27ee1dd614e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_046daac1-fd67-46ca-98cb-6718ad3248b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:to="loc_us-gaap_ReclassificationTypeDomain_046daac1-fd67-46ca-98cb-6718ad3248b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_90c277a4-afd8-469a-9188-127112bdec92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:to="loc_us-gaap_ReclassificationTypeDomain_90c277a4-afd8-469a-9188-127112bdec92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_dc8b9fbf-016d-41ee-a082-67315fe1404c" xlink:href="anip-20231231.xsd#anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationTypeDomain_90c277a4-afd8-469a-9188-127112bdec92" xlink:to="loc_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_dc8b9fbf-016d-41ee-a082-67315fe1404c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669ddffa-44b2-4b3a-8092-98a5d4eb5ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669ddffa-44b2-4b3a-8092-98a5d4eb5ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2e5d6448-452e-41e6-a2b2-d226fa3f1356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669ddffa-44b2-4b3a-8092-98a5d4eb5ceb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2e5d6448-452e-41e6-a2b2-d226fa3f1356" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_92c4dd9b-697c-43ba-81e3-041362715066_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:to="loc_us-gaap_AssetAcquisitionDomain_92c4dd9b-697c-43ba-81e3-041362715066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_92136bf1-da30-49d8-b8fc-c022fd30ae80" xlink:href="anip-20231231.xsd#anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:to="loc_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_92136bf1-da30-49d8-b8fc-c022fd30ae80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AlvogenIncMember_da24ac7f-3e5a-4b21-93df-653381973efd" xlink:href="anip-20231231.xsd#anip_AlvogenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:to="loc_anip_AlvogenIncMember_da24ac7f-3e5a-4b21-93df-653381973efd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember_0fdfff1c-762c-42b1-b865-d1e1a7853b19" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:to="loc_anip_OakrumPharmaMember_0fdfff1c-762c-42b1-b865-d1e1a7853b19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79a1bebb-3dad-460f-b468-f07c75d3c203_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:to="loc_srt_RangeMember_79a1bebb-3dad-460f-b468-f07c75d3c203_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:to="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0c89ad7f-c3b7-45cd-9c6e-7522a0feec5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:to="loc_srt_MinimumMember_0c89ad7f-c3b7-45cd-9c6e-7522a0feec5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26aa4b06-dade-4a08-873d-54d3e3a5e23e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:to="loc_srt_MaximumMember_26aa4b06-dade-4a08-873d-54d3e3a5e23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_78c332d0-cb29-4aad-96fd-1b8a09dbf93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_78c332d0-cb29-4aad-96fd-1b8a09dbf93f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3a503089-9bca-449e-8f4c-66d8326ee788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3a503089-9bca-449e-8f4c-66d8326ee788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e366a2af-c48c-451a-8f1b-970e7a67efb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_NumberOfReportableSegments_e366a2af-c48c-451a-8f1b-970e7a67efb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_361d5793-9962-46bd-a6da-30e87484ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_361d5793-9962-46bd-a6da-30e87484ce9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c5d6667a-5bc7-4b38-a1d9-852d9ef870d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_Goodwill_c5d6667a-5bc7-4b38-a1d9-852d9ef870d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_35d8e50a-2824-4df2-8815-45f9e089d70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_35d8e50a-2824-4df2-8815-45f9e089d70d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4157f614-8ae1-4977-ab56-b22ccf805b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4157f614-8ae1-4977-ab56-b22ccf805b40" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a18cea7d-1d54-4495-8b8e-8c7e1f693d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a18cea7d-1d54-4495-8b8e-8c7e1f693d61" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_032ab68e-27db-4540-bfab-7c0de958b587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_032ab68e-27db-4540-bfab-7c0de958b587" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_10d8fea1-5b35-4b55-8ff8-5b5080e9f469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_10d8fea1-5b35-4b55-8ff8-5b5080e9f469" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e15c600e-d404-4889-b525-41171536e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e15c600e-d404-4889-b525-41171536e8f0" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSComponentsDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e451d79-ba20-4976-b276-3f1778e75944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1e451d79-ba20-4976-b276-3f1778e75944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_53fb0aa8-b40d-4296-8091-fa67f4bdb131" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_53fb0aa8-b40d-4296-8091-fa67f4bdb131" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductRightsMember_c3b3e2d2-29b2-4ea0-a8c3-4e0ae6e70778" xlink:href="anip-20231231.xsd#anip_ProductRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_ProductRightsMember_c3b3e2d2-29b2-4ea0-a8c3-4e0ae6e70778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketingAndDistributionRightsMember_0ba17e3b-5885-4beb-8a7c-e8c86e8f3215" xlink:href="anip-20231231.xsd#anip_MarketingAndDistributionRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_MarketingAndDistributionRightsMember_0ba17e3b-5885-4beb-8a7c-e8c86e8f3215" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NonCompeteAgreementMember_e62fa319-5ff0-4f8d-b9e4-5c83c9ba7617" xlink:href="anip-20231231.xsd#anip_NonCompeteAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_NonCompeteAgreementMember_e62fa319-5ff0-4f8d-b9e4-5c83c9ba7617" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f54a575b-9425-4ad5-b904-b07c28f4d108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f54a575b-9425-4ad5-b904-b07c28f4d108" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4204d24f-cc3c-4085-9e43-668533094f21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_4204d24f-cc3c-4085-9e43-668533094f21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581088a9-afc8-4786-a2a6-bffbe6000276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581088a9-afc8-4786-a2a6-bffbe6000276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_24fe82f0-6f0f-4eeb-bb8a-7275b7f5392b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581088a9-afc8-4786-a2a6-bffbe6000276" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_24fe82f0-6f0f-4eeb-bb8a-7275b7f5392b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab1d1e5c-966b-4ae4-95dd-7c1cdc0695a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab1d1e5c-966b-4ae4-95dd-7c1cdc0695a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f1142f4b-0f95-46fd-8fff-0e86db8a9f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f1142f4b-0f95-46fd-8fff-0e86db8a9f32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08ffd96b-c9fc-43f5-9691-e3db2d9a78e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08ffd96b-c9fc-43f5-9691-e3db2d9a78e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0ceaf64c-459e-4374-a146-bcee8f993b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0ceaf64c-459e-4374-a146-bcee8f993b97" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_196a8178-629c-430c-8808-b1cc3f2249df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_196a8178-629c-430c-8808-b1cc3f2249df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_91e5a194-aa9c-4ce1-806f-e81013416221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_196a8178-629c-430c-8808-b1cc3f2249df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_91e5a194-aa9c-4ce1-806f-e81013416221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_75cef0c6-9932-4b59-a206-ad16bc400236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_75cef0c6-9932-4b59-a206-ad16bc400236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6bfe2760-cc7b-417e-a97f-4fb6464b69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6bfe2760-cc7b-417e-a97f-4fb6464b69b4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4aac485d-9e7b-4625-a4be-f9eadb1848de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4aac485d-9e7b-4625-a4be-f9eadb1848de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71147bd2-4cb6-4feb-a98c-7eb52008d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71147bd2-4cb6-4feb-a98c-7eb52008d3b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6043a57d-fc0e-4bb4-bb2e-37219abbe51a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71147bd2-4cb6-4feb-a98c-7eb52008d3b0" xlink:to="loc_us-gaap_InterestRateSwapMember_6043a57d-fc0e-4bb4-bb2e-37219abbe51a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a8b145b-76dc-4adc-92ff-da8553ab1f06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7a8b145b-76dc-4adc-92ff-da8553ab1f06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd28d585-e1ce-4902-bfd3-5086a0a1ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd28d585-e1ce-4902-bfd3-5086a0a1ab7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_ccdbf6ad-0d53-4cc9-96ab-9f4b317d43e9" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd28d585-e1ce-4902-bfd3-5086a0a1ab7c" xlink:to="loc_anip_NovitiumPharmaMember_ccdbf6ad-0d53-4cc9-96ab-9f4b317d43e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_53b40c1a-4ba7-4706-b18a-989e2e120005" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_53b40c1a-4ba7-4706-b18a-989e2e120005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductIntellectualPropertyMember_6f57a71f-7900-4f14-82b1-06496a498558" xlink:href="anip-20231231.xsd#anip_ProductIntellectualPropertyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_ProductIntellectualPropertyMember_6f57a71f-7900-4f14-82b1-06496a498558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredPipelineProductMember_19756268-5885-4e40-b624-54d6ee5836bd" xlink:href="anip-20231231.xsd#anip_AcquiredPipelineProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredPipelineProductMember_19756268-5885-4e40-b624-54d6ee5836bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredCommercialProductMember_fe7a0b79-113d-4276-8f72-e3e2f119a6c8" xlink:href="anip-20231231.xsd#anip_AcquiredCommercialProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredCommercialProductMember_fe7a0b79-113d-4276-8f72-e3e2f119a6c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredApprovedProductMember_abd74c83-5256-4d67-a968-97612b59d5fb" xlink:href="anip-20231231.xsd#anip_AcquiredApprovedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredApprovedProductMember_abd74c83-5256-4d67-a968-97612b59d5fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredFiledProductsMember_ea91b6cc-a0bf-4da3-b4fd-89d1d12e0ca1" xlink:href="anip-20231231.xsd#anip_AcquiredFiledProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredFiledProductsMember_ea91b6cc-a0bf-4da3-b4fd-89d1d12e0ca1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredNDAIntangibleAssetsMember_c4c200ee-84a1-468d-99be-3094e42eb289" xlink:href="anip-20231231.xsd#anip_AcquiredNDAIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredNDAIntangibleAssetsMember_c4c200ee-84a1-468d-99be-3094e42eb289" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_427d2051-7ed2-40a2-8838-dfe3ca4446c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:to="loc_us-gaap_AssetAcquisitionDomain_427d2051-7ed2-40a2-8838-dfe3ca4446c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember_def83b54-74e8-4a7c-8d5b-22af80c9dbe9" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_OakrumPharmaMember_def83b54-74e8-4a7c-8d5b-22af80c9dbe9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_3f41a832-0a0a-4b63-99ed-5d5ecfccfd92" xlink:href="anip-20231231.xsd#anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_3f41a832-0a0a-4b63-99ed-5d5ecfccfd92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AkornHoldingCompanyPipelineProductMember_39acf7b0-b320-4126-8a9e-4ab6b2ce739d" xlink:href="anip-20231231.xsd#anip_AkornHoldingCompanyPipelineProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_AkornHoldingCompanyPipelineProductMember_39acf7b0-b320-4126-8a9e-4ab6b2ce739d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AlvogenIncMember_f4db8d47-70cf-4068-a4af-8d90ed9af9d5" xlink:href="anip-20231231.xsd#anip_AlvogenIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_AlvogenIncMember_f4db8d47-70cf-4068-a4af-8d90ed9af9d5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_81cc4b67-f90e-428e-95d8-b57bbfecdd96_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_81cc4b67-f90e-428e-95d8-b57bbfecdd96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_729e1598-5f27-4779-bd44-6de5a67e4141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_729e1598-5f27-4779-bd44-6de5a67e4141" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d60be31d-2e34-4a90-98c1-c0030d141bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_729e1598-5f27-4779-bd44-6de5a67e4141" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d60be31d-2e34-4a90-98c1-c0030d141bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_599f6f2f-42f0-4466-b99d-cde76e62a576_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_599f6f2f-42f0-4466-b99d-cde76e62a576_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fb79c80-323b-4aef-8494-e9ba01a18c69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fb79c80-323b-4aef-8494-e9ba01a18c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SandozIncMember_07d863d6-bd00-4e6a-8c4b-091dd0a181cd" xlink:href="anip-20231231.xsd#anip_SandozIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fb79c80-323b-4aef-8494-e9ba01a18c69" xlink:to="loc_anip_SandozIncMember_07d863d6-bd00-4e6a-8c4b-091dd0a181cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_eee004b8-5164-4ffd-9482-9a2fe7c90784_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_eee004b8-5164-4ffd-9482-9a2fe7c90784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d520b82a-0ac7-4b53-b2bc-d48615e5d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d520b82a-0ac7-4b53-b2bc-d48615e5d44e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7c69b895-9093-4e53-833c-198e5a253641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d520b82a-0ac7-4b53-b2bc-d48615e5d44e" xlink:to="loc_us-gaap_SubsequentEventMember_7c69b895-9093-4e53-833c-198e5a253641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_60a0fc22-2279-4ac5-90aa-449d5bf59ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_60a0fc22-2279-4ac5-90aa-449d5bf59ee7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b328050d-880a-4837-984c-7e05df790829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b328050d-880a-4837-984c-7e05df790829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b4d2c3e-4630-4382-93ab-c2cb2b9386d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b4d2c3e-4630-4382-93ab-c2cb2b9386d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_55b6d304-5365-4113-a7f0-e21ea3ac7cb4" xlink:href="anip-20231231.xsd#anip_BusinessCombinationContingentConsiderationArrangementsPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_55b6d304-5365-4113-a7f0-e21ea3ac7cb4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97d9fdaa-f04c-49ea-af7a-d6e9a75c5ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97d9fdaa-f04c-49ea-af7a-d6e9a75c5ee2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f73db0c4-4e81-45ab-810f-1d805d32b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f73db0c4-4e81-45ab-810f-1d805d32b8a0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b5ca4ada-5fbc-4350-b0ef-53010b59e8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b5ca4ada-5fbc-4350-b0ef-53010b59e8c2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fb090498-1266-4906-9daf-13fb45b28ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fb090498-1266-4906-9daf-13fb45b28ac3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1d152dd3-c0a4-44a3-8b46-cb520770cd10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1d152dd3-c0a4-44a3-8b46-cb520770cd10" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ca8be2cf-4d9e-4d78-81a4-bed5f43e2163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ca8be2cf-4d9e-4d78-81a4-bed5f43e2163" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfIntangibleAssetsAcquired_fa3d9b17-6189-4534-8e93-3cc05deab891" xlink:href="anip-20231231.xsd#anip_NumberOfIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_anip_NumberOfIntangibleAssetsAcquired_fa3d9b17-6189-4534-8e93-3cc05deab891" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_3ed81f8b-c7f1-4f1e-9fc3-a62f2cac50c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_3ed81f8b-c7f1-4f1e-9fc3-a62f2cac50c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bcf1823e-59b7-4096-8df4-4ef27033ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bcf1823e-59b7-4096-8df4-4ef27033ed8b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_78143839-1f50-4270-9368-5b9165e4141e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_78143839-1f50-4270-9368-5b9165e4141e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IntangibleAssetMeasurementInput_fc025a45-11d5-4795-ac23-c757cf921602" xlink:href="anip-20231231.xsd#anip_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_anip_IntangibleAssetMeasurementInput_fc025a45-11d5-4795-ac23-c757cf921602" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_4ab2ab23-ce40-4ffd-899e-6766e546d30a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_4ab2ab23-ce40-4ffd-899e-6766e546d30a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_38a1123c-364a-42ca-9e72-a11d66845ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentsForFees_38a1123c-364a-42ca-9e72-a11d66845ba0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6c3d4ac1-98c1-4732-b4b6-67fe7563dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InventoryNet_6c3d4ac1-98c1-4732-b4b6-67fe7563dae5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d67548de-44a5-4b6f-80e4-f1b9d82876cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InventoryRawMaterials_d67548de-44a5-4b6f-80e4-f1b9d82876cf" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryDemo_9dba1812-5b87-402b-904b-7b6cb0f8cdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryDemo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_OtherInventoryDemo_9dba1812-5b87-402b-904b-7b6cb0f8cdcd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_81b3fb35-9c31-4b7c-b3be-619621b281c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InventoryFinishedGoods_81b3fb35-9c31-4b7c-b3be-619621b281c1" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUELevel3Details"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:to="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_aa20e983-9776-4b89-ac69-ee66384e5a4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_aa20e983-9776-4b89-ac69-ee66384e5a4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_eb065f25-d058-45f3-ab77-29234d68638c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_eb065f25-d058-45f3-ab77-29234d68638c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MeasurementInputProbabilityOfPaymentMember_52a61922-c4be-46f6-8ecc-6d11410b0b21" xlink:href="anip-20231231.xsd#anip_MeasurementInputProbabilityOfPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:to="loc_anip_MeasurementInputProbabilityOfPaymentMember_52a61922-c4be-46f6-8ecc-6d11410b0b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:href="anip-20231231.xsd#anip_PaymentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeDomain_71862cc4-9cd0-42ae-87a4-57d1cdc41db8_default" xlink:href="anip-20231231.xsd#anip_PaymentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:to="loc_anip_PaymentTypeDomain_71862cc4-9cd0-42ae-87a4-57d1cdc41db8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:href="anip-20231231.xsd#anip_PaymentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:to="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProjectBasedMilestonePaymentsMember_db257be4-5014-4d2c-a736-a6e1a252a32b" xlink:href="anip-20231231.xsd#anip_ProjectBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:to="loc_anip_ProjectBasedMilestonePaymentsMember_db257be4-5014-4d2c-a736-a6e1a252a32b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductDevelopmentBasedMilestonePaymentsMember_513abc2b-da7d-4ded-825d-390402f8aa8e" xlink:href="anip-20231231.xsd#anip_ProductDevelopmentBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:to="loc_anip_ProductDevelopmentBasedMilestonePaymentsMember_513abc2b-da7d-4ded-825d-390402f8aa8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_33ee5082-dff9-4f1e-9b47-95204154595d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:to="loc_us-gaap_ValuationTechniqueDomain_33ee5082-dff9-4f1e-9b47-95204154595d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_76a5af6a-adc1-42d0-ae41-622ab664f3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_33ee5082-dff9-4f1e-9b47-95204154595d" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_76a5af6a-adc1-42d0-ae41-622ab664f3ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3a052199-8642-44a1-8893-28ffcd3fa602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3a052199-8642-44a1-8893-28ffcd3fa602" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e10aaaf-185b-494b-85da-d3a45e824189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e10aaaf-185b-494b-85da-d3a45e824189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_b244be7a-1409-4a90-bea0-68b04a301139" xlink:href="anip-20231231.xsd#anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_b244be7a-1409-4a90-bea0-68b04a301139" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_08524831-1f1f-476f-8b7a-f670f376d114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_08524831-1f1f-476f-8b7a-f670f376d114" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1e75c19-46ac-49d0-b62b-79a7eea17d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1e75c19-46ac-49d0-b62b-79a7eea17d5a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_59b2cde5-4553-44cc-a153-540a27a04937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1e75c19-46ac-49d0-b62b-79a7eea17d5a" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_59b2cde5-4553-44cc-a153-540a27a04937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b9d157e9-f9f4-4e78-86eb-60dde552ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUEHierarchyDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5008f90-c1c9-4c82-aab8-658aa52bd49b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5008f90-c1c9-4c82-aab8-658aa52bd49b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f08b8aba-3cb6-40de-ab1e-37b6fa951ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f08b8aba-3cb6-40de-ab1e-37b6fa951ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_42e55e50-29b7-40e2-b4cb-c612a873e4dd" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f08b8aba-3cb6-40de-ab1e-37b6fa951ccc" xlink:to="loc_anip_NovitiumPharmaMember_42e55e50-29b7-40e2-b4cb-c612a873e4dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_39b2103e-479f-43db-ba44-15f1ee7931cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_39b2103e-479f-43db-ba44-15f1ee7931cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c5fb55ad-3b5d-4014-939d-c9905f3dbaca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c5fb55ad-3b5d-4014-939d-c9905f3dbaca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7e62a277-e409-4fe3-b012-87940fd47632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7e62a277-e409-4fe3-b012-87940fd47632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_437cbf66-6982-40ef-9376-56aa84c9be86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_437cbf66-6982-40ef-9376-56aa84c9be86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_33c2635e-bac0-4bb4-82ae-e55886eae5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_33c2635e-bac0-4bb4-82ae-e55886eae5f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_826be323-18b0-4126-bbaf-dfa7d85e2bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_826be323-18b0-4126-bbaf-dfa7d85e2bf3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUEAcquiredDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c236ca-0ca5-481a-80a9-662a1559b226_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_81c236ca-0ca5-481a-80a9-662a1559b226_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c28c099b-aec4-4bb8-a312-62fc0659067b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c28c099b-aec4-4bb8-a312-62fc0659067b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SandozIncMember_347c294f-5bc4-4e87-8409-5eff74f1f158" xlink:href="anip-20231231.xsd#anip_SandozIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c28c099b-aec4-4bb8-a312-62fc0659067b" xlink:to="loc_anip_SandozIncMember_347c294f-5bc4-4e87-8409-5eff74f1f158" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e63b334b-6373-4d71-8302-fe33958f2dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e63b334b-6373-4d71-8302-fe33958f2dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_61d81810-9630-46f8-8ddd-32b71dc0b871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_61d81810-9630-46f8-8ddd-32b71dc0b871" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember_216d3c33-43c2-4909-843b-0a28c017221b" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_61d81810-9630-46f8-8ddd-32b71dc0b871" xlink:to="loc_anip_OakrumPharmaMember_216d3c33-43c2-4909-843b-0a28c017221b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1850ae27-cf09-4775-b1c7-6f8105ee084a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1850ae27-cf09-4775-b1c7-6f8105ee084a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b028c79-97d6-41e5-ae36-fc9ab8f05585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b028c79-97d6-41e5-ae36-fc9ab8f05585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_16d18a66-d6d0-4b4e-be16-99ff017ba9b5" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b028c79-97d6-41e5-ae36-fc9ab8f05585" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_16d18a66-d6d0-4b4e-be16-99ff017ba9b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_d20238c7-e0e2-49f1-bfbc-1da26440b0b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_d20238c7-e0e2-49f1-bfbc-1da26440b0b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f37455eb-a185-4659-b469-b19405f91e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f37455eb-a185-4659-b469-b19405f91e79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7d2885f3-95b8-4de1-9d91-6d667c0b4adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f37455eb-a185-4659-b469-b19405f91e79" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7d2885f3-95b8-4de1-9d91-6d667c0b4adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d8b3e050-a32d-45f3-a62a-e9a121ab7bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d8b3e050-a32d-45f3-a62a-e9a121ab7bdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_fbc9c25f-4d2c-401d-8b54-4af789d98702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_fbc9c25f-4d2c-401d-8b54-4af789d98702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_c26c2869-20a5-4d0a-b923-6527f2d96c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_PaymentsForFees_c26c2869-20a5-4d0a-b923-6527f2d96c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46810a8c-5d00-4ba0-a100-66d0944ae7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46810a8c-5d00-4ba0-a100-66d0944ae7c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_92f5f3d8-c41e-4af1-ade0-e16518c41ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_92f5f3d8-c41e-4af1-ade0-e16518c41ae4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IntangibleAssetMeasurementInput_72165c2c-4418-4898-bfe4-04079a9fca91" xlink:href="anip-20231231.xsd#anip_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_anip_IntangibleAssetMeasurementInput_72165c2c-4418-4898-bfe4-04079a9fca91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d6f8d649-ae92-4116-8fc0-cc3a355c0bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_InventoryNet_d6f8d649-ae92-4116-8fc0-cc3a355c0bbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_318c5511-d8ce-49f2-9a91-ab7a2581c845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_InventoryRawMaterials_318c5511-d8ce-49f2-9a91-ab7a2581c845" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryDemo_f7e93646-bb91-4d41-a8bb-3baa08e962d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryDemo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_OtherInventoryDemo_f7e93646-bb91-4d41-a8bb-3baa08e962d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bea92e6c-92f7-436c-ad5d-4a27245ec092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_InventoryFinishedGoods_bea92e6c-92f7-436c-ad5d-4a27245ec092" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_37fc5b03-c8e6-4221-9fd1-d963e8627de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_37fc5b03-c8e6-4221-9fd1-d963e8627de0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_68da5d02-412f-41ac-916c-f7e9481b8c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_68da5d02-412f-41ac-916c-f7e9481b8c91" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#MEZZANINEANDSTOCKHOLDERSEQUITYDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27013327-4c5a-481e-81a5-9f171853c7c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_27013327-4c5a-481e-81a5-9f171853c7c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a36d798b-a0ae-4b9f-96e7-747d46a7b9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a36d798b-a0ae-4b9f-96e7-747d46a7b9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_dace65b7-c717-4b92-afe8-47fbf3e203a0" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a36d798b-a0ae-4b9f-96e7-747d46a7b9f3" xlink:to="loc_anip_NovitiumPharmaMember_dace65b7-c717-4b92-afe8-47fbf3e203a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:to="loc_us-gaap_EquityComponentDomain_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:to="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_736ace1c-f754-438d-bca5-4a7864271196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:to="loc_us-gaap_CommonStockMember_736ace1c-f754-438d-bca5-4a7864271196" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember_928d6273-8113-4e69-91b3-1800e2320969" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:to="loc_anip_ClassCSpecialStockMember_928d6273-8113-4e69-91b3-1800e2320969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55cbffbe-68a9-4978-974e-a3bb05c329ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_55cbffbe-68a9-4978-974e-a3bb05c329ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember_d50112e6-4bb2-4251-924e-a1f602002a4b" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:to="loc_anip_PrivateInvestmentInPublicEquityMember_d50112e6-4bb2-4251-924e-a1f602002a4b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PublicOfferingMember_27c7712d-0504-4d9c-a8c4-e0af51b86143" xlink:href="anip-20231231.xsd#anip_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:to="loc_anip_PublicOfferingMember_27c7712d-0504-4d9c-a8c4-e0af51b86143" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8790e247-d5d1-4f2f-a71c-cd6fee23897c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:to="loc_us-gaap_ClassOfStockDomain_8790e247-d5d1-4f2f-a71c-cd6fee23897c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:to="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_a3157b90-1e2b-4af8-a314-3f8accf3b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_a3157b90-1e2b-4af8-a314-3f8accf3b8ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_427e900b-4602-46ef-957b-eca64178679f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:to="loc_us-gaap_CommonStockMember_427e900b-4602-46ef-957b-eca64178679f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_53a93cfa-c2c5-425e-a0c8-435eab867a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_53a93cfa-c2c5-425e-a0c8-435eab867a9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ac8875cf-3b35-45be-86c9-881394647b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ac8875cf-3b35-45be-86c9-881394647b37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3cc3b12f-1e1f-415b-9b95-343c20d163c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3cc3b12f-1e1f-415b-9b95-343c20d163c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a2966779-5815-4333-af7d-e4b48fd71f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a2966779-5815-4333-af7d-e4b48fd71f96" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2c2f3181-3aa6-4784-a55a-8dcd6a58df22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockSharesIssued_2c2f3181-3aa6-4784-a55a-8dcd6a58df22" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3761c383-6ced-4dcb-97b9-564db0f46828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3761c383-6ced-4dcb-97b9-564db0f46828" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f640000a-113f-48c4-b5b6-750ac47c1831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f640000a-113f-48c4-b5b6-750ac47c1831" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec5bf032-cb0d-41f7-bbc6-df4aba44e54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec5bf032-cb0d-41f7-bbc6-df4aba44e54c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_48d14fbe-4746-4a37-a14d-862642099d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_48d14fbe-4746-4a37-a14d-862642099d52" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_faf30ff6-8158-44b4-ba22-3b3e167f5145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_faf30ff6-8158-44b4-ba22-3b3e167f5145" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockNumberOfVotesPerShare_628ae5c9-9d6b-420a-92e7-23a26497ae41" xlink:href="anip-20231231.xsd#anip_CommonStockNumberOfVotesPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_CommonStockNumberOfVotesPerShare_628ae5c9-9d6b-420a-92e7-23a26497ae41" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockConvertibleConversionRatio_6258f34d-05ee-4d34-95b8-b98aa230a31e" xlink:href="anip-20231231.xsd#anip_CommonStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_CommonStockConvertibleConversionRatio_6258f34d-05ee-4d34-95b8-b98aa230a31e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockConversionPrice_fdc56324-2b31-4525-974c-c7b91de011d0" xlink:href="anip-20231231.xsd#anip_CommonStockConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_CommonStockConversionPrice_fdc56324-2b31-4525-974c-c7b91de011d0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0ab17b83-bcd0-46da-91f3-5d5d32340ae8" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0ab17b83-bcd0-46da-91f3-5d5d32340ae8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_59ae59fd-b3b1-4a1c-8654-7247cb670db6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_59ae59fd-b3b1-4a1c-8654-7247cb670db6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_fef2fc7e-5432-4154-b63a-ec76e105a417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_fef2fc7e-5432-4154-b63a-ec76e105a417" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_972a7314-409e-4287-ae7b-fb97d5435a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_972a7314-409e-4287-ae7b-fb97d5435a67" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_0a9820fe-d301-4065-b744-291fec196c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_0a9820fe-d301-4065-b744-291fec196c79" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_48ed8f08-be08-422a-b89e-c7c0568c5c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_48ed8f08-be08-422a-b89e-c7c0568c5c3b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ThresholdNumberOfTradingDays_b536a1ab-3880-4aa1-932e-a16e9ab64f16" xlink:href="anip-20231231.xsd#anip_ThresholdNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_ThresholdNumberOfTradingDays_b536a1ab-3880-4aa1-932e-a16e9ab64f16" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfConsecutiveTradingDays_137b30d5-f92e-454e-9ecc-f755ad5e7ad1" xlink:href="anip-20231231.xsd#anip_NumberOfConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_NumberOfConsecutiveTradingDays_137b30d5-f92e-454e-9ecc-f755ad5e7ad1" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PercentageOfConversionPrice_a64ce7ee-cd6e-4c78-b456-b661d403b4bc" xlink:href="anip-20231231.xsd#anip_PercentageOfConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_PercentageOfConversionPrice_a64ce7ee-cd6e-4c78-b456-b661d403b4bc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_3ffd5024-1813-453d-b6f2-1442f69a3b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_3ffd5024-1813-453d-b6f2-1442f69a3b85" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7e5c99f1-2a08-4b79-b741-d3da8030c96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7e5c99f1-2a08-4b79-b741-d3da8030c96d" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PreferredStockConvertibleMinimumPeriodOfConversion_a7817aab-8d42-4464-83d5-96910c9acca1" xlink:href="anip-20231231.xsd#anip_PreferredStockConvertibleMinimumPeriodOfConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_PreferredStockConvertibleMinimumPeriodOfConversion_a7817aab-8d42-4464-83d5-96910c9acca1" xlink:type="arc" order="24"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_695f0691-0713-4508-b2bc-51015627c4df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:to="loc_us-gaap_PlanNameDomain_695f0691-0713-4508-b2bc-51015627c4df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:to="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_b95f1af3-cc93-481d-b683-362b31dfff6b" xlink:href="anip-20231231.xsd#anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:to="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_b95f1af3-cc93-481d-b683-362b31dfff6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockIncentivePlanMember_7fdf4dc3-6479-44f1-924d-1f460681c31b" xlink:href="anip-20231231.xsd#anip_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:to="loc_anip_StockIncentivePlanMember_7fdf4dc3-6479-44f1-924d-1f460681c31b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2013687a-f0de-4198-9f7d-89623a262fb5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_2013687a-f0de-4198-9f7d-89623a262fb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeesAndConsultantsMember_4fa79b6a-62d0-4337-acba-a07b204eeea9" xlink:href="anip-20231231.xsd#anip_EmployeesAndConsultantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:to="loc_anip_EmployeesAndConsultantsMember_4fa79b6a-62d0-4337-acba-a07b204eeea9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NonEmployeeDirectorStockOptionMember_6ae4d408-b534-4967-a419-c8b45987046b" xlink:href="anip-20231231.xsd#anip_NonEmployeeDirectorStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:to="loc_anip_NonEmployeeDirectorStockOptionMember_6ae4d408-b534-4967-a419-c8b45987046b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2795148d-591f-4a38-b095-714472f0942f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2795148d-591f-4a38-b095-714472f0942f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2d16207a-21e9-4927-8616-1be7f45e0b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2d16207a-21e9-4927-8616-1be7f45e0b5a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_64a82ac4-b6b6-4a15-a983-aa7e78c50b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_us-gaap_RestrictedStockMember_64a82ac4-b6b6-4a15-a983-aa7e78c50b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PerformanceBasedRestrictedStockUnitsMember_5b4c613e-9527-49be-943b-4f82958ca4ce" xlink:href="anip-20231231.xsd#anip_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_anip_PerformanceBasedRestrictedStockUnitsMember_5b4c613e-9527-49be-943b-4f82958ca4ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember_65e922d0-bf86-4071-aeac-8c306312a01d" xlink:href="anip-20231231.xsd#anip_MarketPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember_65e922d0-bf86-4071-aeac-8c306312a01d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9a8d1321-06c9-4f45-bdb3-b98d48ac26f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_us-gaap_PerformanceSharesMember_9a8d1321-06c9-4f45-bdb3-b98d48ac26f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c5dd6494-fcc2-41d7-8702-584b09085fd5_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:to="loc_srt_RangeMember_c5dd6494-fcc2-41d7-8702-584b09085fd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:to="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3dd146e7-34cb-4d76-a88e-d0e79fb05bb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:to="loc_srt_MinimumMember_3dd146e7-34cb-4d76-a88e-d0e79fb05bb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60535671-9ce5-4b65-8f44-9381e5b40dca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:to="loc_srt_MaximumMember_60535671-9ce5-4b65-8f44-9381e5b40dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a01f83a9-da99-4774-841c-be14fb2a766e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a01f83a9-da99-4774-841c-be14fb2a766e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c87c4143-6cac-4617-bb52-2f301dca0320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c87c4143-6cac-4617-bb52-2f301dca0320" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f80d0b0-8cb0-43cb-8f03-707ed79028c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f80d0b0-8cb0-43cb-8f03-707ed79028c4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f58ffc6e-a9c7-4acb-88d5-b65212455fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f58ffc6e-a9c7-4acb-88d5-b65212455fa7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d02e942c-e2ad-451d-8f86-e798965518b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d02e942c-e2ad-451d-8f86-e798965518b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fa013753-7823-4637-93c9-e0056ee0cc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fa013753-7823-4637-93c9-e0056ee0cc32" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_61d3239a-2176-42ea-a6f0-60b4118824ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_61d3239a-2176-42ea-a6f0-60b4118824ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbbc08e6-dbd2-46b9-8282-5b447409cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbbc08e6-dbd2-46b9-8282-5b447409cf27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130a475c-ee78-4446-967c-effa9eaac1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130a475c-ee78-4446-967c-effa9eaac1fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f38b3825-0585-40b1-88a2-8ff822d3f590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f38b3825-0585-40b1-88a2-8ff822d3f590" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_132f415e-4ef4-40b3-ad71-3a06bbe276be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_132f415e-4ef4-40b3-ad71-3a06bbe276be" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_59d754a9-54ab-4f7b-b4f8-692fcde86169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_59d754a9-54ab-4f7b-b4f8-692fcde86169" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_12b565ab-cdce-412d-b7ba-90567269419c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_12b565ab-cdce-412d-b7ba-90567269419c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ebc5f55a-b1a4-40aa-832b-475479e82707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ebc5f55a-b1a4-40aa-832b-475479e82707" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_448a05ac-ead4-49ed-b4d1-81fa3aac11f7" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_448a05ac-ead4-49ed-b4d1-81fa3aac11f7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_a7fdab3b-d1db-4304-8b86-0351f7eb3a0a" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_a7fdab3b-d1db-4304-8b86-0351f7eb3a0a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_c9d59f2e-e72d-4b4b-b97c-b92c0a8f1b43" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_c9d59f2e-e72d-4b4b-b97c-b92c0a8f1b43" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd66a13-7a5c-4b1b-ae2b-0eddfce6d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd66a13-7a5c-4b1b-ae2b-0eddfce6d44c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_fb9d4d67-79f4-4272-825c-906ade35837e" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_fb9d4d67-79f4-4272-825c-906ade35837e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f384a5b3-917f-407a-b825-6851542c42fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f384a5b3-917f-407a-b825-6851542c42fc" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b0bb67b7-34cb-4cfd-8d31-236f42ca962d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b0bb67b7-34cb-4cfd-8d31-236f42ca962d" xlink:to="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_58436893-6dfb-4a96-a80e-2b3bab0a03d6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_58436893-6dfb-4a96-a80e-2b3bab0a03d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_95369945-e04d-41fc-87ff-15d50dccf35d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_95369945-e04d-41fc-87ff-15d50dccf35d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2c772dbd-b1e0-411c-a22a-1c80f67839aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:to="loc_us-gaap_CostOfSalesMember_2c772dbd-b1e0-411c-a22a-1c80f67839aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4478bc92-29e7-468f-b743-5e659c7207e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4478bc92-29e7-468f-b743-5e659c7207e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:to="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b57146c2-d03e-4a2f-a90c-4de0106b176a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:to="loc_us-gaap_PlanNameDomain_b57146c2-d03e-4a2f-a90c-4de0106b176a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:to="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_cc5ed14b-d590-4354-b6b0-a79d1cbc57e9" xlink:href="anip-20231231.xsd#anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:to="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_cc5ed14b-d590-4354-b6b0-a79d1cbc57e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockIncentivePlanMember_b52b139f-b775-4bfe-a086-899307e5fb7f" xlink:href="anip-20231231.xsd#anip_StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:to="loc_anip_StockIncentivePlanMember_b52b139f-b775-4bfe-a086-899307e5fb7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c7d01146-664f-45e2-9f33-0b5061bf1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b0bb67b7-34cb-4cfd-8d31-236f42ca962d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c7d01146-664f-45e2-9f33-0b5061bf1ac5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONFairvalueoptionsDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:to="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9feff8c3-5203-4353-9b39-8b0c241115b8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9feff8c3-5203-4353-9b39-8b0c241115b8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6420be4d-cd4e-4a02-9081-38ec2c8b95cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6420be4d-cd4e-4a02-9081-38ec2c8b95cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_37b66040-b43e-4c4e-8a25-597ab1f5f879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6420be4d-cd4e-4a02-9081-38ec2c8b95cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_37b66040-b43e-4c4e-8a25-597ab1f5f879" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:to="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db1cd633-7da7-4d2a-bb4a-ec343e585620_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:to="loc_srt_RangeMember_db1cd633-7da7-4d2a-bb4a-ec343e585620_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:to="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6890aca7-0525-4d38-9362-523bf51b8780" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:to="loc_srt_MinimumMember_6890aca7-0525-4d38-9362-523bf51b8780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c472213a-0ed6-46dd-8a40-20b0d2e61bdc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:to="loc_srt_MaximumMember_c472213a-0ed6-46dd-8a40-20b0d2e61bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90ebd01e-bd7e-4b27-bd76-06b1b7bd49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90ebd01e-bd7e-4b27-bd76-06b1b7bd49a1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d973d1c-6ea2-4d24-9d7e-3832e7188f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d973d1c-6ea2-4d24-9d7e-3832e7188f55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5441172-c38b-4c60-8a65-08137813188a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5441172-c38b-4c60-8a65-08137813188a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa5fef67-01da-4fae-a264-1daf29f6a9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa5fef67-01da-4fae-a264-1daf29f6a9f4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONStockoptionactivityDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:to="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35929fb6-229a-40bf-9074-fc3c1322e1fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_35929fb6-229a-40bf-9074-fc3c1322e1fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b21c412-49a7-4836-8b4c-91efa37054a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b21c412-49a7-4836-8b4c-91efa37054a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c8cee4f-522c-44c2-821a-7738e3acb916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b21c412-49a7-4836-8b4c-91efa37054a6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c8cee4f-522c-44c2-821a-7738e3acb916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f57c9e-ce07-4cce-bf63-9069a5d006c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f57c9e-ce07-4cce-bf63-9069a5d006c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98a9eb93-ab87-4b32-be45-38f5125ef8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98a9eb93-ab87-4b32-be45-38f5125ef8d2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8e7b2d7-9d9e-4e92-aa26-9b4003fae291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8e7b2d7-9d9e-4e92-aa26-9b4003fae291" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e67d2ccb-0915-4e02-b58c-9ec3fe8414d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e67d2ccb-0915-4e02-b58c-9ec3fe8414d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e21855a9-1ac1-4d53-b6e9-1be639f62728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e21855a9-1ac1-4d53-b6e9-1be639f62728" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bba05363-31b9-42c4-9620-277704f08176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_777787a5-deeb-4da6-a012-978ce7b25947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_777787a5-deeb-4da6-a012-978ce7b25947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0471fd21-fb86-483b-a61b-f25c5c9fb21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0471fd21-fb86-483b-a61b-f25c5c9fb21e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe6208a2-0d58-46bb-a204-54ef0fe8c741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe6208a2-0d58-46bb-a204-54ef0fe8c741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_58171a21-c75b-4aa2-b0e3-8692f611f01c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_58171a21-c75b-4aa2-b0e3-8692f611f01c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3bf8349-3d13-4dae-bee5-4b585297b2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3bf8349-3d13-4dae-bee5-4b585297b2d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9118bb85-230c-49b2-a285-d84c822b5cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9118bb85-230c-49b2-a285-d84c822b5cb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22811952-63a8-42c0-abc6-a090a1ae1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a40eb7b3-3ae7-487a-aec0-900e7a3a9640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a40eb7b3-3ae7-487a-aec0-900e7a3a9640" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_685d8a73-02f5-4a9d-a3a4-b14f3e581b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_685d8a73-02f5-4a9d-a3a4-b14f3e581b1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_244c10d2-bfab-43f4-8263-fd050711a3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_685d8a73-02f5-4a9d-a3a4-b14f3e581b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_244c10d2-bfab-43f4-8263-fd050711a3ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37060113-c606-4196-9e01-e936ef9913e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37060113-c606-4196-9e01-e936ef9913e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_12286f13-327a-4f86-96ab-73827e497768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_12286f13-327a-4f86-96ab-73827e497768" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e00498a0-97b8-4a76-80eb-ad79006e8094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e00498a0-97b8-4a76-80eb-ad79006e8094" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a5d6f928-5d8a-412b-a3ee-f74ab804ade2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a5d6f928-5d8a-412b-a3ee-f74ab804ade2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_84b3c792-50f5-4959-a448-4c9f4d0c9230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_80d674a6-7b39-4438-9793-20b192519e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_80d674a6-7b39-4438-9793-20b192519e05" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONRSAactivityDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:to="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43a8ce92-3d3e-4e3e-b015-101d6b954590_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_43a8ce92-3d3e-4e3e-b015-101d6b954590_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_256f8aee-ad47-41ba-ab73-71b827249aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_256f8aee-ad47-41ba-ab73-71b827249aed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b410b58e-36bd-40f2-87ae-98964cbb3d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_256f8aee-ad47-41ba-ab73-71b827249aed" xlink:to="loc_us-gaap_RestrictedStockMember_b410b58e-36bd-40f2-87ae-98964cbb3d84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e8c8ac8-3e21-483b-ba67-c80694631acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e8c8ac8-3e21-483b-ba67-c80694631acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_aa94d88d-73ba-491b-89bb-2fa23a2bd36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_aa94d88d-73ba-491b-89bb-2fa23a2bd36b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ebe65d06-0c98-43cc-ab83-e15a9f99dafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ebe65d06-0c98-43cc-ab83-e15a9f99dafe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_613e342e-d9ae-4f05-b2ad-7b7d8e16b1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_613e342e-d9ae-4f05-b2ad-7b7d8e16b1d7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0352f286-e492-4482-a576-7857096787bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef008a0-84cc-4c03-a72a-b2327d82cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef008a0-84cc-4c03-a72a-b2327d82cf40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b4cbcae7-9a85-47bc-9a2d-305d404aaa49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b4cbcae7-9a85-47bc-9a2d-305d404aaa49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c894e660-5bb5-4105-8afe-45d4086ba7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c894e660-5bb5-4105-8afe-45d4086ba7d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c28039cf-3124-4eef-8278-0b26a1d97d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c28039cf-3124-4eef-8278-0b26a1d97d1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8bf4cda-8ccd-4978-9f43-89df8a2e8dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_df41b605-4daa-413f-ac65-28e7d75ec3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_df41b605-4daa-413f-ac65-28e7d75ec3cd" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:to="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95dcbd12-5a86-40dd-8afe-7bc525574ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95dcbd12-5a86-40dd-8afe-7bc525574ce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4e5b41c7-80d2-4029-bc24-3b039c117504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95dcbd12-5a86-40dd-8afe-7bc525574ce4" xlink:to="loc_us-gaap_PerformanceSharesMember_4e5b41c7-80d2-4029-bc24-3b039c117504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e51572c-28b2-49bd-98e8-ccc3ab72ec69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e51572c-28b2-49bd-98e8-ccc3ab72ec69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf1c5381-51c2-41e8-bdc0-878e3bf45cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf1c5381-51c2-41e8-bdc0-878e3bf45cab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a8e912e1-6e7c-4dae-b571-8c827f96cfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a8e912e1-6e7c-4dae-b571-8c827f96cfbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f41ef367-d0c5-4088-b5d2-4c50551a6fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f41ef367-d0c5-4088-b5d2-4c50551a6fc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3eed822a-6251-44f4-b8b7-104a6b5a6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59d61211-335f-4451-9a38-386ef6bd7d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59d61211-335f-4451-9a38-386ef6bd7d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b96c5c0-949f-4fed-adcd-78c9a01b010a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b96c5c0-949f-4fed-adcd-78c9a01b010a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b94c1c16-e963-434c-a08c-bf78dc5d63a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b94c1c16-e963-434c-a08c-bf78dc5d63a6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c183a8f8-99a3-4770-bd66-f201e31ce7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c183a8f8-99a3-4770-bd66-f201e31ce7a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3064bc1-04cf-4325-a992-0eaa04d062a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fffc9d07-d168-43cf-84f6-5beaa88f45bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fffc9d07-d168-43cf-84f6-5beaa88f45bb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1656f082-0ae1-439f-9117-04bfd4e41c71_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1656f082-0ae1-439f-9117-04bfd4e41c71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9091666f-2e43-4737-b94f-428cff5e9deb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9091666f-2e43-4737-b94f-428cff5e9deb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ANICanadaMember_57a67451-2e40-4c7d-8ac5-106f82964f4e" xlink:href="anip-20231231.xsd#anip_ANICanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9091666f-2e43-4737-b94f-428cff5e9deb" xlink:to="loc_anip_ANICanadaMember_57a67451-2e40-4c7d-8ac5-106f82964f4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_acbdddff-328d-49b1-965e-62022e472236_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_acbdddff-328d-49b1-965e-62022e472236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_7725536f-196f-455a-8f87-7cf943a6966d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:to="loc_us-gaap_DomesticCountryMember_7725536f-196f-455a-8f87-7cf943a6966d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d23a141d-fa15-4c62-b6a0-914d4e658ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d23a141d-fa15-4c62-b6a0-914d4e658ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c883eef0-c151-46c3-b079-19f376c7e876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c883eef0-c151-46c3-b079-19f376c7e876" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1fc71c81-74d8-497a-b913-1855b243bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1fc71c81-74d8-497a-b913-1855b243bb97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_ac760646-1383-4283-b4e1-aef28fa078ad" xlink:href="anip-20231231.xsd#anip_OperatingLossCarryforwardsAnnualLimitationsOnUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_ac760646-1383-4283-b4e1-aef28fa078ad" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dd458b64-1738-45c0-95c0-6831332894b1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:to="loc_srt_ProductsAndServicesDomain_dd458b64-1738-45c0-95c0-6831332894b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff124135-0558-4356-87ee-0e6c17166cf2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:to="loc_srt_ProductsAndServicesDomain_ff124135-0558-4356-87ee-0e6c17166cf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_UnapprovedProductsMember_55236fe4-a2d1-4ddb-8005-b4edcf0946b5" xlink:href="anip-20231231.xsd#anip_UnapprovedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff124135-0558-4356-87ee-0e6c17166cf2" xlink:to="loc_anip_UnapprovedProductsMember_55236fe4-a2d1-4ddb-8005-b4edcf0946b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_41e437fe-cdf5-4f96-89bf-28f907c15f7b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:to="loc_srt_NameOfMajorCustomerDomain_41e437fe-cdf5-4f96-89bf-28f907c15f7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_43fefdee-b062-4636-a93a-83170b9cbdb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:to="loc_srt_NameOfMajorCustomerDomain_43fefdee-b062-4636-a93a-83170b9cbdb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ContractCustomerMember_58441aa1-770e-43b1-a9ac-091de3a56389" xlink:href="anip-20231231.xsd#anip_ContractCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_43fefdee-b062-4636-a93a-83170b9cbdb8" xlink:to="loc_anip_ContractCustomerMember_58441aa1-770e-43b1-a9ac-091de3a56389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dc2b618-16f8-4c93-91a4-5caab2b05dbb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0dc2b618-16f8-4c93-91a4-5caab2b05dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AzurityPharmaceuticalsMember_7622bb9a-e49e-4275-8bae-1f4a0d4b6d0d" xlink:href="anip-20231231.xsd#anip_AzurityPharmaceuticalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:to="loc_anip_AzurityPharmaceuticalsMember_7622bb9a-e49e-4275-8bae-1f4a0d4b6d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_35aab8b3-c339-4ac8-a60e-fd84d9b98abd" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:to="loc_anip_NovitiumMember_35aab8b3-c339-4ac8-a60e-fd84d9b98abd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfOperatingLeases_2904874f-a833-4361-90ef-3f9d75b2455e" xlink:href="anip-20231231.xsd#anip_NumberOfOperatingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_NumberOfOperatingLeases_2904874f-a833-4361-90ef-3f9d75b2455e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c838fa72-0b38-430f-9c79-244284fc6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c838fa72-0b38-430f-9c79-244284fc6a87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fe55f63a-57c0-4572-8589-8d5d58d45ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fe55f63a-57c0-4572-8589-8d5d58d45ee4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfProductsMarketed_65dbc61e-0c07-4bba-91f7-964693ba8dd5" xlink:href="anip-20231231.xsd#anip_NumberOfProductsMarketed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_NumberOfProductsMarketed_65dbc61e-0c07-4bba-91f7-964693ba8dd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24aebc1-907f-41c7-b0f0-51b8aff7cda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24aebc1-907f-41c7-b0f0-51b8aff7cda5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_162bedb2-4d1c-46e9-ba48-fbf13d9237af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_162bedb2-4d1c-46e9-ba48-fbf13d9237af" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RoyaltyOnFutureSalesPercent_5141511f-8d7a-48ce-9905-44ed885b7d93" xlink:href="anip-20231231.xsd#anip_RoyaltyOnFutureSalesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_RoyaltyOnFutureSalesPercent_5141511f-8d7a-48ce-9905-44ed885b7d93" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_765eb3cb-bf84-46c5-bdef-fa383776e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_765eb3cb-bf84-46c5-bdef-fa383776e02d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LossContingencyNumberOfManufacturers_10db9a6b-bc3d-46c8-bf88-3b60e3aac1af" xlink:href="anip-20231231.xsd#anip_LossContingencyNumberOfManufacturers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_LossContingencyNumberOfManufacturers_10db9a6b-bc3d-46c8-bf88-3b60e3aac1af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1be2fa40-8198-4fff-ab9c-2fce17b82c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1be2fa40-8198-4fff-ab9c-2fce17b82c8a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_906c67ea-066e-4b71-8ad4-37f99d2a13b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_906c67ea-066e-4b71-8ad4-37f99d2a13b4" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:to="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:to="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2c91ecdb-6765-4673-b88a-f226a6c34a88_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:to="loc_srt_ProductsAndServicesDomain_2c91ecdb-6765-4673-b88a-f226a6c34a88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1b2e8f1-740b-4f29-97b9-ad19ee53efcf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:to="loc_srt_ProductsAndServicesDomain_c1b2e8f1-740b-4f29-97b9-ad19ee53efcf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinGelMember_f56e9f61-9f86-47d7-a7bf-8fed9f57d651" xlink:href="anip-20231231.xsd#anip_CortrophinGelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c1b2e8f1-740b-4f29-97b9-ad19ee53efcf" xlink:to="loc_anip_CortrophinGelMember_f56e9f61-9f86-47d7-a7bf-8fed9f57d651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchCharges_0e150112-0376-4e07-9dbd-b00881e28101" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:to="loc_anip_CortrophinPreLaunchCharges_0e150112-0376-4e07-9dbd-b00881e28101" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e87399df-2740-4cd6-b312-2ed85942d2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e87399df-2740-4cd6-b312-2ed85942d2ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_516ca14d-b513-4f2a-b070-fc5818997431_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:to="loc_us-gaap_ClassOfStockDomain_516ca14d-b513-4f2a-b070-fc5818997431_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dba815a4-fbf1-4f2f-998b-bfe3cf167f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:to="loc_us-gaap_ClassOfStockDomain_dba815a4-fbf1-4f2f-998b-bfe3cf167f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_aab5ab2c-49a4-4658-8300-bcdb08d12a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_dba815a4-fbf1-4f2f-998b-bfe3cf167f7e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_aab5ab2c-49a4-4658-8300-bcdb08d12a8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eba80e94-a728-40ac-95e2-7289b6da6fa3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_eba80e94-a728-40ac-95e2-7289b6da6fa3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6e193c7-cb2d-4303-b282-f7ea102b0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6e193c7-cb2d-4303-b282-f7ea102b0ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember_21172013-99cf-40f1-803f-779f6941f742" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6e193c7-cb2d-4303-b282-f7ea102b0ac8" xlink:to="loc_anip_PrivateInvestmentInPublicEquityMember_21172013-99cf-40f1-803f-779f6941f742" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_ed537ba9-04f8-4223-8584-59852ebe0f42_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:to="loc_us-gaap_RelatedPartyDomain_ed537ba9-04f8-4223-8584-59852ebe0f42_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f8c45788-045d-4619-bdce-30ff10526b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:to="loc_us-gaap_RelatedPartyDomain_f8c45788-045d-4619-bdce-30ff10526b56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3fc91528-3b03-4732-88b9-ee807884c56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_f8c45788-045d-4619-bdce-30ff10526b56" xlink:to="loc_us-gaap_RelatedPartyMember_3fc91528-3b03-4732-88b9-ee807884c56f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_06bf337c-ea50-4032-8ff0-9edd40271aa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_06bf337c-ea50-4032-8ff0-9edd40271aa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScitusPharmaServicesMember_b6aed21b-59e3-478b-82ad-3d50fe970997" xlink:href="anip-20231231.xsd#anip_ScitusPharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:to="loc_anip_ScitusPharmaServicesMember_b6aed21b-59e3-478b-82ad-3d50fe970997" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SsPharmaLlcMember_ab305522-3a29-4962-9010-68be293823f0" xlink:href="anip-20231231.xsd#anip_SsPharmaLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:to="loc_anip_SsPharmaLlcMember_ab305522-3a29-4962-9010-68be293823f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NurayChemicalPrivateLimitedMember_34bee557-8d28-4ceb-b62a-ade2e510514f" xlink:href="anip-20231231.xsd#anip_NurayChemicalPrivateLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:to="loc_anip_NurayChemicalPrivateLimitedMember_34bee557-8d28-4ceb-b62a-ade2e510514f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65752cb6-5040-40bc-a8ec-ea145d0d6f37_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65752cb6-5040-40bc-a8ec-ea145d0d6f37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0706493-4e12-47d9-a703-cfb448b8d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0706493-4e12-47d9-a703-cfb448b8d36c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_0074e3ef-cba6-4ae2-aa69-e972cdc0c50f" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0706493-4e12-47d9-a703-cfb448b8d36c" xlink:to="loc_anip_NovitiumPharmaMember_0074e3ef-cba6-4ae2-aa69-e972cdc0c50f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f217ad2-5325-446d-98a5-abba1d984e10_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4f217ad2-5325-446d-98a5-abba1d984e10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.ShanmugamAndEsjayMember_3106f076-8c02-4aa4-a40b-5144034e5654" xlink:href="anip-20231231.xsd#anip_Mr.ShanmugamAndEsjayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:to="loc_anip_Mr.ShanmugamAndEsjayMember_3106f076-8c02-4aa4-a40b-5144034e5654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ChaliPropertiesLLCMember_ba860901-5a90-4464-8805-303f06fe9d1a" xlink:href="anip-20231231.xsd#anip_ChaliPropertiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:to="loc_anip_ChaliPropertiesLLCMember_ba860901-5a90-4464-8805-303f06fe9d1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_f114c231-c942-45bc-887f-a6ceffc7dd10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_f114c231-c942-45bc-887f-a6ceffc7dd10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0385f37f-306f-45b1-975c-419d4905f1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0385f37f-306f-45b1-975c-419d4905f1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a47dc4d7-ff9a-4230-8ff8-ea28ac3f6887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0385f37f-306f-45b1-975c-419d4905f1bd" xlink:to="loc_us-gaap_SubsequentEventMember_a47dc4d7-ff9a-4230-8ff8-ea28ac3f6887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_35c28d44-9ba9-42c0-81f1-ed8736cc5784" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_35c28d44-9ba9-42c0-81f1-ed8736cc5784" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_b68f881d-c56f-460f-8b53-867acbe621fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_b68f881d-c56f-460f-8b53-867acbe621fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b8d6bb6f-a05c-4852-90b9-a18f04768b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b8d6bb6f-a05c-4852-90b9-a18f04768b8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfExecutiveFounders_24481d1b-a38e-423b-91dc-ca05532aff5b" xlink:href="anip-20231231.xsd#anip_NumberOfExecutiveFounders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_anip_NumberOfExecutiveFounders_24481d1b-a38e-423b-91dc-ca05532aff5b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3e251993-6809-4712-97da-b041952340f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_AccountsPayableCurrent_3e251993-6809-4712-97da-b041952340f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a1a907cc-964c-49d0-993d-ec682dad47c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a1a907cc-964c-49d0-993d-ec682dad47c8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4704d044-b84b-48f6-9319-8f41c8ee2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4704d044-b84b-48f6-9319-8f41c8ee2ba9" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:to="loc_us-gaap_RelatedPartyDomain_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9820d86d-3d55-40e3-9d33-0b8e63c6dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:to="loc_us-gaap_RelatedPartyDomain_9820d86d-3d55-40e3-9d33-0b8e63c6dbe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_a5148569-9e99-46ea-906d-18b6824578d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9820d86d-3d55-40e3-9d33-0b8e63c6dbe2" xlink:to="loc_us-gaap_RelatedPartyMember_a5148569-9e99-46ea-906d-18b6824578d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScitusPharmaServicesMember_17036b67-7230-400c-9c09-d281bea47bff" xlink:href="anip-20231231.xsd#anip_ScitusPharmaServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_ScitusPharmaServicesMember_17036b67-7230-400c-9c09-d281bea47bff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SsPharmaLlcMember_4ee4625a-4beb-430a-b51b-8839efe52fd6" xlink:href="anip-20231231.xsd#anip_SsPharmaLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_SsPharmaLlcMember_4ee4625a-4beb-430a-b51b-8839efe52fd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EsjayPharmaLlcMember_ce6b14de-b64b-407b-a1ad-a4cb3a3ad164" xlink:href="anip-20231231.xsd#anip_EsjayPharmaLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_EsjayPharmaLlcMember_ce6b14de-b64b-407b-a1ad-a4cb3a3ad164" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NurayChemicalPrivateLimitedMember_120b878e-1772-4c37-b55d-fe45d6375236" xlink:href="anip-20231231.xsd#anip_NurayChemicalPrivateLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_NurayChemicalPrivateLimitedMember_120b878e-1772-4c37-b55d-fe45d6375236" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_bc579641-c803-4b63-b21b-e3faca44147b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4704d044-b84b-48f6-9319-8f41c8ee2ba9" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_bc579641-c803-4b63-b21b-e3faca44147b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#SEGMENTREPORTINGRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:to="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7d803db1-fa7e-4d5d-8b5a-e448d2004144_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:to="loc_srt_ConsolidationItemsDomain_7d803db1-fa7e-4d5d-8b5a-e448d2004144_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:to="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d277c1a1-c2f3-4162-a456-24b26d1bad70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:to="loc_us-gaap_OperatingSegmentsMember_d277c1a1-c2f3-4162-a456-24b26d1bad70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_912d4655-5660-4d0f-a7d0-4fdf1df543ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_912d4655-5660-4d0f-a7d0-4fdf1df543ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_149be952-0461-4109-af97-5692cea99ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:to="loc_us-gaap_CorporateNonSegmentMember_149be952-0461-4109-af97-5692cea99ccc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2c8afed6-1e52-444f-9508-29466244bb21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:to="loc_us-gaap_SegmentDomain_2c8afed6-1e52-444f-9508-29466244bb21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:to="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_GenericsEstablishedBrandsAndOtherMember_aeff79f9-635a-43b0-81dd-54a75e99010c" xlink:href="anip-20231231.xsd#anip_GenericsEstablishedBrandsAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:to="loc_anip_GenericsEstablishedBrandsAndOtherMember_aeff79f9-635a-43b0-81dd-54a75e99010c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RareDiseaseMember_0944e8c3-abab-4bac-8748-c3e0175441f5" xlink:href="anip-20231231.xsd#anip_RareDiseaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:to="loc_anip_RareDiseaseMember_0944e8c3-abab-4bac-8748-c3e0175441f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_08b57b60-e367-433d-aee0-d6f7966e7b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_NumberOfReportableSegments_08b57b60-e367-433d-aee0-d6f7966e7b73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a918f70-157a-452f-b34f-0f3d62a80f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a918f70-157a-452f-b34f-0f3d62a80f12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_85ffe79f-526a-4f37-98d0-a44c9089015f" xlink:href="anip-20231231.xsd#anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_85ffe79f-526a-4f37-98d0-a44c9089015f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ef73849f-e0a3-4851-9296-31e139cf795e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_DepreciationAndAmortization_ef73849f-e0a3-4851-9296-31e139cf795e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_462999eb-d777-4602-9301-00c768295b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_462999eb-d777-4602-9301-00c768295b94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_832e4dd1-aa9e-4e1b-9db4-12be7fe2cff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_OperatingIncomeLoss_832e4dd1-aa9e-4e1b-9db4-12be7fe2cff1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_eaf41413-2874-42a1-a9b0-597f8009e470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_eaf41413-2874-42a1-a9b0-597f8009e470" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5ca1fa3f-e211-41d8-b07d-3da25a54d729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5ca1fa3f-e211-41d8-b07d-3da25a54d729" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0128864e-ad9a-46b0-8c60-5c5ce206895b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0128864e-ad9a-46b0-8c60-5c5ce206895b" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#SEGMENTREPORTINGGeographicDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:to="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b870a359-325a-4e39-a161-be8065abd97d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:to="loc_srt_SegmentGeographicalDomain_b870a359-325a-4e39-a161-be8065abd97d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:to="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b6945a79-17c9-4757-992d-5db0e96959a0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:to="loc_country_US_b6945a79-17c9-4757-992d-5db0e96959a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_43861144-2c69-472a-806d-159e59261d62" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:to="loc_country_CA_43861144-2c69-472a-806d-159e59261d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_f3e8b14d-a2f7-4199-b7a9-c5fa23624c7c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:to="loc_country_IN_f3e8b14d-a2f7-4199-b7a9-c5fa23624c7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8beae22-24ee-4571-8bd1-90d67617664d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8beae22-24ee-4571-8bd1-90d67617664d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd244e6-d90d-4437-ad6f-d23ef1ed5192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd244e6-d90d-4437-ad6f-d23ef1ed5192" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_59a3e42b-a917-41e8-9990-9eaf8e1a324d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_59a3e42b-a917-41e8-9990-9eaf8e1a324d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e77ad9e7-118b-4331-b854-a28142475b02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e77ad9e7-118b-4331-b854-a28142475b02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ac613c-6e08-4f66-817d-e1fa6a265089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ac613c-6e08-4f66-817d-e1fa6a265089" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_02b435bc-5646-4938-a248-7eaae591a631" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ac613c-6e08-4f66-817d-e1fa6a265089" xlink:to="loc_anip_NovitiumPharmaMember_02b435bc-5646-4938-a248-7eaae591a631" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9cdd22a6-647f-4ece-bb26-ae6277fdab19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9cdd22a6-647f-4ece-bb26-ae6277fdab19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c70d7314-eee7-44a6-a58a-7ee4244c23ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c70d7314-eee7-44a6-a58a-7ee4244c23ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9397f26d-fe84-4238-877d-2924edcda050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c70d7314-eee7-44a6-a58a-7ee4244c23ab" xlink:to="loc_us-gaap_SubsequentEventMember_9397f26d-fe84-4238-877d-2924edcda050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7fddd38-a67e-466a-bd6c-524aeabe1239_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f7fddd38-a67e-466a-bd6c-524aeabe1239_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5fb915b3-978b-4ae0-ab6b-b846c0d39cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:to="loc_us-gaap_RestrictedStockMember_5fb915b3-978b-4ae0-ab6b-b846c0d39cf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b1cd829d-8241-49c2-8a55-8ef1cdec0526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:to="loc_us-gaap_PerformanceSharesMember_b1cd829d-8241-49c2-8a55-8ef1cdec0526" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62aafed2-826e-469e-977a-3aadd760f86f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_62aafed2-826e-469e-977a-3aadd760f86f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_3d4ca501-baab-4d38-8e15-43ab9a5d55df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:to="loc_srt_OfficerMember_3d4ca501-baab-4d38-8e15-43ab9a5d55df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NewEmployeesMember_5a975d99-15e6-4b5e-ad58-1230aae8aa7e" xlink:href="anip-20231231.xsd#anip_NewEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:to="loc_anip_NewEmployeesMember_5a975d99-15e6-4b5e-ad58-1230aae8aa7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bc6b7221-0e6b-4166-96a9-787339b8c6a2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_bc6b7221-0e6b-4166-96a9-787339b8c6a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a13663f-3822-4a5e-afdf-3155ac726a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a13663f-3822-4a5e-afdf-3155ac726a2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_b3e492bc-a070-4196-aa05-5016d0461ac6" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a13663f-3822-4a5e-afdf-3155ac726a2c" xlink:to="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_b3e492bc-a070-4196-aa05-5016d0461ac6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_bf3c07fb-606f-4f31-b3a2-768b79825a16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_bf3c07fb-606f-4f31-b3a2-768b79825a16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9d14f3c3-f214-46e4-a4b7-cd4a36c80915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9d14f3c3-f214-46e4-a4b7-cd4a36c80915" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f2f1a989-8d43-4d9a-9f5b-4cec113bf1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9d14f3c3-f214-46e4-a4b7-cd4a36c80915" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f2f1a989-8d43-4d9a-9f5b-4cec113bf1d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:to="loc_dei_EntityDomain_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5b600be5-46ad-47f8-a2dd-3aefd5cbc288" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:to="loc_dei_EntityDomain_5b600be5-46ad-47f8-a2dd-3aefd5cbc288" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CGOncologyInc.Member_8fafe551-14e3-40cb-b1ae-22fc0c3de24c" xlink:href="anip-20231231.xsd#anip_CGOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5b600be5-46ad-47f8-a2dd-3aefd5cbc288" xlink:to="loc_anip_CGOncologyInc.Member_8fafe551-14e3-40cb-b1ae-22fc0c3de24c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec704027-318d-4f65-8440-ca2112052d4c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_ec704027-318d-4f65-8440-ca2112052d4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d73ceef5-9ed5-492c-9fdb-12592c09ee78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d73ceef5-9ed5-492c-9fdb-12592c09ee78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c773c100-2dea-4b29-a67d-f93f24b26a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d73ceef5-9ed5-492c-9fdb-12592c09ee78" xlink:to="loc_us-gaap_IPOMember_c773c100-2dea-4b29-a67d-f93f24b26a29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8b4ede72-1bff-48f5-9cb1-7210be933046_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8b4ede72-1bff-48f5-9cb1-7210be933046_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_21ee9223-e4e5-4917-9707-dfc54d797940" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_21ee9223-e4e5-4917-9707-dfc54d797940" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CGOncologyInc.Member_a7b7c219-1a0d-48b2-95c7-6632c40745c7" xlink:href="anip-20231231.xsd#anip_CGOncologyInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_21ee9223-e4e5-4917-9707-dfc54d797940" xlink:to="loc_anip_CGOncologyInc.Member_a7b7c219-1a0d-48b2-95c7-6632c40745c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5f77a58c-7cc5-4719-a27b-f751e874e8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5f77a58c-7cc5-4719-a27b-f751e874e8d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e9b0ab1-f6c0-49c9-8bb4-3f8c85d6d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e9b0ab1-f6c0-49c9-8bb4-3f8c85d6d33e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5bab5c72-b770-4714-bcb2-a1662bb798c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5bab5c72-b770-4714-bcb2-a1662bb798c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_29929f2c-342f-4a8d-a2a1-337ef6c88ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_29929f2c-342f-4a8d-a2a1-337ef6c88ec0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_542f2ce1-bda7-44a2-ac3e-b43c6a469d37" xlink:href="anip-20231231.xsd#anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_542f2ce1-bda7-44a2-ac3e-b43c6a469d37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ec87d168-bcd3-4f7c-a65f-a60405ee9900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ec87d168-bcd3-4f7c-a65f-a60405ee9900" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_d247c6f2-32b5-46c4-a2b5-703e0878d8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_d247c6f2-32b5-46c4-a2b5-703e0878d8bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_d0d289c8-36d7-46b3-831c-f88eda2ed581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_d0d289c8-36d7-46b3-831c-f88eda2ed581" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2b88a143-29d7-4a52-b2d0-daa50e8f694a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2b88a143-29d7-4a52-b2d0-daa50e8f694a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_ad44a11f-1aba-462b-8121-614b27f3586b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_ad44a11f-1aba-462b-8121-614b27f3586b" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PerformanceBasedRestrictedStockUnitsMember_00b6c505-2721-4c95-b58d-bc5a94031c7d" xlink:href="anip-20231231.xsd#anip_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_anip_PerformanceBasedRestrictedStockUnitsMember_00b6c505-2721-4c95-b58d-bc5a94031c7d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember_5657d8f6-aba8-48e1-9250-cf4f303e7494" xlink:href="anip-20231231.xsd#anip_MarketPerformanceBasedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember_5657d8f6-aba8-48e1-9250-cf4f303e7494" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.MuthusamyShanmugamMember_a538a6c9-0cd7-418f-86ee-24596bf8151c" xlink:href="anip-20231231.xsd#anip_Mr.MuthusamyShanmugamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_anip_Mr.MuthusamyShanmugamMember_a538a6c9-0cd7-418f-86ee-24596bf8151c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.ChadGassertMember_c639d630-af8d-4344-bfb2-1318e4445fad" xlink:href="anip-20231231.xsd#anip_Mr.ChadGassertMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_anip_Mr.ChadGassertMember_c639d630-af8d-4344-bfb2-1318e4445fad" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>anip-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d1b0d374-59d3-494d-ab57-0327414dd086,g:e2d69e39-7080-477b-8655-fce353fd237f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_d653245c-ddba-4681-95d0-131cf69bd1f4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_5802d839-c290-44bc-ab52-60f7a0a1e21b_verboseLabel_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Term (years)</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_dcbb8c5d-d5f4-47f6-a9e1-58f474c2fdaa_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d9cd6a23-4752-4387-acfd-2adc9729e28e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_376facda-22de-48a9-abb8-2f412c455ee8_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_2ed7d99c-2db0-4c16-b5e9-7377254358a0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisition (2021):</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_acb4cb39-bd23-4d07-a964-87a2f892c703_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PercentageOfConversionPrice_20068d87-36ac-4db4-b9fe-8d969c84576d_terseLabel_en-US" xlink:label="lab_anip_PercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage of conversion price</link:label>
    <link:label id="lab_anip_PercentageOfConversionPrice_label_en-US" xlink:label="lab_anip_PercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Conversion Price</link:label>
    <link:label id="lab_anip_PercentageOfConversionPrice_documentation_en-US" xlink:label="lab_anip_PercentageOfConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of conversion price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PercentageOfConversionPrice" xlink:href="anip-20231231.xsd#anip_PercentageOfConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PercentageOfConversionPrice" xlink:to="lab_anip_PercentageOfConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c29aa215-49a8-48b8-982d-282499159bcc_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2f127283-c042-47d8-be95-d5eab8f5bf1d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_110f51fe-3a69-4ee2-8317-a7e20a502020_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CranfordPharmaceuticalsMember_c3f9b5cd-5754-44f8-82fd-7096ed324567_terseLabel_en-US" xlink:label="lab_anip_CranfordPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cranford Pharmaceuticals</link:label>
    <link:label id="lab_anip_CranfordPharmaceuticalsMember_label_en-US" xlink:label="lab_anip_CranfordPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cranford Pharmaceuticals</link:label>
    <link:label id="lab_anip_CranfordPharmaceuticalsMember_documentation_en-US" xlink:label="lab_anip_CranfordPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cranford Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CranfordPharmaceuticalsMember" xlink:href="anip-20231231.xsd#anip_CranfordPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CranfordPharmaceuticalsMember" xlink:to="lab_anip_CranfordPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_a5542427-fff8-4977-836a-1f6c54bbcbe2_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration, cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_1e1c4be6-e06f-4307-adb2-5eed8b1774f7_terseLabel_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:label id="lab_us-gaap_FederalIncomeTaxNoteTable_label_en-US" xlink:label="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Income Tax Note [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable" xlink:to="lab_us-gaap_FederalIncomeTaxNoteTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_13ef08ed-f69c-4881-b3d3-61aac6753d0d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_3b5effbb-1cbd-4b3d-8ea5-89ea4bdbfd5a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_3de2fbb2-212c-4a57-8d3c-de4000a36d45_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_f6ef89bf-73ac-4d01-a9ee-0fa1f6954ee1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_cb408fc2-3e05-4eb2-8ab1-7ab4fb1a846b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_6ad3c997-bd2c-40c6-8413-16a42bbd9012_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e78a58d2-5df3-4964-9ff5-568e24819328_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_9848255e-5e59-46cf-88d8-beac13377c35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7dfa266b-4b10-4c26-a9db-551de3204348_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_7f3ce291-6df6-4fb6-b271-2466f462909e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ca8266e6-2c41-4b6f-9654-feb80391528d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_79ef59fb-3e0b-4584-9b29-1897a73207ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_1588b357-6f32-452f-a1b7-b195397ebd52_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_d7225458-8848-4fda-8dc9-b5b5a6a7032d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_8e9bd884-e7cf-4c9d-bee8-5e521d3ff7f9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, noncurrent</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ae1e0865-238c-415e-ab84-398f7b8a8cb8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_dd3b385c-c322-4c08-9975-7c494ffd4f82_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss related to property and equipment recognized</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_eb214d6d-f6ee-4f23-911c-3cb42d84017b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Income (Loss) Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_aeb64e81-716c-4312-9212-00ec747d1777_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e70eb378-24cf-4ab9-8d57-3d7fcbca7ed5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net of $97,262 and $161,052 of adjustments for chargebacks and other allowances at December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_5ca02c44-5479-4aa5-9a2e-2720feca34c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications out of accumulated other comprehensive income/loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_Mr.ChadGassertMember_label_en-US" xlink:label="lab_anip_Mr.ChadGassertMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Chad Gassert [Member]</link:label>
    <link:label id="lab_anip_Mr.ChadGassertMember_documentation_en-US" xlink:label="lab_anip_Mr.ChadGassertMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Chad Gassert</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.ChadGassertMember" xlink:href="anip-20231231.xsd#anip_Mr.ChadGassertMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_Mr.ChadGassertMember" xlink:to="lab_anip_Mr.ChadGassertMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_7f21e3f7-2889-47b6-b6ec-438265c852f8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_0ae5596d-4750-4ad9-98da-5c9847d31829_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PrepaidIncomeTaxesNet_125665e2-c457-4ba1-999b-f728cb4904d0_terseLabel_en-US" xlink:label="lab_anip_PrepaidIncomeTaxesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_anip_PrepaidIncomeTaxesNet_label_en-US" xlink:label="lab_anip_PrepaidIncomeTaxesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Income Taxes, Net</link:label>
    <link:label id="lab_anip_PrepaidIncomeTaxesNet_documentation_en-US" xlink:label="lab_anip_PrepaidIncomeTaxesNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrepaidIncomeTaxesNet" xlink:href="anip-20231231.xsd#anip_PrepaidIncomeTaxesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PrepaidIncomeTaxesNet" xlink:to="lab_anip_PrepaidIncomeTaxesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_28cfce55-b0b7-492a-89d7-b17e2bac1de4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_4e1d7715-c95d-4c29-9d3c-700304905f00_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_f9b3bd55-8528-4961-82c9-6d8d28cae422_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0b98595c-9eaa-4870-98ac-3d6ede9116b2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_a3380472-747c-47c9-a999-764bc495bb7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_94712527-7e68-46ce-ba44-549367530f12_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5f97bd21-b219-4bc7-85c2-c3d481047beb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_56e77880-7f85-4a74-b3c3-4a001f494417_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7f80f786-6302-4d97-b2c1-27f185997b1d_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery, furniture, and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_367a8396-32a6-48f1-865a-c4da168456ee_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ClassCSpecialStockMember_02a2b9a6-517d-4695-88a1-fae1630e73b6_terseLabel_en-US" xlink:label="lab_anip_ClassCSpecialStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class C Special Stock</link:label>
    <link:label id="lab_anip_ClassCSpecialStockMember_label_en-US" xlink:label="lab_anip_ClassCSpecialStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class C Special Stock</link:label>
    <link:label id="lab_anip_ClassCSpecialStockMember_documentation_en-US" xlink:label="lab_anip_ClassCSpecialStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class C Special Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ClassCSpecialStockMember" xlink:to="lab_anip_ClassCSpecialStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ThresholdNumberOfTradingDays_19dd3c1e-2ca6-4e32-ac3f-7868c55f6fda_terseLabel_en-US" xlink:label="lab_anip_ThresholdNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold number of trading days</link:label>
    <link:label id="lab_anip_ThresholdNumberOfTradingDays_label_en-US" xlink:label="lab_anip_ThresholdNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Number of Trading Days</link:label>
    <link:label id="lab_anip_ThresholdNumberOfTradingDays_documentation_en-US" xlink:label="lab_anip_ThresholdNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold number of trading days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ThresholdNumberOfTradingDays" xlink:href="anip-20231231.xsd#anip_ThresholdNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ThresholdNumberOfTradingDays" xlink:to="lab_anip_ThresholdNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_69b83921-49f4-4dc0-ae9e-51ec3f5f172f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_3b806f1c-032a-4b23-bd7b-dfe85ebe8eba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1ad7eece-289b-4c03-8871-33c497528d0b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_62e542fa-eb44-4698-b8cd-41ff688134b5_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_42804b4a-759a-4e20-b0a6-582a45892fd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_de153fd9-e0cd-4d5d-9c4e-4873e4271bdd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_30a4ba29-bffb-4a8e-8cc7-6b9d9ba4e6dc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6e70920a-f0b6-4296-9de1-7f9028fe2678_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation shares available</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5b02fb63-1a41-4662-a8b6-3b031a758424_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0dcab26c-ab6f-468d-912d-9a3e4fd224f6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_07c8ae2a-ac5c-496a-ace8-d290e46423e7_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_92f0b11a-7c72-4ffd-a131-f583e306e6a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_58bba561-a3d5-46ab-839f-c7fbccdd9732_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_FDICGuaranteedAmount_8353a754-3334-4d68-923d-fde3f569d7c0_terseLabel_en-US" xlink:label="lab_anip_FDICGuaranteedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDIC guaranteed amount</link:label>
    <link:label id="lab_anip_FDICGuaranteedAmount_label_en-US" xlink:label="lab_anip_FDICGuaranteedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FDIC Guaranteed Amount</link:label>
    <link:label id="lab_anip_FDICGuaranteedAmount_documentation_en-US" xlink:label="lab_anip_FDICGuaranteedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the total amount of interest bearing and non-interest bearing accounts insured by the FDIC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FDICGuaranteedAmount" xlink:href="anip-20231231.xsd#anip_FDICGuaranteedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_FDICGuaranteedAmount" xlink:to="lab_anip_FDICGuaranteedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c1ee2372-7dfb-46e1-8d39-55e8e5a296b9_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_55fce832-c4a6-499c-888f-efa083728de4_terseLabel_en-US" xlink:label="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBITDA</link:label>
    <link:label id="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_label_en-US" xlink:label="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings/(loss) before interest, taxes, depreciation and amortization</link:label>
    <link:label id="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_documentation_en-US" xlink:label="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents earnings/(loss) before interest, taxes, depreciation and amortization (EBITDA).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" xlink:href="anip-20231231.xsd#anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" xlink:to="lab_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NumberOfIntangibleAssetsAcquired_98321c0e-33b5-4b6b-be4c-499b4d04195d_terseLabel_en-US" xlink:label="lab_anip_NumberOfIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of intangible assets acquired</link:label>
    <link:label id="lab_anip_NumberOfIntangibleAssetsAcquired_label_en-US" xlink:label="lab_anip_NumberOfIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Intangible Assets Acquired</link:label>
    <link:label id="lab_anip_NumberOfIntangibleAssetsAcquired_documentation_en-US" xlink:label="lab_anip_NumberOfIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfIntangibleAssetsAcquired" xlink:href="anip-20231231.xsd#anip_NumberOfIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NumberOfIntangibleAssetsAcquired" xlink:to="lab_anip_NumberOfIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_8aab464a-3eb6-477d-985b-f3081d499320_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_67f52506-6e3f-4928-ab18-b5bb91de901d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income taxes payable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_9223a4d6-2a6b-4e79-95d3-5cb2818c28bf_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, cost</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsDiluted_d63e49ab-7b3e-48f5-aae5-9a5308729066_totalLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available to common shareholders, Diluted</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsDiluted" xlink:to="lab_us-gaap_UndistributedEarningsDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_b9733efa-08ef-4dbd-b31b-7302743aff36_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AkornHoldingCompanyPipelineProductMember_56a70d05-d101-40df-bfc3-36076c33672b_terseLabel_en-US" xlink:label="lab_anip_AkornHoldingCompanyPipelineProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akorn Holding Company, Pipeline Product</link:label>
    <link:label id="lab_anip_AkornHoldingCompanyPipelineProductMember_label_en-US" xlink:label="lab_anip_AkornHoldingCompanyPipelineProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akorn Holding Company, Pipeline Product [Member]</link:label>
    <link:label id="lab_anip_AkornHoldingCompanyPipelineProductMember_documentation_en-US" xlink:label="lab_anip_AkornHoldingCompanyPipelineProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Akorn Holding Company, Pipeline Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AkornHoldingCompanyPipelineProductMember" xlink:href="anip-20231231.xsd#anip_AkornHoldingCompanyPipelineProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AkornHoldingCompanyPipelineProductMember" xlink:to="lab_anip_AkornHoldingCompanyPipelineProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_f407e8ba-b9b6-4b88-95b1-00fa10eca09f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_ee97d09a-0a70-4e09-bd6a-be3c0bf580a1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of carrying value of the current and non-current components of the term loan</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AzurityPharmaceuticalsMember_b7a66d2b-00cc-49b7-b276-dc1bcd7b149b_terseLabel_en-US" xlink:label="lab_anip_AzurityPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Azurity Pharmaceuticals</link:label>
    <link:label id="lab_anip_AzurityPharmaceuticalsMember_label_en-US" xlink:label="lab_anip_AzurityPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Azurity Pharmaceuticals</link:label>
    <link:label id="lab_anip_AzurityPharmaceuticalsMember_documentation_en-US" xlink:label="lab_anip_AzurityPharmaceuticalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information related to Azurity Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AzurityPharmaceuticalsMember" xlink:href="anip-20231231.xsd#anip_AzurityPharmaceuticalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AzurityPharmaceuticalsMember" xlink:to="lab_anip_AzurityPharmaceuticalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b87381cb-7a71-458a-bfdf-7a80e7786301_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f33313e1-18ba-4f96-b87d-488c91423dd3_totalLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_77e0a094-61d0-4d60-a132-ed1a84fd5116_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_3eaee17b-482c-4c78-b7a2-5956ffcc92d0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring accrual</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_71ead130-4007-498f-849a-97f1ccfe82f7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_477ee220-a461-435a-86e1-b8283cbdf726_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_0a94fdbc-88ad-4e09-a7f0-26012ddae864_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e07fc1c1-9bd3-4f49-8d22-495eac43da41_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2aae123f-960a-411a-b5ae-eb3ea1c38c28_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2db03a37-2184-428b-ae48-b147ba258852_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_a1f41cdb-2cda-4550-be1f-4ea734af9277_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_c33147bf-ea3c-40a2-8298-5b395c525506_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_fb1d65ad-1db9-49f3-a1ee-39aa8a57e4ff_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_85171dec-5d06-471e-b9f4-58cb5c9a87f8_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ClassCSpecialStockValue_c4b1fc9e-d074-4a68-910b-a9641538209c_verboseLabel_en-US" xlink:label="lab_anip_ClassCSpecialStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December&#160;31, 2023 and 2022 respectively</link:label>
    <link:label id="lab_anip_ClassCSpecialStockValue_label_en-US" xlink:label="lab_anip_ClassCSpecialStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class C Special Stock Value</link:label>
    <link:label id="lab_anip_ClassCSpecialStockValue_documentation_en-US" xlink:label="lab_anip_ClassCSpecialStockValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockValue" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ClassCSpecialStockValue" xlink:to="lab_anip_ClassCSpecialStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_21ba5560-1402-4f8a-ad0e-6c09526d9b90_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_27110782-c243-4e2a-a6cd-02aeed2f785d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effects of discounting</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_631d5c3f-4bbd-4137-8e21-9c766506477c_terseLabel_en-US" xlink:label="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First purchase price deposit</link:label>
    <link:label id="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_label_en-US" xlink:label="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, First Deposit</link:label>
    <link:label id="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_documentation_en-US" xlink:label="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, First Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" xlink:href="anip-20231231.xsd#anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" xlink:to="lab_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_435a2370-c907-4cda-8e00-d983e79c385b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NovitiumMember_9929cf74-86c2-4dc7-9f22-ef496f88b3f9_terseLabel_en-US" xlink:label="lab_anip_NovitiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novitium</link:label>
    <link:label id="lab_anip_NovitiumMember_label_en-US" xlink:label="lab_anip_NovitiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novitium [Member]</link:label>
    <link:label id="lab_anip_NovitiumMember_documentation_en-US" xlink:label="lab_anip_NovitiumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novitium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NovitiumMember" xlink:to="lab_anip_NovitiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8c113aa7-5b80-4c7a-91a6-a4934e9bdef7_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current lease liability, included in accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_2dc714fd-7f40-4154-a8cc-40b45cd7d383_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_RoyaltyOnFutureSalesPercent_fdf130b7-be62-42ef-ad71-da6291158159_terseLabel_en-US" xlink:label="lab_anip_RoyaltyOnFutureSalesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties on future sales (as a percent)</link:label>
    <link:label id="lab_anip_RoyaltyOnFutureSalesPercent_label_en-US" xlink:label="lab_anip_RoyaltyOnFutureSalesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty on Future Sales, Percent</link:label>
    <link:label id="lab_anip_RoyaltyOnFutureSalesPercent_documentation_en-US" xlink:label="lab_anip_RoyaltyOnFutureSalesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties on future sales as a percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RoyaltyOnFutureSalesPercent" xlink:href="anip-20231231.xsd#anip_RoyaltyOnFutureSalesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_RoyaltyOnFutureSalesPercent" xlink:to="lab_anip_RoyaltyOnFutureSalesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4181827e-fd36-4c83-a661-2d4f48e5d2d8_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_b4596a5d-9324-4d0a-a779-063bf62bd081_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_56e1fdf1-b301-482e-a05e-794b0515b8d8_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_08e7edfc-e18b-42dc-b3f6-0bd1f2c2d379_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_615dcb4f-bdd4-4bb2-9f7d-f3a268299398_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_1f4f34bf-e9fa-4b48-8ad4-eb8fd21372bb_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9e560ccc-1908-46bb-8020-b7ea026c20e4_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_45da0457-19de-4f98-ae54-28d930d3222f_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_b4ec9e90-306d-41e8-8c37-ef6ab688b59f_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings allocated to participating securities, Diluted</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_e4d6bd59-689a-4ea4-9aa2-10c5d867acaf_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_8fec5e75-eddc-4880-82e8-055fb9eef340_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_72524ca5-a4e1-4e02-bf43-c1ebf9328a8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_effe5c87-5597-401b-bb91-f28868dd599c_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_14e09593-ba7b-44d2-a047-c42afdd549fb_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SalesOfGenericPharmaceuticalProductsMember_72498081-3db3-4cfd-8c8c-ff1a44de7aaa_terseLabel_en-US" xlink:label="lab_anip_SalesOfGenericPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of generic pharmaceutical products</link:label>
    <link:label id="lab_anip_SalesOfGenericPharmaceuticalProductsMember_label_en-US" xlink:label="lab_anip_SalesOfGenericPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of generic pharmaceutical products</link:label>
    <link:label id="lab_anip_SalesOfGenericPharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_anip_SalesOfGenericPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of generic pharmaceutical products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfGenericPharmaceuticalProductsMember" xlink:href="anip-20231231.xsd#anip_SalesOfGenericPharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SalesOfGenericPharmaceuticalProductsMember" xlink:to="lab_anip_SalesOfGenericPharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a53ad97d-fdc0-42ef-803d-181ead4b7ab2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_06bfeb94-0cd0-4a87-aab7-217c882c1030_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_9ab20a85-ed79-473c-be97-1455cabbffbb_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate and other unallocated expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_79ac6bca-ae5c-4a6c-ac88-fb2ad418c043_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_55c03f3f-4a50-4353-8668-4945e0a897ac_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss, net of tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_fb399a2e-34a5-4cb3-86c5-bbac9fdd4d6d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_83dde933-d4c7-430c-94e7-a9b9c64bf441_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_78a96333-3ecc-4480-9bc5-278cb1dfb9b8_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps, liability</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredApprovedProductMember_22560ca0-1757-4e0a-82c7-4aac583c4851_terseLabel_en-US" xlink:label="lab_anip_AcquiredApprovedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired approved product</link:label>
    <link:label id="lab_anip_AcquiredApprovedProductMember_label_en-US" xlink:label="lab_anip_AcquiredApprovedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Approved Product [Member]</link:label>
    <link:label id="lab_anip_AcquiredApprovedProductMember_documentation_en-US" xlink:label="lab_anip_AcquiredApprovedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Approved Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredApprovedProductMember" xlink:href="anip-20231231.xsd#anip_AcquiredApprovedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredApprovedProductMember" xlink:to="lab_anip_AcquiredApprovedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_22d99e0e-dae0-4bd2-a0a1-bdab0ffaf1eb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Operating Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_EmployeesAndConsultantsMember_02cde5be-daec-4b74-ab1f-de7c173640a5_terseLabel_en-US" xlink:label="lab_anip_EmployeesAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Consultants</link:label>
    <link:label id="lab_anip_EmployeesAndConsultantsMember_label_en-US" xlink:label="lab_anip_EmployeesAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees and Consultants [Member]</link:label>
    <link:label id="lab_anip_EmployeesAndConsultantsMember_documentation_en-US" xlink:label="lab_anip_EmployeesAndConsultantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to employees and consultants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeesAndConsultantsMember" xlink:href="anip-20231231.xsd#anip_EmployeesAndConsultantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_EmployeesAndConsultantsMember" xlink:to="lab_anip_EmployeesAndConsultantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_0f81bf23-9275-4c37-9da0-455ecce78496_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_9c65a0b9-a49c-49f7-bf66-98f73627f705_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0bf9ffb5-9353-4ba3-8fcb-be7bcb44ce1b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_3c382d91-f8d6-4f26-81f0-9fecd793e7ae_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_13153804-47e1-4143-8a79-23fbcd37861c_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NumberOfPharmaceuticalManufacturingFacilities_53c4b855-3234-4120-a224-0ac43bf30093_terseLabel_en-US" xlink:label="lab_anip_NumberOfPharmaceuticalManufacturingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pharmaceutical manufacturing facilities</link:label>
    <link:label id="lab_anip_NumberOfPharmaceuticalManufacturingFacilities_label_en-US" xlink:label="lab_anip_NumberOfPharmaceuticalManufacturingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Pharmaceutical Manufacturing Facilities</link:label>
    <link:label id="lab_anip_NumberOfPharmaceuticalManufacturingFacilities_documentation_en-US" xlink:label="lab_anip_NumberOfPharmaceuticalManufacturingFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Pharmaceutical Manufacturing Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfPharmaceuticalManufacturingFacilities" xlink:href="anip-20231231.xsd#anip_NumberOfPharmaceuticalManufacturingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NumberOfPharmaceuticalManufacturingFacilities" xlink:to="lab_anip_NumberOfPharmaceuticalManufacturingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_WellSpringPharmaServicesIncMember_d7055c74-b392-4e35-a825-936750026bdf_terseLabel_en-US" xlink:label="lab_anip_WellSpringPharmaServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WellSpring</link:label>
    <link:label id="lab_anip_WellSpringPharmaServicesIncMember_label_en-US" xlink:label="lab_anip_WellSpringPharmaServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WellSpring</link:label>
    <link:label id="lab_anip_WellSpringPharmaServicesIncMember_documentation_en-US" xlink:label="lab_anip_WellSpringPharmaServicesIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WellSpring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_WellSpringPharmaServicesIncMember" xlink:href="anip-20231231.xsd#anip_WellSpringPharmaServicesIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_WellSpringPharmaServicesIncMember" xlink:to="lab_anip_WellSpringPharmaServicesIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_e16af8ba-eba6-4036-8a0b-77493c3aa683_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Purchases for Restricted Stock Vests</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_41583b67-c4c0-4774-a167-b478c3297d9c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_f6690e28-98c9-4438-a27f-9397c92516e5_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (excluding depreciation and amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d8e54874-ca53-4460-928f-b3aaab2e67c0_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_6b1e5626-eebd-4863-9cee-021ebea952c3_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f411798e-de6e-431a-9367-a7e17b385da6_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_796259f0-1a41-4c7c-94af-45085790e83b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_324bbf2f-610b-4108-b24d-4bcf835f461b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_3ac6a411-80a2-4548-8855-6ae9ae9c2a31_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_391c56c8-b525-4fd4-9885-17971cdec36a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_8424450e-b6cf-48f9-aa6a-505c6bb1b29b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_5c2df1be-5ebe-4fff-bc0b-11d0d334ad01_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ReturnedGoodsReserve_2ca2e1cb-4d07-4298-99ce-516e7f53155c_verboseLabel_en-US" xlink:label="lab_anip_ReturnedGoodsReserve" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returned goods reserve</link:label>
    <link:label id="lab_anip_ReturnedGoodsReserve_label_en-US" xlink:label="lab_anip_ReturnedGoodsReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returned Goods Reserve</link:label>
    <link:label id="lab_anip_ReturnedGoodsReserve_documentation_en-US" xlink:label="lab_anip_ReturnedGoodsReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the reserve for goods returned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReturnedGoodsReserve" xlink:href="anip-20231231.xsd#anip_ReturnedGoodsReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ReturnedGoodsReserve" xlink:to="lab_anip_ReturnedGoodsReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1ef8f8f8-1e68-4628-8099-2f689395e188_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_b9b9f5e7-cc26-4c8e-870c-06ea701bada6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_d3205c61-d28f-4e78-952a-58b935349d23_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9610e48f-9469-4cfe-af0f-c60d5e870c52_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_29dc16da-c45f-42be-88a9-1d0ad8d57fba_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS COMBINATION</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NonCompeteAgreementMember_c71a1aa2-f85e-4857-b772-6621a6e8ec97_terseLabel_en-US" xlink:label="lab_anip_NonCompeteAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreement</link:label>
    <link:label id="lab_anip_NonCompeteAgreementMember_label_en-US" xlink:label="lab_anip_NonCompeteAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreement</link:label>
    <link:label id="lab_anip_NonCompeteAgreementMember_documentation_en-US" xlink:label="lab_anip_NonCompeteAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-compete agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NonCompeteAgreementMember" xlink:href="anip-20231231.xsd#anip_NonCompeteAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NonCompeteAgreementMember" xlink:to="lab_anip_NonCompeteAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_98a4cd4d-be78-4bd1-8571-076a98ef0001_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_Mr.MuthusamyShanmugamMember_label_en-US" xlink:label="lab_anip_Mr.MuthusamyShanmugamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Muthusamy Shanmugam [Member]</link:label>
    <link:label id="lab_anip_Mr.MuthusamyShanmugamMember_documentation_en-US" xlink:label="lab_anip_Mr.MuthusamyShanmugamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Muthusamy Shanmugam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.MuthusamyShanmugamMember" xlink:href="anip-20231231.xsd#anip_Mr.MuthusamyShanmugamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_Mr.MuthusamyShanmugamMember" xlink:to="lab_anip_Mr.MuthusamyShanmugamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_747cc008-dee6-440e-9597-cc5804e4d59f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_a987d489-c1a0-4b8c-b781-c827e54ab6df_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f943badd-f1e4-40b0-acb7-b7973f0ac0c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2c4e013b-3233-4d86-88c5-2b99d1c82c12_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_MarketingAndDistributionRightsMember_3392b613-2728-46d0-9e44-b57bb8866688_terseLabel_en-US" xlink:label="lab_anip_MarketingAndDistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing and distribution rights</link:label>
    <link:label id="lab_anip_MarketingAndDistributionRightsMember_label_en-US" xlink:label="lab_anip_MarketingAndDistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing and distribution rights</link:label>
    <link:label id="lab_anip_MarketingAndDistributionRightsMember_documentation_en-US" xlink:label="lab_anip_MarketingAndDistributionRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketing and distribution rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketingAndDistributionRightsMember" xlink:href="anip-20231231.xsd#anip_MarketingAndDistributionRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_MarketingAndDistributionRightsMember" xlink:to="lab_anip_MarketingAndDistributionRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_164bc767-a6bf-4292-b6ff-2c0b5c44eedc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58d8e7e7-50d7-4b04-b447-7ab45d9b3936_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_1378ea9b-fa81-4804-919c-b964db421b54_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_6b0a921a-294e-476c-aa3d-267fc32c1125_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_d5ee1d95-876f-4027-9369-cd3e6b80fbd3_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_157db889-9e87-4913-b276-553eebfe8ea2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fb98b7ef-91f3-4e7f-8494-fd114df0f3a6_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_bf598e27-1126-43d0-ba09-868133cf2639_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual coupon</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_94ddc30b-8c91-4768-812d-9c10a39c981f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_7df64c64-9fbd-4f87-894b-15b783b8b52c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_90ce1b7e-26ec-4ebc-ac52-4108fb801a5e_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_cd470786-0852-4820-8284-2d2afbc48d52_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_974cded3-1e3c-4ecd-b2ec-e2d6ebdf59e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d4dd977-b47e-46dd-baa5-054cb786c51f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_603dbe43-3d91-4441-92d7-524d0759c334_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal settlement expense</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_71c1b08c-5646-469a-aa7d-55b7a8d62e31_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_30178126-3f2c-4628-b17c-a76bc82a2ada_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_e529d9d7-3ed3-4939-8b2e-eb45fd24986d_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_bdf7c856-43d1-4d86-863d-341708b81e29_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_71fa7f44-d3c8-4d38-95d3-9e626319151d_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_5a24eb09-5756-4b91-a0dd-cd7cd06481c5_terseLabel_en-US" xlink:label="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards annual limitation</link:label>
    <link:label id="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_label_en-US" xlink:label="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Annual Limitations on Use</link:label>
    <link:label id="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_documentation_en-US" xlink:label="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual limitations on the use of operating loss carryforwards available to reduce taxable income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" xlink:href="anip-20231231.xsd#anip_OperatingLossCarryforwardsAnnualLimitationsOnUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" xlink:to="lab_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d4a47e66-185d-4c2d-85d6-4115267586ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4118c057-4d87-42d6-966a-6e6893339e0d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b48aa2fb-1557-47f7-8d6e-08d7759f815b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_ef717d15-00fe-4281-882e-2a01417ad098_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4256cb99-02e6-4e84-856b-002f504e7ed7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_56beb40b-4b62-48b2-8367-8ae58f0df011_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bacab5c1-e1d6-486c-b47b-fbeb179ac2fa_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash and Cash Equivalents Used in Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PublicOfferingMember_76c49d36-7078-46e3-9abf-5f5248ea9550_terseLabel_en-US" xlink:label="lab_anip_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:label id="lab_anip_PublicOfferingMember_label_en-US" xlink:label="lab_anip_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_anip_PublicOfferingMember_documentation_en-US" xlink:label="lab_anip_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PublicOfferingMember" xlink:href="anip-20231231.xsd#anip_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PublicOfferingMember" xlink:to="lab_anip_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_4124d372-1a7e-43ed-b756-ac9536d23b8f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_OneMonthDurationMember_ec0cfd8a-3543-4f16-b9e5-5f693a24e7e8_terseLabel_en-US" xlink:label="lab_anip_OneMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Month Duration</link:label>
    <link:label id="lab_anip_OneMonthDurationMember_label_en-US" xlink:label="lab_anip_OneMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Month Duration [Member]</link:label>
    <link:label id="lab_anip_OneMonthDurationMember_documentation_en-US" xlink:label="lab_anip_OneMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Month Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OneMonthDurationMember" xlink:href="anip-20231231.xsd#anip_OneMonthDurationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_OneMonthDurationMember" xlink:to="lab_anip_OneMonthDurationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_f8f3a1af-a230-44e5-85c7-ef08fb5920d2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue generated</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:to="lab_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_0e1eb50c-24bb-4d51-a7ef-9b858059821e_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on borrowings under credit agreements</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_2054a75b-2f81-4bfd-b255-250340cced82_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_GenericsEstablishedBrandsAndOtherMember_efe17539-e205-4a63-b88d-5c638fb62aea_terseLabel_en-US" xlink:label="lab_anip_GenericsEstablishedBrandsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generics, Established Brands and Other</link:label>
    <link:label id="lab_anip_GenericsEstablishedBrandsAndOtherMember_label_en-US" xlink:label="lab_anip_GenericsEstablishedBrandsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Generics, Established Brands and Other</link:label>
    <link:label id="lab_anip_GenericsEstablishedBrandsAndOtherMember_documentation_en-US" xlink:label="lab_anip_GenericsEstablishedBrandsAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of the entity related to generics, established brands, and other and is considered an operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_GenericsEstablishedBrandsAndOtherMember" xlink:href="anip-20231231.xsd#anip_GenericsEstablishedBrandsAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_GenericsEstablishedBrandsAndOtherMember" xlink:to="lab_anip_GenericsEstablishedBrandsAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_27fd535b-774f-4645-a669-5613b31d1354_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9a848962-1a0e-492e-86eb-6fc3bd41694f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of contractual maturity of term loan and DDTL</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1caf55ec-087d-4d8c-b662-79fe19fce761_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_019b52e2-ba1f-42d5-a9e0-8df6feae44e1_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4c8bed20-8aea-4e51-aa5e-6626926c217b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion_8f88561b-5bdf-4fc4-a323-3c08ab32a863_terseLabel_en-US" xlink:label="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Minimum Period of Conversion</link:label>
    <link:label id="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion_label_en-US" xlink:label="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Minimum Period of Conversion</link:label>
    <link:label id="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion_documentation_en-US" xlink:label="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Minimum Period of Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PreferredStockConvertibleMinimumPeriodOfConversion" xlink:href="anip-20231231.xsd#anip_PreferredStockConvertibleMinimumPeriodOfConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PreferredStockConvertibleMinimumPeriodOfConversion" xlink:to="lab_anip_PreferredStockConvertibleMinimumPeriodOfConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_26b3be19-cdff-4845-8f90-7c18a903f2ba_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_9d7690e4-cef9-4295-aab6-6c63096960e9_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of ANDAs</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_b787561f-8ab5-49b2-b289-34edc7f215de_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_780c48e8-5e22-453b-8a04-be161412e63d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_deac9de2-5ead-48bc-ad0b-61a26fe08027_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_215e3cac-0de3-4b4f-a506-78af2534b1b9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_884c0e7e-b11e-4e3e-aa73-70b0fa414d9c_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_a4877d61-c23d-412f-b5d9-9ae1b2ed85c5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTypeAxis_40004a8c-2d13-44fc-a72b-594dba139b07_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTypeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeAxis" xlink:to="lab_us-gaap_ReclassificationTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_52c1f916-e00a-4fa7-9150-2e8b084f08ef_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_00e7d765-9546-4823-acb5-570405197e70_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ScitusPharmaServicesMember_4a17f470-58bc-4c91-896e-5c4a85fb583f_terseLabel_en-US" xlink:label="lab_anip_ScitusPharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scitus Pharma Services</link:label>
    <link:label id="lab_anip_ScitusPharmaServicesMember_label_en-US" xlink:label="lab_anip_ScitusPharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scitus Pharma Services</link:label>
    <link:label id="lab_anip_ScitusPharmaServicesMember_documentation_en-US" xlink:label="lab_anip_ScitusPharmaServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Scitus Pharma Services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScitusPharmaServicesMember" xlink:href="anip-20231231.xsd#anip_ScitusPharmaServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ScitusPharmaServicesMember" xlink:to="lab_anip_ScitusPharmaServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_5ecfd4ed-3ebe-4263-8cc6-0ce72b837fb6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_2cb62073-86e4-40ce-bef5-3f71bd394088_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_489af6d2-5bc2-4f80-a202-38fec7bf4733_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_ef2162ad-ba31-4790-a3bb-e03943784acd_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of customer concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ProductRightsMember_eefcb91a-6956-4229-be66-c85cd3186083_terseLabel_en-US" xlink:label="lab_anip_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NDAs and product rights</link:label>
    <link:label id="lab_anip_ProductRightsMember_label_en-US" xlink:label="lab_anip_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NDAs and product rights</link:label>
    <link:label id="lab_anip_ProductRightsMember_documentation_en-US" xlink:label="lab_anip_ProductRightsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NDAs and product rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductRightsMember" xlink:href="anip-20231231.xsd#anip_ProductRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ProductRightsMember" xlink:to="lab_anip_ProductRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_07f3c8e0-dae1-4016-9571-5cc84c06c7a2_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure for cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount_2ed31167-0002-4958-97da-bc1ecfc313df_terseLabel_en-US" xlink:label="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in notional amount</link:label>
    <link:label id="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount_label_en-US" xlink:label="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Decrease in Notional Amount</link:label>
    <link:label id="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount_documentation_en-US" xlink:label="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of decrease in notional amount of derivative liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_DerivativeLiabilityDecreaseInNotionalAmount" xlink:href="anip-20231231.xsd#anip_DerivativeLiabilityDecreaseInNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_DerivativeLiabilityDecreaseInNotionalAmount" xlink:to="lab_anip_DerivativeLiabilityDecreaseInNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_cb9faa3a-fe97-4fba-a77f-3f8ee53be6a6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CortrophinGelMember_330d9490-d866-42d8-8c97-5ed943dabb87_terseLabel_en-US" xlink:label="lab_anip_CortrophinGelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortrophin Gel</link:label>
    <link:label id="lab_anip_CortrophinGelMember_label_en-US" xlink:label="lab_anip_CortrophinGelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortrophin Gel</link:label>
    <link:label id="lab_anip_CortrophinGelMember_documentation_en-US" xlink:label="lab_anip_CortrophinGelMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to Cortrophin Gel.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinGelMember" xlink:href="anip-20231231.xsd#anip_CortrophinGelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CortrophinGelMember" xlink:to="lab_anip_CortrophinGelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_f3c661a5-2d56-4547-9f2d-5aa5bd19da06_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL AND INTANGIBLE ASSETS</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_00b36fdd-61b6-47e7-bea1-5a6e75bd8d9f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30aede58-e09a-4a86-97e0-7169bb078578_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 liability, beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_62f54d08-7463-4cb7-8021-be21d6b04f29_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3 liability, ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_4657a74a-88b0-4c15-898d-98b27bbeb984_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current income tax provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionPrice_91f659da-d1c0-445e-b369-032b9d8a7b74_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares conversion price</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionPrice_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_5e48b0c7-bf1b-484a-958c-a440fc5a47a0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net of Federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_62b7e2f6-56ef-41e9-bfc6-83d05045db85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_92388616-cbcd-4273-9c05-b0cdf987af0f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_17c735b5-7f92-49bd-85a9-dea28cec5723_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1426b7d2-1f2d-44be-bfc9-b0faec220c6c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_ccf431ba-ba01-49d7-bc6a-a3dbbf292ffe_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d7255eb-afae-4c96-afc6-2560ebb91e2d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash and Cash Equivalents Provided by (Used in) Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_01fdea66-c620-47d5-8c4c-b8fdb9b28591_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_29a65e73-2e41-4ee8-aa7e-67eea9712353_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_87ab20d6-c1b4-4e7a-92f9-d7f6f407f33c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_a731b4b0-fdd8-4172-8d52-66648f1e7c4c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards Forfeitures</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IN_207129e2-ca67-4dbb-b009-bd14269fcbe2_terseLabel_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">India</link:label>
    <link:label id="lab_country_IN_label_en-US" xlink:label="lab_country_IN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IN" xlink:to="lab_country_IN" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_ab68189d-95e7-4a10-8a61-01dffba7a68d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible, shares issuable</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleSharesIssuable_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_9624eb89-13e7-4a85-8efa-cc46e63bc211_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations transferred over time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_1ca1af72-f566-451c-996e-028b2e495a46_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_LossContingencyNumberOfManufacturers_705880b5-a9ef-47f3-96fd-8ae65677ff3b_terseLabel_en-US" xlink:label="lab_anip_LossContingencyNumberOfManufacturers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of potential manufacturers</link:label>
    <link:label id="lab_anip_LossContingencyNumberOfManufacturers_label_en-US" xlink:label="lab_anip_LossContingencyNumberOfManufacturers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Manufacturers</link:label>
    <link:label id="lab_anip_LossContingencyNumberOfManufacturers_documentation_en-US" xlink:label="lab_anip_LossContingencyNumberOfManufacturers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Manufacturers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LossContingencyNumberOfManufacturers" xlink:href="anip-20231231.xsd#anip_LossContingencyNumberOfManufacturers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_LossContingencyNumberOfManufacturers" xlink:to="lab_anip_LossContingencyNumberOfManufacturers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_dc051698-5d34-4de4-bf35-f42887fa3f39_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net revenues</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_c2545d54-a623-4c41-9432-577656c20175_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_f81476cf-ef71-4c2b-9df9-1f8b8f5d76b9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of product rights included in accounts payable</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_535f5a3a-dd77-4032-99f4-6f2e5d1ac138_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c3886c0d-388e-4c50-a289-d7177e25d6bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_LongTermDebtGrossNonCurrent_b742dac4-4fc5-47d0-aa32-138a2b4d0360_terseLabel_en-US" xlink:label="lab_anip_LongTermDebtGrossNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current borrowing on debt</link:label>
    <link:label id="lab_anip_LongTermDebtGrossNonCurrent_label_en-US" xlink:label="lab_anip_LongTermDebtGrossNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross, Non Current</link:label>
    <link:label id="lab_anip_LongTermDebtGrossNonCurrent_documentation_en-US" xlink:label="lab_anip_LongTermDebtGrossNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non current portion before unamortized (discount) premium and debt issuance costs, of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossNonCurrent" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_LongTermDebtGrossNonCurrent" xlink:to="lab_anip_LongTermDebtGrossNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_0ade8beb-4cde-4252-a64d-6ab18f9c9c37_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c7803ac7-e998-41d4-af58-30e59077658a_verboseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and allowances</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_88415165-69a7-4c0f-939e-32b7044575df_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NurayChemicalPrivateLimitedMember_bd2847b1-b400-491a-8fca-1e0c5ed9dbac_terseLabel_en-US" xlink:label="lab_anip_NurayChemicalPrivateLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuray Chemical Private Limited</link:label>
    <link:label id="lab_anip_NurayChemicalPrivateLimitedMember_label_en-US" xlink:label="lab_anip_NurayChemicalPrivateLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nuray Chemical Private Limited</link:label>
    <link:label id="lab_anip_NurayChemicalPrivateLimitedMember_documentation_en-US" xlink:label="lab_anip_NurayChemicalPrivateLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Nuray Chemical Private Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NurayChemicalPrivateLimitedMember" xlink:href="anip-20231231.xsd#anip_NurayChemicalPrivateLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NurayChemicalPrivateLimitedMember" xlink:to="lab_anip_NurayChemicalPrivateLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_566ce0bf-eb17-4dd9-abff-d99e02722cf9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Income (Loss) Per Share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_53c2aff3-8007-4a09-b3a5-5053a7102fc9_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liability not recognized, asset acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PrivateInvestmentInPublicEquityMember_9662c779-21e7-4272-bcdc-9e929c6651fe_terseLabel_en-US" xlink:label="lab_anip_PrivateInvestmentInPublicEquityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Shares</link:label>
    <link:label id="lab_anip_PrivateInvestmentInPublicEquityMember_label_en-US" xlink:label="lab_anip_PrivateInvestmentInPublicEquityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PIPE Shares</link:label>
    <link:label id="lab_anip_PrivateInvestmentInPublicEquityMember_documentation_en-US" xlink:label="lab_anip_PrivateInvestmentInPublicEquityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Private Investment in Public Equity ("PIPE Investment").</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PrivateInvestmentInPublicEquityMember" xlink:to="lab_anip_PrivateInvestmentInPublicEquityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f76dedec-f38c-44e9-b6e9-482ba8efeddc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_674f1f0a-3350-4079-8b83-994d871124b2_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_567d3025-4861-4635-b4f1-38ac5d59a8ac_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_518eee63-0277-485f-8d51-35187436fc55_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_40bb8ae3-0463-4a56-82a1-14a34f40294c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember_46ab1df1-bae8-47e1-8427-7e1b7f55e171_terseLabel_en-US" xlink:label="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakville, Ontario Former Manufacturing Facility</link:label>
    <link:label id="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember_label_en-US" xlink:label="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakville, Ontario Former Manufacturing Facility [Member]</link:label>
    <link:label id="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember_documentation_en-US" xlink:label="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakville, Ontario Former Manufacturing Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember" xlink:to="lab_anip_OakvilleOntarioFormerManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_5a864815-70aa-4777-add3-d86d078924a2_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_6cfb6178-7754-415e-b769-6c75423e260b_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_b42917d3-4141-420f-9116-7b3109d4b0eb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_67234d4b-38d3-48d2-8d9f-753818bc3a28_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_dadb3223-3052-403e-a7ae-4587e23e2fc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_1e66c97b-ca6f-473b-8871-9383483068d6_terseLabel_en-US" xlink:label="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Assets on Completion of Project and Launch of Related Products</link:label>
    <link:label id="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_label_en-US" xlink:label="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of Assets on Completion of Project and Launch of Related Products</link:label>
    <link:label id="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_documentation_en-US" xlink:label="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to reclassification of assets on completion of project and launch of related products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" xlink:href="anip-20231231.xsd#anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" xlink:to="lab_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6fcdac3d-c31e-4f78-9626-c42be771cdd2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_f8df8143-706d-40d9-81de-2108fb5203c2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_733cf8b0-81d7-41f0-8b6e-db2a7873e488_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e3d56c65-49f8-45c1-a959-97cd2ab7c0a9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8413f826-cc2e-4a7c-b079-e81eebcd477c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_9895f03d-1db3-4175-8049-8c8ceaf21bf3_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_b4262a59-d369-417d-8ad6-7be44b76e470_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_91f187fb-b1a6-4ecb-b72e-56f76d4c6937_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CGOncologyInc.Member_5ef1c994-8209-4077-acf2-bb8aca70915f_terseLabel_en-US" xlink:label="lab_anip_CGOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CG Oncology, Inc.</link:label>
    <link:label id="lab_anip_CGOncologyInc.Member_label_en-US" xlink:label="lab_anip_CGOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CG Oncology, Inc. [Member]</link:label>
    <link:label id="lab_anip_CGOncologyInc.Member_documentation_en-US" xlink:label="lab_anip_CGOncologyInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CG Oncology, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CGOncologyInc.Member" xlink:href="anip-20231231.xsd#anip_CGOncologyInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CGOncologyInc.Member" xlink:to="lab_anip_CGOncologyInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_ad6c1983-3572-402d-9fd5-30059b7023eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4b02a46b-c95a-469a-8e8f-eced112e8ac6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_528fcc74-09c6-4086-8d51-df08ea59fd76_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_422cb9c1-6531-4ac3-9535-265f15f5cf14_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_462448f9-0c86-4e4e-9b95-634df52f2c7c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4a5e4af8-1543-4a1a-a610-f02945f5bd25_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_15a07249-19f1-419b-8e7c-79f7eb34901f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_cbe6353f-51c4-4ee1-9a67-8678c4b9dc1c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_f031176b-e665-4de8-a6b5-d4c9478cfcd2_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3aba4777-422e-4b87-9ddf-429ebb13ab4e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_896966ab-96e0-49b1-9f36-b6c9b12c0eef_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_ec364b59-c51b-41fe-a432-7acd288dcfae_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_9ce82ce3-d3ea-4316-abe5-5d09363c08f9_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_a9e752c5-4bff-4e05-b36a-1d93bafc96ed_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NumberOfConsecutiveTradingDays_93902c07-bdda-4ca3-b703-6aea517be149_terseLabel_en-US" xlink:label="lab_anip_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_anip_NumberOfConsecutiveTradingDays_label_en-US" xlink:label="lab_anip_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Consecutive Trading Days</link:label>
    <link:label id="lab_anip_NumberOfConsecutiveTradingDays_documentation_en-US" xlink:label="lab_anip_NumberOfConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfConsecutiveTradingDays" xlink:href="anip-20231231.xsd#anip_NumberOfConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NumberOfConsecutiveTradingDays" xlink:to="lab_anip_NumberOfConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_89ecd993-ef21-4d78-b844-fe657b8509d2_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash and Cash Equivalents Provided by (Used in) Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_2c3156e3-7c2a-444b-bfa8-968e2407ad5c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of deferred tax liabilities and valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_bb50cb38-3471-46e1-971d-d1d91743dc3f_negatedLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings allocated to participating securities, Basic</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Allocated to Participating Securities, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:to="lab_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_fab7fe3e-fa50-4c79-9e2a-58c218add752_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_ca6b5826-6d56-41c2-b5f3-7749e2a928a2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current debt, net of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_c3fb5886-f612-4eb2-aabb-878151e960ab_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current debt, net of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_76159b45-3440-4060-9e5f-5060312d3f7f_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expense, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_52357f2f-f420-4504-89c0-0cb459afc840_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Loss) gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_78a77b46-c6d6-4267-ac03-b614af798775_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative unrealized gain (loss) recorded in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8151a73c-6710-4aeb-8a4f-540b177b5f85_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Income (Loss) Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_f6dc5378-edb8-44b3-8906-63cca1b9b16c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8a5b8b9e-07a9-45ab-8e13-dd063358633f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized option costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_3bae94fd-397f-478b-9fe6-581d1476a3b1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_f441e113-392e-46a3-bc38-d5a8511e8b31_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_acfae05d-96f7-41e2-a9d4-f7543c290721_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_fa70a7f7-f2a8-4295-9395-4239895967bd_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net of deferred tax liabilities and valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f375b68d-c2f7-4bac-b73e-401513008682_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised at the end of the period intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_44ecee6e-6e51-4f00-b8f5-6ebcf1a97fec_verboseLabel_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_2e4eb6f3-957b-4de6-bea8-55b1f169bd7c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a8ec77dc-24df-43c4-8f0a-70035e43e21e_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_05ba9b47-e784-47bb-81be-4905b8ff7ca6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b5baee34-9c97-4b14-8724-7ab49db4bdd3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_c8c3a6b8-12b9-4ad4-a827-2c4a88c09149_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_d0d8cd57-51b4-4333-baa7-64ef2a1d79d9_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_f00760a2-fd4e-4196-a826-46206c6fd626_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_OtherDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_OtherDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDepreciationAndAmortization" xlink:to="lab_us-gaap_OtherDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_11faf059-827f-4d25-a67d-6dbf15e76ef2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Prior Credit Facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_67227f6b-ab00-4fcc-8b19-37f711d5b7d2_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_75218ce5-9745-4f54-984f-af4801778d11_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_0aef520c-59d9-4d08-b8a8-ade31ec83995_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_4b2bb691-69b4-4c52-a425-f78591c60043_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_0e41dfa1-969d-462d-867b-7186c6471176_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_9a83c198-028d-4dde-b896-d7631809cd7d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_36de5ee2-4180-4ff5-b5f9-d664e0ea7a7d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk</link:label>
    <link:label id="lab_us-gaap_SupplierConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_SupplierConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplierConcentrationRiskMember" xlink:to="lab_us-gaap_SupplierConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_70f7f9df-5ffc-4b11-8f48-aa3652bb2766_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_1d0842e7-be0f-4ece-bcdd-23c90f652d9a_terseLabel_en-US" xlink:label="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma Limited Liability Company and Akorn Holding Company</link:label>
    <link:label id="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_label_en-US" xlink:label="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma Limited Liability Company and Akorn Holding Company [Member]</link:label>
    <link:label id="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_documentation_en-US" xlink:label="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma Limited Liability Company and Akorn Holding Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" xlink:href="anip-20231231.xsd#anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" xlink:to="lab_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_99f8e1e4-539d-4c09-99f4-b04996771a23_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_396c0ba1-17ed-44f5-8759-2ab6feefe243_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_f1b8b490-7c17-4660-b86c-a59fa631e17b_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_d13413fa-b973-4661-8f57-bcf67fae8edf_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_17e06a6f-ac80-4ede-9d34-3d3ebfd7363b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_d98d392b-5cc8-42b2-a7f3-0288047e9dfd_terseLabel_en-US" xlink:label="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accruals and allowances</link:label>
    <link:label id="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_label_en-US" xlink:label="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Valuation And Qualifying Accounts Disclosure [Table Text Block]</link:label>
    <link:label id="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_documentation_en-US" xlink:label="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Valuation And Qualifying Accounts Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:href="anip-20231231.xsd#anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:to="lab_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_094cedd0-04fe-482b-aab0-9186a19e67b6_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_c029a476-efc0-4280-9887-ed008fd95d61_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of plaintiffs</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfPlaintiffs_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Plaintiffs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:to="lab_us-gaap_LossContingencyNumberOfPlaintiffs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_6a5ce8bb-3692-4e6d-960d-1b33baa497a0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_5e46e35f-e4f7-4785-a6aa-264d15c33863_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_59a80ea3-455a-4b9d-be92-995d5876fb2c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_f3288d12-ef95-4f1b-9dac-fec0aac48a98_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in acquisition (in shares)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_51c4fffe-ac39-40ff-9814-43a0ed8c8fd8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_0276c5cb-bb75-4fb8-9a93-293d97305520_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_4aa47460-4544-404d-8959-b7179bb61b47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NumberOfProductsMarketed_7723af9f-2395-44e2-bb2d-1dab5fe2bf94_terseLabel_en-US" xlink:label="lab_anip_NumberOfProductsMarketed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products marketed</link:label>
    <link:label id="lab_anip_NumberOfProductsMarketed_label_en-US" xlink:label="lab_anip_NumberOfProductsMarketed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products Marketed</link:label>
    <link:label id="lab_anip_NumberOfProductsMarketed_documentation_en-US" xlink:label="lab_anip_NumberOfProductsMarketed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products Marketed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfProductsMarketed" xlink:href="anip-20231231.xsd#anip_NumberOfProductsMarketed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NumberOfProductsMarketed" xlink:to="lab_anip_NumberOfProductsMarketed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fa24bfcc-cb45-42e2-862d-c359dec29c8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive effect of common stock options, ESPP, and performance stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CommonStockNumberOfVotesPerShare_ab3d550d-f68f-4f8b-bcf8-3321a20d281b_terseLabel_en-US" xlink:label="lab_anip_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share</link:label>
    <link:label id="lab_anip_CommonStockNumberOfVotesPerShare_label_en-US" xlink:label="lab_anip_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Votes Per Share</link:label>
    <link:label id="lab_anip_CommonStockNumberOfVotesPerShare_documentation_en-US" xlink:label="lab_anip_CommonStockNumberOfVotesPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Votes Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockNumberOfVotesPerShare" xlink:href="anip-20231231.xsd#anip_CommonStockNumberOfVotesPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CommonStockNumberOfVotesPerShare" xlink:to="lab_anip_CommonStockNumberOfVotesPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_da8eac72-1a34-42ea-b348-817600f660c4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_af6e1d6c-319e-4175-8e34-61c0b086c8fa_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_f29e558b-bc5c-43c5-8719-45260282edda_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and experimentation and charitable credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AllowancesForSalesReturnsMember_e2ca4ac1-9e25-471d-8d8d-3184fcf8c066_terseLabel_en-US" xlink:label="lab_anip_AllowancesForSalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_anip_AllowancesForSalesReturnsMember_label_en-US" xlink:label="lab_anip_AllowancesForSalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_anip_AllowancesForSalesReturnsMember_documentation_en-US" xlink:label="lab_anip_AllowancesForSalesReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances For Sales Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AllowancesForSalesReturnsMember" xlink:href="anip-20231231.xsd#anip_AllowancesForSalesReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AllowancesForSalesReturnsMember" xlink:to="lab_anip_AllowancesForSalesReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_51636496-7f70-440c-bed2-5f18e5021ab0_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_15d8605d-db4b-472a-877a-a5ae8bd5b600_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ProductReturnPeriod_d3d3024a-d351-44ed-99c6-4c3d3bcda972_terseLabel_en-US" xlink:label="lab_anip_ProductReturnPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product return period</link:label>
    <link:label id="lab_anip_ProductReturnPeriod_label_en-US" xlink:label="lab_anip_ProductReturnPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Return Period</link:label>
    <link:label id="lab_anip_ProductReturnPeriod_documentation_en-US" xlink:label="lab_anip_ProductReturnPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Return Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductReturnPeriod" xlink:href="anip-20231231.xsd#anip_ProductReturnPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ProductReturnPeriod" xlink:to="lab_anip_ProductReturnPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_232e5a97-8988-40eb-81ce-b0189975feab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of proforma information</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="lab_us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_0c229aa9-d08d-4048-a9a2-74f733a48918_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_ca9725bd-90cd-4901-982a-d2ade6868c13_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_d1024577-2230-4035-b019-e08dc0949a20_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedge Accounting</link:label>
    <link:label id="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_label_en-US" xlink:label="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:to="lab_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_26dafbb2-0a9b-4b07-a880-3ea344c63692_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NovitiumPharmaMember_434253e8-b0c0-4149-9d08-fdae56b11d49_terseLabel_en-US" xlink:label="lab_anip_NovitiumPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novitium</link:label>
    <link:label id="lab_anip_NovitiumPharmaMember_label_en-US" xlink:label="lab_anip_NovitiumPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novitium</link:label>
    <link:label id="lab_anip_NovitiumPharmaMember_documentation_en-US" xlink:label="lab_anip_NovitiumPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Novitium Pharma LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NovitiumPharmaMember" xlink:to="lab_anip_NovitiumPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_df800e52-daee-4f23-8910-4e432845147b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6922e302-b60c-4915-b8d1-10376414fd38_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense (benefit) for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_a45fd50f-9904-495a-9177-eaa7e1b37354_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_660f147b-feff-45d2-9797-a70461499bab_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Term (years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_ef9b0a35-89a3-4bed-822d-8da9cba613a8_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2fb1e415-a614-4b7f-941a-94bb3de95c60_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9e396ec6-f085-4a3a-b6a3-6dc961546ea0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_a5f2dcd1-30ac-49e3-82ec-2666b6975142_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_eae95d93-aac5-4d38-9d3d-b31fd26ed768_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_d64ec5ca-abc0-4ebd-946c-70b226985024_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_d58dcd2f-2aae-486f-9aca-44d9578e1391_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative unrealized gain (loss)</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_206a6ef6-d18d-44b5-ba8b-b59ca02a2001_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance shares activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d42fd191-89c8-4ac8-8087-2b277234c25b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_7c1f4ac2-d76b-4b8c-8a3d-4ebc5e03833c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Novitium Pharma LLC, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_0cb4c498-9245-40dc-9cb2-3629b65759e6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_1f031769-deff-4ea9-b973-c205953c1ac3_terseLabel_en-US" xlink:label="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period for shares issued</link:label>
    <link:label id="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_label_en-US" xlink:label="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction Period For Shares Issued In Business Combination</link:label>
    <link:label id="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_documentation_en-US" xlink:label="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restriction period for shares issued in business combination.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RestrictionPeriodForSharesIssuedInBusinessCombination" xlink:href="anip-20231231.xsd#anip_RestrictionPeriodForSharesIssuedInBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_RestrictionPeriodForSharesIssuedInBusinessCombination" xlink:to="lab_anip_RestrictionPeriodForSharesIssuedInBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_7c3bc4c9-0c7e-4a6d-bc67-f62d5518da67_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration in a business combination</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Other Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_33b5e4f1-8bd5-44b3-91e2-5e5393eff078_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Purchases for Restricted Stock Vests (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_c620f054-5206-4f79-a55d-ff3bc467c5e5_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_46404e63-db6e-4416-97b5-8aa416fb603a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a11befa7-cc4b-4e2b-9537-c8688db1b2a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_4b8d13d3-242c-42b6-b4db-f98d22b42ed1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_066cfd54-2965-4088-9858-56c2c403ba49_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE RECOGNITION AND RELATED ALLOWANCES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense_1c750134-d312-48a9-9b94-d8d6c8235df2_terseLabel_en-US" xlink:label="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development ("IPR&amp;D")</link:label>
    <link:label id="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense_label_en-US" xlink:label="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in Process Reserach and Development Expense</link:label>
    <link:label id="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense_documentation_en-US" xlink:label="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in Process Reserach and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredInProcessReserachAndDevelopmentExpense" xlink:href="anip-20231231.xsd#anip_AcquiredInProcessReserachAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredInProcessReserachAndDevelopmentExpense" xlink:to="lab_anip_AcquiredInProcessReserachAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_45cb8463-2a46-41ca-b1ef-88b849ffa193_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_393c1351-117a-496b-b9d3-35baf07e9bce_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_b6178f26-874f-4f0b-ba12-337ab156cc18_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_b740988e-97d0-425e-83ce-e568bc9eccbd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalizedAdjustment_7868ed35-6178-4e2c-8a94-1058a613555c_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized interest</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalizedAdjustment_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalizedAdjustment" xlink:to="lab_us-gaap_InterestCostsCapitalizedAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bd3e85b3-cdee-41bf-8f4a-1c006e6a5bdd_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_0c310dc8-0605-41d7-a368-32db97a8c0f4_terseLabel_en-US" xlink:label="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration period</link:label>
    <link:label id="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_label_en-US" xlink:label="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Period</link:label>
    <link:label id="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_documentation_en-US" xlink:label="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BusinessCombinationContingentConsiderationArrangementsPeriod" xlink:href="anip-20231231.xsd#anip_BusinessCombinationContingentConsiderationArrangementsPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_BusinessCombinationContingentConsiderationArrangementsPeriod" xlink:to="lab_anip_BusinessCombinationContingentConsiderationArrangementsPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_b3c63c7f-04a4-4147-a640-ff240e297348_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_b7f5683c-2714-4ac3-b575-a8d65e4050b8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of finance fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3c78fec2-8b8e-4808-afcf-6ac563db810b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_TermLoanAndDelayedDrawTermLoanMember_54322130-2b3a-4c1e-ae8d-9c90fe2b0942_terseLabel_en-US" xlink:label="lab_anip_TermLoanAndDelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan and DDTL</link:label>
    <link:label id="lab_anip_TermLoanAndDelayedDrawTermLoanMember_label_en-US" xlink:label="lab_anip_TermLoanAndDelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan and DDTL</link:label>
    <link:label id="lab_anip_TermLoanAndDelayedDrawTermLoanMember_documentation_en-US" xlink:label="lab_anip_TermLoanAndDelayedDrawTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Term Loan and Delayed Draw Term Loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanAndDelayedDrawTermLoanMember" xlink:href="anip-20231231.xsd#anip_TermLoanAndDelayedDrawTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_TermLoanAndDelayedDrawTermLoanMember" xlink:to="lab_anip_TermLoanAndDelayedDrawTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_cde83891-47ab-4778-a370-777c1e70d943_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A convertible preferred stock dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_58af2e83-d116-475e-b1a5-7cc6ef6c0e78_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_IncreaseDecreaseInRoyaltyPayable_c4499387-a6fe-41a9-a615-6d552c570044_terseLabel_en-US" xlink:label="lab_anip_IncreaseDecreaseInRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_anip_IncreaseDecreaseInRoyaltyPayable_label_en-US" xlink:label="lab_anip_IncreaseDecreaseInRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Royalty Payable</link:label>
    <link:label id="lab_anip_IncreaseDecreaseInRoyaltyPayable_documentation_en-US" xlink:label="lab_anip_IncreaseDecreaseInRoyaltyPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseInRoyaltyPayable" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseInRoyaltyPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_IncreaseDecreaseInRoyaltyPayable" xlink:to="lab_anip_IncreaseDecreaseInRoyaltyPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8fa94089-5e35-406e-86de-c312980456c8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_9bc85f46-9dfa-4fe1-a97b-0868bc00734a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_27af9215-694a-4928-8c20-f80bf8a32972_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEGMENT REPORTING</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9cb0fff1-4a9c-4a89-8401-5acd6a361f2c_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Change in Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CustomerOneMember_91c61f79-9629-4a54-869f-4894cbdd3cb2_terseLabel_en-US" xlink:label="lab_anip_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:label id="lab_anip_CustomerOneMember_label_en-US" xlink:label="lab_anip_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one [Member]</link:label>
    <link:label id="lab_anip_CustomerOneMember_documentation_en-US" xlink:label="lab_anip_CustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer one</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerOneMember" xlink:href="anip-20231231.xsd#anip_CustomerOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CustomerOneMember" xlink:to="lab_anip_CustomerOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a6296258-c634-4792-939c-07ce9e364d21_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ChargebacksMember_53adfab4-1d70-4e9a-a247-e3d9d8ce81d5_terseLabel_en-US" xlink:label="lab_anip_ChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_anip_ChargebacksMember_label_en-US" xlink:label="lab_anip_ChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:label id="lab_anip_ChargebacksMember_documentation_en-US" xlink:label="lab_anip_ChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ChargebacksMember" xlink:href="anip-20231231.xsd#anip_ChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ChargebacksMember" xlink:to="lab_anip_ChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_19e21f73-9894-492b-b608-91d697e328fa_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value interest rate derivative assets</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_05dc42c0-20f9-4961-ace4-9b0fee028110_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swap</link:label>
    <link:label id="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Derivative Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:to="lab_us-gaap_InterestRateDerivativeAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_dabbf6d0-15e4-4516-b5b9-736f35f01e20_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredPipelineProductMember_bea11792-29ea-4fae-b3ca-f9fa0f0feb90_terseLabel_en-US" xlink:label="lab_anip_AcquiredPipelineProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired pipeline product</link:label>
    <link:label id="lab_anip_AcquiredPipelineProductMember_label_en-US" xlink:label="lab_anip_AcquiredPipelineProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired pipeline product [Member]</link:label>
    <link:label id="lab_anip_AcquiredPipelineProductMember_documentation_en-US" xlink:label="lab_anip_AcquiredPipelineProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired pipeline product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredPipelineProductMember" xlink:href="anip-20231231.xsd#anip_AcquiredPipelineProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredPipelineProductMember" xlink:to="lab_anip_AcquiredPipelineProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_ded73e52-ca62-4d29-83dc-1aa55ce829f8_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_54dc3141-b9e2-49cf-b916-8ee42f99b016_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_07bacdb4-7cfd-41c8-b790-c24177d7144b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d1cb3f3e-0911-486b-8eb7-eed2df078a47_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CommonStockConversionPrice_b0c02312-f6f3-4a52-a771-26135dff6a0b_terseLabel_en-US" xlink:label="lab_anip_CommonStockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollar per share)</link:label>
    <link:label id="lab_anip_CommonStockConversionPrice_label_en-US" xlink:label="lab_anip_CommonStockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Conversion Price</link:label>
    <link:label id="lab_anip_CommonStockConversionPrice_documentation_en-US" xlink:label="lab_anip_CommonStockConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the conversion price for converting shares of common stock into another class of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockConversionPrice" xlink:href="anip-20231231.xsd#anip_CommonStockConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CommonStockConversionPrice" xlink:to="lab_anip_CommonStockConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FacilityClosingMember_aef0ac82-a116-4a38-9e5d-215a25332b26_terseLabel_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing</link:label>
    <link:label id="lab_us-gaap_FacilityClosingMember_label_en-US" xlink:label="lab_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Closing [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityClosingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FacilityClosingMember" xlink:to="lab_us-gaap_FacilityClosingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ChaliPropertiesLLCMember_2c3a3067-b780-492b-bc47-ff7037a88582_terseLabel_en-US" xlink:label="lab_anip_ChaliPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chali Properties LLC</link:label>
    <link:label id="lab_anip_ChaliPropertiesLLCMember_label_en-US" xlink:label="lab_anip_ChaliPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chali Properties LLC [Member]</link:label>
    <link:label id="lab_anip_ChaliPropertiesLLCMember_documentation_en-US" xlink:label="lab_anip_ChaliPropertiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chali Properties LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ChaliPropertiesLLCMember" xlink:href="anip-20231231.xsd#anip_ChaliPropertiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ChaliPropertiesLLCMember" xlink:to="lab_anip_ChaliPropertiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_47e9d038-7032-47fd-86d7-434d1099a29c_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_3b5e6c00-a4ef-43d6-a8db-00f59616caf9_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_908ad7a9-a340-4cbb-a424-373a25894bb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_60812835-9e09-4291-a00d-481d88220f9b_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_adcaec3f-d063-4894-8825-b55dfba0b209_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income/(loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2e122c9e-bcf1-4f98-a038-1fdba4a4e771_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PaymentTypeAxis_a51f701c-d1ce-4647-b92a-c8c5e2762150_terseLabel_en-US" xlink:label="lab_anip_PaymentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Axis]</link:label>
    <link:label id="lab_anip_PaymentTypeAxis_label_en-US" xlink:label="lab_anip_PaymentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Axis]</link:label>
    <link:label id="lab_anip_PaymentTypeAxis_documentation_en-US" xlink:label="lab_anip_PaymentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeAxis" xlink:href="anip-20231231.xsd#anip_PaymentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PaymentTypeAxis" xlink:to="lab_anip_PaymentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_7b55a37f-a1d7-41a5-8c50-6c157e84e7b3_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_MeasurementInputProbabilityOfPaymentMember_8922e1ca-be7e-4c03-9ca5-d0b0afebbf14_terseLabel_en-US" xlink:label="lab_anip_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_anip_MeasurementInputProbabilityOfPaymentMember_label_en-US" xlink:label="lab_anip_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_anip_MeasurementInputProbabilityOfPaymentMember_documentation_en-US" xlink:label="lab_anip_MeasurementInputProbabilityOfPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to probability of payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MeasurementInputProbabilityOfPaymentMember" xlink:href="anip-20231231.xsd#anip_MeasurementInputProbabilityOfPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_MeasurementInputProbabilityOfPaymentMember" xlink:to="lab_anip_MeasurementInputProbabilityOfPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_66a69c80-e850-403c-b4d2-052918d36589_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_eeda01ff-50df-4ef6-b4a5-ac55d7ba5a1f_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f5f1f8f2-abca-41e6-a07a-6447dadf0836_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_80b63335-2127-48b4-9322-99ea2ba4377a_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredNDAIntangibleAssetsMember_67743665-55b9-40c6-a629-79149ab62007_terseLabel_en-US" xlink:label="lab_anip_AcquiredNDAIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired NDA intangible assets</link:label>
    <link:label id="lab_anip_AcquiredNDAIntangibleAssetsMember_label_en-US" xlink:label="lab_anip_AcquiredNDAIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired NDA intangible assets [Member]</link:label>
    <link:label id="lab_anip_AcquiredNDAIntangibleAssetsMember_documentation_en-US" xlink:label="lab_anip_AcquiredNDAIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired NDA intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredNDAIntangibleAssetsMember" xlink:href="anip-20231231.xsd#anip_AcquiredNDAIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredNDAIntangibleAssetsMember" xlink:to="lab_anip_AcquiredNDAIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b70ec7fe-036f-43f8-acda-a5e5bb76a0c4_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_50f1136c-8afe-4c69-b931-db63494ac372_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_f86277cc-53bd-4523-8094-26845db39f83_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_7171c476-d3c8-49a1-bdff-fac029694115_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued royalties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_420477fd-efc9-4815-b13b-b978f3bc75d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1995e213-9c36-48ed-a597-9f40d8bdde45_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e30e5d46-0a72-42a2-8e5d-1e13d47b9ff3_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INDEBTEDNESS</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_f212dbd1-e104-495f-a892-226e4c6464bd_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_771d830e-b1d7-4146-8dff-0005f40a7c99_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c8008f3a-0fda-46d4-8dd0-506cc727616f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_71dfa519-99c3-4c98-879d-bf1dd81a7420_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b37d42e-8981-4d5a-8e94-00263cc4343e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_b09d9a24-56e3-4641-bb7f-4d08cf4aefe8_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_e4244f0c-6c67-4055-af2d-8da37b15d0db_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_459e7f1d-0c2e-4676-8db8-c975309d2e49_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_4aac646a-1b60-4cd7-b0b1-8a365fc8ed81_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_036efb95-9766-4574-a5de-c99f48e706d3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period weighted average remaining term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a66bf80a-247d-445f-ada0-4ffd370f212d_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_71b60ea1-f665-435d-bdd7-c7fb94d02bab_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of open complaints (more than)</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9fcc1b64-ac24-45aa-960e-2e0902d6ea6a_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_5552bc1f-17cc-40ab-a5bf-acc6f63a60de_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 15)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_ff025bf5-e764-484c-8126-3be8162bf995_verboseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_ea06206e-5f4a-48a7-83b8-b8dc67565166_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering, net of transaction expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_e2e6e420-31e7-4227-8f78-61de67c22118_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_7cca7a6e-e7d3-40e3-a425-827b7467b0a7_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_4dd4aa91-8097-4048-bc23-d4611086fa2f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_57822799-7374-4dd0-9573-53c5caadc9c4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_LongTermDebtGrossCurrent_7c493bf3-1c64-4de8-83e6-a6fb33918149_terseLabel_en-US" xlink:label="lab_anip_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing on debt</link:label>
    <link:label id="lab_anip_LongTermDebtGrossCurrent_label_en-US" xlink:label="lab_anip_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross, Current</link:label>
    <link:label id="lab_anip_LongTermDebtGrossCurrent_documentation_en-US" xlink:label="lab_anip_LongTermDebtGrossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion before unamortized (discount) premium and debt issuance costs, of long-term debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossCurrent" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_LongTermDebtGrossCurrent" xlink:to="lab_anip_LongTermDebtGrossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_39009a94-b910-4d2e-a837-2395e6ef657e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_c58275ae-34ec-4ed2-a1da-8a8a1e3fee28_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_21a0b5c3-afc4-44c8-bb71-b47c770e733f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_3305bcc1-c27f-43ec-968e-6a9ffca4887c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d93cce0d-6c9b-495f-87c9-0d89d963c216_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_268a9759-fc07-49f1-ba15-ab5a3d381172_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a94b973a-a3b5-400e-8322-bae3208546a6_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_66c88d7e-7a82-4133-a69a-13c7caa8aad2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1493f2a2-9ce9-4e16-8a0b-442930d55b98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_e9bbf2c3-e627-4899-b2b3-b654129cd287_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_ba08372f-a2eb-4513-9d24-8cc791ea4e2a_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_48a556c2-b870-4c8f-bfe1-96d438a2cea3_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Treasury (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0f3dd11d-2e5b-448f-86db-0c6339131d3a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5303b5df-d8d4-4c36-9d8f-cf95043c12d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_69d8c6c5-0359-40fb-8238-a2249f78da06_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_308b26c9-4fab-43c7-aef4-30b53560ddf8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Shares upon Stock Option and ESPP Exercise</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22f5a01f-98f2-4ee9-af3f-677d70eb0aad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_c41ccbfa-ad0e-482d-9384-823ce9a38acf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_be3a40d7-1880-45b7-bcaa-be579852c7dc_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_89b07cee-9352-4d47-9929-be8183876cf7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2b9fe2c4-2efa-4d6e-8ad0-c23f20b4d53b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_aee7e5a0-f947-4b24-bfb4-f03218519e50_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_128db2dc-a209-453f-a3f8-e640e041c242_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d069aec9-9654-4be9-be39-95d827e3c3c6_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_aa575d05-ccf0-4a3d-b3d1-862b67661648_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_FourCustomersMember_e295c71b-d1f4-4b11-97fe-7ec31438c5ab_terseLabel_en-US" xlink:label="lab_anip_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Customers</link:label>
    <link:label id="lab_anip_FourCustomersMember_label_en-US" xlink:label="lab_anip_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Customers [Member]</link:label>
    <link:label id="lab_anip_FourCustomersMember_documentation_en-US" xlink:label="lab_anip_FourCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Four Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FourCustomersMember" xlink:href="anip-20231231.xsd#anip_FourCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_FourCustomersMember" xlink:to="lab_anip_FourCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CortrophinPreLaunchChargesTextBlock_85dbcbbd-9723-49a5-9de3-766108ac5a8f_terseLabel_en-US" xlink:label="lab_anip_CortrophinPreLaunchChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</link:label>
    <link:label id="lab_anip_CortrophinPreLaunchChargesTextBlock_label_en-US" xlink:label="lab_anip_CortrophinPreLaunchChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortrophin Pre-Launch Charges [Text Block]</link:label>
    <link:label id="lab_anip_CortrophinPreLaunchChargesTextBlock_documentation_en-US" xlink:label="lab_anip_CortrophinPreLaunchChargesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure for cortrophin pre-launch charges.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchChargesTextBlock" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchChargesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CortrophinPreLaunchChargesTextBlock" xlink:to="lab_anip_CortrophinPreLaunchChargesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_31f68b47-6e94-4d57-81ec-9e416296cca1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_09745e2e-020e-47c3-a38f-145eb85c3471_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_02ebb617-853c-4017-96dc-6b3f6ba8caec_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_178ad030-67a7-4fc3-89a4-7171edb5a842_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_69c96c48-7ae9-4f46-824f-2fc8014699b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_8cef4e72-616f-4ce4-bd82-25ef02cec99f_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_IncreaseDecreaseAccruedGovernmentRebates_897034ba-8916-4694-a028-f37e12d67e4f_verboseLabel_en-US" xlink:label="lab_anip_IncreaseDecreaseAccruedGovernmentRebates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government rebates</link:label>
    <link:label id="lab_anip_IncreaseDecreaseAccruedGovernmentRebates_label_en-US" xlink:label="lab_anip_IncreaseDecreaseAccruedGovernmentRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease, Accrued Government Rebates</link:label>
    <link:label id="lab_anip_IncreaseDecreaseAccruedGovernmentRebates_documentation_en-US" xlink:label="lab_anip_IncreaseDecreaseAccruedGovernmentRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in liabilities related to government rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseAccruedGovernmentRebates" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseAccruedGovernmentRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_IncreaseDecreaseAccruedGovernmentRebates" xlink:to="lab_anip_IncreaseDecreaseAccruedGovernmentRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_6190285f-fae0-4783-ab08-93f163dd5c91_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_8aa80954-3013-4cbe-bfe0-bf725e403234_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_eddbd509-5e7f-4796-9d10-c107c6898914_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_8ba5da8e-35d3-462d-b045-042d82c15fa0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_d78a7a43-19c4-4553-ab11-ba0751114b89_terseLabel_en-US" xlink:label="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma Limited Liability, Company Patents and Pending Patents</link:label>
    <link:label id="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_label_en-US" xlink:label="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma Limited Liability, Company Patents and Pending Patents [Member]</link:label>
    <link:label id="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_documentation_en-US" xlink:label="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Slayback Pharma Limited Liability, Company Patents and Pending Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" xlink:href="anip-20231231.xsd#anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" xlink:to="lab_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_9c6fa5d9-8ed2-472a-adda-1bfa92ec8d6d_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring activities</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_bd1750e2-edbe-4257-a0ea-0be3e44551dd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring activity expense</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_45703117-3ba1-4c85-acca-9d09370fd38c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b5e9bf2a-c326-420a-8319-d8cac1df0e0b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general, and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_83d9b54e-238f-439e-b85b-6b2b2b5a482c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_8077a59a-1dfa-4c51-aa63-0b6377ead670_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of ANDA filing earn-out</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_9567cd48-dc65-4764-8c8e-5005cc2cdad3_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations transferred at a point in time</link:label>
    <link:label id="lab_us-gaap_TransferredAtPointInTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredAtPointInTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transferred at Point in Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredAtPointInTimeMember" xlink:to="lab_us-gaap_TransferredAtPointInTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_f4079d04-98eb-4104-a756-97edf6d6cd7c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current lease liability, included in other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_EsjayPharmaLlcMember_3d72fb74-dbf7-428f-8f91-fd4a838b4cd6_terseLabel_en-US" xlink:label="lab_anip_EsjayPharmaLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Esjay Pharma LLC</link:label>
    <link:label id="lab_anip_EsjayPharmaLlcMember_label_en-US" xlink:label="lab_anip_EsjayPharmaLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Esjay Pharma LLC</link:label>
    <link:label id="lab_anip_EsjayPharmaLlcMember_documentation_en-US" xlink:label="lab_anip_EsjayPharmaLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Esjay Pharma LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EsjayPharmaLlcMember" xlink:href="anip-20231231.xsd#anip_EsjayPharmaLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_EsjayPharmaLlcMember" xlink:to="lab_anip_EsjayPharmaLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SsPharmaLlcMember_d31d25d0-5639-4586-b4e2-e1d623df9f27_terseLabel_en-US" xlink:label="lab_anip_SsPharmaLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SS Pharma LLC</link:label>
    <link:label id="lab_anip_SsPharmaLlcMember_label_en-US" xlink:label="lab_anip_SsPharmaLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SS Pharma LLC</link:label>
    <link:label id="lab_anip_SsPharmaLlcMember_documentation_en-US" xlink:label="lab_anip_SsPharmaLlcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to SS Pharma LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SsPharmaLlcMember" xlink:href="anip-20231231.xsd#anip_SsPharmaLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SsPharmaLlcMember" xlink:to="lab_anip_SsPharmaLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_29db20a5-40ae-4471-9075-54b4c9d86b6e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for costs of share issuances</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_28c899e9-7c02-42be-ac51-92a72e77068c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ac58a838-9d75-4de1-bb55-8b59f0efff7f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8447c74e-8b18-4dff-aaed-494c86c59157_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_OakrumPharmaMember_8579f644-db2e-4f25-b30b-612c74546494_terseLabel_en-US" xlink:label="lab_anip_OakrumPharmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakrum Pharma</link:label>
    <link:label id="lab_anip_OakrumPharmaMember_label_en-US" xlink:label="lab_anip_OakrumPharmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakrum Pharma</link:label>
    <link:label id="lab_anip_OakrumPharmaMember_documentation_en-US" xlink:label="lab_anip_OakrumPharmaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to Oakrum Pharma, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_OakrumPharmaMember" xlink:to="lab_anip_OakrumPharmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5d840e80-c3fa-40ef-9a23-44bd0bd3d1ca_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of maturity analysis of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_372d97a1-f569-47b8-bb54-57e94fd3d7b9_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredFiledProductsMember_368c0848-bfa1-4e66-bba2-859279893c27_terseLabel_en-US" xlink:label="lab_anip_AcquiredFiledProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired filed products</link:label>
    <link:label id="lab_anip_AcquiredFiledProductsMember_label_en-US" xlink:label="lab_anip_AcquiredFiledProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Filed Products [Member]</link:label>
    <link:label id="lab_anip_AcquiredFiledProductsMember_documentation_en-US" xlink:label="lab_anip_AcquiredFiledProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Filed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredFiledProductsMember" xlink:href="anip-20231231.xsd#anip_AcquiredFiledProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredFiledProductsMember" xlink:to="lab_anip_AcquiredFiledProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5c26de33-6142-4811-b1a5-a698072cb639_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_a6c0fd92-1d95-4790-a7d9-b241798c6ed2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on Term Loan and Delayed Draw Term Loan agreements</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfOtherLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Other Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfOtherLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_029cab04-d369-4b35-b236-46afd3cec4eb_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at December&#160;31, 2023 and 2022</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4a5107ec-8f8a-4434-b090-f9f9f1f8b568_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9c0c127b-deb1-431d-ae73-818c2d4b2b55_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_3da77ba2-6448-4bfb-b737-584f40682994_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_96071c51-8685-4f11-84f1-60e82e36776a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_12c153c8-f926-4ac2-9d27-feae18b3a13a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5cca9afe-1e9c-4c75-83f8-3a9b1f8bf99f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2df6c8db-f101-485c-9def-2cb385daff8f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8460713e-ac37-4e50-b39d-f08b9bc2676c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_23e0db89-b749-4b2c-96e7-0a2c0c8e03bc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized non-option costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_6d4226a9-3091-4c64-b0d0-1261b550b123_verboseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment purchased and included in accounts payable</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4b231dab-c876-445b-85dd-14b33f4ff77d_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_f3a97fcb-76e2-42dd-9a86-70fb5377919c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals for chargebacks and returns</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_da6c6b9a-b73b-41eb-b26b-354abd7c82a9_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a079ecef-40c1-4639-8a1a-7a6a5d758b2b_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period weighted average remaining term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_89613006-fe72-4984-bb43-9be911bfd3b0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_cea17ebc-39b4-44b6-827a-1093ddfb8ca5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable inputs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f6ad4b4b-d39c-42f8-a6db-3b8b7ed9a169_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance obligations satisfied in prior periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_b82269a3-44be-4d26-9752-3811220b90c5_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of total interest expense related to the notes and term loan</link:label>
    <link:label id="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="lab_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_3dd80080-5b08-4c0d-a709-27c666bc2d2a_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_cd3f7955-51d6-4aa5-a795-06f0de35772f_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_d4be644f-a7d7-4661-8223-c3daa7467ac0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_1bed6570-7d26-40a6-994b-35b62aea264b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_f67e3ba7-e1ca-4485-9106-5af100a1e1a0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_e2b4a03c-73f9-4fd1-9c13-92e5fc1b7712_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e667d13c-bcc7-4f2e-b2fa-6fb52b170cce_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationTypeDomain_7dfb11a6-0798-457a-a889-f9d127764739_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationTypeDomain" xlink:to="lab_us-gaap_ReclassificationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_c3579143-08b3-4062-99d7-d473ace93c1d_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ce74cd3b-c577-4672-a15b-26f0c181bcb3_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b12f7b66-0a6f-482a-86e0-ebe73649a078_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_da64e1a0-bb0a-48c0-9b4d-4dea11caa9f2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_cc249c1c-ac0d-4432-bd97-5ce5efca0a2b_terseLabel_en-US" xlink:label="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in state apportionment factors, state and foreign rates</link:label>
    <link:label id="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_label_en-US" xlink:label="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Foreign Income Taxes</link:label>
    <link:label id="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_documentation_en-US" xlink:label="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and foreign income tax expense (benefit), net of federal tax expense (benefit).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" xlink:href="anip-20231231.xsd#anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" xlink:to="lab_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_783a94c2-9f53-442b-927c-1a8b2e0a4c1c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ReservesForCashDiscountMember_d8f6e29f-9853-47b1-88b0-238b00602cc1_terseLabel_en-US" xlink:label="lab_anip_ReservesForCashDiscountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prompt Payment Discounts</link:label>
    <link:label id="lab_anip_ReservesForCashDiscountMember_label_en-US" xlink:label="lab_anip_ReservesForCashDiscountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prompt Payment Discounts</link:label>
    <link:label id="lab_anip_ReservesForCashDiscountMember_documentation_en-US" xlink:label="lab_anip_ReservesForCashDiscountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves For Cash Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReservesForCashDiscountMember" xlink:href="anip-20231231.xsd#anip_ReservesForCashDiscountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ReservesForCashDiscountMember" xlink:to="lab_anip_ReservesForCashDiscountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9086cab5-105f-46ba-b38d-9ad8a5cb567a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e7b9b8e-e173-4f60-bafa-3b2101ed2d2f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15a937b3-4aa0-4d6e-b1f3-73f6ca6f96a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_153826dc-fe80-4a62-b601-aaa83e61f3de_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_9358d7ee-e23e-4210-804f-1923ee12a4a9_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_1513be54-ef04-4809-8775-ec0410385a48_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a01fddfd-477b-4981-84ea-764611298f91_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets Held-for-Sale</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_b3650f59-b6a1-46e4-b725-60d1c1494394_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset, Held-for-Sale, Not Part of Disposal Group, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5ac77ac9-ae0b-4498-be8c-76cd253a9a05_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_34a19c52-228c-4fdb-8164-bd96e7ddb7ae_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance, Common (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b853dd3d-69c4-4f54-b140-1fc0b7916f38_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance, Common (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_82822dd2-ddfe-4d23-9af2-43a903d6d62c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_88d1deb2-4cc4-4563-be36-f2c231a15fff_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, 263,943 shares of common stock, at cost, at December&#160;31, 2023 and 149,031 shares of common stock, at cost, at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_67ea001e-9d25-4a5b-aa40-299c43cc4fc2_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_085bfc23-c125-4c71-bae4-835458c47c69_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds after issuance costs</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_28f73d06-0dd6-4f8c-bbb8-0709d19b1fdb_terseLabel_en-US" xlink:label="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration fair value adjustment</link:label>
    <link:label id="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_label_en-US" xlink:label="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Cash Flow</link:label>
    <link:label id="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_documentation_en-US" xlink:label="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" xlink:href="anip-20231231.xsd#anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" xlink:to="lab_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_41d9debf-7ae4-4251-9354-3e22bdb134d9_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_c0f18fb1-06b0-4f7d-92cc-5564fe9601df_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of expected future amortization expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NumberOfExecutiveFounders_436c8006-1674-4535-bd2c-e6f67af8e3e6_terseLabel_en-US" xlink:label="lab_anip_NumberOfExecutiveFounders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of executive founders</link:label>
    <link:label id="lab_anip_NumberOfExecutiveFounders_label_en-US" xlink:label="lab_anip_NumberOfExecutiveFounders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Executive Founders</link:label>
    <link:label id="lab_anip_NumberOfExecutiveFounders_documentation_en-US" xlink:label="lab_anip_NumberOfExecutiveFounders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Executive Founders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfExecutiveFounders" xlink:href="anip-20231231.xsd#anip_NumberOfExecutiveFounders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NumberOfExecutiveFounders" xlink:to="lab_anip_NumberOfExecutiveFounders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_cdec1172-e911-487f-930c-baaae9587aff_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments for chargebacks and other allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_bc02a52b-ccf6-4ffd-8d88-29459dc4aff9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6df49284-f133-43a6-bfcf-abf7c87fb0ce_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_4cc2a75d-cf46-4b43-a626-d1feea7eda50_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of cost recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_0531a7b7-1c42-48b1-9aa6-79bc8492deb6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_0b757c29-7fea-4030-b9bd-05d6a4841a21_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_27870003-cc26-4af7-8139-ab41b55f67c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_InterestPeriodAxis_cd38bebc-6547-4716-a989-3306620c8baf_terseLabel_en-US" xlink:label="lab_anip_InterestPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Period [Axis]</link:label>
    <link:label id="lab_anip_InterestPeriodAxis_label_en-US" xlink:label="lab_anip_InterestPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Period [Axis]</link:label>
    <link:label id="lab_anip_InterestPeriodAxis_documentation_en-US" xlink:label="lab_anip_InterestPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodAxis" xlink:href="anip-20231231.xsd#anip_InterestPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_InterestPeriodAxis" xlink:to="lab_anip_InterestPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_f4b22615-71b8-49a3-82e4-c6737729b917_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_0f34d8ed-2e29-4160-a310-0fb48f77fe9d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_UnapprovedProductsMember_65c8281c-c719-4046-8c91-aed4c760bc53_terseLabel_en-US" xlink:label="lab_anip_UnapprovedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapproved Products</link:label>
    <link:label id="lab_anip_UnapprovedProductsMember_label_en-US" xlink:label="lab_anip_UnapprovedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapproved Products</link:label>
    <link:label id="lab_anip_UnapprovedProductsMember_documentation_en-US" xlink:label="lab_anip_UnapprovedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapproved Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_UnapprovedProductsMember" xlink:href="anip-20231231.xsd#anip_UnapprovedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_UnapprovedProductsMember" xlink:to="lab_anip_UnapprovedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_311b1e6e-f838-44af-aeb7-262807a81c7a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_68acc34f-03f6-4348-b5b9-15d9a060a615_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_ca7f084a-af21-4f8e-978d-dea60ac920f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_fb516dda-4bdf-477a-a24e-3952d4525948_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_fc9c0f8e-8416-49fe-85f9-650f1c405294_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CustomerFourMember_5b92ed5f-2162-466d-892b-2654d69f9580_terseLabel_en-US" xlink:label="lab_anip_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 4</link:label>
    <link:label id="lab_anip_CustomerFourMember_label_en-US" xlink:label="lab_anip_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer four [Member]</link:label>
    <link:label id="lab_anip_CustomerFourMember_documentation_en-US" xlink:label="lab_anip_CustomerFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerFourMember" xlink:href="anip-20231231.xsd#anip_CustomerFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CustomerFourMember" xlink:to="lab_anip_CustomerFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_a4306394-f1df-4c2a-b4e9-237a0cce254b_periodStartLabel_en-US" xlink:label="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, permanent and temporary equity</link:label>
    <link:label id="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_71d98bf7-6dd9-4e5c-af9f-917e44f0aa1e_periodEndLabel_en-US" xlink:label="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, permanent and temporary equity</link:label>
    <link:label id="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_label_en-US" xlink:label="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent and Temporary Equity</link:label>
    <link:label id="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_documentation_en-US" xlink:label="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of all stockholders' equity (deficit) items attributable to the parent and temporary equity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:href="anip-20231231.xsd#anip_StockholdersEquityAttributableToParentAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:to="lab_anip_StockholdersEquityAttributableToParentAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_406d6bf5-56c3-491e-9dae-ae1bdceeeffc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f04f49aa-aa93-4368-a567-e82f1e956a01_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_380741a9-5f3d-48d4-b165-343c3544e98b_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_1179f7a4-8e4f-4541-b0d7-8d030ae8d19c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_61221c16-6736-4780-97d0-f71ac7b1503c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Fund</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_e0c5c07e-457a-4785-a9f9-f853f4ded8fe_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and advances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_150b929c-77e2-4655-ad6c-e3e96a304484_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="lab_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_08eaa5cc-8413-48a0-b025-708dbd45762a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_f209eee2-560d-4397-ae61-fdaf9a8eb4f3_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings (Loss) Available to Common Shareholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract" xlink:to="lab_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_c7626a04-465f-41eb-825a-a5851c87fe1d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CortrophinPreLaunchChargesAbstract_f17623ae-5df7-4bca-b908-16830b8a7f74_terseLabel_en-US" xlink:label="lab_anip_CortrophinPreLaunchChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</link:label>
    <link:label id="lab_anip_CortrophinPreLaunchChargesAbstract_label_en-US" xlink:label="lab_anip_CortrophinPreLaunchChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</link:label>
    <link:label id="lab_anip_CortrophinPreLaunchChargesAbstract_documentation_en-US" xlink:label="lab_anip_CortrophinPreLaunchChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchChargesAbstract" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchChargesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CortrophinPreLaunchChargesAbstract" xlink:to="lab_anip_CortrophinPreLaunchChargesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c1cc6f9a-7a84-4f0e-8707-49601cbd681e_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_2b546e4c-8c8a-41f2-8f17-8538e1cb928b_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1584abb4-3704-455b-84d1-bba65a7373b4_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash, beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_6e7d1acf-f2d3-4bab-911a-0f1890a7b68a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock purchases for restricted stock vests</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e9101a3d-a829-499d-a3da-5e12e4f70ec8_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_aa9b6211-6261-4838-8af2-a575723a2f71_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_64df0939-af30-4e50-ae6f-7fc88789a349_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_7247c997-d089-4009-a1fb-916c88fafb8f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dbc33dab-a7de-429f-9b0e-6ac5db3eb932_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_fd933cbe-9cbd-475e-90b6-354db00a4f76_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredAndaIntangibleAssetsMember_70bd26b2-39aa-47ab-8056-0e83af214349_terseLabel_en-US" xlink:label="lab_anip_AcquiredAndaIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired ANDA intangible assets</link:label>
    <link:label id="lab_anip_AcquiredAndaIntangibleAssetsMember_label_en-US" xlink:label="lab_anip_AcquiredAndaIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired ANDA intangible assets</link:label>
    <link:label id="lab_anip_AcquiredAndaIntangibleAssetsMember_documentation_en-US" xlink:label="lab_anip_AcquiredAndaIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired ANDA intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredAndaIntangibleAssetsMember" xlink:to="lab_anip_AcquiredAndaIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_a994512c-9ad4-4349-848e-74a942d17094_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_8cfa28e2-a38a-4567-aa79-c9f7bcf9d874_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Restricted Stock Awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_cc0b8dd1-b265-4206-bb65-744ac386c41c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_066d4586-c3fc-4f1d-9e73-ff1d7496c5dd_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ProjectBasedMilestonePaymentsMember_b836185a-6146-42b4-815d-937cb3462f86_terseLabel_en-US" xlink:label="lab_anip_ProjectBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit-based milestone payments</link:label>
    <link:label id="lab_anip_ProjectBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_anip_ProjectBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit-based milestone payments</link:label>
    <link:label id="lab_anip_ProjectBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_anip_ProjectBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to project based milestone payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProjectBasedMilestonePaymentsMember" xlink:href="anip-20231231.xsd#anip_ProjectBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ProjectBasedMilestonePaymentsMember" xlink:to="lab_anip_ProjectBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_RareDiseaseMember_7a3f5720-a5f3-491e-96fa-d041fc6a9f35_terseLabel_en-US" xlink:label="lab_anip_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease</link:label>
    <link:label id="lab_anip_RareDiseaseMember_label_en-US" xlink:label="lab_anip_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rare Disease</link:label>
    <link:label id="lab_anip_RareDiseaseMember_documentation_en-US" xlink:label="lab_anip_RareDiseaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of the entity related to rare diseases and is considered an operating segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RareDiseaseMember" xlink:href="anip-20231231.xsd#anip_RareDiseaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_RareDiseaseMember" xlink:to="lab_anip_RareDiseaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dd5dac0e-8b00-4246-aa54-cbf2ff66c307_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_612e1af1-7644-4079-a860-00bf1fc64f17_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_84e87506-5192-4a41-b15c-05ee2b19002f_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_44b97613-6b96-49b7-9de8-2b5c6ec35e59_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_c17d0110-bc19-4938-b12e-7445957084f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, current</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_43b2c633-94d3-4b28-a05a-6cbdce74f4ce_terseLabel_en-US" xlink:label="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property, plant and equipment useful lives</link:label>
    <link:label id="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_label_en-US" xlink:label="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]</link:label>
    <link:label id="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_documentation_en-US" xlink:label="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:href="anip-20231231.xsd#anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:to="lab_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SixMonthDurationMember_a2b066ea-f918-43bf-ae00-c1ba35a9b356_terseLabel_en-US" xlink:label="lab_anip_SixMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Month Duration</link:label>
    <link:label id="lab_anip_SixMonthDurationMember_label_en-US" xlink:label="lab_anip_SixMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Month Duration [Member]</link:label>
    <link:label id="lab_anip_SixMonthDurationMember_documentation_en-US" xlink:label="lab_anip_SixMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Six Month Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SixMonthDurationMember" xlink:href="anip-20231231.xsd#anip_SixMonthDurationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SixMonthDurationMember" xlink:to="lab_anip_SixMonthDurationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b6a5d648-a9ac-4d44-8aa7-155bb4e399b1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_c7d0ab0c-cd5b-4d7c-8584-9847761cf5e4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ProductRightMember_90eafb20-cd58-4fbf-819b-2a29f79be302_terseLabel_en-US" xlink:label="lab_anip_ProductRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Rights</link:label>
    <link:label id="lab_anip_ProductRightMember_label_en-US" xlink:label="lab_anip_ProductRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Right [Member]</link:label>
    <link:label id="lab_anip_ProductRightMember_documentation_en-US" xlink:label="lab_anip_ProductRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductRightMember" xlink:href="anip-20231231.xsd#anip_ProductRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ProductRightMember" xlink:to="lab_anip_ProductRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember_62255f06-a9bc-4c3b-8b48-1999953a6902_terseLabel_en-US" xlink:label="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of rare disease pharmaceutical products</link:label>
    <link:label id="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember_label_en-US" xlink:label="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of rare disease pharmaceutical products</link:label>
    <link:label id="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related to sales of rare disease pharmaceutical products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfRareDiseasePharmaceuticalProductsMember" xlink:href="anip-20231231.xsd#anip_SalesOfRareDiseasePharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SalesOfRareDiseasePharmaceuticalProductsMember" xlink:to="lab_anip_SalesOfRareDiseasePharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_4176b80c-a949-4eb6-9f53-531ca980ae2e_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount for Lack of Marketability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:to="lab_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_085017ab-dce1-41a2-9e14-0f96269668a7_verboseLabel_en-US" xlink:label="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses, accrued compensation, and other</link:label>
    <link:label id="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_label_en-US" xlink:label="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease Of Accrued Expenses Compensation And Others</link:label>
    <link:label id="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_documentation_en-US" xlink:label="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" xlink:to="lab_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_d867ab06-db35-40f3-964f-31b147f06723_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in temporary equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_1920a8fd-1131-4afe-8490-57c34974ebe1_terseLabel_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest (in shares)</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_label_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_documentation_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" xlink:to="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_44d69a98-44f3-48fb-9527-31042f0eac88_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer pricing and other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_3fd11585-b486-48c2-b0dc-7d854afeb473_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_9113e8c3-e6e8-4a4f-b4fe-662ec05717f5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_23452daa-93d6-4aba-9900-fe50cfd251d7_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_02d5c684-4ce0-4835-9490-ad4b1f434d13_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Available to Common Shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_71e2d7b4-e935-407c-abf2-561e97824732_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available to common shareholders, Basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SalesOfBrandedPharmaceuticalProductsMember_88e05bbb-460e-42c6-8055-770529611ebf_terseLabel_en-US" xlink:label="lab_anip_SalesOfBrandedPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</link:label>
    <link:label id="lab_anip_SalesOfBrandedPharmaceuticalProductsMember_label_en-US" xlink:label="lab_anip_SalesOfBrandedPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of established brand pharmaceutical products</link:label>
    <link:label id="lab_anip_SalesOfBrandedPharmaceuticalProductsMember_documentation_en-US" xlink:label="lab_anip_SalesOfBrandedPharmaceuticalProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of established brand pharmaceutical products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfBrandedPharmaceuticalProductsMember" xlink:href="anip-20231231.xsd#anip_SalesOfBrandedPharmaceuticalProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SalesOfBrandedPharmaceuticalProductsMember" xlink:to="lab_anip_SalesOfBrandedPharmaceuticalProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ba53f4df-74b0-47f2-83e2-7a93decac991_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_c6c37198-ee2a-4690-af70-1e88962ff162_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares held</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtFairValue_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtFairValue" xlink:to="lab_us-gaap_InvestmentOwnedAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e7fff878-55ff-41ac-8b95-2f41da93d72e_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_2f0a579f-3df3-449d-afdd-21abc5f874e3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_524bccf9-a389-4772-bbae-671097bc2efa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock option and restricted stock activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_fe1e85e9-2ebf-4470-b646-ecdad500a00c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_797a5b95-f48d-4470-8c30-de9b001cc685_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_592831e1-6947-4498-bbd6-5874b713eb3a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Gain Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NewEmployeesMember_b93ef10d-3a10-4344-9f6e-09a20d475624_terseLabel_en-US" xlink:label="lab_anip_NewEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Employees</link:label>
    <link:label id="lab_anip_NewEmployeesMember_label_en-US" xlink:label="lab_anip_NewEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Employees [Member]</link:label>
    <link:label id="lab_anip_NewEmployeesMember_documentation_en-US" xlink:label="lab_anip_NewEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NewEmployeesMember" xlink:href="anip-20231231.xsd#anip_NewEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NewEmployeesMember" xlink:to="lab_anip_NewEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_be777ea7-44c8-40f6-a20c-85d1d44514c4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_72bd605b-6956-4e6f-96e9-994789910ce0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_c0d15fbc-7d29-4d3d-8daf-c3ba3c7af835_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation income tax benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_bc97cf9d-3ddc-4ba8-8d06-13cfc777a4b1_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ANICanadaMember_6ac9794a-3d0a-4a72-9a1b-b84f19fe6c23_terseLabel_en-US" xlink:label="lab_anip_ANICanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ANI Canada</link:label>
    <link:label id="lab_anip_ANICanadaMember_label_en-US" xlink:label="lab_anip_ANICanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ANI Canada [Member]</link:label>
    <link:label id="lab_anip_ANICanadaMember_documentation_en-US" xlink:label="lab_anip_ANICanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ANI Canada [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ANICanadaMember" xlink:href="anip-20231231.xsd#anip_ANICanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ANICanadaMember" xlink:to="lab_anip_ANICanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6582ef16-f0ee-4222-b29a-873341fc77dd_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, $0.0001 par value, 33,333,334 shares authorized; 20,730,896 shares issued and 20,466,953 outstanding at December&#160;31, 2023; 17,643,497 shares issued and 17,494,466 shares outstanding at December&#160;31, 2022</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_GovernmentRebatesMember_feaa000e-8c08-4885-bbe4-6c771a6a4c97_terseLabel_en-US" xlink:label="lab_anip_GovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates</link:label>
    <link:label id="lab_anip_GovernmentRebatesMember_label_en-US" xlink:label="lab_anip_GovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates</link:label>
    <link:label id="lab_anip_GovernmentRebatesMember_documentation_en-US" xlink:label="lab_anip_GovernmentRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_GovernmentRebatesMember" xlink:href="anip-20231231.xsd#anip_GovernmentRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_GovernmentRebatesMember" xlink:to="lab_anip_GovernmentRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_BiosantePharmaceuticalsIncMember_3f0e494b-aa57-4d7e-ae82-7e4884883169_terseLabel_en-US" xlink:label="lab_anip_BiosantePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioSante Pharmaceuticals</link:label>
    <link:label id="lab_anip_BiosantePharmaceuticalsIncMember_label_en-US" xlink:label="lab_anip_BiosantePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioSante Pharmaceuticals</link:label>
    <link:label id="lab_anip_BiosantePharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_anip_BiosantePharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BioSante Pharmaceuticals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BiosantePharmaceuticalsIncMember" xlink:href="anip-20231231.xsd#anip_BiosantePharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_BiosantePharmaceuticalsIncMember" xlink:to="lab_anip_BiosantePharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CustomerThreeMember_886986a9-8441-4236-8894-1cb1bca3238f_terseLabel_en-US" xlink:label="lab_anip_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:label id="lab_anip_CustomerThreeMember_label_en-US" xlink:label="lab_anip_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three [Member]</link:label>
    <link:label id="lab_anip_CustomerThreeMember_documentation_en-US" xlink:label="lab_anip_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerThreeMember" xlink:href="anip-20231231.xsd#anip_CustomerThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CustomerThreeMember" xlink:to="lab_anip_CustomerThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_56dee626-28dd-42cf-885e-d86931271445_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_8ed531ff-01be-40cd-b424-75ffc8becf99_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NonEmployeeDirectorStockOptionMember_e6dc13dd-3db3-45f2-bd9a-3981515e5de6_terseLabel_en-US" xlink:label="lab_anip_NonEmployeeDirectorStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director</link:label>
    <link:label id="lab_anip_NonEmployeeDirectorStockOptionMember_label_en-US" xlink:label="lab_anip_NonEmployeeDirectorStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Employee Director [Member]</link:label>
    <link:label id="lab_anip_NonEmployeeDirectorStockOptionMember_documentation_en-US" xlink:label="lab_anip_NonEmployeeDirectorStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NonEmployeeDirectorStockOptionMember" xlink:href="anip-20231231.xsd#anip_NonEmployeeDirectorStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NonEmployeeDirectorStockOptionMember" xlink:to="lab_anip_NonEmployeeDirectorStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_6f7fabed-e4cc-495f-8bd1-15d61037ed1f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b4fa6e9e-87eb-4c56-8224-1f306a80f9e7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5c4c86ff-bd58-48dc-8359-21fbada54531_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ebe19f22-27f0-40cb-a663-e81d90745605_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AdministrativeFeesAndOtherRebatesMember_d53f5154-b7df-4568-876f-835350210062_terseLabel_en-US" xlink:label="lab_anip_AdministrativeFeesAndOtherRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Fees and Other Rebates</link:label>
    <link:label id="lab_anip_AdministrativeFeesAndOtherRebatesMember_label_en-US" xlink:label="lab_anip_AdministrativeFeesAndOtherRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Fees and Other Rebates</link:label>
    <link:label id="lab_anip_AdministrativeFeesAndOtherRebatesMember_documentation_en-US" xlink:label="lab_anip_AdministrativeFeesAndOtherRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Fees and Other Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AdministrativeFeesAndOtherRebatesMember" xlink:href="anip-20231231.xsd#anip_AdministrativeFeesAndOtherRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AdministrativeFeesAndOtherRebatesMember" xlink:to="lab_anip_AdministrativeFeesAndOtherRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ccc948b7-64b3-4324-a63c-15572863d579_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current contingent consideration, net of current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0f57e30e-973a-4db0-9112-fa4cdf68940d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_3b770604-8dc4-49a2-a932-b8584adc75ab_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_e3bdfae7-8446-487f-acca-878567b3d0df_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_08518d7c-0639-44f9-aca1-cef283dd433d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_d6598993-a6e5-4497-8254-44542274c3e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e20628b8-87d8-4632-b53b-417c18ff5f63_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_49b069d8-3a7e-4aab-9b00-78f8b3da926a_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_b33cca5c-164a-42e3-a385-c9fe82e9bbac_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_9c53dc39-9bc2-4ba3-9b28-d73378e5159c_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_e6b45dbd-e4da-4643-a6f9-4deb59c8ff13_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_927c4733-09eb-4784-b784-8d8e0d76db2f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_14f27a14-a0b5-4f0f-afff-e5059a483cf3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_6bf54b70-1c3f-4c5a-a612-81f46ddbc269_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits Taken Against Reserve</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_9a89cd75-338c-4b12-940b-a7ed6ce3c646_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_8e622930-7a80-43de-a877-25c9afdc12ac_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_603d3877-5505-4222-ad34-f6a770861e22_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7ae8509d-0450-4120-a724-31d1f3abdee4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PerformanceBasedRestrictedStockUnitsMember_f4db19ba-f180-43c3-9e40-91c41aa8ecce_terseLabel_en-US" xlink:label="lab_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_anip_PerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_anip_PerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:href="anip-20231231.xsd#anip_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f2e7a2a8-9b70-4a09-872d-49d16782d70a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_35bf90dc-9742-47ad-9658-433de84c25de_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c0c84ff1-283d-428a-9144-fe783b42d06f_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_dfe43679-85cc-43d0-88cf-40e42e1da435_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_5f571edc-6cb6-47fd-b57a-a581cc5d0a82_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercise tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_34c61499-a1be-4e86-8d41-0e9fe96eeffc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9f734fd5-6f21-4779-ae58-8e6a3a6221d9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of recurring Level 3 fair value measurements of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_Mr.ShanmugamAndEsjayMember_a061a067-43b3-4947-b4cf-919245fa0f48_terseLabel_en-US" xlink:label="lab_anip_Mr.ShanmugamAndEsjayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Shanmugam and Esjay</link:label>
    <link:label id="lab_anip_Mr.ShanmugamAndEsjayMember_label_en-US" xlink:label="lab_anip_Mr.ShanmugamAndEsjayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Shanmugam and Esjay [Member]</link:label>
    <link:label id="lab_anip_Mr.ShanmugamAndEsjayMember_documentation_en-US" xlink:label="lab_anip_Mr.ShanmugamAndEsjayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mr. Shanmugam and Esjay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.ShanmugamAndEsjayMember" xlink:href="anip-20231231.xsd#anip_Mr.ShanmugamAndEsjayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_Mr.ShanmugamAndEsjayMember" xlink:to="lab_anip_Mr.ShanmugamAndEsjayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c4e0743d-5eff-4228-9ef3-fd85016fea86_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_90d13ece-850e-4f17-9b08-f71fe6a938de_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0f694d94-49dd-4c78-996f-679e0fa9b113_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5e1403e6-e699-4ac5-b817-ab9b51b3dc88_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_34434e8d-65fc-40df-bd77-55f61d7ddbd1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Before Expense (Benefit) for Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_f30d8833-b055-4d2d-99f5-5e3c5b9ebbe2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of product rights, IPR&amp;D, and other related assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_3009706d-2c71-425e-8dd3-e9abd269baac_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_66b27da8-94b5-4fca-936b-2812b9fd379e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_50138932-946b-4d4e-82a6-0fad4a422290_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of complaints filed</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_0401d3fa-cfc5-417e-bf6c-4ade235892db_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_15f0c337-b636-4149-872b-e6c65f499591_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_90c31916-de4e-489c-a31b-9ae107fd958c_verboseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of property and equipment by geographic location</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_64f4ac39-a5b0-4d07-b246-52a83bd81ac1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total asset purchase</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_841dba85-cd6a-4f3a-9f01-cf8113358140_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CommonStockConvertibleConversionRatio_7d7b1304-c499-453f-bd6b-537eac7c9af4_terseLabel_en-US" xlink:label="lab_anip_CommonStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock conversion ratio</link:label>
    <link:label id="lab_anip_CommonStockConvertibleConversionRatio_label_en-US" xlink:label="lab_anip_CommonStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_anip_CommonStockConvertibleConversionRatio_documentation_en-US" xlink:label="lab_anip_CommonStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockConvertibleConversionRatio" xlink:href="anip-20231231.xsd#anip_CommonStockConvertibleConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CommonStockConvertibleConversionRatio" xlink:to="lab_anip_CommonStockConvertibleConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_6c7a15e4-f79a-4acc-a0e7-6ec3004c09ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt effective interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_b076f5b8-0b3e-4bec-944c-3b11d50a5414_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2cf5bc12-030e-4b8f-96e0-deb4a1eefe0d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0b6635d1-ad6b-4d07-9ece-e3d11b5a17dc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_46683b51-9d35-4c16-a04e-47b35eab6794_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_4cf8bf5c-1339-4f8f-a86a-3cd882649db0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_284318a5-9865-4a77-813b-f1d866618756_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_5f295891-7b27-43ce-8ac8-2e6d852aa5ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount from market price (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SalesOfContractManufacturedProductsMember_7b54d591-2f96-45ac-b2ab-71b58e73c5e5_terseLabel_en-US" xlink:label="lab_anip_SalesOfContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of contract manufactured products</link:label>
    <link:label id="lab_anip_SalesOfContractManufacturedProductsMember_label_en-US" xlink:label="lab_anip_SalesOfContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of contract manufactured products</link:label>
    <link:label id="lab_anip_SalesOfContractManufacturedProductsMember_documentation_en-US" xlink:label="lab_anip_SalesOfContractManufacturedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of contract manufactured products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfContractManufacturedProductsMember" xlink:href="anip-20231231.xsd#anip_SalesOfContractManufacturedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SalesOfContractManufacturedProductsMember" xlink:to="lab_anip_SalesOfContractManufacturedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f87e76e6-b071-4bc2-80aa-63cc3e48de2f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc923470-b005-4b5d-9995-c83a6ddda1f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_414aa312-e348-41ab-b59e-dd2125c7dcbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_8ce579fc-b6a1-4ac4-9ded-215285b36d8f_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue by geographic operations</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_IntangibleAssetMeasurementInput_e8f05215-cf43-4de7-aae9-da0a53586890_terseLabel_en-US" xlink:label="lab_anip_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset measurement input</link:label>
    <link:label id="lab_anip_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_anip_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_anip_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_anip_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of input used to measure intangible assets acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IntangibleAssetMeasurementInput" xlink:href="anip-20231231.xsd#anip_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_IntangibleAssetMeasurementInput" xlink:to="lab_anip_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1b8cee5d-00a0-42a3-9585-26b698a06e39_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_26bc99ad-7f92-4162-893f-a81723c31afa_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d52fae72-3455-4de7-87b9-5bc31eb4695a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_NumberOfOperatingLeases_e743f69b-b521-442c-bb6a-3f80ba01baa4_terseLabel_en-US" xlink:label="lab_anip_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating leases</link:label>
    <link:label id="lab_anip_NumberOfOperatingLeases_label_en-US" xlink:label="lab_anip_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Leases</link:label>
    <link:label id="lab_anip_NumberOfOperatingLeases_documentation_en-US" xlink:label="lab_anip_NumberOfOperatingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfOperatingLeases" xlink:href="anip-20231231.xsd#anip_NumberOfOperatingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_NumberOfOperatingLeases" xlink:to="lab_anip_NumberOfOperatingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_be2e21b1-1766-4425-99a8-588cf56ae07f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_9825f151-9061-4eb4-b02f-06fc452722e2_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CustomerTwoMember_86406742-10be-4e32-b824-7f0d99de0405_terseLabel_en-US" xlink:label="lab_anip_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:label id="lab_anip_CustomerTwoMember_label_en-US" xlink:label="lab_anip_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two [Member]</link:label>
    <link:label id="lab_anip_CustomerTwoMember_documentation_en-US" xlink:label="lab_anip_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerTwoMember" xlink:href="anip-20231231.xsd#anip_CustomerTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CustomerTwoMember" xlink:to="lab_anip_CustomerTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AccruedGovernmentRebates_87434258-b785-44c0-98a7-0f4169c660f4_verboseLabel_en-US" xlink:label="lab_anip_AccruedGovernmentRebates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued government rebates</link:label>
    <link:label id="lab_anip_AccruedGovernmentRebates_label_en-US" xlink:label="lab_anip_AccruedGovernmentRebates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Government Rebates</link:label>
    <link:label id="lab_anip_AccruedGovernmentRebates_documentation_en-US" xlink:label="lab_anip_AccruedGovernmentRebates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents amounts accrued for government rebates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AccruedGovernmentRebates" xlink:href="anip-20231231.xsd#anip_AccruedGovernmentRebates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AccruedGovernmentRebates" xlink:to="lab_anip_AccruedGovernmentRebates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_26352c94-cd86-4c9b-890f-2d1f49c5c17c_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3ee3b3f8-b79d-4ff1-a843-53dfc9f14df4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9e8ab8d2-997e-4f95-9ae4-4cfa8cb332e2_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AcquiredCommercialProductMember_1240a019-0c93-443a-93f4-03e465ccaf44_terseLabel_en-US" xlink:label="lab_anip_AcquiredCommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired commercial product</link:label>
    <link:label id="lab_anip_AcquiredCommercialProductMember_label_en-US" xlink:label="lab_anip_AcquiredCommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Commercial Product [Member]</link:label>
    <link:label id="lab_anip_AcquiredCommercialProductMember_documentation_en-US" xlink:label="lab_anip_AcquiredCommercialProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Commercial Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredCommercialProductMember" xlink:href="anip-20231231.xsd#anip_AcquiredCommercialProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AcquiredCommercialProductMember" xlink:to="lab_anip_AcquiredCommercialProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_54a4cd7e-0514-4f69-894b-0baf9aa72d71_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AuditInformationAbstract_label_en-US" xlink:label="lab_anip_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_anip_AuditInformationAbstract_documentation_en-US" xlink:label="lab_anip_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AuditInformationAbstract" xlink:href="anip-20231231.xsd#anip_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AuditInformationAbstract" xlink:to="lab_anip_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_54c5fda8-b599-4347-b96e-3701695f2cf0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of allocated expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_a79b444d-2436-47a4-b820-11b98592c08e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_184b4cc9-a9ee-4461-933d-2679c79f37fd_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives and other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e273f6c-967a-4c9a-8d82-4af982bd0675_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_5d8c41d8-e46e-4d07-a8b5-725eb14384a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Amortization Period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5fabf8fd-774a-4303-a30b-b30e0cdba895_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_b7bd84d7-0c6a-4855-8701-e53fbd734f27_terseLabel_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of awards</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_label_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_documentation_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" xlink:to="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OfficerMember_49723e0b-c43d-4302-b82d-b7709d1e2d53_terseLabel_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer</link:label>
    <link:label id="lab_srt_OfficerMember_label_en-US" xlink:label="lab_srt_OfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OfficerMember" xlink:to="lab_srt_OfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_18f6b68a-3bf2-4eaf-9455-69b21c1d4d87_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Activities</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_73bb7e63-ec83-4632-97ab-eb769c05d8b7_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarnings_6ca133d3-3515-4a08-9996-46a5ef2b811c_totalLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available to common shareholders, Basic</link:label>
    <link:label id="lab_us-gaap_UndistributedEarnings_label_en-US" xlink:label="lab_us-gaap_UndistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarnings" xlink:to="lab_us-gaap_UndistributedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_53f22c8f-0d6d-46b8-9189-750f7c9535bd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) available to common shareholders, Diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_511043f6-d23e-42e5-96a3-575416ca23f2_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_fe5f69de-8545-47f9-a954-f7553019dba9_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityRedemptionPricePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="lab_us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_7676db09-34fd-4641-854d-8d97cc298b72_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy_label_en-US" xlink:label="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Liability Reserve Estimate, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:to="lab_us-gaap_ContingentLiabilityReserveEstimatePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_84792b59-8c6f-438b-a341-686a454fef4a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_5bb311a4-4e58-40bf-834b-6c5728997551_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_309fbcde-f4ae-4ac9-9d1f-50a24bbc9624_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue by reportable segments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_1348744e-4eb2-4f49-ad2a-9d909cd07c42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_26a3e223-a416-420a-bf62-e39d076f21e3_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_426f586f-c7a8-4a2d-b02a-f66fb1ea3d8e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsTotalMember_6cd33658-e5f0-473b-bce5-4dbba001ba49_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service Benchmark</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsTotalMember_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsTotalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsTotalMember" xlink:to="lab_us-gaap_CostOfGoodsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_88d537fe-ecd1-4303-a47b-6f6119231f41_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember_023d2899-0a6e-43ac-bb39-27abdda410be_terseLabel_en-US" xlink:label="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development-based milestone payments</link:label>
    <link:label id="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product development-based milestone payments</link:label>
    <link:label id="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Product development-based milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductDevelopmentBasedMilestonePaymentsMember" xlink:href="anip-20231231.xsd#anip_ProductDevelopmentBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ProductDevelopmentBasedMilestonePaymentsMember" xlink:to="lab_anip_ProductDevelopmentBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_IncreaseDecreaseInReturnedGoodsReserve_24894470-fdb1-4161-9685-74348cbc3936_terseLabel_en-US" xlink:label="lab_anip_IncreaseDecreaseInReturnedGoodsReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returned goods reserve</link:label>
    <link:label id="lab_anip_IncreaseDecreaseInReturnedGoodsReserve_label_en-US" xlink:label="lab_anip_IncreaseDecreaseInReturnedGoodsReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Returned Goods Reserve</link:label>
    <link:label id="lab_anip_IncreaseDecreaseInReturnedGoodsReserve_documentation_en-US" xlink:label="lab_anip_IncreaseDecreaseInReturnedGoodsReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of increase (decrease) in returned goods reserve.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseInReturnedGoodsReserve" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseInReturnedGoodsReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_IncreaseDecreaseInReturnedGoodsReserve" xlink:to="lab_anip_IncreaseDecreaseInReturnedGoodsReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_d1275a53-bd96-494f-b248-f91e6d44414b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_b1676e1c-ed5e-4ce3-8753-e837a4ebe757_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_43447c11-2758-4db2-80d4-f40e95c69ce1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_0ec190e1-866a-4be2-b223-b95c0ffe3e65_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_d19aa749-6d29-48f3-83f1-7924f3a7ea4a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_SandozIncMember_be2882f3-d042-4f04-876b-f4f0661796ad_terseLabel_en-US" xlink:label="lab_anip_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz</link:label>
    <link:label id="lab_anip_SandozIncMember_label_en-US" xlink:label="lab_anip_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sandoz</link:label>
    <link:label id="lab_anip_SandozIncMember_documentation_en-US" xlink:label="lab_anip_SandozIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information relating to Sandoz Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SandozIncMember" xlink:href="anip-20231231.xsd#anip_SandozIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_SandozIncMember" xlink:to="lab_anip_SandozIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_9f4cc953-2984-49ca-a283-cf50010c262a_verboseLabel_en-US" xlink:label="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity (in shares)</link:label>
    <link:label id="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bb6f75b2-7477-43e8-95e1-ac8d74397d83_terseLabel_en-US" xlink:label="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary stock issued (in shares)</link:label>
    <link:label id="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of new stock classified as temporary equity issued during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_56381314-c696-418d-996a-9c33d1f9f26b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_fa8849d4-d50b-4933-9782-9de4cffad9ac_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_18547640-efe2-48e8-9fd3-d58d8d1f5b2e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CortrophinPreLaunchCharges_3bd8921c-dfe3-42a7-a4c9-7ddb31dc569f_terseLabel_en-US" xlink:label="lab_anip_CortrophinPreLaunchCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purified Cortrophin Gel pre-launch charges</link:label>
    <link:label id="lab_anip_CortrophinPreLaunchCharges_label_en-US" xlink:label="lab_anip_CortrophinPreLaunchCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cortrophin Pre Launch Charges</link:label>
    <link:label id="lab_anip_CortrophinPreLaunchCharges_documentation_en-US" xlink:label="lab_anip_CortrophinPreLaunchCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of charges directly related to the Purified Cortrophin Gel pre-launch charges commercialization efforts, including but not limited to sales and marketing expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchCharges" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CortrophinPreLaunchCharges" xlink:to="lab_anip_CortrophinPreLaunchCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_36d4ee6e-81c4-41c0-9a2d-1afcfd8614bf_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ContractCustomerMember_900ee5bc-d316-42cb-8db5-efd318ffa1c6_terseLabel_en-US" xlink:label="lab_anip_ContractCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Customer</link:label>
    <link:label id="lab_anip_ContractCustomerMember_label_en-US" xlink:label="lab_anip_ContractCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Customer</link:label>
    <link:label id="lab_anip_ContractCustomerMember_documentation_en-US" xlink:label="lab_anip_ContractCustomerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ContractCustomerMember" xlink:href="anip-20231231.xsd#anip_ContractCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ContractCustomerMember" xlink:to="lab_anip_ContractCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_36ce842d-adec-4e48-9b6f-5b393cee6cee_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds held in escrow for asset purchase</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_e7dc6453-e3b3-4efc-ac6e-b3a124af3426_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_edba115b-0daf-4e13-a5c4-4539ea0a56d8_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_InterestPeriodDomain_44e67c35-b5b8-4dee-a312-5606817bc102_terseLabel_en-US" xlink:label="lab_anip_InterestPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Period [Domain]</link:label>
    <link:label id="lab_anip_InterestPeriodDomain_label_en-US" xlink:label="lab_anip_InterestPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Period [Domain]</link:label>
    <link:label id="lab_anip_InterestPeriodDomain_documentation_en-US" xlink:label="lab_anip_InterestPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodDomain" xlink:href="anip-20231231.xsd#anip_InterestPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_InterestPeriodDomain" xlink:to="lab_anip_InterestPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_6b01bfe8-9bd4-402e-81b1-dd96219cbef7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_450cd1ff-2363-4c67-9a52-a357a03b1a11_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debts assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_810383e9-c04d-40c8-94fe-0d03f8e57c02_terseLabel_en-US" xlink:label="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustment</link:label>
    <link:label id="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_label_en-US" xlink:label="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Measurement period adjustment</link:label>
    <link:label id="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_documentation_en-US" xlink:label="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement period adjustment for liability measured at fair value on recurring basis using unobservable input (level 3).</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" xlink:href="anip-20231231.xsd#anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" xlink:to="lab_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_91f1c45e-9fa6-473c-9c2a-7f521d757867_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_9232f58e-5845-43d2-9415-39453b9f88fe_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_5c4c57d3-451c-4613-9fff-205b2c263514_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-progress</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInventoryDemo_026ec713-91f8-47e1-bb6a-695c31b84438_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInventoryDemo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sample inventory</link:label>
    <link:label id="lab_us-gaap_OtherInventoryDemo_label_en-US" xlink:label="lab_us-gaap_OtherInventoryDemo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Inventory, Demo, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryDemo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryDemo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInventoryDemo" xlink:to="lab_us-gaap_OtherInventoryDemo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_OakvilleOntarioCanadaMember_d6ade9d2-c084-4d90-b346-41a76ad77f61_terseLabel_en-US" xlink:label="lab_anip_OakvilleOntarioCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakville, Ontario, Canada</link:label>
    <link:label id="lab_anip_OakvilleOntarioCanadaMember_label_en-US" xlink:label="lab_anip_OakvilleOntarioCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oakville, Ontario, Canada</link:label>
    <link:label id="lab_anip_OakvilleOntarioCanadaMember_documentation_en-US" xlink:label="lab_anip_OakvilleOntarioCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the Oakville, Ontario, Canada manufacturing plant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioCanadaMember" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_OakvilleOntarioCanadaMember" xlink:to="lab_anip_OakvilleOntarioCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_f2ae3d9c-f7dd-46e0-9dda-d3b191ea6fae_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f4cd1b3b-96d7-4136-8d34-1e51c5178321_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the beginning of the period intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_737a67a3-c3cf-434f-9ed9-66fe1d19bbac_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at the end of the period intrinsic value (in dollars)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_c35e350a-9f1a-4b2b-873c-dbe029da5644_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals/Adjustments</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesAdjustments_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d1724350-d5e3-4cfc-bb26-ca50ae5f3c30_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Performance Stock Units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_CreditAgreementMember_d67aac54-0400-4442-b5af-b2856a72cdbb_terseLabel_en-US" xlink:label="lab_anip_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility - 2021</link:label>
    <link:label id="lab_anip_CreditAgreementMember_label_en-US" xlink:label="lab_anip_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility - 2021</link:label>
    <link:label id="lab_anip_CreditAgreementMember_documentation_en-US" xlink:label="lab_anip_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility - 2021</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CreditAgreementMember" xlink:href="anip-20231231.xsd#anip_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_CreditAgreementMember" xlink:to="lab_anip_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_0332dd32-363c-4730-a211-be7fdafd8edb_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_832c6df5-1b26-4396-bef7-4c3bc0bc8259_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_bb58c10e-c08d-4829-9123-bbdc18d2bf5f_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_ea9fa097-0d29-4fcf-ae48-e04ad8541712_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_PaymentTypeDomain_7d9f716f-453c-4ef4-8f1f-197811d2cd92_terseLabel_en-US" xlink:label="lab_anip_PaymentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Domain]</link:label>
    <link:label id="lab_anip_PaymentTypeDomain_label_en-US" xlink:label="lab_anip_PaymentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Domain]</link:label>
    <link:label id="lab_anip_PaymentTypeDomain_documentation_en-US" xlink:label="lab_anip_PaymentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeDomain" xlink:href="anip-20231231.xsd#anip_PaymentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_PaymentTypeDomain" xlink:to="lab_anip_PaymentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_e71fac4c-752a-4543-bd35-58e0c02a8573_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1ceda3e2-cc40-4a9f-9d85-2b4ea9c7d3a5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration fair value adjustment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_667de563-16b5-4078-beac-5e62218f5265_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_21f6e231-3be8-43f7-ad61-a70b5e0641d8_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_db4636b1-a061-4667-af1a-175aed036400_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under the Credit Facility, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_32ed24e9-ae37-4655-a774-76cdf2e5b7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds drawn</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_23867df2-ada9-4e5d-98f5-10a6d7827a08_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares accrue dividends rate</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_d697859c-6bf3-42f1-b7fc-8fca4aa6f124_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_32b669cd-4f75-430b-a921-f1429deb3998_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_f4e97362-328d-494a-85ea-9eb77a5a5ae1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of financial assets and liabilities accounted for at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a3d61cc8-8cd5-4aa6-8421-3d63620f1f46_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_99bdf878-9dfc-47d4-bfa5-6896de6dcf80_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_35daa594-10d4-4b70-9f6c-6f90169f5558_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_2c4f226f-8d5b-4c9a-a574-fdb19de0da9d_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a6ab2c45-f2ec-40bf-a656-cb7b6f61fa67_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b7e950d7-e7eb-4b1e-b145-797a9129c1b5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_bf578577-7055-4d02-9260-57b11f22a3be_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible costs</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5fa8d91e-6cb0-49ad-a312-57bc8b68f139_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_64c46ef0-759b-429e-83a7-fde6c29e7142_terseLabel_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest percentage</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_label_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_documentation_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" xlink:to="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_cd127c6a-a148-4f2f-b62b-d42f9d4f549b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_51b2b624-2ffb-4565-94a1-56365d304eab_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_29beb7a8-7eb2-4a06-8f0f-f55610019d07_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of disaggregation of revenue and revenue recognized</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_4cfc1b7d-132c-440a-84c6-916b6a5498cd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Common Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_StockIncentivePlanMember_61038d75-df7e-474e-9027-ccbc1e52f65a_terseLabel_en-US" xlink:label="lab_anip_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Plan</link:label>
    <link:label id="lab_anip_StockIncentivePlanMember_label_en-US" xlink:label="lab_anip_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Plan</link:label>
    <link:label id="lab_anip_StockIncentivePlanMember_documentation_en-US" xlink:label="lab_anip_StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related to the entity's Stock Incentive Plan for equity-based service awards.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockIncentivePlanMember" xlink:href="anip-20231231.xsd#anip_StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_StockIncentivePlanMember" xlink:to="lab_anip_StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_77997b73-8145-4b75-950a-9ac1b384d17c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_492c9351-cece-4226-86d6-4d4d30ab7e99_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_5dfc2396-b008-4266-b73a-cb0ee45eb8d1_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_7a09d74f-8880-4863-857b-a0db0efe55d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_1501b803-de80-45e1-ba00-7877f85f41d1_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_TermLoanMember_fee04e80-a67c-446f-a8b7-4e2f7efae173_terseLabel_en-US" xlink:label="lab_anip_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility</link:label>
    <link:label id="lab_anip_TermLoanMember_label_en-US" xlink:label="lab_anip_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility</link:label>
    <link:label id="lab_anip_TermLoanMember_documentation_en-US" xlink:label="lab_anip_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_TermLoanMember" xlink:to="lab_anip_TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_cd49a822-b5eb-46e6-9842-9dba7ddbbea9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_cfe77e61-d54e-41b5-a79e-6b875fe23c75_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_c502b4c7-b38e-4b44-9e0d-a2e12ded74b2_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_b82c6b04-588a-4b3b-be4f-fad150a6ed7f_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_b7683630-e933-45c9-a1b2-2dcb51784050_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock outstanding (shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_02dcd58a-6037-4405-8931-ebad88d8f251_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_0978e5aa-56c1-4ed8-9e66-3d2bb5631ab4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Definite-Lived Intangible Assets:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ThreeMonthDurationMember_9a2a0c84-6e84-4be9-a630-5740155d059c_terseLabel_en-US" xlink:label="lab_anip_ThreeMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Month Duration</link:label>
    <link:label id="lab_anip_ThreeMonthDurationMember_label_en-US" xlink:label="lab_anip_ThreeMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Month Duration [Member]</link:label>
    <link:label id="lab_anip_ThreeMonthDurationMember_documentation_en-US" xlink:label="lab_anip_ThreeMonthDurationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Month Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ThreeMonthDurationMember" xlink:href="anip-20231231.xsd#anip_ThreeMonthDurationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ThreeMonthDurationMember" xlink:to="lab_anip_ThreeMonthDurationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_c9920253-d1b5-42c8-b38e-2564aa91865a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_OneSupplierMember_703dcc32-469c-45fd-9d34-d7833a182d40_terseLabel_en-US" xlink:label="lab_anip_OneSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One supplier</link:label>
    <link:label id="lab_anip_OneSupplierMember_label_en-US" xlink:label="lab_anip_OneSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One supplier</link:label>
    <link:label id="lab_anip_OneSupplierMember_documentation_en-US" xlink:label="lab_anip_OneSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Supplier [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OneSupplierMember" xlink:href="anip-20231231.xsd#anip_OneSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_OneSupplierMember" xlink:to="lab_anip_OneSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_62af6e4d-d26a-403e-8e51-556916908173_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability discount rates (in percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_6841a974-8fc8-4a11-95d9-e1bf5337b807_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and allowances</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b5de17e3-80c9-4fa8-a11a-bf8f62644e6b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest, net of amounts capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_bad7dd7b-f2c9-483b-b944-b52383481a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee share plan issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_ff0f51c7-f8d8-49e3-9883-d3eff7356ae1_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, shares issued</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_0fc086ec-b7d3-4d7f-afd6-4764a97954c6_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current debt, net of deferred financing costs and current component</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_e2f5c916-2644-4689-8544-a82fd039b19b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current debt, net of deferred financing costs and current component</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6ea6afbe-2969-4618-bf31-0e67b36c2de6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Weighted-Average Shares Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a9db70c2-cae8-4e46-b359-0f174f467d9c_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted Weighted-Average Shares Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_8fa7184e-ab45-4b64-9031-6d7e960a540c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_ae64b90b-8281-4379-8d61-077e8e43e9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b2bf4563-209c-4ca8-b55a-88dde331a712_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2208fd2f-c0aa-4c64-892a-ab9c461cc9bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_08bd0aa1-7946-41cf-bb5c-947a0e6f6ec4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_label_en-US" xlink:label="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Owned, Federal Income Tax Note [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:to="lab_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_460a8ca2-5096-414d-8e5d-778760d2ceff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9b803ce7-6710-458e-ade6-08a2f40903e2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e2146d65-5253-4346-a759-029904a6500d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_6361b73c-cd23-4446-8345-ef91fab876b2_terseLabel_en-US" xlink:label="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_label_en-US" xlink:label="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_documentation_en-US" xlink:label="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" xlink:href="anip-20231231.xsd#anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" xlink:to="lab_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_8a510220-1990-4ac3-8c28-75518a04ed40_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_29c3516a-82fc-4ade-a22f-b56aec763668_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_7224edd0-bd30-4bb0-9994-dfc733efb0b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_f0ba870d-1532-4a0d-a894-d0e15a36d0f6_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_6ce94f92-8371-439e-801d-888ad22dae1a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_a0843fc2-da80-4d8f-9aac-48f8e8b07760_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows From Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_01c9edef-98a3-4c29-82fe-98f3508adbe8_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of equity issued as consideration in a business combination</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_540176f4-ac5d-4ffb-978e-d61487de705b_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_9b299aa8-44fb-4d08-9352-b9fb283f6cb7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0159fdcf-bf44-4a0c-96eb-fc274ae2c220_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic Weighted-Average Shares Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_AlvogenIncMember_a2d0acbe-567a-41ef-9ad5-09ca3778cc03_terseLabel_en-US" xlink:label="lab_anip_AlvogenIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alvogen Inc</link:label>
    <link:label id="lab_anip_AlvogenIncMember_label_en-US" xlink:label="lab_anip_AlvogenIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alvogen Inc [Member]</link:label>
    <link:label id="lab_anip_AlvogenIncMember_documentation_en-US" xlink:label="lab_anip_AlvogenIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alvogen Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AlvogenIncMember" xlink:href="anip-20231231.xsd#anip_AlvogenIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_AlvogenIncMember" xlink:to="lab_anip_AlvogenIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember_383448a3-a74c-4870-aaeb-0d4828f1eb5f_terseLabel_en-US" xlink:label="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Performance-Based Restricted Stock Units [Member]</link:label>
    <link:label id="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Performance-Based Restricted Stock Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:href="anip-20231231.xsd#anip_MarketPerformanceBasedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:to="lab_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ce1a034f-b47f-490d-b5d4-3e6c3975b578_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_4ceb04b3-2cbc-4169-a023-b60cf0337961_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_b195ec23-2878-4ec1-9655-3a03a8771664_terseLabel_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate number of shares percentage</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_label_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage</link:label>
    <link:label id="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_documentation_en-US" xlink:label="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" xlink:to="lab_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_525c7173-5d5a-4091-a1c7-3c71d73f73c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_anip_ProductIntellectualPropertyMember_80e76bca-d9ee-43e7-b02d-eb7020db6866_terseLabel_en-US" xlink:label="lab_anip_ProductIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Intellectual Property</link:label>
    <link:label id="lab_anip_ProductIntellectualPropertyMember_label_en-US" xlink:label="lab_anip_ProductIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Intellectual Property [Member]</link:label>
    <link:label id="lab_anip_ProductIntellectualPropertyMember_documentation_en-US" xlink:label="lab_anip_ProductIntellectualPropertyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Intellectual Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductIntellectualPropertyMember" xlink:href="anip-20231231.xsd#anip_ProductIntellectualPropertyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_anip_ProductIntellectualPropertyMember" xlink:to="lab_anip_ProductIntellectualPropertyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_2304538e-476d-45dc-98d1-33e6b07d05ed_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3a279b19-c4de-46f1-946d-e795a948ea27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_05dbc876-dc66-4da0-a24d-5c11cda34aa8_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_892ef5c3-dd97-468a-b8bf-fad17f567ded_verboseLabel_en-US" xlink:label="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Packaging materials</link:label>
    <link:label id="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_label_en-US" xlink:label="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retail Related Inventory, Packaging and Other Supplies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:to="lab_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_4621c314-84a9-4b81-b6a4-5740d2f6b1da_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under Prior Revolver agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_5d15149a-e340-45be-b027-25d2648af912_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current Liabilities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="lab_us-gaap_LongTermDebtNoncurrentAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>anip-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:d1b0d374-59d3-494d-ab57-0327414dd086,g:e2d69e39-7080-477b-8655-fce353fd237f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/Cover" xlink:type="simple" xlink:href="anip-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bf747926-6aa0-4981-8333-9043304b8c2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bf747926-6aa0-4981-8333-9043304b8c2b" xlink:to="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:to="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_731f53a7-8f81-4ae4-8e5d-b833eb74970d" xlink:to="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_8e98298d-c48d-4e0e-b8c9-cc4d59d113b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:to="loc_us-gaap_CommonStockMember_8e98298d-c48d-4e0e-b8c9-cc4d59d113b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember_1457264f-4a59-417a-bd6a-c8c08038087e" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2f97d040-be4b-4d91-9e08-d2a00aaa92a8" xlink:to="loc_anip_ClassCSpecialStockMember_1457264f-4a59-417a-bd6a-c8c08038087e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_8bd54ba5-5469-4dd2-a101-c8aa300bd408" xlink:to="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7633835a-7a97-4237-bda5-ae13d8c3bb5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentType_7633835a-7a97-4237-bda5-ae13d8c3bb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_68901fcc-3a6b-4b44-b604-71cc8fff4e96" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentAnnualReport_68901fcc-3a6b-4b44-b604-71cc8fff4e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5f72dd08-2974-4c95-bf6b-a6884bbee9a3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentPeriodEndDate_5f72dd08-2974-4c95-bf6b-a6884bbee9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_06b56987-ec19-4d86-9236-6120adf15182" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_CurrentFiscalYearEndDate_06b56987-ec19-4d86-9236-6120adf15182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_efb9ceff-76e0-4798-8f3f-4018b011c79e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentTransitionReport_efb9ceff-76e0-4798-8f3f-4018b011c79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_a2207cab-51ee-44d8-a369-084820392316" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityFileNumber_a2207cab-51ee-44d8-a369-084820392316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e721569a-40e8-44e9-9e89-f5a012181443" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityRegistrantName_e721569a-40e8-44e9-9e89-f5a012181443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_29c7276a-216f-4685-8e1e-36a1157ce2d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_29c7276a-216f-4685-8e1e-36a1157ce2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_bd39d53f-1e68-4636-8fa5-0dfea534100f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityTaxIdentificationNumber_bd39d53f-1e68-4636-8fa5-0dfea534100f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d91d1ffc-9f83-4042-9c6a-d6df634005b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressAddressLine1_d91d1ffc-9f83-4042-9c6a-d6df634005b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_cbabc82e-15ee-4316-881e-b23338765c0f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressCityOrTown_cbabc82e-15ee-4316-881e-b23338765c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_76c695ca-fc1c-4e1e-a5e5-fc6307475bf2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressStateOrProvince_76c695ca-fc1c-4e1e-a5e5-fc6307475bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_e4fc4b31-6e05-424b-98d0-f5b03a00867b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityAddressPostalZipCode_e4fc4b31-6e05-424b-98d0-f5b03a00867b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_24eb42d3-e7c2-4a22-b2db-d6ef2df9c75d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_CityAreaCode_24eb42d3-e7c2-4a22-b2db-d6ef2df9c75d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d6b9c97a-e388-4664-9dfc-ef76b935ece7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_LocalPhoneNumber_d6b9c97a-e388-4664-9dfc-ef76b935ece7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_349cd44a-c46a-45bb-9013-92e694221d67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_Security12bTitle_349cd44a-c46a-45bb-9013-92e694221d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0d73a968-bfae-472d-883c-0f694532f20b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_TradingSymbol_0d73a968-bfae-472d-883c-0f694532f20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d709b8e1-b95d-4f40-8a4f-9f8608f38563" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_SecurityExchangeName_d709b8e1-b95d-4f40-8a4f-9f8608f38563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_0c02d1d0-1cdb-4ea9-8f27-cf6d539b2c8f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_0c02d1d0-1cdb-4ea9-8f27-cf6d539b2c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_313f8494-d5a2-4ce5-917a-4104a9d52cdc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityVoluntaryFilers_313f8494-d5a2-4ce5-917a-4104a9d52cdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d787eb0b-1996-435c-bf3f-dc81101d1f2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityCurrentReportingStatus_d787eb0b-1996-435c-bf3f-dc81101d1f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bab73da7-4040-40e0-90c1-6518c3da1ce7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityInteractiveDataCurrent_bab73da7-4040-40e0-90c1-6518c3da1ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fdec23a7-6ef3-46b0-9857-a1a36fd3628e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityFilerCategory_fdec23a7-6ef3-46b0-9857-a1a36fd3628e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_119fe90e-2dbf-4708-a58f-81221bedd4cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntitySmallBusiness_119fe90e-2dbf-4708-a58f-81221bedd4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_46c8b779-0a1f-49c0-9d02-0b42569b65b5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityEmergingGrowthCompany_46c8b779-0a1f-49c0-9d02-0b42569b65b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_210914e5-52d8-411e-81d1-0de64a65047d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_IcfrAuditorAttestationFlag_210914e5-52d8-411e-81d1-0de64a65047d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_1b15ad2d-e3a3-473d-b093-5bf3d9ea869e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_1b15ad2d-e3a3-473d-b093-5bf3d9ea869e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4c09b97c-ae3b-48ea-854e-3081e9510628" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityShellCompany_4c09b97c-ae3b-48ea-854e-3081e9510628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_65f52cc7-bbe9-4161-99d3-86b8be0f9580" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityPublicFloat_65f52cc7-bbe9-4161-99d3-86b8be0f9580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_cb9f8d50-a884-4a4a-a2a6-26eef4bb0ec3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_cb9f8d50-a884-4a4a-a2a6-26eef4bb0ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ad34dde1-f3a3-4488-9268-91f42abb1837" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_ad34dde1-f3a3-4488-9268-91f42abb1837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_a04f9c67-e138-4cba-8a51-f136075e6938" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_EntityCentralIndexKey_a04f9c67-e138-4cba-8a51-f136075e6938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_b075134f-4638-4d45-8e06-4c529b75d1a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentFiscalYearFocus_b075134f-4638-4d45-8e06-4c529b75d1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0b9d044c-60cc-456e-a325-8b5c827545ac" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0b9d044c-60cc-456e-a325-8b5c827545ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_5c3d38b5-92e0-446e-9814-d8a3e5a18a6c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_d6def8fe-3ae1-4f77-a4d9-858e866594b2" xlink:to="loc_dei_AmendmentFlag_5c3d38b5-92e0-446e-9814-d8a3e5a18a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/AuditInformation" xlink:type="simple" xlink:href="anip-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_anip_AuditInformationAbstract_4b27dd52-e183-463c-87da-42a01039fabb" xlink:href="anip-20231231.xsd#anip_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_1ace8589-2f4d-4ce8-8d81-0def4b441f32" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_AuditInformationAbstract_4b27dd52-e183-463c-87da-42a01039fabb" xlink:to="loc_dei_AuditorName_1ace8589-2f4d-4ce8-8d81-0def4b441f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_0091a437-70e5-4b6d-81fe-476e832e88b9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_AuditInformationAbstract_4b27dd52-e183-463c-87da-42a01039fabb" xlink:to="loc_dei_AuditorLocation_0091a437-70e5-4b6d-81fe-476e832e88b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_659802f8-0e48-4c14-ae95-daf766bb6910" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_AuditInformationAbstract_4b27dd52-e183-463c-87da-42a01039fabb" xlink:to="loc_dei_AuditorFirmId_659802f8-0e48-4c14-ae95-daf766bb6910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9a845d31-05c7-487d-bac7-06d13913b140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_90f1f5ec-e100-48ef-8d2f-d5f9670341ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9a845d31-05c7-487d-bac7-06d13913b140" xlink:to="loc_us-gaap_AssetsAbstract_90f1f5ec-e100-48ef-8d2f-d5f9670341ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_90f1f5ec-e100-48ef-8d2f-d5f9670341ec" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0f2e8b5-df10-4272-9b21-6be5181547e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0f2e8b5-df10-4272-9b21-6be5181547e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_7c1c0a2f-c1d3-49cf-989d-94e7fc65686b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_RestrictedCashCurrent_7c1c0a2f-c1d3-49cf-989d-94e7fc65686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_adb580c6-6bfc-4c71-9f1f-38151e1ed16d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_adb580c6-6bfc-4c71-9f1f-38151e1ed16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_b9245621-27e7-49b7-bdac-d9cb9af72faf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_InventoryNet_b9245621-27e7-49b7-bdac-d9cb9af72faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrepaidIncomeTaxesNet_be53b07d-359e-4108-bb7f-b218be8b1d31" xlink:href="anip-20231231.xsd#anip_PrepaidIncomeTaxesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_anip_PrepaidIncomeTaxesNet_be53b07d-359e-4108-bb7f-b218be8b1d31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_bc008e3f-2d4f-479c-87a1-6afb745cad28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_bc008e3f-2d4f-479c-87a1-6afb745cad28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_897c80ea-6594-4dcf-a5e2-fd1f353a6b46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_897c80ea-6594-4dcf-a5e2-fd1f353a6b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4fd679a7-506c-461d-903d-e8d8faa295bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8da7f7f-327d-49b6-ad55-25abd2cf442a" xlink:to="loc_us-gaap_AssetsCurrent_4fd679a7-506c-461d-903d-e8d8faa295bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_90f1f5ec-e100-48ef-8d2f-d5f9670341ec" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_74a4d7cc-94f4-469d-82d8-0f7762ffc2c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_74a4d7cc-94f4-469d-82d8-0f7762ffc2c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_c02fb21a-c78b-4c08-9fb9-e3ed226c9e91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_c02fb21a-c78b-4c08-9fb9-e3ed226c9e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_147ea76a-d3fd-45d0-9cd6-a6b3f87b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_147ea76a-d3fd-45d0-9cd6-a6b3f87b4506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_7a26c8be-4d91-44ba-a49f-87f6040b8445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:to="loc_us-gaap_Goodwill_7a26c8be-4d91-44ba-a49f-87f6040b8445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_29bee2bb-879a-48f3-9509-ee9548a0da9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_22286ef3-820c-484a-bdd1-f0825d6d8768" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_29bee2bb-879a-48f3-9509-ee9548a0da9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_33f55ac2-8e6f-402e-939a-dafb1173aadc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_90f1f5ec-e100-48ef-8d2f-d5f9670341ec" xlink:to="loc_us-gaap_Assets_33f55ac2-8e6f-402e-939a-dafb1173aadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9a845d31-05c7-487d-bac7-06d13913b140" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_923e84c8-4700-4e9e-99aa-caa0d444f657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_LongTermDebtCurrent_923e84c8-4700-4e9e-99aa-caa0d444f657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_83c47c28-0913-41f7-bbee-3f3fbb7c014b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_AccountsPayableCurrent_83c47c28-0913-41f7-bbee-3f3fbb7c014b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_08ef0b21-bc85-4e78-b436-d5fd84b20c13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_08ef0b21-bc85-4e78-b436-d5fd84b20c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ea6ed60-f25c-4caa-9380-d2397eed7287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_0ea6ed60-f25c-4caa-9380-d2397eed7287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AccruedGovernmentRebates_a6258a51-1531-4e27-8db7-8121999729ab" xlink:href="anip-20231231.xsd#anip_AccruedGovernmentRebates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_anip_AccruedGovernmentRebates_a6258a51-1531-4e27-8db7-8121999729ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_28bb761d-7547-417d-a3bb-4d8dbdbb1b81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_TaxesPayableCurrent_28bb761d-7547-417d-a3bb-4d8dbdbb1b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReturnedGoodsReserve_675eb87e-70ed-476b-860d-9f319ff96ef3" xlink:href="anip-20231231.xsd#anip_ReturnedGoodsReserve"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_anip_ReturnedGoodsReserve_675eb87e-70ed-476b-860d-9f319ff96ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9bd0028a-4e2f-4b5c-a213-e7fc77f0a22e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9bd0028a-4e2f-4b5c-a213-e7fc77f0a22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_28fd8423-6978-47ff-a4f9-8a6a67c96dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_28fd8423-6978-47ff-a4f9-8a6a67c96dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_69a59682-b075-4a35-95b0-0726b70aa4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_1380d518-3296-43ce-b883-0ac5a0baf1f3" xlink:to="loc_us-gaap_LiabilitiesCurrent_69a59682-b075-4a35-95b0-0726b70aa4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrentAbstract_3183c132-d137-4909-8d5a-0158e12eba84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_LongTermDebtNoncurrentAbstract_3183c132-d137-4909-8d5a-0158e12eba84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4ab45ae9-1cb4-4d18-826b-1fbafe9424b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3183c132-d137-4909-8d5a-0158e12eba84" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4ab45ae9-1cb4-4d18-826b-1fbafe9424b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09257b8a-9dc4-4c35-a31a-9a0ac4f71492" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3183c132-d137-4909-8d5a-0158e12eba84" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_09257b8a-9dc4-4c35-a31a-9a0ac4f71492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_5dfbc192-beb3-4615-a8b5-7caf1c8094e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtNoncurrentAbstract_3183c132-d137-4909-8d5a-0158e12eba84" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_5dfbc192-beb3-4615-a8b5-7caf1c8094e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ba3d9e88-6efd-4aed-8cc0-12734522b14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_Liabilities_ba3d9e88-6efd-4aed-8cc0-12734522b14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d331e0c0-8a24-4641-998f-09a4bb9e9e09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d331e0c0-8a24-4641-998f-09a4bb9e9e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_c5e7c734-dbff-423c-a175-7eeb89cd4b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_TemporaryEquityAbstract_c5e7c734-dbff-423c-a175-7eeb89cd4b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b12db072-c0cf-457a-b3c8-55205654eee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_c5e7c734-dbff-423c-a175-7eeb89cd4b31" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b12db072-c0cf-457a-b3c8-55205654eee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_45b55b57-a52b-4683-9760-073324ee618b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_CommonStockValue_45b55b57-a52b-4683-9760-073324ee618b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockValue_3e2c4cab-b1dd-48b9-8fc0-700242e42ca7" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_anip_ClassCSpecialStockValue_3e2c4cab-b1dd-48b9-8fc0-700242e42ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5bf4d25e-35cc-4e48-a5a3-ef9ba75cc108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_PreferredStockValue_5bf4d25e-35cc-4e48-a5a3-ef9ba75cc108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_f4f1d5d9-8bb6-4947-a88f-1c3a7a2ce426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_TreasuryStockCommonValue_f4f1d5d9-8bb6-4947-a88f-1c3a7a2ce426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_33c8264f-7f88-477e-b2ad-6e71496ead5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_AdditionalPaidInCapital_33c8264f-7f88-477e-b2ad-6e71496ead5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92a53d28-a3b6-4e23-b364-cd04bc434c98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_92a53d28-a3b6-4e23-b364-cd04bc434c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4faf6283-30b5-4836-b369-257769165662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4faf6283-30b5-4836-b369-257769165662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d6986255-4d7f-418d-81fd-258a61f6ab41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_dde70429-4dca-4e73-bc7e-88f162e8cc53" xlink:to="loc_us-gaap_StockholdersEquity_d6986255-4d7f-418d-81fd-258a61f6ab41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25448871-bfca-4b2f-8b5a-ebe27186f1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_546fe2bd-7521-408d-9372-68bf1630665c" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25448871-bfca-4b2f-8b5a-ebe27186f1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f93e35a0-a3d8-41b6-80aa-31e515a0f140" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f93e35a0-a3d8-41b6-80aa-31e515a0f140" xlink:to="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2feade9f-c091-456f-a875-16616bed70c3" xlink:to="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_c98bf152-e06a-40ce-a04a-86e5c279eeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_c98bf152-e06a-40ce-a04a-86e5c279eeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_12bfbc3a-297d-4932-abf8-ae892e33964d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:to="loc_us-gaap_CommonStockMember_12bfbc3a-297d-4932-abf8-ae892e33964d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember_93176bf1-7668-415a-b45d-d3eee227f9b8" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_10fa2e80-2a0a-49cf-ac81-1450e1f69bee" xlink:to="loc_anip_ClassCSpecialStockMember_93176bf1-7668-415a-b45d-d3eee227f9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_698ddb4e-7c4d-44e0-b0cc-ab2d96ac3cd9" xlink:to="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_245c0726-7af0-4283-b9c2-f36ade8829db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_245c0726-7af0-4283-b9c2-f36ade8829db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_21924c78-7804-4ac8-8877-07c0019dc2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_21924c78-7804-4ac8-8877-07c0019dc2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_bcf01180-9ed1-4e77-b371-8a28c1eb183b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_bcf01180-9ed1-4e77-b371-8a28c1eb183b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_45e88cb5-483b-43ed-a427-d5dd4fbd223b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_45e88cb5-483b-43ed-a427-d5dd4fbd223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0ab3ffb6-6144-49eb-a70a-b08362d507a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0ab3ffb6-6144-49eb-a70a-b08362d507a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_dfc389b6-e3cd-4ed5-960d-f8d1f08c8c58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_dfc389b6-e3cd-4ed5-960d-f8d1f08c8c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_c9e64092-a815-4ff9-8997-713f535fd2c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_c9e64092-a815-4ff9-8997-713f535fd2c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_1547f95d-afc8-4be8-a6a3-828a4010a5da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockSharesIssued_1547f95d-afc8-4be8-a6a3-828a4010a5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d1e4243f-b6c4-42ca-bab3-f2e04a9e8a48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d1e4243f-b6c4-42ca-bab3-f2e04a9e8a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fba1d852-3f1d-435c-8af6-2473ef5c8e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fba1d852-3f1d-435c-8af6-2473ef5c8e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_f54f4773-f15c-463a-81d8-3439718c28a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_f54f4773-f15c-463a-81d8-3439718c28a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4942ddc0-f8da-402b-b500-5750ed2115e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4942ddc0-f8da-402b-b500-5750ed2115e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_46ece8dd-11b9-44fb-b907-48d9e336ee81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_46ece8dd-11b9-44fb-b907-48d9e336ee81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_22b1fdf4-b639-49b3-a61f-93b451edc043" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11ad6319-a464-4f15-8a4d-5226342dbafb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_22b1fdf4-b639-49b3-a61f-93b451edc043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aec40921-a172-4a70-add7-2192e24fc46f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aec40921-a172-4a70-add7-2192e24fc46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1425275e-de68-49f3-989b-90e39c287d62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization_1425275e-de68-49f3-989b-90e39c287d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8bb01d0f-74bb-4776-8e2e-4a59e1351920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8bb01d0f-74bb-4776-8e2e-4a59e1351920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_07b84161-a05f-457e-b2fb-94db8aa990c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_07b84161-a05f-457e-b2fb-94db8aa990c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b16b198a-8b15-47f6-9651-954a6a4c18a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_DepreciationAndAmortization_b16b198a-8b15-47f6-9651-954a6a4c18a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_32612b83-a032-49a2-86af-1b07884384f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_32612b83-a032-49a2-86af-1b07884384f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_f3ff9986-d4f1-45dd-82cc-35ed0fd0fb19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_f3ff9986-d4f1-45dd-82cc-35ed0fd0fb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchCharges_93634573-6c13-4851-a8a2-6f7ee9567baf" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_anip_CortrophinPreLaunchCharges_93634573-6c13-4851-a8a2-6f7ee9567baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a4d542b6-c079-4b06-a6e3-497e102316e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_a4d542b6-c079-4b06-a6e3-497e102316e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_999e0e8d-ad7f-47e6-b0c1-78c83c77e829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_999e0e8d-ad7f-47e6-b0c1-78c83c77e829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_60109570-13a1-4f9b-9be0-1a529a0b7f87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_54685ee0-a170-404f-a3a1-86f5fde4be76" xlink:to="loc_us-gaap_CostsAndExpenses_60109570-13a1-4f9b-9be0-1a529a0b7f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4a8c90f1-b4f3-4ff5-9715-8d1be4c0001b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_OperatingIncomeLoss_4a8c90f1-b4f3-4ff5-9715-8d1be4c0001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c981d33-4bb4-45b9-9f6a-137308db55f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c981d33-4bb4-45b9-9f6a-137308db55f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a948a675-8a77-496c-aa91-789f3b19bd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c981d33-4bb4-45b9-9f6a-137308db55f2" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_a948a675-8a77-496c-aa91-789f3b19bd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a1c1898-8c7f-4472-a2c6-5721b6083126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_8c981d33-4bb4-45b9-9f6a-137308db55f2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a1c1898-8c7f-4472-a2c6-5721b6083126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ecce9865-5bec-4388-ba3e-5e38fa8820b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ecce9865-5bec-4388-ba3e-5e38fa8820b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d38abe96-30ee-4825-b70b-b1bea42c0d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d38abe96-30ee-4825-b70b-b1bea42c0d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_567ff3c4-0ce9-49bc-9d1e-49b3b9d498d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_NetIncomeLoss_567ff3c4-0ce9-49bc-9d1e-49b3b9d498d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9424da42-2d29-403a-9787-06a1dfbfe294" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9424da42-2d29-403a-9787-06a1dfbfe294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8010d37c-df31-4484-af4a-c9304418a576" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8010d37c-df31-4484-af4a-c9304418a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_a8d332df-2265-4d87-8a6e-34565dfceba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_9d849f84-241d-4666-b2aa-8a9ac627c3d6" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_a8d332df-2265-4d87-8a6e-34565dfceba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e44794fb-1871-44d9-aa1a-212d3eb5aca7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a8d332df-2265-4d87-8a6e-34565dfceba0" xlink:to="loc_us-gaap_EarningsPerShareBasic_e44794fb-1871-44d9-aa1a-212d3eb5aca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eb57505d-1f82-4c4f-b54b-ab63835fb9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a8d332df-2265-4d87-8a6e-34565dfceba0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eb57505d-1f82-4c4f-b54b-ab63835fb9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82442322-cf59-4efb-aa8a-e90312cb30f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a8d332df-2265-4d87-8a6e-34565dfceba0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_82442322-cf59-4efb-aa8a-e90312cb30f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e85be89b-8534-4d16-9df7-5256331ce178" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_a8d332df-2265-4d87-8a6e-34565dfceba0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e85be89b-8534-4d16-9df7-5256331ce178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9545cd51-67a8-41c2-b510-192fd7da8073" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_21958fce-474b-46ec-925d-ccf81064bf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9545cd51-67a8-41c2-b510-192fd7da8073" xlink:to="loc_us-gaap_NetIncomeLoss_21958fce-474b-46ec-925d-ccf81064bf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bb41d261-7303-4439-ab78-d0754779c1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9545cd51-67a8-41c2-b510-192fd7da8073" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bb41d261-7303-4439-ab78-d0754779c1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49136127-3daa-4e0f-9bce-1cdcdccfb2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bb41d261-7303-4439-ab78-d0754779c1c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_49136127-3daa-4e0f-9bce-1cdcdccfb2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5d7068ca-a097-43c4-8ab7-318f84c7b058" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bb41d261-7303-4439-ab78-d0754779c1c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_5d7068ca-a097-43c4-8ab7-318f84c7b058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ab45867-7c95-4f3f-81d6-2c447e274943" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_bb41d261-7303-4439-ab78-d0754779c1c1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5ab45867-7c95-4f3f-81d6-2c447e274943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f153bc20-6b5a-4520-a245-67b7f3699205" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9545cd51-67a8-41c2-b510-192fd7da8073" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f153bc20-6b5a-4520-a245-67b7f3699205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7bfe1697-6602-4b76-93b3-ff72307f5285" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7bfe1697-6602-4b76-93b3-ff72307f5285" xlink:to="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2f21a035-86a8-48a8-9311-740327a1568f" xlink:to="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_5085cbfa-fbf7-4a7b-a28e-183eb661e903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_CommonStockMember_5085cbfa-fbf7-4a7b-a28e-183eb661e903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_131c9916-519b-41b4-b0bd-acea68c5e387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_131c9916-519b-41b4-b0bd-acea68c5e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_c2991fc9-7828-4bc0-851d-53cf705f396c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_TreasuryStockCommonMember_c2991fc9-7828-4bc0-851d-53cf705f396c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8ae68cf-aa99-416b-ac9c-21235649c421" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e8ae68cf-aa99-416b-ac9c-21235649c421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_40fc31bb-b0db-49d1-88da-eb88b00b7890" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5e1487b8-c741-40e4-9e70-f40e07894a72" xlink:to="loc_us-gaap_RetainedEarningsMember_40fc31bb-b0db-49d1-88da-eb88b00b7890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee14dafa-ad3f-4c72-80db-e5595d5a1a53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b0623933-7bbd-4317-8edf-214944a9b04d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee14dafa-ad3f-4c72-80db-e5595d5a1a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_16cce125-1191-43cd-a4a1-33177a31de7e" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee14dafa-ad3f-4c72-80db-e5595d5a1a53" xlink:to="loc_anip_NovitiumMember_16cce125-1191-43cd-a4a1-33177a31de7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ef103636-a01d-4088-93be-4276ce84f87e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0b52a3ce-dfb9-409c-a10e-5bbe6b22f625" xlink:to="loc_us-gaap_ClassOfStockDomain_ef103636-a01d-4088-93be-4276ce84f87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_baf31196-2187-48b5-9c6a-af97feb1660a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ef103636-a01d-4088-93be-4276ce84f87e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_baf31196-2187-48b5-9c6a-af97feb1660a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_52ed3345-23ac-424f-884c-296bee15a088" xlink:to="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5e92355d-dec8-4e57-8419-74fb1e65a243" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_5e92355d-dec8-4e57-8419-74fb1e65a243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_02f3d6e4-ffbf-4118-ae96-626b2a4eb593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_02f3d6e4-ffbf-4118-ae96-626b2a4eb593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_50abc0b4-6890-418d-90ab-29a147ce00e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_50abc0b4-6890-418d-90ab-29a147ce00e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_04c9ab56-972d-4f9c-852d-a0302abb6207" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_04c9ab56-972d-4f9c-852d-a0302abb6207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d1d65ad7-b91d-40fd-91ae-dcb52606951e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_d1d65ad7-b91d-40fd-91ae-dcb52606951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4d12fe81-770a-4fc1-b355-b680179924d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_28f64051-b6ff-4e86-8f0f-de7ea7d012fc" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4d12fe81-770a-4fc1-b355-b680179924d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_0cfbe9c8-fc7d-4f83-a71f-f395b75da93b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_144e2997-10d3-420e-afbd-f80041c6ad5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockholdersEquity_144e2997-10d3-420e-afbd-f80041c6ad5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4a3acfc0-d736-4e6e-b163-79fbdbde7549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_CommonStockSharesIssued_4a3acfc0-d736-4e6e-b163-79fbdbde7549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0a881b89-c6f1-4c4a-9bcb-a1585ece481c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0a881b89-c6f1-4c4a-9bcb-a1585ece481c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_d483670d-0b95-42c0-b3b8-dc6feed6eff4" xlink:href="anip-20231231.xsd#anip_StockholdersEquityAttributableToParentAndTemporaryEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_d483670d-0b95-42c0-b3b8-dc6feed6eff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3ab9c74-4e31-4ef5-b633-c9151155fdb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b3ab9c74-4e31-4ef5-b633-c9151155fdb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_360bd319-632b-4c78-895b-b5dcdc7bc737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_360bd319-632b-4c78-895b-b5dcdc7bc737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3a976360-e47e-4cd9-86ba-98dff1cb0039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_3a976360-e47e-4cd9-86ba-98dff1cb0039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_328a99f1-1a84-449b-a3cd-79c3e4e0ba6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_328a99f1-1a84-449b-a3cd-79c3e4e0ba6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cdfdb4ce-1f92-43eb-a06a-bbae5272974d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cdfdb4ce-1f92-43eb-a06a-bbae5272974d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0851cfcf-4322-444f-953a-e0a3020fb4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_0851cfcf-4322-444f-953a-e0a3020fb4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f976152-aa95-4a6a-847c-3e942921a400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_8f976152-aa95-4a6a-847c-3e942921a400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_66648f42-795a-45a7-9609-a3e945a97def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_66648f42-795a-45a7-9609-a3e945a97def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_5bcc6285-faaf-42a6-9190-d54f3bc52d7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_5bcc6285-faaf-42a6-9190-d54f3bc52d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fd983111-6a62-44e5-854e-9f2b71ecfdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_fd983111-6a62-44e5-854e-9f2b71ecfdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b79bd9eb-8135-41de-b0b9-83f72d5fe5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_b79bd9eb-8135-41de-b0b9-83f72d5fe5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_a6b8f16b-9404-49a6-9b78-2b25752446a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_DividendsPreferredStock_a6b8f16b-9404-49a6-9b78-2b25752446a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_6acacf8b-7a5e-4324-9338-f4130420c04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_6acacf8b-7a5e-4324-9338-f4130420c04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23d9451b-98b8-4c63-885c-d77960bdd094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_23d9451b-98b8-4c63-885c-d77960bdd094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1865799e-8dd1-4db4-9b7a-ecc997047cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_NetIncomeLoss_1865799e-8dd1-4db4-9b7a-ecc997047cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8257af2f-c74d-4acb-a0a2-e58f597c6629" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_StockholdersEquity_8257af2f-c74d-4acb-a0a2-e58f597c6629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8cb5bb3b-620e-40fc-9689-1d2bd6cf95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_CommonStockSharesIssued_8cb5bb3b-620e-40fc-9689-1d2bd6cf95c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_aaac7101-e0ba-4819-b59a-5af8bd8fdb94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_us-gaap_TreasuryStockCommonShares_aaac7101-e0ba-4819-b59a-5af8bd8fdb94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_10698695-51b1-4d57-9a0e-bdf78b76f551" xlink:href="anip-20231231.xsd#anip_StockholdersEquityAttributableToParentAndTemporaryEquity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6dc35ab8-d416-4223-9bde-db9208f1db4b" xlink:to="loc_anip_StockholdersEquityAttributableToParentAndTemporaryEquity_10698695-51b1-4d57-9a0e-bdf78b76f551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="anip-20231231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33d0e27d-3d3c-4bd2-87e2-37bf4e40f6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33d0e27d-3d3c-4bd2-87e2-37bf4e40f6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_700201e5-272a-44df-9ed0-f5eeb149e0b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33d0e27d-3d3c-4bd2-87e2-37bf4e40f6cf" xlink:to="loc_us-gaap_ProfitLoss_700201e5-272a-44df-9ed0-f5eeb149e0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33d0e27d-3d3c-4bd2-87e2-37bf4e40f6cf" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8c0fc1bc-4279-4055-8743-6c0188278d34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_ShareBasedCompensation_8c0fc1bc-4279-4055-8743-6c0188278d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_568dc56b-131c-4943-83d7-57c4e0f9445f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_568dc56b-131c-4943-83d7-57c4e0f9445f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDepreciationAndAmortization_b0a9548f-00ad-4a22-9753-fb64674a365c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_OtherDepreciationAndAmortization_b0a9548f-00ad-4a22-9753-fb64674a365c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredInProcessReserachAndDevelopmentExpense_4011b8bd-adba-427e-8c01-9df2ec0178fe" xlink:href="anip-20231231.xsd#anip_AcquiredInProcessReserachAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_anip_AcquiredInProcessReserachAndDevelopmentExpense_4011b8bd-adba-427e-8c01-9df2ec0178fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_153cc059-2e7e-4fc7-a632-874b9320c467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_153cc059-2e7e-4fc7-a632-874b9320c467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6e14b646-2746-49dd-8f03-d6d2f11d6248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_6e14b646-2746-49dd-8f03-d6d2f11d6248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_8f6b78a4-f616-422c-9cbf-51bc858e012f" xlink:href="anip-20231231.xsd#anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow_8f6b78a4-f616-422c-9cbf-51bc858e012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7ee93310-cdd0-4131-9101-f506cb10cd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_7ee93310-cdd0-4131-9101-f506cb10cd1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b32c3c9b-66d6-4661-a0e2-6ef8c0efe3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_AssetImpairmentCharges_b32c3c9b-66d6-4661-a0e2-6ef8c0efe3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_6fa60618-dd8b-4193-a132-d159bbb1df87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_6fa60618-dd8b-4193-a132-d159bbb1df87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e9790455-0923-4919-8070-0d6fbaea0ee2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73f1c5a0-a8d1-4c2b-a635-29739f92c1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_73f1c5a0-a8d1-4c2b-a635-29739f92c1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3a96b9fa-0578-4eab-90de-e00a78741314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3a96b9fa-0578-4eab-90de-e00a78741314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_2af01645-7314-4575-b83b-bd61e2864a54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_2af01645-7314-4575-b83b-bd61e2864a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_babd3840-b74a-4635-83a5-301ed4342a76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_babd3840-b74a-4635-83a5-301ed4342a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseInRoyaltyPayable_0c8809a5-4092-4714-a010-58e7c61dc80a" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseInRoyaltyPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_anip_IncreaseDecreaseInRoyaltyPayable_0c8809a5-4092-4714-a010-58e7c61dc80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_c768ae63-9a0d-4e35-921b-65721018817b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInIncomeTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxes_c768ae63-9a0d-4e35-921b-65721018817b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseAccruedGovernmentRebates_3299cc85-22b0-49fb-b174-7384b574a372" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseAccruedGovernmentRebates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_anip_IncreaseDecreaseAccruedGovernmentRebates_3299cc85-22b0-49fb-b174-7384b574a372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseInReturnedGoodsReserve_629132e1-4a63-41c0-bc61-45768212d360" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseInReturnedGoodsReserve"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_anip_IncreaseDecreaseInReturnedGoodsReserve_629132e1-4a63-41c0-bc61-45768212d360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_80c12482-c66f-4361-94eb-fca6b1b9c2a3" xlink:href="anip-20231231.xsd#anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e0c3e382-dddb-4407-b3fa-17fbdff4fb47" xlink:to="loc_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers_80c12482-c66f-4361-94eb-fca6b1b9c2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b261f729-e392-40df-a5cd-46e8c14c9cb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_33d0e27d-3d3c-4bd2-87e2-37bf4e40f6cf" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b261f729-e392-40df-a5cd-46e8c14c9cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f9bf463d-7c9b-44a3-aad3-d9c1bbedcfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f9bf463d-7c9b-44a3-aad3-d9c1bbedcfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8eec98c4-ff5f-4932-918a-d73a07698f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_8eec98c4-ff5f-4932-918a-d73a07698f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5ec075ce-97b8-4359-b98b-016664f0d385" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5ec075ce-97b8-4359-b98b-016664f0d385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_dad80742-e79a-44c8-a1f7-ed08eca8572a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_dad80742-e79a-44c8-a1f7-ed08eca8572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bf010fa-3c4d-4adf-81f2-80e3c8a5998a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4115a139-d268-47c4-b5e1-2aaf05e27ea0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1bf010fa-3c4d-4adf-81f2-80e3c8a5998a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ff734be-77cc-4227-be2f-b38ef19f73d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ff734be-77cc-4227-be2f-b38ef19f73d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1ff15aba-3d8a-4e03-ba01-01d115f783d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_1ff15aba-3d8a-4e03-ba01-01d115f783d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfOtherLongTermDebt_55e058a0-fdc9-491b-80b5-55f1ac724c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfOtherLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_RepaymentsOfOtherLongTermDebt_55e058a0-fdc9-491b-80b5-55f1ac724c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ff0d747d-7114-44ae-9f18-9bc5440bf1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_RepaymentsOfDebt_ff0d747d-7114-44ae-9f18-9bc5440bf1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_49c9cdd2-920a-400c-b336-630f80175aa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_49c9cdd2-920a-400c-b336-630f80175aa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLinesOfCredit_596a2120-3cca-48c0-97cd-b707b1d722a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_RepaymentsOfLinesOfCredit_596a2120-3cca-48c0-97cd-b707b1d722a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_146a4222-b839-4c9f-a272-28a7bac1c0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_146a4222-b839-4c9f-a272-28a7bac1c0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_182736af-979f-4abf-bb45-3a2e3a30a756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_182736af-979f-4abf-bb45-3a2e3a30a756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_370c100a-65d3-44ba-959d-02667264c1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_PaymentsOfDividends_370c100a-65d3-44ba-959d-02667264c1f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8a39191c-47fe-47ff-b36a-6d95213751e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8a39191c-47fe-47ff-b36a-6d95213751e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ec7333f3-cfb0-4499-97de-0336d28191fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_ec7333f3-cfb0-4499-97de-0336d28191fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb3acf11-bfa4-4e67-b203-b3e90533d973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_60f1a414-5b4a-4c9b-99a2-4b17deb2154d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_fb3acf11-bfa4-4e67-b203-b3e90533d973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39cb1b73-7746-47aa-8af2-498cf3673c87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_39cb1b73-7746-47aa-8af2-498cf3673c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6d9a336-09a6-4da7-8f8e-d12f6ba2f758" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b6d9a336-09a6-4da7-8f8e-d12f6ba2f758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5155b79-0daa-4fd0-8eb2-52f893cfacec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f5155b79-0daa-4fd0-8eb2-52f893cfacec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_06661e89-5776-4861-a680-5bd70d85ddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_06661e89-5776-4861-a680-5bd70d85ddf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9a21ab9-6175-4349-b6b4-801cc21bdfc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_06661e89-5776-4861-a680-5bd70d85ddf6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f9a21ab9-6175-4349-b6b4-801cc21bdfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_6420b65c-0166-49e4-9374-150464729dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_06661e89-5776-4861-a680-5bd70d85ddf6" xlink:to="loc_us-gaap_RestrictedCashCurrent_6420b65c-0166-49e4-9374-150464729dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_387c9503-0e01-4207-ba8e-0e303eb4fe60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_06661e89-5776-4861-a680-5bd70d85ddf6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_387c9503-0e01-4207-ba8e-0e303eb4fe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c97049c6-0874-4aac-be78-c19bf3db4df9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c97049c6-0874-4aac-be78-c19bf3db4df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fad3999d-03f3-404a-a6ff-50f5167de9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c97049c6-0874-4aac-be78-c19bf3db4df9" xlink:to="loc_us-gaap_InterestPaidNet_fad3999d-03f3-404a-a6ff-50f5167de9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_69736dcd-8af1-44a6-9403-8b46eedf4eab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c97049c6-0874-4aac-be78-c19bf3db4df9" xlink:to="loc_us-gaap_IncomeTaxesPaid_69736dcd-8af1-44a6-9403-8b46eedf4eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b1e4395a-6cef-479c-9d7a-cc80cab5adce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c97049c6-0874-4aac-be78-c19bf3db4df9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b1e4395a-6cef-479c-9d7a-cc80cab5adce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_1fe7dc92-5899-4924-9d72-0ffe9a449d88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_b96395e7-8700-4d8f-9ad1-05209fa0a05a" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_1fe7dc92-5899-4924-9d72-0ffe9a449d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_db02bb10-2a30-4db2-99e8-48448fac14b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_1fe7dc92-5899-4924-9d72-0ffe9a449d88" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1_db02bb10-2a30-4db2-99e8-48448fac14b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_88c01f41-7d73-4162-985f-e3f55136bd12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_1fe7dc92-5899-4924-9d72-0ffe9a449d88" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_88c01f41-7d73-4162-985f-e3f55136bd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_d49e86c6-94d0-431c-9a70-74168e887b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_1fe7dc92-5899-4924-9d72-0ffe9a449d88" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_d49e86c6-94d0-431c-9a70-74168e887b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_17ef5658-9d09-41c2-b6f3-794d0f7701ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_1fe7dc92-5899-4924-9d72-0ffe9a449d88" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_17ef5658-9d09-41c2-b6f3-794d0f7701ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b1132a4c-8366-4990-a9fb-f3e338801e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_224faea8-3a3c-419c-9287-ae611b64c741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b1132a4c-8366-4990-a9fb-f3e338801e50" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_224faea8-3a3c-419c-9287-ae611b64c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCES"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b349d32b-1425-4999-8c99-0907caf09347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1548365c-b571-499a-8374-691cfae5d168" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b349d32b-1425-4999-8c99-0907caf09347" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_1548365c-b571-499a-8374-691cfae5d168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION" xlink:type="simple" xlink:href="anip-20231231.xsd#BUSINESSCOMBINATION"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_9248fe1b-c0e1-4d31-88d6-405583baf2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_816356c6-3005-4d2d-9a40-aab894242cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_9248fe1b-c0e1-4d31-88d6-405583baf2fd" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_816356c6-3005-4d2d-9a40-aab894242cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RESTRUCTURING" xlink:type="simple" xlink:href="anip-20231231.xsd#RESTRUCTURING"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/RESTRUCTURING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3fe451eb-ed5c-454b-adb0-e1c04d2d9161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6f49596e-d71f-4716-98e0-e12afa16c43a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3fe451eb-ed5c-454b-adb0-e1c04d2d9161" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_6f49596e-d71f-4716-98e0-e12afa16c43a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESS" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESS"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c233df8a-679f-424c-908b-a3541b5ef8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_810193d6-ed5a-420e-ae85-c973c8e0af23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c233df8a-679f-424c-908b-a3541b5ef8a8" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_810193d6-ed5a-420e-ae85-c973c8e0af23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY" xlink:type="simple" xlink:href="anip-20231231.xsd#DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a7645f68-5068-4eae-8211-88499bc5f32a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_78bc7409-be94-4d88-b332-ce72b21066da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_a7645f68-5068-4eae-8211-88499bc5f32a" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_78bc7409-be94-4d88-b332-ce72b21066da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INVENTORIES" xlink:type="simple" xlink:href="anip-20231231.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_29ce6e50-7585-4704-8ae7-1239fbb68149" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_fa506434-ba92-4833-b6d6-b0a3454c10d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_29ce6e50-7585-4704-8ae7-1239fbb68149" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_fa506434-ba92-4833-b6d6-b0a3454c10d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET" xlink:type="simple" xlink:href="anip-20231231.xsd#PROPERTYANDEQUIPMENTNET"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10b020b0-dbe6-48e1-b163-d362cf9bca8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_40607181-ef44-4385-bf23-247f682288f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_10b020b0-dbe6-48e1-b163-d362cf9bca8b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_40607181-ef44-4385-bf23-247f682288f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETS"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f921fb5c-9e5e-454b-8541-abe0c30cb0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_696acc7c-76e5-42c4-8bd5-2946f6c19c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f921fb5c-9e5e-454b-8541-abe0c30cb0f6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_696acc7c-76e5-42c4-8bd5-2946f6c19c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUE" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUE"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e3a44d92-3274-4be6-9636-0cde46863b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2abdcdc9-fe5e-4cea-a6f7-c4a1be97954c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e3a44d92-3274-4be6-9636-0cde46863b94" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2abdcdc9-fe5e-4cea-a6f7-c4a1be97954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="anip-20231231.xsd#MEZZANINEANDSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f273598a-e36e-4dcd-a2ef-a0711e900a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e1d1d41-9700-4ab8-b7ab-76e5eaecd5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f273598a-e36e-4dcd-a2ef-a0711e900a47" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7e1d1d41-9700-4ab8-b7ab-76e5eaecd5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="anip-20231231.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4141f00d-950d-4c0c-bb92-f7e268c3d75f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_daf0b2cf-77aa-4b7e-9f31-03b783ac181b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4141f00d-950d-4c0c-bb92-f7e268c3d75f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_daf0b2cf-77aa-4b7e-9f31-03b783ac181b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eaddb067-750e-42e1-8661-81aa0a166caf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_02f6fc59-e483-44bb-a113-66a977d5aca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eaddb067-750e-42e1-8661-81aa0a166caf" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_02f6fc59-e483-44bb-a113-66a977d5aca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXES" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3ccee7ae-67e0-46de-b48b-2f55583dc179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_17d8dcc9-ef93-42d3-9e71-a488698665ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3ccee7ae-67e0-46de-b48b-2f55583dc179" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_17d8dcc9-ef93-42d3-9e71-a488698665ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5300b65-25ea-4387-bc8e-f163e32c3ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsDisclosureTextBlock_19df2ac7-986b-42a7-b518-75023af66e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c5300b65-25ea-4387-bc8e-f163e32c3ee2" xlink:to="loc_us-gaap_CommitmentsDisclosureTextBlock_19df2ac7-986b-42a7-b518-75023af66e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES" xlink:type="simple" xlink:href="anip-20231231.xsd#PURIFIEDCORTROPHINGELPRELAUNCHCHARGES"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchChargesAbstract_0e9d2955-2d82-48ec-bcdc-daf410f14b00" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchChargesTextBlock_cb8adb43-3c50-4485-9dc9-8b12fb431c1a" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchChargesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_CortrophinPreLaunchChargesAbstract_0e9d2955-2d82-48ec-bcdc-daf410f14b00" xlink:to="loc_anip_CortrophinPreLaunchChargesTextBlock_cb8adb43-3c50-4485-9dc9-8b12fb431c1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="anip-20231231.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1b3ffc54-26e3-4fe3-806b-f260b0513e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0e200007-de98-4646-90c1-b28d2e3f835f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1b3ffc54-26e3-4fe3-806b-f260b0513e92" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0e200007-de98-4646-90c1-b28d2e3f835f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTING" xlink:type="simple" xlink:href="anip-20231231.xsd#SEGMENTREPORTING"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/SEGMENTREPORTING" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_388a8f64-c972-417f-bde5-2d1904fa9293" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_3c699934-a8c6-41c8-830d-6922ab4dec6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_388a8f64-c972-417f-bde5-2d1904fa9293" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_3c699934-a8c6-41c8-830d-6922ab4dec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="anip-20231231.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_2d9f4abf-c7a9-4732-b46a-7f5ef8a6fa06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_24932568-78b3-4eed-8e87-d64213cfecd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_2d9f4abf-c7a9-4732-b46a-7f5ef8a6fa06" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_24932568-78b3-4eed-8e87-d64213cfecd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1d620d1-b227-40a2-a896-898415cfd941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f1d620d1-b227-40a2-a896-898415cfd941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_b6e15c8e-0a40-49d2-9f36-0513df63ab6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_b6e15c8e-0a40-49d2-9f36-0513df63ab6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_87f1840a-904b-4f7a-be9c-2ec572cabd52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_87f1840a-904b-4f7a-be9c-2ec572cabd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_233fe6f7-47c8-4d08-b9d3-ad672c2a4061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_UseOfEstimates_233fe6f7-47c8-4d08-b9d3-ad672c2a4061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_aec9ae05-7b1c-4a66-a59d-27c6b846c351" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy_aec9ae05-7b1c-4a66-a59d-27c6b846c351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_32620046-7998-40cf-ad07-c363377eb2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_32620046-7998-40cf-ad07-c363377eb2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5dc5dbc0-72b8-4161-a2ea-35080e70eda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5dc5dbc0-72b8-4161-a2ea-35080e70eda2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_515834ea-062b-45fa-94cd-512f0958f1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_515834ea-062b-45fa-94cd-512f0958f1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_0c0382cd-8a88-4478-b803-d46be6ec15e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_0c0382cd-8a88-4478-b803-d46be6ec15e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f1fc51e4-9c0e-46d2-b225-4f4c1ffc9fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f1fc51e4-9c0e-46d2-b225-4f4c1ffc9fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d6b6a9f4-ea30-4495-b36b-92b2c76902fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_d6b6a9f4-ea30-4495-b36b-92b2c76902fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_19e947a6-6f9e-4845-aaeb-4aa79d4b2c89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_19e947a6-6f9e-4845-aaeb-4aa79d4b2c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_80cdec39-4092-40bd-be66-8e38acca0062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_80cdec39-4092-40bd-be66-8e38acca0062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_57757294-adcd-41f5-b9f3-e7d1ab5a698e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_57757294-adcd-41f5-b9f3-e7d1ab5a698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8d34f639-0dcf-4b1f-9dbe-ecdf62821e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_8d34f639-0dcf-4b1f-9dbe-ecdf62821e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_43a58fb1-0983-4aa3-94cb-bfde47806378" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_43a58fb1-0983-4aa3-94cb-bfde47806378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4fc34105-106f-43f3-ae82-addcf07f7eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4fc34105-106f-43f3-ae82-addcf07f7eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_77449f0b-1a5b-48f5-a279-55a18debc3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_77449f0b-1a5b-48f5-a279-55a18debc3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_38872898-c2d4-4fa8-b449-f2a49ecd5f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives_38872898-c2d4-4fa8-b449-f2a49ecd5f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_66d6793e-cb42-4910-a509-55b348b04181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContingentLiabilityReserveEstimatePolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_ContingentLiabilityReserveEstimatePolicy_66d6793e-cb42-4910-a509-55b348b04181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9b18bfc7-9e29-4efc-9107-a122e285bb00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_9b18bfc7-9e29-4efc-9107-a122e285bb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ff220eed-ee6b-4af5-b130-3fe94e95b7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413c4915-96c2-46fe-aefa-c0e811c5f8e7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ff220eed-ee6b-4af5-b130-3fe94e95b7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_08800963-3761-49b8-864d-b6819f483384" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_a69df855-90a2-4ff3-9920-02ac8232abd3" xlink:href="anip-20231231.xsd#anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08800963-3761-49b8-864d-b6819f483384" xlink:to="loc_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock_a69df855-90a2-4ff3-9920-02ac8232abd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c260a8ac-35aa-4be6-b2d7-3637d0ffa9de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_192a4afd-88cb-45e3-b9c0-b1f0dd70d5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c260a8ac-35aa-4be6-b2d7-3637d0ffa9de" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_192a4afd-88cb-45e3-b9c0-b1f0dd70d5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_63cb0c64-0453-4bfb-8874-687a5e477e31" xlink:href="anip-20231231.xsd#anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c260a8ac-35aa-4be6-b2d7-3637d0ffa9de" xlink:to="loc_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock_63cb0c64-0453-4bfb-8874-687a5e477e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_af993ac1-d554-46d7-958f-0889320e2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c260a8ac-35aa-4be6-b2d7-3637d0ffa9de" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_af993ac1-d554-46d7-958f-0889320e2c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONTables" xlink:type="simple" xlink:href="anip-20231231.xsd#BUSINESSCOMBINATIONTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_df39b56f-41df-45f0-a218-02e67e59ca5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_2aa11dc6-af7b-47fc-8dbb-1d41d2abf190" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_df39b56f-41df-45f0-a218-02e67e59ca5c" xlink:to="loc_us-gaap_BusinessAcquisitionProFormaInformationTextBlock_2aa11dc6-af7b-47fc-8dbb-1d41d2abf190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e35ce0b3-51a0-4a08-81b7-859d7717f21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_96fb0b4e-8cf2-4af1-b8bb-140cf1eba268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e35ce0b3-51a0-4a08-81b7-859d7717f21d" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_96fb0b4e-8cf2-4af1-b8bb-140cf1eba268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_eaec5dc1-3e64-4df8-9d7b-72e3052028dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e35ce0b3-51a0-4a08-81b7-859d7717f21d" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_eaec5dc1-3e64-4df8-9d7b-72e3052028dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_59f4e2bb-710b-4913-a2c0-63a4e715edb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e35ce0b3-51a0-4a08-81b7-859d7717f21d" xlink:to="loc_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_59f4e2bb-710b-4913-a2c0-63a4e715edb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="anip-20231231.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_34e1c5ec-1af7-4f30-8568-b0ac2c9031a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1cb07d8f-8f88-4968-9bcf-70d5994ff9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_34e1c5ec-1af7-4f30-8568-b0ac2c9031a0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1cb07d8f-8f88-4968-9bcf-70d5994ff9c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="simple" xlink:href="anip-20231231.xsd#PROPERTYANDEQUIPMENTNETTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c2aab1b9-a2c0-451b-a50a-f8da3f8936f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_94924f90-5b31-4ace-b440-bd79d6bff366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_c2aab1b9-a2c0-451b-a50a-f8da3f8936f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_94924f90-5b31-4ace-b440-bd79d6bff366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71cffc82-e983-4333-abe8-b45b2aaf33b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_3912511a-501a-4078-af22-a1add56cd33c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71cffc82-e983-4333-abe8-b45b2aaf33b3" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_3912511a-501a-4078-af22-a1add56cd33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_53041581-2865-4c6b-81e7-214571fe2274" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_71cffc82-e983-4333-abe8-b45b2aaf33b3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_53041581-2865-4c6b-81e7-214571fe2274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUETables" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUETables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_00f1d4d2-e468-42d7-8ca8-ed39466cb08d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cc596166-fb5e-4c8b-b365-ba0d644f0f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00f1d4d2-e468-42d7-8ca8-ed39466cb08d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_cc596166-fb5e-4c8b-b365-ba0d644f0f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1c59d6d0-48b6-466c-a8e9-bc279da7c5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00f1d4d2-e468-42d7-8ca8-ed39466cb08d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1c59d6d0-48b6-466c-a8e9-bc279da7c5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_26cc3b6e-e133-4c16-bf49-3e4dd6046dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00f1d4d2-e468-42d7-8ca8-ed39466cb08d" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_26cc3b6e-e133-4c16-bf49-3e4dd6046dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="anip-20231231.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_86ceda72-2924-453b-90fe-ec10af1d0551" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f6c329bb-747a-4465-a7d9-2b4c4f12ad13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_86ceda72-2924-453b-90fe-ec10af1d0551" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_f6c329bb-747a-4465-a7d9-2b4c4f12ad13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c676dcba-10fc-4fd3-8bd1-6e224f73ebb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_decd56e6-91bc-47e7-b089-cc515e5fceed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c676dcba-10fc-4fd3-8bd1-6e224f73ebb9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_decd56e6-91bc-47e7-b089-cc515e5fceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5011a40-6474-4ab3-b2dd-adef3609476f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c676dcba-10fc-4fd3-8bd1-6e224f73ebb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d5011a40-6474-4ab3-b2dd-adef3609476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f52f80bb-2afd-424f-93bc-98f39e3afc4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c676dcba-10fc-4fd3-8bd1-6e224f73ebb9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_f52f80bb-2afd-424f-93bc-98f39e3afc4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_14804b5c-a6e2-416c-9644-f4c33ab690ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c676dcba-10fc-4fd3-8bd1-6e224f73ebb9" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_14804b5c-a6e2-416c-9644-f4c33ab690ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_54d81bc8-e97a-486e-81c7-09dc40b38aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c676dcba-10fc-4fd3-8bd1-6e224f73ebb9" xlink:to="loc_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock_54d81bc8-e97a-486e-81c7-09dc40b38aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_76510237-1b14-40c7-b524-24cb359648ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_55cd6591-1e46-4d77-b113-50c3ba52e402" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76510237-1b14-40c7-b524-24cb359648ff" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_55cd6591-1e46-4d77-b113-50c3ba52e402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ec10a8e2-a2bd-4b53-ace9-41edba3756ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76510237-1b14-40c7-b524-24cb359648ff" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ec10a8e2-a2bd-4b53-ace9-41edba3756ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d7cb0616-fb03-424a-90b6-9f7ff20f4260" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_76510237-1b14-40c7-b524-24cb359648ff" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_d7cb0616-fb03-424a-90b6-9f7ff20f4260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_940c5bf2-d58d-48ac-af31-8d6dd7b10dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_16b1af22-1c40-4a50-a467-a63e738a890c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_940c5bf2-d58d-48ac-af31-8d6dd7b10dd5" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_16b1af22-1c40-4a50-a467-a63e738a890c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5218056b-9d98-4c3b-855e-60d9b98c031f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_940c5bf2-d58d-48ac-af31-8d6dd7b10dd5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5218056b-9d98-4c3b-855e-60d9b98c031f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables" xlink:type="simple" xlink:href="anip-20231231.xsd#RELATEDPARTYTRANSACTIONSTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_b03498bb-e239-4a86-8947-188b3e212d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_fd4866cf-95fb-4d12-85f3-d2658d0c1fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_b03498bb-e239-4a86-8947-188b3e212d2c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_fd4866cf-95fb-4d12-85f3-d2658d0c1fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables" xlink:type="simple" xlink:href="anip-20231231.xsd#SEGMENTREPORTINGTables"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_3952eb12-5e1f-41b5-a030-bffe3f10abe5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_27c16cc6-6917-4332-bae3-7122866d4e51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3952eb12-5e1f-41b5-a030-bffe3f10abe5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_27c16cc6-6917-4332-bae3-7122866d4e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_b8752348-5a16-4e6b-ad97-41ec0815cf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3952eb12-5e1f-41b5-a030-bffe3f10abe5" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_b8752348-5a16-4e6b-ad97-41ec0815cf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_dfe44cf5-f53c-4c07-9666-3a4047d1f9db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_3952eb12-5e1f-41b5-a030-bffe3f10abe5" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_dfe44cf5-f53c-4c07-9666-3a4047d1f9db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_728a4f8a-0e3f-45f3-a527-eeb09589d229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_728a4f8a-0e3f-45f3-a527-eeb09589d229" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ec1d2cc-dd2d-41b6-bb7c-9f630955cd93" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2a1ae5b0-30c6-4d53-bc3c-8c4b9e843f63" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ec1d2cc-dd2d-41b6-bb7c-9f630955cd93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CranfordPharmaceuticalsMember_b0edc85e-9118-4253-8919-49b088f4ac89" xlink:href="anip-20231231.xsd#anip_CranfordPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0ec1d2cc-dd2d-41b6-bb7c-9f630955cd93" xlink:to="loc_anip_CranfordPharmaceuticalsMember_b0edc85e-9118-4253-8919-49b088f4ac89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9071080a-ee2d-43bb-95b6-5b1aaae4cf30" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d8cdfea8-dfd3-45dc-a687-e69d8b013a03" xlink:to="loc_srt_SegmentGeographicalDomain_9071080a-ee2d-43bb-95b6-5b1aaae4cf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_130a3401-8778-47d9-93cb-b09aebdd259e" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9071080a-ee2d-43bb-95b6-5b1aaae4cf30" xlink:to="loc_country_CA_130a3401-8778-47d9-93cb-b09aebdd259e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6b28ccd4-96be-4b55-9124-fc4674904868" xlink:to="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_edbb4607-57be-40b2-9d0f-728c4783c14d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:to="loc_srt_MinimumMember_edbb4607-57be-40b2-9d0f-728c4783c14d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f34b3bfd-a042-46c0-9fc7-99fcb541378d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3c2de316-3f20-4047-890e-403b5b7070b2" xlink:to="loc_srt_MaximumMember_f34b3bfd-a042-46c0-9fc7-99fcb541378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f33ebc-6dc9-49a0-9f41-73c07fac46ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_46b797e0-9ec4-4ee8-adf0-0e4fa348af06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f33ebc-6dc9-49a0-9f41-73c07fac46ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d6d89e3c-d932-44d2-938d-d371558f797d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_51f33ebc-6dc9-49a0-9f41-73c07fac46ed" xlink:to="loc_us-gaap_PerformanceSharesMember_d6d89e3c-d932-44d2-938d-d371558f797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e8e41289-156c-471f-b49f-9fa0c57a48e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_606f2321-6787-4aa0-b05d-1a2c35e27dec" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e8e41289-156c-471f-b49f-9fa0c57a48e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_7604964f-48ed-4e2c-9f2d-6e46fb4dabfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e8e41289-156c-471f-b49f-9fa0c57a48e2" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_7604964f-48ed-4e2c-9f2d-6e46fb4dabfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74165042-448c-4d27-80e8-66046b1c5f88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_dfc4192a-b691-47ea-9afd-81b8f76eccef" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74165042-448c-4d27-80e8-66046b1c5f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_eef49a22-a457-4f3f-a7bb-7624131508f6" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_74165042-448c-4d27-80e8-66046b1c5f88" xlink:to="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_eef49a22-a457-4f3f-a7bb-7624131508f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_573dc865-98ef-4f7f-b8e5-333f38882239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_97d2f6e7-2bbf-49fb-af17-024f9d01af68" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_573dc865-98ef-4f7f-b8e5-333f38882239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_0e802eb9-a301-46d3-b813-d48cb2d19cd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_573dc865-98ef-4f7f-b8e5-333f38882239" xlink:to="loc_us-gaap_SubsequentEventMember_0e802eb9-a301-46d3-b813-d48cb2d19cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2d224e42-ec9e-4a29-9632-afd38cc2864d" xlink:to="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a9c2bd4e-ec01-43b8-ba72-dd2b98cda57e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_a9c2bd4e-ec01-43b8-ba72-dd2b98cda57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_7581ae96-9645-4c42-b60e-b5444d1a27f9" xlink:href="anip-20231231.xsd#anip_NumberOfPharmaceuticalManufacturingFacilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_7581ae96-9645-4c42-b60e-b5444d1a27f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FDICGuaranteedAmount_a3923e49-89f2-4a95-9ba0-577a138c1157" xlink:href="anip-20231231.xsd#anip_FDICGuaranteedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_anip_FDICGuaranteedAmount_a3923e49-89f2-4a95-9ba0-577a138c1157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_2f9126e1-0f1d-418a-9abe-ab564378e6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_EscrowDeposit_2f9126e1-0f1d-418a-9abe-ab564378e6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79e4e3c7-d535-44c7-91b9-1249a0ffe897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_79e4e3c7-d535-44c7-91b9-1249a0ffe897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_16af8f3d-2b6c-4f59-9304-b412b6448e24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_16af8f3d-2b6c-4f59-9304-b412b6448e24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_18d9851c-a39b-458c-bc76-93f20028d67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_18d9851c-a39b-458c-bc76-93f20028d67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dced7c7e-eb31-4ef0-ab23-b3f5b8a5e428" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_dced7c7e-eb31-4ef0-ab23-b3f5b8a5e428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_cd5703f7-b41c-4f19-bfe3-035796ec9479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_cd5703f7-b41c-4f19-bfe3-035796ec9479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c70441aa-4997-42b1-a79f-286e12590602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_NumberOfReportableSegments_c70441aa-4997-42b1-a79f-286e12590602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_5c756cfa-de47-4adc-9e44-39905e2de745" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_5c756cfa-de47-4adc-9e44-39905e2de745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82218df4-564e-482d-8270-22881d183741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_980e8ae1-c0cd-41c9-968f-e7c693adc5a8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_82218df4-564e-482d-8270-22881d183741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_010d89c9-65fe-4bcc-82c5-ebac0674f685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_010d89c9-65fe-4bcc-82c5-ebac0674f685" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae88e88a-9442-4662-9631-b02dbd4d7b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_5ebc9110-6496-4fca-ad5b-5d4dd5e96ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_5ebc9110-6496-4fca-ad5b-5d4dd5e96ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_626411a8-2801-41e8-9511-52ba5c0faf05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7446b0a5-bc19-4512-ba42-ee3e6acb11aa" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_626411a8-2801-41e8-9511-52ba5c0faf05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:to="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6fdc75d1-4c0b-4c23-8920-3070911994ee" xlink:to="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_892d404f-b204-44c6-8eee-b18d72adbce0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:to="loc_srt_MinimumMember_892d404f-b204-44c6-8eee-b18d72adbce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d6f8bf1d-a4bd-410b-b3e1-08307882cf81" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_abbe35d1-3a88-4491-b585-a1fd7dbb9968" xlink:to="loc_srt_MaximumMember_d6f8bf1d-a4bd-410b-b3e1-08307882cf81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_72709fdd-62eb-4cc0-84a3-0d0121edfce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7d0ddad3-f9a2-4fcd-b492-4cfdb5657698" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_72709fdd-62eb-4cc0-84a3-0d0121edfce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_165398e0-0c77-4679-b148-5edd4419307c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_72709fdd-62eb-4cc0-84a3-0d0121edfce1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_165398e0-0c77-4679-b148-5edd4419307c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe4d809e-6a04-4c5a-b0db-d69133016836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe4d809e-6a04-4c5a-b0db-d69133016836" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:to="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_50191bf7-dc9a-4c8b-bef3-daa07309f009" xlink:to="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfGenericPharmaceuticalProductsMember_64950bb1-cd55-43d4-baad-25f7b7bfcee7" xlink:href="anip-20231231.xsd#anip_SalesOfGenericPharmaceuticalProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:to="loc_anip_SalesOfGenericPharmaceuticalProductsMember_64950bb1-cd55-43d4-baad-25f7b7bfcee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfBrandedPharmaceuticalProductsMember_57399684-6175-4975-af8e-8d025268ba9f" xlink:href="anip-20231231.xsd#anip_SalesOfBrandedPharmaceuticalProductsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:to="loc_anip_SalesOfBrandedPharmaceuticalProductsMember_57399684-6175-4975-af8e-8d025268ba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfRareDiseasePharmaceuticalProductsMember_85ba06f4-7b94-4136-9ffe-dff11a677c95" xlink:href="anip-20231231.xsd#anip_SalesOfRareDiseasePharmaceuticalProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_62073fa2-05ae-4db0-8b55-1913cc2444b6" xlink:to="loc_anip_SalesOfRareDiseasePharmaceuticalProductsMember_85ba06f4-7b94-4136-9ffe-dff11a677c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bb85542e-1670-47db-825f-b3aae861d736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_e84522c6-f1d1-44ea-aa24-22e0a9b52199" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bb85542e-1670-47db-825f-b3aae861d736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78afa478-8aa8-40a8-a1e2-1242ed92675c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb85542e-1670-47db-825f-b3aae861d736" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_78afa478-8aa8-40a8-a1e2-1242ed92675c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4365a599-1d5b-4b73-ae00-0efa1459bfa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4365a599-1d5b-4b73-ae00-0efa1459bfa9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_35b8123a-ddb7-4c78-98c8-ba930a5a7c56" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredAtPointInTimeMember_fee51494-ff73-4aa0-84e6-19c0b97decc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredAtPointInTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:to="loc_us-gaap_TransferredAtPointInTimeMember_fee51494-ff73-4aa0-84e6-19c0b97decc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_a25727ef-4c9c-48bd-936a-7cca12ca24b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_ca0c44f2-0f63-4074-9b53-d8c626eab924" xlink:to="loc_us-gaap_TransferredOverTimeMember_a25727ef-4c9c-48bd-936a-7cca12ca24b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_41737d15-ba85-4893-be91-6963179392d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_515a8116-774e-4067-b7e0-1253a1bebbff" xlink:to="loc_srt_ProductsAndServicesDomain_41737d15-ba85-4893-be91-6963179392d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SalesOfContractManufacturedProductsMember_57948cac-bb79-426c-b83f-0965370133db" xlink:href="anip-20231231.xsd#anip_SalesOfContractManufacturedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_41737d15-ba85-4893-be91-6963179392d2" xlink:to="loc_anip_SalesOfContractManufacturedProductsMember_57948cac-bb79-426c-b83f-0965370133db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_688837c2-a287-439c-a915-fe529021fda6" xlink:to="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37bc3bf8-59aa-4cd8-9486-4cd2869b3dda" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:to="loc_srt_MinimumMember_37bc3bf8-59aa-4cd8-9486-4cd2869b3dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_12627ece-5d0d-4c91-84ad-a3a6918b797b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fe3b8b57-d4b8-4def-8ded-13aa3cf06a82" xlink:to="loc_srt_MaximumMember_12627ece-5d0d-4c91-84ad-a3a6918b797b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_236dcd87-9c94-4c0d-8297-e49c33850d50" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65d6890a-0de6-4471-93c6-0d124ac6c36a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_65d6890a-0de6-4471-93c6-0d124ac6c36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_babca258-1a90-4161-b1a4-d3bd4fff8847" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_babca258-1a90-4161-b1a4-d3bd4fff8847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea81bdca-8ab4-4cdf-9920-16427f83fa0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_ea81bdca-8ab4-4cdf-9920-16427f83fa0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_3c8cbd3d-b10f-4139-b835-0f92bec18e74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_3c8cbd3d-b10f-4139-b835-0f92bec18e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_816dc9bb-0061-45ab-9cf8-0819e62d23f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration_816dc9bb-0061-45ab-9cf8-0819e62d23f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductReturnPeriod_3e2533f1-3be5-4a5b-8b0c-227859ec3e92" xlink:href="anip-20231231.xsd#anip_ProductReturnPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_afcc26cc-d1f7-4ff4-a382-51c8d9f80006" xlink:to="loc_anip_ProductReturnPeriod_3e2533f1-3be5-4a5b-8b0c-227859ec3e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebde206d-e28d-457a-b849-76790dc7fcb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ebde206d-e28d-457a-b849-76790dc7fcb6" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_8f5b2931-80eb-4f5f-9ceb-2bf9d82fd53a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ChargebacksMember_b6b58bf7-a607-4969-8486-862702133aa6" xlink:href="anip-20231231.xsd#anip_ChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_ChargebacksMember_b6b58bf7-a607-4969-8486-862702133aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_GovernmentRebatesMember_f343b85f-a432-4b36-a983-c23ee1a7a0d4" xlink:href="anip-20231231.xsd#anip_GovernmentRebatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_GovernmentRebatesMember_f343b85f-a432-4b36-a983-c23ee1a7a0d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AllowancesForSalesReturnsMember_e541c46f-8421-445d-9c1c-41437c5edf60" xlink:href="anip-20231231.xsd#anip_AllowancesForSalesReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_AllowancesForSalesReturnsMember_e541c46f-8421-445d-9c1c-41437c5edf60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AdministrativeFeesAndOtherRebatesMember_ad9a58e7-31fd-4b9c-b226-60b3924c5592" xlink:href="anip-20231231.xsd#anip_AdministrativeFeesAndOtherRebatesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_AdministrativeFeesAndOtherRebatesMember_ad9a58e7-31fd-4b9c-b226-60b3924c5592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReservesForCashDiscountMember_be041355-f7d9-401a-828a-90631e59cefa" xlink:href="anip-20231231.xsd#anip_ReservesForCashDiscountMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_a72ce2f8-5c68-4209-979b-34054f8b7c79" xlink:to="loc_anip_ReservesForCashDiscountMember_be041355-f7d9-401a-828a-90631e59cefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5452ca85-a721-4bf7-938b-0b10686eee3e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_c05b9378-088d-4184-8627-b4694ec42794" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5452ca85-a721-4bf7-938b-0b10686eee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_5452ca85-a721-4bf7-938b-0b10686eee3e" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_7ab77625-ea2e-4204-8be2-84383d782fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_7ab77625-ea2e-4204-8be2-84383d782fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_6b711662-80df-4ab3-9b97-061553607a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesAdjustments_6b711662-80df-4ab3-9b97-061553607a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_769bcf8b-1871-4829-9f40-a0df69f99d18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_769bcf8b-1871-4829-9f40-a0df69f99d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_1bb11b17-f128-4a16-b7fc-68f631856fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_14d267b1-45fb-4984-b0f4-6ff8d7d894b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_1bb11b17-f128-4a16-b7fc-68f631856fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e391f010-7b6b-486d-8f49-fa01fa32475e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e391f010-7b6b-486d-8f49-fa01fa32475e" xlink:to="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_258ed4e7-f886-4d06-8bfa-4f1de6bbbb69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1fe9a950-8cb2-44b4-9f85-416f2d4d87ae" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_258ed4e7-f886-4d06-8bfa-4f1de6bbbb69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_08eb71d9-972b-451e-9dbb-693639c9ab47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_258ed4e7-f886-4d06-8bfa-4f1de6bbbb69" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_08eb71d9-972b-451e-9dbb-693639c9ab47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_fbda167c-a9eb-4ba7-b28d-2ea65462434a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_b5a9df6e-3ebd-4cd7-967e-4dbe416f8497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:to="loc_us-gaap_AccountsReceivableMember_b5a9df6e-3ebd-4cd7-967e-4dbe416f8497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_e185f189-85f1-4ab4-ab89-66e455a2988b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0ddb76aa-15c4-430e-83ec-b36d47c0ed10" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_e185f189-85f1-4ab4-ab89-66e455a2988b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4e017aa5-f7b3-479a-8c83-feb10ef0420e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_1d3a45af-1743-43fa-ad5e-1149ca15b023" xlink:to="loc_srt_NameOfMajorCustomerDomain_4e017aa5-f7b3-479a-8c83-feb10ef0420e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:href="anip-20231231.xsd#anip_FourCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4e017aa5-f7b3-479a-8c83-feb10ef0420e" xlink:to="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerOneMember_3c91b782-e0a2-4e4d-906e-a6f371cb4a66" xlink:href="anip-20231231.xsd#anip_CustomerOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerOneMember_3c91b782-e0a2-4e4d-906e-a6f371cb4a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerTwoMember_e6c95076-ced6-4ae7-a452-25ffdc646044" xlink:href="anip-20231231.xsd#anip_CustomerTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerTwoMember_e6c95076-ced6-4ae7-a452-25ffdc646044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerThreeMember_25b91997-c70a-42c4-ab0e-b9604692e766" xlink:href="anip-20231231.xsd#anip_CustomerThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerThreeMember_25b91997-c70a-42c4-ab0e-b9604692e766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CustomerFourMember_3788118c-343e-4b02-9e0b-61c19a24cb99" xlink:href="anip-20231231.xsd#anip_CustomerFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_FourCustomersMember_e8c25d69-9d6e-4ea8-9041-a6ef8b3fbfa8" xlink:to="loc_anip_CustomerFourMember_3788118c-343e-4b02-9e0b-61c19a24cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_c4f1e4f5-ae62-4007-a7aa-6a7af74456d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a6818e92-e6c4-4d58-b99a-84605ef215a5" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_c4f1e4f5-ae62-4007-a7aa-6a7af74456d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_608ba863-e10b-44b1-8641-cf6d60625dea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_c4f1e4f5-ae62-4007-a7aa-6a7af74456d8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_608ba863-e10b-44b1-8641-cf6d60625dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#BUSINESSCOMBINATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_ccd053bc-3ea2-4ec3-9259-09c1c0dcd8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_ccd053bc-3ea2-4ec3-9259-09c1c0dcd8ba" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_161a3aed-ca3a-41cf-8932-3cc5834ca2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8da754b2-c683-4b09-8960-f8c386c90eac" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_161a3aed-ca3a-41cf-8932-3cc5834ca2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_5099f2b7-bb2f-47e1-bf3e-f7138b1c3f1c" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_161a3aed-ca3a-41cf-8932-3cc5834ca2fa" xlink:to="loc_anip_NovitiumMember_5099f2b7-bb2f-47e1-bf3e-f7138b1c3f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_02e26c51-9701-49a9-b069-a1f323b31ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bbcc122b-b39a-4e73-a2d4-b7f9a7430f9d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_02e26c51-9701-49a9-b069-a1f323b31ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_ac63c999-9f82-4403-bc03-2a158e49fdca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_02e26c51-9701-49a9-b069-a1f323b31ab6" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_ac63c999-9f82-4403-bc03-2a158e49fdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_43bba64d-26e0-470d-84f6-882a01cdb9c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_7ec8cdd1-c3a1-4966-b173-067ae5424591" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_7ec8cdd1-c3a1-4966-b173-067ae5424591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_99f87572-0bb6-4157-9103-a55e058b7678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c2b90d0f-bd29-446d-bb7d-2a4aaef03850" xlink:to="loc_us-gaap_CustomerRelationshipsMember_99f87572-0bb6-4157-9103-a55e058b7678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05b17ec1-709d-4ba5-a19b-62a47999df36" xlink:to="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dbe74118-15d0-4201-a897-9fab1ebe7ec4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:to="loc_srt_MinimumMember_dbe74118-15d0-4201-a897-9fab1ebe7ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_761c39cf-a099-453d-9dae-62841cade46f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f56ec405-d2d0-4a32-a81e-0c6eb24ef741" xlink:to="loc_srt_MaximumMember_761c39cf-a099-453d-9dae-62841cade46f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_c9a1369b-e317-4647-9453-5d18bb699c74" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_cd8b6397-43e8-412d-8c36-cb5dd4213bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_cd8b6397-43e8-412d-8c36-cb5dd4213bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_181f1c31-719d-4064-b061-b5f445cb3121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_511a05e8-49c2-4885-881e-2582a44ccff7" xlink:to="loc_us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember_181f1c31-719d-4064-b061-b5f445cb3121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d40a2a11-2315-4937-9644-fb3dea0c0f00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_220f9e9a-c2f5-4f52-af58-c07259c2e880" xlink:to="loc_us-gaap_ClassOfStockDomain_d40a2a11-2315-4937-9644-fb3dea0c0f00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_e5169f62-72e1-4126-9f77-acaa34d2f75a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d40a2a11-2315-4937-9644-fb3dea0c0f00" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_e5169f62-72e1-4126-9f77-acaa34d2f75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99ecd5a9-131d-4bf1-a91a-7d4b4d62d420" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_25909c6b-9307-4822-9840-7e0cdac596f5" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99ecd5a9-131d-4bf1-a91a-7d4b4d62d420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember_9b70a89a-657b-4529-b51d-12edee14ab07" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_99ecd5a9-131d-4bf1-a91a-7d4b4d62d420" xlink:to="loc_anip_PrivateInvestmentInPublicEquityMember_9b70a89a-657b-4529-b51d-12edee14ab07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_8805961d-40c1-4ce6-ad67-0573291f7c33" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_a48f3125-aa0c-4129-a511-e902bcc632a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_a48f3125-aa0c-4129-a511-e902bcc632a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_06b6856e-10b9-4a57-947e-34220118c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_06b6856e-10b9-4a57-947e-34220118c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_90f327bc-f78e-42be-a955-69adc00d1e64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_90f327bc-f78e-42be-a955-69adc00d1e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4c506779-b9e8-44e8-9240-45dc4653a5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_4c506779-b9e8-44e8-9240-45dc4653a5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4205b3da-aaef-44c1-b27c-d5f81bfb2829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_4205b3da-aaef-44c1-b27c-d5f81bfb2829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_ebca76b1-31aa-4a92-a7e1-b7fbce07a32d" xlink:href="anip-20231231.xsd#anip_RestrictionPeriodForSharesIssuedInBusinessCombination"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_anip_RestrictionPeriodForSharesIssuedInBusinessCombination_ebca76b1-31aa-4a92-a7e1-b7fbce07a32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3de54d0c-745a-412f-839f-78630c7104b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3de54d0c-745a-412f-839f-78630c7104b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_dfc4cc5f-54b8-47b2-94f2-c1b2d3dfb21b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_dfc4cc5f-54b8-47b2-94f2-c1b2d3dfb21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3c73b207-7081-40e0-bd3c-321bfff167cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3c73b207-7081-40e0-bd3c-321bfff167cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bd676c8d-75ce-4f58-aa79-87857d6286d0" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_bd676c8d-75ce-4f58-aa79-87857d6286d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_ac590fee-7849-489c-949e-a2bf0ede791e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_ac590fee-7849-489c-949e-a2bf0ede791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2244bab4-322a-4fe3-923e-12334e5d26b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_2244bab4-322a-4fe3-923e-12334e5d26b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2dab98d0-edcc-4bad-a3cc-65c275fa98ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_2dab98d0-edcc-4bad-a3cc-65c275fa98ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_20dfb66b-51a3-4327-bba5-f6350de68949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_Goodwill_20dfb66b-51a3-4327-bba5-f6350de68949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_6e2964fb-de85-48b8-a8b4-77cea53c595a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual_6e2964fb-de85-48b8-a8b4-77cea53c595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a89bf62b-2b6b-46b8-ada7-cbf54806d32f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_a89bf62b-2b6b-46b8-ada7-cbf54806d32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78c9ea40-b61a-466b-8102-deaea7e56eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8a85d427-5411-4ef6-b483-f2136d2459ba" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_78c9ea40-b61a-466b-8102-deaea7e56eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#BUSINESSCOMBINATIONProFormaDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_b07e906c-2a66-404e-84db-fed952b24241" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4ab481d7-c1b1-48ad-8186-a5d133693be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b07e906c-2a66-404e-84db-fed952b24241" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaRevenue_4ab481d7-c1b1-48ad-8186-a5d133693be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_aa87dae5-fb54-4618-aea5-55824bbebdd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_b07e906c-2a66-404e-84db-fed952b24241" xlink:to="loc_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_aa87dae5-fb54-4618-aea5-55824bbebdd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#RESTRUCTURINGDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5a1abc84-176a-4baf-b815-0e49cf6ac2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5a1abc84-176a-4baf-b815-0e49cf6ac2ac" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_ad4b3f30-3841-485c-b0b4-11661eca0db5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8ff64ec-becb-4dd5-9f33-d125f15c0699" xlink:to="loc_us-gaap_RestructuringPlanDomain_ad4b3f30-3841-485c-b0b4-11661eca0db5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioCanadaMember_8a3a0d94-8adc-4f54-ab1f-2e4506389d4c" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioCanadaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_ad4b3f30-3841-485c-b0b4-11661eca0db5" xlink:to="loc_anip_OakvilleOntarioCanadaMember_8a3a0d94-8adc-4f54-ab1f-2e4506389d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_14a35e72-95ca-4115-8640-fab052847fc0" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_57b0859b-3fdf-4d6f-a203-ea3d320eca51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_57b0859b-3fdf-4d6f-a203-ea3d320eca51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FacilityClosingMember_40b178f9-22af-4f47-8072-bda1585063a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FacilityClosingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:to="loc_us-gaap_FacilityClosingMember_40b178f9-22af-4f47-8072-bda1585063a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_be73dc07-508c-430e-9b61-91e0aa32f1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d7608779-ce3f-4193-94f5-acf4bd9caf2e" xlink:to="loc_us-gaap_OtherRestructuringMember_be73dc07-508c-430e-9b61-91e0aa32f1dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_1266e0e4-e1fd-4568-b662-dc1ebe5b4900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_a0506e06-b1f3-4b4a-beec-6465dc9ae3b4" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_1266e0e4-e1fd-4568-b662-dc1ebe5b4900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_9748e04c-10c7-40f3-8124-d0bd859829dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_1266e0e4-e1fd-4568-b662-dc1ebe5b4900" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_9748e04c-10c7-40f3-8124-d0bd859829dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_904dde36-a391-417e-bb1c-4b994947e2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d943f5a9-fe14-44a9-ab62-ebc20396c0e4" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_904dde36-a391-417e-bb1c-4b994947e2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_e9e60ea7-6a95-45cf-8aed-57e4e69a94e8" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_904dde36-a391-417e-bb1c-4b994947e2bf" xlink:to="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_e9e60ea7-6a95-45cf-8aed-57e4e69a94e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ac0177fa-5333-4f28-8e32-95cdf232aa13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_4279d57b-8da4-4708-8aa4-667f09e868d2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ac0177fa-5333-4f28-8e32-95cdf232aa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_89e62995-9ccc-457b-8fda-66b6833cece1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ac0177fa-5333-4f28-8e32-95cdf232aa13" xlink:to="loc_us-gaap_SubsequentEventMember_89e62995-9ccc-457b-8fda-66b6833cece1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6859f2e8-7c91-4283-ac44-f694f9b9c563" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_1d560025-b451-47f1-a6ac-f87fe2356d39" xlink:href="anip-20231231.xsd#anip_NumberOfPharmaceuticalManufacturingFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_anip_NumberOfPharmaceuticalManufacturingFacilities_1d560025-b451-47f1-a6ac-f87fe2356d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_5e0b28c4-b1d8-428b-b654-46445bbbee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_5e0b28c4-b1d8-428b-b654-46445bbbee6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_5dc15d1a-d9f5-442f-903d-b631a96df653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_RestructuringReserve_5dc15d1a-d9f5-442f-903d-b631a96df653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_96eca771-c850-4c58-8171-9b549ba4a12c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_96eca771-c850-4c58-8171-9b549ba4a12c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ebb3025a-d173-46f8-94e4-2e4994b0ee83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_583bf0ba-23bf-4b71-adde-fdf9deb4b414" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_ebb3025a-d173-46f8-94e4-2e4994b0ee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSCreditfacilityDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_314dd406-73ec-4b31-915b-cb5e87beac10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_314dd406-73ec-4b31-915b-cb5e87beac10" xlink:to="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_d48a7ada-390c-4af1-810f-30e28b3999e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_99957c66-5e58-4359-98ce-d7ce93fc3da7" xlink:to="loc_us-gaap_CreditFacilityDomain_d48a7ada-390c-4af1-810f-30e28b3999e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CreditAgreementMember_003c4fc4-9e59-4969-bf0f-8b169f5af355" xlink:href="anip-20231231.xsd#anip_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_d48a7ada-390c-4af1-810f-30e28b3999e0" xlink:to="loc_anip_CreditAgreementMember_003c4fc4-9e59-4969-bf0f-8b169f5af355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af95506c-50df-42cc-bbc0-b82e5c4d06c7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember_45cede8c-e89a-4c7b-a576-4fd36ee5500e" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:to="loc_anip_TermLoanMember_45cede8c-e89a-4c7b-a576-4fd36ee5500e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_d82374a7-a6d9-4ce8-914e-3abbd02bcd57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_efad81bf-49b8-46d0-b77a-8b6d21627a68" xlink:to="loc_us-gaap_LineOfCreditMember_d82374a7-a6d9-4ce8-914e-3abbd02bcd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_05bd7712-107d-4d14-8e3e-25f81d3aa3e2" xlink:to="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_f6f76174-9ce1-476d-9dc1-e6e2e17fefdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:to="loc_us-gaap_BaseRateMember_f6f76174-9ce1-476d-9dc1-e6e2e17fefdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e4c6b496-cd7b-483a-8852-d0fde21c3c32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_5d9dd8fe-a071-4e2a-8994-42ea8827ca2f" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e4c6b496-cd7b-483a-8852-d0fde21c3c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:href="anip-20231231.xsd#anip_InterestPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:href="anip-20231231.xsd#anip_InterestPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_InterestPeriodAxis_2210edfe-aae4-41a0-a98b-607b37a04cd0" xlink:to="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OneMonthDurationMember_7ac07820-da8b-42e3-b8d6-dfb6da151d32" xlink:href="anip-20231231.xsd#anip_OneMonthDurationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:to="loc_anip_OneMonthDurationMember_7ac07820-da8b-42e3-b8d6-dfb6da151d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ThreeMonthDurationMember_6906fcc8-333f-484b-994c-9e4dc5a53790" xlink:href="anip-20231231.xsd#anip_ThreeMonthDurationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:to="loc_anip_ThreeMonthDurationMember_6906fcc8-333f-484b-994c-9e4dc5a53790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SixMonthDurationMember_193ef41d-52c9-4b13-a282-fedde69d641e" xlink:href="anip-20231231.xsd#anip_SixMonthDurationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_InterestPeriodDomain_f1454c41-776c-4661-a7c9-cb17dcea4490" xlink:to="loc_anip_SixMonthDurationMember_193ef41d-52c9-4b13-a282-fedde69d641e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7282f00c-6e97-4a9f-ac02-7010f3214f82" xlink:to="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6744e28c-b572-4761-85d1-f863585a40d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_6744e28c-b572-4761-85d1-f863585a40d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba5d58e8-1ef4-4d29-9973-b22fda27ad0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_ba5d58e8-1ef4-4d29-9973-b22fda27ad0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_91501366-5300-4ed3-9b42-7b918134c697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_91501366-5300-4ed3-9b42-7b918134c697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_0ede7cc1-6d56-4f71-abb4-fea8d759662d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_0ede7cc1-6d56-4f71-abb4-fea8d759662d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e574d9dd-2392-4c4a-8e43-8a0ee77fcbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e574d9dd-2392-4c4a-8e43-8a0ee77fcbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_218977a9-9acf-4398-8e86-64c659946cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_218977a9-9acf-4398-8e86-64c659946cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0a14d984-d261-4923-9c07-85af419a00df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_8ac89626-ca69-4248-a5d8-d817cf3bb493" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_0a14d984-d261-4923-9c07-85af419a00df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSFacilitycomponentsDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9e57d7bb-c80b-4fbe-a0b5-6f5750faa09e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9e57d7bb-c80b-4fbe-a0b5-6f5750faa09e" xlink:to="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_b0da18fc-97ef-4c4c-b3f9-7925b4dbf590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd0c2e0e-f988-4ddc-a9dd-baff4d3c981d" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_b0da18fc-97ef-4c4c-b3f9-7925b4dbf590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanAndDelayedDrawTermLoanMember_6c02af7d-b610-4e9d-8ad9-e445bf36c8aa" xlink:href="anip-20231231.xsd#anip_TermLoanAndDelayedDrawTermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_b0da18fc-97ef-4c4c-b3f9-7925b4dbf590" xlink:to="loc_anip_TermLoanAndDelayedDrawTermLoanMember_6c02af7d-b610-4e9d-8ad9-e445bf36c8aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ca1b5bba-d039-428c-8793-de25b7c42069" xlink:to="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossCurrent_a4f4260c-a1b0-4510-94f5-ef00d519a393" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_anip_LongTermDebtGrossCurrent_a4f4260c-a1b0-4510-94f5-ef00d519a393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_8391f9e0-7833-4e43-b1ab-a7a3f01aa563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_8391f9e0-7833-4e43-b1ab-a7a3f01aa563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_eea79871-c529-4c0d-a723-bd0ff97ce6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_LongTermDebtCurrent_eea79871-c529-4c0d-a723-bd0ff97ce6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LongTermDebtGrossNonCurrent_00c8e968-8b34-4ada-8c71-79a5d1eca570" xlink:href="anip-20231231.xsd#anip_LongTermDebtGrossNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_anip_LongTermDebtGrossNonCurrent_00c8e968-8b34-4ada-8c71-79a5d1eca570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_15414dd2-8e42-4c65-a305-ede57a41897a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_15414dd2-8e42-4c65-a305-ede57a41897a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8ccb8f89-17ab-4f1a-8539-39aa54b53ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_5c8c6d79-f0c3-4ee1-b044-ee3712c06598" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8ccb8f89-17ab-4f1a-8539-39aa54b53ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_abd16d63-2a94-4ca6-90d5-c73253b5cb77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_abd16d63-2a94-4ca6-90d5-c73253b5cb77" xlink:to="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:to="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_66e7e748-5d79-4787-9890-aa02dda4106c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_acf5688c-fd99-4304-8102-18b9d4038bd4" xlink:to="loc_us-gaap_CreditFacilityDomain_66e7e748-5d79-4787-9890-aa02dda4106c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CreditAgreementMember_5c4aab12-d033-41fd-9d3d-911f6b26fcdc" xlink:href="anip-20231231.xsd#anip_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_66e7e748-5d79-4787-9890-aa02dda4106c" xlink:to="loc_anip_CreditAgreementMember_5c4aab12-d033-41fd-9d3d-911f6b26fcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_fd4e4831-e1e1-4a99-97c9-1277d7fc0d4c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember_015e2fa8-98ba-457c-933f-6ab81d242a9b" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:to="loc_anip_TermLoanMember_015e2fa8-98ba-457c-933f-6ab81d242a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_0c850f49-9407-43fb-8827-585b6cf5b1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2c3f7b1c-4a16-484b-8bf9-9355d05d585e" xlink:to="loc_us-gaap_LineOfCreditMember_0c850f49-9407-43fb-8827-585b6cf5b1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_2956a3ab-ba41-428d-a55a-d2bb2938f56d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c6e1ed99-8b36-41eb-9876-a0f05ae0eaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c6e1ed99-8b36-41eb-9876-a0f05ae0eaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_719d08ce-d6b2-4dda-9701-989a40e4c4ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_719d08ce-d6b2-4dda-9701-989a40e4c4ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d56899bf-2318-4a72-ad3f-174c2b3075a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d56899bf-2318-4a72-ad3f-174c2b3075a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_9e2a24f2-2b15-4f58-a9d2-a6ff2dbb2439" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6ce04b0b-bf4f-4edf-9559-46a2d4a4cacf" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_9e2a24f2-2b15-4f58-a9d2-a6ff2dbb2439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSCreditfacilitymaturityDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_38b96ae4-1bcb-435c-9fc7-ec5c1ea2b714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_38b96ae4-1bcb-435c-9fc7-ec5c1ea2b714" xlink:to="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6b672654-86c8-415d-a2bb-6a62f804ce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_45b72556-a185-48c2-be6b-8712b5a76ede" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6b672654-86c8-415d-a2bb-6a62f804ce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TermLoanMember_944079b7-8102-411f-97e1-65f3a242decb" xlink:href="anip-20231231.xsd#anip_TermLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6b672654-86c8-415d-a2bb-6a62f804ce3d" xlink:to="loc_anip_TermLoanMember_944079b7-8102-411f-97e1-65f3a242decb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_af51e421-4428-474a-b3d8-ee0e18b19914" xlink:to="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_476e4a7c-3ebc-4886-b9d5-6a9e0e74fb1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_476e4a7c-3ebc-4886-b9d5-6a9e0e74fb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_af60c782-d5f5-4251-a4dc-9c4177703f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_af60c782-d5f5-4251-a4dc-9c4177703f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_53255070-1669-46ed-8fe6-29961197c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_53255070-1669-46ed-8fe6-29961197c4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cb485fa3-58c4-4ca8-9a8b-d3ce24718707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_cb485fa3-58c4-4ca8-9a8b-d3ce24718707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_178cecb9-39f1-4c5d-8c0e-0064733c6878" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_4b026289-6ee4-4e80-839b-24343a15a656" xlink:to="loc_us-gaap_LongTermDebt_178cecb9-39f1-4c5d-8c0e-0064733c6878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INDEBTEDNESSInterestDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_c5ebcde6-d4e5-4e68-9ad2-a6a1c9cfdfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_59e768ff-168c-4995-b279-b903ca76dc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5ebcde6-d4e5-4e68-9ad2-a6a1c9cfdfc3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_59e768ff-168c-4995-b279-b903ca76dc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_a9d53ad8-59c7-4052-8f79-720dfbb90a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5ebcde6-d4e5-4e68-9ad2-a6a1c9cfdfc3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_a9d53ad8-59c7-4052-8f79-720dfbb90a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalizedAdjustment_d727ed93-6aca-49a1-90d7-c68a7e6bf306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalizedAdjustment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5ebcde6-d4e5-4e68-9ad2-a6a1c9cfdfc3" xlink:to="loc_us-gaap_InterestCostsCapitalizedAdjustment_d727ed93-6aca-49a1-90d7-c68a7e6bf306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_ea234738-83c2-4466-bb70-6f1da8428c34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_c5ebcde6-d4e5-4e68-9ad2-a6a1c9cfdfc3" xlink:to="loc_us-gaap_InterestExpenseDebt_ea234738-83c2-4466-bb70-6f1da8428c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1bd42ff2-9052-4f63-a3d5-b2fc1d99caa0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_1bd42ff2-9052-4f63-a3d5-b2fc1d99caa0" xlink:to="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_da16c517-a975-4a43-a3a2-7f7dd2d0bec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_b27861f2-6a21-4c7e-b279-8710460b50ee" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_da16c517-a975-4a43-a3a2-7f7dd2d0bec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1aed65f3-d14b-4ca6-a9d0-09195b01a31e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_da16c517-a975-4a43-a3a2-7f7dd2d0bec8" xlink:to="loc_us-gaap_InterestRateSwapMember_1aed65f3-d14b-4ca6-a9d0-09195b01a31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_ab7c2caa-b812-4b40-ab63-df4cb6a068fd" xlink:to="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_568cb419-629b-4783-bf9a-779defb78021" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_568cb419-629b-4783-bf9a-779defb78021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2de8f3c9-df77-4fcc-927d-a4abfdc79e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2de8f3c9-df77-4fcc-927d-a4abfdc79e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_DerivativeLiabilityDecreaseInNotionalAmount_c5580cbc-9df0-475c-a9a4-13cfe1086186" xlink:href="anip-20231231.xsd#anip_DerivativeLiabilityDecreaseInNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_anip_DerivativeLiabilityDecreaseInNotionalAmount_c5580cbc-9df0-475c-a9a4-13cfe1086186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ba863a30-cf16-446f-a423-9c896226e2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_ba863a30-cf16-446f-a423-9c896226e2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_941ab6c2-ad41-478a-a923-f73fb9dae73d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_941ab6c2-ad41-478a-a923-f73fb9dae73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_447aa99b-08f5-471b-b0e8-01b1c987483a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_447aa99b-08f5-471b-b0e8-01b1c987483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_18a61cc6-8b9b-43e3-85ce-e54d2a052a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_18a61cc6-8b9b-43e3-85ce-e54d2a052a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_94d2457d-9eb4-4350-a821-d67dced8d5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_InterestExpense_94d2457d-9eb4-4350-a821-d67dced8d5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7b9a39cc-fc27-4d9e-a0fb-ad375e1bebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_c3b85460-9964-4312-8bff-5a1ff0b7a65b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_7b9a39cc-fc27-4d9e-a0fb-ad375e1bebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INVENTORIESScheduleofinventoryDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_64529831-8640-432a-92cf-6ce8e7e65d56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_a5f25ff2-8660-4a27-9186-9904a9897a19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64529831-8640-432a-92cf-6ce8e7e65d56" xlink:to="loc_us-gaap_InventoryRawMaterials_a5f25ff2-8660-4a27-9186-9904a9897a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_95cf1fd5-ba33-4333-a7c5-758d3333c1eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64529831-8640-432a-92cf-6ce8e7e65d56" xlink:to="loc_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies_95cf1fd5-ba33-4333-a7c5-758d3333c1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a33b3b92-29e4-4149-9c3f-e38b60f537a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64529831-8640-432a-92cf-6ce8e7e65d56" xlink:to="loc_us-gaap_InventoryWorkInProcess_a33b3b92-29e4-4149-9c3f-e38b60f537a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bbd244be-13d0-4c4d-a8d6-667ea1cbb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64529831-8640-432a-92cf-6ce8e7e65d56" xlink:to="loc_us-gaap_InventoryFinishedGoods_bbd244be-13d0-4c4d-a8d6-667ea1cbb73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_4f1f29f7-3b0c-4336-9934-be4dc436d7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_64529831-8640-432a-92cf-6ce8e7e65d56" xlink:to="loc_us-gaap_InventoryGross_4f1f29f7-3b0c-4336-9934-be4dc436d7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INVENTORIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8b9be253-872b-4d02-9446-365aa3cf1062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8b9be253-872b-4d02-9446-365aa3cf1062" xlink:to="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44c1f1ad-2aba-4e1e-8937-2a3fa0308b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a5d74b86-0a95-4818-a2eb-b049c4bcb426" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44c1f1ad-2aba-4e1e-8937-2a3fa0308b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsTotalMember_0ecd8162-b3c9-42fe-a74d-0cfe975c8c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsTotalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_44c1f1ad-2aba-4e1e-8937-2a3fa0308b5e" xlink:to="loc_us-gaap_CostOfGoodsTotalMember_0ecd8162-b3c9-42fe-a74d-0cfe975c8c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4267184a-d3d9-4709-bb15-6b00d75c013a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_38306443-4611-458c-8cc4-950796eb736a" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4267184a-d3d9-4709-bb15-6b00d75c013a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplierConcentrationRiskMember_c2374688-1dbe-43a5-9166-072ec862a82e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplierConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4267184a-d3d9-4709-bb15-6b00d75c013a" xlink:to="loc_us-gaap_SupplierConcentrationRiskMember_c2374688-1dbe-43a5-9166-072ec862a82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_7d606843-10a8-455a-9aed-d6cfd315d4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4a0eb83c-dc90-4805-a8bb-d15516db2737" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_7d606843-10a8-455a-9aed-d6cfd315d4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OneSupplierMember_10f1851c-961d-43b4-870c-4afe1a747650" xlink:href="anip-20231231.xsd#anip_OneSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_7d606843-10a8-455a-9aed-d6cfd315d4e6" xlink:to="loc_anip_OneSupplierMember_10f1851c-961d-43b4-870c-4afe1a747650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_ab6c7d33-4570-45e0-8c79-2c119dca5ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_219e0485-3459-4e82-91d0-e4e0061ee52e" xlink:to="loc_us-gaap_InventoryLineItems_ab6c7d33-4570-45e0-8c79-2c119dca5ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2785d5c7-00f5-43f3-9ed9-4fad9fe0a048" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_ab6c7d33-4570-45e0-8c79-2c119dca5ae5" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2785d5c7-00f5-43f3-9ed9-4fad9fe0a048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7b17adb3-8b20-4da0-8b53-d011204176a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_7b17adb3-8b20-4da0-8b53-d011204176a6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_4b738aec-87cc-41ef-bd11-01e17c41877c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_156cd700-ce22-4484-8d85-00781f15c238" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_LandMember_156cd700-ce22-4484-8d85-00781f15c238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_207cc2ed-58fd-440d-b602-c8efa4abc866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_BuildingMember_207cc2ed-58fd-440d-b602-c8efa4abc866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_5bb3ed5a-ae61-4da5-97c1-58d44da3a4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_5bb3ed5a-ae61-4da5-97c1-58d44da3a4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_3c8dd0b9-8e97-4b67-8465-83278647b623" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_957ae0d9-e64f-4560-b44d-f29d13fda02d" xlink:to="loc_us-gaap_ConstructionInProgressMember_3c8dd0b9-8e97-4b67-8465-83278647b623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_20b82bf4-e2b0-486d-8a50-413801f9c433" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_83beb6c8-08c7-44e4-b1e3-b143d42d38df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_83beb6c8-08c7-44e4-b1e3-b143d42d38df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27470205-96dd-41ec-a692-ef41cfa6aee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_27470205-96dd-41ec-a692-ef41cfa6aee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_34bbdbdc-b01d-483b-807d-ffd0cec61fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a4ec75ab-45c0-422a-814a-1c70097db291" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_34bbdbdc-b01d-483b-807d-ffd0cec61fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4706e126-67d3-46d5-b215-da8e73c2243a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_bbf92ef2-c8e0-496e-b1fa-5edf92272297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4706e126-67d3-46d5-b215-da8e73c2243a" xlink:to="loc_us-gaap_Depreciation_bbf92ef2-c8e0-496e-b1fa-5edf92272297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_5c348f52-6558-48a9-8805-1d22726bbc7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4706e126-67d3-46d5-b215-da8e73c2243a" xlink:to="loc_us-gaap_InterestCostsCapitalized_5c348f52-6558-48a9-8805-1d22726bbc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_103e0f58-bdc2-4c35-b602-df009ee65b30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_103e0f58-bdc2-4c35-b602-df009ee65b30" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e9bc388e-f4cf-4ba2-a483-44230992be17" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BiosantePharmaceuticalsIncMember_95687d34-2492-40dc-a8db-afdefc3ac504" xlink:href="anip-20231231.xsd#anip_BiosantePharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:to="loc_anip_BiosantePharmaceuticalsIncMember_95687d34-2492-40dc-a8db-afdefc3ac504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_WellSpringPharmaServicesIncMember_aefcf68c-7ca4-4da9-9173-1f743a091524" xlink:href="anip-20231231.xsd#anip_WellSpringPharmaServicesIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:to="loc_anip_WellSpringPharmaServicesIncMember_aefcf68c-7ca4-4da9-9173-1f743a091524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_e4adb901-68e4-4b05-9cc5-d91e029b6ea0" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1457b34e-417e-48bf-9cfa-36163490345d" xlink:to="loc_anip_NovitiumMember_e4adb901-68e4-4b05-9cc5-d91e029b6ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6bdd7dcb-ee6c-407f-85ce-00c6b7ac36bb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_5a702227-f42a-4d6a-a5c4-51aeb46b5179" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_5a702227-f42a-4d6a-a5c4-51aeb46b5179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductRightMember_a6e33a9b-7c57-4e63-9c2b-d27ee1dd614e" xlink:href="anip-20231231.xsd#anip_ProductRightMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e554e0c7-fa49-4ca2-a0d0-61c26345b11b" xlink:to="loc_anip_ProductRightMember_a6e33a9b-7c57-4e63-9c2b-d27ee1dd614e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationTypeDomain_90c277a4-afd8-469a-9188-127112bdec92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeAxis_046daac1-fd67-46ca-98cb-6718ad3248b4" xlink:to="loc_us-gaap_ReclassificationTypeDomain_90c277a4-afd8-469a-9188-127112bdec92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_dc8b9fbf-016d-41ee-a082-67315fe1404c" xlink:href="anip-20231231.xsd#anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationTypeDomain_90c277a4-afd8-469a-9188-127112bdec92" xlink:to="loc_anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember_dc8b9fbf-016d-41ee-a082-67315fe1404c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669ddffa-44b2-4b3a-8092-98a5d4eb5ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_491f9c78-53e1-4d0a-a6e6-1c3a9c08fb87" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669ddffa-44b2-4b3a-8092-98a5d4eb5ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2e5d6448-452e-41e6-a2b2-d226fa3f1356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_669ddffa-44b2-4b3a-8092-98a5d4eb5ceb" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2e5d6448-452e-41e6-a2b2-d226fa3f1356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_92c4dd9b-697c-43ba-81e3-041362715066" xlink:to="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_92136bf1-da30-49d8-b8fc-c022fd30ae80" xlink:href="anip-20231231.xsd#anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:to="loc_anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember_92136bf1-da30-49d8-b8fc-c022fd30ae80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AlvogenIncMember_da24ac7f-3e5a-4b21-93df-653381973efd" xlink:href="anip-20231231.xsd#anip_AlvogenIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:to="loc_anip_AlvogenIncMember_da24ac7f-3e5a-4b21-93df-653381973efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember_0fdfff1c-762c-42b1-b865-d1e1a7853b19" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_e318d01a-6b9e-466e-b0a4-b1e845fc217e" xlink:to="loc_anip_OakrumPharmaMember_0fdfff1c-762c-42b1-b865-d1e1a7853b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_79a1bebb-3dad-460f-b468-f07c75d3c203" xlink:to="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0c89ad7f-c3b7-45cd-9c6e-7522a0feec5f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:to="loc_srt_MinimumMember_0c89ad7f-c3b7-45cd-9c6e-7522a0feec5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_26aa4b06-dade-4a08-873d-54d3e3a5e23e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a465b88e-84f8-4f37-b873-ea72584fa3aa" xlink:to="loc_srt_MaximumMember_26aa4b06-dade-4a08-873d-54d3e3a5e23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_d9811d6b-09a3-4041-a762-23320ee03eaf" xlink:to="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_78c332d0-cb29-4aad-96fd-1b8a09dbf93f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_78c332d0-cb29-4aad-96fd-1b8a09dbf93f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3a503089-9bca-449e-8f4c-66d8326ee788" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3a503089-9bca-449e-8f4c-66d8326ee788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_e366a2af-c48c-451a-8f1b-970e7a67efb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_NumberOfReportableSegments_e366a2af-c48c-451a-8f1b-970e7a67efb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_361d5793-9962-46bd-a6da-30e87484ce9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_361d5793-9962-46bd-a6da-30e87484ce9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c5d6667a-5bc7-4b38-a1d9-852d9ef870d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_Goodwill_c5d6667a-5bc7-4b38-a1d9-852d9ef870d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_35d8e50a-2824-4df2-8815-45f9e089d70d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_35d8e50a-2824-4df2-8815-45f9e089d70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4157f614-8ae1-4977-ab56-b22ccf805b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease_4157f614-8ae1-4977-ab56-b22ccf805b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a18cea7d-1d54-4495-8b8e-8c7e1f693d61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a18cea7d-1d54-4495-8b8e-8c7e1f693d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_032ab68e-27db-4540-bfab-7c0de958b587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_032ab68e-27db-4540-bfab-7c0de958b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_10d8fea1-5b35-4b55-8ff8-5b5080e9f469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_10d8fea1-5b35-4b55-8ff8-5b5080e9f469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e15c600e-d404-4889-b525-41171536e8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_0dcaeae9-946a-4ddd-9c40-91bd64dcdfa1" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_e15c600e-d404-4889-b525-41171536e8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSComponentsDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc98003c-fa77-4f03-b86e-3f776298ad23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bc98003c-fa77-4f03-b86e-3f776298ad23" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1e451d79-ba20-4976-b276-3f1778e75944" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_53fb0aa8-b40d-4296-8091-fa67f4bdb131" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_53fb0aa8-b40d-4296-8091-fa67f4bdb131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductRightsMember_c3b3e2d2-29b2-4ea0-a8c3-4e0ae6e70778" xlink:href="anip-20231231.xsd#anip_ProductRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_ProductRightsMember_c3b3e2d2-29b2-4ea0-a8c3-4e0ae6e70778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketingAndDistributionRightsMember_0ba17e3b-5885-4beb-8a7c-e8c86e8f3215" xlink:href="anip-20231231.xsd#anip_MarketingAndDistributionRightsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_MarketingAndDistributionRightsMember_0ba17e3b-5885-4beb-8a7c-e8c86e8f3215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NonCompeteAgreementMember_e62fa319-5ff0-4f8d-b9e4-5c83c9ba7617" xlink:href="anip-20231231.xsd#anip_NonCompeteAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_anip_NonCompeteAgreementMember_e62fa319-5ff0-4f8d-b9e4-5c83c9ba7617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_f54a575b-9425-4ad5-b904-b07c28f4d108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56bd9d19-529f-440c-87d0-82e5a70bff49" xlink:to="loc_us-gaap_CustomerRelationshipsMember_f54a575b-9425-4ad5-b904-b07c28f4d108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581088a9-afc8-4786-a2a6-bffbe6000276" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_4204d24f-cc3c-4085-9e43-668533094f21" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581088a9-afc8-4786-a2a6-bffbe6000276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_24fe82f0-6f0f-4eeb-bb8a-7275b7f5392b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_581088a9-afc8-4786-a2a6-bffbe6000276" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_24fe82f0-6f0f-4eeb-bb8a-7275b7f5392b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_954aa3b1-1596-47fc-b58c-661504352ce1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab1d1e5c-966b-4ae4-95dd-7c1cdc0695a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_ab1d1e5c-966b-4ae4-95dd-7c1cdc0695a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f1142f4b-0f95-46fd-8fff-0e86db8a9f32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_f1142f4b-0f95-46fd-8fff-0e86db8a9f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08ffd96b-c9fc-43f5-9691-e3db2d9a78e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_08ffd96b-c9fc-43f5-9691-e3db2d9a78e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0ceaf64c-459e-4374-a146-bcee8f993b97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_d5d79de8-15f4-438d-bf60-af84f661de7e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_0ceaf64c-459e-4374-a146-bcee8f993b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_196a8178-629c-430c-8808-b1cc3f2249df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_196a8178-629c-430c-8808-b1cc3f2249df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_91e5a194-aa9c-4ce1-806f-e81013416221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_196a8178-629c-430c-8808-b1cc3f2249df" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_91e5a194-aa9c-4ce1-806f-e81013416221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_75cef0c6-9932-4b59-a206-ad16bc400236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_75cef0c6-9932-4b59-a206-ad16bc400236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6bfe2760-cc7b-417e-a97f-4fb6464b69b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8f35ed7-6148-436d-8cea-820c47723534" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_6bfe2760-cc7b-417e-a97f-4fb6464b69b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#GOODWILLANDINTANGIBLEASSETSAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_04630084-d44f-4ae6-bff2-b5ec9f11209b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_04630084-d44f-4ae6-bff2-b5ec9f11209b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_960cc417-85c4-492c-9245-b450ac51b7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_960cc417-85c4-492c-9245-b450ac51b7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e9ad8824-ddf0-41ae-9fb0-df704dbd0cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_e9ad8824-ddf0-41ae-9fb0-df704dbd0cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ca7f8896-d963-4125-85a2-be03c2f1719e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ca7f8896-d963-4125-85a2-be03c2f1719e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_affef467-b033-42be-87c5-4dbbff2ce161" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_affef467-b033-42be-87c5-4dbbff2ce161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1bf6fadb-fecf-4485-b520-5485507b2112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1bf6fadb-fecf-4485-b520-5485507b2112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_533bce8f-15cf-42a4-b465-a87252841c61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_533587c9-c4bd-46be-8179-5b5e84b0d5a6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_533bce8f-15cf-42a4-b465-a87252841c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0c4b8936-a151-4498-9e6d-740842bdc0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0c4b8936-a151-4498-9e6d-740842bdc0c8" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_71147bd2-4cb6-4feb-a98c-7eb52008d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_4aac485d-9e7b-4625-a4be-f9eadb1848de" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_71147bd2-4cb6-4feb-a98c-7eb52008d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_6043a57d-fc0e-4bb4-bb2e-37219abbe51a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_71147bd2-4cb6-4feb-a98c-7eb52008d3b0" xlink:to="loc_us-gaap_InterestRateSwapMember_6043a57d-fc0e-4bb4-bb2e-37219abbe51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd28d585-e1ce-4902-bfd3-5086a0a1ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7a8b145b-76dc-4adc-92ff-da8553ab1f06" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd28d585-e1ce-4902-bfd3-5086a0a1ab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_ccdbf6ad-0d53-4cc9-96ab-9f4b317d43e9" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_cd28d585-e1ce-4902-bfd3-5086a0a1ab7c" xlink:to="loc_anip_NovitiumPharmaMember_ccdbf6ad-0d53-4cc9-96ab-9f4b317d43e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9a5deaa3-d2b0-4c0d-878a-1b3fc4fa18ce" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_53b40c1a-4ba7-4706-b18a-989e2e120005" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_53b40c1a-4ba7-4706-b18a-989e2e120005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductIntellectualPropertyMember_6f57a71f-7900-4f14-82b1-06496a498558" xlink:href="anip-20231231.xsd#anip_ProductIntellectualPropertyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_ProductIntellectualPropertyMember_6f57a71f-7900-4f14-82b1-06496a498558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredPipelineProductMember_19756268-5885-4e40-b624-54d6ee5836bd" xlink:href="anip-20231231.xsd#anip_AcquiredPipelineProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredPipelineProductMember_19756268-5885-4e40-b624-54d6ee5836bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredCommercialProductMember_fe7a0b79-113d-4276-8f72-e3e2f119a6c8" xlink:href="anip-20231231.xsd#anip_AcquiredCommercialProductMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredCommercialProductMember_fe7a0b79-113d-4276-8f72-e3e2f119a6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredApprovedProductMember_abd74c83-5256-4d67-a968-97612b59d5fb" xlink:href="anip-20231231.xsd#anip_AcquiredApprovedProductMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredApprovedProductMember_abd74c83-5256-4d67-a968-97612b59d5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredFiledProductsMember_ea91b6cc-a0bf-4da3-b4fd-89d1d12e0ca1" xlink:href="anip-20231231.xsd#anip_AcquiredFiledProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredFiledProductsMember_ea91b6cc-a0bf-4da3-b4fd-89d1d12e0ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredNDAIntangibleAssetsMember_c4c200ee-84a1-468d-99be-3094e42eb289" xlink:href="anip-20231231.xsd#anip_AcquiredNDAIntangibleAssetsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f2338219-afe9-46f2-8502-66b8f3e68147" xlink:to="loc_anip_AcquiredNDAIntangibleAssetsMember_c4c200ee-84a1-468d-99be-3094e42eb289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_427d2051-7ed2-40a2-8838-dfe3ca4446c5" xlink:to="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember_def83b54-74e8-4a7c-8d5b-22af80c9dbe9" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_OakrumPharmaMember_def83b54-74e8-4a7c-8d5b-22af80c9dbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_3f41a832-0a0a-4b63-99ed-5d5ecfccfd92" xlink:href="anip-20231231.xsd#anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember_3f41a832-0a0a-4b63-99ed-5d5ecfccfd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AkornHoldingCompanyPipelineProductMember_39acf7b0-b320-4126-8a9e-4ab6b2ce739d" xlink:href="anip-20231231.xsd#anip_AkornHoldingCompanyPipelineProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_AkornHoldingCompanyPipelineProductMember_39acf7b0-b320-4126-8a9e-4ab6b2ce739d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AlvogenIncMember_f4db8d47-70cf-4068-a4af-8d90ed9af9d5" xlink:href="anip-20231231.xsd#anip_AlvogenIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_7d67f5e6-2b2a-4c0f-9349-dadccdce53b0" xlink:to="loc_anip_AlvogenIncMember_f4db8d47-70cf-4068-a4af-8d90ed9af9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_729e1598-5f27-4779-bd44-6de5a67e4141" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_81cc4b67-f90e-428e-95d8-b57bbfecdd96" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_729e1598-5f27-4779-bd44-6de5a67e4141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_d60be31d-2e34-4a90-98c1-c0030d141bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_729e1598-5f27-4779-bd44-6de5a67e4141" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_d60be31d-2e34-4a90-98c1-c0030d141bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fb79c80-323b-4aef-8494-e9ba01a18c69" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_599f6f2f-42f0-4466-b99d-cde76e62a576" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fb79c80-323b-4aef-8494-e9ba01a18c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SandozIncMember_07d863d6-bd00-4e6a-8c4b-091dd0a181cd" xlink:href="anip-20231231.xsd#anip_SandozIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0fb79c80-323b-4aef-8494-e9ba01a18c69" xlink:to="loc_anip_SandozIncMember_07d863d6-bd00-4e6a-8c4b-091dd0a181cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d520b82a-0ac7-4b53-b2bc-d48615e5d44e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_eee004b8-5164-4ffd-9482-9a2fe7c90784" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d520b82a-0ac7-4b53-b2bc-d48615e5d44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_7c69b895-9093-4e53-833c-198e5a253641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d520b82a-0ac7-4b53-b2bc-d48615e5d44e" xlink:to="loc_us-gaap_SubsequentEventMember_7c69b895-9093-4e53-833c-198e5a253641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_d658fb0e-6825-46b8-8299-953fd0b88b92" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_60a0fc22-2279-4ac5-90aa-449d5bf59ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_60a0fc22-2279-4ac5-90aa-449d5bf59ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b328050d-880a-4837-984c-7e05df790829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue_b328050d-880a-4837-984c-7e05df790829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b4d2c3e-4630-4382-93ab-c2cb2b9386d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_6b4d2c3e-4630-4382-93ab-c2cb2b9386d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_55b6d304-5365-4113-a7f0-e21ea3ac7cb4" xlink:href="anip-20231231.xsd#anip_BusinessCombinationContingentConsiderationArrangementsPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_anip_BusinessCombinationContingentConsiderationArrangementsPeriod_55b6d304-5365-4113-a7f0-e21ea3ac7cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97d9fdaa-f04c-49ea-af7a-d6e9a75c5ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_97d9fdaa-f04c-49ea-af7a-d6e9a75c5ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f73db0c4-4e81-45ab-810f-1d805d32b8a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f73db0c4-4e81-45ab-810f-1d805d32b8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b5ca4ada-5fbc-4350-b0ef-53010b59e8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_b5ca4ada-5fbc-4350-b0ef-53010b59e8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fb090498-1266-4906-9daf-13fb45b28ac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fb090498-1266-4906-9daf-13fb45b28ac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1d152dd3-c0a4-44a3-8b46-cb520770cd10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_1d152dd3-c0a4-44a3-8b46-cb520770cd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ca8be2cf-4d9e-4d78-81a4-bed5f43e2163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ca8be2cf-4d9e-4d78-81a4-bed5f43e2163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfIntangibleAssetsAcquired_fa3d9b17-6189-4534-8e93-3cc05deab891" xlink:href="anip-20231231.xsd#anip_NumberOfIntangibleAssetsAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_anip_NumberOfIntangibleAssetsAcquired_fa3d9b17-6189-4534-8e93-3cc05deab891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_3ed81f8b-c7f1-4f1e-9fc3-a62f2cac50c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_3ed81f8b-c7f1-4f1e-9fc3-a62f2cac50c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bcf1823e-59b7-4096-8df4-4ef27033ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_bcf1823e-59b7-4096-8df4-4ef27033ed8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_78143839-1f50-4270-9368-5b9165e4141e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_78143839-1f50-4270-9368-5b9165e4141e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IntangibleAssetMeasurementInput_fc025a45-11d5-4795-ac23-c757cf921602" xlink:href="anip-20231231.xsd#anip_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_anip_IntangibleAssetMeasurementInput_fc025a45-11d5-4795-ac23-c757cf921602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_4ab2ab23-ce40-4ffd-899e-6766e546d30a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_4ab2ab23-ce40-4ffd-899e-6766e546d30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_38a1123c-364a-42ca-9e72-a11d66845ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_PaymentsForFees_38a1123c-364a-42ca-9e72-a11d66845ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6c3d4ac1-98c1-4732-b4b6-67fe7563dae5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InventoryNet_6c3d4ac1-98c1-4732-b4b6-67fe7563dae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_d67548de-44a5-4b6f-80e4-f1b9d82876cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InventoryRawMaterials_d67548de-44a5-4b6f-80e4-f1b9d82876cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryDemo_9dba1812-5b87-402b-904b-7b6cb0f8cdcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryDemo"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_OtherInventoryDemo_9dba1812-5b87-402b-904b-7b6cb0f8cdcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_81b3fb35-9c31-4b7c-b3be-619621b281c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_17cbebaf-80b0-4c6d-8769-8e9f70b28695" xlink:to="loc_us-gaap_InventoryFinishedGoods_81b3fb35-9c31-4b7c-b3be-619621b281c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUELevel3Details"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8ba1f1fe-5e1c-4384-88fe-b96f6c909f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8ba1f1fe-5e1c-4384-88fe-b96f6c909f20" xlink:to="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_aa20e983-9776-4b89-ac69-ee66384e5a4c" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_eb065f25-d058-45f3-ab77-29234d68638c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_eb065f25-d058-45f3-ab77-29234d68638c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MeasurementInputProbabilityOfPaymentMember_52a61922-c4be-46f6-8ecc-6d11410b0b21" xlink:href="anip-20231231.xsd#anip_MeasurementInputProbabilityOfPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_eaae060c-6948-461c-8b68-4e4d08da2df4" xlink:to="loc_anip_MeasurementInputProbabilityOfPaymentMember_52a61922-c4be-46f6-8ecc-6d11410b0b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:href="anip-20231231.xsd#anip_PaymentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:href="anip-20231231.xsd#anip_PaymentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_PaymentTypeAxis_71862cc4-9cd0-42ae-87a4-57d1cdc41db8" xlink:to="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProjectBasedMilestonePaymentsMember_db257be4-5014-4d2c-a736-a6e1a252a32b" xlink:href="anip-20231231.xsd#anip_ProjectBasedMilestonePaymentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:to="loc_anip_ProjectBasedMilestonePaymentsMember_db257be4-5014-4d2c-a736-a6e1a252a32b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ProductDevelopmentBasedMilestonePaymentsMember_513abc2b-da7d-4ded-825d-390402f8aa8e" xlink:href="anip-20231231.xsd#anip_ProductDevelopmentBasedMilestonePaymentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_PaymentTypeDomain_a93b7522-638f-4f43-8aea-802054225885" xlink:to="loc_anip_ProductDevelopmentBasedMilestonePaymentsMember_513abc2b-da7d-4ded-825d-390402f8aa8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_33ee5082-dff9-4f1e-9b47-95204154595d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a4bbd6a1-8b0d-4160-8ac2-5b30edcc30a0" xlink:to="loc_us-gaap_ValuationTechniqueDomain_33ee5082-dff9-4f1e-9b47-95204154595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_76a5af6a-adc1-42d0-ae41-622ab664f3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_33ee5082-dff9-4f1e-9b47-95204154595d" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_76a5af6a-adc1-42d0-ae41-622ab664f3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5bc55ff6-3220-40cb-b1ec-8fa5932d3249" xlink:to="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3a052199-8642-44a1-8893-28ffcd3fa602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3a052199-8642-44a1-8893-28ffcd3fa602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7aecc88f-f0a2-4ca2-8d71-6ccdc9e79815" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e10aaaf-185b-494b-85da-d3a45e824189" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1e10aaaf-185b-494b-85da-d3a45e824189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_b244be7a-1409-4a90-bea0-68b04a301139" xlink:href="anip-20231231.xsd#anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment_b244be7a-1409-4a90-bea0-68b04a301139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_08524831-1f1f-476f-8b7a-f670f376d114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_08524831-1f1f-476f-8b7a-f670f376d114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1e75c19-46ac-49d0-b62b-79a7eea17d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1e75c19-46ac-49d0-b62b-79a7eea17d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_59b2cde5-4553-44cc-a153-540a27a04937" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f1e75c19-46ac-49d0-b62b-79a7eea17d5a" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_59b2cde5-4553-44cc-a153-540a27a04937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b9d157e9-f9f4-4e78-86eb-60dde552ee6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_bc419911-83b3-456a-9a5b-4c93055dcec9" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b9d157e9-f9f4-4e78-86eb-60dde552ee6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUEHierarchyDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c70636ab-6904-475d-bc8a-c98de8be3c88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c70636ab-6904-475d-bc8a-c98de8be3c88" xlink:to="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f08b8aba-3cb6-40de-ab1e-37b6fa951ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5008f90-c1c9-4c82-aab8-658aa52bd49b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f08b8aba-3cb6-40de-ab1e-37b6fa951ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_42e55e50-29b7-40e2-b4cb-c612a873e4dd" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f08b8aba-3cb6-40de-ab1e-37b6fa951ccc" xlink:to="loc_anip_NovitiumPharmaMember_42e55e50-29b7-40e2-b4cb-c612a873e4dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_7384bb11-8bdd-4784-85ef-fa9ea9bcf9f4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_39b2103e-479f-43db-ba44-15f1ee7931cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_39b2103e-479f-43db-ba44-15f1ee7931cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c5fb55ad-3b5d-4014-939d-c9905f3dbaca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c5fb55ad-3b5d-4014-939d-c9905f3dbaca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7e62a277-e409-4fe3-b012-87940fd47632" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f78f46ed-2675-4c5c-b7fa-2738d4b2f1b8" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7e62a277-e409-4fe3-b012-87940fd47632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_911c7b26-eb2c-41d9-9552-a75a718b5fbc" xlink:to="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_437cbf66-6982-40ef-9376-56aa84c9be86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_437cbf66-6982-40ef-9376-56aa84c9be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_33c2635e-bac0-4bb4-82ae-e55886eae5f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateDerivativeAssetsAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_InterestRateDerivativeAssetsAtFairValue_33c2635e-bac0-4bb4-82ae-e55886eae5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_826be323-18b0-4126-bbaf-dfa7d85e2bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3ccf17d9-560f-4303-af4a-df44dae47b4f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_826be323-18b0-4126-bbaf-dfa7d85e2bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#FAIRVALUEAcquiredDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ff3768ad-68ab-447e-b486-3f07819d8bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ff3768ad-68ab-447e-b486-3f07819d8bc4" xlink:to="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c28c099b-aec4-4bb8-a312-62fc0659067b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_81c236ca-0ca5-481a-80a9-662a1559b226" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c28c099b-aec4-4bb8-a312-62fc0659067b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SandozIncMember_347c294f-5bc4-4e87-8409-5eff74f1f158" xlink:href="anip-20231231.xsd#anip_SandozIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c28c099b-aec4-4bb8-a312-62fc0659067b" xlink:to="loc_anip_SandozIncMember_347c294f-5bc4-4e87-8409-5eff74f1f158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_61d81810-9630-46f8-8ddd-32b71dc0b871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_e63b334b-6373-4d71-8302-fe33958f2dc4" xlink:to="loc_us-gaap_AssetAcquisitionDomain_61d81810-9630-46f8-8ddd-32b71dc0b871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakrumPharmaMember_216d3c33-43c2-4909-843b-0a28c017221b" xlink:href="anip-20231231.xsd#anip_OakrumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_61d81810-9630-46f8-8ddd-32b71dc0b871" xlink:to="loc_anip_OakrumPharmaMember_216d3c33-43c2-4909-843b-0a28c017221b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b028c79-97d6-41e5-ae36-fc9ab8f05585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1850ae27-cf09-4775-b1c7-6f8105ee084a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b028c79-97d6-41e5-ae36-fc9ab8f05585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AcquiredAndaIntangibleAssetsMember_16d18a66-d6d0-4b4e-be16-99ff017ba9b5" xlink:href="anip-20231231.xsd#anip_AcquiredAndaIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b028c79-97d6-41e5-ae36-fc9ab8f05585" xlink:to="loc_anip_AcquiredAndaIntangibleAssetsMember_16d18a66-d6d0-4b4e-be16-99ff017ba9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f37455eb-a185-4659-b469-b19405f91e79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_d20238c7-e0e2-49f1-bfbc-1da26440b0b4" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f37455eb-a185-4659-b469-b19405f91e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7d2885f3-95b8-4de1-9d91-6d667c0b4adf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_f37455eb-a185-4659-b469-b19405f91e79" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7d2885f3-95b8-4de1-9d91-6d667c0b4adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_410988b1-703c-4644-9713-59964fdc46fd" xlink:to="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d8b3e050-a32d-45f3-a62a-e9a121ab7bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d8b3e050-a32d-45f3-a62a-e9a121ab7bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_fbc9c25f-4d2c-401d-8b54-4af789d98702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_fbc9c25f-4d2c-401d-8b54-4af789d98702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_c26c2869-20a5-4d0a-b923-6527f2d96c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_PaymentsForFees_c26c2869-20a5-4d0a-b923-6527f2d96c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46810a8c-5d00-4ba0-a100-66d0944ae7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_46810a8c-5d00-4ba0-a100-66d0944ae7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_92f5f3d8-c41e-4af1-ade0-e16518c41ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_92f5f3d8-c41e-4af1-ade0-e16518c41ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_IntangibleAssetMeasurementInput_72165c2c-4418-4898-bfe4-04079a9fca91" xlink:href="anip-20231231.xsd#anip_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_anip_IntangibleAssetMeasurementInput_72165c2c-4418-4898-bfe4-04079a9fca91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d6f8d649-ae92-4116-8fc0-cc3a355c0bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_InventoryNet_d6f8d649-ae92-4116-8fc0-cc3a355c0bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_318c5511-d8ce-49f2-9a91-ab7a2581c845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_InventoryRawMaterials_318c5511-d8ce-49f2-9a91-ab7a2581c845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInventoryDemo_f7e93646-bb91-4d41-a8bb-3baa08e962d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherInventoryDemo"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_OtherInventoryDemo_f7e93646-bb91-4d41-a8bb-3baa08e962d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_bea92e6c-92f7-436c-ad5d-4a27245ec092" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_InventoryFinishedGoods_bea92e6c-92f7-436c-ad5d-4a27245ec092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_37fc5b03-c8e6-4221-9fd1-d963e8627de0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_37fc5b03-c8e6-4221-9fd1-d963e8627de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_68da5d02-412f-41ac-916c-f7e9481b8c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d620eac4-873c-4dcf-a8b4-8b4e41577ecf" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_68da5d02-412f-41ac-916c-f7e9481b8c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#MEZZANINEANDSTOCKHOLDERSEQUITYDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_cf7a6222-80a4-4245-b4f3-f13f82f2ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_cf7a6222-80a4-4245-b4f3-f13f82f2ee05" xlink:to="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a36d798b-a0ae-4b9f-96e7-747d46a7b9f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_27013327-4c5a-481e-81a5-9f171853c7c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a36d798b-a0ae-4b9f-96e7-747d46a7b9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_dace65b7-c717-4b92-afe8-47fbf3e203a0" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a36d798b-a0ae-4b9f-96e7-747d46a7b9f3" xlink:to="loc_anip_NovitiumPharmaMember_dace65b7-c717-4b92-afe8-47fbf3e203a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_f2d03ecc-a1cd-4ddd-a580-ed997ddf0500" xlink:to="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_736ace1c-f754-438d-bca5-4a7864271196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:to="loc_us-gaap_CommonStockMember_736ace1c-f754-438d-bca5-4a7864271196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ClassCSpecialStockMember_928d6273-8113-4e69-91b3-1800e2320969" xlink:href="anip-20231231.xsd#anip_ClassCSpecialStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_86799763-cb8d-4173-9cb8-53c27f15fdb6" xlink:to="loc_anip_ClassCSpecialStockMember_928d6273-8113-4e69-91b3-1800e2320969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_55cbffbe-68a9-4978-974e-a3bb05c329ea" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember_d50112e6-4bb2-4251-924e-a1f602002a4b" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:to="loc_anip_PrivateInvestmentInPublicEquityMember_d50112e6-4bb2-4251-924e-a1f602002a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PublicOfferingMember_27c7712d-0504-4d9c-a8c4-e0af51b86143" xlink:href="anip-20231231.xsd#anip_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1d42528-d421-4e21-9375-53acda431352" xlink:to="loc_anip_PublicOfferingMember_27c7712d-0504-4d9c-a8c4-e0af51b86143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8790e247-d5d1-4f2f-a71c-cd6fee23897c" xlink:to="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_a3157b90-1e2b-4af8-a314-3f8accf3b8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_a3157b90-1e2b-4af8-a314-3f8accf3b8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_427e900b-4602-46ef-957b-eca64178679f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_303b495c-b251-4515-a16f-2f443615ae2a" xlink:to="loc_us-gaap_CommonStockMember_427e900b-4602-46ef-957b-eca64178679f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_b33482ff-6090-4d11-9423-06dbd170d0c2" xlink:to="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_53a93cfa-c2c5-425e-a0c8-435eab867a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_53a93cfa-c2c5-425e-a0c8-435eab867a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ac8875cf-3b35-45be-86c9-881394647b37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ac8875cf-3b35-45be-86c9-881394647b37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_3cc3b12f-1e1f-415b-9b95-343c20d163c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_3cc3b12f-1e1f-415b-9b95-343c20d163c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a2966779-5815-4333-af7d-e4b48fd71f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_a2966779-5815-4333-af7d-e4b48fd71f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2c2f3181-3aa6-4784-a55a-8dcd6a58df22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockSharesIssued_2c2f3181-3aa6-4784-a55a-8dcd6a58df22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_3761c383-6ced-4dcb-97b9-564db0f46828" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_3761c383-6ced-4dcb-97b9-564db0f46828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f640000a-113f-48c4-b5b6-750ac47c1831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_f640000a-113f-48c4-b5b6-750ac47c1831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec5bf032-cb0d-41f7-bbc6-df4aba44e54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ec5bf032-cb0d-41f7-bbc6-df4aba44e54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_48d14fbe-4746-4a37-a14d-862642099d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_48d14fbe-4746-4a37-a14d-862642099d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_faf30ff6-8158-44b4-ba22-3b3e167f5145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_faf30ff6-8158-44b4-ba22-3b3e167f5145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockNumberOfVotesPerShare_628ae5c9-9d6b-420a-92e7-23a26497ae41" xlink:href="anip-20231231.xsd#anip_CommonStockNumberOfVotesPerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_CommonStockNumberOfVotesPerShare_628ae5c9-9d6b-420a-92e7-23a26497ae41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockConvertibleConversionRatio_6258f34d-05ee-4d34-95b8-b98aa230a31e" xlink:href="anip-20231231.xsd#anip_CommonStockConvertibleConversionRatio"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_CommonStockConvertibleConversionRatio_6258f34d-05ee-4d34-95b8-b98aa230a31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CommonStockConversionPrice_fdc56324-2b31-4525-974c-c7b91de011d0" xlink:href="anip-20231231.xsd#anip_CommonStockConversionPrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_CommonStockConversionPrice_fdc56324-2b31-4525-974c-c7b91de011d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0ab17b83-bcd0-46da-91f3-5d5d32340ae8" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_0ab17b83-bcd0-46da-91f3-5d5d32340ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_59ae59fd-b3b1-4a1c-8654-7247cb670db6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_59ae59fd-b3b1-4a1c-8654-7247cb670db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_fef2fc7e-5432-4154-b63a-ec76e105a417" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_fef2fc7e-5432-4154-b63a-ec76e105a417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_972a7314-409e-4287-ae7b-fb97d5435a67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_972a7314-409e-4287-ae7b-fb97d5435a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_0a9820fe-d301-4065-b744-291fec196c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_0a9820fe-d301-4065-b744-291fec196c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_48ed8f08-be08-422a-b89e-c7c0568c5c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_48ed8f08-be08-422a-b89e-c7c0568c5c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ThresholdNumberOfTradingDays_b536a1ab-3880-4aa1-932e-a16e9ab64f16" xlink:href="anip-20231231.xsd#anip_ThresholdNumberOfTradingDays"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_ThresholdNumberOfTradingDays_b536a1ab-3880-4aa1-932e-a16e9ab64f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfConsecutiveTradingDays_137b30d5-f92e-454e-9ecc-f755ad5e7ad1" xlink:href="anip-20231231.xsd#anip_NumberOfConsecutiveTradingDays"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_NumberOfConsecutiveTradingDays_137b30d5-f92e-454e-9ecc-f755ad5e7ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PercentageOfConversionPrice_a64ce7ee-cd6e-4c78-b456-b661d403b4bc" xlink:href="anip-20231231.xsd#anip_PercentageOfConversionPrice"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_PercentageOfConversionPrice_a64ce7ee-cd6e-4c78-b456-b661d403b4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_3ffd5024-1813-453d-b6f2-1442f69a3b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockConvertibleSharesIssuable"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_3ffd5024-1813-453d-b6f2-1442f69a3b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_7e5c99f1-2a08-4b79-b741-d3da8030c96d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_7e5c99f1-2a08-4b79-b741-d3da8030c96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PreferredStockConvertibleMinimumPeriodOfConversion_a7817aab-8d42-4464-83d5-96910c9acca1" xlink:href="anip-20231231.xsd#anip_PreferredStockConvertibleMinimumPeriodOfConversion"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_a3490de2-f44a-4d0c-95df-fa377058cc48" xlink:to="loc_anip_PreferredStockConvertibleMinimumPeriodOfConversion_a7817aab-8d42-4464-83d5-96910c9acca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_32620b30-96d5-4079-9ea1-012dcb2258a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_32620b30-96d5-4079-9ea1-012dcb2258a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0cc1a7c7-b261-4248-84b4-32d80854e4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_32620b30-96d5-4079-9ea1-012dcb2258a8" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_0cc1a7c7-b261-4248-84b4-32d80854e4b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_b7ffc226-830c-43d3-bfa4-902601e5acbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_32620b30-96d5-4079-9ea1-012dcb2258a8" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic_b7ffc226-830c-43d3-bfa4-902601e5acbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings_967569df-b863-48ff-bc9a-302bfd78ea08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract_32620b30-96d5-4079-9ea1-012dcb2258a8" xlink:to="loc_us-gaap_UndistributedEarnings_967569df-b863-48ff-bc9a-302bfd78ea08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f51ad5d3-b90c-4a2b-a3e9-79522b0dd486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f51ad5d3-b90c-4a2b-a3e9-79522b0dd486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1683f979-acf0-47d5-9dea-d285fb39a67d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f51ad5d3-b90c-4a2b-a3e9-79522b0dd486" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1683f979-acf0-47d5-9dea-d285fb39a67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_ae37a7cf-f6de-42c4-9228-d8eb5cd482cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f51ad5d3-b90c-4a2b-a3e9-79522b0dd486" xlink:to="loc_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted_ae37a7cf-f6de-42c4-9228-d8eb5cd482cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsDiluted_56dd18a9-dd70-4326-a426-a62e80b60400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UndistributedEarningsDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_f51ad5d3-b90c-4a2b-a3e9-79522b0dd486" xlink:to="loc_us-gaap_UndistributedEarningsDiluted_56dd18a9-dd70-4326-a426-a62e80b60400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5a36f9d2-8d1c-40a3-affe-597f9bb781c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5a36f9d2-8d1c-40a3-affe-597f9bb781c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_efe893f2-68bb-4fc0-bd0f-125d398e7482" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract_5a36f9d2-8d1c-40a3-affe-597f9bb781c0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_efe893f2-68bb-4fc0-bd0f-125d398e7482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_af839810-8e3f-4bba-80ae-52f70c4e7212" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_af839810-8e3f-4bba-80ae-52f70c4e7212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2024b5d5-b9bd-46da-93d2-f4d6b08fa678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_af839810-8e3f-4bba-80ae-52f70c4e7212" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_2024b5d5-b9bd-46da-93d2-f4d6b08fa678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54b701cb-ce9c-471f-a317-689aab5b8736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_af839810-8e3f-4bba-80ae-52f70c4e7212" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_54b701cb-ce9c-471f-a317-689aab5b8736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_9ac3a20c-3915-4b48-b522-a7be57c6db6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_9ac3a20c-3915-4b48-b522-a7be57c6db6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3e4ead1b-a08f-4673-8c63-28e9ddacc1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_9ac3a20c-3915-4b48-b522-a7be57c6db6d" xlink:to="loc_us-gaap_EarningsPerShareBasic_3e4ead1b-a08f-4673-8c63-28e9ddacc1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_abf4b5ef-c844-4b8a-b8a4-f47f98dfb835" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_abf4b5ef-c844-4b8a-b8a4-f47f98dfb835" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_d332c909-7d3e-4bff-8023-dc784f77d1d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_abf4b5ef-c844-4b8a-b8a4-f47f98dfb835" xlink:to="loc_us-gaap_EarningsPerShareDiluted_d332c909-7d3e-4bff-8023-dc784f77d1d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bc518dee-17eb-421f-8e71-bf05b5f9d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c22342dc-03df-45ed-a140-f2b995fc68a4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_bc518dee-17eb-421f-8e71-bf05b5f9d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_461a4b15-7889-400e-aacb-48663ec43501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_461a4b15-7889-400e-aacb-48663ec43501" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_695f0691-0713-4508-b2bc-51015627c4df" xlink:to="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_b95f1af3-cc93-481d-b683-362b31dfff6b" xlink:href="anip-20231231.xsd#anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:to="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_b95f1af3-cc93-481d-b683-362b31dfff6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockIncentivePlanMember_7fdf4dc3-6479-44f1-924d-1f460681c31b" xlink:href="anip-20231231.xsd#anip_StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e4aa04ad-06c7-4839-bf36-12d3660fc9a6" xlink:to="loc_anip_StockIncentivePlanMember_7fdf4dc3-6479-44f1-924d-1f460681c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2013687a-f0de-4198-9f7d-89623a262fb5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeesAndConsultantsMember_4fa79b6a-62d0-4337-acba-a07b204eeea9" xlink:href="anip-20231231.xsd#anip_EmployeesAndConsultantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:to="loc_anip_EmployeesAndConsultantsMember_4fa79b6a-62d0-4337-acba-a07b204eeea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NonEmployeeDirectorStockOptionMember_6ae4d408-b534-4967-a419-c8b45987046b" xlink:href="anip-20231231.xsd#anip_NonEmployeeDirectorStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_f305c497-89d4-4113-8c68-699e284a3a3c" xlink:to="loc_anip_NonEmployeeDirectorStockOptionMember_6ae4d408-b534-4967-a419-c8b45987046b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2795148d-591f-4a38-b095-714472f0942f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2d16207a-21e9-4927-8616-1be7f45e0b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2d16207a-21e9-4927-8616-1be7f45e0b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_64a82ac4-b6b6-4a15-a983-aa7e78c50b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_us-gaap_RestrictedStockMember_64a82ac4-b6b6-4a15-a983-aa7e78c50b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PerformanceBasedRestrictedStockUnitsMember_5b4c613e-9527-49be-943b-4f82958ca4ce" xlink:href="anip-20231231.xsd#anip_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_anip_PerformanceBasedRestrictedStockUnitsMember_5b4c613e-9527-49be-943b-4f82958ca4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember_65e922d0-bf86-4071-aeac-8c306312a01d" xlink:href="anip-20231231.xsd#anip_MarketPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember_65e922d0-bf86-4071-aeac-8c306312a01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_9a8d1321-06c9-4f45-bdb3-b98d48ac26f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d68198c6-5102-46ed-a27f-d3dedfbb776f" xlink:to="loc_us-gaap_PerformanceSharesMember_9a8d1321-06c9-4f45-bdb3-b98d48ac26f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c5dd6494-fcc2-41d7-8702-584b09085fd5" xlink:to="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3dd146e7-34cb-4d76-a88e-d0e79fb05bb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:to="loc_srt_MinimumMember_3dd146e7-34cb-4d76-a88e-d0e79fb05bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_60535671-9ce5-4b65-8f44-9381e5b40dca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1b75d1e8-b9c4-4f5b-840b-23c73250a70d" xlink:to="loc_srt_MaximumMember_60535671-9ce5-4b65-8f44-9381e5b40dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_017f4c74-76fa-4a78-ba58-d7a351e93b9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a01f83a9-da99-4774-841c-be14fb2a766e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a01f83a9-da99-4774-841c-be14fb2a766e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c87c4143-6cac-4617-bb52-2f301dca0320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_c87c4143-6cac-4617-bb52-2f301dca0320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f80d0b0-8cb0-43cb-8f03-707ed79028c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_1f80d0b0-8cb0-43cb-8f03-707ed79028c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f58ffc6e-a9c7-4acb-88d5-b65212455fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_f58ffc6e-a9c7-4acb-88d5-b65212455fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d02e942c-e2ad-451d-8f86-e798965518b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_d02e942c-e2ad-451d-8f86-e798965518b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fa013753-7823-4637-93c9-e0056ee0cc32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fa013753-7823-4637-93c9-e0056ee0cc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_61d3239a-2176-42ea-a6f0-60b4118824ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_61d3239a-2176-42ea-a6f0-60b4118824ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbbc08e6-dbd2-46b9-8282-5b447409cf27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dbbc08e6-dbd2-46b9-8282-5b447409cf27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130a475c-ee78-4446-967c-effa9eaac1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_130a475c-ee78-4446-967c-effa9eaac1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f38b3825-0585-40b1-88a2-8ff822d3f590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f38b3825-0585-40b1-88a2-8ff822d3f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_132f415e-4ef4-40b3-ad71-3a06bbe276be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_132f415e-4ef4-40b3-ad71-3a06bbe276be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_59d754a9-54ab-4f7b-b4f8-692fcde86169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_59d754a9-54ab-4f7b-b4f8-692fcde86169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_12b565ab-cdce-412d-b7ba-90567269419c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_12b565ab-cdce-412d-b7ba-90567269419c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ebc5f55a-b1a4-40aa-832b-475479e82707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_ebc5f55a-b1a4-40aa-832b-475479e82707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_448a05ac-ead4-49ed-b4d1-81fa3aac11f7" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards_448a05ac-ead4-49ed-b4d1-81fa3aac11f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_a7fdab3b-d1db-4304-8b86-0351f7eb3a0a" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage_a7fdab3b-d1db-4304-8b86-0351f7eb3a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_c9d59f2e-e72d-4b4b-b97c-b92c0a8f1b43" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares_c9d59f2e-e72d-4b4b-b97c-b92c0a8f1b43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd66a13-7a5c-4b1b-ae2b-0eddfce6d44c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9dd66a13-7a5c-4b1b-ae2b-0eddfce6d44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_fb9d4d67-79f4-4272-825c-906ade35837e" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage_fb9d4d67-79f4-4272-825c-906ade35837e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f384a5b3-917f-407a-b825-6851542c42fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ec73bcce-bcfd-48ae-902b-b1db98fa1bf0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f384a5b3-917f-407a-b825-6851542c42fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b631357b-1a1e-40d2-ba38-4e781c8199b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b631357b-1a1e-40d2-ba38-4e781c8199b0" xlink:to="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_58436893-6dfb-4a96-a80e-2b3bab0a03d6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_95369945-e04d-41fc-87ff-15d50dccf35d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_95369945-e04d-41fc-87ff-15d50dccf35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_2c772dbd-b1e0-411c-a22a-1c80f67839aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:to="loc_us-gaap_CostOfSalesMember_2c772dbd-b1e0-411c-a22a-1c80f67839aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4478bc92-29e7-468f-b743-5e659c7207e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_6be02e33-825c-4a4d-ad46-ea3f24ac1e89" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4478bc92-29e7-468f-b743-5e659c7207e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:to="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b57146c2-d03e-4a2f-a90c-4de0106b176a" xlink:to="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_cc5ed14b-d590-4354-b6b0-a79d1cbc57e9" xlink:href="anip-20231231.xsd#anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:to="loc_anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember_cc5ed14b-d590-4354-b6b0-a79d1cbc57e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_StockIncentivePlanMember_b52b139f-b775-4bfe-a086-899307e5fb7f" xlink:href="anip-20231231.xsd#anip_StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89f09d77-df7b-4355-b6a4-afd393578e26" xlink:to="loc_anip_StockIncentivePlanMember_b52b139f-b775-4bfe-a086-899307e5fb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b0bb67b7-34cb-4cfd-8d31-236f42ca962d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2214f17-26a2-497f-919b-c3fec6b80d45" xlink:to="loc_us-gaap_StatementLineItems_b0bb67b7-34cb-4cfd-8d31-236f42ca962d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_c7d01146-664f-45e2-9f33-0b5061bf1ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b0bb67b7-34cb-4cfd-8d31-236f42ca962d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_c7d01146-664f-45e2-9f33-0b5061bf1ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONFairvalueoptionsDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a0e349c4-d4d0-4b69-9bbc-77549d725abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a0e349c4-d4d0-4b69-9bbc-77549d725abf" xlink:to="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:to="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6420be4d-cd4e-4a02-9081-38ec2c8b95cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9feff8c3-5203-4353-9b39-8b0c241115b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6420be4d-cd4e-4a02-9081-38ec2c8b95cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_37b66040-b43e-4c4e-8a25-597ab1f5f879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6420be4d-cd4e-4a02-9081-38ec2c8b95cb" xlink:to="loc_us-gaap_EmployeeStockOptionMember_37b66040-b43e-4c4e-8a25-597ab1f5f879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:to="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_db1cd633-7da7-4d2a-bb4a-ec343e585620" xlink:to="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6890aca7-0525-4d38-9362-523bf51b8780" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:to="loc_srt_MinimumMember_6890aca7-0525-4d38-9362-523bf51b8780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c472213a-0ed6-46dd-8a40-20b0d2e61bdc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2bcc4351-f572-4150-a910-04c66f43ae97" xlink:to="loc_srt_MaximumMember_c472213a-0ed6-46dd-8a40-20b0d2e61bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9596001c-67a1-4be2-bdf4-e3df3e231590" xlink:to="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90ebd01e-bd7e-4b27-bd76-06b1b7bd49a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_90ebd01e-bd7e-4b27-bd76-06b1b7bd49a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d973d1c-6ea2-4d24-9d7e-3832e7188f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3d973d1c-6ea2-4d24-9d7e-3832e7188f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5441172-c38b-4c60-8a65-08137813188a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b5441172-c38b-4c60-8a65-08137813188a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa5fef67-01da-4fae-a264-1daf29f6a9f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_63778284-7b15-4dad-a1b1-f28e6afb6a27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_aa5fef67-01da-4fae-a264-1daf29f6a9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONStockoptionactivityDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f2ef142-944f-42a6-853f-bae61cbdf1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4f2ef142-944f-42a6-853f-bae61cbdf1bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:to="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b21c412-49a7-4836-8b4c-91efa37054a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_35929fb6-229a-40bf-9074-fc3c1322e1fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b21c412-49a7-4836-8b4c-91efa37054a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0c8cee4f-522c-44c2-821a-7738e3acb916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b21c412-49a7-4836-8b4c-91efa37054a6" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0c8cee4f-522c-44c2-821a-7738e3acb916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2bd9eb10-2e91-4e08-83af-0ad1ea6e4d9a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f57c9e-ce07-4cce-bf63-9069a5d006c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_81f57c9e-ce07-4cce-bf63-9069a5d006c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98a9eb93-ab87-4b32-be45-38f5125ef8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_98a9eb93-ab87-4b32-be45-38f5125ef8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8e7b2d7-9d9e-4e92-aa26-9b4003fae291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b8e7b2d7-9d9e-4e92-aa26-9b4003fae291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e67d2ccb-0915-4e02-b58c-9ec3fe8414d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e67d2ccb-0915-4e02-b58c-9ec3fe8414d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e21855a9-1ac1-4d53-b6e9-1be639f62728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_e21855a9-1ac1-4d53-b6e9-1be639f62728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bba05363-31b9-42c4-9620-277704f08176" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_06dbc4c5-778c-4240-a354-8709fc0b515f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bba05363-31b9-42c4-9620-277704f08176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_777787a5-deeb-4da6-a012-978ce7b25947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_777787a5-deeb-4da6-a012-978ce7b25947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0471fd21-fb86-483b-a61b-f25c5c9fb21e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0471fd21-fb86-483b-a61b-f25c5c9fb21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe6208a2-0d58-46bb-a204-54ef0fe8c741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fe6208a2-0d58-46bb-a204-54ef0fe8c741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_58171a21-c75b-4aa2-b0e3-8692f611f01c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_58171a21-c75b-4aa2-b0e3-8692f611f01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3bf8349-3d13-4dae-bee5-4b585297b2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_e3bf8349-3d13-4dae-bee5-4b585297b2d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9118bb85-230c-49b2-a285-d84c822b5cb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_9118bb85-230c-49b2-a285-d84c822b5cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22811952-63a8-42c0-abc6-a090a1ae1ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0381fc7c-42c5-47ab-a449-f043b22e0f96" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22811952-63a8-42c0-abc6-a090a1ae1ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a40eb7b3-3ae7-487a-aec0-900e7a3a9640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a40eb7b3-3ae7-487a-aec0-900e7a3a9640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_685d8a73-02f5-4a9d-a3a4-b14f3e581b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_685d8a73-02f5-4a9d-a3a4-b14f3e581b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_244c10d2-bfab-43f4-8263-fd050711a3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_685d8a73-02f5-4a9d-a3a4-b14f3e581b1c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_244c10d2-bfab-43f4-8263-fd050711a3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37060113-c606-4196-9e01-e936ef9913e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_37060113-c606-4196-9e01-e936ef9913e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_12286f13-327a-4f86-96ab-73827e497768" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_a12cbb72-93af-4633-8e68-9d9bdb2c6a7b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_12286f13-327a-4f86-96ab-73827e497768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:href="anip-20231231.xsd#anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_91125896-87ae-4a7f-81d1-4bbf1671d2d3" xlink:to="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e00498a0-97b8-4a76-80eb-ad79006e8094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_e00498a0-97b8-4a76-80eb-ad79006e8094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a5d6f928-5d8a-412b-a3ee-f74ab804ade2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a5d6f928-5d8a-412b-a3ee-f74ab804ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_84b3c792-50f5-4959-a448-4c9f4d0c9230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_84b3c792-50f5-4959-a448-4c9f4d0c9230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_80d674a6-7b39-4438-9793-20b192519e05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_491196ad-278a-43c9-81f9-7ac28225f2bf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_80d674a6-7b39-4438-9793-20b192519e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONRSAactivityDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489efaab-81e7-4530-8247-4f6403e46982" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_489efaab-81e7-4530-8247-4f6403e46982" xlink:to="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:to="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_256f8aee-ad47-41ba-ab73-71b827249aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_43a8ce92-3d3e-4e3e-b015-101d6b954590" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_256f8aee-ad47-41ba-ab73-71b827249aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_b410b58e-36bd-40f2-87ae-98964cbb3d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_256f8aee-ad47-41ba-ab73-71b827249aed" xlink:to="loc_us-gaap_RestrictedStockMember_b410b58e-36bd-40f2-87ae-98964cbb3d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_119c7250-00d6-4d1c-ba0c-c451128f3d54" xlink:to="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e8c8ac8-3e21-483b-ba67-c80694631acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6e8c8ac8-3e21-483b-ba67-c80694631acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_aa94d88d-73ba-491b-89bb-2fa23a2bd36b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_aa94d88d-73ba-491b-89bb-2fa23a2bd36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ebe65d06-0c98-43cc-ab83-e15a9f99dafe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ebe65d06-0c98-43cc-ab83-e15a9f99dafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_613e342e-d9ae-4f05-b2ad-7b7d8e16b1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_613e342e-d9ae-4f05-b2ad-7b7d8e16b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0352f286-e492-4482-a576-7857096787bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ea2971a2-d1b0-43eb-84c2-154c687b40ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0352f286-e492-4482-a576-7857096787bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef008a0-84cc-4c03-a72a-b2327d82cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1ef008a0-84cc-4c03-a72a-b2327d82cf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b4cbcae7-9a85-47bc-9a2d-305d404aaa49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_b4cbcae7-9a85-47bc-9a2d-305d404aaa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c894e660-5bb5-4105-8afe-45d4086ba7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c894e660-5bb5-4105-8afe-45d4086ba7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c28039cf-3124-4eef-8278-0b26a1d97d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c28039cf-3124-4eef-8278-0b26a1d97d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8bf4cda-8ccd-4978-9f43-89df8a2e8dcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a588f100-2bc4-4c23-ba5b-ba2753d7ee90" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f8bf4cda-8ccd-4978-9f43-89df8a2e8dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_df41b605-4daa-413f-ac65-28e7d75ec3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_02ac5a94-731a-4b1a-b29c-668af3f1b806" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_df41b605-4daa-413f-ac65-28e7d75ec3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c942211-ee0b-4945-a6ad-a68249d849bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7c942211-ee0b-4945-a6ad-a68249d849bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:to="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95dcbd12-5a86-40dd-8afe-7bc525574ce4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d9a1bc1d-8336-4347-a7a3-a1e96b0697b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95dcbd12-5a86-40dd-8afe-7bc525574ce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_4e5b41c7-80d2-4029-bc24-3b039c117504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95dcbd12-5a86-40dd-8afe-7bc525574ce4" xlink:to="loc_us-gaap_PerformanceSharesMember_4e5b41c7-80d2-4029-bc24-3b039c117504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7b8ecaf-7b25-4745-b46b-b0608f495152" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e51572c-28b2-49bd-98e8-ccc3ab72ec69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2e51572c-28b2-49bd-98e8-ccc3ab72ec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf1c5381-51c2-41e8-bdc0-878e3bf45cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bf1c5381-51c2-41e8-bdc0-878e3bf45cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a8e912e1-6e7c-4dae-b571-8c827f96cfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_a8e912e1-6e7c-4dae-b571-8c827f96cfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f41ef367-d0c5-4088-b5d2-4c50551a6fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_f41ef367-d0c5-4088-b5d2-4c50551a6fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3eed822a-6251-44f4-b8b7-104a6b5a6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_b39ecd20-4676-4c2b-9c4a-e9b633f0f8d4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3eed822a-6251-44f4-b8b7-104a6b5a6e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59d61211-335f-4451-9a38-386ef6bd7d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59d61211-335f-4451-9a38-386ef6bd7d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b96c5c0-949f-4fed-adcd-78c9a01b010a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8b96c5c0-949f-4fed-adcd-78c9a01b010a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b94c1c16-e963-434c-a08c-bf78dc5d63a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_b94c1c16-e963-434c-a08c-bf78dc5d63a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c183a8f8-99a3-4770-bd66-f201e31ce7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c183a8f8-99a3-4770-bd66-f201e31ce7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3064bc1-04cf-4325-a992-0eaa04d062a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6e3bba2b-8a52-4dae-8d5f-ed89c537c89b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f3064bc1-04cf-4325-a992-0eaa04d062a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fffc9d07-d168-43cf-84f6-5beaa88f45bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4484d192-b9dc-4a37-af74-1f83e3a568b9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_fffc9d07-d168-43cf-84f6-5beaa88f45bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f811cfca-dd9c-4ab9-865a-6d928e100eba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FederalIncomeTaxNoteTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f811cfca-dd9c-4ab9-865a-6d928e100eba" xlink:to="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_9091666f-2e43-4737-b94f-428cff5e9deb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1656f082-0ae1-439f-9117-04bfd4e41c71" xlink:to="loc_srt_ConsolidatedEntitiesDomain_9091666f-2e43-4737-b94f-428cff5e9deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ANICanadaMember_57a67451-2e40-4c7d-8ac5-106f82964f4e" xlink:href="anip-20231231.xsd#anip_ANICanadaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_9091666f-2e43-4737-b94f-428cff5e9deb" xlink:to="loc_anip_ANICanadaMember_57a67451-2e40-4c7d-8ac5-106f82964f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_acbdddff-328d-49b1-965e-62022e472236" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_7725536f-196f-455a-8f87-7cf943a6966d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:to="loc_us-gaap_DomesticCountryMember_7725536f-196f-455a-8f87-7cf943a6966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_d23a141d-fa15-4c62-b6a0-914d4e658ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_d8e4626a-1184-45df-a34d-bd801511fd76" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_d23a141d-fa15-4c62-b6a0-914d4e658ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FederalIncomeTaxNoteTable_9df4b6bc-b0f6-4569-8268-f7630c70e9e8" xlink:to="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c883eef0-c151-46c3-b079-19f376c7e876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_c883eef0-c151-46c3-b079-19f376c7e876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1fc71c81-74d8-497a-b913-1855b243bb97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1fc71c81-74d8-497a-b913-1855b243bb97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_ac760646-1383-4283-b4e1-aef28fa078ad" xlink:href="anip-20231231.xsd#anip_OperatingLossCarryforwardsAnnualLimitationsOnUse"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems_5d4d5fe1-06f5-4e09-a3f3-29c91af4270a" xlink:to="loc_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse_ac760646-1383-4283-b4e1-aef28fa078ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESProvisionDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_314374f5-33e9-4cca-98c2-dd4c395d140a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5cd76a07-5a82-4d86-9f0f-495462502c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314374f5-33e9-4cca-98c2-dd4c395d140a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5cd76a07-5a82-4d86-9f0f-495462502c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fd44d114-875d-4318-8a4a-54f9e25a26c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5cd76a07-5a82-4d86-9f0f-495462502c9e" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_fd44d114-875d-4318-8a4a-54f9e25a26c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a487dc6b-743f-4c1d-ae9c-7d93c58a65f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5cd76a07-5a82-4d86-9f0f-495462502c9e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_a487dc6b-743f-4c1d-ae9c-7d93c58a65f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_25a5e7f4-62f7-4b91-b059-6e70bdd091cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5cd76a07-5a82-4d86-9f0f-495462502c9e" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_25a5e7f4-62f7-4b91-b059-6e70bdd091cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a6d77134-19e3-4e76-9b6d-776439df4101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_5cd76a07-5a82-4d86-9f0f-495462502c9e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a6d77134-19e3-4e76-9b6d-776439df4101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27654b38-2748-43dd-8c34-3d344a50950e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314374f5-33e9-4cca-98c2-dd4c395d140a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27654b38-2748-43dd-8c34-3d344a50950e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5389bc4a-a20b-462c-99d6-905da8c5e3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27654b38-2748-43dd-8c34-3d344a50950e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5389bc4a-a20b-462c-99d6-905da8c5e3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fc3dec4c-793f-4102-b5a0-ca0ca85bbfa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27654b38-2748-43dd-8c34-3d344a50950e" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_fc3dec4c-793f-4102-b5a0-ca0ca85bbfa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c9953e4e-28bc-4e1f-a1f4-322fb5917184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27654b38-2748-43dd-8c34-3d344a50950e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_c9953e4e-28bc-4e1f-a1f4-322fb5917184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_014eee50-9ce3-4a53-aaac-516ca0e683b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_27654b38-2748-43dd-8c34-3d344a50950e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_014eee50-9ce3-4a53-aaac-516ca0e683b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f871fd93-58e9-4f78-b975-979e85716331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314374f5-33e9-4cca-98c2-dd4c395d140a" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f871fd93-58e9-4f78-b975-979e85716331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_daefca06-786d-4ab7-b022-7493d5b5b0ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_314374f5-33e9-4cca-98c2-dd4c395d140a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_daefca06-786d-4ab7-b022-7493d5b5b0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESEffectiverateDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11cdf4d2-b4f6-42ee-8ee8-e8b8e2f9fd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_11cdf4d2-b4f6-42ee-8ee8-e8b8e2f9fd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_26f00f27-15b7-47d8-b74b-d8dbf257e6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_26f00f27-15b7-47d8-b74b-d8dbf257e6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b1322883-0acc-4c1d-9f7a-74ab00b6b4d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_b1322883-0acc-4c1d-9f7a-74ab00b6b4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8973d6e9-9304-4437-92c8-3ce61ccee3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8973d6e9-9304-4437-92c8-3ce61ccee3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_25529531-de2e-45a7-8849-fec66e7cbf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_25529531-de2e-45a7-8849-fec66e7cbf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_3c1b0912-cfa4-4998-b4b1-a62c61939e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_3c1b0912-cfa4-4998-b4b1-a62c61939e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_e55bb0ce-1156-4002-9c8e-1604870ee831" xlink:href="anip-20231231.xsd#anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes_e55bb0ce-1156-4002-9c8e-1604870ee831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_27153595-e0b0-4e5e-9076-83e00f543923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_27153595-e0b0-4e5e-9076-83e00f543923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_75459088-8965-4792-9040-12d604d9f6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_75459088-8965-4792-9040-12d604d9f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_620b8a93-89c9-4de3-aa63-b7a0d6793eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f2a5cf44-2553-4ba6-b20b-080b65e2f4c5" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_620b8a93-89c9-4de3-aa63-b7a0d6793eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#INCOMETAXESDeferredtaxDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6f4239b6-2781-4b21-bd33-a2201c794f49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6f4239b6-2781-4b21-bd33-a2201c794f49" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_dd0d76c8-cb77-4305-a089-75bfda248d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_dd0d76c8-cb77-4305-a089-75bfda248d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1ac810c3-8336-4bc9-98b9-1fb321fc259a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1ac810c3-8336-4bc9-98b9-1fb321fc259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_12e7b3b7-4432-44a0-b99c-43b2e2109776" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances_12e7b3b7-4432-44a0-b99c-43b2e2109776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_9bd247d8-fd3f-4769-9df6-40d35526bd50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInventory"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_9bd247d8-fd3f-4769-9df6-40d35526bd50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fc9ab435-cdb0-4c9a-99ac-371622200a77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_fc9ab435-cdb0-4c9a-99ac-371622200a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b9411ffa-a0e2-4a73-ac6d-6725dc6f3a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_b9411ffa-a0e2-4a73-ac6d-6725dc6f3a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a41a030d-6bc0-4e59-84a7-9b57d37b3697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a41a030d-6bc0-4e59-84a7-9b57d37b3697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_04b2f8d3-abfd-4a07-a950-3af95d74e1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_04b2f8d3-abfd-4a07-a950-3af95d74e1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f84325-4975-406f-aeb4-4e5fc8e76fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_08a4868f-ae09-401e-8b4b-44ab2086a7dd" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40f84325-4975-406f-aeb4-4e5fc8e76fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_230c1f85-4a3f-4c51-a02a-158faa731d8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6f4239b6-2781-4b21-bd33-a2201c794f49" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_230c1f85-4a3f-4c51-a02a-158faa731d8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9194dc5e-2b01-4dc4-9701-b788d3d9a749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_230c1f85-4a3f-4c51-a02a-158faa731d8b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_9194dc5e-2b01-4dc4-9701-b788d3d9a749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4a039260-53d6-45be-a244-25c0832540a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_230c1f85-4a3f-4c51-a02a-158faa731d8b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4a039260-53d6-45be-a244-25c0832540a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_8e93e604-c96e-4ba7-89fa-6870e578835e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_230c1f85-4a3f-4c51-a02a-158faa731d8b" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_8e93e604-c96e-4ba7-89fa-6870e578835e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_30282ac7-58d3-4098-b37f-19e1c974c7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6f4239b6-2781-4b21-bd33-a2201c794f49" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_30282ac7-58d3-4098-b37f-19e1c974c7c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d9d8f491-7adb-4477-abbb-8f99a3d811fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6f4239b6-2781-4b21-bd33-a2201c794f49" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_d9d8f491-7adb-4477-abbb-8f99a3d811fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_863ad75a-1be9-40d2-8980-4e9aba361106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_863ad75a-1be9-40d2-8980-4e9aba361106" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff124135-0558-4356-87ee-0e6c17166cf2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_dd458b64-1738-45c0-95c0-6831332894b1" xlink:to="loc_srt_ProductsAndServicesDomain_ff124135-0558-4356-87ee-0e6c17166cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_UnapprovedProductsMember_55236fe4-a2d1-4ddb-8005-b4edcf0946b5" xlink:href="anip-20231231.xsd#anip_UnapprovedProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff124135-0558-4356-87ee-0e6c17166cf2" xlink:to="loc_anip_UnapprovedProductsMember_55236fe4-a2d1-4ddb-8005-b4edcf0946b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_43fefdee-b062-4636-a93a-83170b9cbdb8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_41e437fe-cdf5-4f96-89bf-28f907c15f7b" xlink:to="loc_srt_NameOfMajorCustomerDomain_43fefdee-b062-4636-a93a-83170b9cbdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ContractCustomerMember_58441aa1-770e-43b1-a9ac-091de3a56389" xlink:href="anip-20231231.xsd#anip_ContractCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_43fefdee-b062-4636-a93a-83170b9cbdb8" xlink:to="loc_anip_ContractCustomerMember_58441aa1-770e-43b1-a9ac-091de3a56389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0dc2b618-16f8-4c93-91a4-5caab2b05dbb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_AzurityPharmaceuticalsMember_7622bb9a-e49e-4275-8bae-1f4a0d4b6d0d" xlink:href="anip-20231231.xsd#anip_AzurityPharmaceuticalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:to="loc_anip_AzurityPharmaceuticalsMember_7622bb9a-e49e-4275-8bae-1f4a0d4b6d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumMember_35aab8b3-c339-4ac8-a60e-fd84d9b98abd" xlink:href="anip-20231231.xsd#anip_NovitiumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_676f9be8-aa8f-4b2c-aed4-826fea160c2a" xlink:to="loc_anip_NovitiumMember_35aab8b3-c339-4ac8-a60e-fd84d9b98abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_cfa11a46-407b-4f64-990f-d52d09eaf5e3" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfOperatingLeases_2904874f-a833-4361-90ef-3f9d75b2455e" xlink:href="anip-20231231.xsd#anip_NumberOfOperatingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_NumberOfOperatingLeases_2904874f-a833-4361-90ef-3f9d75b2455e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c838fa72-0b38-430f-9c79-244284fc6a87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c838fa72-0b38-430f-9c79-244284fc6a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fe55f63a-57c0-4572-8589-8d5d58d45ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fe55f63a-57c0-4572-8589-8d5d58d45ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfProductsMarketed_65dbc61e-0c07-4bba-91f7-964693ba8dd5" xlink:href="anip-20231231.xsd#anip_NumberOfProductsMarketed"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_NumberOfProductsMarketed_65dbc61e-0c07-4bba-91f7-964693ba8dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24aebc1-907f-41c7-b0f0-51b8aff7cda5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b24aebc1-907f-41c7-b0f0-51b8aff7cda5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_162bedb2-4d1c-46e9-ba48-fbf13d9237af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_162bedb2-4d1c-46e9-ba48-fbf13d9237af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RoyaltyOnFutureSalesPercent_5141511f-8d7a-48ce-9905-44ed885b7d93" xlink:href="anip-20231231.xsd#anip_RoyaltyOnFutureSalesPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_RoyaltyOnFutureSalesPercent_5141511f-8d7a-48ce-9905-44ed885b7d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfPlaintiffs_765eb3cb-bf84-46c5-bdef-fa383776e02d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNumberOfPlaintiffs"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LossContingencyNumberOfPlaintiffs_765eb3cb-bf84-46c5-bdef-fa383776e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_LossContingencyNumberOfManufacturers_10db9a6b-bc3d-46c8-bf88-3b60e3aac1af" xlink:href="anip-20231231.xsd#anip_LossContingencyNumberOfManufacturers"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_anip_LossContingencyNumberOfManufacturers_10db9a6b-bc3d-46c8-bf88-3b60e3aac1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1be2fa40-8198-4fff-ab9c-2fce17b82c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_1be2fa40-8198-4fff-ab9c-2fce17b82c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_906c67ea-066e-4b71-8ad4-37f99d2a13b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_7adb907b-adef-4440-8284-62834030a2c3" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_906c67ea-066e-4b71-8ad4-37f99d2a13b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e1f2877-edbc-416f-8044-fd949f59f4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_47f650ff-fe0f-461a-bc11-a1810dea346c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e1f2877-edbc-416f-8044-fd949f59f4ed" xlink:to="loc_us-gaap_OperatingLeaseCost_47f650ff-fe0f-461a-bc11-a1810dea346c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_47720608-bba1-4afb-9b3a-7d00ef27612b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e1f2877-edbc-416f-8044-fd949f59f4ed" xlink:to="loc_us-gaap_VariableLeaseCost_47720608-bba1-4afb-9b3a-7d00ef27612b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_cd549959-1180-472d-910f-24340dc5dfd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1e1f2877-edbc-416f-8044-fd949f59f4ed" xlink:to="loc_us-gaap_LeaseCost_cd549959-1180-472d-910f-24340dc5dfd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#COMMITMENTSANDCONTINGENCIESLeasematurityDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b65d2011-6461-4cd1-a90f-f8616da7ea67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b65d2011-6461-4cd1-a90f-f8616da7ea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8f9a29c6-21fa-4579-843a-b2dd38cab584" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8f9a29c6-21fa-4579-843a-b2dd38cab584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fbdf886e-6bb5-46c5-9fd4-1054b803d954" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_fbdf886e-6bb5-46c5-9fd4-1054b803d954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c712d0fa-241d-4c53-bb19-84f01131c7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c712d0fa-241d-4c53-bb19-84f01131c7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d4dc38d9-162d-4ee5-a5d5-8ca49a25dd65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_d4dc38d9-162d-4ee5-a5d5-8ca49a25dd65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_19a68845-8b77-44af-bbe3-bb9f18fb7288" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_19a68845-8b77-44af-bbe3-bb9f18fb7288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2aa07bb0-da6a-4678-8d60-8f267a76d47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2aa07bb0-da6a-4678-8d60-8f267a76d47d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1a3091c5-f6a6-4859-a5d0-c88a559986a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_1a3091c5-f6a6-4859-a5d0-c88a559986a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ddda6921-d9c1-4c31-91bd-f9e5a8479580" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_OperatingLeaseLiability_ddda6921-d9c1-4c31-91bd-f9e5a8479580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d4c194b-5a78-4370-9def-256c6843eb32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d4c194b-5a78-4370-9def-256c6843eb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_125f448b-d696-4539-906f-d80e961e0e96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_8d4c194b-5a78-4370-9def-256c6843eb32" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_125f448b-d696-4539-906f-d80e961e0e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d7ae121a-1f92-41c5-8b24-542949a51b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1ca53926-e417-4d83-9c2d-ed6ba1c37a06" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d7ae121a-1f92-41c5-8b24-542949a51b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f7b93312-eec6-4f19-a4b8-ce70dac04b96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d7ae121a-1f92-41c5-8b24-542949a51b1a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_f7b93312-eec6-4f19-a4b8-ce70dac04b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchChargesAbstract_4bea0dca-56e6-4387-89d6-2d78730b0ac1" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchChargesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_anip_CortrophinPreLaunchChargesAbstract_4bea0dca-56e6-4387-89d6-2d78730b0ac1" xlink:to="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:to="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c1b2e8f1-740b-4f29-97b9-ad19ee53efcf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2c91ecdb-6765-4673-b88a-f226a6c34a88" xlink:to="loc_srt_ProductsAndServicesDomain_c1b2e8f1-740b-4f29-97b9-ad19ee53efcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinGelMember_f56e9f61-9f86-47d7-a7bf-8fed9f57d651" xlink:href="anip-20231231.xsd#anip_CortrophinGelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c1b2e8f1-740b-4f29-97b9-ad19ee53efcf" xlink:to="loc_anip_CortrophinGelMember_f56e9f61-9f86-47d7-a7bf-8fed9f57d651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f280899c-a236-4442-bd95-e67a465b2aa5" xlink:to="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CortrophinPreLaunchCharges_0e150112-0376-4e07-9dbd-b00881e28101" xlink:href="anip-20231231.xsd#anip_CortrophinPreLaunchCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:to="loc_anip_CortrophinPreLaunchCharges_0e150112-0376-4e07-9dbd-b00881e28101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e87399df-2740-4cd6-b312-2ed85942d2ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_357c6d4a-b5bd-4d1f-ae5c-eab2756adadc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e87399df-2740-4cd6-b312-2ed85942d2ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#RELATEDPARTYTRANSACTIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_d9882185-f2ca-4614-95fc-32f7b60ba757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_d9882185-f2ca-4614-95fc-32f7b60ba757" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_dba815a4-fbf1-4f2f-998b-bfe3cf167f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516ca14d-b513-4f2a-b070-fc5818997431" xlink:to="loc_us-gaap_ClassOfStockDomain_dba815a4-fbf1-4f2f-998b-bfe3cf167f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_aab5ab2c-49a4-4658-8300-bcdb08d12a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_dba815a4-fbf1-4f2f-998b-bfe3cf167f7e" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_aab5ab2c-49a4-4658-8300-bcdb08d12a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6e193c7-cb2d-4303-b282-f7ea102b0ac8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_eba80e94-a728-40ac-95e2-7289b6da6fa3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6e193c7-cb2d-4303-b282-f7ea102b0ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PrivateInvestmentInPublicEquityMember_21172013-99cf-40f1-803f-779f6941f742" xlink:href="anip-20231231.xsd#anip_PrivateInvestmentInPublicEquityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a6e193c7-cb2d-4303-b282-f7ea102b0ac8" xlink:to="loc_anip_PrivateInvestmentInPublicEquityMember_21172013-99cf-40f1-803f-779f6941f742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_f8c45788-045d-4619-bdce-30ff10526b56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ed537ba9-04f8-4223-8584-59852ebe0f42" xlink:to="loc_us-gaap_RelatedPartyDomain_f8c45788-045d-4619-bdce-30ff10526b56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_3fc91528-3b03-4732-88b9-ee807884c56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_f8c45788-045d-4619-bdce-30ff10526b56" xlink:to="loc_us-gaap_RelatedPartyMember_3fc91528-3b03-4732-88b9-ee807884c56f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_06bf337c-ea50-4032-8ff0-9edd40271aa7" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScitusPharmaServicesMember_b6aed21b-59e3-478b-82ad-3d50fe970997" xlink:href="anip-20231231.xsd#anip_ScitusPharmaServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:to="loc_anip_ScitusPharmaServicesMember_b6aed21b-59e3-478b-82ad-3d50fe970997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SsPharmaLlcMember_ab305522-3a29-4962-9010-68be293823f0" xlink:href="anip-20231231.xsd#anip_SsPharmaLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:to="loc_anip_SsPharmaLlcMember_ab305522-3a29-4962-9010-68be293823f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NurayChemicalPrivateLimitedMember_34bee557-8d28-4ceb-b62a-ade2e510514f" xlink:href="anip-20231231.xsd#anip_NurayChemicalPrivateLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_5f1ea055-197a-4fc1-9e30-d419053f556b" xlink:to="loc_anip_NurayChemicalPrivateLimitedMember_34bee557-8d28-4ceb-b62a-ade2e510514f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0706493-4e12-47d9-a703-cfb448b8d36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65752cb6-5040-40bc-a8ec-ea145d0d6f37" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0706493-4e12-47d9-a703-cfb448b8d36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_0074e3ef-cba6-4ae2-aa69-e972cdc0c50f" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e0706493-4e12-47d9-a703-cfb448b8d36c" xlink:to="loc_anip_NovitiumPharmaMember_0074e3ef-cba6-4ae2-aa69-e972cdc0c50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4f217ad2-5325-446d-98a5-abba1d984e10" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.ShanmugamAndEsjayMember_3106f076-8c02-4aa4-a40b-5144034e5654" xlink:href="anip-20231231.xsd#anip_Mr.ShanmugamAndEsjayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:to="loc_anip_Mr.ShanmugamAndEsjayMember_3106f076-8c02-4aa4-a40b-5144034e5654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ChaliPropertiesLLCMember_ba860901-5a90-4464-8805-303f06fe9d1a" xlink:href="anip-20231231.xsd#anip_ChaliPropertiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b5b1c6ba-93c3-496d-999a-105cdc8897c0" xlink:to="loc_anip_ChaliPropertiesLLCMember_ba860901-5a90-4464-8805-303f06fe9d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0385f37f-306f-45b1-975c-419d4905f1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_f114c231-c942-45bc-887f-a6ceffc7dd10" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0385f37f-306f-45b1-975c-419d4905f1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_a47dc4d7-ff9a-4230-8ff8-ea28ac3f6887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_0385f37f-306f-45b1-975c-419d4905f1bd" xlink:to="loc_us-gaap_SubsequentEventMember_a47dc4d7-ff9a-4230-8ff8-ea28ac3f6887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_691fbc0f-a0cc-4969-a3ff-e5417c328010" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_35c28d44-9ba9-42c0-81f1-ed8736cc5784" xlink:href="anip-20231231.xsd#anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_35c28d44-9ba9-42c0-81f1-ed8736cc5784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_b68f881d-c56f-460f-8b53-867acbe621fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_TemporaryEquityRedemptionPricePerShare_b68f881d-c56f-460f-8b53-867acbe621fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b8d6bb6f-a05c-4852-90b9-a18f04768b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_b8d6bb6f-a05c-4852-90b9-a18f04768b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NumberOfExecutiveFounders_24481d1b-a38e-423b-91dc-ca05532aff5b" xlink:href="anip-20231231.xsd#anip_NumberOfExecutiveFounders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_anip_NumberOfExecutiveFounders_24481d1b-a38e-423b-91dc-ca05532aff5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3e251993-6809-4712-97da-b041952340f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_AccountsPayableCurrent_3e251993-6809-4712-97da-b041952340f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a1a907cc-964c-49d0-993d-ec682dad47c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_f73de6d5-9052-402a-acfe-1e66bcf6fab3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a1a907cc-964c-49d0-993d-ec682dad47c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ea77c5c8-b313-4ecb-a97a-e7d723e5b996" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ea77c5c8-b313-4ecb-a97a-e7d723e5b996" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9820d86d-3d55-40e3-9d33-0b8e63c6dbe2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bb0ad3d0-9f2b-47f4-bf72-e69f0698ed98" xlink:to="loc_us-gaap_RelatedPartyDomain_9820d86d-3d55-40e3-9d33-0b8e63c6dbe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_a5148569-9e99-46ea-906d-18b6824578d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_9820d86d-3d55-40e3-9d33-0b8e63c6dbe2" xlink:to="loc_us-gaap_RelatedPartyMember_a5148569-9e99-46ea-906d-18b6824578d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_8aa54e13-8a10-48cd-bc1c-a1dac5f471b4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_ScitusPharmaServicesMember_17036b67-7230-400c-9c09-d281bea47bff" xlink:href="anip-20231231.xsd#anip_ScitusPharmaServicesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_ScitusPharmaServicesMember_17036b67-7230-400c-9c09-d281bea47bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_SsPharmaLlcMember_4ee4625a-4beb-430a-b51b-8839efe52fd6" xlink:href="anip-20231231.xsd#anip_SsPharmaLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_SsPharmaLlcMember_4ee4625a-4beb-430a-b51b-8839efe52fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EsjayPharmaLlcMember_ce6b14de-b64b-407b-a1ad-a4cb3a3ad164" xlink:href="anip-20231231.xsd#anip_EsjayPharmaLlcMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_EsjayPharmaLlcMember_ce6b14de-b64b-407b-a1ad-a4cb3a3ad164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NurayChemicalPrivateLimitedMember_120b878e-1772-4c37-b55d-fe45d6375236" xlink:href="anip-20231231.xsd#anip_NurayChemicalPrivateLimitedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_1a9b910c-2150-407f-9d0c-84109d58ade2" xlink:to="loc_anip_NurayChemicalPrivateLimitedMember_120b878e-1772-4c37-b55d-fe45d6375236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_4704d044-b84b-48f6-9319-8f41c8ee2ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b2462591-1d02-462f-8ab5-1be8a3656b0c" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_4704d044-b84b-48f6-9319-8f41c8ee2ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_bc579641-c803-4b63-b21b-e3faca44147b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_4704d044-b84b-48f6-9319-8f41c8ee2ba9" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_bc579641-c803-4b63-b21b-e3faca44147b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#SEGMENTREPORTINGRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f823096b-a071-4d45-995b-ef6d350d7296" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f823096b-a071-4d45-995b-ef6d350d7296" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:to="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_7d803db1-fa7e-4d5d-8b5a-e448d2004144" xlink:to="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_d277c1a1-c2f3-4162-a456-24b26d1bad70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:to="loc_us-gaap_OperatingSegmentsMember_d277c1a1-c2f3-4162-a456-24b26d1bad70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_912d4655-5660-4d0f-a7d0-4fdf1df543ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_912d4655-5660-4d0f-a7d0-4fdf1df543ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_149be952-0461-4109-af97-5692cea99ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_30e0740e-d11c-4759-8f7a-cd5218514436" xlink:to="loc_us-gaap_CorporateNonSegmentMember_149be952-0461-4109-af97-5692cea99ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2c8afed6-1e52-444f-9508-29466244bb21" xlink:to="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_GenericsEstablishedBrandsAndOtherMember_aeff79f9-635a-43b0-81dd-54a75e99010c" xlink:href="anip-20231231.xsd#anip_GenericsEstablishedBrandsAndOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:to="loc_anip_GenericsEstablishedBrandsAndOtherMember_aeff79f9-635a-43b0-81dd-54a75e99010c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_RareDiseaseMember_0944e8c3-abab-4bac-8748-c3e0175441f5" xlink:href="anip-20231231.xsd#anip_RareDiseaseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_d324d87d-1d9a-40ce-b35e-f0551fe61dff" xlink:to="loc_anip_RareDiseaseMember_0944e8c3-abab-4bac-8748-c3e0175441f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_ec50105d-bb36-4205-83b6-0d1640916194" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_08b57b60-e367-433d-aee0-d6f7966e7b73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_NumberOfReportableSegments_08b57b60-e367-433d-aee0-d6f7966e7b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a918f70-157a-452f-b34f-0f3d62a80f12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a918f70-157a-452f-b34f-0f3d62a80f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_85ffe79f-526a-4f37-98d0-a44c9089015f" xlink:href="anip-20231231.xsd#anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization_85ffe79f-526a-4f37-98d0-a44c9089015f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_ef73849f-e0a3-4851-9296-31e139cf795e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_DepreciationAndAmortization_ef73849f-e0a3-4851-9296-31e139cf795e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_462999eb-d777-4602-9301-00c768295b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_462999eb-d777-4602-9301-00c768295b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_832e4dd1-aa9e-4e1b-9db4-12be7fe2cff1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_OperatingIncomeLoss_832e4dd1-aa9e-4e1b-9db4-12be7fe2cff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_eaf41413-2874-42a1-a9b0-597f8009e470" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_eaf41413-2874-42a1-a9b0-597f8009e470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5ca1fa3f-e211-41d8-b07d-3da25a54d729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5ca1fa3f-e211-41d8-b07d-3da25a54d729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0128864e-ad9a-46b0-8c60-5c5ce206895b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3d263bff-438e-4c28-8cac-9badabdcfb76" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0128864e-ad9a-46b0-8c60-5c5ce206895b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#SEGMENTREPORTINGGeographicDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cb9a6200-dc9e-48cc-9b91-d29b7579bda6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cb9a6200-dc9e-48cc-9b91-d29b7579bda6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:to="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b870a359-325a-4e39-a161-be8065abd97d" xlink:to="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_b6945a79-17c9-4757-992d-5db0e96959a0" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:to="loc_country_US_b6945a79-17c9-4757-992d-5db0e96959a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_43861144-2c69-472a-806d-159e59261d62" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:to="loc_country_CA_43861144-2c69-472a-806d-159e59261d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IN_f3e8b14d-a2f7-4199-b7a9-c5fa23624c7c" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_IN"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_9ca07562-49b3-49de-9784-92854f53cea4" xlink:to="loc_country_IN_f3e8b14d-a2f7-4199-b7a9-c5fa23624c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c993ab95-49a3-4e1b-a34e-3821309155b8" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8beae22-24ee-4571-8bd1-90d67617664d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d8beae22-24ee-4571-8bd1-90d67617664d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd244e6-d90d-4437-ad6f-d23ef1ed5192" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8fd244e6-d90d-4437-ad6f-d23ef1ed5192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_59a3e42b-a917-41e8-9990-9eaf8e1a324d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a036f6bd-e7a2-41f1-bf86-03347e98a489" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_59a3e42b-a917-41e8-9990-9eaf8e1a324d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="anip-20231231.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_3f64c5d5-df91-47e0-a020-1fa9a5c37306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_3f64c5d5-df91-47e0-a020-1fa9a5c37306" xlink:to="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ac613c-6e08-4f66-817d-e1fa6a265089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e77ad9e7-118b-4331-b854-a28142475b02" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ac613c-6e08-4f66-817d-e1fa6a265089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NovitiumPharmaMember_02b435bc-5646-4938-a248-7eaae591a631" xlink:href="anip-20231231.xsd#anip_NovitiumPharmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_75ac613c-6e08-4f66-817d-e1fa6a265089" xlink:to="loc_anip_NovitiumPharmaMember_02b435bc-5646-4938-a248-7eaae591a631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c70d7314-eee7-44a6-a58a-7ee4244c23ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9cdd22a6-647f-4ece-bb26-ae6277fdab19" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c70d7314-eee7-44a6-a58a-7ee4244c23ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_9397f26d-fe84-4238-877d-2924edcda050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c70d7314-eee7-44a6-a58a-7ee4244c23ab" xlink:to="loc_us-gaap_SubsequentEventMember_9397f26d-fe84-4238-877d-2924edcda050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f7fddd38-a67e-466a-bd6c-524aeabe1239" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5fb915b3-978b-4ae0-ab6b-b846c0d39cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:to="loc_us-gaap_RestrictedStockMember_5fb915b3-978b-4ae0-ab6b-b846c0d39cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_b1cd829d-8241-49c2-8a55-8ef1cdec0526" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d5e22da4-6f41-4038-97ba-8713c8f5e822" xlink:to="loc_us-gaap_PerformanceSharesMember_b1cd829d-8241-49c2-8a55-8ef1cdec0526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_62aafed2-826e-469e-977a-3aadd760f86f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OfficerMember_3d4ca501-baab-4d38-8e15-43ab9a5d55df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:to="loc_srt_OfficerMember_3d4ca501-baab-4d38-8e15-43ab9a5d55df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_NewEmployeesMember_5a975d99-15e6-4b5e-ad58-1230aae8aa7e" xlink:href="anip-20231231.xsd#anip_NewEmployeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1d22ea42-1a93-4451-b6f1-9ed4bcdfcd24" xlink:to="loc_anip_NewEmployeesMember_5a975d99-15e6-4b5e-ad58-1230aae8aa7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a13663f-3822-4a5e-afdf-3155ac726a2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_bc6b7221-0e6b-4166-96a9-787339b8c6a2" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a13663f-3822-4a5e-afdf-3155ac726a2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_b3e492bc-a070-4196-aa05-5016d0461ac6" xlink:href="anip-20231231.xsd#anip_OakvilleOntarioFormerManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_2a13663f-3822-4a5e-afdf-3155ac726a2c" xlink:to="loc_anip_OakvilleOntarioFormerManufacturingFacilityMember_b3e492bc-a070-4196-aa05-5016d0461ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_9d14f3c3-f214-46e4-a4b7-cd4a36c80915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_bf3c07fb-606f-4f31-b3a2-768b79825a16" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_9d14f3c3-f214-46e4-a4b7-cd4a36c80915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f2f1a989-8d43-4d9a-9f5b-4cec113bf1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_9d14f3c3-f214-46e4-a4b7-cd4a36c80915" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_f2f1a989-8d43-4d9a-9f5b-4cec113bf1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_5b600be5-46ad-47f8-a2dd-3aefd5cbc288" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c8e79a4f-ee05-41d1-bc46-1796ad6d81b7" xlink:to="loc_dei_EntityDomain_5b600be5-46ad-47f8-a2dd-3aefd5cbc288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CGOncologyInc.Member_8fafe551-14e3-40cb-b1ae-22fc0c3de24c" xlink:href="anip-20231231.xsd#anip_CGOncologyInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5b600be5-46ad-47f8-a2dd-3aefd5cbc288" xlink:to="loc_anip_CGOncologyInc.Member_8fafe551-14e3-40cb-b1ae-22fc0c3de24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d73ceef5-9ed5-492c-9fdb-12592c09ee78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_ec704027-318d-4f65-8440-ca2112052d4c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d73ceef5-9ed5-492c-9fdb-12592c09ee78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_c773c100-2dea-4b29-a67d-f93f24b26a29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d73ceef5-9ed5-492c-9fdb-12592c09ee78" xlink:to="loc_us-gaap_IPOMember_c773c100-2dea-4b29-a67d-f93f24b26a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_21ee9223-e4e5-4917-9707-dfc54d797940" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_8b4ede72-1bff-48f5-9cb1-7210be933046" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_21ee9223-e4e5-4917-9707-dfc54d797940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_CGOncologyInc.Member_a7b7c219-1a0d-48b2-95c7-6632c40745c7" xlink:href="anip-20231231.xsd#anip_CGOncologyInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_21ee9223-e4e5-4917-9707-dfc54d797940" xlink:to="loc_anip_CGOncologyInc.Member_a7b7c219-1a0d-48b2-95c7-6632c40745c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_3bd45a61-6f04-4cb4-800c-bbcf1e27c342" xlink:to="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5f77a58c-7cc5-4719-a27b-f751e874e8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5f77a58c-7cc5-4719-a27b-f751e874e8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e9b0ab1-f6c0-49c9-8bb4-3f8c85d6d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6e9b0ab1-f6c0-49c9-8bb4-3f8c85d6d33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5bab5c72-b770-4714-bcb2-a1662bb798c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5bab5c72-b770-4714-bcb2-a1662bb798c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_29929f2c-342f-4a8d-a2a1-337ef6c88ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_29929f2c-342f-4a8d-a2a1-337ef6c88ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_542f2ce1-bda7-44a2-ac3e-b43c6a469d37" xlink:href="anip-20231231.xsd#anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit_542f2ce1-bda7-44a2-ac3e-b43c6a469d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ec87d168-bcd3-4f7c-a65f-a60405ee9900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_ec87d168-bcd3-4f7c-a65f-a60405ee9900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_d247c6f2-32b5-46c4-a2b5-703e0878d8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_d247c6f2-32b5-46c4-a2b5-703e0878d8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_d0d289c8-36d7-46b3-831c-f88eda2ed581" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_d0d289c8-36d7-46b3-831c-f88eda2ed581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_2b88a143-29d7-4a52-b2d0-daa50e8f694a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_2b88a143-29d7-4a52-b2d0-daa50e8f694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtFairValue_ad44a11f-1aba-462b-8121-614b27f3586b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentOwnedAtFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_cc3e66f6-c7be-4132-83ed-1214ca288d30" xlink:to="loc_us-gaap_InvestmentOwnedAtFairValue_ad44a11f-1aba-462b-8121-614b27f3586b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_PerformanceSharesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:href="anip-20231231.xsd#anip_PerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_anip_PerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:href="anip-20231231.xsd#anip_MarketPerformanceBasedRestrictedStockUnitsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_anip_MarketPerformanceBasedRestrictedStockUnitsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.MuthusamyShanmugamMember" xlink:href="anip-20231231.xsd#anip_Mr.MuthusamyShanmugamMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_anip_Mr.MuthusamyShanmugamMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_anip_Mr.ChadGassertMember" xlink:href="anip-20231231.xsd#anip_Mr.ChadGassertMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_anip_Mr.ChadGassertMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>anip-20231231_g1.jpg
<TEXT>
begin 644 anip-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 1V"&,# 2(  A$! Q$!_\0
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MZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\
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MG_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\
MDFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZ
MJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\
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M^J?_ "31_P .N/V8O^B9_P#E?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\
MR31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9
MB_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]
M4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\
MY)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^
M5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7
M_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\
M*_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_
M ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/
MV8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5
M_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_
M .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ*
M/E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S
M%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__
M "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI
M_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#K
MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
ME?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4
M_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_ ,DT?\.N/V8O^B9_^5_5/_DFOJJB
M@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_X=<?
MLQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))KZJHH ^5?^'7'[,7_ $3/
M_P K^J?_ "31_P .N/V8O^B9_P#E?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^
MJ?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_P
MZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_
M )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_
M5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJ
MHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7
M'[,7_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$
MS_\ *_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*
M_JG_ ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?
M\.N/V8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G
M_P"5_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E
M?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^
MJJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_A
MUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\
M1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\
MROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-
M'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B
M9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\
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M31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\
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M,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\
M\K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH _FN^.US>?#'XY?$?PCX6U/4M&\
M.:'XFU33].T^WOYMEO!%=RHB ER3@ <DDGJ22<T4W]K'_DZ;XR?]CGK/_I=-
M10!^U/\ P2X_Y,3^&7_<3_\ 3I=U]55\J_\ !+C_ ),3^&7_ '$__3I=U]54
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\UG[6/_)T
MWQD_['/6?_2Z:BC]K'_DZ;XR?]CGK/\ Z7344 ?M3_P2X_Y,3^&7_<3_ /3I
M=U]55\J_\$N/^3$_AE_W$_\ TZ7=?55 !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117/>//B%X:^%_A
MJY\0^+==L?#NB6^!)?:A.L488]%!/5CV49)["@#H:*^)?$G_  5^_9]T'4'M
MK2Y\2>((U?9]JTW2ML1&?O#SGC;'_ <^U>L_ G]N[X,?M$:FND^%O%B0:\YQ
M'H^KQ&SN9O:,/\LIZ\(S$8R10!] T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !117BGQG_:\^'GP%^(/A?P9XKN=0AUOQ)Y?V!+6S,L;;Y?*7<P
M/R_-^E 'M=%%% !1110 4444 %%%% !1110 4444 %%%% !15?4-0M=)L+F^
MO;B*SLK:)II[B=PD<4:@EG9CP% !))X %?%?B3_@K_\  #0==GTZWE\2ZY#$
M[)_:.FZ8OV=L=U\V1'(/8[: /MRBJ6BZM#KVCV&IVZR);WMO'<QK,NUPKJ&
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MHHH ***QM7\9:%H.M:/H^HZO966K:S(\6G6,TZK/=LB%W$:9RVU5+$@8 '-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /YK/VL?^3IOC)_V.>L
M_P#I=-11^UC_ ,G3?&3_ +'/6?\ TNFHH _:G_@EQ_R8G\,O^XG_ .G2[KZJ
MKY5_X)<?\F)_#+_N)_\ ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH ****
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M]D?RT%TTEM&S9P ))45#D]/FYXQ7O44J31I)&ZR1N RNIR&!Z$'TKY$^,/\
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MN_:R^#_@7P7HWBW6OB%HMMX>UEG73;Z*?SQ>;&*2&)8PS.%888@8!ZXKA/\
M@I#_ ,F2_%+_ *\K?_TK@KX)_P""=O[$NB?M;?#VZ\7?%'4M3U'P[H$C>'=
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MB_1]#U[5=GV'3KZ[2*>YWOY:;%)RV7&T8[UVM?E7_P %,/\ D_K]GK_N%_\
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MC<W]T@XKZE_8+_8SM?V0?AQ>VU]>0ZMXSUUXY]8OK<'R4" B.WBSR43>YW$
ML7)P!@  ^1OC'$LW_!:'P2KC(#6#?B+)R/U K]5Z_.KXF? 'XAZQ_P %5/"G
MQ%L_">H7'@BU^R>=K:*/LZ;;1T;)SGAB!TK]%: /RI_X)-J/^&J/CXV!N E
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M_L;Z>0 "VM7Y/O\ ,M?:U?*7_!,WX8^*OA%^RW8^'O&6AW7A[6DU6\F:RO%
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MPY\'O@+X[^(WC'XG^)/''B#1]-,EG)<A;>$W#,D:;P[2NP+,/E#CMR:^@/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 444UW6-69F"JHR68X 'K0 ZBJ>DZ
MQ8:]8QWNF7MOJ-G)D)<6DJRQM@D'#*2#@@C\*N4 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ:)&W"&7&V6+/JDBNA]U- '<T5YI^T1^T!X6_9G^%^H>-_%DLGV*!E@MK2W
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MB/:OVB/V@/"W[,_POU#QOXLED^Q0,L%M:6X!GO+A@2D,8) W':QYX"JQ/ -
M'I=%?FWIG_!0']J'XE:?_P )%X _9M:?PI,#+:7%Y'<SM/%U#(X,0DR!U12/
M2O6OV0/^"C&F_M%>.KKX=>+/"=U\/_B';K(4T^XD9XKEH@3+& ZJ\<J@,QC8
M'A6.[C% 'V51110!^?\ ^Q+^V=\2?CK^UU\1_AYXJNM.F\-Z%9:E/9QVMDL4
MH:&_@@CW.#S\DC9]3@U^@%?D7_P3#_Y2'?&C_L&:U_Z=K2OL#]J[]NZ/]EWX
MX?#KP7J&@VEQH/B7R9-0UVYO6A_LV!KGRI)=@1MX1,OU&<8H ^M**_-O7O\
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MS:#\I0$XS@4 ?J'17%_!OXM^'_CI\,] \<^&)GFT;6+?SHEF $L+ E7BD )
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&(1$QD:-"KXW+G>M 'C?PC_X+1?#GQ%#:VOQ!\,ZOX0ORJB6]T\"^LMV/F;
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MBW%U#?PRJT#PE=PD#@X*XYSTQ0!^6'[2'_*8KX;?]=M(_P#06KZ _P""PO\
MR9^__8P6/\I:^2/''Q<T'XS?\%<_!NL>&;R+4M%L];T_3(;^!@T=RT*8D=".
M"N\N PX(4$<&OK?_ (+"_P#)G[_]C!8_REH [W_@FGX!TSP)^QOX!>QM5BN]
M:MY-6OI]FUYY99&(+>NU B#V05\5?\%CO!]MKG[1_P *(H8UAOM:TQ=/EG4
M%E^UE4S]/-:OT"_85_Y,_P#A)_V+]O\ RKX?_P""LG_)TWP#_P"V?_I<E 'Z
M@^%_#.F>"_#>EZ!HMG'I^D:9;1VEI:PC"Q1(H55'T %?EU\";6'P_P#\%EO'
MEGIT26=K.=1,D,*A5)>V25N!ZO\ -]:_5FORK^$/_*:/QK_V^_\ I"E 'FG_
M  4C^*&AZY_P4$T'1_'BW5UX \&KIL-_I]J-[2PR*EW.%7</FD65$/(.%'/
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M[<!B1RR%,DDG<3FOH+]J?6O&OAO]GGQWK/P[N/LOC'3=.:^L9?(CG(\IEDD
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?S6?M8_\ )TWQD_['/6?_ $NF
MHH_:Q_Y.F^,G_8YZS_Z7344 ?M3_ ,$N/^3$_AE_W$__ $Z7=?55?*O_  2X
M_P"3$_AE_P!Q/_TZ7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=[MW?9M2U2"WDQZ[7<'%;VDZQ8:_I\-_IE];:C8S#=%=6DJRQ2#U5E)!'TH
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MBDE )1)TF>0%">"5PPSG/&* /N*HKJZAL;66YN9H[>WA0R232L%1% R6)/
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M +9).L<QB>5&1I"SM&RPRK(CLP.0.A(H _7FBN2^$7CQ?BE\*?!OC%8!:_\
M"0:/::H;<'(B,T*2%,]\%B/PKK: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _FL_:Q_Y.F^,G_8YZS_Z7344?M8_\G3?&
M3_L<]9_]+IJ* /VI_P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_
M^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/E6P7/\ ST.G2B/_ ,?VU^IE 'Y:?L._$SQQ^RA^UAJ?[,'C_69]7\.3%XM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?S6?M
M8_\ )TWQD_['/6?_ $NFHH_:Q_Y.F^,G_8YZS_Z7344 ?M3_ ,$N/^3$_AE_
MW$__ $Z7=?55?*O_  2X_P"3$_AE_P!Q/_TZ7=?55 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?A;H/Q*^(G[+O[;/Q7\
M?:#\.=1\2M=:SK5E'%<65RL+1RWQ<2*R+S]P8[$&OH*U_P""K'QWOYA!:_L^
M27$[ [8XK6_=C@9Z!,FOU0HH _(3Q+\+/VMO^"C7B328/'^@M\,OA_8W0<V]
M[9R6$,!Y!E6VE;S[B782%8_)R<% QK]2_A%\*] ^"7PWT#P1X8MS;:+H]L((
M=^"\AR6>1R ,N[EG8X&2QZ5V%% 'Y6_M*_ #XK?L<_M2W?Q^^"GAZ;Q#X7U1
MI+C5=*LXWG\EI3FYAFA3YS"[?O5=<A&'.W:N[HKS_@L];ZUH,UEX6^$&N7?C
M9E,<=C-<"6WBE.%!/EIYC@,3\NU2< 9&<C],** /SQ_X)R_LJ_$;3?B1XH^/
M/QA2ZT_Q1X@,QM-(O 4G#S,&DN98\_NCMS&D9&55FR%^6M__ (*6?L@^*OBO
M-X7^+7PL@DE^(WA-D#6UJP6>ZMXY#+$\.>#+%)N8+U8.0,E54_=]% 'YF>'?
M^"QUWX?TE="\=_![7(?B';1^5-8V;_9XYY@#DF.5?,ASC[N'QSR:F_9!^ OQ
M-_:*_:EG_::^+^B2^%K*W_>:!HES&8WD/EM%#B-L.L42'<&8 NY5AD9K]+:*
M /S9_;Y_95^(W@_X[:+^T?\  [39M0U^S:.?6--L5,DYFC78)EA',L<D7[N1
M$^8@9P=S$5M-_P""T%K#HYT[5?A!K@\=0IY<NFVUT%@:8*=WWD\R,9Q\I1B
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MP#ILYO/[-B9[J]*[3<W,C%YI,=@68[1V4*,G&:]1HHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^:S]K'_DZ;XR?]CGK
M/_I=-11^UC_R=-\9/^QSUG_TNFHH _:G_@EQ_P F)_#+_N)_^G2[KZJKY5_X
M)<?\F)_#+_N)_P#ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#^:S]K'_ ).F^,G_ &.>L_\ I=-11^UC_P G3?&3_L<]9_\
M2Z:B@#]J?^"7'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-O['7[16D_"']H;5O\ A*?"^N21Q:?XFGE\UHA(VR.X2<@,\6_Y9%E^9/O
M@##_ *A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY8_\$V_^3IO#G_9%;;_TNM:_4Z@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RQ_P""
M;?\ R=-X<_[(K;?^EUK7ZG5^6/\ P3;_ .3IO#G_ &16V_\ 2ZUK]3J "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA?KRORB^/##X!?\ !7_P%KFEJ+&#Q<^GM=QQ+M207A>PE+ =<LF\_P"T,]:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[E"Q0QLRYY1&E>3^Z",\@@?I;I\.B_!_X8VT-U=1Z?X=\+:.J2W4ORI!:VT
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M+K6OU.H \P_M#XO_ /0)\)_^!,]']H?%_P#Z!/A/_P "9Z]/HH \P_M#XO\
M_0)\)_\ @3/1_:'Q?_Z!/A/_ ,"9Z]/HH \P_M#XO_\ 0)\)_P#@3/1_:'Q?
M_P"@3X3_ / F>O3Z* /,/[0^+_\ T"?"?_@3/1_:'Q?_ .@3X3_\"9Z]/HH
M\P_M#XO_ /0)\)_^!,]']H?%_P#Z!/A/_P "9Z]/HH \P_M#XO\ _0)\)_\
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MZ]/HH \P_M#XO_\ 0)\)_P#@3/1_:'Q?_P"@3X3_ / F>O3Z* /,/[0^+_\
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MST?VA\7_ /H$^$__  )GKT^B@#S#^T/B_P#] GPG_P"!,]']H?%__H$^$_\
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MTQQD?M(^"QWA9BZ=Y8'$1FNTDXO[U=/\#]"/[0^+_P#T"?"?_@3/1_:'Q?\
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M?"?_ ($ST?VA\7_^@3X3_P# F>O3Z* /,/[0^+__ $"?"?\ X$ST?VA\7_\
MH$^$_P#P)GKT^B@#S#^T/B__ - GPG_X$ST?VA\7_P#H$^$__ F>O3Z* /,/
M[0^+_P#T"?"?_@3/1_:'Q?\ ^@3X3_\  F>O3Z* /,/[0^+_ /T"?"?_ ($S
MT?VA\7_^@3X3_P# F>O3Z* /,/[0^+__ $"?"?\ X$ST?VA\7_\ H$^$_P#P
M)GKT^H;J[@L;>2XN9H[>WC&YY96"JH]23P*!I-NR/-O[0^+_ /T"?"?_ ($S
MT?VA\7_^@3X3_P# F>LGQQ^U]\*? OF)<>*;?5;I/^7;1P;MB?3<GR _5A7S
M[XX_X*42-YD7@_P@J?W+O6YL_G#&?_:E82K4X[L^NR_A+.\RLZ&&DHOK+W5_
MY-:_RN?3']H?%_\ Z!/A/_P)GKFO&'Q<\9_#^ R^([WP#HPQD)=ZE*DC_P"Z
MGWF_ &O@OQQ^UM\5?'GF1W?BNYTZT?C[+I %HH'IN3#D?[S&O([BXENIGFGD
M>:9SN:21BS,?4D]:Y98Q?91^DY?X65I6EF&(4?*"O^+M;[F?<7B/_@H?>:/,
M8K"PT;7"/^6MJES''^<FT_\ CM>;>+/^"A/Q,UZ!H=+ATCPXIZ36EL99OSE9
ME_\ ':^9K>VFO)T@@B>>:0[4CC4LS'T '6O7/ _[)/Q5\>>7):>%+G3K1^?M
M6KD6B@>NU\.1_NJ:YG6K5-(_@?=TN$N%\A@JN+47YU9+\G:+^XX7QA\3O%OQ
M FW^(_$>I:SSD1W=RS1K_NIG:OX 5S-?<?@?_@FN?W<OC#Q?C^_::)#_ "FD
M'_M.OH#P/^R#\*? OEO;^%K?5;I/^7G6";MB?7:_R _113CA:L]9'/BO$'(,
MMA[+!ISMLH1M'[W;\$S\G**^POVF_P!E'XD^.?C?XCUOPKX3CN= N!:K:R17
MMI I"6L4; (TBE<,K#D#IZ5Y?_PQ)\:?^A,_\JME_P#'JQE1FFTD_N/K,'Q1
ME&)PU.O4Q5.$I13<74C>+:O9ZK5;/1'AM%>Y?\,2?&G_ *$S_P JME_\>H_X
M8D^-/_0F?^56R_\ CU3[*I_*_N.O_6+)O^@VE_X,A_F>]?L)77CN'X1ZNOA>
MQT.YT_\ MR8N^I2RI()/L]OD +QMQM_'-?1O]H?%_P#Z!/A/_P "9ZXW]BGX
M6^*/A'\*]5T?Q9IG]E:C/K4MW'#]HBFS$T$"!MT;,/O(PQG/'TKZ!KVZ*:II
M,_DCBJM2Q&=XJK1DI1<M&G=/T:/,/[0^+_\ T"?"?_@3/1_:'Q?_ .@3X3_\
M"9Z]/HK8^4/,/[0^+_\ T"?"?_@3/1_:'Q?_ .@3X3_\"9Z]/HH \P_M#XO_
M /0)\)_^!,]']H?%_P#Z!/A/_P "9Z]/HH \P_M#XO\ _0)\)_\ @3/1_:'Q
M?_Z!/A/_ ,"9Z]/HH \P_M#XO_\ 0)\)_P#@3/1_:'Q?_P"@3X3_ / F>O3Z
M* /,/[0^+_\ T"?"?_@3/1_:'Q?_ .@3X3_\"9Z]/HH \P_M#XO_ /0)\)_^
M!,]']H?%_P#Z!/A/_P "9Z]/HH \P_M#XO\ _0)\)_\ @3/7P]_P5ZNO'<W[
M-?AI?%%CH=MI_P#PEML4?3997D,GV.]P"&XVXW?CBOTPKX _X+5_\FL^%O\
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M+9(FA.NZNRM)"C?>6%% 6,'N>6P2-V#BOIFBB@ HHHH **** /RQ_P"";?\
MR=-X<_[(K;?^EUK7ZG5^6/\ P3;_ .3IO#G_ &16V_\ 2ZUK]3J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX%VJH%:]?S1GG$V,S;'2Q5.<J<=HI-JR7>W7JS[/"X*GAZ2@TF^IXC=?L4_
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MDK_<CR(Y'!X-)7O/A?P+XB\<7)MO#^A:AK<N<,MC:O-M_P!XJ" /K7NG@O\
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M*DG%[,>VI_0-\/?$_P#PFW@#PSXBV>7_ &OIEK?[!_#YL2R8_P#'JZ"ORG^
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M (+5_P#)K/A;_L<[7_TAOJ /5?\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\
M)B?PR_[B?_ITNZ^JJ "BBB@ HHHH _FL_:Q_Y.F^,G_8YZS_ .ETU%'[6/\
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ML72_\O&LN;HG_@#?NQ^"BO::*ZHT*<=D?G&/XNSO,KJMB9)/I'W5_P"2VO\
M.Y!8V-MIEK';6=O%:6T8PD,"!$4>@ X%3T45N?(-N3NPHHHH$%%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$N4_\<KWGP7_ ,%"/AOX@\N/6X-3\,3G[S7$'VB ?1H\M^:"OB_QI^RK\4_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW'0K@ ]__P""T/Q.N_"_P%\+^#[.Y>W_ .$HU8O=JG_+:VMD#F,^WFR0-_P
M>]?6G[*_P?TSX%_ 'P5X2TZTCMI+;3H9K^2- #<7DB*T\K'J27)QGHH4= *_
M/O\ X+E-(;[X,*V1 (]8*G'\1-EN_0+7ZM=.!P* /R__ ."Q_P /X/!.H?#'
MXR^'8ETKQ1:ZI]AGU"W4*\LB*)[5V(ZLABD )YP0.BC'Z/?#?QA%\0_AWX6\
M50*J0ZYI5KJ:*IR LT*R  _\"KXH_P""TOE?\,J^'?,^_P#\)A:>7U^]]CO?
MZ;J^F/V-UE7]D[X/B8 /_P (III&/[IMDV_IB@#V*ORD_;=C/[2?_!2OX8?!
MZ_FDE\,Z0+5+NQR0I\P&[NB/0O;K$F>VT>]?JW7Y26;22?\ !=%C,#O\QP,C
ML/#9V_IB@#]5+*QMM-L8+*TMXK6SMXUAAMX4"1QHHPJ*HX"@   < "ORCUVQ
ML_V3?^"NV@1^'88])\.^-C;QRZ? /+AVWP,+* . OVJ,2 #@$ #@5^L=?E'_
M ,%%UW_\%*OV?1;C=>M%H0"D''_(9GV?KF@#U'_@M#\3KOPO\!?"_@^SN7M_
M^$HU8O=JG_+:VMD#F,^WFR0-_P  'O7UI^RO\'],^!?P!\%>$M.M([:2VTZ&
M:_DC0 W%Y(BM/*QZDER<9Z*%'0"OS[_X+E-(;[X,*V1 (]8*G'\1-EN_0+7Z
MM=.!P* /R_\ ^"Q_P_@\$ZA\,?C+X=B72O%%KJGV&?4+=0KRR(HGM78CJR&*
M0 GG! Z*,?H]\-_&$7Q#^'?A;Q5 JI#KFE6NIHJG("S0K( #_P "KXH_X+2^
M5_PRKX=\S[__  F%IY?7[WV.]_INKZ8_8W65?V3O@^)@ _\ PBFFD8_NFV3;
M^F* /8J*** "BL'QEKFJ>']+BN-(T&;Q%<M,(VM89TA*J58E\MQ@$ 8_VJX[
M_A9GC;_HE]__ .#.#_"@#X _X)M_\G3>'/\ LBMM_P"EUK7ZG5^6'[%K#P3\
M>M$U3PVP\:ZI'\,8--32;96MWDLQ=0,+X.P("EE5=A&[Y\]J^\?^%N>//^B3
MW_\ X,D_^-T >O45YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P
M?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P?X4 >GT5
MYA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM
M_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\
M_P &<'^%'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%
M'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_
M $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_
M  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P?X4
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M_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\
M_P &<'^%'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%
M'_"S/&W_ $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_
M $2^_P#_  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_
M  9P?X4 >GT5YA_PLSQM_P!$OO\ _P &<'^%'_"S/&W_ $2^_P#_  9P?X4
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M;_HE]_\ ^#.#_"C_ (69XV_Z)??_ /@S@_PK\^E)R;E)W;/5VT1Z?17C&O\
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M++S:==\6:1I:GM90R7;#ZAO+&?QKZX_X69XV_P"B7W__ (,X/\*/^%F>-O\
MHE]__P"#.#_"MXX2FM]3Y#%>)6>5]*/)3](W?_DS:_ ^!OVJOV:M-_9WM_"0
ML=9NM9GU?[7Y[W$2QJOE>3MVJ,XSYK9R3T%?/]?I)\=/AYJ/[07]B?\ "1?#
MWQ)9?V1Y_D?V9K%I'N\WR]V[?$^<>4N,8ZGK7E/_  Q;I?\ T)7CK_P?:?\
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MSQ1H6GZ_8')$.H6ZRA2>ZY&5/N,&N0_X69XV_P"B7W__ (,X/\*/^%F>-O\
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M /X,X/\ "@#T^BO,/^%F>-O^B7W_ /X,X/\ "C_A9GC;_HE]_P#^#.#_  H
M]/HKS#_A9GC;_HE]_P#^#.#_  H_X69XV_Z)??\ _@S@_P * /3Z*\P_X69X
MV_Z)??\ _@S@_P */^%F>-O^B7W_ /X,X/\ "@#T^OPWK]>?^%F>-O\ HE]_
M_P"#.#_"C_A9GC;_ *)??_\ @S@_PKFK4?;6UM8_0>$^+/\ 5?V_[CVGM.7[
M7+;EYO[LKWYO+8_(:BOUY_X69XV_Z)??_P#@S@_PH_X69XV_Z)??_P#@S@_P
MKE^I?WOP/T#_ (BQ_P!0/_E3_P"T/R&K]C_@3_R0_P"'G_8NZ=_Z31UD_P#"
MS/&W_1+[_P#\&<'^%'_"S/&W_1+[_P#\&<'^%=-&A[%MWN?#\5<9?ZS4:5'Z
MO[/D;?Q<U[JW\L3T^BO,/^%F>-O^B7W_ /X,X/\ "C_A9GC;_HE]_P#^#.#_
M  KJ/S8]/HKS#_A9GC;_ *)??_\ @S@_PH_X69XV_P"B7W__ (,X/\* /3Z*
M\P_X69XV_P"B7W__ (,X/\*/^%F>-O\ HE]__P"#.#_"@#T^BO,/^%F>-O\
MHE]__P"#.#_"C_A9GC;_ *)??_\ @S@_PH ]/HKS#_A9GC;_ *)??_\ @S@_
MPH_X69XV_P"B7W__ (,X/\* /3Z*\P_X69XV_P"B7W__ (,X/\*/^%F>-O\
MHE]__P"#.#_"@#T^BO,/^%F>-O\ HE]__P"#.#_"C_A9GC;_ *)??_\ @S@_
MPH ]/HKS#_A9GC;_ *)??_\ @S@_PH_X69XV_P"B7W__ (,X/\* /3Z*\P_X
M69XV_P"B7W__ (,X/\*/^%F>-O\ HE]__P"#.#_"@#T^BO,/^%F>-O\ HE]_
M_P"#.#_"C_A9GC;_ *)??_\ @S@_PH ]/HKS#_A9GC;_ *)??_\ @S@_PH_X
M69XV_P"B7W__ (,X/\* /3Z*\P_X69XV_P"B7W__ (,X/\*/^%F>-O\ HE]_
M_P"#.#_"@#T^BO,/^%F>-O\ HE]__P"#.#_"C_A9GC;_ *)??_\ @S@_PH ]
M/HKS#_A9GC;_ *)??_\ @S@_PH_X69XV_P"B7W__ (,X/\* /3Z*\P_X69XV
M_P"B7W__ (,X/\*/^%F>-O\ HE]__P"#.#_"@#T^BO,/^%F>-O\ HE]__P"#
M.#_"C_A9GC;_ *)??_\ @S@_PH ]/HKS#_A9GC;_ *)??_\ @S@_PH_X69XV
M_P"B7W__ (,X/\* /3Z*\P_X69XV_P"B7W__ (,X/\*/^%F>-O\ HE]__P"#
M.#_"@#T^BO,/^%F>-O\ HE]__P"#.#_"C_A9GC;_ *)??_\ @S@_PH ]/HKS
M#_A9GC;_ *)??_\ @S@_PH_X69XV_P"B7W__ (,X/\* /3Z*\P_X69XV_P"B
M7W__ (,X/\*/^%F>-O\ HE]__P"#.#_"@#T^BO,/^%F>-O\ HE]__P"#.#_"
MC_A9GC;_ *)??_\ @S@_PH ]/HKS#_A9GC;_ *)??_\ @S@_PH_X69XV_P"B
M7W__ (,X/\* /3Z*\P_X69XV_P"B7W__ (,X/\*/^%F>-O\ HE]__P"#.#_"
M@#T^BO,/^%F>-O\ HE]__P"#.#_"C_A9GC;_ *)??_\ @S@_PH ]/HKS#_A9
MGC;_ *)??_\ @S@_PH_X69XV_P"B7W__ (,X/\* /3Z*\P_X69XV_P"B7W__
M (,X/\*/^%F>-O\ HE]__P"#.#_"@#T^O@#_ (+5_P#)K/A;_L<[7_TAOJ^L
M/^%F>-O^B7W_ /X,X/\ "OA[_@KUXP\1>(/V:_#5OJ_@VZ\.VR^+;:1;J:\C
MF#,+.] 3"\Y().?]F@#Z&_X)<?\ )B?PR_[B?_ITNZ^JJ^5?^"7'_)B?PR_[
MB?\ Z=+NOJJ@ HHHH **** /YK/VL?\ DZ;XR?\ 8YZS_P"ETU%'[6/_ "=-
M\9/^QSUG_P!+IJ* /VI_X)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\
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M&ODK]E/_ ()N6_P>^)#_ !0^)?BZ;XE?$4NTL-S<!V@MYF&#.6D)>:7&0';
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M\+O">PZ?X&T?>@PLEW;BZ<>X:7<<^^<U<<)-[L\S%>)V44=,/3G-^B2_%W_
M_)'1_#^J>(;CR-*TV\U.;_GG9P/*WY*#7I_AO]DGXN>*-IMO!-_:HV"6U(I:
M8'N)64_AC-?K)9V=OI]ND%K!';0(,+%"@15^@' J:MHX./5GR&*\5,7+_=<-
M&/\ B;E^7*?G3X<_X)Q^/-0VOK&NZ)H\9Q\L327,H]<@*J_^/5ZIX<_X)L^$
M[/:=<\6:OJA')%E#%:*?J&\PX_&OL*BMXX:DNA\?BN/N(,5HJ_(NT8I?C9O\
M3Q+PW^QC\(?#>UU\)QZC,ISYFI7,L^?JA;9_X[7J7A_P/X<\)H$T/0-,T=1V
ML+..#_T%16W16\81CLCX_%9IC\=_O5><_P#%)O\ -A1115GF!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^*O!N@^.=
M)DTOQ%HUCKFG2?>M=0MTFCSCJ P.#[CD5\B?%[_@E[X"\7>=>>"-2NO!=^V6
M%J^;NR)ZX"L=Z9]G('9>U?:=%>UEV=9AE,N;!5G#RZ/U3T?W'-6PU+$*U2-S
M\4_B]^Q#\6O@[YUQ>^'7UW2(\DZIH.;J(+ZLH D0>[*![UX-TX-?T2UX_P#%
MS]DSX6_&I9I?$/A>VBU23)_M;31]EN]Q_B+I]\_[X8>U?KV5>)LE:GFE&_\
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M***\DW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^
M/^"U?_)K/A;_ +'.U_\ 2&^K[_KX _X+5_\ )K/A;_L<[7_TAOJ /5?^"7'_
M "8G\,O^XG_Z=+NOJJOE7_@EQ_R8G\,O^XG_ .G2[KZJH **** "BBB@#^:S
M]K'_ ).F^,G_ &.>L_\ I=-11^UC_P G3?&3_L<]9_\ 2Z:B@#]J?^"7'_)B
M?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /RQ_P"";?\
MR=-X<_[(K;?^EUK7ZG5^6/\ P3;_ .3IO#G_ &16V_\ 2ZUK]3J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX"-2O_CPK]):*WCA(+?4^/Q7B=G%;2A"%->C;_%V_ ^+O#?_  33T6#:VO\
MC6_O><F/3;1+?'MN<R9^N/PKU3PW^PW\(O#VUI=!N-9F4Y$FI7LC_FJ%4/XK
M7OM%;QH4X[1/C\5Q=GN,_BXN2_POE_\ 2;'+^&_A;X.\';/[#\+:/I3J<B2T
ML8XWSZE@N2?<FNHHHK9)+8^6JUJE>7/5DY/NW?\ ,****9B%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ"BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:?.8;J"2VF !,<R%6 (!!P?4$'\:^PRG),/E#DZ=24Y2ZR:Z=DDDON/S//\
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M#&UN8;D+][R9 ^/K@U8K\X::T9[ 4444@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKJZAL
M;:6XN)5A@B4N\DAPJJ.I)JKKFNZ?X9TFZU35;R'3].M8S+/<W#A$C4=22:_+
MK]LC]O*?XK_:O"'@5[BQ\**VRXOF^22^QUP!RL?XY/H*^BR;(<=GE7V>$A=+
M=]%\^_D3[;#TY+ZQ4Y(]]7^"U9^B7PM^/?@CXRW.L6_A36HM0N-*N&M[B+&U
MN/XU!Y9#SAAP<&O0J_ GX8_%3Q!\)/%UIXB\.W9M;ZW/(R=LBYY5AW%?J_\
MLR?MQ^$?CXMMH]ZO_".^+=F&L;B13'<,!R8FXSZX('XU[^=\&9CE,'B(TW*F
MMVK-KUMT\RL1C,LG5Y<#5YD^C33_ ,F?2]%%%?GP!1110 4444 %%%% !111
M0 4444 %%%% !1110 5\ ?\ !:O_ )-9\+?]CG:_^D-]7W_7P!_P6K_Y-9\+
M?]CG:_\ I#?4 >J_\$N/^3$_AE_W$_\ TZ7=?55?*O\ P2X_Y,3^&7_<3_\
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MH-^B.FCA:^(=J,'+T39] 45^?7CK_@K!:)YD7@WP)--_<N]=NQ'CZPQ;L_\
M?P5\\^-_^"@7QL\=-)%#XAB\.VTG_+MH-HL./I(V^4?@]>W2R+&5-9I17F_\
MKGT>'X8S"O;FBH^K_17/U_U;6+#0;%[W4[ZVTZSC^_<7<RQ1K]68@"O#_'7[
M=7P5\">9'+XRM]:NEZ6^AQM>;OI(@\O\W%?D!XDUSQ-XPO/MWB+5M0U6Z/\
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MKV.OD:M*I1ER5(V?F?"5J%7#S=.M%Q?9A11161@%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!5?4-/M=6LIK.^M8;VTF79+;W$8DC=?1E(P1]:L44TVG= ?"7[;W[&OPP\-_
M"#Q/\0/#FB2>'-;TU89!;Z7)LM)M\\<9W0D%5 #D_N]G('6OS&K][_C=X!'Q
M2^$GBSPKTEU/3Y(H2>@F W1G\'537X/ZYHMYX<U>[TS4()+:\M9#%+%(,,K
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M^%_C/(..- NR/S\NJ5S\"?B59S&*X^'OBJ"4=4DT2Y5A^!2C_5+A*>D81_\
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MU]][>1^@9?6E7P\92WV"BBBOBCT@HHHH **** "BBB@ HHHH **** "BBB@
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M_P#)TWAS_LBMM_Z76M?J=7Y8_P#!-O\ Y.F\.?\ 9%;;_P!+K6OU.H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BL[7?$>D^%[%KW6=4L](LU^]<7UPD,8^K,0*\)\=?M\_!7P/YD?_"5?
M\)!=)_R[Z% USN^DG$1_[[KHI8>M7=J4&_1'51PM?$NU&#EZ*Y]#T5^>_C;_
M (*L.RR)X-^'[%?X+W7;O _&*,?^U*^>?'7[>_QH\:^9&WB^'PW:O_R[Z# L
M./I( T@_[[KW\+P[F&+=H0_5_=&Y[#R.O17-C)PHK^_)(_7[6_$&E^&K%KW5
M]2L]*LU^]<7TZ0QCZLQ KPSQU^WE\%? OF1MXM37KI/^7?0H6NMWTD&(O_'Z
M_'O7_%5]XGOFO=:U;4M=O6^]/?3M(Y_X&Y8UF?;D7_5VR#T,A+'^@_2OM<'X
M?XRK9U(NWRC^;<OP.>5;AS!_[QC'4?:$7^=K/[T?HCXY_P""L$0\R'P9X#D?
M^Y=ZY=!?IF&+/_HRO ?&_P"WI\<O&RN@\0IX9LY/^66CVR6H'TE?=(/P>OFI
MM2N>BRF(>D0"?RQ59F+,2Q))ZDU]M@_#^%.SJ.*^3G^?+;[CEEQADN$_W+ N
M;[S:7X>_^:.D\1>)-5\57QO?$/B&ZUB]/6:^NI+J4^OS,3_.LHSV4?03S_E&
M/_9JSZW/#/@7Q)XVG,/A[P_JFO3 [3'IEE)<,#Z8137U=/A;+\/'FKSDTN[4
M5^"37WGFU_$+-ZON8:$*?:T;O_R9M?@43J87_56L*?[3 N?U./TICZM=NNW[
M0Z+_ '8_D'Y#%>^>#_V _CAXP*,/![:+;M_RWUBZBM]OU0L9/_':]P\'_P#!
M)GQ)=!'\4^/-,TSNT.DVDEV?IN<Q8/X&N2IF/">5ZRG3NNWOR^]<S/GZV:\0
MYCI5K5&GTORQ^Y67X'P226.3R:2OUG\(?\$OOA%H/EOK%QKOB:4??2ZO!!"Q
M]EA56 _X&:]P\'_LQ?"?P'L;1?A_H-O,GW;B:S6XF7Z22[F'YUXN*\2LJHZ8
M>G.;]%%?B[_@>=#)J\M9M+\3\3/"?PU\6^/)!'X;\,:QKS$X_P");8RS@?4H
MI _&O;O!_P#P3T^-_BW:\GAB'0+=NDVL7L47YHI:0?BM?LE'&D,:QQHJ1J J
MJHP !T %.KX[%^)V/J76%H1AZMR?_MJ_ ]"GDM)?')O\/\S\V_!__!);5YO+
MD\5?$"RL^\EOH]B]QGV$DC)CZ[#]*]P\'_\ !,CX-^'=CZI'K7BB08+#4+\Q
M1Y]A L9Q]2:^M**^-Q?&6>XRZEB7%?W;1_%)/\3T:>786GM"_KJ>=^#_ -G;
MX8^ ?+;0? >@V$T?W;G[#')./^VK@O\ K7H8 4  8 I:*^2K8BMB9<]>;D^[
M;?YG?&$8*T58****YRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "JFJZ38Z[IUQI^I6=OJ%A<)Y<UK=1++%*I_A96!!'L:MT4]M4--IW1\8_'#
M_@F=X+\;>?J/@.[/@O5FRWV)@TUA*WIMSNBR>ZD@=DKX ^,7[-OQ"^!5X4\5
M^'YK>Q+[(M5MOWUG+Z8E7@$_W6VM[5^YM07UC;:I9S6EY;Q7=I,I26"= Z.I
MZAE/!'L:^BP>>8G#VC4]^/GO]_\ G<^LP'$F+PEHU?WD?/?[_P#.Y_/;'(\,
MBR1LR2*0RLIP01T(-?4?P/\ ^"AOQ)^%?V>PUV;_ (3G0(\+]GU.0BZC7_8N
M,%O^^PX[#%?6WQP_X)L^ OB#]HU+P;*W@;6GRWD0)YFGR-[Q=8_3]V0H_N&O
MS\^-'[+GQ&^ ]PY\3:#(VE[MJ:Q89GLW]/W@'R$]E<*?:OKJ>,P&:Q]G.U^S
MW^7_  #[NCC\LSR'LJB3?:6C^3_R9^J?P0_;'^&GQT6"UTK6!I&OR8!T35BL
M%P6](SG;+W^X2<=0*]PK^>56*L"#@CD$5]+? _\ ;]^)GPA\BQU"\_X33P_'
MA?L.L2LTT:^D5QRR\< -N4#H!7B8SAUJ\L++Y/\ 1_Y_>?.8_A.2O/!2O_=?
MZ/\ S^\_82BO O@?^VS\,OC@;>QM=4_X1_Q%+@?V/K!$4CMZ1/G9+ST .['5
M17OM?(5J-3#RY*L6GYGP5?#UL+/V=:+B_,****P.<**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNY;"(\:I:0O):LO8^8!@?3-?T;PIQ7A<XPL*->:C7BK--_%;JN]^O6Y^>X[
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M#"YQEB2 ,_9?_;T^%W[5EU-I?ANZO-'\30QF9]"UJ-8KAXQU>(JS)(!WVMN
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MX:7)6BTSX#$86OA)^SKP<7Y_UJ+1117.<H4444 %%%% !1110 4444 %%%%
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M_;S_ *1[$<ERC KFK)>LG_PR_ I>,OVN/C#X\WKJOQ UA(7X:#3Y191D>A6
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?
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M_&C_ (7YIO\ T*_BS_P4-_C7I]% 'F'_  OS3?\ H5_%G_@H;_&C_A?FF_\
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MA_POS3?^A7\6?^"AO\:/^%^:;_T*_BS_ ,%#?XUZ?10!YA_POS3?^A7\6?\
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MA_POS3?^A7\6?^"AO\:/^%^:;_T*_BS_ ,%#?XUZ?10!YA_POS3?^A7\6?\
M@H;_ !H_X7YIO_0K^+/_  4-_C7I]% 'F'_"_--_Z%?Q9_X*&_QH_P"%^:;_
M -"OXL_\%#?XUZ?10!YA_P +\TW_ *%?Q9_X*&_QH_X7YIO_ $*_BS_P4-_C
M7I]% 'F'_"_--_Z%?Q9_X*&_QH_X7YIO_0K^+/\ P4-_C7I]% 'F'_"_--_Z
M%?Q9_P""AO\ &C_A?FF_]"OXL_\ !0W^->GT4 >8?\+\TW_H5_%G_@H;_&C_
M (7YIO\ T*_BS_P4-_C7I]% 'F'_  OS3?\ H5_%G_@H;_&C_A?FF_\ 0K^+
M/_!0W^->GT4 >8?\+\TW_H5_%G_@H;_&C_A?FF_]"OXL_P#!0W^->GT4 >8?
M\+\TW_H5_%G_ (*&_P :/^%^:;_T*_BS_P %#?XUZ?10!YA_POS3?^A7\6?^
M"AO\:/\ A?FF_P#0K^+/_!0W^->GT4 >8?\ "_--_P"A7\6?^"AO\:/^%^:;
M_P!"OXL_\%#?XUZ?10!YA_POS3?^A7\6?^"AO\:/^%^:;_T*_BS_ ,%#?XUZ
M?10!YA_POS3?^A7\6?\ @H;_ !H_X7YIO_0K^+/_  4-_C4_CK]I#X8?#42#
MQ%XXT:QGC^_:QW(GN!_VQCW/_P".U\[>.O\ @J5\.M#\R+PSH.L^*+A?NR2A
M;*W;_@3;G'XQUWT<!BL1_#IM_E][T/3P^68S%?P:3:[VLOO>A]!?\+\TW_H5
M_%G_ (*&_P :#\?M,4$GPQXL _[!#?XU^>GCK_@I]\4_$7F1>'[+1O"4!^Y)
M#;FZN!]6E)0_]^Q7SOXZ^.7Q!^)F\>)_&.LZQ"_)M9[MQ;CZ1 A!^"U[E'AW
M$SUJR4?Q?^7XGTF'X3Q=36M)07WO_+\3]6?$7[>7PI\*3/#JE[J%K<)]ZW^S
M*TH^J!R1^5>5>,O^"JO@;3867PQX4UO7+D=#?/%90_4,#(W_ (Z*_,*KND:+
MJ'B"^2RTNPNM2O)/N6]G"TLC?15!)KW*/#^$IZU6Y?@OP_S/I*'"N!HKFK2<
MOG9?AK^)]5^._P#@IM\6?$WF1:''I'A*W/"M9VOVB<#W>8LOXA!7SGX\^+7C
M/XH7"3>+/$^J:^8V+1QWUTSQQ$]=B9VI_P ! KU/P)^PC\:O'GER1^$)M"M6
MZW&O2+9[?K&W[W\DKZ)\"?\ !)^=O+E\9^.HX_[]IH-J6SZXFEQ_Z+KI^L97
M@/A<4_+5_A<Z_K62Y7\#BFNVK^]7?WGY[T5^J_B__@F7\,Y_A[?:;X:_M"T\
M3 >9:ZS?WC2L6 /R.@VQ[6[D*"."#V/YF_$+X=ZY\+_%-YH'B"R>RO[9BI#
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M*8%:O_"_--_Z%?Q9_P""AO\ &O3Z*\QMR=V>/*3D[MW9YA_POS3?^A7\6?\
M@H;_ !H_X7YIO_0K^+/_  4-_C7I]%(1YA_POS3?^A7\6?\ @H;_ !H_X7YI
MO_0K^+/_  4-_C7I]% 'F'_"_--_Z%?Q9_X*&_QH_P"%^:;_ -"OXL_\%#?X
MUZ?10!YA_P +\TW_ *%?Q9_X*&_QH_X7YIO_ $*_BS_P4-_C7I]% 'F'_"_-
M-_Z%?Q9_X*&_QH_X7YIO_0K^+/\ P4-_C7I]% 'F'_"_--_Z%?Q9_P""AO\
M&C_A?FF_]"OXL_\ !0W^->GT4 >8?\+\TW_H5_%G_@H;_&C_ (7YIO\ T*_B
MS_P4-_C7I]% 'F'_  OS3?\ H5_%G_@H;_&C_A?FF_\ 0K^+/_!0W^->GT4
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M*'"F#I:UI.7X+_/\3[$\=?\ !43XE^(/,B\-Z3HWA2!ONR^6;RX7_@4F$/\
MW[KYV\=?M!?$CXF>8GB7QKK.J6\GWK5KIH[<_P#;%,)_X[76^!/V+?C-\0?+
M>Q\#W^G6S<_:=9VV* ?WL2E68?[JFOHGP)_P2BURZ\N7QCXWL=.7JUKHMN]R
MQ]O,DV!3_P !:NOVF58#;E3\M7^K.WVV299\/*FNWO/]6?!%6=-TN\UB\CM+
M"TGOKJ0X2"VC:1V^B@$FOUW\"?\ !.OX,>#/+DN]'O?%-TG/FZU=LRY_ZYQA
M$(]F!KW_ ,+>!O#G@>S^R^'= TS0;;&#%IMI' I^H0#/XUP5N)*,=*4&_73_
M #/,Q'%V'AI0IN7KHOU/QW\"?L/_ !H\?>6]MX+NM(M6Y-QK;+9!1Z[)")#^
M"FOHCP)_P2AU*;RY?&7CFVM1_':Z';-,3["63;C_ +X-?HY17AUL_P 94TA:
M/HO\SYO$<48^MI3M!>2_SN?-G@3_ ()Z_!;P3Y<DV@7'B:Z3I/KETTH/UC39
M&?Q4U[YX;\(Z%X-L19Z!HNGZ'9_\^^G6L=O'Q_LH *UZ*\.MB:U?^+-OU9\W
M7QF(Q+O6J.7JPHHHKF.0*\Q^+O[./@7XX7NCWGBK2C<W6ESK-%-"_EM(H.?*
MD./F0]QU]"*].HK2G4G2ESTW9FM*K4HRYZ<FGW17L+"VTNR@L[.".VM8$$<4
M,2A510,  58HHK,RW"BBB@ HHHH **** "BBB@ HHHH 9+$DT;1R(LD;#:RL
M,@@]B*YS5/AAX.UMB=1\):'?ECDFZTV&3/&/XE/:NFHJHRE'X78N,Y0UB['E
M6I_LJ_![5O\ 7_#7PS'T_P"/73H[?I_US"UR&J?L"_ G5%.[P,MM)C >UU&[
MCQSGH)=OYBOH2BNF.,Q,/AJ27S9UPQ^+I_!6DO\ MY_YGR;JG_!,KX-:AN\@
M>(-,W;L?9=1#;<],>8C].V?QS7(ZI_P2D\!S%O[-\9>(K09X^U+!/CC_ &43
MO7W!175'-<;':J_S_,[89UF,-JS^>OYGYXZG_P $E>K:=\3?3]W=:)^9W+/_
M $KD-3_X)2^/H0?[.\8>&[HXX^U"XAYS_LQOV_SWK]/:*ZHYYCX[SO\ )?Y'
M9#B3,X[U+^J7^1^2FJ?\$R_C-I^[R$T#4\;L?9=1*[L=,>8B=>V?QQ7(ZI^P
M-\=M*+%O LES&#P]KJ-I+GC/02[OS%?LS173'B+%QW47\G_F=D.+,?'>,7\G
M_F?AQJ?[*WQATG_7_#3Q,_3_ (]=-DGZ_P#7,-7(:I\,_&&B G4?"FN6  R?
MM6G31X&<9^91WXK]]J*ZH\2U?M4T_G_PYVPXOK+XZ*?HVO\ ,_GFDC>&1HY$
M9)%)5E88((Z@BFU_0?J.CV&KQ^7?V5O>QX*[;B)9!@]1@CO7*:I\#?AQKFXZ
MCX \+WS-R6N-&MW.<8SDIUQWKICQ+#[5+\?^ =D.,(/XZ+7H[_HC\&Z*_;74
MOV-_@IJV?/\ ASHR9Q_Q[(\'3_KFRUR&J?\ !.SX%Z@#Y/A:ZTTD?>M=5NCW
MSG]Y(P]JZH\1X5_%&2^[_,[8<6X)_%"2^[_,_'N.1X9%DC9DD4AE93@@CH0:
MZ/2_B;XPT10-.\5ZY8 # %KJ,T>!G./E8=Z_3/5?^"7'PEOMS6NJ^*=.;YBH
MBO8'09Z9#PDD#Z_C7(ZI_P $G?#,V[^SO'^K6HSQ]JL8I\<?[+)WKH_MS 5/
MB?WK_ASJ7$F5U=)M_./_  Y\4Z9^U5\8=)_U'Q+\3/U_X^M2DGZ_]="U==I?
M[?/QVTMAM\=/<IG)2ZTZTDSQCJ8MWY&O>M3_ ."3&KQ9_L_XD65UTQ]JTEX?
MK]V5ZY#5/^"5_P 4;4%K+Q!X5OE ^ZUS<1.3GL#"1TYY-'US**N_+\X_YH/K
M^15]^1^L?\T86E_\%-/C-I^WSWT#4\;<_:M.*[L=<^6Z=>^/PQ77:7_P5:\?
M0J/[1\'>'+HXY^RFXAYS_M2/VK@-5_X)O_&_3]WV?1--U/;NQ]EU2%=V.F/,
M*=>V?QQ7(ZI^Q'\<='W"?X>:A)M.#]EF@N.V?^6<C9H]CD]7;D^]+]0^KY#6
MV]G]Z7ZH^G-,_P""M71=1^&7K^\M=;_(;6@_K77:7_P5;\!S,/[1\'>(K49Y
M^RM;S]O]IT[U\#ZG^SM\4]'S]L^''BJ%>!YG]C7!3)[;@F,_C7(:IX6UK0U)
MU'2+^P"C)-U;/'@9Q_$!WXH_L?+:GP+[I/\ S#^P<HK?PX_=)_YL_5;2_P#@
MIK\&M0V^>WB#3,[<_:M.#;<]<^6[].^/PS3_ !U_P4B^$FB^#;Z_\-:K/XBU
MY8R+72C8W%OND/"EY'C"A<\G!)QVS7Y)45'^K^#YD]?2_P#P#/\ U5R_F4KR
M]+_\"YU7Q,^)NO\ Q;\77GB/Q'>-=W]RQ..0D2YX1!V I?AG\3O$'PC\66?B
M'PY>M9WUNX8KDF.5?[KKW!KE**^B]G#D]G;W=K'U?L:?L_9<JY;6MTL?I!>?
M\%8M'A\/V;6G@&^N];:%?M,<]\D-LDN/FV,%=F7/3*J?IUKQOQG_ ,%._BSX
M@\R/1+?1/"\1^Y);6AN)E^K3%D/_ 'P*^1[>WENYXX((GFFD8*D<:EF8GH !
MU->^>!_V$?C5XZCAFB\(2:/9R@$7&LSQVN >F8R?,_\ '*\1Y=EF#]ZI%+_$
M_P#,^<>4Y/@/?JQBO\3_ $;.%\9?M&?$_P"( =->\=ZY?02?>MEO'B@/_;)"
MJ?I7G-??/@W_ ()/ZW<-')XK\>6%BHY>#1[1[@GV$DACQ]=I^E>[>#?^":OP
M;\,^6^IVNK>*9EY/]I7[1IGV6 1\>Q)]\UE+.<OPRY:>O^%?\,C*?$&581<M
M%W\HK_AD?DA7H/@W]GSXE_$ QG0/ VNZA$^-MPMDZ0<_]-7 0?G7[2>#/@GX
M ^'GEMX;\&Z)H\T?2XMK&,3?C)C<?Q-=M7E5>)>E*G][_1?YGB5^+WM0H_>_
MT7^9^3G@W_@F/\7?$'EOK$FB>%XC]];R\\^8#V6%74GZN*]V\&_\$H_"UEY;
M^*?&VJZLW5HM+MH[-?IE_-)'Y?A7W;17CU<\QM7:7+Z+_AV?/U^),QK;3Y5Y
M+_.[_$\(\&_L._!3P5L>W\#V>J3KUFUEWO=WU20E/R45[3H^@Z;X=LUM-*TZ
MUTRT7I!9P+%&/HJ@"KU%>/4KU:VM2;?J[G@UL37Q#O6FY>K;"BBBL#F"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KX _P""
MU?\ R:SX6_['.U_](;ZOO^O@#_@M7_R:SX6_['.U_P#2&^H ]5_X)<?\F)_#
M+_N)_P#ITNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HHHH **** /YK/VL?^
M3IOC)_V.>L_^ETU%'[6/_)TWQD_['/6?_2Z:B@#]J?\ @EQ_R8G\,O\ N)_^
MG2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** /RQ_X)M_\ )TWAS_LBMM_Z
M76M?J=7Y8_\ !-O_ ).F\.?]D5MO_2ZUK]3J "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK^1^4XW&UL?6=:L]7]R\D%%%%<APA1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 >9_&']G'X??'2R:+Q9X?@N;P+MBU2W_ '-Y%Z;9
M5Y(']ULK[5\ ?'#_ ()F^,_!?VC4O -XOC+2%R_V&3;#J$:^F/N2X'=2&/9*
M_4NBO5PF9XG!Z4Y7CV>W_ ^1[>!SC&9?I2E>/9ZK_@?(_GOU;2+[0=1GT_4[
M*XTZ_MVV36MW$T4L;>C*P!!]C72_#7XO>,?@_K0U3P?X@O-$NLCS%@?,4P':
M2-LHX]F!K]J?BU\ ? ?QPT[[+XO\/6VI2HNV&^4&*Z@_W)5PP&>=N2I[@U\!
M_'#_ ()B^*/"HN-3^'6HCQ7IJY;^R[PK#?(OHK<)+_XX>P4U]IALZPN+C[.N
MN5OOL_G_ )GZ'@^(L%CH^RQ*Y&^CUB_G_F>B? __ (*BZ;J M],^*&D'2[CA
M?[<TB-I(#[R0Y+I[E"V2?NBOM_PAXVT#Q_HL6K^&]8LM;TV7[MS8S+(N<9VG
M!X8=P<$=Q7X'Z]X?U3PKJUQI>LZ==:3J5NVR:SO86BEC/HRL 16Q\/OB?XK^
M%.M+JWA+7KW0K[@,]K)A9 .BR(<JZ^S BLL7D%"LN?#/E?WK_@?UH88[A?#8
MA>TPDN1OIO%_Y?CZ'[YT5^?'P/\ ^"H\,WV;3/BCHWD-PAU[1T)3_>EM^H]2
M4)]D%?<W@?XA>&OB7HB:OX6UNRUW3FX\ZSE#[3_=8=4;_98 ^U?%8K XC!NU
M:-EWZ?>?GF-RW%9>[5X67?=??_3.AHHHK@/+"BH/M]M]M^Q_:(OM>SS?L^\>
M9LSC=MZXSWJ>@84444""BBB@ HK!\6>/?#7@.S^U>)/$&F:#;XR)-2NXX ?I
MO(S^%?/_ (Z_X*,?!GP=YD=EJM]XJNDX\K1K-BN?^NDNQ"/=2:ZJ.%KXC^%!
MOY';0P6)Q7\&FY>B_4^GJ*_-CQU_P5<\07GF1>#_  3I^EKT6ZUBY>Z<^_EI
MY84^VYA_*OG;QU^V=\9?B%YD>H>.=0LK5^/LVD%;% O]W,05F'^\37N4>'\7
M4UG:/J_\CZ3#\+8^KK4M!>;N_P +_F?L9XP^)'A3X?6OVCQ-XDTK0(L9!U"\
MCA+?[H8@L?85\^>.O^"D7P<\(^9'IE[J7BRY7@)I5FRQ[O>2;8,>Z[J_)"ZN
MY[ZXDN+F:2XGD.YY96+,Q]23R:BKW*/#E".M6;E^'^9])A^$L-#6O4<O31?J
M_P 3[K\=?\%6/%.H"2+PCX.TW14/"W&J3O>28]0J^6H/L=P^M?.WCK]K_P",
M/Q$\Q-5\=ZG#;2<&UTQQ91;?[I$(7</][-9/@7]FCXI_$GRV\/\ @76;N"3[
MEU-;FWMV^DTNU/\ QZOHGP+_ ,$LOB#K7ER^*/$.C>&8&^]%!OO;A?7*C:GY
M.:[N7*L!ORI_>_U9Z/)DF5[\B:_[>?ZL^+9II+F9Y9I&EE<[F=R2S'U)/6FJ
MI=@J@LQ.  .37ZN^!?\ @F+\*?#?ERZ]<ZQXLN%^]'<7'V:W/T2(!Q^+FOH?
MP/\ !/P#\-53_A&/!^C:-*O2XMK-!.?K*07/XFN.MQ%AH:4HN7X+^OD<.(XL
MPE/2C!R_!?Y_@?C=X%_99^+/Q'\MM#\":Q);R?=NKN#[) 1ZB28JI'T)KZ)\
M"_\ !*WQQJWER^*O%&D>'86Y:&S1[V<>Q'R(#]&-?I]17AUN(<54TII1_%_C
M_D?-XCBK&U-*24%][_'3\#Y*\"_\$S?A)X7\N76CJ_BVX7EEOKOR(<^R0A3C
MV+&OH?P3\(?!'PWC5?"_A/1]"8#!FLK.-)6_WI -S?B37745X=;&8C$?Q9M_
M/3[CYK$8_%8K^-4;^>GW;!1117&< 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5\ ?\%J_P#DUGPM_P!CG:_^D-]7
MW_7P!_P6K_Y-9\+?]CG:_P#I#?4 >J_\$N/^3$_AE_W$_P#TZ7=?55?*O_!+
MC_DQ/X9?]Q/_ -.EW7U50 4444 %%%% '\UG[6/_ "=-\9/^QSUG_P!+IJ*/
MVL?^3IOC)_V.>L_^ETU% '[4_P#!+C_DQ/X9?]Q/_P!.EW7U57RK_P $N/\
MDQ/X9?\ <3_].EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!^6/_  3;_P"3IO#G_9%;;_TNM:_4ZORQ_P""
M;?\ R=-X<_[(K;?^EUK7ZG4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+?\ 8YVO_I#?5]_U\ ?\%J_^36?"W_8YVO\ Z0WU 'JO_!+C_DQ/X9?]Q/\
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M117FGD!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&+2?_ Z+_P"*H WJ*P?^$]\,_P#0Q:3_ .!T7_Q5'_">^&?^ABTG_P #HO\
MXJ@#>HK!_P"$]\,_]#%I/_@=%_\ %4?\)[X9_P"ABTG_ ,#HO_BJ -ZBL'_A
M/?#/_0Q:3_X'1?\ Q5'_  GOAG_H8M)_\#HO_BJ -ZBL'_A/?#/_ $,6D_\
M@=%_\51_PGOAG_H8M)_\#HO_ (J@#>HK!_X3WPS_ -#%I/\ X'1?_%4?\)[X
M9_Z&+2?_  .B_P#BJ -ZBL'_ (3WPS_T,6D_^!T7_P 51_PGOAG_ *&+2?\
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M]#%I/_@=%_\ %4?\)[X9_P"ABTG_ ,#HO_BJ -ZBL'_A/?#/_0Q:3_X'1?\
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M_H8M)_\  Z+_ .*H WJ*P?\ A/?#/_0Q:3_X'1?_ !5'_">^&?\ H8M)_P#
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M?#/_ $,6D_\ @=%_\51_PGOAG_H8M)_\#HO_ (J@#>HK!_X3WPS_ -#%I/\
MX'1?_%4?\)[X9_Z&+2?_  .B_P#BJ .(_P"&8_AY_P +<_X6/_8:?\)%Y>W&
M1]G\S.?.\O'^LQQG./;/->JU@_\ ">^&?^ABTG_P.B_^*H_X3WPS_P!#%I/_
M ('1?_%5I.I.I;G=[:&U2M4K6]I)NRLK]C>HK!_X3WPS_P!#%I/_ ('1?_%4
M?\)[X9_Z&+2?_ Z+_P"*K,Q-ZBL'_A/?#/\ T,6D_P#@=%_\51_PGOAG_H8M
M)_\  Z+_ .*H WJ*P?\ A/?#/_0Q:3_X'1?_ !5'_">^&?\ H8M)_P# Z+_X
MJ@#>HK!_X3WPS_T,6D_^!T7_ ,51_P )[X9_Z&+2?_ Z+_XJ@#>HK!_X3WPS
M_P!#%I/_ ('1?_%4?\)[X9_Z&+2?_ Z+_P"*H WJ*P?^$]\,_P#0Q:3_ .!T
M7_Q5'_">^&?^ABTG_P #HO\ XJ@#>HK!_P"$]\,_]#%I/_@=%_\ %4?\)[X9
M_P"ABTG_ ,#HO_BJ -ZBL'_A/?#/_0Q:3_X'1?\ Q5'_  GOAG_H8M)_\#HO
M_BJ -ZBL'_A/?#/_ $,6D_\ @=%_\51_PGOAG_H8M)_\#HO_ (J@#>HK!_X3
MWPS_ -#%I/\ X'1?_%4?\)[X9_Z&+2?_  .B_P#BJ -ZBL'_ (3WPS_T,6D_
M^!T7_P 51_PGOAG_ *&+2?\ P.B_^*H WJ*P?^$]\,_]#%I/_@=%_P#%4?\
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M  .B_P#BJ -ZBL'_ (3WPS_T,6D_^!T7_P 51_PGOAG_ *&+2?\ P.B_^*H
MWJ*P?^$]\,_]#%I/_@=%_P#%4?\ ">^&?^ABTG_P.B_^*H WJ*P?^$]\,_\
M0Q:3_P"!T7_Q5'_">^&?^ABTG_P.B_\ BJ -ZBL'_A/?#/\ T,6D_P#@=%_\
M51_PGOAG_H8M)_\  Z+_ .*H WJ*P?\ A/?#/_0Q:3_X'1?_ !5'_">^&?\
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M>^&?^ABTG_P.B_\ BJ -ZBL'_A/?#/\ T,6D_P#@=%_\51_PGOAG_H8M)_\
M Z+_ .*H WJ*P?\ A/?#/_0Q:3_X'1?_ !5'_">^&?\ H8M)_P# Z+_XJ@#>
MHK!_X3WPS_T,6D_^!T7_ ,51_P )[X9_Z&+2?_ Z+_XJ@#>HK!_X3WPS_P!#
M%I/_ ('1?_%4?\)[X9_Z&+2?_ Z+_P"*H WJ*P?^$]\,_P#0Q:3_ .!T7_Q5
M'_">^&?^ABTG_P #HO\ XJ@#>HK!_P"$]\,_]#%I/_@=%_\ %4?\)[X9_P"A
MBTG_ ,#HO_BJ -ZBL'_A/?#/_0Q:3_X'1?\ Q5'_  GOAG_H8M)_\#HO_BJ
M-ZBL'_A/?#/_ $,6D_\ @=%_\51_PGOAG_H8M)_\#HO_ (J@#>HK!_X3WPS_
M -#%I/\ X'1?_%4?\)[X9_Z&+2?_  .B_P#BJ -ZBL'_ (3WPS_T,6D_^!T7
M_P 51_PGOAG_ *&+2?\ P.B_^*H WJ*P?^$]\,_]#%I/_@=%_P#%4?\ ">^&
M?^ABTG_P.B_^*H WJ*P?^$]\,_\ 0Q:3_P"!T7_Q5'_">^&?^ABTG_P.B_\
MBJ -ZBL'_A/?#/\ T,6D_P#@=%_\51_PGOAG_H8M)_\  Z+_ .*H WJ*P?\
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MM?LO^%X-/U:QOIE\8VKF.VN4D8+]BOAG"D\9(Y]Z /:/^"7'_)B?PR_[B?\
MZ=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH **** "BBB@#^:S]K'_DZ;XR?]
MCGK/_I=-11^UC_R=-\9/^QSUG_TNFHH _:G_ ()<?\F)_#+_ +B?_ITNZ^JJ
M^5?^"7'_ "8G\,O^XG_Z=+NOJJ@ HHHH **** "O'O&7[6WPK\ _%_2/A?KG
MB5K+QQJLUM!:Z8VGW)5VG.(3YWE^5AFPOW^IP>]>PU\0?\%&OV'==_:*;0/B
M!\.KA+;XD>'8U@2"2X\C[9;J[2QB.0\)-'(S,I)4'>V2,+0!]OU^1W_!92".
M;X_?"(:-A?%4FGL@9,;\?:A]FZ<_?,N*[_1_^"@G[4/@KP_!X=\4?LSZ[KGB
MZ)%@35H;"]BBN6'&\Q1P.LA/&?+D"YS@#H+/[*O['7Q4^,/[0R_M!_M%P"RU
M&UF2YTGP[,JA_-08A9H@3Y$4/#(A.]G 9NY< Y#_ (+*:;=>%?BE\%?'@1IH
M(%F@8JORB2WGBF ]MPD; S_"?2OU/TW4+?5M/M;ZTE6>TNHEFAE7HZ, RL/8
M@BO$_P!LW]F2S_:N^"&H^#VGBL-:AE6_T>_F!*07:!@N_'.QU9T;&<!LX)4"
MOASX4_M0?M4?LD^&;?X8>+?@9K/C\:3']DT?4;6"X?;"N%CC$T$4B3HH "@8
M8 @$\"@#8_X+;:XMYIWPB\)VG^D:E=WE[=BW3E\ 0Q1_]],[ ?[IK])? ^@-
MX3\%>']$9E=M-T^WLRR]"8XU3(]OEK\Y/V>_V8/B_P#M2?M+67QX_:#TB3PY
MI>D/'-HWANZB\IR8W+P1>0QWQ11N2Y\SYG;J"&)K]'/&D^I6O@W7IM'#MJ\=
MA</9B- [&<1L8\*00QW8X(.: -JOR?\ VRE/PN_X*M?"3Q9>GR],U5](E:X<
M?(B^>]K)S_LJ Q]F%?2'_!._QU^TAXRO/':_'VVUFWAMX[(Z-_:VB0:<"S&?
MS]GE0Q[^!%G.<<=,UT'_  4._8YG_:P^&.GOX>D@M?'?AR5[C2I+AMB7,;@>
M;;,_\.[8C*QX#( <!B0 ?6%?E)_P4HC_ .%E?M\_ SP+I[+-=(FGQS <^49[
M]L[OI&@<^QK7\(?MU?M6_#'PW'X)\4?L]Z[XO\86,8MX=:^P79\_&</(L,3)
M.<#&^-U!P3UR:[7]A[]D#XCZO\;M4_:(^/B-%XSN]S:7I-P$\V)GC\OSI$4D
M1!(OW<<?51R0"HR >;_\%E]-N?"OQ4^"WCQ(VEMH5F@.!E5>WGBF4'W82-C_
M '#Z5^IVFZA;ZMI]K?6DJSVEU$LT,J]'1@&5A[$$5XG^V;^S)9_M7?!#4?![
M3Q6&M0RK?Z/?S E(+M P7?CG8ZLZ-C. V<$J!7PY\*?VH/VJ/V2?#-O\,/%O
MP,UGQ^-)C^R:/J-K!</MA7"QQB:"*1)T4 !0,, 0">!0!L?\%MM<6\T[X1>$
M[3_2-2N[R]NQ;IR^ (8H_P#OIG8#_=-?I+X'T!O"?@KP_HC,KMINGV]F67H3
M'&J9'M\M?G)^SW^S!\7_ -J3]I:R^/'[0>D2>'-+TAXYM&\-W47E.3&Y>"+R
M&.^**-R7/F?,[=00Q-?IM0 4444 9FO^&M*\56:6FL:?;ZE;)()5BN8PZAP"
M V#WPQ'XU@?\*;\#?]"GI/\ X"I_A7944 ?EC^P:6^(?[16@Z-XE>36M*E^$
MT&KR6EVY>-KPWENAG(SRY5F&[K@FOT5_X4?X"_Z%;3_^_?\ ]>OSJ_X)M_\
M)TWAS_LBMM_Z76M?J=0!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A
M7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W
M_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\
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M^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\
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M3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_
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M_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\
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M^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\
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M3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_
MW_0IZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5
M% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*
M>D_^ J?X4?\ "F_ W_0IZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_  IO
MP-_T*>D_^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=
ME10!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A7944 <;_ ,*;\#?]
M"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *
M;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A
M7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W
M_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\
M"F_ W_0IZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?
MX5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP
M-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_
M  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*
MG^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A7944 <;_ ,*;
M\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1
M_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X
M"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"
MF_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X
M4?\ "F_ W_0IZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_
M^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI/_@*G^%=E10!QO\
MPIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G
M^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W_0IZ3_X"I_A1_P *;\#?]"GI
M/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0IZ3_X"I_A7944 <;_
M ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&_P#"F_ W_0IZ3_X"
MI_A1_P *;\#?]"GI/_@*G^%=E10!QO\ PIOP-_T*>D_^ J?X4?\ "F_ W_0I
MZ3_X"I_A7944 <;_ ,*;\#?]"GI/_@*G^%'_  IOP-_T*>D_^ J?X5V5% '&
M_P#"F_ W_0IZ3_X"I_A7PG_P6,\ ^'/"O[,OAF[T?1+'3;E_%]K$TMM"J,4-
ME>DKD=LJ#^%?H]7P!_P6K_Y-9\+?]CG:_P#I#?4 >J_\$N/^3$_AE_W$_P#T
MZ7=?55?*O_!+C_DQ/X9?]Q/_ -.EW7U50 4444 %%%% '\UG[6/_ "=-\9/^
MQSUG_P!+IJ*/VL?^3IOC)_V.>L_^ETU% '[4_P#!+C_DQ/X9?]Q/_P!.EW7U
M57RK_P $N/\ DQ/X9?\ <3_].EW7U50 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^6/_  3;_P"3IO#G_9%;;_TN
MM:_4ZORQ_P"";?\ R=-X<_[(K;?^EUK7ZG4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\ ?\
M%J_^36?"W_8YVO\ Z0WU??\ 7P!_P6K_ .36?"W_ &.=K_Z0WU 'JO\ P2X_
MY,3^&7_<3_\ 3I=U]55\J_\ !+C_ ),3^&7_ '$__3I=U]54 %%%% !1110!
M_-9^UC_R=-\9/^QSUG_TNFHH_:Q_Y.F^,G_8YZS_ .ETU% '[4_\$N/^3$_A
ME_W$_P#TZ7=?55?*O_!+C_DQ/X9?]Q/_ -.EW7U50 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^6/_!-O_DZ;PY_
MV16V_P#2ZUK]3J_+'_@FW_R=-X<_[(K;?^EUK7ZG4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5\ ?\%J_P#DUGPM_P!CG:_^D-]7W_7P!_P6K_Y-9\+?]CG:_P#I#?4 >J_\
M$N/^3$_AE_W$_P#TZ7=?55?*O_!+C_DQ/X9?]Q/_ -.EW7U50 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***R]$\3:;XCDU%-.N?M#:?=/97(\ME\N9,;E^8#.,CD
M9'O0!J4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%9;>)M-7Q*GA
M\W.-7:U-ZMOY;<PA]F[=C;][C&<^U:E !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1167KWB;3?#,=D^IW/V9;VZCLH#Y;/OF?.Q?E!QG!Y/'O0!J444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%5M2U"WTC3KJ^NY/*M;6)
MIYI-I;:B@LQP!DX /2FZ3JUKKNEVFHV,OGV5W$L\,FTKN1AE3@@$<'N* +=%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !167HGB;3?$<FHIIUS]H;
M3[I[*Y'ELOES)C<OS 9QD<C(]ZU* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *^ /^"U?_)K/A;_L<[7_ -(;ZOO^O@O_ (+)Z3=Z]^S?X(TR
MPB\^^O?'5C;01;@N^1[.]55R2 ,DCDG% 'I7_!+C_DQ/X9?]Q/\ ].EW7U57
MS!_P30TF[T']BKP!IE_%Y%]93ZM;3Q;@VR1-5O%9<@D'!!Y!Q7T_0 4444 %
M%%% '\UG[6/_ "=-\9/^QSUG_P!+IJ*/VL?^3IOC)_V.>L_^ETU% '[4_P#!
M+C_DQ/X9?]Q/_P!.EW7U57RK_P $N/\ DQ/X9?\ <3_].EW7U50 4444 %%%
M% !1110 4444 ?E;_P %R-:E6/X/:0DA$+'5;J6//!8?950_@#)^9K]1-#TF
M'0-%T_2[88M[*WCMHQC'RHH4?H*_+W_@N-H$SVWPAUM%S;QOJ=E*V.C,+9T&
M?<))^5?I]X9UR#Q-X<TK6+9E:VU"TBNXF4Y!61 X(/T(H ^!?^"V&EPS?LX^
M#-28#[1;^+(K=#CG;)9W3-S]8EKZU_9.UJ;Q!^R_\)M0N)/-N)O"VFF63^\X
MMHPQ/OD&OD7_ (+9:U#!^SWX(TAF47%UXI2Z1<\E8K2X5B!Z9G7\Q7V)^S!X
M?F\*_LV_"O2+F/R;NS\+:9#/'_=E%K'O'_?6: /3:_)_5I!XS_X+@6-K=2&6
MVT^=! IY"&#0S, /^VH8_C7ZP5^3OB&,> ?^"W6F7UX%CMM4N(S Q^4-]HT8
MVX_'S21[D4 ?K%7Y._MX2_\ "'_\%3/@?JUHXAEN5T&>=L8R#J<\+ XZYC3'
MTK]8J_*']MF'_A//^"KGP3T:T59Y-/\ ["BN44\A4OYKJ3/N(GS^5 %S_@N1
MK4JQ_![2$D(A8ZK=2QYX+#[*J'\ 9/S-?J)H>DPZ!HNGZ7;#%O96\=M&,8^5
M%"C]!7Y>_P#!<;0)GMOA#K:+FWC?4[*5L=&86SH,^X23\J_3[PSKD'B;PYI6
ML6S*UMJ%I%=Q,IR"LB!P0?H10!\"_P#!;#2X9OV<?!FI,!]HM_%D5NAQSMDL
M[IFY^L2U]:_LG:U-X@_9?^$VH7$GFW$WA;33+)_><6T88GWR#7R+_P %LM:A
M@_9[\$:0S*+BZ\4I=(N>2L5I<*Q ],SK^8K[$_9@\/S>%?V;?A7I%S'Y-W9^
M%M,AGC_NRBUCWC_OK- 'IM%%% !16#XR\#Z)\0-+BT_7K+[?9QS"X2/S7CPX
M5E!RC ]&;C..:X[_ (9H^&W_ $+G_D]<_P#QR@#\P/V1?CUX$_9W^/OA+Q)\
M0M=_X1_1;KX16FGPW/V.>YW3M=0R*FV&-V&5BD.2,?+UR1G[D_X>C?LQ?]%,
M_P#*!JG_ ,C5HZM^PAX?U'4[JZM_B)XXTN":1G2RM&TMHH%)R$0R6+N5'0;F
M8^I-5/\ A@/1/^BI?$#_ ,H__P KJ (?^'HW[,7_ $4S_P H&J?_ "-1_P /
M1OV8O^BF?^4#5/\ Y&J;_A@/1/\ HJ7Q _\ */\ _*ZC_A@/1/\ HJ7Q _\
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MG_E U3_Y&H_X>C?LQ?\ 13/_ "@:I_\ (U3?\,!Z)_T5+X@?^4?_ .5U'_#
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MOV8O^BF?^4#5/_D:C_AZ-^S%_P!%,_\ *!JG_P C5-_PP'HG_14OB!_Y1_\
MY74?\,!Z)_T5+X@?^4?_ .5U $/_  ]&_9B_Z*9_Y0-4_P#D:C_AZ-^S%_T4
MS_R@:I_\C5-_PP'HG_14OB!_Y1__ )74?\,!Z)_T5+X@?^4?_P"5U $/_#T;
M]F+_ **9_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-4W_  P'HG_14OB!_P"4
M?_Y74?\ # >B?]%2^('_ )1__E=0!#_P]&_9B_Z*9_Y0-4_^1J/^'HW[,7_1
M3/\ R@:I_P#(U3?\,!Z)_P!%2^('_E'_ /E=1_PP'HG_ $5+X@?^4?\ ^5U
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M[,7_ $4S_P H&J?_ "-1_P /1OV8O^BF?^4#5/\ Y&J;_A@/1/\ HJ7Q _\
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MO^BF?^4#5/\ Y&J;_A@/1/\ HJ7Q _\ */\ _*ZC_A@/1/\ HJ7Q _\ */\
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M_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-4W_  P'HG_14OB!_P"4?_Y74?\
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M (?^'HW[,7_13/\ R@:I_P#(U'_#T;]F+_HIG_E U3_Y&J;_ (8#T3_HJ7Q
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M$#_RC_\ RNH A_X>C?LQ?]%,_P#*!JG_ ,C4?\/1OV8O^BF?^4#5/_D:IO\
MA@/1/^BI?$#_ ,H__P KJ/\ A@/1/^BI?$#_ ,H__P KJ (?^'HW[,7_ $4S
M_P H&J?_ "-1_P /1OV8O^BF?^4#5/\ Y&J;_A@/1/\ HJ7Q _\ */\ _*ZC
M_A@/1/\ HJ7Q _\ */\ _*Z@"'_AZ-^S%_T4S_R@:I_\C4?\/1OV8O\ HIG_
M )0-4_\ D:IO^& ]$_Z*E\0/_*/_ /*ZC_A@/1/^BI?$#_RC_P#RNH A_P"'
MHW[,7_13/_*!JG_R-1_P]&_9B_Z*9_Y0-4_^1JF_X8#T3_HJ7Q _\H__ ,KJ
M/^& ]$_Z*E\0/_*/_P#*Z@"'_AZ-^S%_T4S_ ,H&J?\ R-1_P]&_9B_Z*9_Y
M0-4_^1JF_P"& ]$_Z*E\0/\ RC__ "NH_P"& ]$_Z*E\0/\ RC__ "NH A_X
M>C?LQ?\ 13/_ "@:I_\ (U'_  ]&_9B_Z*9_Y0-4_P#D:IO^& ]$_P"BI?$#
M_P H_P#\KJ/^& ]$_P"BI?$#_P H_P#\KJ (?^'HW[,7_13/_*!JG_R-1_P]
M&_9B_P"BF?\ E U3_P"1JF_X8#T3_HJ7Q _\H_\ \KJ/^& ]$_Z*E\0/_*/_
M /*Z@"'_ (>C?LQ?]%,_\H&J?_(U'_#T;]F+_HIG_E U3_Y&J;_A@/1/^BI?
M$#_RC_\ RNH_X8#T3_HJ7Q _\H__ ,KJ (?^'HW[,7_13/\ R@:I_P#(U'_#
MT;]F+_HIG_E U3_Y&J;_ (8#T3_HJ7Q _P#*/_\ *ZC_ (8#T3_HJ7Q _P#*
M/_\ *Z@"'_AZ-^S%_P!%,_\ *!JG_P C4?\ #T;]F+_HIG_E U3_ .1JF_X8
M#T3_ **E\0/_ "C_ /RNH_X8#T3_ **E\0/_ "C_ /RNH R?$/\ P4C_ &<_
M&6@:GH&C_$3[9JVJVTMC9V_]B:BGFS2H4C3<UN%7+,!DD 9Y(J+PK_P49_9X
M\ ^&=*\-:]\0OL&MZ1;1V-[:_P!BZC)Y4T:A'3<EN5;# C*D@]C6W_PP'HG_
M $5+X@?^4?\ ^5U'_# >B?\ 14OB!_Y1_P#Y74 0_P##T;]F+_HIG_E U3_Y
M&H_X>C?LQ?\ 13/_ "@:I_\ (U3?\,!Z)_T5+X@?^4?_ .5U'_# >B?]%2^(
M'_E'_P#E=0!#_P /1OV8O^BF?^4#5/\ Y&H_X>C?LQ?]%,_\H&J?_(U3?\,!
MZ)_T5+X@?^4?_P"5U'_# >B?]%2^('_E'_\ E=0!#_P]&_9B_P"BF?\ E U3
M_P"1J/\ AZ-^S%_T4S_R@:I_\C5-_P ,!Z)_T5+X@?\ E'_^5U'_  P'HG_1
M4OB!_P"4?_Y74 0_\/1OV8O^BF?^4#5/_D:C_AZ-^S%_T4S_ ,H&J?\ R-4W
M_# >B?\ 14OB!_Y1_P#Y74?\,!Z)_P!%2^('_E'_ /E=0!#_ ,/1OV8O^BF?
M^4#5/_D:C_AZ-^S%_P!%,_\ *!JG_P C5-_PP'HG_14OB!_Y1_\ Y74?\,!Z
M)_T5+X@?^4?_ .5U $/_  ]&_9B_Z*9_Y0-4_P#D:C_AZ-^S%_T4S_R@:I_\
MC5-_PP'HG_14OB!_Y1__ )74?\,!Z)_T5+X@?^4?_P"5U $/_#T;]F+_ **9
M_P"4#5/_ )&H_P"'HW[,7_13/_*!JG_R-4W_  P'HG_14OB!_P"4?_Y74?\
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M+_HIG_E U3_Y&J;_ (8#T3_HJ7Q _P#*/_\ *ZC_ (8#T3_HJ7Q _P#*/_\
M*Z@"'_AZ-^S%_P!%,_\ *!JG_P C4?\ #T;]F+_HIG_E U3_ .1JF_X8#T3_
M **E\0/_ "C_ /RNH_X8#T3_ **E\0/_ "C_ /RNH A_X>C?LQ?]%,_\H&J?
M_(U'_#T;]F+_ **9_P"4#5/_ )&J;_A@/1/^BI?$#_RC_P#RNH_X8#T3_HJ7
MQ _\H_\ \KJ (?\ AZ-^S%_T4S_R@:I_\C4?\/1OV8O^BF?^4#5/_D:IO^&
M]$_Z*E\0/_*/_P#*ZC_A@/1/^BI?$#_RC_\ RNH A_X>C?LQ?]%,_P#*!JG_
M ,C4?\/1OV8O^BF?^4#5/_D:IO\ A@/1/^BI?$#_ ,H__P KJ/\ A@/1/^BI
M?$#_ ,H__P KJ (?^'HW[,7_ $4S_P H&J?_ "-7S;^W#^V9\'?VB/#?PJ\-
M_#WQA_PD&M6OQ"TK4)K;^S+RVVP*EQ&S[IH44X:6,8!S\W3 ./IC_A@/1/\
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M8/E>XF*(A"<1J 3DC+?KI'&D,:QQJJ(H"JJC  '0 4D,*6\211(L<2*%5$&
MH'  '84^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[MCR6I99(6[++$X#QMQG:Z@XYH [>BBB@ HHHH **** "BBB@ HHHH ****
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M,;35=2A4O)IDZ/:W84=6$4JJS*,C+*"!D9->PT %%%% !1110 4444 %%%%
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M:;I5C;:9IUKX/U.."SLX5BAB06LF%1% "CV KYV_X(P_\FH:W_V-MY_Z2VE
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M= TN96@%O;QA'/E6Y^9(SYBX9SN<\G(P:_?/X>_\B#X9_P"P9;?^BEK\X/\
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MS:SH-_IR*!DEIK=XP/S:OSR_X:6_X* _]$;T_P#\$S__ "37V%^QKXZ^,GQ
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M8-/TNW^>25SNGNYB &FF?'SNV!SP    %  [^OS _P"&EO\ @H#_ -$;T_\
M\$S_ /R37Z5^%;K4+WPQH]QJT(MM5FLX9+N%5VB.8H"ZXR<8;(ZT :E%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% 'BO[5G[5GA']DWX=OXB\1O]LU.ZW1:3H<+A9]0F &0.NU%R"\A&%!'4E5
M/P)\#_V9?B7_ ,%&/']M\8_CO>7.F_#Q6W:1H4!:$74.[(BMTSF* X&Z4_/)
MC@G[Z\?^VQ\$_P!HCXU_M8:WXKB^%NJ>)O#&BWJV6B6ES#OL9K.!N,J)%)25
M@SM@@G?U QCU*W_:._;[L[>*"#X+:9!!$H2../1&544#   N> !VH _3+P]X
M>TSPGH=AHNBV%OI>DV$*V]K9VL8CBAC48554<  5^6'_  4,4_"W_@HY\$?'
M]V6CT><Z3--/(,(/L]\RSJ#TXB:,^V^O4_@W\?\ ]MCQ!\5O">F^-OA79:5X
M1NM2AAU6^32FC:"V+@2.&^T'&!GG!^E>Y?M]?LAK^UQ\(X-.TV>WL?&6AS->
M:-=7)(C8LH$MNY&=JR!5^;'#(AZ9! /INORB_P""K0'Q+_:X^!OPZL76:_D2
M"-HP,[&O+U8UW?A#G'88/>MCP+^U5^V3\$_"MOX"U[X ZOXWUC38EM+/7O[/
MNKA"H.$,TMN&BFP !N#H2 "Q)R3VO[%?['?Q)\0?'2__ &B/C^/+\73[I=*T
M64HTD+LGEB61%)6)8XL)'%G<,Y;:5&0#]!-8U>Q\/Z3>:GJ=W#I^G6<+W%S=
MW,@CBAC12S.['@* "23TQ7Y4?&[]I+XE_P#!1KXE77P<^!44^E_#F%MNKZ]+
MNA6[AW8,MP^,QP'!VPCYY,<@_=7Z0_X*E>'_ (L?$#X.Z)X(^&'AS4]=@UF]
M:37&TQ1N%O"%:.)R2/E>1@WOY6.F<_(O[/EU^V7^S)X%'A7P1\#+2WLGG:YN
M;JZTEI+FZE;^*5Q<#.%PH    ''4D _1S]E']D?P7^R7X'_L;PY#]NUJ[56U
M77KA +B^D'3_ '(UR=L8.!GDEB6/=_&3XP>&_@/\/=2\:^+I[BU\/Z>8UN)K
M:V>=D,CK&GRJ"<%V5<]/F&:_/;_AI;_@H#_T1O3_ /P3/_\ )-?9W@SPKKO[
M1W[*<&@?&O0QI.O>)-.FMM:TZWC,!MV\UQ&R LVUE"QN,D\@'VH [KX+_&+P
MU\?/ASI7C?PE<2W.A:D95A:XC\N4&.5HF#)GY3N0\'L0>]>0_P#!1KPEH'BK
M]CGXC-KT$+C3+'^T;&:0?-!=QL/*9#V+%MGN'(Z&OC7X:^%OVJ?^"<>M:QX<
M\.^!)/C%\.+ZX-W NDPRSX<X&]%B!D@D*JH=61DR!@GJ;/Q,TW]K3_@H=+I_
M@_5O 3?!OX<B9;F].JPRP>85;*F42 2S%<Y6-452PRV, J >V_\ !&_Q!JNM
M?LE7=IJ#R26FE>)+RST_S"<+ 8H)BJ^WFS2GZDU]TUY]\ _@GH/[/'PGT#P'
MX<#-8:7"0]S* )+J9B6EF?\ VF8DXZ 8 X KT&@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#^:S]K'_DZ;XR?]CGK/\ Z7344?M8_P#)
MTWQD_P"QSUG_ -+IJ* /VI_X)<?\F)_#+_N)_P#ITNZ^JJ^5?^"7'_)B?PR_
M[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH _FL_:Q_Y.F^,G_8YZS_Z7344?M8_\G3?&3_L<]9_]+IJ* /VI_P""7'_)
MB?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_^G2[KZJH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /YK/VL?^3IOC)_V.>L_P#I=-11
M^UC_ ,G3?&3_ +'/6?\ TNFHH _:G_@EQ_R8G\,O^XG_ .G2[KZJKY5_X)<?
M\F)_#+_N)_\ ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#^:S]K'_DZ;XR?]CGK/_I=-11^UC_R=-\9/^QSUG_TNFHH _:G_
M ()<?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_ "8G\,O^XG_Z=+NOJJ@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** /YK/VL?^3IOC)_V.>L_^ETU%'[6/_)TWQD_['/6?_2Z:
MB@#]J?\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#^:S]K'_DZ;XR
M?]CGK/\ Z7344?M8_P#)TWQD_P"QSUG_ -+IJ* /VI_X)<?\F)_#+_N)_P#I
MTNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\
M+FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH
M_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\
MA'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1S
MXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-_
M_10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\ A'/C?_T4
M/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'
M_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\
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M_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\
MT4/X?_\ A!WW_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#
M^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A_
M_P"$'??_ "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\
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MYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N:
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M_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\
M+FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH
M_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\
MA'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1S
MXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-_
M_10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\ A'/C?_T4
M/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'
M_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\
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M_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\
MT4/X?_\ A!WW_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#
M^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A_
M_P"$'??_ "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\
MA!WW_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=
M]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_
M "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N
M:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_
M (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$
M<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\ A'/C
M?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]
M%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_
MA_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\ A'/C?_T4/X?_
M /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X
M0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\ ^$'?
M?_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\ A'/C?_T4/X?_ /A!WW_R
MYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N:
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M_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\
M+FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH
M_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\
MA'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1S
MXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-_
M_10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N:/\ A'/C?_T4
M/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'
M_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\
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M_P#10_A__P"$'??_ "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\
MT4/X?_\ A!WW_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#
M^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A_
M_P"$'??_ "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\
MA!WW_P N:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=
M]_\ +FC_ (1SXW_]%#^'_P#X0=]_\N: /5:*\J_X1SXW_P#10_A__P"$'??_
M "YH_P"$<^-__10_A_\ ^$'??_+F@#U6BO*O^$<^-_\ T4/X?_\ A!WW_P N
M:/\ A'/C?_T4/X?_ /A!WW_RYH ]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_
M (1SXW_]%#^'_P#X0=]_\N: /5:*\A\-^)/B'H'QDT3PAXOUOPSX@L-8T#4]
M6BFT30+C3);>2TN-/BVMYM]<AU<7S'@*08QR<\>O4 %%%% '\UG[6/\ R=-\
M9/\ L<]9_P#2Z:BC]K'_ ).F^,G_ &.>L_\ I=-10!^U/_!+C_DQ/X9?]Q/_
M -.EW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !1110 4444 %%%% !1110 4
M444 %%%% !1110 5Y5^R=_R:S\&_^Q,T;_TAAKU6O*OV3O\ DUGX-_\ 8F:-
M_P"D,- 'JM%%% !1110 4444 %%%% !1110 4444 %%%% !114<]Q':P2332
M+##&I=Y)&"JJ@9))/0 4 245Y_<?M"?"RTF>&?XE>#X9D.UHY->M593Z$&3B
MH_\ AHSX3_\ 13_!O_A06G_QRM_85?Y']S.GZM7_ )']S/1**\[_ .&C/A/_
M -%/\&_^%!:?_'*/^&C/A/\ ]%/\&_\ A06G_P <H]A6_D?W,/JU?_GV_N9Z
M)4$M];P7,%O)/%'<3[O*B9P'DVC+;1U.!R<=*\@^(7[7WPG\ ^$=0UL>-]"U
M^6V3,6FZ+J<%U=7#GA45$<D9/5CP!R37Y2?%/]I[QU\4?BQ;^/9M5FTG4M/E
MW:1#92$1Z<@.0D?KG^(D?/SGC 'K8'**^,NW[J75]SW,MR'$Y@Y-^Y%=6NO;
M_,_<&BOE?]F7]N[P;\5?!H7QMK>D>#O%=BJI=IJ5W':V]UV$L+2,!SCE,Y4^
MHP:]D_X:,^$__13_  ;_ .%!:?\ QRO.JX/$49NG.#NO(\JM@,5AZCI3INZ\
MCT2BO._^&C/A/_T4_P &_P#A06G_ ,<H_P"&C/A/_P!%/\&_^%!:?_'*R]A6
M_D?W,P^K5_\ GV_N9Z)17G?_  T9\)_^BG^#?_"@M/\ XY75>&/&OA[QM:O<
M^'=>TS7K9,!IM+O([E%STR48@=#4RI5(*\HM?(B5&K35YQ:7H;5>3?M5?'"+
M]G7X!>,/'9$+WVG6FS3X9P2DMY(1' I ()7>RE@#G:K=.M>LU^7G_!73Q]J7
MQ+^(WPN_9_\ ##^?J6HWD5_=P*3@SSN;>T5L=, S,0>SJ:R,3L/V!?\ @HAX
MY^/'QHN_A]\4+#2=,O+_ $M=0T5K"TDMFD8()BI#.VX/ _F*1CA#ZU^B=?DW
M_P %'?A?/^R?\3_@7\8O!$!CMM!@L]"D ^56DL5'D*Y_Z:VXDC/^S$:_4CP/
MXPTSXA>#=#\4:--]HTG6+*&_M9.,F.1 ZY]#@\CL<T > _\ !0C]HKQ5^S#\
M![?QAX/CT^75I-9M[ KJ<#31>6\<K-\JLISE%YSZURW_  3P_;F;]K3POJVE
M>*$L=/\ B%HK&:XMK%#'#=VC-A)XT9F(VDA'&3@E#_'@<Q_P62_Y-'L_^QFL
MO_15Q7P%_P *\\7?L=>'O@7^TGX%>6?2=8LXCJ$3L3''=?,LMM+_ -,IXU8C
MT8/C&$H _>>OA+]L+]M;X@_ O]L#X9_#+PY#HS^'/$5OIDMZU]:/)<!KC4)K
M>38XD 'R1KC(.#D\]*^N/@S\7/#_ ,=?AEH'CCPS<>?I.K6XF56(WP2#B2%P
M.CHX93[KQD8-?F5_P4F_Y22? O\ Z\M"_P#3Q=4 ?IS\9O%E[X"^#_CGQ-I@
MB;4=%T*^U*V$ZEHS+#;O(FX C*[E&1D<5\Y_\$WOVJO&G[5WP[\6:WXUBTN*
M]TO55LH!I=LT*>685?Y@SMDY)[U[E^TU_P FV_%?_L4M6_\ 2.6OBO\ X(C_
M /)%_B'_ -C!'_Z3)0!^C]<Y\2/$%UX3^'?BG6[(1F\TW2KJ]@$J[D\R.%G7
M<,C(RHSS71UQ7QN_Y(OX^_[%_4/_ $FDH _*[X<?\%(/VO/C!#?3>"? .D^*
MHK%D2Z?2O#]Q.(6<$J&VS<9VMCZ&N[M?VS?V[M.AF>?X"P7P W?O?"FH%E '
M11'< GZ8)]*N?\$.?^15^+?_ %^Z;_Z+N*_3^@#\^/V9?^"JG_"??%"U^&_Q
M;\&_\*_\375R+&&[0R1PBZ)PL$T,HWPLQPH)9N6 ..M?2'[;WQK\0_L\_LU>
M*?'GA9+*36]-DLT@74(FEAQ+=11-N4,I/RNV.>N*_/K_ (+8:3H>E?%?X::O
MIBI;^++O3KC[=)!A9&BBEC^RN<<YW-. W7" 9^7CZU_X*7-?M_P3Y\4MJ@"Z
MF8](-T!T$WVVVW_^/9H ]>_8U^+VN_'K]FKP7X\\2I:1ZWK$=R]RMC$8X08[
MJ:)=JEF(^6->YYS7M-?DU^S9_P %!S\(OV8_AK\,?AO\/]6^*7Q'M[2[EO+'
M3X96BL@U[/(H(C1WE;8RL0H"@,,MG*UW_@[_ (*X:UX5^(-KX:^./PDU'X>0
MW10_:]D\4UJC$@226T\:LT>>K*<@ X#=* /TFHJE)K-A'H[:LUY -+6#[4;S
MS!Y7D[=WF;NFW;SGIBOS^\7_ /!5S4/%_C"^\-_ ;X0ZY\4)+-\2:H(YO+90
MVW>L$4;N(V[/(R>ZT ?H=17YGS?\%8OB%\*?$UE9?&7X!ZIX3TV[;"3QF>VF
MV@_,\23QA9\9' =?K7Z*>!_&FC_$;P=HOBCP_>+?Z+K%I'>VEPHQOC=0PR.H
M/."#R""#R* -RBOS\U3_ (*Z>'O#MU\5;+6O [6-_P"$+YM,TNVAU@32:U<"
M>6(?+Y"^2@$1=FR^T'')(!VOV-/^"AWC#]I/XFZIX/\ $'PP7P\;/29-8-_;
MW4BK%$I55#QR)D[V< ,#Z\$ D 'W317YY>%/^"PWAG7OA?J&NW7@*YA\9-J2
MZ;H_@[3=4^VW&H$HK&5G$">4@+;?N,2>%!YQREQ_P5D^)?PSU[3/^%L_L_ZI
MX2T*^<JDLL=U9W!48W-$+B)5E*@CY05Z]10!^G%%?$/QJ_X*<:-I.HZ;X<^"
M?A'4/C/XKOK&+4&BT>.62"TBD564.L2/(\F&7<@ V%@&8,"M<A\#?^"K5SKW
MQ=T_X>?%WX<7'PYU/4+B.S@NW>1!!.[;8UN(9D5XU8D#?DX)Y&,D 'Z&T5B>
M-O&FB_#GPGJWB;Q'J$6E:'I=NUU=WDV=L<:CDX ))[  $DD  DU^?UQ_P54\
M<?%#6KJV^!WP#U[QKI5I+LDU2X2:0GC(#1P1LL6>HW2'.>@H _1RBOS;\,?\
M%<-:\%^/+7PU\<?@]JGP^6X92;Q1-'+;QL<"1K::-6>/.265LX!PK&OT?M;J
M&^M8;FVE2XMYD62.6-@RNI&0P(Z@@YS0!+17Q!^TA_P5 \/_  L^(4WPZ^'7
MA*^^*7CF&<VD]O8.RP0W )#0KL1WFD7!W*BX!XW9! \]C_X*H?$'X7ZUI:_&
MWX!:WX+T#4&VQZC#'/%(. ?DCG15D(YRN]2 ?P(!^D-%8?@WQMH?Q!\(Z7XG
M\/:E!JF@ZE;K=6M]"WR21D=>>A'((."""#@@U\-?%[_@JU;Q_$.?P-\#_A]?
M_%O6;=V22^M/,:"1D/S^1%$CR3(.GF?*O&1N7!(!^@-%?G+H/_!5KQ-\/O&5
MEHOQY^"^L?#NQOGVQ:G''.IC7(!?R9HP94&02T;$@=%8\5^@%OXLT[5?!Z>)
M=(NH-7TJ>R^WVMQ;2!H[B(IO5E89X88Y]Z -JBOE_P#8=_;8_P"&SM*\77O_
M  AG_"'_ -@36T.S^U/MWG^:LASGR8MN/+]\Y[8KW7XL>.O^%7_"OQEXR^P_
MVG_PCNC7FK_8O-\K[1]G@>7R]^UMN[9C=M.,YP>E '5U\Y:?^VQX9\1?M:I\
M"-#TN\O=5M8[E]5U:8^5!;R11>9Y4:D%I#TRWR@=MW;F_P!G_P#;FU/]H+]F
M[QW\4-&^&-VVJ^&[J:TMO"UCJ+7L^I.D$4H".MN&!;S<8$;'Y<\YP/S6^'/[
M17C;P_\ \% /$?Q-L_@UK^K^+;R2\:;P! T_V^V,D(5@Q%LS_(/F.8AQZ=:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ./UPU.(<'"3BE)VZI*WYGFU>*L!3FX)2E;JDK/TNT?C717[*?\ #OSX!_\
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M!^SW_P $Y_BQ\1OCE8_%?]I;6(M0GLIDNET:>[2]GNI4YCCD\O,,<"M@[$+
MX*[0#FOHK_@JI_R8YX^_Z[:;_P"E]O7UK7R5_P %5/\ DQSQ]_UVTW_TOMZ
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M^N.L?^G:&OU4U;_D%7O_ %Q?_P!!- 'Y'_\ !$OX;:5KOQ ^(OC2^M([C4=
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MW'RY[(W:OJ_X6>#)?BO_ ,$WO#OA2VB5KO6OAQ'IMNKL /.:Q\N,Y/ ^?::
M/G/_ ((L_"S36^'OC;XG7UL+KQ'?:PVD0WMP-\D<$<4<LA1CR"[S_,<\^6OI
MS]V?'KX*Z%^T)\*=?\">(5VV.J0[4N5C5Y+68',<T>?XE8 ^XR.A-?!W_!&7
MXJ:=I/A7QU\(M8F_LSQ78ZS)JL.GWA$<LJ-%'#,BJ>2T36^67&1Y@]\?<'[3
M'QRTS]G7X)^*/'%_/:I<V%G)_9UK=,0+N]*D00@ ACN?&=O(4,> ": /E_\
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M2OM'_@H!\5M"^%O[*'Q$_M>_AM[O7M'NM$TZU=P)+F>XB:'"+U.T.7/H%)H
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MPRW[6EY^SWXK\(_V4DK&T&L:I=QM:W3O$LL*>44P5E5@!EOO$+@YH Y/X?\
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M[-M@"[NH#L.YK]4O"?\ R2O1O^P+#_Z(6OS@_P""&O\ R"OC)_UVTG_T&\H
M^Z_VOO#.G>+/V6_BO8:I:QW=LOAG4+I%D4'9-%;O+%(,_P 2NBL#Z@5\I_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\3OB3>^/_A_XUOOAQXDOKIKVZCBMS/;FX8DO+$5='A9B2QPS#). N:?\+?\
M@E1I&E:W/XD^*/Q"U;XJ>)5M9(+"34HW^SV;LI592LDLC2LA(906501]TG!'
MWE10!X%^QK^R=:?L?_#O5_"EGXDF\3QZAJKZH;J>T%L4+0Q1;-H=LC]UG.>]
M>0_M;?\ !+_PY^TM\3&\?:/XPNO ?B2Z6/\ M"2.P^VPW+QJ$24)YL9C<*J
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MTNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH ****
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M[XK_ !H^+$,[/X7\,ZI9>'M.91E)%+21Q;3_ '66WGE/?,B^M?KA_P $\?\
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M]_PF/@N6Z;3%NY+&6&^B$4\,R!25=0S 95T8<]&%?GY^U5JB?M:?\%,/AO\
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MVN[:,%I7C0Y,<J*-PVD*0I&,D&@#]+J*^0?^"9/[3VH_M'? 1H/$EV]]XO\
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M>6K\!7;(PXYSZUZ%XV\<>'_AOX7O_$?BC6+30M#L4WW%]?2B..,$@ 9/4DD
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M>//#27<>B:PLKVRWT0CF CE>)MRAF ^:-NYXQ7S#_P %>?\ DS;4?^PU8?\
MH;5VO_!,O_DQSX8?]<;[_P!+[F@#Z@KP/XR_MK?#[X%_&3PO\,O$<.M/XC\1
M1VLMDUC:));A;BX>WCWN9 1\\;9P#@8//2O?*_)7_@I-_P I)/@7_P!>6A?^
MGBZH _3?XR?%C1/@;\--<\<^(TNGT71XTEN5L8Q),5:18QM4L >7'<5XO^SO
M_P %#/A3^TU\0&\&^$_[;M=:^QR7L:ZM9I"DJQE0RJ5D;+8;=C'16.>*F_X*
M0_\ )DOQ2_Z\K?\ ]*X*_(#X)S7G[,_B3X _'.%I%T74=2N[>_9<GB&X:&Z0
M>FZVG7 ]0QH _H4K+\5>)=/\&>&=7\0:M.+72M*LYKZ[F/2.&)"[M^"J36C#
M,EQ$DL3K)$ZAE=#D,#R"#W%?%O\ P5F^+TGP]_9@E\,:>[?VUXVOH])BBB&9
M#;J1).5'?(5(R/\ IM0!V'P"_P""C7PI_:0^)%IX(\)V_B*/6;J":X1M1L8X
MH=L:EFRPE8YP..*^I:_%'_@GA\.[GX2_\%&D\'7LGFWVC65_:7+=O.6U_> >
MP8L![ 5^UU 'D7[2G[47@C]E7PCIWB'QM)?&VU"]%C;6^FPK-.[[&<MM++\H
M"\G/!91WJ_\ L\_M$>$/VG/A]_PF/@N6Z;3%NY+&6&^B$4\,R!25=0S 95T8
M<]&%?GY^U5JB?M:?\%,/AO\ "-%&H>%?!\Z'482-T4CA1=WH;M@QQ10G/\2D
M=ZA_X)]Z]/\ LK_MM_$[]GW5YFBTG5;F4Z5YS=9809;9N>AEM7)/J50<T ?J
MO7SQ^TO^W1\./V4?$FD:)XU@UR6\U2T-[ =+LTF3RPY3YBTBX.0>U?0]?D3_
M ,%D(TF_:.^$T<BJZ-I:JRL,@@WC9!% 'T9_P^2^ G_/GXP_\%<7_P ?JYI?
M_!83]G[4+M89Y?$^F1GK<76DAD'/I'([?IVKZ>_X9[^%G_1-/!__ ((;7_XW
M7+^//V,O@?\ $?1;G3M7^%_AB(3IL^V:;ID5E=Q]<%)HE5UQG.,X]0: .Y^%
MOQ<\'?&SPG!XE\#^(+/Q'HLK;/M%JQRC@ E)$8!XW ()5P& (XYKSW]I[]L+
MP)^R7!X=E\;PZO*FO-<):?V3:I,081&7W[G7'^M7'7O7YV_\$V9M6^!'[?'C
M_P"$%GJ$NH^'V?4]-N-WW9&LY6,-P5!PK[593Z>:1Z5W/_!<K_D%?!O_ *[:
MM_Z#9T ?IWH.M6_B/0].U:T#BUO[:.ZB$@PVQU#+D=C@BH/%7BK1_ WAO4=?
MU_4;?2-%TZ%KB[O;IPD<,:CDD_TZDD <UROA'Q5H_@;X$>'M?U_4;?2-%T[P
M_:7%W>W3A(X8U@3))_IU)( YK\N?BM\4OB3_ ,%5OC,/AY\.([C0?A+H\ZS7
M-Y<J5C*!B!=W6/O.<'RH,YZGLS* ?=OP%_X* ?#W]I3QU)X7\":'XLU*>%3)
M<ZA+ID<5G;1C.'ED,N5#$848W$]!P<?3->8_L\_L[^#OV9OAW:^$?!UCY,"X
MEO+Z;!N;Z? #32MW)[ <*,   5Z=0!Y'^TI^T[X/_95\&Z=XF\:1:G+IM_?K
MIL0TNW6:3S6CDD&0SKA=L;<YZXKYQ_X?)? 3_GS\8?\ @KB_^/U]D>-OAUX4
M^)>FPZ=XO\,:-XJT^&87$5IK>GQ7D4<@4J'5)%8!L,PR!G#$=Z\Y\3_LJ?!.
MW\-ZM+%\'O ,<J6DS*Z>&+(%2$)!!\K@T ?/O_#Y+X"?\^?C#_P5Q?\ Q^MW
MP%_P5@^"GQ&\<^'?">E6OBI=4U[4K;2[1KC38EC$T\JQ)O(F)"[G&3@\=J^1
M/^"-_P *?!/Q0U+XKKXR\'Z!XM6RATLVJZYID%Z("[76\IYJMMW;5SCKM'I7
MZ>Z3^S+\'M!U6SU/3/A/X'T[4K*9+FUO+3PY9Q302HP9)$=8P596 (8'((!%
M '!_M+_MT?#C]E'Q)I&B>-8-<EO-4M#>P'2[-)D\L.4^8M(N#D'M7CG_  ^2
M^ G_ #Y^,/\ P5Q?_'Z^<_\ @LA&DW[1WPFCD571M+565AD$&\;((K]-O^&>
M_A9_T33P?_X(;7_XW0!\PZ7_ ,%A/V?M0NUAGE\3Z9&>MQ=:2&0<^D<CM^G:
MOJ_X6_%SP=\;/"<'B7P/X@L_$>BRML^T6K'*. "4D1@'C< @E7 8 CCFN&\>
M?L9? _XCZ+<Z=J_PO\,1"=-GVS3=,BLKN/K@I-$JNN,YQG'J#7YR?\$V9M6^
M!'[?'C_X06>H2ZCX?9]3TVXW?=D:SE8PW!4'"OM5E/IYI'I0!^P=%%% '@>L
M?MK?#[1/VEK?X&7$.M'QK/)%$DB6B&SW26XG7,GF9^X1GY>M>D_&3XL:)\#?
MAIKGCGQ&ET^BZ/&DMRMC&))BK2+&-JE@#RX[BOS(^(O_ "FTT?\ Z_=/_P#3
M2E?:O_!2'_DR7XI?]>5O_P"E<% '3_LS_MA?#O\ :PL=9F\$75ZESI$B)=6&
MJ0+!<*KC*2!0S H2&&<]5.0.,^W5_/#^SSXO\=?LBZMX ^.NF6[W7A35[NYT
MNZBB8A+E(W GM).P8KMD0GNH/.PU^_WP_P#'FB?$_P $Z+XL\.7JZAH>KVJ7
M=K<+_$C#H1V8'(*GD$$'D4 >5?M/_MD^ OV2?^$:_P"$XAUB7_A(/M/V/^R;
M5)\>1Y7F;]SKC_7IC&<\UZWJWBRRT7P;>^)K@2G3K2P?4I B@R>4L9D.!G[V
MT=,]:_,7_@N=_P T3_[C?_MA7Z$_$+_DVWQ+_P!BE<_^D;4 ?,'_  ^2^ G_
M #Y^,/\ P5Q?_'ZD@_X+'? *:9$>#Q; K'!DDTJ,JON<3$_D*^>?^".?PA\"
M?$[PW\4)?&/@KP[XLEL[O3UMGUS2H+TP!DG+!#*C;0<#..N!7Z#:Q^QC\!]<
M@,5S\(/!<:E2N;/1(+5L'_:B53GWSF@#2^!O[4'PR_:.T^:Y\ >*K769K=0]
MS8,K07=N"<9>&0!P,\;@"I/0FO5*_&W]M_\ 99O?V!?B+X3^,WP8O[O1]#DO
M_)%K)*TQT^Z*LWE;CR]O+&KKM<D\,"2&&/U8^!GQ6L/CE\(?"?CO38_)M=<L
M([HP$Y,,GW98L]]DBNN?]F@#Y:U?_@K_ / K1=6O=/N+3Q<;BTG>WDV:9$5W
M(Q4X/G=,BJG_  ^2^ G_ #Y^,/\ P5Q?_'Z^4O\ @F+\-_"7Q,_:L^+-CXO\
M+:+XKL;>QNIX;;6]/AO(XY/MT:[U656 ;!(R.<$U^H7_  R=\$/^B-_#_P#\
M)>Q_^-4 ?-7_  ^2^ G_ #Y^,/\ P5Q?_'Z^M_B+\4K#X;?#'4O'5WINJ:KI
M.GV@OY[?2H%EN1!@%G"%E!"J2S8/ 4GG%<[_ ,,G?!#_ *(W\/\ _P )>Q_^
M-5Z@MM"EN+=8D6 )Y8B"C:%QC;CIC':@#Q?]F?\ ; ^'?[5^GZS/X(N[Q+G2
M952[T_5(5AN55QE)0H9@4)#+D'JIR!QGVVOQS_:2^&OB+_@F?^U5H_Q;^'EJ
M[?#O7;AU.GH2(4#G=<:=(>@4@;XB>FT8R8B3^@_Q2_;:\ _#_P#9A@^-%G>+
MJ^E:I;+_ &+8APDMY=N"%MR.=C*ROYG78(WZD $ E_:,_;@^&G[,?B71?#OB
MF35-1\0:M'YL.F:%:K=3HA8*C.I=<;VR%').T\5[KI-^VJ:59WKV=QI[W$*3
M&TNU59H2R@['"D@,,X."1D'DU^9?_!.S]G3Q#\?/B=J/[47Q=#7]]>7;S^'[
M6X4A9)1\OVD(>D40 CA7U7=QL4G]/Z "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /*O$?_)TWP\_[$SQ-_P"EV@UZK7E7B/\ Y.F^'G_8F>)O_2[0:]5H ***
M* /YK/VL?^3IOC)_V.>L_P#I=-11^UC_ ,G3?&3_ +'/6?\ TNFHH _:G_@E
MQ_R8G\,O^XG_ .G2[KZJKY5_X)<?\F)_#+_N)_\ ITNZ^JJ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KRK]D[_DUGX-_]B9HW_I##7JM>5?LG?\FL
M_!O_ +$S1O\ TAAH ]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<?
MVVOCIKGP:\$:3;^&Y!::MK<TD0OB@8V\4:J7*@C&\EU )Z#..>1]'5YW\</@
MAH7QW\'_ -AZRTMK)#)Y]I?6^/,MY,$9P>&4@X*]_8@$9U%*4&H[GO9%B,%A
M<RH5LPAS44_>5K]--.J3LVNJT/RWF^/GQ,N)GD;XA>* S')":Q<(OX . /PI
MG_"]OB7_ -%#\5_^#NY_^+KZK;_@F2-QQ\2,#MG0O_NFC_AV3_U4G_RA?_=-
M>3[&O_3/Z3_UMX.7VX_^"I?_ "!\J?\ "]OB7_T4/Q7_ .#NY_\ BZ@O_C1\
M0=4L;BRO?'?B:\L[F-H9[>XU>X>.6-@0R,I?#*02"#P0:^LO^'9/_52?_*%_
M]TUA>//^">'_  A/@?Q%XB_X6!]M_LC3KB_^S?V-Y?F^5$TFS=]H.W.W&<'&
M>AH=&O;7\S:EQ5PE4J1A3G'F;27[N6_3[!\<4445R'Z8%=5H?Q9\<>&=+ATW
M1_&7B#2M.@W>59V.J3PPQ[F+-M17 &6))P.I)KE:^J_@C^PO_P +D^&&B^,/
M^$V_LC^TO._T/^R?/\ORYY(OO^>N<^7GH,9Q[UI3C.;M#<\#.<QRW+,/&MFC
M2IMV5XN6MF]DGT3U/#?^%[?$O_HH?BO_ ,'=S_\ %T?\+V^)?_10_%?_ (.[
MG_XNOJO_ (=D_P#52?\ RA?_ '31_P .R?\ JI/_ )0O_NFM_8U_Z9\;_K=P
M=_/'_P %2_\ D#Y4_P"%[?$O_HH?BO\ \'=S_P#%U[3^RW^U1X\L?BIX>\/Z
M[KM[XDT76+N.PDBU*5IY8FD;8DB2-EAAB,@D@C/L1Z%_P[)_ZJ3_ .4+_P"Z
M:](^!O["^@_"/QA;^)=2UZ;Q/J-F=]DAM!;0PO@C>5WN689XY !YQG&-*=&N
MI)_J>-G'$W"&)P%:E#EG)Q=DJ<D[VTLW%6L^MSS3_@L=JESI_P"R+!! 6$5]
MXDLK>?;T*".>09]MT:?I7JO_  3CT>VT7]BKX70VRHJS6,UTY0YW/)<RNQ)]
M<L1[8QVI/^"B'P=O?C9^R;XRT?2H)+K6=/2/6+&WA7<\LENV]D5>I9H_,4 <
MDD?2O(/^"1/[0&E^/_V?8OAU<7:)XG\'22J+9V^>>QEE:2.51W"M(T9Q]W:F
M?O"O6/YF/O*LWQ-H=MXF\.:KH]XBR6>H6DMI,D@RK)(A1@1Z8)K2KQ#]LSX]
MZ;^SK^SWXJ\375W'!JLUK)8:/ 6P\][*C+$%'?;RY_V4:@#X#_X(=ZG<1^+/
MBSIXWFUELM/N&Y^4.DDZCCU(=ORJY\4O^4UGAG_KM8_^FVO1O^"+?P?O/"OP
MC\8>/[^&2#_A*;Z*UL5D3&^VM0X,JGN&DFD7ZPUYS\4O^4UGAG_KM8_^FV@"
M_P""5/[(O_!6S5M#8?8_"OQ(#FW!&$/VP^;%M7IQ>1O"/0,?I7W!^VM\9/\
MA1'[,?COQ5#/Y&J+8M8Z:RMAOM<Y\J)E]2A?S/HAKY3_ ."QWPVO;?PC\/OC
M!H0:#6/">J+:3747WHXY&$D$A/HDT0 ]YORX_P#;:^*H_;,UW]F7X4>&IBMO
MXU6U\3:K';MN-LDJF/GWA1;TL#_=% 'FGC_X-?\ "I?^"1.@7=S#Y6K>*_$=
MIX@N21SY<JNMN,^GDI&V.Q=J_0W_ ()X_P#)EOPJ_P"P8W_H^6O(?^"N6FVN
MC_L6V^GV4"6UE:ZUI\$$,8PL<:I(JJ/8  ?A7KW_  3Q_P"3+?A5_P!@QO\
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M5M/A_;T_8WM(],L[+4_&7A.P'EP100)KUKY2]-FT&YBC Z [ !V %=W\,?\
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M$W?%7P!^$S_$>X^*-]\2%TZZAMKJ&\TUX'M()&*B42-<RY E,:[<#_69SQR
M?M3/(889'5&D95+!%ZM@=!7Y&?\ !%F)/$'QK^*GB.]Q+JITJ,><W+8GN2\G
M/NT2?E7W]^P[\=A^T-^S1X0\47%QY^MPP?V9JY9LM]L@ 1V;W<;)?I**_/#]
ME76K?]AW_@HUXR\ ^*9&TWP[X@DFTJSOKKY(]DLJS6$S'IA@!&3T5I#D@*<
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M,-%*[./5GS0!Z]_P7!_Y$'X6?]A.]_\ 14=>?_#W]N+]LGP_X!\-:7H7[/\
M_:6B6.F6UM87O_"&:S+]HMTB58Y-Z3!6W*%.Y0 <Y'%>@?\ !<'_ )$'X6?]
MA.]_]%1U]Z?L]_\ ) OAI_V+.F?^DL= 'YU_\-]?MO?]&Y?^6-KG_P ?K[4_
M8I^+WQ3^-'PKU76_B[X*_P"$$\26^M2V5OIW]E76G>9:K! ZR^7<NSG+R2KN
M!VG9C&0:^@** /R5_P""KG_)Z'P3_P"O*Q_].,E>L?\ !5K]DNZ\5Z#;_''P
M1%);>+_"Z))JOV/*RSVD9W)<J1SYD!&<]=F>?W8%>3_\%7/^3T/@G_UY6/\
MZ<9*_6>:&.XADBEC66*12KQN 592,$$'J* /FS]@G]K*U_:L^"]M?WLL2>-=
M%"66O6J8&9<?)<*O9)0"WH&#K_#7Q7^P]_RE>^.'_7[XF_\ 3FM<[\6/#>M?
M\$MOVS-.\<>&;6>?X5>)W?-C$?D-LS W%D?]N(E9(B>VP9/SUH?\$]_$FG>,
MO^"G7Q:U_1[E;W2=5;Q!?6=R@($L,NH(\;C/8JP/XT ._P""RLC:Q^T5\*M$
MN]T>F'25/F9X!EO&23\0L:?F*_7:WMX[6".&%%BAC4(B*,!5 P !Z8K\R?\
M@M=\*+R^\-^ /B5812/'I4\ND7\D8R(UEQ) Y] '21<^KJ/3/W=^S;\:-,_:
M ^"?A3QOIERDYU"S07D:D;H+M0%GB8#H5<-]001P10!Z9117P-^U!_P4%\7_
M  ]_:R\+?"'X6Z7H/BN>Y-O8ZG#?B1BE]/+M6)9(W&PHFQF)# ;R" 5H Z3_
M (*\_P#)FVH_]AJP_P#0VKY _9;^.?[8GA'X#^%=)^&7PRL]>\#6R3C3=1ET
MQI6F4W$K2$N)USB0R#H.E?7_ /P5X_Y,UU'/7^V;#_T-J[7_ ()E_P#)CGPP
M_P"N-]_Z7W- 'S!_PTM_P4!_Z(WI_P#X)G_^2:^7?B]XX^,'C_\ ;5^#VH?&
MOPS#X5\51W>CV]M9PVQ@#V8U)V23:7?),C3#.?X>G%?O#7Y*_P#!2;_E))\"
M_P#KRT+_ -/%U0!]J_\ !2'_ ),E^*7_ %Y6_P#Z5P5\'^'?@Z?BQ_P1W^V6
ML'G:KX3UB]U^WVCYO+CF=;@9]!"\CGWC%?>'_!2'_DR7XI?]>5O_ .E<%>?_
M /!*G2;37OV&-,TR_@6YL;R]U.VN(7^[)&\K*RGV()'XT >@?\$Z_C!_PN;]
MDGP3J$\_GZIH\)T&_).2);;"(6/<M#Y+GW>OFSXM_P#&5G_!5'P9X*3_ $KP
MK\+K5=2OUSNC,Z;)W..G,K6<+#_8;Z5P_P#P3_\ B,G['GQ;_:(^%/BZX9--
M\.V]UKUN96VF466[<R?[4T#PN..1&/I7K7_!(_P1J.O>&_B1\;_$:>9KWCO6
MY1',PZQ)(SRNA_NM/*ZX_P"F H \<_9\_P"4R7CO_K]UC_T2:_3KXO?$C3_@
M_P#"_P 4^-=5(^Q:%ITU\R%L>:R*2D8/]YVVJ/=A7YB_L^?\IDO'?_7[K'_H
MDUZ9_P %G/C4^@_#'PO\+=,F9M0\3W8OKZ&+EC:0,/+0C_;F*D>\!H Y_P#X
M(^?#G4/&?B3XG?'CQ*#<ZMK%Y)IMM<NOWY9'%Q>2#/JS0J"/1QZUF?\ !6[P
M+J?PF^+OPO\ V@/"P^S:A;W,5E=3*/E%W;MYUJS>N]!*A!_AA [U:\#_ /!'
MOQK8^$]*'_#0&J>&)Y;>.>XTFQTB4Q6LSJ&DC#+>J&VL2-VT9QG SBJWQ(_X
M(_\ C:;P/K,Z_'G5/%]W9VLMW::+>Z1*([N=$9HX]S7KA"Q^7=M.-W0T ?I-
M\+?B'IGQ:^'/AKQEHS[M-URPAOH03DH'4$HW^TIRI'8J:_*K_@M!>/I_Q^^%
M]U''YSP:-YJQC^,K=,0/QQ7KG_!&/XZGQ%\-_$OPIU*<F_\ #<YU+38Y#S]C
MF;]ZBCT2;+'_ *^!7EO_  6,_P"3DOA'_P!@Q?\ TL:@#LI?^"N7Q0AC>23]
MG6^CC0%F=KFZ 4#J2?LW2N9LO^"JGQW_ &@+JX\*?"/X56$7B"XA)6:W:2_F
MMEZ&4;MD:X)'S."H[@U^M%?F?_P4Z_8]G\/*O[0?PICDT#Q'HLBW.NQZ/F%R
MH/%_'LQB1#_K".JG<?NL6 /0?^"=/["/B+X!ZOK/Q-^)MTES\0]<A:)+-9_/
M:RCD<23--("5>:1@N=I(4 _,2QQY)_P7*_Y!7P;_ .NVK?\ H-G7U-_P3]_;
M!@_:P^$OF:J\4/CS0?+M=;MXP%$V0?+ND4=%D"G('"NK #&W/RS_ ,%RO^05
M\&_^NVK?^@V= 'S[\</C?\6OVZ/"$^@?#_P[J2_"[X>:+!<W]O#@&X:&)5,\
MYSAW^5VCA7)"JS8)!(^WO^"1_P 9/ OB_P" 8\$Z)I5CX>\7^'F+ZO:P??U$
M.<+?$GYG+<(W)V%0!M4H*^F_V8?AEX:^%'P)\':)X7TJ'2[!]-M[N98QEYYY
M(E:261CRSL3U/8 #   _,+]L+X/^(O\ @GC^TYH?QJ^&$'V?P=JUXTBV:@BW
M@F;)N+"0#@0R+N9/09"X,0- '[(45P/P*^-7AW]H/X7:)XY\,3^9IVI1 O S
M RVLPXD@D Z.C9!['@C(()[Z@ K)\6?\BKK/_7E-_P"BVK6K)\6?\BKK/_7E
M-_Z+:@#\MO\ @AK_ ,A7XR?]<=)_]"O*_5^OR@_X(:_\A7XR?]<=)_\ 0KRO
MU?H _('_ (+07CZ?\?OA?=1Q^<\&C>:L8_C*W3$#\<5WDO\ P5R^*$,;R2?L
MZWT<: LSM<W0"@=23]FZ5QO_  6,_P"3DOA'_P!@Q?\ TL:OUTH _)>R_P""
MJGQW_: NKCPI\(_A581>(+B$E9K=I+^:V7H91NV1K@D?,X*CN#7O/_!.G]A'
MQ%\ ]7UGXF_$VZ2Y^(>N0M$EFL_GM91R.))FFD!*O-(P7.TD* ?F)8X\^_X*
M=?L>S^'E7]H/X4QR:!XCT61;G78]'S"Y4'B_CV8Q(A_UA'53N/W6+?1G_!/W
M]L&#]K#X2^9JKQ0^/-!\NUUNWC 439!\NZ11T60*<@<*ZL ,;<@'U)1110!^
M2OQ%_P"4VFC_ /7[I_\ Z:4K[5_X*0_\F2_%+_KRM_\ TK@KXJ^(O_*;31_^
MOW3_ /TTI7VK_P %(?\ DR7XI?\ 7E;_ /I7!0!\[_L&_ O0?VCO^";=YX%\
M0IMMM0U6_:WNU4%[.Y5P8IT]U;MW!93P37GG_!.OXY:_^RO\<]>_9G^*#_8;
M>;4&CTF:5CY=O?-@JJ,?^6-RI5D/]XKQF0U]%_\ !(;_ ),VT[_L-7__ *&M
M<Y_P52_9%E^*_@.+XJ^$;9U\<>$H=]TMJ");VP0ESC')DA.9%QSM+CD[10!Y
M'_P7._YHG_W&_P#VPK]"?B%_R;;XE_[%*Y_](VK\3/VNOVLO^&I/@K\$?[7E
MW>-_#/\ :UAK?'^OW+8^3=?]M CY']]'X Q7[9_$+_DVWQ+_ -BE<_\ I&U
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3!_9_P#CG^S'XH\:>&O'WA$Z?X*U:-;NVU"/5;.XC2\B;9Q'',S@2QMR2O\
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M'[Q!&""OV710!^4>C_$#_@H9\&M*3PW/X0D\7PVJBUMM1NK2#4I-O"JWG0R
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MC-\IS\H-?HO10 5!?6-OJ=E<6=Y!'=6EQ&T4T$R!TD1AAE93P002"#US4]%
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M==\6:'X7\C^V=9T_2//W>5]NNHX/,VXW;=Q&<9&<=,BM:ORK_P""YW_-$_\
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MXM;V(9:/>HD@N8\]&4E7'KT/!(K\Q?V%OC!K_P"PS^TYX@^ ?Q+G^R>'M5U
M017$A(@M[Q@!!=(3TBG38I)Z9C)QM:@#]@ZJ:KJ]CH5C)>ZE>V^GV4>-]Q=2
MK%&N2 ,LQ &20/J:MU^3'[>OQ<\0_MH?M':#^S?\,9_M.C:;?[=4O(B3#+>)
MGSI)"/\ EC;)N'N^\8)"4 ?JOHOB#2_$EJUUI&I6>JVRN8VFLITF0, "5+*2
M,X(./<5H5P?P-^#7A[X ?"[0? WAF#RM-TN (TS "2YF/,D\A[N[$L>PR ,
M 5WE !7(>+OC%X!^']]%9^*/&_ASPW>2E1';ZOJUO:R.3T 61P3GM7$?MC_%
MK5O@;^S+X^\;:"@;6=-L56S9H]XBEEEC@64KT.PR[^>/EYXKX%_86_8%^'_[
M4_P7N?BC\3]:USQ1XFU[4+E'>/4F1[8QN4W2,06>5B-^6)&UDXZD@'ZJZ3J]
MCKVFV^H:9>V^HV%PN^&ZM)5EBD7U5E)!'N#5NORA_P"">>M:[^S_ /MR>/\
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MH;]G_P )?$+4?'.L:1>:U'</)9VMK$\<?EW,L(P6Y.1&#^- 'ZL_\+9\#_\
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M ?37C+XM>!OATRIXK\9^'_##,-RKK.J06A(SC(\QQQDC\Z?X.^*G@KXB;O\
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M2Q/0#'.:H:%XLT3Q1YYT;6=/U<0;?-^PW23>7G.-VTG&<'&?0UQ?QQL5TO\
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M*>?$'P!J>JW.BV=_K.I3->6D:O(IBB:0 !N.2N/QH _9W_A;/@?_ *'+P_\
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M2'S,8SMW$9QD=/45IQR)-&LD;*Z, RLIR"#T(-?EO_P7*_Y!7P;_ .NVK?\
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M9^#?_8F:-_Z0PUZK7E7[)W_)K/P;_P"Q,T;_ -(8: /5:*** "BBB@ HHHH
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M'<^$==O<BR6:Y6YM[AP"3&) J$,0. 5P>F<X!_,__AG#XM?]$N\:?^$_=_\
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M)?'SX9:/KL-E:^(/"NOV<=[!!J=JLB21NN0'C<$;AG!!Z$&OYN/L3Y8^&O\
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M<XA+995BCVJ$!"@3+QP, 'D__!9"1(?VCOA-)(RHBZ6K,S'  %XV237Z;?\
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M>[CE_(N@K]5* /RB_P"";[#P;_P43^/WA"UPFFH-9C2-1@9MM5C2/CL KO\
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M "EP^+W_ %^^(?\ TK% 'IO_  6R\9W6E_!KP%X9AG,4&L:U+=3QKQYBV\6
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MXXI^T/\ LY^#?&3RK)JDUJ+35%!Y6]A_=S9';<R[P/[KK7PU\1OCE^V]\5/
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M  3!_9K^%?Q0_95L-<\6_#[P]XCUA]6O(FOM2L(YI2BL J[F&<"@#?\ $_\
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M-S! -S>YR:O>+O%6G>!O"FL^(]7F^SZ5I%G-?W<O]R*)"[G\E->6_LR_M;^
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MH]2T75;:.[M+J(_+)&XR#['L0>000>17Y7_\$.?^1J^+?_7EIO\ Z,N*U/\
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M=>Z^!_VX/AE\0/V@-9^#NE3:L?%^F75Q:,S6):TF>!2TQ25&;:%*LN9 F67
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M*^S_ -FWPP?&W[ _@CPZ"JG5_ L>G@O]T>;:&/GV^:OB[_@BCXH'A_QA\6_
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M,_X)Y3_\*D^-G@?5-0\+6,SKIMW;X$\$98LQMI&Q'=0DDD#>I7<1N&-H]O\
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M)&LL;(ZAT8896&01Z&LK0_"&@^%VF;1M$T[26F $K6-I'"7 S@-M SC)Z^M
M'@'[=W['UI^UU\*H]/LY;?3O&>C.USHFHW (C#, )()" 2(Y JY(!PRH<'!!
M^,/@A_P4)^(/[&-G:_"O]H+P#KMS;Z.OV;3]4A51>"W3Y51?,(CN8U'"R+(.
M !ENM?K+67X@\+Z-XML39:YI%CK-EG/V?4+9)X\X(SM<$="1^- 'P+XZ_P""
MTWPNT_1Y!X/\)>)O$.M.I$$-_%#9V^[H-SB1WZXX"'/J*\Q_9I_97^*/[8W[
M0$'QX^/FG2:9X<MYEN+'1;V)H&NO+.8(8H&Y2U0_,2W,G^UO9J_2?PW\$?AU
MX,U 7_A_P!X7T*^WF3[3INC6UO+O/);<B YX'/M7:T >:?M-?\FV_%?_ +%+
M5O\ TCEK\>?V!?V^M _8]\(^*M'UCPKJ7B&76+Z*[CDL;B.,1A8]F#NZFOW,
MNK6&^MI;>XACN+>9#')#*H9'4C!4@\$$<8-<S_PJ?P/_ -";X?\ _!7!_P#$
M4 ? '_#[SP1_T33Q!_X&P?X5]/?L<_MH:+^V-IOBB\T;PY?^'ET&:WAD6^F2
M0RF59""NWICRSU]:]A_X5/X'_P"A-\/_ /@K@_\ B*U]#\*Z+X769=&T>PTE
M9B#*MC;)"'(S@MM SC)Z^M 'YL?MG?L>?$?X-?',?M%_L_VTMQ>BX^W:KHFG
MQ&6=)VR)I$A'^NAE!/F(/F!9B!@Y3I/AY_P6B\ SZ6+;XA^"_$7AKQ% -EQ'
MI<4=U;&0'# ;WCD0YS\I4XY&X]_T7KCO%GP;\ >/+AY_$W@;PWXBG?!:35M(
MM[ICC&,F1#Z#\A0!^;?QN_X*@>+?VC+*X^'/[.W@7Q"-4U=#;2ZM-"&OHXF^
M5O)BB+K%D'_7,_R@DX4X8?3'_!.[]B5OV3_ M]J?B7[/=?$/7POV^2W?S([*
MW'*6R-W.?F=AP6P!D("?J7PSX-T#P79M:>'M#TW0K5CN:#3+2.W0GU*H .Y_
M.MB@#RW]I?\ 9_T+]IKX/ZUX%UW]R+I1-8WRKN>RNT!\J=1WP201D;E9ER,U
M^8/PV^-WQZ_X)<ZI<^"/'O@Z3Q5\-C<&2UFC=UM59VY>TN]A4;N6,,@!SSA"
MQ)_9"H+VRM]2M)K6[@BNK:92DD,R!T=3U#*>"/8T ?GR_P#P6P^$0TLR)X+\
M;-J6W_CW:"S$.[/3S/M&<>^S\*^<?BY^T!\<_P#@I^]OX%\ _#G^R/ T-\EQ
M++DR(LB@A7N;UU5%"ABPC0!CS]_ K]5I/V</A+-J'V]_A=X+>^QC[2WA^T,F
M"<XW>7GJ37?6=E;Z;:Q6MI!%:VT2[8X84"(BCL%' % 'F?[+OP=N_@#\ O!O
M@"_U&'5;[1;5HI[NV0I$[O*\C!0>< OM!."<9P,X'J=%% 'Y%^!_^4WMS_V$
M]1_],DU?KI6/'X/T&+7#K2:)IJ:QDM_:"VD8N,E=I/F8W<J2.O0XK8H ****
M /RN_P""E?P1\=?!_P#:&T']IOP!:3:C#;O;3:H8HO-%E<6R*B/*HY\B2)%0
MMT!5@2-RUZ5I7_!:3X1S>"TOM0\,^*+7Q((5\S1X((9(C-CD).9 "F?XF56Q
M_#VK]!F4.I5@&4C!!Z&O/Y/V>/A5+K!U9_AEX.?52VXWS:!:&?.<YW^7NSGG
MK0!^.WCCX0_'/_@I'XE\7_&C3_!5MH>D6=@J:9:NIA-_'$3M@MW* W,N-Y,A
MPN0$!7Y5'VQ_P3!_; U_XS>';KX7^+]!U"/Q)X,LUA;6A;E87A1A$D-P,#R[
MA<;<$?.(V/!4Y^\(XUBC5$4(BC"JHP /051T[P_I>CWFHWEAIMI97>I2B>]G
MMX%C>ZD"A \C 9=@JJN3DX ':@#0KY?_ ."FG_)CGQ/_ .N-C_Z7VU?4%5=4
MTNRUNQELM1L[>_LY<"2WNHEDC?!!&58$'D _A0!^,_[%?_!3+PS^RW\#K7P+
MJG@S5M<NX;ZXNS=V=S%'&1(P(&&YR,5[Q_P^\\$?]$T\0?\ @;!_A7W_ /\
M"I_ _P#T)OA__P %<'_Q%'_"I_ __0F^'_\ P5P?_$4 <'^R?^TSIG[5_P +
MY?&NDZ+=Z%:QZC-IQM;R59'+1JC%LKQ@^8/RK\_/V/?^4N'Q>_Z_?$/_ *5B
MOU;T;0=,\.69M-)TZTTNU+%S!9P+"FXXR=J@#/ Y]JKV?A#0=.U>;5;31-.M
M=4F+&6^AM(TG<L<L6<#<<GKD\T ?(/\ P5Y_Y,VU'_L-6'_H;5VO_!,O_DQS
MX8?]<;[_ -+[FOI+6-#T[Q#9FSU73[74[0L&-O>0K+&2.AVL",BI-+TNRT2Q
MBLM.L[>PLXLB.WM8ECC3)).%4 #DD_C0!:HHHH _#?Q)\?=/_9E_X*>?$'Q_
MJ>E7.M6=AK.I0M9VDBI(YEB:,$%N."V?PKZ>_P"'WG@C_HFGB#_P-@_PK]!K
M[X:^$=4O)KN]\*Z+=W<S;Y)Y].A=W8]2S%<D_6H/^%3^!_\ H3?#_P#X*X/_
M (B@#X _X?>>"/\ HFGB#_P-@_PK[?\ V</C?8_M'?!CP]\1--TRXT>RUG[1
MY=E=.KR1^3<RP')7@Y,1/T(KH/\ A4_@?_H3?#__ (*X/_B*Z#2])L=#L(K'
M3;*WT^RBSY=M:Q+%&F22<*H &22?J30!;KX<_P""GG[&FM_M&>$-&\8>!X?M
M/CCPNLB"Q1MLE_:,0Q2,DX\Q&!91QG<XZ[17W'10!^5OP4_X+!W_ ,/=-C\)
M_'/P/K4OB#2E^S7&J:7$D=W*RC \^UF:,+)Q\S!P#G.T5O?$C_@M-H6H:3<:
M=\+OA]KM]XCNE\FQFUX1(D<C<!O)A>1I"#T4,,^O:OT0\6_#7PAX^V?\)/X5
MT3Q'Y:E$_M;3H;K:IZ@>8IP.:J>#_@[X"^'=QY_A7P1X<\,S[2OF:/I-O:-M
M/49C0<&@#XT_X)=?LF^+OA-;^*?BG\2;>XL?&GBY?+BL;S*W,%NTGFRR3K_#
M)+($;:>5"#."Q V/^"EG[$VJ_M$:%I7COP%&H^(GAN(H+='\N34;4$NL:/VE
MC<LR9(SO89SMK[BHH _+WX*_\%>Y_ 6G)X2^/G@K7[3Q3IBK;SZGIUJB33,.
M,W%K*T9C?')*DY/1%J3XU?\ !86#QAI,GA;X&^"]?O/%6J!K2VU'4[=/,A=@
M0&M[:)I&EDYRN[ ! RK=*_1KQ9\-O"/CS9_PDWA;1?$6U=J_VMIT-U@<\#S%
M/')_,U'X1^%G@OP!@^%_"&@^&\*5']D:9!:\'&1^[4<<#\J /C/_ ()D_L4Z
M[\#;/5OB;\1%FB\?^)(&@33[EM\UE;-()':9N29I656(S\H !Y+ )_P6>_Y-
M0T3_ +&VS_\ 26[K[UK/UKP_I?B2T6UU?3;/5+57$@AO8$F0, 0&VL",X)Y]
MS0!XU^PK_P F?_"3_L7[?^5?D/\ LF_M::3^R#^T+\1O$FL:#>^((-36ZTY(
M+&5(V1OM:R;B6[80C\:_>6QL+72[.&TLK:&TM(5V1P0($1%'0*HX ^E<])\*
M_!4TC22>#]!=V)9F;3("23U).V@#\_O^'WG@C_HFGB#_ ,#8/\*/^'WG@C_H
MFGB#_P #8/\ "OO_ /X5/X'_ .A-\/\ _@K@_P#B*/\ A4_@?_H3?#__ (*X
M/_B* .%\;^.(/B;^QSK_ (PM;:2RMO$/@*XU:*VF8,\23Z>TH1B."0' ./2O
MCK_@B'_R2SXE_P#89M__ $0:_2!-+LX]-73EM(%T]8?LXM%C41"+;MV;,8VX
MXQC&.*K:'X9T?PS%+%H^DV.DQ2MND2QMDA#D<9(4#)H NWEG!J%I/:W4,=S;
M3HT4L,JADD1AAE8'@@@D$&OP$_X*!?LJW_[*?Q;N]/TH7 ^'GB24ZEH_S,8T
M*;@UN_J\/FL%)R=DBG.2U?T UFZYX;TCQ-!'!K&E66K0QMO2.^MTF56QC(#
MX..] 'DW[%/_ ":/\(?^Q9L?_12U\/?MG?LO?$K]G#]H0?M'_ RQDO8)KAKS
M5=+L;=IWMIW!%PSPKS);S EF(Y5F8_+\K#]1;&QMM-LX;2SMXK2UA4)%! @1
M$4= JC@#V%3T ?G7X"_X+4_#.^T&,^,_!WB;0M>C0^?!I<<-Y;,P_N.\D; D
MY^5EXZ;CUKQ+]HG]N3X@_M\1O\(_@=X$UJWT34'0ZC<28-W<Q9X68H3';0;L
M%B7.[ !8 E3^I7B+X&_#?QA?->:]\/\ PMK=XS^8UQJ.BVUQ(6R3N+.A.<DG
M/O71>'O"NB^$;+['H6CV&BVF0?L^GVJ01\# ^5 !T&* /(/V,_V8[/\ 90^"
M5AX/CNDU'6)YFU#5[Z-<)-=NJJP3(SL545%SR0N< DBORK\2?'W3_P!F7_@I
MY\0?'^IZ5<ZU9V&LZE"UG:2*DCF6)HP06XX+9_"OW(KF[[X:^$=4O)KN]\*Z
M+=W<S;Y)Y].A=W8]2S%<D_6@#\^?^'WG@C_HFGB#_P #8/\ "C_A]YX(_P"B
M:>(/_ V#_"OO_P#X5/X'_P"A-\/_ /@K@_\ B*/^%3^!_P#H3?#_ /X*X/\
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MI86VI6;$%K>[A66,D'()5@1P:72=&T_0;%++3+&VTZS0DK;VD*Q1J2<DA5
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M+?C-J>G7GA7P]X=U"739;6\E26>XF6&&1%BVX!9S.J*OJ.<#FO>/^%3^!_\
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M HHHH \J\1_\G3?#S_L3/$W_ *7:#7JM>5>(_P#DZ;X>?]B9XF_]+M!KU6@
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M('_@#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X
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M ^'O_E51_P *;\7?]%V^('_@#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\
MY54?\*;\7?\ 1=OB!_X ^'O_ )55ZK10!Y5_PIOQ=_T7;X@?^ /A[_Y54?\
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M%V^('_@#X>_^55'_  IOQ=_T7;X@?^ /A[_Y55ZK10!Y5_PIOQ=_T7;X@?\
M@#X>_P#E51_PIOQ=_P!%V^('_@#X>_\ E57JM% 'E7_"F_%W_1=OB!_X ^'O
M_E51_P *;\7?]%V^('_@#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\ Y54?
M\*;\7?\ 1=OB!_X ^'O_ )55ZK10!Y5_PIOQ=_T7;X@?^ /A[_Y54?\ "F_%
MW_1=OB!_X ^'O_E57JM% 'E7_"F_%W_1=OB!_P" /A[_ .55'_"F_%W_ $7;
MX@?^ /A[_P"55>JT4 >5?\*;\7?]%V^('_@#X>_^55'_  IOQ=_T7;X@?^ /
MA[_Y55ZK10!Y5_PIOQ=_T7;X@?\ @#X>_P#E51_PIOQ=_P!%V^('_@#X>_\
ME57JM% 'E7_"F_%W_1=OB!_X ^'O_E51_P *;\7?]%V^('_@#X>_^55>JT4
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M;\7?]%V^('_@#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\
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M;X@?^ /A[_Y54?\ "F_%W_1=OB!_X ^'O_E57JM% 'E7_"F_%W_1=OB!_P"
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M('_@#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X
M^'O_ )55ZK10!Y5_PIOQ=_T7;X@?^ /A[_Y54?\ "F_%W_1=OB!_X ^'O_E5
M7JM% 'E7_"F_%W_1=OB!_P" /A[_ .55'_"F_%W_ $7;X@?^ /A[_P"55>JT
M4 >5?\*;\7?]%V^('_@#X>_^55'_  IOQ=_T7;X@?^ /A[_Y55ZK10!Y5_PI
MOQ=_T7;X@?\ @#X>_P#E51_PIOQ=_P!%V^('_@#X>_\ E57JM% 'E7_"F_%W
M_1=OB!_X ^'O_E51_P *;\7?]%V^('_@#X>_^55>JT4 >5?\*;\7?]%V^('_
M ( ^'O\ Y54?\*;\7?\ 1=OB!_X ^'O_ )55ZK10!Y5_PIOQ=_T7;X@?^ /A
M[_Y54?\ "F_%W_1=OB!_X ^'O_E57JM% 'E7_"F_%W_1=OB!_P" /A[_ .55
M'_"F_%W_ $7;X@?^ /A[_P"55>JT4 >5?\*;\7?]%V^('_@#X>_^55'_  IO
MQ=_T7;X@?^ /A[_Y55ZK10!Y5_PIOQ=_T7;X@?\ @#X>_P#E51_PIOQ=_P!%
MV^('_@#X>_\ E57JM% 'E7_"F_%W_1=OB!_X ^'O_E51_P *;\7?]%V^('_@
M#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X ^'O_
M )55ZK10!Y5_PIOQ=_T7;X@?^ /A[_Y54?\ "F_%W_1=OB!_X ^'O_E57JM%
M 'E7_"F_%W_1=OB!_P" /A[_ .55'_"F_%W_ $7;X@?^ /A[_P"55>JT4 >5
M?\*;\7?]%V^('_@#X>_^55'_  IOQ=_T7;X@?^ /A[_Y55ZK10!Y5_PIOQ=_
MT7;X@?\ @#X>_P#E51_PIOQ=_P!%V^('_@#X>_\ E57JM% 'E7_"F_%W_1=O
MB!_X ^'O_E51_P *;\7?]%V^('_@#X>_^55>JT4 >5?\*;\7?]%V^('_ ( ^
M'O\ Y54?\*;\7?\ 1=OB!_X ^'O_ )55ZK10!Y5_PIOQ=_T7;X@?^ /A[_Y5
M4?\ "F_%W_1=OB!_X ^'O_E57JM% 'E7_"F_%W_1=OB!_P" /A[_ .55'_"F
M_%W_ $7;X@?^ /A[_P"55>JT4 >5?\*;\7?]%V^('_@#X>_^55'_  IOQ=_T
M7;X@?^ /A[_Y55ZK10!Y5_PIOQ=_T7;X@?\ @#X>_P#E51_PIOQ=_P!%V^('
M_@#X>_\ E57JM% 'E7_"F_%W_1=OB!_X ^'O_E51_P *;\7?]%V^('_@#X>_
M^55>JT4 >5?\*;\7?]%V^('_ ( ^'O\ Y54?\*;\7?\ 1=OB!_X ^'O_ )55
MZK10!Y5_PIOQ=_T7;X@?^ /A[_Y54?\ "F_%W_1=OB!_X ^'O_E57JM% 'E7
M_"F_%W_1=OB!_P" /A[_ .55'_"F_%W_ $7;X@?^ /A[_P"55>JT4 >5?\*;
M\7?]%V^('_@#X>_^55'_  IOQ=_T7;X@?^ /A[_Y55ZK10!Y5_PIOQ=_T7;X
M@?\ @#X>_P#E51_PIOQ=_P!%V^('_@#X>_\ E57JM% 'FOA+X,W.@>/;3Q=K
M/C_Q/XTU.RTRZTJTCUN+38H;>*YEMI9BHM+. LQ:S@Y8L  <#FO2J** "BBB
M@#^:S]K'_DZ;XR?]CGK/_I=-11^UC_R=-\9/^QSUG_TNFHH ^LOV:O\ @J;)
M^RW\%]!^%TGPO7Q))X>DO(FU1?$/V83F2[FF.(_LK[0/-V_>.=N>,X'IW_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W
M%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_
M^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J
M)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_
M *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%110 ?\/S/^J)_^77_ /<5'_#\
MS_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\ <5'_  _,_P"J)_\ EU__ '%1
M10 ?\/S/^J)_^77_ /<5'_#\S_JB?_EU_P#W%110 ?\ #\S_ *HG_P"77_\
M<5'_  _,_P"J)_\ EU__ '%110!^=OQ)U"[^,7Q(\7>.X[:'2T\2ZU>ZN+%I
9S*;?S[AY/+W[!NV[L;L#.,X'2BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341941584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 22, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANI PHARMACEUTICALS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">58-2301143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">210 Main Street West<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Baudette<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">56623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">634-3500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANIP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 824.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:3pt;margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Portions of the definitive proxy statement for the registrant&#8217;s 2024 annual meeting of stockholders to be filed within 120 days after the end of the period covered by this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001023024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,068,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember', window );">Class C Special Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345814384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Philadelphia, Pennsylvania<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338192240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 221,121<span></span>
</td>
<td class="nump">$ 48,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Current restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of $97,262 and $161,052 of adjustments for chargebacks and other allowances at December&#160;31, 2023 and 2022, respectively</a></td>
<td class="nump">162,079<span></span>
</td>
<td class="nump">165,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">111,196<span></span>
</td>
<td class="nump">105,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_PrepaidIncomeTaxesNet', window );">Prepaid income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">8,020<span></span>
</td>
<td class="nump">8,020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,400<span></span>
</td>
<td class="nump">8,387<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">519,816<span></span>
</td>
<td class="nump">344,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">44,593<span></span>
</td>
<td class="nump">43,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net of deferred tax liabilities and valuation allowance</a></td>
<td class="nump">90,711<span></span>
</td>
<td class="nump">81,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">209,009<span></span>
</td>
<td class="nump">251,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">28,221<span></span>
</td>
<td class="nump">28,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Derivatives and other non-current assets</a></td>
<td class="nump">12,072<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">904,422<span></span>
</td>
<td class="nump">760,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current debt, net of deferred financing costs</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">36,683<span></span>
</td>
<td class="nump">29,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">16,276<span></span>
</td>
<td class="nump">9,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related expenses</a></td>
<td class="nump">23,786<span></span>
</td>
<td class="nump">10,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_AccruedGovernmentRebates', window );">Accrued government rebates</a></td>
<td class="nump">12,168<span></span>
</td>
<td class="nump">10,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">8,164<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ReturnedGoodsReserve', window );">Returned goods reserve</a></td>
<td class="nump">29,678<span></span>
</td>
<td class="nump">33,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Current contingent consideration</a></td>
<td class="nump">12,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other</a></td>
<td class="nump">5,606<span></span>
</td>
<td class="nump">5,394<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">145,477<span></span>
</td>
<td class="nump">99,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Non-current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current debt, net of deferred financing costs and current component</a></td>
<td class="nump">284,819<span></span>
</td>
<td class="nump">285,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Non-current contingent consideration, net of current</a></td>
<td class="nump">11,718<span></span>
</td>
<td class="nump">35,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">4,809<span></span>
</td>
<td class="nump">1,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">446,823<span></span>
</td>
<td class="nump">421,547<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 15)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at December&#160;31, 2023 and 2022</a></td>
<td class="nump">24,850<span></span>
</td>
<td class="nump">24,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value, 33,333,334 shares authorized; 20,730,896 shares issued and 20,466,953 outstanding at December&#160;31, 2023; 17,643,497 shares issued and 17,494,466 shares outstanding at December&#160;31, 2022</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ClassCSpecialStockValue', window );">Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December&#160;31, 2023 and 2022 respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December&#160;31, 2023 and 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock, 263,943 shares of common stock, at cost, at December&#160;31, 2023 and 149,031 shares of common stock, at cost, at December&#160;31, 2022</a></td>
<td class="num">(10,081)<span></span>
</td>
<td class="num">(5,094)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">514,103<span></span>
</td>
<td class="nump">403,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(80,132)<span></span>
</td>
<td class="num">(97,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income, net of tax</a></td>
<td class="nump">8,857<span></span>
</td>
<td class="nump">12,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">432,749<span></span>
</td>
<td class="nump">313,690<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Mezzanine Equity, and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 904,422<span></span>
</td>
<td class="nump">$ 760,087<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_AccruedGovernmentRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents amounts accrued for government rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_AccruedGovernmentRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ClassCSpecialStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ClassCSpecialStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_PrepaidIncomeTaxesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_PrepaidIncomeTaxesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ReturnedGoodsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the reserve for goods returned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ReturnedGoodsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338926848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Adjustments for chargebacks and other allowances</a></td>
<td class="nump">$ 97,262<span></span>
</td>
<td class="nump">$ 161,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares at cost</a></td>
<td class="nump">263,943<span></span>
</td>
<td class="nump">149,031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="nump">1,666,667<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">33,333,334<span></span>
</td>
<td class="nump">33,333,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">20,730,896<span></span>
</td>
<td class="nump">17,643,497<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">20,466,953<span></span>
</td>
<td class="nump">17,494,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember', window );">Class C Special Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="nump">781,281<span></span>
</td>
<td class="nump">781,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="nump">10,864<span></span>
</td>
<td class="nump">10,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="nump">10,864<span></span>
</td>
<td class="nump">10,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=anip_ClassCSpecialStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338860608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">$ 486,816,000<span></span>
</td>
<td class="nump">$ 316,385,000<span></span>
</td>
<td class="nump">$ 216,136,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization', window );">Cost of sales (excluding depreciation and amortization)</a></td>
<td class="nump">181,513,000<span></span>
</td>
<td class="nump">138,785,000<span></span>
</td>
<td class="nump">100,610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">34,286,000<span></span>
</td>
<td class="nump">22,318,000<span></span>
</td>
<td class="nump">11,369,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">161,697,000<span></span>
</td>
<td class="nump">124,044,000<span></span>
</td>
<td class="nump">84,294,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">59,791,000<span></span>
</td>
<td class="nump">56,972,000<span></span>
</td>
<td class="nump">47,252,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration fair value adjustment</a></td>
<td class="nump">1,426,000<span></span>
</td>
<td class="nump">3,758,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Legal settlement expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CortrophinPreLaunchCharges', window );">Purified Cortrophin Gel pre-launch charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">780,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring activities</a></td>
<td class="nump">1,132,000<span></span>
</td>
<td class="nump">5,679,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">2,374,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total Operating Expenses</a></td>
<td class="nump">439,845,000<span></span>
</td>
<td class="nump">351,668,000<span></span>
</td>
<td class="nump">255,929,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="nump">46,971,000<span></span>
</td>
<td class="num">(35,283,000)<span></span>
</td>
<td class="num">(39,793,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Expense, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="num">(26,940,000)<span></span>
</td>
<td class="num">(28,052,000)<span></span>
</td>
<td class="num">(11,922,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="num">(159,000)<span></span>
</td>
<td class="nump">670,000<span></span>
</td>
<td class="num">(4,343,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) Before Expense (Benefit) for Income Taxes</a></td>
<td class="nump">19,872,000<span></span>
</td>
<td class="num">(62,665,000)<span></span>
</td>
<td class="num">(56,058,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">1,093,000<span></span>
</td>
<td class="num">(14,769,000)<span></span>
</td>
<td class="num">(13,455,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">18,779,000<span></span>
</td>
<td class="num">(47,896,000)<span></span>
</td>
<td class="num">(42,603,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Dividends on Series A Convertible Preferred Stock</a></td>
<td class="num">(1,625,000)<span></span>
</td>
<td class="num">(1,625,000)<span></span>
</td>
<td class="num">(190,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss Available to Common Shareholders</a></td>
<td class="nump">$ 17,154,000<span></span>
</td>
<td class="num">$ (49,521,000)<span></span>
</td>
<td class="num">$ (42,793,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Basic and Diluted Income (Loss) Per Share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic Income (Loss) Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
<td class="num">$ (3.40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted Income (Loss) Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
<td class="num">$ (3.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic Weighted-Average Shares Outstanding (in shares)</a></td>
<td class="nump">18,001<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted Weighted-Average Shares Outstanding (in shares)</a></td>
<td class="nump">18,194<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CortrophinPreLaunchCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of charges directly related to the Purified Cortrophin Gel pre-launch charges commercialization efforts, including but not limited to sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CortrophinPreLaunchCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of product sold and service rendered, excluding depreciation, depletion, and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342069616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 18,779<span></span>
</td>
<td class="num">$ (47,896)<span></span>
</td>
<td class="num">$ (42,603)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income/(loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">44<span></span>
</td>
<td class="num">(112)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">(Loss) gain on interest rate swap</a></td>
<td class="num">(3,355)<span></span>
</td>
<td class="nump">15,335<span></span>
</td>
<td class="nump">8,370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income, net of tax</a></td>
<td class="num">(3,311)<span></span>
</td>
<td class="nump">15,223<span></span>
</td>
<td class="nump">8,382<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 15,468<span></span>
</td>
<td class="num">$ (32,673)<span></span>
</td>
<td class="num">$ (34,221)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334278720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Mezzanine Equity Series A Convertible Preferred Stock</div></th>
<th class="th"><div>Novitium</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>Novitium</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Novitium</div>
</th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Gain Net of Tax</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (decrease) in temporary equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,246)<span></span>
</td>
<td class="num">$ (11,437)<span></span>
</td>
<td class="num">$ (4,972)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balance, Common (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning Balance, Treasury (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_StockholdersEquityAttributableToParentAndTemporaryEquity', window );">Beginning balance, permanent and temporary equity at Dec. 31, 2020</a></td>
<td class="nump">195,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based Compensation Expense</a></td>
<td class="nump">10,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock Purchases for Restricted Stock Vests (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock Purchases for Restricted Stock Vests</a></td>
<td class="num">(889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Common Shares upon Stock Option and ESPP Exercise</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of Restricted Stock Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">541,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted Stock Awards Forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(81,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted Stock Awards Forfeitures</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,467,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock</a></td>
<td class="nump">69,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,734<span></span>
</td>
<td class="nump">$ 91,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Convertible Preferred Stock</a></td>
<td class="num">(190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="nump">24,850<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">8,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(42,603)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,603)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,135)<span></span>
</td>
<td class="num">(3,055)<span></span>
</td>
<td class="num">(47,765)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance, Common (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending Balance, Treasury (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_StockholdersEquityAttributableToParentAndTemporaryEquity', window );">Ending balance, permanent and temporary equity at Dec. 31, 2021</a></td>
<td class="nump">358,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">24,850<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based Compensation Expense</a></td>
<td class="nump">14,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock Purchases for Restricted Stock Vests (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock Purchases for Restricted Stock Vests</a></td>
<td class="num">(1,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,959)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Common Shares upon Stock Option and ESPP Exercise</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of Restricted Stock Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted Stock Awards Forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Convertible Preferred Stock</a></td>
<td class="num">(1,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">15,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">(47,896)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47,896)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 313,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,094)<span></span>
</td>
<td class="nump">12,168<span></span>
</td>
<td class="num">(97,286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance, Common (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending Balance, Treasury (in shares) at Dec. 31, 2022</a></td>
<td class="nump">149,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_StockholdersEquityAttributableToParentAndTemporaryEquity', window );">Ending balance, permanent and temporary equity at Dec. 31, 2022</a></td>
<td class="nump">$ 338,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">24,850<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based Compensation Expense</a></td>
<td class="nump">20,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Treasury Stock Purchases for Restricted Stock Vests (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury Stock Purchases for Restricted Stock Vests</a></td>
<td class="num">(4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,987)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Common Shares upon Stock Option and ESPP Exercise</a></td>
<td class="nump">8,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of Restricted Stock Awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of Performance Stock Units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Restricted Stock Awards Forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Restricted Stock Awards Forfeitures</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Common Stock</a></td>
<td class="nump">80,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends on Convertible Preferred Stock</a></td>
<td class="num">(1,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="num">(3,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,311)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">18,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,779<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 432,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 514,103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,081)<span></span>
</td>
<td class="nump">$ 8,857<span></span>
</td>
<td class="num">$ (80,132)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balance, Common (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,731,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending Balance, Treasury (in shares) at Dec. 31, 2023</a></td>
<td class="nump">263,943<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_StockholdersEquityAttributableToParentAndTemporaryEquity', window );">Ending balance, permanent and temporary equity at Dec. 31, 2023</a></td>
<td class="nump">$ 457,599<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_StockholdersEquityAttributableToParentAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items attributable to the parent and temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_StockholdersEquityAttributableToParentAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338983168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 18,779,000<span></span>
</td>
<td class="num">$ (47,896,000)<span></span>
</td>
<td class="num">$ (42,603,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">20,652,000<span></span>
</td>
<td class="nump">14,599,000<span></span>
</td>
<td class="nump">10,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred taxes</a></td>
<td class="num">(11,740,000)<span></span>
</td>
<td class="num">(15,253,000)<span></span>
</td>
<td class="num">(16,754,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">59,791,000<span></span>
</td>
<td class="nump">59,653,000<span></span>
</td>
<td class="nump">47,252,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_AcquiredInProcessReserachAndDevelopmentExpense', window );">Acquired in-process research and development ("IPR&amp;D")</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,151,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">1,269,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Non-cash interest</a></td>
<td class="nump">3,922,000<span></span>
</td>
<td class="nump">3,961,000<span></span>
</td>
<td class="nump">2,512,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow', window );">Contingent consideration fair value adjustment</a></td>
<td class="nump">1,426,000<span></span>
</td>
<td class="nump">4,058,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,458,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">574,000<span></span>
</td>
<td class="nump">2,374,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of ANDAs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(750,000)<span></span>
</td>
<td class="num">(1,822,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisition (2021):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="nump">3,359,000<span></span>
</td>
<td class="num">(36,912,000)<span></span>
</td>
<td class="num">(5,548,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(5,841,000)<span></span>
</td>
<td class="num">(23,626,000)<span></span>
</td>
<td class="nump">3,224,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(9,015,000)<span></span>
</td>
<td class="num">(798,000)<span></span>
</td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">7,552,000<span></span>
</td>
<td class="nump">5,038,000<span></span>
</td>
<td class="nump">10,166,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IncreaseDecreaseInRoyaltyPayable', window );">Accrued royalties</a></td>
<td class="nump">6,969,000<span></span>
</td>
<td class="nump">3,082,000<span></span>
</td>
<td class="num">(267,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxes', window );">Current income taxes payable, net</a></td>
<td class="nump">11,991,000<span></span>
</td>
<td class="num">(160,000)<span></span>
</td>
<td class="num">(7,573,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IncreaseDecreaseAccruedGovernmentRebates', window );">Accrued government rebates</a></td>
<td class="nump">1,296,000<span></span>
</td>
<td class="nump">5,380,000<span></span>
</td>
<td class="num">(3,078,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IncreaseDecreaseInReturnedGoodsReserve', window );">Returned goods reserve</a></td>
<td class="num">(3,722,000)<span></span>
</td>
<td class="num">(2,399,000)<span></span>
</td>
<td class="nump">6,503,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers', window );">Accrued expenses, accrued compensation, and other</a></td>
<td class="nump">12,271,000<span></span>
</td>
<td class="num">(905,000)<span></span>
</td>
<td class="num">(3,638,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash and Cash Equivalents Provided by (Used in) Operating Activities</a></td>
<td class="nump">118,959,000<span></span>
</td>
<td class="num">(31,203,000)<span></span>
</td>
<td class="nump">3,322,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Novitium Pharma LLC, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,000)<span></span>
</td>
<td class="num">(84,494,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of product rights, IPR&amp;D, and other related assets</a></td>
<td class="num">(9,643,000)<span></span>
</td>
<td class="num">(7,579,000)<span></span>
</td>
<td class="num">(21,081,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Acquisition of property and equipment, net</a></td>
<td class="num">(8,868,000)<span></span>
</td>
<td class="num">(8,876,000)<span></span>
</td>
<td class="num">(2,557,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of long-lived assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">2,649,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash and Cash Equivalents Used in Investing Activities</a></td>
<td class="num">(18,511,000)<span></span>
</td>
<td class="num">(15,738,000)<span></span>
</td>
<td class="num">(105,483,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering, net of transaction expenses</a></td>
<td class="nump">80,555,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">69,584,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="num">(12,500,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Payments on Term Loan and Delayed Draw Term Loan agreements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,862,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments on borrowings under credit agreements</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings under Prior Revolver agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of Prior Credit Facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(200,148,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings under the Credit Facility, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,032,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Series A convertible preferred stock dividends paid</a></td>
<td class="num">(1,625,000)<span></span>
</td>
<td class="num">(1,625,000)<span></span>
</td>
<td class="num">(190,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">8,996,000<span></span>
</td>
<td class="nump">1,458,000<span></span>
</td>
<td class="nump">2,069,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Treasury stock purchases for restricted stock vests</a></td>
<td class="num">(4,987,000)<span></span>
</td>
<td class="num">(1,959,000)<span></span>
</td>
<td class="num">(890,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash and Cash Equivalents Provided by (Used in) Financing Activities</a></td>
<td class="nump">67,439,000<span></span>
</td>
<td class="num">(5,126,000)<span></span>
</td>
<td class="nump">194,595,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net Change in Cash and Cash Equivalents</a></td>
<td class="nump">167,887,000<span></span>
</td>
<td class="num">(52,067,000)<span></span>
</td>
<td class="nump">92,434,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year</a></td>
<td class="nump">53,234,000<span></span>
</td>
<td class="nump">105,301,000<span></span>
</td>
<td class="nump">12,867,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year</a></td>
<td class="nump">221,121,000<span></span>
</td>
<td class="nump">53,234,000<span></span>
</td>
<td class="nump">105,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash, beginning of year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">221,121,000<span></span>
</td>
<td class="nump">48,228,000<span></span>
</td>
<td class="nump">100,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,006,000<span></span>
</td>
<td class="nump">5,001,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash</a></td>
<td class="nump">221,121,000<span></span>
</td>
<td class="nump">53,234,000<span></span>
</td>
<td class="nump">105,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure for cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest, net of amounts capitalized</a></td>
<td class="nump">31,431,000<span></span>
</td>
<td class="nump">21,477,000<span></span>
</td>
<td class="nump">9,705,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="nump">288,000<span></span>
</td>
<td class="nump">10,371,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">4,715,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1', window );">Fair value of contingent consideration in a business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of equity issued as consideration in a business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">91,199,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Acquisition of product rights included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchased and included in accounts payable</a></td>
<td class="nump">$ 328,000<span></span>
</td>
<td class="nump">$ 452,000<span></span>
</td>
<td class="nump">$ 152,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_AcquiredInProcessReserachAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Acquired in Process Reserach and Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_AcquiredInProcessReserachAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_IncreaseDecreaseAccruedGovernmentRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in liabilities related to government rebates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_IncreaseDecreaseAccruedGovernmentRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_IncreaseDecreaseInReturnedGoodsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in returned goods reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_IncreaseDecreaseInReturnedGoodsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_IncreaseDecreaseInRoyaltyPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_IncreaseDecreaseInRoyaltyPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420434869264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Business</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, &#8220;ANI,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The team is focused on delivering growth by scaling up the Rare Disease business through the successful launch of its lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. The Company owns and operates three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at the Oakville, Ontario, manufacturing facility as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium Pharma LLC (&#8220;Novitium&#8221;) in November 2021. The Company has fully completed the transition of the products manufactured or packaged at Oakville to one of the three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (Note 19).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. Unless otherwise noted, all references to &#8220;$&#8221; or &#8220;dollar&#8221; refer to the U.S. dollar. The Company&#8217;s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders&#8217; equity accounts, intercompany, and fixed assets, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders&#8217; equity within accumulated other comprehensive income (loss), net of tax.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In the consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and potential adjustments, income tax expense or benefit, deferred taxes and valuation allowance, stock-based compensation, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Activities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the consolidated statements of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Revenue is recognized using the following steps:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price, including the identification and estimation of variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when we satisfy a performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives its revenues primarily from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold is transferred to the customer. Generally, the Company does not incur incremental costs to obtain contracts that would otherwise not have been incurred. The Company has not identified any agreements or arrangement that would qualify as a significant financing component.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Distribution Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may enter into marketing and distribution agreements with third parties in which products are sold under Abbreviated New Drug Applications (&#8220;ANDAs&#8221;) or New Drug Applications (&#8220;NDAs&#8221;) owned or licensed by third parties. These products are sold under the ANI label. The Company controls the products sold under these marketing and distribution agreements and therefore are the principal for sales under each of these marketing and distribution agreements. As a result, revenue is recognized on a gross basis when control has passed to the customer and the performance obligation has been satisfied. Under these agreements, the Company pays third parties a specified percentage of the gross profit earned on sales of the products. These profit-sharing percentages are recognized in cost of sales in the consolidated statements of operations and are accrued in accrued royalties in the consolidated balance sheets until payment has occurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Product Sales Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing arrangements consist of agreements in which pharmaceutical products are manufactured by the Company on behalf of a third party. The performance obligation is to manufacture and provide pharmaceutical products to customers, typically pharmaceutical companies. The products are sold at predetermined standalone selling prices and the performance obligation is considered to be satisfied when control of the product is transferred to the customer. Control is transferred to the customer when the product leaves the shipping dock to be shipped to the customer, as  contract manufactured pharmaceutical products are sold on an FOB shipping point basis and the inventory risk and risk of ownership passes to the customer at that time. Payment terms for these sales are generally fewer than two months. Typically, there are no material returns for contract manufactured products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties from Licensing Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into licensing agreements, under which the Company licenses to the seller the right to sell the acquired products. Because these royalties are sales-based, the Company recognizes the revenue when the underlying sales occur, based on sales and gross profit information received from the sellers. The Company may enter into agreements which include profit-sharing percentages on gross profits. The profit-sharing percentages are recorded in cost of sales in the consolidated statements of operations when the associated revenue is recognized and are recorded in accrued royalties in the consolidated balance sheets when the associated revenue is recognized and until payment has occurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with original maturities of three months or less from the date of purchase are classified as cash equivalents. Cash and cash equivalents consist of cash deposited in checking accounts, time deposits with maturities of less than three months, and money market accounts with maturities of three months or less at the date of purchase. Cash and cash equivalents include cash on-hand and money market funds which invest exclusively in high-quality, short-term securities that are issued or guaranteed by the U.S. government. Due to the short-term maturity of the funds invested in the money market accounts, the carrying amounts are a reasonable estimate of fair value. All interest bearing and non-interest bearing accounts are guaranteed by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250 thousand. The majority of the Company's cash balances are in excess of FDIC coverage, which the Company considers to be a normal business risk.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash at December 31, 2022, represented $5.0 million of funds held in a bank account owned by the Company to be used to pay for future milestones related to the purchase of  the rights, title, and interest in the NDA for Inderal LA, as well as certain documentation, trademark rights, and finished goods from Cranford Pharmaceuticals, LLC in April 2016. This amount was was released from restricted cash during the first quarter of the year ended December&#160;31, 2023. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company extends credit to customers on an unsecured basis. Expected credit losses are measured at amortized cost, including trade and unbilled receivables, on a collective basis, based on their similar risk characteristics. Expected credits losses are based on historical credit loss experience, review of the current aging or status of accounts receivable and current and forward-looking views from an economic and industry perspective. Receivables are written off when it is determined that amounts are uncollectible. The allowance for credit losses was immaterial as of December&#160;31, 2023 and 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consist of raw materials, packaging materials, work-in-progress, and finished goods. Inventories are stated at the lower of standard cost or net realizable value. The Company periodically reviews and adjusts standard costs, which generally approximate weighted average cost. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation is recorded on a straight-line basis over estimated useful lives as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of asset's useful life or remaining life of lease </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of multiple projects, primarily related to new equipment and expansion of laboratory and manufacturing facilities to expand manufacturing capability as product lines grow. Construction in progress includes the cost of construction and other direct costs attributable to the construction, along with capitalized interest. Depreciation is not recorded on construction in progress until such time as the assets are placed in service.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment loss related to property and equipment was recognized during the years ended December&#160;31, 2023, 2022, and 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets Held-for-Sale </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of December&#160;31, 2023 and 2022, approximately $8.0 million of assets held for sale were recorded on the consolidated balance sheets. See Note 4 to the consolidated financial statements for additional information. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the Company does not separate lease and non-lease components of contracts. There are no material residual guarantees associated with any of the Company&#8217;s leases, and there are no significant restrictions or covenants included in the Company&#8217;s lease agreements. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. As of December&#160;31, 2023 and 2022, the Company did not have any finance leases.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The definite-lived ANDAs, NDAs and product rights, marketing and distribution rights, customer relationships, and non-compete agreement are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from <span style="-sec-ix-hidden:f-537">seven</span> to ten years, based on the straight-line amortization method. In the case of certain NDA and product rights, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Management reviews definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. During the year ended December&#160;31, 2023, no impairment charges were recognized on intangible assets.. During the year ended December&#160;31, 2022, the Company recognized a full impairment of a definite-lived ANDA asset with a remaining carrying value of $0.1 million. During the year ended December&#160;31, 2021, the Company recognized an impairment charge of $2.4 million related to a definite-lived ANDA intangible asset. No events or circumstances arose in 2023, 2022, or 2021 that indicated that the carrying value of any of the other definite-lived intangible assets may not be recoverable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets other than goodwill include in-process research and development (&#8220;IPR&amp;D&#8221;) projects. IPR&amp;D intangible assets represent the fair value of technology acquired in a business combination for which the technology projects are incomplete but have substance. When an IPR&amp;D project is completed (generally upon receipt of regulatory approval), the asset is then accounted for as a definite-lived intangible asset. Indefinite-lived intangibles are tested for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying amount of the asset might not be recoverable. Judgment is used in determining when these events and circumstances arise. No events or circumstances arose in 2023 that indicated that the carrying value of any of the indefinite-lived intangible assets may not be recoverable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost, using the purchase method of accounting, and is related to past business combinations with BioSante Pharmaceuticals, Inc., WellSpring, and Novitium. Goodwill is not amortized, but is subject to periodic review for impairment. The Company is organized in two operating segments, and two reporting units, and has determined that goodwill resides in one reporting unit, Generics, Established Brands, and Other.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews goodwill for impairment on a reporting unit basis annually, on October 31, and whenever events or changes in circumstances indicate the carrying value of goodwill might not be recoverable. Under the authoritative guidance issued by the FASB, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company&#8217;s financial condition and results of operations. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the assets qualitatively, and concluded it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit is greater than its carrying value as of October 31, 2023 and 2022, and therefore no quantitative testing for impairment was required. No impairment loss related to goodwill was recognized in the years ended December&#160;31, 2023, 2022, and 2021.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Arrangements </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may enter into collaborative arrangements with various commercial partners to further business opportunities. In collaborative arrangements revenues and costs generated by collaborative arrangements may be presented on a gross or net basis depending on the specific facts of the collaborative arrangement. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development ("R&amp;D") activities are expensed as incurred. R&amp;D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock options and restricted stock awards, which are awarded in exchange for employee and non-employee director services. From time to time, the Company may grant awards through an inducement grant outside of the incentive plan to induce prospective employees to accept employment with the Company. These grants are made pursuant to inducement grants outside of the shareholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock awards is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#8217;s requisite service period and classified where the underlying salaries are classified. Forfeitures are accounted for as they occur. Excess tax benefits or tax deficiencies are recognized as a component of the current period provision for income taxes.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards may also be issued in the form of Performance Stock Units (&#8220;PSUs&#8221;) to certain employees of the Company. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted vest over a three-year performance period. Currently, the PSU&#8217;s vesting is contingent upon the Company meeting certain total shareholder return (&#8220;TSR&#8221;) levels as compared to a select peer group over the over three years, and contingent upon the Company meeting certain adjusted non-GAAP year-on-year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings before interest, income taxes, depreciation, and amortization (&#8220;EBITDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates over the vesting term. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also administers an Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The estimated fair value of stock-based compensation awards are recognized and classified in the expense where the underlying salaries are classified. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of the Company's stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in various U.S. jurisdictions, Canada, and India, and all of our income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into an interest rate swap agreement (Note 6) designated as a cash flow hedge designed to manage exposure to changes in SOFR-interest rate underlying our variable rate debt. Due to the effective nature of the hedge, the initial fair value of the hedge and subsequent changes in the fair value of the hedge are recognized in other comprehensive income (loss) in the consolidated balance sheets. Income taxes are allocated to the hedge component of other comprehensive income (loss) based on appropriate intra-period tax allocations when those effects are deemed material.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedge Accounting</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate swaps to hedge exposure to interest rate risk, as well as benefit from favorable conditions. The Company recognizes all derivative instruments as either assets or liabilities at fair value. For all of the Company&#8217;s derivative positions that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivatives is reported as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on derivatives representing any ineffective component of the hedge are recognized in current earnings. All of the Company&#8217;s cash flow hedges have been deemed effective as of December&#160;31, 2023 for both accounting and tax purposes. The Company has elected hedge accounting for both U.S. GAAP and tax purposes. The Company maintains formal documentation through a periodic memo and accounting analysis that cover what is being hedged, how it is being hedged, hedge effectiveness, the nature of the risk being hedged, among other required analyses. Company policy further includes a quarterly probability analysis covering hedge effectiveness.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the acquisition agreement between ANI and Novitium Pharma LLC include the potential payment of future consideration that is contingent upon the achievement of certain regulatory and financial performance milestones. At the acquisition date, contingent consideration is recorded at fair value based on the additional consideration expected to be transferred, which is based on the estimate of probability-weighted future cash flows as discounted to present value. Significant inputs used in the measurement of the fair value include discount rates, probabilities of achievement of regulatory-based milestones and payments, and projected revenues and gross profits. The discount rates are derived using accepted valuation methodologies. The probability of achievement of regulatory milestones is based on historical and projected success rates. The projected revenues and gross profits are based on internal forecasts and long-term plans. The contingent consideration is remeasured each reporting period using Level 3 inputs. Changes in fair value, which incorporate changes in assumptions and the passage of time, are recognized as an operating expense in the consolidated statements of operations. As payments are not expected to be made shortly after the acquisition, any future payment of contingent consideration will be reported as a financing cash flow for amounts paid up to the acquisition-date fair value of the consideration, and as an operating cash outflow for any amounts in excess of the acquisition-date fair value in our consolidated statement of cash flows.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets include certain financial instruments (primarily cash and cash equivalents, prepaid expenses, accounts receivable, accounts payable, accrued expenses, and other current liabilities) that are carried at cost and that approximate fair values as of December&#160;31, 2023, 2022 due to their short term nature. See Note 10 for additional information regarding fair value.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on the consolidated financial statements.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. </span></div>In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company&#8217;s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340644256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION AND RELATED ALLOWANCES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE RECOGNITION AND RELATED ALLOWANCES</a></td>
<td class="text">REVENUE RECOGNITION AND RELATED ALLOWANCES <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products we sell is transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All revenue recognized in the accompanying consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products and Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of rare disease pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timing of Revenue Recognition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations transferred at a point in time</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations transferred over time</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the years ended December&#160;31, 2023 or 2022, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. As of December&#160;31, 2023, there were no contract assets recorded which were related to revenue recognized based on percentage of completion but not yet billed. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an increase of $4.1 million of net revenue from performance obligations satisfied in prior periods during the year ended December&#160;31, 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consisting primarily of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2023 and 2022, the Company recognized less than $0.1 million of revenue that was included in deferred revenue as of December&#160;31, 2022 and 2021. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> million, which consists of firm orders for contract manufactured products. We will recognize revenue for these performance obligations as they are satisfied, which is anticipated within six months.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Chargebacks</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chargebacks, primarily from wholesalers, result from arrangements with indirect customers establishing prices for products which the indirect customer purchases through a wholesaler. Alternatively, the Company may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, the Company provides a chargeback credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler&#8217;s invoice price, typically Wholesale Acquisition Cost (&#8220;WAC&#8221;).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior period chargebacks claimed by wholesalers are analyzed to determine the actual average selling price (&#8220;ASP&#8221;) for each product. This calculation is performed by product by wholesaler. ASPs can be affected by several factors such as:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in customer mix</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in negotiated terms with customers</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A change in the volume of off-contract purchases</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in WAC</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As necessary, ASPs are adjusted based on anticipated changes in the factors above.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between ASP and WAC is recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets, at the time revenue is recognized from the product sale. The Company continually monitors chargeback activity and adjusts ASPs when the Company believes that actual selling prices will differ from current ASPs.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Rebates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government rebates reserve consists of estimated payments due to governmental agencies for utilization of our products by beneficiaries under such governmental programs. The two largest government programs are Medicaid and Medicare.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the Medicaid Drug Rebate Program and pays rebates to the states related on Medicaid beneficiary utilization of the Company's products. Medicaid rebates are billed 60-90 days of the end of the quarter in which the product was dispensed to a Medicaid beneficiary. Medicaid rebate amounts per product unit are established by law, based on the Average Manufacturer Price (&#8220;AMP&#8221;), which is reported on a monthly and quarterly basis, and, in the case of branded products, best price, which is reported on a quarterly basis. Medicaid reserves are based on expected claims from state Medicaid programs. Estimates for expected claims are driven by patient usage, sales mix, calculated AMP or best price, as well as inventory in the distribution channel that will be subject to a Medicaid rebate. As a result of the delay between selling the products, dispensing the products and rebate billing, the Medicaid rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the products are also covered under Medicare. ANI participates in the Coverage Gap Discount Program in order for its branded drugs to be covered by Medicare Part D and must provide a rebate for any products sold under NDAs dispensed to Medicare Part D beneficiaries while the beneficiaries are in the Coverage Gap phase of the benefit. This applies to all products sold under NDAs, regardless of whether the products are marketed as branded or generic. Estimates for these discounts are based on historical experience with Medicare rebates for products. Medicare rebates are billed quarterly for drugs dispensed to Medicare beneficiaries in the prior quarter, which is typically 120 days after the product is shipped. As a result of the delay between selling the products, dispensing the products and rebate billing, Medicare rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to Medicare Part D participants.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate the adequacy of the government rebate reserves, reserves are reviewed on a quarterly basis against actual claims data to ensure the liability is fairly stated. The Company continually monitors the government rebate reserve and adjusts estimates if it is expected that actual government rebates may differ from established accruals. Accruals for government rebates are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to accrued government rebates in the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Returns</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A returns policy is in place that allows customers to return product within a specified period prior to and subsequent to the expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date to up to one year after its expiration date. Product returns are settled through the issuance of a credit to the customer. The estimate for returns is based upon historical experience with actual returns. While such experience has allowed for reasonable estimation in the past, history may not always be an accurate indicator of future returns. We continually monitor estimates for returns and make adjustments when it is expected that actual product returns may differ from the established accruals. Accruals for returns are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to the return goods reserve in the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Administrative Fees and Other Rebates</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administrative fees or rebates are offered to wholesalers, group purchasing organizations, and indirect customers. Fees and rebates are accrued, by product by wholesaler, at the time of sale based on contracted rates and ASPs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To evaluate the adequacy of the administrative fee accruals, on-hand inventory counts are obtained from the wholesalers. The Company continually monitors administrative fee activity and adjust accruals when it is expected that actual administrative fees may differ from the accruals. Accruals for administrative fees and other rebates are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prompt Payment Discounts</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales discounts may be granted to customers for prompt payment. The reserve for prompt payment discounts is based on invoices outstanding. Based on past experience, it is assumed that all available discounts will be taken. Accruals for prompt payment discounts are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accruals for Chargebacks, Returns, and Other Allowances</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government<br/>Rebates</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Administrative<br/>Fees and Other<br/>Rebates</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Prompt<br/>Payment<br/>Discounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals/Adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">642,409&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,657&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,252&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,044&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,302&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits Taken Against Reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(587,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(45,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022 (1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,399&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586,511&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,915&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,360&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,798&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,932&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits Taken Against Reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(650,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023 (1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Returns are included in returned goods reserve in the consolidated balance sheets. Government Rebates are included in accrued government rebates in the consolidated balance sheets.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Concentration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023 four customers accounted for 10% or more of net revenues. During the years ended December 31, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, three customers accounted for 10% or more of net revenues. As of December&#160;31, 2023, accounts receivable from these customers totaled 81% of accounts receivable, net.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The four customers represent the total percentage of net revenues as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338975104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">BUSINESS COMBINATION</a></td>
<td class="text">BUSINESS COMBINATION<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company acquired all of the interests of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021. This acquisition was accounted for as a business combination. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total consideration consisted of cash of approximately $88.1&#160;million, 2,466,654 restricted shares of common stock valued at $91.2 million, and up to $46.5 million in additional contingent consideration. Additionally, the Company agreed to pay certain debts of Novitium in the amount of $8.5 million. The contingent consideration is based on the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future. As of the acquisition date, the contingent consideration had a fair value of $30.8 million. Total consideration including cash, restricted shares and contingent consideration, net of cash acquired of $12.1&#160;million was $206.5 million at the date of purchase.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was $24.0 million and $35.1 million as of December&#160;31, 2023 and 2022, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10 for changes in contingent consideration and changes in fair value.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash consideration was funded in part by borrowings under the cr</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">edit facility (Note 5) and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> through issuance of convertible  preferred stock sha</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">res. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the &#8220;PIPE Investor&#8221;), pursuant to which the PIPE Investor agreed to purchase, 25,000 shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Series A Convertible Preferred Stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Note 11)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he acquisition of Novitium was completed due to its proven track record of being a research and development growth engine capable of fueling sustainable growth, to expand the research and development pipeline via niche opportunities, to enhance the contract development and manufacturing organization (&#8220;CDMO&#8221;) business and U.S. based manufacturing capacity, and to diversify the Company's revenue base.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net assets were recorded at their estimated fair value. In valuing acquired assets and liabilities, fair value estimates were based primarily on future expected cash flows, market rate assumptions for contractual obligations, and appropriate discount rates. In connection with the acquisition, $46.9 million of indefinite-lived in-process research and development intangible assets, $67.4 million of acquired ANDA intangible assets, $24.9 million of customer relationship intangible assets, and goodwill of $24.6&#160;million was recognized. Goodwill is considered an indefinite-lived asset and relates primarily to intangible assets that do not qualify for separate recognition, such as the assembled workforce and synergies between the entities. Goodwill established as a result of the acquisition is tax deductible in the U.S. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novitium operations generated $149.9 million and $90.3 million of revenue during the years ended December&#160;31, 2023 and 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transaction Costs</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the acquisition, approximately $9.4 million in transaction costs were expensed during the year ended 2022 as selling, general, and administrative expense in the consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Shares</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novitium acquisition consideration included 2,466,654 restricted shares, which were valued at $91.2 million. These shares contained restrictions on their transfer for periods from <span style="-sec-ix-hidden:f-663">three</span> to twenty-four months following the completion of the acquisition. A Finnerty model was used to value the restricted shares. It includes inputs of not readily observable market data, which are Level 3 inputs. These unobservable inputs include ANI stock volatility with a range of 65% to 71%, and the discounted lack of marketability with a range of 7.5% to 21.5% depending on the length of restriction.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pro Forma Consolidated Financial Information (unaudited)</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma consolidated financial information summarizes the results of operations for the periods indicated as if the Novitium acquisition had been completed as of January 1, 2020.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">272,888</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,740)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340903632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING</a></td>
<td class="text">RESTRUCTURING <div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 31, 2023 the Compan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Company's three U.S.-based manufacturing sites. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2023, restructuring activities resulted in expenses of $1.1 million. This included $0.2 million of severance and other employee benefit costs and $0.7 million of asset-related impairment and accelerated depreciation costs, and $0.2 million for other miscellaneous other costs. As of December&#160;31, 2023, $0.1 million of the severance and other employee benefits are unpaid and accrued. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2022, restructuring activities resulted in expenses of $5.7&#160;million. This included $2.1&#160;million of severance and other employee benefit costs and $3.1&#160;million of asset-related impairment and accelerated depreciation costs, and $0.4&#160;million for other miscellaneous other costs. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no restructuring expenses incurred for the year ended December 31, 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These costs are recorded as restructuring activities, an operating item, in the accompanying consolidated statements of operations. Certain of the severance and other employee benefit costs contain a service requirement, and as such, are being accrued over time as they are earned. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the exit of the Canadian facility, the Company has determined that the land and building at the Oakville, Ontario, Canada plant will be sold together and met the criteria to be classified as held for sale as of March 31, 2023. The land and building have a net carrying value of $8.0 million, which is presented as assets held for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the accompanying consolidated balance sheets as of December 31, 2023. These assets are part of the Generics, Established Brands, and Other segment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with a potential buyer for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (Note 19).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340858176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">INDEBTEDNESS</a></td>
<td class="text">INDEBTEDNESS<div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company, as borrower, entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the &#8220;Term Facility&#8221;) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the &#8220;Revolving Facility,&#8221; and together with the Term Facility, the &#8220;Credit Facility&#8221;). The Term Facility proceeds were used to finance the cash portion of the consideration under the Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility has a subjective acceleration clause in case of a material adverse effect. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement (&#8220;Amendment No. 1&#8221;). SOFR will be applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and replaced all LIBOR terms.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility permits both base rate borrowings (&#8220;ABR Loans&#8221;) and Eurodollar rate borrowings (&#8220;Eurodollar Loans&#8221;), plus a spread of (a) 5.00% above the base rate in the case of ABR Loans under the Term Facility and 6.00% above the SOFR Rate (or alternate benchmark rate as defined in the Credit Agreement) in the case of SOFR loans under the Term Facility and (b) 3.75% above the base rate in the case of ABR Loans under the Revolving Facility and 4.75% above the SOFR Rate (as defined in the Credit Facility) in the case of loans under the Revolving Facility. Amendment No. 1 also includes the addition of a credit spread adjustment of 0.11448% for an interest period of one-month duration, 0.26161% for a three-month duration, and 0.42826% for a six-month duration, in addition to SOFR and the applicable margin, as noted above. There were no other changes or modifications to the Credit Agreement. The Company has applied the optional expedients in ASC 848, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and elected to treat the change in the benchmark interest rate to SOFR as a continuation of the existing Credit Agreement and account for the change prospectively.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate under the Term Facility was 11.46% at December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $0 drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum on any unused portion of the Revolving Facility.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.&#8217;s and its principal domestic subsidiary&#8217;s assets and any future domestic subsidiary guarantors&#8217; assets. The Credit Facility is subject to customary financial and nonfinancial covenants. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the current and non-current components of the Term Facility as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current borrowing on debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt, net of deferred financing costs </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current borrowing on debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current debt, net of deferred financing costs and current component</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, outstanding principal was $294.0 million on the Term Facility. Of the $0.6 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.4 million is included in other non-current assets in the consolidated balance sheets, and $0.2 million is included in prepaid expenses and other current assets in the consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturity of the Term Facility is as follows for the years ending December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:62.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of total interest expense related to the Term Facility recognized in the accompanying consolidated statements of operations for the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,692</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,129</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance fees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,363</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">914</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,945</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420344683440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY</a></td>
<td class="text">DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY<div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage exposure to changes in LIBOR-based interest rates (or alternate benchmark rate as defined in the Credit Agreement) underlying total borrowings under term facilities related to the Prior Credit Agreement. The interest rate swap matures in December 2026. Concurrent with the termination of the Prior Credit Agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on November 19, 2021 was novated and Truist Bank became the new counterparty. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described further below, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. The notional amount of the interest rate swap was $139.4 million and $151.5 million as of December&#160;31, 2023 and 2022, respectively, and decreased quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of December&#160;31, 2023, the fair value of the interest rate swap asset was recorded in other non-current assets in the consolidated balance sheets was $6.2 million. As of December&#160;31, 2023, $8.9 million was recorded in accumulated</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the change in fair value of the interest rate swaps was a loss of $3.7 million. During the year ended December&#160;31, 2023, losses on the interest rate swap of $3.4 million were recorded in other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net of tax. Di</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fferences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the years ended December&#160;31, 2023 and 2022, $2.6 million and $2.3 million, respectively, of interest expense was recognized in relation to the interest rate swaps. Included in these amounts for the years ended December&#160;31, 2023 and 2022 are reclassifications out of accumulated other comprehensive income (loss) of $2.8 million in expense, related to terminated and de-designated cash flow hedges. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the amendment of the Credit Agreement (Note 5), the Company&#8217;s derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform, hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340711920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the Company's inventory by asset class as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Packaging materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vendor Concentration</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials are sourced for products, including API, from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. As a result, we are dependent upon current vendors to supply reliably the API required for on-going product manufacturing. During the year ended December&#160;31, 2023, no single vendor represented at least 10% of invent</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ory purchases. During th</span>e year ended December&#160;31, 2022, the Company purchased approximately 19% of inventory from one supplier. During the year ended December&#160;31, 2021, no single vendor represented at least 10% of inventory purchases.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340608112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text">PROPERTY AND EQUIPMENT, NET<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s gross property and equipment by major asset class and accumulated depreciation as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense for the years ended December&#160;31, 2023, 2022, and 2021 totaled $7.5 million, $7.4 million, and $5.5 million, respectively. During the years ended December&#160;31, 2023, 2022, and 2021 there was $0.6 million, $0.1 million, and $0.1 million, respectively, of interest capitalized into construction in progress, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340730288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">GOODWILL AND INTANGIBLE ASSETS</a></td>
<td class="text">GOODWILL AND INTANGIBLE ASSETS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the 2013 merger with BioSante Pharmaceuticals, Inc. (&#8220;BioSante&#8221;), the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc., the Company recorded goodwill of $1.7 million in 2018. From the acquisition of Novitium in 2021, the Company recorded goodwill of $24.6&#160;million. As of December 31, 2023, the Company had two operating segments, which were also deemed the Company's two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in the Generics, Established Brands, and Other reporting unit.reporting unit.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is reviewed for impairment at least annually, at October 31st, or more frequently if a triggering event occurs between impairment testing dates. The Company&#8217;s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is &#8220;more likely than not&#8221; that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of the reporting unit to its respective carrying value, including its goodwill. If it is determined that it is &#8220;not likely&#8221; that the fair value of the reporting unit is less than its carrying value, then no further testing is required. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the qualitative assessments performed by the Company, it was determined that it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit was greater than its carrying value as of October 31, 2023, and therefore no impairment charges have been recognized, and no quantitative testing was required.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the qualitative impairment analysis performed at October 31, 2023, there were no events or changes in circumstances that would have reduced the fair value of the reporting unit below its carrying value from October 31, 2023 to December&#160;31, 2023. No impairment loss was recognized during the years ended December&#160;31, 2023, 2022, and 2021, and the balance of goodwill was $28.2 million as of December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net definite-lived intangible assets and net indefinite-lived intangible assets other than goodwill are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.175%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Amortization<br/>Period(1)</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definite-Lived Intangible Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired ANDA intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">209,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(100,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">195,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(75,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NDAs and product rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">244,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(184,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">242,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(162,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketing and distribution rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-compete agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Definite-Lived Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">497,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(308,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">189,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">480,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(255,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5 years</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Intangible Assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">517,132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(308,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">209,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">507,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(255,855)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">251,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average amortization period as of December 31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (&#8220;ANDAs&#8221;), New Drug Applications (&#8220;NDAs&#8221;) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from <span style="-sec-ix-hidden:f-851">seven</span> to ten years years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment annually, or when events or changes in circumstances indicate that these asset might be impaired.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets other than goodwill include primarily IPR&amp;D projects. IPR&amp;D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&amp;D project is completed (generally upon receipt of regulatory approval), then the IPR&amp;D will be accounted for as a definite-lived intangible asset.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, definite-lived intangibles increased approximately $16.4&#160;million, which includes $6.8 million which was reclassified from indefinite-lived IPR&amp;D to acquired ANDA intangible assets upon completion of projects and launch of related products, and the Company added approximately $9.6&#160;million of intangible assets, comprised of $7.1&#160;million of ANDA intangible assets related to asset acquisitions with Slayback Pharma Limited Liability Company and Akorn Holding Company, $2.0&#160;million in product rights related to the transaction with Alvogen, Inc., and other asset acquisitions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, approximately $20.3 million was reclassified from indefinite-lived IPR&amp;D to acquired ANDA intangible assets upon completion of projects and launch of related products. The Company added $7.2 million in ANDA intangible assets related to the July&#160;21, 2022 transaction with Oakrum Pharma, LLC (Note 10). These assets will be amortized over a <span style="-sec-ix-hidden:f-862">seven</span>-year useful life. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for definite-lived intangible assets was $52.3 million, $49.5 million, and $41.8 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. Refer to Note 10 for more details on acquired definite-lived and indefinite-lived intangible assets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense is as follows for the years ending December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected amortization expense is an estimate. Actual amounts of amortization expense may differ due to timing of regulatory approvals related to IPR&amp;D assets, additional intangible assets acquired, impairment of intangible assets, and other events.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets and definite-lived intangibles when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31, 2023. The Company performed qualitative assessments to determine whether it was more likely than not that the assets were impaired in order to determine the necessity of performing a quantitative impairment test, under which management would calculate the asset&#8217;s fair value. When performing the qualitative assessments, the Company evaluated events and circumstances that would affect the significant inputs used to determine the fair value of the assets. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the assessments of the aforementioned factors, it was determined that it was more likely than not that the fair value of assets are greater than their carrying amount as of October 31, 2023, and therefore no quantitative testing for impairment was required.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the qualitative impairment analysis performed at October 31, 2023, there were no events or changes in circumstances that would have reduced the fair value of the indefinite or definite-lived intangible assets below their carrying values from October 31, 2023 to December&#160;31, 2023. No impairment loss was recognized during the year ended December&#160;31, 2023. During the years ended December 31, 2022 and 2021, impairment losses of approximately $0.1 million and $2.4 million, respectively, were recognized in relation to ANDA assets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340620208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE</a></td>
<td class="text">FAIR VALUE<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the funds. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to the Company, the carrying values of these borrowings approximated their fair values at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Money Market Funds</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Money market funds are readily convertible into cash and the net asset value of each fund on the last day of the reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of December 31, 2023 was approximately $191.8&#160;million.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Swap</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve. The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 5, the fair value of the interest rate swap was a $6.2 million and $8.8&#160;million at December&#160;31, 2023 and 2022, respectively, and was classified as a non-current asset.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Novitium, the Company may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discounted cash flow method used to value this contingent consideration includes inputs of not readily observable market data, which are Level 3 inputs. As of the November&#160;19, 2021 acquisition date, the contingent consideration had a fair value of $30.8 million. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021, on December 12, 2023, the Company paid $12.5&#160;million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Agreement and Plan of Merger, as the holders of Novitium ownership interests, for the achievement of the "ANDA Filing Earn-Out," as defined in the Agreement (Note 17). Furthermore, on February 22, 2024, the Company paid $12.5 million to Company Members of Novitium upon the achievement of the "Gross Profit Earn-Out," as defined in the Agreement (Note 19).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the contingent consideration was approximately $24.0 million and $35.1 million as of December&#160;31, 2023 and 2022, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the consolidated balance sheets.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payment Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assumptions</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profit-based milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability-weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025-2035</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product development-based milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability-weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in contingent consideration balances classified as Level 3 balances for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of ANDA filing earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-900"><span style="-sec-ix-hidden:f-901">Change in fair value</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Value Rights</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contingent value rights (&#8220;CVRs&#8221;), which were granted coincident with the merger with BioSante expired during June 2023, were considered contingent consideration and were classified as liabilities, and there were no payments made pursuant to the terms of the CVR agreement. The Company determined that the fair value of the CVRs was immaterial as of December 31, 2022, and also determined that the changes in such fair value were immaterial for the years ended December 31, 2022, and 2021.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents financial assets and liabilities accounted for at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, by level within the fair value hierarchy:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)<br/>Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value at <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Fund</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value at <br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no financial assets and liabilities that are measured at fair value on a non-recurring basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no non-financial assets and liabilities that are measured at fair value on a recurring basis.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment, ROU assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis. During the year ended December&#160;31, 2023, there were no impairment charges recognized related to non-financial assets and liabilities measured at fair value on a non-recurring basis. During the year ended December&#160;31, 2022, the Company recognized an impairment charge of $0.1 million related to a definite-lived ANDA intangible asset. There were no other fair value impairments recognized in the years ended December&#160;31, 2023 and 2022. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquired Non-Financial Assets Measured at Fair Value</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 27, 2023, the Company acquired from Alvogen, Inc. the rights to certain pharmaceutical products for total cash consideration of $2.0&#160;million (Note 8), which we plan to launch commercially in early 2024. The transaction was accounted for as an asset acquisition and there were no transaction costs directly related to the acquisition. Intangible assets amounted to $2.0&#160;million as NDAs and product rights. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The intangible asset will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2023.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August 14, 2023, the Company acquired one ANDA and registered patents and pending patent applications from Slayback Pharma Limited </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability Company for total consideration of $3.0 million (Note 9). The Company also acquired an NDA which has yet to be filed. The transaction was funded from cash on hand. The transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. Intangible assets amounted to $2.8 million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDA will be amortized in full over its useful life of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seven years</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and therefore </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment loss was recognized for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of fiscal 2023, the Company acquired two ANDAs and one pipeline product from the Chapter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates for total consideration of $4.8 million. The transaction was funded from cash on hand. This transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. The product portfolio included two commercial products and one pipeline product. The Company recognized $4.3 million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDAs will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023, and therefore no impairment loss was recognized for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;21, 2022, we acquired four ANDAs from Oakrum Pharma, LLC for total consideration of $8.0 million plus an immaterial amount for the purchase of finished goods inventory. The transaction was funded from cash on hand. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. The product portfolio included one commercial product, one approved product with a launch completed in September and two filed products, with approval pending. We recognized $7.2 million as acquired ANDA intangible assets and $1.2 million as research and development expense because certain of the generic products have significant remaining work required in order to be commercialized and the products do not have an alternative future use. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. We used the present value of the estimated cash flows related to the products, using a discount rate of 13% to determine the fair value of the acquired intangible assets and in-process research and development. The inventory acquired was immaterial. Contingent liabilities are accrued when they are both estimable and probable. We accrued $0.2 million in contingent payments due to a third party upon the launch of a product completed in September. This was accrued and recorded in the fair value of acquired intangible assets as it was probable at the acquisition date and has been paid in 2022. The ANDAs will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023, and therefore no impairment loss was recognized for the year ended December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, we acquired three NDAs and an ANDA and certain related inventories from Sandoz, Inc. for total consideration of $20.7 million. We also incurred and paid $0.4 million in transaction costs directly related to the acquisition. The acquisition was funded via borrowings under our Revolver. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. We recognized $11.4 million as acquired intangible assets and $9.7 million of inventory at fair value, including $0.6 million of API, $1.0 million of sample inventory, and $8.1 million in finished goods inventory. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to determine the fair value of the intangible assets, we used the present value of the estimated cash flows related to the product rights using a discount rate of 10%, which are level 3 unobservable inputs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the inventory was determined based on the estimated selling price to be generated from the finished goods, less costs to sell, including a reasonable margin, which are level 3 unobservable inputs. The intangible assets are being amortized in full over a useful life of seven years and are tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023 and therefore no impairment loss was recognized for the years ended December&#160;31, 2022 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340805136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MEZZANINE AND STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">MEZZANINE AND STOCKHOLDERS' EQUITY</a></td>
<td class="text">MEZZANINE AND STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Authorized shares</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 20.7&#160;million and 20.5&#160;million shares of common stock issued and outstanding as of December&#160;31, 2023, respectively, and 17.6&#160;million and 17.5&#160;million shares of common stock issued and outstanding as of December&#160;31, 2022, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Offering</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2023, through a public offering, the Company completed the issuance and sale of 2,183,545 shares of ANI common stock, resulting in net proceeds after issuance costs of $80.6&#160;million. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021, the Company issued 1.5&#160;million shares related to a public offering of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock and 2.5&#160;million shares as consideration for the acquisition of Novitium.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Class C Special Stock</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were 11&#160;thousand shares of class C special stock issued and outstanding as of December&#160;31, 2023 and 2022. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of the Company's common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of the Company's assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PIPE Shares</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the execution of the Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the &#8220;PIPE Investor&#8221;), pursuant to which the PIPE Investor agreed to purchase, 25,000 shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Series A Convertible Preferred Stock (the &#8220;PIPE Shares&#8221;), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely in </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> control. The Company incurred $0.2 million in issuance costs associated with the transaction.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to the Company's common stock. The PIPE Shares are convertible into the Company's common shares at the conversion price of $41.47 (i) beginning two years years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the Company's common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of December&#160;31, 2023, the PIPE shares are currently convertible into a maximum of 602,901 shares of the Company's common stock.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Company's common stock, the greater of (i) the PIPE Shares&#8217; purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock. The PIPE Shares will have voting rights, voting as one series with </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &#8220;Certificate&#8221;) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares&#8217; purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the holder of the PIPE Shares would have received if it had converted into </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> common stock.</span></div>There were 25,000 shares of Series A convertible preferred stock outstanding as of December&#160;31, 2023 and 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340078304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings (loss) per share by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under our ESPP, and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share for the years ended December&#160;31, 2023, 2022, and 2021 are calculated for basic and diluted earnings (loss) per share as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) available to common shareholders </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) available to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,596</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,596</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of stock options, ESPP, and performance stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,194</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,596</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings (loss) per share, were 2.4 million, 2.6 million, and 1.7 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. For the years ended December 31, 2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because the Company reported a net loss</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340711920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 ESPP. As of December 31, 2023 there are 0.1&#160;million shares of common stock available for issuance under the ESPP. Under the ESPP, participants can purchase shares of common stock at a 15% discount. The Company issued 38&#160;thousand, 29&#160;thousand, and 14&#160;thousand shares in the years ended December&#160;31, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Incentive Plan <br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Equity-based service awards are granted under the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the &#8220;2022 Plan&#8221;), which was approved by the Company's stockholders at the 2022 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) held on April 27, 2022. Prior to this approval, the Company granted equity-based incentive awards under the Sixth Amended and Restated 2008 Stock Incentive Plan (the &#8220;2008 Plan&#8221;), which was renamed, amended and restated to the 2022 Plan. The 2022 Plan, among other things, increased the number of shares reserved for issuance thereunder by 1,150,000 shares. As of December&#160;31, 2023, 1.1&#160;million shares of common stock were available for issuance under the 2022 Plan. On May 23, 2023, the Company&#8217;s stockholders approved an amendment to the 2022 Plan (such amendment, the &#8220;2023 Stock Plan Amendment&#8221;). Subject to adjustment, the 2023 Stock Plan Amendment increased the number of shares reserved for issuance under the 2022 Plan by 750,000 shares.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may grant stock options to employees through an inducement grant outside of the 2022 Plan to induce prospective employees to accept employment with us (the &#8220;Inducement Grants&#8221;). The options are granted at an exercise price equal to the fair market value of a share of the common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of the stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of equity-based service awards are measured based on the grant-date fair value of the award. The cost is recognized ratably over the period during which an employee is required to provide service in exchange for the award or the requisite service period. Stock-based compensation expense is recognized ratably over the vesting periods of the awards.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense incurred for stock options, restricted stock awards, performance-based restricted stock units, and Inducement Grants and included in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,676</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,094</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,818</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">863</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">710</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">543</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">482</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,185</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,286</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,366</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax benefits of approximately $3.3 million, $1.7 million, and $1.0 million were recognized for stock-based compensation-related tax deductions in the 2023, 2022, and 2021 consolidated statements of operations, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding stock options granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of <span style="-sec-ix-hidden:f-1089">one</span> to four years and have 10-year contractual terms. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, 2022, and 2021, the fair value of each option grant was estimated using the Black-Scholes option-pricing model, using the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.50 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.50 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.71% - 2.83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.68% - 1.39%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.4% - 50.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.2% - 49.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the simplified method to estimate the expected option life of options. The risk-free interest rate used is the yield on a U.S. Treasury note as of the grant date with a maturity equal to the estimated life of the option. The calculated estimated volatility rate is based on ANI's historical stock price. The Company has not issued a cash dividend on the common shares in the past nor does the Company have any current plans to do so in the future; therefore, an expected dividend yield of zero was used.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2022 Plan and Inducement Grants during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.09&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.56&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.52&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.05&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $1.6 million of total unrecognized compensation cost related to non-vested stock options granted under the 2022 Plan and Inducement Grant. The cost is expected to be recognized over a weighted-average period of 1.1 years. During the year ended December&#160;31, 2023, ANI received $8.3 million in cash from the exercise of stock options and recorded approximately $0.2 million tax provision related to these exercises. During the year ended December&#160;31, 2022, ANI received $0.7 million in cash from the exercise of stock options and recorded a $0.1 million tax provision related to these exercises. During the year ended December&#160;31, 2021, ANI received </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.7 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash from the exercise of stock options and recorded a $0.1 million tax provision related to these exercises.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards (&#8220;RSAs&#8221;) granted to employees generally vest over a period of four years. RSAs granted to non-officer directors generally vest over a period of one year.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of common stock delivered to employees and directors will be unrestricted upon vesting. During the vesting period, the recipient of the restricted stock has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of the Company's stock on the date of grant.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSA activity under the Plan during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Term<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.02&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">707&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.52&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">748&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.76&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,141&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">674&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.30&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$41.5 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of total unrecognized compensation cost related to non-vested RSAs granted under the Plan, which is expected to be recognized over a weighted-average period of 2.4 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance-Based Restricted Stock Units</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards may also be issued in the form of PSUs. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a <span style="-sec-ix-hidden:f-1206">three</span>-year performance period. On February 28, 2023, as part of the Company's equity compensation program, PSUs were granted to certain executives. Of these PSUs, 50% were market performance-based restricted stock units (&#8220;MPRSUs&#8221;), vesting of which is contingent upon the Company meeting certain total shareholder return (&#8220;TSR&#8221;) levels as compared to a select peer group over the over <span style="-sec-ix-hidden:f-1208">three</span> years starting January 1, 2023. The MPRSUs are also subject to the recipient&#8217;s continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the <span style="-sec-ix-hidden:f-1209">three</span>-year period and have a maximum potential to vest at 200% (85,099 shares) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $68.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the <span style="-sec-ix-hidden:f-1214">three</span>-year performance period and are reflected under &#8220;Granted&#8221; in the table below.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other 50% of the PSUs were performance based restricted stock units (&#8220;PRSUs&#8221;), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over <span style="-sec-ix-hidden:f-1216">three</span> years starting January 1, 2023. The PRSUs are also subject to the recipient&#8217;s continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (85,099 shares) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $41.84 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the <span style="-sec-ix-hidden:f-1222">three</span>-year performance period and are reflected under &#8220;Granted&#8221; in the table below.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PSU activity under the Plan during the years ended December&#160;31, 2023 and 2022 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Term<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there was $2.5 million of total unrecognized compensation cost related to non-vested PSUs granted under the Plan, which is expected to be recognized over a weighted-average period of 2.0 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340635296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2018, ANI Pharmaceuticals Canada Inc. (&#8220;ANI Canada&#8221;) acquired all the issued and outstanding equity interests of WellSpring in a non-taxable transaction. Following the consummation of the transaction, WellSpring was merged into ANI Canada. For U.S. Federal and state income tax purposes, ANI Canada is not part of ANI&#8217;s consolidated group; rather, ANI Canada is subject to income taxes only in Canada and solely based on its stand-alone operations. The foreign current and foreign deferred provisions (benefits) below represent the Company's tax provision (benefit) from the Canadian and Indian taxing jurisdictions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to establish a valuation allowance is required to be established for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Projected future taxable income and tax planning strategies in making this assessment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023 and 2022, the consolidated valuation allowance was $0.4&#160;million and $0.4&#160;million, respectively, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total income tax expense (benefit) for income taxes consists of the following for the years ended December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,677&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,307&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax benefit</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,946)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,722)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,576)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,232)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,949)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expense (benefit) for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,093&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,769)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,455)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between expected income tax expense (benefit) from applying U.S. Federal statutory tax rates to the pre-tax income (loss) and actual income tax expense (benefit) relates primarily to the effect of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of Federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in state apportionment factors, state and foreign rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and experimentation and charitable credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer pricing and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Deferred income tax assets and liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals and advances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for chargebacks and returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,098)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,074)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of deferred tax liabilities and valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, U.S. federal net operating loss carryforwards were approximately $8.0 million, all of which arose as a result of the 2013 merger with BioSante Pharmaceuticals, Inc. Net operating loss carryforwards related to the 2013 merger, if not used, expire in annual increments through 2033 and are limited on an annual basis as prescribed by Section 382 of the U.S. Internal Revenue Code; and the current annual limitation is approximately $0.8 million per year. Additionally, as of December&#160;31, 2023, there were total net operating losses in various states of approximately $13.0&#160;million which begin to expire through 2042, and in Canada of $1.0 million that expire through 2038. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous jurisdictions in the U.S., Canada, and India. Significant judgment is required in evaluating the tax positions and determining the provision for income taxes. Liabilities are established for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These liabilities are established when it is believed that certain positions might be challenged despite the belief that our tax return positions are fully supportable. These liabilities are adjusted in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of changes to the liability that is considered appropriate. There were no material uncertain income tax positions identified as of December&#160;31, 2023 and 2022.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to income tax audits in all jurisdictions for which tax returns are filed. Tax audits by their nature are often complex and can require several years to complete. All of the Company's income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340789776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All existing leases as of December&#160;31, 2023 are classified as operating leases. As of December&#160;31, 2023, there are 14 operating leases for facilities and office equipment with remaining terms expiring from 2025 through 2028 and a weighted average remaining lease terms of 3.9 years and 2.6 years, as of December 31, 2023 and 2022, respectively. During April 2023, the Company entered into a lease agreement for additional warehouse space in East Windsor, New Jersey. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Company's square footage and also extended the termination date to December 2028. Many of the operating leases have fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of twelve months or less are not recorded on the balance sheet, and the Company does not separate lease and non-lease components of contracts. The Company&#8217;s lease agreements do not provide for determination of the interest rate implicit in the lease. Therefore, the Company used a benchmark approach to derive an appropriate incremental borrowing rate. The Company&#8217;s incremental borrowing rate is the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived an incremental borrowing rate, which was used to discount its lease liabilities. The weighted average incremental borrowing rates as of December 31, 2023 and 2022 is 8.12% and 3.99%, respectively. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any finance leases, any sublease arrangements, or any leases where the Company is considered the lessor.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense consisted of the following for the years ended December 31:</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">701</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">236</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,252</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the lease liabilities recorded on the Consolidated Balance Sheet as of December 31, 2023:</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:85.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,967</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,610</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,290</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,289</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">506</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,662</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: effects of discounting </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,672</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1361">Less: current lease liability, included in accrued expenses and other</span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,561)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1363">Non-current lease liability, included in other non-current liabilities</span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,111</span></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (&#8220;DEA&#8221;), the Food and Drug Administration (&#8220;FDA&#8221;), the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;), the Central Drugs Standard Control Organization (&#8220;CDSCO&#8221;), The Narcotics Control Bureau (&#8220;NCB&#8221;), and India&#8217;s Ministry of Health and Family Welfare (&#8220;MoHFW&#8221;). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANI's products. The DEA and NCB maintain oversight over products that are considered controlled substances. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unapproved Products</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three products, Esterified Estrogen with Methyltestosterone (&#8220;EEMT&#8221;), Opium Tincture, Thyroid Tablets, and are marketed without approved NDAs or ANDAs. During the years ended December&#160;31, 2023, 2022, and 2021, net revenues for Esterified Estrogen with Methyltestosterone (&#8220;EEMT&#8221;), Opium Tincture and Thyroid Tablets products totaled $22.4 million, $14.2 million, and $16.2 million, respectively. The Company obtained the rights to Hyoscyamine, a product without an approved NDA as of December 27, 2023, which we plan to launch commercially in early 2024 (see further discussion below).</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA's policy with respect to the continued marketing of unapproved products appears in the FDA's September 2011 Compliance Policy Guide Sec. 440.100 titled &#8220;Marketed New Drugs without Approved NDAs or ANDAs.&#8221; Under this policy, the FDA has stated that it will follow a risk-based approach with regard to enforcement against marketing of unapproved products. The FDA evaluates whether to initiate enforcement action on a case-by-case basis, but gives higher priority to enforcement action against products in certain categories, such as those with potential safety risks or that lack evidence of effectiveness. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to believe that, so long as we comply with applicable manufacturing standards, the FDA will continue to operate on a risk-based approach and will not take action against us. However, we can offer no assurance that the FDA will continue to follow this approach or that it will not take a contrary position with any individual product or group of products. If the FDA were to move away from the risk-based approach to enforcement against marketing of unapproved products, we may be required to seek FDA approval for these products or withdraw such products from the market. If we decide to withdraw the products from the market, net revenues for generic pharmaceutical products would decline materially, and if we decide to seek FDA approval, we would face increased expenses and might need to suspend sales of the products until such approval was obtained, and there are no assurances that we would receive such approval.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One group of products that the Company manufactured on behalf of a contract customer, Hyoscyamine, was marketed by that customer without an approved NDA. Contract manufacturing revenues for Hyoscyamine, for the years ended December&#160;31, 2023, 2022, and 2021 were $1.9 million, $2.6 million, and $2.4 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. On December 27, 2023 the Company purchased the intellectual property and product rights to Hyoscamine from Alvogen, Inc. (Note 10).</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal proceedings </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved, and from time to time may become involved, in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal fees for litigation-related matters are expensed as incurred and included in the consolidated statements of operations under the selling, general, and administrative expense line item. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Litigation </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company&#8217;s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys&#8217; fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York as In re Bystolic Antitrust Litigation, Case No. 20-cv-005735 (LJL). On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendants&#8217; motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit.  Oral arguments were held on December 6, 2023 and a decision from the court is pending. ANI continues to dispute any liability in this matter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 24, 2021, Azurity Pharmaceuticals, Inc. (&#8220;Azurity&#8221;) filed a complaint in the United States District Court for the District of Minnesota against ANI, asserting that ANI&#8217;s vancomycin hydrochloride oral solution drug product infringes U.S. Patent No. 10,688,046. The complaint sought injunctive relief, damages, including lost profits and/or royalty, treble damages, and attorneys&#8217; fee and costs. On February 15, 2022, the Company entered into a settlement agreement with Azurity to resolve all claims related to this action. Under the terms of the agreement, Azurity granted ANI a non-exclusive, non-transferable, non-sublicensable, royalty-bearing license under its patents to sell ANI product in the United States and dismissed the action with prejudice. In exchange, ANI paid Azurity $1.9&#160;million of royalties from past sales and will pay Azurity a royalty equal to 20% of gross margin of sales of the ANI product for a contractually defined term.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2021, United Therapeutics Corp. and Supernus Pharmaceuticals, Inc. (&#8220;UTC/Supernus&#8221;) filed a complaint in the United States District Court for the District of Delaware against ANI, asserting that ANI&#8217;s proposed Treprostinil extended release drug product, which is subject to ANI&#8217;s Abbreviated New Drug Application No. 215667, infringes U.S. Patent Nos. 7,417,070, 7,544,713, 8,252,839, 8,349,892, 8,410,169, 8,747,897, 9,050,311, 9,278,901, 9,393,203, 9,422,223, 9,593,066 and 9,604,901 (&#8220;the Asserted Patents&#8221;). The complaint sought injunctive relief</span><span style="color:#353535;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">attorneys' fee and costs. On May 26, 2022, the parties&#8217; respective claims and counterclaims were dismissed pursuant to a confidential settlement agreement.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2022, Azurity filed a complaint in the United States District Court for the District of New Jersey against Novitium, seeking a declaratory judgment that Novitium&#8217;s manufacture, use, sale, importation and/or offer to sell Bionpharma Inc.&#8217;s (&#8220;Bionpharma&#8221;) enalapril maleate oral solution drug product (the &#8220;Product&#8221;) would infringe U.S. Patents Nos. 11,040,023 and 11,141,405 (the &#8220;Novitium Action&#8221;). The complaint sought injunctive relief, and an award of Azurity&#8217;s costs and expenses. On October 12, 2022, Bionpharma filed a motion in the New Jersey court to intervene on Novitium&#8217;s behalf in the litigation and on October 14, 2022, Novitium and Bionpharma jointly moved to transfer venue to the District of Delaware. Transfer was granted on January 20, 2023. On March 27, 2023, the transferred Novitium Action (assigned Delaware Civil Action No. 23-163-MSG) was consolidated with the Delaware Third Wave Suits against Bionpharma (Civil Action Nos. 21-1286-MSG, 21-1455-MSG), which include Azurity&#8217;s infringement claims against Bionpharma involving the same patents asserted in the Novitium Action, as well as Bionpharma&#8217;s antitrust claims against Azurity. On August 3, 2023, Azurity filed an amended complaint against Novitium seeking damages for supplying Bionpharma's ANDA product. On November 14, 2023, the court dismissed all of Azurity's claims against Novitium with prejudice and dismissed Novitium as a party from the Delaware Third Wave Suits. Bionpharma has agreed to indemnify Novitium under the terms of its manufacturing and supply agreement for any damages, costs, and expenses relating to actual or alleged infringement of intellectual property rights or sale of the Product by Bionpharma. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 29, 2023, Orphalan SA ("Orphalan") filed a complaint in the United States District Court for the District of Delaware against Novitium, asserting that Novitium's proposed triethylenetetramine tetrachloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218493, infringes U.S. Patent Nos. 10,988,436 and 11,072,577.  The complaint seeks damages, injunctive relief, attorneys' fees and costs. On December 1, 2023, Orphalan voluntarily dismissed the action without prejudice. Novitium disputes any liability in this matter.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2023, Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS filed a compliant in the United States District Court for the District of Delaware against Novitium and certain other defendants named in the complaint, asserting, among other things, that Novitium's proposed pitolisant hydrochloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218495, infringes U.S. Patent Nos 8,207,197, 8,354,430 and 8,486,947.  The complaint seeks damages, injunctive relief, attorneys' fees and costs.  Novitium disputes any liability in this matter.</span></div><div style="padding-left:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ranitidine Related Litigation</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State of New Mexico Litigation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In July 2020, ANI and Novitium were served with a complaint brought in the First Judicial Court, County of Santa Fe, State of New Mexico by the Office of the Attorney General of the State of New Mexico against manufacturers and sellers of ranitidine products. The complaint asserted a public nuisance claim and a negligence claim against the generic ranitidine manufacturer defendants, including ANI and Novitium. As damages for the nuisance claim, New Mexico asked that the defendants fund this medical monitoring program.  With respect to the nuisance claim, New Mexico asserted that it paid for ranitidine products through state-funded insurance and health-care programs. On April 16, 2021, New Mexico filed an amended complaint in the New Mexico First Judicial District Court in Santa Fe County. It did not name ANI in the amended complaint, effectively voluntarily dismissing ANI from the action. Novitium was named as a defendant in the amended complaint. On September 1, 2023, the court entered an order dismissing Novitium without prejudice.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420344681728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CortrophinPreLaunchChargesAbstract', window );"><strong>PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CortrophinPreLaunchChargesTextBlock', window );">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</a></td>
<td class="text">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES<div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2016, the Company acquired the right, title and interest in the NDAs for Cortrophin Gel and Cortrophin-Zinc. Subsequently, the Company assembled a Cortrophin Gel re-commercialization team of scientists, executed a long-term supply agreement with a supplier of pig pituitary glands, our primary raw material for corticotrophin API, executed a long-term supply agreement with an API manufacturer, with whom ANI has advanced the manufacture of corticotropin API via manufacture of commercial-scale batches, and executed a long-term commercial supply agreement with a current good manufacturing practice (&#8220;cGMP&#8221;) aseptic fill contract manufacturer.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the third quarter 2019, all purchases of material, including pig pituitary glands and API, related to the re-commercialization efforts were consumed in research and development activities and recognized as research and development expense in the period in which they were incurred. In the third quarter of 2019, the purchase of materials commenced that were intended to be used commercially in anticipation of FDA approval of Cortrophin Gel and the resultant product launch. The FDA granted approval of the sNDA of this product on October 29, 2021. Prior to FDA approval, under U.S. GAAP, the Company was prohibited from capitalizing these pre-launch purchases of materials as inventory, and accordingly, they were charged to expense in the period in which they were incurred. Subsequent to approval, these purchases are recorded as inventory at net realizable value. During the year ended December 31, 2021, the Company recognized $0.8 million of charges for the purchase of materials. Other charges were incurred directly related to the Cortrophin pre-launch commercialization efforts, including, but not limited to, sales and marketing and consulting expenses. During the year ended December 31, 2021, the Company incurred $14.0 million of these charges, which are included on the consolidated statements of operations as a selling, general, and administrative expense. There were no comparable expenses in 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CortrophinPreLaunchChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CortrophinPreLaunchChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CortrophinPreLaunchChargesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cortrophin pre-launch charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CortrophinPreLaunchChargesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340795376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which  25,000 shares were purchased for $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The Chairman of the Company's board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&amp;D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company's board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (&#8220;Scitus&#8221;), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC (&#8220;SS Pharma&#8221;), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited (&#8220;Nuray&#8221;), which manufactures and supplies API to Novitium, and a majority interest in Esjay Pharma LLC (&#8220;Esjay&#8221;), which provided research and development and facilities consulting services through September 30, 2022. Mr. Gassert holds a minority interest in Scitus. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of payments to related parties is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scitus Pharma Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,075</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SS Pharma LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,235</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esjay Pharma LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nuray Chemical Private Limited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">365</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,881</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,955</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Includes payments during the period from November 19, 2021 to December 31, 2021, subsequent to the acquisition of Novitium. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the outstanding balances due to Scitus and SS Pharma were $0.7&#160;million and $0.6&#160;million, respectively. There was no outstanding balance due to Nuray or Esjay at December&#160;31, 2023.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2023, the Company paid $12.5&#160;million of cash consideration to the Company Members of Novitium for the achievement of the "ANDA Filing Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $6.7&#160;million and $1.9&#160;million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.</span></div>On February 22, 2024, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $6.7&#160;million and $1.9&#160;million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340675376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT REPORTING</a></td>
<td class="text">SEGMENT REPORTING<div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity&#8217;s chief operating decision maker (&#8220;CODM&#8221;) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. Prior to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, based on this definition, the Company was organized as one operating and reporting segment. Prior period segment disclosures have been recast for the new segment presentation. Effective in the first quarter of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and prospectively, in conjunction with the principal completion of the buildout of infrastructure in the areas of commercialization of rare disease therapies and the launch of Cortrophin Gel, it was determined that the Company has two operating segments as follows:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Generics, Established Brands, and Other</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Rare Disease</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CODM evaluates the performance of the Company as two operating segments based on revenues and EBITDA, exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not manage assets of the Company by operating segment and the CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information by reportable segment, including historical information that has been retroactively re-cast to reflect two reporting segments, is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, Established Brands, and Other</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374,699</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274,699</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,117</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,686</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment earnings (loss) before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) and reconciliation to income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, Established Brands, and Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,990</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,958</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,418</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Disease</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,348)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,571)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate and other unallocated expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,920)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating income (loss)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,971&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,283)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,793)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,343)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before expense (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62,665)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,058)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.27pt">Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our consolidated statement of operations.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Information</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operations are located in the United States and India. The Company has ceased operations at the Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table depicts the Company&#8217;s revenue by geographic operations during the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Location of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">312,427</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211,893</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">565</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,958</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,243</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table depicts the Company&#8217;s property and equipment, net according to geographic location as of:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,343</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,856</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,430</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,246</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts as of December&#160;31, 2023 and 2022 exclude the land and building at the Canada facility, which are classified as held for sale as of December&#160;31, 2023 and 2022. These assets have a carrying value of $8.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340892432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS <div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2024, the Company granted RSA and PSU awards to officers and employees of the Company under the 2022 Plan. The Company granted 525,729 RSAs to employees and officers of the Company. These RSAs vest over four years. The Company granted 73,588 PSUs to employees and officers of the Company (66,433 to officers of the Company). PSU performance will be measured over three years from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. PSUs granted to date vest over a three-year performance period. Additionally, on February 15, 2024, the Company granted 13,054 RSAs to new employees of the Company, which will vest over four years.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 16, 2024, ANI Pharmaceuticals Canada, Inc. and 1540700 Ontario Limited entered into an agreement of purchase and sale for the Oakville, Ontario manufacturing facility for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The first and second deposits, each amounting to approximately 1.0 million Canadian Dollars or approximately $0.7 million US Dollars, based on the current exchange rate, were received on February 20, 2024, and February 27, 2024, respectively. The remaining balance of the purchase price, less deposits, will be paid upon closing, which is expected to occur by the end of March 2024. The closing of the transaction is subject to customary termination conditions, including the buyer&#8217;s right to terminate the agreement if the property is materially damaged prior to the closing.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 22, 2024, the Company paid $12.5 million to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2010, ANI, formerly Biosante, entered into an assignment and technology transfer agreement and stock subscription agreement (collectively the "CG Agreement") with CG Oncology, Inc. formerly, Cold Genesys, Inc. (&#8220;CG Oncology&#8221;), pursuant to which the Company sold to CG Oncology exclusive, worldwide rights to develop and commercialize BioSante&#8217;s oncolytic virus technology. The technology includes a replication-competent adenovirus that has completed clinical trials for treatment of superficial bladder cancer. Under the terms of the CG Agreement, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d an equity investment in CG Oncology, an upfront cash payment and the right to receive future royalty payments. Historically, this equity investment was recorded at cost and as of December 31, 2023, this equity investment was valued at zero. On January 24, 2024, CG Oncology completed their Initial Public Offering, at an offering price of $19.00 per share. The Company currently holds 219,925 shares of common stock in CG Oncology. As of February 27, 2024 these shares are valued at approximately $10.2&#160;million. </span></div>On February 28, 2024, CG Oncology disputed the Company's rights to receive royalties. The dispute is unresolved at this time.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342187184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 18,779<span></span>
</td>
<td class="num">$ (47,896)<span></span>
</td>
<td class="num">$ (42,603)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420339127968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=anip_Mr.MuthusamyShanmugamMember', window );">Mr. Muthusamy Shanmugam [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 27, 2023, Mr. Muthusamy Shanmugam, Head of R&amp;D and COO of NJ Operations, adopted a trading arrangement for the sale of securities of the Company&#8217;s common stock (a &#8220;Rule 10b5-1 Trading Plan&#8221;) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Shanmugam's Rule 10b5-1 Trading Plan, which has a term from March 4, 2024 through November 29, 2024, provides for the sale of up to 400,000 shares of common stock pursuant to the terms of the plan.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mr. Muthusamy Shanmugam<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Head of R&D and COO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 27, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">270 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=anip_Mr.ChadGassertMember', window );">Mr. Chad Gassert [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 12, 2023, Mr. Chad Gassert, Sr. Vice President, Corporate Development and Strategy, adopted a trading arrangement for the sale of securities of the Company&#8217;s common stock (a &#8220;Rule 10b5-1 Trading Plan&#8221;) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Gassert's Rule 10b5-1 Trading Plan, which will terminate September 30, 2024, provides for the sale of up to 100,000 shares of common stock pursuant to the terms of the plan.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mr. Chad Gassert<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Sr. Vice President, Corporate Development and Strategy<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 12, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">293 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=anip_Mr.MuthusamyShanmugamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=anip_Mr.MuthusamyShanmugamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=anip_Mr.ChadGassertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=anip_Mr.ChadGassertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342015968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. Unless otherwise noted, all references to &#8220;$&#8221; or &#8220;dollar&#8221; refer to the U.S. dollar. The Company&#8217;s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders&#8217; equity accounts, intercompany, and fixed assets, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company&#8217;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders&#8217; equity within accumulated other comprehensive income (loss), net of tax.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of the Company&#8217;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In the consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and potential adjustments, income tax expense or benefit, deferred taxes and valuation allowance, stock-based compensation, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy', window );">Restructuring Activities</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restructuring Activities</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the consolidated statements of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Revenue is recognized using the following steps:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the contract, or contracts, with a customer;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Identification of the performance obligations in the contract;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Determination of the transaction price, including the identification and estimation of variable consideration;</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allocation of the transaction price to the performance obligations in the contract; and</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Recognition of revenue when we satisfy a performance obligation.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company derives its revenues primarily from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold is transferred to the customer. Generally, the Company does not incur incremental costs to obtain contracts that would otherwise not have been incurred. The Company has not identified any agreements or arrangement that would qualify as a significant financing component.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Distribution Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may enter into marketing and distribution agreements with third parties in which products are sold under Abbreviated New Drug Applications (&#8220;ANDAs&#8221;) or New Drug Applications (&#8220;NDAs&#8221;) owned or licensed by third parties. These products are sold under the ANI label. The Company controls the products sold under these marketing and distribution agreements and therefore are the principal for sales under each of these marketing and distribution agreements. As a result, revenue is recognized on a gross basis when control has passed to the customer and the performance obligation has been satisfied. Under these agreements, the Company pays third parties a specified percentage of the gross profit earned on sales of the products. These profit-sharing percentages are recognized in cost of sales in the consolidated statements of operations and are accrued in accrued royalties in the consolidated balance sheets until payment has occurred.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Product Sales Revenue</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing arrangements consist of agreements in which pharmaceutical products are manufactured by the Company on behalf of a third party. The performance obligation is to manufacture and provide pharmaceutical products to customers, typically pharmaceutical companies. The products are sold at predetermined standalone selling prices and the performance obligation is considered to be satisfied when control of the product is transferred to the customer. Control is transferred to the customer when the product leaves the shipping dock to be shipped to the customer, as  contract manufactured pharmaceutical products are sold on an FOB shipping point basis and the inventory risk and risk of ownership passes to the customer at that time. Payment terms for these sales are generally fewer than two months. Typically, there are no material returns for contract manufactured products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties from Licensing Agreements</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into licensing agreements, under which the Company licenses to the seller the right to sell the acquired products. Because these royalties are sales-based, the Company recognizes the revenue when the underlying sales occur, based on sales and gross profit information received from the sellers. The Company may enter into agreements which include profit-sharing percentages on gross profits. The profit-sharing percentages are recorded in cost of sales in the consolidated statements of operations when the associated revenue is recognized and are recorded in accrued royalties in the consolidated balance sheets when the associated revenue is recognized and until payment has occurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, and Restricted Cash</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid investments with original maturities of three months or less from the date of purchase are classified as cash equivalents. Cash and cash equivalents consist of cash deposited in checking accounts, time deposits with maturities of less than three months, and money market accounts with maturities of three months or less at the date of purchase. Cash and cash equivalents include cash on-hand and money market funds which invest exclusively in high-quality, short-term securities that are issued or guaranteed by the U.S. government. Due to the short-term maturity of the funds invested in the money market accounts, the carrying amounts are a reasonable estimate of fair value. All interest bearing and non-interest bearing accounts are guaranteed by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250 thousand. The majority of the Company's cash balances are in excess of FDIC coverage, which the Company considers to be a normal business risk.</span></div>Restricted cash at December 31, 2022, represented $5.0 million of funds held in a bank account owned by the Company to be used to pay for future milestones related to the purchase of  the rights, title, and interest in the NDA for Inderal LA, as well as certain documentation, trademark rights, and finished goods from Cranford Pharmaceuticals, LLC in April 2016. This amount was was released from restricted cash during the first quarter of the year ended December&#160;31, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span></div>The Company extends credit to customers on an unsecured basis. Expected credit losses are measured at amortized cost, including trade and unbilled receivables, on a collective basis, based on their similar risk characteristics. Expected credits losses are based on historical credit loss experience, review of the current aging or status of accounts receivable and current and forward-looking views from an economic and industry perspective. Receivables are written off when it is determined that amounts are uncollectible. The allowance for credit losses was immaterial as of December&#160;31, 2023 and 2022.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div>Inventories consist of raw materials, packaging materials, work-in-progress, and finished goods. Inventories are stated at the lower of standard cost or net realizable value. The Company periodically reviews and adjusts standard costs, which generally approximate weighted average cost.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation is recorded on a straight-line basis over estimated useful lives as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of asset's useful life or remaining life of lease </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr></table></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress consists of multiple projects, primarily related to new equipment and expansion of laboratory and manufacturing facilities to expand manufacturing capability as product lines grow. Construction in progress includes the cost of construction and other direct costs attributable to the construction, along with capitalized interest. Depreciation is not recorded on construction in progress until such time as the assets are placed in service.</span></div>The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Assets Held-for-Sale</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets Held-for-Sale </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Property, Plant and Equipment</span>. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the Company does not separate lease and non-lease components of contracts. There are no material residual guarantees associated with any of the Company&#8217;s leases, and there are no significant restrictions or covenants included in the Company&#8217;s lease agreements. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. As of December&#160;31, 2023 and 2022, the Company did not have any finance leases.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The definite-lived ANDAs, NDAs and product rights, marketing and distribution rights, customer relationships, and non-compete agreement are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from <span style="-sec-ix-hidden:f-537">seven</span> to ten years, based on the straight-line amortization method. In the case of certain NDA and product rights, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Management reviews definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. During the year ended December&#160;31, 2023, no impairment charges were recognized on intangible assets.. During the year ended December&#160;31, 2022, the Company recognized a full impairment of a definite-lived ANDA asset with a remaining carrying value of $0.1 million. During the year ended December&#160;31, 2021, the Company recognized an impairment charge of $2.4 million related to a definite-lived ANDA intangible asset. No events or circumstances arose in 2023, 2022, or 2021 that indicated that the carrying value of any of the other definite-lived intangible assets may not be recoverable.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets other than goodwill include in-process research and development (&#8220;IPR&amp;D&#8221;) projects. IPR&amp;D intangible assets represent the fair value of technology acquired in a business combination for which the technology projects are incomplete but have substance. When an IPR&amp;D project is completed (generally upon receipt of regulatory approval), the asset is then accounted for as a definite-lived intangible asset. Indefinite-lived intangibles are tested for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying amount of the asset might not be recoverable. Judgment is used in determining when these events and circumstances arise. No events or circumstances arose in 2023 that indicated that the carrying value of any of the indefinite-lived intangible assets may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost, using the purchase method of accounting, and is related to past business combinations with BioSante Pharmaceuticals, Inc., WellSpring, and Novitium. Goodwill is not amortized, but is subject to periodic review for impairment. The Company is organized in two operating segments, and two reporting units, and has determined that goodwill resides in one reporting unit, Generics, Established Brands, and Other.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews goodwill for impairment on a reporting unit basis annually, on October 31, and whenever events or changes in circumstances indicate the carrying value of goodwill might not be recoverable. Under the authoritative guidance issued by the FASB, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company&#8217;s financial condition and results of operations. </span></div>The Company assessed the assets qualitatively, and concluded it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit is greater than its carrying value as of October 31, 2023 and 2022, and therefore no quantitative testing for impairment was required.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Arrangements </span></div>The Company may enter into collaborative arrangements with various commercial partners to further business opportunities. In collaborative arrangements revenues and costs generated by collaborative arrangements may be presented on a gross or net basis depending on the specific facts of the collaborative arrangement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div>Research and development ("R&amp;D") activities are expensed as incurred. R&amp;D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company issues stock options and restricted stock awards, which are awarded in exchange for employee and non-employee director services. From time to time, the Company may grant awards through an inducement grant outside of the incentive plan to induce prospective employees to accept employment with the Company. These grants are made pursuant to inducement grants outside of the shareholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock awards is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#8217;s requisite service period and classified where the underlying salaries are classified. Forfeitures are accounted for as they occur. Excess tax benefits or tax deficiencies are recognized as a component of the current period provision for income taxes.  </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Awards may also be issued in the form of Performance Stock Units (&#8220;PSUs&#8221;) to certain employees of the Company. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted vest over a three-year performance period. Currently, the PSU&#8217;s vesting is contingent upon the Company meeting certain total shareholder return (&#8220;TSR&#8221;) levels as compared to a select peer group over the over three years, and contingent upon the Company meeting certain adjusted non-GAAP year-on-year </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earnings before interest, income taxes, depreciation, and amortization (&#8220;EBITDA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> growth rates over the vesting term. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also administers an Employee Stock Purchase Plan (&#8220;ESPP&#8221;). The estimated fair value of stock-based compensation awards are recognized and classified in the expense where the underlying salaries are classified. </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of the Company's stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in various U.S. jurisdictions, Canada, and India, and all of our income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has previously entered into an interest rate swap agreement (Note 6) designated as a cash flow hedge designed to manage exposure to changes in SOFR-interest rate underlying our variable rate debt. Due to the effective nature of the hedge, the initial fair value of the hedge and subsequent changes in the fair value of the hedge are recognized in other comprehensive income (loss) in the consolidated balance sheets. Income taxes are allocated to the hedge component of other comprehensive income (loss) based on appropriate intra-period tax allocations when those effects are deemed material.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives', window );">Derivative Instruments and Hedge Accounting</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedge Accounting</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses interest rate swaps to hedge exposure to interest rate risk, as well as benefit from favorable conditions. The Company recognizes all derivative instruments as either assets or liabilities at fair value. For all of the Company&#8217;s derivative positions that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivatives is reported as a component of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">other comprehensive income (loss)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on derivatives representing any ineffective component of the hedge are recognized in current earnings. All of the Company&#8217;s cash flow hedges have been deemed effective as of December&#160;31, 2023 for both accounting and tax purposes. The Company has elected hedge accounting for both U.S. GAAP and tax purposes. The Company maintains formal documentation through a periodic memo and accounting analysis that cover what is being hedged, how it is being hedged, hedge effectiveness, the nature of the risk being hedged, among other required analyses. Company policy further includes a quarterly probability analysis covering hedge effectiveness.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentLiabilityReserveEstimatePolicy', window );">Contingent Consideration</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of the acquisition agreement between ANI and Novitium Pharma LLC include the potential payment of future consideration that is contingent upon the achievement of certain regulatory and financial performance milestones. At the acquisition date, contingent consideration is recorded at fair value based on the additional consideration expected to be transferred, which is based on the estimate of probability-weighted future cash flows as discounted to present value. Significant inputs used in the measurement of the fair value include discount rates, probabilities of achievement of regulatory-based milestones and payments, and projected revenues and gross profits. The discount rates are derived using accepted valuation methodologies. The probability of achievement of regulatory milestones is based on historical and projected success rates. The projected revenues and gross profits are based on internal forecasts and long-term plans. The contingent consideration is remeasured each reporting period using Level 3 inputs. Changes in fair value, which incorporate changes in assumptions and the passage of time, are recognized as an operating expense in the consolidated statements of operations. As payments are not expected to be made shortly after the acquisition, any future payment of contingent consideration will be reported as a financing cash flow for amounts paid up to the acquisition-date fair value of the consideration, and as an operating cash outflow for any amounts in excess of the acquisition-date fair value in our consolidated statement of cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1&#8212;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2&#8212;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3&#8212;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated balance sheets include certain financial instruments (primarily cash and cash equivalents, prepaid expenses, accounts receivable, accounts payable, accrued expenses, and other current liabilities) that are carried at cost and that approximate fair values as of December&#160;31, 2023, 2022 due to their short term nature. See Note 10 for additional information regarding fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on the consolidated financial statements.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Adopted </span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued ASU 2020-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. </span></div>In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company&#8217;s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentLiabilityReserveEstimatePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(13)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentLiabilityReserveEstimatePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 25<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480270/815-25-40-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEEE<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4EEEE<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 920<br> -SubTopic 350<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340870128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock', window );">Schedule of property, plant and equipment useful lives</a></td>
<td class="text">Depreciation is recorded on a straight-line basis over estimated useful lives as follows:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.687%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.297%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings and improvements</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leasehold improvements </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shorter of asset's useful life or remaining life of lease </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338978496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of disaggregation of revenue and revenue recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All revenue recognized in the accompanying consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products and Services</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">269,449&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">210,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143,571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64,578&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72,565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of rare disease pharmaceutical products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Timing of Revenue Recognition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations transferred at a point in time</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">214,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Performance obligations transferred over time</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock', window );">Schedule of accruals and allowances</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December&#160;31, 2023, 2022, and 2021:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.086%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accruals for Chargebacks, Returns, and Other Allowances</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Chargebacks</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Government<br/>Rebates</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Returns</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Administrative<br/>Fees and Other<br/>Rebates</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Prompt<br/>Payment<br/>Discounts</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2021 (1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,492&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals/Adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">642,409&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,657&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,252&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42,044&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21,302&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits Taken Against Reserve</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(587,913)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,277)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(25,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(45,702)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022 (1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148,562&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,872&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,399&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals/Adjustments</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">586,511&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,915&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,360&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55,798&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22,932&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Credits Taken Against Reserve</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(650,865)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,619)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(22,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(53,828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(24,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2023 (1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,168&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29,678&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,865&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Returns are included in returned goods reserve in the consolidated balance sheets. Government Rebates are included in accrued government rebates in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of customer concentration</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The four customers represent the total percentage of net revenues as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 1</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 2</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 3</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Customer 4</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Valuation And Qualifying Accounts Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340848400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of proforma information</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following unaudited pro forma consolidated financial information summarizes the results of operations for the periods indicated as if the Novitium acquisition had been completed as of January 1, 2020.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">272,888</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31,740)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340825872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of carrying value of the current and non-current components of the term loan</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the current and non-current components of the Term Facility as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current borrowing on debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current debt, net of deferred financing costs </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Current</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current borrowing on debt</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">291,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8,331)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current debt, net of deferred financing costs and current component</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">284,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of contractual maturity of term loan and DDTL</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturity of the Term Facility is as follows for the years ending December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:62.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term Facility</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">285,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">294,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of components of total interest expense related to the notes and term loan</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of total interest expense related to the Term Facility recognized in the accompanying consolidated statements of operations for the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual coupon</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30,692</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26,150</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,129</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of finance fees</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,364</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,363</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">914</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(587)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(95)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(98)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32,469</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,418</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,945</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340852912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventories</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the Company's inventory by asset class as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62,237&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Packaging materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Work-in-progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,889&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finished goods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28,020&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111,196&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105,355&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420434883472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s gross property and equipment by major asset class and accumulated depreciation as of the years ended December&#160;31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Land</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Buildings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Machinery, furniture, and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53,146&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,692&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,935)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(32,712)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342029776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of components of intangible assets</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net definite-lived intangible assets and net indefinite-lived intangible assets other than goodwill are as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.175%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted Average<br/>Amortization<br/>Period(1)</span></td></tr><tr style="height:32pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Definite-Lived Intangible Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Acquired ANDA intangible assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">209,780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(100,660)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">109,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">195,862&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(75,606)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">120,256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">5.2 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NDAs and product rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">244,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(184,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">60,010&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">242,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(162,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">80,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.1 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketing and distribution rights</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(14,271)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">2,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,157&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(13,309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3,848&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-compete agreement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(624)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">624&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(602)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">- years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Customer relationships</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(7,707)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">17,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4,150)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">20,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.8 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Definite-Lived Intangible Assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">497,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(308,123)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">189,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">480,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(255,855)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">225,060&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">4.5 years</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Indefinite-Lived Intangible Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">In process research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">19,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">26,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indefinite</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Total Intangible Assets, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">517,132&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(308,123)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">209,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">507,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(255,855)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">251,635&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Weighted average amortization period as of December 31, 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Schedule of expected future amortization expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense is as follows for the years ending December 31:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50,364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47,128&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,895&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2029 and thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,502&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">189,209&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340688800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of recurring Level 3 fair value measurements of contingent consideration</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.931%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Payment Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Unobservable Input</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assumptions</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Profit-based milestone payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability-weighted discounted cash flow</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025-2035</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Product development-based milestone payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability-weighted discounted cash flow</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Probability of payment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Projected fiscal year of payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of changes in contingent consideration</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in contingent consideration balances classified as Level 3 balances for the years ended December&#160;31, 2023 and 2022:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Measurement period adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of ANDA filing earn-out</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,500)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-900"><span style="-sec-ix-hidden:f-901">Change in fair value</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,426&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,758&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities accounted for at fair value on a recurring basis</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents financial assets and liabilities accounted for at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, by level within the fair value hierarchy:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)<br/>Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value at <br/>December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money Market Fund</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">191,841&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swap</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23,984&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value at <br/>December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest rate swaps</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,759&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420339271392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of earnings per share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share for the years ended December&#160;31, 2023, 2022, and 2021 are calculated for basic and diluted earnings (loss) per share as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Diluted</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) available to common shareholders </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings allocated to participating securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,679)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,663)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss) available to common shareholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(49,521)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42,793)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,596</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,001</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,596</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive effect of stock options, ESPP, and performance stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">193</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted Weighted-Average Shares Outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,194</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16,260</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,596</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.05)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3.40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338056576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of allocated expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in the consolidated statements of operations:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">360</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">222</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></td></tr></table><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense incurred for stock options, restricted stock awards, performance-based restricted stock units, and Inducement Grants and included in the consolidated statements of operations:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general, and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,676</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,094</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,818</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">863</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">710</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">543</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">482</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20,185</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,286</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,366</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation assumptions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For 2023, 2022, and 2021, the fair value of each option grant was estimated using the Black-Scholes option-pricing model, using the following assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected option life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.25</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.50 - 6.25</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.50 - 6.25</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.71% - 2.83%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.68% - 1.39%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected stock price volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.4% - 50.0%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.2% - 49.5%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of stock option and restricted stock activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity under the 2022 Plan and Inducement Grants during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Option<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average<br/>Remaining<br/>Term<br/>(years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">936&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">372&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">168&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.09&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15.71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">552&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">988&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.56&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.6</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,786&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.52&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">907&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,868&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,894&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(21)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding at December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">689&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46.05&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.9</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,370&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">580&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.75&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,815&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Restricted stock activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSA activity under the Plan during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Term<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">352&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.7</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">541&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.02&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(125)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">707&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.52&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">748&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.76&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(245)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(69)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,141&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33.86&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">674&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43.30&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(383)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(81)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38.11&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.4</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock', window );">Performance shares activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of PSU activity under the Plan during the years ended December&#160;31, 2023 and 2022 is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share and <br/>remaining term data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted<br/>Average Grant<br/>Date Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Remaining Term<br/>(years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41.84&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341940784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text">expense (benefit) for income taxes consists of the following for the years ended December 31:<div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current income tax provision</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,117&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,296&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,677&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">467&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,307&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax benefit</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7,601)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,382)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3,946)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,722)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,122)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,576)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(15,232)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(16,949)</span></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expense (benefit) for income taxes</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,093&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14,769)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13,455)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between expected income tax expense (benefit) from applying U.S. Federal statutory tax rates to the pre-tax income (loss) and actual income tax expense (benefit) relates primarily to the effect of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">US Federal statutory rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State taxes, net of Federal benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in valuation allowance</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-deductible costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change in state apportionment factors, state and foreign rates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and experimentation and charitable credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(19.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfer pricing and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective income tax rate</span></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Deferred income tax assets and liabilities consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals and advances</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for chargebacks and returns</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitalized research expenditures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,294&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,840&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,658)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other liabilities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5,440)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,298)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total deferred tax liabilities</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,098)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10,074)</span></td><td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(438)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets, net of deferred tax liabilities and valuation allowance</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90,711&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345435696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of rent expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease expense consisted of the following for the years ended December 31:</span></div><div style="margin-top:12pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:59.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.676%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,031</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">701</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">240</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease costs</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">221</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1.37pt 0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">236</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease costs</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,252</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">937</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">288</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturity analysis of operating leases</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the lease liabilities recorded on the Consolidated Balance Sheet as of December 31, 2023:</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"><tr><td style="width:1.0%"></td><td style="width:85.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.203%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,967</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,610</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,290</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,289</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">506</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,662</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: effects of discounting </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Present value of future minimum lease payments </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,672</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1361">Less: current lease liability, included in accrued expenses and other</span></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1,561)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:f-1363">Non-current lease liability, included in other non-current liabilities</span></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,111</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340920480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Related Party Transactions</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of payments to related parties is presented below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands) </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021 (1)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scitus Pharma Services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,646</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,075</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SS Pharma LLC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,235</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,669</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Esjay Pharma LLC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nuray Chemical Private Limited</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,110</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">365</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,881</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,955</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">390</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span>Includes payments during the period from November 19, 2021 to December 31, 2021, subsequent to the acquisition of Novitium.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420340697072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of revenue by reportable segments</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information by reportable segment, including historical information that has been retroactively re-cast to reflect two reporting segments, is as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Revenues</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, Established Brands, and Other</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">374,699</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">274,699</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112,117</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41,686</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total net revenues</span></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment earnings (loss) before interest, taxes, depreciation and amortization (&#8220;EBITDA&#8221;) and reconciliation to income (loss) before income taxes</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generics, Established Brands, and Other</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152,990</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78,958</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63,418</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare Disease</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,348)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(18,571)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(59,791)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(47,252)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate and other unallocated expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(58,726)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(38,920)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(37,388)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating income (loss)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46,971&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(35,283)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(39,793)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(26,940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(28,052)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11,922)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense), net</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(159)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">670&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4,343)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before expense (benefit) for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19,872&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(62,665)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(56,058)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.27pt">Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of revenue by geographic operations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table depicts the Company&#8217;s revenue by geographic operations during the following periods:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Location of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,251</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">312,427</span></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">211,893</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">565</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,958</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,243</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">486,816</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">316,385</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">216,136</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of property and equipment by geographic location</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table depicts the Company&#8217;s property and equipment, net according to geographic location as of:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,163</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40,343</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Canada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,856</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,430</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,047</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44,593</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43,246</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts as of December&#160;31, 2023 and 2022 exclude the land and building at the Canada facility, which are classified as held for sale as of December&#160;31, 2023 and 2022. These assets have a carrying value of $8.0 million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -SubTopic 10<br> -Topic 280<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334350608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Feb. 14, 2024</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfPharmaceuticalManufacturingFacilities', window );">Number of pharmaceutical manufacturing facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_FDICGuaranteedAmount', window );">FDIC guaranteed amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss related to property and equipment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,020,000<span></span>
</td>
<td class="nump">8,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">2,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anip_CranfordPharmaceuticalsMember', window );">Cranford Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Funds held in escrow for asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_FDICGuaranteedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total amount of interest bearing and non-interest bearing accounts insured by the FDIC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_FDICGuaranteedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfPharmaceuticalManufacturingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Pharmaceutical Manufacturing Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfPharmaceuticalManufacturingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_CranfordPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_CranfordPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334187104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE and Intangibles (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">40 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, furniture, and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, furniture, and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334895552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 486,816<span></span>
</td>
<td class="nump">$ 316,385<span></span>
</td>
<td class="nump">$ 216,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_SalesOfGenericPharmaceuticalProductsMember', window );">Sales of generic pharmaceutical products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">269,449<span></span>
</td>
<td class="nump">210,121<span></span>
</td>
<td class="nump">143,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_SalesOfBrandedPharmaceuticalProductsMember', window );">Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">105,250<span></span>
</td>
<td class="nump">64,578<span></span>
</td>
<td class="nump">72,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_SalesOfRareDiseasePharmaceuticalProductsMember', window );">Sales of rare disease pharmaceutical products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 112,117<span></span>
</td>
<td class="nump">$ 41,686<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anip_SalesOfGenericPharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anip_SalesOfGenericPharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anip_SalesOfBrandedPharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anip_SalesOfBrandedPharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anip_SalesOfRareDiseasePharmaceuticalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anip_SalesOfRareDiseasePharmaceuticalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338813984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">$ 486,816<span></span>
</td>
<td class="nump">$ 316,385<span></span>
</td>
<td class="nump">$ 216,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Performance obligations satisfied in prior periods</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ProductReturnPeriod', window );">Product return period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ProductReturnPeriod', window );">Product return period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_SalesOfContractManufacturedProductsMember', window );">Sales of contract manufactured products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligations</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration', window );">Performance obligations period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember', window );">Performance obligations transferred at a point in time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">$ 486,441<span></span>
</td>
<td class="nump">313,436<span></span>
</td>
<td class="nump">214,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Performance obligations transferred over time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 2,949<span></span>
</td>
<td class="nump">$ 1,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ProductReturnPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Return Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ProductReturnPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anip_SalesOfContractManufacturedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anip_SalesOfContractManufacturedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredAtPointInTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338954688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Accruals and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">$ 161,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">97,262<span></span>
</td>
<td class="nump">$ 161,052<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ChargebacksMember', window );">Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Accruals and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">148,562<span></span>
</td>
<td class="nump">94,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals/Adjustments</a></td>
<td class="nump">586,511<span></span>
</td>
<td class="nump">642,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits Taken Against Reserve</a></td>
<td class="num">(650,865)<span></span>
</td>
<td class="num">(587,913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">84,208<span></span>
</td>
<td class="nump">148,562<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_GovernmentRebatesMember', window );">Government Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Accruals and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">10,872<span></span>
</td>
<td class="nump">5,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals/Adjustments</a></td>
<td class="nump">23,915<span></span>
</td>
<td class="nump">20,657<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits Taken Against Reserve</a></td>
<td class="num">(22,619)<span></span>
</td>
<td class="num">(15,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">12,168<span></span>
</td>
<td class="nump">10,872<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AllowancesForSalesReturnsMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Accruals and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">33,399<span></span>
</td>
<td class="nump">35,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals/Adjustments</a></td>
<td class="nump">18,360<span></span>
</td>
<td class="nump">23,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits Taken Against Reserve</a></td>
<td class="num">(22,081)<span></span>
</td>
<td class="num">(25,684)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">29,678<span></span>
</td>
<td class="nump">33,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AdministrativeFeesAndOtherRebatesMember', window );">Administrative Fees and Other Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Accruals and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">9,442<span></span>
</td>
<td class="nump">13,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals/Adjustments</a></td>
<td class="nump">55,798<span></span>
</td>
<td class="nump">42,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits Taken Against Reserve</a></td>
<td class="num">(53,828)<span></span>
</td>
<td class="num">(45,702)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">11,412<span></span>
</td>
<td class="nump">9,442<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ReservesForCashDiscountMember', window );">Prompt Payment Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Accruals and allowances</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning balance</a></td>
<td class="nump">6,488<span></span>
</td>
<td class="nump">4,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesAdjustments', window );">Accruals/Adjustments</a></td>
<td class="nump">22,932<span></span>
</td>
<td class="nump">21,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Credits Taken Against Reserve</a></td>
<td class="num">(24,555)<span></span>
</td>
<td class="num">(19,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending balance</a></td>
<td class="nump">$ 4,865<span></span>
</td>
<td class="nump">$ 6,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_GovernmentRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_GovernmentRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AllowancesForSalesReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AllowancesForSalesReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AdministrativeFeesAndOtherRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_AdministrativeFeesAndOtherRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ReservesForCashDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=anip_ReservesForCashDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341965088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Accounts Receivable | Four Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue from Contract with Customer Benchmark | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">31.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue from Contract with Customer Benchmark | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue from Contract with Customer Benchmark | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Revenue from Contract with Customer Benchmark | Customer 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=anip_FourCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=anip_FourCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=anip_CustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=anip_CustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=anip_CustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=anip_CustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=anip_CustomerThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=anip_CustomerThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=anip_CustomerFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=anip_CustomerFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420337778768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of equity issued as consideration in a business combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 91,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,221<span></span>
</td>
<td class="nump">28,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | PIPE Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary stock issued (in shares) | shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary stock issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Consideration, cash</a></td>
<td class="nump">$ 88,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares) | shares</a></td>
<td class="nump">2,466,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Fair value of equity issued as consideration in a business combination</a></td>
<td class="nump">$ 91,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Additional contingent consideration</a></td>
<td class="nump">46,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Debts assumed</a></td>
<td class="nump">$ 8,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_RestrictionPeriodForSharesIssuedInBusinessCombination', window );">Restriction period for shares issued</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 30,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="nump">35,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired</a></td>
<td class="nump">12,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">206,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 24,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual', window );">Revenue generated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,900<span></span>
</td>
<td class="nump">90,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_RestrictionPeriodForSharesIssuedInBusinessCombination', window );">Restriction period for shares issued</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Minimum | Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">0.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Minimum | Measurement Input, Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_RestrictionPeriodForSharesIssuedInBusinessCombination', window );">Restriction period for shares issued</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Maximum | Measurement Input, Price Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">0.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Maximum | Measurement Input, Discount for Lack of Marketability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">0.215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Acquired ANDA intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite intangible assets acquired</a></td>
<td class="nump">$ 67,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite intangible assets acquired</a></td>
<td class="nump">24,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium | In process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Indefinite intangible assets acquired</a></td>
<td class="nump">$ 46,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_RestrictionPeriodForSharesIssuedInBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restriction period for shares issued in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_RestrictionPeriodForSharesIssuedInBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345424672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS COMBINATION - Pro Forma (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenues</a></td>
<td class="nump">$ 272,888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,740)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334314688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfPharmaceuticalManufacturingFacilities', window );">Number of pharmaceutical manufacturing facilities | facility</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring activity expense</a></td>
<td class="nump">$ 1,132,000<span></span>
</td>
<td class="nump">$ 5,679,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">8,020,000<span></span>
</td>
<td class="nump">8,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-Sale, Not Discontinued Operations | Oakville, Ontario Former Manufacturing Facility | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember', window );">Oakville, Ontario, Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring activity expense</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring accrual</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember', window );">Oakville, Ontario, Canada | Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring activity expense</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember', window );">Oakville, Ontario, Canada | Facility Closing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring activity expense</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember', window );">Oakville, Ontario, Canada | Other Restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring activity expense</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfPharmaceuticalManufacturingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Pharmaceutical Manufacturing Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfPharmaceuticalManufacturingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=anip_OakvilleOntarioCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342308208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS - Credit facility (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 19, 2021</div></th>
<th class="th"><div>Jul. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 286,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments of debt issuance costs</a></td>
<td class="nump">$ 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Term Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Term Facility | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Term Facility | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Remaining borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee (as a percent)</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Line of Credit | One Month Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.11448%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Line of Credit | Three Month Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.26161%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Line of Credit | Six Month Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.42826%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Line of Credit | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Credit Facility - 2021 | Line of Credit | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread (as a percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=anip_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_InterestPeriodAxis=anip_OneMonthDurationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_InterestPeriodAxis=anip_OneMonthDurationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_InterestPeriodAxis=anip_ThreeMonthDurationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_InterestPeriodAxis=anip_ThreeMonthDurationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_InterestPeriodAxis=anip_SixMonthDurationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_InterestPeriodAxis=anip_SixMonthDurationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338058768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Facility components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current debt, net of deferred financing costs</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current debt, net of deferred financing costs and current component</a></td>
<td class="nump">284,819<span></span>
</td>
<td class="nump">285,669<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=anip_TermLoanAndDelayedDrawTermLoanMember', window );">Term Loan and DDTL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_LongTermDebtGrossCurrent', window );">Current borrowing on debt</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing costs</a></td>
<td class="num">(2,150)<span></span>
</td>
<td class="num">(2,150)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current debt, net of deferred financing costs</a></td>
<td class="nump">850<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_LongTermDebtGrossNonCurrent', window );">Non-current borrowing on debt</a></td>
<td class="nump">291,000<span></span>
</td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Deferred financing costs</a></td>
<td class="num">(6,181)<span></span>
</td>
<td class="num">(8,331)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current debt, net of deferred financing costs and current component</a></td>
<td class="nump">$ 284,819<span></span>
</td>
<td class="nump">$ 285,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_LongTermDebtGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion before unamortized (discount) premium and debt issuance costs, of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_LongTermDebtGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_LongTermDebtGrossNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non current portion before unamortized (discount) premium and debt issuance costs, of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_LongTermDebtGrossNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=anip_TermLoanAndDelayedDrawTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=anip_TermLoanAndDelayedDrawTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334489856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Outstanding (Details) - Credit Facility - 2021<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Term Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Borrowing on debt</a></td>
<td class="nump">$ 294.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember', window );">Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Total debt issuance costs, net</a></td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Debt issuance costs, noncurrent</a></td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current</a></td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=anip_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=anip_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341516992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INDEBTEDNESS - Credit facility maturity (Details) - Term Facility<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">285,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 294,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=anip_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341592336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INDEBTEDNESS - Interest (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual coupon</a></td>
<td class="nump">$ 30,692<span></span>
</td>
<td class="nump">$ 26,150<span></span>
</td>
<td class="nump">$ 11,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of finance fees</a></td>
<td class="nump">2,364<span></span>
</td>
<td class="nump">2,363<span></span>
</td>
<td class="nump">914<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalizedAdjustment', window );">Capitalized interest</a></td>
<td class="num">(587)<span></span>
</td>
<td class="num">(95)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Total</a></td>
<td class="nump">$ 32,469<span></span>
</td>
<td class="nump">$ 28,418<span></span>
</td>
<td class="nump">$ 11,945<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalizedAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalizedAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338865472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Fair value interest rate derivative assets</a></td>
<td class="nump">$ 6,236<span></span>
</td>
<td class="nump">$ 8,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net of tax</a></td>
<td class="num">(8,857)<span></span>
</td>
<td class="num">(12,168)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative unrealized gain (loss) recorded in OCI</a></td>
<td class="num">(3,355)<span></span>
</td>
<td class="nump">15,335<span></span>
</td>
<td class="nump">$ 8,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Derivative liability, notional amount</a></td>
<td class="nump">139,400<span></span>
</td>
<td class="nump">151,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt effective interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.26%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_DerivativeLiabilityDecreaseInNotionalAmount', window );">Decrease in notional amount</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Fair value interest rate derivative assets</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net of tax</a></td>
<td class="nump">8,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Derivative unrealized gain (loss)</a></td>
<td class="num">(3,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Derivative unrealized gain (loss) recorded in OCI</a></td>
<td class="num">(3,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications out of accumulated other comprehensive income/loss</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_DerivativeLiabilityDecreaseInNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in notional amount of derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_DerivativeLiabilityDecreaseInNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420440556560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES - Schedule of inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 62,237<span></span>
</td>
<td class="nump">$ 67,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies', window );">Packaging materials</a></td>
<td class="nump">9,617<span></span>
</td>
<td class="nump">7,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-progress</a></td>
<td class="nump">3,144<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">36,198<span></span>
</td>
<td class="nump">28,020<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory, total</a></td>
<td class="nump">$ 111,196<span></span>
</td>
<td class="nump">$ 105,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345376032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember', window );">Cost of Goods and Service Benchmark | Supplier Concentration Risk | One supplier</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=anip_OneSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=anip_OneSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334906896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 77,528<span></span>
</td>
<td class="nump">$ 75,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(32,935)<span></span>
</td>
<td class="num">(32,712)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">44,593<span></span>
</td>
<td class="nump">43,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,549<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17,875<span></span>
</td>
<td class="nump">16,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery, furniture, and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">50,412<span></span>
</td>
<td class="nump">53,146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 7,692<span></span>
</td>
<td class="nump">$ 4,604<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345451200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest capitalized</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338348192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,221,000<span></span>
</td>
<td class="nump">28,221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease', window );">Increase (decrease) in definite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,332,000<span></span>
</td>
<td class="nump">480,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,300,000<span></span>
</td>
<td class="nump">49,500,000<span></span>
</td>
<td class="nump">41,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">2,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember', window );">Oakrum Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationTypeAxis=anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember', window );">Reclassification of Assets on Completion of Project and Launch of Related Products | In process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,800,000)<span></span>
</td>
<td class="num">(20,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,780,000<span></span>
</td>
<td class="nump">195,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Slayback Pharma Limited Liability Company and Akorn Holding Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Oakrum Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Reclassification of Assets on Completion of Project and Launch of Related Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">$ 20,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightMember', window );">Product Rights | Alvogen Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_BiosantePharmaceuticalsIncMember', window );">BioSante Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_WellSpringPharmaServicesIncMember', window );">WellSpring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisition of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,600,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationTypeAxis=anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationTypeAxis=anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_AlvogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_AlvogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_BiosantePharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_BiosantePharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_WellSpringPharmaServicesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_WellSpringPharmaServicesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420337732144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 497,332<span></span>
</td>
<td class="nump">$ 480,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(308,123)<span></span>
</td>
<td class="num">(255,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 189,209<span></span>
</td>
<td class="nump">225,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 517,132<span></span>
</td>
<td class="nump">507,490<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Carrying Amount</a></td>
<td class="nump">209,009<span></span>
</td>
<td class="nump">251,635<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">19,800<span></span>
</td>
<td class="nump">26,575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">209,780<span></span>
</td>
<td class="nump">195,862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(100,660)<span></span>
</td>
<td class="num">(75,606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 109,120<span></span>
</td>
<td class="nump">120,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightsMember', window );">NDAs and product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 244,871<span></span>
</td>
<td class="nump">242,372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(184,861)<span></span>
</td>
<td class="num">(162,188)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 60,010<span></span>
</td>
<td class="nump">80,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember', window );">Marketing and distribution rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 17,157<span></span>
</td>
<td class="nump">17,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(14,271)<span></span>
</td>
<td class="num">(13,309)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,886<span></span>
</td>
<td class="nump">3,848<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_NonCompeteAgreementMember', window );">Non-compete agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(624)<span></span>
</td>
<td class="num">(602)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-Lived Intangible Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,900<span></span>
</td>
<td class="nump">24,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(7,707)<span></span>
</td>
<td class="num">(4,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 17,193<span></span>
</td>
<td class="nump">$ 20,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted Average Amortization Period</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_NonCompeteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_NonCompeteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420440535904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GOODWILL AND INTANGIBLE ASSETS - Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 50,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">47,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">33,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">24,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">17,895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">2029 and thereafter</a></td>
<td class="nump">15,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 189,209<span></span>
</td>
<td class="nump">$ 225,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420330919456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2023 </div>
<div>USD ($) </div>
<div>intangibleAsset</div>
</th>
<th class="th">
<div>Jul. 21, 2022 </div>
<div>USD ($) </div>
<div>intangibleAsset</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($) </div>
<div>intangibleAsset</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>intangibleAsset</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money Market Fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">2,374,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,643,000<span></span>
</td>
<td class="nump">7,579,000<span></span>
</td>
<td class="nump">21,081,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497,332,000<span></span>
</td>
<td class="nump">480,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286,000<span></span>
</td>
<td class="nump">22,318,000<span></span>
</td>
<td class="nump">$ 11,369,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,196,000<span></span>
</td>
<td class="nump">105,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,237,000<span></span>
</td>
<td class="nump">67,726,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,198,000<span></span>
</td>
<td class="nump">28,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anip_SandozIncMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryDemo', window );">Sample inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IntangibleAssetMeasurementInput', window );">Intangible asset measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember', window );">Oakrum Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember', window );">Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_AkornHoldingCompanyPipelineProductMember', window );">Akorn Holding Company, Pipeline Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,780,000<span></span>
</td>
<td class="nump">195,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Oakrum Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent liability not recognized, asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Oakrum Pharma | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IntangibleAssetMeasurementInput', window );">Intangible asset measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfIntangibleAssetsAcquired', window );">Number of intangible assets acquired | intangibleAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets | Akorn Holding Company, Pipeline Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductIntellectualPropertyMember', window );">Product Intellectual Property | Alvogen Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredPipelineProductMember', window );">Acquired pipeline product | Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfIntangibleAssetsAcquired', window );">Number of intangible assets acquired | intangibleAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredCommercialProductMember', window );">Acquired commercial product | Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfIntangibleAssetsAcquired', window );">Number of intangible assets acquired | intangibleAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredApprovedProductMember', window );">Acquired approved product | Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfIntangibleAssetsAcquired', window );">Number of intangible assets acquired | intangibleAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredFiledProductsMember', window );">Acquired filed products | Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfIntangibleAssetsAcquired', window );">Number of intangible assets acquired | intangibleAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredNDAIntangibleAssetsMember', window );">Acquired NDA intangible assets | Slayback Pharma Limited Liability, Company Patents and Pending Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfIntangibleAssetsAcquired', window );">Number of intangible assets acquired | intangibleAsset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Additional contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_BusinessCombinationContingentConsiderationArrangementsPeriod', window );">Contingent consideration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,984,000<span></span>
</td>
<td class="nump">35,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue', window );">Interest rate swaps, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_BusinessCombinationContingentConsiderationArrangementsPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_BusinessCombinationContingentConsiderationArrangementsPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure intangible assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Intangible Assets Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryDemo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of merchandise, goods, commodities, or supplies to which the entity holds the title and uses for the specific purpose of showing the benefits and features of the entity's products to existing or potential customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryDemo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_SandozIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_SandozIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_AkornHoldingCompanyPipelineProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_AkornHoldingCompanyPipelineProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_ProductIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_AlvogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_AlvogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredPipelineProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredPipelineProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredCommercialProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredCommercialProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredApprovedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredApprovedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredFiledProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredFiledProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredNDAIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredNDAIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342061920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE - Level 3 (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Changes in contingent consideration</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Level 3 liability, beginning balance</a></td>
<td class="nump">$ 35,058<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment', window );">Measurement period adjustment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payment of ANDA filing earn-out</a></td>
<td class="num">(12,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="nump">$ 3,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Contingent consideration fair value adjustment<span></span>
</td>
<td class="text">Contingent consideration fair value adjustment<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Level 3 liability, ending balance</a></td>
<td class="nump">$ 23,984<span></span>
</td>
<td class="nump">$ 35,058<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Profit-based milestone payments | Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">0.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Product development-based milestone payments | Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">0.120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=anip_MeasurementInputProbabilityOfPaymentMember', window );">Probability of payment | Product development-based milestone payments | Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Unobservable inputs</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Measurement period adjustment for liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_PaymentTypeAxis=anip_ProjectBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_PaymentTypeAxis=anip_ProjectBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_PaymentTypeAxis=anip_ProductDevelopmentBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_PaymentTypeAxis=anip_ProductDevelopmentBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=anip_MeasurementInputProbabilityOfPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=anip_MeasurementInputProbabilityOfPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338887504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE - Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 19, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money Market Fund</a></td>
<td class="nump">$ 191,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="nump">6,236<span></span>
</td>
<td class="nump">$ 8,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money Market Fund</a></td>
<td class="nump">191,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money Market Fund</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="nump">6,236<span></span>
</td>
<td class="nump">8,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money Market Fund</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestRateDerivativeAssetsAtFairValue', window );">Interest rate swap</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">23,984<span></span>
</td>
<td class="nump">35,058<span></span>
</td>
<td class="nump">$ 30,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 23,984<span></span>
</td>
<td class="nump">$ 35,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRateDerivativeAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRateDerivativeAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338319808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE - Acquired (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 497,332,000<span></span>
</td>
<td class="nump">$ 480,915,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,286,000<span></span>
</td>
<td class="nump">22,318,000<span></span>
</td>
<td class="nump">$ 11,369,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">111,196,000<span></span>
</td>
<td class="nump">105,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,237,000<span></span>
</td>
<td class="nump">67,726,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,198,000<span></span>
</td>
<td class="nump">28,020,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">$ 2,374,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember', window );">Acquired ANDA intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,780,000<span></span>
</td>
<td class="nump">195,862,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember', window );">Oakrum Pharma</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life of intangible assets</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember', window );">Oakrum Pharma | Acquired ANDA intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total asset purchase</a></td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Contingent liability not recognized, asset acquisition</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life of intangible assets</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember', window );">Oakrum Pharma | Acquired ANDA intangible assets | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IntangibleAssetMeasurementInput', window );">Intangible asset measurement input</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anip_SandozIncMember', window );">Sandoz</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Total asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible gross carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInventoryDemo', window );">Sample inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible asset impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anip_SandozIncMember', window );">Sandoz | Measurement Input, Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_IntangibleAssetMeasurementInput', window );">Intangible asset measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure intangible assets acquired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInventoryDemo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of merchandise, goods, commodities, or supplies to which the entity holds the title and uses for the specific purpose of showing the benefits and features of the entity's products to existing or potential customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInventoryDemo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=anip_OakrumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_SandozIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_SandozIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338003168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>MEZZANINE AND STOCKHOLDERS' EQUITY (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>tradingDay </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,666,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CommonStockConvertibleConversionRatio', window );">Common stock conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,730,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,643,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,466,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,494,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember', window );">PIPE Shares | Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary stock issued (in shares)</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary stock issued (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity | $</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cash paid for costs of share issuances | $</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Shares accrue dividends rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Shares conversion price | $ / shares</a></td>
<td class="nump">$ 41.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ThresholdNumberOfTradingDays', window );">Threshold number of trading days | tradingDay</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfConsecutiveTradingDays', window );">Number of consecutive trading days | tradingDay</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_PercentageOfConversionPrice', window );">Maximum percentage of conversion price</a></td>
<td class="nump">170.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Convertible, shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_PreferredStockConvertibleMinimumPeriodOfConversion', window );">Preferred Stock, Convertible, Minimum Period of Conversion</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=anip_PublicOfferingMember', window );">Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,183,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds after issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,731,000<span></span>
</td>
<td class="nump">16,913,000<span></span>
</td>
<td class="nump">17,644,000<span></span>
</td>
<td class="nump">12,430,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Common Stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=anip_ClassCSpecialStockMember', window );">Class C Special Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CommonStockNumberOfVotesPerShare', window );">Number of votes per share | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CommonStockConversionPrice', window );">Conversion price (in dollar per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Shares issued in acquisition (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CommonStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the conversion price for converting shares of common stock into another class of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CommonStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CommonStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Convertible, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CommonStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CommonStockNumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Number of Votes Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CommonStockNumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_PercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_PercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_PreferredStockConvertibleMinimumPeriodOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Convertible, Minimum Period of Conversion</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_PreferredStockConvertibleMinimumPeriodOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ThresholdNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold number of trading days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ThresholdNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anip_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anip_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=anip_ClassCSpecialStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=anip_ClassCSpecialStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420343098672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income (loss) available to common shareholders, Basic</a></td>
<td class="nump">$ 17,154<span></span>
</td>
<td class="num">$ (49,521)<span></span>
</td>
<td class="num">$ (42,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic', window );">Earnings allocated to participating securities, Basic</a></td>
<td class="num">(1,679)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarnings', window );">Net income (loss) available to common shareholders, Basic</a></td>
<td class="nump">15,475<span></span>
</td>
<td class="num">(49,521)<span></span>
</td>
<td class="num">(42,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) available to common shareholders, Diluted</a></td>
<td class="nump">17,154<span></span>
</td>
<td class="num">(49,521)<span></span>
</td>
<td class="num">(42,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted', window );">Earnings allocated to participating securities, Diluted</a></td>
<td class="num">(1,663)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsDiluted', window );">Net income (loss) available to common shareholders, Diluted</a></td>
<td class="nump">$ 15,491<span></span>
</td>
<td class="num">$ (49,521)<span></span>
</td>
<td class="num">$ (42,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic Weighted-Average Shares Outstanding (in shares)</a></td>
<td class="nump">18,001<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive effect of common stock options, ESPP, and performance stock units (in shares)</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted Weighted-Average Shares Outstanding (in shares)</a></td>
<td class="nump">18,194<span></span>
</td>
<td class="nump">16,260<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per share basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings (loss) per share (in dollars per share)</a></td>
<td class="nump">$ 0.86<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
<td class="num">$ (3.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per share diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings (loss) per share (in dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="num">$ (3.05)<span></span>
</td>
<td class="num">$ (3.40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 65<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-65<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-66<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338566448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 23, 2023</div></th>
<th class="th"><div>Apr. 27, 2022</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Stock-based compensation income tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,996<span></span>
</td>
<td class="nump">$ 1,458<span></span>
</td>
<td class="nump">$ 2,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized option costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of cost recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Stock options exercise tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of cost recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized non-option costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43.30<span></span>
</td>
<td class="nump">$ 32.76<span></span>
</td>
<td class="nump">$ 33.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anip_PerformanceBasedRestrictedStockUnitsMember', window );">Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards', window );">Percentage of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage', window );">Maximum potential to vest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares', window );">Maximum potential to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage', window );">Estimate number of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=anip_MarketPerformanceBasedRestrictedStockUnitsMember', window );">Market Performance-Based Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards', window );">Percentage of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage', window );">Maximum potential to vest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares', window );">Maximum potential to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage', window );">Estimate number of shares percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period of cost recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anip_EmployeesAndConsultantsMember', window );">Employees and Consultants | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anip_EmployeesAndConsultantsMember', window );">Employees and Consultants | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember', window );">Non Employee Director | Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember', window );">Non Employee Director | Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember', window );">Non Employee Director | Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember', window );">Non Employee Director | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based compensation shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Discount from market price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Employee share plan issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anip_StockIncentivePlanMember', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Stock-based compensation shares available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Stock-based compensation additional shares authorized</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="nump">1,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anip_PerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anip_PerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=anip_MarketPerformanceBasedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=anip_MarketPerformanceBasedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=anip_EmployeesAndConsultantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=anip_EmployeesAndConsultantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=anip_NonEmployeeDirectorStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anip_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anip_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338912912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember', window );">2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=anip_StockIncentivePlanMember', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">20,185<span></span>
</td>
<td class="nump">14,286<span></span>
</td>
<td class="nump">10,366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative | 2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general, and administrative | 2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">18,676<span></span>
</td>
<td class="nump">13,094<span></span>
</td>
<td class="nump">9,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | 2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of sales | 2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">646<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2016 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total expense</a></td>
<td class="nump">$ 863<span></span>
</td>
<td class="nump">$ 710<span></span>
</td>
<td class="nump">$ 543<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=anip_StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=anip_StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345117248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Fair value options (Details) - Stock Option<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.40%<span></span>
</td>
<td class="nump">48.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option life (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
<td class="nump">1.39%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">49.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342930768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Stock option activity (Details) - Stock Option - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Option Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end of the period (in shares)</a></td>
<td class="nump">689<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="nump">988<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end of the period (in shares)</a></td>
<td class="nump">580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 45.47<span></span>
</td>
<td class="nump">$ 45.56<span></span>
</td>
<td class="nump">$ 48.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">41.84<span></span>
</td>
<td class="nump">34.52<span></span>
</td>
<td class="nump">33.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">44.09<span></span>
</td>
<td class="nump">30.03<span></span>
</td>
<td class="nump">40.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">33.45<span></span>
</td>
<td class="nump">36.91<span></span>
</td>
<td class="nump">59.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">55.15<span></span>
</td>
<td class="nump">55.07<span></span>
</td>
<td class="nump">55.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">46.05<span></span>
</td>
<td class="nump">45.47<span></span>
</td>
<td class="nump">45.56<span></span>
</td>
<td class="nump">$ 48.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">48.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 22.12<span></span>
</td>
<td class="nump">$ 16.82<span></span>
</td>
<td class="nump">$ 15.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Term (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at the end of the period weighted average remaining term</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end of the period weighted average remaining term</a></td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning of the period intrinsic value (in dollars)</a></td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="nump">$ 6,786<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised at the end of the period intrinsic value (in dollars)</a></td>
<td class="nump">2,894<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="nump">552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end of the period intrinsic value (in dollars)</a></td>
<td class="nump">8,370<span></span>
</td>
<td class="nump">$ 3,868<span></span>
</td>
<td class="nump">$ 6,786<span></span>
</td>
<td class="nump">$ 372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end of the period intrinsic value (in dollars)</a></td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334625392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - RSA activity (Details) - Restricted Stock - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">748<span></span>
</td>
<td class="nump">541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(383)<span></span>
</td>
<td class="num">(245)<span></span>
</td>
<td class="num">(125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="nump">707<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 33.86<span></span>
</td>
<td class="nump">$ 36.52<span></span>
</td>
<td class="nump">$ 48.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">43.30<span></span>
</td>
<td class="nump">32.76<span></span>
</td>
<td class="nump">33.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">34.59<span></span>
</td>
<td class="nump">36.99<span></span>
</td>
<td class="nump">48.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">38.10<span></span>
</td>
<td class="nump">38.08<span></span>
</td>
<td class="nump">48.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, ending balance (in dollars per share)</a></td>
<td class="nump">$ 38.11<span></span>
</td>
<td class="nump">$ 33.86<span></span>
</td>
<td class="nump">$ 36.52<span></span>
</td>
<td class="nump">$ 48.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Term (years)</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341751408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Performance shares activity (Details) - Performance Shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares) | shares</a></td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">41.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">41.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 41.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Term (years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420341966768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets and liabilities</a></td>
<td class="nump">$ 90,711<span></span>
</td>
<td class="nump">$ 81,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse', window );">Operating loss carryforwards annual limitation</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=anip_ANICanadaMember', window );">ANI Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems', window );"><strong>Investments, Owned, Federal Income Tax Note [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets and liabilities</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_OperatingLossCarryforwardsAnnualLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual limitations on the use of operating loss carryforwards available to reduce taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_OperatingLossCarryforwardsAnnualLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=anip_ANICanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=anip_ANICanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420332237440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income tax provision</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 9,117<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 1,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">3,534<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">1,320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">691<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="nump">12,677<span></span>
</td>
<td class="nump">467<span></span>
</td>
<td class="nump">3,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income tax benefit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(7,601)<span></span>
</td>
<td class="num">(13,382)<span></span>
</td>
<td class="num">(12,163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(3,946)<span></span>
</td>
<td class="num">(1,722)<span></span>
</td>
<td class="num">(5,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total</a></td>
<td class="num">(11,576)<span></span>
</td>
<td class="num">(15,232)<span></span>
</td>
<td class="num">(16,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Change in valuation allowance</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total expense (benefit) for income taxes</a></td>
<td class="nump">$ 1,093<span></span>
</td>
<td class="num">$ (14,769)<span></span>
</td>
<td class="num">$ (13,455)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420345960640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Effective rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of Federal benefit</a></td>
<td class="nump">4.80%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="nump">10.80%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible costs</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes', window );">Change in state apportionment factors, state and foreign rates</a></td>
<td class="num">(11.80%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research and experimentation and charitable credits</a></td>
<td class="num">(19.00%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Transfer pricing and other</a></td>
<td class="num">(2.40%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">23.60%<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and foreign income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342060928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and advances</a></td>
<td class="nump">$ 12,470<span></span>
</td>
<td class="nump">$ 9,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">6,013<span></span>
</td>
<td class="nump">6,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances', window );">Accruals for chargebacks and returns</a></td>
<td class="nump">17,358<span></span>
</td>
<td class="nump">15,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories</a></td>
<td class="nump">4,569<span></span>
</td>
<td class="nump">5,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">40,193<span></span>
</td>
<td class="nump">33,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">5,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenditures</a></td>
<td class="nump">11,294<span></span>
</td>
<td class="nump">4,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">7,450<span></span>
</td>
<td class="nump">11,840<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">102,247<span></span>
</td>
<td class="nump">91,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(5,658)<span></span>
</td>
<td class="num">(5,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other liabilities</a></td>
<td class="num">(5,440)<span></span>
</td>
<td class="num">(4,298)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(11,098)<span></span>
</td>
<td class="num">(10,074)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(438)<span></span>
</td>
<td class="num">(446)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net of deferred tax liabilities and valuation allowance</a></td>
<td class="nump">$ 90,711<span></span>
</td>
<td class="nump">$ 81,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338219584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 15, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 08, 2021 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 03, 2020 </div>
<div>plaintiff</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>claim </div>
<div>product </div>
<div>operatingLease</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 30, 2020 </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>product </div>
<div>operatingLease </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>manufacturer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfOperatingLeases', window );">Number of operating leases | operatingLease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease liability discount rates (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.12%<span></span>
</td>
<td class="nump">3.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfProductsMarketed', window );">Number of products marketed | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486,816<span></span>
</td>
<td class="nump">$ 316,385<span></span>
</td>
<td class="nump">$ 216,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfPlaintiffs', window );">Number of plaintiffs | plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_LossContingencyNumberOfManufacturers', window );">Number of potential manufacturers | manufacturer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of complaints filed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anip_AzurityPharmaceuticalsMember', window );">Azurity Pharmaceuticals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Settlement amount awarded to other party</a></td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_RoyaltyOnFutureSalesPercent', window );">Royalties on future sales (as a percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=anip_NovitiumMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of complaints filed | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of open complaints (more than) | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_UnapprovedProductsMember', window );">Unapproved Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400<span></span>
</td>
<td class="nump">14,200<span></span>
</td>
<td class="nump">16,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_UnapprovedProductsMember', window );">Unapproved Products | Contract Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_LossContingencyNumberOfManufacturers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Manufacturers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_LossContingencyNumberOfManufacturers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Operating Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfProductsMarketed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Products Marketed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfProductsMarketed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_RoyaltyOnFutureSalesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties on future sales as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_RoyaltyOnFutureSalesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfPlaintiffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plaintiffs that have filed claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfPlaintiffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_AzurityPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_AzurityPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_NovitiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_NovitiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anip_UnapprovedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anip_UnapprovedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=anip_ContractCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=anip_ContractCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334412176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Leases expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 2,031<span></span>
</td>
<td class="nump">$ 701<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 2,252<span></span>
</td>
<td class="nump">$ 937<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342263680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Lease maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">1,290<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">6,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: effects of discounting</a></td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">5,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liability, included in accrued expenses and other</a></td>
<td class="num">$ (1,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current lease liability, included in other non-current liabilities</a></td>
<td class="nump">$ 4,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420339989136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_CortrophinPreLaunchCharges', window );">Purified Cortrophin Gel pre-launch charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">161,697<span></span>
</td>
<td class="nump">124,044<span></span>
</td>
<td class="nump">$ 84,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=anip_CortrophinGelMember', window );">Cortrophin Gel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general, and administrative</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_CortrophinPreLaunchCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of charges directly related to the Purified Cortrophin Gel pre-launch charges commercialization efforts, including but not limited to sales and marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_CortrophinPreLaunchCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=anip_CortrophinGelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=anip_CortrophinGelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420342149408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 08, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>founder</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_NumberOfExecutiveFounders', window );">Number of executive founders | founder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,683,000<span></span>
</td>
<td class="nump">$ 29,305,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Novitium | Mr. Shanmugam and Esjay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Novitium | Mr. Shanmugam and Esjay | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="nump">$ 6,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Novitium | Chali Properties LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Novitium | Chali Properties LLC | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Scitus Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | SS Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party | Nuray Chemical Private Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,850,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock | PIPE Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Temporary stock issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Temporary stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Convertible Preferred Stock from Mezzanine Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_NumberOfExecutiveFounders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Executive Founders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_NumberOfExecutiveFounders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_Mr.ShanmugamAndEsjayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_Mr.ShanmugamAndEsjayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=anip_ChaliPropertiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=anip_ChaliPropertiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_ScitusPharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_ScitusPharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_SsPharmaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_SsPharmaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_NurayChemicalPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_NurayChemicalPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=anip_PrivateInvestmentInPublicEquityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420343049472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS - Schedule of related parties (Details) - Related Party - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payments to related party</a></td>
<td class="nump">$ 11,881,000<span></span>
</td>
<td class="nump">$ 6,955,000<span></span>
</td>
<td class="nump">$ 390,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Scitus Pharma Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payments to related party</a></td>
<td class="nump">3,646,000<span></span>
</td>
<td class="nump">2,075,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">SS Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payments to related party</a></td>
<td class="nump">8,235,000<span></span>
</td>
<td class="nump">3,669,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Esjay Pharma LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payments to related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">101,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Nuray Chemical Private Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Payments to related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,110,000<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_ScitusPharmaServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_ScitusPharmaServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_SsPharmaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_SsPharmaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_EsjayPharmaLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_EsjayPharmaLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=anip_NurayChemicalPrivateLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=anip_NurayChemicalPrivateLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420334313872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING - Revenue (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 486,816<span></span>
</td>
<td class="nump">$ 316,385<span></span>
</td>
<td class="nump">$ 216,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,791<span></span>
</td>
<td class="nump">56,972<span></span>
</td>
<td class="nump">47,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Corporate and other unallocated expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">161,697<span></span>
</td>
<td class="nump">124,044<span></span>
</td>
<td class="nump">84,294<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,971<span></span>
</td>
<td class="num">(35,283)<span></span>
</td>
<td class="num">(39,793)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,940)<span></span>
</td>
<td class="num">(28,052)<span></span>
</td>
<td class="num">(11,922)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (expense) income, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(159)<span></span>
</td>
<td class="nump">670<span></span>
</td>
<td class="num">(4,343)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (Loss) Before Expense (Benefit) for Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,872<span></span>
</td>
<td class="num">(62,665)<span></span>
</td>
<td class="num">(56,058)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Generics, Established Brands and Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">374,699<span></span>
</td>
<td class="nump">274,699<span></span>
</td>
<td class="nump">216,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization', window );">EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,990<span></span>
</td>
<td class="nump">78,958<span></span>
</td>
<td class="nump">63,418<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Rare Disease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,117<span></span>
</td>
<td class="nump">41,686<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization', window );">EBITDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,498<span></span>
</td>
<td class="num">(18,348)<span></span>
</td>
<td class="num">(18,571)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,791)<span></span>
</td>
<td class="num">(56,973)<span></span>
</td>
<td class="num">(47,252)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Corporate and other unallocated expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (58,726)<span></span>
</td>
<td class="num">$ (38,920)<span></span>
</td>
<td class="num">$ (37,388)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents earnings/(loss) before interest, taxes, depreciation and amortization (EBITDA).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=anip_GenericsEstablishedBrandsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=anip_GenericsEstablishedBrandsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=anip_RareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=anip_RareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420338086928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT REPORTING - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 486,816<span></span>
</td>
<td class="nump">$ 316,385<span></span>
</td>
<td class="nump">$ 216,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">44,593<span></span>
</td>
<td class="nump">43,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">8,020<span></span>
</td>
<td class="nump">8,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">486,251<span></span>
</td>
<td class="nump">312,427<span></span>
</td>
<td class="nump">211,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">43,163<span></span>
</td>
<td class="nump">40,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">565<span></span>
</td>
<td class="nump">3,958<span></span>
</td>
<td class="nump">$ 4,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Assets held for sale</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IN', window );">India</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment reporting</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">$ 1,430<span></span>
</td>
<td class="nump">$ 1,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140420331025824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 22, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 15, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 14, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 12, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 27, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Feb. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 24, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">674,000<span></span>
</td>
<td class="nump">748,000<span></span>
</td>
<td class="nump">541,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | CG Oncology, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment, cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Shares held (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Value of shares held | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Oakville, Ontario Former Manufacturing Facility | Disposal Group, Held-for-Sale, Not Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 14,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit', window );">First purchase price deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">525,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Restricted Stock | New Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Performance period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Performance Shares | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Shares granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember', window );">Novitium | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Payments on contingent consideration | $</a></td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, First Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>anip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of investment owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=anip_CGOncologyInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=anip_CGOncologyInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=anip_OakvilleOntarioFormerManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=anip_NewEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=anip_NewEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_OfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_OfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=anip_NovitiumPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>111
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<<$S6@"&MW/K$WQ<NJX**!%_9?C(3XZ!DK*A]%6=_)',+4<QP@3'0J5 \N>
MEY@0E4GR^+=.:C5CJL#3X[?LOY7BI9@-XGA)R=]9(M*Y-;5 @K=H3\1G>OP=
MUX(F*E],"2^_P;'"!I$%XCT7-*^#)8,\*ZI?]*V>B), Z)\)<.L ]]( KP[P
M2J$5LU+6,Q)H,6/T")A"RVSJH)R;,EJJR0KU&->"R;N9C!.+)2TX)5F"!$[
M$R*HB#%8JW0<W*T0PX5(L<AB1.[!+^#K^AG<?;@''T!6@"\IW7-4)'QF"\E$
MY;/C>M2G:E3WS*C/.'X 'OP(7,?U!L*7EX>[>K@M]3>3X#:3X);Y_#/Y/B7_
MR)F6BU.*EI4!XA2Q%[Q!\2L'4B"@<@X80$2N>34_@X*K$<)R!%4[AT44NH%D
M=SC5U4?! #J3%J;Q]QK^WBC_E5SZF#'Y!->"QJ\?P0XQ<$!DC\&=?% ))00Q
M#G92!)?2\/V0@&J(Z0DUY\%Q'-A18(1I"OQ&@7^=@I*GG/V]2"G+_L/)$.4J
M9Z#-IOJ$'<YFG$9ZTI">W$0ZXWP_3'C2(^)TJ(XA-))!0S*XB:1LZ5S(Q9T5
M+T-, R/3,83&-&R8AJ-,OT@;XGOV'7!]"0@04RZ&2(8]"F[@1;[78=J'03]R
MO#-+=MK0G8[2E9WS@)G(-@2#SB0/<1U-ILSZD>]0C.>6=&..V0%;BY]_@H'S
MZU![?*=DFNZHT1W=JONVQA-=UGB,,$T-=%H#=&[7<U$;J@<P]Z$+@+J($Q>'
M/RSB?%NJDVN%-)%SVZ5O@NGD6_>%X_9["7E#NZI',"HPP70%K?_"<0->TCR7
M_TG/%O]X^+75_U[9=+&M5<-QKSX5>UO%UP,82]Z,TR6TQ@W'G5N7<%F1]YW9
MJSY^E_4%2)UWZ^5PW,P'>8_4==^C72?TG&D4=#GWD3 ,?,^/SK6FUM7AN*T/
M<C:5\X"S.WX01).NMP\@8>A'O@2?(=[Z.S08/$&<@R58[W"<(3)2W>_J[>^5
M35?=NCLTV?L/5_>%AF[&Z2]SK:.[)D>_NKK=OC.'4^A.NYS-.)US:^"NR<"O
MJFRW;\70F0;=5F2$Z6Q/WI=-CGU]3;M][QVD;()5E.V3+0^UW_2G?&//"@X(
MWLHXYR&439A56SC5B:"[<A=D0X6@>7F88I1@I@#R_I92\7:B-E::C;3%_U!+
M P04    " #1.EU8G0O4[^(&  #['0  &    'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;*U9VV[C-A#]%<(MBBP0QR9U3Q,#B;5M%]BVP6;;?2CZP$BTK:XD
MNB*=I/WZ#B7%BL,1DP)^2&S)9X8\P^'PD+QXD,U7M1%"D\>JK-7E9*/U]GPV
M4]E&5%R=R:VHX9>5;"JNX;%9S]2V$3QOC:IRQN;S<%;QHIXL+MIW-\WB0NYT
M6=3BIB%J5U6\^>=:E/+A<D(G3R\^%>N--B]FBXLM7XM;H7_;WC3P--M[R8M*
MU*J0-6G$ZG)R1<]3EAB#%O%[(1[4L^_$4+F3\JMY^)!?3N:F1Z(4F38N.'S<
MBZ4H2^,)^O%W[W2R;],8/O_^Y/V'ECR0N>-*+&7YI<CUYG(23T@N5GQ7ZD_R
MX2?1$PJ,OTR6JOU/'CIL".!LI[2L>F/H0574W2=_[ /QS("&(P:L-V O#?P1
M Z\W\-YJX/<&?AN9CDH;AY1KOKAHY -I#!J\F2]M,%MKH%_49MQO=0._%F"G
M%TM9*UD6.=<B)[<:/F!0M2)R17[=BH:;P5%D2GZ[3<G)M^^(VO!&*%+4Y/-&
M[A2O<W4QT] 1XVZ6]8U>=XVRD48I(S_+6F\4>5_G(C]T, ,&>QKLB<8U<WI,
M179&/'I*V)QY2(>6;S=GB'GZ=G/J8./M!\5K_7DC_C[4F:S$,!SDCZL[I1N8
M(W]BP>Z<^;@S4SC.U99GXG("E4&)YEY,%M]]0\/Y]UB@CNDL/9*S@R#Z^R#Z
M+N^+7Z!H?A+WHMX)-$4[ZZBU-M7Q?N''80R-S^<7L_OG(;&1'@V].+"0J8UD
M-*3>@<\#,L&>3.#,B'XNUFOR_A%*OL(I!<=,A&,Z2X_D["!VX3YVH3,1EE)I
M4\\4+Z%RG8C'K-SE)I2Y@-:R@G<+4)T37LE&%_^V+]YA >X:"I^-+XUI0#T[
M9Q"D%T=8SB!(6+/A;RQGHCWOR,G[$T22-]FFI9;#3"CEUE03C%AD=<+S68S,
M!1O(F$=CFY8-I# 1DE%6\9Y5[&1U"Q(!!N^4K$4-<Z(\[48NA[6Q,#72R B,
M86SW)Z1A$MD4$23SY[YO<[21L<\2?Y1CLN>8.#FFKL3$R"561X(D2JC-#0%"
M#)A-S0;Z$0O8*#4Z'P3'_)7I6)M"9I:U#+1%D?<J@ZQXT9![7NX$#.=?('W&
MDK5OX&"$?(8D*P+TH@!)5@1H9NHHV6?JBCK)?A1K7A(EM"Z[E5QTY1NE1:U.
M6(1>A:0()(X"!Q<V<&%.+C>[IE@5(!.7D(R-W&Y !/XH2@*Y.BWYKH9*DX$Z
M7.-K4^_<R>Y52(I HMA!;E!<U*E%3+'4S2[3P!%6AG8W4NABA(J'U39[$BT1
M8!!&"9)_-G",T2!_J%O_?*@UK]?%70G324$&DJ+:P@QKL[ ;)Y2;__HPV1!*
MD1*"X)@7C5='.H@AZM0+B\]2PZQZFR;J71U4,B^)?7LE7B)0+Z!AB!4,&\J"
M(&'CZQL=Y IUZY6!5[\/./DHE4+U"+7%@P_U'"G\"'+J!2RVI4N*0F$Y\<:Y
M#9*$1FX=JS>B>1JO4U(+O, [A<W_%;)']98>R]MA  ?U0]WR!V:U +_[A60\
MAK8XF;*P%2=6;F#0>!Y@<QJ!4IHPAS 81 ]UJYXN-TYZ8N](T6;_.$%;HDQI
M8!?7)0(,(SL,*>;0]_SQM&>#YF%NS7,PD<FU6,E&/,T"<G(-2G95Z'<$7C_-
M^<_\$:]G#!$_28Q(N"6"G(8L#)$]" 8-POFA5#KD/D@@YI9 /2'-'Y]REIS<
M]8Q1@K: H?,$V6(AP"GUHQ!97U&HYP?!.+]!%C&W+#+G#*\6:F;K%AI'B!18
M(LBI'\6)+6]3% HZV)&Q@QYB;CV4@O[)19TK LK\5C0@A<@5*+_Z7L!.Q(B*
MFT:L1-.TQX8R^XJRMF7-E(8,67K?C$Q19#(N =D@F-CK!T9F ,G5/2]*;CAJ
M"92KRH3 G'MN9 F[%7Q:VD<_-**!O6E<(LBIGP3,7K13%,I<*S$;-!1SGRA=
M<U5D[>8R+<J=.?T]+%(W4(M;TN<HW:,>-1W56WHL;X>!'>0;<\NW+K CP20G
ML&G*95GR1A'0>=UY.EXRNF:2YTK\+ Y?9I.-FGIG\^!E)J$P?R2)!CG'W$=,
MKZ3._V$;86R#EVQM%,H6A8VQ';07<VNO;F2_M%=)(I]>02GD:]%15>37G5:P
MXVI/%@WO[J8$)XL<,<%22U^RQ<ZLH+Z_9(L=6 5).$)WT&/LE5.H?G"/0=B6
M5C2FB?^2, +#"",PA/#LV:U8)6"_:VX7%<GDKM;=S=+^[?X&\ZJ]MWOQ_IJ>
MI]T]Y."FNQ;]&;;11:U(*5;@<GX60>EINIO&[D'+;7OW=B>UEE7[=2,X+"(&
M +^OI-1/#Z:!_7WOXC]02P,$%     @ T3I=6#D%/C]N P  ? L  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RM5MMNVS@0_15"&Q0MT$02=776%I#8
MN]@"O01)NWTH]H&1QI9:B71)VD[_OD-)T=J2;.3!+Y9(G3F>,YP9SG0GY ^5
M VCR5)5<S:Q<Z_6U;:LTAXJI*[$&CE^60E9,XU*N;+66P++:J"IMZCBA7;&"
M6\FTWKN3R51L=%EPN)-$;:J*R5^W4(K=S'*MYXW[8I5KLV$GTS5;P0/H+^L[
MB2N[8\F*"K@J!"<2EC/KQKU>3 R^!OQ;P$[MO1.CY%&('V;Q+IM9CG$(2DBU
M86#XV,(<RM(0H1L_6TZK^TMCN/_^S/YWK1VU/#(%<U%^+3*=SZS8(ADLV:;4
M]V+W#[1Z L.7BE+5OV378AV+I!NE1=4:HP=5P9LG>VKCL&?@AD<,:&M ^P;^
M$0.O-?!>:N"W!GX=F49*'8<%TRR92K$CTJ"1S;S4P:RM47[!S;$_:(E?"[33
MR5QP)<HB8QHR\J#Q@6>J%1%+,A<59E)NCG@+Y!U/107D]7NAU!MR2;X\+,CK
MBS?D@A2<?,[%1C&>J:FMT2E#;:>M [>- _2( RXE'P37N2)_\0RR0P(;U722
MZ+.D6WJ2<0'I%?'<MX0ZU!MQ:/YR<SIBOGBYN7M"C=<=D%?S>4?XNC,Y>B3?
M;AZ5EEA _XU%OV'WQ]E-4[E6:Y;"S$)B!7(+5O+J#S=T_AR+W#G)%F<B.XBJ
MWT75/\6>?,2&6K0979J,'@M=0Q'5%*9];A,WCJ+)U-[NQV2(NO2C>!(>PA9C
M,!HZ7@<[T!%T.H*3V?%)YR!)>I 6C2Z[T?66<*A31[.GZS&1P3GSXYQDBS.1
M'<0U[.(:GLP/O%/PQN#8@:4$GOXB6&!<E:RYJ[+OV)A-38X%M"$.]P[:]WLI
M,X1<NB[M)<P0M <Y$!5UHJ*3HMK>O<)A@*",@FO R&DBL<,0M6/K,3G1T%?/
M"X*>HB'*#1#6DS1$Q5[DC(N*.U'Q25&?A68E$2-UT!1 6P[[=3 F,QZ3Z;H]
MF4.4&U#J]60.4;$7'SF[22=S\@*98X5.AH4^)G R;&:!'\8]@4/4I4?#J*]P
M#.93ZO8TVGMS205R5<]W"E5LN&[N\VZW&R%OZLFIMW^+HV4S"?Y/T\RE'YA<
M%5R1$I9(Z5Q%V#5D,^LU"RW6]?3S*#3.4O5KCN,Q2 / [TLA]//"_$$W<">_
M 5!+ P04    " #1.EU86%I$'G,0  #NX@  &    'AL+W=O<FMS:&5E=',O
M<VAE970W+GAM;,6=:W.C1A:&_PKE3>UFJM:QN$K*SK@JL;@T[,65278_,Q*V
M59&$@_!,DE^_2-8(-]UJ@>?)[I<9RZ:?TZ!^:>"\?7C[J:Q^WCX416W]NEYM
MMN\N'NKZ\=NKJ^W\H5CGVV_*QV+3_.6NK-9YW7RL[J^VCU61+_:-UJLK9S0*
MKM;Y<G-Q_7;_N]OJ^FWY5*^6F^*VLK9/ZW5>_?9]L2H_O;NP+S[_XH?E_4.]
M^\75]=O'_+YX7]0_/=Y6S:>K(V6Q7!>;[;+<6%5Q]^[B._O;+)CN&NRW^/>R
M^+1]\;.UVY4/9?GS[H-8O+L8[7I4K(IYO4/DS7\?BYMBM=J1FG[\<H!>'&/N
M&K[\^3,]VN]\LS,?\FUQ4Z[^LUS4#^\N)A?6HKC+GU;U#^6GI#CLD+_CS<O5
M=O^O]>FP[>C"FC]MZW)]:-ST8+W<//^?_WHX$"\:V.Z)!LZA@=-IX'LG&KB'
M!F[?"-ZA@=>W@7]HX'<:.,Z)!L&A0=!M,#[18'QH,.XT<(,3#2:'!I/N/O@G
M&DP/#:;=PWJJ@3WZ_,V-NGMQ\KL^?MG/@^YYE.R'V"RO\^NW5?G)JG;;-[S=
M#_MQNF_?C*SE9B>I]W75_'79M*NO;\K-MEPM%WE=+*SW=?-?HY=Z:Y5WULU#
MOKDOMM9R8_VC^/WW?-,TM<)?GI;U;U:^V6U=SG]^*%>+HMK^Y?,?+JV?WL^L
MK[]Z8WVU:_CC0_FT;3;>OKVJF][N8E[-#SW[_KEGSHF>_5C6^4K3[,;<3.GJ
M^Z):-GOQG=7LZL>BJI<?5H5UVPBWJ*KBL!>:,#-SF'^6'Y?U\FFM:1F:6]Z4
MZW5S+CD5-^K?VC)T(C9COELLEKM36KZR;O/EXK+YJF[RQZ7^B">O99DZ*,Y\
M^\W\L'VJ?CMYG-(SG9K/G]9/J_VP_E?]4%3-U[]N)IV'W6SPL;"^_GNYW;ZQ
MXF;2L?[9S%S->/\Q_U43)^L?9U;<+>?+6H9<-8(\JM(YJM+94[T3U._S5;Z9
M%U9>-]#Y-Y9K_]5R1LY(IR(C:3<C?[M]S.?%NXMF[[=%];&XN/[SG^Q@]#>=
MMIYAXSUL-QM_O&YB?GPI"S)<2,(B$A:3L(2$"1*6DK ,@DF*<8^*<7LIYNM&
MS]N'O GPII=ZC-2AZGF&!0;UD.%"$A:1L)B$)21,D+"4A&403%*/=U2/MZ>[
M)]0C-O/=?-O(9U$\__1F=_767 P^EE5SIV45^VLIG8 \4D D;$;"0A(6D;"8
MA"4D3)"PE(1E$$S2FG_4FF^<J<1V^[2?JII+SC[W)M9=5:Z5.S"=%'WEXLWQ
M)GYG"KKIM=7,N ]#Q4/"(A(6D["$A D2EI*P#())X@F.X@G^!^)Y>96H$Y*Q
M#T/GM$"Y*'3\T:BK-S)D2,(B$A:3L(2$"1*6DK ,@DEZ&Q_U-G[-@PA;IQHC
M::AJQKUF*3)D2,(B$A:3L(2$"1*6DK ,@DFJF1Q5,_G2AQ%:!1FI0Q4TZ37O
MD"%#$A:1L)B$)21,D+"4A&403%+0]*B@*?8 W$@:JAH2-B-AX529$6U9RQ$9
M+E;#.;;G^IX<,R%C"C7FI>-X@1PRU6QE-UT;RYMEFLV\Z=@Y;B6-2WO4YDM'
MYI%9W"\WS;W$O748HW^U#CFYH8^>S8&&#ER4-D-IX8'V<BZR'<\=*=-1A,:-
M45J"T@1*2U%:1M%DB;VP)-A#)79,!P\6F3'48)&1M!E*"U%:A-)BE):@-'&@
MO3PYC0/ES)2B03.*)BNLM1?89_P%1X5]^*RPQZ):YYMB4^^]/=W,3S^M.>II
M?NJ/NX?RQMRYP2I"'0DH+4)I,4I+4)I :2E*RRB:++;6F6"[KTFNZNQS6E6A
M%@64-D-I(4J+4%J,TA*4)E!:BM(RBB9KK_4UV,94[O5>9)<[S_5B;P L-MM\
M;^4.?]W]7&@%YZG3V,B;3+NS&&I60&DA2HM06MSO\"9H4('24I264319(JT=
MP3;[$62GK77[5,T?&KULK;NRLGXHMG6UG-?'?.J_FU]LS^5/S1$'3UDD;8;2
M0I06H;08I24H31QH4G9BHKGI0HT+%$T66FM=L,W>A5<(32LNU5!P.5%G)S(%
M/4-I(4J+4%J,TA*4)@ZTL?&;3]&8&463-=/:#VRS_^"EW^?STI?]O&,]/1Z7
MP?SK\7EUWF9AA>]O;YMKNZ*:+[?%V6D*=2R@M!E*"P^TE^<,7WW&%:%!8Y26
MH#2!TE*4EE$T67*M=\$VFQ>^2'):F6F<"*- F;#(W/4,I84H+4)I<:^CFZ Q
M!4I+45I&T63UM+X%VVQ<>*D>Y9KNNT]YM3A_]X0:&E#:#*6%!YHT+7FV9EY"
MG0TH+4%I J6E*"VC:/**V-9XX9B-%Z?4%)757;&LGW8SU!EEF2,,519*FZ&T
MT%$=%Y<3C;+0J#%*2U":T!T11STB*1HUHVBR9EHGA6-V4O30C%8G:DK\LF,V
MNS%''CSZ42L$2HM06MSCV"9H1('24I264319'ZT/PC'[('3W.GN=G)M(V*(+
MJ!\"I86.QM.QLY&K,XFZH>,%8V7#&.U?@M($2DM16D;19*FT+@;'7&#AE%2T
M\E +(033L>MUIQ#4BW"@O7PZ.K7M:>=..$2#1B@M[G?<DGY[*M"^I2@MHVCR
M8&YM 8[9%C!;?EPNBDUS)=0,XV%UH;YWU/SUI3WM>MS,'1@\ME%W $J+4%J,
MTA*4)E!:BM*R<Z-2%DIK#G#^7\4*'$T&6%.MP.E7KL"\&X,%@F;U45J,TA*4
M)E!:BM(RBB8+J4W^.^;D_W,-NKE4@VZY:3YK4R:.FN.?N!.GJPTTQX_20I06
MH;08I24H3:"TM-<XRJB8LC3:'+]CSO'ORB^*O10.51FUBE SV)>>$XS<KB;0
M+#Q*"U%:A-)BE):@-('24I26G1^7LBK:-+S3KX9 G[H!9M3@QU%H)AZEA0>:
M:14T&C!VU/2Z.QE//.6>'$VP:W;STK5=OYNK4#MWZ8Y\OWM^UVSFC<>!?V*,
MMLENQYSL#C>+@0NA]<,737BCM!E*"QTUX6T'4]O5/$Y%4]XH+4%I J6E*"VC
M:'))VS;E[9I3WEU]]5D%K568.<Y0A:&T&4H+45J$TF*4EJ TX:KI\8EZ6DK1
MH!E%D^759L==<W;\(*]7+H'6"TW-[KK^9.QU'VN9>S980FCV'*5%*"U&:0E*
M$R@M16D919.5UN;9W5>]S\#12DB72%8?#+OJJPIT#X;-'1LL#;0Z $J+45J"
MT@1*2U%:1M%D:;QX;\$7O[A +Q/VS05JYEE7+1 -&J*T"*7%*"U!:0*EI2@M
MHVBRFMK$OON<Y_R#:FVX9$[V!J7-4%J(TB*4%J.T!*4)E):BM(RBR=IKO0*N
MV2OPFEH;KNH"L#V_:V6Z,4<>K"34+(#2(I06]SN\"1I4H+04I644399(ZP)P
M\1( YZS(YHB#IRS44H#20I06H;08I24H3;BJ"2#0%#A$@V84319:ZREPS9X"
MJ-:&J\GNVE-?F9Y0TP%*"U%:A-)BE):@-.&J;Z#0?/4I&C2C:+)J6L^!^P<N
M_3\[4:$F!90V0VFAJ^;;?4=-\:)!8Y26H#2!TE*4EE$T67*MA<+M7R\ J;;A
M:BP&GC_ISEBH20*EA2@M0FEQKZ.;H#$%2DM16D;1Y+>6M@8)SVR0 *IMF",,
MG990V@REA9Z:XA][:M&]"(T:H[0$I0F4EJ*TC*+)RFJ]$=X75PXXJRSTU0LH
M;8;20D^SIC^8:I2%>B%06H+2!$I+45I&T61EM5X(S^R%^)*UIY[JC;BT Z=C
M^+TQ]V"P5E +!4J+4%J,TA*4)E!:BM*RL\-2EDKKC?#,WHAAB^8\U<-@^X[3
M72%DCCE8'*@C J5%*"U&:0E*$R@M[3>0,BJH+([6ZN 9T[G]ELT=&)VE'Y-I
MT!4%:E5 :2%*BU!:C-(2E"906HK2LO/C4E9%:T+PS":$(4Y33ZTMX-INH-3R
M,(<<+ [4?:#9A^Z".#1@[*F6 F_D3D?=&F9H5*'9S4M_-.VLPDLUG;,=.YAT
MS]SJ9I?3L3,Y-?K:_+YGSN\/7Q"G'YAH3A^ES5!:Z*FY:7L<>)[FWAG-UZ.T
M!*4)E):BM(RBR?IJT_J>.:W_F@5Q>H6IB7W;FX[<;I5+<W\&:P?-[*.T"*7%
M*"U!:>+$=Z\88M"H&463E=.F]CUS:O_+UKKI-:0N4G?=B:^L=3/W;+"&T%0]
M2HM06HS2$I0F4%J*TC**)BNMS>A[YHS^B3L05RLA-9VL6^OFJ>^RUZUU,W=L
ML#30-#Q*BU%:@M($2DM16D;1)&GX;;K>-Z?K>ZQUT\K$C!UZ/^2K>7#=6C<T
M:(C2(I06H[0$I0F4EJ*TC*+):FI3]/YSHO(/6NOFH^EYE#9#:2%*BU!:C-(2
ME"906HK2,HHF:Z]-XOOF)/YKUKKYFL(&H\#O5O4T1QZL)#1YC](BE!;W.[P)
M&E2@M!2E911-EDB;O/?-R?L_8*V;.>+@*0LU J"T$*5%*"U&:0E*$[XF=6^K
M%_<I&C6C:++26B> ;W8"0(O=?%U.=CH9=^<GU"J TD*4%J&T&*4E*$T<:&/S
M5Y^B03.*)JNF=0KX_5]M@"]V,\<>/%.A!@24%OJ:]S@XZFN?(C1JC-(2E"90
M6HK2,HHF:Z[U1_AF?P2^VLW7%+B?*NXV<Z\&ZP=U0*"T"*7%O8YN@L84*"U%
M:1E%D]73NA]\L_L!6.UFCC!X7D+=$2@M]-4L?S#6^(K0J#%*2U":0&DI2LLH
MFJRLUAWA]R]\<%M4S7W3>O_Q65H_;98]GDV@Y0U0V@REA;Y:WF"BWF)':- 8
MI24H3:"T%*5E%$T65FN&\,UFB%/3U(!EI.8(@X6%%CY ::&OND$N-478(S1J
MC-(2E"906HK2,HHF*2MHO12!V4O10UDZ-06J^4%YM;LY\E"-H+00I44H+>YQ
M;!,THD!I*4K+*)JLC]8=$9@+&+SVU>YF[-#I!J7-4%H8J%4+;'6R06/&*"U!
M:0*EI2@MHVBRF%J[0V"V.PQY^7N@YN$G(]_O/I,S1QRL#-3F$&C>+6%/O*XR
M4/O"B</F=^</U+Z TE*4EE$T><BW]H7 ;%_XDC(=@9J%UI7I,/=@L 10 P)*
MBU!:C-(2E"906HK2LK/#4I9*ZS\(S/Z#864Z HW-P'5MY28$M1F@M!"E12@M
M1FD)2A,H+>TWD#(JJ"R.UF80F&T&O<IT!)IUZY/QN%MGVAQJL"90'P!*BU!:
MC-(2E"906HK2LK/#4M9$:P,(S#: (4OD#JB7U^*>ZXP]11MHCA^EA9I]<+HW
M$VCB7A/0MSU[Y';O)M#4O2;JI3T:33IGY%2SW63BC[OG;0UM,K)=Y\3H:]/H
MP; B N>+=.@')II*1VDSE!8&:BK=&8U=W<,B-)F.TA*4)E!:BM(RBB;KJTVF
M![U*#0PJTJ%7F)IH=@)WZG4K^IG[,U@[:+(<I44H+49I"4H3VN]>M>^D:-2,
MHLG*:;/E@3E;_F5%.O0:4DL'>/Y8?<.:N6>#-83FQ5%:A-)BE):@-('24I26
M4;1GI5UM'XJBGN5U?OWV,;\O_I%7]\O-UEH5=PU^],VXN9&IEO</QP]U^?CN
MPKZP/I1U7:[W/SX4^:*H=ALT?[\KR_KSAZN&_ZFL?M['N/XO4$L#!!0    (
M -$Z75CM$PHX$@P  ,(]   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
MM9MK<]NX%8;_"D?M["0S44P !"]9QS..N&XSDTT]=M)^ABC(8D,16I*RX_WU
M/2 E0C(.0;E5OR22_ +2B\O!@P/P\DE5/^J5E(WW<UV4]<?)JFDV'RXNZFPE
MUZ)^KS:RA+\L5;46#;RM'B[J327%HBVT+BZH[X<7:Y&7DZO+]K/;ZNI2;9LB
M+^5MY=7;]5I4SY]DH9X^3LAD_\%=_K!J] <75Y<;\2#O9?-]<UO!NXN^ED6^
MEF6=J]*KY/+CY)I\2,.V0*OX9RZ?ZH/7GK8R5^J'?O-Y\7'BZU\D"YDUN@H!
M_SW*F2P*71/\CC]VE4[Z[]0%#U_O:[]IS8.9N:CE3!7_RA?-ZN,DGG@+N13;
MHKE33W^7.T-<UY>IHF[_]9YV6G_B9=NZ4>M=8?@%Z[SL_A<_=PUQ4("$ P7H
MK@!]62 8*,!V!=BI!8)=@:!MF<Y*VPZI:,359:6>O$JKH3;]HFW,MC38STO=
M[_=-!7_-H5QS-5-EK8I\(1JY\.X;^ \ZM:D]M?1FHEYY-S P:F_J?;]/O3=_
M?7MYT<"7ZJ(7V>X+/G5?0 >^@%#O=U4VJ]K[K5S(Q7$%%_!K^Y],]S_Y$W76
MF,KLO<?(.X_ZE"$_:'9Z<8H43T\O3AQN6-\!K*V/#76 :>6;2JV]?VQD)9J\
M?/"N]93(FUS66*MWM09XK3I:?*@W(I,?)Q .:ED]RLG5+W\AH?\KUF+GK"P]
M4V5'K1GTK1FX:K_Z"I$R+S.UEMZ;0M4U.F"[*J*V"AT7'Z]('$6)[_N7%X^'
MS6(+IT$4)Z&E3#$E#7UVJ#PRQ'M#W#D\KA?_AB#0S<E&0:3-5)GEA?3*ET[U
MG_6'F1Y0HEQT+^0?V_Q1%&WY3:4><YB#WOS9>[.MX45>OO54/^!$/^ ^8,W&
MSSGBSEE9>J;*CCHH[#LH=(ZX^T9E/Z9ZZ8$65VM8CVNA5S2L!;N:PH-10OV0
M4WO@V4(2\,0>H2DB](,X&1QV4>\J<KI*Y5)6%5AJQ$\\_D36-T\)B0+?-H,I
M.>7,=H,IPX@'@W;BWDX\8@=Z/LM%AQHP-\1:54W^YV!/Q=8OX4F4$-L<)@PQ
M;[8PB.AQWQ]92WIKB=/:=08SO&KG\A0F>";KVM.C7%19%P86\A'H;J-#B/=F
M\OGV[A>QWOR:3M#0F%B_\J5A6T$(MQLF==5T9)3X!E5\=W!7Y;0-:B9D%1(F
MGB=_ZFDG43CQ[=]+0R36(\*7EIR28T\'^$5.\Y27C81^:U 3Q/IBEE D;J#"
M$.D=1$@Y&1Z-A!I#U&D(@%+WC!YML%35L-Y4W;1;BKSR8"G:2D_TBQKJEB+1
MC]J+[@P1!CZ/$;>VD/O^L%G#;L0),U=?8.'UP)O\J3UO\WK53C. YX6<X^;8
MZ P;EZ2(!!:(>-B1X2?B!JCKNM9@L=Y ;[5>LI6H'O E8%>5TXLMX5& ])"M
MHRP:#OS$\!-QKOY7?X.]K^ZB&B!(=\SUU_0:=\/'W=B2:<3M)2_%A"2FCOEE
M<(.$[OW"2L#LJCWMRI";[K6Z#?=%+N9YT5+<NY8'P;/0:T2=M]/PC=ZWO$4!
MCSA)Y[6$=];:TG/5=MSJ!H>(FX>NLTQM-4,#1D@ ZGDAV]9%F]'&&,8XMN0@
MO,/"A-B!/<6DG >.&6_0B+C9Z'/Y"/-<50/[3&*#RY3' 8)"F)*R$(G<*2)E
ME#JFNZ$AXL:AVTI"Z%KLD:";$ZI9R<K+MD"T$-&ZR8)ZM:%EFOB$(UX1991@
M2P_"2S0:-$H-#%$W#/4C<B.>]7#$_% ;6"*.[3<0(?<98@<1$I^$X; A0T+4
M34)@J-H"QU;J611#60]J<TN88#B'")D?(S,+$4YIZ.@A0T)TA(1VXVVW2V]W
M4OO>&@P>%($?DF [#T0)NR5D,<*$$8^&<Q/4\ ]U\\^^SQ[4HZS*EA<J.1?-
M0.<AU$*1;,H,$?)V-%K6;.&4^=%P6*0&A*@;A.YDLZW*UIM:=%LJ6%106S:[
M3%F$X3FFI S;UR/*D#O22=3P$'7ST+[+]@'R'=!!]\EA]N*=B9NH99MO"*41
M-DH1$DI\.Z*FF)"%S-&5!IFH.T6CDX*S?5:L??';05;L]C K]GV?%3LU#4N1
M# R)$VRY1Z13!HL]DBQ I(PY\)$:D*'1J]+->O6O3_'IY*/7LN%9:TO/5=MQ
MDQJ HFZ NCZ@:X#MKTJWXG;MW<+.:2V\+U]F/8AWN=E=Q@9M9AN,K&&$8!;#
MQA"BBX,@&:8L:BB+GI!T,I8WE5IL,XC]^I -(DJ?9#H((Q!!B_:0:1B_*(9?
M86![FV%*6-*P0(HH*?%C,M@*S" 8&T.PEZT 0:-Y;CWKO'N;<QM<Z9F-4M,X
M#FWHFN'*".%J3$DY'Z899O",N?'L5N<6):R$2QTVH$?['76ARH=ID3\Z^Y;9
MF&79M"7HYAK1T3 8SGDS0VS,36SNA6*W-IP<,AD&:#$GR"J)2@'1$ )'I3YL
M!8?A@!V<1;[N,/(F+T69G6#UO*>1YSV._'^<1S+#D<S-D<?S9K.=%WD&LV8I
M*VC6?F%H*@'DU5V%V),9VM V%\8^Y\@.%5%:0PF!S 3V]L,#R5 F<U/FK7C>
MW2,H=1H8S0BC_K#$&7V1K-T9',W7I4[)L3,#D\P-DX?.OLEJ[7U1HCM32F&!
M>X80D5;BZ?!/#Y7L+E6@AFW2LXR.2E)$ D$A#H>)D1EB9.[4UZ'AN:J@/'1F
M[6W+A<ZI ,?DS9A'+,_EHWUZJC)%E$-.#<@Q-\A]>NGNMLI5Y=W)1U7 _M:X
M1$V.D]NX)$4D;5ILN!\-LS$WL]W)3=>3.MYTSF9=[]V(3&>,GU%;XR>"XY(4
MD4QA;!)' C,P&!:X,<SJ-@TG+ZSU@3:OZRTL:1)"48V/UF#T(' V+DD1"8U#
MGPW/R,"@6/ :%.L=Z?V% C:IFGP.9 :KV>X,O]97%%"KXU V+DD1R2YB#SDU
M0!:X@>Q>ZK2T=^TRYBURO7\O%SJYEJ.[J@!-E5%DU3Q9F:+*Q&':0%C@3JH=
M=V_G46UV:""K+-^GM7^[O[T%HJBRE1C A<#.C\4)EG%#A"\/%'>V;2'UPV'X
M#@YN;KE!Z5LE1;VMGG>.>U_>4NG-8]U4>=;TG:X1'+>,Y-B")(X0SXB28)F;
M%%/&KKXVG!2X.>F_24V="N6!33]A%##LGAM"79Q@!S>(DB0!3_AP6QBR"DY(
MT[6GFWJ7-=@JJ%4D"Q=&,=KK""IQ&,*V-$6D"0W8,!\'!JH"-U3-AB[IO?/F
M\B$O2]V]$-"?I4 3L(&-/YQ19I^LSQ E;!>9CUP*P:2P: UG#P*#5H$;K1Q^
MI<X0.9PB1$0)H<@N&I'BC9(B2KM1CJT:S@H2YQ[Z;G=%<W?;;)?U>X<XU^UQ
M$-@ZV6G=[T2]U^ZWSUI;>J[:CJ_+&AKD;AH<'&GHE5:$T@8&%R(-8DJ1)1)1
M0GW, 43<H!]WH]_=\7!!/8U#'2*! (Z$>UPX/$NX(3ON)KMOJA'%:V8&:M5F
ML,'N0ZZ X;$!48[$!F[0CKOS:_?;S:9HMY!@?I'76:$ >62+.&TK+ NH,B^[
MYWD@?. 7L<^:;3MK;>FY:CMN8 .1W V1[>QO+X#H)MW?J307H=;=G8E,;'+H
M@OQ/_!2&V[S'2,"P887<6R-!A, $HDPB?YB;^,$3 FZ&?.G9W#9 O:%'M\BI
M R*D,1;ND I]%CFFBR%"[B;"]BFTJ5I.M[7<WW%3\T;D99>)ES^SCA>U\>XJ
ML)H7^4,[=7#W-M(%$7;!!Q%:QEV28\>&"[G[>/8H0)3F;O#^Q$$'QF7/_V,/
M;)SUS/:LM:7GJNVXG0V/<C>/WIC+R%W:!+^S#&-,>/-M#:7K6E^0F$/;#^6N
M^7@&<%R2(A+FNVXK<T.FW)T!/#:M%]SFN4T?M2=W_Y/U\2SAN"1%)(F^_#1H
M/314&+[VJ/;@P%K'S&*[Z&**..%>73B>(D0D!$UD.^LZ=FLH,1Q-$"(GT7U*
M9=%^_FK3W7<>/N/&L'4#T07(G<,4T1'L>9B+@X=;U[)Z:!\2UB,2?G#WT&C_
M:?\@\G7[^.V+SS^1#VGW.+&IIGNZ^7=1P::KAB5D"57Z[R-8TJKN@>'N3:,V
M[2.T<]4T:MV^7$D!<T4+X.]+I9K]&_T%_6/;5_\!4$L#!!0    ( -$Z75AS
M5B:V "H  !B&   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&ULM5UM<]M&
MDOXK*-W6GEU%T9+L.-G$<94LV5EM.9;.LC>U=74?0&!((@8!!@-(UO[ZZZ>[
MYPT$)?EV[T,<BAS,]/3T>_<T7MVVW1>[-J;/OF[JQOY\L.[[[8_/GMEB;3:Y
MG;=;T] OR[;;Y#W]V:V>V6UG\I(?VM3/3HZ.7C[;Y%5S\/H5?W?5O7[5#GU=
M->:JR^RPV>3=W1M3M[<_'QP?N"\^5JMUCR^>O7ZUS5?FVO2?MU<=_?7,SU)6
M&]/8JFVRSBQ_/C@]_O'-"XSG 7^OS*V-/F?8R:)MO^"/B_+G@R, 9&I3])@A
MI__=F#-3UYB(P/A#YSSP2^+!^+.;_1WOG?:RR*TY:^O?JK)?_WSPPT%6FF4^
MU/W']O:O1O?S'>8KVMKRO]FMC/V>5BP&V[<;?9C^WE2-_#__JGB('OCA:,\#
M)_K "<,M"S&4YWF?OW[5M;=9A]$T&S[P5OEI JYJ<"C7?4>_5O1<__K\[?79
MQXNK3Q>7'[++=]F;S]<7']Y>7V>G'\ZSZ\^__GKZ\1_X_OKBEP\7[R[.3C]\
MRD[/SBX_?_AT\>&7[.KR_<79Q=OK5\]Z@@4S/BMTW3>R[LF>=8]/LE_;IE_;
M[&U3FC*=X!EMPN_DQ.WDS<F],YZ;8IX]/YYE)T<GS^^9[[G'S'.>[_F>^4Z+
MHAV:OFI6V55;5T5E;/;?IPO;=T1)_S.U8YGOQ?1\X*X?[38OS,\'Q#[6=#?F
MX/6?_^/XY=%/]T#[PD/[XK[9_Q_/\=YUIW?U[P$FN^Q6>5/],Q?V;<KLS6!I
M>6MIHHOL:IT35Q9FZ*LBK^TLNVB( #"LZFU6M(VE4ROSWI0D<1:V*JN\PQD^
MZ=N5Z=>FFV5__H\?3DZ.?J+99OSQ^*>,?G!?G[6;;=[<^9_TZULS_F:P_INV
M<U^V0Z=?/LTJF^592=*GL]6R(H 657NX3> G@'FU#"@$S6UIVZ:AG51-UA@\
M<T?2YH:DZ)9^GI$,:(8E4>+0\9_8-TG5+X8)=DVR*/MCR.NJO\L670X6XR$K
MTYBN*C*<5=%56T;M=HS)JBGJH<1$)/4)<&M([EF23/U:IAZ:#>F+C2D9=( W
MSSX1YGJ3;[#;94NBBY:DR4M38^.8;$4T33/01BP]AF^&+2/\8]Z9[%R6R1;N
MD/MUUPZT&$;8H2CHN^509W4^-,4Z:Y=\SC4IHBRWUO2S[*SM^J[=K@ECOYAZ
MEA&KFF9%CS=8BP[$;=^&17A/IEGG34'P*H))Z?19D6_S104, B%->R-T2),;
MV^>+NB*A6PIR+>.VIH>[?.76^D#0K+/3#1;,F_2\PN1$D8(ZI;:LO6UD.M*[
M'5$OX\&8T2&-IJ-/.MD,B+E=5X2A_K;-@-BZ+9@+"/(W^5":OC>S[%?:DK%M
MGPOIM(W!N45#W^:VSWZK:',M<<H'4J]_(_(UA S,Z7A(-E(;K+KMVG(H>/L=
M0<CLEY4M':G\TA-P.6&<-##^;\VF.N1!]'U=_3%4BL>>*%SHD)B8#K2NE85[
M')(5@+=MCT-R,Q.2<B)(TI?9PD3(D;WD&1%.?7>(^<A.H2]-<U-U;8.#3M&_
M)L@*T*$[ #IS JMG*KS,O]Q4!,XLNZ2)NJJ=39_#'?9'&/DU[^@<G$["0I $
M8H[<TI!MWO48US:K%H]7#9UA#C.%-M0"M]A"  18O2,*7D&.+0DQ[2T> VAY
M00BT%4]-,WYH;^CSL%$IF;U_?Y8]4<GD?@OBJ<%XLUG0>1*@Q[L88?2QB*H-
MZ ,KDAYLPH+XQA]&@G^2(*0?OI"%5P*/#H?8(*A.GQ4B_SR_GA\N&/LI8FDA
M,,IE!.E+P>IL2AED9WF3ESFK!*(78H@6&R#>BK7!G5O<27HBB]X(S1!TQ+3Y
MBJ!B:0!!R((HKSW,.^2PAQIFV;J]A7"8R5'Y24$#@,;\,="?!""M3C:>8T&R
M:/RA/(?8W P]R?0PP9PVF+TSBV[ 9FC4BUF\GT=L9SL0A4+J@J>F]L:8G_'X
M/(S>DDSCH<=_F9^065K7( -&>D7KG!.V\PZRB)[:$EE\K<A^-K3!/QV_B![X
M?!V&RJG3EUB]&+H.8)JOM%ZS,ADDH9 E TEL9+YNR; '+1*CU) RA#%A." B
M>_*!) 3!]W1.4L]6S(]7L%#HJ)AH,5EB)2P)\TU1@<EH"./)$O7?D$HRIH'*
M)'Y5@4*V85="'(D"R8.M2*BA28A/K&B;'(1'OYNMGBKV]YD8G?ZZ[EG $V2J
M)CR/@A&R7TY/KQR3SK-3.E#R6.A L:Q,1+MNVEZD!2&:K%06QBN2I0P<;7MC
M<D(D_<[/X@/3X-"OVZ[J6=CP0A!92]J$AS&R?PG.ILP[DL]G;4D63"$8=,">
M7I]Y60(ZFGSR\[;DS8:'/ON'E.;>^0.8G.%-2__SS[\[O7X3D',5L$Z3G?EC
M??Q!B\UC5)CR\G(R#YJ:L75)QT3:K0+?.8/.3\:Z#4)3-(!E14K64<3Q10SX
M/"._D[Q*8BQFA^+N<9H*QD<DXVC:";VE G*?G@K+*"O6LF >SQQ9"Q<-?:4/
M\LPJQ:/1M#=H!R-(2Q!!$S#!ER(,&%->F)1>0@P]/[HD^T^U8>$0 TG*C!6F
M$6@8L&87FL";"I>=!$L>S[IA:V!YB&$%)5[;=A\PLC")FJ$6$@(:F[8YC( ;
M$0+M=Y'7;-XP571$E+EUYDN*&S%%(FY/A*3-2E$^+-U)J+1B^ LX:M(S47G<
M1:!D*S*/U)IMK55HE#6\9" 34O64*O^&G $:U&Y41F,6R'[,P2(]WFQIFC8B
M^1$XL&R849R%4:O93=18L+$$JJOCX232$@R!%JH-%$X''G>J[L[@1\.ND->L
MCN;YWQ,Q+<4$^MS4\ ]:6+FWE0K:DD80?WLQS(NK0/K3K@\H$+GO$P&\0ZC*
M;QA\_/U/5GP:.8E*_9!(E'0!.[0=.#.K_8I3N1R_*Y5E$O"#.)QA+"DGQI,E
M06?(5BK)U%=(,C).XK5GB703C"VKKT:],,\DDR"2_=NW'3LP3*QS<BQZ0LR-
M:08]>.CUQIH']@ICAKVM$?EG9!UV,>W+>:M9L;M[DM?E[^0UB Z(F*1K-SLT
MJ#B<5!^I)>E/T5%W$H%@<RQEZHXW/&P&V:1(6M@;V!-P3:9RP^1_SQ'!%!'C
MQ$_4BI-&$]!#"*7>&.74[ FX\^F,F1?0YU^)Z"U;=6]MSP:;9<H4PR=!P<XV
MIS4J9"OBQ@XX,30Z@$NHAK5,!\CV: _;^8N!:ZTK@Q:(HH;-5L0&.WCY<DE&
MGPC C9 ' 4>.=A!.DZ#P9(72+,Z7K28VG_O'6 >S&# Z*PYN+.$80RG19!G4
MN%BCL^R&CIDE,^:M2M7-7FPB:N",70**C/>:"24C.NY69D'.$IS<DH96B#:R
MB;8TBI..!O3012N0.GNPX;O.D.NA EP\9.PC#R0^<Z=/Q^U9C99>D#I<5OT,
M 6W30>_0 %WQ)J\'C<'!XP0'(;;2%E]4K0*O-!&/F85!O*>J(=XFGB=?:T$X
M-K8P_'R8E$@JH)RT3]\-X="(58BW*R#3B9<492U;B4""$Y,<! D1K&A$>AS,
M*=YIIF>6>=4Q7$;43+,Z1.@J"+8=O=<AY'_8+@\'Z^#32!"<I 2@%"L%8;CJ
M5<?.O,(K#?%:(;13<Q1@"I#4/EMP: ZF2"!1@BZ2M#AFDCM8FT,]+!(D5GAH
MR8F"00\:D!\Z4YL;N P[S%<AME)71J,3"Y@IN273!^"2XZ""MZ@ZDC\:K"'Y
M6K#/ZLPA$NIUF9$3 5W(4M8.I"T\[.2MF2(?K'=$R;XR':(VO8C.M6$%5S6C
M!T$8R4J;_"Y9AQP>:^*%/AK0FG/63Y$>XL-*T$O\@$ A9HT&YV$P8<*Y#D5K
M:=V29%L!>YD0V-)A0BI(E/$K85#BJ=O6@B_]+//L&IN1"?QTN:6'-MNZO3-&
M8F&Z1<N1QO1 8])4;H8#WIA#VK )\\3CTGG"4VZM9+!()_ 68:;J6/"H7"62
M"?K!$;%(C!$.)K@J;&$'08P/EM)JKI-Q :J#\PW)TM8#_)D[O[M#D"^OQG-A
MZG0R,DX,R_S.2%1>XXHL8[=D'3![>F2E"')S;_,[E5 =![T6S %LO#!UT5_L
MNP7L3Q].$%)"FQ)*D Q 89R>Q%(S+ZLKJ_L'1G4O'EYU*6DW?2V1$1IKL#7F
M%;>RES>B0S.$IV-NOO-<4LZSM[JPV[R$[?9OZYY=),"+H4:S<%"80VOZ1&5#
MI'$.7WZ7%KTV)-CR6B5L2D<39P_D!+_/0Y(SR\%P+L="(>)S<<N*=M54_U0+
MK7&.-XWTYS-A4:1F8G#6L1I;OO1_GMB'*YST\0M:9R1/19].K\^RET<O9WXZ
MEG<.<7HB9YQ+)J,Q"\OJ>>B6@A<10LNV-UO[H_@S+W_*+DH0EP\ J8AVXH+C
M?>X/. )""86N_-,#TQ!>N,@ ^VH7=;7*O1L>KQ*F.1_K8V^PJS?+8<J4SVC3
MZ>*!;=TLT^9;6/:TYL#'?6LZ+^_16P(4;OZ8&&!DZ&$QM]\B -I7=GF'<.SD
M[/.1_NK8D*AZ&_PL@I'T?T5,(!HXU[B9IL?(C@2U:]YOYE"4YKS&":F0X^G:
MNUV>'(U67K?[:)$W&V,LV!<X<X:V2 F\\ 0.X 5+%3QV\4<#X[?D'W6J"33#
MM)/!(.8M 1*?K+.(6W6Q99UY]HN;,HVZERUA$SX!2Q7\*^+/RR&(T 5,FF@+
M;&'=LG&4A!RB '004N,P("^F9,V)WKL0ZK<<A.\ZN,CB:H65.$.\O%-WD_Q4
M9@ND!\0@9_-9?4\R41R9[#EYP?NP^)U=M':O&S0P>R3.SCV^S(XG%&C*#\57
M;"T1R4K48![YL!H @O%7!S&\!SI55PDV?A_*E:1;$@%[#I@J<@#QW&G ]SNV
M-ED_MJKA8O* 7<J)&8D#A*2]:JPP9W2&3.'DW7<E)PW%%%;*3O$/PA5F.5TL
MB./%^$+^]KP;R,R5N*$PE8_%?S@_M2$:WSTP/!W-.34$^XB?&RN%"@FD3*]1
M%G@,)R<;/EQD=4[NQ2CX+.QI)YC3/VO-(W&H5D]G$)21L!+/RID##12**)2Y
M32YE!M^P!KD[8"5Q069!9R>R#4^@%L):.&_52!*M.2]L[:[ \6;;M-SG)UE0
M>-F'*&; 4@ S)4@R9^V(MD@:B&,(:]=T!:37RKMD CL=!]E[A*6ND4UY-1(?
M5G3X-/H0T2O.DOE)=RPK%HM68ET\X[>85.*12#2M&WRRCC]ZO30Y8Q(;! GT
M5>TL?48MJXTN,4E_3=*]5[)EE9-.5/C!:6XXDLA2K%3)EB-Z#0Q^C[Q-4NW,
M>5$I":SR=5XO>>+HB#5%L8>.*BOA.#^Q6-I=>T-B<B\P$.E. Q-]W7$-!VG;
MR3(G7_6R*Q-R%'68*%9F.0%8HU; FKK6'&L1Y0GV[\/)=F&F1606W*?^'U3\
M9_K8_>."?^;FK4W.P1,X.^MJBT(NLA:*+PXX?+<[#SM(Q2X9F;TV6, F&[C9
MN\LW8<%M2WI')8_#8(C2=97](LXN/H"W2+YW>%BDDMV52FI20-/-LROE&+'2
M@NH55DX]L*6Y9>%$$*)6:</UH$07CG9FZJCCJ084J1D=%^5<1N[&""]>^GST
M3,\Z^STK*8[W/%IAL[+6J'WMGX^EJ>@+K;J*GE25Z'$&^E6%QZ%#?(_O0@5/
M"KP+A0D*@_P2 Y<0*@'8%-S(9^2%8O=! FH$;,U1<)78$&Q1 88>%:H%8T%?
M-5("+E82AQ7*D">1K8UBDR-3)[9G))&JD:Y[E -RDA$406P\I$VZ\E_6)1YE
M411K6J4[K1,O_']2.]^VY+U*BNSA&?^;O27"NJ'M-R[<QD&.BG/Q/  U"ZCK
MK.^T$(\%@LN*L>W9$L%6#1<>0H/Q?EAJHFQ+.)>-0.1,/5&4G)%;1E5&A*.B
MIKVIHV(UR!D %,"#11_]%*M)L?;-MK65*YU8F^*+Q&Q<HI)96@?I-E+H:RDS
MA?R)]J'%M*1P[M3J"\G(B4DF4:!9^C$"[MM=$O9MF\,U$]48DN6 <E/'/C@D
M)$#K 9F]FHL]<)"'6OL[([IJN_X0TIA8M'!@2S*-8Z!V$/-]->2DRGH3S C.
M4 ;/;)Z=#SZP$4VKV/#%= *AP!;2<I/H%,%5D"W$XLBE]-A^BY,++AS)N2*?
MI8EJ;0S7?8HP ,I0;;'[0YQ1WMWN.P,GL,[.A6"RB\8.$OL]:[MMVZ4U3^_.
M+T+1$\J8V^Q/)]\=(9([6 )!Y-0F_[V-<:."\3^5[I.:#Q06?RVXYF"987JB
M=TEQSR94B[-L7"HFISV3=*Y#93,4^#QF=5Z2SGU<_' "1V4KI7$T[$_?S8]\
MA1X0SN>Y-K66TB[RYHO#I7I_([M3(!K4A2'QQ)IZ.; M23,32*WD5'Q(N8]K
M$159K"*9C?M:HU#^3)6JR!/EN2\:.;OWITF)L6:.8&-Q3E$SE&0PE :DZ)>0
M(H9&PENKMBU5B)T1 2R1;-BI $-!+<U\2J9H34@\?NFJ>R6DCAH4_(=L&NM5
MGJX;'494JK.L.MH6L6T'=:D80,G*OHJ5N2N2@ZL!;<R<$FM?\[4W.#I--L8&
MNMJ%0\,R01+2E95@OX 7)RC%T7 %29 <&^)^UD+0KDF %:A5W;2HN'*[\]!Q
M/@H!891T\VTL63<M_B3VMA51"6V=;5 $BLBN(]./I$"Q"Z2-H?031?G/:"]1
M+I2]<]P:<T%LK9S1 OZ.S8)!ZK<<HL-61(2[1QHN!KC-N_*P;EO60IA:B8@0
M36H;14^%$G%)YT"V-H$"-QN(F$>'*#NY);G1(PBZ7(I54+%?$CE&(L0CF3DT
M#K.<@0(MW)-V'M=)29'0#IVYDJ@3Y.'$2X &B3]'>KG+;[V=3N<JA=_ 1_0E
MKNF1=#XD(XX,0CO)?NEB;._V4ADCBI5V)6QBM3Q4[;R.RUE(==35/_F<5%/$
M?"&50>J>"A%HW(#K)&PZI]T-($<ES21J($( F)8CX1G4H\*.1-D4S0O[2^Z4
M)%\;_W5B.N:]SL&9-SJOH=,@)NIP*BV/Q'U+(@_)3<*JXG JRU)?017GM<[C
MK&R2AP-'(KC*M0RXWJ6^(2?H?"(0XIQOWW V(7?7#^R/V9G:<YH2^0>7V;T9
MJAH"0:LX-H@>J(U]<I0=9B^.M![O/<3CFJ/M\:!KV!=RPIPG)HWI 5ARQ4IG
M@ *0EGRSU*J+7_-B39OHR/99DI?(Z)N-\/V<(#AV$*!8F%-^6A3BR-*1-;/%
M!G5AVYH]#\2W0=L^B1+IL88$2G2N4L^6RQ56@)@O8$C T99#G+[$HZ>X.R3<
M2<(1^+ "5RC@=M5\_V[4O+3J@J@9'8\.@74I87!9TUXBG<Q.SOF/GD-M2TNP
M21(FWU8]F,\$9;U+?,A7Q 18[ -:'!Q.7K,QKYEB5VK3<<Z^$"M34TKS40)5
MV'L[S7A<H13*&2!G#9/]C<N<2&VA%+/%A2V0XB!YH\&/73M6*G^UCA.>,':]
M$$:'K& 9_='](8>JNFA<):%U_-8%^7()HY%&C)*PNZM[5.'8U/PB8TYS)#05
M9"4;(DNP<G*E8N$"-7VP[W@NDLQ+.9'H%';B;()4%YJ(4.P*AT*X-]U:5)9
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M _56$"%+[_]IP&%\95"=&Q^.")G!*#.N.34.0M>N<XY_Q,WF+GJP&''F*Q3
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M%=5@GEEIE46@I=.-E4WFD+U,TP:C> FF 5\'.:+MA1!WH " (JZP1F%6JJK
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MIX3M-89CM=FW<:.N"8K26_/G%;4X$BBE"V*V$C/KP.X,1EIS,01.*!0NM"8
M:EB)0S;O^(B/#9FSU2)#>1%])BK2B0'J@Y[E"A DIR@[D5V07?*ZA]HW284%
M$T!72PV TV'J12456U@G()+LAH&WB4,QEY,/B!I8^09(@(58+G1H"/L6YOCX
MN&%R/O*R0!WY.A\#\;N&&-0](!X&"YDNQ2&=]^LOT]%H\/GA]N&FUF8=OQM^
M/NIN]8YEII/HRM;F-L75D ,8CKN#P:#%PRW7_N+%(PH>[R\I5$T\'YIX/G(\
MWYCWR-HVQG&/:0Y%/G1,TL&0#X?_T8#(*\#2 I8NJ#QVR(R.6X"W.]IO#8[A
M\$@ >^(5G[2YDA#89CQJ=8+X"Z3UK,!.F&:> )7$.J[LF2*V8/ H;K)D;PH&
MSVW)"04K+Y%2919HI<!\*2E>D)Q7B@@6X[HG5N37<7.7SE0O902RVJ^[U"7I
M4.)92V&082@NB>TK V^H5Y BDW$%K'F#QK$M+:2UD*9")87(\+B#2*/_%VOR
ML$[C]9>[K^O\;28#$O[1>^S576Q;#WF; /FQ.\"6%)3BO)ZO7F'*P1R#6,\:
MSB,FE=XK1'Z)6JHC'@< R()) & >*](M8KDU_(N3TDQ940_9D&LY([K@X+1X
M=:VL/BTZ X#A(J5!! A#;$F4%L7]@-EKCCL7%&'7$^QU!$\<5A5E''^9*.N0
M5V@V=I;K11R-ZX9)TQ&.(<%4>Q[ 6(UG3R!KZMM50T4MX'9YXCG=('\.QL&-
M22/[ZD..6!,%?< 1":5J+XQ 4R!IKN,8*B@^^=B;M!4WP;R\_W*Y4P)=9\N4
M>+E"$3J51Y^)MW9(DCD+:].ECM,P:3K9:I:4_ 4 J=*>^.MZI_9-\U!,$6]\
MYP-8/9N@?"NC5-6O38GS2&J%L4'\1,((J)1#K]"**$>U(3'XOJ)8^I@5*"B@
M*>5+,F22R%Q^!<)>$%_.5%@J%<<;!)TAV/(&  0#:)_%F9T)!1??7>,/' _R
M!1FD(8K-KZ<FKL.&R6Q9=U4OT)OI-U0?#">GK33Q<' ZZ(W;B5L78S/N*;$"
M<#S,I@+\\X/#=R>-EQ&_UY:N-A'3_\6P]PZH7UT93EM U$S C=*$E7+%4ET:
MWQY2H]6UT60>Q=6KG$BW6X<DK\LPQ<U?TTV53%_K6H>54(;I.=ZGD*;03.>;
M$-.4U(R*L=<QC379:"=PU\Q)-NZ_#77K!LZN[KD),6_"ZKIO$^^@K:BTT<90
MB-<,\!['D08[ G@<XD%8SA8T.RGJZ%;P=QGJ\QO_?T.G,HD&F=V:^,F*>T1E
M).9F;#B*$ZO-<Y[81+- #52PQ'9 YXU"W5(8OV&AXOVZ Z(8_';,V7):75L/
M M#)^M:K8^'L3 #=#F94C)M.'X?BOZ-]2=Q](K('/?$O@M#-6]P?,C9L14.:
M/XHSQCVU@%@[&,+%Z..H.YU.^75.-[,#<0C1CY/!T:[O%_W6-Z:"IDOZDD9I
M1$N(GYN:M\W'NLOXC6JS/7[IPVT?PX87N9I#=-#[>-P1+GX]BP_!EOS%:F8#
M*)I_9DH"D;0!ZW.+::E^H .:3Y@7?P!02P,$%     @ T3I=6.>Q WGE!0
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MB4JFJ6[+L&OB3;1E^B<RE\GQ-1Q&T7@\_95+ \UJNS*PQ13J]YQ&/52ZQYT
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;*U8;6_;1A+^*P/5[26
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MEJ+U!KR_-L8=)]Y!]SHO_@%02P,$%     @ T3I=6#7%1)MW P  Q0<  !D
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MS8Y0R$#&V,NY6,K,N(#B["M$E#FG^M5>E)-]<Z%1%@0L+RPXL GTMH(G\EY
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MI?M?_CI0%%](;:A&81I)"Z8S">2)S[.,HOO1Y$U\1=&H@'3NUJ1/2EM]^EY
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M.;]I_JATR3]U0W)4Z3D_SI2$A], ?)]J735_T +AMX]/_P-02P,$%     @
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M6H#W,XNC8WU#"MJOXQ=_ E!+ P04    " #1.EU8"<):H'D%  #V#@  &0
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M_Q4[($W4:E]Z.S0S-:8M<]9_JC:F$I!^4QK 3ZQNWLVH-ZNLRJT!TN"53I'
M<6PJU)5:ZS1EI#-J5CHOR(<4BO("/4IMTT'])A!\;^*02*P(Z -ME;)=B7;9
MBOUUZZ1*FRD&_\26"VXA4$,37?:KR0=9+.57NZW?FWC&J(?D2U[%M ,_<2A-
M&53?*%<)TJ B+F!&V&BPR:<<:5ZW9L'H1Y[=T:(I81;9.@73 $Y*(A\(W[4U
M&$[H##6WRLE$@[*T5VJRP=-A96ZPE2)!8:IMU;2MP$/ U#D=&PN$O>')A2[;
M*4:C8V)D7<?6(O)C"&I#A!ZV_%J9L!IY1<__XIN4J_BF]IJ&D5L],&!R5R*'
M#*]BZLE*!V0+M^, )"O[SM JU65AR-*=3/[_I7%>-!B-1W01#-Q)B(O)(/*B
M^XE;- K$V ._"X-]TA>.1!CY8DB\T!UX$5UXX<"/6+X["$8C(@<98;2\ 1BD
M:J6-PYR*-QH]/VBU>!(X05U)!^*)YXS;.[('3]RFTG))[>RG9ED/;(+37,6&
M34 _(E@M#*;:%3G$^!^W3/M]@<&)CQ:R/P*#2@BD#=LO/S60]\H0J2:M55SR
MYFG1EE+#)(JL$QQF,.B:-H:F;B16UG-/Z0G)X0:;2P)P#0GT*&M2!*O!BB50
M8E%F^;=-R5(EWF(!#O=.34%J@$U);#&CWN(\,4$"@(3C716<Y)AW'DLLZ7P!
M["9>Q5-.J>#1@"1;*NSP=G0+$!(\(MG:7'IL\ES<T%H2,!O38KU2XIA#?")&
MCC\40P<-SNG=ZTM=?#E=Y02P""6!! &<$J'C/05!'./S5/A.%#Q%ASV*Z,YS
M@LG35J59$E/*KS-L5QU3<0HGCOL4^>6$-&?HVCN?[O ;NN,WFA <P;[5U!,P
M._2?W_GNMLY5P:P' *JQUGJEH3]10!NS(^TR\ AU*"2< QQ;@\OY/=Y7W%@8
M5<8Z.AX4GYTYYN5<"V^QY8AA-'C?H1W,EB2J?8EJAECT&$Z[66J3RH8MV7(I
MXT5E\KX=W DMFPCKFEJ,UA%-&_HF['EJ'+MKTC][0*-.=M=G$!*ZB@WRQ:Y$
MEO8(5N_<82L1G12YLLSL(K1"J?FBHQXJ5 @"$1,FDLM,%%DM8%4A'.JYZ5>
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M]I"Y-2K)NZ\ <-5]SUUC\(#/,9" ),M "9T(+C8:")98S*3S%]/"=D[K1,;
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MN P>Z^:D@S&V/(V#-4I/5:F:/MJ4F-0T=7M4PXE^%:A-8T/WP%7IV*(X?]4
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M Y2 -5=!]W(J9%LP+ 2O&,),*"%)@E%($EP+?XR'T?F31!Z8204[&QX+HKK
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M#JU!U&Y*&J5)5DSZY]AEEI;2#96<BT%O0LY^L(^V"'B5N7?>M#FW/]!L]#1
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MY@'^Z0)\3S\\$M[0 O'GL5[\'U!+ P04    " #1.EU86;'#&6<%   N#0
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M-.1X >;GUH;U V^P^40Z^!M02P,$%     @ T3I=6//N4Y(H!@  K0X  !D
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M%3;4\Q8U$]7*H'F_EY32JJ1.9#ZX >H4=!V/O0\^O)2C.ZSO#7>'^ T]_^,
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MH,B) );2&/>ZDK9O<0TQ4I=9[6#K.)>%N<SOR0WO,&@'7]$^=0=WJ#W\M44
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MQX+AG%I6@3+KTE-:5$:;Y2:&..?JVCL_9)\WZ1<.N$NMJO=)BI<8^70GXNB
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M2OA:X/6>+&_ \]R@"K8_^(+^'P:7_P=02P,$%     @ T3I=6'KE&T5D @
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M(J_V9\9E6U/\2]-:]"V1*\H5JF!I*/W1Q)B:;&VO#;2HG1$\"&ULQ2U+\Z4
M:1/,^5((O0UL@?[;D_X!4$L#!!0    ( -$Z75B;G7W0,@4  $48   9
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M0$%O2-.&-.#I!#IAH&C*C+%B82FYYLR&R?3,1%;0?/WRQ5E 3B\4A"++\%#
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M=N:LJ?YIRV[U\]X/>ZHT"]U7W4US_W<C&R( BZ9R]*^ZEW</]U31NZY9RV"
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M&78X#C [ 4MMS9L*:B0]K.3PX>U]=+PIYQ$FW3+P2"PZ=M-IQJ^Q[-@QXD!
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M(RV4N@_X@("M'LB[8XF-@FVF.+L3Y#C20";H;<V5,&PE472CC"%>WIK+U??
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MTLJ2 ,Z/C?'+#AE8O<T'_P)02P,$%     @ T3I=6.>L^8;% @  SP4  !D
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MN*!= .X72MF=X0[H9GCR%U!+ P04    " #1.EU81T&B;O\#  "M"@  &0
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M/1JHM15<XE2#61<%T]LQ"K49>I&W/YCQ56[=03 :E&R%<[2_RJFF7="@9+Q
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M;"]W;W)K<VAE971S+W-H965T,S@N>&ULM5=9;^,X#/XK1.9 "Z2-[1R39MH
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M+1/ZXX":!>@\5LJN7MA!_5=D_"]02P,$%     @ T3I=6( DJQ"! P  1P@
M !D   !X;"]W;W)K<VAE971S+W-H965T,SDN>&ULG59MCQHW$/XKHTT4@;1A
M7WB_ !+D:!.IN2!H&U55/YC=@;7.N][:WN/R[S/VPH;F@%;]PMKS\LPSMF>&
MR4&J1YTA&GC.1:&G7F9,>1<$.LDP9[HC2RQ(LY,J9X:V:A_H4B%+G5,N@C@,
M!T'.>.'-)DZV4K.)K(S@!:X4Z"K/F?JZ0"$/4R_R3H(UWV?&"H+9I&1[W*#Y
MK5PIV@4-2LIS+#27!2C<3;UY=+?H67MG\#O'@SY;@\UD*^6CW7Q,IUYH":'
MQ%@$1I\G?(]"6""B\?<1TVM"6L?S]0G])Y<[Y;)E&M]+\86G)IMZ(P]2W+%*
MF+4\?,!C/GV+ETBAW2\<:MMNWX.DTD;F1V=BD/.B_K+GXSF<.8S"*P[QT2%V
MO.M CN4],VPV4?( REH3FEVX5)TWD>.%O92-4:3EY&=FR_GZX>/#SQMH_?)Y
MLVG#:KF&S8?Y>@FM7]E6H&Y/ D-QK'60'#$7-69\!3.*X9,L3*9A6:28_A,@
M(((-R_C$<A'?1+S'I /=R(<XC+LW\+I-UEV'U[V6-5,%+_8:5JA@DS&%\.=\
MJXVB1_+7I81KN-YE.%LX=[ID"4X]J@R-Z@F]V9M7T2!\=X-LKR';NX4^VU A
MII5 D#O $_&2B&M+_!+;VWA-\BTAM6Y_AP*J<3 9PE<*HP'MY0$=/>9;,CD=
MO_N-?6!%:E<16,^$B:02S)"#!:$ZX8FS2+FHK!2O!F6:7 0U!WT'"^=W?_1I
M\8+HR$H3D/8!GQ,LS;EG+JO"$-@?CN_R)=^K"IN(RZ-.X8?M S5#7B0RQQ-=
M]L2XL/4 1@(I<FHHCD0F18H4XS5$0S_J]VC1ZHW]?ARUW3+VA^-N^]_4S94P
M.HC$'2/%*9DR/.$E,Z0#C4FEN.%(9QCY@^&X#6]>C>(H?M=\K7S0?2G_?_GT
M_=ZP?ST?4H^C*^KZ'K^XEHCIV_D3*NKP=:5I^%P9;>A.;5;1R _#"**!'P]"
MB&*_/QY<%KI701T<<+>CEFZK@;IC\@BRM/V='LARLUK5[Y+>B)M718)'HZK@
M1D,T[KXXG--K^X]LHW'O!V+7Z^DUA)W1P!Y,MQ/VV_6B%[9K1?^EXE*W",Z:
M>XYJ[T:8IDNCMU_W^4;:3,EY/1R^F]<C]A-3>UYH$+@CU[ SI*&DZK%5;XPL
MW:C82D.#QRTSFO2HK 'I=U*:T\8&:/X[S+X!4$L#!!0    ( -$Z75C5A#?H
MI08  %82   9    >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;,U8;6_;-A#^
M*P<W*1) D452;TZ3 $Z:;L70QHC3%,.P#XQ$VT+TXHETW.S7[XZR92=QU X#
MMGV1*8EW]_#N>8ZT3I95?:]G2AGX5N2E/NW-C)D?]_LZF:E":K>:JQ+?3*JZ
MD 9OZVE?SVLE4VM4Y'WN>6&_D%G9.SNQST;UV4FU,'E6JE$->E$4LGX\5WFU
M/.VQWOK!=3:=&7K0/SN9RZD:*_-E/JKQKM]Z2;-"E3JK2JC5Y+0W9,?G,<VW
M$VXSM=1;8Z"5W%75/=U\3$]['@%2N4H,>9#X\Z N5)Z3(X3QQ\IGKPU)AMOC
MM?</=NVXECNIU465?\U2,SOMQ3U(U40N<G-=+7]6J_4$Y"^I<FVOL&SF!GX/
MDH4V5;$R1@1%5C:_\MLJ#UL&L?>* 5\9<(N["611OI=&GIW4U1)JFHW>:&"7
M:JT17%924<:FQK<9VIFS\<W5Q2]'Y\/QY7NXN/HTNOP\'MY\O/H,!S?R+E?Z
M\*1O, Q-[B<KE^>-2_Z*2\;A4U6:F8;+,E7I4P=]Q->"Y&N0Y[S3XWN5N""8
M ]SCHL.?:!<MK#_QVJ)GLE9'YUC,%$;R$3EF8%C7LIPJ._YM>*=-C83Y?=?J
M&]_^;M\DHF,]EXDZ[:%*M*H?5._L[1L6>N\ZD/LM<K_+^]FXT0Y4$Y!Y7B72
MX!+4-Y2H5KNP=GN[F2F85.AGF953,%3PE3JS/Q66;SP:K9U#5B:+NL9H"RQJ
M#09-N<="N"SF>?6H%(Q-E=S#:%$G,TPLC'*)FBM3,LP7R ,<6*ND*G659ZF%
MK@W^4,XU+0E;32U)K/H8#NST:J'1ASZ$7Y6L5X0"I(,J[A#$FA)TX71A,$9]
MXV(<F*H2G>6.Q2!3E$Y&-:4> 'L@0@^O'*WV(([@HM*& &B)E =\%WC  KC&
M^DE<C_61J@=L87-+$#\"GP&&VP,_C,@?$WAE".4[.=64I:,[2[VD*BBW=L4O
M\XP-MYF-:;$Y<; )XA*RI$D<O9%+6:?X O-F^W.9J)7O%U,7969TDXV/9;I(
M&J;_A*3'W/]OZ\1B)XQ"&@C'&_@X&#@QBU^O3!P*B!@6T!?/J^J'X,<< BJ\
MY["8!LQW>&S]>XX(PPZ%!JU"@TY-W<I\T514:JQ[4[I=TNQV@UN.39E-'&^R
M0XES;&TF,JOA 2,I6I^2F(B&)#"E@L)2:D "9(4MWD);*J+=>2Z1?>-D5E%&
M&I.C.?*$)A15JK .F]D;&F\MY?B'2WR)C+8$7$'+LXF"@T>R/H30Y0$$+NKL
MZ.7X.M/W1Y-:D1J,(BH#,D*![[)]8&Z$UR/@;BSVP7/#F.Z8*P;[FY -YVEE
M"AZJ' N29^81_('K[2,+7)]L F]UQ^D.WP7[\#Y[R%*%R7[,5)["VS<Q9_S=
M\]\.GH0M3\(?[>3;*K>%?JES.KO@ G;QJ#/,[NUHN#Z#O8R^"O2DRV-!VV[^
MLG>DBWI-&%M;4+N9\9S)D&FPD$I:YQT=#Y]U$P>;8J+FAMH;:-JSK?%5 _6K
M/7"AZ0<2PZT50_ML.)W6:DJ<N5H8;%YE2AB?8_)@($C\1 @?(I?ZN8AXLS+T
MPL(8A'"] 36( 'F'!%-UDE&#/?#Y(?B>I6[  ?4Z41D9';#!(00#-_:)CAFU
M\H,@P$?(\$$G' :#."8X.#-$)1"TT(FP/ZT!(5KANP'M6BQTL9EMX>'B$ 0R
M6B!4L8W'C_!%Z [8!@\]0CQ>] 2/-"\@<1AX40,)][S 0A).C'EI(>%.2&NE
MW=1E3Q"Q&#/A^Y0_[L38O;= <79(J?6##2C&+"C<=[\#2D 8#^S6ZWH!-@4:
MQXZ(O'5PN^GN- QBKZEW1(:T P2XGP30(>BH%734*>CKOR/:;E=/]'D]'NZ2
MI57DOZX]>W+6&YUM!/> N_A4P9?R ?. #W:DWP-AJ8OI9S[V[Z@E48"G*1(:
MA]O&^H!QE Q.%$^D%3+[$(^=77$81):T2'J,A_M$&R?R4= 8.&SC<#]HU#%X
M$@>)*V+7BSOC<& .\VW3$"ZJE+L;I8:1#[YPA==&$C$)U*<FL!4I9C82GEBZ
M(J&F'1'82#@73YZNW\'8N&5LW$FST>;4V)18=W*VV]D3SH[&7_XQ9]=DY?\-
M67F[Y^^]. 6LBXQ'R*;YK6K\?-[VIG"XFMI=9MM(FXG<]7;5N+_U7[]0]=1^
MT=!X6E^4IOG;WSYM/YH,FV\%F^G-%Y=/LIYFI89<3=#4PY[8@[KYBM'<F&IN
MOQS<5<94A1W.E,1JT@1\/ZDJL[ZA .VGI+._ %!+ P04    " #1.EU8#S)K
MGB@&  "Z#@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R-5VUOVS80
M_BN$EQ8VH-JB7JTT,9"D*59@?4&2=@.&?: E.A8BB1Y)Q\E^_9ZC9,5I'2.
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M'Z<8];J]*;5_K%JYV\E<6=QUW.,2ETNIB0#O%TK9[1\2T%]79_\#4$L#!!0
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M>A]E55<[XS?BM:GNK)5E*7Q%YZX RY+Z0;!O3Q_[?C$<QI?PQ"5*##\+58>
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MDZ0!+MD[:4XKT()$5Q<IJ0A'!5R!I548Y]((N@_/R.3VGH%N"?,E2GM3Y[P
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M&3SG-27PGVYA2'Z$_L'YZ<7-^Q/W$AR,W#YH*92ZZE51!]13U>*%0;?HK/U
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MRW2#J7_:X-+GD_28QM*#YAD*VOY=-Z-.I^81)?/X.83:@A3:/@:E.2A:=7>
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M$$S>3:6?&"_G7^:+SW.TG,_N_ES<?+JY6Z#)@LCQ[>33G*#)[>W=U\EB-G]
MOZ,9+6(H!(OT(WM'0$1IQM^K.SI28"V39<J?AJZ0<:K5W+B,:7J,R3\3$_;1
M1UJ(A*-YL8)5$\"5"599^L]93OU.1 +Q!0KP;\CW_, 0T.SE[K[!G;S<'7=D
M$U3/+-!XX1F\21S372$X6D(,Z3YZS #]BS[0':N> S>QWHFJ#IAKOHUB&#GR
M!.' ]N",?_T%][P_3(S9!".6P!ILAA6;H48/SK#Y_QV+_KZ5-NA&0,Z_F8@,
M;1)I$XQ8 FL0>5D1>=FY+9M$,D7D%IB:DB\0$XU'..QI//6"VH^]BP'V3O^D
M7O:G;'6&\%JV+($UV.I5;/4ZV5K"'HH=H#6CN3HU)6^QD(>_2.K#= I%G,C7
M\9.4=S6)351VKO7:'6D3C%@":W#<KSCNVY9VWR:1-L&(); &D8.*R(%=:0],
MT@[:8C9:^;VF%3%;7556C8RNJHRN?H[\3.__:>=:K]TU-L&(); &Q]BKBTO/
MM@!+1$M<6D4CMM":;)Z4ZMBN"DN\EG1PT)+A&;-!2X=F,S\P"Q'[=5K^SY&B
MJ9*?=B_VZOUC$XW80FL277\VX,"Z&JU^,UA%([;0FFS6GPVXLYA^@QK#EZG1
M;';95J/9K'=&C741C[NK^#>K,33F;+->GUE%([;0FD37]3_N65>CU3+?*AJQ
MA=9DLZ[T<6?]^P8U]HWZ\=MJ-)IY[1K5:-:2HGO2I9."V>AN)T>ZEW-L956S
M54=UHON(K?FIZK3J[E\-<VS3?HS8)BTXRF M(;V+OMSB[-CY/ X$W>I>X",5
M4K7Z,H%H!4P9R/MK2L7S0"U0]9_'_P%02P,$%     @ T3I=6#G'-ML("@
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M-DT>=W?!N27>/7;!;3+Y39;)F/+;)LS"(KZT[.1U1?':*46\_9JM^5Q<]F1
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MZ)+_P^<OQ?W'6YZ^B)P_'@_5T)0>*"V TBB4QE T_:)0II&+2>EQH2D]4%H
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MU=G0ZWLHA2TIF7X6A\]0U^,,)H(I]T6'*K=KDI-2:9'78.,@I[SZD[=Z'TX
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M]/?S+%,O V6#S=MO)O\!4$L#!!0    ( -$Z75C%@)TV%P,  /(+   9
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M-[@TU-5\$4M$_@M61:QG&R!:",G2$JP4I(06_^BE7(@- .SL -@EP-X7X)0
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M%8GZYJ@GBI?VM*ZYTF??#C-]V8(P!7I_P[DZ3,P%T%[?\1]02P,$%     @
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M%L9!G\\Y5]N-"5"_I_%?4$L#!!0    ( -$Z75ADY![G$@L  $J1   9
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MQ^3Z7F6Q:HTKM%Z":A2J!5"-034.U014DRC-/**]Z:K< 68"X4)K*JA&H5H
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M@*';R*&:@&H2I9G9;'H[U][;_9^?NT'+/*A&W?USP/:"N+^(TSI_A79O4$U
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M:[706;5 ^?N[-"U>;U0K>$JSA\UFS_X'4$L#!!0    ( -$Z75BV)"1S,@8
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MQR"& PH#3Y,5[-&A1$L&,L@I!NGN >R+.H,)[J.G^SFQ;Q',RU-2R@&G:1E
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M5 M13:%:A&HQJFE*,]/9%*S&]H+5S_O5I[1P\L\=UZD>CIW.'T^^>%E]K3/
M:/T*U7Q4$^..PM2WQ]'V(J-O+Q6C;:J.#7KF!A6ZP0C58E33E&9FJJE(C>T5
MJ>/7?__"_8WMV^X=,[0UA6H"U22J!:@6HII"M0C58E33E&;D?-)TJR:#E[W
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MI9E_ )JFUW3RPL-RM"F&:CZJ"523J!:@6HAJ"M4B5(M135.:F?6F3C:UU\G
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MR_@HN7I+E)\<W8QO9^AY?/=TC<[0':P@1CXZF8+$)!:GZ LB%'V-6"8P#<7
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M=FV@WB\8DYN!_D#YCX71OU!+ P04    " #1.EU8/K7N1^\#   .&   &0
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MJ, Q(+F8N\*6PX<97*7)_<1QAR-S?QR-MHT-[;J-W[:!J+*IK7U0KGWP/S)
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M:))=;@@."5,&\OF*4O%VHR8H^Z23_P!02P,$%     @ T3I=6)>(-F.A P
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M!J8FR/$UI>*]H1:H/KC,_P502P,$%     @ T3I=6(>9$MM@!@  AR<  !D
M  !X;"]W;W)K<VAE971S+W-H965T-S8N>&ULM5K;;MLX$/T5PELL4J"11.IB
M.>L82"RU6RS:!''2/BLV;0O5Q4O1<?/WJYMUH6A:%K@OB42?.>2<$<D9B=-#
M3'XE6XPI^!T&47([VE*ZNU'59+G%H9<H\0Y'Z2_KF(0>36_)1DUV!'NKW"@,
M5*1IEAIZ?C2:3?.V1S*;QGL:^!%^)"#9AZ%'WN]Q$!]N1W!T;'CR-UN:-:BS
MZ<[;X 6F+[M'DMZI%<O*#W&4^'$$"%[?CN[@C8OLS"!'_/#Q(6E<@\R5USC^
ME=U\7=V.M&Q$.,!+FE%XZ;\W/,=!D#&EX_BW)!U5?6:&S>LC^^?<^=295R_!
M\SCXZ:_H]G9DC\ *K[U]0)_BP]^X=,C,^)9QD.1_P:'$:B.PW"<T#DOC= 2A
M'Q7_O=^E$ T#9)TP0*4!8@V,$P9Z::#W-3!* X,UT$\8F*5![KI:^)X+YWC4
MFTU)?  D0Z=LV46N?FZ=ZN5'V8.RH"3]U4_MZ&SQ_##_Y_K^;N$Z8/[P[=']
MOKA[_OKP'5R#!8V7OT"\JP/JTW=PY6#J^4'RL4(\%(AK\+)PP-6'C^ #4$&R
M]0A.@!^!E\BGR:=&P_,VWB=>M$H;/[3NIRI-/<K&I2[+T=\7HT<G1@\1^!9'
M=)L -UKA59M 3:6H]$!'/>Z1D-'!2P7H\!- &M(Y YKW-T<<<Z>_.>28N_W-
M-8$8>O5PZ#F??H*OC.PB#QTO.H6YP3?/UKB;9.<M\>TH7<023-[P:/;G']#2
M_N(I*Y/,D4GF2B)KQ<"H8F"(V&</>YK0=';XT09X%- M!J]XXT=1UA"O\X8=
M)GZ\ E?I9"JFV4=>L(I^K+R?;/]XFTVT\51]:\: @['M-L;A8'2KC7&%/@U4
MS*P4,X6*?2%>1/%9.<R.&SHC!@?!^.ET(=!B]'*%HQVHA55I80FU<']CLO23
M\VI8'4>NH3UA!.& $".:P\$8B%%$..:!BHPK1<9"1=+T8HW]'L_'F.,L9 3A
M8 QF2CD<#&2$=85#'BB(70EBGWE$=CXY+X?-<8.5@X/IR,'!F"8CAW#  ^68
M5'),+EUO<;2Z;*6=='RT.G.IB^FLQ@X'PZ[&+@?36*5:$D"M3@JU/LN&]QK@
MP2*4731'9MH:HX)X')=N^E+97%EL[1@T$G,H3+Y^YC5..C'OWC!):S9P7,O!
M(_&7F"LYE)F/265SI+*YLMC:L4%U;)#,I&P5!X%'DJRIF#'\"5/T.6E,&,-4
MV 5TSH>9;&;"@]F*83#+A]C1H4+6!084YLZM7*VG2@4AA$W'H&(;K$P<G&XH
M)F)UXN%T16.W:+$C0X6JJP H+@/:B5Q/J0R.5$;'M3D/IVN*QJ9V7#Y-0>SV
M+79EJ%1U^@_%^7\[P^LIE<E]"@R3E8J'LY0)9*7BX,Q)YREUQ:X,E:JN#N"Y
M\J#._7H*97$<,Q78$8J/ZZ0X)W!F9_K]'S4#K(L&**X:>F>%/54<<V:2I6@=
M%7FX[I[@G,"QFX);XDYO"FUYZA("GJLA>N:+/>6Q.>[8RK@CCZ1"H111)ILK
MBZT=D;J*@1-A]OC9\PGXX05[?J(HK($N3A1ELCE2V5Q9;.V7R74AA<2%U.7Y
M34G8G*((*9!)6^8<&+04F\UN>#!3&3/;E2OV8JA*=:F#+BQUGG#VC2M;;)\Q
M"<'5.TZ%X\LEM>21RN9(97-EL;5C5)<\Z.*2I[O$'XZ!],I DBJ0- TD-X#B
M;@V0QQY #83%EQYD@)7WSOL<,3_#999<XR.5=8K).<-D]69RSS"-C_X53%RB
M=L3JV@J):ZM>F_*0B(F[/4;,*K7A!DKJMQZI;*XLMG;4ZD(/&<*U\&ZS(7CC
M40R^1I3X4>(O3^_C2%*E549%)ILCE<V5Q=:.2EU3(G%-><$+'[\*VUL6MN;6
MS]_!BI['S8K29C\BS3DH:VRS+WUX7&/VZXO8U:%2UC4GZOM)ZN2B=+&$W8].
MR)ZP;X0X*&BR[S@X()-]9^2*/1RJ8%V,(@G%Z,4:=K]3V?J8?5]?HL0/J\-!
M=1]6E\?5>%C;XM2E*))0BEXLCMT9JFEWWGF(1W;Q^BFU')7%5D1%;1PX"C'9
MY">]$K",]Q$MSMI4K=5ILKO\#!73?@]OW.),6$U3'%'[YI%T?4U @-<II986
M_R- BE-?Q0V-=_FQIM>8TCC,+[?86V&2 =+?UW%,CS=9!]79N]E_4$L#!!0
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M9H%^O^ ZJ8N!<5#V]^-_ 5!+ P04    " #1.EU8?ORA4\T#  "/#@  &0
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M!MN>.SQ9M3AJ.\X@1+-S4\] K*J.IT 1W^:ROO6VLVU7=5_U$H/YA[+;JCJ
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MB2HE;VY$34.R?7VI6#.IKBCUXT[=(C'7!NK[AC'YU-#WE/9>.O\/4$L#!!0
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MPO#8"J.ZPNC8"A=UA8N="N?TT('35D=..W;'TO7!/OIHT]7AIGO'^^ [:G7
M:77$N\OW8O5&-IA@-U=Y]D;RLKSTRE^J:*CJR_=OE):!^R1R^6HDZXF;^R]A
MZ'X+S8=O3^3VP2#W7QZ^N0^V^7#OFD_D-_+ \IR5L44^&5RP*"X^DU](E))O
MLVQ1L'127'6%[$>I=<=UF^:R3?U FY2$62IF!3'3"9^TU'?4]?6/ZKOJ^OV/
MZGL?]%_5@:X\ .NCH*^.PIVN%"W^?$;H^:]$UW2=?'\RR*=?/K=T[%[->(OX
MC&BCBJ%D'+,H:4$,-6+PL41Z%:*1N412$4VG;8?Y"*A'*ZBW[ V9Y]ED,19$
MGGC*MU7Z$G YZK;8EMI^XG-I:_4..[2EMAJY7;RL.W@8<1 ]<8_955J]SP\A
MWBG[NWX3'=CC!]OPCV]#]48-CF>H@@F/9F1,)BQ=3.5$8)'S7!&3O?7(V*OP
MW@'\RVJ'D6J/3<AM47!1D/\$LB!Q!4^*_[9T^6ZI]MO5<AYV6<S9F%]WY$2K
MX/DK[]S\\Q]TH/VK+=Z1F('$3"1F(3$;B3E(S$5B'A+SD5B Q$(0UA@"^NLA
MH*_2;QX6R3//23;=C)XD+@>#@OSU\2GL3HF?.A(@,0.)F4ML4&'E.O'UAO:O
MNJ_;\8ULST9B#A)SD9CW\6[UD>T%2"P$88VH/5]'[;DR:K\T8_57\E:MWN49
MG+W*5UXXR7GYD<:Z!!$\;YL+W2G;.36 D9B!Q$SU[NR1=\[R@E"-),M5C]XG
M$_;>MO"SD/VRD9B#Q%PDYN%VOZ^F])H:KJ3!(2A ;F (PAJ#P6 ]& Q.&0Q(
M'+'G*([$.YE$Q3A;I(+(U^4)_5.4$EEVS%/1MA*Y4S9SZEB Q PD9BXQVMLZ
M[6AGVHC2B^U_.Z=W9 ]L).8@,1>)>7]G1_OME7J[Y0)D3T,0U@C?X3I\AT?.
MP.O/,0JYS,]_\/)L_M?JN;9P5;*GABL2,Y"8.=R;)/9V8A/9G(W$'"3F(C'O
MP[WJ(YL+D%@(PAK1.EI'ZT@=K5R0K_R5IPO>-JNX4]8^-2B1F('$3"1F(3$;
MB3E(S$5BWA(;;L5O?S08T<%.$.\7Z]%!;W2^<S+=+Z;3 >WM:"%H"QJ!=[$.
MO(MC3Y.KZS7E1U2JBS=W2O'48$1BQL7>\+NSKTUD<Q82LY&8@\1<).8A,1^)
M!4@L!&&-F*;:YM*\=FQ49T*N2R,6-RYRE2%^^*+7,LK539P:YE#-@&HF5+.@
MF@W5'*CF0C4/JOE0+8!J8:UMGZ:&Z]-4,^*WDG'HD1$_SI+EV;L@TRBN5KN'
M+MG?J=&38YSN7W@X'S5/P :T2;.E25W3=A:R;86:1>R6(CLS!Z>ER+!9Q&TI
MLC,E]*";[T.U *J%**T9$/HF('1E0-S^;Y&7']8^SEB>R&86(AJSN'5QJ99.
MC@*D9D U$ZI94,V&:@Y4<Z&:!]5\J!9 M1"E-<> 31X6_3F)6!2:B075#*AF
M0C4+JME0S8%J+E3SH)H/U0*H%J*TYH"PR<JBZK2L)RY$S!.Y(B8LJ2[ALC>6
M3^3((#*2B9F<0<]9+MY;!X7^WJ=Y]&)WKGFO[L#)P0Y-MX)J%E2SH9H#U5RH
MYD$U'ZH%4"U$:<U@WR1S4772RM?LG<4BX@7)4C)=E!]TD8+%9<8&*PA3YFS4
M=+E2W[I>KN\&.S0S"ZJ94,V":C94<Z":"]4\J.9#M0"JA2BM&>R;9"VJSM9Z
MR%XC$2W:/^6"9F!!-0.JF5#-@FHV5'.@F@O5/*CF0[4 JH4HK1GTFQ0O.OPY
MZWMHCA=4,Z":"=4LJ&9#-0>JN5#-@VH^5 N@6HC2F@/")HN,?I!&]O>N@D&S
MRZ": =7,6FM<"1OM7BV#YHU!-0>JN5#-@VH^5 N@6HC2FD&^R5BCQZ:LE3>A
MV8[T3TDFU_ABQM+/RGB')K!!-0.JF70_(6ZX?WD<FL8&U1RHYD(U[YB=ZT.;
M#*!:B-*:-R[9)*GIZB2U[RF;S_/L59Z<'^L_T6B+5K5R:K1"-0.JF5#-@FHV
M5'.@F@O5/*CF0[4 JH4HK1G_FY0UG?Z4U;L.35J#:@94,Z&:!=5LJ.9 -1>J
M>5#-AVH!5 M16G- V*3LZ>J4O8_^"$Q=_>3 A^;I0343JEE0S89J#E1SH9I7
M:XV_W]+[>U/\NECS?BM[6<A!6['!7K$0M0G-&-RDS.G*#)RV2;E<2M]GJ<C9
M6)#[ZLZ2[7\PHI9/#D]HUAQ4,Z&:!=5LJ.9 -1>J>5#-AVH!5 M16G-,V&3-
MZ?V?,U%'9A/=0S4#JIE0S8)J-E1SH)H+U3RHYD.U *J%**TY(&PRZW1U9MV'
M$W7H[<^@F@'53*AF034;JCE0S85J7JVI4[/]EE+Z8'^:WE)J;\X?HOJ_#,#N
MUEW8Y>3ZI?HZ@H)4-QE;WG9X_>SZ*P]NJQN_[SQOTDN;MCSOT<MP^84&&W[Y
M_0HARU^BM" QG\JFM+.AW+!\^94%RP<BFU?W@'_.A)SY5[_..)OPO"P@7Y]F
MF5@]*!M8?W'$S?\!4$L#!!0    ( -$Z75A=6G61X (  #@(   9    >&PO
M=V]R:W-H965T<R]S:&5E=#@T+GAM;*U676_:,!3]*U963:VT-2$)H>L@$A"V
M(0U:%=H]3'LPR8583>S4-M#]^]E)R&@(M ]](?ZXY_B>X^1>NEO&'T4,(-%S
MFE#1,V(ILVO3%&$,*1:7+ .J=I:,IUBJ*5^9(N. HQR4)J9M69Z98D(-OYNO
MW7*_R]8R(11N.1+K-,7\[P 2MNT9+6.W<$=6L=0+IM_-\ IF(.^S6ZYF9L42
MD12H((PB#LN>T6]=!YZ.SP,>"&S%WAAI)0O&'O5D'/4,2R<$"812,V#UV, 0
MDD03J32>2DZC.E(#]\<[]F^Y=J5E@04,6?*+1#+N&5<&BF")UXF\8]L?4.II
M:[Z0)2+_1=LRUC)0N!:2I25899 26CSQ<^G#'J#E'0'8)<"N ]PC *<$.&\%
MN"7 S9TII.0^!%ABO\O9%G$=K=CT(#<S1ROYA.IKGTFN=HG"27]X,YF,YY/1
M=#Y#_6F AC?3^7CZ?30=CD<S]!G]!&6J0/"LWC,!Z#P B4DB+M36_2Q YV<7
MZ P1BN8Q6PM,(]$UI4I+DYMAF<*@2,$^DD++1A-&92S0B$80O20PE9Y*E+T3
M-;!/,@807B*G]0G9ENTT)#1\.]QN@ =OA[=.J'&J*W)R/N?8%;$T)5)]:E(@
MY3 :*K,(70$-B;J9@(@P86+- ?WN+X3DZDOZTW0)Q2%N\R&ZNER+#(?0,U3Y
M$, W8/@?/[0\ZVN3@>])%KP3V0MSW<I<]Q2[?Y,!Q]I.E.@W'85,R,9WN*#I
MY#2ZEFY\VW+4]6[V;3D,ZEBUF*"!R+6JF!<BVI6(]DD1#Y@3O$C@-0T%B[=_
MM%V7T!#C>#4)AS'N5;,"KU+@G50P9Q(GKZ7O'3IGM^U:_H=!7YQ.+?\&HJNZ
M '.OIJ; 5WEO$BJY-95%):I6J_;7SZM^;7V@VF+1Q?[3%#UU@OF*4*%D+Q6E
M==E1OO*B3Q43R;*\<B^85'T@'\:JM0/7 6I_R9C<3?0!U9\%_Q]02P,$%
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M=AC6=>CHU&&S53=U2!>3_"]-NB#)3LV[%AV5N+KDGYR*S GS"8L-85(W(-6
MX*:K>:(XM!4#Q7?VH+3B2A^[[.56'W1!F!?T\Y1S]38P9Z_JZ#SZ#U!+ P04
M    " #1.EU8S6QTP-T"  !W"   &0   'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6RU5FMOVC 4_2M65DV=U#8/TM!V$ D(+4A]("C;9S>Y$*N)S6P'NG\_
M.PDIT,"8U'U)_+CG^)Y[;5^W5HR_BAA HK<TH:)MQ%(N;DQ3A#&D6%RP!5 U
M,V,\Q5)U^=P4"PXXRD%I8CJ6Y9DI)M3P6_G8B/LMELF$4!AQ)+(TQ?QW%Q*V
M:ANVL1X8DWDL]8#IMQ9X#A.0T\6(JYY9L40D!2H(HXC#K&UT[)O T_:YP0\"
M*['11EK)"V.ONC.,VH:E'8($0JD9L/HMH0=)HHF4&[]*3J-:4@,WVVOVVUR[
MTO*"!?18\I-$,FX;5P:*8(:S1([9:@"EGDO-%[)$Y%^T*FR;RCC,A&1I"58>
MI(06?_Q6QF$#8'M[ $X)<'8![AY HP0TC@6X)<#-(U-(R>,08(G]%F<KQ+6U
M8M.-/)@Y6LDG5*=](KF:)0HG_=%T/+P=]@/4>QH_CY]&@^$CNNO?H]&X?W[?
MF3[V!J@WZ(SO^A-T&H#$)!'?T#F:3@)T>O(-G2!"T7/,,H%I)%JF5"YI8C,L
ME^\6RSM[EK<=],"HC 7JTPBB;0)3::D$.6M!7><@8P#A!6K89\BQG$:-0[WC
MX4X-/#@>;A]0TZC2T\CYW'WIR3B9$8A0CW')V2)6X;Z#!*DC?I[@C(8Q"F/,
MYU ;^X*[F7/K\[_TK9:YW S&7RV"CQ;-JW>;+5%N)<H]*&JB3CFA\S,T!PH<
M)V=(;1Z$([6]B9 <ZYN@3D[!ZFVX8GNV=]W<T51CYKB6Z^X(<S\(NW*=:[=>
MVF4E[?*@M.TTU8DXB->7_(U8X!#:ADJQ +X$P__ZQ?:L[W5[^3/)@D\BVXJ;
M5\7-^R];PON01-NUK-U=?I15<-##?]5O;ES)*:@#JDN;0"'+J"PNLVJTJIZ=
MO&CLC'=552V*X#M-49(?U+DG5* $9HK2NFBJ!/*BS!4=R1;YQ?_"I"HC>3-6
M+P/@VD#-SQB3ZXY>H'IK^'\ 4$L#!!0    ( -$Z75A_?JS4<@D  )QX   9
M    >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;+7=;6_:2@(%X+\R8J]6O=+>
M #8OH9M$2O#,>*0D%Y7<7:U6^V$"D^ MMJEM2'/5'[]^"V:"F>+LH1\:2#R/
M37,*$TX\OG@)HZ_Q0JF$?/>707S96B3)ZG.['<\6RI?Q6;A20?J5IS#R99+>
MC9[;\2I2<IX/\I=MJ],9M'WI!:VKB_QSD^CJ(EPG2R]0DXC$:]^7T>N-6H8O
MEZUNZ^T37[SG19)]HGUUL9+/:JJ2/U:3*+W7WBISSU=![(4!B=339>NZ^UGT
M[&Q OL4_//42[]PFV4-Y#,.OV1TQOVQULB-22S5+,D*F'S9JK);+3$J/XUN)
MMK;[S ;NWG[36?[@TP?S*&,U#I?_].;)XK)UWB)S]237R^1+^.*J\@'U,V\6
M+N/\;_)2;#M,]SA;QTGHEX/3^[X7%!_E]_(?8F> 91T88)4#K&,'V.4 ^]@!
MO7) []V 7N? @'XYH'_L@$$Y8/!N@'UHP+ <,#SV,9R7 \[?#Q@=&# J!XSR
M.!3?O_R;[\A$7EU$X0N)LJU3+;N1)R@?G7[/O2 +^S2)TJ]ZZ;CDZ@N]O7Z@
M#IE<?WGX%WGX<GT_O1X_B-_OI^0W<B^C2&9A))\<E4AO&?]ZT4[2O69CV[-R
M#[S8@W5@#UV+W(5!LH@)#>9JK@/M]'"WQVR]'?.-9129>CPCUNAOQ.I8/?+'
MU"&??JD[L/$QC/53QC$SCIJ=D6[!V :&FIG[<),RQ8/JOC'D%](F\4)&*BX_
MU,#,#-_)Z(QTSC\ \R,>N-W5'SAY"M?IMSFJX=SC.<OP[RB.9ZJ'6_<8M>S9
MV_\O=L[;A_Z_J*5,U)Q,9)2\DH=(!K$LGK;_?9MN2D2B_/@_-8=]4[B]>C=[
M3?L<K^1,7;;2%ZU811O5NOKK7[J#SM_KDHW$'"1&D1A#8AR)N4A,@# MT+UM
MH'LF_4K$\5H&,T7")S)5D9<^(5R3<1AL5)1XCTM%)NGL0T51FOEI$LZ^DJ<H
M],F=^O-/&62!I]_67O):%WCC?IL&'HDY2(PB,8;$.!)SD9@HL&&.9=/QS975
M.^]WTC\7[4U-F/O;,/>-8;Y?^X\JRJ*LOJO9.I^ZE"](,?EA>&VZ,;I-PXK$
M'"1&D1A#8KS !KN1V&:A2"!R=P*$:2D=;%,Z,*;462N2A.F/BL548I5.);S:
M"=B-T6F:2B3F(#&*Q!@2XX.])RI[,#BW=Y^HBG#N;VB-[$Y_;T,!.CPM>,-M
M\(;&X$WDJZ^")";I='66_DSF!<_IW>QF[*7/BS*;Q];%T*@VC2$2<Y 816(,
MB?'AWI-CU\I?+M_'<+@7P_?Y,VVAA>I\&ZIS\VMNN/$2;^W7!<<XLFEPD)B#
MQ"@28TB,(S$7B0D0ID5VM(WLZ$0_Q(^0@49B#A*C2(PA,8[$7"0F0)@6Z&ZG
M>ANW<Y*7=C/;--%0S2FUX4]?]BATOPRJ<:CF0C6!TO30[G0/W:.F#NF/YM/U
M8ZR^K;/,TDWZ=VU6C5KCK"(U!ZI1J,:@&H=J+E03*$W/LU7EV3K1O**$4=%&
M:@Y4HU"-034.U5RH)E":'NVJ]NH:2XB/SR^@M5>I_7Q&X$#W2Z$:@VH<JKE0
M3: T/;15M=4U=UOZ\_$/LC/?N(O.R'0A W_]+'TB@SFA\7]E;8]EWDGC"$.;
M+*A&H1J#:ARJN5!-H#0]YE7IU>V?:MH!K;V@F@/5*%1C4(U#-1>J"92F1[MJ
MRKKFJNS#TPYH<P;5G%+;?3=_,*Q]5P/:BT$U#M5<J"90FI[9JF3KFENVYK..
M8]__@/9P4,V!:A2J,:C&H9H+U01*TY-?-8'=\U--1*!-(51SH!J%:@RJ<:CF
M0C6!TO1H5XUAU]C??'PB,MI[QZ+VQ7YLWG_CS$+K0*C&H!J':BY4$RA-/TNB
MZ@0M<R=HF(B,%W+ID4D4KE3^RV?D]G9<%U_S'IH^+T,U!ZI1J,:@&H=J+E03
M*$W/>%4A6MT333DL:)L(U1RH1J$:@VH<JKE03: T/=I5FV@9*YT/3SG,;.-@
M0[O$4M,*G%'=>Q_0W3*HQJ&:"]4$2M,S6]6$EKDF;#CE./*-#_-.&R<:>O(<
M5*-0C4$U#M5<J"90FA[[JFBT>J>:A4#+1:CF0#4*U1A4XU#-A6H"I>G1KLI%
MRWQ*W8=G(?WC7NG'YOTWSBRT-81J#*IQJ.9"-8'2],Q6K:%E;@W?ST*F,R]9
MQV2RD)$OL[.<-]ZL_H0[,]SXZ1C:&T(U"M485.-0S85J J7IT:[*16MXJID&
MM#V$:@Y4HU"-034.U5RH)E":'NVJ/;3,)Q(>?UJT&6H<96A;"-4H5&-0C9?:
M[N^QU#5;+G2O J7I(:UZ0,O< ^Y-+:9OTXI##0KTE$&HYD U"M485.-0S85J
M J7IZUE5+:'=.=&,PH:6@U#-@6H4JC&HQJ&:"]4$2M.C796#MOG\PN-G%&:H
M<92A92!4HU"-035>:MIOQM;-**![%2A-#VE5\]GFFF^O,EE'\I6,%\KW9G))
M)I&W2;].;CW?2]XOGUF&%UKX034'JE&HQJ :AVHN5!,H38_XSIJ9)ULT$[MJ
M)G;93.RZF=B%,[$K9V*7SL2NG7F*YL^NFC_;6+\TF6) FSZHYD U"M485..E
M9E@ARX7N4* T/9]5?6>;ZSO#2JZU(86>$ C5'*A&H1J#:ARJN5!-H#0]SU6U
M9P].-96 5GM0S8%J%*HQJ,:AF@O5!$K3HUU5>[;YO,$'Y:_"2$:O),X7VO;B
M>)TF_9,7E,O7_YK^='APL?X;L]XXW]!^#ZI1J,:@&H=J+E03]OXRHE;_X)K;
M=E7<V>;B[G1+R)MWW#C3T*(/JE&HQJ :AVHN5!.E=OQ2\G95]=GFJL^4X!]D
M(B8T.Y?[T+,QM/:#:@Y4HU"-034.U5RH)E":?M6/JO;KG:KVZT%K/ZCF0#4*
MU1A4XU#-A6H"I>G1KFJ_GKGV^S\GTF:]<;ZA72!4H[W]OLW:OV0!.VXS#CTV
M%ZH)E*8GLNKX>N:.SY#(>;A<RB@F*Q45F<S"65V=K3:@T+X/JCE0C?9J3A>L
MR><Q6W'HD;E03: T/9Y5/]<SG[5WPFN 0?L[J.9 -=K;7YJT7)ET+Z[';LFA
M1^A"-8'2BLBV=ZY@ZJOH.;_\;4QFX3I(B@N#;C^[O<3N=7YAV7>?Y]W/HKA0
M;L44U^V]D]&S%\1DJ9Y2LG,V[+=(5%P*M[B3A*O\.JF/89*$?GYSH>1<1=D&
MZ=>?PC!YNY/M8'M!XJO_ 5!+ P04    " #1.EU85IK$?]T#  !3%   &0
M 'AL+W=O<FMS:&5E=',O<VAE970X."YX;6RU6%V/XC84_2M6NJIVI>XD3B#
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M_Y(\.J+:H4'I39)YMOZH/%;+]CK*9)7ER:(:7&S!(HJ?_P__J'X06P,T;<\
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M ,*DN*J]^D^6/7 ZVHZ=&E=4,U#-1#6KTK9GD6>#W2DINE('U5Q4\U#-1[6
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M&AKI@[.S5W^V05=JH9J-:@ZJN:CFH9J/:@&ER8FL>TSZSYX$J1TX.85H9>G
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MB:(D<2. N1U$$8; ;L01S %XP) H,L_!G>=1L'Y.!9O_1(_^ E!+ P04
M" #1.EU8EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M8@DAF--,=**)2<BFWD%P'#-IJAQB8A*RJ?<3',>,$Q?6OS:ZAYE80@BFWG$
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M:E<48W4N+.=5MGQ^(O7Y:=I/_P!02P,$%     @ T3I=6%].Z@JF @  F#4
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\W:36[B0!"&X:L@'R"F
MJ[NKRJ.0U6RRC7(!BS0_"F!D>Y3D]H/( CYK%K.)_*U0VZ+\RHM'J.G'EW)H
MQWUW&G;[\[#X/!Y.PZK:C>/Y5UT/ZUTYML-#=RZGRYU-UQ_;\;+LM_6Y7;^W
MVU++<JEU?S^C>GJ\G[EX_3J7_YG8;3;[=?G=K?\<RVG\Q^#ZH^O?AUTI8[5X
M;?MM&5=5_7FX71[JZT=XN$RN%L]OJZI_?@M5/7>00)#,'Q0A*,X?E" HS1^4
M(2C/'Z00I/,'&039_$$.03Y_4 -!S?Q!88DR+@F2)E@3:!V0ZT#@=4"P X'8
M <D.!&8'1#L0J!V0[4#@=D"X X'< >D.!'8'Q#L0Z"VHMQ#H+:BW$.@MDQ_;
M!'H+ZBT$>@OJ+01Z"^HM!'H+ZBT$>@OJ+01Z"^HM!'H+ZBT$>D?4.Q+H'5'O
M2*!W1+TC@=YQLEE"H'=$O2.!WA'UC@1Z1]0[$N@=4>](H'=$O2.!WA'UC@1Z
M)]0[$>B=4.]$H'="O1.!W@GU3@1ZI\EF-X'>"?5.!'HGU#L1Z)U0[T2@=T*]
M$X'>"?5.!'IGU#L3Z)U1[TR@=T:],X'>&?7.!'IGU#L3Z)TG?U82Z)U1[TR@
M=T:],X'>&?7.!'IGU#L3Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2
MZ*V3PR8$>BOJK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM
M!'H;ZFT$>AOJ;01ZV^2P(('>AGH;@=Z&>AN!WHYZ.X'>CGH[@=Z.>CN!WHYZ
M.X'>CGH[@=Z.>CN!WHYZ.X'>CGH[@=X^.>Q-H+>CWDZ@=X-Z-P1Z-ZAW\Y-Z
M#^/7H0RWGN\U/O\GJ1XOWRVWQU^7WQ<G+^&*<WU?,3S]!5!+ P04    " #1
M.EU8>S86[3T"  #Q,P  $P   %M#;VYT96YT7U1Y<&5S72YX;6S-V]]NVC 4
MQ_%70;FM2(CCV&$JO6EWN_5B+^ EID3DGVRWHV\_$]I*FSJTBDG[WA"![?,[
M\9$^=UQ_>YZL7QSZ;O";9!?"]"G+?+VSO?'I.-DAKFQ'UYL0O[J';#+UWCS8
M3*Q6*JO'(=@A+,.Q1G)S?6>WYK$+B\^'^+-OQV&3.-OY9'%[VGC,VB1FFKJV
M-B&N9T]#\UO*\B4AC2?G/7[73OXJ;DBR=Q..*W\.>#GW]<DZUS9V<6]<^&+Z
MN"L[=)D/SYWUZ?D2[_0X;K=M;9NQ?NSCD=1/SIK&[ZP-?9>>BEZ=3P[QANWI
M,[\X?RYS+C#NO'?CY./$G/UXW.M(CJ>74RQD76C/O^);8BQ]\?O9X[0;V_QE
M=KS>'Z/;S_/PV?RX_(Y_G?%;_0_V(2!]%) ^)*2/$M*'@O2A(7U4D#[6D#[R
M%:41BJ@YA=2<8FI.036GJ)I36,TIKN846'.*K((BJZ#(*BBR"HJL@B*KH,@J
M*+(*BJR"(JN@R%I09"THLA8460N*K 5%UH(B:T&1M:#(6E!D+2BR2HJLDB*K
MI,@J*;)*BJR2(JNDR"HILDJ*K)(B:TF1M:3(6E)D+2FREA192XJL)476DB)K
M29&UI,BJ*+(JBJR*(JNBR*HHLBJ*K(HBJZ+(JBBR*HJLFB*KILBJ*;)JBJR:
M(JNFR*HILFJ*K)HBJZ;(6E%DK2BR5A19*XJL%476BB)K19&UHLA:462M*+*N
M*;*N_Z>LW\=Q_X_CYV?:FW9XS<_F?_K<_ 102P$"% ,4    " #1.EU8!T%-
M8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+
M 0(4 Q0    ( -$Z75CE+M]\[@   "L"   1              "  :\   !D
M;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -$Z75B97)PC$ 8  )PG   3
M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ T3I=6&5#0,YU"   (C<  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -$Z75A4UQQJ.@(  +T%   8
M              " @;@0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #1.EU8D_IS.YL(  !7)P  &               @($H$P  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ T3I=6/PI>?HG!
M5!,  !@              ("!^1L  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( -$Z75B="]3OX@8  /L=   8              " @58@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #1.EU8.04^
M/VX#  !\"P  &               @(%N)P  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ T3I=6%A:1!YS$   [N(  !@
M ("!$BL  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( -$Z
M75CM$PHX$@P  ,(]   8              " @;L[  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #1.EU8<U8FM@ J   8A@  &
M        @($#2   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ T3I=6!(S/1V\$   S3,  !D              ("!.7(  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #1.EU8-<S@K: (  #.%
M&0              @($L@P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( -$Z75CGL0-YY04  +4.   9              " @0.,  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ T3I=6&RDFK$C
M"0  9Q@  !D              ("!'Y(  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #1.EU88*W=#Z('   F$P  &0
M@(%YFP  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -$Z
M75B'1V%&LP,  *D'   9              " @5*C  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ T3I=6#7%1)MW P  Q0<  !D
M         ("!/*<  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #1.EU89Y9"64(,  !\)   &0              @('JJ@  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( -$Z75CSF> >WP\   <Y
M   9              " @6.W  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ T3I=6#D/0IQ3"   *1<  !D              ("!><<
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #1.EU8"<):
MH'D%  #V#@  &0              @($#T   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( -$Z75A6\:.>3PT  *XG   9
M  " @;/5  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MT3I=6 4N8!B^"@  &QH  !D              ("!.>,  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #1.EU8O/NL'^\:   J2P  &0
M            @($N[@  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( -$Z75A9L<,99P4  "X-   9              " @50) 0!X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ T3I=6//N4Y(H!@
MK0X  !D              ("!\@X! 'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #1.EU8_C&D7^\(  !5%@  &0              @(%1
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -$Z75CI
M6F&Q]P8  #P0   9              " @7<> 0!X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ T3I=6'KE&T5D @  AP8  !D
M     ("!I24! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -$Z75CGK/F&Q0(  ,\%   9              "
M@8A: 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ T3I=
M6$=!HF[_ P  K0H  !D              ("!A%T! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #1.EU8\D"C.\,"  #%!0  &0
M        @(&Z80$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( -$Z75@;5!#N&@,  'P&   9              " @;1D 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ T3I=6*Y#B.F^!   S@H
M !D              ("!!6@! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #1.EU8TPLHJ8X$  "6#   &0              @('Z; $
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -$Z75B )*L0
M@0,  $<(   9              " @;]Q 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ T3I=6-6$-^BE!@  5A(  !D
M ("!=W4! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #1
M.EU8#S)KGB@&  "Z#@  &0              @(%3? $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -$Z75B_;N:QX0,  )<(   9
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M970T-BYX;6Q02P$"% ,4    " #1.EU87';A!<X#  !($0  &0
M    @(%VFP$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M -$Z75@IN84ZPP0  #4<   9              " @7N? 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ T3I=6!HH9:5W!0  *AT  !D
M             ("!=:0! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #1.EU8283P?N #  "+%@  &0              @($CJ@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( -$Z75@YQS;;" H
M --G   9              " @3JN 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ T3I=6,*EU#A3 @  (P4  !D              ("!
M>;@! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #1.EU8
MXC0#WI0%  "Z*@  &0              @($#NP$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( -$Z75B6!6?UUP8   E'   9
M      " @<[  0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ T3I=6,6 G387 P  \@L  !D              ("!W,<! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #1.EU8TT#Q[X8"  ![!P
M&0              @($JRP$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( -$Z75@@HTG30@(  ,H%   9              " @>?- 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ T3I=6"GFBJ+Z
M @  T@@  !D              ("!8- ! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #1.EU8$.YNU^@$  !9&@  &0
M@(&1TP$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( -$Z
M75@N.3DON@(  (8'   9              " @;#8 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ T3I=6#EF#]UB @  =P4  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( -$Z75A;JUM;Y (  (\)   9
M  " @;SV 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
MT3I=6&19_S7@%   3E\! !D              ("!U_D! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " #1.EU8$'FM#DX$  !D$   &0
M            @('N#@( >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( -$Z75@^M>Y'[P,   X8   9              " @7,3 @!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ T3I=6#U==^$>!P
M4CT  !D              ("!F1<" 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " #1.EU8=@9]Z&,*  #Q:P  &0              @('N
M'@( >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( -$Z75B[
M3X#JT 0  !\7   9              " @8@I @!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ T3I=6,B>Q@%M"P  C7P  !D
M     ("!CRX" 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -$Z75CJ63N32P,  (<+   9              "
M@;)- @!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ T3I=
M6'(YR_&9 P  ZP\  !D              ("!-%$" 'AL+W=O<FMS:&5E=',O
M<VAE970W.2YX;6Q02P$"% ,4    " #1.EU8?ORA4\T#  "/#@  &0
M        @($$50( >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0
M   ( -$Z75@'A);O%00   </   9              " @0A9 @!X;"]W;W)K
M<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ T3I=6&A5+A +!   HPX
M !D              ("!5%T" 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q0
M2P$"% ,4    " #1.EU8-'/2#M((  !$8@  &0              @(&680(
M>&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( -$Z75A=6G61
MX (  #@(   9              " @9]J @!X;"]W;W)K<VAE971S+W-H965T
M.#0N>&UL4$L! A0#%     @ T3I=6"+&!SNI P  1@L  !D
M ("!MFT" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " #1
M.EU8S6QTP-T"  !W"   &0              @(&6<0( >&PO=V]R:W-H965T
M<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( -$Z75A_?JS4<@D  )QX   9
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M970Y,2YX;6Q02P$"% ,4    " #1.EU8^GH@@&0#  "6%@  #0
M    @ & EP( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -$Z75B7BKL<P
M !,"   +              "  0^; @!?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M -$Z75B/.P\,[P8  -$[   /              "  ?B; @!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #1.EU87T[J"J8"  "8-0  &@
M@ $4HP( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #1
M.EU8>S86[3T"  #Q,P  $P              @ 'RI0( 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     8P!C "P;  !@J (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>399</ContextCount>
  <ElementCount>495</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>132</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>16</UnitCount>
  <MyReports>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES</Role>
      <ShortName>REVENUE RECOGNITION AND RELATED ALLOWANCES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - BUSINESS COMBINATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION</Role>
      <ShortName>BUSINESS COMBINATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - RESTRUCTURING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/RESTRUCTURING</Role>
      <ShortName>RESTRUCTURING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - INDEBTEDNESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESS</Role>
      <ShortName>INDEBTEDNESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - GOODWILL AND INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - FAIR VALUE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/FAIRVALUE</Role>
      <ShortName>FAIR VALUE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY</Role>
      <ShortName>MEZZANINE AND STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES</Role>
      <ShortName>PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - SEGMENT REPORTING</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/SEGMENTREPORTING</Role>
      <ShortName>SEGMENT REPORTING</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - . DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>. DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables</Role>
      <ShortName>REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - BUSINESS COMBINATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONTables</Role>
      <ShortName>BUSINESS COMBINATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - INDEBTEDNESS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables</Role>
      <ShortName>INDEBTEDNESS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/INDEBTEDNESS</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/INVENTORIES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - FAIR VALUE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/FAIRVALUETables</Role>
      <ShortName>FAIR VALUE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/FAIRVALUE</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/INCOMETAXES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - SEGMENT REPORTING (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables</Role>
      <ShortName>SEGMENT REPORTING (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/SEGMENTREPORTING</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE and Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE and Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails</Role>
      <ShortName>REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails</Role>
      <ShortName>REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails</Role>
      <ShortName>REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails</Role>
      <ShortName>REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - BUSINESS COMBINATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails</Role>
      <ShortName>BUSINESS COMBINATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails</Role>
      <ShortName>BUSINESS COMBINATION - Pro Forma (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - RESTRUCTURING (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails</Role>
      <ShortName>RESTRUCTURING (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/RESTRUCTURING</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - INDEBTEDNESS - Credit facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails</Role>
      <ShortName>INDEBTEDNESS - Credit facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - INDEBTEDNESS - Facility components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails</Role>
      <ShortName>INDEBTEDNESS - Facility components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - INDEBTEDNESS - Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails</Role>
      <ShortName>INDEBTEDNESS - Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - INDEBTEDNESS - Credit facility maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails</Role>
      <ShortName>INDEBTEDNESS - Credit facility maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - INDEBTEDNESS - Interest (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails</Role>
      <ShortName>INDEBTEDNESS - Interest (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails</Role>
      <ShortName>DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - INVENTORIES - Schedule of inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails</Role>
      <ShortName>INVENTORIES - Schedule of inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - INVENTORIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails</Role>
      <ShortName>INVENTORIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails</Role>
      <ShortName>GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - FAIR VALUE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails</Role>
      <ShortName>FAIR VALUE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - FAIR VALUE - Level 3 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details</Role>
      <ShortName>FAIR VALUE - Level 3 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - FAIR VALUE - Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails</Role>
      <ShortName>FAIR VALUE - Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - FAIR VALUE - Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails</Role>
      <ShortName>FAIR VALUE - Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails</Role>
      <ShortName>MEZZANINE AND STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - STOCK-BASED COMPENSATION - Fair value options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Fair value options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - STOCK-BASED COMPENSATION - RSA activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - RSA activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - STOCK-BASED COMPENSATION - Performance shares activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Performance shares activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - INCOME TAXES - Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails</Role>
      <ShortName>INCOME TAXES - Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - INCOME TAXES - Effective rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails</Role>
      <ShortName>INCOME TAXES - Effective rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - INCOME TAXES - Deferred tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails</Role>
      <ShortName>INCOME TAXES - Deferred tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - COMMITMENTS AND CONTINGENCIES - Leases expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Leases expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - COMMITMENTS AND CONTINGENCIES - Lease maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Lease maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails</Role>
      <ShortName>PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - RELATED PARTY TRANSACTIONS - Schedule of related parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS - Schedule of related parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - SEGMENT REPORTING - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails</Role>
      <ShortName>SEGMENT REPORTING - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - SEGMENT REPORTING - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails</Role>
      <ShortName>SEGMENT REPORTING - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="anip-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>91</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="anip-20231231.htm">anip-20231231.htm</File>
    <File>anip-20231231.xsd</File>
    <File>anip-20231231_cal.xml</File>
    <File>anip-20231231_def.xml</File>
    <File>anip-20231231_lab.xml</File>
    <File>anip-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>anip-20231231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1358">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="14">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>118
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "anip-20231231.htm": {
   "nsprefix": "anip",
   "nsuri": "http://www.anipharmaceuticals.com/20231231",
   "dts": {
    "inline": {
     "local": [
      "anip-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "anip-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "anip-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "anip-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "anip-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "anip-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 448,
   "keyCustom": 47,
   "axisStandard": 43,
   "axisCustom": 2,
   "memberStandard": 54,
   "memberCustom": 75,
   "hidden": {
    "total": 21,
    "http://www.anipharmaceuticals.com/20231231": 1,
    "http://fasb.org/us-gaap/2023": 14,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://xbrl.sec.gov/ecd/2023": 2
   },
   "contextCount": 399,
   "entityCount": 1,
   "segmentCount": 132,
   "elementCount": 909,
   "unitCount": 16,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1358,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 14
   },
   "report": {
    "R1": {
     "role": "http://www.anipharmaceuticals.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.anipharmaceuticals.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
     "longName": "0000005 - Statement - Consolidated Statements of Operations",
     "shortName": "Consolidated Statements of Operations",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income (Loss)",
     "shortName": "Consolidated Statements of Comprehensive Income (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
     "longName": "0000007 - Statement - Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Mezzanine Equity and Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-16",
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES",
     "longName": "0000010 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES",
     "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION",
     "longName": "0000011 - Disclosure - BUSINESS COMBINATION",
     "shortName": "BUSINESS COMBINATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.anipharmaceuticals.com/role/RESTRUCTURING",
     "longName": "0000012 - Disclosure - RESTRUCTURING",
     "shortName": "RESTRUCTURING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESS",
     "longName": "0000013 - Disclosure - INDEBTEDNESS",
     "shortName": "INDEBTEDNESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY",
     "longName": "0000014 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.anipharmaceuticals.com/role/INVENTORIES",
     "longName": "0000015 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET",
     "longName": "0000016 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS",
     "longName": "0000017 - Disclosure - GOODWILL AND INTANGIBLE ASSETS",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.anipharmaceuticals.com/role/FAIRVALUE",
     "longName": "0000018 - Disclosure - FAIR VALUE",
     "shortName": "FAIR VALUE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY",
     "longName": "0000019 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY",
     "shortName": "MEZZANINE AND STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE",
     "longName": "0000020 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION",
     "longName": "0000021 - Disclosure - STOCK-BASED COMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.anipharmaceuticals.com/role/INCOMETAXES",
     "longName": "0000022 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000023 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES",
     "longName": "0000024 - Disclosure - PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES",
     "shortName": "PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "anip:CortrophinPreLaunchChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "anip:CortrophinPreLaunchChargesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS",
     "longName": "0000025 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTING",
     "longName": "0000026 - Disclosure - SEGMENT REPORTING",
     "shortName": "SEGMENT REPORTING",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS",
     "longName": "0000027 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-394",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-394",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - . DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": ". DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "9954472 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "anip:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "anip:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables",
     "longName": "9954473 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)",
     "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONTables",
     "longName": "9954474 - Disclosure - BUSINESS COMBINATION (Tables)",
     "shortName": "BUSINESS COMBINATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables",
     "longName": "9954475 - Disclosure - INDEBTEDNESS (Tables)",
     "shortName": "INDEBTEDNESS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.anipharmaceuticals.com/role/INVENTORIESTables",
     "longName": "9954476 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETTables",
     "longName": "9954477 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables",
     "longName": "9954478 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.anipharmaceuticals.com/role/FAIRVALUETables",
     "longName": "9954479 - Disclosure - FAIR VALUE (Tables)",
     "shortName": "FAIR VALUE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables",
     "longName": "9954480 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables",
     "longName": "9954481 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.anipharmaceuticals.com/role/INCOMETAXESTables",
     "longName": "9954482 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables",
     "longName": "9954483 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables",
     "longName": "9954484 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables",
     "longName": "9954485 - Disclosure - SEGMENT REPORTING (Tables)",
     "shortName": "SEGMENT REPORTING (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
     "longName": "9954486 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "anip:NumberOfPharmaceuticalManufacturingFacilities",
      "unitRef": "facility",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "anip:FDICGuaranteedAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
     "longName": "9954487 - Disclosure - DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE and Intangibles (Details)",
     "shortName": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - PPE and Intangibles (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-60",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
     "longName": "9954488 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)",
     "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Disaggregation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-69",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
     "longName": "9954489 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)",
     "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Timing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails",
     "longName": "9954490 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)",
     "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Allowances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-85",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "anip:ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails",
     "longName": "9954491 - Disclosure - REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)",
     "shortName": "REVENUE RECOGNITION AND RELATED ALLOWANCES - Concentration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-110",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
     "longName": "9954492 - Disclosure - BUSINESS COMBINATION - Narrative (Details)",
     "shortName": "BUSINESS COMBINATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails",
     "longName": "9954493 - Disclosure - BUSINESS COMBINATION - Pro Forma (Details)",
     "shortName": "BUSINESS COMBINATION - Pro Forma (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:BusinessAcquisitionsProFormaRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
     "longName": "9954494 - Disclosure - RESTRUCTURING (Details)",
     "shortName": "RESTRUCTURING (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "anip:NumberOfPharmaceuticalManufacturingFacilities",
      "unitRef": "facility",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-140",
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
     "longName": "9954495 - Disclosure - INDEBTEDNESS - Credit facility (Details)",
     "shortName": "INDEBTEDNESS - Credit facility (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromLinesOfCredit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-162",
      "name": "us-gaap:PaymentsOfDebtIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
     "longName": "9954496 - Disclosure - INDEBTEDNESS - Facility components (Details)",
     "shortName": "INDEBTEDNESS - Facility components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "anip:LongTermDebtGrossCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails",
     "longName": "9954497 - Disclosure - INDEBTEDNESS - Outstanding (Details)",
     "shortName": "INDEBTEDNESS - Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails",
     "longName": "9954498 - Disclosure - INDEBTEDNESS - Credit facility maturity (Details)",
     "shortName": "INDEBTEDNESS - Credit facility maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails",
     "longName": "9954499 - Disclosure - INDEBTEDNESS - Interest (Details)",
     "shortName": "INDEBTEDNESS - Interest (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InterestExpenseDebtExcludingAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
     "longName": "9954500 - Disclosure - DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)",
     "shortName": "DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InterestRateDerivativeAssetsAtFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails",
     "longName": "9954501 - Disclosure - INVENTORIES - Schedule of inventory (Details)",
     "shortName": "INVENTORIES - Schedule of inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails",
     "longName": "9954502 - Disclosure - INVENTORIES - Narrative (Details)",
     "shortName": "INVENTORIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-172",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-172",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails",
     "longName": "9954503 - Disclosure - PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Schedule of property and equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "longName": "9954504 - Disclosure - PROPERTY AND EQUIPMENT, NET - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT, NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
     "longName": "9954505 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
     "longName": "9954506 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Components (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Components (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails",
     "longName": "9954507 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)",
     "shortName": "GOODWILL AND INTANGIBLE ASSETS - Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
     "longName": "9954508 - Disclosure - FAIR VALUE - Narrative (Details)",
     "shortName": "FAIR VALUE - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-232",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details",
     "longName": "9954509 - Disclosure - FAIR VALUE - Level 3 (Details)",
     "shortName": "FAIR VALUE - Level 3 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-38",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
     "longName": "9954510 - Disclosure - FAIR VALUE - Hierarchy (Details)",
     "shortName": "FAIR VALUE - Hierarchy (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-214",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
     "longName": "9954511 - Disclosure - FAIR VALUE - Acquired (Details)",
     "shortName": "FAIR VALUE - Acquired (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
     "longName": "9954512 - Disclosure - MEZZANINE AND STOCKHOLDERS' EQUITY (Details)",
     "shortName": "MEZZANINE AND STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "anip:CommonStockConvertibleConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails",
     "longName": "9954513 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "longName": "9954514 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
     "longName": "9954515 - Disclosure - STOCK-BASED COMPENSATION - Expense (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-257",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-257",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
     "longName": "9954516 - Disclosure - STOCK-BASED COMPENSATION - Fair value options (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Fair value options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-288",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-288",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails",
     "longName": "9954517 - Disclosure - STOCK-BASED COMPENSATION - Stock option activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-298",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-288",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails",
     "longName": "9954518 - Disclosure - STOCK-BASED COMPENSATION - RSA activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - RSA activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-307",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-308",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
     "longName": "9954519 - Disclosure - STOCK-BASED COMPENSATION - Performance shares activity (Details)",
     "shortName": "STOCK-BASED COMPENSATION - Performance shares activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-314",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-314",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails",
     "longName": "9954520 - Disclosure - INCOME TAXES - Narrative (Details)",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-318",
      "name": "us-gaap:OperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails",
     "longName": "9954521 - Disclosure - INCOME TAXES - Provision (Details)",
     "shortName": "INCOME TAXES - Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails",
     "longName": "9954522 - Disclosure - INCOME TAXES - Effective rate (Details)",
     "shortName": "INCOME TAXES - Effective rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails",
     "longName": "9954523 - Disclosure - INCOME TAXES - Deferred tax (Details)",
     "shortName": "INCOME TAXES - Deferred tax (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "longName": "9954524 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "anip:NumberOfOperatingLeases",
      "unitRef": "operatinglease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails",
     "longName": "9954525 - Disclosure - COMMITMENTS AND CONTINGENCIES - Leases expense (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Leases expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails",
     "longName": "9954526 - Disclosure - COMMITMENTS AND CONTINGENCIES - Lease maturity (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Lease maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails",
     "longName": "9954527 - Disclosure - PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details)",
     "shortName": "PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "anip:CortrophinPreLaunchCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-339",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:SellingGeneralAndAdministrativeExpense",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
     "longName": "9954528 - Disclosure - RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-15",
      "name": "us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "anip:NumberOfExecutiveFounders",
      "unitRef": "founder",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails",
     "longName": "9954529 - Disclosure - RELATED PARTY TRANSACTIONS - Schedule of related parties (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS - Schedule of related parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-354",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-354",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails",
     "longName": "9954530 - Disclosure - SEGMENT REPORTING - Revenue (Details)",
     "shortName": "SEGMENT REPORTING - Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-364",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-365",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails",
     "longName": "9954531 - Disclosure - SEGMENT REPORTING - Geographic (Details)",
     "shortName": "SEGMENT REPORTING - Geographic (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-377",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "9954532 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-392",
      "name": "us-gaap:InvestmentOwnedAtCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "anip-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "anip_ANICanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ANICanadaMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ANI Canada",
        "label": "ANI Canada [Member]",
        "documentation": "ANI Canada [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "terseLabel": "Due to related parties",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r953"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net of $97,262 and $161,052 of adjustments for chargebacks and other allowances at December\u00a031, 2023 and 2022, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r380",
      "r381"
     ]
    },
    "anip_AccruedGovernmentRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AccruedGovernmentRebates",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued government rebates",
        "label": "Accrued Government Rebates",
        "documentation": "Represents amounts accrued for government rebates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalties",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r913"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r252",
      "r715"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income, net of tax",
        "negatedLabel": "Accumulated other comprehensive loss, net of tax",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r166",
      "r262",
      "r711",
      "r746",
      "r747"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive (Loss) Gain Net of Tax",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r21",
      "r52",
      "r624",
      "r627",
      "r663",
      "r742",
      "r743",
      "r1068",
      "r1069",
      "r1070",
      "r1081",
      "r1082",
      "r1083"
     ]
    },
    "anip_AcquiredAndaIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredAndaIntangibleAssetsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired ANDA intangible assets",
        "label": "Acquired ANDA intangible assets",
        "documentation": "Acquired ANDA intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AcquiredApprovedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredApprovedProductMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired approved product",
        "label": "Acquired Approved Product [Member]",
        "documentation": "Acquired Approved Product"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AcquiredCommercialProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredCommercialProductMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired commercial product",
        "label": "Acquired Commercial Product [Member]",
        "documentation": "Acquired Commercial Product"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AcquiredFiledProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredFiledProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired filed products",
        "label": "Acquired Filed Products [Member]",
        "documentation": "Acquired Filed Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "anip_AcquiredInProcessReserachAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredInProcessReserachAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development (\"IPR&amp;D\")",
        "label": "Acquired in Process Reserach and Development Expense",
        "documentation": "Acquired in Process Reserach and Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AcquiredNDAIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredNDAIntangibleAssetsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired NDA intangible assets",
        "label": "Acquired NDA intangible assets [Member]",
        "documentation": "Acquired NDA intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AcquiredPipelineProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AcquiredPipelineProductMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired pipeline product",
        "label": "Acquired pipeline product [Member]",
        "documentation": "Acquired pipeline product"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1009"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r953",
      "r1173"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r568",
      "r569",
      "r761",
      "r1081",
      "r1082",
      "r1083",
      "r1150",
      "r1175"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by (used in) operating activities:",
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based Compensation Expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r110",
      "r529"
     ]
    },
    "anip_AdministrativeFeesAndOtherRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AdministrativeFeesAndOtherRebatesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Administrative Fees and Other Rebates",
        "label": "Administrative Fees and Other Rebates",
        "documentation": "Administrative Fees and Other Rebates"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r991",
      "r1001",
      "r1027"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r994",
      "r1004",
      "r1030"
     ]
    },
    "anip_AkornHoldingCompanyPipelineProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AkornHoldingCompanyPipelineProductMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Akorn Holding Company, Pipeline Product",
        "label": "Akorn Holding Company, Pipeline Product [Member]",
        "documentation": "Akorn Holding Company, Pipeline Product"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r995",
      "r1005",
      "r1022",
      "r1031",
      "r1035",
      "r1043"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r575"
     ]
    },
    "anip_AllowancesForSalesReturnsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AllowancesForSalesReturnsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns",
        "label": "Returns",
        "documentation": "Allowances For Sales Returns"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AlvogenIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AlvogenIncMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alvogen Inc",
        "label": "Alvogen Inc [Member]",
        "documentation": "Alvogen Inc"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of finance fees",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r169",
      "r470",
      "r651",
      "r1073"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r651",
      "r932",
      "r933",
      "r1073"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r83",
      "r88"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Anti-dilutive shares (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liability not recognized, asset acquisition",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1141"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r89"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r256",
      "r292",
      "r349",
      "r364",
      "r370",
      "r388",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r615",
      "r619",
      "r640",
      "r706",
      "r805",
      "r953",
      "r968",
      "r1100",
      "r1101",
      "r1157"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r266",
      "r292",
      "r388",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r615",
      "r619",
      "r640",
      "r953",
      "r1100",
      "r1101",
      "r1157"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets held for sale",
        "label": "Asset, Held-for-Sale, Not Part of Disposal Group, Current",
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r953"
     ]
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current Assets",
        "label": "Assets, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "anip_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974",
      "r987"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974",
      "r987"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974",
      "r987"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1038"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1039"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1037"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1036"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "anip_AzurityPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "AzurityPharmaceuticalsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Azurity Pharmaceuticals",
        "label": "Azurity Pharmaceuticals",
        "documentation": "Represents information related to Azurity Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "anip_BiosantePharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "BiosantePharmaceuticalsIncMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BioSante Pharmaceuticals",
        "label": "BioSante Pharmaceuticals",
        "documentation": "BioSante Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings and improvements",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Buildings",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r608",
      "r945",
      "r946"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r608",
      "r945",
      "r946"
     ]
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued in acquisition (in shares)",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business acquisition",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of proforma information",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607"
     ]
    },
    "us-gaap_BusinessAcquisitionsProFormaRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionsProFormaRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONProFormaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net revenues",
        "label": "Business Acquisition, Pro Forma Revenue",
        "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period."
       }
      }
     },
     "auth_ref": [
      "r606",
      "r607"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Business Combination, Consideration Transferred",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r19"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of equity issued as consideration in a business combination",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debts assumed",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r3",
      "r119",
      "r611"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration fair value adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r1072"
     ]
    },
    "anip_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration fair value adjustment",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Cash Flow",
        "documentation": "Cash flow impact of amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement."
       }
      }
     },
     "auth_ref": []
    },
    "anip_BusinessCombinationContingentConsiderationArrangementsPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "BusinessCombinationContingentConsiderationArrangementsPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration period",
        "label": "Business Combination, Contingent Consideration Arrangements, Period",
        "documentation": "Business Combination, Contingent Consideration Arrangements, Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional contingent consideration",
        "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High",
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r120",
      "r612"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contingent consideration",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r120"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unobservable inputs",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current contingent consideration, net of current",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r120"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS COMBINATION",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r609"
     ]
    },
    "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue generated",
        "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual",
        "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite intangible assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets",
        "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combinations [Abstract]",
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "country_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "CA",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canada",
        "label": "CANADA"
       }
      }
     },
     "auth_ref": []
    },
    "anip_CGOncologyInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CGOncologyInc.Member",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CG Oncology, Inc.",
        "label": "CG Oncology, Inc. [Member]",
        "documentation": "CG Oncology, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment purchased and included in accounts payable",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r250",
      "r910"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money Market Fund",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash, Cash Equivalents, and Restricted Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of year",
        "periodEndLabel": "Cash and cash equivalents, end of year",
        "totalLabel": "Total cash, cash equivalents, and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r178",
      "r289"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of cash, cash equivalents, and restricted cash, beginning of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Change in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r178"
     ]
    },
    "anip_ChaliPropertiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ChaliPropertiesLLCMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chali Properties LLC",
        "label": "Chali Properties LLC [Member]",
        "documentation": "Chali Properties LLC"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "anip_ChargebacksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ChargebacksMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chargebacks",
        "label": "Chargebacks",
        "documentation": "Chargebacks"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ClassCSpecialStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ClassCSpecialStockMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/Cover",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class C Special Stock",
        "label": "Class C Special Stock",
        "documentation": "Class C Special Stock"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ClassCSpecialStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ClassCSpecialStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December\u00a031, 2023 and 2022 respectively",
        "label": "Class C Special Stock Value",
        "documentation": "Aggregate par or stated value of issued nonredeemable Class C Special stock (or common stock redeemable solely at the option of the issuer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/Cover",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r259",
      "r260",
      "r261",
      "r292",
      "r321",
      "r325",
      "r333",
      "r337",
      "r343",
      "r344",
      "r388",
      "r435",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r480",
      "r481",
      "r485",
      "r488",
      "r495",
      "r640",
      "r751",
      "r752",
      "r753",
      "r754",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r793",
      "r814",
      "r837",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r1051",
      "r1075",
      "r1084"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r343",
      "r480",
      "r481",
      "r483",
      "r485",
      "r488",
      "r493",
      "r495",
      "r751",
      "r752",
      "r753",
      "r754",
      "r934",
      "r1051",
      "r1075"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative Arrangements",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r231"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and Contingencies (Note 15)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r150",
      "r707",
      "r792"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "anip_CommonStockConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CommonStockConversionPrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price (in dollar per share)",
        "label": "Common Stock Conversion Price",
        "documentation": "Represents the conversion price for converting shares of common stock into another class of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "anip_CommonStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CommonStockConvertibleConversionRatio",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock conversion ratio",
        "label": "Common Stock, Convertible, Conversion Ratio",
        "documentation": "Common Stock, Convertible, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/Cover",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r956",
      "r957",
      "r958",
      "r960",
      "r961",
      "r962",
      "r965",
      "r1081",
      "r1082",
      "r1150",
      "r1170",
      "r1175"
     ]
    },
    "anip_CommonStockNumberOfVotesPerShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CommonStockNumberOfVotesPerShare",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per share",
        "label": "Common Stock, Number of Votes Per Share",
        "documentation": "Common Stock, Number of Votes Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r793"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, shares issued",
        "periodStartLabel": "Beginning Balance, Common (in shares)",
        "periodEndLabel": "Ending Balance, Common (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, shares outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r157",
      "r793",
      "r811",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common Stock, $0.0001 par value, 33,333,334 shares authorized; 20,730,896 shares issued and 20,466,953 outstanding at December\u00a031, 2023; 17,643,497 shares issued and 17,494,466 shares outstanding at December\u00a031, 2022",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r709",
      "r953"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive income (loss), net of tax",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r272",
      "r274",
      "r281",
      "r702",
      "r721"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r140",
      "r141",
      "r378",
      "r892"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r140",
      "r141",
      "r378",
      "r748",
      "r892"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r140",
      "r141",
      "r378",
      "r892",
      "r1054"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r140",
      "r141",
      "r378"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r72",
      "r73",
      "r140",
      "r213",
      "r892"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r72",
      "r140",
      "r141",
      "r378",
      "r892"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r615",
      "r616",
      "r619",
      "r620",
      "r672",
      "r903",
      "r1099",
      "r1102",
      "r1103"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r615",
      "r616",
      "r619",
      "r620",
      "r672",
      "r903",
      "r1099",
      "r1102",
      "r1103"
     ]
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r351",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r372",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r443",
      "r445",
      "r446",
      "r1100",
      "r1101"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r298",
      "r351",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r372",
      "r435",
      "r436",
      "r437",
      "r438",
      "r440",
      "r441",
      "r443",
      "r445",
      "r446",
      "r1100",
      "r1101"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Principles of Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r917"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentLiabilityReserveEstimatePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContingentLiabilityReserveEstimatePolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Consideration",
        "label": "Contingent Liability Reserve Estimate, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the claims loss reserve for insurance contracts with a life contingency (permanent life, some term life, accident and health, some annuities), describing the loss exposures and bases and methodologies for making the relevant accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215"
     ]
    },
    "anip_ContractCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ContractCustomerMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Customer",
        "label": "Contract Customer",
        "documentation": "Contract Customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations satisfied in prior periods",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "verboseLabel": "Mezzanine Equity Series A Convertible Preferred Stock",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r480",
      "r481",
      "r485",
      "r960",
      "r961",
      "r962",
      "r965"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate, Non-Segment",
        "label": "Corporate, Non-Segment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372",
      "r1087"
     ]
    },
    "anip_CortrophinGelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CortrophinGelMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cortrophin Gel",
        "label": "Cortrophin Gel",
        "documentation": "Information related to Cortrophin Gel."
       }
      }
     },
     "auth_ref": []
    },
    "anip_CortrophinPreLaunchCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CortrophinPreLaunchCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purified Cortrophin Gel pre-launch charges",
        "label": "Cortrophin Pre Launch Charges",
        "documentation": "Amount of charges directly related to the Purified Cortrophin Gel pre-launch charges commercialization efforts, including but not limited to sales and marketing expenses."
       }
      }
     },
     "auth_ref": []
    },
    "anip_CortrophinPreLaunchChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CortrophinPreLaunchChargesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES",
        "label": "PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES",
        "documentation": "No definition available."
       }
      }
     },
     "auth_ref": []
    },
    "anip_CortrophinPreLaunchChargesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CortrophinPreLaunchChargesTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES",
        "label": "Cortrophin Pre-Launch Charges [Text Block]",
        "documentation": "The entire disclosure for cortrophin pre-launch charges."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales (excluding depreciation and amortization)",
        "label": "Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization",
        "documentation": "Cost of product sold and service rendered, excluding depreciation, depletion, and amortization."
       }
      }
     },
     "auth_ref": [
      "r1059",
      "r1060"
     ]
    },
    "us-gaap_CostOfGoodsTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsTotalMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Goods and Service Benchmark",
        "label": "Cost of Goods and Service Benchmark [Member]",
        "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Activities",
        "label": "Costs Associated with Exit or Disposal Activity or Restructuring [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cost associated with exit or disposal activity or restructuring. Excludes entity newly acquired in business combination and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r195",
      "r196"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r452",
      "r483",
      "r670",
      "r914",
      "r916"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "anip_CranfordPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CranfordPharmaceuticalsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cranford Pharmaceuticals",
        "label": "Cranford Pharmaceuticals",
        "documentation": "Cranford Pharmaceuticals"
       }
      }
     },
     "auth_ref": []
    },
    "anip_CreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CreditAgreementMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility - 2021",
        "label": "Credit Facility - 2021",
        "documentation": "Credit Facility - 2021"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1078",
      "r1139"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1078"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r595",
      "r601",
      "r1078"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current income tax provision",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1058",
      "r1078",
      "r1139"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r378"
     ]
    },
    "anip_CustomerFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CustomerFourMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 4",
        "label": "Customer four [Member]",
        "documentation": "Customer four"
       }
      }
     },
     "auth_ref": []
    },
    "anip_CustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CustomerOneMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 1",
        "label": "Customer one [Member]",
        "documentation": "Customer one"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "anip_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 3",
        "label": "Customer three [Member]",
        "documentation": "Customer three"
       }
      }
     },
     "auth_ref": []
    },
    "anip_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer 2",
        "label": "Customer two [Member]",
        "documentation": "Customer two"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INDEBTEDNESS",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r290",
      "r448",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r464",
      "r471",
      "r472",
      "r474"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis spread (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowing on debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r218",
      "r475"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt effective interest rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r144",
      "r477",
      "r652"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r652",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r1076"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r100",
      "r103",
      "r143",
      "r144",
      "r146",
      "r151",
      "r200",
      "r201",
      "r298",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r455",
      "r460",
      "r461",
      "r462",
      "r463",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r473",
      "r652",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r1076"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsCurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails": {
       "parentTag": "us-gaap_DeferredFinanceCostsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred financing costs",
        "terseLabel": "Debt issuance costs, current",
        "label": "Debt Issuance Costs, Current, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total debt issuance costs, net",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r1105"
     ]
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails": {
       "parentTag": "us-gaap_DeferredFinanceCostsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred financing costs",
        "terseLabel": "Debt issuance costs, noncurrent",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r1078",
      "r1138"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net of deferred tax liabilities and valuation allowance",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r581",
      "r582"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r208",
      "r239",
      "r600",
      "r601",
      "r1078"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred income tax benefit",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r154",
      "r217",
      "r589"
     ]
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred taxes",
        "label": "Deferred Income Taxes and Tax Credits",
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1078",
      "r1138",
      "r1139"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research expenditures",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Deferred Tax Assets, Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails",
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets and liabilities",
        "totalLabel": "Deferred tax assets, net of deferred tax liabilities and valuation allowance",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1136"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals and advances",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals for chargebacks and returns",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Returns and Allowances",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated returns and sales allowances."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other liabilities",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESDeferredtaxDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r1137"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r90"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r90"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r783",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r825",
      "r826",
      "r827",
      "r828",
      "r831",
      "r832",
      "r833",
      "r834",
      "r867",
      "r869",
      "r873",
      "r875",
      "r956",
      "r958"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r129",
      "r130",
      "r131",
      "r780",
      "r783",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r825",
      "r826",
      "r827",
      "r828",
      "r831",
      "r832",
      "r833",
      "r834",
      "r867",
      "r869",
      "r873",
      "r875",
      "r916",
      "r956",
      "r958"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r212",
      "r622",
      "r629"
     ]
    },
    "anip_DerivativeLiabilityDecreaseInNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "DerivativeLiabilityDecreaseInNotionalAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in notional amount",
        "label": "Derivative Liability, Decrease in Notional Amount",
        "documentation": "Amount of decrease in notional amount of derivative liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLiabilityNotionalAmount",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, notional amount",
        "label": "Derivative Liability, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability."
       }
      }
     },
     "auth_ref": [
      "r868",
      "r870",
      "r872",
      "r874",
      "r1145",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r130",
      "r132",
      "r133",
      "r134",
      "r629"
     ]
    },
    "us-gaap_DerivativesMethodsOfAccountingHedgingDerivatives": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DerivativesMethodsOfAccountingHedgingDerivatives",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Instruments and Hedge Accounting",
        "label": "Derivatives, Methods of Accounting, Hedging Derivatives [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for derivatives used in hedging relationships, which may include how gains or losses are recognized and presented in the financial statements, and amortization policies for deferred amounts."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r1149"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of disaggregation of revenue and revenue recognized",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1106"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCK-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r532",
      "r563",
      "r564",
      "r566",
      "r948"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r245"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Held-for-Sale, Not Discontinued Operations",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r29",
      "r245"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "anip_DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First purchase price deposit",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, First Deposit",
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, First Deposit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946"
     ]
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on Convertible Preferred Stock",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r202"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974",
      "r987"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974",
      "r987",
      "r1023"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Line Items]",
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Information [Table]",
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1008"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic Tax Authority",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "anip_EarningsLossBeforeInterestTaxesDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "EarningsLossBeforeInterestTaxesDepreciationAndAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EBITDA",
        "label": "Earnings/(loss) before interest, taxes, depreciation and amortization",
        "documentation": "Represents earnings/(loss) before interest, taxes, depreciation and amortization (EBITDA)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic Income (Loss) Per Share (in dollars per share)",
        "verboseLabel": "Earnings (loss) per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r318",
      "r321",
      "r333",
      "r336",
      "r337",
      "r341",
      "r632",
      "r633",
      "r703",
      "r722",
      "r920"
     ]
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share basic",
        "label": "Earnings Per Share, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted Income (Loss) Per Share (in dollars per share)",
        "verboseLabel": "Earnings (loss) per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r321",
      "r333",
      "r336",
      "r337",
      "r341",
      "r632",
      "r633",
      "r703",
      "r722",
      "r920"
     ]
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDilutedAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per share diluted",
        "label": "Earnings Per Share, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and Diluted Income (Loss) Per Share:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r317",
      "r338",
      "r339",
      "r340"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r584"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "US Federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r584",
      "r602"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1140"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign taxes",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1140"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible costs",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1140"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Transfer pricing and other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1140"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1052",
      "r1135"
     ]
    },
    "anip_EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in state apportionment factors, state and foreign rates",
        "label": "Effective Income Tax Rate Reconciliation, State and Foreign Income Taxes",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and foreign income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State taxes, net of Federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1140"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESEffectiverateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Research and experimentation and charitable credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1140"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation and related expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Period of cost recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r565"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized non-option costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized option costs",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1134"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation income tax benefits",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r562"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercise tax benefit",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r236"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "anip_EmployeeStockPurchasePlanTwoThousandAndSixteenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "EmployeeStockPurchasePlanTwoThousandAndSixteenMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016 Employee Stock Purchase Plan",
        "label": "2016 Employee Stock Purchase Plan",
        "documentation": "2016 Employee Stock Purchase Plan"
       }
      }
     },
     "auth_ref": []
    },
    "anip_EmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "EmployeesAndConsultantsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employees and Consultants",
        "label": "Employees and Consultants [Member]",
        "documentation": "Information related to employees and consultants."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r970"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r243",
      "r276",
      "r277",
      "r278",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r316",
      "r342",
      "r389",
      "r390",
      "r496",
      "r567",
      "r568",
      "r569",
      "r596",
      "r597",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r663",
      "r742",
      "r743",
      "r744",
      "r761",
      "r837"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r991",
      "r1001",
      "r1027"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r988",
      "r998",
      "r1024"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funds held in escrow for asset purchase",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r893"
     ]
    },
    "anip_EsjayPharmaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "EsjayPharmaLlcMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Esjay Pharma LLC",
        "label": "Esjay Pharma LLC",
        "documentation": "Represents the information pertaining to Esjay Pharma LLC."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "anip_FDICGuaranteedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "FDICGuaranteedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FDIC guaranteed amount",
        "label": "FDIC Guaranteed Amount",
        "documentation": "Represents the total amount of interest bearing and non-interest bearing accounts insured by the FDIC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FacilityClosingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FacilityClosingMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facility Closing",
        "label": "Facility Closing [Member]",
        "documentation": "Closing of a facility associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of recurring Level 3 fair value measurements of contingent consideration",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r138",
      "r139"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r636",
      "r676",
      "r677",
      "r678",
      "r930",
      "r931",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "FAIR VALUE",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r519",
      "r524",
      "r636",
      "r676",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r519",
      "r524",
      "r636",
      "r677",
      "r930",
      "r931",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r636",
      "r678",
      "r930",
      "r931",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in contingent consideration",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of changes in contingent consideration",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r137"
     ]
    },
    "anip_FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement period adjustment",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Measurement period adjustment",
        "documentation": "Measurement period adjustment for liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment of ANDA filing earn-out",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Level 3 liability, beginning balance",
        "periodEndLabel": "Level 3 liability, ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r676",
      "r677",
      "r678",
      "r930",
      "r931",
      "r942",
      "r943",
      "r944"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r35"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_FederalIncomeTaxNoteTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FederalIncomeTaxNoteTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal Income Tax Note [Table]",
        "label": "Federal Income Tax Note [Table]",
        "documentation": "Table of federal income tax note for schedule of investments. The federal income tax note may be qualified for security investments, non-security investments and/or for the combination of security and non-security investments."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period",
        "verboseLabel": "Useful life of intangible assets",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r414"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of expected future amortization expense",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r188"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r413",
      "r414",
      "r416",
      "r686",
      "r687"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finite-lived intangible gross carrying amount",
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r687"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSAmortizationDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Carrying Amount",
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r686"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-Lived Intangible Assets:",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in definite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in carrying value of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Amortization Period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r686"
     ]
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets acquired",
        "label": "Finite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition."
       }
      }
     },
     "auth_ref": [
      "r411"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign Currency",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r995",
      "r1005",
      "r1031"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r995",
      "r1005",
      "r1031"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r995",
      "r1005",
      "r1031"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r995",
      "r1005",
      "r1031"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r995",
      "r1005",
      "r1031"
     ]
    },
    "anip_FourCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "FourCustomersMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Four Customers",
        "label": "Four Customers [Member]",
        "documentation": "Four Customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of ANDAs",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossRelatedToLitigationSettlement",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Legal settlement expense",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r94",
      "r95"
     ]
    },
    "anip_GenericsEstablishedBrandsAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "GenericsEstablishedBrandsAndOtherMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Generics, Established Brands and Other",
        "label": "Generics, Established Brands and Other",
        "documentation": "Component of the entity related to generics, established brands, and other and is considered an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r397",
      "r700",
      "r924",
      "r953",
      "r1090",
      "r1091"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Acquisition of goodwill",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r924"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "GOODWILL AND INTANGIBLE ASSETS",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r185"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r409",
      "r924"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill, impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r398",
      "r404",
      "r409",
      "r924"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r924"
     ]
    },
    "anip_GovernmentRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "GovernmentRebatesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Rebates",
        "label": "Government Rebates",
        "documentation": "Government Rebates"
       }
      }
     },
     "auth_ref": []
    },
    "country_IN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "IN",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "India",
        "label": "INDIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IPOMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IPO",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r974",
      "r987"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset impairment charge",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1092"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss related to property and equipment recognized",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r89",
      "r193"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets Held-for-Sale",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r194"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In process research and development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income (Loss) Before Expense (Benefit) for Income Taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r167",
      "r220",
      "r349",
      "r363",
      "r369",
      "r372",
      "r704",
      "r717",
      "r922"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r946"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r423",
      "r821"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r423",
      "r821"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r578",
      "r585",
      "r586",
      "r593",
      "r598",
      "r603",
      "r604",
      "r605",
      "r756"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense (benefit)",
        "totalLabel": "Total expense (benefit) for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r227",
      "r240",
      "r315",
      "r316",
      "r357",
      "r583",
      "r599",
      "r723"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r579",
      "r580",
      "r586",
      "r587",
      "r592",
      "r594",
      "r750"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r64"
     ]
    },
    "anip_IncreaseDecreaseAccruedGovernmentRebates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "IncreaseDecreaseAccruedGovernmentRebates",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued government rebates",
        "label": "Increase Decrease, Accrued Government Rebates",
        "documentation": "The increase (decrease) during the reporting period in liabilities related to government rebates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current income taxes payable, net",
        "label": "Increase (Decrease) in Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes, and in deferred and other tax liabilities and assets."
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of acquisition (2021):",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "anip_IncreaseDecreaseInReturnedGoodsReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "IncreaseDecreaseInReturnedGoodsReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returned goods reserve",
        "label": "Increase Decrease In Returned Goods Reserve",
        "documentation": "Amount of increase (decrease) in returned goods reserve."
       }
      }
     },
     "auth_ref": []
    },
    "anip_IncreaseDecreaseInRoyaltyPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "IncreaseDecreaseInRoyaltyPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalties",
        "label": "Increase (Decrease) in Royalty Payable",
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in Stockholders' Equity",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in temporary equity",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "anip_IncreaseDecreaseOfAccruedExpensesCompensationAndOthers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "IncreaseDecreaseOfAccruedExpensesCompensationAndOthers",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses, accrued compensation, and other",
        "label": "Increase Decrease Of Accrued Expenses Compensation And Others",
        "documentation": "The increase (decrease) during the reporting period in liabilities related to accrued compensation, accrued expenses, and others."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive effect of common stock options, ESPP, and performance stock units (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r337",
      "r531"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r412",
      "r415"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets:",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r189"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r995",
      "r1005",
      "r1022",
      "r1031",
      "r1035",
      "r1043"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1047"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1047"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1047"
     ]
    },
    "anip_IntangibleAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "IntangibleAssetMeasurementInput",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible asset measurement input",
        "label": "Intangible Asset, Measurement Input",
        "documentation": "Value of input used to measure intangible assets acquired."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r682",
      "r683",
      "r684",
      "r686",
      "r918"
     ]
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "terseLabel": "Net Carrying Amount",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r86"
     ]
    },
    "us-gaap_InterestCostsCapitalized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestCostsCapitalized",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest capitalized",
        "label": "Interest Costs Capitalized",
        "documentation": "Amount of interest capitalized during the period."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_InterestCostsCapitalizedAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestCostsCapitalizedAdjustment",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalized interest",
        "label": "Interest Costs Capitalized Adjustment",
        "documentation": "Amount of interest costs capitalized disclosed as an adjusting item to interest costs incurred."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r222",
      "r279",
      "r353",
      "r650",
      "r822",
      "r966",
      "r1174"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r468",
      "r478",
      "r932",
      "r933"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails": {
       "parentTag": "us-gaap_InterestExpenseDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSInterestDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contractual coupon",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r469",
      "r932",
      "r933"
     ]
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of components of total interest expense related to the notes and term loan",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense, net",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "documentation": "The net amount of nonoperating interest income (expense)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for interest, net of amounts capitalized",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r287",
      "r288"
     ]
    },
    "anip_InterestPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "InterestPeriodAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Period [Axis]",
        "label": "Interest Period [Axis]",
        "documentation": "Interest Period"
       }
      }
     },
     "auth_ref": []
    },
    "anip_InterestPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "InterestPeriodDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Period [Domain]",
        "label": "Interest Period [Domain]",
        "documentation": "Interest Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRateDerivativeAssetsAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateDerivativeAssetsAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value interest rate derivative assets",
        "terseLabel": "Interest rate swap",
        "label": "Interest Rate Derivative Assets, at Fair Value",
        "documentation": "Fair value as of the balance sheet date of interest rate derivative assets, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRateDerivativeLiabilitiesAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateDerivativeLiabilitiesAtFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest rate swaps, liability",
        "label": "Interest Rate Derivative Liabilities, at Fair Value",
        "documentation": "Fair value as of the balance sheet date of interest rate derivative liabilities, which includes all such derivative instruments in hedging and nonhedging relationships that are recognized as liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestRateSwapMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestRateSwapMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate swap",
        "label": "Interest Rate Swap [Member]",
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period."
       }
      }
     },
     "auth_ref": [
      "r907",
      "r963",
      "r964"
     ]
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "INVENTORIES",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r391"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1063"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory, total",
        "label": "Inventory, Gross",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r911",
      "r953"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r249",
      "r263",
      "r391",
      "r392",
      "r393",
      "r681",
      "r919"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1065"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Work-in-progress",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1064"
     ]
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, cost",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r778",
      "r779",
      "r851",
      "r853",
      "r863",
      "r882",
      "r958",
      "r968",
      "r1171"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Value of shares held",
        "label": "Investment Owned, Fair Value",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r749",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r781",
      "r784",
      "r785",
      "r796",
      "r797",
      "r845",
      "r849",
      "r850",
      "r852",
      "r860",
      "r861",
      "r864",
      "r865",
      "r866",
      "r876",
      "r877",
      "r881",
      "r883",
      "r884",
      "r958",
      "r968",
      "r1171"
     ]
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentOwnedBalanceShares",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares held (in shares)",
        "label": "Investment Owned, Balance, Shares",
        "documentation": "Number of shares of investment owned."
       }
      }
     },
     "auth_ref": [
      "r773",
      "r781",
      "r848",
      "r862",
      "r880",
      "r958"
     ]
    },
    "us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsOwnedFederalIncomeTaxNoteLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Owned, Federal Income Tax Note [Line Items]",
        "label": "Investments, Owned, Federal Income Tax Note [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1169"
     ]
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r1107"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r656",
      "r952"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of rent expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of maturity analysis of operating leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: effects of discounting",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r662"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r292",
      "r388",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r616",
      "r619",
      "r620",
      "r640",
      "r791",
      "r921",
      "r968",
      "r1100",
      "r1157",
      "r1158"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Mezzanine Equity, and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r219",
      "r713",
      "r953",
      "r1077",
      "r1089",
      "r1152"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities, Mezzanine Equity, and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r248",
      "r292",
      "r388",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r616",
      "r619",
      "r620",
      "r640",
      "r953",
      "r1100",
      "r1157",
      "r1158"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Liabilities",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee (as a percent)",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining borrowing capacity",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of property and equipment by geographic location",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r218",
      "r461",
      "r476",
      "r930",
      "r931",
      "r1166"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current debt, net of deferred financing costs",
        "totalLabel": "Current debt, net of deferred financing costs",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r257"
     ]
    },
    "anip_LongTermDebtGrossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "LongTermDebtGrossCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": {
       "parentTag": "us-gaap_LongTermDebtCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current borrowing on debt",
        "label": "Long-term Debt, Gross, Current",
        "documentation": "Current portion before unamortized (discount) premium and debt issuance costs, of long-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "anip_LongTermDebtGrossNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "LongTermDebtGrossNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current borrowing on debt",
        "label": "Long-term Debt, Gross, Non Current",
        "documentation": "Non current portion before unamortized (discount) premium and debt issuance costs, of long-term debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r298",
      "r466"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r298",
      "r466"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r298",
      "r466"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r298",
      "r466"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current debt, net of deferred financing costs and current component",
        "totalLabel": "Non-current debt, net of deferred financing costs and current component",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r258"
     ]
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrentAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current Liabilities",
        "label": "Long-Term Debt, Excluding Current Maturities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r93"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of complaints filed",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1096"
     ]
    },
    "anip_LossContingencyNumberOfManufacturers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "LossContingencyNumberOfManufacturers",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of potential manufacturers",
        "label": "Loss Contingency, Number Of Manufacturers",
        "documentation": "Loss Contingency, Number Of Manufacturers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyNumberOfPlaintiffs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyNumberOfPlaintiffs",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of plaintiffs",
        "label": "Loss Contingency, Number of Plaintiffs",
        "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of open complaints (more than)",
        "label": "Loss Contingency, Pending Claims, Number",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1096"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery, furniture, and equipment",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r378",
      "r937",
      "r1106",
      "r1167",
      "r1168"
     ]
    },
    "anip_MarketPerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "MarketPerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market Performance-Based Restricted Stock Units",
        "label": "Market Performance-Based Restricted Stock Units [Member]",
        "documentation": "Market Performance-Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "anip_MarketingAndDistributionRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "MarketingAndDistributionRightsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketing and distribution rights",
        "label": "Marketing and distribution rights",
        "documentation": "Marketing and distribution rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reconciling Items",
        "label": "Segment Reconciling Items [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r526",
      "r680",
      "r741",
      "r782",
      "r783",
      "r846",
      "r854",
      "r858",
      "r859",
      "r878",
      "r904",
      "r905",
      "r923",
      "r934",
      "r947",
      "r955",
      "r1104",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_MeasurementInputDiscountForLackOfMarketabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountForLackOfMarketabilityMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount for Lack of Marketability",
        "label": "Measurement Input, Discount for Lack of Marketability [Member]",
        "documentation": "Measurement input using amount by which value of business ownership interest is reduced to reflect lack of ability to convert business interest into cash quickly."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Price Volatility",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "anip_MeasurementInputProbabilityOfPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "MeasurementInputProbabilityOfPaymentMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Probability of payment",
        "label": "Probability of payment",
        "documentation": "Represents information pertaining to probability of payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r526",
      "r680",
      "r741",
      "r782",
      "r783",
      "r846",
      "r854",
      "r858",
      "r859",
      "r878",
      "r904",
      "r905",
      "r923",
      "r934",
      "r947",
      "r955",
      "r1104",
      "r1159",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accruals and allowances",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "anip_Mr.ChadGassertMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "Mr.ChadGassertMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Chad Gassert [Member]",
        "documentation": "Mr. Chad Gassert"
       }
      }
     },
     "auth_ref": []
    },
    "anip_Mr.MuthusamyShanmugamMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "Mr.MuthusamyShanmugamMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mr. Muthusamy Shanmugam [Member]",
        "documentation": "Mr. Muthusamy Shanmugam"
       }
      }
     },
     "auth_ref": []
    },
    "anip_Mr.ShanmugamAndEsjayMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "Mr.ShanmugamAndEsjayMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mr. Shanmugam and Esjay",
        "label": "Mr. Shanmugam and Esjay [Member]",
        "documentation": "Mr. Shanmugam and Esjay"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r378",
      "r937",
      "r1106",
      "r1167",
      "r1168"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash and Cash Equivalents Provided by (Used in) Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows From Financing Activities",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash and Cash Equivalents Used in Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r286"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows From Investing Activities",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash and Cash Equivalents Provided by (Used in) Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r179",
      "r180"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Flows From Operating Activities",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Income (Loss)",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r180",
      "r221",
      "r246",
      "r270",
      "r273",
      "r278",
      "r292",
      "r307",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315",
      "r316",
      "r330",
      "r349",
      "r363",
      "r369",
      "r372",
      "r388",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r633",
      "r640",
      "r719",
      "r813",
      "r835",
      "r836",
      "r922",
      "r966",
      "r1100"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": "us-gaap_UndistributedEarnings",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss Available to Common Shareholders",
        "verboseLabel": "Net income (loss) available to common shareholders, Basic",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r309",
      "r310",
      "r311",
      "r312",
      "r318",
      "r319",
      "r332",
      "r337",
      "r349",
      "r363",
      "r369",
      "r372",
      "r922"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": "us-gaap_UndistributedEarningsDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) available to common shareholders, Diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r320",
      "r326",
      "r327",
      "r328",
      "r329",
      "r332",
      "r337"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "anip_NewEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NewEmployeesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Employees",
        "label": "New Employees [Member]",
        "documentation": "New Employees"
       }
      }
     },
     "auth_ref": []
    },
    "anip_NonCompeteAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NonCompeteAgreementMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-compete agreement",
        "label": "Non-compete agreement",
        "documentation": "Non-compete agreement"
       }
      }
     },
     "auth_ref": []
    },
    "anip_NonEmployeeDirectorStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NonEmployeeDirectorStockOptionMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Employee Director",
        "label": "Non Employee Director [Member]",
        "documentation": "n/a"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r995",
      "r1005",
      "r1022",
      "r1031"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition of product rights included in accounts payable",
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of contingent consideration in a business combination",
        "label": "Noncash or Part Noncash Acquisition, Other Liabilities Assumed",
        "documentation": "Amount of liabilities, classified as other, assumed in acquiring a business or in consideration for an asset received in a noncash or part noncash acquisition."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r67"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Expense, net",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted stock activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "anip_NovitiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NovitiumMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novitium",
        "label": "Novitium [Member]",
        "documentation": "Novitium"
       }
      }
     },
     "auth_ref": []
    },
    "anip_NovitiumPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NovitiumPharmaMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novitium",
        "label": "Novitium",
        "documentation": "Information related to the Novitium Pharma LLC."
       }
      }
     },
     "auth_ref": []
    },
    "anip_NumberOfConsecutiveTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of consecutive trading days",
        "label": "Number of Consecutive Trading Days",
        "documentation": "Number of consecutive trading days."
       }
      }
     },
     "auth_ref": []
    },
    "anip_NumberOfExecutiveFounders": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NumberOfExecutiveFounders",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of executive founders",
        "label": "Number of Executive Founders",
        "documentation": "Number of Executive Founders"
       }
      }
     },
     "auth_ref": []
    },
    "anip_NumberOfIntangibleAssetsAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NumberOfIntangibleAssetsAcquired",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of intangible assets acquired",
        "label": "Number of Intangible Assets Acquired",
        "documentation": "Number of Intangible Assets Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "anip_NumberOfOperatingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NumberOfOperatingLeases",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating leases",
        "label": "Number of Operating Leases",
        "documentation": "Number of Operating Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "anip_NumberOfPharmaceuticalManufacturingFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NumberOfPharmaceuticalManufacturingFacilities",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of pharmaceutical manufacturing facilities",
        "label": "Number of Pharmaceutical Manufacturing Facilities",
        "documentation": "Number of Pharmaceutical Manufacturing Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "anip_NumberOfProductsMarketed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NumberOfProductsMarketed",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of products marketed",
        "label": "Number of Products Marketed",
        "documentation": "Number of Products Marketed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1086"
     ]
    },
    "anip_NurayChemicalPrivateLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "NurayChemicalPrivateLimitedMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nuray Chemical Private Limited",
        "label": "Nuray Chemical Private Limited",
        "documentation": "Represents the information pertaining to Nuray Chemical Private Limited."
       }
      }
     },
     "auth_ref": []
    },
    "anip_OakrumPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "OakrumPharmaMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oakrum Pharma",
        "label": "Oakrum Pharma",
        "documentation": "Information related to Oakrum Pharma, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "anip_OakvilleOntarioCanadaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "OakvilleOntarioCanadaMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oakville, Ontario, Canada",
        "label": "Oakville, Ontario, Canada",
        "documentation": "Information related to the Oakville, Ontario, Canada manufacturing plant."
       }
      }
     },
     "auth_ref": []
    },
    "anip_OakvilleOntarioFormerManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "OakvilleOntarioFormerManufacturingFacilityMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oakville, Ontario Former Manufacturing Facility",
        "label": "Oakville, Ontario Former Manufacturing Facility [Member]",
        "documentation": "Oakville, Ontario Former Manufacturing Facility"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OfficerMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer",
        "label": "Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r379",
      "r1172"
     ]
    },
    "anip_OneMonthDurationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "OneMonthDurationMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Month Duration",
        "label": "One Month Duration [Member]",
        "documentation": "One Month Duration"
       }
      }
     },
     "auth_ref": []
    },
    "anip_OneSupplierMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "OneSupplierMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One supplier",
        "label": "One supplier",
        "documentation": "One Supplier [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating Expenses",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating Income (Loss)",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r363",
      "r369",
      "r372",
      "r922"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of future minimum lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current lease liability, included in accrued expenses and other",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liability, included in other non-current liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasematurityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash operating lease expense",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability discount rates (in percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r661",
      "r952"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r660",
      "r952"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "anip_OperatingLossCarryforwardsAnnualLimitationsOnUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "OperatingLossCarryforwardsAnnualLimitationsOnUse",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards annual limitation",
        "label": "Operating Loss Carryforwards, Annual Limitations on Use",
        "documentation": "Annual limitations on the use of operating loss carryforwards available to reduce taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r372"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r183",
      "r211"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivatives and other non-current assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r255"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Loss) gain on interest rate swap",
        "verboseLabel": "Derivative unrealized gain (loss) recorded in OCI",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications out of accumulated other comprehensive income/loss",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income, net of tax",
        "terseLabel": "Other comprehensive income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r34",
      "r271",
      "r274",
      "r280",
      "r642",
      "r643",
      "r648",
      "r701",
      "r720",
      "r1068",
      "r1069"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income/(loss), net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Other Depreciation and Amortization",
        "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r90",
      "r171"
     ]
    },
    "us-gaap_OtherInventoryDemo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherInventoryDemo",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sample inventory",
        "label": "Other Inventory, Demo, Gross",
        "documentation": "Gross amount of merchandise, goods, commodities, or supplies to which the entity holds the title and uses for the specific purpose of showing the benefits and features of the entity's products to existing or potential customers."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental non-cash investing and financing activities:",
        "label": "Other Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r174"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "us-gaap_OtherRestructuringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherRestructuringMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Restructuring",
        "label": "Other Restructuring [Member]",
        "documentation": "Restructuring and related activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r926",
      "r927",
      "r928"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r993",
      "r1003",
      "r1029"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r996",
      "r1006",
      "r1032"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r996",
      "r1006",
      "r1032"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments on contingent consideration",
        "terseLabel": "Payments on contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "anip_PaymentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PaymentTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Type [Axis]",
        "label": "Payment Type [Axis]",
        "documentation": "Payment Type"
       }
      }
     },
     "auth_ref": []
    },
    "anip_PaymentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PaymentTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Type [Domain]",
        "label": "Payment Type [Domain]",
        "documentation": "Payment Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction costs",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury stock purchases for restricted stock vests",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Series A convertible preferred stock dividends paid",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for costs of share issuances",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration, cash",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r610"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of Novitium Pharma LLC, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of product rights, IPR&amp;D, and other related assets",
        "terseLabel": "Consideration",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total asset purchase",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r1142",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of property and equipment, net",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "anip_PercentageOfConversionPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PercentageOfConversionPrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum percentage of conversion price",
        "label": "Percentage of Conversion Price",
        "documentation": "Percentage of conversion price."
       }
      }
     },
     "auth_ref": []
    },
    "anip_PerformanceBasedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PerformanceBasedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-Based Restricted Stock Units",
        "label": "Performance-Based Restricted Stock Units [Member]",
        "documentation": "Performance-Based Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares conversion price",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "anip_PreferredStockConvertibleMinimumPeriodOfConversion": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PreferredStockConvertibleMinimumPeriodOfConversion",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, Convertible, Minimum Period of Conversion",
        "label": "Preferred Stock, Convertible, Minimum Period of Conversion",
        "documentation": "Preferred Stock, Convertible, Minimum Period of Conversion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible, shares issuable",
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares accrue dividends rate",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r847",
      "r855",
      "r857",
      "r879"
     ]
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Dividends on Series A Convertible Preferred Stock",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r480"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r793"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r480"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock, shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r793",
      "r811",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December\u00a031, 2023 and 2022, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r708",
      "r953"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r394",
      "r395",
      "r912"
     ]
    },
    "anip_PrepaidIncomeTaxesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PrepaidIncomeTaxesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid income taxes",
        "label": "Prepaid Income Taxes, Net",
        "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "anip_PrivateInvestmentInPublicEquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PrivateInvestmentInPublicEquityMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Shares",
        "label": "PIPE Shares",
        "documentation": "Information related to the Private Investment in Public Equity (\"PIPE Investment\")."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from public offering, net of transaction expenses",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of convertible preferred stock",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Borrowings under the Credit Facility, net of issuance costs",
        "terseLabel": "Proceeds drawn",
        "label": "Proceeds from Lines of Credit",
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r1076"
     ]
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings under Prior Revolver agreement",
        "label": "Proceeds from Long-Term Lines of Credit",
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of long-lived assets",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r176"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from stock option exercises and ESPP purchases",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r28"
     ]
    },
    "anip_ProductDevelopmentBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ProductDevelopmentBasedMilestonePaymentsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product development-based milestone payments",
        "label": "Product development-based milestone payments",
        "documentation": "Represents the information pertaining to Product development-based milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "anip_ProductIntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ProductIntellectualPropertyMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Intellectual Property",
        "label": "Product Intellectual Property [Member]",
        "documentation": "Product Intellectual Property"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r685",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r908",
      "r935",
      "r954",
      "r1057",
      "r1097",
      "r1098",
      "r1106",
      "r1167"
     ]
    },
    "anip_ProductReturnPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ProductReturnPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product return period",
        "label": "Product Return Period",
        "documentation": "Product Return Period"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ProductRightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ProductRightMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Rights",
        "label": "Product Right [Member]",
        "documentation": "Product Right"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ProductRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ProductRightsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NDAs and product rights",
        "label": "NDAs and product rights",
        "documentation": "NDAs and product rights"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r374",
      "r685",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r908",
      "r935",
      "r954",
      "r1057",
      "r1097",
      "r1098",
      "r1106",
      "r1167"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r270",
      "r273",
      "r285",
      "r292",
      "r307",
      "r315",
      "r316",
      "r349",
      "r363",
      "r369",
      "r372",
      "r388",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r442",
      "r444",
      "r446",
      "r447",
      "r614",
      "r617",
      "r618",
      "r633",
      "r640",
      "r704",
      "r718",
      "r760",
      "r813",
      "r835",
      "r836",
      "r922",
      "r950",
      "r951",
      "r967",
      "r1070",
      "r1100"
     ]
    },
    "anip_ProjectBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ProjectBasedMilestonePaymentsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Profit-based milestone payments",
        "label": "Profit-based milestone payments",
        "documentation": "Represents the information pertaining to project based milestone payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r232",
      "r237",
      "r238"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r251",
      "r716"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Total property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r705",
      "r716",
      "r953"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r232",
      "r237",
      "r714"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of property and equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "anip_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1010"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r518",
      "r526",
      "r558",
      "r559",
      "r560",
      "r679",
      "r680",
      "r741",
      "r782",
      "r783",
      "r846",
      "r854",
      "r858",
      "r859",
      "r878",
      "r904",
      "r905",
      "r923",
      "r934",
      "r947",
      "r955",
      "r958",
      "r1093",
      "r1104",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r518",
      "r526",
      "r558",
      "r559",
      "r560",
      "r679",
      "r680",
      "r741",
      "r782",
      "r783",
      "r846",
      "r854",
      "r858",
      "r859",
      "r878",
      "r904",
      "r905",
      "r923",
      "r934",
      "r947",
      "r955",
      "r958",
      "r1093",
      "r1104",
      "r1160",
      "r1161",
      "r1162",
      "r1163",
      "r1164"
     ]
    },
    "anip_RareDiseaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "RareDiseaseMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rare Disease",
        "label": "Rare Disease",
        "documentation": "Component of the entity related to rare diseases and is considered an operating segment."
       }
      }
     },
     "auth_ref": []
    },
    "anip_ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of Assets on Completion of Project and Launch of Related Products",
        "label": "Reclassification of Assets on Completion of Project and Launch of Related Products",
        "documentation": "Represents the information pertaining to reclassification of assets on completion of project and launch of related products."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification, Type [Axis]",
        "label": "Reclassification, Type [Axis]",
        "documentation": "Information by type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "us-gaap_ReclassificationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReclassificationTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification, Type [Domain]",
        "label": "Reclassification, Type [Domain]",
        "documentation": "Type of reclassification adjustment affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1061"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r988",
      "r998",
      "r1024"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related Party, Type [Domain]",
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r667",
      "r668",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r810",
      "r812",
      "r844"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r295",
      "r667",
      "r668",
      "r669",
      "r670",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r810",
      "r812",
      "r844"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Axis]",
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r668",
      "r1156"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Domain]",
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transaction [Line Items]",
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r817",
      "r818",
      "r821"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to related party",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party Transactions [Abstract]",
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related Party, Type [Axis]",
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r667",
      "r668",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r810",
      "r812",
      "r844",
      "r1156"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r664",
      "r665",
      "r666",
      "r668",
      "r671",
      "r757",
      "r758",
      "r759",
      "r819",
      "r820",
      "r821",
      "r841",
      "r843"
     ]
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on borrowings under credit agreements",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of Prior Credit Facility",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r1076"
     ]
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfOtherLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on Term Loan and Delayed Draw Term Loan agreements",
        "label": "Repayments of Other Long-Term Debt",
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r296",
      "r297",
      "r452",
      "r483",
      "r670",
      "r915",
      "r916"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r577",
      "r1165"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "anip_ReservesForCashDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ReservesForCashDiscountMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prompt Payment Discounts",
        "label": "Prompt Payment Discounts",
        "documentation": "Reserves For Cash Discount"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r989",
      "r999",
      "r1025"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r990",
      "r1000",
      "r1026"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r985",
      "r997",
      "r1007",
      "r1033"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current restricted cash",
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1074"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "anip_RestrictionPeriodForSharesIssuedInBusinessCombination": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "RestrictionPeriodForSharesIssuedInBusinessCombination",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restriction period for shares issued",
        "label": "Restriction Period For Shares Issued In Business Combination",
        "documentation": "Restriction period for shares issued in business combination."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Activities [Abstract]",
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRUCTURING",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r420",
      "r422",
      "r425",
      "r430"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restructuring activities",
        "terseLabel": "Restructuring activity expense",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r424",
      "r427",
      "r429"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r427",
      "r428"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring accrual",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r426"
     ]
    },
    "us-gaap_RetailRelatedInventoryPackagingAndOtherSupplies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetailRelatedInventoryPackagingAndOtherSupplies",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESScheduleofinventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Packaging materials",
        "label": "Retail Related Inventory, Packaging and Other Supplies",
        "documentation": "Carrying amount as of the balance sheet date of items used in storage, presentation or transportation of physical goods that are targeted for sale to end users."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r202",
      "r712",
      "r745",
      "r747",
      "r755",
      "r794",
      "r953"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r316",
      "r389",
      "r390",
      "r567",
      "r568",
      "r569",
      "r596",
      "r597",
      "r623",
      "r625",
      "r626",
      "r628",
      "r631",
      "r742",
      "r744",
      "r761",
      "r1175"
     ]
    },
    "anip_ReturnedGoodsReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ReturnedGoodsReserve",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Returned goods reserve",
        "label": "Returned Goods Reserve",
        "documentation": "Represents the reserve for goods returned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Revenues",
        "verboseLabel": "Total net revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r362",
      "r367",
      "r368",
      "r374",
      "r376",
      "r378",
      "r514",
      "r515",
      "r685"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESConcentrationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r1053"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r906"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE RECOGNITION AND RELATED ALLOWANCES",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r504",
      "r505",
      "r517"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of revenue by geographic operations",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining performance obligations",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r235"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Performance obligations period",
        "label": "Revenue, Remaining Performance Obligation, Optional Exemption, Remaining Duration",
        "documentation": "Remaining duration of performance obligation for which optional exemption was applied not to disclose amount of transaction price allocated to and timing of revenue recognition for remaining performance obligation, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r952"
     ]
    },
    "anip_RoyaltyOnFutureSalesPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "RoyaltyOnFutureSalesPercent",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties on future sales (as a percent)",
        "label": "Royalty on Future Sales, Percent",
        "documentation": "Royalties on future sales as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds after issuance costs",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "anip_SalesOfBrandedPharmaceuticalProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SalesOfBrandedPharmaceuticalProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services",
        "label": "Sales of established brand pharmaceutical products",
        "documentation": "Sales of established brand pharmaceutical products"
       }
      }
     },
     "auth_ref": []
    },
    "anip_SalesOfContractManufacturedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SalesOfContractManufacturedProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of contract manufactured products",
        "label": "Sales of contract manufactured products",
        "documentation": "Sales of contract manufactured products"
       }
      }
     },
     "auth_ref": []
    },
    "anip_SalesOfGenericPharmaceuticalProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SalesOfGenericPharmaceuticalProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of generic pharmaceutical products",
        "label": "Sales of generic pharmaceutical products",
        "documentation": "Sales of generic pharmaceutical products"
       }
      }
     },
     "auth_ref": []
    },
    "anip_SalesOfRareDiseasePharmaceuticalProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SalesOfRareDiseasePharmaceuticalProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESDisaggregationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales of rare disease pharmaceutical products",
        "label": "Sales of rare disease pharmaceutical products",
        "documentation": "Related to sales of rare disease pharmaceutical products."
       }
      }
     },
     "auth_ref": []
    },
    "anip_SandozIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SandozIncMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sandoz",
        "label": "Sandoz",
        "documentation": "Represents information relating to Sandoz Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r116",
      "r608"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of carrying value of the current and non-current components of the term loan",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r100",
      "r103",
      "r143",
      "r144",
      "r146",
      "r151",
      "r200",
      "r201",
      "r930",
      "r932",
      "r1079"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of earnings per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1085"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of allocated expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r385",
      "r386",
      "r387"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of financial assets and liabilities accounted for at fair value on a recurring basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r635",
      "r636"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSComponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r87",
      "r686"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r924"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of components of intangible assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r163",
      "r164",
      "r165"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of contractual maturity of term loan and DDTL",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPPEandIntangiblesDetails",
      "http://www.anipharmaceuticals.com/role/PROPERTYANDEQUIPMENTNETScheduleofpropertyandequipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "anip_ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of property, plant and equipment useful lives",
        "label": "Schedule of Property, Plant and Equipment, Useful Life [Table Text Block]",
        "documentation": "Tabular disclosure of the useful life of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r817",
      "r818",
      "r821"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Related Party Transactions",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r423",
      "r424",
      "r427",
      "r428",
      "r429"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of revenue by reportable segments",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r78",
      "r79",
      "r81"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of stock option and restricted stock activity",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r107"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r530",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Valuation assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r103",
      "r200",
      "r201",
      "r202",
      "r259",
      "r260",
      "r261",
      "r343",
      "r480",
      "r481",
      "r483",
      "r485",
      "r488",
      "r493",
      "r495",
      "r751",
      "r752",
      "r753",
      "r754",
      "r934",
      "r1051",
      "r1075"
     ]
    },
    "anip_ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of accruals and allowances",
        "label": "Schedule Of Valuation And Qualifying Accounts Disclosure [Table Text Block]",
        "documentation": "Schedule Of Valuation And Qualifying Accounts Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of customer concentration",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r72",
      "r73",
      "r140",
      "r213"
     ]
    },
    "anip_ScitusPharmaServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ScitusPharmaServicesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scitus Pharma Services",
        "label": "Scitus Pharma Services",
        "documentation": "Represents the information pertaining to Scitus Pharma Services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SOFR",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg."
       }
      }
     },
     "auth_ref": [
      "r1148"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r378",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r424",
      "r429",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r924",
      "r1057",
      "r1167"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r775",
      "r777",
      "r779",
      "r849",
      "r856",
      "r864",
      "r883",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r909",
      "r936",
      "r958",
      "r1106",
      "r1167"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTING"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEGMENT REPORTING",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r361",
      "r366",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment reporting",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general, and administrative",
        "terseLabel": "Corporate and other unallocated expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general, and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount from market price (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "terseLabel": "Shares granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum potential to vest percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum potential to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Maximum Potential to Vest, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, beginning balance (in shares)",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Unvested, beginning balance (in dollars per share)",
        "periodEndLabel": "Unvested, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r545",
      "r546"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Percentage of Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate number of shares percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Estimate Number of Shares, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected stock price volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r558"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r528",
      "r530",
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation additional shares authorized",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation shares available",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at the end of the period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r539"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised at the end of the period intrinsic value (in dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r552"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r551"
     ]
    },
    "anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Intrinsic Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the period intrinsic value (in dollars)",
        "periodEndLabel": "Outstanding at the end of the period intrinsic value (in dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the period (in shares)",
        "periodEndLabel": "Outstanding at the end of the period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Option Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)",
        "periodEndLabel": "Outstanding at the end of the period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r538"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Term (years)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share plan issued (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONPerformancesharesactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r534",
      "r535",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r542"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r544"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r543"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r536",
      "r555",
      "r556",
      "r557",
      "r558",
      "r561",
      "r570",
      "r571",
      "r572",
      "r573"
     ]
    },
    "us-gaap_ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance shares activity",
        "label": "Share-Based Payment Arrangement, Performance Shares, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of number and weighted-average grant date fair value for nonvested performance shares."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Axis]",
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier [Domain]",
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected option life (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at the end of the period intrinsic value (in dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercisable at the end of the period weighted average remaining term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Outstanding at the end of the period weighted average remaining term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering price (in dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "anip_SixMonthDurationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SixMonthDurationMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Six Month Duration",
        "label": "Six Month Duration [Member]",
        "documentation": "Six Month Duration"
       }
      }
     },
     "auth_ref": []
    },
    "anip_SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Slayback Pharma Limited Liability Company and Akorn Holding Company",
        "label": "Slayback Pharma Limited Liability Company and Akorn Holding Company [Member]",
        "documentation": "Slayback Pharma Limited Liability Company and Akorn Holding Company"
       }
      }
     },
     "auth_ref": []
    },
    "anip_SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Slayback Pharma Limited Liability, Company Patents and Pending Patents",
        "label": "Slayback Pharma Limited Liability, Company Patents and Pending Patents [Member]",
        "documentation": "Slayback Pharma Limited Liability, Company Patents and Pending Patents"
       }
      }
     },
     "auth_ref": []
    },
    "anip_SsPharmaLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "SsPharmaLlcMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSScheduleofrelatedpartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SS Pharma LLC",
        "label": "SS Pharma LLC",
        "documentation": "Represents the information pertaining to SS Pharma LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r346",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r372",
      "r378",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r418",
      "r424",
      "r429",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r924",
      "r1057",
      "r1167"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/Cover",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r259",
      "r260",
      "r261",
      "r292",
      "r321",
      "r325",
      "r333",
      "r337",
      "r343",
      "r344",
      "r388",
      "r435",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r480",
      "r481",
      "r485",
      "r488",
      "r495",
      "r640",
      "r751",
      "r752",
      "r753",
      "r754",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r793",
      "r814",
      "r837",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r1051",
      "r1075",
      "r1084"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r49",
      "r243",
      "r276",
      "r277",
      "r278",
      "r304",
      "r305",
      "r306",
      "r308",
      "r314",
      "r316",
      "r342",
      "r389",
      "r390",
      "r496",
      "r567",
      "r568",
      "r569",
      "r596",
      "r597",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r631",
      "r642",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r663",
      "r742",
      "r743",
      "r744",
      "r761",
      "r837"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r376",
      "r377",
      "r775",
      "r777",
      "r779",
      "r849",
      "r856",
      "r864",
      "r883",
      "r891",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r909",
      "r936",
      "r958",
      "r1106",
      "r1167"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r342",
      "r685",
      "r749",
      "r772",
      "r784",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r812",
      "r815",
      "r816",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r837",
      "r959"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEAcquiredDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUEHierarchyDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/PURIFIEDCORTROPHINGELPRELAUNCHCHARGESDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONFairvalueoptionsDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONRSAactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r342",
      "r685",
      "r749",
      "r772",
      "r784",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r793",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r812",
      "r815",
      "r816",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r837",
      "r959"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r992",
      "r1002",
      "r1028"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "anip_StockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "StockIncentivePlanMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONExpenseDetails",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Plan",
        "label": "2022 Plan",
        "documentation": "Related to the entity's Stock Incentive Plan for equity-based service awards."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Common Stock (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r157",
      "r202",
      "r751",
      "r837",
      "r886"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Restricted Stock Awards Forfeitures (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r157",
      "r202"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Restricted Stock Awards (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r202"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Performance Stock Units (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r157",
      "r202"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONStockoptionactivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Shares upon Stock Option and ESPP Exercise (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r157",
      "r202",
      "r542"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Common Stock",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r157",
      "r202",
      "r761",
      "r837",
      "r886",
      "r967"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Restricted Stock Awards Forfeitures",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r156",
      "r157",
      "r202"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Common Shares upon Stock Option and ESPP Exercise",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r49",
      "r202"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Stockholders\u2019 Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r160",
      "r161",
      "r184",
      "r795",
      "r811",
      "r838",
      "r839",
      "r953",
      "r968",
      "r1077",
      "r1089",
      "r1152",
      "r1175"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "anip_StockholdersEquityAttributableToParentAndTemporaryEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "StockholdersEquityAttributableToParentAndTemporaryEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, permanent and temporary equity",
        "periodEndLabel": "Ending balance, permanent and temporary equity",
        "label": "Stockholders' Equity Attributable to Parent and Temporary Equity",
        "documentation": "Total of all stockholders' equity (deficit) items attributable to the parent and temporary equity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MEZZANINE AND STOCKHOLDERS' EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r291",
      "r479",
      "r481",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r494",
      "r496",
      "r630",
      "r840",
      "r842",
      "r890"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/FAIRVALUENarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r649",
      "r674"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r675"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental disclosure for cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplierConcentrationRiskMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INVENTORIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier Concentration Risk",
        "label": "Supplier Concentration Risk [Member]",
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_TemporaryEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mezzanine Equity",
        "label": "Temporary Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at December\u00a031, 2023 and 2022",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r438",
      "r439",
      "r440",
      "r446",
      "r447",
      "r574",
      "r710"
     ]
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, par value (in dollars per share)",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r96"
     ]
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Temporary stock issued (in dollars per share)",
        "label": "Temporary Equity, Redemption Price Per Share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r96"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Preferred Stock, shares outstanding",
        "periodStartLabel": "Balance (in shares)",
        "periodEndLabel": "Balance (in shares)",
        "terseLabel": "Convertible preferred stock outstanding (shares)",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "anip_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of Series A Convertible Preferred Stock from Mezzanine Equity (in shares)",
        "terseLabel": "Temporary stock issued (in shares)",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/BUSINESSCOMBINATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity",
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails",
      "http://www.anipharmaceuticals.com/role/RELATEDPARTYTRANSACTIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Series A Convertible Preferred Stock from Mezzanine Equity",
        "verboseLabel": "Issuance of Series A Convertible Preferred Stock from Mezzanine Equity",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "documentation": "Value of new stock classified as temporary equity issued during the period."
       }
      }
     },
     "auth_ref": []
    },
    "anip_TermLoanAndDelayedDrawTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "TermLoanAndDelayedDrawTermLoanMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSFacilitycomponentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Loan and DDTL",
        "label": "Term Loan and DDTL",
        "documentation": "Information related to the Term Loan and Delayed Draw Term Loan."
       }
      }
     },
     "auth_ref": []
    },
    "anip_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilitymaturityDetails",
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term Facility",
        "label": "Term Facility",
        "documentation": "Term Facility"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ThreeMonthDurationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ThreeMonthDurationMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Three Month Duration",
        "label": "Three Month Duration [Member]",
        "documentation": "Three Month Duration"
       }
      }
     },
     "auth_ref": []
    },
    "anip_ThresholdNumberOfTradingDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "ThresholdNumberOfTradingDays",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/MEZZANINEANDSTOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold number of trading days",
        "label": "Threshold Number of Trading Days",
        "documentation": "Threshold number of trading days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1106"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r1106"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1088",
      "r1155"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
      "http://www.anipharmaceuticals.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r225",
      "r382",
      "r383",
      "r384"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransferredAtPointInTimeMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations transferred at a point in time",
        "label": "Transferred at Point in Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred at point in time."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESTimingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligations transferred over time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares at cost",
        "periodStartLabel": "Beginning Balance, Treasury (in shares)",
        "periodEndLabel": "Ending Balance, Treasury (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, 263,943 shares of common stock, at cost, at December\u00a031, 2023 and 149,031 shares of common stock, at cost, at December\u00a031, 2022",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r104",
      "r105"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock Purchases for Restricted Stock Vests (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r157",
      "r202"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofChangesinMezzanineEquityandStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Treasury Stock Purchases for Restricted Stock Vests",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r104",
      "r202"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/RESTRUCTURINGDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r421",
      "r422",
      "r427",
      "r428"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "localname": "US",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/SEGMENTREPORTINGGeographicDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "anip_UnapprovedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "UnapprovedProductsMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unapproved Products",
        "label": "Unapproved Products",
        "documentation": "Unapproved Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) available to common shareholders, Basic",
        "label": "Undistributed Earnings, Basic",
        "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r335"
     ]
    },
    "us-gaap_UndistributedEarningsDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) available to common shareholders, Diluted",
        "label": "Undistributed Earnings, Diluted",
        "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed. Includes the adjustments resulting from the assumption that dilutive securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": "us-gaap_UndistributedEarnings",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Earnings allocated to participating securities, Basic",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Basic",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the basic earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r334",
      "r335"
     ]
    },
    "us-gaap_UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": "us-gaap_UndistributedEarningsDiluted",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Earnings allocated to participating securities, Diluted",
        "label": "Undistributed Earnings (Loss) Allocated to Participating Securities, Diluted",
        "documentation": "Amount of undistributed earnings (loss) allocated to participating securities for the diluted earnings (loss) per share or per unit calculation under the two-class method."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r334",
      "r335",
      "r1050"
     ]
    },
    "us-gaap_UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UndistributedEarningsLossAvailableToCommonShareholdersBasicAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Undistributed Earnings (Loss) Available to Common Shareholders, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DERIVATIVEFINANCIALINSTRUMENTANDHEDGINGACTIVITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative unrealized gain (loss)",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r831",
      "r832",
      "r833",
      "r834",
      "r871"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/DESCRIPTIONOFBUSINESSANDSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r229",
      "r230",
      "r233",
      "r234"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INCOMETAXESProvisionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesAdjustments",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals/Adjustments",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Increase (Decrease) Adjustment",
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves from adjustment."
       }
      }
     },
     "auth_ref": [
      "r1080"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments for chargebacks and other allowances",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r303"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Credits Taken Against Reserve",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r302"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accruals and allowances",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/REVENUERECOGNITIONANDRELATEDALLOWANCESAllowancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Technique, Discounted Cash Flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/FAIRVALUELevel3Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/COMMITMENTSANDCONTINGENCIESLeasesexpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Variable lease costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r952"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/INDEBTEDNESSCreditfacilityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted Weighted-Average Shares Outstanding (in shares)",
        "totalLabel": "Diluted Weighted-Average Shares Outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r320",
      "r337"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.anipharmaceuticals.com/role/ConsolidatedStatementsofOperations",
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic Weighted-Average Shares Outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r337"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "anip_WellSpringPharmaServicesIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.anipharmaceuticals.com/20231231",
     "localname": "WellSpringPharmaServicesIncMember",
     "presentation": [
      "http://www.anipharmaceuticals.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WellSpring",
        "label": "WellSpring",
        "documentation": "WellSpring"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "b",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "a",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "b",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(27)",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 5.P.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//250/tableOfContent"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482309/360-10-15-4"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//815/tableOfContent"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(13)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "65",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-65"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-66"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//420/tableOfContent"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12A"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEEE",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4EEEE"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//850/tableOfContent"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "920",
   "SubTopic": "350",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483256/920-350-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "35A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "SubTopic": "10",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-4"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "25",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480270/815-25-40-8A"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>119
<FILENAME>0001023024-24-000026-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001023024-24-000026-xbrl.zip
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MP7QD+,Q7,XI1YO&1L3!?S2A&&<-'58+YUB;*V_&5RE(X50+W?F+V*$O-5 G
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MS!_!![[U,';ADU2$K@,2*8FH<@<M:AEIZ5?YZ0QXI9%FK?: 3EYB0!S*0%&
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M-)[FWJ B"K/5WFL>K]>M9]FMC@[W#MN;:>-SM'=R\G1"<BF9+R7W@5F1-V]
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MZJFZG"X)Q<<-65H&M2Y<?.R_X(E0.9LIN)=# J<>BY"E7M?X+)V'M$DBIN@
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M8/"=;.LEI5^56I&0 3HN*22%,(9&2\ : "\-R$)X?[*87*DIZ=J<;)#0ZR3
M/L0<_8C,#S)Y/)C[H9-ULJXC9KGEHB99I8R8K ZBI+E].OLJGY-29+TTB4S!
M.&BW86/Y[\I8P2!WDEJ476K1_M,\F^7X IR]] #,MVW(Y\9IL@SX*/:ENI>/
M4S9/[I1XB%WG&BGESDVFY!==?-0&L$LW+&0CL#''UL4_DDY=\@;WZ:Y*.W1F
MO=OI?;W;>8]*CH:S4;<F%[,9L8I#>=Z8OT,J9*[GKN#\>V%1*)5E J)L$Y45
MZIK%4J6BFUI0H2\Q7"%J10PHOTH53F+W)A9G&L=&][[(M#1, %<C.9U*XJ_9
M]S#),<OU;7\(M$(+<\8KDTTST,R6\RPRJO\YD$S9I@E0^1"HM>CTQ6+P,*W;
M[XU9F8'1*;[$D747@LW!>8(?<4KDD>CB]R#TK=\"3W5[EI&>[+ >E=W*ALA:
M<II#9L/ >0F+^V5DM+I 1%@9TE!!UTE!'\[P\!7+ZJ(M^5E^@ P1N.^Q&;Y7
MDNNHBIZ^N5J/JOW,[1CR<C1>R&*9A Y,H$U.\ ))CEH][2)4?"M:WDWW(IN%
M27&XE$<5IHP:)A_W58EW@L/Q)BLSR]-=[SX ,:1G?"4KT(:\\A'3@R>=<DY#
M53!)[@=QMNH9#'.9V<E&ZF0>L<01T<I_86 D3:[7Q8*-;-5@(ZG>:^BBO;1Z
M.*T43LJ.LR7(Q>+CAJYY:^AJ8LDSL@1-!F\(1Y$)Z3)1A_1NL!L%N]H,TIA(
M8J-2H!C;AV;4Q\;2NHPW]I5I;]TH;CC-&" ].-BNHQ/XMG)27O% V.IM0)AD
MTG' ':?8&C*+PV5B,?*.%"5I4GW2Q92,/["Q,C^D\3'SX>DMC3\QH+U-6>RZ
MN*\-YM2J=F6DX3SP;:+97IF&#ODUJ]OR*M-$]3/.!F,+!4CIX# ]ORB225C:
M149.5$DGB,;88&M/ D<&F$+NH7?0R#J(4H3*>%6F6Z,NT<CV"4L7E3M A84D
M)X8JN[+N@JXY2A >.02,U+2L#R(07'#L"YKS3-/#-]\M>#DJ4Y^L%Y^L2ZDS
M^]E]+N4X_3'F1?$LBZXRK)$VE4:[$],L[UTG3IF:3%K,6H0U92LLM(=/I13:
M2L ^U-(]85$:(2EZP+G:J3_P;X>S^X"6-8U#$6<'"B#L*&)LS89X?NY)Y.=F
M) !%5+-CD'2.2!1B)KSG?@?_;HR#(A$[Y01AJ$E,JBXEVS]]$$3C[+(]Z5"A
M(%$]T^M#M,5#=$-;;-UH=+S<DW21/T=4 97@]I(;9 PK>VIP9I_-5, AG2[I
M%$9RJ3; C65GQ$K;K8F(ZJ'D8-&B?LG6T-6LN57YGK%(2I;P"D\D%YV@P(+6
MSUE%F=$0R)+HY"[H.$FR%!B06E7JFF]525N<,M'0F7GVF*J2<*YF)OJ '!J$
MLO$E]]*[$#/K%HJN/XT56!/$$?V[\)0G_,J:G5_,SKT4W:Z6N5(P450\( G1
MY"R4#(1/-D?QK"1G \V7!!##.GM5(K' !J'0D#QDV$K!)O X>_X2L$A.P4I5
M0+Z*+KNT:SG&=F%I?A*.933*EXX)V3QXF8Q7J-'5:6=-G5.79+TT4LQQR#&X
MH>,1LCZ 8@0SJI_W] 2)!=Y"G5:WB(/WZ[0Z ]:RM;2Z<LJ9>AFK4,..=S)V
M6&EL\4YE7=]R%D<@IG2^7E>.6V@W6T=))C!<EZ8D2^R9,NLH\,ZB\0,.7I@I
ML88W!8G<T-'"$$OE13*E7D6 L'9/AUQ1HM)(,W(8DV'KS(%?XK=9$:DDM>[/
MPXIXS5QX5S?_^7JG7P![!CZS,IV2CIJ%HCNHR!PWXNIWY([34 H5*J)H#[U#
M\E*.7!P\>,_Z'4^'C&5^O=-;ECY&*19!SC*+8DIBIP]IU+:\>^NXN>LP;&UO
M>[%P[]'(D\.\98&%BC3* <GDF\BIL?JM!%92""X7C(D+[CT1$5>4"7Y+'9BD
M"63:;8PI%2S-UU1^/59,?,<;!B%Y]ND(0[QS.K80-;5J^:YJZ3-A=*VS-?EP
M*X45+]HVT^L?54QB>:>N\BJGUXRR&/PF3_<73F+ EN>*9.)(,G[+=]*16XOG
M_JBLEJ2E%@'#8!!%LM4)WNV!#V2+E8>'ASTPW J8]QXL8?4ZR/(BL8LI?YEO
M1M9/9[7@QMRR!^M2%7=5CCG^D')?>C#*>P8&T8YVMG M5_&35) A;X%)KQSU
M7(0!X].R69+TGQ<S%W7_H9*BX@TRV2(Y+-3!JCMG63LM$*K4.$L6H&%IOM)K
MJISL]$PKJ#_C(&(*YI4-@4CO38#3(E4E1[7(7*J4S-+ :</X=QRE55IT,Y%F
MZ<!C9(H4S2?&*0H#G@*\F0=2RY]TQC'=(#<1:&4);Q!/R;I-:1YD62BIW$X]
M7'Q?0K>=8(*0HJW"8&HHH&P4EIZXC#<<<IG **-->](>37+3B(6'P,T^8N46
M#E#QDH4IZN)J8MESB;,T5*SKQV2Q@I#A!4KS4F>%L"10X]3-B+[53V,ZW2M]
MD#Q58&;Y,SUR&IG:3R:OX$K2<=C$O+&03;(&/%L'J)-#;\#,";%^4I8RI.65
MB7UWTTWKZ]*1NC+GD7J>")$W3C!+3M^/UFS3@[I]0AVTB- C/(820W; "K/
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M.32$B-BW7C"(+BSRL&4<4+]/TF7MVVGBHE:14TG<W%#F?":'4%474K7M':*
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M%KBI^7%'--XCZ1Z6)60V:565N2/\3MC5!_0?B5OFF 3EG(:DT%^M'#]\+;)
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M)5S@U&G<P>"&_/X9R0ME.P;OF>9_#*CTD'H. )(&46/5B,?HP8#:!)E-/8\
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M,DV>#3OWP ?N^5.&EMSE&V?G^NEG7C*=XX'OOG(>&+ 4_&?]Y3"^%_@D$/7
M^C_K<_>9U\7%]%G_^>I<+YS\4F8]:MO\3QR__[5WUYC[SEW/>[^0<^R9YBGN
MV_&N+^ 3+8;J+^@9X,ASZQ^-"V"?*SO*$R X697MUJ?I#L3#E%-A]DMF?U"R
M*6JY/F&.+/07W,F&+&EZ )Z_#/GK-?%S-A&I5AA#9DT\==ME:3LG@FQA3VU.
MZQ+L]>#2!UD9^CQ\KM7'D0IQCY+T[,T@*7#AHC:Y:\I:XC01W'W@]MAE6_;.
MAK_O/OJ HS^_P7X<W"6<<:1JV)^&\NB<DJ=*^_KPP<.O0BO6-U\]3(KMKFKV
M!?FI2DGW]3??TJE3-<O,T-<=A!:]&%R@TS@C#Y#$&6E@AV\^RNH,R".LH;\^
M'%_7F?0RHPQ _)1?RE/FR3</'LP^Y%???O/^#_G5WPX]XM>3J\HC@CMJN<PZ
MLB=$[5AH(L)$K+ P)[3-F$FX1C(@(QY-'^VYN*YP^XV(';3?Q)FHNB@@?_TQ
M2\CH-7%/A=83V _,I!N BC@J"6<@M,KJJ$@0/+0A(8G7IL%CZMF/?Z@>+._/
MNW$(0E\,+=BBZ5T>(=C^!3PY]X_3 MPU9-26;-10))&^*&WG),N]'LJ< VPZ
M8\S;+_'VQ!*D0'_YH_O6*^3UL;&DS\\Y75M2"W2_>P89$B&C")=(F**:B66_
MA]H07+ALB]PK,X1=2,+FJ8L&UD3E^6_9=O<=8149\95JQY4>@/R!UX8W-I6)
MVSI_>2M5LR=OEP6D$2!/."96NN*EO?SA$@(E./@R3N^X19[5ZR%;2WE'65*=
M8> D%Y.ZEMPQ7-8B=+YHAM[G '$N9[+EENX"5'=$3<C=?MNX+V3L[K-.,6<;
MT2;I?@-&=23#]DF.A-5>:@<\$5RG:B\**1T4S<X%69=<5J*-G(H*#BE.":^]
M'@JB^<-SHAQE59&U-173D&WK6;0A-]B[.*-W6>C '?8&#FR2__Q?B_;?_W/R
MK;MB'A[Q/*7)$^IAQ;MK$Q":OFF)//GO@9>*^_73FHCG[A]69;Q)0.&0+;GI
MB3+XM0>+N*G&<H7<A!\4#GRI:.W6L#^_L2&6VCHIQ6PI.WIF,SE;/(5XG[VA
MQ%CN@1B\-U/=-*GLVNU6UI_?14NR ;*+:%]2$=&M?.K03ZFTWH<B;<FS)158
M]SH79=MP65W;9MUISX5,KZNJ??WBQ%"K+';U:I8GXZLSS[6 >[AA<MXZ2;AS
M+V[6):MBBUH0.=W1=\'7$'\4'_2*KJ3&Q+VVD[M^?>U=J4VWXS(-+3+D,I%?
M71<U<#W\5^FP'SW7U_ZYN$I+71(W1+#>I44O9));93@47LJ^J>"FL2)L6WH6
M?; F9VW6=2JU1>LAD[;B-4IMK=LM&4XM]]FBW]0NLH-ID*S0P/*\RTU9$548
MS0N.ED73TB)F@C[=/FXZ=D.ORYV[65;-<A!>):GD#<[R[\V6<\\EK=Y+]R8[
M*&Q\7IRN3T>3^# LD?!=+B:6._6%5<Z[5_WAC(D4Y::B=?@%>\O06'-W7S=4
MV&F%Y)+K9&T!+5YS@$B0;SQ]TG;T!1T7JZ*J.6SU6_1 A :@#G0^J?C#$!EI
M6:Y#G6Y^XV=E_:;(W79Y)N<9)"B).@83=<GLL.8X%AY!/P9D@.2%W!.@AIY5
MS7HHF.,*3E7)).8>@93+B7G_^ C.>[@9-"S125!S.WZWH8+5NB&+ +]F"YD+
MV$*/;MI34$,&RM/Y@,J'+BI4[]@'<&<BU*HZB><=4#:4T?""><CE)9\+\ G?
M?''^0I%.(=\J_AQ",O)$*)<A]3A]4.;D1,-AWP3OZ4#75^,E#3,JU(QY]@.%
M^EP6ADC\F]2/5>9?+$5)"-?-B.%>BGWZB- FLB57O"\J6>)>Y?K8)U39 >."
MIRP /L;Y9'BWNJG=%T#]&?=?>(0CE6^48M?=PU?/MB4S%V![,O R&=R!V'.T
M*A[^!KXQ9?*I["[5],X_ 2A-2ZH[=>HPL)2)L.Q?T&#1*R-]3M73H$ ARK1T
M_)(^#;O._S,"RN$M,C*[9!!O24ONX3MJR=V;J/=UTY,D&] 6]R[.M>LU>I'D
MA3M8FZ[9;3C,I3P<'V2J>N"\&@+%U0+^!;ZODZHL!WXHYM1=T&'Q!Z#?/!Z9
M>!&MT]VHQJ IDH@0<?Q=RIWX8U *2+\U"^:K2H@(Y\0G6YP?HD$CO1"T8L47
M]E?M,M;63&&QD9QR_@T<7;AK%Z*M0@3&X[]8_+/8:A=H^K-5LL8M:]K4X31F
MIYI3\2[ ;-8UDO$,LB0TCW=GS.!["AGBZ.:'(J/DG>_(+)FLS#2>SY)- [5D
M9Q5:60@^VR&G%H$+UL 7[!L=K_E);@+-=5$)-ZPVJ&$2/?9'7I4%RGXMO/%;
M 9N^J'0$7*04\)U9Z\Z)M5Q5O!><#G%<<2SQ^Q+_PV.)_PX\RZV5^._*<2@M
MG-BQK[)5T>^3P"A%OWTMT<Q].RKG\B*<.J"WI.X9?O=Q*)AZ3].@SC4]N!L6
M;F"=G]]'"1XY#'$=XT<6I-B)".!-4>Q& 2>=7IZ]#(^%5$)%,HF4 ^XV/A>J
M:(EUDX&Z5%UCVVR2Z>NP.AV]I*KOB8PV!]!!# "YCI(2V6&Z_8D5$EQ\/TZ*
MU$5%P^I5R'A<D;<B*D))_@JDZY)(^2R1'0UCHQDLPK,1<K:MN5H4UIX\LP0_
MSEDAU0*,\MJ=[]D^_%,YR.@^V7)S^#@.[Z!Q*WOPS))O5@<W"-I9U7/,),J8
M89/B'F9(I[&V[0D%214*-1V5HFV[&2"X:UT(/NN?(%;*\;3>]Z%4N%+C<?8-
MD3HMW'K1$!7,FM!Z9@V'Q/3,PHA2%)Q'0\I$?QNBEL:P\+$R'U9+6"79)0H1
MDM.4B[OU/PC9.RU8316.[^WO4G9FL_@ZA1N'U8H6&WF0WC.3Y)/""K>9V]U"
M%Q'TT<R2ZYNFDC=Y@T4TA)UO1L1K2&KF-<_VSJ:=H.C@2Y=WH6/TYO:=S."3
ML%[=3+SJV4O<E#LV^6Z!N=FXIS ;F*6RBTW\M:4ZR;9Q10B(8I:#)?4+T]1D
MU)!LOHU,>#2DW6A(NVA([;;]U6?-L!C='MC"/%U"]U=,+Y\<72IU!EBQH5,+
MMMPO*U^(@*>.NI?%>/\:B]-K-P8_,S(NO=DELIG<I$4K)$U>@<5!"%"XUXZL
MTN>?/7GUPV=?8 455*-[)*-.]VJHR%!(T+8:6!N5T$H^'\(&P5UE[AJL,>O[
M!DCT$';C,4T3X(5V!GYN.#$M!LP\9K@BF:O1X@CY,44B)\..!?N<T:D*="3U
ME\ ENQU//4EW8,-?B>0Y9ZB2\QJ>AI:W^[:/W<)=D>-3X]Q,T077.IM>[<5'
M8NR6+!':'&_W"8DZ>G%(Z3:V?7_HZ2M;+T;B+(.[$A=MG[SELS<Y7](I>O;M
MEU]1KB+;,B/[Y_B"N![VPYI\-8I9YK+,&22?II7(GJ!F<%\]>:07H-U*!U+F
M9Y#2LU0C0;.&=MU<%HL.G%N?7UY>GF9U.<JUG+H%_@53K=+H^9WDOOX]E#K/
M'IS\PP[IS-__3SH>9/_7O^'+LP-.)7T,EX3T*C_N9M)M,!*5ZAKD&-!2E3FW
MR[VC-X?TODQP2QD&3RCN=BQ1,SN#)"W!*U)LIN%&"GMH:_9WQ6%S8^H<(N0X
M7(QOE(QTV"1#)3/PM':&B,P)Y5?. +=H=PU5O((548>R4W6UEHWHW&>3'X H
MP9KNH'^7TPP^<6[CLO,Q R:T+PQ$^GS(R][0[A8II7HU+\/&=V3D9F_NS1UK
MKONU3\WZK6@14TI&S&<:#PZKBF7J3J9J-?';$H2#?$O*>#4IMZOQ$J'+@U2>
M]IV;!9GX4_=,:-[7J"K\I>..$7V+=7B+0-9 "7J_(;2"(!N"),\$>JD=NU@&
M.JG)2^TA=NOYWQDY<@"&_?#L 4C2:N"Q 5#[M0! Y^_9D!?NZFGR4^FBA*[I
MLS3Y^IMO'GXY<PR4^?_WV?59@;-O/[NS9\=3A#AGYZ> K+])OL_HG'VWL^.#
M)LKFW\(\O'-GM^BD_],@6GEEBSJ#8*FVJ$'WS?(-&M$YO,RX^SPOUG*" $M^
MFOS_S:!)8!26N-G=IW@S'U/Y-GG:WN=\C+PL=A\3GDD6QIQ@ACS]JC%1A3$,
M@&?H!26Y,V'42\B#H%K88M_[LL<9(V>$W0W**Q%?%B"X6BJL0E1S31-+Q E\
MI +^ U*VL^14L1XM#C(LD!7@E[%LQ'SG.]%A,/]_+T12.IG:)6L#K&RYH4H,
M%F#12B&: 5XJJ>=[,BT\NWCKABO7%F I+F%1K24Q8IMKTQ%2+!2]?1.#TGIX
M:O^0K_#R['6QSJ2%5KM,OSLNPUM:AD *4 ;JXH"J\E@W&8W2M,HF*TKP"QR>
M*A9/E\P26KWD07%;]5@$E3NLA\XN5@9'2';BN 1N:PF<0ZZ5:XY:,L:QQ;$2
M:RDY6]0.NWY*K0#;)(9+][K6+SG4Y>U-I#FTYX_3>%O32!):<HZ'SI= QX.
M#C-U_N*IS&K@Q*B*>MUOD%FNLKT0:S32[9Z4*YPN0!;1J<(I W_=XX3>UH2^
M$KZA6 BZ\RT!06:9D6J+PM)MY>ISNG_#@&K2!V)% [$9+15*Z<LF3.E4BE"U
MUGGZ0-45T7F=NK"_-L4@+Z0[__%$UE_(-X,%KO1,4B6Q+,Y^<[Q<!W#^P*@,
M=7!VPC%4)+$<_7>)&<H)+V T9D+LX+R.-U0PI'<RLL!IZ R74?>4-C1BUSZG
M<:&,GH=_TB.HQ(-*OCR"2N[ LWQ(WHCC*?$>IX1@1PQS30R17A4YF3ZJ]^%7
M295==HD"D]WGN<!,>-Y5FPUL_+.%5O,\?#KD7W9M>0&>'H9F4DUA'V GJZRL
MJ#HN%+E[Z5)%\ISNC1!"U#A1-Q$]3N-:'GV*VW02)>SB]H]#=&Y4W!'$C_:Q
M4.0V/N.<U:"*@D]4$564\"$QK)QHN49'K^_L$@*E%6!&G#RG4]>CC;Z[$6S[
MN!C>8S&\F,TL)8HJ4'"/T"?W19:7E)#T9((-=]Z-YG1EO"-JJ6=OS%].!#-%
MDE)\V)[$@7U&8*M:;NJ1M<72WHK9@D-.ZF@Q;FN1?#\Y/U99U17"<&+)8A94
MM7.^+7*#+L(8B$.0S@HJ;KI)*7,2V-238AWXD<=F9>D^+$XUM_:YN2_<_[(3
MGF=;)G%;D>D)174]U@35=UP6MWF02)]D5:R!A AH06E>*-9E5PDIL!=R(=MN
MF+C&\QY.!&8=AEW@SD()52E\BD\2REI8!D#/"QAR6H'2&/U6GI?QN$!N;X$$
M:B<2C/9(6YC^'2G*DXT@2VYY,X/MCV)U5.0S++E!5H6A_70?/L[D[56JO+^H
M+)_C/ KO8B5<U_*.\1<Y8>5+.\IN,6+K/<[A;<WACR'&<_$\*M7>/!/&WLR1
MQS=)B"9[<SQ7Z4S*/SWF_#_LM/X]:]M2A%BY:L8N<V '(#OK'&I#$!.5U8YS
M?U_G_M=B4HNE=@(S^;Y?DD5N2./>U_I@Q']N+DK(Y"G'Y[-GCSP"5/^F,-#C
M3-ZF+]TL*HFCV%]5*DDY;74R4FHE"G1[$D8/M9UVYRD-]9NZN:Q3_8!2;!.S
MMB\@A>^DYGHYXBW(GF Y,=6)72K.]QJ.V_KVDC+4M.?[_8:>JAO.Y!:[,B^V
MY;)+F8:AYG\EGWMASN>_/'U\<O;M%S*[HPRK5/4PPY&HTC$5^_%V_?=-P[-"
MTK_G.6T\%>900_S]XW-/I)(W!2.>M5\.)(%4?06LD-O#J@Q]]^X(%H&@D6P:
MAU>"4R?2$X7_X&7Y05#;%[+(<!X\/N_\<[@KGR_<RKPHR>)<_<US^U6U-.QW
M1(T_02TA$.F.U>*DN(!VM\NLK34-)6CU[B:EU./"_9T90:)(G:VD'UQ9C\\I
M@*>5H# $:"XP&U4MTE18R(&FB%3:""B&!2^98HG^BY+2?:3[Q7?)JIE%@'OB
M8?(V$_F.4=Z82)#D8LNLNP+">(V?*^MY$3H$JFF1ZPADO+U5^911,F2%GM1$
MV4:)Y0-&]?&3&:,JZY7!37L%W@ P90!0!B\BF&X"@ "5W0T+9H^*:AP6_!&^
M>NAK#"^AQ5143&I7B$ 31W+<4QS!6XZ+ZA;1L3\1 5:)4'I!M #+93NP6BL2
M63Y?+:VNTYY6D8L=A5]*"[CHT!T$ZE\JG+HU1ZIN!HW+]?C!F=36O4ZN"G"S
MGSW:EUL%2NO4:W,<KXT6S6U"*?=#M@-='G$A*SG>>*7(@C I&;LNCE-XBQD3
M4IV]*-<-B2(?T &^4O-8O!.*IXFK+VJJ,#AWQ3Y0(2/VEHY3?(M3K)K##?A5
ML;<B]<UL2SN3Y!J5A90:L+LB:Y=3!FTA(TC%6KM/*#V!)M]"[9)=2CKLCS-]
MZWF2 % 7,96&&P5EKV&+%D9,Q8BI6TBT=]N))P]-#B$9MI1^Q%!T1/3)Q<>J
M)&5;J3?C(4C&Q7F-Q#1\G/=;W.$MAIG<8(/,%GUCY^E+ SY<<W=),N%2MR3]
M0'&>Y5O"'BN<A[2&J(VN/O'P]S0IM8PY:4UC^Z^WZ;EV L/O4QED:3R/DL:J
MWR5":GT(#)51VST!G_*&RN6E.[$J!D]4%&7WW(<>P%%9Y4ZE?'_BPVYS,!T-
MTJT'H+:OP0UWKZE46)8*1!$#SX-;:[W/P?[S]-4IK1BW_-P=J!9;LYC:9,E)
M>M8'"I2J. 8 '\KP*(M*\18^GE304#VIF80DFVF_LDT[8FJ(S+QUGUTZ_[&@
MD\N77?5JSI"!VDAS:9*P^JTA[959)"U%E]/UIT$I.E2&FB]/IB/+J:>\+7 !
MU(I.-LUE:I!T[NN;V@WW6I3<5 6&=*3X/8_=*J%;Y:MCM\H=>)9CM\H=-Z(D
M)BW$ S DP/N3AC="-0($[HQ"]QNKF&&;TK<D6N /P:ZHP;@1&#F9Q:)JF.OQ
M<M-LY32=K74&#H+CZ7G;;KN)Q=F)MWU%_LS9>]HNJ?=A\MV1]=]#!B$Q'ZN5
M0AZE34AN0>T8E,QIFG ]A3E)N[HY*GGVBXC=V^)1CVOBEEO7A!N(E6P$H;!P
MUGT;_XE@YG!LED61$T<7U_*@Z@B"-?=?BV():1DIKW!AN8$\8FH[#PI3+!*(
MLC88:-H^HCQHB]W0&^ZS786<8D88=Q*B\4Y_+'9S7$>WW@+9D6,NQ;9#HKQL
M&C1[MQ Y&.XZ\QHQLI)2=#/)>;4:JM2W*]A:-#0>[!KKANUQLF_5@_!:S"S#
MS&5XR*,B& *1# ,)*/BAED*PHTF@%+H+/*=SEC>[GA> <Q5<<.T"[+83*R*(
M=JJ]$LY64%.KLJ.F.2*D/L[WK<WW3]D;)E!S]K00T>M=ZUS!<D<!\YYY:B@&
M8.9+-V=EGYR#8"ZPL[]N!Z0&9>=V!ZL"RZS;'"?S%BVU264:I4.? ;ETP?%8
MPUA.4LUCD 9R .8PQZ=GFQYUH!M*^.#4*6>^F^_QU;T4UM+M?"P46 $N 92>
MD-5=MVJ8Z&2%EUAZ#<R9QSJNIML\"F2W?\\5'>*,Q'3C: "[BF@\U'E$1N>,
M>:;<P.7*$^>A[330V6CBK2O"-Q@>U@P]-3.S7<J+A3L\:M9@RPEC[2+;57@@
M*3"A-,R"E;E?J!6)46JJ%TI/C/=AM;FEUTH.ER[\E8^PGUM;6"^SDOK;5> /
MV$(W =2\"L6(T=]864N#T#(R&KFS1+U(K+"$)1<DB0+4.1LY$2E==4-*:\H1
MV-A/+'GI@U:),K:+IFV)M-/6-Z$6*T^,A4I/IEPA@PAIV>V@;=1T3*H"EOC+
MNJ7&29/C0KQ-"V<8,OD8DR-+5H$2<$9S:E:)*3Z2\@'NR+(24H&:O1R3<_@*
ME17'0PM*D%V *\XPF8AF=JZ$?BOM9?CU+<\:7?'F*B;'W?!A=H/-!S.=/Z\)
M,H#7];O1^B956;OX[<4)>![OJK#620+%N1K-%FJ&8%I.1QHF;]W"%1=TKJV!
MCW,D#$Z@1:6I3*[+2?&.?Y.]M54YXD_B+!1MZW<2^KDK&AJO+<,TIVY,++9B
M.FLJ2M;<;68[R0V\WF=SKS8<33L#UR=^_V";>*WT+$HAW>M@I*'V!'/+L+"B
M'EM_39XEAJ =6J;NKY!ST80G*9Z"@.FD:IHWW&4OZA7NSGGAV<XYHF!I&F;W
MSDGM> &'4EQ8&.RFAG0&?0". .@'(<1ECH0#U.!$9\C^B;N"&7]11L^(9CI\
M(G<!-CX ]-16!REE%<]K.;[>P<@3;(<07HK>D3>@"4,98>D>ZO>V;G0#3794
MH"#]LDP^F%H.;&*UTOI31'4OC+E,BV7X= /;"<6.!%5KO3@:>_R!>??PIO[T
M:NM?'VOK=^!9/F1M_>.<5H=%.SK6:V%H'HE^B9FY@T?O07=U_O7^8!T""@WK
M=:-20(9L4('3,VR]07R 3K*AMC67:T4%WD]3X-ZY3<_KY+ESC8 L>_AMFCQ\
M\/",T*-ML2Q*%$E#(Z0V.:*#4GF_1Q.MXZVM+#TZ&LCI0!9< !C+#8E;H?NH
M*2&#2LNA:7/2F0V.3;8$BW'QUBV/=B%##_)_N.,[9PBZ956T[N )/<$_O?+M
M=S1[FV)P'D13PI7I-TBCA,^^/ _-PW"9Q).A/M"W!"4!K#MK]^PY@Y22.VSJ
M8N=> (KCW;[.W:"P*#NUX^3%18,-;5U/JB53D:BI"XZ7F7H;8GLT%22TUZF@
MEVT4H#/<K..NI"2BH>GNR6]S%_'?#W1E;C;/O@D/QW[ ;%,9_C!"44B@/E5B
M&#]3B.CMY"V&LLJ9;@OZ6@POI9JX[8:@:5:U82^C+C6TU,OV#E5U@L(8:&:=
M=TE9AO^=U0-FQZW8A]1PZY?Q@X=?TA(&621\T9Q6K%_'PD+NFVM8;8LC*/=N
M67)VLGUV(2CKL5"%U57%(L_RWTCK\>+ 6I=7$T$47M%K-R1[LR)7E3-/H@ZI
M#X)K<WQ(C7FXG5U3-3F+//Z^C.C#B/E-*7:+45$,B1J!5H)]!*8&B1F[GC!N
M]>"&#4U.'))(5&7F_4;2/F3_CHF*=TQ41+/CA:_U2-22E)R)6I+"MDM#>3J-
M.>*QG;EJ16G WYS%Z_)RZ?."G&Z;'N:^%P#+%/=P0_;M5\>:U,>?^K@E:9GM
M N&/;V#I#8EB4/(@B<6?GG=R27L9QLCU44^B^T7=>R:AT1+)O#8/''9P;M)5
ME0.8A7PBZ*5Y!2UFK$%C$C^(:@G[0WSYPT\OHB/?TPS+J@X9K20P#UMAU(NL
M1>$X:J=Q)A= $%[4Q\SK;:WJ1=MDN6UNG2XD4/UN]EWIEARI0GM-ZQFU,-;Z
M9-$P=4H,"SW6[E"[M7&<UMN=5N*+BR95&Y8]L%&]I-%L0P0 I*Y$ZW/VU^](
MH]OMRE9E9NC2H8NE+_FSQ^F\Q>FT)+K2VNZFTC<045Z8O<' P,QIW0WTI.O@
M+&2YL^O-$@"698-Y!R.9FV$7%@56IT>O?_0&'5?-=GO;$!N2I;9ZJ"WV$UHJ
MDA(PX52K79'RV\(7))6V#)E9X\E3">7HW=SJ"M-0%%&A6PR>50="8TP^1I6Q
M%6*?Y7[&;@C$QMF)C@/XL$XM9]-X6H^FXY8G=A1>6MT6S>99(,&(K#(L"_,A
MX/S< \\B\BWTTN!HWNZD)3*7+S#,VA/:L?9<AQ9[5D\'Y[LL/--'DI*^^HDB
M(Y2SNATU:C.1& @N*6;GRW!ER:CC]('H/E[+$?3@N"#_Z 6YD" CM1%'*MT:
M(3XN5H4"\>:ZK"7?1HN4T/_W+NO[=&5ZAY7H%^<P3DC(1/NBJ$_QH$C+!&)O
M 4\OF(TF%MZ+XM0X'3].I%E*LBD!PN_(SE,N4/=_&OK:1V>&1U!.6N$Y+B3=
MF(NBW;,#Z^'%PH&+Q>!BVVT7/"$O=*S4J1Z/=,'-W*L1HVX'_4#*.K;)JB7"
M+O2A3:]LD'>7SL\IXC1O%XD-4E7=C6(3\"D>M$H)]'HR%2$,9]NH_AWX#2=*
MD6.NPQ2#E4W"YST@L&6/8<R F8_':=OPY)B\%)K7U2+'=[R+F^L=RV'22V0U
MLH(""=9ZI$RD:[9=9[4FW6ES<79\G&NIA6A=>0+,_O3T0>P*$;"#20:B(EP.
M>D/UE @7(<+?@60PJA?HD\\]=91R0GIPO-JBUC?!0P$C<1>G^4H;"N(O*FCZ
MA%S!C G1V(XSL%CH4?XU&C"JV3P\FTXJM(_*?C ^S=P4QZ55/Z&_,AZSSL<"
M[D$$)P&$H8%+8I_4+, PPU3$\08<$Z@NE?7 R.UR1ACM#JEIHC8,6131EU(^
MHPO1*WO_7=#RL_1I^.ZB;*)>7'=TU,+9TQ;+=BB=<=J4://E)DH^,J@L,[=R
MW9"Z\*$NJB-*)J!DOCFB9.[ L_R)43+O>))^+VF:#ZDN?^].)D":A0?4E'P)
MYH"J3ZK0^!!A&Q]>SH0T]M\Y,')&76F! E%0<!]+HCS<-0BW5=1]%.2K!#@1
M9%Y0XQXXN@MVVTF&8EFVRV%K*8]%5X+C=WM^X27C">XWI!?(F>(8ILT<9U@B
M@ WH-_0<\L1$: #.F*P(LA9Z0=_29_*)7++7AL-ER%H-)5>^[!,LT=N5DWJN
M9= '7SGRD2726XP'=4OA!+*IP]9'I"BA52*!=QDD6M  )@[:./0B.C=BL8AJ
MAV\+@B 8Z3SX:*9GTNXLBPH&QVG.F39W1C)%HF :S%;DM5 <40"WEL+(2^JW
MX85FW"J/,EHU2]6_"Y8LWB/4RH.-QRBKL$95J#X('A9K2<:ZS5Q5!1)EQT3X
M[27"&_ .9"9PG^>/#4YK3#ZP(BS2D7+H%N?(!1"PE3Q!$954R(QX<![')$>R
MGUN;#6NA)&LT'GRI):.Q@U@PV5$Q:7U+\+49W+]"B&J;I#(C^>";_8\;[59A
M!*J.4:KG)LE-TM-0;H74$"N$]E%B<D$5V/J&&;78H!383#Q$^%2<<LF6;XK<
M@.CF;A3=Y[@(;L_;$;>8>7DJ]F8(LBP;GQK@S*X_2HS=]IR$?E,"0&./>!S@
MG $>>96=BUI 2SS>@#:09$I9F&D4(WCG<Z4M32[*I@K- &A=M:$JPOZ=BW Z
M:G*-! ^#*><*#K<J\L_F<\>%<UL+)ZY^7;9E7YPTJQ47T8E1JSN6OV]WY_:"
ML A=Q4)?-Q/8S^[EL(_M?E6]/#C &CP.';7SP-%" ZQA)DG#W2.R_7N79WO*
MG=;6B]!^9G@3E+_MLS>B_V;XHR3\COJ._9CX^F]1D\-*-()SB9?XUH?RH'-*
M$VVA/7('I'U]^3^Z06-[B6%VS:7=8AC:48';6-4T3KUZGXR[6RHT11^K+K[J
M\M=CU>4./,NQZF)*W=(V=D"1(+21P"<\?_'T-/E!=W;*&&%P(]9KM&U2;(UO
M00.Q[+AG@Y+/W/5&1>TB6V[\62*=E]R/V/6A=!RIFURXR^0DI@?6K 8Y,G\K
M%E^D2C-,LRF@(ZG9;\ [4;G= ]B*D65D;"#JXWA6?<N8AVBL<J\0IGK,\#L'
M5KIO1][S&-)IM2>CSC*CEEIV@8G=U*"H =&M"/"-%4H4!C>CJ>F?,M@$QJ*#
M,2HU%=I\)*C-H>\@7.S%3QYSPQ#^C>;:I" ]D\?%DCC>_^U_G'WSX+LOSU)I
M%JT;79P7[H.D?8/"%,M:N .]*M"K>_;@+TSN"#P7BED[M[HV[O[==?=+Y%8/
MJ9RE7Y/>ZK<EEH[;(6??_D6Y/\(].)%?%W[QW?1>9W_$:YW7>RVDDDH'8^4C
M)5/:KF$6F]9.(@+$>A]<&KY V?H^K0G]CB%UN=DZBP6#:0TQF[+B@IGBVT:"
M\\0_\W=65\G=@CTC<=,NRZZXDBOH(.W,+V4K##-&6$SD-SG7E.%5M(4^#/8\
M5P)3'PS.P=XRZ2,SDWYFW$V^Q&=PTP>:UG\J[R-H*/F7J5B^&/8E-Z<F<P 4
MJ7U<6O_V1HJ&/%) ;$+C,U$8)^29,)G KN?V:GU6GYC5]980!0 3XNB'8#UH
MKU=LD)&!HT7 Y-B 1 5H8E%U!0,DM4XZ$#MON5T, &)&%];Q93HF.@H617]9
M%*$VCHD03A[M/N)_11>ZS 03E2MOMWE.GL'QDU)AM:4T2#IIPN8S"Z X)!?K
M?M1JB8-HQ;H4IC/2#=.R91XQ.N3D*C1QV:5?YITG;O"KAPP,4??E[G4Z\!IP
M(&$YS/SY'IWK;H3Y[-Y?><3?\%2_[E#7[L[5_JH#'A9+3FWBS?=T2O8 [WAE
M#!WO0Y31M4E)Z_U9\H(RQ>=*&_ *W^54E#8KO3@/?!.+O7)C<-6<4L6L%.)1
MYZ$;BF&U#!1.W&4(!J P.EV&*Z8$RY.SOX$[HM\ RK<I*R:  !^6CY[LR$13
M@+&'[AS>/EH(J4)LZ2GMB/M+N8>M9!%<V#G-9J^()=CO=UB![GFV>+6*+BVZ
MJ(HKO2S:PKA6WL25[$EF\44IQ1A2#GZMZ.[U'_1X[C6)J'KT1J$TW#AX(;AL
M<,@,ZC8GZR-I!2%]!]\8W18,K'3'C=R&J,&X5TS.&7IR_8ZW;-X!A#$6, <Q
MI\+.,CDK;3_W6U!4E'6W4XJ^IITEG&;-;IFLT-'L;B\GZHA<#*A]]^R>TH&D
MWO35TM#SHFW0RI,7/"VY;HKT>VEX,GC#\2E7-?7Z!$3#!E,%4&S)3_1(SH0@
M?1[L4(0]GM+:^4X^+G*+=!EQBNB._?GQ.1W+Y_@A9>8_6JLY#^Y!2_;]C-*'
M@(U"? !HD'-G6F"&@B?435VA97A)VM? X+=X8&P4,77Q)'=7Y#SN36CX"DT,
MDRZ!+L"V? 81="P$6;+M"I[B/+0XD$A/._J8UA"RY9MLS4%!E#OT>.1";R15
MNWDX.[$J<[>+[JP0A?JC/]9H9I/3&&0U)<3(I9G[!NU?):;RC6^K(L=XI<S'
MJ-L'_MP<"^?OI1]<%,;#32?<B?>0K^K7T;I2_8T8&"A_=7\DRU9$SFKGL[1=
M4;R9,(>=)J\ 0_31S3S2$0RN6$W$7+SJUV@IRG9N[#77^<(Y9K2<)A1";3%]
M$EVTG@;31CR3/3(U\L3 C;?!?JB+ME.H_WA9QKM4.9*+35:M/+SPH!3N* PS
M.Q)_FHA(GB;/RC>%DEFB?I!J5UG9;L4)LYL#=!ZV4/=NF\4(MQP46W=_/$U^
M;FI#R4^FI D/%3657F8M>6Y5T?=<S\!.3 WY$OP=Q1U@I#)BX.R;G@X;J(4K
M6F]GQ*5'+#SS5LK=*[_>+GT (Q34A,/#C=GVXJUR58+L#^/ICLCB:DJ\N2GT
MO&GF\+G#K63763M1GF?'3Y9LM#?WH_4PZO'Q#-(3HH/ \N>C$C[ET !MLPOC
M,UMC)-[8594M&D%%96V;2<%>]@3?ATR3:<H6='I#'6U@9:'@5I)X,GE18Y1R
MXEZCO'[E:6]YC^:.]J*++6-8X3@P Y\1'-VP*48X;$-U;Y)4Y!&&+%7/,<VJ
M["7%QKEG:@TS@!<)50X]]0'QR=";J?U-4;_9S+F&6(-7Q0?>P,=.JU#S^]NQ
MYG<'GN58\QOU+*M8@3-M_ZRIZO>JIR86\2$8BXY?L>]@2"X,^=:JS0;F'<T6
M@Y!Q\)\CJ=9=6UZ XH6N*>JKLP)<UIDAVTKWOI8>?FIO>+3_\W\MVG__SX/&
MZ.,[ V=?_P6B=5,7F^;(N05K$JA<48U'TMWD"+$DQ'2N9/"7$HRP9*$2%_Q4
MY,YM+EULQ3\AD'K]\NFC\Y=/4O7[^3+CKMRN*[EQRU_4>P$A7-%,"17J#CT:
M/=FLE[_CKPL0=&YE*4V<TH@I7T<KKJ[P-Q.;J]L,>G1'*P5)=!]#FTUPS:)6
M*EM=R89_T,49E&:GI2QO;11C=95WO+T\^R;Q;M3,?_6G6,H/1:PC*C>@%.+.
M8)YQKPTU7Y)3;65I-DLI,:M:%8I-Z)O_2#XOOP@5X7/(HORC7+Z!;"<9L:'W
M;>RT$#C&G=(Q^#8<I9]TBQH*GII2#$M=B>X" )V^+BMW4^[$IS.+"'YWF4L<
M)T(?4NTA:@WW]TVY*(6\==N@F4NA<_6:L@^X%_^=W7GFTT!52_@&=MF>G2YP
M;;?2]I"[P&A)<MDH-^N_4MZJVR)C?&V)E:<$'2C@O)6\O9LP-PJE/ HB"7<_
M2002G8!;=&4^2#2\*6R5#\\)W[K.?><&OD+BB9#=;B]*DD=E0T;;4Z1M_,:)
M1Y#9HM5\X6YJN&@&U)[YF?K.+0VW-B(#M'3/*^30;0G%O,H=.!472 %N]+:(
M/PC6.FHD=0&^>Y2]()%Y.>FDS<]8&!N:= ]EH&PU\,BHX.P3*=7KX -L)S9O
M422^CI]Z\"5/-#<#-L9R^[?W"^SP( K_8DB[\Q 008TS=D/EKDZ#YT8/4:(?
M/!VRCO>5;[;@<9"^4V;[[I:;8BOT$VI"]_99!(7HGXFRM&\XT,/3>"6;N"7
M7,&Y$\C6X$DOC EXH52BR0M5>'TU8%_617*.\I(8@YDY\Q*O>GB-<C K*F1
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MQ5=%44HLL2JUXX9Z.475 U&T:<">U7WUE+_N<3C]VQH$?6WE<H'UC>"A1 B
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MR1794.,:\"#-> ;)/TGH >MSG'2+J,CP ?]B)OQ(_3 1T:FFUK!*MPPCG64
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M0BW).HV>9/*F:> F(UK)4 3T#$:4#2/X>%W(> U,*>BE<Z/W&MS&$:UE/Y[
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M@_&2+?DPOD0L,H,-*_"OTF\T"_X-JAICB-I.R0Q2C$A%)=C*'3[:,;#!VKB
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MT]2*,&MPZ$9N<DU'H327TUX(-P1&71M"%K+&"-0Z14(NAF:%\3JV*#BZLY@
M*NDQ\!RFDG1B9&X9G&,YK.!\+L\FW+(77M8\%/NYJ6?[ BUJL5/Q-(@P>&5
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M4]K#T<9QL$ 9UMP=7-K^58UP:;ZPE0BS.J(@&X':4@76_P1P-J8W7I=+8(E
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MC#GS5S#*L,3^$I7K7XPH_9JMR7+6P?I@I=@NAZR%'!>7M^KX/HF9N46CAB<
M"Y7XH!S=K#YC) _;XM(\&J #=3P&YHQ+KI#\!9QGPZ-&Y#ELNPM NF*M$F8M
M$LICX@5)\X%D<TRJQ_Z*(.O+RP<V1Y"GH5'WJH4/>N1UXCKD))4C5J+)QM#7
M(8EV 1YM ="3*=?[./E^:K0JLQ"X>5"LCYY;[\Z>/.UZ/9IBTV91N7+"V$?H
MG>D D*0_3%POC"M\I*%P;YHZ'VR1L>0J5VC$U\:]:]($Y(VYJ8*EBRN1\H<
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M?9';,@CN#I52B&KVJ ZT(0$992POG2^2>%VZG."L3V?5-8A;]*ERCE*4;%G
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M%F%YB<"Y.9O' 2=9XM=9I[B/(MUVFLIS*WU;)9](.FV<SUUU^AE*CD2SE$U
MY43)PL%7K+2?@W06<-3<^/1&"VE213>5MI?4UB,YA#::*84JJXAQE:/P&8P.
MYD67.%#;?#''B!-F $"X$6P.[3RG=54GF6F!YR4L56:(K:*XR-%31B-)RV7X
M]:NW:_MXJ<R+>GBY'TH*O<1.3ZD780+V1QJ.M#%&+)H,SYU6$ "U<7:ER#XK
MF6=WG$*V;VJMRE8,RYL:M"C .B0.TUMKA;!^X$#,:>Y&5.R'A"W8.)4SKCX1
M>DX3#1"J$9/AA:+BT:$+ZX>$D)6NUDDYUBE%FPBIGY5&Z9I15S.J(>?Y25(3
MI4>G+_>7K(5EVA3VPRIPP 8R$C-=L8E,&Y#@*JFHT*K?X\0OU8/<LQ(YG/SR
MZNYX6Z_WJK'A-,)L[_Z&D+ XQ^16@@<_G5*[#D<&=TLS?$KB.G6VWE)U#TY.
M#KO=8>^X?WC2]%4[ZWAG-T@)RAOT9MV5:HS%2C'<"FLJ@1>KB[4_IBEB][?#
M8LAZ.54S<&PP;:7Y!*<.P9HP]F7"RFHHP+C$6,._T-D%Q@A=0Q[@V%UQ N()
MM,=GFEXN& ^)S3>J\Z>#_Y("=_10=]8=(@IL?I)RZT@%$ZD'SU4P1Q\;^1O%
M;EH@"&Z<,\R:P,"1!57'B^%KEN)9 :^MT)MI,(P)QB@UF ^S'Z-OF9%_/*6L
M(IEO.EI6I8.XY>L0@)R]')U KSY;.KAT!+TTQ1HQ^):Z[A>7\AL<M"F_!HSE
MI7+-_LWA<0.4P*4&I'HB[RI%)M,R1T]Y,]_H2!/I8JT,E/ZC=/H5.;XX<_!D
M!+5<ZVR_HLM=#<Z*N^Q*:Y6%1?6BMBZ55FL89_#29(2@'A7](PI,L#\YIIQY
M<VRG6T3*?EL4W#"XA6+@+*IZT3#HX-)8C#<X8U&7E]]C*5K-63(CF$U8<V:6
M,9<2$W>4<[.%9G"%&0"'/)>)2&*$R7<=C)LRU0Q7%=%H226[*.OD^>YS>;6&
M#14X_C2S;9%.JX/#.TG+H ]BAX32#&,.C@V"O-55ZW%)"<T"_5N[ZEQI-5_D
M1+A$CB/'1RF @)5UH.90:J;E3S;O,DZYPRXSUO)0[7QQ#8G2&H6Q[KY@6:V@
MMFK;R:_'YE@%7*F!87*.##H<BYIC!\,1+-*K;9"U0PB-,3__1)N!K(]=,S8_
MU]9F^BRS$Q4IB1[H8#QN3$%&RY5  MJM07D=@F+!"<FH65>")U4KJ[SR)!*,
M(UUO-5H*Z*7<EQBE=5]1\<O/9J&:>K^;)OO/W&3/%EWYR_ 6V,^(\I36[*L2
MXX;.O$E5G.U/O.'@J6XDPX@.PQ^A(HQU09V!<8HKM%<.'QQ- 9T9D:,]]:D0
M,IFUANV9SXL8:_/<S@_;9*FW7S"N&,#:B;#Y,<M:;JOB2LOFD/&5-,4R<;0P
MGKMD7Z;1+(GW+Q*NWX09%D\ 41WS5,47V#59\VISR-19TVM&4PX;[I?W.LAX
MAQ($7L,N:A:+*,IX%IP_C)(QH^SF7J][X'W$\^D<UEKE<(8CNM5OL!E5CNKD
M8PBG:I;D@7<X'"(VQ3<'8=>WO#+)5>Q;BR;!LBY*J7N3)%/887PUD7W.1&P.
M:9+VF1?!^#N97 @Y#QYW4F3*:5A'R0VB&\J68.I93 8-2S &BRO$O4K9E"@8
MX6=CT@"F?BRI,4TI+9/!=RI,2])-="69,8RK4AZB 2PF5;+J4V_[+M(?E;1/
MF0QICC;CR'T(1[D#(8@4,&"TY-R-OVJZUOMBGZTV+13PNIKE=Z8%Y!=C.PEU
M,YI9N>OVJ@+G9YG;X;;?L>C[;]@W&19"X";X'U0WELC V,ON%-NO9])OL_"6
M4\O)%M7/BDR#"#.>$&/!I7? ,&XC-J@RF.Y<#@9[@SDIZMJ8>9D- J;T]-,'
M[TM)@C/O#/;E)/!AA<<='W%69HE Y1 _J;ZY8H>X O,Y^'X91IC _@SR#=:%
M+P\5G)R/00H+8_%Q"'%%$BRA72%PA.I.L7&P<-'?J6\[NXD5+ 05F>AT"]-"
MUBZPQ5S4^Y#I'B=5<$3Y1K.K2QL9=S_I@O)72S.\/N#1!E<>%MA)94U9H\"+
M*+SG2-S0%WS-U:LCBU-F'XDM2J2!L]2 +_CSTK*LT(@T&L,#BR3#/!S:,>8-
MN*\,@#NY(?."2F0""\ )2N(/-4H+%!=XQL O2<S=HQ=2-=9S=9]"T^=KRC)]
MM<D3_5=X_39.XC]2$2YL9?B*<9EQ,'E%VA>V*_]B__ 5EA*$<YCD7U[AOV*P
MAWYY563[%T&P>/N>\*>#Z$]D>_N@4]SOL0]<>( _:WD\<VN.7G'P(P?[Z3I_
M&Q?S_4E",2-\TRL/213A+<-79&)-]_M'KW[MGG1Z__6F//1?#6L,"4 (T_4>
M)#U(I2>_A&'UT\KO+K*F?O<Q?/?@MN_^Q[G]8D,Z1]5^ K2CKJ5B"NTC<7U0
M9$"CH-<PEG /%I=2V0=K(11+;Z^NVVR;8+NDQ#.%Q$-@ZX% >.<V#?[[)8?B
M)7,<)[DM[EJG]-'[@@KVPP>?::&/>5/!-)TRW_I7M;WFNU>_<NH_1F+LN=<]
MV/]?K]>#;6G8\<N4 V2)<'#2&G5E(]+A:;G5:*((4<(<AR2Y7/QD3*'*@\[
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M-^CH94C(E5^%<)U@AV*<83]*DN\$1V]N179A)O-R;QDAC_#JFW!0J+Z\[OV
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M,H'Y/9B=9$3)I!HKC.H&>+\BO,.8DEGN5C:IA7#*E7_Z7"H5/9:&1FG_%>@
MIKHG\.8JX$0E67UX&2>4>6BTPSESK.O)35TG%;/S!TX59I]UPIB;L"A?>D,M
M_-)*#NMQ;[B5PUYS>_'^8&0U:F1V8G5K@XPV/S3T>V2A(M_#CB&LT.<9?/P<
M>Z?%!0)(]+JZUA;/J]^2()V4OI]2QY\^>'L.6 Q=Y719+!8)QC FWL<@A\NN
MO+]4$N.#J" B18S]V'E\P @Q_ +M=E%G%JB?D.MH\MJ&&FI$#K@#=ZZ49F=Q
MZQ [WL>T8P9 ;\_XC7.EBZ7QT:<(^4K:B $OZ674\B0ZJG3UIX2:^K6:/$O2
M14)P)7]B5JQR/Y4RZ^DUI<SOL?<J 'WD_=9!(H:9[WWLO.]@E2+H',F/FOG'
MJ!,V@A-$)\)^ZMJ25"DMIN5Y+$_Q+?,G'<P?[?R=._-76NB:Z_6R=^B#\#OJ
MBF!PS74-0JKF 6Z%5'\7+75Y\ 7<S!93S2N=5\T(2@6QSNO6M/JY/!=9B*OS
M,:"FP&..\Y4><P9FW?U66JK18" ?UQ6NAZHH:+PV_5*,X$+OLU0)/$\]^B$6
MP2(%NLT:)%.TN>!YU]49E;HKHF+)LH*$TD4,Z?G=X[Y_.#AD.\WH_3*)#)>+
M.\O9J-7@J!S%$L=*(< 2)K/M]V)L@C[LI^.#SE"C9M1;]T])^V/'FRH))!*B
M&%5#[L-J@I^*111BR">Z=]_MLR28&UUY![*H&7K(A#76.KH#5*KGX\.GA12V
M+_<Y2:>)4W'GP_-S.HHB*<G*$Y_$)ZL LG$$-Q9)X:X6+.&G.@N6P53AS7@A
MGA+BW6-?IBA;J16YS2G^$76Y/:WX5>F&!)R:?RP0A.1YXC\]*YRQQF.(>2W<
MUF[ ;2%PU48X58CXU (\M0!/JT_"EU?4>-06-39@+,^'J&E3UU:?YG])9]NS
MP2?[JJ:</T##XTJ-\"Q#HPT!TQ'QO&Q+=,#LH8..8UC2*!B7+)Y2FYV0;H)Z
M?F/Z[&_)"#=U_?]D?^79K/H','ZDO@S7?9L''^/G-] .(7MORS/3:^;,I)89
MRKIZI5Z]A,(R*5CT<4&HW7R9$QSPJ0H2:=8=8 #YHX]W^[JR$YG4\N!:<;3$
MHB80U6\32<ON#/]8%Y1:5L'!F<-HX2$,G%([O=8?(=KY3.M6-5E=];VL3N5]
MVB!$Q+!]ZMQ99.JM_N'=),P647#S-HQI_'33?2B)F?.9#*L\A?^;Z#?+GSOP
MIS?+OQ^"QW30K_W30:=;^_M5C^KV.X/!X4:/6OW[P<'PX09U^Z/>T'SQG,&R
MX/K^\JK_REJZ5+_P]L#KPK*^*5]VLG19;W&-%[Y;,N>K2\BKMZ5\\_^+%%Z_
M$YD#Q;M<GG CXOED[<FI^6JL]]C2-]=K@SWR9I,B0Z",UZ6OK/^XE<I?-C/M
M]44N] 3X >]V2PI<>^"V>;CS<VOWQB8/V)GYZFVR.Y8%:#Q6"@1HPVT#$[>E
M/?,)+(NO8EE4)>6NCUQOU0^\7= =/SW2Q[L?35WRC?KJP?'0/^X.__,_NL.#
M=X\S _BGC69BM9*Y:[.Y2JJ5W><NN_WNT.\?'S9-=C<^,<3DV)D3X[/Q/G\7
M[_-'+*UU#8PGN__9G_AGV&*"97]4>["GKG6<8:(6J1J'@>&L#N:(],PE#:O-
MZ=YF<U.K4ING7;K'7?^PV[^?=FG ^??<EZ=_[!_=5_FW*O[./$8]%-Z]=$#-
MQ^^(D/4'?N]X4^.X?JT?306L<PP^S]7I]?Q^]W@[J_/LC81S%454M2C%A8*G
M/,%6*4*P"B_52[,(AEU_>'+46@0-79[>P#\8#%J+X'%H(V[S#5Z867!XXA^=
M=%NSH*&K,_1/CGJM6?!(L0-L4[L@O'@79,Z;8@\8LQL@&PACS[\T \$?].X9
M2F_-@T?WY?RCPTV=A=8X6#M<X'3E8&O)99D=XF78!5V_V]_2P=.:!7>:!?[P
MZ*2U"AZIC3</XHN0F)>)E2"<+\ >8%J969!>O+10 ;70]]ZUMD SEZ?;W51-
M[Y8EL-7)M>GA#UQMO/=7DMU2C;?&<?,#M1K-$[X!^J?WC!YLO^+F@0R(9[6B
M>_U#OW?<7Q+Q[:WF$UD<6YWU#[KAP6US>&%VQEX/E,G@8'W):TV,)UN98__@
ML/?D*_,B+ SJ;MJ3??]:NIKNO_]WUZG=ZQZ>;'SL[)BIL(/+,CPZ>-:1ABV?
M^XY7X?VF$(M;5Z)Z>[^I6$W#_#4U^,FEW[#=\4<L@V=EK79/_..-\V.[4/'_
M8E=T;]CSA\/#C6V-!OD?.VB%?#"]U-H#\?9&HGU>F!G2]0].-JV4;HV1)[,1
M!_[1\.G-Q)=@BV#SY*U1SC55L,  ]&&:)TF!>112PVV/VH].3;.W9O?8/]HX
M*?F T]/LULQV4[S(3;$W./*/3X9;4:7W/N?>$*I+"RZ('>4MN& #QO+4X(*-
M!H123+23S_S5N$^^%^9JGFGR^A(&JH-\6D:1(NX"^"?N..0=A;^Z2%VUE'</
M/Q/U4"8&;6TG4*J.NAT0QX<!A.IU#HXW1:-Z=)0J'-3M*%PM2M6/HU2]')BB
M%M:IA76Z(S*Q"M;IQ0;*Z6QJ5.9C._/P\[T 6]K42RM1ZTG4LV]X:2&0UBY>
M.D0ZV$8'X5H\I+7ZYXXZVP!#:H(Z:ZL=[PSZ]3OW3&/LO' \T%FW([JR!8:B
M:3C:V.A[B*1Z$\2]K;>X6S:V 0W2!-EX669CBY"U;"/V.]MHK&R"[+<VXIW"
M<?)BA>-EV8@M5)@3'^QM[#4_%VN@M13O+O][L6[$RS(56]2T6R;GH(TKMC;C
M*@W9FHPOPF1L >1$%6X#/JX)XMX:BW>KPFU W3=!-EZ6K=ABZ34&2Z\)PO^0
M-N*/U3<V;Z8..@>/9S1U!XU7%2W2WNWS<]*Y)W?/,R[-:W'^?J23'OS1IJ#\
M-4&87IQEU@(.PC(]+:9=$^2\#=3=*1?'G0T01IZ+7+RL(-U]8!=_K.B_>>N_
MY'*T@:LVJ/D4YE'WI.':H85E_,$2^HW+1I]_'UG;F?@CSNK)/4RR9RQ,+29E
MFTM]$69':Y+>J1L'G:.GQ<-L@EP\J#G:_.S(G=B<]S -'AZ2L'E"<^]6SJT
M\#5A8VW'3'T)LKC7/=PDX_+2!7$%%&4X^>75W3B AX>O[H;YVQ)^TU>5%1&C
M[WVVZ'L:RP]!Q#)!$7,!Q#R$R:(.E!+^T]8^D9[X-LQ!;L9K?'0MA-/=@]\)
MN+_#7J?7OQT.[^DQ^L!A'FX&0=B.J4EC>CQXQ1:%\39+YR&F[L<O6W-]=R&,
MLQ?&<+ E!3QC<HO?TL)?MO"7]X._?)"=MQO??C8+XEMJII_YU__LU7S_78&@
M^TC]%G5H_9?_B:@<X3CSO=\SM&[#; ;'VV\IJE2&ZN!ZAG-U<6O3Y2,HV8<Y
M %_P>UY6W:%(LK>8!>D\&*N"1N8MTF12C//[(4_^ #O+"V!9V2&VE-[PQ!\,
MM@&^]S1<0*VT->G;>MT#O]N[9Z%**VVMM&WT;8<G?K^W:==K<X3MF9=\]XY;
M<(874??M^D\C])]66:*^ER8W083 #>QA)>1A5:Z&45R&XT=$3'^>-2O=@T._
M=[@E7OEV>>Y:GN' /SS:!D)#NSKK%%<?^,.-.>_;U7FJO=-O<?!>4B0+K -5
MM2E*%D/&,5DO3W(P&%Q&Q:<.=K5DP[M.)]P_&OC#DQ\K:=QI&NU6=G=6=GNM
M[+:RNZ.RVSTX\.$-SU!V[U&K_3RJL?O#SJ!1Z[F3%GRCVPI7E%\'J?+>AYD*
M,K5!P<3N$!ZV][>$D1N@%>-VF,AV>**JC&>>3.IV>WZW>]3F^IJY/(.N/SS>
M%$RQ.:O3IOUWR7,X.O '_=VM,7GFJJ [/+DOXWEKZ^^4F?/M8:+OM]B<=]WS
M:)W.C9OK]?7Y0TY-L_?>X'CH'W=_#,+Y:7O '\83:W=%NRMN"<)UAW[_^+#=
M%>VN:'>%M4KOY33L_J[8I#+H!>'&'&X.8K1-66B,;[.,'2-CH@\)XXF*X>YC
M Y+R*\$%K 0G67'7G8OP5#/PM_)@.<-+Y67%*,N#. ^#*+KQX'\0:B8I4N/Z
M>-,TF7M9$"E"H;G@2B;?2YU8,)<P+94VK5$N[24Q.5KF^6.0DR",G6OOK*?N
M>!^#^$:/NV84\B@OR+PK!5\(_\4K+W1[H?[[%)X-BF6^4'G(+*7XZ4N7X3.O
M%.%,CG/$X9E[>8+\IGD($X8_K_D@ CM0WK3(BU1UO&_P\R(-YT%ZX\T5K"[-
MA_.48)[$%^8Q( 0%O CO36%0*=T\AJWHTUC2  >GTCE,H<R4%\&:1C*EJ8K"
M8!1&87[30;BX%!=R4GH?O8GD(A48(ACQ1.E+ ]C3P06($,PIO)9>7Q(2>D]E
M#1*XR<M!EO&E'NH.?)7OZ:VT#7TPX57+8,YR=8$K%*0Y?$$V"Q>9-U+YE5*Q
M=S5+0$9!3E,6 9'&&R0G"V.859")&<P)"48:JGBL)K(Q1%+*0F(O\Q%1GB:5
M9MCN![@*!<1Y,[PES&?PG!269)'$J'K-DM3?71EG9Z72DCD98'AFD62T,&]!
M3((<%(5%/4+$(^<N.3 .["W!"(Z'(E]]RQ)RP+;\[)/R7+C_.TOU:!8@X_LC
MF.#O^\$4!OLVB*Z"FPSM$!>.*HSWW0FL?OO*+YQ.'^T+^10&Z4@8..PM'#@J
MQ:M@3$%CQN+-4C7]Y=5_W(W4=O3JUV\$\@4Z!JFE07BR_WH3_%JWC*NAPM[=
M<3H_E?A]<@*,!M+M!A&)5 G1C>TY ^MVI4#5_S0X'G:./1A5A)H:M3:< !/<
M\S^!H]P9F#_I!V?!''0!C#29H)I 9!343D;UX)S^!-Z$O=7WX%8T*'_VY5P*
MT40 [2?G =Y"!U@21<D5:B(\CY(T>[LN:MNJI;C#O!*;<Q\]U+?]8>4Y^]M9
MTVY/.!M[PW=;.LU@".]*<\-HM36B=G$[M(((66]XXDC2A$F*UY+2)='"ILF?
MZZ9EF[8P+5EY\_2Z!YWN>IMG@@9T[(UNS(=.O$LX^>9LUN)](_SZ49'!2[/,
MK[F.#$.\$OX4P75P'TX6/-^+@B(>S_A0=_$<^W#$7^F5,E=UO#_P48'Y XPV
M0[,#QNCK-_!J7,$6AOT<C\,%&7?V.\HV/RTRV6OT4\E&,8*2%>,9ZH33L1H5
M.2Q9Y(-J!O,C#Q?X\_OP(KD.09?\ =9K'H)HPG#^B(KD&JQ,_/DO=9F,@S0.
M^9\?PVN8GM/Y8J9R6.U8>><!6IZ_7^<L;U]5Q"['QS!+8!A9CJ_Y%.9I,BW
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M_J0?@?AOL?M;[/ZM8/<_(Y#Y%I2_!>5O0?GO_/I[@?(_> LM;* MJ4AMUW(
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M%3F).]X[*Q"T\YQ7V20T:XL%ET.X0UJ6M;D<%@>J73/::3%:R^PTN@=GM'.
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M[%^6TQ\O[VYNXEX.47CL!(I4)#1#YI%$W?"P&ZNNE'C#+X0V,GZC\T@4:"]
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MC-W@A>1V8^QQ1)-XL-?8P>W,)WRPBYP.Z=#,9)>]( Z=1\.;^4QS2FH&\(&
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M*D?3R<)I9&R<Q",-K*IQ]4!)3''#D;)$6TL.X43G, @$,\<.+[U?\2^%FRA
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M#:#*$S7ED?BZ\'P#4=O*3>0K$B\X!3H*V[#^)N%=)$I+UFK%E&89G,/W<L'
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M''/6>'789)R5B4[DGE& XG2S:F$)7CHYVMXG@&]"<F0B^)M@N1:/YKC&IJ$
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MI[NSMM66:_&8:8VVW3LS8053S6Q8^RIET$9L3L7[Z,&*W"D?H30$HFIK=BN
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M#"_DS3>R@PMFM6DWS7;;[+72">[-/*C\M,HM*5O2"GQ@JV.VFPVSV4N'2/9
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M?^9!N&%PN>S<OYKYO\P#>'P07'C3H>/22<8G?*$>\,#W;?@MM0->/.&/5^Z
MNN:N'Y9\17:_OUIY!:F#"1FS6<\9C-:NSO$NY*)R$N8US$XK9RA:<]+Q+N2#
M<5*:6>I@"=9T#OBMN.0[>T2@"Q:&$R*:P7@ 1#O4V][?O]J.BXBBMXQ 1^^]
M[T[H/!*GWT7'G&,B6*=1M(E@VADZY"V^=WYJ:GXJ-3^E[O(E,/5;,-8&QET+
MH;8[K9VA-K6[O6S"]AR^YK"Q<>'YH>_-GAS7^)5-C)G//DSLN3MZ,D9/MO^X
MH@_C?.S:5;/GH^.[\=EW.K@+?FYYE&E[2V6JO9G#WZA[)'M'D[UX9%_BQ*XE
M>YJ\W4J_T]5.YQL6'H?^?!3"38:SS7%F.0%R:J=SA\+C^$0'[EC8=%BW?^6.
MYCB.&G_.;<UALT;F*"OM*92 I]97(+\%4W5K.):UW2E*^:AFJ@.7(N=GJI7&
M6-<J6D"C?$[GE1O:[J.#\)IV$+#0<*8SV_$I8LR]3>ULKKFBKZ(3NWZ(CQ/!
M0,+@FP//91/GF8WS,'Y=>R'%XX(UE^K&;) F-_5=Y#3%-*F/=]5M)?$;V$_-
M2K]N-CK'*366C]L$S^?-<#S6HQ;MBA!RUBO;PGZQFL4V8/B\J1Q81>>CQ=:W
M_F/3OSRPW-H*(3L;/;/;U'@/Q:'Y!K @.Q$=<2);EMG..Q95$_VX(!\[$1W!
M"5LMLU?/&=G1EHE>V?E:)K%-PJ=1&^^P*$,CG*TS3*)SBX=XY]987;!-L,TH
M9\.:OJ7R4?W=;K;)DOJE?3! #^T4L]Y-0]:E!%#3_@"TW[1V;0^T[]6 ]MBM
M>CC:%\E0T=_?R;0HL#T1/C%?QC=,PV7+6^XVVEWQ5,K&.,(Y,;OUYD]P\V=4
M-G6%T[)8$/7HK!;N<I8BY#,G-K0FY,%R8T*HSA^>ZTDKXP?+7>72LRK].O@6
MS709X3+S0E>XG A;;>JAO E?(9)CUZQE !IHOCIQOMK4^WD3ON*HCKUZ ?BJ
M?/53W"A_)R[N]X9#E-OT B\]XV_J]>,IJGR>$( LID:PQE8Z':&#.\7+.>8G
M;JO2;W<.W*5Q;A1^H_#=&EKGO+K:E7[3;#3/,Y!7BKQ><5=6EK!@(KEH?&$@
M8DQ&"8UW7YC+'ISP/4J>S$/>VS]U?=3ZLNXH 2$'/SKN'(Y#9"@\-^!GS3]'
M9WKY,_1MX$#'M?W7JY!- U"%^%+?(VQ::=[GUH,=L'9Z9C<O:J*^$XL1+"@.
M(W7!LJJ;[7:Z9$];SD6VJXK$0SV"<*UEP+R=@U6FO[^'RBVKV$$=82>%]D^9
MD3'>#84AI>VFC>PF4$'"!A46:$XU4Z\1+&DMHXA#FSPG8O+LS@,6\$#3[&0,
M)-+F2O'-E=WI7\>1HF:S=3ASM4BF1BG"+,5=60E+SG^P<'6Q^::**FM;1]53
MOVRRDV*KVCW:6$#GK>MCZS5,"'?-3EZ<EL-=K9I+3\4@V-0@W(UAFS3JH]M+
MCR@XOAFH>?54>'53XW4W7L6NZ+K9KIU]SK(!6QE[<T06*IIE>,I+*Z'5^M5Y
M=L;,'0<&B/ =/ ,>/3 N/)=6B$=QX[,'A@ABQEWHC?[05FUQMK!;/5A2\T9D
M)BI';,&U\5UHAX1<CN@[H_RQA#;&$]OU(F:^-/^>"O^N*75[4P;N: ;6#+QW
M(W@7!D[S:!<+539OC"FIZ7NZ,='BKJR$=F\J6FL,GFUG8J/%&WI@ $^G:! _
MV3Y[\B9P4*FB/:UWRQ?.C7C@WN,<0*I8,, 7.W!&N2T'!'OOF%;KP,"2VGXX
M!3X^0,!W_RQMU2K]9L]LU=, /]H:UMS\IB'A-^!FBX+&YXI84Y+(;(&7=GJ]
M+IU,Z2;I,FQW;'QU)O.0C1?LYQOF<WOYT_YQ5([[L3VAH12!M-F*FY-V"3EW
MZ5,_[:MWLRT6^TY>=24#B8G"*SVF^N)]?&G[+FP^D-\6MZZX6&OQQ5JO]&O5
M;KINX&0'$FG./R7.7VF-+F7]Y@+O+S%*-Q:"1J7?J-8VSQMH_M?\?TS^;^V9
M_YO(_T6 ZSH],WQ9P<9*XUM'J8NSA;>WO00S9 E>BZROPHX'T7QY:C?#EI;1
M"A9MY[2--'=J[MRSW;*".SLY+9<R187U]T\^B+LJTO=O^A4;?QC PNQ'QDW'
MP+B>AT%HN[B5LL&;+U4J 6T]9]& /$!Q?C_FTR'SKQ_X,2JGN%U&JDL]8K5:
M.K]ZI@CE>8FWIE+T;:F'!1]ML]Y.WQR:>AM1;TV9Y)M2KX[(%W6SE='N]A8
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MHE5MM?/A8BS_?;VY&A;C%-94[MWI->DUG>N:.M6:M2\LH3*?4[O::*U>4ZE
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MVED*6![Y6G)WV:Z3)5)9:<V!.U[(/>46O'JEWVATS5:S^)G.LO?^$,T_#.V
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MQ_W_V7O3YK:1+%'TKR T/7=<$1"+^V+/4P0MVS6ZX;)T);L[^M,$2"1%M$&
MA44R^]>_<TXN2"S<1$@$)4S$5,LDD<@\>?;5\J8._"B,X(,%'#%LK(64>'FW
M!_M=^J&#Z/,^8*X5.0_LPZ-C1W,X#-&']I1 D6;RB#6!'<31^D=R=_!\(-\(
MX/XH#0O]O[A=I"ZG.YF.>I-NNSOKV-W^Q)K8W=9H,ADVF_U1!_;WOZ/6F7QH
M'L@C+*U[=CX)F/7SW)K!"=];[J.U"A'%==P$Q!0[ZO1ARUF K07+;/9L8.'T
M +P&^!%=)S '%N"O8$]69?9BS /DO_^Q_7X&0$G(3_C454 W#^>H6A=%=U_,
M-UKM(L;Q[$@[*$3:\;<KX^9_QK=_CB\___A^=3G^>F<:5]\N&\;XVR?C[L?'
MNZM/5^/;J\]W:PF]*D>YU'G5G>)0=%%6.#>^N/YC6(53[,FXWSD><&,_AE7M
M\+?< 4  $SXJ!DK"%+;K6LN0O9=_?+"=<.E:J_>.1Z^@ASX(M!1<%UEU-E\6
MP<*_3OA)H\EYBDC7%6\67S?@J]_SG_>&C5:W7?A5L]$J_'S=4JUVHSDL?F3=
M4NL_[S;[KWQ3W8U+;<F[WA@):O5RORNP4(1B=!2%O)A3_)-9@?$9F+^=RL9.
M:;6'P"7_LY, 2U$R^MLY>OOM'KVU#^:??"5&H@P87P)_85PO&>J#8!&-P<9]
M *N#K>^TNWOP^\3#V\6&_A&2"&HXUG LAF-)K8^X5[5388Z%/9 <*O4SWF$?
M\(,:KK\R+W+1"2N-R"56@-X$_LR)GE+^V>U7K/RSA,+AF@A.APCVZ_27*PM8
M$\T\@!X&9Q?=@3D<Y4>ZGN)PE)H47BLIY'*>RR>%(9!"V^P7Y#S7@UY*OONQ
M_:\XC+B;.O*-@,%M3QV7&5Y6X\.O\<,I&J^69_,_V%^Q\P#WA\\O Q_G_-C&
M9&6\BT/XP_%^,WQEW%K*N'U?AC5RHC;#"]M>-;3>$+3>C#U*B2CG$PN9#"84
M,"^D@.K;ZM!;HB%'E1X?$9Z7&CCWEMR\KK7?.[@2NSJ:;(U"ZZV@Y\"A'@Z)
M[):1^E7C4 5Q:%O)9#DXU*(2G.ZP*CA4DAE1?<'\20SX-"+KUX8@5CT\8M?A
M$1*@O-'>=X0JYM=:OR[A0R?:V[CN875:RQQT\SVQZF$QIXU1NSHI2T>I#J!4
MSVSW#O'7U"A5193:U=E7.DIA6]F^.>CE2\Q/=;[-*<CN90 W0AH7>?BLA0\[
M^W=M61]B6=/T)QVT0!AC#;![DT;O[*(W,@>C?'EY;1^=/C)ML;%+QZ8^85._
M0';7V'3ZV+3%VBX=FW@0NUT9_]^;L;O'T[]B)Z"0V_DR\*<L#(V A<P*ICQ:
M9[,'YOI+C/09[\ZN;F[_C[58?OATEE.G7K?Z6X)@ITI8">\K[X9#^Q: #8O.
M@8(^):#^_ M]6"Q-1S/G%[//_\T"OXB$AMHXF5)*7VN3JDHXM4:^'XQ4.S#G
M$=A49JMWL-Y8XU4%\6J-I']>9M5O5HU9O1EC_9OOG5,&3I)?XS(K9 ;CMUC;
MZT^UUR4\OR(X;_$EU[,?(1N'(8MTY?B);+B/L2FSW:]*:*HVN%[2?#\(N3;S
MXG9IO+C&K IBUC93_ADQJU,US'HS9KV2\M@=!^SYR*C-]2?*=9T&KF=?>"<A
M[_[2#R.,57URPBG.G=H[5-7OGEUTS%&[K.$CM5E5)9S:(L^?#:EZA%3]VE9_
MC4BU190_&U+A.#RSUZH*IWHSMCIVZ8(-H^L=V]DY-N/MOXR9Y03&@^7&S+!4
M(4YMN3_%(?\Q#F'M,+ST%Q.@&%PK ?NE#O5Q$%CP*=4\7<[QSRN/SYR\GJUY
MY*MC31R79E2&<VS<L3?I#=#H[[;SQ9VU:7;Z:+G)IU]QO,122[/9&]9X^0KQ
M<E-,X*7Q,H]ZH[.+7O/@R;RU1V$_!,*"; ,0![8'^XZ=<$XI ?X,4&7R--WC
M;2CMFW7V/RS'"Q&V++SV/J=@>SW[!)#=P]\VJ%Q4K3;_7M"G4"HJM6I4>LVH
MM&M^_IXXM5UQ'+3)H#E<<:Q]"7LF^F$\QW 62\L)2')/YU9P_\12N[>A!F_Q
MMB% KQ0\+SDX]^&QE0N/U5;42X8 UN!/'D^Z8/ ,\@5--8Z</HYL\^COP&-V
MD+D]]-]W*H-";\9F1NT);>;0XE,WQM\^C=]8;7O)IC*JHM?>)R>40W:N9U=>
M9'GWSL3E*2M[2>!^;>6<&#X=6-G^1(S*8\[@[&+0JULAO#:$V2*/G\2"=A#0
M0S2*AP6I0*=:M%Y9D<P#$:&!@CEI,$FW1N5NKHA ."PTJ6TEB&T+RR#X71OO
M<.C$;T_K0[D=5)6CG@,Z*^YB -30JJ'U# -<JF\9C*<\%0L;YS+G 2>:$;NI
MC8-#^UY=>=, ,]D_,?Z_5YZ$]:T"]=[R>819E9U>64-E:Z6O4DK?%BOA.3!J
MV 2,ZINC@IS*VH0X;6S:8D(\"S:USBYZ9J^;#ZJ=JOU0?0E^Y3TP+_*#32/7
M7J5_^[!NE=N(00/KWE301BH8=O.U#Z<X"*5&H@,$]"%8U#F[:'?,?D'*=8U&
M54.C9\EY*1>=J,JOW:YC;R^,&C<!6UJ.+=M:<.^>CWW+C&D<!)@!P]U^;\OD
M?E[I+8#^Q X7P][9Q<ALMGK'5V-KF^BX CR+2'E<Z9]=#$85,'AJ3*F&C-Z.
M,5A*UQY4Q(7W9NQDY>E>6BOT;;PM8_E9I:T$[0V'[-[B=@@LU.Q5IN=J;>V\
M8/9I^=B$97EFLU-7A+Y&;'JR4_N)V#1JTB"F5K\JA>]OQFZ&BPMB9AN!O[+<
MZ*G>[;>AK6XHD\Y3Q"T!=/54@FB=7?3-T>'='VNSIX*(M*D11.F8U$:/9'-8
ME6X^-2:]Z.2E'7$JCS88%^GGS><ZPOQLJ:K"32VFJ=-@1&E%/SU9[&WHJ_L'
M#-7\L;WY:9<&(X[JN4JG@DG/,QUQ"U+E\::'H^H.*2&I\:6*^')(F/GI3*A/
MOKS!(9,T:TOY:9;RO0\[\JBG0L F5E2;S.68S *^?RCPWG+H[DT;U$.Q/3K8
ME50;/!5$J'U,Y](P:HB^[L[PX"9T-4:=H@1_7MRB6I/FH *I#6_&TKYE41QX
M),I]F\\_#![>6*3ZL,2P'9U, LY_()AO.93WI _8/-+'X*!:Z=IPJB).;3.T
MGQ.I6M0A9Y2/KM1(536D*JV3\3.A4AL#=;UF5>9BOSES7"9\FX8E/IGZ"_R(
M.DR;21YX;:678:5?SP3@1>8E-@97T!Y[-HT*WU<+[C8[F*QIM@?U()L3P:\7
MD/6[HEH>F[IG%Z-F75;PVK#H28;Z,S$L&KS5+TA_/%6SO;*"_AN+#)P/09*<
M_OC\5^P\P(5@FOE-X#\X-DC]R<IX]R.$/QSO-T--N33&<"L/SI,3VP2L)GY@
ML^ <8/ >KRCT7<<V\.0G2',E!M;A:O!"Y!U\7.$%7'D*^@GP]Z:O/D;9A^;H
M\"8L>UWA"9APKPD7GR<T_XQH.0"VWS+;!>;>WIZ#&B$KB)!E9LD_(QH.J4'5
MX;-DGQT5A7(B=Z!@#8A6KGI</[__\Z]=<R1E$<>*A<:7P%\8V-<AW%4K?/W=
M%^M>E36TZLZ>![NADV;!_LSXYB-;B1?&S=P"B6Y\_7JI^@I/R8C%WP?,KKW1
M3[0Y;ZP5C9C\[H\Y*.6$2A:"PG4]0Z8OOK%WGPW0;8[JV0 GAE2E]B39#ZUR
MZ-/"-(5#C,(:::J(-%LLO*?SHNTV7JMU=C'LFMU1OI78J;J83TZ:+P/?CJ>1
M0> )3>/JYO;_6(OEAT]:6-D(F&M%S#ZDO=C))F>4V5XL1TP'CMGHMMK87ZS?
MK4"11)WE<U19?C F=7BY39TO]MHP:5\!?S F=<\NVBVS.:Q U^*W:J.#5%_"
MSE8DPQE\M<0[?H/S.)Y5>M\(*-^XEA>-/?NS!/3>)-,#1=@<]BN0:E%;5T<5
MX^6A5)]0:G!(S^\:I:J(4OO*\_)0:H E!;U>W3'EY5 #+@\@9H?&#*-[8(RK
MR;NN[]V?N\[#&S7+RY3K L880+T#Z%[/=B29C=[VUK T;WMM5U40I[9)]GV0
M*H\\H^)AO#7BG#[B;)/?3^5&VP5XNXD"O-\M*]^T(M9Y987WYK1ND<F]7\K.
M#OKO:\I5++6$>TO2HKJ'IR<MMEMG%ZVAV6L=XOK:ZQI/P!Y[N_AX8#)W&0C9
M!H3LF8,RBGAJA#QYA-RUD=LS(B16P39[9G=80B9)Q7.Z2TZ3K)]_:D[WB:F-
MV9SN+XYG>=,2<KJWPZ%R_.V +.622PIJ:+T!:+U1O_(RGKC.U/!G,UC,NU?I
MW%$ ;Q"*A6Q"PJ&6_V_M?B[!_7P5AC'P>G8]N_07"]^[B_SIS[UUK.[9Q;!I
M]GKY]A"U__#TL6D/Q_,.Z+0QAM'NU3&,UXQ*>[BBR^%,_;.+_LCL#>O9T2\M
M[T56@ $H@4@ F\?NWO!G"!9^0)UBZLRPW41X<TW*Q1<_N%2@O=0A^]6Q)H[K
M1"MERAW@0:&AKV:O><B<A3JSIX+<N/M22+99YI>7MU!C606QK%<-+*M<+>K;
M,?TU5> ["Q;&5Q_V@"'J3\RU5@S^-[ >]:_N \;HD=K&?Z*-?\N6 NK7,^K&
M]]7W[A'"G]ADGZ2R3K,VR%XS%FVQ[4M#HU:-1B>&1J7FB.^!1]L-DDZ;!EL/
M^Q687_ F[?F)'P3^(VP_!*0 /<V8!LQVHD/E]LFJPV76?.F4\B3BZ-#LF]I8
M?W5XLX>H?A+B=&O$.17$>2[1O*]65UZTIK:I]\. CUD1?!,X?F#<L@??A3TF
MHKBVH$N(DDMM]2LV(KJ>79*ZLP^A]&OSYS5CTAX1\H-1:5"CTFM&I3TBY#N@
MT@YJW_#LHMTMU/OJ"/FSHH52O##QC8MO?H7&%VM*$8^W944_DQ']9$9;N8!1
M;18=R?/]5!3JEA<\J5&HBBZ9/4SK@X1T%V>K-IMFJUN!ADUOU\;&;B@9$:TR
MUQV1K@@@":/0J,WN,LSNI_+==FTCO68,VL?<?BH*=6H4>LTHM(^9?9#DQMZD
MP[[9[)0U5ZJVKY]4<:;D,PX-\3W:Y,1EQC)@,Q; W<+N_.G/VN0NN:A,0?I&
M GK?FJ!NY:),M155@?*R$A"KO*A,C5@51*PG%IOMA%@[2'YL7MHKP[%>V^W[
M(<D=/ 6+C3?)><-VL-.,!^K!TG*>-CGL9#7EY^A1?CW[)"&Z-Z4,SRY:9K^=
MKQZO)T&<-NKLV(S\$-P9U;CS.G%GQZ[C*=S)H4>O">@Q.B2EL;:Z#[&ZN:SU
MEZ*A"PNF3@BOPMJOSW<W-\8R#J9S*SRL_^CI4<)S]1)':%\3L,// MA[S\CK
MX8P\<S3*SW&H;:+31Z9]FHB7@DU8JV-V>_FX98U-IX]-^W06+P6;.MA/O-D_
MN)]X;5+OAQ7? V:%<; 2 EV);;P_(V!A%#C32-G6V+3UC95N/X=)_<4/;ID$
M]4%MD'K=LXNN.1H>,DBGMI*JB$D[6M@EHE(/!?JH5X_M?&VHM*/!O0F5\MB"
M0^%>D?U=60&]>?*'[*MN3%;&.S$&Y+?]VCR_L3;W)8KS-;WM2^C,UAN<7?0'
M9K=3ECY<3URH("J^Z B0,K!R>';1,UOM$@:!UOA807PL4ZEX1BS$P-"H:_9&
M!S>EKH=_O.7GWX3F.+>\>X:SX=;JD'6 YHGJ'P(2_U^#Y:URF.$78\].?Z#]
M\@9V[P-#G*+_C7UB_'_AWVZ,$/W\:THW=VM%[/-LQJ9[YR?W,4 *.N2PP#=4
M>^@KB9O/HP]6'$U;H%.BY[\"H\!K!'U!!;'B:-D^NQBUP0 _>+Q M0)2E556
ME'HRQ3]8<M6F,6'WCN>A-\N?&2MF!6\K +4/T0V>D>;V)J$.</:.V3Z<A.JH
M0O4PK3.L$JIU^2C03C,_+;G&M9/'M7:[2KC6HZ$IPP*%]:3+/D]1,V#PZ1J=
MX!G]MD70.28I_>V9SOYJ^$>_2NRC?W;1;K?,5OM@474*H92:#&LRK*1Q,BC+
M.*FIL%((65/A21ENP](,MRK&<G<-66[=\Y8%3O<]SP?4D_H9@>'WR)JX#/[7
M=AXN_AO^DX%*MP?,8.F'#I+'^X"Y5N0\L ^/CAW-W[>:Q BTISCFOF\FCU@3
MN(HX6O^(1@Q3(&<6E,W.6LV=^-F@J<B>8*'_=QXD4+QGYY. 63_/K1EL]KWE
M/EJK$.&IG6GA>'+Q3A_>GCW[VA/.9L]V0LYU@"WZ?!+B>^I"B+^"/5F5V8LQ
M#U!F_(?3G4Q'O4FWW9UU[&Y_8DWL;FLTF0R;S?ZH ]O[7]"FOB/RHC6.TQYY
M7H%U472-]!]"]0R_@/.ZUC)D[^4?'VPG7+K6ZKWCT:[IH0\+*[B'.Q7HC321
M]53@@?C7R6TWFOS&A:-$O%E\W8"O?L]_WALV6MUVX5?-1JOP\W5+M=J-YK#X
MD75+K?^\V^R_\DUU-RYU:"RLD#MCO/* 8!KGE\=1"@>%3/2?S J,SQXFAW]B
M4[:8L,#HM,R40K4%DGN*LY, 2[O9[JP-(+[ZH[??[M%;19A?B<S,@_7R>F<[
MV!BO-D!R"[J;ATVK27^C-IA@E9L%\1*,HF@UO?QGNZ=7' :SRGE-BAT,I66
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M$\[Q5A"X(<'6A8<#ZUZ^ZQOL9FZ,B>4 A:3N*UD<,)*#3F";X3]Z?#F?6DD
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M(G?!)L=ZG:0J<K&$:BERL9"VMOH-=%<!$!KH^C1:3EKG:C'2]%&%Y$*(!XO
MU-7TGZD.YS+Q\HL? $B\2Y)J@)/:-L:>3?]TN>:_%FF[U4=:<4I#'O,4,76K
M68:. DVA!ZPI,-*$-;#.*$M>(_0<E[_0TE?63.,K#SX2#]+*PF31?@T(B*80
MXS21PG-8@"22S34M(@2E<=I*_8HC>G06>U-A^DW%/9+90)(O68;OAC;FY7>3
M"$^QK[!P6_QQ(XB7#,UL[D5 B]4-_76;X2\&U25V.8= ,&+[/VUS&3J'\TXL
MEVQY(OH >(X52EL]#1MN=VOB.*6!AH;-+2TR90#+?.ZDX]L1[C>B 04[;2O&
MO>6(_8"^&HK=Z%FHN*S-I%$F+%V<C\G')/&SXRIH(. :I"_KAP4:\C6.EMD.
MFO'$!Z4Y[0H7&6#CE#P#B'6N_G/0.5(00EQP%FB5!,C"9T^.XS1 D7+1H>>C
M7^?1$>J0#;\ 'JZ4)=J!4!O^EG?:\FW)SU-J4@Y;!=%1LO;@0\B=D/PZ9-M7
M35P$"8C@3.A]O%]OF@A2Q^\%JAGAG,'J*/),_"VHD 2L$(09F_LN&%6AV(GL
MWB'?;:8DF"DZ6?YBPFVJ**5PBW,GC/R 7':$L0W@CA$ YH&!8<=O'RTG+V1;
MSHKF.[E',S1@^ \LT F 7[HPW/*G!YEL_RL.(R[G-4H)_$4.$04,"U6$M.]$
MW:)$\53(@!P0:<H.Z,#Q(N:'Y.P6K0(\$\+:]_!:X2T;K@@-!FY"J(5\[I:$
M!> A@"OJY&*JV3LDT=_4A-O(^K5%J?@]$]IZXSDH[?4Y*'4ZR='W4J>3U.DD
M53E.N>DDZQ,,VH4)!IVS/>W!'R&[GGT.(_+NAHF1U\LOW^KEDRRJ9_K]"(FX
MU9$VB[GJFX+K4(!N@PQ%[E%,:2TYS:38T8%7C(YTJ4]P#U[ J/208ED@T2AH
M$F& YR?#\#4'*V&MA;WZEES=IRBD-9NQJ3!<%ERC@\WY@>:S+-P*+99+HJ48
M3[2+T\;4-P;J%240S#!ZB\8D+&:@=X6[Z$WC 1@C"8%T:SII[F!D7D8 8%-!
MC%$U5)A!]0SN&2968R36AI^"AAMPW^>,"9@$\(,(;<A[U$XIS)I\%K H#H3A
MQ<.X> XKT4I-;0RMTH[AU1,P8V=.9,(F>9L6/J>6%L+6>R)Y!\.BJ/1B_H(_
M_2G,880K+$2_,9,?B:FWH(Z#FKXR?%3&@+H9/9\L"BB5@!RL1B#\Y-(<5;:J
M+((TR'S5D]I->CSJ62(;NU8GD5UX9I;J,^CZWOTYIH<DMDC.7J64],PT-)YM
M@9&\U(;24)D"A)U(V,:F,E1M!K0VY;CC4JBZ:"-IO\J$TE_0A9"@*.Q.,X[P
MFD%2X[LI'X&T>)Z/<QXNX7TS8..P*?X%J-GL 7WQ.>)S, ' =9@(H4_0O6"%
MOD?;)66)$Y,3@,D@,@K ))I28%6Z,< .<VW#=F9HOI)A%,9@X*F]-XR/;&K%
MH8J6QK!,@*D%$;=VYHQL4L?+/(B(D7K3PEJEWA/-,7*6O"AO@A@'A,\N_3#"
MWJ(^7!_P@7\ M_O\RXFN QF"'*NQ#-?!+4,L%[%LX0A-1&._^D(P=0 C.=HI
M^T&!\V':%>*/=K9DF@;BO/3=3_&V ;N 6M&C::E[%SE;</,&STZCN]=6:8#R
M#&C+%U#+X3P/MEBZ_HHQGIHCD#FDO*TTZ>I,2/!MC*/#V0"U6;*._KOT.LE3
M\EVI'W,YA%P4(.,$)&*$! 7FD&@"DEUQV9"!00'_3(Z0 Q#!@^2Q<*B:QB/R
M%XQ?H@P!,QX]SBMUNG.#_ &8;X1KX=+IQ8S'.2/I'C">XRC2G$B:+EV+/(8)
ML-( DFLOK96010'EX$R(UY%GB?@(_*MAH$:NH%]\.8DXXER(1V-Y/N6428T(
M7V4JJ>R$XOP(47$6M5\1TX'31"Y/#(#?,CP:<47Y9B59N+9D8+*?SK=7BA_:
M#>.S>+$\/,\B6G^L#:=(;9Y[T6 5RE&C3!_QA!,FB4\-LI=SN*CT'MB;Y0I9
MFL:C@KM'X"2>>;43BTB.:N(:QNTZ.N>.\ZE_[P$GX>XS3X9&X)?J?@ITQ[0/
M+PFGE!EAN^4.SB\@TR3$4-I<@HH'BEVP-JPV*+"X!J=@<8D#PX71G9QJ9%C*
M&85:H?15%Z5JC.\NC7ZS;RJ=I!K5B/(N2*.2Z"<X@<3 \)FWO'&#2-<"J*%.
MQ4E4(TGN#".VU(9D;<,E4:%ZCG75[P=9[#H_(GI14*C_X7AP3\.FU6WT$!97
M")@D#T<H]%+EH-0_^0^,]'!I,A58]&&7>^G7UU+6M8"LHIQ'Y$#:R&Y-S-%%
MU=?R7-?R*>M=4!%#$5.GS."T+@E<+GV9B6HJ5REV1M77^%S7.'8IG673'<I@
MQ*XDA[=:W]<SW9>F59)+3V@/9'$]8@YVY(2S%6;H%][6^D8*)Z"* C<@+Z,3
MA4G>!* H;!U>+-QSEDC-%/5IIA&@@20*[TS)<=)%9]F2JJ1**?!7>3,N\VMA
M'H;K=#FZ&YU@$N<CLM!0#BO4=%.I57#KCE^J@QDX/+\DL17]*=B'PGD@:J1R
M-3A@[]FXI2CI:BY)6KZG8?PAETS7C=@^0!,#!F2(XG\#.=F5FZYH==/T9NT(
MY'Y]),]I*H5(2_M.[-IL;A^]3$@)JK1<)<4J(95?! &FO/ X3/(F*M&<K43Z
MB .P1RF#!2YJU*S*)3DY*KB36+T&43F:Q)-_4;C)7QO2B8F9IP(W&^(RN:A.
M0@+JI_@1^0-MK%+!$%<C"3;*)#1T9+N)HV'-[H1#)G5Y_XKM>U[?5.?G[)&?
MTZGS<^K\G#H_I\[/J4Q^3J<P/Z>[(:$#G;W'<>\>XF3\A-+2F<1TE+%27$Y-
MX?A"(6@*I?@B&**KA1BL)JSE^;Q)MPP1W$A H.ENI-E&<R>PJ=R=Q\>%1IM6
M9%!AY4KR> ("ZH''Z?!HGX+XWACS(@"N3*O*MV^?QF%2^Q9L^7GZUU0-CIG[
MH,=[(>\0DMHIZ:E:_X+L/JFT#YB<:TV8FZDDX6IY6*"4JV=#MB,,18 ,Y(>/
M:=,!$ZM249K(^N<F$%^;6;R_QQ[O:!AC5*%Y7H*9./U3-@T^@4U(PA S.IR,
M!3*GC@9AF#<T5(2OV#RE)\E 4#8/5B,D4$JVF4;()2@N&=P"><^S13 PR@+D
MLI@R+ZPCOG>XCID3 90"CQ]*F8_Z96F7#[\^QRQTJDE5B^:"<&0.A3QGG5;<
M)_K&@]<\*SZ(56DL_:GLT<(54SG^B *1X\J@,(&6S$4TNW;E1Y5ALBK:FFJO
M8MR(64W<0!*<^-28K3I;NFF$9NB*L;$<HS1VD/#/#79AJ@<',3:M10[&Q^>6
M.Z.%-0H2Y5QKR-0)>0JD6IC'O /_ <RYM9M!TU,Z-H!\5]3<Q5UE?\_S'E4W
MGSS+M;#;"]/R$T.J9G:QB4C(7%<4C$^UFJKUYY V*.=5$\W;LLFKLM6?<BD>
MV_R[)%-"KNLRBQ+6,.U@[BRQ095A^].?<G/X67X=2E5(LF-2-[[198#@)#^\
M\>7Z8_+&I0]R77!V"<(D-3)PPI\\[P3_0-X%\C/ ASG7#_-<7[AJ4)-H&#>"
M(W'O5^(CX*PRG0PQ8X_$_&&'V,5H 4><(V)(Y#%%S@P^Y2%*BO(WF5HZTZ)V
M&;A([GYRO/!6"0%2.;^2TD*9;:]5WR1=4Q2/N>JXNC+ U1W1[DI[4FAT"B61
M/PA]C=)A\7/\+&F=E,(-E=[),301O]PO"_C*DXK3V]5R)NA%NI.>)XFB*X R
MNX7"@7)9Z[0B* &[S.EZBN/Q/B_<6T8)5'92KL>/ELFWS6CJNCK.BWI%3M\&
MW0;K8[5=)&QYFS(4V >K0@ID6KY>L48JE2;]Q4_2FO9[Y<XZ5MY#N5_"+LY'
M\FS\'QQ)^@"@!&BMS9XJ: K:*F@*6KWL*3P@ENF'<T,[)_<Z4 J<0[7T^(-3
MXW'8 0-;/KHKT>2.1*JLOR7KV >>Y'C4U ^50$)94CRP)1J7?62F8G6VHGN;
M:G]G6@<O((.I"^@K0BBAR-A-X-G@$%;.>^TK7=/DCGU&#G!!RG,V_<D3$&5)
M-'%M\2-QC/3N7=Z!$B6X=@[19Q-TMI6P2Y.RYX)%"D$@F@)D ;#I=*D<9M\[
MGQ/?R.YD%F,G2LDA\9*PU-J-L8;8I=X2>)'GHBVH":S##Z)SU&> "T_EMGD-
M$"7TXM1@W/9];($V&+%$$Z=:Z"0(TS ^Q2KBKBTKH*$:U?$=\KTEU42%X.2R
M:0KF!$D<68E$%J9>$R%S:ZG$1167:)U;&/54Y/P>08;-'?)?Z+7K^>-^81CO
M<8U/'&&,*R^,>2+SI1\LA:\\:4?TZ2II@H0=3OW]^JWUBX=04/=.7/L/M;\Q
M067?\8ZMT=E%NY<?[HAYTS'P"A'?7%C_\O7+$\+YOP1AIGI@8%/47U-JOS S
M<(]P)%[M;Q:H-])ZD24N%EP*',!-NK*BCKXEG[?ZK'.MDQAEVH4F%PB>0'6J
M8:+P7K?1D;7D?=7@9_LU[1MM[MKW.9P&_J- Z'U;\;6;9Q>]1@$&R4Y\2(Q$
MZW/FBA:F$\O[*>E,^"XS9CU'AE@XX$ [(3MH%I.I#BL#P'Q>/*)RYR.]!R2\
M-%&1B<='KDB>4 0O6,ZW3V-:_,KCA/UUG.KM*JJAT(:E.CE1=0?VF,V03ZE7
M\%X:'L_*N/=]6TBX2R#0&995Y.)'V,D45AZ#J>_"';?ZLJTJ+Q[ ?BCX_U@A
M1GHU+1=D<$5K&S-S C@6\/0 U65!JA@7V1@6V5Z8M3$VO2/!;>DE_O8BW-TZ
MPEU'N.L(=QWAKDR$NUL8X>[MVX'B.TI&L/2OT:\I.G:&M^3L03K)5-^V"P9K
MM%NG8.C+HQG)V5ZKEDH7DLIDA?TRU.E$8;T>&!'N^-@C0Y(W7W!"7N[(U1:]
M&)\'>&33/#0W%V RDG<*O6ZI]'M$+.&SFCC42C]0H*>*7"QGP1[[4TKVH_>F
MNS^#31@Z #A0B<CUCXF$H*\"M,!TG.8W&>J[5 MIM?[:6;2Z?PHZ.W GL@1'
M-'83 R$"<A?&O,>@Q*+D*-SNEX]XU/CBT0KL<]?WR76!2POE$@ -X@L;\TV%
M<FO#/00K=&=B]!@!T= PE)_D$6RY"'-Z9S/N+70H'J0%I+CEKQG:L2<A2S6X
MB L;6BQD>_GQ'G;%3$MRJW;)'0*N9+AGG8^Q7=!RI]T^!=8CCY83QJ^(Y>!%
MZ ?5W7J!]:@"94#A?"8#4H;VX:,?_(3SG2\#_QYLID(##0O@DQ=01"3B+?RX
M7P[PFQM2H>@V+2(! ?7= [7<=?Y-%"L<33J'Y"T,18"8LP.1&$'=8<+TFF$^
M,U[KTF]P$.+&1-]$?*9D>I&#[6]<RXM ?G^6L^W7TD]!2ER[<PKT(X]*]Z'.
M>6KN^-0IF#Q%.H9D11Q5#'U.+?%K;#+EB)Z]"VSWPCS>C@%][Y1?3UX5U=%3
M+^7?#;'(27DW!6J+78;3XM;@UX^0S6+WJS-C9$@5(%J!9MKN%DR(T_MCI#HB
MH&: 10#4/P@A*5(#J%6":LF _B::*D5%.I:<2X,ERT\8&D<[W(+\-#XW\6;0
MK%Z4L]8R9._E'Q^PV8)KK=X['B$!/?1!+"9<(.@WR8SJ)2SE7R<>@4:3>P5P
M>&\R6UA\W8"O?L]_WNLVFKU6X5?-QKZ?=YO]O9Y8MZEVHSDL9T^PTJ!=TI[Z
MPT'%X-3I--JCS9NB2<X"(0IFKV<&16^;> [8?:S(JX@83M/##,08[0TGTX?'
MJY]AQ\3M$!#3K%]DQOF.8/@GN@E2I]]RP?G)XM,I8\ED\>W#PZN $\4R\F/L
MN+A3T=UN@1E^&;?/>OPX #"%*/5<(#\J$JY7Z]=J"/WFSKIGHAODQP_:<8 N
ML41-Z)U=M)MK9?6SW/-IW,9Y#81M*+F[.;072O;/+KHOC)(ORGJ*N/U1;WEU
MN/2;T?^=CHS[BM'A.=7(:_+->!*69<Z^33,J"WA'19D[3%+B?A[JG/A?86((
MSJA;;\#00D8'$_]D)CK.EJ)EG0R>_6E-Y_!AL#*-61QXY$LPT\Z'0SC;H?SK
M-4FC]O-(H\'91:=,871:(#]("SJMHV[&KL[S8-?P[*)5JJ[SC!RA<D)HC=[R
M.SG[RDS$.D)M(._[*GK RWB,C.=09'"!DYN6+A5E8 L8#.JHMDA:CI\'>](\
MW7SB%,[NYGF&KC7!5!XL\>)N[>+!\L*OG?\)38!74\]511NUJ08,>Z2JN.+3
MB+3L4%1GB/1S_==)[QG>QUJVSHUX#3-Y@F79F?8<MK+W86^\K9*UI"(K7J++
M\Q@;1M;OC1V(=-_W=-VF>>T'=3"F)'C1+EAVU@^H<?.49V>+)E&O-A.7(E>9
MQK$\:+<LCK/0M(6D83?&T1F%$QYDHR<^VHP/YM";]&.4'KV43-04YI/;^?1!
M,48.*Z#P2B<\KH,10(K!W\I_<(P5N0;9/N!BV&\HBV<M7IX:.*'6(C3_=H4'
MB),B[Q8XK.B1!$MA!)024&<8(DG-S)[(^L<H2>REM1K&U8RCFX9BN?I5#E19
MDJ:!6 Y!2*K4TT?3&F_#OY)<\TW'"RE9G=D<\Y-04'HX1?+SPJ#K'KG8K=0$
M]:MO7W)I"^J\U[.O<)=?\2K'].[_8:[]Q0] **>3M&F"W_F_6> 79/BW1TH=
MV&V#+[R_3G//_75?>H,MS"C,Y;=O_T!'74H0T@39&I["T[T5?FNYW4^9@GE(
M\DP"1#51(P?.=8D!G8+$FLY))-;P<QF()^> (.?8E6%+X[;])-X:X<.A4P"S
M=@6Z5JI*O%"RS+F$#Q;$&LZ,YJJF/YP&#J7B<!X=865&&(N1\]AKO=-OGK>:
M56NW+@TATR!3:$U^2$X+KY(>PY$&-%5U :)@4)O^!1K PHFD3%75XVJH UI3
M2U1;, -2%!W1O&5':;)4W8<7/6'4X0&+LNUD9 ?(3/Z%FC<A!YQBCPMD9MBE
MAY I7>B9QB+>%"%*)I]H==)ZTF@J68OG>>:$?J#+=)=;(*$"0#IYBYI A$*;
M3ZL"5@9,IJCDI%HVT5 4%S1YZR(^+DT4F.-,6R<2[L0M)Z>I*/@L7QNGJ8"<
MH(L0:B4?E)$,&U/6@SQY2GW)[MH*2564.C]:5ID'5>M4KB&)'AH.C3C;Y1UI
MD&:32_'WZ^>;*_F(O -_6LQ=BK2Q\2ZYIJ:>7@<VYGY%F=W-]70I90-%R#<_
MNK$"T$>D*/T#X<.'V>]=<-?I[*<P]7M'W6WW[&)84!ZXL5Y0$S.J(9CQR/3$
M-G]K'X2&<<>8@;4@1E<WK#<.'J37H=M(S(;7&E84=7"M.[:J>K9>7<]6U[/5
M]6QU/=O6X[Q4/5O!R&/XM+]O/=M7U 09!=G76[R]ZMNV_ 2GEN1^K>; \9![
M:@3LN[/;ZQ]GOZ5&P29#8'.#Y;CA@P5:I"Y3UQ6].DR9.LE06GJGFDK()^NA
MK4&?HT*+;E@OR@X1U)N,KLT[SR[$+TC,9?*4JDW=4U#!?F3N0[Z#C+"0=E>,
MDO&WN1D)(1\\+;<E6Z3P?ZGA ^EY#Z3E%_:O P:+(S55"Y4P-[.2&C@63[BF
M=R:C>I,7Z,WU92\$ZK1%??(>L(HAZ9*C^LH4+I_J&9M%-, LW4NM+\BC. @9
M5:67(*"?62>+D/I"LKV7P)Y0BQ$E?^GOT1?;W@FLL:LME$(&QTY&7> '7$T6
M.%'J9,4K-6R:VR!?$.49.1@S5<*=$YC1FYQ&>#9.C=5>96=_<R*E.;U.)"=D
M4]<E5:.;*:Y=6A&0/]EPJBQ5C"]5/,]97W%#/@\,NO&.QTG]7#K6QAT+<E\B
MV$7MLTWLYA+*7JX4O97M63:TCI8_4=T^N:$&A#5WEH('$17BW/5(8QN9DD%>
ML(R!,;1A.8SDD';LA)B4]BGX:4!)DLR*P8.#@#RJ<J3*WQ2*8$+&N?/K?.[8
M@$7OD6) C\<9N[(. M7'S5DA@YQC0#23U,@R2['_$'6)8UZ6N"5=Y!$D%,C7
MA*J'9Q=8ABQR']*L)%VXG9&B.G#1133W;1IFS-U?O/^/;-R#_7V*$,+RD@'+
M>'_Y)5&:RQ9$$X:8C>)-!!5QLC&V+*>1R!E<SX5#16-AV.2?B1=6QI<SB.SD
MR/!9(\W%T663-VH"G@(XJVKFR02Q>.B[.(*%W=]2,:LM^OUS12:+10L!>&OH
M3W->C<XNO'SH3[\,,;L[\4XEJE_N(AM[0:>]IB4KH*H!5.;JN^!^Z3Q#%"%\
M,>HSX3!Y]^U>#M#6%@?HSC>1@WBW>7;1;+36>@?W@F!K/02]_!WN#X4MCM4G
MX>-VCVJW=7;1;G37.U"U,',Q4F01LV%\\W5FDN(@5N#SX=NZ00Z_0OAR;B!Y
MC%W 9)*P2:+JBR2H;5QO3=K+Z6E56T_* 4(-1K$MP:-#_2IYU(YW,*!VBFB<
M6L&4]P6UX;Y<GV<-R&:35S>W_\=:+#]\4ATG93H="$?Y7<'[56/!@G!7Q*9S
M#T!UOTJ:2_,>?K(_(VA%$S4]WM=;6&O/RHU($TA$!6$586E@?(LPKF'\ SN2
M "R2+8NG4_/KC7>)/A4O93_I)>\/P>YC5^0!8I@'3O.;J:4T.13S\F3S%<:C
M##1X;\ME-8P-]\E/%_&&IAFA;5%G_!!#RE[,^[[SIBC7T\B7?1[Q8DO/(TN.
MO:!^X46I9/]73*E3&@\V/!0!.UQ-MI3&.7@/:HY+EE$XV+EV5U;R--[A;*>F
MG?C&07;K'X)(QUY.(99?9>S7;D%&3/<D,F+D@4Z-[<I]R[XJBL>)1#_5H5:U
M#.6C@I5G+LT&T:B33A[!!DUB1X"LCF[])7/OU<+"F$B:/<$O1"O2=$X8LH<B
MMBH,\8^.?X>.M.*PAFG\@[GN'4Y2$JM_ YLC<N)%P_A#217NYU/VITD,&#[5
M1F]*PUOVL"JRO:5*A:[,X-Y2,X/6JD\A(_ZRKTH/! F\\7JFG'-W?)TP;U^"
MXJ3L2Z$S-1/ZZX"E^5B@R2?>.K%#8>X_UT%N*:4#&=)33])=<Y(DT03W*HZ!
M[?RSB1=*Q2 /+1<KF)237L#D W6=*:ST61LW_!''#8O5J</?%L9:1\E34?)^
M'26OH^1UE+R.DE<F2MXOC)(/UB>8=@MSE;L\5[GZBF%1A8\2B1FCC>*W:;FH
M9HI)*PY^4Y()5V3ZJ)VMM]W4=$G#BD'1#)R(SSJ_CP'],7 GAG?(^17CNX]I
MO]A<I(#Z2[IFK/>A1O(\"9:^XG-"^+I8+N?S>0U*M< CDQ.#-Q)=X&Q/U_F)
MF97DUL!]*P,O7UJ3 ;$3:B-7T)N>M6K)4N<7@3>6L52UC7@,U7PK6 G%%E4M
M>/0OS$17<%+*L59I1'5U5ZG0='):,1AE_[/FD&G;24WNI\"5UFT3UQ G8V):
MQ]J?B@'U87;4@AJ<LM/U4$C>%V5D.SY#!DS! 160M17T@JQB>'B^?K14SH5:
M,(LS*D%"7UY[*XB^:4RVF'A)H8\XG=\A)O\9MC.;L8"1]PHOX%_"G8+."/+A
MI5"49YJ01TL.<> U=#+6M.XZIK EF5^!0WQ@=].H,+TA26U-9^WSF;B9&65[
M);96E*MO$%;M-,\7J?VV7@*HL3=RS*%ORU=Y&KPL:U^>MJ/Y5, 1[D'SCZ1#
M.$4S_ 5YOV$VM3TU8QF()<7OD!-0%#D35:32,^[:.+C(<5N-GG1()"&2KWX8
M[E&4UTW:TI<2.SQ\0_T]-[2M#O3P'0V>H6Y1B99,I:)(1GI"E>(!18J7V""5
M*OX!K\?)L.&Q<K-EW; %4P6[IS%54#^J,=8'*[_6@GRZF!3KSHP"G:9@DAHV
M3>K& U84Q2%/^@Q(&N)@:$\,&YO% 3%@Y7'UE\B)D6AI=/.5M^D-8J"F"(10
MX5>JYGW#HWB,B4HV9:E9]**U.-=M;48]FW%D@$B"X?/@IZ2#JRGO:U]5<H/P
M6Q%_''OVIR3Z^)GG+F8I;51 ::-3H+1;/<JJG=,0!WVU'??I>M+'3P69ST0T
M%O.M<:Y$DM(JTE?M=)-P&;Q5R:U)1Q>ME;_HA4)%G:[K\UB@>D2NQ@E:*,XR
M<H.2,'9%@MT4#DH3.624G(L8T)C0"43Z;R;Y&"L>94Z8=M"2B>8.[ ;V$3/9
MD(O!J6C):S*U*7Z(3B:@6ZPW#C-$U&OFB:C7/ 4BNHO\Z<]S.K:AG_O4HHCI
M6%>(_#[$HPE?B4Q951/Y^)<63FM1$QTH818_X6H2F)_D"R+]FRV6KK]B2:J]
M^H#3!=8^\KX[()"VC!A'L7(?4-4ZO1^^#/SX7M02 )KSK$/^$S^.,/B3A-4%
M&F+#'W(!\2>00.08&;59DIZ8.KF,Q&?<@) D*C9$IG#(^ O%G!^TAO5. -E]
MA=F-X71NZFV)*?&4RL%XMF&TXENUR/NQP'DVMIBACL]]LT+;^LL@/#3^Y.-D
M78<;/D'L(C@YCO(DTZF&H[PLG,I.4U>='I C[#X.3:HDX9%?V)+PHV$\F6:2
M^#9SZ8+#K6]<@TKX[E0V[!3T<C[OA$XF0M<"9/S![/ZX9R+=T087SXX$#U4M
MR_;J%8D1RN] !B3.6I9H*ZO>24M*RMT?J:(#ETA/DK?4();DQX#X?C!C8G0%
M45,V;0<66O&QY3CH@N1#9/U*LG'130/_QM21*0YH*BH."D5G)"IQR0YN$J>@
M--Y0)CI1&A/#E1&=C%/C;6..6L@VP ;EG9>XIU@8<^0L!4#<<.\B^9(Y0?W
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MH7M$SAM0JU[9KC._!\KM4%FF?-+ R97<9BJ4M-HF.*@EIR#(]( ?C;L&R(+
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MSBM+,8F'!/<C1<QXI(\1,R9G+'=RN2PUG1T]74@&2 -"'@+E))D<Q$ED95A
M41[=]:7$%I: 6?8#2#7@,1B7%K5=HI!+%VN\G"OQ]C#58 2)%EA_@ 6PQ,U1
MOKC<\SP+ $L?_>"GX'QP7HHP_EM.WK"\GQP25'A!?&F""JTF6#+REF^*?%":
M\YAG6X$@#51FU?N=,66)R@=.L&>SZ'VGG\&=\R,B#R4$]C\<SQ&;ADVKV^@A
M++BT:Y&7LOWA_\4^<CG"Y=!X%WNR-N0W/F^(G),<LS2/O45"GC=1+D8WGGM$
ML6=2$HJ""%R :_Q78N+*N">?+7EBX3@8^Q#81^VGQ!&DP-X%5_HUJCP55=H"
M5:X%<;L2(81F*VA<:TK_5PJI\GBT"V[4E_JLE]H1E_K#\Y-K%3>)%$X<FX+;
M<!\1BK" 3VLC&0,43H/:11:2RW8B91RX74C)G7THN4KZP??->0K*>I0F>V*C
MZ['6=UJC"U0P*>D;_\! !8"3VXE@U9+>('M=F#*V$@JM@X_A41^"%J\^20V-
M,[59<05SXGY+V'RF6;DP;/#+9!:V=NGAQB@6=\)I.6SP&-DD?& A#^%H,YA;
MS0VSE=%$M0([HTF4J),#@FA=H0+?\V,Q!E+HXVLSH@M*)7J#4^C!<<O0G:ME
M6!CI<^]*G,^W?5KQO1-9 /H=J'/;@1#/C'\".QO;/KI,3HW[%/3WP!XU6LAU
MF3XOS5+)-7=%ULZY ?:8M;'% PAD>G[BVWJ6ML7A)!]..B2J5A*J%#Z); OC
MPZ.^I?2>1R?DCJP8^RJFFY),F(N>J##IE"CS#F?$YK"Z7)Y!;E=33-'YL8(;
M35ZO$I37YS.B_TGSGLK43-Y>(]_^DCMF"18X8&ISG"2/)1?_/0E^7Q\&JPAN
M77GHW"8V+KBW0A<!?8VL[M1%_%B2\O_N;'R'<W;QR?/FP"S,H3D>8Q"C%(Q;
MY0]\]]U?@E!H#YN_O3>N%M0WAM,,D%8R@\&03WY29G)XS$0;Y93D.Y9I3+15
M,7A"M^A%YL-"*A12ZY )',R;H_9B:\^DFCGJHW3E\E*K$)V$50]I]%* A@AX
M@(IB0H\SD2FVC"=P69A:RUWH^/G,P::4(J W8<!SJ?\M]UA*K<)H]:1"0:7H
MZ"MV%BI["+L*D::UQU)=DS<C@A^C@]26#7EDGZ#LV4(J+7/(HQTE#8]<4FGI
M<&(S2<L^)ULKDSAT32/FS)&GO.!=HKTT3?1JK39A*EML&$PX^&6Y3%(6I@Y
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M+\TA5?%LREI^WU[^,EKIX"<F,F<1C^/<D?3<&RE+*?XIY+VBR,C>=L8FGE#
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MQD$%3/ :Q1(4ZQ\?Q09G%]V6V1_V:PQ[C1@V>&8,FSF_F'W^;Q;X1<@UY/T
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M8$&T*^Y"'I#]6G+W(OE(0ZXT$S(D3R:$EHX"99^E>7$!Z,<>^38!2Y "XQ"
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M6^BVS6ZSK!'E.U[B"4PO?\/HN&5X\/.A8^_LHMTT^[U!C8TU-DIL;!\+&_N
MC1VSW3M8ZZBQ\?5@8^=8V#@ %;AM-KO=&AMK;)38N&48^/-AXQ '!9N=Y@GP
MQI)B\J=@DEU2VX/0^([%&<98-)P1]_TDVZP %B="1^]>S@+[)(M9]J>CT=E%
M;S@P1ZW\T+N]<RDJX"NL<:HL,^K).-5O-L\N6CVS/<A;435*G3A*'60+'8!2
M+1#W/;,_S"N?-4J=.$H=9- <@%)ML&=ZYJ! @ZQ1ZL11ZB"KY "4ZH#@&YG=
M7C[1[\51JJ0X4'5-C0V)P.V]$H'S!N ;BB+O=_AJ\XB]6,01$H'[S2[PA^[0
M[/6?P6MQI+R-#2ZTFN)JBM,H[@B9P/UF#RBN:0X'-<'5!/?6".X(J<#]9O_L
MHM,Q.Z-GR.>H":XFN$H3W!%2@?O-P=D%F)R'9R;6]%8MS*OI;2N]'2$3N-\<
MGEWTS>YP6'EZ>T-AY](R@?/IV6\LH:/5/%(J<+])D>B^V6L]0Q79L1*,2G+8
MOV5\/%(N<+_5I.S+4:M7HV.-C@H=CY0,W&^USBY:0[/3?X:2OQH=3Q8=CY0-
MW&^U05KWS,'H8#VX1L=7A(Y'2@?NMSH@K-OFJ/,,!9I'3P<NCLR?@EU6?CIP
M 2Q.A)#VRF YT Q[>@I+"PLR>TUSV,^KO7NG5%3 8U@C56FVU %(U2/NW&_E
M@T(U3ITZ3ATI([C5)YQJ#O/>HAJG3AVGCI02W!J 4=,QA^V\45/CU*GCU)%R
M@EM8J-@U>[T*Z%-ON3EPYX#FP&*Z3M80?)O1YC)!4VT&LQ]_.49"<6MT=C'L
MFNUFR5ZX@VZUVEWB:EJN:7DK+1\C5;F-5;-ML]6O:;FFY9J62Z/E8V1!M[%<
M>63V!S4MU[1<TW)IM'R,!.LV]EINF=U6R:'%FI9K6G[+M'R,Y.TVM7$NBFV>
M%BF3(^]WF@"M#9@^SJW_;\'_K9U]+0Y^CO1\S/'AFB_PY5__(06%?J/313AH
M,UII7+WC3=U8CJOW#'\V"UED1'[1G'G3\. [?V9,]44\V_!IKJ\VT'R'@?1&
M>NZ@D9XY:(AY@_0)'TUGB+%TAAI)ES\ ;%9XT \^@AS7#BNS7TOFA4S_X2X'
M%),ST[N$!P/Z'/Z^]WT;-T?,9J<ED^&K"8 RJ\M-WR<_#<1/=WA#FJ0$^_H6
M+P !IUO&RS\OAJ^9.$R9/\:E[^% Q8 X^5JND-DR9X2.9\.3QV02EW$(_)8%
M_"J7 0B5 -YB/,Y]EX4@6@P;J<29Q)$?A"9B+ERD'<3WL%,?L,<T4&HLC64<
MP'<AD#P@[[WE.?\F>(C9VQQOEX#V"VO*8N+X@ H+.+'#LA?_=*BMC2J]%#@_
MQ0%" !%]Q:S 8!X2AHS3< &L@C4S/PZ,:7(!G&' [W&.>:OYG\@%%@!CY!C(
M. +VP+P8P&5D7A-FWD/QH./Q?NPOWF[3O>/$RJ*-'/VB3 !>P-C3P#\.\;/B
M6S6+&+\Q R&"UQ7J;XS\" C,-M;JE*#LP?HYM;*5RIMK9[7*%#^Z=<*?-RS
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M/>!XZOSC  !PSPNC;O&OZ]EU','5L! ;D;#_ 6+=^^ @$+K]1MYW*0].30%
M^\$/.>F+K:6Y #9DD#]R5QDVC?S51L@MK94Q!26)2M#9),.D18,!:X'\$[\Y
M&GI]=:R)X\*N@,:\:8P?[0W8#C"5#7!%Z<'6@M, P3*Q0N2I BC3N<,>N)1"
M>A1 A,4 _WT/R_AY&P<L*T\^Q<?OD2<:P(YG3I06BGX0S7S8#'Z)C2_@YP_8
MQF*+,M16?7 LSUF^OQ4, [8-"KOCVU_\0.=/5UX!Y%/@!(DT?6_' ;"8:)Y
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MTT\"%(:,3523M+AX;AVSE>S9Q>OI#VE\/R8<,^X;W9F':J7N^<)8C8'NHF4
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M$#XEZ&@G*"_X8HK#]. -L4*70L'_A^D":%UG@K?YZI,=RP/H-^/-'^"[>![
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MO0]<RID77;K<Z==RI])R9WM\*$ONH%NW+;>;PUKNG VOV$;N#,'(D@>=LB:
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M[9@LL5*QGRKRFX*-J7(B*9]$>]G/07?9 .01B(\M[!_-[:U[_.MV?NLZ4Q.
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M1$R/H75#&F>FC_HWA)2]P&"/<405F.Y/).ZMDMC2&@KE\K@@LH BI:#A  <
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M=ENMGC)HXQR(.M6\*FNI4\WK5/.J;*?<5/,3:D>F%&U'=J5:&$_P\SMC[<>
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MLTY\F+0.?QV<"I6+46<H=Y5XD5+,!U$38$V 9T. W:H08!L(4)'[P_BXM)H
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M&X.XU#G9^N0:]4\)]3,3 U-QO[.&_"GY@9M3@7(Q:C>:\8+(4VP'41/ ^1-
MMVP":",!=.*6:$T 54"2<R: _2L_?D9X MYW2/W9N1*^1OX:^2NO_F310;=6
M@&H2."$2V%(!RB*!7E54(')C_4H1;OAWICV/O#7=N$L \I1_1HAHAJMR)S%<
MYBU,S+DG#[[B8;9FS)@!,!^0IWCM=A\(S>&EPF$-/['9V/&_;A\)/1X73#+(
MVXXY;BHL['+FY;YQ5[XLO2RTZ4):J/#5A#$#1R+K+LZWG5OF4G+@"5-SN7(=
MOE=XS$S$N%F:/PV>R2PF[11=[*XCXQ@6[ZT]Z/1U)1;[%=;Z.5CF[7P==\<T
MUWFSR$(OA-?]BY'2B <<)3@L'?Z0"^^R4\EM#G";<3]6L$U,A=PM*E25K6+@
ML-%/W2H^C[#^E48]L\BH9Z[8MENRA/-5Z;\*APW.PY0E@,**37%#^FM#^IKQ
M)$D\1 G=[;'*,*=(Y9.'8B&JKDLKTP'VI\&?K](:_^"D'N4LN*,$+J+J4U>/
M<1'D':'YZQ,V55V;T1UX_*KQ"E!=F19>JTH&<^@.7ZK$6/FQK+ TB0"LOQ%?
M9C :E"142/Z(!W<P@7IEVAI>_L%B"+AG]O%%FSD+6!:]-707EW\?FL$MZL0V
M$<*IM\3FRQY)1@W[45B$_XO+15AJG<ETV)UTE,Z\/>OT)NIDUFD-)Y-!L]D;
MMF%]_]O">G]QU\*/\*[4)W8YL9CZXU*=PQ8_J/J+^FJCGA 6^2#OQ9*&N.8T
MB(55@R9I BGPFL_W!B^NCP!_,RW"I _ &9B%5\%RU,JL15I8* 3^(__@X-@>
MJ>4C\(3/*#\,3*Y71ZD$$CJ%0=*8Y",-1![?7$MWP,*6ZI2YI)J";G5M3!O$
M#A_<B0W"3K7"\R+6=U:5K=P N[>Q!2=GP@9EL= 4C*^:H1I3$ 32 XAEGBA:
M^>UDB>%L@9[$F-)-A2-MK]5N>)J9L'#BBG54\?JBV5,0HJ[%;N<H8YEA$_W>
MHY1AL\^F[=BQW&#[$9[X23>G/P)=JMM,,'>Z37PC \UKA4A@N<"9'AYO/__?
MRT_CAZLOTN?;[W=7-P_CQ^O;F[AI%@9XFE3E;TAZL9+.L(]W0%?+E6Z^,B;1
MK"#ISK6F"P"L=*>KQB9<+LT,/8:POC:D?[J@!2K-5D^.*&G8KI<94]329B!0
ML;6(K^OA=>G\$9]%!5<-:6SCY>LZ<AL?@%IF<:-2Z?:RC9  S\.4$$J$__0:
M3Y-_4:U9M$K/GPL%S.8WN+>X7=*E7(*T_F"><2*4;@"2UQZ9<"IHG(S6BV;;
M+M6KD3PFZ'/P_A[Y+ <3C8"\03\WI)6'FVGO<4 '3ST"[FF('T$_,^"P]0D@
M&T,3$"W%[ZKU@SEWP$.81U]?@)?Y@$;'C ]I+)2..VM_ 9.$/[ A/880&Z')
M"AN_:[N.YT1NO6V.<->TJFL#K&'-+-ZOIXLART$*LCD+TP4F,2OLW%"Z@TIO
MNG,Q4N*3G]8WO86K0^D.*[UQK,]+F[/J;=RC><THR?T1$^:;:R@/TP6;N3KH
M)Y[P?&#6,Q!W"ASY1 !R$]V#.?)D@$B;<6"1-I.DN_225(A>7'<Y :F,[&IN
M A!>-.-)(M^W9+M+6"T\Q"9F+[&?""Z&'?==RX)##80#%\ 96@H=,=S(/3H"
M0:9AP\#VS0&4&>:*<>%O?UA3H=?4O4Q=+57]ZR6K?SU2_\3N/;<(I>/#.>CJ
MRF8?O#\^ JM?Z>KK!\T@:-)-'\42A"\%'3#KN:MXW/SGP$G0:')'@4B=%6\6
M/S?@IU_CWW<'C59'2?P)=(#$[],>U5(:S4'R+6F/2O^^T^R=^:(ZF8_*R8$N
MF.I\H,A@LM7QCLB4LW8[%H7S-X=.^OS=<?N]4OO[%\FGJYA3O4B]Z:8Y]-L4
M]5009"BT-RF.RMWNVX&74L.K$+Q:1<BOK!%&1\W >&!@F1M/LO3$#-!Z=*X/
MAWT@SYL7F+R%EKT^(F2-0"O6"K;1[A?-%*E>NF;,INPULVU*?PY:LE%TQ17^
M1'NP#]9_696S=6OJ&L]WP_.<O@([X#FFM: ,K_&\QO/CX[FR-SP?7HP&\92F
M;4RA4T!!=.E1SSZ PR:-^%)PZW2[,"1B5WM?V 5ZR&@[96%#^^=MG$].PY0=
MSJ=U,>K6Y[/K^>3T,-GA?)+CC6_.4KYG-E.MZ8(,Y!E[9KJYPI!!&=K8>:-F
M;V^HV;X8=7(4AV-V;3S;$\U)#MCA1'%F:DD=X.L3+7"B.9D/.YQH%XS8G!/=
M(LX1]3V+F.=Z5_8W9[B6 (TSM5[S\IEV0/ >L*S>5E*H1NP:L7=&[/UQ;G2S
MM[9JBUXC=HW8.R-V3D[B#HB-G7B5',2.%F(?N$XO.4#-4]NN#8R=8Z$BY;;]
M]\3Z-;W:Z/@9?BT%:PC^=C7G]7*"AR39/!=24C%!U*:T^"?,.8\D]:7GVX^7
M/*L3S7"PR1U*X*-2U$3XO,.G87=WI?F1KL)OZ7/KXWNO?/Q%A76L5I;Y#,^:
MO(8K _[+YLGC"U.'M=F80\Z3#N%18P/P09>^,^9@YJ(YYTOP+@V_.GJI]WYI
MP?29!)0P7EF:+BE]GI3:D.XL#<M^L(9)\Y:&P?EPR8('-!8&KN;O7H W .F#
M]M-9I(&O.=@$?'!5&O@LAN2)^<>A%UC>"T0UEG\ /$?=_XAWF0A!K)3 /1M/
M<-P:3@&@73F11@ BTQ?^'S ):W3#10-4:\$W#0=9-!&Z%V$ZUS=?2R^X& /C
MQEM4791>N,["Q$37#?.B0UTK>E@++K>Z31FH-UX1SK>X7I6RG@1=%$+]YHE4
MI/2QJ_*V%2F\+#RO+"6$SK>&]%U]E41:>3M"J31;HO]QG9%X_ 83E)%F$!(Q
M0I'>V2[Z'+T+^(,#?M;V$I[QVK%WE4>@#:S<_ MG1,%SU=E?KNT$#TF]>SO"
M2P#+-A38;YT0!<)B1_T<^CNU&KFOU/$ GDBX"/]&I<Y2%9)'BLP<PXN9R,&'
M#PO+=)_050ZX-'.G="[B-M-U;&W&O,*Z %G@"?QB"0C#J\0(/Q10>#IEH.KR
M[^B9+QK(-#<J:Z^#5Q+KL -R0*GCK3BL>&!E&/:.8=94LW$!J*" 8 61+2AR
MKFH6;![KM"00Q2YM0!5M'\1>(BS$Y'4&05&)V#]6'/ D.WP_S[K37[UW$[O1
ML(V':XD%J%QUT R0I;K.JQ0F#%#'(*6#OV:N63;NP8 76;9JO7IK2GP_!P1]
MYG!8JG B*]="6G:"DPB.S5X_MQ O"U@95T6D%15=4%^,I>9$%;L;U9ZI?PN^
MP^O>)%VS28&R7/T$">:13I[']%F.HKL$MNIB^0J_0AP>0?B2$(/0S,<O_)'N
MY@=&;]&0 7M%0I*EHHD"I_TLX+NBLB%IYEH(4:Z?(6I[]3%T.ZS2XEH9'AR>
MJK=6C3HH+9"7^JUD: 62^$ WVYH3W,+?V.!'*K8^#;'FH'8G>^7/C&,!?YX=
MV?\Z5F04UV0745<):3)JGNQ<6'IU4'A(:],?4>L&!L8+FZCNE4 HAX=!BF?'
M+J7ID#P).,9&2ZNCRJR;JBN@JE)L5,E%U150=05470%55_34%5!U!51= 565
M,%:=,9\0P>J7E#%?L%U&7Z%!D[U^SCBYNG*DIH/#T$%)N?U%Z:"-W>7D9ED#
M5VLZJ.E@-SHHJ8:B*!UT+D9#>="*]\LZUPJK'5+UWT2V;W]OQ2+PY-&@5UK.
MV)L]H+V53,"31_U676ZUZP'M+9T8GCSJ=C9)3CMSN[QHF>S;+N#H[RT-&)X\
MZG7V;TO61[I^I'M+@(4GCSJ#_3>6J(]T[4@'>^N) T\>[5:D6^?LUSG[.^-W
M2;UP"EJX\-J1TI1;";,\ZV*5&O$/@?C'<?4/T-7?D97!5NI9C?@UXN^,^,?Q
M[0_0M]^4V[T<Q$\9IQFMY<H<J/GV!IH-T@>:U:/)CKZ6>C19/9JL*MLI=S19
MQKRLI+G$\'7[)%*] 55-K*91?TH39K"YQK.CJ6CB)P@XA^FOTG\6D;HYLX8W
M&CKRJ/[\Q%?CC:K=2B:'"NX&'1RB'?=<!U-XBVTR9]3PL7;9S1[ RW&\V$YS
M)@T?:Z<]W&E"89M7.TE%DJ&*#K\4(:%PX=+BT_F(#(!/N%->A"6J"))XQ&:E
M!6MC>PH4&AROA/^65VJ<6J'3K>O *1AHTJP5_WEE=)$B0#Q'/$)7=ZAZ)*AU
MPTH?7O>C>O5*<*:9,Y84X"YE%8+2?_[@U49\RE(K0AP G^F'F6N]@&%G,R-$
M$:!246$>";SU<4"T81I$O]5.)OD[F:SO!$A;XW20,%HK?1O8_Z)YB9N([0'7
MBH1.E8_,6MH-::-CAV=<^C5F,PVX@F-:&YQY&(]QP9?:S\N%-@-4_T!+'5Z,
M3,/+O\47Y<"V=WPL&39+P9+^D;%DV"J$):6,2TL9(H=()WCF'ZK.U<.Q;;M+
M_AU9.0DSTH;*"0Y#0YTZ>3R=7X7LEX<R=;H0Q"B*>[$3!Z+LDF2F:U-Q(=SW
M25=!+ .@31V['= MEUCEC!<LS1G3Y=#506&B&D#Y_&KXNHU.JUM69=IPF/S3
M4<OE*KJH=ADU?(F!YKH:[DU5*]75<'4UW#[A]?:JX=!90.T A%JA:W,FO2--
M-KT&>0,8G!Y29 ;'TI3V06E*^U?0]%#992%%USN<1U"YDXT1/*B0 MR^&/4:
M2G==?S]FGM=6B)!))A6,H>5@R;!:6-*Y&'4;P0@.W\J[S#%1P="MU#ZZ.=C.
M8PTUSA\#YX=QJ_^HN-+;%N>5:NVCOS'.%]9>YO2_D])>[C7[Q^7<PC972 GH
M<K14)U:^7]+VJZN>Q,-.O(EC/'TG4C90GHL]";?Q<+["V5R+H[F'D_'C3ACB
M]9%Z<#'J)'3N_*6,<RS,PW<D@^IRZLV19%A%)!E2'#8!2P(>OO$.A\WJ[;#5
M;((-VAC$ ^J_[*#1_'_VWKRY;23+%_TJ"/;T;3N"H@'NM/LI0I:74H\7A:7J
M>G/_F0#)I(@R"+"Q2%9]^GO.R4P@L7 !Q04D,?>]:EDB@5S.OOTJ;G@I-PR,
M,M**4;O4&]ULB_=&W- LXPZQU+G1&JS%#6<5J>$Y63ZR]M'%PE3;"IZWUC%9
MV3PO(&]Y2?^.[F4Q@2.8W2"GWF8SLV<7;7GG)>CW:?84H1.$R.LWLD-MRF[X
M%-EC!S%AE_+"P8(Y9\P1^S1]BE!+ES@BV\]<=N.GR!Y[I!VR#8Y;,7^.,-3S
MP<*YY<Y8>[:8/2YUA.<:OC;TK$-:.=O$T5A&R?)6.!VK!<<3ZQ<;7_S%/#>?
MOONU2\)):;[;SEB"W3NZ1TP<@]9Q$<>@(HX]$D?[J(C#T-<DC@6]H&K6I/SE
MH?<*%$_H$]0.TWQK-K>MB<7&VHP%4Y<7XHLR4/H$RROKH#X*N@0.+^+E9T_P
M/6,$[Z!6+TL@UIG:[XT[^)Y'B";/FN,BK$V$VJ%@W1!$CZG!6D(/T6$2L#IQ
ML:I<4A!!] C0$],>A;QW)/YP'.?@2X3518@J5]]N_N%K4\L/7 ]Y3PV0\$?*
M YS">F'=A&&%($#P+G^JC:5EX3H)5!\.?B4:5N8FG([C>MK8%9<0/Q3!]^ '
M NB 0T T'&KZ&[N:[\H'3$(X#O:.X]4!N;,Z1R 2]S1.F#=*>\2&!D!^VK(\
M3&S4+O&/V68CK&A& DQU]E0]VXF>[4'5LUWU;%<]VU7/=GEZMEOY/=OM%95"
M:W4')506MGZ"(;"@"\@PCK$+Z$J @1&,G]ITIYEBN[EXF_FP70(+;K-;1]-J
MCHB?U.DW9+;[='*=0*U.H]E=WI1R@$X9^$.S=!!<U:*.?E%;Z;XJ5XAX#02U
M.N):(GCL'*0F1VU%$??/H??FTF,STR(T56QF1:_57*?989.!V"7*IN<?&N^S
MI6/A\,CG>A!_T#_8F([B"E8&WA/]_%&B!-]B1.%<CP?# !K% <[U!!82R \I
M3NA?6,I-/ZS?1762QW7U\."Q!ZS&QL.X<0(P2GTP_[,TM&GUEM)FH3=ZG42G
M14ZS!<UB[#0ZI=%BJZ>NJ)W!:)WK.RL-VAJ63^X4T",:>LG#OMDDR0H(E8W#
MJV+.A7+KWT1\-S,%TS!:M<M!*SL"DWMTNP$M-(H.,=V\PJ9"V-HNW.21<F#H
MCV^91]RR@@VWE^3(<J'4]D+12R.0;,"(-W6%-T697K9.[P2Y<[O-D"^MS-MK
MFV9I&6E1 V/^A*Q-&AA7,DED"&,J0\R+0G.XN;JST3 ZM<M>W 2VJ];U2J^<
MLUXYI%D7>4#D .6:=]W:9:N7+6LMFP(I%C(\$K?K,Y]M^%)O/0,B@.>?1A X
M!W]I!?;I2QF+I[INQ(3#SY[K^[DLU:M=&CEM<LM9:KV;VY[M55'4VO9_^V7V
MOU^(K K[ 'T0X*V&GFU:+#^]Y0COX[9R3L1DV1DKO(03Z(\?S(!%Q8&Y[( M
M^YV\GOVE['  &;NWCVVI4?E(;"HI,#=KU]E2V/H(5>.KK5M;6%%T0U7/'Z@X
MB',U3_BJXY:C&\LSIIIZ[;*==4\R&:Y-B/E0 :S3)*!2VE:2MC8VKYH&T)^N
M3+]ZH8=<)CH\]^^?'Q_NW67.\-^]&YCVZK!4LUF[['2V%9:J@D_Y1=H39FTU
M_'2$W+)]L^>%'".N)?1BGLEE$ 2GS/K\B^RB@\:0CI L2FG,Y)!&87,&Y_ .
M&OV"&>-3=H\K9_M%\\$LKW*UCUWGQ.!-RW4.3DS*.D*5+UXZ"BNE^LJALL+J
M"T=J@U@LFNPX!DJLOE_\^R?IF"TKQC9V4BMPAJ75O1*45C=[M<M!?_-"@;W4
M:"XK:#N'NK53+T];; [TREKVW,39_2#'BS8EE(!S]O:Q8Y+:BZJ(MX=AO-,J
MXN8 \5&Z&U015S4QY=I"L=3)_DR(=+Y$'7KEA+.+L4M#@7 I>79&2P<"K??Z
M!>7ECK,F)Q8*6[^6=Q_-DJ=<J[G(I&^5HOJW9=0N=]$NN9\JS8HV=VA0M\I<
M1]QJ MVV&UO+N9>;=%\<\RV=_BG<>'4B=MG.V&WWM<HMS.%W&_VRE+D<.II[
MZ.^?9#2Y2#WTZ=9S%$^YKK(FMU+=W&K7+IM9\+VJBN>(]<;.2Y);';#4](:>
MI9NJAJ<B[)Q U8X=XTUK?%M=;-7:,Q6?5U"J2(UO53^S2W-A/U7!+43PZE45
M6N6GL%*:)ELH,&YA.WJW,2C8?WL4E%A]O_*I"Y8]GZX)6CH5N681<VM02$56
M+O<)Z+4M5!ZW=:H\UK.44SG=5>/,BVI\S2!3YMLL21G!&18&]TM0&-PV:I>#
MHJ+F.*>Z[I 82\?TU6S,]2V"'0%+OKSXN-VDXN,<$_($N?,8OW],:FE1Y7.^
MVBE=Y7.[!4;Q1I7/5;'.61;K'-+<>F$1=;M=NVS5^X7GNE8S::J!R(=R9OH[
MYJXU2Z+;6+!PA.-ISY>>EIGF+\5\WVT9<[L+YKE1>,!-*>BM:OTZ,U;8?8EQ
MNU>[;#8;1L$2XU,.6Y]7H+D:A[RG].9*6VLK!</M?NW2Z*\_]^\HZBI.DX)*
M:5R]N/BXC>GS=G&XB6.@PW/__OGQX=X]YO5JI0N&ICHZ&'GU_F!;,)!5:*H:
ME[PWLV@_A=$= U@D6Y-:57V=L*VSA6KF3I/ M=H%T1].V7VNG/%J7/*9ZYPU
M*XT[V-Z_OLXY"A?I-"FLE.IK"T7+G385+1L5>%'U_9-US%:44K>JB<G;*8P>
ME* PNM.I779SPM^EG_OZ<@HJ'=]5$Y.7LTB9BI8[6!71;>A%#8$2<,[>/G9,
M4GM!W3":I,=0-]S!,06-034Q^:3+9@YI0KPTH]*O7?;KK9Y>#:?9>6F*B95V
M&QKNN^Z!Y.>3*0D\DRK0 WD""ETL\00&M<M.OR!_[O:ZR]U!N0-2+IU$V;3!
M\H5G<Z3L?4!71F'QHJY,5P?;L=_H;2NF><RL?XS?/R:5N#<W:S$_+'*SC#7<
MK*Z!;E:G:L^LVC-WZ;%MA^Z3'IM1V&7K-L$@K/=+D^LB7^Y-@%N#_QU;CY<9
M/H1?RF7,3._!<GBDK2FYPW+&<%YOC3ZPVF&(Y<K7W$GDF?&#E.Y970NFS&/:
MD^EK__42JNJDJ>KC;&Z[SXS=,>\1K(!\8^.;ZSPR'P4ETI-/=93JWZ]=/_CF
M!O_#X+4C]\&!78_5,OOU"*RK$!BF\QM99!<-SMW&/<-)!;@*V+P7O1+V'J\)
M_N$'FL=L$]8-'];@.1=\%W"SL#;-Y8O3'G@C+#P*S \\:)H*I-W:0 .F,]9N
MG'$X(@[3J!&HH=W#9^CQEJ^Q7W,V$J\8,DU9C0OTJIG:DU R%R;7,MJ<\LNX
MA:*J;V>7Q5/>GUQ/_ H_MY;6:^,]&6ENT_!3?D/CS1=TI/@;C<$)CQ>2^-6W
M&SP^9CW"AXI1>:H*)4/EMYX+DF;L?_+<V8+^CZ(4VJE=]AO93MN(0BV@0-.?
M:A-X)9T $^_"BT\2(!(9THV'IV/.YY[["UX;,/MYR\>P%OW<F[_>,X=-K !/
M2Y[0]\G+&+I;N]0;V<ZXZ+@"\Y<&&W^T?/R7PK9P='Y\>,6(JODBHDH-4=P'
M4?7PE++3;EY.5%O>^@$)J8]'E*WTVBTA&2E"D@:.:B=DK9L)_=^[_5G2A:ZX
MO7?J'J"R6$S=>8>ZK[/;'V>M./8M<E;V!GKZMI@GLO#)V%YL7._<EN[E7N</
M,(# $,'%TYEHW!9:=]5E<0F4;7 2-&D;VJO_\[=^LZF_^W%WY=./QKO7D1D+
MM\4$$8%M"V3BF398$F@32I-T30NTI>M;"T;2?_X-:XBZ<?/MRR=@*Y\Y"LT:
MM<N)&WK<IDQ;F@T-ST#=.YKY[F0"O.-I8POX-'"]%Y^#48)S )_;=;BJRIS"
ML1$V[\3&@P>7;>8Z@KS'S ;UZJ6)& 5N?)5/(*O0TT+/+V*/< X/>>3'FM#L
MXG?BJLF/1N%MS2WTY]"-I%^D^&P*?O8DA/<\NO1MBC_ 0N#_XY^8NC8ZB[BR
M)S>TQ](T@'4^6G"Z8[^N61.4]#;L%-[+'AF(UZD;/DSS7^E1\-'7_'#X)^R4
MA"Y0DS^!U\@/1^J'SB"F:3B-B6R9XT<1,&]F.=P1%IN43#&'@_#P\=%QH3L[
M,2U/>\1P$'Z>F:,I<A8ZN!1/TO"9\#&@IY\LB#^(OT,.,)WG?_A23_*/CD%W
MX$>(-U,4BO2+/&8Y(:TQ0;."4MJ84Y^[/CFC;TD7P0&_>[+&P13HC.)KRK=$
M4D&/OV(.?=<.@\5?40),(Z &YAV(&V!EJ>-1_COUXHJ'!W8Q])CY\\*<P&K?
MFO:3^>QC $SE>&!W\?0!OG[1YE7)H"\3!)/)SK;.Q=$8;2DB@[<4@L%/P7+,
MTJQ%FWJH"/YFM8>C06?8;K8GK7&[.S2'X[8Q& [[NMX=@++4_Q?\MWNJL0"Z
MQR0"MA[\\XUYN8Y\[B<#]7NBR'S["9V=6Y#1,W/$0HJY@CR[<48-DCYWX="W
MQI;I66RQ2566K7QS W@8-V'Q3JBPDLS:3R @G9%EVF CPB]F_+)*OIU/KA=Y
MK/Z*@!J/@."-H0N;)V)28E@:&WI'OVASUP7^Q,970?3KSHJ$7<92BL*1L3%+
M)CDW :Y J3U:P3-QS3T\YKT-?U.LGE9-8^#(S/$*O) MEF%K6#<']]"O0+O/
M8-'/*!]0O9IB^TKLF<+.XV1HHMA%H]*>P]DR,HF'S':?WA;PURB-DJI*A@.R
MS;G/WLH?WHTM?VZ;SV\MA[9)7WHG'B94,>KO5,J&+HC_.59,#9TK)U&,)]XL
M_MR /[W)_K[3;G3T;NZ?P,$M^/MVP2<M6I31;.C]HB\_ST5U&H;17OJH8OU3
M)4EQY\OL5Q8W_>$9Z!>P7R,V#] CT:CJCQCWGT/OS:4G"Q#(?D<+VLQTL.ZD
M^)ZKM%(=&M</Y[I[69E"9"'*4WCVD7Z#LP@U'$9(_Z(L_KF?E"9.B4XDJN31
ML'Z'?O6*%&F2G3:M 2_6JU/^ZO#?A8F65QJNEZ T_"R[0%MZ<T>UWQ__$X+-
M>>. /1Z2U_,=JTONIZ8C<@>1S;ZX)KR'(]H[!4>='B<PQPZ)M'22H(+-6;=L
M.\6>VRO;7I\[-YI2W.M03;>QK0%VI6;=G2CUHZ#E19FL/6J1XOVL_AHE9[UN
M[;(95Q'D%EJ?Y.R-/>)UG(N!U3Z4@96<-I]K7_5JEYUV463OM6^T1& >IT9L
M2VV&]H%LABW &_3Z-)]1+VKSEXTFJPF)@H+_349D-2!QIP,2#ZAD^/TN53)8
MD=G,=O%48Q-+1W?'I6Z2I+>1NNGSWN/6MD),92+1:IY@->C].'5*=&'+U$K?
MJ%UVJP'PE2I(38;?3 \T>;PRVPQZ1&/AS\NQ6)9.-$J23M0;O4XBRGMJ88A%
MJJ-3XJ1BOU6[[.G9#K$79R96WG;Y4XN;$6SI9,-+$HRKC^!(>76IXNX<99JQ
MC_4!W<8N*@3*RLSG.:&)+,OC3BGV.YA2[%<IQ2JE^&+SJEO>E&*_"]95NW_D
MZ9MS)+:E]D'W>%.*_1X8"<U&KZ!O7SJ:K#S_*J6XS_#OP93,ZI1BOP^V5 Z&
M8Y52+!W='9>ZV49*<4 ^Z:#"4Z]2BB>>(SHBG;)62G&@URZ[6;ZM4HKGJ I>
MFE(<&* '^@V]H"M<.1;E3"DVJY3B86->O=*D% O.,1\T:Y=&W2A<9G_$28HJ
MXUAE'%?I]=Y19AP'+>I/Z!<-)AXQ,Y]KQK%[[!G'01LSCMTJXUAE'%]L??7+
MFW$<((1XKVBG>=FR.^=(;$OM@_[Q9AP'",[=:K2*@EF6C2:KP$"5<=QG=/A@
M2F9UQG& 103]+!)/E7$L'=T=E[K90L9Q@#WS[4:GRCA6&<<33R$=D4Y9+^,X
MJ%WVJR;&2A5L(>/8U'7*.!H%W8[*L2AGQK%5@HQC/H@ZGDF5DFSIZV IES$E
MV=0-3$FV.EM.26Z'6LJ=L]PA1Y1..FV:U-S2&1VIM%AJ6PR.,>L)RHA;%I6\
MJ-*B&;SP(TN+-O46ID7;J].B;PAO1D634S]>?OS#*\(^7 3G@V?-M"?3/P&<
MX;0IMAG@[2:8]O&3^)?2)%P4O[BIMVN7;:.1[6TI!8 Q@C'BL1 NICP#A->,
M#@G^X0<JJ"]"I0HG)X&BF@2CJFM/4VLT150I]FO.1N++0\+1E.\1@*I/0A9<
MF *R9&V$U8SLVAE=\) />/3B5_BY? S6E'#JY HG#M!5=D!DV#1MT!FQ"SI%
M+0.1_#L<Q=$A)/-[UV;FLP;RA:C2\OT0-F5Q%%+<-9+?[=WO?H/^"V0KT-$X
M$"L^#0E:(KB:FD.N&P%_1SBU N144_%JZQI'R'O 9W'857B@.9I:[)'4*ST"
M6,::6+"B>7P'FDL@K_ Z7V*]F0L^R3E(+%W!.29X517,.''^2,(7UJ^+J36&
M*WI+]-NM7093CTFDH L"O<][U7='^\2&7HA =<V^U$J@CN:F%V117QD9"TE1
M,_=<6.NLSI?]A/I,6?L(;"HP$A!/?!32*<!+)P)D'+]1UQ;J&$?XU2D!8ABJ
MFKGY]DG*$].Q=FD( 6,A*!+(NN\33HR1ZKAH*L(#QWEGHW]_YT<C4'65N[C@
MJ+L9E& \AAC_^^OM#S@LB0!>C\".X8HBF9U'HI*89XS1Y^5]< 5"1"\ CCT6
MA)X3O?#^[D>$-VX#D=N$B8PW;PK49B!C9B-^\9S!U]%.F7,")0AB_&$EG?:3
M="H0$,'<]&BQ_S(=HDQA+G'X8GX2&J&IH1Q04915Q&=<O=%[)X\%!07'F>;L
MZL'J2=W MSS":DZ'_CJ)]XUL:S+A7&AR<<*<L>20E1L=+&!(U)B("3<U21S-
MS%_6+)QI<Q?Q9!&O5( WXSN/A4^^\DW<RCW<NYA>C;DGEVL,'52NGL<VA;--
MY=KWG5CD.A:HXNS#)B[[G;J>T\$J5-7K&*X;>%65*)QNI?5'GQ9")B&XT<1S
M?-2B<%P<11Q!1%4,<!0R,WI*$C0<_\9!DY^13Z7NS$$#)^JV?-6 A ,T41-?
MH(Z/)8:4:+@2OH/X[?Q1]&!E(3&LHEB28%5TIY9Z+@LC0\:A@'Y>7N_6A+5?
M=ON-;H[30CCR*+U->Q1RJ@A];HE\Q0/0KDW/!DD*Y&MSVIBY8V;3+?@)B6LY
M(SL<\U1)6>21H!(>A?\^X0RW2MRT!!9[1MP(4I*TE[40BTM_H[V>.4;WA*?L
ML8G-O2_NGPF5+"JJA5J69B\'\27LW[5=D[+8],CE+K)"<6)JE=H(-#H+C$!!
M,K&MK)+!6I;@E@U!<_QG2'$!#!%\OKJZ)2/L OY!5/KQ_<W]ARNT[IZ"J>:9
MB+!>S,@SNAL8>7NV\=8Q\98&-<!\V9:NH/_\F]\J5P?Y(8LG%XB/.0K-]<1!
MT\UE@A>[MC8/Q)";69O][5F;I=KWIM;FH("U65QBG(I!*F6HZ9CV,WZ38A_,
MC]ZD"O,'%RB"_&3?QX_@WVWK)[.MJ<OCI$KX:$.#]\7VKGZ\]FY3IQA]/]MS
ME"29D>V2K3OW4!&(@^.*-8\^I-&[)9MW1])A$YNW::QI\XZW8?0VFX<Q>G%W
MPAJ@TTR8P<+X;&-%VAS( C_PEN22]<C>/5GC8 JF*^5?E6^)#+D>?\4<^JX=
M!HN_D@%2/Y"!;>A&ZGB4_TZ]N #P 22RQ\R?%^8$5OO6M)_,9Q^3[*H3 1Z$
M>/H 7[]H\ZJSH2_S+2:3G6V=>SC >JY'9/"6:P?X%"S'+,U:-. 0D!1_L]K#
MT: S;#?;D]:XW1V:PW';& R'?5WO#EJPO/\%X^Z>B)XR% YJ??^?;\S+=5R^
M?K+:84\4F9^>NOIVH]V"4)F9(Q92N85?UVZ<48,$P5TX]*VQ97H66YR@*LM6
MOKGH#0F?!.Z$JF-(?GZR'!!Q:%'?!?"+&;^LDF_GD\OM'NZ?@:B'C2RJ6\!9
M/'6ZL030AR)<4F)8:B&]HU]T5I2W&.O9(4JBD^L_4HVRF/<*<VY@A!#3W,/#
MW]N@\A5M")J9@9:<XPUX(5LLPM:(EQR\4.,*7.39#-UHG@#53+']5(9?IB#7
MNV=YP4TTF$4F%2UR5+MO"Z3!N;9.-MC"R=CFW&=OY0_OQI8_M\WGMY9#^Z,O
MO1,/$RH8]7:J2HMNAO\Y5D@-G2LE4<(NWBS^W( _O<G^OM-N=/1N[I_TAE'P
M]^V"3UJT**/9T/M%7WZ>B^HT#*.]]%'%6M)*4A2<+ZM?D1WLAO",,>A/]FO$
MYH'B'R+C_G/HO;GT9(T>N;'HZIB9OJ:7-X[D'!E79:4Z-*XESG7WTLDFLA">
MMD;>%?T&_6T-'6[Z%WG=YWY2FC@E.I&HV%7#$E?ZU2O2H*^S-:L;=$XIM=9&
MHM#Z!'NJJBF.AVV9,@Z&*;JT96IB_6+CB[^8Y^9U2S7;M4M*]S3?G<_4MYT3
M<^GD1C7"L6@(_U!HKT6:F5:PN1K5[YPAFY_X+!AQGX>9@U+8(!.1F^,TN]8?
MNKARXX4)5'S_?";GY9M7W?).:6PVNYCG?ZE@+7S1NQ2K%=5NSYCH'N^XQV:S
MMZ@<X-2I>Y/OG]> EVIRY"FKO?3<R (QA?ZVG8W*F:CTVDOF2A9PE >G3+L[
MF#AY8IY>D5&4.[.:CU!^%"WP/IQ>6V=V9;.EUR[7'UU9B =*[*T=(=T=E=YZ
MZ1#,EK%=9ZQ,Y%FY6]4\S5.0.XN2PYW2)(=SM%VS=OERH7)"\^\.3_&EDS[5
MO,RMIY@[1Y!BSC%"6ELR0DY(7ISGO,SNT8_+;!&*H%Z-RY3C,HM-IDP9-?N;
M3)DW7+)%TP47SY9\X7S'Q/2X_<]WS/):Z<8[MKJYS)0[WC&_G12?M+IES\#@
M3%G'1!KMQO*+S'1AW3A @NS>_/7!\K&I.O3R^JI:O5H\C>,JD+_$QR7;K6Z^
M77__^E&[O_K_/]XME&O+6LG$4_->UGQ1-]>^9-UW1[L*'T+@Y"X*.*-?UW*Z
M([5KTS'')N^1E$-@\'/\]]&0/G,$J@E'\YFV31POIF-B*X@;*R4YP]'"LGO@
M.)*W?S#;OIM39QB.A"%Q$IB_J&T+5!7P((FHAO;)M6WW27:0P=%3VUD@I=8T
M\?&Z^EP4VG"Y#S2O$X1.O -\JJ?]WKB#'QB(*Q!\N&8?.R>Q^1Z(3H/%://0
MF[L^\^O*=U&4.6X0C:N$OZ@S8>*.3!I/^ ['48 *23]!&2\3OX_F1]AX4/*3
MM"K79O#+:,( 3N:AHP4CR,7I$2 FZ3S$T L01G#E(+!#SV-B^H3\W9A-F.?Q
M,1*/EH]?TEX-F<,F\-37O,TN-<(T'L5))R*_%WWMM3;QW!G_*"[: JK&5]XX
M]"-\">_BS]"S_+$UXNL\QJ%1<A('#?(0= ^W!_0,-&OY4Z!A')G!*=-$FJ61
M ZF/#UG\#4;W$M\)GB].[H#[M2;UY$@)OCP:X?%H6C:Q"7NTX&!&K XD@>^9
MP27S>1_/\!TX)213^ &= B"PN>MQKO&(7P7SY+W]":P"^C*I:3"U0?-QV@IM
M,:.,_SIBP]P]X$R5.:/+BX="/0#5>-'W)B%&?#7)^((5E(Y1;@+XR!+<D BF
MP)!:P&:P'6P^'5L3>#4>@P_+Y5]GXQ (#1[8T&X]]T]N=>2_"BF5Z!IL%6JU
MP<DL 7NP&+US9O[D*[%\,52%1J<<&_TN,W&CCMMZ)& C$99'T!N8PMWEIO '
M03R@YZ^(=+Y8YM"RP;AB_C<6%!ZEWNK7+O7&(A]<FKRX[8+[Z.UY'X,U]E''
MX6US/N[9?J['(X^XUL!9SCF\B7+'88'4'4#B8%WAM$;/>X:_\;G70/]R9!NI
M2JX>CUR2DY>CJ/B"8P%&(+5#FWV?H#H [8ON^"0R4S_R<5+ON69<- >@K>>8
MD&T]:Z_*Z52*JH5[2]@+R*Z6,*GX1')I+4V6S%;06L;;S0Q@6N9)]-[W&T:[
M><+-Z:5=U'EVS!=I@3^.GN4U4ZLGV:^]9DOQJ>[=V$H#>CEY.=]NN!;.M!H<
MD*[P2^H+"B9PRIT1R4]R[3.!5!UG=9P%CO,T$>-Y1',-U.?CKJXXD1J(=)C!
M6%X,)121N.2,SUD8$K@-[MR@;AB]LH*'5W1[)'2[8L3+2L+-H<UF[=+H-"O*
MK"CS192YHKYTZR(5D5[JS4%WOX1[7A7?-.5VH6U\?HV(FYD1=(I7SOB+.]H*
MY;=KEZUZI[6M^L<RE2]6)+6FAE]%4SED@^5I[2P02$4T)T TZRG?;0NB+JK@
M5C,+/5'*D5#'J8(_\:*B-93PJ=/X>O8E/Z[U)&(/).*>[<<-4ACG<\-K.K=%
MKKA?N^Q65UR>*U[32RQRQ0.XXD&V5_YHW$ ZYC*K("KG>8D7>$[MMQMKK@7U
M386ML@Y.CFC6N[V"P>9S&;1Z[L2XGI)=2(TY!(=#(;H5M574MK&^WYKL:V)H
MK*4?"S$>91U>/E7(NFRU>$=4U+ZL**]\#+!VR<C+*].JS9=]\^>5$%I0]G+B
MH=C%L^76L?9]6#_\M*B111SIUE1@JW;9JW?UEPR/JV+\I22LC.6^9\IJ@V,)
MUE4_6RM2D=:1DU;&3-\S:74H9F%T6X<GK9/,(JU;R''RA%Z0SA,9TZU1>Q>]
MU$$[FY=81.Q52J),>G4W1-'#9'JON;YRK8BB3!IQ-T31KUUVZL8>B>+,W-FU
MBRO.US0L:AGR(RV2/QC4+IO9NK3*ISARPBGLKA:FG"ZE.OL5Z92?=+:9-'H!
MP1A@>;<*U@.5R=,\G5J1T\N+[E2M;LNB[&*WEU'O]-9W/@^3D5]71IX['175
MLELC).R_ZM2;K0+1X(J02DQ(11W>K1$2IA6Z]4%.:\JA".DL9JU,<20ZCI_+
MF3]8.<0;5W/^6Y[FE3S,],1"?O(WSM4,3B_?3.W4+BNOYN0(9T7EY58HIUN[
MS/:%5I13.LK9B6K>"@5A'J*_K0+*JD R-11U];31Y39/A?BT[:,X(3FQ7+]L
MS6#O8Z92'V1K-9;+B'+"+"U#7ZM8[AQ9;C?QEZUQWP Q7NJ];F%WN>*\BO-.
MB?/6M8JWQ7D]G>I?VYTLQ%=I.6\!=EP2^2H?"TML05Q0&TLYYJY/8%QO"?_
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MP"E?JX=<G&D0Z+T^T+>%;EU9OV4BK*+B>)N$U49S>#!X<9"A,H<WF1IISJT
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MNJX%5H#229I$4B;CMKDQ)R_[*E\Z"Z&H_8ZM5[ 62^ZP+A>F34V!4"N S:R
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M:CCTV",OP)"MUMAAC7X1,0'9\T:GV^W5%RH<D.R]>MOHU?6>7H<?.^UVO6>
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MOAQY),?=$"!R; +FEX.6-(;%[:7#TGVY3B2R60X;6R^=/!5F1 DR#KYH3Y(
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M@?D3-)Z8IBSS;&+LGJ0@A+XB3A;=+ZD$HY)!6I"=2Y7_]]7R_TPF#T'HJ!K
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M\,OL"*"[CY^_?OQVK_WX>/O]Q_W-M\\;C;04C\Y[X\M&6AY\Z.J5.F//YU>
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MG3$KG9R*N?UW/I<P-%%,]G5SJO='"CNOT3DR1]#J>*JYL7Y=![M:)6@JV&J
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M0/YE;1\5U#AZ6(N]HI1/*J;=@6D\QPSY(*P0=_YD$OB_X*81=V?KQ1#*\N8
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M-#[_M-3QYYGOA=1 8&A<.*''@]YXP@/CZ]>;/39'#QY&#^?W;QZJ8:-JJ#Y
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M5H#!TC\&^3<C *T16YWF$*KB;M3MCT8PF(^^-(<5.DDJBHJ9\\0"/H(Q?A9
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M5 MK<GW33"PYHINY__9A(IN^P$  8[Q@P5U_6:/T%;:JP =LOF6N.D465[F
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MV+I$S(;0^E0SH'4(UEPT[<ZBSL[#<%H5TU&YV0_F#3G_<QR1ZY\'(E! :'0
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MB@_-.R0] *=M$GA@0@?'.7A>+X (+\&79*%(E[5+O#ALW41LZR3P_66OMN'
MPPG?V\SX7O3VY1B936X)2OO:JL4;<L,3(Z\_)(^I,%]DZR3P5K6[]I>AV@U%
MFLOGN6.EM3?3-CJZ?.B>XJ&[!]$H EK6);I>K>IZT:+E@?G5#ZY\\P-.AY-Z
MF[T6&\77N/J;_KTZZSG\FI8)7<<TF,-2,-6;\U(DR_.J'[!2RH.3* &+CAF#
M$$JU3G_8[P@;V,4*X<-T4B]NY5^__7V&]/[+;=D#\EX^KSK%&DR<%Z&A-K<"
MY>J)BG2.-+HKWGH64+=.T-X<7:\L:G\Y?H>1[D+\+>_NW86OECF:W<0G,'B5
M%&CID3P,I2%DDT%HYR,69QUV<%]V0W2]LN8_/#UW%7_7]'PS'(=QNHZ/0LKL
MC3 @N?/D)PD)KE8>T-RQE+B.4K3>U=L<79^V]']\>NXJ_N?0GDDAAF"J\Q[K
M)9\<(#J,4&+(3ADKLV^=R_54[;G]/'P(WY;.[<GD(!%7ZG'0]?2Z03%2J%JE
MWF9.VJ/VKG")9&2%5S%Z)WQJ?3_Q45!]*RG0!95N51-H*JEVI>ANPKJX;X*K
M.'6IEE;_)0^P9)YRH:6>>4WX9PEB9K7W:PE!.32(K?WD;?#U*OGKN6C52G[=
M,8RFA)SP^;</HS">UW0V^G1YEW<@@^9DLY!<&QY H2&+946&H&ST&9G,LG-=
M=2^Z+3V)GY-=;637L)#F)"'F98I$K?5Y5.X'&(W)!;4F)TB;Z@XA^-JSA4F;
M(THIK&[?,6EC>'VZ:[LO<G4DO*Z=S+NV$$I@1H5"[,^I'KO56EY><Q!26Q>T
MD\)T<.SRI!VD[>?AXVD@NT+11JX[VCB>K6Y*6[(6HC8(=474-L"!9)^]@*@D
MUTH+84+K5-2[D?1IAZPCSMPJ<+"[2-K<R-S/]>2+G?N!T8B"90M6.@IL:[W#
M&(,%4:07VAAOS8U@[IY;GOO%W:=-LHX9VG=6-*SCL:H.=R4!<Y7)\XH^'-9X
MS@EI9(CU^AHG5&2XZK$>\%!83($X*5I[LX]AZM-NV)XT95,QM3V_?Z@,B9:Z
M:.:1/!QE:<BEUJ6WI,Y]JL?17,INT@!_D'(P>R)/4S&U;43Q_4[MQ6W]H(.1
M&!U@D!2!)9W USJ4)14A+*NG"*U/A.]&TJ=:+'LB2@.1M/''+O9ZWHZ7X54M
MX3&CH=Y7-LV05^0=*Y!J>HLRG$'@M8,<$U&1P^3ES2(*]_A3V[VW3RTF]N$/
M=2B5=EKEBEX[*I<G/1>73E\/9ZNF2P,RJ!:#,P2G'BX9X>HM?0_>2AG(=#*.
MK4W3IMCZ5*%E7YJG"[&UO"Q\X[SR=N^N@?4YN*1K#Z>::,>)^-[4^!5EP+IG
MS43KS9--<&U9QN59-GQ;LZFYO#IDTD5'L#KFF Q+(@7(,7E0,FF(01A(A>4D
M:]F9TMKW>1#0EJ5<?E+N/%5"'9+F>ANH05%1J4(L)B^>+"UW B*S GA4EA69
M4VI>$/$Q3!OM9K*?GCL["*J-)WT;TO'D6QC-OWT(WY9J4*)4,EB$2'! V4*V
M5&6RK]P[[VJM))XW\IT?>]-&C/A)-KC;3WVG%NAR3VE@-<FT7M\3.=2Z_SE!
MK/UH,X^!%1-MRMT[,5< ;42:GV3/N;V$NE$AY$M-%YA_FWS&Z;@&?,<8P[P:
M1V]HW%R#96K9QKI 3%:!P%@L1AGUS5M;&ZJ2^]ZX$3M^DIW@[D31F:'!^6(Z
MKN@F>;55\+FV.D])H*&Q,E_C-Z: -" !TYF0<5W;ESS5W-SQOHT8\I-L]W8E
MAF[X<536Y+VH W;U")A"_N6F]8QL)(NU:'FE+WE,P5J(6DL*U5PL,3/D*3Z)
M+YN]?R/^_"2[P/L2TQZV92X\K(@ADL'D((V@<(TAQ?@4IH%(QC%A,JKF-;<?
M!;41I7Z2;>-N)-6T</NL7F;%V='X\&L=\&(X.UV5>'V-<3X(B5Z=" R%]F1'
MTW*3R!/*I-'R%'1BK8L[/0IJ(P+9GRRT;BNJEJF;93A?WJ"/+ 3N; 2C"J\,
MIM@^)0U:>6>\,MR4UHWKOK]](T[LJUKWGBCQQ+EOWO;A:/QZ.#N?S(:KPXM;
M-R)DH2A-%E&;KY"O);F'&&I7OA*5MZHHW;S?\X;0-F+-S[;!VX78VI?Q?E?-
MY'&=]J-"\[#$=/60[&)'T5D79= *G)*ZEG<@GXL9FIBZ,V"B%JSY!?IM,6Z4
M-LA^+MW4J1R?XWHLYT(C9QRT2 Z4BYSPT4]UQXDQD4L(>TH-?_1Z[&X7,-Y-
MQI].<'KVKJ9^'I55?MW "^2>8P*2R=(]E>"T(BY8[6+4IJ32^G;PHZ!^@(3Q
M79GTT&6+W075L-G+^?J*T5%9!L07V):.J>$<A4NEWBFJ Y:TM+U@H#%9%,IY
MSMOWUGP T(]PP; U<=I)J)M;7[65\]'YLB#NX5><IB'-PD!A28:B&D*D"5;&
MVLS,!W!&2DEXT97F%PD? _4#Y%YWJ71V%U3S&ZD4_EXT=1^@]KQD7F^4U4S-
MC#5/RKK:1B,:'HM0S7NTW@%CRQ3KGT+!["J-3M3*V]EL0:/$Y264STA.)X4W
M'Z;KNP1++@\RN9U,D6^;C$P4YI"_&W.)D!W71=F0S<WS_Z9*9@.(/T B=I<J
MI[40.V?:V=EDO(*%-B0KD@;ND(.B]0#.>5*.GK1B#,YPW7KW]%%0/T#2]K[8
M]#1!-3=@;R93<L\6TW2Z/&^ZBDLJ$8MC"*Q("L%C3#3J;*#(8*)A0=K4^OSF
M<51;IF?_5.:MD:PZB;RN!X)D>[65GD,JA$09@Q!2H+C0:AN$-U:7]BW@[@'S
M(^1@=QEQ/5TRG1BKZW!$8 $CC4K*F@JA"8X3VH)1R*6T2GC17,?<!Z9/O3.?
M8TOGR8+I1*&L]@82,X%G158QUX8&P4(HS()'KAD&2?QM77[Z)H8?(I>Z2_VQ
MM2!:^RAD]AZ[QG_7^&F,T=8C YE2K$=(&IRR'DKMBU&*",6E;MR7IP'>-D7[
MIR#:_D3<KBW$+B4X!XH[R1*MH:R6JTG2&O(T=Y@965Y!:RJUUF@[ 6XQ6_3\
M&T\](')-I]](FO\(HP4.0D;),$?@2M0:4(:!3RY!B4K'6H'#J>;M-#8!UJ=3
MGOWQ[E;3V.8R;.@Q7!WPJK4,62M;4C UGRU+<EX*>3#!YPQ(>@&E-$JDUG2Z
M$TB?:O8\'WUVE]&>.E>\??_Z\->3P]?O#S]^?!/2TNS0?SR?C.L<O,9Y&(Z>
MU+UBLP>W[6#QA,$TZF)Q]72O=H^\$+CTAC-!UKGX0)%G+!!X,?3/5+0D!2%-
M:W_L;B0[9=)??>1OT]J*93*^H#3#*+1R",C0@/*UAE3MCDE\%C(4+-J%QZCR
MV$OZ9)$:"/I:^GNKN6U>GVOE>^*R(,+W@=:>N 0K:*L*6/*"06729]'3@ UZ
M[J*+!+1U9?!'0?4JQ: A1[J12C.R7!WI!6N+]C+6=+(@ ZM5Y>BG@ **1XJ<
M6=&1M=[>N@-&%\O@U??9YH*3^1<(GF<:I X1@L,,EH68&-<T_M:;O0\CZE5M
M^%UIL0G[GRB,-G?+;FGMBU$&KS2% I'"@.A!<1[!9?J#B:29%9'</?8T<]A#
M][J5F-M-Z3,XS4>+^6P>QK692"-O^8XG=N<F/P:_D7]\I_VJ5HM((;4PD#69
M+B69@2B7>90J6Y]$2+&UL;@'2L<&(Z,PSB@&B8>:,&$=!&8BY,(#DQJMS*WW
MP)H:C$X520MV;&DSMI'''GUK*[GU N4Z+T)Q))>?M*G&(K(07#C3.NV[M6_]
M4S#EZ5)Y!A.T.KXLZPT/FL?%E/YN9(T>?GAWAFF+076PAS,@9\.HG!+8Q$GD
M$C5$IAR@#DX9S;7.K1W\^U/F=QO+[ZNY&^+LZA'GA^EPG(;G8?1V_)XF\.0+
MCC[C[Y/Q_'0V4)'E(DH QTUM>.,LD*X4P)44&*/SJKFQV@EPGVS9DUET4RWM
M3X2=; <\"OD_,4Q/ODP&:)6.A@N0DE'$$)$P*Z8A:&<L+YQYT;HNZE-P]LD*
M/@_'GB*P9Z06<05KH7$IN?:@16VO%**"&!R#'+A3FK.H1.MF*T]#VJ=K+L](
MKZV%]GP$>S-93&DM2*F=C!!)J8(J"B%0' '2&*3YR9&BB>?F5P7:IR8$ST>O
MK47V#,[\V_$<ISB;-W+?;SZN.X?]0>"-7/2+=ZPOL2\9I+.VRE/\[DOU=!S)
MTSE2&>3^T/\Q6\O0-5Z"=\#8O;34K4<>?ETW*;[6.L-%SM%5Z^MKUKNBGP*R
M!%H+'XC6+#?/'MX46Y_<\%V9<KN@5 ?RV4L3@H'0&HVQ&8SSM:Q$9A0*+"N0
MRUATCM'<;/[5:>.!/CG2K5G23 X-2]:M1KC:_PSGPWD8#?\'\T'^K\5LOFP2
MF;1P$C."0'*RE(\)'*EJH'E 5[3)1K3V81Y'U:NVL5TIDT9"V9N7\H_#]R='
MQV_)V*=3S(L13LIP7:M^M^W&31[<VG/9>C#-?)CU2Y:GG /,Q:>J%9CG'I0H
MI?87H8C':,\\"S[HUA'J=02[:YCUTX[#%_+"<3JDB1YH(^N>>P;ZBY:'5A:B
MS FP1!94*<S:UKLZ=P+IET_R9,G?UB"[3GK#=.2Z5HZ1IK7>EECC^A#2O\.G
MZARM2[9^7)R?C^H%!I<,!?%2@E$JU;*)')R/&9(JF0*Q&+)H?<2U)<1^>2C-
M.-.EH!KZ*VM<_YQ,_WW9]VM +K1E/K%Z<;. "HZPU(U'[<G?9D8HI=NW";@+
M29_VZ;K0)T^?]O84(/]Y.#M=%Q(?1/2*<9&!\\Q!127(X6(!%'/>*E6W;CJC
MP#4D?=I+ZX("3Y_V/3FB'XZ//AP>G_SGP?O7A__W[V\__$Z>W/O#D^]^W/ET
M<H[3^;= [MI_+X;+)H$[^*<[O:^MV]INZ(V\V0_K]WT8A?&<3,CAQ4N7>1-)
M^L 5J]OW]09--/5"M:L1+[+LM#6B@W(L]^)I<*7_[F>O%I^)(21;:P);@Z0L
MEQ7%(Z<(KN3LHU*^?2VL!Q'UR?=MQI,[KO.W$DJ[[;B4%F>+I9]UM0LR_3S"
M=1N#JSM%]PYAP!.O521K=3<N02E,X%7MYJ6"]]SJF%+K@GRML/?J1D9G['L6
M2>_)S/YV=/3ZGV_?O2-;\_;]R<'[W][^^N[PX.-',C=7Q[2#8=WR#6U-Z2[#
M:V0\JZ<UQW?#SS4>NUX-O!)3,8\B!5)6V5$ QKT$IU""E"%[PY6+NO7J?QC1
MKGKQ@:??4:+Z5DZ3=(9)+S@87V];AR0H+BD&M&91JV198*W3TG9#W"<#W)!K
M-Y7@'L7:S$1OA_DB]2E%4S@C+6U*$$#!;P07F 43K"STDN)SZ\/7)P'MTPY6
M;XCW%"$^)]^6N5 ^.<E83, PD/]:"*QWJ)?E"#QS,I;2.KOAB5#[M#/6+\YM
M+<AG9-TR1<IK24N$USH5B32RS5CG1X,/F6FF2V+V^=5<W]+:>L6YK<7XG)0;
MUOZ0,IBZGPC"E^5.<X08,4(RW@4;'1:V1U_W :1]*@[=+\IM*\9GHMQ!F>/T
M$K"QM=N?%\"9]J"2%!3\1P_")!&-E![#\_+N&MP^U9+N#?F>+M ];:0<'AR_
M?_O^MX_OCCY^_'!X_/%O!\>'.^R://2XMELD&P-OM!_RSR5O,1]\QFGXA.\7
M9Q&GM<'!:$&??B28.+MR87W +4.F=00B6LVU9)D\^9) *BN5<#+SYB67MX38
MI.-LW2 ,HW7IZ^4;#N;SZ3 NYK63Z<ED^=FO889Y75KR8#JE1;/\O=G ,)U-
M]HZ67SW&%YI!T)Z#RX6F2,J88OM,G%U1]VGGI$M6WMFW=G_R;F:"[YFC6Y-#
MJ(=I4 J7&&V *&HF+-.\-@,OD(4+**5ER;8VNEL![-/VR3[9UYT4FQ'M[P1@
MMEH,F _#=$QP9@.;D!6''JQU%.FPK"'F:OYMIF G6V%D:T+=":23T=7>H0>C
MY2]C/IE\".0 U4M-M73P1TSK:T\KF0A6A,S. WJ: Y6*J@D@)"*?>8XB,97\
M/B9B"\R]JERU.[UNKJF]BK1EHTXR19,S7"+]3![?RO1<Z;]Q.AF1;-8@0TT,
M4J0&F!(4]ZFHP463("M=O$'KDNJ@6^<V$/NDT]NSK$MY=:N[UX9L($6D",<7
MLB&U=UE 6T<OP$=N4XI.NN8;0 _AV=\"NIB 5&0.Y+R!T(;$+[*O-SXL8$F,
MZ<*<M:V3I;8&V2>WO!F;GKZ6GB*Z;E?39H;E G<,"H4E7S'[JF<TDQ!+DA"*
MY-DG[;QIK;5W1]VKQ*+.2+AGZ>[M"MFKH]\/3P[^=?AQV65CMEO^T$./:WU=
M;$/@C7;"UI7J5GKH)'Q=;W7^BF,LP_F@"&$%"P@Y25>;3BMPQ6L(J@21543-
M6M<5?QC1SBTS5D]_@[4'RNCV@#V+,BIB,..N-KPE=Y@8;(&[:'4(V3/?>J?O
M$4A],H4-V7*K#T9#P;1K1[,"]7%.>O!@G-_1+]P!31HO4DP(1GDDJ^P]1,O(
MO2:KG+0I$E7K?.R-@/4I$NF>.0V%U)H_;R93FN/Q;5 4:IG(E(5LZN5K;BP$
M[VL5(E%<LC[9YG=R'X'4I^2:/6B;%H)I7K7UW@$KX2)Y5(">&Z)P;0)4L@#E
MDHXB2N]XZQ2M1R UJU.[TOKW#;QV\!6J=GW.N6Y82"1/U]+HM14A:C( HJN!
M/XRL3[:Y)7ONK5S;3D[-5\TU_7\?PBAI*=-$@-'1750!\S4/V'C+I0@9NV+2
M)OCZ9+'WP:?F,FM?07ME(>[#AE$J=(4B;UE#WWIKW7-R4B5#(P(JSWWKO;3-
MD/7)CN]%,[634\/[Y7>#\9I+4HXT7A%";2/B(#K-P$@?2(-*"G1$^T2)+NQW
M;4ZX8M5H-/E2BYI?R(->M<RC>G5:$P;>C@_.)HOQ?"!*6MYV VTE^57(&-#L
M"V &"^=2J]B\VO6V&'MU3-B"0C>73*=":QTZW3<!SAA?E,[ LB>=D7V!:&*$
MY+$4X6-0IO4ISC8;4\]=RZ4]:QK*8V\!DT454B9S(J,B?S1Q 1Z3!Y\SAARD
MD[9UDL)6 =-S5W5ISY*6$MG_4<%A*5@;8-?VV-CFN.#.1W9V9/#X !H=&UR^
MZ%+0Q_3&59OQQ7#\Z>A\W6)\-A#.B\ \@LR:- .9$JB=MNB/8*-BT>?26E-O
MCFY7#73WFXXQ3<:UG\AJ:5]L:M=H9U$+WUS[\L"3\VE0"-"J=M^TQH&O5>^+
M4A:U067S?B9H*]A]VOKHB(TWE=N^A=W,3FX"_.Y0'.N,%2=BMA"%C12=)5XC
M;S(,,6A3DHN86^]1[X*W3WY8CWC91+Q[)>3-B+Y^X_60?K&ZH<,P&G#)"E,Y
M $I=*YG4_ =!,YBMB:@*ELR?0V\^AKM/+F"/"-I4W'LEZD6T?#.*GMT.M <Z
M8C2UR3::ND-NI 3GE($08PRUU[8KYADXN\40^G03ND?T[8H$>V7RLBSK]]K@
MLX%V.7&6.60I$JTYB@>C3(;@%JZSL(4W[P'Q%)Q]NBK=(T[N),[].I^7%\U>
M3<[JAL'ZVFVM#4N_L-X]^(#35$N8.:.%UL76U@:<?.@4(:CDP!CC;.(E1=5Z
M_[SY(/ITP;I'E.V."'OE\_M)W6-9T-?B"-=;8(-(L'@1!IBP=>]+D\]-3C:P
MG$H)"7EVK=/$GHIU$W;:___8N;-8=R;ALH/]-O'>3;<:EU: 2;0:.,5X%/'1
M+#GRH6GI",'0DR'@-P+ZVSN<#7!LPC'W<W!LWU+;JZZC#U<ME&<#6Y3UZ"5D
MG@LH5+67C/606-&E&*^+>0X-]QWA)ISS^SK;[9%B>Z(,]W]"<Q%>S</7-N<S
M=SRPL].9Q\ W.INY=0;W;AAB;6Z^[+514&BN+ @5?=WD8Q -(CB&Q06%+-C6
M35$>PM/J!/CZ4^^O?EQXB=$F 0D-JU>5,@3-,UCE;+;<LH)=Y6MM"+%/YRK-
MF'3?,7$78FN>77 =Y#*H'GB>F.3<@TZUE&SA"3QF3\89BTJQ&!=:U[IY $Z?
MSCSVS)GMQ=$%/U9;?5=@U<)DT<5B?0BU?;FCZ%04B*76*6-66<.E8+JK[)-[
M(#4?\;H9C R12VL!E<DUN=*"X[0Z-1-!TI"5EUTE55]'TD?=V8(=#RR%I\JA
MNQRLJ^N]9'),==&@>4FDMTN D"A4]J)PX5U$YUH?=VSN;3SSC>Y]$&1GH72G
M+.\X%V%!)(?(26U7_BH=P"NN('"+2C E0NS0.=OEP&MO#6+WJE5V%%%WW%FI
M.Q4=AN *<.LM*'((P=6R& 5STI[+D'CG]K5)8]-;3SVI >+JL_4NXS'.</H9
M9[7-2TK3!868R[\Q7UW9$8,0G'% P34H5A>U91%BP"*5]$8UK^'>"GNO3??V
M?'MT;>U#Q-TMP-OHKQ[7T C6!S6SN\]S:CMJB@6LR@;)1\&H2)44 9Z\% BD
MM&B68_&B]2E>%^/H8^RU7^)V*_I]DOB.)7B,\\5TO/SDP@C2A(JB9;6RR3,D
M*^MI$2K'((=$=A;1D77LA9Z]"WV?\L]ZHVEW%G-W-+ULESI@7&4690;OG !2
M]AR"H?C.&8E!)\<Q=&[>+]'T*0]L'S1ZFA@Z]($GD_QE.!H196^6KA^(8DVV
M,0*K51Y5E@8BBQ4A$YY\]&!2A[N3C^+K4[K6/JC32E3=D6E]U#C^5 N_O0K3
MZ;<RF7X)TSP;&)^EEX+8;AP!E$Z#J]TV2K%,6L-<2:TK@&T!KT]I5/N@4B-!
M=<BDY7X\<]:3(BQ0--8Q.PG1U]*O4A8E!0NLL[((UY'T*9%I+_S8>OJ[=%P^
M3"<U<:_Z6_2"4])_K_$SCB:K0STI/%.!%5"Q.%!.$4"LM8BY\$4Y;I/L/ !\
M!&.?<I3VX^2T$]F>DD->'?W^^]N3VI[^X\'[UZ^.WI^\??_;X?M7;P\_OD.*
M/F>X<OIW2!?9]A5M$TAV&F"CE)+EBY:A.XO!B2 XI!08Q40!R=Z@!F$=%TQ*
ME*IU_LCERW?54-^-Y^5PLM=(AM&!M#Z",MP!C<-"E.AKB[&,H;6ANHVB3WN?
M3Y/T3<6RXTPWLTG_"--AK:G]'0;7GHDB'+#:KU %46L-%4].MZKU!+E%T]J=
MO06B3UN&;>2]VSSWQ%+0?-7"UM\ZM!0W7[%?2_'@ !M9BNLK_^+DXML@<YU3
MK?%E32TJ(A*%N))KHH<@NIF<+&]=^.D>*&VMR.5CU_5Q!M(F&Y.EX24*XQ6O
MJ4BZ<*@59C4M"DENTGX&ND;4)^O2@AT/VYJ=Y-',[MR#Z?UDG-:P$KG-U@@-
MW(EZ=<DH",9J2,5;A=6ECZU3Y1\%U2>[M$>F/%$JS<CRCN(MQ'O K1OOS5XO
M<&"S%-I)!;%X0I>B@*B5@6QL#?A-*K&U[[(IMGW-P7LR4R=?</09?Y^,YZ>S
M 2LQ9(D<:NDH4"I9"#S1\E92"V%(:K%U$8BG8NV3(NZ$<S?7VUZ$NO=E6!L
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M9&5F+GAM;.2]6W-;.9(N^CZ_HD[OUX,NW"\=,[-#ENT:Q799/K:K9L]Y822
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ME$M4NU?$:H[GW14,!L^N)[2\R:0G1"@8.#*98R%W@'L&QA?F!?ET$7/6:;_
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MA1]D4T(A#1.B%K37-&'0()BB)3M0(J-;>_&UY',/;PDTEOJHC<@ZB"2L;D[
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MB8N.VL \F4>L^*0\V;X<H74?UA50CA57[5;]H_9JZ.!B;AFL^B79THM&+QL
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MW([LL"VA'L<&ZTSUFU.LF=XZ. VWA9UD##SSPF*6@?9=F^M$:EH%:  LO Y
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MKA&K.B8[9$5_"%%LE+:DG-89B$^^J>-68E_?U'$;F1VJJ6/)&K57@J&H'1&
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MM,V)P(E'1D/BM6.ITS+P;K?_MS_[])6WI[P:9J;-IO/1!W)DEO<2UF,=B!I
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M!P_V#B%?@OF ?_U&RYW2NF>C9*RN<P=K#%+7EC9UH5E!X<$G)VBIL?1%B*M
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ME(QSV6U0<@_@GAE]1,IO>,&U[QNZX07]F.?S93+>;,2<%LI)#KSP LK6ZH!
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MEM0Z,B]]@N@]TX608NSM+O,VG*=&D(=H8: =1*ZSP;,1**R%O,AS*5E"8%R
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MA]HKYPY&[1UP73>Q7P5K%H[/>23+B+RAD;<";4TA4LR3/20<.=S9!BC!VT2
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M SG#(GL26F8.G,0"#!//:+)*OKE=T0K\8$DMP[+TUDY\$&4?9_Z,U)Z.AF!
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M53 >'6UW46T/=+WB'RR@SU8E<BKKH'BTX&H[<,6$AQ"% AEJ&(QSJUEKQFV
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MAT_OK^$'C.:'M-G;\L2JUZV[H*]TJ_IY<3=T#=_'DW)5_V&4QPCNL7N)Q+7
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MWR-(9XA\.KM)7)JH,R>"AY(A$8OL-OYDJ !JC4TVU&ZI\R*0$_&0PXW<02W
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M#CATS=C,&&!C7=?8K@$ <QJX G"PL_]]L2Y.UHN+AXN+DY.+CYO[ (\ GX
M/Q\__T%!D4,'!84%^?D/21P2%A43%Q<7$)*4DA"3$A$3%_L["1L'ZSV<7+Q<
M7+QB!_D/BOT?7\PV0)B',XS'BX/M*, NS,8AS,;L D  P,;%]J\+^.\7&SL+
MXP%N'EX^?M8-]8< =C8.#G9.CK^H67^-8OT=X!3F$CER^M(!4>M;W$>#Q<X\
M3B_@4;Q<W2YN\X.HI.49$LO+)R$I)2VCK*)Z[/@);9VSNN?.7[ARU<C8Q-3L
MFJV=O8.CD[.+UVUO'U\__SL/'H:&A4,C'CUY&A>?\"PQ*2/S159VSLM7N85%
MQ27O2M]_**NIK:MO:/S4U-S1V=7=T]O7_V5X9'1L?&)R"HM?6/RY]&OY]\HJ
M:6M[9Y?\A[*W_S<N-H"#[7]<_]NXA%EQL7-R<G!R_XV+C3W\[PW"G%Q'3A\0
MN63-?2M8].B9QSQBE],+JMMY%;5LB.*>(3_X))2T\<JDOZ']*[+_7&"Q_Z\B
M^[? _F=<6$" @XVU>1S" !A8P]R"3-KB$GKA4U[M>7JD^2=*)*'DT(11)<SH
MTG@H3QX^@_%+Q\=IV?[;J)6IW**J4J;''R8@^(G^$O/[%1-8@MLQ@9^Y8%P.
M:,L3+H#94&4"I>;-^V4QAO9,(,$M>@"R<YT);&'*X%L6(.(:8BJ9D8AD..Y:
M,LQ09>_SA;+@^ E0K21=%$Q#K2)IF2:T"XMD3R90Z,L$LNBV3" C8+7L&,<2
MA!+:N][-!*X.,0&U_5(FH/3C/\+8+TL"]AP9\L'4T_ ?6DS@"^,#$^C7AG=6
M@7TT]U7@>Y Q\)X*NJSP'W3_H/L'W3_H_D'W#[I_T/V#[A]T_Z#[!]T_Z/Y!
M]P^Z?]#]@^X?=/^@^P?=___1_6I9K!]<[@2E081IBOA 2YL?K><+**_M1G8(
MAG.,P&RB4?B)H^QNF3'<2AF/,LP&Q>:QO8P;KQ=5Z6F/AA@Y%D9 ]"@3:#\)
M_MG%D(;/6#*!&SFAN_:P<B; ^8D)9(I2O)E ,)A^P7UBS ZP-A+[9_PS_M?!
M1AN/'@=O/9R7!J\_&(?O--\Y1J^ _UQ!GX%/+E<P@96'HU;<!$N:R"+CNB4^
MA][%!'96PB'VCE\P1'/$WFEP/.2/*!,8*9F-LK_()6;]7VPX&BP./?.0H4#P
MY<A#E$;W:N)&8M!C97+!A6XIKQ^7#)S(UAF1?,!O/U0BS(P)<$73D0_E+Q$J
M3\+,%GC&R%'E%L,-7<;1Q.V\L[TT;L.Q-3 [_-[F$U"=\;MFR[A6I^<!WX(5
M$.5==S=\R"G@K\?7.K2$4](O@B[^^']<>FAI#QR[C5]N@SPSE"3Z)FV$\H1B
M1"+@-\U=M=0#T9#CX:? FH/[5MSU_[=SV>\>O#QA]K$)_?E3TK<O6)7<R,09
MI6#C_.PPKS8K-J4\0)P$203C4$P T)8/B[HP!Q%9>]ZUCL1>N/<2XWLW''+V
M:HB05T.,X4SA![_FN@MDQ*T/TQ6)09%!\@,!9PCWJPIB;DWBMDX0 #''00]U
M)A"+B/Z&/D"Z48T?#%HX7#O^,+F_0C-PPFC46]A2]$6Z;DF30^=Q:1L3.9DO
MK!98]+<%VH*W'K,ZH X096_T@ &0R'&D*^W-EDFTTU'TTOP['Y.3]3 JIJV3
M_8IZ2O;>/Q5X#C3S <=0;PU5&7/S?(8"-%<$?CYEHSZ0WRT=9_^I:61ZW>=\
M=4W0.;F(""4)ADB%(%_N_G&G"_$VTJ9]B@7Y7(5)>XM=D$9XQV>.Q0R88MJ:
M_3CL[D3Z9%2FV<> 9^/AP/H9CL=UH#<[U\^:8N^S[1C\[Y/G*Q.0!..*Y]D,
M!5='5G09)R\P*N\1Y,C1\HVZ>;::7"Z7GCUAYU'#'$Z[F"_T_A@J!2;,RJ&[
M="3,J^R2=VA9@(>$/_*K<_V@[MW#RT!MUQ87]RA.D(+ZJ&WQP()T-M._;$4F
MKJK\G7N/<N/GFE<^\;<-I.7-!(3>:[,]2CJ6S_X?AMH@&AS]W4.8GDOC!R7#
M G1F9/3F3#QEOLU\8P24UZ3F[W3H:K.M:#OJ$;=['SFRBI7]MX?&]SEG[:@[
MW_36C// &@,W"E[4D,\9J!7^]SE[QFC>!7X7QA%%JQ<^9V575O21_,>U;I0;
M3!^5#);QU:BWJSY\DVW0AV9'>54(DZ5$5E)&NA#:+@H(GKP5PL(94[&/'F*A
M2W% Z$-'-J+N8D(<$_ +2FA :Q-AC;9^X5KFG$$1;/$6/QK&OR"#W>F F+71
M_QR._4Q !(XK!7$:BE&VW8GQF*A*DXK?$Y:^81_] X_R2E:-#RG.-:$HD4/K
MVTS@$N@0'/>6"?3$&(X5HD^P$JR5,03>$29Q,WCG:0%S8%]+;$X;LEXEN7PU
MC^L3^E/=<)4(]N>\RTN>,/=.(,_X&,>$7V$2<*RPNAXN[><B6%_T>S\-Y>U=
M'G!&WR4T9:1L**PO;L;XU== >W53*>#!15GM?X.:%,W2!O7+G4-8B M))0OW
M^NWE2(S0'OR>9(,/H%M;1E"BS?2,$1X"UDZ&!J2J5\3Y=ID_2;OOTK5317H"
M+Q,*+#:.)/(WV6_<+TW:4V0H;%/UF<!WDRX0115.RA>J]T.EW&4"N"IP;>5H
MN]+X;HM1#ZR_SO\:W="]=P<%H9RFWH%)4>@?JG)P0W+.<VOJO.XGM\ZK;T#D
MPY2^O+MQ?D\W^*+"O)&8%=N_AM<=QIGO=?(!)C]VY3V^?'48OPVM6Y,NM<\C
MI/-_2M7*QI8Y/3\%_&KP PJ3COU7'QQ[%?^>EZRI3BSQ-0*[S02JAYR9P/ *
M2U!AD13E7MI+9*<F-9%UU_ &N@R5!?^/__WE.U;X7VHH?F*U[SGGY?1;L<J:
M2AER)]Y+*^6U\='NC1205&GB"'+K:'[KF.9#^-,\Z8$?[?QR5_Q GIRV6\FO
M8_DE#A/8T,24X_2S](\ZB3N:4XX+LX0JTOT\R5%K&:WXR^,;KQ^39Y$=:$-6
M]U;\'9;-! Y$'UGC>:99M4LA* ?_20EV5<PW;!M2,7P78]A(#%J'$#7;'LD]
M<GA%+.VHO5C],C?0W#QI?\'^7%]$J6,8MSQO-RR8U>D$6/-!*4%&1/UY<<.#
M?D%XA*C?F=[0\*+?QU9S3F]:+U^2 <V:"W<RUH&+7JEMHONWC "HYOH5$J@7
M+ KVA0O= 8EH&T"NDK(*(F5'*B8-WN04G/)JL@MU2TC-5#_ S]TKO@H2-CP!
MU<,K/-.!RT!?FQ-[<@>72GI*0SXFRDIC8]ZT>-7$!CAV1RO5$L/C=E/A5H'9
M,O9O)B8$]$Q$)!_L'4?UH::NX+X5L=!J4?"+FDE@*1W^-12OOVBQE1]Y0D/N
M[E"VN>D77*]8\/L9VX#3]\-O5^<+_1#B8\R! 'W?JMZB%;C8C@HFO<$XYP;Y
M/>$-E[.RO8W9;[9^@L=6A?R5XP+%MX6_3_1 9,&X+#AG:R1.=AK$ PW4%UV
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M]7R,MTZ9X\6.!5..2YBVT2>3A<=5IL^5*^D9O"Y4.GW=PF:^)Y+D5[I%^<?
M^G1%W\.)=H) FSQ5YV?)_.GL .Y[O:2H.1LK9LAYJ^,/6-/==&]-N(#VDG8
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MD8-VL.WW)XIZ(/SUK77D,(J=T;1@9R[A\S%+$&FX)UT@R8KM/HH7SG(MR6^
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M;0?S936.(RS"I(M#?#D/EHWI5N_N;DM[!.['>+$HD!D-?50JP@IX1:+@VG@
M# TMFK98SGD][3%;?-WI!<U0O[?47OJUD<C9Q*7Y?7:L FKAW7Q-\A$(A#Q.
M90<B\>P4HY(%116J06"X?\M.?.CXA/1\FWV?0OFUNL-;1-W%*C0)AP<_IX:\
M]W/T"[1.72\R_74J6\(]R>B#3!,D6(OIUXBS-^4R<EA:E/:&+K8AK4MR^QR>
MR'Y7M5+UJ^;<O;/RIY(%V9?JT@S9[BA$^"[Z:=*Y6"@WJ%?'&%I(ALBQ-3T&
MV+BXUWYI2?W]-%^M,+T]WN*%?E'ZNC'DW4N[;NQG#JJPJQ6MJ"4XF+C9E2_4
M!*!(?+-N2J6_S(=$^B]S9IV5LEUZ9>RA\<E06>K7@U9'\A=:%4*)<@K@FG$B
ML0KY-+TO5C8I\:JO$G3LN<&=U\F?7N#^"SC_JYCUA2++K")FX">M&>OK9&EY
M!'J>=IWV)@^A6S-DFS5.VCXAW7CSE<>W/1DHX@1#;DXVDW>)\X10OO(27FD4
M)S!F'F\=6C1T]HVS5#M/M46=):B3G:?@@_OFVV&.'T%V?; Z,*$KG&*('$;S
M&9V8 4SG':.[T.[S9?V(X;J&O*=^@_RR_E\EFI+W,)5>H**VR\ ;2C , :75
M(C2(9Z#''.>F?<$>*97:%+GTT(7,^);/?!JT;=\1Z$.&]+59)=L Y^;T:H<?
MD"2+;T;U;-VZEQO<&3E(:'=\/_=ZQUAZYPHR%)Y$YXI>3).R]SH!^SH48P<3
M0-B>3O/\X#L0(-75E9]I6*W<6B5[8U3X0>^]SSQ5(-<7$D1U.E=E\&/2Q0 0
M(I1X#\5==V4.6OON7#MO<\S<!T--WEYQ,[[C45=)T5] R+@1V%MI908$7R.<
M25T#9 S1;.%TY6(:DWUSMZ%)F7=#)JW&&Z>O<O(,TU!_XR2/Z,QP&'1+E]&^
M@T:AOA^T_5ANCC!Z4E+W*_!TR=@X2D>B3-?OW&5S'J[J&]]P*1LF>@;&1E^*
M6I+(;VBE5''*&2K42($4WOG9<-ME;*_9^,3O0Q?-:J:3( Z5U1C6D).0Q* T
M0!%#,"#)7LWMDF:EO74X G7P6#I^]PM0F[O-P=$?-"F_1YN6Y ]79-D;3#Q0
M)NLQ9A\##R 7C?M3(>5>V=(<0-*##,,FU;$WLE\$WIH_>/(QY -EY',LR_E?
M(O%DS+0L.8+8L#5$Q-X@89/D,[=NG&OW\_9GRM_%1RKQN+S0E:H(73A3;<AB
M+)U]!>FWCB;>@$S'+=Y!'X$XQ2*@'N/HCDP6U9*NY1#-6E(P3RK/Q6N1/X73
MKNYCIECH7!KOZ2/.^DU \.(0YRP""L3Y?Q8>VY;S3%PI8NT_SO>1]*U \_BD
MM$CJMH8QQ/V?Z^+!$8@B2)^:%T3JTR=@ G1I^,?-Z[FX9R)9)1?>/JVW%"XL
MQ$8=^WO>D)JA$WZ=%QEAMPRC"H'I-E*D8GI[S@0]KU)Y"SS=3-Y.(SL!>.)F
M^[/8:._'!4!V7^:-"?\ !\C6Y(G5;QE.D1+PR_W[XMV*+)M7E?\$.#/BED.]
M#R0$AGU$\ ,LY?#<=IU44E4=JG3V5VY>:48YB.LYZI%F_IN>JWO8R08ZEX4[
MQ0(^'1#7ID[L(\+2BBT<CKNFY\P1_GTS.Z;%=&/7ZH9'*7_<'D1<N$5> PI)
M$+S8U_$)NJAWQL:<$GVLH4&4N%Z)G+/DF$.4L))B5NM"CD UF,06RZ6TR#;.
M":J[#]E9Z8=6;Y6V1*AJ2HV9!N0LH[5;\TVEU3#Z3TOTE.5"/_SWF$E2YY,4
M4VY(M=43OPE!#H,&-O_<9ZZM@?DG:1\,0W2W, NPQ/QC@&/@DA^J$^61$<#K
M_:?W][B2;'J.U::XBDBZV'9:FR)SP)0C>7P$Y:L.05P:I6H7.7D?<L3<&;G_
M0_TM)R;GSEO-T$OQ/T)EQ1]<W\IK57[[#V8(?Z"+:(USYFL"H$5#%7/SL[^N
ME,F=,-B0E[U]\7D,AX>%87[=01>#_G8 $DE]8;".= (5=P0Z5@=.^..#=J4@
M=-3/Y/*F/+KUM'=^1^SQH!$>,SHTDTL>P=+2$*H+!(>9CD?P#*=GBUYR48O[
ME2TI\2D_9#UW7!NN@@[M.OYF.\3%UN:6+VO,#7GSU!1:Q;BYL<4:/+$6*;TW
M ]^T&J5+@X_[9I]=.[RF[_)37>TT:G;FRDIHJD7/*=.PIYA(==1"&:,!4(?G
MWAS#>NY$G8A+KIWA9+8H]^'4BHR48Q[I9,8UBTLLRZ7B6$'@D4/E/TK8A8\P
M$2,^>%O/=6"=:(3B6<].OOCK;L^%VF8FG*&EAAM:.G%SHA*9#G?MS E);M$M
M\9V^,.J\KE]285>?K4&;NI_.4@S^^,*+93$-4- EA)+ Y&S21!>O<O>$/H*<
M#Z% )Z^\ROEJ>N!YYY?)P9<4W^V/U')&K#51?;<!1F?JCSXT^HVU501AAA@5
M/)L\"&22)LA-0!KQ3Y>=0]"<Q'!%G=+64MWGNR6\O%1^L\;VU>7TFHU'OGO,
M6 8;+[Q&[;[828&0><:Q>P1O8TC52[L^5%T(81:RU<P@QHFH?5[VT243DGKF
MZ<*J7W.UT*E/VD.OY)J9=8@)V1N:R79QF_/$6[!DJ(!:0+!U% 04'" $/STR
MISV.V:,T9P;6[MJZ,-U(VV8/'#O_WRBO<[XZ@"J<T4_.(-7.@Q$P?.8"%F*:
M47NV1U:[=>8?X56Q=,E$]+CZXR5^]W8%H>HG"*T5R!ZD M&F?R$><0D/X^>P
M#]9 C%@&R/FW^; *?%+H#W;O$S\5]W"88_R'K9_NC?J?>Q3'3:6,WX,;\OGB
MQ7KV A'N+N''3DY\P];/$X;4MTH7P:Q P"7B.Z0V23?A6G)3F+-$H""'^:*A
MK*#;4W<66FP!N&(-8P14DLIQ\TQ(D5_PF47>Y6=6>6\U#DB.0LJ6CW#Q)SG8
M355?Z#_B/ ]*)\9F,ZJ^"D A9871;BT<@;8HIZOQEG9>X[O;RKGOG[0L?4_N
MSB5%N3IUNCT)BT"^OLFH9?TPHDVY>A),(!L?USETS FA"22/AN=S.[Y8Y$Z(
MVMZU=[/-X#2GE!WP#NM<_7 XMAC"Z.ZH$")?PY*Z\%P*U&2$,-#U?=EMZ93M
M;910C8BM\];7D *^HD3JKS'40C$:TJ:IW5U.#"2'HFV)1>8CN+*-B]XMA%*.
MU4N2834_;7.ESOG6T?)0"^\S@;%%0FD'.FD.U 1X+SDV9HU.FYT[YO8EH%&H
M2R8N'LO$=T_C?F^O',MF0,J\V)YU!):+:K(T+V 6K)-6U/%Y0"3Y_N\7+4DG
MSC ;]X7<[ -YRDWH,N@,#JUM:%>56(20C8>+?WHVFU<8'H'.=Z??Z^/:1O!4
M"T0] O5U(1H9H7L U"VE<.--L0M.NOB!WY4+*;"KM8T_$)X2YZ.M7L*4!,X>
MLY/KXE^).QP!2#"B)2H-(DB@@HD[^$[8L3K.-FG#Z=@="$?VUN8;M=.&H6'P
M[+\P% 8KS'3H?07A3LJD<VF_HW+1RG/Q(8E[CF%@SIGUWX<[G=WKTW>/0,/+
M>0(N GG?!S\<EVA44^ZB7F',2 ,X I5YAQAI$=%;.T^QO#=Y.QW>EWJ&:EYH
MRO<XUU,G<O7/"W$[])N( 1 R9P3& 0^A<ZT0_]P%) UMU6*>(1 3T=?BOF8%
M)E2I^1]WE];387S<!>ZM7Q+*=:FZH0$)T(4R-,1(>,[>!RN ]>PS-,!;-G:8
M3MR9J+=Y<?TI9PF;X4 !M83I_" ;"%DX<@_6CDU"0AA59LB8-!1[.K36[\'\
M8(('R)*;V7;Q!;-Q4+"["Z?XK2@S[=T)@CUC_JJC1ES '[I(#VZ'YQ[" DCX
MG11:0;"G)GFGF3]*'-)JU3S!E+Q0OW ;%%YS!>GE@R7:6$]#&-"=TL8D06HZ
M<V#/W=SL,7[WF^HT_,^+O_H>CUE+J\U_(^6[HQ[Y;Z-;F7(1<7[,T&]A<[QY
M9"=$R2+3;7SW PYWQHT0?"'T9-0Q>7,YEM:B-C5@BC$=R"B=&?E3D'J.=#V2
MMR'&+V@<VT@2G*VY#IY<SI,QU[G_9OEVPI,E^9ZKI %?.I<3Q03(Z0X0!EC(
M@3].$P78"'7*-*-#POMX(<HLB=7JRV;#(V>D:_(PQWK)OUO2;E*N>4$^IW5\
M0/AA)IU]JEM'[SK<G22 +_07?U;RP(L)5*L.@A:$(A#]Y).TMEKP#-?,K='E
MD1F<M.9HH9BNOB=Z%6?(%G4PW,;T]4'AR^2J_96:G -7.C<;R;?G1%8:-$*-
M+CEW%Q"R'G\8H$+U_TZ_LOQ[\*(+Z/VO:)7B6(6_9FG&X%%P%)9?'J@DQK4C
MM?('M-9;3-XY;*1Y2V3?O3:BDLO"KYDR.<C^>+3Y*A!-YQPC+2W"DJD*"T.L
M\&B\:"$>Q;9N)-A 'R(]WU&*N[F;=6QQFN<^"IX\>+8G9F>\;;Z .7'!Z#PB
MB(C:VB'2_W0;Z?S UNSE/KV;<7X"\?=<PVRB\*#3(&>/,9-<!"?DV!2J_9J1
M 17F.VN]\'?K3W %X#QG=_F'^JG&IC\Z^VQ%DY&DJ)OVO8/GGC&"Z'=S0CL)
MQK?6%%L>KO#*W35 _L<NZJF6S7<4B!=A3?GGF&>M-90($Y %?$G0CA (3TN8
M7,?H\6W+I-!MN/0EE40,Z_.W9]I,#/W[0'\A#1/=0_%H'D..D&) %Q]^!$K5
MR@N\]*/H9W"2;KJ=F;5RP.L9U_M_G68RH#]S0 ?<[4>@^C@"B@*#CW6*05B#
M4@S,B'/99S+]76J4>1XZ?K,H;1H\.*[4FR:E&:&\-[;PAE2.D"<6(TQWXU)S
M.G3&106.W_XBJU+\3?[\^DL#"W%)NV4QJA"&' ^4$V%?C92K@7"BI0U0Z![V
MX=V$0TS2MZ(Y$\%(@2DA\D'CA4WR:(22K\- =EQ0&,W1IM'R@G['G&5Y;H+1
MUDV9K!"C=A-H#/+N''("4EM*Z%M$BZS/,^-KB;JXUM.ZCGDVN^<[4SAY:X<T
MWSTWQUL(?&V\V2[W!'4)ZSW$Y9.O3\LS.@T/NYSR_N<^E \V/=V!?F9_@H/[
M^!$(3L6F(!FA:3_=9@!7OP@H+&%C#NM+O8O@;587-VWJ&EH><V)3+>\NS8@'
MM,IH*2CJM;.RQ'[E2$"P 7T4*^0W=$W:<Z0\@/0%\U,%<[;AN69?4O7NC-!_
MROG+G[KCU= K62[[V7TB1$X5V89@ J8*D2,03@1T:0?,*?/IYP/YRO='('N_
M<QH6#P)LJBHTAR..+20>E-,YYXE'H(O /V?\W\2AYRU6[K3B@@W<K8;FNC\G
M+JP%<P[QO#OW-L*$52#Q, X/;D>Q4SF(\41LI);M<- I@WM)5[[DH.;.WAAH
MLO-85MS9^37,X0=[BZ[SI HO!O RX%N*PSZWF_8OY7GV5J>)_HF8%.^4?]NZ
MYNM4^QEN_\?I&2"HLMT'Y"R$&^5EG3JG.(Q@(V+MTSJ.0&!,$#F ?V/T^B=E
M W.[/H\;'H]<(1O#; :?5EGM5GL(5A1%((Q\A2'SH;@3:H7!%7-S=76_2SXZ
M\<8N!M3'?#/E%"C@ MW+W+ "(=?L4I$_H;5_8U'ND)@):342L_;^CXSPW&NC
MI\(SYG^],#>>-! &V;^-$N9[_J)T<G,WC<XE([&431666!CJ",O*<&)G"+U@
M?XL9>N83YY6(OU'GNU%3!;P#8N0R6A-2!0A&A"U@8QRTL=$E[(NCDS,*;QZ#
MB:\LJD2]33EX3T1,?4L68#09E']G7XQ543X&A%OM=*41(48F" :]]%88>_DI
MEB!2WSNB3%U;F^25$#0U8:7.(%L;&A+'CRU$:<4>_R%C=B+&]L99$$L!2QWR
M)GUZ!/?/)[G=JDV(>G$D:O(*1CNF^[VKQ.7G@^1LL[0=QU=#C7*_(Z W6SR7
MI"#XG>?[ 8) U.$%W<NCE?G;N]OW"*E:X@HL&>&@Y0Q0G_9!JROE&7(,5J<;
M7X<&/%&Q.AIP:ZN7.%KQQ_AINPMVB!I+R3,KQD8VL<K-67KLK=QT;@T2\RH.
M6F.4@I^Q=TMH,:OJ$NFU,0Z#NX9>1</FCEV'3F'>85UAL60T%\I])[:)K;)I
MIE?+,:R_M3QJ0K,@Q\.H%)&LMP4B&$.4$6S_?(. ^4O B#<QDYQ"],-&42^%
MGG&<WB"3:@4X)1=/G=/4?QFXFU#L5[ D*W[_\!0L[PA$=+".TW%H^(KE N;.
MBP3G@1TM-9X4\Y*]EYY\LW:62Y2Y<&ZN;I^ASYI)7*A$; T&AQ:9LUR=WW@F
M59&=L;KSZUC'-92XR!K+#Z__!3:^__]-\O]+@[VYPN?[=Y';;C62H N^).4.
M="T&EQ;/4#2JCHM_.^<%U=(6*@47[;5TPBR32G*W%BYYB)Q*F0K[Y1:ARS)D
M2$]F9(U9VWE41RKM)=4VV/?QLN^SPR.0BW>7(X]<WEWSA7VV^_9WI3M5$0>,
MHKA$>XZ4!'+)WJ,MCB39]F>H^'V,P*]^E,]T5+672KM 9P'S>;^4TV$);*!@
M5"V&,$1113P#A):LF:U(JH:S,.N@VE M7FN!V=-R#8'TE!%W\SXR>\L2_1B&
M-$.QQ"%5 <NR7[_#M8] #5HO7?LB>RV?2_<K9$WNOVE5WIP'7*!3J_0$**-O
MWAD[ I%L#W"D/[AZ+/'Z$0A0#(A!W,<W0[8P3#[L$LLU#3RNEGH<4SL%-_.O
M4G<5"4W0JR *F,[5153NFC^!\B2H+;63[?0'YF/WK0D2>:='+/L-V15,@TSZ
MFT0YO%A?>?9<@XC3T-"%:FDQ!BG$[$&Y$%9$C]*B>>\[U>NC/@XR[SX)"3[_
M1=ZZ680/M56/'F;Z>IA&'J?5+M/2J5+X  %[N"9=R$^W4["/-23=Y\'X<4F9
MEE 9A3DIRT_=T)_YH56#%#RL'3*]^?40EE@'Y@3"NAV<JQ]FBQZ6.YYLFL9M
M'ZPGW(R;=?]U3#FZMP!L %@5T_N/0+4[W8])V>UV6<A30()+];4_E\*"O0/]
M;QJ69%A>[$._W%+IO;WWN^42G8M #.C1WT+S(17AEM=R89^)2?WD3<4"3=KK
M-S)9>M.G,D8RQ>W.+YQ9C4[_@^K!1-.E:2\9C7$!FJ<V(.I$R;+=A%A34(VW
MP*S6CKO*A %O-2)+2>ZNO&1FW: %C_+._/0\>3>.? TH7DCCV93FR3H"F9#X
M4^U;+,A'(%55&:&#D.//+W>;IG"UZ:J%5(+@\QU00%4,AQ:XY.M+XL#I8Y^K
M?RO+^FO-?-C_U,CC:^='SF5%LYX/&^$4<B 02M&#3RR*-I)*\2KU^CT)^TKR
M].$?#X,E(AYX$T=5LI(7+M]+F82W]_96-?<<@3YCO^Y,@ZV3;D^T<.,)X>I+
M0CT5DZ8G\X,>-]Z[]]7VE^2R5&?@#BP'RH80<J5 &:B_4WL$8D'(3ZAK0WE5
MQZ:=NU9#"^_KI,AWM52TF,L\"C4LEXG^HZ3%M(8BW@(?0#%3FW0\ZC#8AW8;
M\PT"* >W_\<!!=UNN\=6TF]\>:Y/*/*!IS#/J\K3%KEE\O4.8I"EWODG1_<K
MV6<</_U0]=\+2WH<S$L]5VY,?/5+CH^/:^GM7A<(>1<Y"ME]C8F=WY\Q9[1C
M#O]Q>)!!^'UH+"U9%/K-X4"V!R*F!4F>)]I!V3>EQ5N2;$8>[K="K\72V7FE
M^B^^3A].Y=I18^$[=L.,O:WA/[T;M(-:R$$RC1ER4B0 MBV_.\JM/G-6#H?A
MN<ZA[NGQJIMUS"?))C 15+MK"\2O"CER!.*2B=6.I3B,B5EG!8-$876OKM$,
MQS'#ZI-V]&M'(+P"+8FQOM_^W8(2]1G5-X9@^8\?[N^]9#J,QJ-XUO.Y&?*U
MP*O^\?JAZ1L_J9*2"EEN8?-"6[-A)E@VC-GO/B.;J**./5G/@BP\??5^7'O1
M47@[N][",7+C"*0[CKWCNXO!@ZGOT[JQ9,H1Z)V2L;0WHXF2!0H+-]'$&U8<
M9J3%62<X2WOY>QRJ=#J%H'+NC-.@2 @XY\HK_ET^X<"OF H_[$(UM(:6UW*'
M?!B2=#)*3J!'^-FU,V4%+HK,"!"'S\$JF3HR0P[]CQUBV27IQG='(&] W2%,
M;[OAXN?B X'*NA\&=UV^/)>->+9SW% 2^0:PZX!QMP3B9WC#<-,<,<%Y)^BG
MM"OW7\6TI%^-:_H$*S-ZSN_%0IH@9],JC:2 &7(+$$)*PU]VJ(H.=]5N]@UT
M=JBLN3[2'[6L_,F/J&DZM?&1:=!W!PPHBWW%B"&\:>C:YC2.J7N;ND@)AC;S
M#\J]HJY"/)XG/L*AMG97JD#0%BUU-M!(G3XQSX/@I%AZ0=A;9(G1N",0?UWE
M1?C#JNVME%I.]V"YW,MRX7DXX7N:>5]/GC>,9?F)\H?,R&R2SQ.'XK1?4\$*
M282ZW(2*[_/34+?4<7=;-UY*J6HKH@/4<U@SI,6TB]UB%'HVAJ:-HZH7 K<6
M Z*U+XA2KM:E7<^T&1&1CWC]\O1JPX,4,>YO'Q#2$7P<HS#.6M04BIP'#!J=
M \[L#G5"!51$E?*] OPKU?R^*;S\;.%EK[F;%_.&*__M1!$,H0S(4IS@$$O2
MG4(\% SOMQQ7S5B<M_5U$W.\&SY_0>/,64I%<R3;HU"1@U#2YC^K4JP[%%!4
MP*E*+,1^"!79[]K.4YF^'&)E,&6I/8A[")-/M!#E-),C!&9<X@+1JO[=\[ZK
M3N=DL(02'\# L\N [Q'H^OC+'4#%-&I.B5;2QK_V ;?AX&.?_*P/?NMP#/6?
M]@*=.*@BRG3K2V0D@X>@M/.)()HQ$1L;A&4# BR'M2S/[]%DK]6G#HZ."SQ/
ME+OQL7@-A/F&GM:UJ"6BJ:)@?-=@)O/=_@]SZV*ZIFR<ORUDM6PT>IY>$=_O
M&W*@^6"^@:>Q=!L2,9/>[(4ZO+#&L@8&5-2I;QA@GVQWI99@?&@QJ.4ANB!J
M$AM +>]"+7S"[GKN'(%<V=)VLUK+R2+_SML#%D>@!S3L;@$X'KJ0@-K51CPZ
M GWQI">W5$73N:./0#+@CB$*Y]P1:*UL,YL!=.7Y&48>\;=IK^OJGL5]N%:O
M+E)^7M"\NC]([HQ!C-H;V??X32<SJA@'_3(D!DT6^G>^XN8PQTR; F!1A BB
MY:D:@A<-DC;]P'=&'V:L[ZUW:OI=235F>?'H7+3ADW-@]A:6K^C:TJUB"A]<
M'"FQAN8O:G4R"BU]]7 Q\U;CEQRS7]T6E8N[266G]&2YCSL7U4 7BAGSH5H0
M_Y(Y1X9BM]T_^WG7$F1O?(D@!-5D3$T;2WP*/&$:;MN[<Q=-O+XSB5U MC)(
MP:S[L#0V""T%)-FEK+8V_1QVZ@I03'\Y4Z'ZTBG76,_&HF_P&(CE*Y3!8\0;
MJ)A_A-G^H44(#P%O_LW.FGY^XOFSP4)OX;..+U7>54FA?]NY+ZO/8=H8Q)>?
MH86N1G5D;-T] KE_7C[D? ="7FR[SXA=';"$/P+A(!$Z*"ZJMG?QNCZYX</,
MG&7QNBC)9-D!U]@R)7A69SL\L1&B.Y#6Y+L> "A<^-I(2T2*?#G>C3X3/#3;
M^ 95 D*$,$24QQ$HXP-I@CX+W0L?0'ZT6X']%_LA8S;D%09%G3T"K9R:/P'=
M$J]$K4^/8IV4_X? !OT?(7MBXV\,5;,$4,<]<XXLLN\I73_A7OOT:=:G9+F;
M,C&V$,9E8(S+V&"7]Z">.Y3 (]!8_#]#0^HK6G%0KC4GXW\N=,E[ZV?EDYOR
MMM,#@UQNY+ME:%Z1E0QQNXF^]W8?\QFU\ [%BL*'T+\9*37410^.4PW9L:4+
M[DG&Q[]%-ZIR7RL(>=#V:A=,8%Q("?X/M$ZU4)KT_F&SG+>6GV1B53+7YT^]
M)_=9;W#T08B6Z!0HL0'K-@^>FK5>]946>CJL%@W)[8]G;WCX+%3UQ&IC2OEO
M]1@&TG$>J'9;PTM+"D>@:\0 7/T1Z++K=\^M=S@_!JW7/7+[(OW-]WL0.B$;
M1KP.3D759D>>"JT,HMF99\!X"'U=N$^^'-+-LHTO-/;C4W^%IS&6)?W?T6&N
M'K*[M?!<^\JFD4Z3?F8-S]G:-(T9);+L]Q=A5L80'49$?)"G+$-)E_"E$?Y5
M'@W#E4'D\:HL2<$!K9UCX:U3@IPZJ_1GNI5A 8P47*A UP1$(%1+X('&(PB[
M]VM-3I\='!PNE5P651P&%=-0"JD6RV\S^S",A8[J1D!_4K5)$'Q(MZ.!>OUZ
MSK.>DEG1&WV2PX,39Y6C]"W:[@]!3ALDTU:(R(#G$$DZQ-M(@Y@=UZ)9MN[P
M_ Q@I3_UKN%%F2I/@=*4C%#LK6&*RS#'\@Y56)G!17844Q\Z.RD$9QD>:$J:
MBW[4X7=]8T35S<O$[GF<Q?&LU"ORSUQ#?V,O07VM68!,\B=:U"VZ@'& -L'U
MZBC5A.VMF_H,//%I?)#X&8N;LZ_,$!.R%!?D^#P#(NYH<7A8A_Z_YVCUT!5_
M7/??ZQ=NB+)DE;_L6,V:^^Y%]0R$@T4NN2H\E_R65OS/W9N11M+ZTLST2<M0
M597M6DO+_?HT:\%3+'^C3K.)&J<3HW<^L-2!$$(4A7_@5,%ZHD!>6"ZZ B-
M%4.Q/RNN;&<E9A_+3>#6KF@^N_2XG[UOL^$"\N-P,&K*@+P+O&*DJK!)>, B
M6-KKT8?/-3D;.]=:D\T4<DJ_\8KG]C^LMX.+ZRVV2N KYSM@,\T+Z#CJ_4K
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MKH17,S1>/\(*N(]')3MS_T H+/%*\P:88*UJ' :/+3^IJCC;NQ'*\X[_V0F
M04#T8VLYTG6AZKB=5"-YHG-*D/4;EX??=T6@'>Z)B_PXR2=Q),S(M"++\OQ4
M")VSF3A!]B8QPTM*6TF8E%N/D^Z.,\?4N^8-L%YZ_@ \]X PP>J6>.C8XRR2
MU./,20+'KN817,:U-E/T+99 M;XJ5N(N8!L63V+E-T66KRB&#)\"F]/2J+)5
M:_K0>/46$[Y*1,.0]IZ2A&G'V5QCYV(6[9T?-XTY)Z)[,9%0+VM 'A)%M<3X
M&ND#(8NMEOC8VG[5Y?IZ_H/Q,*)]2XE="OY7X O)LB$N4%?X@?DW<7/9DT23
M G O9!)%YZPKHH_,<R D2"S==(-Q?X2!W-^+8"X'A6Q)2ZGO\=].>_I]W(K)
M?:!TD*9W4+Z/[I 6&&EAP:=HXMJDQEQ&M:QTV!IJ/]<[57<=7^/X([=K(;><
M,UI7$]7!%C5]C("_1TB5XRI64 #=_@&R^XZMG=C2+*2/P81;Q)?\K#L/8Y."
M\2]33M751NE:U%NO\G8U2I*ZPK49O-M%=6$ T#J5SO3#4&KI@JJVD^ ><U_&
MYRLRM"G7Q]_T\Y\_>_&$DZ.V* *J<YH!:JT\H\7#'AQ6"G&I&'Z=4*.6.AWR
M>A1L(:4F:V;T^\SA&-F>EDIEHL@#3[?[.Q[=<_9IBITG\ ;>= \KSVL56@')
MN61<5-SI<QT(RQ-F8MM/J?_@^M@]-$!D-J_3CV?\STGXLBGKN<_YQTZ^,-G,
MH=)(JU0!"FX4_BT<A0_H' C$>WWQ\*R)FJT:/3EKHV!?&&SMX7DXL68ES+0+
MWFIFU+(Q(L?6ZN(^*8]>CEJ:/]%I7[E_P5;T?.6;6)[T3F[D']:4K>^F\/;?
M;6W_"QRX^O\/:/W?-L"\$RA_< 1=?$*;%W(;0!=.^3P+[\S*OO.YEX+/T5%<
M0SH71D)BS%PIP<BAZ>CS28OSL4(!,*.]2P<!+- 8Y#T$&PV-D*5<1;5?-CH+
MM^S^-#M4_+X$ V.K^7(6FI,3^],@8CW.7WG;,@V0 V_]U5)+\%XT>'J_,WUC
M^3--]Q3D=0&X@@HFZ79 A!XZ_^V05AI!W/(69_H]LK/8=%NAYO@DP:@G9[V<
MA"._I\50[2AL0^ZD[ 5LLG9"D)_:HE8SY9)BRR>^;Q_=W+@ROV[;BE\%MQ3$
MLJ8?6E-.TD>R8'4*7UN%NHE7I*K>=574^2K6U$^3SQIVW?M3&VMV+^-I;^.J
M%A-!^':(F(!#N]Q8[PO<B:Q0.9>/'_7D,H?M9$NH7D!XE4_Z>E-(:HMVF<\Y
MG<Z:NI^$Y3>YPS*-<I0'$09G_GGZ*V?\;%.'"YG\''SU 9C -3TM*_6N;O[I
MDO@H,/FA)^];BMVM@,<B*RVWVL]8LWZ4UI-U^;9A:L+ZR$1JC?FJDF:J-?.7
M>F"&N'WAVGKET@Z/6O'O4)B;_L"G;-3?IP&#X=7&4I7"B>TO^9^ 3R96AG^T
M]_9)"0UA*VKL>+-RFV,]TUBTK$)=!/X'9\06RXFP6%15P(U<[WJ0:=N6..7F
M<NYB]OW,O?(FL7@MK+!WM8^^3HEG^?KN$:B\N3KO= (]]5WTP3![C$C_YKR(
MH1C>Z7Y0GF_7(5_ZQ[,V];J';_FO7PH?%7BM>^'+[R9SA=2-X[]CKV2)"^M;
M2+#?L3EW3+9,)N+\!<NEO[@!V<5@#*Y\2-2;3-=MFEE>2QU8;5M6^W*\YPSG
MIG,D[!7JO]_?5QQ'JL(E<#D]9-/*)2AX_5G5[?#8/[>CQ'?G@T(?XAL)/5I,
MXS>M4B_G:&?HV)DRO7JYS/^,W_L'Z.8]3(*1,B#;WG $NC]!=2WP"FD."<^U
M^7FR(5.ZV:F]*\!;ORL66XI#O8<Y^NAH\HXX.5S]W'5R_XZ-">0JJ/'*E<!@
MWK=@[<[J=JXGH^;MM\,M*O(">Z0EB8.I.?75B[SJ%J/O4*KJ&(QK++LK^J7!
M61NXH6<=R&_D]EZ*IS6)/9>]L&3>T>>.4-5:5<5O^P<OGI5_.)E6^*%JN_!3
M7<[OQ2NQ<\+><NF#S&7B<A20(HM8]SQ_BSIQPE2_(0EA5@+WM)Q=H=78M:2.
MRW0*"FN^X):49.JK8NE U?UMATIL<I9X885;5$,_6"C&*M_ZT"/Q?7E!Y7[O
M'TZ%E,8A'^HH#8V4F$.UWX)ZITG"5Q>-2L,AD8;Z(TE^TJ.NTK*OWCK.F%Y_
MJM9K_\X=I^E:^##M8YLFJEV.S@5O^!HRWL8VXF\HLOBZP.-36Y)-XY=$"V-Y
MP: WRVR<"Z]P/*N&#R*,%LNJJ@JKZ[)^__8B$/"7Y#*OMM\4YLF2(X*D!I!(
M1C=\"N6%%J1>(XHE&4'@360_LQO$H!<2$N5]XMN\M>^-[S^5RY"!?^)<D[-=
M*_J" A0G.M.$Z<.0VM)HJ#N68T.]9/UOQHQ%Y;=6^2R3WVEG6;)2CW/D-L@&
MZLJNW#*&^!R!<#X(#OJO$]9452RG1,<,N[9Y2\7J\3^!-1B*[596]B/8-"[0
M5RM$9^QDAE*A2^^&Z24E27ZSQ[#C5@QF2P:8%' [6\?W6N^H!IE\@J,I5UV#
M?Q-Z7C^874[/?WH W](8;[&C<W:1Q+I@-3L$I27H5$#WLTP?G:>?[UD6F2_C
M3Z=<?G?Y^(IK#K/'#%7>8N.?J2F]):T;6M?3'@#R%5QW. )U@;DG?1[U+P]X
M!"LN9W%L?SXCZ"HKN=VMO#(/*&,(4AC$&< =/\0$W"%;\CIVVWQ7V_:[5]GY
M],7KW7BS,VZA(D_T/W[9<9AG02UDH-A;%!9X]2'Q^G)T3=+#\8W#F!\YKSKY
M<<J*\Y+*K/$Z2KT\4Z[)RYX@EBT8"\*,6-I)D-O(YR>I92ZFZ#GV^U9*DPW*
M1HA\XXH]OBYI+W>5BS$]D&E7?/@.57"5'$.$=H)C<JH*$!",5M'2I>8OGG?N
MVAMNVH.EW1YF*B77V]\5>ENFL+=*3@1*RJEZ-+3AK25K#F\[(]F)4V//<ZQ*
M7KW+ME(9?67^MCNB1B:;;W[KPZ BRZU%&(&-.+:P/-*^%""YYGRBZ95A+T%]
M)UU-2C.E7S3DU= CC3MT"<1#(KA;V=N3:)8<]+^Q]YY137W;WO 6$*0((KT&
M 06EJ70$8J/I7RE*+U'I(B H/21(E1H! 14E*B *0J3W1+J B!3I$A) E!I:
MV)#VQC/>]QG/N?>.,^X[QO.,<^Z]?I@?8/RR]UQKS;KV6G/"!)5E-+K?N!14
MG.>[\I-WC@$\V =[@?S01158.P]N$R3ZDQF ]*MO39:8T&@Z@3"XS?UTY2'G
MD=0?:&\S[J?\I,;H.-:8Y[P7R" M^SYF[)H5R:03%BV>^GN7GV)]_Y<& Z@Q
MT^LZE3AO;/RHLNK.AYX*N4K61WJ'%5FW?R3-8?E#UQ''X<=)_BDV^WP8 "<[
MRKM8XFZ@K/KY#,%^N+ <Z7<UY7^!#C%_NL_\:Q#KAAKY  -X7 AG9D%ET[(,
M8"C#=JD0841O@6P\QJ0@MR?;87N!EVCW7_*RDJ-)S9A4['[X^:^8(Y<?JFUQ
M_[QD-A3P@(R^)<$FW<X*0\-(%]"'G::\("(:'%FIA:4CN9$\3C/Z[^YF: \_
ME*4F%$9V4&[ 32M 2V;6;KHN--?+B3*JJZZ>0M ^?[KY(')3/A%T(V-0T)E$
M0]:& ;H@]<+Z_0']NS[/2IM3>-I8C*I3QSYL2Y39WULL"-;8MP 3@]O/HL'C
M"BN1)51A4O_#-Z2%UGX>,QUL-EY%LM>/J.OG=M;VB\?C8N."&18)2.AH56@E
M_4 ;*9[2LF$/AL#6M=*).D2HYS>_U==UJ?-=[%ZQM[D6*@3UMS%QN)NP: 8@
M:*@&MUC_D3NCEC@$5U\WBI5VIY97=1^=0H396EG$;'37RNS<_ 7S0;;QT$=@
M6T%Z"72V:>3Z]7T*5('+Y/CU-R^8F1ZZLJA#Y?SLM77M.!?7-S G4P__$R+\
M?7[N^@TI^9U7KPZVR9Q(^EV7V)A6V.3C2NSGA+. [D$!GD0U067SMTYV9A7$
MBWG7>(2+9Q]/]WR>.Q2\+#;QF6FG>O]V SZ3Y$]^,417 6N)O@G)JY><WA0V
MB*5^PS_U&WBGNI AT:M/=EC'I66_Z:5S:\XD!IT]6-CW)>MH$9WUCCDUY4V4
M ;(%2C(VCQ,VY+OL+PS&M#LL)!U#:>L59O4X7I L>A<OF_J1 ;R)2USJO*N+
M&NMJ18KAW% 3C?:@.O(F$2H"EZ[_3KX2L2S0??.6@[JR@/*3XYQWGA2<#6A:
M  .1EY6RA[$G0M6,UN-J8[?Y1+R"I8\W7(^(%%ZRC%?JSAHK%HQ[<H;E'"LP
MEP10YVGUV-.A.^1LVCL-W+@_H09S++%0Q#1H\I/DV[I[(FCM)Q^C;\9+9HK*
M1<1SR*L:B$_^7DYW?>EG]_=VD@I'FW"Y#FF+@I_K%F4V>F+[27,U.O@\G]DK
M:H2B-*P"LN42DQ-DJ[1N)F$AN6!4LWYY.^ATR9/8+ZU'%2\<_/I\[V:DTA(4
MO(F>Z*6G%5DP@(^Y_?034;K(L4QB2!K476VBY!HM!RN[=,]G3W)66JHIT%X&
MJ?0EN;?[J&RV<HRTJ9G@OI1Z+>1,'71#AJK, #Z\6*,GI54U\3$7:A#$%=&_
MYG&!A;.0%!L7U>$JJ4N#/\+\9>LRB#ZA!?M?\78UB+#J'_R6RY2$%@:0SD'P
MI,6N(;>NW]]71,+0.2?0U<CX9;H:_:NTVNBVOTAHS8C*>;SYH'O:R$&]0:/O
M/&=/0R^ZGS'^VOCP2*XRPG*X"IT$^X!>\2;^[O (OQQP=UK9T5?I:@:);YK[
M0S3G4Y.>RO8O/4<[V45G6&QPM[%B'VMPO/K'N3S=PJ^\YMG^&+<?X8'X>K>P
MBRI\@=#ZZ=6P5O8,Q#KU$_0!0!?<]TO[M]0 BW3^ADC7KFFE8:R,L]R5 $R?
MQA6VG+\X5;]6B+@I!YY[5+_P0ZS,GWY@=UVN0U@<WXZ/P<H,PRPJ29^C(T3G
MT@N$WU=JJ'>)&<@I\T=' 4?33G?B_EK:8(Z7Z<$47E'.,H#)!?KS*T"8_PJ(
M/95+Y[+W]R'1B3Y0,9>6-V._<@Y)ZEOU^<E.27#XL6;BP(#&% _LJZ^_3PLQ
M .XYDD\;$2D4BK9=?S$HYE<]INJ:=NINX&7YOU*SI@)#*D^U[,:';J*2#GKA
M2 X8=HFI,$/K#TX,H/]"T24Y!M!%'EUT!Q .B#:<@'X 11$Q(HY>;IFE>43"
MVC)%DL\^LSYZY''1"^Z.YUE)7CNLTJ;V!R2EYB@A5"$!<MTHU!.5X* 61Q6Z
M3W;16/>YE(X_][G&IGR%=WW/='DQZ?N'N1M1)OV0ZJUX)*B$:MD:%,).2GV)
MJHT(@ZYO]1V9I3_AMX.0;&E:.Y:T,JR((S-Z6,YU+.4=/*#)SF,U<0UY5]H%
MVB"NI;/P8.6L="\)1C^P/4/!<UPH@<-&JU?\N\0+SO\@GU'J2%+2=7+/#+/U
M=K-1."T\84J(0,NNXV*IOPM(98$TPA6?-NS1;_KG2)[M.\HY#<Y#2J:66HD9
M%T4OG%8JZ3H1^SVZB#4X,I<NZDFN8 #Y[X:AI&.;#""I[#)1C7J8 <SN=/09
MCG1UXJIX7(Y75C_N9Q-_V_#BUJ/HPL>G9F;2ST*N,=-GS,MA9D*#3+3-KN L
M+=-8LK^5'GY:<WB_Z5ZTTF8C^30-136B!%-U*G(ZI=4:2<PP&<>2>-_@<+]Y
MHO-\7?K$(H'4=?N1YU_803M!R]2LG9R50D+NVGYFP*Y%O4)8N;IJ<,%J$*[[
MQL[9N;70*NQ6]KC4L/19#ZNSAM7IS'$FE<>/DM4'W1.UFK^4(Y6+*)_E.=&4
M>4&$X+YE7(7:,JZ0W@WC<B-Y/"VY4E:UE]69'_"V_T!<H>?$6RWV.[ZI<BZ\
MG#QC$A\,:I(464KS<MR+NC6R:QXYFIUBMXT_>A[\HGU(=S%\[]GN GF.5E;E
M/VY.4%F9^'Y!.TW3SJWVJ\;G^.#'*9&O1NEA)H_:\PKV+T[=I$_B:VOC&8!;
M'X^WS:DVHMK#4=+:AX$+]-7OYBP1&;K7^R]"U-,?/,B&Z"%ZH!]RDND&( D>
M1'LC7S>\S=WE6'JF33QZIDZR<Y1_*TT($CRU#TT$W.U8?V\[GZ-_"<>U\<4Y
M++2K\4_V>K\#O[WTD0CKE+HCQ]-]O%^F9U#]QO9U8_J)#5A4>V@CG5MEEF8\
M\W1^Z.@P]8UKS^Y=E;<KXW:EB%+9][>+BX6NWSB1 A@H;602SC. UM\UYK^"
MC5>:;_*/%&)/:7^WH1AE?'^Y\TETQW!KWUXC+!,OK0HEB#!AO>#AO6]-[S!E
M&E5944L_)G,]($DW;)<.(BRI5U.HS(=%#X;"S#]PGQHHK/!^:LX]9Y>;T[TM
MUC7*#-.L<(/+U7;M(36/7(QYSSM=+..8,;H2$"#THJFR_\0YMDLN9O(WBI/8
MS7ZG;HL)B4U7"D.UV_;BZ\MN"^_9H(I:1T5L:ZW8DD2'W2H%OMK.FW2J3:@3
M$ZB"&.+!_E98='"(GD*;HK-Q::E3?/+**4^:[Q"OE5Q,Q;YLN/L#RMM]"92_
M0GL6Z%PW*3=!<P*FC;B#8".UF68N66"ZY]6[R)-?P^^TFDB&43ZS0T<"]AB
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MVG+)NL05,)V(0D%%K9;,UTT>\G0.F3;M5^!39\_X8;=)R:\]5>#F;IU[!.&
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M4B&K1-KZHQD IZ>OC_&0WUS$2N"!7D<QR*U>'0-"M*8_.K7CDQ.U@%[E]<P
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MB<+<VW+9.M;R,W?W&91L^M.Y^+Q#*-KT:0@75E_S_6#H[945&[K7-04X6T<
MA-)W9]'6P-1_]1E N_ZWBUL9M$8ZES/%T'[R1>V=9UR<[*>Y?=3C( \6T XT
M/1*^'<83BFNQF58;V%[B7N-Q<J25:GHM6/K/[\OXW"41\.7"C;(#.K(X-?V#
M[QWIDVB2M1?<E3"%!T5:C@NUA\?(L86N7'_X(A":MGB^AY?SK/DM118\543U
M.&*<Y'$!+=_U7G$A=;RB_Z<1XKV);)_XIQ0I478;EW,<KS QR)ERZ '_IDB*
M[B_$B2&5B1^SK>(Y$V76(LHU]Q1RE-) VT.9/U\E_G+9I C2!Z2E::^P+"#,
M<BA(QT]SY8QY;<7(LO8^S>I!8_Y>!>>TZQ6UY_G>R@#PWW>C]K]Y]KLV#9)7
M+JI?(7GE_/U/LE](F;L!X.@0K/Q;4PVN MDREU5[BI3W9(8!5(P,5* ^)8%J
M=*ZB=;U)<A182,+/\$65Y8]L@]O.>P]KSQ"C5RW*+TB<7GALG#5'_RFG'\WQ
MRP_-FTQ"$E*KM&TM?]&E2#5I[U2&<2?.^?@"/ M2+*\%0 L.2]CC8$HI<J9!
MK,ZWL="W$&4Q+7G&9'$_(AVN!,[/J*62P^-&'^A;NA(C(@V-DA8O"\M?_,QI
M$<AAP3</>XXC641<QHWCR"30>IU0ZI'99NM_NW;S_-,S,\>4'C* :1]/J_K%
M"\C[7SD6"Q&63'VZF+.")UFMC6]\F5II=/MJ87KJD:/]<T4JG_[>Z*_1>+HL
MZ-I!YZI91Z P=K#06T3\BG>)B5XR4I$GVT-G,BU08O_=<RU"NV$SOK?PY"FF
M%R^Y, OA9?JKCUA.TS*Y83%1N:[;!1>7TJDA5L(6=R^Q1/"?%68 ,_4!E\G]
M,:<E=X\9W#31]^O+1IY7VKZE*^PU<O'&SX^G*S8.&!R$2_RMS>>%R-FU\?[+
MZS9/_4:UI0\-8[\%OJUWKWRJ7^\4TEH7BS;B,;^T@QXK(C\D[:P<)(FT[J7E
MOFL+P'A/1#9GU]ZLXRPMRSB99J^W'%B8U7 H\AS RDQ"016-@2Z*$A@@R1ZF
M#[LM\.:<<$@LNA?5B7U&2RN=KZ9ETOGD2^M1L5M='+3LFM3'B(NV+4B2-31Q
M!%_%T:$6SP  ^/X@Z5I,5_':L%$]7E D,"Y)=#Q'_[4&1F'GG-C<(:@Y7(*0
MZ[\_],(%TO:CCKQ,U_VQ  ]B5?&;"(KI1\9>)RFR<G1>"\V04CU&:L:B[[T-
M^ZAW^^HO492/6W33ZA=\FV87T@L.8WI=\U@&0#H6OK6GR+K11E:YZ;F^=#&3
M0(I@ (?YXD^:\.A-Q-;HV4Z\G)03O &GT>UDX'7'L.OT$9 9:9V%<3( _#@.
MG(=#_J/8"]CD6^%+9EII3A*:SM9O0D[H8 ![;"#3PK)X8LQ?1^FW42X0&0"-
MY7?AAP?J [17ZTCZ T.F$?_X=&GHYTN^D_2O(([Y(C3S13-_;?U[GC]#JPS5
M&,!7A58D*&  F8"(,("? @0HE3.OV3#I#P-_&/C#P!\&_C#PSV6@D0$<"HTQ
M)]4DAY7<'@T8^S42\-2S[@G!U7+X&762]A(Z\V9:9K@Z(E6;$(6Z-/CZ5KYU
M7:V]0F[-^;HC)D5B.YB"[E D!'W];DN745->.@PZ<#N &'#_0_$VI/?=CMK?
M#2;_[\8Q.J>!K^[OO)P<_Q0K!\;9IQ'?1<IB9E[.\+4VU\Z@J8*575C^X=)2
M^+T38,G%*6$S<<'+!3"+I=0NVO+HY*TFK3XOJZ#C5]5]7C<@E4H0)KGF.J^.
M.YCE;ZG_@^EZ!P:M0Y@YDA!<R9.H=A#V)K_PNZJ5T<R[U?=\,C&/3*KO?]N]
M<NE>OO;5UU79J09#!F/=9LYWPA+^T3B*!NQ3_F<+T7\!!MZJ^9=63=JK^JW*
M5M>DN/]XVBJ+LC)G>5 P6:&/_P><273B:R"M*-;=1.VD(]]6<PIK4MXLU]9L
MT\:@-D(STEK,X/=Q_:8L*2'F&[(^J-0<_464&6?.WSPQ/-MHV+BO57?:W=/D
MH#S:/H*9LQZKIML:/OF[<6X_(.*2I'5)*C@T40(-_"R?E5N9>)S.C);O"V13
ME690$HA1M%#3O1\F <3&5-5O#&!^TH1EX.S6%%H78J,YIVU[#^]D%G!/(T?D
ML%2_\GO[)WL98<?JW5-@[I""&_K*[9<&NXB"\-<8L-%QU7.*_KL+8ZS33W4-
MK>")8PT]=UTZSV2AH&MFE5"+@Z&CG>:3KATXT2:QMZ$V2R:#&GVR8*>'UB^E
MJ\&F%8H\_0\V9?I[808F$GVR7>*5C8>*BT^;&0!"X\YPD?41] RE7W :=+0:
MVN(^FZJRLGQL?UO#ZRR^Z)G*M[OGEIPJ,#:O?5[M'6.-J8N0*[GZ/FOQ6+W3
M/$9SJV+ A5R34]\Q8"34@W@DE$]H1FRVYLD.;C<;9*EM3;[%J(R/!B;*W5TT
M73V=G_2EA [YBM&WQ'@W:+TXE&LQ['>KLB;UB6*8V]V'IT/%Y -#7[GLB5G/
MD0/)N(,OUJH;IO8PQK]+Q82.'/BF:<[K%>+&(^8[XI6X(_/)&/$$<Y&$7B&H
M)4G)9B!Y?MXK_XBR%K%$=0R?YNN(@]^;A3Z@&X(1S4WG""K7S.,,M_L?N44A
M)Z_W(*K;1F^U6\=G4,T_GY+D;'M:95 F\!WG$-A 09^FO$=4>AEJ@2ABR9&P
MUPR@]6#)!&37W_5M[^E[JP5)0W\O +MRA3XB>T*++MZUHWJ1$Y&3R?8.QT5^
M]IP36I[FH55AE4'M6\A6$UK]'=Q&F\-#)\\EA</(V>TA23?$H"&W%,%#]<7\
M@W9CGZK,9,JW(2K?5]0_T(-<*E-I]A]_4&-$Q'.80796JQRC&,!C*U<&8&S;
M!*J1<:#EK&]Z"[$Q4G4>-X^WO>9E4K.SRS?3V>#J\+S&<R%T5>#+QE(#Z&T?
MA&K"@M-X==@_T)Y!9?^5ZC-VJW=691MK'KD?>]"6SV=APEY4VI_AW3&>=_-_
M!__\^VGYM64A]U_;Y/QAX \#_PT8B%]<Y98(4U7U2)N>/E4_GQ5=_+\<Y^0_
M>+)"%Z1ZIQ7-LIL80,R-M/D%9?HM]I5$IM^287K.S;4TZ$SA8>VG(C%4F7>T
MWF:_._2[G4ARX?_K.-4(RFNG*U_%9R0OJ04AYT9P/0M#?S?R>HPHW&D=W0;R
M8.6:2;PIIQ[EA#]^)\< &M!A.,!G!B>)&,$+P<-^F(00&U_H#8 4U4?[7S_X
M57]R#MG4V91&)#J^R_.>"WMSK[X@/5D=8F7N,)]]*O(Q(C,'M'>PR;[YT'(C
M&D=<\:]'!X2BZ%R0L/S/MSY\&*ANA<Z7%CMU01:.#3& M-'<T$HZE\"ZNLN#
M5X.$07V=HH*1[$Y[G*Y]#@.0PCPM77G3]$(F6B'/FW<X35/Y<R0@Y3.JST>1
MIUJO+^0<+8I3O;]DLK#B4"^<Q%$VVI9.7WSV(ZCD^B#TP<[]NLMQ&Z(GZJI%
M%FPN;P0G4])$.B$"38[K++YTN77IPO>;Z5+?>S5\Z(N>M^F K3HL (30.<N0
M(6HI^C#4VH37(P9PO !"N8J-(D&78TA%'[&.DZ #WKK!?#=LA+/Q5F0P[A/?
M@)$.X7:_O22(.13(4R/=R_Y\I2+6%](\2?J+^OPUMI7VA@&X0Q(-=4$\T<"_
M%2N0MG"V3KC$1]ZVYM%Q3A_!.RP:2;8\[W59BPK#D-13"IWH/0'H1HD[ ^@J
M$;-\YBM/GUTZ";=\?.ON\-)PQ[780L$I9]-IE9+QQ6I' WY"E6T]LNTPW)L!
MO%)G "=J8-1P%'C+/!6Z=0PY;]/+ %#7*2?0/?19#.U6-^ZG5@Z=)V$W;YO"
MZ1RZ"HD-;P!=NB[4,Q>B]ICJWN.*@FCSRLDYH,FW$]^EN>7_=ZI0IDT^#CH2
M4;%(KFUG2,<S3[)-OF&URM1=VNOCE0+G6-B_2YRD?&H3ZX=<VF-O;CA>[*V^
M*Y=48M7N&5I<Y58HHB(>8CZ0_X]U<6SWPG\S:S':AB?9EF"D^BB:H#?<TO75
M)'.I2-F3@I%:]BX7%,;6[A[PTYH-F4VBG?R7/.#)UX\70+:(TR5"*]N?U=0C
M9_M%JLE%(9K+RV]&V<TD&R';AN]]U.F2.:1*>@)&%(FWP5$]<$9>+W]/DB>&
M^= HI"<T19RCW4"@(T]^>-L LB)]I72W=@/VI3:#_7O%R2GE@A3IE[9#:!$L
M+V@R6_O O^G(K+.LBN?%AB.?_2XU6:D&]TJ@GDH%WOVX(S-WF,_;"$#<G4*V
M".F+T?(UM)""^I:^A'JWPUI/2.<W#O.Q?3H9&W67+X<N1/9?WF'..A_Y%LDU
M]-['!D>'<^J)&+6R@DT_C!OKOOE,5ATIH;.6F7%BNMOBBBS85T43BWN1?:G;
M5=K9MI8: I-.,J'SJ0]LC*^U6'&R21_0)*FUJX%RJ+;2>QW7EJ0YU].:9T15
M[5,:?.L<WUHZ'LDXYF%K+5>IOK,2!3W[]B7?4YP[$E18:U,;O[J[72JDIG^.
M."[K=;6QI*+J47[D?)S@_A3IA>P6N6!>I>]8^=!CHT3/-IP@>'XOK/0._%RA
ML[=ZOS_JM,Y"W&N/OZ*U@;F4Z--*^4P!XR:;T=+@ZA3(3ZSL$%RS]/;$L,.W
M=EL!P^);4ZGB%5%8!S6.@"67S/6(F;58Q)E084JKM.:@[,C]RZ\E.^=*.F07
M[I37[::/*O#P!?*>DR$_MN!8.-A%Y;_6@IY0O^"Y?J%#>%HB^YR<-XI-[8@,
MZ:^8 Z8<P"Z2 /.@]R,K8<QPUT.-73M!G[NPND! Y]G&WJ*YUB+Y[$EI^Y/J
M#P:N[Q?3L<Q$6[Z.4EH4CRS#%$V-X1TOA+D'"9PSJ&[E2+,;$W)SUQ>2>71N
M)@;&\K=&5#I4O5%]:\/R&;3HTO2^Z/DGO6\FXQKBA"K$9#W<@ZS.J$,18ZQ;
M7$G ;B[9EHE'4$_3'J^A'0:L-MNE53*.Q2XU-"J9<6E/VUF>M6M9#;MS6/L&
M$?OT?^ IS>-BT<<]CESGR0AEP4:"]90@N!QHLC#91]R_?@PC;4+VB]K?R[[E
MO8^_C,_"42Z/5PG'$=7A(620?3CS>5,6G8Y7/Y%UT^C>]:ST34^JD-RL^W99
M?@%<>\@OQ09U1ZWZ:"IVU^.(G/]+9SQ)C[J&,:<5(#0@*+Q(-5HL]515J!J;
M99O;4%B?N,GASM.3QF:3C:*SP;J=YD]LMQG 07?DN)BUI$9^[QD7&#&\N;8&
M+[=)=?=_;_MXJ.'73T%+HTC=UDAK"CM].!NV#^X=5 @6646H[5]\V*<??_R8
MHW>6F2VG>*7D(Y$'5/L5V,ML7*W)QY)^I5XPX1;6@VNWIO;4K&%CO@12TI:8
M=101]N*NH>.+6WFGWQ=R5F-4WJ^,7M_>S<-*J)?&)U0F70E#UY&1U6LM$<16
M:*(AQ+D9OE0N,M\H1E5R&24_!B^'B6O !)H@F\]/8!OOI(Y"[M=!"Q&'!F":
M:MPD/D+[%7@FC7^LLJ'Y!@J?#$N>9L,^ZO*=A?%.F;(3RV]_.-55QCK2C$G1
MD/A)[?7UOUJ'TL$+3=U1__7(9Y?TNOXHP1=2F>Q#GX)1,S3LYQJ&J,@9R,")
M#^YLDC&?9+-Q+Y8BGK[_8?\R:R8+L9Q>;B/I&JWD,-0E+3?T+:X,5^S(/A^K
M77$,47=[+B<NDZ+#]/*3:%JCACUQR7R= 40AS]VWG?'%=.(>!AO:CC>%$7V0
M2M*PK/=.JI_O=T*2QBMI189J=I4:2 &J4T<\WXM2)U,H\"7 *8.$$\9*_@7K
MQFQJV'\W_."YVB<$AOE0;L%O5Z:ZFB>*+YW8X*E,Y'/:L#N,%)^LIC4;ZH_W
M_C!99R?DBK;7"&?P=;^2K7<GI'EAN8;Q=#8<><3AR]N@9"KT,^WM:YQ$*73F
M-4[:=U9)(7EE-5<7KY7N<8"\>XMU:\U1"T>Z9IX:O"9A%O)J*FZQXE<4^RQV
M!/)&*<-%?,%RXCZ>UL0 [/*-GA/0)CO(%JB+(J:; @5/(#N6?.D>F02EYK&N
M%S?O:M&TIOA&:E20,^\A_):N%/-8N-IQ4?R\2H_?=J?['41UMQKOYMB**(X2
MAJA1\0!=UE:A5HJ8/@ES4,DVD;^[ 8PH_/QDYL);,['^X7R;ZEJJT&#00VY4
M7'JO6C *I@B5NX-\$7@YJB[^S,W?01-A[]. QQ/S!2ID%Y(O:/O1!D^RZ>,L
M9)DE?,D7=)XPN*H-34]!ZHU6,<U/.2CT-1>S'TP2Z6<1DWGDNNCLD^$DTLZ/
MYZ*#N.YGRKT'Z/@?D7U&</??9Q=LP"OJQI5>AB=K55(_WRFU%]R9<W)#M9%*
MDZ'@\=&6B!=TU]#H(;]3"]XO5_=\[^V-RM==TX\'S6BCU%3A,SP,8)YH6/T:
M>^MWYRT4E;O.=,*<'^\HS)Q9;3:, ?D53=TB%$WG,B-=-JK&OUG22WBX(/?P
MSOWQURT[WB,GH3RCDB!2I^C]AR HB1.9/G"I67S((L[T^TX&+-D;8F4)>T[7
M8#[Y]>UGS[I%XN[[JAD])*EJ<DHO^K\%9&.V>91:FKPI5J&S1(4GST91?C]J
M,]<<)J>2O0YLG>JJ-B<J]98\^'P<;N> !MER?B(2L^]F=CE8EU<=Q^SMBD$;
M5##4)S2[=4P7'T ]LRG2;J@\I+$[2QG!AF8PXY8[F6I[ME'@))U+<Z8/\CFY
MS4&XD'@\YX%FBZ,.7YW"/;J7TF9ZD.,Q2FWVRE86LK/TU\^)ZN'@D4O^JO(Z
MIKZ=.ZX_@;G13!N=L36SKCD&\(GFJ#*C*E7P>%T4?8<!M.=#&E09P.ZIK9Q4
MG']_(EUA4VZP<(BJ=F=JWTT_^1SI-=75R&&54),D>! 1*NG,C3JTU)!6?5+7
M!ML05L/,GT0?<7S F(.1%&GJ7^##GI$]:VRF7T"#K\VO6\?1:\:-!9"=CDB^
M&31XK/,%1XY:,MPY(/B[PZA)U,7\R<^9 7)T0"EN"&-)Z:;VYX=U'2 1JSFO
M6<$^U1=NWF8 R88'R_);<-QPV#K76:PD:;KHO>I=]^H:CT3D=*:$[;HLSDI?
M@*)$52%!LO>0L<I^9=?H+M4G_>;Z=Q*>F%ZC_Q1:++_XR#B],UG22ZM8\2-P
M'[ I;\%5]3_J M]=TDYCY<$__X[;C^R#Y$XS(^3H,.K%=?;NH*4^]5:2I)^9
M.^6OV9_E5#0(8A D<ZI %V$U9KX7,[V(4'P>^7,N<_D#!.1!ZC  [-+B;:4R
MG=L!O^YMIB"E/<<H&-]EXMZY0+I>[[JN.3OU!"FD;>P;7)=0JFYZX]2"HZ/B
M8YI;YRSX+'^]D8"BJIK'BX_&,( J7 6TJ@F]U2_7OT&MG\U9]7-:Z.VR3%F8
M:'S6M1Z2K-'/ OI8C%;G9E4.*=\ZW:=^G_4EQ,J4=6KTNK=>JE5T8[A]&%I$
M$G$L3U8'[_7=5/.H0DE#B+GC='_]NO,.5<!C\G)E]NH.,44K^T/9+P6TT8&'
M!I<EGN_;QLB-8MFIHJ1OE'$\8D /EM<$J?AIY82A;0M^QI6&*:R<H]P(+2)'
MK1]LYY\RS"%<#N,:_T4ZW/@X 'OA.PIVAXB-Q$Q6H+E^?GM=[&$MZ4;_'!Y>
M&QDI\GD)0^PZ;&R3_[!AE<!'OT@#2)#E'-(L\<YK" \U8C#H3/:O.PVF:?>V
M4E<O0'J:0SXB2>9\X'EX  '/CVS]2/$G&^?[(YG!K;]:WT:AO98?Y=SDB[HO
MO.I?1^>OI-*^/ V2ZBOH]]?W#.P6:V''F4%O0B8#&4#GLQ=%;?U2WY4G8H[U
MJ5_/C,^5DF4FN!$O.7 $%RA_J#\MY[S=9[87IB8VZ/:<2 U$N-PE:<4 ]E/Z
MAG+\?KZ&!^SQ16VO=KZ%[:1"/1E  NP0O',4#BG\;GXLQ-F(+UUWKU=Z%/HB
M_*#0[IE+#AIA3^#6<'G:&^G\V,8W0Y2!#>T49K[U'''P6U,W7!NS&,[6]REI
MWF:5?YFCAP'DBI/\Q9EFG:X0ZO\YT\Q9NYV\]$G85O9X^6K&BAB9QV>K)^E'
MMOCS!CO*%!]D84SBN+6UB'<)_<0@U;P#)0P_LV[^P.-4:$+;1';2^$>?2=M4
M1]J(W$%0?*%DYS!Q6NFMBQC1[%5 =7[Z!26^\WP.&RAQ1 ^4BQKTPV G5OG]
M*@Q=]>O&>!UTFC;.U46;\<FVTR;;[QWCZ+ATNBH ](3HG*'SXG.A2OKJL_Z'
M0E675O38Z]_^K%PXNJR:=QCO7. 6Z3/5)$()AU\CU>9(T>91B:4YJ0TO/O"A
M/%$W%;Y7N@S-FC/5/2O@QV6"N8BSO72);\G9RG?D30%O5CJ+SV]CR0>W(R4\
ME==3-CQ28[[KFS_%R4>C^%9 6JZX+B\-3BR,O%^*K4L,',W25J N95%S:V?Z
M7^O_WHN6)7UY5:$F&.IJ,3"G+[:U:[.HO/=H4I3OS>(.BATQB.9IBIPO2Y]5
MT?A"5?E_V'OS<+;^KE\XK;:4MNE@J%:EOZ)J3%&T-:23FHI62\QIBYJ*JJH@
M$J4HBJ)F%354U9":IQ"SHFH60PV)F2(QQ":1O/$[YYV>^W[.=9[G.N<ZUWG?
M^X_]1V3;>^?[7</GL];::Y5.!PT^]=VOPQNST8G6<4H5&L!#O9]O?I+=TJX^
MY[R:/R[(R3CHI_C)2,A(:T'&0%F05*;[/K*DOOW1:BGV"N8L@6V76XV/?/[H
MS_5#I$8&+0^HD.?"T9 B3(,*.?RA3KC^G>,6Y='HPNA'S LU4_48ROW5=TG@
M>.$:VRP@:=]69K2(DPJF+F.;<Y=J^:#E)D.G=:Z"!3JBH",0=S+3$<<XN/MK
MB<U,85I?<;$H0?:O.PE@"KS<EG9>YY!R(L<_M,BF(8"3J#DF@$-2[%H,.!BW
MAE15R/G01XE5YLTOTS$M%QLCF^#W'&]A>& JK3:"!::>88WM$AZE1.:! L*I
MHO10J8=U_U.PMV0-[;-3UDB;AY?[T:P2:^B5E1.\WM%(OBFKJ[M%M;Q(R,]P
MAE;26"^FHS8T:!Z;&7""Z?I0XB[LE-H18<OW/\7:WF;\EPI7F4CG]-J3U%8&
M;_J*@3R$"WGW$B=E;.FA@#AS6-,/MEJ,4$=.T;X!65.K<HI@_O$1,P+$MH^K
M)!(RIF[% ]X**3!]FM/J;-!3Q ;=ZWF66>]F,O%C$V-GF3*0K^/R0.XD6WT+
MXZCB(:_&SOG]")J=N9,'&XY42:8<JL50"0Q>S;HSX$2!X))EW>93N+$/XL,R
MH\P#4T@6B."QW2H:>25<-*)7JU7ZYTOMS8N9Q<45_;(99:7^NLDAQ_J#>&7_
M^(*$DJ;C9%U)QC"M.J1U+"E>72GS&QN(N+12JMD<+#*+X<K>V4- %!DF+W-2
M1KEA<+FAM 1FCQ5>O0BG<DG5X4VIX":F:L4Z0X-\5-<,-:.QW/$CE[D8$[@#
MDNI5!=//,>#4P;:_*$U5:KF8CE]%#?U@@ --87([S4,XV*1.D82019Q&5DXS
M=[^$<3T ],ZS"1[A:49TC?.*CX$"25C0.'VA17=;X$JML^7N'\"L"G.((4=U
M;9)XBSY+F<W*6P\0RR^^XL1<GW)DBL(7Q=^P^2$+%)BZ;VVZD/(I:[-WG98/
M5W;%WA=MSV&!7G%O)CR.&.0-/3UXZ8.S2<^M;Y$W.'5&KBK3$M<$@T,_6B-G
M@->,V65 BFG/(%%@;+])%GBG6HFZZ?,%,!NKW7BI3<MEWP(4R88CK<V^^R8Q
M@#BN$7=L^^42\7I\J(OFN&D67;%R1Q3IVMGIJZ'AT0K65Y-%.R>XC?M&5M'&
M?T$S!:!35+2X,@D<Q.2C'*P(;DP5[GMEV\)C.GI!A07"3[JX-B4M7$JO.JE[
M!R5F5BK5V9\K+J&>/Q;(^^#>C__>*FZI23 @@V D=042_KBS=[3W["*=60MB
MXX0!]L;F >;,5A7$[E^U:>!_%J/Z]SI$[1T<VWG_=C3) [K)'F-'L1>^L,N4
M?;.%KVG@$>P_Q*EPL?\8(_L/JR],&C.9C%E[-2[$ A5).;- 68.E.Y\0<3"*
M'F'[NNLQS# ?&]OU+IGMZO\OGZ_V'SLD8O3.X:'2!84:9^*\A/R^I=E$&]R\
M 4ZO=0$JZ1B4" "?&VG,5P[S0*ZI-Z;MNQZTX1!R(L*;%'):%=XT(0";_ (Y
MA7K=9X:T4D'L7W#^H-YRL'E*8C.QA7/@A-8FKJ*]0N%JI_.EWND ^L,M>)L+
M4V?<+A$AU]C=T[Y:!#.H_8OMV#P;PJ'TV\WC(GT;/$\/&Y3^/! ]]35"+L[]
M3UH20"1O,?@>WNQ%T:'!ZN>2+2L$C084W]<[8U>E;V]%P,;EDACC1,5=@Z:1
MS)&XPJ]CBU7OYUZ5>Q:7]%9NVCW59CBZ'@7@IM2X?/[XM 7EJL$LZ.^2ON5Q
M!_/?DOYN"-Q,[3G;A--TBP:77//=!!QQ]?6:.KK,U2QW)K,2P^\-:<:-8,F8
MEF)IJXM4O;Z% LPTGPVZTY[S<_AEB#"N@DZ,(0X3N B3";#C>-OI<>0O9E_]
M&7=4RV_RRF8P_=VH@,C FDJ^;R$EF"8 :%."?U0&-"Z1U9ZJ0I9E, *RISVU
M?ISX KXEH#Y;34VQ_6!SA8GSUW'V37)XN4OW)3Y[M/;'2F*]OZ]S!7W78>(0
MPST7J;3>'%?+.Y!%&4CRBG'$VMKZ0;\5GGZLLOQ+A7@6T;U,PSKGF'38NA]P
M-VL/4@[LYY.\*Q<*0*98(,:I8S*NALEPP!;CG"V8@$^ZFS;S]"$+="]!HL5K
M<A)LMBZ/./&]8J0W*T'C@0')NW1!?.+7X(9RT_1Z-I\D-)G X%AW#-U1=P7$
M(ULK5LRN4'3T3C\_' \OY-8L.%+'C%UF@0ZP<5S<3F=+EC.&*O6PO.C[K7,E
M-===Y1U@PYX<CI$>%VM'!9J]9$_&Y$H_$IL1E(!5(JBJ[4@A/>V77Q47\UXB
M*/J$X3AHB)4TMB55HD=F$\+MT$Z]Z9IC+CVX%2,?V])ZT$36O7OR#2)-&5%4
M7C_:&I4)V)(\H/5K)149Y^3JC$XSI&HHN+<;V /S2DE*P4^.)7\Q2]-RGK3\
MEF9<@[EBEZ+WOK.PM_EA2DZK?>9(D>4R,5>]B\<_.S@SK=<UAZR,*#2HH_]H
MT*8LZ1AQPJH<K&%)%;! FS%T'0RT*K8N2CG@.-1R80": 8G^==#WL(;7B2X%
M$]35JC#F1/SV)_#1FZMZOC^V_9>8AZLI\N0+(:3=6\.1C)(PHY0H%LA7#I)E
MLS=\]3+SB(5\0NL[YQNGI8ZE9T(P20H(\P>6;N3GBRI/YUB@-\K;B7A^-L;I
M*-V"G+;$U$LP>75G$U1O3W&="[ET=";W@H_UGVT1:E>-M16F_B+C&%V]8PIQ
M_#;1\Q/O2;N^TT:M2XA7[.M-'=DY^S0+@'4>7V-(T;F _>SG$DNO_N%<*XIH
M"EXY_"KSY=65.[FIZ-@P#_;NA5=HU9<!6;R]=K'Q-^3>>T];E)<[[@JF5TVU
M6MR&;+.-:ML3-B=.Q!=S,5O)+-!/1E<5VY;K (FVS>5-YRZ:4+>ROL<>0[^)
M7,_3Q0%BX*;8D'!"*$-*.I%D&SVSCW%'?!N^:,E'A!Q7 %:-8/37L/2[KA(-
MA&*@>,U[E7G8FHH>^ZCY#:D_?R*Z>^(7B+:=QO?WDW4!HZZSVZ_/*/[ZN;Q6
M>N4L=:'B6"V (U9)%:B+S+E-L!=WE##= Q9O5&>!O(!A+_;_+ .;SL4=E%<"
M/E7;UVL21C?'+NU*"2_13@"KS]:DL6"7H6SQ]IK2#Z^Z#MI>8TC1"BH1@JA'
M%$SCT#!>DVRIH/E8F<NEP,CV"?.GU^\)/\4!R*EB>\:KG-U>%FBZ/:N1TJ3W
M,#U+0CT,OB6*EK=$M[) 9YY/L1_!V>O-U=V!\@2,F"A3,<:#KH"R+([OB"$%
MAPT7IC1__OT#IGA+:F.T98*-@(.3.!/YW]CE .EN6S81T*)1;*[V>B1]DNB'
MG&!R"[*QCK"-V<'41)+/:SI.".%8 8''3,.VZKZQ0.\*PX*;;X'[DAE=Y77
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M=M3M:;%NG]"/;7<@:3,'R J*IUXN0M#6,.DPZ9]778\&Q\N>$EA&;0O!R:L
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M(4AQW1N9V!6" #-*>_#6.<TNV->#LXB2!LZTB/OM,)#4^-_!G/-4J^0BZ"G
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M'V=:-OS1BP^(4Y7;@T_(KQW>X5^\FM+&3!JL>F.FLW_6<OU=^'"%0HR7+?*
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MTC-3;(MA7.AKC,-4:!U&T'*^:CG%?]@&9D-XI&[4Y)L L? X%SEGY8KH%H]
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M O>AC(-,=Q;(ESAPQ?AE]F&&UA;E&M,ISO2)W,E02RA;'_RJ<76,,2J6<8I
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MDB$)55UAF_QE,0$.=N+#CT6Z,V_>!A>P!:I"T]F@9XT%.NK^WB@KQ"T3/Z%
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M<N5DLO-0:M;")NS]OXFW_,&;>XH=4(*#WP@](H@!HG-,,D!L?WL-^M_>"=#
M#F+^CMA4Y!AO#PP,0*\2($H,D"D-MZJ=63Q#M2Z=F:4O8Y$>RNA?+HI;<_^F
M&.3#LU"!).B5_02 #-!=Z"X3!8JA)W.VH9-&P!L&*!RSK;(PL6<H\8@!^C?-
MA%[=\ *W\;E&,DP$E=OG;+R'*YIV ZP'*\O6?_[/_.=%Z 5M2.3&WU,5P?_H
M](]._^CTW[;3OW84-/=O99T22&?;(G+Q^(5LNY+Z:[&3(]CC(ZI1;E^MLK!2
M[\^Q:W;QL?^^*3U'2P;MB?UWB -57,?2V3\Q0.>-Z$04U0Z>G; .6UFA'I]
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M;DULC>1O([9S+29[G9  Y_%;*S8!.>H[Z<1 LZ[S'=QQ<'W:W!VHU L;N5>
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M9X :)1V9LE-!%U1#E66@:3<$M\>CWQZ<2''(&74I2X(ON6=XTGJ8F!XD-<D
M4>14F]<$CHX3KQ60IL]Z)9GC8IYJW]*9O;@GT!D8'L*$][@RY4(C <352#7
M;%C[!6)ORD+8GD[)/^U0+?4.XM2&.;LD@%<%CIV&UF"T7W?XA9RS+H_<DA'J
M;OW._+6& 0FJ-8\=Q+,RE<)Y.AO%L=V5RFGU<QTK4V)X-4&? ?(Y(-Q2@*]U
M'=4"DU0)$XWK>82)0TZ7;[?W3$T811M2?ND2*<GD J3L3''^CSY'C3DG;#^=
M%6,DDZ<:JX^4FX*%T(\"5RG!!;APA #6E1MG$&4#,0LGQ[MW4Y)WN/:?JTY7
MIV#LX<[)\+"'[KXNPR_YT#MVO-Q!KP7V&" =A+OJS]&VO '1Z!/5:W)[JG6;
MSM/%]N167!U (J$ 7K.3A4;\P#4?.JT4_4!H/5$7NG?XGX;F(_10M<*O'4N5
M+U/Z][XF-W^>=NS+M;7$?+$.A/5NPIJG*#CM9OCPPZ]).VY@FFQ+NI%J0^\P
M^QQVUI/.1=&>A(<O8D@Q%.CU;HD @\=V_,_X%JU5IH):L:&H)QY_UJ8\FM9B
M)67)<F'59U6+J=A"6O+2RG:!?XJR7<P+6(*YW=MPJ;(,9(RQK:#8N68[M:<M
M)MFTKS:K8VO3:Y5!QBL$UT;..WFG3:*))BK*^MKJ=Q8[U:5[BJ @+6]2;Q.8
M8RO+"\,W7V:I^T5H/,Q;0ONJR*' $.NV+)^&ERU=;/17)6L<3G2%0E=M#_V"
M 66QO!I:H9$( Q1<?JK""AP,Y3A?];6BD.))$#-X=TG_<U>><=_>2ZE?V)$S
M=/GK0ZJY=ACHNV)40"5@%)EZ<[>F=6$>>0DX37M'ET,\+-.H%2/E=0XDXP(6
M+1Z675_^!KMKU(.[B[.;> 61HBB2T"9="*,,U".X?FZ[MSC8*=*M^SSW";?N
MHN,6P@\^DC>Q7^QC3L:8G+^O(VRZ7Y^6?Q%H>4W!"/TT?;A(?4<L%AS/VT(E
MW0BRA;<F32[:G;RCW)G3F=GY."^QU* V*<BVW@(I3:I%$Y4E@^1L>Y:W8LYZ
M1BBK?K:P]WB6>Q2/<^E+J]76$/)BNZ.R])P CP63#&@L<*IN)JGW/D2B]DEY
M]Y:@\Y,_>](?6\'$ZB#%270DC@7P(,',J*S16E#OKXD/?XR=72O%T"O:*LR(
M'UG>CK+1"-FBLR'?*"D&Y;WJ09#!^[WY0H\&DM[D%MRL9:*[^F:Y%I4GO-B%
M2@:0#- &I/' SS_5RE_@.V\W)M:6-JCXN<7&NY4]:R>K"RN2?Z^R\NIXNL](
MQX3KFHDS3:TE[+ZI98*21$"YG<?/O?*;T[56Q9S;#7AEL**B)O=\XV4+=:J&
MRK0S^80::A4WME3#+5^04K\.>2R/%/::_PHZ,#,%:!ROUT$<(S_?1I'7ZFA7
M1ORJ&@<O(SBH)_NX_4OC]YY\>/:5^.EKF$0=-B=,ZD"*7IR91U$W@)L$>QH)
M),S]V'Y6%)0:9XLAB3#EBF2_G49Y3IX:$VH4W;2_/U)I*$DYJBI%E-MY!$SZ
M/E)BS0MH0FE?&+QG,:KCZ:'TQHB/-=;\3X[4\:N'GG$&V9"@=#9U,A<A<ZAX
MC=^^Q9+?#[ZYP ;7Q2WC0W"#.R\B%LIA(=&$H>;UAC:Z$0I'%]Z-1K'=$4IE
M@]FD,E?SL@G[K;1(,OXEIB2ST2.6W'3\15[>M\+&V6[OVU=]N-*RI/6WKHU3
ML/;8M_LFXK/[,9@/I(3OIHV=O7E"0D.A_,86PO_EWOO_B ;K.T^UL6QSU5PR
M]W"3M8D;&=65CAGL?A?-LY7#?\\PTXNU 5ZZL^Q*:FQ$'=4R(K,T)DNGB@]L
M]H==]<AH+>QQVV@1&3MV^#YHFK[F>,(;V^%"6Z.,3?*0#0AR45J*/39&1G'R
M^O.R+%Z.).][\)"]V2A_0J?MVNV^$W'#ZP/7^0MNGFFKVX-MXL,OY5G[L.5Q
M&,(N-5C:C*T7Y^$,OB%L/:^=SVZ^&Q,/C[@6*8\=P(-..W<W;]Q\FY;D<]+T
M_C/]><7-JLDD@$^OCGZ" O_LDGHAQ2;\9]*/H+19,<WBR(N-O,;7WK>R.HQN
M]"7OCBY!ZA^=_P(3GJA>CH.A2"T.8NSW!.1$@[@Z%I,'5@-/ORK=T#^4'DQ6
M,P.:D+GCJ'I%.O=HX?LME)!E\!DS,>HSKHHQ=Y>$08 737!MB?+@\ZL]?6XG
MHZ+$$_VY##X'EZ^^\2NC.H.I!C]-# EG= ?-S1[TPYC')"29U9K=>]/^;#)D
M:: 82GCD5T;_*\WV$3X4V71/1P[@#2208U[Z-?[,IFA:U/Z^HATA:8Z?LV!*
MR@+Z&*IK-P\U*<WD\\%\,4P3%'C+ +U!/28*MI.A$ *EDWQP7#U65<(O\6*?
MG;%Z8#!HDR7(MH3VN5;^CZY]*25^BNK7.FJF[+-P%5+.&\A&336B2,=&/WJ(
MX55-.+>>XWSSID0AHAO3EF6#JI=2'K\]@K@7)T_>>=S%\I&FT\8 *4 'C_.G
MQB7O]B8Q0*? 0Y290@"VBQ&Q1/:BA)Y\504SF5M(30I<.[#Z"!Q_2< '/-Q.
M5.+-C2*K_@Q]-\W:)Q$^=:P><%W2Q%&DW7H4:$E3[\Y=\.=SDCT#>5_^I%]D
MGR0LAQN:P:_W$'%,&[DUXW+6WMO3+3-Z>^T- NK/PG^G,$#3+(O^+^?I^UC2
M"28-8<2@\^E+\!TRBI+<#1]))V9_-R8?IX+L4ZP>HJ J-7-T";6IB3WP>3AP
M*+D(1^AE@+BI?KA&Z*<6!D@TG>H8XH@K9*[_*-KW(+@:O'-G_Y!=W B=[0!Y
M?8!'U(^N:SQNJ- TLN%T+*<413)619N- 'B1Z[Y5PAO%42?+%DI/[@U^'D75
MGT8J*'6<(*N&3$=1+ URBNU;GBK'7MK)UL"0#,!1VTTW K"O\HOZ&E%/U;;&
MW*&W(%7UII?O#E+?PJE.@5JM*(UQ!JAC-F\_Z21<G/#!9HL&(>@!1?&W@D\S
M[?3[X(%\-.4TNKGN*M4],@A7) 2XC T"?"Q$]6J9;N#2LR$&"":81L"1Y^MH
M+O'[( 6YD%T@BHR>Y@BU,3P;5,'__.G]+5K+&+]@1](&4C8)T!8B@H$]BCW3
MBEMG@,B+-5R  &QJVECA0NCDPOOCCP+%<C'Y*E> 4$_FY[<*C9W85!I"30Z/
M,$!1V7RH>FT(I$5*@2+PV/3B\>2F,+%1AZ<H-;U^/X4 VW#Z88&]<,@C7,JJ
MXS=+5#T,*9M6-ERM3+B4HB5L5QE]8/-<B6W)OE_";T5:=JX>*9&H];1 :_[Y
MELI$6_7#I6TVRH;C"7T(V/H<#V;,1? 95Z>#%"D;ABK@:E&4;VPEK9D\N -]
MKG06W/I(%KV<SY%55C!8/+AP8GLWDNY113^PR8$BF:$%CG&W3DI(I/\:S?%7
MB-,,?OH4Q0)C@ @KPV4T/BM50 S' (E@WSO08I'J]7PW)SBW&K+/7KLF3 >)
M8QJ88-HH#S ')\UQR@,0;*7SHW( L/9]9^8$,;^<UO"!C<,3JTP1#_(% P+=
M+^51H2<QX@EDP0.0QN5JTR4X13$T1"<%$Z:AIH^I$BS-5]LZPS4#Y]-8GB [
MFV=1X$2MD-CS[(50J$J6-7",DN"H%DDDK$5^?N>M?]X@P8["GTXS(9Q>$&::
M!$<,F+#.A24.K-#: 73U"G0R#RGIXU&"T.PC@!NG%]5:,?G&GC WYJOECG,Z
MOS.<='MV$1>17A[Z/NB %/03TM\6(4/^C2E:L>4@'RX%5C:**WHO+D5G&)>3
MN"*6"<Z.I-F\0P;]TP4)]Y$R3@R0R44'% =D ;?!M:+D,D9G73 "M$,(<S0V
M23D@;S\)!;-/XP"2EP'JJB$: 0>+]X\  ^40\?YWO%Y5=:PTIH2;>8/)7(7'
M +4D^J%&JA5_F>LJU&+_%;.@K-]";9:U3%DD"UHS&\R#?#KTEF!NT,E,^.%5
MTVCT%+O)Y6/%7<\WAV=Q4DZY&83?NMMS\.T=X""N5 T"]Z0>8&K,PPJ4DYXJ
MK>INED.>F+,V*B80C(K1 LQ^/P<_XJBC*42^^LH=]@OQWB]6/260EXS-<9S/
M8,6+JM0 *! !'[F8VKZ*FD7^1C4V0$"H+AH#],[M.@/T=ND:=*1J\D9W.O:G
MXI5<%LX!WUO^6T>40I9=R7<BFRCV[[QR[JVA&: 3L.T!J5T8D>ZXTHE=R2-!
MUL^2 =V>A.?H\0A[:/R)\[L,D!OXY052-98LIJ<0(JW[R ?@/RU'$J"$ZSP$
MU-H#8!@Z<U9_)195UCS \2VNC01N-\83\:^YPJM5?4_Y\=9OB"T[)=-O<_Q:
M_*-Y]7?_"1]I%KA\MPX2DS!3CLADYY 4L52CCBQ.I&A9Z_@_=+D<MRB@_FEZ
M+ZA/XT*1OH<G.Y.4WO]%2E[JG *+VEZ.EZA@ZC%D=P\02($KE^92 2/"AD3-
M!E'RV44/%?CM3]%'P6,[V(RE]1'ZL>O9UBWDG"9+ERKV2]60G>,5NP89G959
M>U-Z0"?RZR"9 1*>*2ZLGBT19>ORB;/)SQ^<"/0'?WZ\E0'G$C$(>LE<I".U
M3_SC5.!_RJE 14T;LF0\(5"P9L#;0/M4)W*K::OANO!>$;=B \*;B@ $2- /
M8$ &3GIC(P=4S=]5_[WV]>,-U%KE?$9XGLWP.[%-/5-Q981!B?"E $7,]6YX
M*GV_XEJNIE+$Y$3X,HRBZCU2S=4LWT+OPZ8R[Q@(.)&Q'\3\:L&<PSCF#<\H
M7=R[R7)S/^<VJ5KS_<.Q+US]M.Z*9:W8&H'.Z(_RV+56J2VJ%?E($B%'L*9_
M2U%;8?\E-Q<X[!<[KF YR(,K,R187>TCMZF^P?QXNLVFO.62;\_5USCR'A X
M")@&307.U@R4N!G8U'C4:&^N2&$H8HGJ'[:GX5L^O[0Y7A700S:Q)?445'2.
MHXG*A#S=K9UT:<8J_ QJ3;C%>/L5?,X56@-.^VN+]<<-K5\(D<E+8&I2P$P7
M_)M=%'3O;#5K,P-4EMFB*J;XF<SFY_#;:/=Q^HC,=[ ^W"N$%+";5:*8&G7Z
M=<"-@R@E4X>''0:\^HN&0:5<C91[1=^G:N^@,,JUQ$1KNS@"=/2'BD?U,#P<
MMYO^E2P4H0X7@(M-<%/"ELQKM!UJ*^,6[RUMJ$%_%T9O&V_RX7=UH=LN^#P\
M!T7H9^J%CXV$-:[%Y,VZ%;6%1!-K)@;IJ&]Y4:Q4&UN2JZ=[5OM@D_%P_]E!
M,KM&SJK=%[:@/#$<\*&$PG_GFQ#--/<TO??@W-9%VFETCDWE"O5Z&@/D WV#
MO"ZPELI%"Z9?]*M+YV(MC7*?6)\PKXR<\.AG%X&2A__)WR&+T/?B >X1.\_=
M7NU:N!!G@_DVI_: ?J1"P4%++F'I=&_EREK[FG7'[MX0EGOVLFF><68/4$!-
M2)I$\.K;Q[=^Q0Z@CJ+J56MYG"!62T*B:Q$9X" 5["'N@FUS4W,NB@CV*0FU
MW$3"U 6*Z5!0GT<Z,#Y3KNKE'Y!Q!A7A<[8JBC]SLV/?!SQ/V32&1^$F_;M:
M<]HMBG%\Y',-*$Z$%;'U$%*,U%R 5;O( $6X11>]V)+_RM5<4U6_7WK'*(:N
M/+SN]U#BX%BE8:YMD]!LI.552AZR54_TNFB+J(+N9X7L:!#KE<.7:S6%IGP@
M&0."K^P61S'T81Q+5V9<#UP\!8!V "/[OALK6$I[?!.<6RF7VNJ1_J>F.>A5
MW%G[I1\TQ5$M, -TZ!=%@S"&SM;+\TN[^K+Q+DY-#V-WL-ES2[:V.*U60ZC9
M8O7LHGF2 &U$CZP/_;GI///',O :O3+5=Y(!&AHAH(,1I5T(UL]_#,%C%52.
M9W>@*SDO&:"\ .']6GMLEHK3.0\5'S[&V[H;5;G1'1%VPHHZYDQ5,J?T=W<H
MON5\_;-4Z=V,R;(86104.C;3Z>K-V\Z?C0I->'$H4+1,1[OD.M-X0]B3&^G'
M/DWBQ/SWT,&K^)=;#NU!$2&&=HH!;K_G"P.S3OC<HK 0A99'R.R3I@0C 0K2
M-9"7>JK?#1?DJ/I-QO8 =,PM;P5>47)X*Z8TRU$]8Z8:YA-_6O_!)Y;TK$41
M(^:S]I0D_2,:A]6U*;MK3(3^A,^M\Y15/>;43YM&[% 9H-]S&R/B:(XHZ2>M
MI]ZTM3V]*G%4?0M<QV0)>8^?F%"4XX]!!P;HU=P5-/MVT)UK*NGP;94S5G3J
M<4T.V,"$.'0R!7*0$K(=8U!?6/:B)+/=GUON0^:O<;(WNG?GD3R=@,7C8\"%
M<S\]@G>.(PP__QJV7<G*-7<(U-BD38)/:B<T8%SV%OTZCKB"'37A11,S#!"(
M6GD1*-(*+_P>'Y21O@M==US$U'.-@ F9+3HO!V\-''F+;0WV,C3/%3I<(W5I
M1!55KM]R5W%4<7?&3*$NY.6E0[">"18&R&,B G,4$25Q;8/.9\35$DH]7J!X
MOAO[%29>2*[CK+@R?]CO_6\)E_6&]FD&2(^.\M]X3^>+JR:9X';@\PP0?@UJ
M)X\]2 %3GP!G*9-NRV[>1A0]0$>%=1ORXX:)9L"-W2%5;9!F0;].X HBU$7]
MS/ITCB#F \F4M/6C:-L[;0IHB)3//?Y?=-+_Y2)]N*6-:OC3C.[Z.GW#6F5'
MF]\Q"_*.*RAB/BWRT'](%">Y926>>JR)G+\.%Z1HYVTR0 ++3&0H0TC#_LSK
M+]-IU&ULP3S62K%3S0(B\_!'7''2Z*!#93I;W\G7X3(Z7RB<1'RHI"K%,6"[
M5HZT_26]LN#NCMF:*$0SA_N Y%11M=PDBMMOZ:X5F,MI<+AS1/QH[F=GJ_6[
MKGML:3@;=*1IS:>,5]:TW;':57@?D^N6+T[<2@Y U4.A4/M]*S0/'[;E"A8!
M;H5!2ZT*VQ]_>2,NY<UU0<^X6:@,TK]WN/=%748:[O3O<[D._J_W?JO @GB'
M5'[M/*4$^)D_NW=5AQ_VROOO>VG,N"(1000,2YTL6>BU5]Z14V?!)C6QHSPK
M-6$NZ4)R3CD)PFWNW3"'+8&-\!CHY.>)0P"X1HJL-'ZRXLX/I])G!KLWZ^VA
M(8.O*'@Z6Y-3"I&4%.R0 O59LJSA(2[QV_VU.13@55CMYA&6LKNPF]K)D73F
M)X+?<JMWHV"/W3!.)T9D[.6IOX+[LK"_X"*H>CW(>4I.AX&VE1&I@ZL>??/'
M;2)MM[H9?%?'#Q8-4?3#3[&KD34BMV*\^# J]#W]NT'\G])) LL]A+9UNE(/
M@/JUQR8N$YE:DBV_9X/KW8 Z <Y40^ T!57MFJK=M?+-J,;C<%?%)V2!SGYA
M.1*&^<R[M8+SM\CSECX54\XM8WXK P,L6\YB?DP+67$][5MQ42I]5C/07+JB
M_,W*S2_7?K=T'6C%/DPZ3K#+T[^$9-_;3:5)\M??&\C]B#M,1T5L.\8RS0Y;
MF4&9]Y3 .HA8-]#8L1=9LCEQ5R^Q8B\+B]'RIQH@="CHDVYP6QZLCN'E'C'M
MG(\K1Z3-I!8-G?S.;>M0FH@-X0845*X>W[I<WT-!X[>+HL^"T=]<QZK%F(L'
MEA*:X__,#_TS&1S^Q3W+8];V#L[T -]ZP(KIV=$C/9&NO]>V'&&R.DFKGY.9
M1()9Q$?EJ\A4OVOWE,(K>OL+%T COI>BK^["%CV8B\9D(HYS\YYX[<E!;SSO
M;5S >:_B%TS\Q4UOK8ZST^+IW)1#S</01IHP<ZTIKPU9B<O:XE+S89UW%?UH
MI)OZ[B-F$H=].SMU,40A]MW"<P9H)$NU!5X'V) R&]'\?JN>7&' N>RE'KZ8
M2K?H>.)2P1VHZ [T"),6-&O5_:KL\80EH^-6./V2E#XT^#X:$4*VI+UZ^?]4
M<8E59\O6!DDHW%K/]G1GLA?KV&X97:]CZMRB]_F,T&\U#S'SZ-\3^_>3M:BN
M0%@0^^!KP_.ETG237XT,D,Y@.05./U9%@C:20FNZU<$\K>BMRF^9"IC\$VK8
M!?C=;EO3.U*=BQX1R9OQ\+<;YI$3%C@MJ?5HV#2ZT6@X?K)O@H5^SB^D<<&%
MY QV=BX>>/)FH,/W!(=^Z]TKVNN*K8K;2]MIM/=>1L,&#:<?>[5G+B5^<.6\
M+6LI11M8O;L#'L#)0U3H[2@>)(>+QIDEI&158H-4<Y8S>ZM+^Y_=X =!Y^#=
MU:>;_*R)[&SJL^FV"IT:9*OL-62-.S(PM@[/I2&?TY2JKV/9N]E>8[FN::7H
M[+[ZZ.)-NVL=S,\0;H7LQ)",H$+ S7ZFCA<;&O6#-ZJ]6>-L.^\+T]Y^=4*
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MCCRD$,2QJHC3:F#@"N.BM#!=Q=(KZJ';U2PZMA,D_@53B= CKOVPW:+ : -
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M*-U),";OJ#QGK$YL$/7G#CW\5XEANZ8A%((J:5N08;'3_)L-$H6-HQT)ZU"
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M85-ID*0SRLHB7.UH/=_*6O_-YU[E19A#<\))TME@4G%-<#K26U+G-DTR:*C
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MSYH(40&GUED-8]L 0Z_5^#W$#T>I0Q<1^H)._M6=(W>3M-X7'^C5@8H?H'*
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M(&8X@.0 D@-(_NN0,$O/3(\/SY@T7ZS<JS.80ZV.U.F]_?9^R8.<@I0;DRD
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M[\4\D60O8IA/J%YY[?-:OL3G79X4R[M\@*Z7SH#MM!>'#H>,S\G(6]IAN=Z
M<*3F_U<E[J#]]V__2RH!_E-:7<1<P)H/+HW@ER&(% &_]^@/.-GBESZTGQH<
M9W/@9#O3%1=\'B@<JMO";I"X:@F!8&*IS1)/CIJMY/6:M,XHC?N=P2H3B_2[
MWW.L%Q,\O8.$?]$OGSE=UO&Q[7V",)^CE;&V2%Z-20)4N(X>!VDN+@6)+01-
MP;*GZ=%KC#EN47R=K1STXD\<'$Z^<)8(4QN3_@EEHN6[US'.<'XP7.,D3.#K
MZV[%G-O* O4HI<K:M'Z%CVO:ZS]U0BW8?DQ<%BI3_<85QR]^B>5CRE-M81U
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MJM$1/^;6\! -GBE<'7]WO_O>U(7/'XT:;ZROZ-5:.DCVQGPU76_4 4)]=)S
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MW.+9_F$G_!LZ$)5 9@S3$-**)=^P01&_X,8L:,:_54M^#=.!U(.O.U?E^^C
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M- ,AGV;!D[ 6R;,'F0ODR8"@1O]DAT>HVL<&A[(G=B_RNK*+Y>8^DS-K_4X
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MUT(1M4H-.YF-,X@K4/!=M*PAJ)>(-_JH]UQX<W@0*[3W#3(KP+#\ 4)2 \Q
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M<?N-]O8ER;/&P3E"$/?(ZF\_*1.=Y]@HJUOYYU>P9E7^?^5??*WS7_K4>2M
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M*^M;Z!0J9C]Q%HYU/VRJ7PZL%]D[U902L2AX$$\1B*?=SE[(IH;: P'W0!!
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M4!*&T#G^BQ2K\PL].5:G\72VR4SNBJ-6>W_<K1E+/8C\G.&2WY'830&&PT6
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MSZCKY$^,'#QP;=*I,13F5NPM)O3\=FYP7V[TC:_VU.MQ-Z([KO(E<2T:2;&
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M-@EUNC",8+UWH;_MRJ>D^)]F9TP,O:7/_.'BFXBU@!^9!=#9P^C_/F=XS^#
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M>=<!GAP)$9Z "<6<(4(0Q!#YX!!RO:W9G0AOMP;, ]F32M*.W_;//^#E1/<
M.VC*=-_=7ER67.VIL49&#2.&!T3F=-CY5'G:KQ)5?Y7]2;%X^0NI=9+/?-^]
MC)W;-$5FOY/#\D4*\AP5C]TSZEI9G?O^7=STED%5YT9?R,%G@[GWZO^\2@ V
M(I%=4Q(4QJ+C0JY\?_!$-5OVU-K.D;? &K?]]? /R'\A(/()"Z@M;'OIGSA-
MN9RCW.*0E3Z_54_SV FNM3WB'G\K^4I%3(O\J<4IS#]=<17RY'\Z=6DB1L1C
MY+[RHJ#7L);G$<ELIL%3#Y&C;<)R!L8'_I((^O\DKZ6^L3];_C^, #I_#7@M
M*ST,>S9UV4IKP5:.=C948(E:#WM:)E-F #U8#JSCOE*"F-L;;RETV<'FIZ/_
M9]ZYOR,UA.OT%_=@RD,VO<@<O3>^DGI@.)_RLKVD^71=VJFT@%NU)_76EWOV
MFITZ[6H<*KI#FYF6]G!5IOBF)FPTV8\OMF75>&,$WBKP<D>5+?]*.1&E_T>B
MY9N&L7AU<J@U91D[OOD?1I\4[FO,N6G=E3?9SC=0E7.SS;4\9?M\4^V@S^QG
MJT1+^ZL3'#&QETZW<*!%_\I3K3IEH7D7_9XY9 ^'T95.]::V$'B^NG\:%!1U
M2#I0X?)17O;6JRZ>)Q8<Y>R:;IN8%E>^'^@#H)4EI2_.YU#_AO6QGZJ^J@?A
M*H%%S=L*FPIKE@IK'NQ^_S_=JJK<BS9"15+ZEI:)]ZCP>%G/L^F1N=\Z!]EU
M!MN%1$_+ 8!".1%VR=CH&?(PIN4LQKU/&!4 AN:[@A=^5JLZM(T(GQ^_YAM7
M%VMJ^XM-S_VRU,S])\XRE,BOJ;"'';^U/=P*>\[9.$3<]^Y?^<)0"[KI?BE'
M\EQZ8]IL*)SB8)'I+HA2#C_(]2O<T'C_X^T]H^1U'3C]U 3SO3GS&H;1C934
M79JF>EZ-H31TAG/)A*$AI;JL;P.ZPQ*1&U:-D+!YR)AF =*XN;[-RP\QZ0CP
M!)+^@LH"7+NV,2 /"Y!?6@4C:AF74G<K_-+24\$(W/_Q :_! F(#P&H6<+:A
M$PO:_&0!5(CJ7J%5,3_4J(5,X6T,W0^[\[X5T0VG2ZLSSQLU/0_]KZMF4[=3
M=/SC736'#6W*KDF7.ERI\XZ?W.#(%8T4-1,1:&:[QG <K)IH@MM^^DBHSN[<
M&3>+C?!^_O5N^T+ YR_&QYJC]QDFE"+?7DHZVGK\7:E(5<WPO%M7AF_-ME(Y
MOFY W7=552E]?&7*-%OR]4V<]'M.1XNYTT#,,A+C@:38-RP>$+:I&61*O2M\
M;^(O$ZI;OIA[;O*<"-<3\ZT[HQ*SR]V=@1E(;&28Z)PW[23]:II=UDQ<THNK
MMS1!]%+T*<S02)^[H_W%%T4JPT?7IC/7 C>'=-!QKK+X0\F,F.E(M4@L"X#=
M8P$?+K* +"ABW[WXC\\.G0C*-[@882XK#"(5;AJ!J6M.UXKKP.TH3D%BJ14-
M1;'DD:^8#Z_DZ6E0Q*^ 7.7;-.[.@6GF'L)GF@%3%J+O*V]8@!J".8N[R<A!
M$//QPN \F1?)LR!UH.]AR,1DHF+V+S_?%9D]YV\:%YD(ZG$&W'?7XUI',"7;
M2",,H54IS PBE 5T+DZR #?"&(QD_Y[:T+K#_#23[-R:+?8 (U 0&%(\WNVQ
MIGW^P*%D&66CW[;<[(!PQG<X7'<F5^1-5*G]RR2%U^->;_R@5*(4@<\<R?\1
MUTDNL-<(]<1/4V#]?>.PF0.$KM1H_'&*:&_7:.>GZUO4:VEI?,UQ\9]7Q$S/
MF ?PHR^@A!D?C-0Q+5I^JW@)^ED0M8.+'=]<*7V3>2<J>A2F6/#9WM+-9^]$
MBD#XI:L."ZM=J>.\+9A*_YC2QHODXL5DA'E=H_.^WS55Z<07+PX,G<M3V"./
MMI$$W-.<IB1'#!6IZS.9J65MM[U),)[%K<"IEKV%7A4*:?6S7,DMTK$!I^=.
MXWZ3EVPR_[.>ZH)G#YO)CW&J'V[<';&CS-%RS=,-WRW9,E+O\:XF[%QN,9($
M;<C)-^'Q3.$?C0=+O;8_W:+>>^;NK3KXR4:5T)\6FE$[*U=C3-QQ2*)?AN*L
M&[./(#R3D]52/'/@C/&]Z; [;NZ_,B9-OB+^"D!CIE, $OY3J)YS[W<C\2X2
M=TCJ/O##VK=><E?6@<VF"0G?WV%K9ZQ$"J7CE-SXEN\>8=]RUINE*%-PY.WV
M4ODM!*-.!RE-YZ+&OL0Y3UHJ]C*Q O.E!],=#O_N-+^FDI8I'=OYY19?[/F1
M<0+E*GQ<W 6\3,EH0_-2?BUE^TXGO?OD/-$3SG.N)F#?=OO;NQS)FGN"OA2K
MF^E,HK\2*!?\8XT !G;"F'KA@3<)L1]\8V4W$F+UE%_ECJG]FN_SI/;R&IX*
M8J9Q5QX/VPR\7!V*+SA(G0BI8*#8DL@\4DX5=G8AFW]7D1"ISN;F3E:\\.2M
M3VB)B4I'3/GL*@.!ZUCE *'H0;'$C/M?IDP_=FN@PMH.A$E>:6MNBA(Z5)]H
MJ$+-J#F[PBT3(^WP'4,Y!X_'BN-/AF61$$F-GJ2?2'L*ZI)TA 'O?%+-8H1V
M;M!CJ]O/;J9Z/>0X(JPNPP>$(^AB9\[&;:6 U@I)18D%Q5H:S8#K"4N='8AT
M^+DIE9#<W"UB&NG- KJ4UV%,WI,WL[.6.2DUWR[UB':F_M*XL(__7C-Y.GM[
M&KQ;V +;D4++88B=72S@R1S[*,+#'SPBWM+W$ D+:>A%=#F))S1:;GFZ#6Q$
M\NP8S"M^&C]3$GNH1RB6UD%MUNMN1D QLT48+>Q5CXA%8:@"S!_$@9"LV@'M
M3\[R?8)5I0'-H;:]4K&;Y@>2[V]'8XBID.1 *7TP#T?E'J;>[&SI**M]G_>0
M7"Y&/6NQI80MB'P)31W8?*[P#Y6J2'&;FOZJEQ*9O-[*>IE'\I/-]GQX$,55
M#7@X_-FFBV6T5WIB*A&Q&\^=/88,K?:]Q#;)W%O':S!90":&A\&&^[8*JL:F
MGAI9HA%+S^FH<A;&VQ^U8,(UAV^^I:%7X8_S!!Q:IRFV4&IDH^M3X*V(,18P
M4[#:H;X_#-,VO-\KJ^9[K\Y;X7V7O^W1.^W.(!_WY#T4^TTWI!032Z#8JV):
MIP5+#0_2SJ"TZL 0G6;;\:<G1@0CL8&MW8I5S82GX7^'7A:R-41"),@Q#;KG
MHTXRTE#<1FG>/*[>6U8E7@X>FMO"/1GKLC1Q+[91]<%<>2;/3\KT6:K[4F)I
M6.;..'P9RPM);<]MZ_;$/]<Z_%6N;]L[WG7(/U+X,0^61_#$"=7$T#3I%T=4
MU,2_QK1F/^LH;?>1#&6DFTBSO]J?_@YO"KGKD3D-)^:W7,WA$[Z?FJCG,Y=&
M:3\Z//T@P2Z;>6X<9'_O11 E$--VDIOZ7H84X6(VFS3WODB4Y"2,NT7MB>!,
MT99]&=A?@2$FW/\:BJST3]SHI96I&CIH=X3]=4OO'U5GGI+^SC4U=?@[D:H;
MI^,B^\NNM)K7TE?17I+SUIF'^S<.$XYCB(_1AR,B862UEP;P\C'\2W3,]XJ?
M*G%K"8@O!-OJGZXPV-S]V/=W[TU<G>@..JHD<>52%S9/YV\09#A+RM>LW /@
M4(1*6$T3L_=CBLDKL2L-FK O$$+I S;@H4>-N0K4N,X^,21S^_(3S[D!MTRM
M[A 5PDNS6(*=]QJ.N2\C8$?],5X']-O>=H!(X,ZGA^1C-R/J?M$3\W!#YP#Z
M:\A*_A\I_G01&_+V0]6 ;"_^.]K)9GM]JZ_V&QD 92P@!UTV\DN7+IRKL=O2
M>'69D_3RBOJ[\N$<!2XYR4V/*:/((?@:;B@;4*9V,;G]=]]-P;<^@M6A).L(
M*PJC9%C\HKG1^_ #%08,O%:5UD<.HO"#.>\M?0+$Z&[P,?-69'7MLB15N2U7
M?3"D]$27=<*B;:RU4-C-M+>TFUVQFAURRG&G@)-=VFPTU1":!4KAXX/"3^ ;
M8D.8@_3;K/83"6^4V!6ZD2^F*5=6Q]M:IJMT<#%&HBA-/%+RIVF)ZG+'[^QW
M%KG$-Z<Y&U53IRK#OUF>3ZW7O!"X"J?\LHF&;VC3C2$O3H9\\^#()Q0[9 \,
M79R1HU,4TL</WG,Q;P_ O!\.:8@)"81)?'7;HS?!0?\2M686:"RCV\D"XD(1
MW!"HWN^*P=DYV/YH%/?W#-N_C1O?T_7']U37<Z3L$-6?+KS.Y%'<;6H&RA>!
M!AWU2@DA!RZ0KV$O6T+BT//&_L;C<AS=@=)^7ZT[)Z^G1"+,$/Y]?[7\$^%;
M>S$,?N5?-J "KGDU#BZ$N.."O$+U;]MMW5EX.;5]VWX^HM2C9B1#Y>;4X$/8
M(2U.SN=DO1ZX$["(F-G$<"#F[,'=FGB+<.9Y7 *!^!914QN-\%$''3"4V'E7
MN0'$S 'F#QIR:[EQOS_-?.Q>./I*O[NLR1^]A;H^/08&0L(+(*0OSOI#@8DI
MM(6@>Q%T,,0*+#=]/X7 %.6B'\3S4R#NQ/]DE&\1EE35>-6K?&AB?5I?3'_6
M1I!/=O[NNFP,+_W'GO;?2G11MTZIU,[55"POPAW'?]YU9N7&IR:[7V(+OQKK
M0E.FKAC,*M$J[Q"L?$)ZU/GH)VN'=8X.CUP8V"AH^)3#7 HTWQ?JMB0B##J0
MN%JF'\.ET4?00[)J((,R,-,:MNZ8P P7.W5FW')Y22PX;,8F_6KWK2@?N$:S
MI'Q^'NP''#R2NM1S@X0<?52%%' D^<?9UVSO7/'2;!T?5S]VJX\1,#6Z\J/4
M!].BCC; M,XQ,H.]I2=2#5PIB9@;KGX^#6<3^*MRZS1$S^>6"H\\G$(/8FKO
MO7$_53"R1)WI2?0D>Q3$6A]:?O8C5M*"%BH7;1HF3A<.[7(]R,AD 3Z)V%BF
M7O^*H8JALY1GK9/+Z-&MB K#B<,M"CD37[V[(5H_F0?K1X!'0NDO_#N0N]M;
M4Q/PZM H>C#'I_<BW%G V/"?-EDC:M:60-W.<B]IG 7<GIK\+9XB6(J7< D_
M,NEN&(RK@BAR>NTV012S)$'8,3H&;C.Y$VER=#CXBZ8[":9V&7%74_=6U6\.
MO?[9&VCH<^CJS+$Z2Y$ QX;0/%CA;^C?%:"_!K:O$(2<[.T4S+(%"C.W)&O8
ME2830/&M#^"/8DS+!;Q^F%(SEL?P5!$6YM%[J)2Q)"'WE1I?]H?'(D'DZHCD
M24,6(,P)/\L<@9" P.$ENV<094I!6M9];W1^U^EW^;3S>S7?$,5KF<EG"UXH
MRJ_,U*2?>"8YJ8,@9A*J_\09'9K71?"%( 7FC/BIOQZB;[F9#MP<F!D^F'3C
M>9=4D7"AXE-@GV*4Q'7 J :LGJ%AN-$]:*WORR>K!PRE(V[#)/[*EP>[&B4H
MKREOW0?UT<<Q+;K,$XD>A@SG-K1<7/N)&V8V*ZI9WV0+CQM.ANKA1K'CPDP+
M\78"32P$P5!,QTM"5CCFV/(>Q0L^\PSAN>9\S3M1Y.-GS;)DKP=/4XC1ID $
M"Z +FY!A=#78F'BK32 BYP,8K!N'T[Q[NI:]6VF1_<S=B-^-WDR>(3*_>4<-
M@1?-$7;7>GPZN;KH7:[VJ4,.^\_(8 (+GN C(K'5 02*-:TX=8RPU0EVT! +
M=RN<KEELZR.SP^_5*I+DIZP<'\:-'W1F 7M&F%)OF#R)5':2S/-Z"J'-^4Y_
M55<G2/\U[2\+.R.9O-2\L]Q5"H3#VG%<\[MECHG%T]R-ZF^[?LW?/S8G%?(A
M][5>:9JX$7@QF_$(U^T_#F->5B3:[#!^L( -"UP]"_#K2X8X*@]SFP5(@BE3
M&'G'^EKFE_['>O[5U_8D+*XDN")I=SS89Q"Q%? )Z/G>OP][FQ%.[&.S<*_V
M*W]>\K*GYAAFOF @G!C*V:2\FV4:PGBO@.Y4Y9E0B+9X8_R+KOXT+?QY[8B<
MZE<!/U7)\I$ X:-;R>;W*=C1N*N,0LA02A='T"(HB0JJ60:I,R6HQ"M3^$M_
M%W>P:5+!UZO&O0=G[UX(2G(H0J&IV\OY-#.4RE C-ZEOC&:5:D'0L!B10K^X
MFW7<\*Y* E7+58__6=>QNQ(I&VP[<90WI!,OJ!$SN%B4YYN:X.4@F]@=Q4F)
MKJ;3'J,L(%SZ6.3@R&]QNMB;=H?Q[?;51[*<T7?E:#*UK8  7^6W@_;R> X5
MKJ$F[^\L@)B$.2#M F)(F(?CK]J]9&5>+=SWN01_N91A=-C8@./YBM'V?XHE
M._7Q3,U-"QJ)@&O[UOU\[PPD%=.%VHY]C6*<Q:5N2T4A+J/@,Q%P=M#&E+*2
M)=3V;OZ$[:BS61Y0WOY Y'K$D=*$#@HR80D52F3 VK/=XK67;W;RTNYQR'2I
M>"WV_7CD:\LE2E*/QK-1,<DJ=)<R4/?L<*/U;KE"K^SDI*#>/?*5168!]YY\
M:]_?=\K[%Q)44:>_H+& T18W>@'N.KA."T!I,5ZAY3UD>:A)XQ\6QGN+&N*K
M%H6#G^0_Z8PVM5_77"JM.G;B7NXK]RX"\>,K9E<?E+XY4]<RHPPSMDY"XYN!
M$@./TK1!Z1:CP_CAFR/!B9ZOZZU\=0J2M*Z=(_/!$,H)6_Y@1-_2.@LX#1?$
M$',@O5J)N$X80Q)90"KF%B9.GP4\9DJ'>3L/XWR5(E[2EO5/WGGQZ.L77@U)
M/1ZN&5?HAODN4X29\;!=R+\L#MJRT72AX )#>!% "\+,GD^#:HB/Z+ZMZ5K'
MEZAPIG]6K1)V4QU[X93W^@23%W)G)45**K,ED044)",+(<G Y GC)6YOI=+E
MF((_Z$<9;WXQ*FF'?\BMTYNF7!EO<O!NY%.Z<"<ZE'&CA\Z,VW2L/JR?&JBE
MZ8=P278GS,BDTA\?8=_L3$CA)M?'GGP=DGY41%__5>PES7WOC["O.?SK),'F
M!X("@HC=YB4AP&/BG:5.WU>KTN@F]P[<->L:DA^'H(]==&?:&)Z#I#C;_)5S
MY60!Y<\Q\RJ;F[@E2-\?SJ=$,#M4H61@Z89+)Q!KL&O&C;S00!QG ?V.BXO(
MT56FM0EQFY'@A-RM6R_;@DPGE*_2"]I(VPST[IK_N0YTM<,L;@D*7$<#P"86
M@,1#^;V_W%CV):1:*Z@YPUD4[V97R=@@$:G.:M5!*D[VYD1'%.RC9TM7$?+<
MSN*6 >44K@T[YC]S+]Y3J%W8N*K^^;'EK^N=AU^4KRJD>,_B0%7,@Y7JU&A7
M+NK9_>%/YK(')J[M'Q(BJ4G/UXL@BU4C;],D0=((26FIE%+K5/W$0N"!M[O&
MI,#AVM,<>61F]ME!MJ6AKK!UXO0#]%$O*=/5))3\F[#79,MU_D2OK8N3B1@M
MO[4/Q)1[2OXSHJ,C\>C^Z>KMW2:,9@A^1,JM0>.1/YG2-]Y-E"Q+=7YP-;_T
MY1[_G)%MEXK>@C%750O'O8]=?!HEMIWY0GJ#QR!)!1P 1/_JT.S/3]?$T44*
M6PC<OB_*&H_.G!0;L>4)DA7D33Y=25?X\%:&!8BX#1/,\0KTX!^&G#2C!18@
MVN(9[.TK3+OY0\TM3#:2&EN;G!9UR]T].<!8KH8?K</LU-]>EISQ%PW#DE;;
MU&,%46<(([D1RDWN=I69MX2TBPV9R"Q#I);&F:[<YQ*_HXSZ=YO8HD0Q0G1)
MRFI[SC$Q:ZN6D=?2+P[^=?19X2GR24%;9LK<#T_R7D".+I(3T% (JL3&H&ZM
ME62_'7X]<,4VW'D4$WK"W/=K0S-SL12E0Y4F9RTW42\W&\E1T$TTP[E+<SN_
MDFK$SYQ2F].S%'E_Z_!&U&+.EX  XU/%7+L-B*C.ET!/JG<7G-W03F3<Y1>Y
M.]SW1O")1JE''\>"!*97M;TD:,[?N1HP+>Z$V4%M&YJT#Y0S,E>:1K;8=ZOY
M@C8LX/HM%O!]JE&9R7MJ=\Z^QHQ.0-3RMC9DA? 13G]1VXJAL2LQ8S?8-CC#
M5Y>Y*"G3Y*X6I$08SV_RDMNUCQ%A91:?8Z^;M,^&\A[*EZ_;V\33"/W%,B>1
M,%;;,CQUA#JTV8E],^FJ^C#(V<DRX/S7E(4"6R&V_02EI"BMSWFP+^K1F&KS
MCE7PL._/[3;X8RP,:T>9<&T:JKK[];N@,]MLU2>>;A7?J(G EKYC5CPTK1D<
M772"J)LB):%37.K=O.V_AEU.%%:0;N)X(JFW?1T/XM[3M<K"K,A_VE3A+K%?
M1MIE14>6R$W1_!>&;EG*AWR&24?K\A%COL>X\E-MF-RI-".Z3>P]Y%[<PQ!N
MMHG(F1?)V$R;0!CDIK/ZP)8_!^@^@TC1>8Q6 FW,*+'5Q5._,CK&[7)*:B_]
M,JR!O-1TZL+TD^@Q]IAYUT1D,GQO%4$<$BF&"&+>.%<K2#^M5CX#%W5U'&L,
M6R/C:QO<^!O[9"TL;SXE!\PNW<@I,T7W?&<S%;'EZMF-DS9_-?KB6<#F[C*'
MU7(Q"3L*9_(<I>"VO!FYRX:BI F,8'>):=%/%RW/&HT>L6X)T;_9=B?)_?CA
M?VU><H7&F*.%D<T4I=LRGOGH](G1C2C;CS?CAG"'O)?/M9XL.%*RI^RW9',>
M/X1^T"U[&/'-[R@.CBO%T1U+O/)MQI8/5\6.*Z$"\38Z";CW/%VC(UJ[>Q5!
M<9*Z"-V8BEU6)TOZI*]VX$(8.>[N^E:][23/7]=+4(V"^R_B?<0^P]70152N
M)5&:$9AAE=U*GC&/\W5[9K%>14-6G&]T4U8PO0KO)!B@Q2:\L+L- \"CLEA*
MS^D1M4UU=C![I\<FO9]TX4XLA;/6\PH_WD>SNRU*,V]#P!2(G(8"H#8TA65
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MM@ZX3)7Z6!>3!T=6AX.9 Q?Q/ZIZG?X>CCF7<E)-HN?.#[6AM!\7I(PO7 V
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M05I4>@T*@M*EUP1$BB*"A2Y&!:094.F""46*5 4!!25TE!8Z"$@OTCL("$E
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M5M(UJLJN&9F/8>KKRSCT#@$6F@&O-J4T"W^@JIW)UR@OX/1DZ]_(.T183FN
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MC1?>2L?3M[WZI3"G7$+J(YEMF!A$KV28<)S6'QJH3CAHD5YK)HH? LCOY%]
MUO9H_D<_N]#_: Z!;+]KYD%\,SLZO&USM.7X;P>* Y:;SA$ENA>LVH=.$V_=
M#/>0\2G17&ASF8TM?EWQ0Z3#690@*D"F8=504?_"56&[A=KP/ >" W=\]FL%
MT>ZS5>5?$2<=ADBAS:;P\_X+0UAD.X*36&F>?*9JQ'LV9L]5$+#_I)+Q(!%
M_UG4:MF9?)+V#*9@"/RMSHH<5HA<GTGT)0[Q5^_.O7*>T(V!;$4#L @84O@7
ME V"*101P7O4;7?G_*S\63L%8X [1+T^];9P3UU8>AWX#VQI1BG5ULKWKZ6R
MS&+9>6W+:B>4TTES'/.KO:L*>%-!J>.&MUH9?%$CJ/\9R94V A<H6@N\H3M
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M@BQ^ZR55_OO1 7^1!V_]XY<MFT:KONC"ZDGZC^4>QO"]O &W7L"@F%C+]6B
MHHU&WT_@"#?DPQNYL6AV8SKS W R8U;KH.%1M_RM,CE,!P7]\V#O/0L=.\.Q
MW37>BO%U6+6@FFCUE^_2,H_TOIZS/OG8A7[)DW@.2GZ[$HQ8J\D[!.3M<>^6
MW!KU#F0_WJ4EJ]B+OEZ9<$YVXZQUSIW$Z]RZ].))Q(E> %D-+]D]!R$X_9?
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M>S:^U0A@SO2.VM?,Y$$%D(_A/(/E=_E\[#9X)K(S-J=9+F]N-\9RB3QFW6#
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M.#OY"G[/C/(.@2E G@Q"?/IEI3GQ(:+RTZ5)WT0IXV7K- 4]#W599%M3QI\
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M'[X6_+O__"< :CKR;"$^B@2H__WUX\W)+N,?U14_+L6C&MM[D:<9_U22O/Q
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M\EQ"FG-&*68!ASQ($$11$D(2"Q<&.$$18E[""='S>\[V-3TGI8$*Q%<U@J(
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MBMP LCC@*DN5G FIDH:1-,:1#E"0.$:[1R?ZF=H+N0,3*)P]0[1/\:HW(;+
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M F+&(AC2F,>4(!%R9A81U-';U%R59G%Q _+<5DX/@G6C@BS1-DI@D %C/>*
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M'AV@>CW: D4&2<HL4#56&NKU@7_U^,J/BEK:D4_D.E]G\X0NLV4NN!#/54J
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MS2)Y<;-D;7!,Y 0!BQ"D?NQ!)/P $NRIQ>HP"AS'"RE/M#\)9[N;VF=@ ]A
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MV78"N@$'PE:VS $0CIM0<SB*#W)N#MB5>?[O3X*M\K1\=3WZD)8+,:<QC9-
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MO()ML@6DP[C.WIEE'H?>1!N;0I/M-,M4CK6OUIM2PQTV WJZM]IT&AIQS\W
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M38;EXGA'.OHFI?!.&WRJ\%W''6;:4.3E_*-:.JH*LR4TQC02B9RV)[[*-)Q
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M0D;C&#J>""$2&$$<A%2^KUX2.$A$@D<]7=Y3?4[MQ=WUX%[D[/.S@@O>I$O
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MR[)XP7<+H?ZC_M34='H0U_2?Z[S@_$<N3:M^*:N":)\E\5Y7?;AG(A4A]K&
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MPRSA'DS\."/$2](H26>O5>//'RM<K/2(9Q!=3=;=OL;#+<&OJLX]"+=GME>
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MBV9+C^_&FH&!.7!C1M<;5)8<;.CW*P-N/Z]FK3F@=4>2+O!U1)P7J3(JF;H
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M&B8F/K>9^*GQ=*,@*#8:FCG%AN#K>;[#03HPD;>*@S^EYJ!5?:<J4POX]_.
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MN%$YA/=\-4,>(2GFD@2DHP 1CF*8!MB'/L(A$L@+,B2=A>4*SW6W'4?E&)'
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M;-T)6;8<PL[AO6:LBMK#<W7@<K>XP:_Y"L^;'O<HHB1%<0@#C&*(?(HA\;F
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M"6@46.V"_(DT-0.I2A9@;95T#RBET__]TT('K\S 4FST">J&_/BO'NT*KYM
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M]L0<(%;1 @Y?*6$=(XV;$G99Y:.4,(M;>L0PUFU!=7Z9.0XB22BS(&20ATQ
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M/4O-B*?GU9JL7ROJ,2V!/Y6EVHV]-\4JJBK$)@3\B_C3_$LYEU$8<<I#*,(
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M%J-.SXAKA#9%;EIB@UINQV-/&^3M&,DSF@/ST248Q^GVYH"9)W:R&7%4;G*
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M"&&9Y9P$3N%(5J-.;3/=2%KU%"E:\KHFQ-A ;L?-WH$<F&\;(0V$V[^T11[
M,><$DK>L&9LQ1TZ?<8#A.(_&Y>:>FQ>]&=*%R 5__Z+K\%>%Y8RWT/S;?O-U
MP>=QD-,H98J2)%&;DYAED B)8!S0)$[2@'/I5DG<58*I<=2I8ON5S^_EN2F\
M7ULLU?'XM[L[T&CC:(XZSY:EN3GD' QM3AI\*^%!)7U=CW/6G$.TIZ#<0N^S
M7F=?_'Q9@L[CCVOI]87GR)+K_2#WT(4OJ^6=6'T1JYOO#R9BBVU>R&+Q>D<*
M[A#Q>.$Q4R,S)2[4(7]?U/^:7*;]35HM/] *.$=&7@*UFZX\XSDP,?F%TBD$
MPA*D7M$0EYX]6F"$I9+M& G;6][&$6RRFLI/RXK4+J8\S:-()B0()<2YC" 2
M D,B8PG3+.-9(&A "'<KT#NR!BZ+=9R:OT9&P;U4@!G[=1C'LSC@%/^%_(X5
M"D"])8VI>65J^NC.R9[S.!'7I:OT?RG'9L^I\>WV["M&S\:R8E/5K?Z\*LLY
M0R%C5!)(>" @RB,.<9PC[0%E I,X)TS.-SJ9PN[#MO=T)YM[.\: AJ+8-(WA
M?]+R.7YG]I&C(B8HX!D,\SR **$9I(P02$62X3R)6,:="B?U1VZ,W8I"KJB1
M6UR+7(YID#$AU)N6*'.*HPQB'&&HFQ3G<9ZE3&:.78K[8C>.L>/UO;.S/GHC
M,O1>S1H*]^:_IU3VU=5W[]GCMNL]I=91']Z3%_6L?5LGLA9B6_T]HEB*B"$8
M"?6I0#P5,%<?#,BB6$8!13R)J<M7XGB(J7TJZDS,NCY\2U['XK?'6-JMW^L0
M&G@1MX2[W&3 O;CM6=5]U;0]'F#<4K9G%3RJ8'O^RGYK^[TR,;\K\_2[T%GL
MND#2O7K0^]43*99S(D0F$A) B=4G&=$(02HI@C*(HS!/0BR2P,6BZ1IL:@;.
M3E;0" M^KT1U3%7MA-AN\?L";F :Z(69,QW8@.&)&#J'&I4B;)0^) NK>WKF
MIZW6:E>ZK#B(O=[O.L>7-TMN_KHPF]ZC"N]AE',:<09)%&"U2XHE)+',H4A1
M( *U^8Q0Y&;K]Y9E>ON"6A70Z.*8Z-9[4NQ8:!2@!Z:H0X1!6PL3)-#6 ]0U
M^P>MW7\UK+[R['K+,6X6WK5P'>7H7?U ]R/N=X_:%<COA%C_LEZ]/']<[A:C
MY?%VQR.F9DO5H@(M*S#"SL#'U6JS7&TLPW N87;Y]-H37 /34Q=2GIL[6H+2
MZZ2ZZ[FCG5);*-<^H;:YO,="7WT3"\$V@O]J<J#$%S7[UDO\U,V36]RKIV>R
M? 6-J*"6%6AA'5;W2: LUO6U& V]HGO!X[:*NR#HMWY//G&\E=NET-Z:[;SP
M:F^G^OR;V+;'U4+=7U9%<YM"TG,>I)@(AB%.$P01%?K (E9_37@>92)F,4O=
M=C*V0T]OX[+G /Q5_.M?9*D;051BSXQ=W5;GW_\MC\+LO^M_[^U![9X?9[^J
M-\S'\[9NJWYM7@<I<>Z*CG^';/>P;^6FM0*CPWEK=W]/WTRQ+#;B<_%=\$_+
MC7IQ"KH0-V4I-N7G;2L:0I(LX4$"&9,!1"3FD,8\A'D:T31+TS!%N:,;QF+8
MZ1%7)34T8H.=W* 2_(K>IU:S8.EW\8SLT"X6#Y"Z.U$<,/+E+[$9<ES7B ,(
M1UX0EWM[M+#_J-ZO=R_E9O6D^*[.^A,13E@64LA#J2VH,(0XDP)F@L4ABG.6
MJ+MMN]>?&&!J6R4M(MC*Z-"%_11XW=SA Y+!7;%M-"YG0MK!XM"7_DIX1FI)
M;_G2N/6/[U"]LW7\J?O&ZQK?(?5>P_BNZWI0U[O5>K->/3\6R[NUHHB7)7M\
M]TC6#Z+<.2#SA%-&*5<$%L4089) S$4,M2D5Y$0Q66[5V=5VP*E1V]UO7S]]
M_/3A/7AW^_7^Z^W=_WSZ G[Y\!G<??T /]_\]N7=_X!W_W/S]9</WQS6MPWP
M%C3H&<[!'4:-M$")"RMY02VPG0^X'Y(.S.D9T9&8]-Y4J-D4:P%X4;+%ROCA
M=&</ML/\66&^J#!GE4K_Z8ES'4#KY&";YXS'R0Y:[7&TRWW]]L'OM/0Z[D&_
M55^+\H^?A1KDB:S_J&-OXE"F.4493 56YB=/,IB'NMVM0&$:X90Q$KJ$-UT:
M<&J<O2<OT *#K<0]8YTN8FZWX_6)Y.!T?0V(SOM<6V0\[7$O#C?J_M96^<.]
MK?5]7BMY5*4H3A>'"'"&$A$)&$0ZRR9C,21Q+F&H?DOSA,4H<Z(>=Q&F1D97
MU?*XHLQ<C[F+!*5IJ#X62<P@"M1/..4,IC26*24Y(X+U:#0XT!2.WUUP*]^H
MLV+W81EVG0S\J?&91MOHU\JD';PHBP7*PU9EZ1)@"F59+ "RK,MB\Z1^'[M/
MR^_J?5JM7W]9Z^2S,--Y/W$ TXQD$$GU(<LQ03 +LU!PFI <12Z)0/N/=_I(
MC9 $M)5N!LQP;JQV )T=8_4'9& V:F%A1/-''Z=5]D0-!P\?==F?5NQP29^Y
M:N3**.8_?Q?E9LLIX3S%3.V*40XSHCO/2)3"/$(21I+E08A2C*E;/SN/PDW-
MGJVEJ^L@CU2_Y-2D61I&;S05TS>9S!^@F4[OIM( N+]UI9!3HOTURH!T@.JM
MQD?7&/TX_H;]\Z58"]YQA']00^2W4LB7Q>="BGG.A$0BBV :IA(B)A"D/(]@
ME @91$PPC*T.KGP(,S4.KR0#"R6:&X%?-2-VA#T6S@,3=*,&Z(X:.E'EJ9Z<
MSUV3XTS'/E#U1+]7B3(JW?H [9!>O3RSQUG_IR73S6K$>U']></86NVM?UFI
M09::P[\*2C9"UZS)@AA1HK:[80J5[8L@":(<RC@38<333"!I%T#I-*[+TATG
M@K*6%#QL107K2E:'\VEKV"V.^X> <O"]="4J:&169F<-ZTYL\'4X6!W._H>
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MS"\[\74A]T8![2 P58&,#G6V[CCM(J[!TU>$31\1QHVZN0*DHTB<:Y[5L^2
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M32B&8<(Q"=* I*%3-Z,38TQM#U&'/VVTI."Y$M6QV/0)(.T^%%?",S"3&^E
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M=@764_V@C:_F:S9I]D6Y+(O7[_GBH90;=+6@WV_D%,^\VIAOON25D' 8,9%
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MC?:^%@M(2?4=%.L2F$VA4-[(>TF=4(WET'.4#0GRP&1Z4%FTEAX6 DKY0:U
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M2!^#(C5Z>/>3S3 H#LPV+8"UP%=@2^3N/VHX'P>!TZ#\CW-81ZH$Y )>L^I
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M+^7C0K-4]V1_)YT&H_Y*N*KM_7_M[V/@$^UP*S[]P^U]UV!K2_LKT.D/6@!
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M;NCVB>1E7:]7$M7JI>FC\IA7__I4<MY=0SRJEL*(!TDH8@IQG!"5MT-@RM(
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MMT.WMSZZX9#C53BWTW6G1KGE$!;?D+L%+;D<^Y8W_WNW:-KI<E:;MVT"P2Q
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M6-6;JJG>47_>?!/5_3>RZM(7/I*?BZ?MT]UZTY9/O%__4]2;P;UH!!E$0L8
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M98C&$.1%013:&0540 DDX4D>$Z3PEAW:[]1T?26L^Z[_U$AC5&0HBX$HLPS
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MBWA#X=0=+WEO1>1BI8[X^IS$UO6F=>WT;^B2>>O5F)_;9A1$*G-6)@CHLSR
MJ"A!D:N?2)%*'F<E34IUOM=,GE.-P4MG_W^,@)E-OQ[7P.;\D)5LX KH8/M(
M=($KOT?^<5@\$I6=Z&1RJK+SBIXB*QMYVLV.'X1F/FUU9/JS?+M8;M5OCV_W
M(4$0D52 M$3JP(^2 E"9)2 6"-,,L90+*_I"R_[GME_LY-Q%,4$?Q3R^(NA^
MQK<=(U)RBF.6 D:$VK\+B #-\A+$,L%00H2YSC4W-_\AQVB"=6&68V2V0 1$
M/O#*<136;V77R_$Q[#=1IY&_-<01.4^+BVWODZXZCM <+D>NS=C7OGRO-%5;
M,\UTHOKZ]>ZG]IQVA;4^/#WK.SL+UN7NO)2$,ZR1Z=3XW):A3HFHUT+OU'9Z
MZ#EWJ(EYX4TW\,?-VR2X!S9PUI!'?WBMUG<UADZE0-UZG*QDZ%6 #$N+7M?0
M=5'Z#RMU%A6J2[&JA=KHK_OXJHXM%Y+@I( "$-K4A4$0E+':?R..18EBDL/8
MJBZ,2:=SLW:[^+1HQ6T.^FXA^U&L[>+XOA"<*KC?RAO]I9/XKS?14.CF+K/_
M*+X)2)Y#^Z-=ODJ\WP2$<TD 1N].G!G0;_UN.5_H5\BRW?W=;C??UI7.%GD@
M D%:QA04:9$ F.$2%!PE(,98% )FHJ3I)'D"EV6=F[5K@D]=C3<VC$J3G0I]
M9(KLE)@HB<!@Y .G%/@=S_DG&+P<HU\T[D_4MY>'?[I\ _.!>>WL P-)_QRY
M".:0>\M,L.CRREM.W9)7[RAF:$HES%&FO@1])9.1 M \)Z H.!=9EJA]<FH7
M:CS;U_RBC2\YE[VLCA>3CF UL]=>H IL;8\Q"L+-<Q$*WQ>'COIYG1M"Y]0]
M>Q7H[ MNEJ$S0_7]NJ,YOJOT9GCS2]=MW=RNN,YY>-://*1I7$B>2L!B0I2I
M4(?FHDR).D.7#**$L9*RAY5XU-5WS4R%>>=&$Z)L)\10A'#SHI&X7O1^JN=.
M\B8:+GJQ'<[4%@-B9F0\@SR-U>F%UE6<.[&C7NZ;IG2SPE9#O1/>GRFR!\R3
M;;+H>%)C90_(H?5R:,$^P/%F_54L!5-3_Z,@];82MT\;T_C%J7?G=H35FTJR
M4N>:3M*H$S6Z;:[>F <C3@)U.=9P+4:!388K/%:Q@C$,G$(!)QN<S-,_IL[0
MD3_ZG*N?_KNH-XU5^/QC)?A[H=XER]8S=T]^?EIKCL&5^+ 13_5#7%"N=AT)
MP"5$ "9, DIS!DJ(22R01()9L9!:]3XW0S 0_B9JQ+^).@5Z?[0F;-(Z1']H
M+:)&#<LJH78#9.KE#P1[<'>_9\0=7/\.R'F+ =CT/7$PP &6XZB 2R.!P@/U
M.2?1YV?]9*W.?XN6:+#N+[$<Y)"\^RDJMJC5'FO!Q -$,2D824$>E]IR0J[Y
M:CC N, HYBD34MHY>*9687Y^HT:![KXA7R^7I*HUM4T;0/!]]=#W!^$IE/"*
M@SR#^$)](<#0@="DL_0PO%QD/,'7TX,1-6A,&'D(-(Y3A2-\BS^O&$6@P;$.
M7(22PVT-[:A72UT6G D,$$YT9?!" ,(% G%!4@GC,LY$:I.@[5!@<X*\ZWO=
MQR5RU3&8S.S][+AG?=/)!B&*?0T*V'%RUZMH6_51OYG6]9NEVD7=KS^NGA>:
M9^S#BG]28V7J31MK8VZ':2V3N>ML%)W++C1?P(2>>XV842.GWK7<+]0!=[..
M/GZZ^] P"ZH_;%6'33'7Q?<%WRH3-0JDE9/-!"4G9]MHPY,YW4S4&SK?C)YW
M7$GY?V^[D^_]^B7[0'/D?%AU/$7-PD\/-P=?1!O^$E]%]5TMZ>VBWY51U0]H
M5B[Q(-($(HYRD&M^>IA!! C6EZC2LHPA07D<6S';A!9X;M9IF+:V=Q;IPL"6
M.X+0PVVXUYC1((:VI'<?WMR</BB^[*ZU&655PYZKJ=7>K.M---#)XQYH(N!]
M[:Y"BSOMOFTB\(]VA%/UZU BH.?R:LS<G9ITWY0,.B9\_V-]_VV]K<E*E]W^
MNOBY$:(OR(,RE%"<,<!XJM84J-:4(H,Y$+),)*$%1F99T,X2S&V12.,$13M:
MM$:3J%>ER96P8-UW&I%QLS\)SH'M^*M#;%'[(#34$Y5'<(?<KE+"-7"-%E-P
M:GBZ>@O7Z+U7DN&JAAR9RHFRJPNRU&O1BBW4DX]-<*Z;+ 7)DSA-8Z ^LAA
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M=?0B[KJEW'A>+O+#8K2NE,$3+QVZ 29K*FFP4M:>//TJL+2<#*P,EJW$V@M
M',\O8+HJDP%W 8"'@'27Z4(6I>(41=,)3DGK:?*N]GGYDX3T(7%8&2J["[P7
MN%EP,! B*^4C)Q;*["#*@3B!'"2? V-&>/]LJ\#M ZP^[#@5PZE7";('$?>7
MH0_#T7 ^A!GZ[LV-VHO)"(4^*W[\_,>M:)34&8&=B%$<#2*U"?DRG&@;,M."
M:JUJ V13VKKUAENOY&I%1;VP/?<X6TV!,6%I4LP2P9MFB1%(L%80ZJ/R-'A<
MI\]=G=\1;KVJ]FI'_^M!MHLJ^@&KR?CK.4PO/T*X/?-W7("5T9:^:&C9P:%9
M=AY#2H][LI0R:_7<_?FM\/28C-X :2<=KT)G1W'W(&2_*1<Y\3]*K<CMP8J(
MTD1N"443323+35\2("*+'(*)E,GJ9Q-/4M+M#M<2;BH(O1?F!OF87D,ZG?SP
MHWLR&E!T'VDI:0S1*EP#QI(@A2[.9+(R8,3!:F]A:TCIUL=N#SX[B[T'IN?@
M\FHT^0%P"J-R!^6QL 84O(:D*<E<E7(U-*,.Y482%\X ),-M[:WK1:*Z3?VT
MA*BZJNB^0FRY0CY/\(GC$J&<0D#&9@.ON6J:DS"%(8D$;C#,#:9TBF7..<.=
MW_"V\9HW=)ONJ0R/>K+LQ7;55+JM[+G<XLY:B@.,DAB>,@Q/O0B!R(2\I!!8
ML+4/MYX@H]O:KY:,RJ[B[G"+:H!_"O/KZ;@@?Y)FIZB2Z3<8:*,@6 /EZG(J
M%Y8#L9IBN)D%<SF[DE/=R( \]?1NB[;:,!X[R[ 7AN.FT?C^Y#(,QXU"]B?C
M,N "A53NT0Y1,\O+N L9_K@-!T.BE%M?[&,F,N#FZ3DK@QQS-"93S_ES'7>W
ML2_;4]MM15A+9NB-E-<#AWJY4S_AO7%;(@ NB':F9"9R)EYF1ZS77IOH=$JU
MS]S7$K,1R*IW<GV;D&Q'T??"V#W!@W9>.6TY*7W<B/1"$:<")=1P'0SU7L;:
M\-D2-ZQZ/]>V4XB[2;L/YVCWDJ!/'#0+9D5D@I/$1+E:1!'Z27E"F;+ .,82
M5M;&SK,4]2:CV.*11CV5],,D/<G/0/H@E0='6 RE^A]7H,4E0EC&-0>N#$JO
M70#T-"4='VY4U/9&0'J5X'L!H"U\P'OL4L>5">@&NA21W8@&V0N&__1HX64V
M3+KG.K^]D0__2CBV9^':@^/;J;$'WGQ3975ON[C'B4HY1.;00X!0FG QY*0T
ME# 1?8UHJ9-0^T[(>FHZ/F)I#VV5%- + WB/C4'P9>J,M66(7D+_$A*Q,5+"
MN!%2<1Z8;+&>J3<G<F]24?(J8?? F2_C)8;S9BA :61S8UQC824)P8#&,C^<
MEQLMLDPHL9E0YV4(#AS0YSI@;M5%:#TYO3F':P]'M931"PMT#I=EPL3TQXJ
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M+URNY_'7@^]7,$8V[M_DLPJ %D8H^H@R$R\\(U9GE1/( *;VDEM+3+?E*&U
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M*Y6[]K4#Z6UT%%V[(+,H%P@4<:84*2060$9**:M]3?$),KK-G[5Z5K6EK'L
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MCEKYX&?#.+"4T21,)"D+AMXKRM1GZ4ET@DK)K%?5B[]?26*W2?W6C5ME'?7
M_-W,O;NY$'\*Z"W&X6A9/W4C06\Q'N,I$\YUF2>%JPHC="!"*JU2CA!\[8K;
MS2CK^!B@#<2UH))>N&&K?"W6"V 0[LK=5%9&2$F9'/&>><(93P*"\H_F=U='
MUN:6J[6D6QLZ?P%6KQ=_#U)MJTQ\'(ZN<3<>(*5&494(RY83&64F0<E ?-#"
M"I6#B[4;%JPAI=OD6@<XVD8%/4#2WV'X]0+IWD,3Y[_"T77IJW^<'UVC7^[J
M7$HN."<Q*W0M 1>,]]83<%0P'H.@N;:5>A6!W1YOO@'JVE-7?[&X7%F/.SN
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M@EBFWYL%0H/B7D0@*9>QDA3=+\\H$!4"Z,!YUKRUDY=58GIR3ELQH[R3N'N
MF_OTWZR@S*C00A-/RUU8E$(YG@&4D-$1K,QVU7#LGA-\1$5/\LB[J7<U,;B;
MK/N ELGX&TSGI4GNPTX/2Z,9?!9H+S7NOK8,K@V*N*C1%F=G,@2F-?75T\G/
MDM0MCG;5^*/,<CWQ]^**^1/C<6G, 5RT)$>#\LEEGH5AF63A5# J>9166]O5
M+17=9FS:V*>V$W /3,YJM=[A^!PNKR93/_VQ2$B<3D:C3Y/I[WZ:!MQF+:EB
M).B,SA]836RFF11GS9M$&<^UD\JOH:\GF]J66'C<;JP=Q?0 ="N<[/OI]$<9
M2-#,XMF;SZ?#<#U?])4Y:60_4."X4"HA1RA."0K#4,D<,3('!EIY7G_F^6N)
M['RT<$MX63W]:%5Y6Z/SJBD^QD4XG;>!T<=7F"G/(FF0).> ,F3,$E_: &J.
MCJJ7$)1K&9+;73-O<P)Q)PC<336]!5QQ/ ]GLVM('YMQ+8OJ^K_YT34<P>_-
M=V8#17V(-$BBK:/(J4W$X4?HO'@F301*H?:YW#9T=CYNH!M@5E=AUSG0S1A<
M+,@[#JF,S@>EB3.\N$$8U%N%7WDJ*/<A:$Y72EK6I$JW>GWG\PG:Q=X;Z:47
M\>SK78_$$OH7R9#@FG1 QL7%/) 4@^*::J=8[61;.WYCFYVZ^^HWOD9Y.V[C
M!^,Z+4Q?=$UD0AF!9<08ZG'-190E^L8H4$N9<8[+5+MG:16OL<U6W3WQ&E^C
MFI[ [;'P'M\+N2\_G:)0/EB2)--$<BZ("PE75'"<VLQ2D+6S?Z\DL2>U%&WE
M<.JIIP=IG,?,#)B4P)TSI'3]10XH$)]#(ME2*EG4/JG:^^VZRX']2<145/JC
M_/-.&NA-['NOIG]AEQ?.ZT!ZX6..E"0C4#:@@02F!3$.64(A&25KCV190TK?
M4BOM8:J&+GH#K"=*M1=,#:BWE@7K2-1ESG:4OK1O"<0S915$D):]08'\@IB^
MI4?: U<=?70.KR;H?N(*[A-13&F4\M#S'"1IA38T$1I*GPJ.:RJ((D]D'2!I
MR'EE;,::?,BV%/0M)5(?;V^GH,ZQ>'>QZ:9%U>Q\LN:64[/6 LJ\:: !XUFC
M]%-85/O!&4R_#2,LLD6E2^S7<?.4)F,Y",('%XU$VU]&.4 NH9$0)#JF&%,J
MIU"[TJUMGOJ6>FG/\/8*'3V(71YL1(LM:%GIF@9"TY $<T0+'DJ-JR46@ST2
M5.GL9D(THO85S&?(Z5MZYHV<@QUTTC=X-0ODAI,RT_Q7F%],D"?OC$;&"$@#
MR%-RQ.J ?H]-.;,8D*[:T<TF='4^D:T;P-70TJYCM,[KYF;6'0$UWSR^:F9F
M'GR':1S.RA+CUCN'SC?S%LVX=.A\E[I\XZ( "31X7;NZ]/54=C[3[6US.^UI
ML =&\KGS\:<9C G="%F:K&;'B12 #%+M20@>%#?<F>IW_EY-9.<SW[I&:"7]
M]1>@BR5X"C,,)N-\62.^5\3Y>5H:PE.K6,PQ(X,<N90R$Z>$)T"]H)SF(%/M
M?7T[2KN?%M<U5FNJLN^ O1ES]C"\&]B,_@U3O#014$3B%D&L-)$(<)([SKRD
MM:_?;T'F9E#]XQSJM*C$ON/TJ=6(<LTP+'/5M-;29LG1J6FZL'I#G*8.'1UD
M5:&OGJ!^%[]MJ=T,M7^(8Z,W4FGO(ZS&^WF&W^MRV*%"C)I;1;+WN+=PKXEC
MCI*D9!8A*I[,&X5:FY"[&8K_$.=3;Z747LS;WK!,-"=G!6.,:*^+#P2*6"6!
MN,R#81!SJCY,M&)E+WO7YU@MJJH7%;V;E<@'@X)R&"Q:)M"[82BT0(,C5F3#
MD\J@H';19+UK#>P/<7Y47U&]P-_'X;=A@G&:/;SP/? ZH$!T($Y22:0KMKS,
MJN"!*Z.XE-K7OE>SAI3-,/:'./^IH8Q>;*Q;W0/2/OJ8;2#&*RCY!DF<$)9D
MR025G$8J:P<VK5WE8G^,XZ&VU=@+$[C1:!TN$H9B#)>@15G*J 6Q5D62C''E
M9#91)RN#L]I,)/:'. ZJKJ8>I($>SE%E5BOC'!";$B,2A5',O"<0HW.&2A-3
M[=KQ+>;7_B%.;K87?"],UA-E[Q9= 9]Y+GU2$Y&^5(Y2SPDHFY4S46O>RIG+
MZR\>\#_.><KV*NC)_:EUM>XV!A6""$27^Q.E82YQVCK"$@])Q^Q4K#WN8Z=[
M!W^(<X\:RN@)KM:7N7OOHV&4D5*-0:1EC@3E/%$>?<9D,PJJMB.UV[4#_H<X
MG:BCD([1M5M1.Z/:6>T40?^P[/+*$.=Q0864C0U&9Z564AI=W#K@[_H8X>TT
M5!6*;S]D<CEG>/:0G1T'2-X^]*V&0S[-1?W!C[<ONINEZ[1P"@RQAE*$BLT(
M%73>J>+4972[J*I_@+B>G@J!8'GFR712,H#IPX_?9I .Q\<(5M3<^.M>G ]+
M^VBXDX 0B0(WB8@D(I$A<90%<"),R!+02T#/H'ZT^$HJ>]*1<%<$/1$^MJFN
M7L28R%P>SIOX& 7$*0-%N.'H(LB$HH)$258 @4F'GD/MJ:-W;^\60FUK>E)%
MZ#U(9=V[7W4T&4>46=,^XGQ2+DJ-XW $#W(NYY/7BA6<<50J1:A#3T0Z]%,M
M-930I'/P@'X"U Y)V^:IVSOU;PSM7@&D%Q9V72ECQ B?A=**V906\,B1-5(0
M'2FSEAN;1.T(>9>2T[;@V2^\K&;_=E==#VSVQ^5K%U(\]]]1.AB5^>_[^.%P
M/ALH;5-4.I R%A)%A*Q8D0Q1)DJ@V4FI:ON8+]'4K<WL-2BKJK,'\&Q._#X"
MOCX.%QH>I[W+R70^_-=BN07JG9+HN%/J2\*=<^*,$B0'+;617FA5NX7)2S1U
MV\FDU_"LJLZN&\'>W),]'*/X(LQ*A3>*+5X@4Q_A&XPF5\V<\.]E<X"!I(P%
M6^;HII)DY08([A6,N)0YX!?&YLV&9;WNO=WV.>DE&MO67A_LYHW(OI0T[^GP
MZ\7\.*,T]V8SF-]?<3?\,25BI,H1#N6&=XZ&>"V*;R^#$YQ&7'ZU[>@K:>RV
M44DOD?PFZNX!G.^S<)P_#<<>)3[^6CH4%/_FXW 62P?=V4 #DV6K(-S@']*E
M5)JC"I)TXIFQI+FLG:;:E+9N>YCT&KZMJ+=K]^!FCB1&AP$Y*KSM3\9%>F7H
MVV0\0\E.E_J?>ORT4<[^1?GR<+QH"7V<U_S*EZ$/PU'30GJ1U![8K(.Q7I*L
M%T=UD;@8<CE'BU99*'V!-W(OWI;N;ANM]')5]!T]/=@//OOA>%8T K-CW-,*
MC]?#V<7BG.<CA/G  #@A&"4QI3)10J"K5BH<LJ(Z!D9CJM[T_D6BNNW;TDNL
MMZ/07ER :'ROP\LK/YPV8SXO_/1KN1XD>!31!:)UPI6F-2,H&4XT9 PHD%B1
M:[<??YJ2;GNT]!J-%537$R-99'<\1@?J:K(897V<#U'+XZ]EP&?#)CI5V6NJ
MF24IV8 KRPGB&<8"B2D70F IV]JAWX:D==R;I=<8;4.[O;";CVO4;D6X[-%Y
M)S\:!0B+S*2$O$EJ2!#9$V9R2#G+'&1MY&Y.7<?=6GH-WI9TW .C^YBSO;@(
M7E'N,/S6C-LU(K.H/"7>ELLFD8>2?5&$.R-<=CRR7/MF[29T]6UF1!U,O B]
M'1744Z-Y./Z&0I],<<F6]ITZ.!005:8,'_6!.)J  *7>6%.<Z=KE!,\2U+=!
M$F\$M&U5TE.$G4P!/>1TDU+F/E.FI2(&22=2&46"%8&$I!EPJZ57[8/L(4U]
MFRGQ1CC;03$]A=J-B3[Q/QK[''Q(PDI*@I$>(S$TS59X101ED*20W)O:S5!>
M)*IO R7>>/?<1C6=EN U:=;'_)Q.?OC1_,<-.S1:2QW2+VGIUFIP!7G**%$6
M3-0L14M7+AFL2:N_]*:^C6&H"I_ZLNZEJW^OZFH0C;8>M"C7EU(9"*&(XRP0
MK0QGI120F?;'#-XCJ&\C%-[,Y]I.)?TS36AHI]>0/D_P#>,2UY]"P"T774GN
M7(P6HQ,>* ;B&;=V9B1N]U8&58JF#-_*1*U[8]^&([1OJJK(OG^00@L,\^OI
MN' V28L*J&\PT-PQP8&5'KJ"2%9&/Z']+:ZCMISQ)#3==L][XGU]&V?P)CO?
MKG+ONKIAE:7CO%PCRZAC=K\H?F^<FLK/V<#2R+A$$4:M2T-QY,Y)""1'KP,+
M+G(OMH+69N_OVUR"]J'6@EYZ<7%F\YM+@\ URX8[ J*XE31EXE5$!T"#C4Q&
M%T/M6V.;4]=MBN*-[W^UI+3M;>$$UUR;<"P9O]D:04K&E&?"D<2UQ6@G2A(4
M&G_N?:8*10R^]LR!UU/9DU'D;W1YNY:Z>F$A,:J^&76X*'6_*2F#1:^\(H#;
MT7+9X>K5(A%3ZALD^JW$^R1(<I&% "GF5'NHT&OHZ^4%\&IH6;T WI;B>I'<
M?<3=HXH%"Q"=18GEK- 7<8(3QZPO,[<]-=K9;$7;6-RJ$N6MKVF_&0!W4E$_
M48>R1*]C_N-DY)L^1*7]4'/A9Z @4J,B$&=*_U"A' G.!D)9F=&1:1*V=JO_
MS:GKI;OX9CBLH[1^ +)<.H,T^X1"/O,CC-/6,Y=\LM1(3L"XT@8D6N+1.2:0
MJ(7HK3*\=J.C5Y#7[;G76T.R);7UX#AC<TD.6,B4T>R)B$V74PS.+,L8"%(0
MT7KEG*T-R,VIZ_8@[8WQV)+2^AM1WUX.>T*0FF;F)9-$A7+T7!QBYSPG,C"3
M('"FJD]&?3V5W>[@;QU1UU)7/R+J>\:_].5%SJ#<L;IMV3M0.1LA Q!C8ND
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M[V[5GD_]>+:@K$3K\Q\W+O&L%#U#0N$WU<^E([TM,]ZS9,0D4SKR:F3=JDQ
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M_0R)N4.89))E2A-Q"O^0L<R##+A!9@-<VRB24;GRTEQ'RZ[V:/6Y=P!//M/
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M_'L=+;N/=WOXW'N5?-()KK0EQ@;<J $2L6!Q/]62,Q$SQ%2]3FL=,5T/X*J
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M7L!N?S+"3R?39F["WG2*S$'3=WBE!F%@DY!9XX*B*68B \O$I0 $8LJ:6\[
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MMC8TV(LDQ[WV%8^XO"PCE_[5:'89/:_&S()*IBPCW&I%9-0! W4PA#.I#,O
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M<I+7?[B D&3,NFXZJQ=$1<]BW8.6LZR3GC(8]UB?Z=$!Y1ZTCCP\[GB8/!8
M#B6SL2/ =]=5#Y^77]]\/!1I3'!QX8P7@,'6_09UW3W=Z&@YLFBTUEF =&6W
M1S9[?>W(H^": 6M@AH\-I=]>O7GY^S7,87J%F,^^UE;O"U!!*M2!^5 H#(9
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M,L BSY%E&X127%BO6@^8WI&T!L]=;_&Z-A(MOW9E/]!K(R4YC^114""B$1B
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MX@]YGY -,B%T2"!,)% T:#NZ_\WC5H4:.D\-&#LR+-[!5SPOOYQA,PD6N7
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M3?$BEBB];.T('T?QN U0/2CJ8\4X=@KI YF7^629'WF_W$_ZVVQ^VXEZ,WV
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MY*4<*+M9:T9VH4167[OJI5XEHM9'>8=7%UX%40)RYGP=1UR3FE% 9.! %2X
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M-H3M.HS'G<$$XO(=R+M9E05<KA^N&NM3U"(P*T.L4X 4BR4 <RYD+-%Y+L6
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MNTLID)"B5(F!%];Z9?P!4D:N4AWZ8FNA@$YQ=#&R[=+68A(N::<A\TB&X9F
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M+\AZ(*4^41@$_8_XJ_-*UQ70SE-,9*PQ6:OZQ-EZ6]&!)&^'W.?Y1'),;7<
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M6N_?W(/,3J[--N@;6DTG-<KX<@%DBV*#VY\U5*W!HS0?H]2@U.ID1Y$>_1!
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M0I>TXMK:W+R,?\_"Q<%&3#2\S X4< <0N=R9\FF^\>LV2U:N2I@FR069F6:
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MK2L:]J%S._R=2LY^<$UU@,;+Y1";_-TZ()U%<API2IUX*]#6HE3%/+F+PEG
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M# &<U1$HY$A7SC9,V)**2E&"49:< %4X>*$2\*(,,XY'R;<#ST/?,.XK5"N
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M'&[WFLC^,K%CHZD#6WN_F,><T[)F-*Z?&:__R(LX7=;]F5(4Q74&E8NJ#$G
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MYI.UD&HUMY*Z3I%!!5B2]!38NBS^--OG=]+DX]OG=Q'KV$]:>VU!CU'GQ%6
MI'T=VJ77"WL8H/6)QQ"US;NM7CW9[?,[J?K@[?.[R'UL8#VX/3UH$;CT]>:T
M=8ITR8#,&7#>2[H_=0FV; 6>D]@^OS= FLBO@ROGIZMV];P46 C&ALL!\O6-
MR27)04A3E(CHC6@>?]^A8N09CNW\D0,%W %$7IRM_\[UII?[IH!%FQBG.QJ,
M4064S@)\(5^?!<T,#X5C;/U6L1UEG:28]]3_[46[[971#&)'?HJM14K?:Y'2
M_**TJ?F;[$-?<)3'V:VXZ^.5%EF6JFZN2*KNH _&@P\A EV BBY7H3&T7G7<
MU2NMU]XPQB,8BYSX)V,+J2C(,A69"6/M1VD\HU?:7=#SQ"OM+HKHX6*]L=W:
MEUR*BQ*T8+*ZHI+D(#VXP*)0G'/=?(3J[FOLC_42NY,F']U%OXM8.\#$D^5A
M^^P?-$JPD%6"F%1-GC#R!ICC(%V.(KK@=6P]1&L(/GK:1;\3K(ZQBWX7'7>
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M'V+B1"/Q/M*ZAT&BCYB[W=%P:Y_A9>SV?C&-N9YDY?(DDXZ7:.LA1L>9LA@
ME?)0F))!B,R*[_B*V9++$XWY^["K@4'U9S*\"5.6ER0XE+I*6SE)@C$\0!$Z
MZNA+$#R?IK4]FV>703 ^CDGN!+?3>:AYL-)BF\6^-P54,OG)#@6PI!TH$TA
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M(3 AP"HODPXZL#S8:V=/Y]Y0\&HA]V;GV3$J#UZ7DNM"^'H[-.KWOO<CAZM
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M%PZEO8_VAL/Q]!10CZ':4P'U]80H<;])A2[OSYB^G"]7$X[1<1;)PY"2 O]
M;H9WP0,O00I>HM"^=?G($'STT3$Q!MB'57D'N9[]#/Y#7ITO9NO?N7SY6DZX
MR#;(6J:@I*@*8!!\W1@A@\B",V^'GYNW-_5]-&!T<IX?K-X^3_0Z$&Q6:\(F
M/B2Q+J8IJ?8W64-&FFI!&$M2:V%"TJVGUCY,31^]%\-#;S_Q]PFEO\_GZ??I
MV1F9R!M2UNQS?7*Z^*-)B1Z#DAIBJIE6^E7=DAE!6FX$!0L,;>NLSR[TC?NT
M?3RXM5)1GP!\9)9E\(KS4I <[DP'-5J*4:-)8*S0*9HBD;6NO]B!O'&?IX\'
MOT8*ZA-];V;O%_-:$5*=!R+N"QG9J_P]G\V_U:S^!!5')AFQ%.+ZL<F#(S[!
M!VV3)#?"-!]ONRN-X[Y2'_/6;:>J'N.5]8/2A*D@BDMD2*'4SB9F ;UF(+%X
MG:S*O/E+R_V4C/O6?,3C;6>Q]WF2_7U!Q_-$L>+6BXQ5;:I4S%0A!57-H427
MK2DXU'2?FY2,^S!\1.=L9[%WT%]]C8N;@^E_-J-+%GEQNNX$KM/_-*<[7B!P
M[0K2/<^3:UWE_211_7;5-'I1::"+WLZF:RS1[4V>Y.K'^S.<K>CNKFN@+VYN
MS[U*46<0@9'X4E3@+?TL6$='<O)HFS]2[DAB-X\D+2"R%0#;:*N+^JO[&;RX
M]^FFEUX8!EJFNELF9#+:=;U&9(X.=,4&F_!T#SG=/$\<#6:[:Z$K2%U="M=?
M#%WV,ANF('J3:]&/!><I2#:U0E:3E4@]^(3%71]XC_$@,""H#M;#P:-&AO#-
M'NS-DDPX@=&"KB&+8K450-JZB2_SZ*V*-@XU=NG0OKI1ND:;5KP<J(^NSJ\K
MIF[MITH^.9()!XNI!D:6PN$0 KCB/<KD."^#AY%[; X;I6FS*;@.T$/_A9TO
MW_WVVYM/O[U^^^GCB[>O7KY[^^G-V[^_?OORS>N/;W%1D\S?#YEYL\O'-R[Z
MW)NS1B6@+^=?OTXOZM#)5[^H$?Z<9['N*+^+6&<D)JOIB@UU(A-+@BY&5W.F
M'@-*PSEK[?3N1.#!JU[CEYS.S_*[\O/M(M<:E\O*@;I5,A;D'%5]J[5D6L50
M&.-9@:1%8CYCT;GU';H-72-O11D,1W<VP;;6T8@I_>5B-:%XN39LOEM\S(OO
MTYC7V[I34MH%HII;Z2BNB0Q\_<$XR:44SJNPU5A"^H)K^*)?_<360]\]+H[:
M:W?>4-1]0*5:V(:#Y6:U<BE<*"XU,*WK"%!MP-F<@643N>7&Q"+:X>4N >.
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M)M%DZ/7)OG57[$IJS@Z1D=UO] ?SOXK>.K_K\2"%\5]O06#(830LC4: ZF"
M,D0#X2#T 0N.<.Y63>^(*!MC/)T$'<?]*@3HA73K&%6**8!0*MH4V &%XBG
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M3TMUC!$2&$8S02D;(L.BOI>0!""$"EQ1% 1=2S;>\C#:ZG.%Q28SP$VOW*Y
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M1EI!$3TCQ6ERCQP$<>L.>,LE=MI1D;VL]BB"R\:2>Q7'TP%9?Z_U;9VU5F\
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MR7K%J]2:41_M!:D1!%1:!XQ%%FCDM&4A.NZ&GN:B^UE[C_5PLQV,3+U"MCR
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MFV]CKO#GCV;"1?WK# )!"Q\Y%O<B371H/:7211JB(FXE;GO[<FSZ>BWAV)X
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MIFC#=RLGK8#TI<\=KJ4*C((5.*W!"CQ4R3O<M&)!0"[H'##C:6190X* FB^
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M%^Y#EZR(F#SS"BB/F Q0_5#^ ,TIJQ_'1BF.(SU?Y.421K-G!?169R=;D:7
ML$*1R 1.\BG-Z@0L^$LT_6IZ,MZ>MF3>L.Y:+_"8D;J=Z;JC<\$#_-N,3@ZL
M,2]1]ZT#W#YMX?DZAW> DPX3!BLO)Q:*?$0EL)DI*=ED!3(; 1NQ)M5<7NAD
MKF%(9@;O8![DECP%18R-0%+9SPO/[Q#3TLE='1^$NZGKA_AQ"4I!/7H??VUN
MZ2^T81\_B7%QZGE ?@%=H^^_,*Z2T<>]_NGT%S<_6+062"/OK+U60/FX=5HU
MLYA\)9>%L.,*_IR7P#8/^N0W5S#;AD1C Y1N.2[;;ZBPR4BLZK".5=8L%/=
M9OZI16]&X<KVOM/:C,(FD^#OO<^R.8S%VEBY,,(#_H#5V">QPBQ;7R$Q^PM<
M@XC/V0PK2G]$X@#LQ3K!DT6.:YB>?Y;8&AM09D'OT'G#@^@"YHRJ"5W?&92G
M .-.X8'MHAP,2-*(/.+^\^7!?&)#2HI_Q$/?3Z>TXG;PWB5X.LED0M+JSL@:
M0OQP>HO2>3=\,I!9UF6NB4/ DGER79X5\Q&%(?!?])@DJJV!B'MD80B")VP/
ML;=4)K( 0^E/64UV,Q'+-:@)J'N%-W:7=*[CNR!TS[N>N&T0M5V.X:S%IB^&
MV0F(%YU]6N@"U=,]\D!,226=:%#U@"G]V::72'L@&O +<27.RQ8UV(7*2(K5
MNFER9A/6?&59*B8PNJV2MJJ8]_7G4ANW:!K@.QM8MG1&G6"+19C1%%"2>&I"
MUP:&IVGF+\+.4A%0O3F0?./#?4E'MS+S(#NI-RK*F(XCA&4),1I\&_R7YW\0
M_2Z<),V A64U\5[B1 D(",,Y^@Y?NUKT[C#3]^)^.8X=HR2^T[]SR(KL6*CL
M,],QI)/D;0J+.6D-\Q?;/H>Y4NRDQ,>!0#,/9#-&37%]@"10L*)HUI\2O9"E
M*LK!G'AL&)>H2;;;Y^(WM#8VXG,+-*F+RX>YGC8OGL,)6\- 'Q\>/%E\^>AD
M^&SOJ?U__>/HZ>'+X?]+5B%;5G[%KT<*8-UF).Y@@Q.M4Q'JK&"80\UN*MQT
M5"Y=7, G$-2.0"1>EJ SST7)AC&GZ%:@>!H3-^JM;06J=4U:>:WR@"U"+D,-
MC$"B"5U1#O?7K7)'OJL'&QH_>KHWL0KH>S?8V2=X> %Z_4E"<SQZ_NCQJ'[I
M7]S1,VN@[5Q5O6>3,:'1\,YA85F+K4#E3] A W^VH+N0%K?&Y=FAND=/;TAV
MWQ)%3S:D:/1(M4D38%Q,R4# ()98X*1(UN+KA!O;2D8PH;T_@53J-)/06LGJ
M] 3CNN@6@;7+T<NI6C#81%5D11;6#G:8?>$@AJ(Y*(@\K37;[>,SC(K]H@+;
MI\FN]"AB8U(V33E_<>AN41-03&$&@UM&Z<+__ZQR)'*I'TY @'U\2$SZA<JO
MU;)^< \LV7)@R9TZVU'OYQOA6,DHQQ)+.LFJI)V#."!G#D7/)(S:U7<PH/=I
M4>FZ!GX#<H;((!2BN8DPN>GR?4NR)-WWJ(U,=/3AB4'N N>HR+#06*BET7ZL
MN4*JS$#Y%#-<H0L^2\5_GZ,O+\--<A'R10D;%_)O# ?0!<PDT8H'X"<M$:A!
MO@0R7<CQ8:V//;9=R"W0-4SZCCBK:V>%70-17WP  5U5DV9CED(T_T[8/UXQ
MJ7O:W(PVM:'-#+:!514PL1-2+7U%!701U- [*HK8D'/5--8JLP !-J?&& Q:
M:K!EJ*WL <W%UJX6J@"KKA1O\XH0D%.05 K:<!>40!JZ\8P.U7$<SFK9\ Q0
MFFH;6.S/&(^F(5"Z65!)Q@FFC?;M6P]DXF<.S[1H)W &S4DDH!0CL"H-XP,5
MMX5W]"3 BK,1C-24HZ,]V[1L\Y2BG^U$' [")(!75^6BRM 8X#TD/S(JH7+W
M/A\2^/3^G*P[)U.?ATN M1"+C^%QJTW;@%?),V<_,RA>"=)) #LV %6["%3M
M?$ONV0/+]D;/C:.];!^(-4<6O5Z#J/1_VJQBNIQHEF,<4L"!W$AB49L%NT;+
MN&UF907;9+UH:U%*-.;ZZ74]5-[=L+.X!#U'>SRT_<MK1"U=Z;HQ7D&WG")3
M.\H26>][V=6^$8$]KZ*X#^KHZ(A._M$C<E>5TUURJC^Z"T[U$]DHV,_?++W6
MT5LZ9!]0"8+_^"(*I%6&/-X%XD/;X)+WF)+U=2*>K\F=-.F?(?&H#OSBQ@OV
M"!6*OD=$,1 9(VH+535+"545I.M5++3)?5U8=A&X4AS=[E(XG;H@ID%!>N!\
M&@_E.#>.T?SAV&AVE>6@1U;HWD;GF4K)S]U4Y /AS<-#3O%, IE&A4*?>1QY
M6B_^%]CP4$"0,/L2R95OI@1U-/C';G >WWL=RB VZ((*%+BT33+$[O6?>D,6
MS]LA3Z>(),('),X)'%W !G_E$9_[6BZR341*3!M# ;2Q& P@Y=*+ :C"!,(]
M_ &250$L?)8M8GNU,T(2:[ 8*,<$2&T*E+3(%=S^9YG!U# .3K305 B>MZ*6
M4E- ]T+;!#[L[+C!MN+%1NF$"V;9W$(',&*%@DN0^LN#Z+>.^/'/V0"_9X^P
M!X8+AM,ZL3/X2.6DMN[9U41)A?%>@FZ)W[E1GW2]OV&LC:W9:_0T?$;8+:!D
MT:JLT++VUE "<S)[GG&45$]Q-8AX%PN-&&:6NPAX&+ PE8BX)^P;X7<DY0%H
M&1AR(>: =XOWLA.=9_K*\C9*]Z YE@O&76P"GR;#(![X$<C#(VS,,*,>TYNI
M%.-;#O?+^ ">#<VL V QKFWD *!.D;6V2\K(X[NDC.RLHO'X;U(T./7N2V@;
MT822I)KUN@$^#._#D+SR@J!LDTS555^6W&L/GZ$]?/.Z@X7-;: _//Y\_6$C
MF=Z;6E^@D__"26!/=S#).Y\M[;\)8<\>.H>!*:]AR"JV6)6@?\/N(/&TH:N=
M_(GPPG7=,HV)!U<1MV.E+4@4OK]58MG\<DC[N0U/V",M3AC*%RPX8XBPEAXT
MB:^74/CI#-WZCOT,\+C&Y<7^3 L764<HR(4,$^Z[J0DI*JX:FUF"E%(O,D%L
M^CY3G(T[Z4AU,(NK3!.&&$>FZ7F1-KNCB:IU*-D&Z*H:GB%?+(Z<17KKSSZ,
MWLKQ:IJ%T7-<NH6N=DG7>W(7=+V?D V](3;T&E&0V39@.M_@46LK9&GU$)DX
M+EV0T)B\B:O<)J^]Q\?<XV.^6N&5V^5SGK;]&2X$>UHW\"2,I#J$G JD>WDR
MG.4U)7-C4DNV+W8#9B*153$IRX_V]'I@O%Y(:ZA/.]<61KJ+)!-\)/$JR?^G
MF%2&@=BYJ%,M:@<Z /TU3BM79F/M'%PQ ]#(#8 Z,PE>=@;RSAC63NBJ7%\J
MS&YI0=CG@\3LP(-L;)=B3O[[4/81K^4E\+&"-42P;@Q@MJO&!=^"ZLZ05H+&
M,!6C8GP[+)/$N65?%-M@? /&I!7<7WF#@@*#VH=)0!.B] BKTKTH76A&NZ2L
M/#W8=DVEEW="]&HU5<1*MPD"?!#^\1LZ7&Y;B;DH&Z0[U-A3D^' %-;/=>PI
M-V&#I@-180<(\[)@*OSGN3X\=Y;,%!8R2[*%8H^1&'IU/>(,AC]Q;F3-U78[
M8I-H,H?%;-SHU\(^G06]%LQ?P965Q/U=?#MZ1&K=8PENQ^(1ZPWK6ZB>@=J8
M//0-W/QI5J.'!',>_:G:U+A%I<FJ&]ID?Z\#9&50@UX(9X3YH9>J2G.!O9GX
MI*BQ :*:Z\; ? S*@,A7D8R<>NL-8SR6_&)^=5P-8P!+PH[G'C(W/MLEEOK]
MP5;S4V22J*ML5S[?^<!CAL ?X[@0$$RQ=#PTD+G6#/.M>L(>94==SMEI%Z&:
MX@'Z@K',+Y4'..*_#/L88^-A#+LUD6'&EGUVANCQT537H)1/.B@A<ZH-$R4_
M%*,J?<=1",:(,V[*!C5\6ASC >W6VY!\.G0VPL?$E493-<VHWM9T7%/A./.7
MVZ8Q'Z9'G+O$VI[=!=<6 :E22D4%:GK=$4Y 3V>\;X9C;!4;W!U*ZB?.["D?
M%/NAE)J! [83*A4PHG4QBKEO@8*V6R&VN3#!0]^23Z6,L=2:))^A,W9M%I['
M.]25RG(_8.''? B6[5_MRJ'!U2YN8#0T2;V^1MW?V@&C0G'(E+D""/!UK((Q
MB+SRLL14H6G1P&PH7&%J*J%F:^.I 7AX++CX,>@L!E 0K$X63]AVD='UH*KG
M070"T[.J\,W%9L YM.)5!NG?H)]/RJKH^P8..D4&I$"44^1%WM@:/UA]</C:
MU9PDGJF[LLE+NDR ;#X'P:T:3=E3L%-$I5@@46,B3E:)QXW@A;S9H)0GI.%,
M)2#:8W\CRZ6[7'&P07]W3OKV,J*)SXC^%X](CV$$=BQ$9"$[J*=JD;WO+?PP
M\3>@>/71X[B_ 8>"'QVQ=39EYES;#$F)2RJ2ELC%%1'.6GJ(FCF!TYG;S+%"
M'ZEC':KBH@7H6J6\GU-.@X&3>@J+7Y4YE=KPRR5(V8U]/Q)<)GP<"-)Z[OD"
M3\5-.3K(GH?Y'\@ LV5][C1\"S^?8(3%[9'5D&!^3R-%@"C>[Y*7*+1D(^Q,
M%9)8QKY@LTW6, 9RV^? E*&R<I$5DK0=GD=,DUAX9>^\K<Z!%50A_[+GPQW?
M*5?ZHK<I>R?[>T?[-\B<H'2ON?JSK#"V?55*[!U3G3AB!G/T5G9L<[$Z5(2>
MALM9)+N,KM_H/VU9M7/.@SC>-\EE9F-6/"F5TEE\&#:=8+S11'[<%^ '0JXJ
M;3$58W/!N F-V[EKU2T661*B"MF<S=^I+L4_6(^>NJ]!F0?HPIT%'V]OMR[]
M<0HD88QY:E<AH7K K'P*VAI:!N78,E(]OE*>Q]78 O=U.31<+P^.>?=N]"H,
M5 &&;"N"!:$J-+!X9YEI2P$^[WX#NQ 2[_)L?BX)\_=#[@=/6ZT"])! G'39
MF*2%QT^PJP!L AU?HU/V0RW3H?8=$IT'QALD+PKO8,MK=V<=S!.]D<HL0"5T
M>(/H%_\O#&JSC7TX3U M]DH36Z%C%7Z@B@IW@B]2#$T:3&%>FM?C]$SQ5M?.
M75W3FG R:ET.2F??Z)5CFP@]-%FZFXSZ-<HVV"YO=X?[L$(]O(<]W,,>OA#L
MX8Y[0)[?#5^:KMOY@O,"*,U=2LA-J0@=>FB\O,5[Y]FM.\_.K;A4/5G91^BL
M%O?CD<P%D83%QZV2K<[/8@HN!&J\$I:NK5)=2+4UDI"BRM*;2-"U^SI<>)0]
M:=*9P9+JSKHKSL>M@Z *Z>Q^S](/!G"M+AET*AD'Y@WU$(\*4,'VO Q]XF4M
M;8V&*NK*IKHH+8=U C>23@+&4A-XPTV5XQX4E2 1MA/7V)$RRDT/JQT"Y,=X
ML0MFT;!SU,,QI$L%W6Q2T H'*(<_I1R3O&'8T]XM/, >T=[2]+$;?S4$B5ME
MHGQ(MRDF*?AA3THGO,KDD<9$@Q?*M<()?6$Q1".^R!I@!\D&)[: )Q.WXMJ3
MMRCH'[Q"4FC@4 *97ZF<UM>Z?&+!#.E\ZCQZ7+R9B,5RUZ#)D68IFTY)LP9Y
MS8X!K]W&]B2UC@<N5F%3!_>L!*AV_7"N$+9*KX 3(POH5P$/%=4.<5-7"P2+
M\DYZY6ZSFTG%.ZXA@46Q[:KU27J%CAOC^#>!H=N&+Y[X#@P=P*?=+#K7S7=E
MA8-QD2O@?MTJR3W)G5&%+BI$9[)6N=)85OLENM;D<3%.O/1BDH/7B8U"<7SH
M*Q2"'Q]U<%D,.*E<%A#N2@=WTD[HZ=:[95^L,K_6P:X.$MIFOU[_$5[I[?[-
M8^&^;OI7IR9VQ%6O[:Z/[/'*\E2UUFR2%+W\MXI:5K)\J$ 5J4(AKFY7@/>=
M=^ZM\<#_II$!XHKZ *_/P%1RW8K.NB 0G3,&</,S4XO7^#>!BV<&.!"L#3TB
M,SS)22)F.BJ5#&K30#7]$L+=OFN;@"C8?R[?-6QX<9+Y &O<E4.57BC)$184
M6&8\E6T.1,C1Z_4>RS[@;*-,Q=X!'"><#OKX(#I36$Q$MLI_9?(%+RV*3$YA
MR@U-<;_Q<H,/-OTEO1XEY$*&@V![PV$-/XR@.0)BJ@%1K1V,E@#.3*BEET]B
M<D.-641KO6O=,8Z.MEZ6OT.CSZORWF4HITI2%;I8- )C.P#:4HIPBUZP-0K!
MN32UN7(M('KF<69R?38[V.->(F15$OF1" 7R.3Y)&'Z%5S/5:QV$H3^;]<9Z
MP,%11\_HA#Z/91).[ZDXV&4Y0<@]<G0X[B_S7]U41>U(P:PPZ4S=$INKHH%^
M1Z;5M=\WAOP$T_^=(G( FB$L<T&!FWPY>%]02^)HW!0J%Z*)@2I KQN2^\SU
M1889@8K%47-MK^,4X0X"IFIS=_1.,-LDP:IYWL G=5T"0_4"=OQ\KUR+Z'I/
M1==S],4:9BZ.2'9_S6TK+?>0@T!+&F>ZCL+43!,I61@C23=1D[IT@)%#48_H
MWHR;,1JMK#O97J!ONSPF%%Z^*F^3\<7C_CH1[#;G)^V55>FQHSVV,W"9]S^3
M0U+L=XSIEM6XSW$4*N;<NG"[^>.Y\;]]3DAYZ-PG4"7P=5R>0.B^HP\AMA&5
MZI1-&%77F &Z JS5D0MF'>R\%Q8!#L_VBE/T B)*EE!V@*J6Q]$D$_NT6[Z\
M>[RG;<6(7=?AL<D6;4[]B_VJ.<R=T53 NLS> 7?L;-"M&N9C5\Z4 5F5.VB
MQKU5-'$@=,_R@GK-DTWXQ&(M[$R]F7T&O((M]!$!'R(3TK;_7I_#YAQT78T_
M6KO%0N>TL8Z;UOL[I8 ?;[T"?E$V'IX&6Z&Y)-!3E(RWK47_9D#WP:A4US,
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MOT-<#PKE6_+>*6;]9.N9]?M%V=9;5W=X& L;<P0YIHHO(J5AARD]<'0HVD!
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M5]L:-_UN4J9+^&?6S/-7_P]02P,$%     @ TCI=6+1[[/EZ P  ;18  !<
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M=RCR-Z/$W7\[[NW[,?.?4$L#!!0    ( -(Z75C;>.1Q[ <  %8G   8
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ML2[=TQ9LDR7X0EI0A9U\?%O$QO/:W:]"$68"]GC$T0#/ W7QSJ!NR9PAH.O
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M4HP(**E'"FE651H*P%P383P?0HJDU^,JZ@63+K.QIIQ[V-5Y=@&71LW4KE&
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MF/ KBEDV39E2QBS\-YPAIF2(J:0B:MH'-C,H/%LH;Q8S&N%JE*;9#85%%+&
M2BNSI)TR3GC $)::AE 8,96A5K1? %(TBPHD$8W["%!Y$".O76,,\8Y'"JZY
M6*,=5W1_K]<?/3H9920,L:0X"8W0A?TZ/3&TA.NA8YX\TTDZ\ YK*YY^^VU<
MWK0Z78.#<4YUA*,\2= UZ*G$G)3-Z9'TSYQ):HJM,OY<5I'@=0[((>")]7H'
MX6'MZ7MG;7/.IH$V9&_0Z:(K!R-S8OX/[FQ_E>YD'--(:@N[25R:,!.\K SP
MVM>$271V)JDR;FT:,DD2P&6H#,8O$C+TLRJS0+2):Q08,BO:1#URY4EY*D1&
MRV9"?13SK:\\O:]BIJJ$A&G:FH8/,BENF,F_2B34()5+E1/4#I/5O5J]"053
MJS'QDE!DIJF]SUXSF5I8!PF1/N%4.8O;A!9U?)A:^#EH:>(GM";[0F*F=A"U
MA&2*#NLOHY"I+"'%D'%KNUTTJH3Y0FN1#DV+>V,0P#)5=1(VQDKR7??;<LL.
M6&/;J\-ZYXK<LJ0C'>[2NOW6P'V8[+:\!VE?2.R15;E4&Y%1>##?-CJ->D$5
M2\-V=@O>=C]KPNMC<$I<[K\*/.&A];IHU8EY=;)E$4ZI+W,BB[)!: ]L@]#]
MZ+6DPN<+FOX<5N_O=;$OL)]PSJYCEL [DJP)9QMS/\/9KK&W\4EPJJ"R,9=I
MDPM8",;.T6?"AA*>";,GP>F;0>,"*Q8SC<-6"_*=@O% /_^]PW*028;-3H;=
M#MU@4[V;'.Z"<V0KZDO!?BG8+P7[4P5[J6D64PX7+9@128N7DOT0:D^$U+>#
M!^5,2/@5$S!L"GBS&C;1ETI>5_*=Z=OW#LN]2GXWP3!S"Q($(N?:7#Q]D<+^
M''.+*51C62$9JH.6V>$"4["63&O,'TICT;%W;=4(+P2_V!I'Q$2!3Y%U,^[0
M8FM>:\!:LR1!+A12C9+\8H<GRB5G*KX3\)B1LP2FE=$RBB#/\(E1DRK]\ SD
M_IU<)I0=1 TE38CIT79NZ>Y*@FV:W+LEQ,>ZD.O=)?]RL5=]EG>,1_9N\V]0
M2P,$%     @ TCI=6%KYBLXH%@  /H\  !@   !A;FEP+3(P,C,Q,C,Q>&5X
M>#DW,2YH=&WM76MSV[::_KZ_@IO,Z4EF9-6RDSBV<S+C..ZN9U,WXZ2GLY]V
M(!*R<$P1+$#:5G_]OA< !"5*=M*DHG+2F;:218*XO)?GO?+5M)KEKU]-I<A>
M_\>K_]S92=[JM)[)HDI2(T4ELZ2VJKA*?LNDO4YV=MQ5I[J<&W4UK9*]W;UG
MR6_:7*L;P;]7JLKE:S_.JQ_Y^ZL?Z2&OQCJ;OWZ5J9M$9?]XI/9>',I]L7\@
MQ_+@V?[A>)Q*N3=YMC]Y,=Y[]E(>_-_^LT=P+US/-]EJGLM_/)JI8F<J<0)'
M!WME=7RKLFIZ--K=_=LCNN[UJXDN*GB:@9OY8QCC<W_SSZ[D7;4C<G55'-$6
M/.*;_,^ISK4Y>KQ+_QSC+SL3,5/Y_.CO']5,VN1"WB:7>B:*OP^L*.R.E49-
M^$*K_I"P"E@0?;UU*X1Q<E5(O^+1WN[?CFD6F4RU$972Q5%=9-+@58]>G]U-
MU5A5R>'!<-1>Q;JUI'!8TBPL9BS2ZRNC8? =MZX)_7/\YU<YNF^5A_MPF"<7
MY\G[_SZY_/GD].S7C^>G)^\^#)+SB]-A<O+SV<7;L[?)R<7;Y/+LP\>3C_#E
M]-W);V].3O\G>?_+N_/3_WW(&;;6O8XJ>K,GYT,_PQY-Z[@460:28B>7D^IH
M[^7P\* $UGA?FU);.5Q_$@J(MZB.GM$MFUK5L\55C?9@LS].9?)&=VWX7S4#
M8;)$3Y*WRLBTTL8F3WYX_')O;_=X<Y-:)WW>:)CP)O>+=F=T_!0WC<3'5)B9
M2&5=J53D%L1'D0Z3)Q4<;*\W\E3/2E',>[&58V$1"I2Z2'#?@!+U#+1[1I/&
MC5:537#"LK#\-_@R4U4EY7;L-,^U#WL]2*;")B+3):*O:JH6-O82EE"7!-'>
MZURE<]Q@N*C7.\PS[</V)@KHU<#$DDHG:E;FDK92)/ $(&=MYDF:BUO4.TG)
M^ZN8Z.4-7@BT+N ,; 7@F.Z$7X$9RER)(I7)K:JF=/5)"7]*Q3B7R66=2PN
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M;!#*@M@HY?:CTJA5MS)EUG7KO"I(Z,<R!V7%94J#2'#08LH%Q91I@?B&G&W
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MZ&A2KWM<RX*?2JNYPQW>A(G,KQ05QG2[]\O6=D#E6W5 ]I(]X&.\M2<?M\'
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MO/KX+2#T*P&A6UWS%%VC@R1GLA.G/^L;*0AB2:JBF,@$/KB519G1IYFX!4'
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M9A6>QO7P_-O=;BUYUT17<7XN!K?]&MQ_U?F9 YN?L0?*8FZ#KV(FWFJ&=LU
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M<XW $#F!J@J(Q</!8%.$>9!VU6=_*.>NA.@Y:B#7=$EP@OTBJ!VL<:5$B>M
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MQFDD S7<B#0]M+LS*J H*2E'R%]K@]HU.W)Q(=,T#D1Y741M7]RF<11$EF"
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M3KR,HX@*E*J>5UQD"L'T Y',&;_<L;V%>K;T*$:^(EV [1ZX>-#N@5S68)]
M%9JR0-9RQ%V:&Y P/\CX(WJ9<'D4*OP+_CDK1_! H3]7#PHI\L,,R]9[XD[B
MAVD4][ H0TXUJS@"81%.2*4FLVB&4D_CI:H3I N$E[#%XK/T <F'D>MD-DD3
MQ?_TZHH9FHSP]Y)6=9;&>+>'*.-N0O0];,@[[#!$T%&S\LQ*RZ4CB.]/YN*:
M2%ZHC%UA)S2B^?=*.G0_PD8=KNF1:LIH;+/4#=K)AYW;R<R+$*HQM:5%YN0L
M4]2+G2OU6-&&*2K:GI%O>7<'/X)UZMG5XK9O,F*8<IDKHGK@TB>OWL<OK=V@
M=3WJW+I2^T"KLI"!@(NUF)B<=#(ND%FH&LD$L1PQ3)Q.<KW536<V^GD.ZK)D
M=+ENAJPA]"WMDS=HJ8\[N=33"/M?J23(4M"Y?.+ ],.6S+"$@__&DLV_4NY]
M%Q,%2IIH@A$L";84*!NY14\ZN6X5A@^OIV*._'XS6"1+]>%_&WHDQUY_%LNM
M8^P>[SNNWTYLW3;M9&UZ, ']/19YE 6KZN9Y[6BB?KA3^U5712>/<JHKKEK0
MW&V1_UVUSWTCEZECTD;EXV/&<9;.P:^+5/7FJ#BF;(/B?["+I<=65$141,:?
MV.,'5$\B[Z,[,C[)IM6V?,5J?^$UY=,G#\CO'=&=D#V:ZTX&F&'-TH?$=KSB
M RK-YM[XETP/7?>?$D30LA[T_'V@"1=^7./U=2>WP=]I0K)*GEVI6Y%:)[+F
M6\Y?QO*!UAU-7+?L5)7&O8^Q4M9Q6_2\/K3$!!G-8''U?71!N[T52':$*?Y"
M#ZKZW6+GE96V?8&*M#94=&_1T[U;^6]-W=928Y77#_C>5WEFGUNPU9U8Z:WN
M0_N<(<(.;-'NQ0//;?=%I+S&-,.KGU\=G?0LAQ_3=+Q5HZQ$:HF#?:PTWCOL
M&7X ,%F8=<90C9Q.9'*G! *:7EX]P%FS1 R[NU+=B^DU5XH30HN7Z@B7:O_$
M+I48(M?HF$M<!SKR1>1D\CXMZ=.#HY-71\<_6U[]I;SFW5V][L5QVE?O9/\S
M5H^)FJOK-:SBULSQ,40["]U[33Z^CFO8O9A-<PV/#_9.#AH[\/_(A)?PF);P
MM5M")#:UI+6.+.4J"S^7.FN+V_J1<5M? UD:R>#C79;"$U_JEQW3_]ZL"K1U
M^KU!6]]Q!MK07,L6_^R/@3@[OSC_?7!Y"O\:7)S_.;@Y_P9I].4.P$IEA" [
MOM<3%6J:ZU:*Z/R@SQ/Y[:VM(KU.*3^M\V;<[R3#3KX8HNOY=#+$ZZH)6C2I
MHR5&KU$.<<928G-8\+OR)B<1)E9GD;*E\/967UZ:4CE_2$<^=BRO?,EDZWF]
MXF'5#O+]W3UJ/W)CL0]B!() /<\-L$%36^8V3N6 $DBJIY! T/+2RAC$26;$
M>I C!=,!789<3)\165J/!1ZMP0)K2^V#S##TB'L2T]Q$^&07[3>+8)CGJ%G\
M&!*QOZ?IF+BK8/$W;A&#-5A$LTMQ\ZE/.H8^2.ZC+*4NW#(6MYA_Z3LPDEU<
M$SBC;6A7VC&[:W;=C5O7< W6U8L*WY;9O?H:Q,%ZK(I:@U4QNZV?4UB^H+0F
M;ZC*!J28_<NTQ*!XL=G+-EZ#93O8W:=E(^-6?EXF:SU6X6X-5D&K-'OJX'\D
M;1?,;GK00FL:@O- I(_Z0S83\9M-6KK)^BS=1907.L=N?#AJ7Y#<I^0%C E?
M.4,N26XK H9$B;A+IB>O:D*T-A>N]!.#L(T5/CC\DN[0V]ML;[.]S?8VZWX;
M_WQ;AU3(?X_2< [_F133^-?_'U!+ P04    " #2.EU8&8.0TD0#   2"@
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M?;*V;[(S]Q;\"U!+ 0(4 Q0    ( -(Z75AG0B^NF5L# &95)  1
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M &%N:7 M,C R,S$R,S%?9S$N:G!G4$L! A0#%     @ TCI=6,[&?<(SI $
M?481 !4              ( !MR\' &%N:7 M,C R,S$R,S%?;&%B+GAM;%!+
M 0(4 Q0    ( -(Z75A4_I?2^1<!  [0#  5              "  1W4" !A
M;FEP+3(P,C,Q,C,Q7W!R92YX;6Q02P$"% ,4    " #2.EU8.PYF]C\*   7
M5   &0              @ %)[ D 86YI<"TR,#(S,3(S,7AE>'@Q,#,R+FAT
M;5!+ 0(4 Q0    ( -(Z75BA^#4D^P4  -DD   9              "  ;_V
M"0!A;FEP+3(P,C,Q,C,Q>&5X>#$P,S,N:'1M4$L! A0#%     @ TCI=6$,8
M3*=7,   VC0! !D              ( !\?P) &%N:7 M,C R,S$R,S%X97AX
M,3 S-"YH=&U02P$"% ,4    " #2.EU8M'OL^7H#  !M%@  %P
M    @ %_+0H 86YI<"TR,#(S,3(S,7AE>'@R,2YH=&U02P$"% ,4    " #2
M.EU8VWCD<>P'  !6)P  &               @ $N,0H 86YI<"TR,#(S,3(S
M,7AE>'@S,3$N:'1M4$L! A0#%     @ TCI=6)?=^W+W!P  <2<  !@
M         ( !4#D* &%N:7 M,C R,S$R,S%X97AX,S$R+FAT;5!+ 0(4 Q0
M   ( -(Z75A2]G779 4  .(<   8              "  7U!"@!A;FEP+3(P
M,C,Q,C,Q>&5X>#,R,2YH=&U02P$"% ,4    " #2.EU86OF*SB@6   ^CP
M&               @ $71PH 86YI<"TR,#(S,3(S,7AE>'@Y-S$N:'1M4$L!
M A0#%     @ TCI=6#IYG25]"0  I"\  !H              ( !=5T* &%N
M:7 M,C R,W@Q,C,Q>&5X>#$P,C0N:'1M4$L! A0#%     @ TCI=6)B+B=E#
M5@  C[ " !H              ( !*F<* &%N:7 M,C R,W@Q,C,Q>&5X>#$P
M,S$N:'1M4$L! A0#%     @ TCI=6!F#D-)$ P  $@H  !D
M ( !I;T* &%N:7 M,C R,W@Q,C,Q>&5X>#(S,2YH=&U02P4&     !( $@#5
)!   (,$*

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>anip-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:anip="http://www.anipharmaceuticals.com/20231231"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="anip-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-22</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">anip:OakvilleOntarioFormerManufacturingFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-16</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:CranfordPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfGenericPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfGenericPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfGenericPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfBrandedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfBrandedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfBrandedPharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfRareDiseasePharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfRareDiseasePharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfRareDiseasePharmaceuticalProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredAtPointInTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:SalesOfContractManufacturedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:GovernmentRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AllowancesForSalesReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:AdministrativeFeesAndOtherRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">anip:ReservesForCashDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:FourCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:CustomerFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountForLackOfMarketabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">anip:OakvilleOntarioCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="anip:InterestPeriodAxis">anip:OneMonthDurationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="anip:InterestPeriodAxis">anip:ThreeMonthDurationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="anip:InterestPeriodAxis">anip:SixMonthDurationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">anip:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanAndDelayedDrawTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanAndDelayedDrawTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">anip:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">anip:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:BiosantePharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:WellSpringPharmaServicesIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:MarketingAndDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:MarketingAndDistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:NonCompeteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:NonCompeteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyAndAkornHoldingCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AlvogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationTypeAxis">anip:ReclassificationOfAssetsOnCompletionOfProjectAndLaunchOfRelatedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-21</startDate>
            <endDate>2022-07-21</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-22</startDate>
            <endDate>2024-02-22</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="anip:PaymentTypeAxis">anip:ProjectBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="anip:PaymentTypeAxis">anip:ProductDevelopmentBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">anip:MeasurementInputProbabilityOfPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="anip:PaymentTypeAxis">anip:ProductDevelopmentBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AlvogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-27</startDate>
            <endDate>2023-12-27</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AlvogenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:ProductIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-27</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-14</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredPipelineProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AkornHoldingCompanyPipelineProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AkornHoldingCompanyPipelineProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:AkornHoldingCompanyPipelineProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredCommercialProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredApprovedProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredFiledProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredAndaIntangibleAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-21</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:OakrumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">anip:SlaybackPharmaLimitedLiabilityCompanyPatentsAndPendingPatentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">anip:AcquiredNDAIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:SandozIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">anip:ClassCSpecialStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:EmployeeStockPurchasePlanTwoThousandAndSixteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-27</startDate>
            <endDate>2022-04-27</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-23</startDate>
            <endDate>2023-05-23</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">anip:StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:EmployeesAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:EmployeesAndConsultantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NonEmployeeDirectorStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:MarketPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:MarketPerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">anip:PerformanceBasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">anip:ANICanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">anip:ANICanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:ContractCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:ContractCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">anip:ContractCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:UnapprovedProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2020-12-03</startDate>
            <endDate>2020-12-03</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:AzurityPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-15</startDate>
            <endDate>2022-02-15</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2020-08-20</startDate>
            <endDate>2020-12-30</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2021-07-08</startDate>
            <endDate>2021-07-08</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:NovitiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:CortrophinGelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">anip:CortrophinGelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-08</startDate>
            <endDate>2021-03-08</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">anip:PrivateInvestmentInPublicEquityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-08</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:EsjayPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:EsjayPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:EsjayPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:ScitusPharmaServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:SsPharmaLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">anip:NurayChemicalPrivateLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:Mr.ShanmugamAndEsjayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:ChaliPropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-12</startDate>
            <endDate>2023-12-12</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:Mr.ShanmugamAndEsjayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">anip:ChaliPropertiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">anip:NovitiumPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-29</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:GenericsEstablishedBrandsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:GenericsEstablishedBrandsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:GenericsEstablishedBrandsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">anip:RareDiseaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:OfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-14</startDate>
            <endDate>2024-02-14</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">anip:NewEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-15</startDate>
            <endDate>2024-02-15</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">anip:CGOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-24</instant>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">anip:CGOncologyInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-27</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.MuthusamyShanmugamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.MuthusamyShanmugamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.MuthusamyShanmugamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.ChadGassertMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.ChadGassertMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001023024</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">anip:Mr.ChadGassertMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="facility">
        <measure>anip:facility</measure>
    </unit>
    <unit id="segment">
        <measure>anip:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="intangibleasset">
        <measure>anip:intangibleAsset</measure>
    </unit>
    <unit id="vote">
        <measure>anip:vote</measure>
    </unit>
    <unit id="tradingday">
        <measure>anip:tradingDay</measure>
    </unit>
    <unit id="operatinglease">
        <measure>anip:operatingLease</measure>
    </unit>
    <unit id="product">
        <measure>anip:product</measure>
    </unit>
    <unit id="plaintiff">
        <measure>anip:plaintiff</measure>
    </unit>
    <unit id="manufacturer">
        <measure>anip:manufacturer</measure>
    </unit>
    <unit id="claim">
        <measure>anip:claim</measure>
    </unit>
    <unit id="founder">
        <measure>anip:founder</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001023024</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-66" id="f-537">P7Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <anip:RestrictionPeriodForSharesIssuedInBusinessCombination contextRef="c-134" id="f-663">P3M</anip:RestrictionPeriodForSharesIssuedInBusinessCombination>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-195" id="f-851">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-204" id="f-862">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-14" id="f-900">http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-901">http://fasb.org/us-gaap/2023#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-285" id="f-1089">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-310" id="f-1206">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-310" id="f-1208">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-310" id="f-1209">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-310" id="f-1214">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-310" id="f-1216">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-310" id="f-1222">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1361">http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1363">http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <ecd:TrdArrDuration contextRef="c-395" id="f-1510">P270D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-398" id="f-1511">P293D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-31812</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ANI PHARMACEUTICALS, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">58-2301143</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">210 Main Street West</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Baudette</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">56623</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">218</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">634-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ANIP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-29" unitRef="usd">824200000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">21068122</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-31" unitRef="shares">10864</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-bottom:3pt;margin-top:2pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Portions of the definitive proxy statement for the registrant&#x2019;s 2024 annual meeting of stockholders to be filed within 120 days after the end of the period covered by this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-37" unitRef="cad">19200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-38" unitRef="usd">14200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-39" unitRef="cad">19200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-40" unitRef="usd">14200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-41" unitRef="usd">221121000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-42" unitRef="usd">48228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-6" decimals="-3" id="f-43" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-44" unitRef="usd">5006000</us-gaap:RestrictedCashCurrent>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-6" decimals="-3" id="f-45" unitRef="usd">97262000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-7" decimals="-3" id="f-46" unitRef="usd">161052000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-47" unitRef="usd">162079000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-48" unitRef="usd">165438000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-49" unitRef="usd">111196000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-50" unitRef="usd">105355000</us-gaap:InventoryNet>
    <anip:PrepaidIncomeTaxesNet contextRef="c-6" decimals="-3" id="f-51" unitRef="usd">0</anip:PrepaidIncomeTaxesNet>
    <anip:PrepaidIncomeTaxesNet contextRef="c-7" decimals="-3" id="f-52" unitRef="usd">3827000</anip:PrepaidIncomeTaxesNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-6" decimals="-3" id="f-53" unitRef="usd">8020000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-7" decimals="-3" id="f-54" unitRef="usd">8020000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-55" unitRef="usd">17400000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-56" unitRef="usd">8387000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-57" unitRef="usd">519816000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-58" unitRef="usd">344261000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-59" unitRef="usd">44593000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-60" unitRef="usd">43246000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-6" decimals="-3" id="f-61" unitRef="usd">90711000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-7" decimals="-3" id="f-62" unitRef="usd">81363000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-63" unitRef="usd">209009000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-64" unitRef="usd">251635000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-65" unitRef="usd">28221000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-66" unitRef="usd">28221000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-67" unitRef="usd">12072000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-68" unitRef="usd">11361000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-69" unitRef="usd">904422000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-70" unitRef="usd">760087000</us-gaap:Assets>
    <us-gaap:LongTermDebtCurrent contextRef="c-6" decimals="-3" id="f-71" unitRef="usd">850000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-7" decimals="-3" id="f-72" unitRef="usd">850000</us-gaap:LongTermDebtCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-73" unitRef="usd">36683000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-74" unitRef="usd">29305000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-6" decimals="-3" id="f-75" unitRef="usd">16276000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-7" decimals="-3" id="f-76" unitRef="usd">9307000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-77" unitRef="usd">23786000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-78" unitRef="usd">10312000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <anip:AccruedGovernmentRebates contextRef="c-6" decimals="-3" id="f-79" unitRef="usd">12168000</anip:AccruedGovernmentRebates>
    <anip:AccruedGovernmentRebates contextRef="c-7" decimals="-3" id="f-80" unitRef="usd">10872000</anip:AccruedGovernmentRebates>
    <us-gaap:TaxesPayableCurrent contextRef="c-6" decimals="-3" id="f-81" unitRef="usd">8164000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-7" decimals="-3" id="f-82" unitRef="usd">0</us-gaap:TaxesPayableCurrent>
    <anip:ReturnedGoodsReserve contextRef="c-6" decimals="-3" id="f-83" unitRef="usd">29678000</anip:ReturnedGoodsReserve>
    <anip:ReturnedGoodsReserve contextRef="c-7" decimals="-3" id="f-84" unitRef="usd">33399000</anip:ReturnedGoodsReserve>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-6" decimals="-3" id="f-85" unitRef="usd">12266000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-7" decimals="-3" id="f-86" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-87" unitRef="usd">5606000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-88" unitRef="usd">5394000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-89" unitRef="usd">145477000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-90" unitRef="usd">99439000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-3" id="f-91" unitRef="usd">284819000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-7" decimals="-3" id="f-92" unitRef="usd">285669000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-93" unitRef="usd">11718000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-94" unitRef="usd">35058000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-95" unitRef="usd">4809000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-96" unitRef="usd">1381000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-97" unitRef="usd">446823000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-98" unitRef="usd">421547000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-99" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-7" id="f-100" unitRef="usd" xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-101"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="c-9"
      decimals="INF"
      id="f-102"
      unitRef="usdPerShare">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-9" decimals="INF" id="f-103" unitRef="shares">1666667</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c-8" decimals="INF" id="f-104" unitRef="shares">1666667</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-8" decimals="INF" id="f-105" unitRef="shares">25000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="INF" id="f-106" unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c-9" decimals="INF" id="f-107" unitRef="shares">25000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="INF" id="f-108" unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">24850000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-7" decimals="-3" id="f-110" unitRef="usd">24850000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-10"
      decimals="INF"
      id="f-111"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-11"
      decimals="INF"
      id="f-112"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-11"
      decimals="INF"
      id="f-113"
      unitRef="shares">33333334</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-10"
      decimals="INF"
      id="f-114"
      unitRef="shares">33333334</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-10"
      decimals="INF"
      id="f-115"
      unitRef="shares">20730896</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-10"
      decimals="INF"
      id="f-116"
      unitRef="shares">20466953</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-11"
      decimals="INF"
      id="f-117"
      unitRef="shares">17643497</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-11"
      decimals="INF"
      id="f-118"
      unitRef="shares">17494466</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">2000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-12"
      decimals="INF"
      id="f-121"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-13"
      decimals="INF"
      id="f-122"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-13"
      decimals="INF"
      id="f-123"
      unitRef="shares">781281</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-12"
      decimals="INF"
      id="f-124"
      unitRef="shares">781281</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-13"
      decimals="INF"
      id="f-125"
      unitRef="shares">10864</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-12"
      decimals="INF"
      id="f-126"
      unitRef="shares">10864</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-12"
      decimals="INF"
      id="f-127"
      unitRef="shares">10864</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-13"
      decimals="INF"
      id="f-128"
      unitRef="shares">10864</us-gaap:CommonStockSharesOutstanding>
    <anip:ClassCSpecialStockValue contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">0</anip:ClassCSpecialStockValue>
    <anip:ClassCSpecialStockValue contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">0</anip:ClassCSpecialStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-131"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-132"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-133" unitRef="shares">1666667</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="INF" id="f-134" unitRef="shares">1666667</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="INF" id="f-135" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-136" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-137" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="INF" id="f-138" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:TreasuryStockCommonShares contextRef="c-6" decimals="INF" id="f-141" unitRef="shares">263943</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-7" decimals="INF" id="f-142" unitRef="shares">149031</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">10081000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">5094000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">514103000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-7" decimals="-3" id="f-146" unitRef="usd">403901000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">-80132000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">-97286000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">8857000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-150" unitRef="usd">12168000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">432749000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">313690000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-153" unitRef="usd">904422000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">760087000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-155" unitRef="usd">486816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-156" unitRef="usd">316385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-157" unitRef="usd">216136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-158" unitRef="usd">181513000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-14" decimals="-3" id="f-159" unitRef="usd">138785000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization contextRef="c-15" decimals="-3" id="f-160" unitRef="usd">100610000</us-gaap:CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-161" unitRef="usd">34286000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-162" unitRef="usd">22318000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-163" unitRef="usd">11369000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-164" unitRef="usd">161697000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-14" decimals="-3" id="f-165" unitRef="usd">124044000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-15" decimals="-3" id="f-166" unitRef="usd">84294000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-167" unitRef="usd">59791000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-14" decimals="-3" id="f-168" unitRef="usd">56972000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-15" decimals="-3" id="f-169" unitRef="usd">47252000</us-gaap:DepreciationAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">1426000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-14" decimals="-3" id="f-171" unitRef="usd">3758000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-15" decimals="-3" id="f-172" unitRef="usd">500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-14" decimals="-3" id="f-174" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-15" decimals="-3" id="f-175" unitRef="usd">-8750000</us-gaap:GainLossRelatedToLitigationSettlement>
    <anip:CortrophinPreLaunchCharges contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">0</anip:CortrophinPreLaunchCharges>
    <anip:CortrophinPreLaunchCharges contextRef="c-14" decimals="-3" id="f-177" unitRef="usd">0</anip:CortrophinPreLaunchCharges>
    <anip:CortrophinPreLaunchCharges contextRef="c-15" decimals="-3" id="f-178" unitRef="usd">780000</anip:CortrophinPreLaunchCharges>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">1132000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-14" decimals="-3" id="f-180" unitRef="usd">5679000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-15" decimals="-3" id="f-181" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-14" decimals="-3" id="f-183" unitRef="usd">112000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-15" decimals="-3" id="f-184" unitRef="usd">2374000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">439845000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-14" decimals="-3" id="f-186" unitRef="usd">351668000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-15" decimals="-3" id="f-187" unitRef="usd">255929000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">46971000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">-35283000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-190" unitRef="usd">-39793000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">-26940000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-14" decimals="-3" id="f-192" unitRef="usd">-28052000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-15" decimals="-3" id="f-193" unitRef="usd">-11922000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">-159000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">670000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-196" unitRef="usd">-4343000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">19872000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-198" unitRef="usd">-62665000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-199" unitRef="usd">-56058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">1093000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-201" unitRef="usd">-14769000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-202" unitRef="usd">-13455000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">18779000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-204" unitRef="usd">-47896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-205" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c-1" decimals="-3" id="f-206" unitRef="usd">1625000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c-14" decimals="-3" id="f-207" unitRef="usd">1625000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="c-15" decimals="-3" id="f-208" unitRef="usd">190000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">17154000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-210" unitRef="usd">-49521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-211" unitRef="usd">-42793000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-212"
      unitRef="usdPerShare">0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-213"
      unitRef="usdPerShare">-3.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-214"
      unitRef="usdPerShare">-3.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-215"
      unitRef="usdPerShare">0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-216"
      unitRef="usdPerShare">-3.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-217"
      unitRef="usdPerShare">-3.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-218" unitRef="shares">18001000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-14" decimals="-3" id="f-219" unitRef="shares">16260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-15" decimals="-3" id="f-220" unitRef="shares">12596000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-221" unitRef="shares">18194000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-14" decimals="-3" id="f-222" unitRef="shares">16260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-15" decimals="-3" id="f-223" unitRef="shares">12596000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">18779000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-225" unitRef="usd">-47896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-226" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">44000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-228" unitRef="usd">-112000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-15" decimals="-3" id="f-229" unitRef="usd">12000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">-3355000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-14" decimals="-3" id="f-231" unitRef="usd">15335000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-15" decimals="-3" id="f-232" unitRef="usd">8370000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">-3311000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-14" decimals="-3" id="f-234" unitRef="usd">15223000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-3" id="f-235" unitRef="usd">8382000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-236" unitRef="usd">15468000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-14" decimals="-3" id="f-237" unitRef="usd">-32673000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-15" decimals="-3" id="f-238" unitRef="usd">-34221000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-16" decimals="-3" id="f-239" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-16" decimals="-3" id="f-240" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-241" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued contextRef="c-17" decimals="-3" id="f-242" unitRef="shares">12430000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-243" unitRef="usd">214354000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-19" decimals="-3" id="f-244" unitRef="shares">76000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-245" unitRef="usd">-2246000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-246" unitRef="usd">-11437000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-247" unitRef="usd">-4972000</us-gaap:StockholdersEquity>
    <anip:StockholdersEquityAttributableToParentAndTemporaryEquity contextRef="c-22" decimals="-3" id="f-248" unitRef="usd">195700000</anip:StockholdersEquityAttributableToParentAndTemporaryEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-249" unitRef="usd">10489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-15" decimals="-3" id="f-250" unitRef="usd">10489000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-24" decimals="-3" id="f-251" unitRef="shares">28000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-24" decimals="-3" id="f-252" unitRef="usd">889000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-15" decimals="-3" id="f-253" unitRef="usd">889000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-25" decimals="-3" id="f-254" unitRef="shares">56000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-23" decimals="-3" id="f-255" unitRef="usd">2069000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-15" decimals="-3" id="f-256" unitRef="usd">2069000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-25" decimals="-3" id="f-257" unitRef="shares">541000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="c-25" decimals="-3" id="f-258" unitRef="shares">81000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="c-23" decimals="-3" id="f-259" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="c-24" decimals="-3" id="f-260" unitRef="shares">21000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="c-15" decimals="-3" id="f-261" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-26" decimals="-3" id="f-262" unitRef="shares">2467000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-263" unitRef="usd">91199000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-264" unitRef="usd">91199000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-25" decimals="-3" id="f-265" unitRef="shares">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-23" decimals="-3" id="f-266" unitRef="usd">69734000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-267" unitRef="usd">69734000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DividendsPreferredStock contextRef="c-29" decimals="-3" id="f-268" unitRef="usd">190000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="c-15" decimals="-3" id="f-269" unitRef="usd">190000</us-gaap:DividendsPreferredStock>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-30" decimals="-3" id="f-270" unitRef="usd">24850000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues contextRef="c-30" decimals="-3" id="f-271" unitRef="shares">25000</anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-15" decimals="-3" id="f-272" unitRef="usd">24850000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-31" decimals="-3" id="f-273" unitRef="usd">8382000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-3" id="f-274" unitRef="usd">8382000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-29" decimals="-3" id="f-275" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-3" id="f-276" unitRef="usd">-42603000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-32" decimals="-3" id="f-277" unitRef="usd">24850000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-32" decimals="-3" id="f-278" unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-279" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued contextRef="c-33" decimals="-3" id="f-280" unitRef="shares">16913000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-281" unitRef="usd">387844000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-35" decimals="-3" id="f-282" unitRef="shares">83000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-35" decimals="-3" id="f-283" unitRef="usd">-3135000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-36" decimals="-3" id="f-284" unitRef="usd">-3055000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-285" unitRef="usd">-47765000</us-gaap:StockholdersEquity>
    <anip:StockholdersEquityAttributableToParentAndTemporaryEquity contextRef="c-38" decimals="-3" id="f-286" unitRef="usd">358740000</anip:StockholdersEquityAttributableToParentAndTemporaryEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-39" decimals="-3" id="f-287" unitRef="usd">14599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-288" unitRef="usd">14599000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-40" decimals="-3" id="f-289" unitRef="shares">66000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-40" decimals="-3" id="f-290" unitRef="usd">1959000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-14" decimals="-3" id="f-291" unitRef="usd">1959000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-41" decimals="-3" id="f-292" unitRef="shares">52000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-39" decimals="-3" id="f-293" unitRef="usd">1458000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-294" unitRef="usd">1458000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-41" decimals="-3" id="f-295" unitRef="shares">748000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="c-41" decimals="-3" id="f-296" unitRef="shares">69000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:DividendsPreferredStock contextRef="c-42" decimals="-3" id="f-297" unitRef="usd">1625000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="c-14" decimals="-3" id="f-298" unitRef="usd">1625000</us-gaap:DividendsPreferredStock>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-43" decimals="-3" id="f-299" unitRef="usd">15223000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-14" decimals="-3" id="f-300" unitRef="usd">15223000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-42" decimals="-3" id="f-301" unitRef="usd">-47896000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-302" unitRef="usd">-47896000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-8" decimals="-3" id="f-303" unitRef="usd">24850000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-8" decimals="-3" id="f-304" unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-305" unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued contextRef="c-44" decimals="-3" id="f-306" unitRef="shares">17644000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-307" unitRef="usd">403901000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-46" decimals="-3" id="f-308" unitRef="shares">149000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-309" unitRef="usd">-5094000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-310" unitRef="usd">12168000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-311" unitRef="usd">-97286000</us-gaap:StockholdersEquity>
    <anip:StockholdersEquityAttributableToParentAndTemporaryEquity contextRef="c-7" decimals="-3" id="f-312" unitRef="usd">338540000</anip:StockholdersEquityAttributableToParentAndTemporaryEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-49" decimals="-3" id="f-313" unitRef="usd">20652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">20652000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-50" decimals="-3" id="f-315" unitRef="shares">115000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-50" decimals="-3" id="f-316" unitRef="usd">4987000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">4987000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-51" decimals="-3" id="f-318" unitRef="shares">227000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-49" decimals="-3" id="f-319" unitRef="usd">8996000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">8996000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-51" decimals="-3" id="f-321" unitRef="shares">674000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-51" decimals="-3" id="f-322" unitRef="shares">85000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited contextRef="c-51" decimals="-3" id="f-323" unitRef="shares">83000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="c-49" decimals="-3" id="f-324" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-51" decimals="-3" id="f-326" unitRef="shares">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-51" decimals="-3" id="f-327" unitRef="usd">2184000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-49" decimals="-3" id="f-328" unitRef="usd">80555000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">80556000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:DividendsPreferredStock contextRef="c-52" decimals="-3" id="f-330" unitRef="usd">1625000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">1625000</us-gaap:DividendsPreferredStock>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-53" decimals="-3" id="f-332" unitRef="usd">-3311000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">-3311000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-52" decimals="-3" id="f-334" unitRef="usd">18779000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">18779000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c-9" decimals="-3" id="f-336" unitRef="usd">24850000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesOutstanding contextRef="c-9" decimals="-3" id="f-337" unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-338" unitRef="usd">2000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued contextRef="c-54" decimals="-3" id="f-339" unitRef="shares">20731000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-340" unitRef="usd">514103000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-56" decimals="-3" id="f-341" unitRef="shares">264000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-342" unitRef="usd">-10081000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-343" unitRef="usd">8857000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-344" unitRef="usd">-80132000</us-gaap:StockholdersEquity>
    <anip:StockholdersEquityAttributableToParentAndTemporaryEquity contextRef="c-6" decimals="-3" id="f-345" unitRef="usd">457599000</anip:StockholdersEquityAttributableToParentAndTemporaryEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-346" unitRef="usd">18779000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-347" unitRef="usd">-47896000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-15" decimals="-3" id="f-348" unitRef="usd">-42603000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-349" unitRef="usd">20652000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-14" decimals="-3" id="f-350" unitRef="usd">14599000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-15" decimals="-3" id="f-351" unitRef="usd">10489000</us-gaap:ShareBasedCompensation>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-1" decimals="-3" id="f-352" unitRef="usd">-11740000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-14" decimals="-3" id="f-353" unitRef="usd">-15253000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="c-15" decimals="-3" id="f-354" unitRef="usd">-16754000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-355" unitRef="usd">59791000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-14" decimals="-3" id="f-356" unitRef="usd">59653000</us-gaap:OtherDepreciationAndAmortization>
    <us-gaap:OtherDepreciationAndAmortization contextRef="c-15" decimals="-3" id="f-357" unitRef="usd">47252000</us-gaap:OtherDepreciationAndAmortization>
    <anip:AcquiredInProcessReserachAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-358" unitRef="usd">0</anip:AcquiredInProcessReserachAndDevelopmentExpense>
    <anip:AcquiredInProcessReserachAndDevelopmentExpense contextRef="c-14" decimals="-3" id="f-359" unitRef="usd">1151000</anip:AcquiredInProcessReserachAndDevelopmentExpense>
    <anip:AcquiredInProcessReserachAndDevelopmentExpense contextRef="c-15" decimals="-3" id="f-360" unitRef="usd">0</anip:AcquiredInProcessReserachAndDevelopmentExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-3" id="f-361" unitRef="usd">1269000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-14" decimals="-3" id="f-362" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-15" decimals="-3" id="f-363" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-364" unitRef="usd">3922000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-14" decimals="-3" id="f-365" unitRef="usd">3961000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-15" decimals="-3" id="f-366" unitRef="usd">2512000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow contextRef="c-1" decimals="-3" id="f-367" unitRef="usd">1426000</anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow>
    <anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow contextRef="c-14" decimals="-3" id="f-368" unitRef="usd">4058000</anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow>
    <anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow contextRef="c-15" decimals="-3" id="f-369" unitRef="usd">500000</anip:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityCashFlow>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-14" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-15" decimals="-3" id="f-372" unitRef="usd">-1458000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-14" decimals="-3" id="f-374" unitRef="usd">574000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-15" decimals="-3" id="f-375" unitRef="usd">2374000</us-gaap:AssetImpairmentCharges>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-14" decimals="-3" id="f-377" unitRef="usd">750000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-15" decimals="-3" id="f-378" unitRef="usd">1822000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-379" unitRef="usd">-3359000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-14" decimals="-3" id="f-380" unitRef="usd">36912000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-15" decimals="-3" id="f-381" unitRef="usd">5548000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-382" unitRef="usd">5841000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-14" decimals="-3" id="f-383" unitRef="usd">23626000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-15" decimals="-3" id="f-384" unitRef="usd">-3224000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-1" decimals="-3" id="f-385" unitRef="usd">9015000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-14" decimals="-3" id="f-386" unitRef="usd">798000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="c-15" decimals="-3" id="f-387" unitRef="usd">-127000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-388" unitRef="usd">7552000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-14" decimals="-3" id="f-389" unitRef="usd">5038000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-15" decimals="-3" id="f-390" unitRef="usd">10166000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <anip:IncreaseDecreaseInRoyaltyPayable contextRef="c-1" decimals="-3" id="f-391" unitRef="usd">6969000</anip:IncreaseDecreaseInRoyaltyPayable>
    <anip:IncreaseDecreaseInRoyaltyPayable contextRef="c-14" decimals="-3" id="f-392" unitRef="usd">3082000</anip:IncreaseDecreaseInRoyaltyPayable>
    <anip:IncreaseDecreaseInRoyaltyPayable contextRef="c-15" decimals="-3" id="f-393" unitRef="usd">-267000</anip:IncreaseDecreaseInRoyaltyPayable>
    <us-gaap:IncreaseDecreaseInIncomeTaxes contextRef="c-1" decimals="-3" id="f-394" unitRef="usd">11991000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInIncomeTaxes contextRef="c-14" decimals="-3" id="f-395" unitRef="usd">-160000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <us-gaap:IncreaseDecreaseInIncomeTaxes contextRef="c-15" decimals="-3" id="f-396" unitRef="usd">-7573000</us-gaap:IncreaseDecreaseInIncomeTaxes>
    <anip:IncreaseDecreaseAccruedGovernmentRebates contextRef="c-1" decimals="-3" id="f-397" unitRef="usd">1296000</anip:IncreaseDecreaseAccruedGovernmentRebates>
    <anip:IncreaseDecreaseAccruedGovernmentRebates contextRef="c-14" decimals="-3" id="f-398" unitRef="usd">5380000</anip:IncreaseDecreaseAccruedGovernmentRebates>
    <anip:IncreaseDecreaseAccruedGovernmentRebates contextRef="c-15" decimals="-3" id="f-399" unitRef="usd">-3078000</anip:IncreaseDecreaseAccruedGovernmentRebates>
    <anip:IncreaseDecreaseInReturnedGoodsReserve contextRef="c-1" decimals="-3" id="f-400" unitRef="usd">-3722000</anip:IncreaseDecreaseInReturnedGoodsReserve>
    <anip:IncreaseDecreaseInReturnedGoodsReserve contextRef="c-14" decimals="-3" id="f-401" unitRef="usd">-2399000</anip:IncreaseDecreaseInReturnedGoodsReserve>
    <anip:IncreaseDecreaseInReturnedGoodsReserve contextRef="c-15" decimals="-3" id="f-402" unitRef="usd">6503000</anip:IncreaseDecreaseInReturnedGoodsReserve>
    <anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers contextRef="c-1" decimals="-3" id="f-403" unitRef="usd">12271000</anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers>
    <anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers contextRef="c-14" decimals="-3" id="f-404" unitRef="usd">-905000</anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers>
    <anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers contextRef="c-15" decimals="-3" id="f-405" unitRef="usd">-3638000</anip:IncreaseDecreaseOfAccruedExpensesCompensationAndOthers>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-406" unitRef="usd">118959000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-14" decimals="-3" id="f-407" unitRef="usd">-31203000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-15" decimals="-3" id="f-408" unitRef="usd">3322000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-409" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-14" decimals="-3" id="f-410" unitRef="usd">33000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-15" decimals="-3" id="f-411" unitRef="usd">84494000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-3" id="f-412" unitRef="usd">9643000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-14" decimals="-3" id="f-413" unitRef="usd">7579000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-15" decimals="-3" id="f-414" unitRef="usd">21081000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-415" unitRef="usd">8868000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-416" unitRef="usd">8876000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-417" unitRef="usd">2557000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-418" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-14" decimals="-3" id="f-419" unitRef="usd">750000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-15" decimals="-3" id="f-420" unitRef="usd">2649000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-421" unitRef="usd">-18511000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-14" decimals="-3" id="f-422" unitRef="usd">-15738000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-15" decimals="-3" id="f-423" unitRef="usd">-105483000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-424" unitRef="usd">80555000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-14" decimals="-3" id="f-425" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-15" decimals="-3" id="f-426" unitRef="usd">69584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="0" id="f-427" unitRef="usd">12500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-14" decimals="0" id="f-428" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-15" decimals="0" id="f-429" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="c-1" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="c-14" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfOtherLongTermDebt contextRef="c-15" decimals="-3" id="f-432" unitRef="usd">10862000</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-1" decimals="-3" id="f-433" unitRef="usd">3000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-14" decimals="-3" id="f-434" unitRef="usd">3000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt contextRef="c-15" decimals="-3" id="f-435" unitRef="usd">0</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-1" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-14" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit contextRef="c-15" decimals="-3" id="f-438" unitRef="usd">24000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-1" decimals="-3" id="f-439" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-14" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="c-15" decimals="-3" id="f-441" unitRef="usd">200148000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-1" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-14" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-15" decimals="-3" id="f-444" unitRef="usd">286032000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-1" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-14" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-15" decimals="-3" id="f-447" unitRef="usd">25000000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsOfDividends contextRef="c-1" decimals="-3" id="f-448" unitRef="usd">1625000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-14" decimals="-3" id="f-449" unitRef="usd">1625000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-15" decimals="-3" id="f-450" unitRef="usd">190000</us-gaap:PaymentsOfDividends>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-451" unitRef="usd">8996000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-14" decimals="-3" id="f-452" unitRef="usd">1458000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-15" decimals="-3" id="f-453" unitRef="usd">2069000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-454" unitRef="usd">4987000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-14" decimals="-3" id="f-455" unitRef="usd">1959000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-15" decimals="-3" id="f-456" unitRef="usd">890000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-457" unitRef="usd">67439000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-14" decimals="-3" id="f-458" unitRef="usd">-5126000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-15" decimals="-3" id="f-459" unitRef="usd">194595000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-460" unitRef="usd">167887000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-14" decimals="-3" id="f-461" unitRef="usd">-52067000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-15" decimals="-3" id="f-462" unitRef="usd">92434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-463" unitRef="usd">53234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-38" decimals="-3" id="f-464" unitRef="usd">105301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-465" unitRef="usd">12867000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-466" unitRef="usd">221121000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-467" unitRef="usd">53234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-38" decimals="-3" id="f-468" unitRef="usd">105301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-469" unitRef="usd">48228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-38" decimals="-3" id="f-470" unitRef="usd">100300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-22" decimals="-3" id="f-471" unitRef="usd">7864000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-472" unitRef="usd">5006000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-38" decimals="-3" id="f-473" unitRef="usd">5001000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-22" decimals="-3" id="f-474" unitRef="usd">5003000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-475" unitRef="usd">53234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-38" decimals="-3" id="f-476" unitRef="usd">105301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-477" unitRef="usd">12867000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-478" unitRef="usd">221121000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-479" unitRef="usd">48228000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-38" decimals="-3" id="f-480" unitRef="usd">100300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-6" decimals="-3" id="f-481" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-7" decimals="-3" id="f-482" unitRef="usd">5006000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-38" decimals="-3" id="f-483" unitRef="usd">5001000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-484" unitRef="usd">221121000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-485" unitRef="usd">53234000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-38" decimals="-3" id="f-486" unitRef="usd">105301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-487" unitRef="usd">31431000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-14" decimals="-3" id="f-488" unitRef="usd">21477000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-15" decimals="-3" id="f-489" unitRef="usd">9705000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-490" unitRef="usd">1228000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-14" decimals="-3" id="f-491" unitRef="usd">288000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-15" decimals="-3" id="f-492" unitRef="usd">10371000</us-gaap:IncomeTaxesPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-493" unitRef="usd">4715000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-14" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-15" decimals="-3" id="f-495" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="c-1" decimals="-3" id="f-496" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="c-14" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1 contextRef="c-15" decimals="-3" id="f-498" unitRef="usd">30500000</us-gaap:NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-1" decimals="-3" id="f-499" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-14" decimals="-3" id="f-500" unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-15" decimals="-3" id="f-501" unitRef="usd">91199000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="c-1" decimals="-3" id="f-502" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="c-14" decimals="-3" id="f-503" unitRef="usd">1000000</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 contextRef="c-15" decimals="-3" id="f-504" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-505" unitRef="usd">328000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-14" decimals="-3" id="f-506" unitRef="usd">452000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-15" decimals="-3" id="f-507" unitRef="usd">152000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="c-1" id="f-508">DESCRIPTION OF BUSINESS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization and Business&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ANI Pharmaceuticals, Inc. and its consolidated subsidiaries (together, &#x201c;ANI,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; or &#x201c;our&#x201d;) is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals, including for diseases with high unmet medical need. The team is focused on delivering growth by scaling up the Rare Disease business through the successful launch of its lead asset, Cortrophin Gel, strengthening our generics business with enhanced development capability, innovation in established brands and leveraging our North American manufacturing capabilities. The Company owns and operates three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. The Company has ceased operations at the Oakville, Ontario, manufacturing facility as of March 31, 2023. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium Pharma LLC (&#x201c;Novitium&#x201d;) in November 2021. The Company has fully completed the transition of the products manufactured or packaged at Oakville to one of the three U.S.-based manufacturing sites. On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (Note 19).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. Unless otherwise noted, all references to &#x201c;$&#x201d; or &#x201c;dollar&#x201d; refer to the U.S. dollar. The Company&#x2019;s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders&#x2019; equity accounts, intercompany, and fixed assets, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders&#x2019; equity within accumulated other comprehensive income (loss), net of tax.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In the consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and potential adjustments, income tax expense or benefit, deferred taxes and valuation allowance, stock-based compensation, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Revenue is recognized using the following steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determination of the transaction price, including the identification and estimation of variable consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Recognition of revenue when we satisfy a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives its revenues primarily from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold is transferred to the customer. Generally, the Company does not incur incremental costs to obtain contracts that would otherwise not have been incurred. The Company has not identified any agreements or arrangement that would qualify as a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may enter into marketing and distribution agreements with third parties in which products are sold under Abbreviated New Drug Applications (&#x201c;ANDAs&#x201d;) or New Drug Applications (&#x201c;NDAs&#x201d;) owned or licensed by third parties. These products are sold under the ANI label. The Company controls the products sold under these marketing and distribution agreements and therefore are the principal for sales under each of these marketing and distribution agreements. As a result, revenue is recognized on a gross basis when control has passed to the customer and the performance obligation has been satisfied. Under these agreements, the Company pays third parties a specified percentage of the gross profit earned on sales of the products. These profit-sharing percentages are recognized in cost of sales in the consolidated statements of operations and are accrued in accrued royalties in the consolidated balance sheets until payment has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Manufacturing Product Sales Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing arrangements consist of agreements in which pharmaceutical products are manufactured by the Company on behalf of a third party. The performance obligation is to manufacture and provide pharmaceutical products to customers, typically pharmaceutical companies. The products are sold at predetermined standalone selling prices and the performance obligation is considered to be satisfied when control of the product is transferred to the customer. Control is transferred to the customer when the product leaves the shipping dock to be shipped to the customer, as  contract manufactured pharmaceutical products are sold on an FOB shipping point basis and the inventory risk and risk of ownership passes to the customer at that time. Payment terms for these sales are generally fewer than two months. Typically, there are no material returns for contract manufactured products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties from Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into licensing agreements, under which the Company licenses to the seller the right to sell the acquired products. Because these royalties are sales-based, the Company recognizes the revenue when the underlying sales occur, based on sales and gross profit information received from the sellers. The Company may enter into agreements which include profit-sharing percentages on gross profits. The profit-sharing percentages are recorded in cost of sales in the consolidated statements of operations when the associated revenue is recognized and are recorded in accrued royalties in the consolidated balance sheets when the associated revenue is recognized and until payment has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments with original maturities of three months or less from the date of purchase are classified as cash equivalents. Cash and cash equivalents consist of cash deposited in checking accounts, time deposits with maturities of less than three months, and money market accounts with maturities of three months or less at the date of purchase. Cash and cash equivalents include cash on-hand and money market funds which invest exclusively in high-quality, short-term securities that are issued or guaranteed by the U.S. government. Due to the short-term maturity of the funds invested in the money market accounts, the carrying amounts are a reasonable estimate of fair value. All interest bearing and non-interest bearing accounts are guaranteed by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250 thousand. The majority of the Company's cash balances are in excess of FDIC coverage, which the Company considers to be a normal business risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash at December 31, 2022, represented $5.0 million of funds held in a bank account owned by the Company to be used to pay for future milestones related to the purchase of  the rights, title, and interest in the NDA for Inderal LA, as well as certain documentation, trademark rights, and finished goods from Cranford Pharmaceuticals, LLC in April 2016. This amount was was released from restricted cash during the first quarter of the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company extends credit to customers on an unsecured basis. Expected credit losses are measured at amortized cost, including trade and unbilled receivables, on a collective basis, based on their similar risk characteristics. Expected credits losses are based on historical credit loss experience, review of the current aging or status of accounts receivable and current and forward-looking views from an economic and industry perspective. Receivables are written off when it is determined that amounts are uncollectible. The allowance for credit losses was immaterial as of December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consist of raw materials, packaging materials, work-in-progress, and finished goods. Inventories are stated at the lower of standard cost or net realizable value. The Company periodically reviews and adjusts standard costs, which generally approximate weighted average cost. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation is recorded on a straight-line basis over estimated useful lives as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of asset's useful life or remaining life of lease &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery, furniture, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress consists of multiple projects, primarily related to new equipment and expansion of laboratory and manufacturing facilities to expand manufacturing capability as product lines grow. Construction in progress includes the cost of construction and other direct costs attributable to the construction, along with capitalized interest. Depreciation is not recorded on construction in progress until such time as the assets are placed in service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. No impairment loss related to property and equipment was recognized during the years ended December&#160;31, 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets Held-for-Sale &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria. As of December&#160;31, 2023 and 2022, approximately $8.0 million of assets held for sale were recorded on the consolidated balance sheets. See Note 4 to the consolidated financial statements for additional information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the Company does not separate lease and non-lease components of contracts. There are no material residual guarantees associated with any of the Company&#x2019;s leases, and there are no significant restrictions or covenants included in the Company&#x2019;s lease agreements. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. As of December&#160;31, 2023 and 2022, the Company did not have any finance leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The definite-lived ANDAs, NDAs and product rights, marketing and distribution rights, customer relationships, and non-compete agreement are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:f-537"&gt;seven&lt;/span&gt; to ten years, based on the straight-line amortization method. In the case of certain NDA and product rights, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Management reviews definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. During the year ended December&#160;31, 2023, no impairment charges were recognized on intangible assets.. During the year ended December&#160;31, 2022, the Company recognized a full impairment of a definite-lived ANDA asset with a remaining carrying value of $0.1 million. During the year ended December&#160;31, 2021, the Company recognized an impairment charge of $2.4 million related to a definite-lived ANDA intangible asset. No events or circumstances arose in 2023, 2022, or 2021 that indicated that the carrying value of any of the other definite-lived intangible assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets other than goodwill include in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects. IPR&amp;amp;D intangible assets represent the fair value of technology acquired in a business combination for which the technology projects are incomplete but have substance. When an IPR&amp;amp;D project is completed (generally upon receipt of regulatory approval), the asset is then accounted for as a definite-lived intangible asset. Indefinite-lived intangibles are tested for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying amount of the asset might not be recoverable. Judgment is used in determining when these events and circumstances arise. No events or circumstances arose in 2023 that indicated that the carrying value of any of the indefinite-lived intangible assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost, using the purchase method of accounting, and is related to past business combinations with BioSante Pharmaceuticals, Inc., WellSpring, and Novitium. Goodwill is not amortized, but is subject to periodic review for impairment. The Company is organized in two operating segments, and two reporting units, and has determined that goodwill resides in one reporting unit, Generics, Established Brands, and Other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews goodwill for impairment on a reporting unit basis annually, on October 31, and whenever events or changes in circumstances indicate the carrying value of goodwill might not be recoverable. Under the authoritative guidance issued by the FASB, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company&#x2019;s financial condition and results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the assets qualitatively, and concluded it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit is greater than its carrying value as of October 31, 2023 and 2022, and therefore no quantitative testing for impairment was required. No impairment loss related to goodwill was recognized in the years ended December&#160;31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborative Arrangements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may enter into collaborative arrangements with various commercial partners to further business opportunities. In collaborative arrangements revenues and costs generated by collaborative arrangements may be presented on a gross or net basis depending on the specific facts of the collaborative arrangement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development ("R&amp;amp;D") activities are expensed as incurred. R&amp;amp;D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock options and restricted stock awards, which are awarded in exchange for employee and non-employee director services. From time to time, the Company may grant awards through an inducement grant outside of the incentive plan to induce prospective employees to accept employment with the Company. These grants are made pursuant to inducement grants outside of the shareholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock awards is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#x2019;s requisite service period and classified where the underlying salaries are classified. Forfeitures are accounted for as they occur. Excess tax benefits or tax deficiencies are recognized as a component of the current period provision for income taxes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards may also be issued in the form of Performance Stock Units (&#x201c;PSUs&#x201d;) to certain employees of the Company. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted vest over a three-year performance period. Currently, the PSU&#x2019;s vesting is contingent upon the Company meeting certain total shareholder return (&#x201c;TSR&#x201d;) levels as compared to a select peer group over the over three years, and contingent upon the Company meeting certain adjusted non-GAAP year-on-year &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earnings before interest, income taxes, depreciation, and amortization (&#x201c;EBITDA&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; growth rates over the vesting term. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also administers an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The estimated fair value of stock-based compensation awards are recognized and classified in the expense where the underlying salaries are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of the Company's stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in various U.S. jurisdictions, Canada, and India, and all of our income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has previously entered into an interest rate swap agreement (Note 6) designated as a cash flow hedge designed to manage exposure to changes in SOFR-interest rate underlying our variable rate debt. Due to the effective nature of the hedge, the initial fair value of the hedge and subsequent changes in the fair value of the hedge are recognized in other comprehensive income (loss) in the consolidated balance sheets. Income taxes are allocated to the hedge component of other comprehensive income (loss) based on appropriate intra-period tax allocations when those effects are deemed material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedge Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses interest rate swaps to hedge exposure to interest rate risk, as well as benefit from favorable conditions. The Company recognizes all derivative instruments as either assets or liabilities at fair value. For all of the Company&#x2019;s derivative positions that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivatives is reported as a component of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other comprehensive income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on derivatives representing any ineffective component of the hedge are recognized in current earnings. All of the Company&#x2019;s cash flow hedges have been deemed effective as of December&#160;31, 2023 for both accounting and tax purposes. The Company has elected hedge accounting for both U.S. GAAP and tax purposes. The Company maintains formal documentation through a periodic memo and accounting analysis that cover what is being hedged, how it is being hedged, hedge effectiveness, the nature of the risk being hedged, among other required analyses. Company policy further includes a quarterly probability analysis covering hedge effectiveness.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the acquisition agreement between ANI and Novitium Pharma LLC include the potential payment of future consideration that is contingent upon the achievement of certain regulatory and financial performance milestones. At the acquisition date, contingent consideration is recorded at fair value based on the additional consideration expected to be transferred, which is based on the estimate of probability-weighted future cash flows as discounted to present value. Significant inputs used in the measurement of the fair value include discount rates, probabilities of achievement of regulatory-based milestones and payments, and projected revenues and gross profits. The discount rates are derived using accepted valuation methodologies. The probability of achievement of regulatory milestones is based on historical and projected success rates. The projected revenues and gross profits are based on internal forecasts and long-term plans. The contingent consideration is remeasured each reporting period using Level 3 inputs. Changes in fair value, which incorporate changes in assumptions and the passage of time, are recognized as an operating expense in the consolidated statements of operations. As payments are not expected to be made shortly after the acquisition, any future payment of contingent consideration will be reported as a financing cash flow for amounts paid up to the acquisition-date fair value of the consideration, and as an operating cash outflow for any amounts in excess of the acquisition-date fair value in our consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets include certain financial instruments (primarily cash and cash equivalents, prepaid expenses, accounts receivable, accounts payable, accrued expenses, and other current liabilities) that are carried at cost and that approximate fair values as of December&#160;31, 2023, 2022 due to their short term nature. See Note 10 for additional information regarding fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. &lt;/span&gt;&lt;/div&gt;In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company&#x2019;s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <anip:NumberOfPharmaceuticalManufacturingFacilities
      contextRef="c-6"
      decimals="INF"
      id="f-509"
      unitRef="facility">3</anip:NumberOfPharmaceuticalManufacturingFacilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-510" unitRef="cad">19200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-511" unitRef="usd">14200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-512">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of ANI Pharmaceuticals, Inc. and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-514">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has ceased operations at our subsidiary in Oakville, Ontario, Canada as of March 31, 2023. The Company currently has a subsidiary located in India. The Canada-based subsidiary conducted its transactions in U.S. dollars and Canadian dollars, but its functional currency was the U.S. dollar. The Indian-based subsidiary generally conducts its transactions in Indian rupees, which is also its functional currency. The results of any non-U.S. dollar transactions and balances are remeasured in U.S. dollars at the applicable exchange rates during the period and resulting foreign currency transaction gains and losses are included in the determination of net income. The gain or loss on transactions denominated in foreign currencies and the translation impact of local currencies to U.S. dollars was immaterial for the years ended December&#160;31, 2023, 2022, and 2021. Unless otherwise noted, all references to &#x201c;$&#x201d; or &#x201c;dollar&#x201d; refer to the U.S. dollar. The Company&#x2019;s asset and liability accounts are translated using the current exchange rate as of the balance sheet date, except for shareholders&#x2019; equity accounts, intercompany, and fixed assets, which are translated using historical rates. Net revenues and expense accounts are translated using an average exchange rate over the period ended on the balance sheet date. Adjustments resulting from the translation of the financial statements of the Company&#x2019;s foreign subsidiaries into U.S. dollars are accumulated as a separate component of shareholders&#x2019; equity within accumulated other comprehensive income (loss), net of tax.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-515">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of the Company&#x2019;s financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. In the consolidated financial statements, estimates are used for, but not limited to, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and potential adjustments, income tax expense or benefit, deferred taxes and valuation allowance, stock-based compensation, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, including contingent consideration in acquisitions, fair value of long-lived assets, determination of right-of-use assets and lease liabilities, allowance for credit losses, and the depreciable lives of long-lived assets. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from such estimates. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy contextRef="c-1" id="f-516">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restructuring Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company defines restructuring activities to include costs directly associated with exit or disposal activities. Such costs include cash employee contractual severance and other termination benefits, one-time employee termination severance and benefits, contract termination charges, impairment and acceleration of depreciation associated with long-lived assets, and other exit or disposal costs. In general, we record involuntary employee- related exit and disposal costs when there is a substantive plan for employee severance and related payments are probable and estimable. For one-time termination benefits, including those with a service requirement, expense is recorded when the employees are entitled to receive such benefits and the amount can be reasonably estimated. Expense related to one-time termination benefits with a service requirement is recorded over time, as the service is completed. Contract termination fees and penalties, and other exit and disposal costs are generally recorded as incurred. Restructuring activities are recognized as an operating expense in the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-517">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Revenue is recognized using the following steps:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Identification of the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Determination of the transaction price, including the identification and estimation of variable consideration;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Allocation of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Recognition of revenue when we satisfy a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company derives its revenues primarily from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products sold is transferred to the customer. Generally, the Company does not incur incremental costs to obtain contracts that would otherwise not have been incurred. The Company has not identified any agreements or arrangement that would qualify as a significant financing component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may enter into marketing and distribution agreements with third parties in which products are sold under Abbreviated New Drug Applications (&#x201c;ANDAs&#x201d;) or New Drug Applications (&#x201c;NDAs&#x201d;) owned or licensed by third parties. These products are sold under the ANI label. The Company controls the products sold under these marketing and distribution agreements and therefore are the principal for sales under each of these marketing and distribution agreements. As a result, revenue is recognized on a gross basis when control has passed to the customer and the performance obligation has been satisfied. Under these agreements, the Company pays third parties a specified percentage of the gross profit earned on sales of the products. These profit-sharing percentages are recognized in cost of sales in the consolidated statements of operations and are accrued in accrued royalties in the consolidated balance sheets until payment has occurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Manufacturing Product Sales Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing arrangements consist of agreements in which pharmaceutical products are manufactured by the Company on behalf of a third party. The performance obligation is to manufacture and provide pharmaceutical products to customers, typically pharmaceutical companies. The products are sold at predetermined standalone selling prices and the performance obligation is considered to be satisfied when control of the product is transferred to the customer. Control is transferred to the customer when the product leaves the shipping dock to be shipped to the customer, as  contract manufactured pharmaceutical products are sold on an FOB shipping point basis and the inventory risk and risk of ownership passes to the customer at that time. Payment terms for these sales are generally fewer than two months. Typically, there are no material returns for contract manufactured products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalties from Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into licensing agreements, under which the Company licenses to the seller the right to sell the acquired products. Because these royalties are sales-based, the Company recognizes the revenue when the underlying sales occur, based on sales and gross profit information received from the sellers. The Company may enter into agreements which include profit-sharing percentages on gross profits. The profit-sharing percentages are recorded in cost of sales in the consolidated statements of operations when the associated revenue is recognized and are recorded in accrued royalties in the consolidated balance sheets when the associated revenue is recognized and until payment has occurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-518">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid investments with original maturities of three months or less from the date of purchase are classified as cash equivalents. Cash and cash equivalents consist of cash deposited in checking accounts, time deposits with maturities of less than three months, and money market accounts with maturities of three months or less at the date of purchase. Cash and cash equivalents include cash on-hand and money market funds which invest exclusively in high-quality, short-term securities that are issued or guaranteed by the U.S. government. Due to the short-term maturity of the funds invested in the money market accounts, the carrying amounts are a reasonable estimate of fair value. All interest bearing and non-interest bearing accounts are guaranteed by the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;) up to $250 thousand. The majority of the Company's cash balances are in excess of FDIC coverage, which the Company considers to be a normal business risk.&lt;/span&gt;&lt;/div&gt;Restricted cash at December 31, 2022, represented $5.0 million of funds held in a bank account owned by the Company to be used to pay for future milestones related to the purchase of  the rights, title, and interest in the NDA for Inderal LA, as well as certain documentation, trademark rights, and finished goods from Cranford Pharmaceuticals, LLC in April 2016. This amount was was released from restricted cash during the first quarter of the year ended December&#160;31, 2023.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <anip:FDICGuaranteedAmount contextRef="c-6" decimals="-3" id="f-519" unitRef="usd">250000</anip:FDICGuaranteedAmount>
    <us-gaap:EscrowDeposit contextRef="c-59" decimals="-5" id="f-520" unitRef="usd">5000000</us-gaap:EscrowDeposit>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-521">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Accounts Receivable&lt;/span&gt;&lt;/div&gt;The Company extends credit to customers on an unsecured basis. Expected credit losses are measured at amortized cost, including trade and unbilled receivables, on a collective basis, based on their similar risk characteristics. Expected credits losses are based on historical credit loss experience, review of the current aging or status of accounts receivable and current and forward-looking views from an economic and industry perspective. Receivables are written off when it is determined that amounts are uncollectible. The allowance for credit losses was immaterial as of December&#160;31, 2023 and 2022.</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-522">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;Inventories consist of raw materials, packaging materials, work-in-progress, and finished goods. Inventories are stated at the lower of standard cost or net realizable value. The Company periodically reviews and adjusts standard costs, which generally approximate weighted average cost.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-523">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Expenditures for repairs and maintenance are charged to expense as incurred. Depreciation is recorded on a straight-line basis over estimated useful lives as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of asset's useful life or remaining life of lease &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery, furniture, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress consists of multiple projects, primarily related to new equipment and expansion of laboratory and manufacturing facilities to expand manufacturing capability as product lines grow. Construction in progress includes the cost of construction and other direct costs attributable to the construction, along with capitalized interest. Depreciation is not recorded on construction in progress until such time as the assets are placed in service.&lt;/span&gt;&lt;/div&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <anip:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock contextRef="c-1" id="f-524">Depreciation is recorded on a straight-line basis over estimated useful lives as follows:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.072%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:2.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leasehold improvements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shorter of asset's useful life or remaining life of lease &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery, furniture, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</anip:ScheduleOfPropertyPlantAndEquipmentUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-60" id="f-525">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-61" id="f-526">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-62" id="f-527">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-63" id="f-528">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-15" decimals="INF" id="f-529" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-530" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-14" decimals="INF" id="f-531" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-532">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets Held-for-Sale &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies assets held-for-sale if all held-for-sale criteria is met pursuant to ASC 360-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;. Criteria include management commitment to sell the disposal group in its present condition and the sale being deemed probable of being completed within one year. Assets classified as held-for-sale are not depreciated and are measured at the lower of their carrying amount or fair value less cost to sell. The Company assesses the fair value of a disposal group, less any costs to sell, each reporting period it remains classified as held-for-sale and reports any subsequent changes as an adjustment to the carrying value of the disposal group, as long as the new carrying value does not exceed the initial carrying value of the disposal group. The Company determined that the Oakville, Ontario, Canada property met the held-for-sale criteria.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-64" decimals="-5" id="f-533" unitRef="usd">8000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-65" decimals="-5" id="f-534" unitRef="usd">8000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-535">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use ("ROU") assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Rent expense is recognized on a straight-line basis over the lease term. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the Company does not separate lease and non-lease components of contracts. There are no material residual guarantees associated with any of the Company&#x2019;s leases, and there are no significant restrictions or covenants included in the Company&#x2019;s lease agreements. Operating lease ROU assets are included in other non-current assets and operating lease liabilities are included in accrued expenses and other and other non-current liabilities in the consolidated balance sheets. As of December&#160;31, 2023 and 2022, the Company did not have any finance leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="c-1" id="f-536">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite lives are amortized based on their pattern of economic benefit over their estimated useful lives and reviewed periodically for impairment. The definite-lived ANDAs, NDAs and product rights, marketing and distribution rights, customer relationships, and non-compete agreement are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:f-537"&gt;seven&lt;/span&gt; to ten years, based on the straight-line amortization method. In the case of certain NDA and product rights, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Management reviews definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable, in a manner similar to that for property and equipment. During the year ended December&#160;31, 2023, no impairment charges were recognized on intangible assets.. During the year ended December&#160;31, 2022, the Company recognized a full impairment of a definite-lived ANDA asset with a remaining carrying value of $0.1 million. During the year ended December&#160;31, 2021, the Company recognized an impairment charge of $2.4 million related to a definite-lived ANDA intangible asset. No events or circumstances arose in 2023, 2022, or 2021 that indicated that the carrying value of any of the other definite-lived intangible assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets other than goodwill include in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects. IPR&amp;amp;D intangible assets represent the fair value of technology acquired in a business combination for which the technology projects are incomplete but have substance. When an IPR&amp;amp;D project is completed (generally upon receipt of regulatory approval), the asset is then accounted for as a definite-lived intangible asset. Indefinite-lived intangibles are tested for impairment at least annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying amount of the asset might not be recoverable. Judgment is used in determining when these events and circumstances arise. No events or circumstances arose in 2023 that indicated that the carrying value of any of the indefinite-lived intangible assets may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-67" id="f-538">P10Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-539" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-14" decimals="-5" id="f-540" unitRef="usd">100000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-15" decimals="-5" id="f-541" unitRef="usd">2400000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-542">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which represents the excess of purchase price over the fair value of net assets acquired, is carried at cost, using the purchase method of accounting, and is related to past business combinations with BioSante Pharmaceuticals, Inc., WellSpring, and Novitium. Goodwill is not amortized, but is subject to periodic review for impairment. The Company is organized in two operating segments, and two reporting units, and has determined that goodwill resides in one reporting unit, Generics, Established Brands, and Other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews goodwill for impairment on a reporting unit basis annually, on October 31, and whenever events or changes in circumstances indicate the carrying value of goodwill might not be recoverable. Under the authoritative guidance issued by the FASB, the Company has the option to first assess the qualitative factors to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform a quantitative goodwill impairment test. If the Company determines that it is more likely than not that the fair value of a reporting unit is less than its carrying amount, then the goodwill impairment test is performed. The goodwill impairment test requires the Company to estimate the fair value of the reporting unit and to compare the fair value of the reporting unit with its carrying amount. If the fair value exceeds the carrying amount, then no impairment is recognized. If the carrying amount recorded exceeds the fair value calculated, then an impairment charge is recognized for the difference. The judgments made in determining the projected cash flows used to estimate the fair value can materially impact the Company&#x2019;s financial condition and results of operations. &lt;/span&gt;&lt;/div&gt;The Company assessed the assets qualitatively, and concluded it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit is greater than its carrying value as of October 31, 2023 and 2022, and therefore no quantitative testing for impairment was required.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-543"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-544"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-14" decimals="INF" id="f-545" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-546" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-15" decimals="INF" id="f-547" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-548">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaborative Arrangements &lt;/span&gt;&lt;/div&gt;The Company may enter into collaborative arrangements with various commercial partners to further business opportunities. In collaborative arrangements revenues and costs generated by collaborative arrangements may be presented on a gross or net basis depending on the specific facts of the collaborative arrangement.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-549">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;Research and development ("R&amp;amp;D") activities are expensed as incurred. R&amp;amp;D expenses primarily consist of direct and allocated expenses incurred with the process of formulation, clinical research, and validation associated with new product development.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-550">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company issues stock options and restricted stock awards, which are awarded in exchange for employee and non-employee director services. From time to time, the Company may grant awards through an inducement grant outside of the incentive plan to induce prospective employees to accept employment with the Company. These grants are made pursuant to inducement grants outside of the shareholder approved equity plan as permitted under the Nasdaq Stock Market listing rules. Stock-based compensation cost for stock options is determined at the grant date using an option pricing model and stock-based compensation cost for restricted stock awards is based on the closing market price of the stock at the grant date. The value of the award is recognized as expense on a straight-line basis over the employee&#x2019;s requisite service period and classified where the underlying salaries are classified. Forfeitures are accounted for as they occur. Excess tax benefits or tax deficiencies are recognized as a component of the current period provision for income taxes.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards may also be issued in the form of Performance Stock Units (&#x201c;PSUs&#x201d;) to certain employees of the Company. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted vest over a three-year performance period. Currently, the PSU&#x2019;s vesting is contingent upon the Company meeting certain total shareholder return (&#x201c;TSR&#x201d;) levels as compared to a select peer group over the over three years, and contingent upon the Company meeting certain adjusted non-GAAP year-on-year &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;earnings before interest, income taxes, depreciation, and amortization (&#x201c;EBITDA&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; growth rates over the vesting term. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also administers an Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;). The estimated fair value of stock-based compensation awards are recognized and classified in the expense where the underlying salaries are classified. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation of stock awards requires us to make assumptions and to apply judgment to determine the fair value of the awards. These assumptions and judgments include estimating the future volatility of the Company's stock price and dividend yields. Changes in these assumptions can affect the fair value estimate.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-68" id="f-551">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-68" id="f-552">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-553">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in various U.S. jurisdictions, Canada, and India, and all of our income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We use a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. We have not identified any uncertain income tax positions that could have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has previously entered into an interest rate swap agreement (Note 6) designated as a cash flow hedge designed to manage exposure to changes in SOFR-interest rate underlying our variable rate debt. Due to the effective nature of the hedge, the initial fair value of the hedge and subsequent changes in the fair value of the hedge are recognized in other comprehensive income (loss) in the consolidated balance sheets. Income taxes are allocated to the hedge component of other comprehensive income (loss) based on appropriate intra-period tax allocations when those effects are deemed material.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives contextRef="c-1" id="f-554">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Derivative Instruments and Hedge Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses interest rate swaps to hedge exposure to interest rate risk, as well as benefit from favorable conditions. The Company recognizes all derivative instruments as either assets or liabilities at fair value. For all of the Company&#x2019;s derivative positions that are designated and qualify as part of a cash flow hedging relationship, the effective portion of the gain or loss on the derivatives is reported as a component of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;other comprehensive income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and reclassified into earnings in the same period or periods during which the hedged transactions affect earnings. Gains and losses on derivatives representing any ineffective component of the hedge are recognized in current earnings. All of the Company&#x2019;s cash flow hedges have been deemed effective as of December&#160;31, 2023 for both accounting and tax purposes. The Company has elected hedge accounting for both U.S. GAAP and tax purposes. The Company maintains formal documentation through a periodic memo and accounting analysis that cover what is being hedged, how it is being hedged, hedge effectiveness, the nature of the risk being hedged, among other required analyses. Company policy further includes a quarterly probability analysis covering hedge effectiveness.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesMethodsOfAccountingHedgingDerivatives>
    <us-gaap:ContingentLiabilityReserveEstimatePolicy contextRef="c-1" id="f-555">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The terms of the acquisition agreement between ANI and Novitium Pharma LLC include the potential payment of future consideration that is contingent upon the achievement of certain regulatory and financial performance milestones. At the acquisition date, contingent consideration is recorded at fair value based on the additional consideration expected to be transferred, which is based on the estimate of probability-weighted future cash flows as discounted to present value. Significant inputs used in the measurement of the fair value include discount rates, probabilities of achievement of regulatory-based milestones and payments, and projected revenues and gross profits. The discount rates are derived using accepted valuation methodologies. The probability of achievement of regulatory milestones is based on historical and projected success rates. The projected revenues and gross profits are based on internal forecasts and long-term plans. The contingent consideration is remeasured each reporting period using Level 3 inputs. Changes in fair value, which incorporate changes in assumptions and the passage of time, are recognized as an operating expense in the consolidated statements of operations. As payments are not expected to be made shortly after the acquisition, any future payment of contingent consideration will be reported as a financing cash flow for amounts paid up to the acquisition-date fair value of the consideration, and as an operating cash outflow for any amounts in excess of the acquisition-date fair value in our consolidated statement of cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ContingentLiabilityReserveEstimatePolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-556">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value. These tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1&#x2014;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2&#x2014;Observable market-based inputs other than quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3&#x2014;Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated balance sheets include certain financial instruments (primarily cash and cash equivalents, prepaid expenses, accounts receivable, accounts payable, accrued expenses, and other current liabilities) that are carried at cost and that approximate fair values as of December&#160;31, 2023, 2022 due to their short term nature. See Note 10 for additional information regarding fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-557">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and are adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued Accounting Standards Update ("ASU") 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which improves reportable segment disclosure requirements, primarily through enhanced disclosures related to significant segment expenses. The guidance in this ASU is effective for all public entities for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The guidance is applied retrospectively to all periods presented in the financial statements, unless it is impracticable. The Company is currently evaluating the effect the adoption of this ASU may have on its disclosures in the notes to the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which includes guidance to expand the disclosure requirements for income taxes, specifically related to the rate reconciliation and income taxes paid. These amendments are effective for all public entities for fiscal periods beginning after December 15, 2024, with early adoption permitted. These amendments apply on a prospective basis, but entities have an option to apply it retrospectively for all periods presented. The Company does not expect that the adoption of this guidance will have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Adopted &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the FASB issued ASU 2020-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This ASU provides optional expedients and exceptions, that may be elected over time as reference rate reform activities occur, for applying GAAP to contracts, hedging relationships and other transactions that reference the London Interbank Offered Rate ("LIBOR") or another reference rate expected to be discontinued because of reference rate reform. The guidance in this ASU was extended in December 2022 when the FASB issued ASU 2022-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, extending the sunset date under Topic 848 to December 31, 2024 to align the temporary accounting relief guidance with the expected LIBOR cessation. &lt;/span&gt;&lt;/div&gt;In August 2023, the Company completed the transition of its debt and derivative instruments from LIBOR to Adjusted Term Secured Overnight Financing Rate ("SOFR") and applied the optional expedients in ASC 848 related to contract modifications and changing critical terms of the Company&#x2019;s hedging relationships. Application of these expedients allowed the Company to preserve presentation of derivatives as qualifying cash flow hedges and to account for the debt modification as a continuation of the existing contract. The adoption of this guidance did not have a material impact on the consolidated financial statements.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-558">REVENUE RECOGNITION AND RELATED ALLOWANCES &lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues are primarily derived from sales of generic, rare disease, and established brand pharmaceutical products, royalties, and other pharmaceutical services. Revenue is recognized when obligations under the terms of contracts with customers are satisfied, which generally occurs when control of the products we sell is transferred to the customer. Variable consideration is estimated after the consideration of applicable information that is reasonably available. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. The Company does not adjust revenue for the promised amount of consideration for the effects of a significant financing component because our customers generally pay us within 100 days.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All revenue recognized in the accompanying consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products and Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of generic pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;210,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of rare disease pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Timing of Revenue Recognition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations transferred at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations transferred over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the years ended December&#160;31, 2023 or 2022, the Company did not incur, and therefore did not defer, any material incremental costs to obtain or fulfill contracts. As of December&#160;31, 2023, there were no contract assets recorded which were related to revenue recognized based on percentage of completion but not yet billed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized an increase of $4.1 million of net revenue from performance obligations satisfied in prior periods during the year ended December&#160;31, 2023, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consisting primarily of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revised estimates for variable consideration, including chargebacks, rebates, returns, and other allowances, related to prior period sales. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2023 and 2022, the Company recognized less than $0.1 million of revenue that was included in deferred revenue as of December&#160;31, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the aggregate amount of the transaction price allocated to the remaining performance obligations for all open contract manufacturing customer contracts was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; million, which consists of firm orders for contract manufactured products. We will recognize revenue for these performance obligations as they are satisfied, which is anticipated within six months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of pharmaceutical products are subject to variable consideration due to chargebacks, government rebates, returns, administrative and other rebates, and cash discounts. Estimates for these elements of variable consideration require significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Chargebacks, primarily from wholesalers, result from arrangements with indirect customers establishing prices for products which the indirect customer purchases through a wholesaler. Alternatively, the Company may pre-authorize wholesalers to offer specified contract pricing to other indirect customers. Under either arrangement, the Company provides a chargeback credit to the wholesaler for any difference between the contracted price with the indirect customer and the wholesaler&#x2019;s invoice price, typically Wholesale Acquisition Cost (&#x201c;WAC&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior period chargebacks claimed by wholesalers are analyzed to determine the actual average selling price (&#x201c;ASP&#x201d;) for each product. This calculation is performed by product by wholesaler. ASPs can be affected by several factors such as:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A change in customer mix&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A change in negotiated terms with customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A change in the volume of off-contract purchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Changes in WAC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As necessary, ASPs are adjusted based on anticipated changes in the factors above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between ASP and WAC is recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets, at the time revenue is recognized from the product sale. The Company continually monitors chargeback activity and adjusts ASPs when the Company believes that actual selling prices will differ from current ASPs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government rebates reserve consists of estimated payments due to governmental agencies for utilization of our products by beneficiaries under such governmental programs. The two largest government programs are Medicaid and Medicare.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the Medicaid Drug Rebate Program and pays rebates to the states related on Medicaid beneficiary utilization of the Company's products. Medicaid rebates are billed 60-90 days of the end of the quarter in which the product was dispensed to a Medicaid beneficiary. Medicaid rebate amounts per product unit are established by law, based on the Average Manufacturer Price (&#x201c;AMP&#x201d;), which is reported on a monthly and quarterly basis, and, in the case of branded products, best price, which is reported on a quarterly basis. Medicaid reserves are based on expected claims from state Medicaid programs. Estimates for expected claims are driven by patient usage, sales mix, calculated AMP or best price, as well as inventory in the distribution channel that will be subject to a Medicaid rebate. As a result of the delay between selling the products, dispensing the products and rebate billing, the Medicaid rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to plan participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the products are also covered under Medicare. ANI participates in the Coverage Gap Discount Program in order for its branded drugs to be covered by Medicare Part D and must provide a rebate for any products sold under NDAs dispensed to Medicare Part D beneficiaries while the beneficiaries are in the Coverage Gap phase of the benefit. This applies to all products sold under NDAs, regardless of whether the products are marketed as branded or generic. Estimates for these discounts are based on historical experience with Medicare rebates for products. Medicare rebates are billed quarterly for drugs dispensed to Medicare beneficiaries in the prior quarter, which is typically 120 days after the product is shipped. As a result of the delay between selling the products, dispensing the products and rebate billing, Medicare rebate reserve includes both an estimate of outstanding claims for end-customer sales that have occurred but for which the related claim has not been billed, as well as an estimate for future claims that will be made when inventory in the distribution channel is sold through to Medicare Part D participants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To evaluate the adequacy of the government rebate reserves, reserves are reviewed on a quarterly basis against actual claims data to ensure the liability is fairly stated. The Company continually monitors the government rebate reserve and adjusts estimates if it is expected that actual government rebates may differ from established accruals. Accruals for government rebates are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to accrued government rebates in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A returns policy is in place that allows customers to return product within a specified period prior to and subsequent to the expiration date. Generally, product may be returned for a period beginning six months prior to its expiration date to up to one year after its expiration date. Product returns are settled through the issuance of a credit to the customer. The estimate for returns is based upon historical experience with actual returns. While such experience has allowed for reasonable estimation in the past, history may not always be an accurate indicator of future returns. We continually monitor estimates for returns and make adjustments when it is expected that actual product returns may differ from the established accruals. Accruals for returns are recorded as a reduction to gross revenues in the consolidated statements of operations and as an increase to the return goods reserve in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Administrative Fees and Other Rebates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Administrative fees or rebates are offered to wholesalers, group purchasing organizations, and indirect customers. Fees and rebates are accrued, by product by wholesaler, at the time of sale based on contracted rates and ASPs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To evaluate the adequacy of the administrative fee accruals, on-hand inventory counts are obtained from the wholesalers. The Company continually monitors administrative fee activity and adjust accruals when it is expected that actual administrative fees may differ from the accruals. Accruals for administrative fees and other rebates are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prompt Payment Discounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales discounts may be granted to customers for prompt payment. The reserve for prompt payment discounts is based on invoices outstanding. Based on past experience, it is assumed that all available discounts will be taken. Accruals for prompt payment discounts are recorded as a reduction in both gross revenues in the consolidated statements of operations and accounts receivable in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accruals for Chargebacks, Returns, and Other Allowances&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Government&lt;br/&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Administrative&lt;br/&gt;Fees and Other&lt;br/&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Prompt&lt;br/&gt;Payment&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;642,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credits Taken Against Reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(587,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(45,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credits Taken Against Reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(650,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Returns are included in returned goods reserve in the consolidated balance sheets. Government Rebates are included in accrued government rebates in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Credit Concentration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023 four customers accounted for 10% or more of net revenues. During the years ended December 31, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, three customers accounted for 10% or more of net revenues. As of December&#160;31, 2023, accounts receivable from these customers totaled 81% of accounts receivable, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The four customers represent the total percentage of net revenues as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-559">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All revenue recognized in the accompanying consolidated statements of operations is considered to be revenue from contracts with customers. The following table depicts the disaggregation of revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Products and Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of generic pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;269,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;210,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;143,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;64,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;72,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales of rare disease pharmaceutical products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Timing of Revenue Recognition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations transferred at a point in time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;214,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Performance obligations transferred over time&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-560" unitRef="usd">269449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="-3" id="f-561" unitRef="usd">210121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-71" decimals="-3" id="f-562" unitRef="usd">143571000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-563" unitRef="usd">105250000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-73" decimals="-3" id="f-564" unitRef="usd">64578000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="-3" id="f-565" unitRef="usd">72565000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-75" decimals="-3" id="f-566" unitRef="usd">112117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-567" unitRef="usd">41686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-568" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-569" unitRef="usd">486816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-570" unitRef="usd">316385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-571" unitRef="usd">216136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-572" unitRef="usd">486441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-3" id="f-573" unitRef="usd">313436000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-574" unitRef="usd">214826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-575" unitRef="usd">375000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-576" unitRef="usd">2949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-577" unitRef="usd">1310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-578" unitRef="usd">486816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-579" unitRef="usd">316385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-580" unitRef="usd">216136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod contextRef="c-1" decimals="-5" id="f-581" unitRef="usd">4100000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-582" unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-14" decimals="-5" id="f-583" unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-84" decimals="-5" id="f-584" unitRef="usd">6300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration contextRef="c-84" id="f-585">P6M</us-gaap:RevenueRemainingPerformanceObligationOptionalExemptionRemainingDuration>
    <anip:ProductReturnPeriod contextRef="c-66" id="f-586">P6M</anip:ProductReturnPeriod>
    <anip:ProductReturnPeriod contextRef="c-67" id="f-587">P1Y</anip:ProductReturnPeriod>
    <anip:ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes activity in the consolidated balance sheets for accruals and allowances for the years ended December&#160;31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Accruals for Chargebacks, Returns, and Other Allowances&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Government&lt;br/&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Administrative&lt;br/&gt;Fees and Other&lt;br/&gt;Rebates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Prompt&lt;br/&gt;Payment&lt;br/&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2021 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;94,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;642,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;42,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credits Taken Against Reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(587,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,277)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(25,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(45,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2022 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;148,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals/Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;586,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22,932&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Credits Taken Against Reserve&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(650,865)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,619)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(22,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(53,828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(24,555)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance at December 31, 2023 (1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"&gt;Chargebacks are included as an offset to accounts receivable, net of chargebacks and other allowances in the consolidated balance sheets. Administrative Fees and Other Rebates and Prompt Payment Discounts are included as a reduction to accounts receivable, net of chargebacks and other allowances or accrued expenses and other in the consolidated balance sheets. Returns are included in returned goods reserve in the consolidated balance sheets. Government Rebates are included in accrued government rebates in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</anip:ScheduleOfValuationAndQualifyingAccountsDisclosureTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-85" decimals="-3" id="f-589" unitRef="usd">94066000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-86" decimals="-3" id="f-590" unitRef="usd">5492000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-87" decimals="-3" id="f-591" unitRef="usd">35831000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-88" decimals="-3" id="f-592" unitRef="usd">13100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-89" decimals="-3" id="f-593" unitRef="usd">4642000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-90" decimals="-3" id="f-594" unitRef="usd">642409000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-91" decimals="-3" id="f-595" unitRef="usd">20657000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-92" decimals="-3" id="f-596" unitRef="usd">23252000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-93" decimals="-3" id="f-597" unitRef="usd">42044000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-94" decimals="-3" id="f-598" unitRef="usd">21302000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-90" decimals="-3" id="f-599" unitRef="usd">587913000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-91" decimals="-3" id="f-600" unitRef="usd">15277000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-92" decimals="-3" id="f-601" unitRef="usd">25684000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-93" decimals="-3" id="f-602" unitRef="usd">45702000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-94" decimals="-3" id="f-603" unitRef="usd">19456000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-95" decimals="-3" id="f-604" unitRef="usd">148562000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-96" decimals="-3" id="f-605" unitRef="usd">10872000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-97" decimals="-3" id="f-606" unitRef="usd">33399000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-98" decimals="-3" id="f-607" unitRef="usd">9442000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-99" decimals="-3" id="f-608" unitRef="usd">6488000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-100" decimals="-3" id="f-609" unitRef="usd">586511000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-101" decimals="-3" id="f-610" unitRef="usd">23915000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-102" decimals="-3" id="f-611" unitRef="usd">18360000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-103" decimals="-3" id="f-612" unitRef="usd">55798000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesAdjustments contextRef="c-104" decimals="-3" id="f-613" unitRef="usd">22932000</us-gaap:ValuationAllowancesAndReservesAdjustments>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-100" decimals="-3" id="f-614" unitRef="usd">650865000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-101" decimals="-3" id="f-615" unitRef="usd">22619000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-102" decimals="-3" id="f-616" unitRef="usd">22081000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-103" decimals="-3" id="f-617" unitRef="usd">53828000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-104" decimals="-3" id="f-618" unitRef="usd">24555000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-105" decimals="-3" id="f-619" unitRef="usd">84208000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-106" decimals="-3" id="f-620" unitRef="usd">12168000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-107" decimals="-3" id="f-621" unitRef="usd">29678000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-108" decimals="-3" id="f-622" unitRef="usd">11412000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-109" decimals="-3" id="f-623" unitRef="usd">4865000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-110" decimals="2" id="f-624" unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The four customers represent the total percentage of net revenues as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Customer 4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-111" decimals="2" id="f-626" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-112" decimals="2" id="f-627" unitRef="number">0.26</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-113" decimals="2" id="f-628" unitRef="number">0.29</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-114" decimals="2" id="f-629" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-115" decimals="2" id="f-630" unitRef="number">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-116" decimals="2" id="f-631" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-117" decimals="2" id="f-632" unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-118" decimals="2" id="f-633" unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-119" decimals="2" id="f-634" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-120" decimals="2" id="f-635" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-121" decimals="2" id="f-636" unitRef="number">0.06</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-122" decimals="2" id="f-637" unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-638">BUSINESS COMBINATION&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company acquired all of the interests of Novitium pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021. This acquisition was accounted for as a business combination. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total consideration consisted of cash of approximately $88.1&#160;million, 2,466,654 restricted shares of common stock valued at $91.2 million, and up to $46.5 million in additional contingent consideration. Additionally, the Company agreed to pay certain debts of Novitium in the amount of $8.5 million. The contingent consideration is based on the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future. As of the acquisition date, the contingent consideration had a fair value of $30.8 million. Total consideration including cash, restricted shares and contingent consideration, net of cash acquired of $12.1&#160;million was $206.5 million at the date of purchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration was $24.0 million and $35.1 million as of December&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 10 for changes in contingent consideration and changes in fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cash consideration was funded in part by borrowings under the cr&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;edit facility (Note 5) and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; through issuance of convertible  preferred stock sha&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;res. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the execution of the Merger Agreement, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the &#x201c;PIPE Investor&#x201d;), pursuant to which the PIPE Investor agreed to purchase, 25,000 shares of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Series A Convertible Preferred Stock (the &#x201c;PIPE Shares&#x201d;), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Note 11)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he acquisition of Novitium was completed due to its proven track record of being a research and development growth engine capable of fueling sustainable growth, to expand the research and development pipeline via niche opportunities, to enhance the contract development and manufacturing organization (&#x201c;CDMO&#x201d;) business and U.S. based manufacturing capacity, and to diversify the Company's revenue base.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net assets were recorded at their estimated fair value. In valuing acquired assets and liabilities, fair value estimates were based primarily on future expected cash flows, market rate assumptions for contractual obligations, and appropriate discount rates. In connection with the acquisition, $46.9 million of indefinite-lived in-process research and development intangible assets, $67.4 million of acquired ANDA intangible assets, $24.9 million of customer relationship intangible assets, and goodwill of $24.6&#160;million was recognized. Goodwill is considered an indefinite-lived asset and relates primarily to intangible assets that do not qualify for separate recognition, such as the assembled workforce and synergies between the entities. Goodwill established as a result of the acquisition is tax deductible in the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novitium operations generated $149.9 million and $90.3 million of revenue during the years ended December&#160;31, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Transaction Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the acquisition, approximately $9.4 million in transaction costs were expensed during the year ended 2022 as selling, general, and administrative expense in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Novitium acquisition consideration included 2,466,654 restricted shares, which were valued at $91.2 million. These shares contained restrictions on their transfer for periods from &lt;span style="-sec-ix-hidden:f-663"&gt;three&lt;/span&gt; to twenty-four months following the completion of the acquisition. A Finnerty model was used to value the restricted shares. It includes inputs of not readily observable market data, which are Level 3 inputs. These unobservable inputs include ANI stock volatility with a range of 65% to 71%, and the discounted lack of marketability with a range of 7.5% to 21.5% depending on the length of restriction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#252525;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pro Forma Consolidated Financial Information (unaudited)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma consolidated financial information summarizes the results of operations for the periods indicated as if the Novitium acquisition had been completed as of January 1, 2020.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;272,888&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-123" decimals="-5" id="f-639" unitRef="usd">88100000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-123"
      decimals="INF"
      id="f-640"
      unitRef="shares">2466654</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-123" decimals="-5" id="f-641" unitRef="usd">91200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-124" decimals="-5" id="f-642" unitRef="usd">46500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-123" decimals="-5" id="f-643" unitRef="usd">8500000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <anip:RestrictionPeriodForSharesIssuedInBusinessCombination contextRef="c-123" id="f-644">P24M</anip:RestrictionPeriodForSharesIssuedInBusinessCombination>
    <anip:RestrictionPeriodForSharesIssuedInBusinessCombination contextRef="c-123" id="f-645">P24M</anip:RestrictionPeriodForSharesIssuedInBusinessCombination>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-124" decimals="-5" id="f-646" unitRef="usd">30800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c-123" decimals="-3" id="f-647" unitRef="usd">12100000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-123" decimals="-5" id="f-648" unitRef="usd">206500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-125" decimals="-5" id="f-649" unitRef="usd">24000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-126" decimals="-5" id="f-650" unitRef="usd">35100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-127"
      decimals="INF"
      id="f-651"
      unitRef="shares">25000</anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c-128"
      decimals="INF"
      id="f-652"
      unitRef="usdPerShare">1000</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-127" decimals="-5" id="f-653" unitRef="usd">25000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-129" decimals="-5" id="f-654" unitRef="usd">46900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-130" decimals="-5" id="f-655" unitRef="usd">67400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="c-131" decimals="-5" id="f-656" unitRef="usd">24900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
    <us-gaap:Goodwill contextRef="c-124" decimals="-3" id="f-657" unitRef="usd">24600000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c-132" decimals="-5" id="f-658" unitRef="usd">149900000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual contextRef="c-133" decimals="-5" id="f-659" unitRef="usd">90300000</us-gaap:BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-133" decimals="-5" id="f-660" unitRef="usd">9400000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-123"
      decimals="INF"
      id="f-661"
      unitRef="shares">2466654</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable contextRef="c-123" decimals="-5" id="f-662" unitRef="usd">91200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <anip:RestrictionPeriodForSharesIssuedInBusinessCombination contextRef="c-135" id="f-664">P24M</anip:RestrictionPeriodForSharesIssuedInBusinessCombination>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-136" decimals="2" id="f-665" unitRef="number">0.65</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-137" decimals="2" id="f-666" unitRef="number">0.71</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-138" decimals="3" id="f-667" unitRef="number">0.075</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-139" decimals="3" id="f-668" unitRef="number">0.215</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="c-1" id="f-669">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following unaudited pro forma consolidated financial information summarizes the results of operations for the periods indicated as if the Novitium acquisition had been completed as of January 1, 2020.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;272,888&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(31,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="c-15" decimals="-3" id="f-670" unitRef="usd">272888000</us-gaap:BusinessAcquisitionsProFormaRevenue>
    <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="c-15" decimals="-3" id="f-671" unitRef="usd">-31740000</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-672">RESTRUCTURING &lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 31, 2023 the Compan&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;y ceased operations at the Oakville, Ontario, Canada manufacturing plant. This action was part of ongoing initiatives to capture operational synergies following the acquisition of Novitium in November 2021. ANI has fully completed the transition of the products manufactured or packaged in Oakville to one of the Company's three U.S.-based manufacturing sites. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2023, restructuring activities resulted in expenses of $1.1 million. This included $0.2 million of severance and other employee benefit costs and $0.7 million of asset-related impairment and accelerated depreciation costs, and $0.2 million for other miscellaneous other costs. As of December&#160;31, 2023, $0.1 million of the severance and other employee benefits are unpaid and accrued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December 31, 2022, restructuring activities resulted in expenses of $5.7&#160;million. This included $2.1&#160;million of severance and other employee benefit costs and $3.1&#160;million of asset-related impairment and accelerated depreciation costs, and $0.4&#160;million for other miscellaneous other costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no restructuring expenses incurred for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These costs are recorded as restructuring activities, an operating item, in the accompanying consolidated statements of operations. Certain of the severance and other employee benefit costs contain a service requirement, and as such, are being accrued over time as they are earned. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the exit of the Canadian facility, the Company has determined that the land and building at the Oakville, Ontario, Canada plant will be sold together and met the criteria to be classified as held for sale as of March 31, 2023. The land and building have a net carrying value of $8.0 million, which is presented as assets held for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on the accompanying consolidated balance sheets as of December 31, 2023. These assets are part of the Generics, Established Brands, and Other segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 6, 2023, ANI Pharmaceuticals Canada Inc., a wholly owned subsidiary of the Company, entered into an agreement with a potential buyer for the sale of the Oakville, Ontario manufacturing facility, however, the agreement was subsequently terminated in December 2023 by mutual agreement. In February 2024, the Company entered into an agreement for the purchase and sale of the Oakville site, for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The sale is expected to close in March 2024 (Note 19).&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <anip:NumberOfPharmaceuticalManufacturingFacilities
      contextRef="c-6"
      decimals="INF"
      id="f-673"
      unitRef="facility">3</anip:NumberOfPharmaceuticalManufacturingFacilities>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-140" decimals="-5" id="f-674" unitRef="usd">1100000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-141" decimals="-5" id="f-675" unitRef="usd">200000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-142" decimals="-5" id="f-676" unitRef="usd">700000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-143" decimals="-5" id="f-677" unitRef="usd">200000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringReserve contextRef="c-144" decimals="-5" id="f-678" unitRef="usd">100000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-145" decimals="-5" id="f-679" unitRef="usd">5700000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-146" decimals="-5" id="f-680" unitRef="usd">2100000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-147" decimals="-5" id="f-681" unitRef="usd">3100000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-148" decimals="-5" id="f-682" unitRef="usd">400000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-149" decimals="INF" id="f-683" unitRef="usd">0</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-144" decimals="-5" id="f-684" unitRef="usd">8000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-685" unitRef="cad">19200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-686" unitRef="usd">14200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-687">INDEBTEDNESS&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company, as borrower, entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) with Truist Bank and other lenders, which provides for credit facilities consisting of (i) a senior secured term loan facility in an aggregate principal amount of $300.0 million (the &#x201c;Term Facility&#x201d;) and (ii) a senior secured revolving credit facility in an aggregate commitment amount of $40.0 million, which may be used for revolving credit loans, swingline loans and letters of credit (the &#x201c;Revolving Facility,&#x201d; and together with the Term Facility, the &#x201c;Credit Facility&#x201d;). The Term Facility proceeds were used to finance the cash portion of the consideration under the Merger Agreement, repay the existing credit facility, and pay fees, costs and expenses incurred in connection with the merger. The Term Facility matures in November 2027 and the Revolving Facility in November 2026. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facility has a subjective acceleration clause in case of a material adverse effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR pursuant to the terms of Amendment No.1 to the Credit Agreement (&#x201c;Amendment No. 1&#x201d;). SOFR will be applied to the Credit Facility for the interest period (as defined in the Credit Agreement) beginning on August 1, 2023 and replaced all LIBOR terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facility permits both base rate borrowings (&#x201c;ABR Loans&#x201d;) and Eurodollar rate borrowings (&#x201c;Eurodollar Loans&#x201d;), plus a spread of (a) 5.00% above the base rate in the case of ABR Loans under the Term Facility and 6.00% above the SOFR Rate (or alternate benchmark rate as defined in the Credit Agreement) in the case of SOFR loans under the Term Facility and (b) 3.75% above the base rate in the case of ABR Loans under the Revolving Facility and 4.75% above the SOFR Rate (as defined in the Credit Facility) in the case of loans under the Revolving Facility. Amendment No. 1 also includes the addition of a credit spread adjustment of 0.11448% for an interest period of one-month duration, 0.26161% for a three-month duration, and 0.42826% for a six-month duration, in addition to SOFR and the applicable margin, as noted above. There were no other changes or modifications to the Credit Agreement. The Company has applied the optional expedients in ASC 848, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reference Rate Reform&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and elected to treat the change in the benchmark interest rate to SOFR as a continuation of the existing Credit Agreement and account for the change prospectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate under the Term Facility was 11.46% at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $0 drawn on the Revolving Facility and $40.0 million remained available for borrowing subject to certain conditions.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company incurred $14.0 million in deferred debt issuance costs associated with the Credit Facility. Costs allocated to the Term Facility are classified as a direct reduction to the current and non-current portion of the borrowings, depending on their nature. Costs allocated to the Revolving Facility are classified as other current and other non-current assets, depending on their nature. A commitment fee of 0.5% per annum on any unused portion of the Revolving Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Facility is secured by a lien on substantially all of ANI Pharmaceuticals, Inc.&#x2019;s and its principal domestic subsidiary&#x2019;s assets and any future domestic subsidiary guarantors&#x2019; assets. The Credit Facility is subject to customary financial and nonfinancial covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the current and non-current components of the Term Facility as of the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current borrowing on debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current debt, net of deferred financing costs &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current borrowing on debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current debt, net of deferred financing costs and current component&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;284,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, outstanding principal was $294.0 million on the Term Facility. Of the $0.6 million of unamortized deferred debt issuance costs allocated to the Revolving Facility, $0.4 million is included in other non-current assets in the consolidated balance sheets, and $0.2 million is included in prepaid expenses and other current assets in the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturity of the Term Facility is as follows for the years ending December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of total interest expense related to the Term Facility recognized in the accompanying consolidated statements of operations for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual coupon&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finance fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;914&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,418&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,945&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-150" decimals="-5" id="f-688" unitRef="usd">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-151" decimals="-5" id="f-689" unitRef="usd">40000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-152" decimals="4" id="f-690" unitRef="number">0.0500</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-153" decimals="4" id="f-691" unitRef="number">0.0600</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-154" decimals="4" id="f-692" unitRef="number">0.0375</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-155" decimals="4" id="f-693" unitRef="number">0.0475</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-156" decimals="7" id="f-694" unitRef="number">0.0011448</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-157" decimals="7" id="f-695" unitRef="number">0.0026161</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="c-158" decimals="7" id="f-696" unitRef="number">0.0042826</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-159" decimals="4" id="f-697" unitRef="number">0.1146</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-160" decimals="INF" id="f-698" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-161" decimals="-5" id="f-699" unitRef="usd">40000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-162" decimals="-5" id="f-700" unitRef="usd">14000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage contextRef="c-163" decimals="3" id="f-701" unitRef="number">0.005</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-702">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the current and non-current components of the Term Facility as of the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current borrowing on debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current debt, net of deferred financing costs &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Current&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current borrowing on debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;291,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(6,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8,331)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-current debt, net of deferred financing costs and current component&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;284,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <anip:LongTermDebtGrossCurrent contextRef="c-164" decimals="-3" id="f-703" unitRef="usd">3000000</anip:LongTermDebtGrossCurrent>
    <anip:LongTermDebtGrossCurrent contextRef="c-165" decimals="-3" id="f-704" unitRef="usd">3000000</anip:LongTermDebtGrossCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-164" decimals="-3" id="f-705" unitRef="usd">2150000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-165" decimals="-3" id="f-706" unitRef="usd">2150000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:LongTermDebtCurrent contextRef="c-164" decimals="-3" id="f-707" unitRef="usd">850000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-165" decimals="-3" id="f-708" unitRef="usd">850000</us-gaap:LongTermDebtCurrent>
    <anip:LongTermDebtGrossNonCurrent contextRef="c-164" decimals="-3" id="f-709" unitRef="usd">291000000</anip:LongTermDebtGrossNonCurrent>
    <anip:LongTermDebtGrossNonCurrent contextRef="c-165" decimals="-3" id="f-710" unitRef="usd">294000000</anip:LongTermDebtGrossNonCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-164" decimals="-3" id="f-711" unitRef="usd">6181000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-165" decimals="-3" id="f-712" unitRef="usd">8331000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-164" decimals="-3" id="f-713" unitRef="usd">284819000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-165" decimals="-3" id="f-714" unitRef="usd">285669000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-159" decimals="-5" id="f-715" unitRef="usd">294000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-161" decimals="-5" id="f-716" unitRef="usd">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="c-161" decimals="-5" id="f-717" unitRef="usd">400000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="c-161" decimals="-5" id="f-718" unitRef="usd">200000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-719">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturity of the Term Facility is as follows for the years ending December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.236%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term Facility&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;285,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;294,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-166" decimals="-3" id="f-720" unitRef="usd">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-166" decimals="-3" id="f-721" unitRef="usd">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-166" decimals="-3" id="f-722" unitRef="usd">3000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-166" decimals="-3" id="f-723" unitRef="usd">285000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebt contextRef="c-166" decimals="-3" id="f-724" unitRef="usd">294000000</us-gaap:LongTermDebt>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c-1" id="f-725">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of total interest expense related to the Term Facility recognized in the accompanying consolidated statements of operations for the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual coupon&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26,150&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,129&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of finance fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,364&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,363&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;914&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(587)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(95)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32,469&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,418&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,945&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-1" decimals="-3" id="f-726" unitRef="usd">30692000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-14" decimals="-3" id="f-727" unitRef="usd">26150000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-15" decimals="-3" id="f-728" unitRef="usd">11129000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-1" decimals="-3" id="f-729" unitRef="usd">2364000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-14" decimals="-3" id="f-730" unitRef="usd">2363000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-15" decimals="-3" id="f-731" unitRef="usd">914000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-1" decimals="-3" id="f-732" unitRef="usd">587000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-14" decimals="-3" id="f-733" unitRef="usd">95000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestCostsCapitalizedAdjustment contextRef="c-15" decimals="-3" id="f-734" unitRef="usd">98000</us-gaap:InterestCostsCapitalizedAdjustment>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-735" unitRef="usd">32469000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-14" decimals="-3" id="f-736" unitRef="usd">28418000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-15" decimals="-3" id="f-737" unitRef="usd">11945000</us-gaap:InterestExpenseDebt>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-738">DERIVATIVE FINANCIAL INSTRUMENT AND HEDGING ACTIVITY&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, the Company entered into an interest rate swap with Citizens Bank, N.A. to manage exposure to changes in LIBOR-based interest rates (or alternate benchmark rate as defined in the Credit Agreement) underlying total borrowings under term facilities related to the Prior Credit Agreement. The interest rate swap matures in December 2026. Concurrent with the termination of the Prior Credit Agreement and entry into the Credit Agreement with Truist Bank, the interest rate swap with a notional value of $168.6 million at origin on November 19, 2021 was novated and Truist Bank became the new counterparty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described further below, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company amended its Credit Agreement to transition from LIBOR to SOFR due to the cessation of LIBOR, and accordingly, the interest rate swap transitioned from LIBOR to SOFR. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The swap is used to manage changes in SOFR-based interest rates underlying a portion of the borrowing under the Term Facility.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate swap provides an effective fixed interest rate of 2.26% and has been designated as an effective cash flow hedge and therefore qualifies for hedge accounting. The notional amount of the interest rate swap was $139.4 million and $151.5 million as of December&#160;31, 2023 and 2022, respectively, and decreased quarterly by approximately $4.0 million until December 2023, after which it remains static until maturity in December 2026. As of December&#160;31, 2023, the fair value of the interest rate swap asset was recorded in other non-current assets in the consolidated balance sheets was $6.2 million. As of December&#160;31, 2023, $8.9 million was recorded in accumulated&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; other comprehensive income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2023, the change in fair value of the interest rate swaps was a loss of $3.7 million. During the year ended December&#160;31, 2023, losses on the interest rate swap of $3.4 million were recorded in other comprehensive income (loss)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, net of tax. Di&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fferences between the hedged SOFR rate and the fixed rate are recorded as interest expense in the same period that the related interest is recorded for the Term Facility based on the SOFR rate. In the years ended December&#160;31, 2023 and 2022, $2.6 million and $2.3 million, respectively, of interest expense was recognized in relation to the interest rate swaps. Included in these amounts for the years ended December&#160;31, 2023 and 2022 are reclassifications out of accumulated other comprehensive income (loss) of $2.8 million in expense, related to terminated and de-designated cash flow hedges. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the amendment of the Credit Agreement (Note 5), the Company&#x2019;s derivative positions automatically transitioned to SOFR, the designated fallback terms, as determined by the International Swaps and Derivatives Association on August 1, 2023. Concurrently, the Company updated its hedge documentation to reflect the change of the benchmark index, which changed solely as a result of reference rate reform. Under ASC 848, Reference Rate Reform, hedge accounting may continue without de-designation if certain criteria are met. For cash flow hedges in which the designated hedged risk is LIBOR (or another rate that is expected to be discontinued), the guidance allows an entity to assert that it remains probable that the hedged forecasted transaction will occur. The Company applied the optional expedient within ASC 848 to conclude the updates to the hedge relationship due to reference rate reform did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-167" decimals="-5" id="f-739" unitRef="usd">168600000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-167" decimals="4" id="f-740" unitRef="number">0.0226</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-168" decimals="-5" id="f-741" unitRef="usd">139400000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-169" decimals="-5" id="f-742" unitRef="usd">151500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <anip:DerivativeLiabilityDecreaseInNotionalAmount contextRef="c-170" decimals="-5" id="f-743" unitRef="usd">4000000</anip:DerivativeLiabilityDecreaseInNotionalAmount>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-168" decimals="-5" id="f-744" unitRef="usd">6200000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-168" decimals="-5" id="f-745" unitRef="usd">-8900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-170" decimals="-5" id="f-746" unitRef="usd">-3700000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-170" decimals="-5" id="f-747" unitRef="usd">-3400000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:InterestExpense contextRef="c-170" decimals="-5" id="f-748" unitRef="usd">2600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-171" decimals="-5" id="f-749" unitRef="usd">2300000</us-gaap:InterestExpense>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-170" decimals="-5" id="f-750" unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax contextRef="c-171" decimals="-5" id="f-751" unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-752">INVENTORIES&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the Company's inventory by asset class as of the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Packaging materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Vendor Concentration&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials are sourced for products, including API, from both domestic and international suppliers. Generally, only a single source of API is qualified for use in each product due to the costs and time required to validate a second source of supply. As a result, we are dependent upon current vendors to supply reliably the API required for on-going product manufacturing. During the year ended December&#160;31, 2023, no single vendor represented at least 10% of invent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ory purchases. During th&lt;/span&gt;e year ended December&#160;31, 2022, the Company purchased approximately 19% of inventory from one supplier. During the year ended December&#160;31, 2021, no single vendor represented at least 10% of inventory purchases.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-753">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the Company's inventory by asset class as of the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;62,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;67,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Packaging materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Work-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;28,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;111,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;105,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="c-6" decimals="-3" id="f-754" unitRef="usd">62237000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="c-7" decimals="-3" id="f-755" unitRef="usd">67726000</us-gaap:InventoryRawMaterials>
    <us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies contextRef="c-6" decimals="-3" id="f-756" unitRef="usd">9617000</us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies>
    <us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies contextRef="c-7" decimals="-3" id="f-757" unitRef="usd">7720000</us-gaap:RetailRelatedInventoryPackagingAndOtherSupplies>
    <us-gaap:InventoryWorkInProcess contextRef="c-6" decimals="-3" id="f-758" unitRef="usd">3144000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="c-7" decimals="-3" id="f-759" unitRef="usd">1889000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="c-6" decimals="-3" id="f-760" unitRef="usd">36198000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="c-7" decimals="-3" id="f-761" unitRef="usd">28020000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross contextRef="c-6" decimals="-3" id="f-762" unitRef="usd">111196000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross contextRef="c-7" decimals="-3" id="f-763" unitRef="usd">105355000</us-gaap:InventoryGross>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-172" decimals="2" id="f-764" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-765">PROPERTY AND EQUIPMENT, NET&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s gross property and equipment by major asset class and accumulated depreciation as of the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery, furniture, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense for the years ended December&#160;31, 2023, 2022, and 2021 totaled $7.5 million, $7.4 million, and $5.5 million, respectively. During the years ended December&#160;31, 2023, 2022, and 2021 there was $0.6 million, $0.1 million, and $0.1 million, respectively, of interest capitalized into construction in progress, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-766">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s gross property and equipment by major asset class and accumulated depreciation as of the years ended December&#160;31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Buildings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Machinery, furniture, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;53,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;77,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;75,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,935)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(32,712)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-173" decimals="-3" id="f-767" unitRef="usd">1549000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-174" decimals="-3" id="f-768" unitRef="usd">1549000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-175" decimals="-3" id="f-769" unitRef="usd">17875000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-176" decimals="-3" id="f-770" unitRef="usd">16659000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-177" decimals="-3" id="f-771" unitRef="usd">50412000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-178" decimals="-3" id="f-772" unitRef="usd">53146000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-179" decimals="-3" id="f-773" unitRef="usd">7692000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-180" decimals="-3" id="f-774" unitRef="usd">4604000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-775" unitRef="usd">77528000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-7" decimals="-3" id="f-776" unitRef="usd">75958000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-777" unitRef="usd">32935000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-778" unitRef="usd">32712000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-779" unitRef="usd">44593000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-780" unitRef="usd">43246000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-781" unitRef="usd">7500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-14" decimals="-5" id="f-782" unitRef="usd">7400000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-15" decimals="-5" id="f-783" unitRef="usd">5500000</us-gaap:Depreciation>
    <us-gaap:InterestCostsCapitalized contextRef="c-1" decimals="-5" id="f-784" unitRef="usd">600000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-14" decimals="-5" id="f-785" unitRef="usd">100000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized contextRef="c-15" decimals="-5" id="f-786" unitRef="usd">100000</us-gaap:InterestCostsCapitalized>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-787">GOODWILL AND INTANGIBLE ASSETS&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the 2013 merger with BioSante Pharmaceuticals, Inc. (&#x201c;BioSante&#x201d;), the Company recorded goodwill of $1.8 million. As a result of the acquisition of WellSpring Pharma Services Inc., the Company recorded goodwill of $1.7 million in 2018. From the acquisition of Novitium in 2021, the Company recorded goodwill of $24.6&#160;million. As of December 31, 2023, the Company had two operating segments, which were also deemed the Company's two reporting units, Generics, Established Brands, and Other reporting unit and the Rare Disease reporting unit. All of the goodwill is recorded in the Generics, Established Brands, and Other reporting unit.reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is reviewed for impairment at least annually, at October 31st, or more frequently if a triggering event occurs between impairment testing dates. The Company&#x2019;s impairment assessment begins with a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. Qualitative factors may include, macroeconomic conditions, industry and market considerations, cost factors, and other relevant entity and Company specific events. If, based on the qualitative test, the Company determines that it is &#x201c;more likely than not&#x201d; that the fair value of a reporting unit is less than its carrying value, then we evaluate goodwill for impairment by comparing the fair value of the reporting unit to its respective carrying value, including its goodwill. If it is determined that it is &#x201c;not likely&#x201d; that the fair value of the reporting unit is less than its carrying value, then no further testing is required. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the qualitative assessments performed by the Company, it was determined that it was more likely than not that the fair value of the Generics, Established Brands, and Other reporting unit was greater than its carrying value as of October 31, 2023, and therefore no impairment charges have been recognized, and no quantitative testing was required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the qualitative impairment analysis performed at October 31, 2023, there were no events or changes in circumstances that would have reduced the fair value of the reporting unit below its carrying value from October 31, 2023 to December&#160;31, 2023. No impairment loss was recognized during the years ended December&#160;31, 2023, 2022, and 2021, and the balance of goodwill was $28.2 million as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net definite-lived intangible assets and net indefinite-lived intangible assets other than goodwill are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Amortization&lt;br/&gt;Period(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Definite-Lived Intangible Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired ANDA intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;209,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(100,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;195,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(75,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;NDAs and product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;244,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(184,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;60,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;242,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(162,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Marketing and distribution rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-compete agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;- years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total Definite-Lived Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;497,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(308,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;189,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;480,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(255,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;225,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total Intangible Assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;517,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(308,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;209,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;507,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(255,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;251,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Weighted average amortization period as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Definite-lived intangible assets arising from business combinations and other asset acquisitions include intangibles such as Abbreviated New Drug Applications (&#x201c;ANDAs&#x201d;), New Drug Applications (&#x201c;NDAs&#x201d;) and product rights, marketing and distribution rights, customer relationships, and non-compete agreements. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows. Definite-lived intangible assets are stated at cost, net of amortization, and generally amortized over their remaining estimated useful lives, ranging from &lt;span style="-sec-ix-hidden:f-851"&gt;seven&lt;/span&gt; to ten years years, based on the straight-line amortization method. In the case of certain NDAs and product rights assets, an accelerated amortization method is used to better match the anticipated economic benefits expected to be provided. Definite-lived intangible assets are tested for impairment annually, or when events or changes in circumstances indicate that these asset might be impaired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets other than goodwill include primarily IPR&amp;amp;D projects. IPR&amp;amp;D intangible assets represent the fair value of technology acquired in a business combination or asset acquisition for which the technology projects are incomplete but have substance or alternative future use. When an IPR&amp;amp;D project is completed (generally upon receipt of regulatory approval), then the IPR&amp;amp;D will be accounted for as a definite-lived intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, definite-lived intangibles increased approximately $16.4&#160;million, which includes $6.8 million which was reclassified from indefinite-lived IPR&amp;amp;D to acquired ANDA intangible assets upon completion of projects and launch of related products, and the Company added approximately $9.6&#160;million of intangible assets, comprised of $7.1&#160;million of ANDA intangible assets related to asset acquisitions with Slayback Pharma Limited Liability Company and Akorn Holding Company, $2.0&#160;million in product rights related to the transaction with Alvogen, Inc., and other asset acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2022, approximately $20.3 million was reclassified from indefinite-lived IPR&amp;amp;D to acquired ANDA intangible assets upon completion of projects and launch of related products. The Company added $7.2 million in ANDA intangible assets related to the July&#160;21, 2022 transaction with Oakrum Pharma, LLC (Note 10). These assets will be amortized over a &lt;span style="-sec-ix-hidden:f-862"&gt;seven&lt;/span&gt;-year useful life. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for definite-lived intangible assets was $52.3 million, $49.5 million, and $41.8 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. Refer to Note 10 for more details on acquired definite-lived and indefinite-lived intangible assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization expense is as follows for the years ending December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;189,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected amortization expense is an estimate. Actual amounts of amortization expense may differ due to timing of regulatory approvals related to IPR&amp;amp;D assets, additional intangible assets acquired, impairment of intangible assets, and other events.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Indefinite-lived intangible assets are not amortized, and the Company tests for impairment of indefinite-lived intangible assets and definite-lived intangibles when events or circumstances indicate that the carrying value of the assets may not be recoverable, and the Company performs an asset impairment analysis annually, as of October 31, 2023. The Company performed qualitative assessments to determine whether it was more likely than not that the assets were impaired in order to determine the necessity of performing a quantitative impairment test, under which management would calculate the asset&#x2019;s fair value. When performing the qualitative assessments, the Company evaluated events and circumstances that would affect the significant inputs used to determine the fair value of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on the assessments of the aforementioned factors, it was determined that it was more likely than not that the fair value of assets are greater than their carrying amount as of October 31, 2023, and therefore no quantitative testing for impairment was required.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the qualitative impairment analysis performed at October 31, 2023, there were no events or changes in circumstances that would have reduced the fair value of the indefinite or definite-lived intangible assets below their carrying values from October 31, 2023 to December&#160;31, 2023. No impairment loss was recognized during the year ended December&#160;31, 2023. During the years ended December 31, 2022 and 2021, impairment losses of approximately $0.1 million and $2.4 million, respectively, were recognized in relation to ANDA assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-181" decimals="-5" id="f-788" unitRef="usd">1800000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-182" decimals="-5" id="f-789" unitRef="usd">1700000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-28" decimals="-5" id="f-790" unitRef="usd">24600000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-791"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-792"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="-5" id="f-793" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-794" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-15" decimals="INF" id="f-795" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-14" decimals="INF" id="f-796" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill contextRef="c-7" decimals="-5" id="f-797" unitRef="usd">28200000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-5" id="f-798" unitRef="usd">28200000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-799">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of net definite-lived intangible assets and net indefinite-lived intangible assets other than goodwill are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.175%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Amortization&lt;br/&gt;Period(1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:32pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Definite-Lived Intangible Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Acquired ANDA intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;209,780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(100,660)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;109,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;195,862&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(75,606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;120,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;NDAs and product rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;244,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(184,861)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;60,010&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;242,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(162,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;80,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Marketing and distribution rights&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(14,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;2,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(13,309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Non-compete agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;- years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(7,707)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;17,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;24,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;20,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.8 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total Definite-Lived Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;497,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(308,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;189,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;480,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(255,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;225,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;4.5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Indefinite-Lived Intangible Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;In process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;19,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;26,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Total Intangible Assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;517,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(308,123)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;209,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;507,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(255,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;251,635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1) Weighted average amortization period as of December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-183" decimals="-3" id="f-800" unitRef="usd">209780000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-183" decimals="-3" id="f-801" unitRef="usd">100660000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-183" decimals="-3" id="f-802" unitRef="usd">109120000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-184" decimals="-3" id="f-803" unitRef="usd">195862000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-184" decimals="-3" id="f-804" unitRef="usd">75606000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-184" decimals="-3" id="f-805" unitRef="usd">120256000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-183" id="f-806">P5Y2M12D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-185" decimals="-3" id="f-807" unitRef="usd">244871000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-185" decimals="-3" id="f-808" unitRef="usd">184861000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-185" decimals="-3" id="f-809" unitRef="usd">60010000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-186" decimals="-3" id="f-810" unitRef="usd">242372000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-186" decimals="-3" id="f-811" unitRef="usd">162188000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-186" decimals="-3" id="f-812" unitRef="usd">80184000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-185" id="f-813">P3Y1M6D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-187" decimals="-3" id="f-814" unitRef="usd">17157000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-187" decimals="-3" id="f-815" unitRef="usd">14271000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-187" decimals="-3" id="f-816" unitRef="usd">2886000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-188" decimals="-3" id="f-817" unitRef="usd">17157000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-188" decimals="-3" id="f-818" unitRef="usd">13309000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-188" decimals="-3" id="f-819" unitRef="usd">3848000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-187" id="f-820">P3Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-189" decimals="-3" id="f-821" unitRef="usd">624000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-189" decimals="-3" id="f-822" unitRef="usd">624000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-189" decimals="-3" id="f-823" unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-190" decimals="-3" id="f-824" unitRef="usd">624000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-190" decimals="-3" id="f-825" unitRef="usd">602000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-190" decimals="-3" id="f-826" unitRef="usd">22000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-191" decimals="-3" id="f-827" unitRef="usd">24900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-191" decimals="-3" id="f-828" unitRef="usd">7707000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-191" decimals="-3" id="f-829" unitRef="usd">17193000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-192" decimals="-3" id="f-830" unitRef="usd">24900000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-192" decimals="-3" id="f-831" unitRef="usd">4150000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-192" decimals="-3" id="f-832" unitRef="usd">20750000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-191" id="f-833">P4Y9M18D</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-6" decimals="-3" id="f-834" unitRef="usd">497332000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-6" decimals="-3" id="f-835" unitRef="usd">308123000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="-3" id="f-836" unitRef="usd">189209000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-7" decimals="-3" id="f-837" unitRef="usd">480915000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-7" decimals="-3" id="f-838" unitRef="usd">255855000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-7" decimals="-3" id="f-839" unitRef="usd">225060000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-6" id="f-840">P4Y6M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-193" decimals="-3" id="f-841" unitRef="usd">19800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-193" decimals="-3" id="f-842" unitRef="usd">19800000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-194" decimals="-3" id="f-843" unitRef="usd">26575000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-194" decimals="-3" id="f-844" unitRef="usd">26575000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-6" decimals="-3" id="f-845" unitRef="usd">517132000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-6" decimals="-3" id="f-846" unitRef="usd">308123000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-847" unitRef="usd">209009000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-7" decimals="-3" id="f-848" unitRef="usd">507490000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-7" decimals="-3" id="f-849" unitRef="usd">255855000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-7" decimals="-3" id="f-850" unitRef="usd">251635000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-196" id="f-852">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease contextRef="c-1" decimals="-5" id="f-853" unitRef="usd">16400000</us-gaap:FiniteLivedIntangibleAssetsPeriodIncreaseDecrease>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-197" decimals="-5" id="f-854" unitRef="usd">-6800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-198" decimals="-5" id="f-855" unitRef="usd">6800000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-1" decimals="-5" id="f-856" unitRef="usd">9600000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-199" decimals="-5" id="f-857" unitRef="usd">7100000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-200" decimals="-5" id="f-858" unitRef="usd">2000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-201" decimals="-5" id="f-859" unitRef="usd">20300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-202" decimals="-5" id="f-860" unitRef="usd">-20300000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-203" decimals="-5" id="f-861" unitRef="usd">7200000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-863" unitRef="usd">52300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-14" decimals="-5" id="f-864" unitRef="usd">49500000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-15" decimals="-5" id="f-865" unitRef="usd">41800000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock contextRef="c-1" id="f-866">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected future amortization expense is as follows for the years ending December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;189,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-6" decimals="-3" id="f-867" unitRef="usd">50364000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-6" decimals="-3" id="f-868" unitRef="usd">47128000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-6" decimals="-3" id="f-869" unitRef="usd">33643000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-6" decimals="-3" id="f-870" unitRef="usd">24677000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-6" decimals="-3" id="f-871" unitRef="usd">17895000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-6" decimals="-3" id="f-872" unitRef="usd">15502000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="-3" id="f-873" unitRef="usd">189209000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-874" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-14" decimals="-5" id="f-875" unitRef="usd">100000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-15" decimals="-5" id="f-876" unitRef="usd">2400000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-877">FAIR VALUE&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is the price that would be received from the sale of an asset or paid to transfer a liability assuming an orderly transaction in the most advantageous market at the measurement date. U.S. GAAP establishes a hierarchical disclosure framework which prioritizes and ranks the level of observability of inputs used in measuring fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs used in measuring the fair value of cash and cash equivalents are considered to be Level 1 in accordance with the three-tier fair value hierarchy. The fair market values are based on period-end statements supplied by the various banks and brokers that held the majority of the funds. The Term Facility bears an interest rate that fluctuates with the changes in SOFR and, because the variable interest rates approximate market borrowing rates available to the Company, the carrying values of these borrowings approximated their fair values at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Money Market Funds&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Money market funds are readily convertible into cash and the net asset value of each fund on the last day of the reporting period is used to determine its fair value. Money market funds are included in Cash and cash equivalents within the Consolidated Balance Sheet, and is classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. The Company does not adjust the quoted market price for such financial instruments. The fair value of the money market funds as of December 31, 2023 was approximately $191.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest Rate Swap&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the interest rate swap is estimated based on the present value of projected future cash flows using the SOFR forward rate curve. The model used to value the interest rate swap includes inputs of readily observable market data, a Level 2 input. As described in detail in Note 5, the fair value of the interest rate swap was a $6.2 million and $8.8&#160;million at December&#160;31, 2023 and 2022, respectively, and was classified as a non-current asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Novitium, the Company may pay up to $46.5 million in additional consideration related to the achievement of certain milestones, including milestones on gross profit of Novitium portfolio products over a 24-month period, regulatory filings completed during this 24-month period, and a percentage of net profits on certain products that are launched in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The discounted cash flow method used to value this contingent consideration includes inputs of not readily observable market data, which are Level 3 inputs. As of the November&#160;19, 2021 acquisition date, the contingent consideration had a fair value of $30.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 8, 2021, on December 12, 2023, the Company paid $12.5&#160;million of cash consideration to the Company Members, defined as the holders of Novitium ownership interests in the Agreement and Plan of Merger, as the holders of Novitium ownership interests, for the achievement of the "ANDA Filing Earn-Out," as defined in the Agreement (Note 17). Furthermore, on February 22, 2024, the Company paid $12.5 million to Company Members of Novitium upon the achievement of the "Gross Profit Earn-Out," as defined in the Agreement (Note 19).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the contingent consideration was approximately $24.0 million and $35.1 million as of December&#160;31, 2023 and 2022, respectively, and is reflected as a current and non-current accrued contingent consideration liability in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Payment Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assumptions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Profit-based milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability-weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025-2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product development-based milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability-weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in contingent consideration balances classified as Level 3 balances for the years ended December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment of ANDA filing earn-out&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-900"&gt;&lt;span style="-sec-ix-hidden:f-901"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Value Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contingent value rights (&#x201c;CVRs&#x201d;), which were granted coincident with the merger with BioSante expired during June 2023, were considered contingent consideration and were classified as liabilities, and there were no payments made pursuant to the terms of the CVR agreement. The Company determined that the fair value of the CVRs was immaterial as of December 31, 2022, and also determined that the changes in such fair value were immaterial for the years ended December 31, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents financial assets and liabilities accounted for at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;br/&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value at &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value at &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no financial assets and liabilities that are measured at fair value on a non-recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no non-financial assets and liabilities that are measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Non-Financial Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment, ROU assets, intangible assets, and goodwill, are measured at fair value on a non-recurring basis. During the year ended December&#160;31, 2023, there were no impairment charges recognized related to non-financial assets and liabilities measured at fair value on a non-recurring basis. During the year ended December&#160;31, 2022, the Company recognized an impairment charge of $0.1 million related to a definite-lived ANDA intangible asset. There were no other fair value impairments recognized in the years ended December&#160;31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquired Non-Financial Assets Measured at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 27, 2023, the Company acquired from Alvogen, Inc. the rights to certain pharmaceutical products for total cash consideration of $2.0&#160;million (Note 8), which we plan to launch commercially in early 2024. The transaction was accounted for as an asset acquisition and there were no transaction costs directly related to the acquisition. Intangible assets amounted to $2.0&#160;million as NDAs and product rights. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The intangible asset will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;August 14, 2023, the Company acquired one ANDA and registered patents and pending patent applications from Slayback Pharma Limited &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability Company for total consideration of $3.0 million (Note 9). The Company also acquired an NDA which has yet to be filed. The transaction was funded from cash on hand. The transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. Intangible assets amounted to $2.8 million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDA will be amortized in full over its useful life of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;seven years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and therefore &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; impairment loss was recognized for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of fiscal 2023, the Company acquired two ANDAs and one pipeline product from the Chapter 7 Trustee for the estates of Akorn Holding Company and certain of its affiliates for total consideration of $4.8 million. The transaction was funded from cash on hand. This transaction was accounted for as an asset acquisition and the transaction costs directly related to the acquisition were capitalized. The product portfolio included two commercial products and one pipeline product. The Company recognized $4.3 million as acquired ANDA intangible assets. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. The ANDAs will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023, and therefore no impairment loss was recognized for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;21, 2022, we acquired four ANDAs from Oakrum Pharma, LLC for total consideration of $8.0 million plus an immaterial amount for the purchase of finished goods inventory. The transaction was funded from cash on hand. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. The product portfolio included one commercial product, one approved product with a launch completed in September and two filed products, with approval pending. We recognized $7.2 million as acquired ANDA intangible assets and $1.2 million as research and development expense because certain of the generic products have significant remaining work required in order to be commercialized and the products do not have an alternative future use. The payment was allocated to the acquired intangible assets and in-process research and development based on relative fair value, which was determined using Level 3 unobservable inputs. We used the present value of the estimated cash flows related to the products, using a discount rate of 13% to determine the fair value of the acquired intangible assets and in-process research and development. The inventory acquired was immaterial. Contingent liabilities are accrued when they are both estimable and probable. We accrued $0.2 million in contingent payments due to a third party upon the launch of a product completed in September. This was accrued and recorded in the fair value of acquired intangible assets as it was probable at the acquisition date and has been paid in 2022. The ANDAs will be amortized in full over its useful life of seven years and will be tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023, and therefore no impairment loss was recognized for the year ended December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, we acquired three NDAs and an ANDA and certain related inventories from Sandoz, Inc. for total consideration of $20.7 million. We also incurred and paid $0.4 million in transaction costs directly related to the acquisition. The acquisition was funded via borrowings under our Revolver. We accounted for this transaction as an asset acquisition and capitalized the transaction costs directly related to the acquisition. We recognized $11.4 million as acquired intangible assets and $9.7 million of inventory at fair value, including $0.6 million of API, $1.0 million of sample inventory, and $8.1 million in finished goods inventory. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to determine the fair value of the intangible assets, we used the present value of the estimated cash flows related to the product rights using a discount rate of 10%, which are level 3 unobservable inputs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the inventory was determined based on the estimated selling price to be generated from the finished goods, less costs to sell, including a reasonable margin, which are level 3 unobservable inputs. The intangible assets are being amortized in full over a useful life of seven years and are tested for impairment when events or circumstances indicate that the carrying value of the asset may not be recoverable. No such triggering events were identified during the period from the date of acquisition to December&#160;31, 2023 and therefore no impairment loss was recognized for the years ended December&#160;31, 2022 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-6" decimals="-5" id="f-878" unitRef="usd">191800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue contextRef="c-168" decimals="-5" id="f-879" unitRef="usd">6200000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:InterestRateDerivativeLiabilitiesAtFairValue contextRef="c-169" decimals="-5" id="f-880" unitRef="usd">8800000</us-gaap:InterestRateDerivativeLiabilitiesAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-205" decimals="-5" id="f-881" unitRef="usd">46500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <anip:BusinessCombinationContingentConsiderationArrangementsPeriod contextRef="c-206" id="f-882">P24M</anip:BusinessCombinationContingentConsiderationArrangementsPeriod>
    <anip:BusinessCombinationContingentConsiderationArrangementsPeriod contextRef="c-206" id="f-883">P24M</anip:BusinessCombinationContingentConsiderationArrangementsPeriod>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-207" decimals="-5" id="f-884" unitRef="usd">30800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-208" decimals="-5" id="f-885" unitRef="usd">12500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-209" decimals="-5" id="f-886" unitRef="usd">12500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-125" decimals="-5" id="f-887" unitRef="usd">24000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-210" decimals="-5" id="f-888" unitRef="usd">35100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-889">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements of contingent consideration for which a liability is recorded include the following significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.931%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Payment Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Assumptions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Profit-based milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability-weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025-2035&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Product development-based milestone payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability-weighted discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;100%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Projected fiscal year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-211" decimals="2" id="f-890" unitRef="number">0.12</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-212" decimals="3" id="f-891" unitRef="number">0.120</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-213" decimals="3" id="f-892" unitRef="number">1</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-893">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in contingent consideration balances classified as Level 3 balances for the years ended December&#160;31, 2023 and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;31,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Measurement period adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment of ANDA filing earn-out&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-900"&gt;&lt;span style="-sec-ix-hidden:f-901"&gt;Change in fair value&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-7" decimals="-3" id="f-894" unitRef="usd">35058000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-38" decimals="-3" id="f-895" unitRef="usd">31000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <anip:FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment contextRef="c-1" decimals="-3" id="f-896" unitRef="usd">0</anip:FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment>
    <anip:FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment contextRef="c-14" decimals="-3" id="f-897" unitRef="usd">300000</anip:FairValueMeasurementWithUnobservableInputsReconciliationMeasurementPeriodAdjustment>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-1" decimals="-3" id="f-898" unitRef="usd">12500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="c-14" decimals="-3" id="f-899" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-902" unitRef="usd">1426000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-14" decimals="-3" id="f-903" unitRef="usd">3758000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-6" decimals="-3" id="f-904" unitRef="usd">23984000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-7" decimals="-3" id="f-905" unitRef="usd">35058000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-906">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents financial assets and liabilities accounted for at fair value on a recurring basis as of December&#160;31, 2023 and December&#160;31, 2022, by level within the fair value hierarchy:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;br/&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value at &lt;br/&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money Market Fund&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;191,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swap&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value at &lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;35,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-6" decimals="-3" id="f-907" unitRef="usd">191841000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-214" decimals="-3" id="f-908" unitRef="usd">191841000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-215" decimals="-3" id="f-909" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-216" decimals="-3" id="f-910" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-6" decimals="-3" id="f-911" unitRef="usd">6236000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-214" decimals="-3" id="f-912" unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-215" decimals="-3" id="f-913" unitRef="usd">6236000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-216" decimals="-3" id="f-914" unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-205" decimals="-3" id="f-915" unitRef="usd">23984000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-217" decimals="-3" id="f-916" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-218" decimals="-3" id="f-917" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-219" decimals="-3" id="f-918" unitRef="usd">23984000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-7" decimals="-3" id="f-919" unitRef="usd">8759000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-220" decimals="-3" id="f-920" unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-221" decimals="-3" id="f-921" unitRef="usd">8759000</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:InterestRateDerivativeAssetsAtFairValue contextRef="c-222" decimals="-3" id="f-922" unitRef="usd">0</us-gaap:InterestRateDerivativeAssetsAtFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-210" decimals="-3" id="f-923" unitRef="usd">35058000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-223" decimals="-3" id="f-924" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-224" decimals="-3" id="f-925" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-225" decimals="-3" id="f-926" unitRef="usd">35058000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-226" decimals="INF" id="f-927" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-227" decimals="-5" id="f-928" unitRef="usd">100000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-228" decimals="-5" id="f-929" unitRef="usd">2000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-228" decimals="-5" id="f-930" unitRef="usd">2000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-229" id="f-931">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-230"
      decimals="INF"
      id="f-932"
      unitRef="intangibleasset">1</anip:NumberOfIntangibleAssetsAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-231" decimals="-5" id="f-933" unitRef="usd">3000000.0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-231" decimals="-5" id="f-934" unitRef="usd">2800000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-230" id="f-935">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-232" decimals="INF" id="f-936" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-233"
      decimals="INF"
      id="f-937"
      unitRef="intangibleasset">2</anip:NumberOfIntangibleAssetsAcquired>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-234"
      decimals="INF"
      id="f-938"
      unitRef="intangibleasset">1</anip:NumberOfIntangibleAssetsAcquired>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-235" decimals="-5" id="f-939" unitRef="usd">4800000</us-gaap:PaymentsToAcquireProductiveAssets>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-233"
      decimals="INF"
      id="f-940"
      unitRef="intangibleasset">2</anip:NumberOfIntangibleAssetsAcquired>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-234"
      decimals="INF"
      id="f-941"
      unitRef="intangibleasset">1</anip:NumberOfIntangibleAssetsAcquired>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1 contextRef="c-235" decimals="-5" id="f-942" unitRef="usd">4300000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-236" id="f-943">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-237" decimals="INF" id="f-944" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-238"
      decimals="INF"
      id="f-945"
      unitRef="intangibleasset">4</anip:NumberOfIntangibleAssetsAcquired>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-203" decimals="-5" id="f-946" unitRef="usd">8000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-239"
      decimals="INF"
      id="f-947"
      unitRef="intangibleasset">1</anip:NumberOfIntangibleAssetsAcquired>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-240"
      decimals="INF"
      id="f-948"
      unitRef="intangibleasset">1</anip:NumberOfIntangibleAssetsAcquired>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-241"
      decimals="INF"
      id="f-949"
      unitRef="intangibleasset">2</anip:NumberOfIntangibleAssetsAcquired>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-204" decimals="-5" id="f-950" unitRef="usd">7200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-203" decimals="-5" id="f-951" unitRef="usd">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <anip:IntangibleAssetMeasurementInput
      contextRef="c-242"
      decimals="INF"
      id="f-952"
      unitRef="number">13</anip:IntangibleAssetMeasurementInput>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration contextRef="c-203" decimals="-5" id="f-953" unitRef="usd">200000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-243" id="f-954">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-244" decimals="INF" id="f-955" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <anip:NumberOfIntangibleAssetsAcquired
      contextRef="c-245"
      decimals="INF"
      id="f-956"
      unitRef="intangibleasset">3</anip:NumberOfIntangibleAssetsAcquired>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-246" decimals="-5" id="f-957" unitRef="usd">20700000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsForFees contextRef="c-246" decimals="-5" id="f-958" unitRef="usd">400000</us-gaap:PaymentsForFees>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-247" decimals="-5" id="f-959" unitRef="usd">11400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:InventoryNet contextRef="c-247" decimals="-5" id="f-960" unitRef="usd">9700000</us-gaap:InventoryNet>
    <us-gaap:InventoryRawMaterials contextRef="c-247" decimals="-5" id="f-961" unitRef="usd">600000</us-gaap:InventoryRawMaterials>
    <us-gaap:OtherInventoryDemo contextRef="c-247" decimals="-5" id="f-962" unitRef="usd">1000000</us-gaap:OtherInventoryDemo>
    <us-gaap:InventoryFinishedGoods contextRef="c-247" decimals="-5" id="f-963" unitRef="usd">8100000</us-gaap:InventoryFinishedGoods>
    <anip:IntangibleAssetMeasurementInput contextRef="c-248" decimals="0" id="f-964" unitRef="number">10</anip:IntangibleAssetMeasurementInput>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-247" id="f-965">P7Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-249" decimals="-5" id="f-966" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-250" decimals="-5" id="f-967" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-968">MEZZANINE AND STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Authorized shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is authorized to issue up to 33.3 million shares of common stock with a par value of $0.0001 per share, 0.8 million shares of class C special stock with a par value of $0.0001 per share, and 1.7 million shares of undesignated preferred stock with a par value of $0.0001 per share at December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 20.7&#160;million and 20.5&#160;million shares of common stock issued and outstanding as of December&#160;31, 2023, respectively, and 17.6&#160;million and 17.5&#160;million shares of common stock issued and outstanding as of December&#160;31, 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2023, through a public offering, the Company completed the issuance and sale of 2,183,545 shares of ANI common stock, resulting in net proceeds after issuance costs of $80.6&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2021, the Company issued 1.5&#160;million shares related to a public offering of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; common stock and 2.5&#160;million shares as consideration for the acquisition of Novitium.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Class C Special Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were 11&#160;thousand shares of class C special stock issued and outstanding as of December&#160;31, 2023 and 2022. Each share of class C special stock entitles its holder to one vote per share. Each share of class C special stock is exchangeable, at the option of the holder, for one share of the Company's common stock, at an exchange price of $90.00 per share, subject to adjustment upon certain capitalization events. Holders of class C special stock are not entitled to receive dividends or to participate in the distribution of the Company's assets upon liquidation, dissolution, or winding-up the Company. The holders of class C special stock have no cumulative voting, preemptive, subscription, redemption, or sinking fund rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;PIPE Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the execution of the Merger Agreement, and as financing for a portion of the acquisition, on March 8, 2021, the Company entered into an Equity Commitment and Investment Agreement with Ampersand 2020 Limited Partnership (the &#x201c;PIPE Investor&#x201d;), pursuant to which the PIPE Investor agreed to purchase, 25,000 shares of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Series A Convertible Preferred Stock (the &#x201c;PIPE Shares&#x201d;), for a purchase price of $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The PIPE Shares are classified as mezzanine equity because the shares are mandatorily redeemable for cash upon a change in control, an event that is not solely in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; control. The Company incurred $0.2 million in issuance costs associated with the transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The PIPE Shares accrue dividends at 6.50% per year on a cumulative basis, payable in cash or in-kind, and will also participate, on a pro-rata basis, in any dividends that may be declared with respect to the Company's common stock. The PIPE Shares are convertible into the Company's common shares at the conversion price of $41.47 (i) beginning two years years after their issuance date, at the election of ANI (in which case the PIPE Investor must convert all of the PIPE Shares), if the volume-weighted average price of the Company's common stock for any 20 trading days out of 30 consecutive trading days exceeds 170% of the conversion price, and (ii) at any time after issuance, at the election of the PIPE Investor. As of December&#160;31, 2023, the PIPE shares are currently convertible into a maximum of 602,901 shares of the Company's common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In case of a liquidation event, the holder of the PIPE Shares will be entitled to receive, in preference to holders of the Company's common stock, the greater of (i) the PIPE Shares&#x2019; purchase price plus any accrued and unpaid dividends thereon and (ii) the amount the holder of the PIPE Shares would have received in the liquidation event if it had converted its PIPE Shares into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; common stock. The PIPE Shares will have voting rights, voting as one series with &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; common stock, on as-converted basis, and will have separate voting rights on any (i) amendment to the Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the &#x201c;Certificate&#x201d;) that adversely amends and relates solely to the terms of the PIPE Shares and (ii) issuance of additional Series A convertible preferred stock. In case of a change of control of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the PIPE Shares will be redeemed at the greater of (i) the PIPE Shares&#x2019; purchase price plus any accrued and unpaid dividends thereon and (ii) the change of control transaction consideration that the holder of the PIPE Shares would have received if it had converted into &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; common stock.&lt;/span&gt;&lt;/div&gt;There were 25,000 shares of Series A convertible preferred stock outstanding as of December&#160;31, 2023 and 2022.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-44" decimals="-5" id="f-969" unitRef="shares">33300000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-54" decimals="-5" id="f-970" unitRef="shares">33300000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-44"
      decimals="INF"
      id="f-971"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-54"
      decimals="INF"
      id="f-972"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-251"
      decimals="-5"
      id="f-973"
      unitRef="shares">800000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-252"
      decimals="-5"
      id="f-974"
      unitRef="shares">800000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-251"
      decimals="INF"
      id="f-975"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-252"
      decimals="INF"
      id="f-976"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="-5" id="f-977" unitRef="shares">1700000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="-5" id="f-978" unitRef="shares">1700000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-979"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-980"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-54" decimals="-5" id="f-981" unitRef="shares">20700000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-54" decimals="-5" id="f-982" unitRef="shares">20500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-44" decimals="-5" id="f-983" unitRef="shares">17600000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-44" decimals="-5" id="f-984" unitRef="shares">17500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-253"
      decimals="INF"
      id="f-985"
      unitRef="shares">2183545</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-253" decimals="-5" id="f-986" unitRef="usd">80600000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-25" decimals="-5" id="f-987" unitRef="shares">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="c-254"
      decimals="-5"
      id="f-988"
      unitRef="shares">2500000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-252"
      decimals="-3"
      id="f-989"
      unitRef="shares">11000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-252"
      decimals="-3"
      id="f-990"
      unitRef="shares">11000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c-251"
      decimals="-3"
      id="f-991"
      unitRef="shares">11000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-251"
      decimals="-3"
      id="f-992"
      unitRef="shares">11000</us-gaap:CommonStockSharesOutstanding>
    <anip:CommonStockNumberOfVotesPerShare contextRef="c-252" decimals="INF" id="f-993" unitRef="vote">1</anip:CommonStockNumberOfVotesPerShare>
    <anip:CommonStockConvertibleConversionRatio contextRef="c-6" decimals="INF" id="f-994" unitRef="number">1</anip:CommonStockConvertibleConversionRatio>
    <anip:CommonStockConversionPrice
      contextRef="c-252"
      decimals="2"
      id="f-995"
      unitRef="usdPerShare">90.00</anip:CommonStockConversionPrice>
    <anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-127"
      decimals="INF"
      id="f-996"
      unitRef="shares">25000</anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c-128"
      decimals="INF"
      id="f-997"
      unitRef="usdPerShare">1000</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-127" decimals="-5" id="f-998" unitRef="usd">25000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-127" decimals="-5" id="f-999" unitRef="usd">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="c-127"
      decimals="4"
      id="f-1000"
      unitRef="number">0.0650</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="c-128"
      decimals="2"
      id="f-1001"
      unitRef="usdPerShare">41.47</us-gaap:PreferredStockConvertibleConversionPrice>
    <anip:PreferredStockConvertibleMinimumPeriodOfConversion contextRef="c-127" id="f-1002">P2Y</anip:PreferredStockConvertibleMinimumPeriodOfConversion>
    <anip:ThresholdNumberOfTradingDays
      contextRef="c-128"
      decimals="INF"
      id="f-1003"
      unitRef="tradingday">20</anip:ThresholdNumberOfTradingDays>
    <anip:NumberOfConsecutiveTradingDays
      contextRef="c-128"
      decimals="INF"
      id="f-1004"
      unitRef="tradingday">30</anip:NumberOfConsecutiveTradingDays>
    <anip:PercentageOfConversionPrice
      contextRef="c-128"
      decimals="INF"
      id="f-1005"
      unitRef="number">1.70</anip:PercentageOfConversionPrice>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="c-255"
      decimals="INF"
      id="f-1006"
      unitRef="shares">602901</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-9"
      decimals="INF"
      id="f-1007"
      unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c-8"
      decimals="INF"
      id="f-1008"
      unitRef="shares">25000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1009">EARNINGS (LOSS) PER SHARE&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) available to common stockholders by the weighted-average number of shares of common stock outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For periods of net income, and when the effects are not anti-dilutive, we calculate diluted earnings (loss) per share by dividing net income available to common stockholders by the weighted-average number of shares outstanding plus the impact of all potential dilutive common shares, consisting primarily of common stock options, shares to be purchased under our ESPP, and performance stock units, using the more dilutive of the treasury stock or the two-class method. For periods of net loss, diluted loss per share is calculated similarly to basic loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested restricted shares and Series A convertible preferred stock shares contain non-forfeitable rights to dividends, and therefore are considered to be participating securities; in periods of net income, the calculation of basic and diluted earnings (loss) per share excludes from the numerator net income (but not net loss) attributable to the unvested restricted shares and the common shares assumed converted from the preferred shares and excludes the impact of those shares from the denominator.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share for the years ended December&#160;31, 2023, 2022, and 2021 are calculated for basic and diluted earnings (loss) per share as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.810%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) available to common shareholders &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,596&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive effect of stock options, ESPP, and performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,194&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of anti-dilutive shares, which have been excluded from the computation of diluted earnings (loss) per share, were 2.4 million, 2.6 million, and 1.7 million for the years ended December&#160;31, 2023, 2022, and 2021, respectively. For the years ended December 31, 2022 and 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;all potentially dilutive shares were anti-dilutive and excluded from the calculation of diluted loss per share because the Company reported a net loss&lt;/span&gt;.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1010">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share for the years ended December&#160;31, 2023, 2022, and 2021 are calculated for basic and diluted earnings (loss) per share as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.810%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) available to common shareholders &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings allocated to participating securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,679)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss) available to common shareholders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(49,521)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,596&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,001&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive effect of stock options, ESPP, and performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;193&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diluted Weighted-Average Shares Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,194&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16,260&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,596&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings (loss) per share&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.05)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3.40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-1" decimals="-3" id="f-1011" unitRef="usd">17154000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-14" decimals="-3" id="f-1012" unitRef="usd">-49521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="c-15" decimals="-3" id="f-1013" unitRef="usd">-42793000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-1" decimals="-3" id="f-1014" unitRef="usd">17154000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-14" decimals="-3" id="f-1015" unitRef="usd">-49521000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c-15" decimals="-3" id="f-1016" unitRef="usd">-42793000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-1" decimals="-3" id="f-1017" unitRef="usd">1679000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-14" decimals="-3" id="f-1018" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic contextRef="c-15" decimals="-3" id="f-1019" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-1" decimals="-3" id="f-1020" unitRef="usd">1663000</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-14" decimals="-3" id="f-1021" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted contextRef="c-15" decimals="-3" id="f-1022" unitRef="usd">0</us-gaap:UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted>
    <us-gaap:UndistributedEarnings contextRef="c-1" decimals="-3" id="f-1023" unitRef="usd">15475000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarnings contextRef="c-14" decimals="-3" id="f-1024" unitRef="usd">-49521000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarnings contextRef="c-15" decimals="-3" id="f-1025" unitRef="usd">-42793000</us-gaap:UndistributedEarnings>
    <us-gaap:UndistributedEarningsDiluted contextRef="c-1" decimals="-3" id="f-1026" unitRef="usd">15491000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:UndistributedEarningsDiluted contextRef="c-14" decimals="-3" id="f-1027" unitRef="usd">-49521000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:UndistributedEarningsDiluted contextRef="c-15" decimals="-3" id="f-1028" unitRef="usd">-42793000</us-gaap:UndistributedEarningsDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1029" unitRef="shares">18001000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="-3"
      id="f-1030"
      unitRef="shares">16260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1031"
      unitRef="shares">12596000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1032" unitRef="shares">18001000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-14"
      decimals="-3"
      id="f-1033"
      unitRef="shares">16260000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-15"
      decimals="-3"
      id="f-1034"
      unitRef="shares">12596000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-1035" unitRef="shares">193000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-14"
      decimals="-3"
      id="f-1036"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-15"
      decimals="-3"
      id="f-1037"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1038" unitRef="shares">18194000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-14"
      decimals="-3"
      id="f-1039"
      unitRef="shares">16260000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-15"
      decimals="-3"
      id="f-1040"
      unitRef="shares">12596000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1041"
      unitRef="usdPerShare">0.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-14"
      decimals="2"
      id="f-1042"
      unitRef="usdPerShare">-3.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-15"
      decimals="2"
      id="f-1043"
      unitRef="usdPerShare">-3.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1044"
      unitRef="usdPerShare">0.85</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-14"
      decimals="2"
      id="f-1045"
      unitRef="usdPerShare">-3.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-15"
      decimals="2"
      id="f-1046"
      unitRef="usdPerShare">-3.40</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-1047" unitRef="shares">2400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-14"
      decimals="-5"
      id="f-1048"
      unitRef="shares">2600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-15"
      decimals="-5"
      id="f-1049"
      unitRef="shares">1700000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1050">STOCK-BASED COMPENSATION&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company commenced administration of the ANI Pharmaceuticals, Inc. 2016 ESPP. As of December 31, 2023 there are 0.1&#160;million shares of common stock available for issuance under the ESPP. Under the ESPP, participants can purchase shares of common stock at a 15% discount. The Company issued 38&#160;thousand, 29&#160;thousand, and 14&#160;thousand shares in the years ended December&#160;31, 2023, 2022, and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Incentive Plan &lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Equity-based service awards are granted under the ANI Pharmaceuticals, Inc. Amended and Restated 2022 Stock Incentive Plan (the &#x201c;2022 Plan&#x201d;), which was approved by the Company's stockholders at the 2022 Annual Meeting of Stockholders (the &#x201c;Annual Meeting&#x201d;) held on April 27, 2022. Prior to this approval, the Company granted equity-based incentive awards under the Sixth Amended and Restated 2008 Stock Incentive Plan (the &#x201c;2008 Plan&#x201d;), which was renamed, amended and restated to the 2022 Plan. The 2022 Plan, among other things, increased the number of shares reserved for issuance thereunder by 1,150,000 shares. As of December&#160;31, 2023, 1.1&#160;million shares of common stock were available for issuance under the 2022 Plan. On May 23, 2023, the Company&#x2019;s stockholders approved an amendment to the 2022 Plan (such amendment, the &#x201c;2023 Stock Plan Amendment&#x201d;). Subject to adjustment, the 2023 Stock Plan Amendment increased the number of shares reserved for issuance under the 2022 Plan by 750,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may grant stock options to employees through an inducement grant outside of the 2022 Plan to induce prospective employees to accept employment with us (the &#x201c;Inducement Grants&#x201d;). The options are granted at an exercise price equal to the fair market value of a share of the common stock on the respective grant date and are generally exercisable in four equal annual installments beginning on the first anniversary of the respective grant date. The grants are made pursuant to inducement grants outside of the stockholder approved equity plan as permitted under the Nasdaq Stock Market listing rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The cost of equity-based service awards are measured based on the grant-date fair value of the award. The cost is recognized ratably over the period during which an employee is required to provide service in exchange for the award or the requisite service period. Stock-based compensation expense is recognized ratably over the vesting periods of the awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense incurred for stock options, restricted stock awards, performance-based restricted stock units, and Inducement Grants and included in the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,094&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,818&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;710&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;482&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,185&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,366&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax benefits of approximately $3.3 million, $1.7 million, and $1.0 million were recognized for stock-based compensation-related tax deductions in the 2023, 2022, and 2021 consolidated statements of operations, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding stock options granted to employees and consultants generally vest over a period of four years and have 10-year contractual terms. Outstanding stock options granted to non-employee directors generally vest over a period of &lt;span style="-sec-ix-hidden:f-1089"&gt;one&lt;/span&gt; to four years and have 10-year contractual terms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For 2023, 2022, and 2021, the fair value of each option grant was estimated using the Black-Scholes option-pricing model, using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.50 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.50 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.71% - 2.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.68% - 1.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.4% - 50.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.2% - 49.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the simplified method to estimate the expected option life of options. The risk-free interest rate used is the yield on a U.S. Treasury note as of the grant date with a maturity equal to the estimated life of the option. The calculated estimated volatility rate is based on ANI's historical stock price. The Company has not issued a cash dividend on the common shares in the past nor does the Company have any current plans to do so in the future; therefore, an expected dividend yield of zero was used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity under the 2022 Plan and Inducement Grants during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share and &lt;br/&gt;remaining term data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Option&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $1.6 million of total unrecognized compensation cost related to non-vested stock options granted under the 2022 Plan and Inducement Grant. The cost is expected to be recognized over a weighted-average period of 1.1 years. During the year ended December&#160;31, 2023, ANI received $8.3 million in cash from the exercise of stock options and recorded approximately $0.2 million tax provision related to these exercises. During the year ended December&#160;31, 2022, ANI received $0.7 million in cash from the exercise of stock options and recorded a $0.1 million tax provision related to these exercises. During the year ended December&#160;31, 2021, ANI received &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.7 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in cash from the exercise of stock options and recorded a $0.1 million tax provision related to these exercises.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards (&#x201c;RSAs&#x201d;) granted to employees generally vest over a period of four years. RSAs granted to non-officer directors generally vest over a period of one year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of common stock delivered to employees and directors will be unrestricted upon vesting. During the vesting period, the recipient of the restricted stock has full voting rights as a stockholder and would receive dividends, if declared, even though the restricted stock remains subject to transfer restrictions and will generally be forfeited upon termination of the officer prior to vesting. The fair value of each RSA is based on the market value of the Company's stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSA activity under the Plan during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share and &lt;br/&gt;remaining term data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Remaining Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$41.5 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of total unrecognized compensation cost related to non-vested RSAs granted under the Plan, which is expected to be recognized over a weighted-average period of 2.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Performance-Based Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Awards may also be issued in the form of PSUs. PSUs represent the right to receive a number of shares of Company common stock, contingent upon the achievement of specified performance objectives during a specified performance period. PSUs granted to date vest over a &lt;span style="-sec-ix-hidden:f-1206"&gt;three&lt;/span&gt;-year performance period. On February 28, 2023, as part of the Company's equity compensation program, PSUs were granted to certain executives. Of these PSUs, 50% were market performance-based restricted stock units (&#x201c;MPRSUs&#x201d;), vesting of which is contingent upon the Company meeting certain total shareholder return (&#x201c;TSR&#x201d;) levels as compared to a select peer group over the over &lt;span style="-sec-ix-hidden:f-1208"&gt;three&lt;/span&gt; years starting January 1, 2023. The MPRSUs are also subject to the recipient&#x2019;s continued employment or service through December 31, 2025. The MPRSUs cliff vest at the end of the &lt;span style="-sec-ix-hidden:f-1209"&gt;three&lt;/span&gt;-year period and have a maximum potential to vest at 200% (85,099 shares) based on TSR performance. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The estimated grant date fair value per share of the MPRSUs was $68.65 and was calculated using a Monte Carlo simulation model. These MPRSUs are included at 100% of the estimate number of shares at the end of the &lt;span style="-sec-ix-hidden:f-1214"&gt;three&lt;/span&gt;-year performance period and are reflected under &#x201c;Granted&#x201d; in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other 50% of the PSUs were performance based restricted stock units (&#x201c;PRSUs&#x201d;), vesting of which is contingent upon the Company meeting certain adjusted non-GAAP year-on-year EBITDA growth rates over the over &lt;span style="-sec-ix-hidden:f-1216"&gt;three&lt;/span&gt; years starting January 1, 2023. The PRSUs are also subject to the recipient&#x2019;s continued employment or service through December 31, 2025. The PRSUs cliff vest at the end of the three-year period and have a maximum potential to vest at 200% (85,099 shares) based on adjusted non-GAAP year-on-year EBITDA growth rates. The related share-based compensation expense is determined based on the estimated fair value of the underlying shares on the date of grant and is recognized straight-line over the vesting term. The Company analyzed progress on the performance goals to assess the likelihood of achievement. The estimated grant date fair value per share of the PRSUs was $41.84 based on the closing price of the stock on the date of grant. These PRSUs are included at 100% of the estimated number of shares at the end of the &lt;span style="-sec-ix-hidden:f-1222"&gt;three&lt;/span&gt;-year performance period and are reflected under &#x201c;Granted&#x201d; in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of PSU activity under the Plan during the years ended December&#160;31, 2023 and 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share and &lt;br/&gt;remaining term data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Remaining Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there was $2.5 million of total unrecognized compensation cost related to non-vested PSUs granted under the Plan, which is expected to be recognized over a weighted-average period of 2.0 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-256"
      decimals="-5"
      id="f-1051"
      unitRef="shares">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="c-257"
      decimals="2"
      id="f-1052"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-257"
      decimals="-3"
      id="f-1053"
      unitRef="shares">38000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-258"
      decimals="-3"
      id="f-1054"
      unitRef="shares">29000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-259"
      decimals="-3"
      id="f-1055"
      unitRef="shares">14000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1056">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes ESPP expense incurred under the 2016 Employee Stock Purchase Plan and included in the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;360&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;222&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;87&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;60&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;313&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;123&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expense incurred for stock options, restricted stock awards, performance-based restricted stock units, and Inducement Grants and included in the consolidated statements of operations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Selling, general, and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;18,676&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;13,094&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,818&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;863&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;710&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;543&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;482&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20,185&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;14,286&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10,366&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-260" decimals="-3" id="f-1057" unitRef="usd">360000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-261" decimals="-3" id="f-1058" unitRef="usd">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-262" decimals="-3" id="f-1059" unitRef="usd">87000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-263" decimals="-3" id="f-1060" unitRef="usd">60000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-264" decimals="-3" id="f-1061" unitRef="usd">50000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-265" decimals="-3" id="f-1062" unitRef="usd">15000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-266" decimals="-3" id="f-1063" unitRef="usd">47000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-267" decimals="-3" id="f-1064" unitRef="usd">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-268" decimals="-3" id="f-1065" unitRef="usd">21000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-257" decimals="-3" id="f-1066" unitRef="usd">467000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-258" decimals="-3" id="f-1067" unitRef="usd">313000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-259" decimals="-3" id="f-1068" unitRef="usd">123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-269"
      decimals="INF"
      id="f-1069"
      unitRef="shares">1150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-270"
      decimals="-5"
      id="f-1070"
      unitRef="shares">1100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-271"
      decimals="INF"
      id="f-1071"
      unitRef="shares">750000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-272" decimals="-3" id="f-1072" unitRef="usd">18676000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-273" decimals="-3" id="f-1073" unitRef="usd">13094000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-274" decimals="-3" id="f-1074" unitRef="usd">9818000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-275" decimals="-3" id="f-1075" unitRef="usd">863000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-276" decimals="-3" id="f-1076" unitRef="usd">710000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-277" decimals="-3" id="f-1077" unitRef="usd">543000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-278" decimals="-3" id="f-1078" unitRef="usd">646000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-279" decimals="-3" id="f-1079" unitRef="usd">482000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-280" decimals="-3" id="f-1080" unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-281" decimals="-3" id="f-1081" unitRef="usd">20185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-282" decimals="-3" id="f-1082" unitRef="usd">14286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-283" decimals="-3" id="f-1083" unitRef="usd">10366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-1084" unitRef="usd">3300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-14" decimals="-5" id="f-1085" unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-15" decimals="-5" id="f-1086" unitRef="usd">1000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-284" id="f-1087">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-284" id="f-1088">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-286" id="f-1090">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-287" id="f-1091">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1092">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For 2023, 2022, and 2021, the fair value of each option grant was estimated using the Black-Scholes option-pricing model, using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected option life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.50 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.50 - 6.25&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.71% - 2.83%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.68% - 1.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected stock price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.4% - 50.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.2% - 49.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-288" id="f-1093">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-289" id="f-1094">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-290" id="f-1095">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-291" id="f-1096">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-292" id="f-1097">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-288"
      decimals="4"
      id="f-1098"
      unitRef="number">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-289"
      decimals="4"
      id="f-1099"
      unitRef="number">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-290"
      decimals="4"
      id="f-1100"
      unitRef="number">0.0283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-291"
      decimals="4"
      id="f-1101"
      unitRef="number">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-292"
      decimals="4"
      id="f-1102"
      unitRef="number">0.0139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-288"
      decimals="4"
      id="f-1103"
      unitRef="number">0.490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-289"
      decimals="4"
      id="f-1104"
      unitRef="number">0.484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-290"
      decimals="4"
      id="f-1105"
      unitRef="number">0.500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-291"
      decimals="4"
      id="f-1106"
      unitRef="number">0.482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-292"
      decimals="4"
      id="f-1107"
      unitRef="number">0.495</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-288"
      decimals="INF"
      id="f-1108"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-293"
      decimals="INF"
      id="f-1109"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-294"
      decimals="INF"
      id="f-1110"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-288"
      decimals="2"
      id="f-1111"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-1112">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity under the 2022 Plan and Inducement Grants during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.023%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share and &lt;br/&gt;remaining term data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Option&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;59.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;16.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;30.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;22.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;55.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Outstanding at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exercisable at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-295"
      decimals="-3"
      id="f-1113"
      unitRef="shares">936000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-295"
      decimals="2"
      id="f-1114"
      unitRef="usdPerShare">48.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-296" id="f-1115">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-295" decimals="-3" id="f-1116" unitRef="usd">372000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-294"
      decimals="-3"
      id="f-1117"
      unitRef="shares">168000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1118"
      unitRef="usdPerShare">33.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-294"
      decimals="2"
      id="f-1119"
      unitRef="usdPerShare">15.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-294"
      decimals="-3"
      id="f-1120"
      unitRef="shares">42000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1121"
      unitRef="usdPerShare">40.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-294" decimals="-3" id="f-1122" unitRef="usd">552000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-294"
      decimals="-3"
      id="f-1123"
      unitRef="shares">19000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1124"
      unitRef="usdPerShare">59.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-294"
      decimals="-3"
      id="f-1125"
      unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-294"
      decimals="2"
      id="f-1126"
      unitRef="usdPerShare">55.59</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-297"
      decimals="-3"
      id="f-1127"
      unitRef="shares">988000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-297"
      decimals="2"
      id="f-1128"
      unitRef="usdPerShare">45.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-294" id="f-1129">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-297" decimals="-3" id="f-1130" unitRef="usd">6786000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-293"
      decimals="-3"
      id="f-1131"
      unitRef="shares">36000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-293"
      decimals="2"
      id="f-1132"
      unitRef="usdPerShare">34.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-293"
      decimals="2"
      id="f-1133"
      unitRef="usdPerShare">16.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-293"
      decimals="-3"
      id="f-1134"
      unitRef="shares">23000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-293"
      decimals="2"
      id="f-1135"
      unitRef="usdPerShare">30.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-293" decimals="-3" id="f-1136" unitRef="usd">153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-293"
      decimals="-3"
      id="f-1137"
      unitRef="shares">47000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-293"
      decimals="2"
      id="f-1138"
      unitRef="usdPerShare">36.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-293"
      decimals="-3"
      id="f-1139"
      unitRef="shares">47000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-293"
      decimals="2"
      id="f-1140"
      unitRef="usdPerShare">55.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-298"
      decimals="-3"
      id="f-1141"
      unitRef="shares">907000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-298"
      decimals="2"
      id="f-1142"
      unitRef="usdPerShare">45.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-293" id="f-1143">P5Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-298" decimals="-3" id="f-1144" unitRef="usd">3868000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-288"
      decimals="-3"
      id="f-1145"
      unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-288"
      decimals="2"
      id="f-1146"
      unitRef="usdPerShare">41.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-288"
      decimals="2"
      id="f-1147"
      unitRef="usdPerShare">22.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-288"
      decimals="-3"
      id="f-1148"
      unitRef="shares">189000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-288"
      decimals="2"
      id="f-1149"
      unitRef="usdPerShare">44.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-288" decimals="-3" id="f-1150" unitRef="usd">2894000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-288"
      decimals="-3"
      id="f-1151"
      unitRef="shares">21000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-288"
      decimals="2"
      id="f-1152"
      unitRef="usdPerShare">33.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="c-288"
      decimals="-3"
      id="f-1153"
      unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-288"
      decimals="2"
      id="f-1154"
      unitRef="usdPerShare">55.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-299"
      decimals="-3"
      id="f-1155"
      unitRef="shares">689000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-299"
      decimals="2"
      id="f-1156"
      unitRef="usdPerShare">46.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-288" id="f-1157">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-299" decimals="-3" id="f-1158" unitRef="usd">8370000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-299"
      decimals="-3"
      id="f-1159"
      unitRef="shares">580000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-299"
      decimals="2"
      id="f-1160"
      unitRef="usdPerShare">48.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-288" id="f-1161">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-299" decimals="-3" id="f-1162" unitRef="usd">5815000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-299" decimals="-5" id="f-1163" unitRef="usd">1600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-288" id="f-1164">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-288" decimals="-5" id="f-1165" unitRef="usd">8300000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-288" decimals="-5" id="f-1166" unitRef="usd">200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-293" decimals="-5" id="f-1167" unitRef="usd">700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-293" decimals="-5" id="f-1168" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-294" decimals="-5" id="f-1169" unitRef="usd">1700000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions contextRef="c-294" decimals="-5" id="f-1170" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-300" id="f-1171">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-301" id="f-1172">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-1173">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSA activity under the Plan during the years ended December&#160;31, 2023, 2022, and 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share and &lt;br/&gt;remaining term data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Remaining Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(125)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;32.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(245)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;36.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(383)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;34.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;38.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-302"
      decimals="-3"
      id="f-1174"
      unitRef="shares">352000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-302"
      decimals="2"
      id="f-1175"
      unitRef="usdPerShare">48.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-303" id="f-1176">P2Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-304"
      decimals="-3"
      id="f-1177"
      unitRef="shares">541000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-304"
      decimals="2"
      id="f-1178"
      unitRef="usdPerShare">33.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-304"
      decimals="-3"
      id="f-1179"
      unitRef="shares">125000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-304"
      decimals="2"
      id="f-1180"
      unitRef="usdPerShare">48.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-304"
      decimals="-3"
      id="f-1181"
      unitRef="shares">61000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-304"
      decimals="2"
      id="f-1182"
      unitRef="usdPerShare">48.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-305"
      decimals="-3"
      id="f-1183"
      unitRef="shares">707000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-305"
      decimals="2"
      id="f-1184"
      unitRef="usdPerShare">36.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-304" id="f-1185">P2Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-306"
      decimals="-3"
      id="f-1186"
      unitRef="shares">748000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-306"
      decimals="2"
      id="f-1187"
      unitRef="usdPerShare">32.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-306"
      decimals="-3"
      id="f-1188"
      unitRef="shares">245000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-306"
      decimals="2"
      id="f-1189"
      unitRef="usdPerShare">36.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-306"
      decimals="-3"
      id="f-1190"
      unitRef="shares">69000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-306"
      decimals="2"
      id="f-1191"
      unitRef="usdPerShare">38.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-307"
      decimals="-3"
      id="f-1192"
      unitRef="shares">1141000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-307"
      decimals="2"
      id="f-1193"
      unitRef="usdPerShare">33.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-306" id="f-1194">P2Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-308"
      decimals="-3"
      id="f-1195"
      unitRef="shares">674000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-308"
      decimals="2"
      id="f-1196"
      unitRef="usdPerShare">43.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-308"
      decimals="-3"
      id="f-1197"
      unitRef="shares">383000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-308"
      decimals="2"
      id="f-1198"
      unitRef="usdPerShare">34.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-308"
      decimals="-3"
      id="f-1199"
      unitRef="shares">81000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-308"
      decimals="2"
      id="f-1200"
      unitRef="usdPerShare">38.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-309"
      decimals="-3"
      id="f-1201"
      unitRef="shares">1351000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-309"
      decimals="2"
      id="f-1202"
      unitRef="usdPerShare">38.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-308" id="f-1203">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-309" decimals="-5" id="f-1204" unitRef="usd">41500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-308" id="f-1205">P2Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards
      contextRef="c-311"
      decimals="INF"
      id="f-1207"
      unitRef="number">0.50</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage
      contextRef="c-311"
      decimals="INF"
      id="f-1210"
      unitRef="number">2</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares
      contextRef="c-311"
      decimals="INF"
      id="f-1211"
      unitRef="shares">85099</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-312"
      decimals="2"
      id="f-1212"
      unitRef="usdPerShare">68.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage
      contextRef="c-311"
      decimals="INF"
      id="f-1213"
      unitRef="number">1</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards
      contextRef="c-313"
      decimals="INF"
      id="f-1215"
      unitRef="number">0.50</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageOfAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-310" id="f-1217">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage
      contextRef="c-313"
      decimals="INF"
      id="f-1218"
      unitRef="number">2</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestPercentage>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares
      contextRef="c-313"
      decimals="INF"
      id="f-1219"
      unitRef="shares">85099</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVestShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-310"
      decimals="2"
      id="f-1220"
      unitRef="usdPerShare">41.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage
      contextRef="c-313"
      decimals="INF"
      id="f-1221"
      unitRef="number">1</anip:ShareBasedCompensationArrangementByShareBasedPaymentAwardEstimateNumberOfSharesPercentage>
    <us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock contextRef="c-1" id="f-1223">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of PSU activity under the Plan during the years ended December&#160;31, 2023 and 2022 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share and &lt;br/&gt;remaining term data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;br/&gt;Average Grant&lt;br/&gt;Date Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Remaining Term&lt;br/&gt;(years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationPerformanceSharesAwardUnvestedActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-314"
      decimals="-3"
      id="f-1224"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-314"
      decimals="2"
      id="f-1225"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-68"
      decimals="-3"
      id="f-1226"
      unitRef="shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-68"
      decimals="2"
      id="f-1227"
      unitRef="usdPerShare">41.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-68"
      decimals="-3"
      id="f-1228"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-68"
      decimals="2"
      id="f-1229"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-68"
      decimals="-3"
      id="f-1230"
      unitRef="shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-68"
      decimals="2"
      id="f-1231"
      unitRef="usdPerShare">41.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-315"
      decimals="-3"
      id="f-1232"
      unitRef="shares">84000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-315"
      decimals="2"
      id="f-1233"
      unitRef="usdPerShare">41.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c-68" id="f-1234">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-315" decimals="-5" id="f-1235" unitRef="usd">2500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-68" id="f-1236">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1237">INCOME TAXES&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 6, 2018, ANI Pharmaceuticals Canada Inc. (&#x201c;ANI Canada&#x201d;) acquired all the issued and outstanding equity interests of WellSpring in a non-taxable transaction. Following the consummation of the transaction, WellSpring was merged into ANI Canada. For U.S. Federal and state income tax purposes, ANI Canada is not part of ANI&#x2019;s consolidated group; rather, ANI Canada is subject to income taxes only in Canada and solely based on its stand-alone operations. The foreign current and foreign deferred provisions (benefits) below represent the Company's tax provision (benefit) from the Canadian and Indian taxing jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to establish a valuation allowance is required to be established for deferred tax assets if, based on the weight of available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Projected future taxable income and tax planning strategies in making this assessment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023 and 2022, the consolidated valuation allowance was $0.4&#160;million and $0.4&#160;million, respectively, related solely to deferred tax assets for net operating loss carryforwards in certain U.S. state jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total income tax expense (benefit) for income taxes consists of the following for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total expense (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between expected income tax expense (benefit) from applying U.S. Federal statutory tax rates to the pre-tax income (loss) and actual income tax expense (benefit) relates primarily to the effect of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State taxes, net of Federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in state apportionment factors, state and foreign rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and experimentation and charitable credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfer pricing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Deferred income tax assets and liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals and advances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for chargebacks and returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets, net of deferred tax liabilities and valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, U.S. federal net operating loss carryforwards were approximately $8.0 million, all of which arose as a result of the 2013 merger with BioSante Pharmaceuticals, Inc. Net operating loss carryforwards related to the 2013 merger, if not used, expire in annual increments through 2033 and are limited on an annual basis as prescribed by Section 382 of the U.S. Internal Revenue Code; and the current annual limitation is approximately $0.8 million per year. Additionally, as of December&#160;31, 2023, there were total net operating losses in various states of approximately $13.0&#160;million which begin to expire through 2042, and in Canada of $1.0 million that expire through 2038. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to income taxes in numerous jurisdictions in the U.S., Canada, and India. Significant judgment is required in evaluating the tax positions and determining the provision for income taxes. Liabilities are established for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These liabilities are established when it is believed that certain positions might be challenged despite the belief that our tax return positions are fully supportable. These liabilities are adjusted in light of changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of changes to the liability that is considered appropriate. There were no material uncertain income tax positions identified as of December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to income tax audits in all jurisdictions for which tax returns are filed. Tax audits by their nature are often complex and can require several years to complete. All of the Company's income tax returns remain subject to examination by tax authorities due to the availability of net operating loss carryforwards.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-316" decimals="-5" id="f-1238" unitRef="usd">400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-317" decimals="-5" id="f-1239" unitRef="usd">400000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1240">expense (benefit) for income taxes consists of the following for the years ended December 31:&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;691&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(7,601)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,382)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(12,163)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(3,946)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,122)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(15,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(16,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total expense (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(14,769)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(13,455)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1241" unitRef="usd">9117000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1242" unitRef="usd">152000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1243" unitRef="usd">1296000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1244" unitRef="usd">3534000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1245" unitRef="usd">249000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1246" unitRef="usd">1320000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1247" unitRef="usd">26000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1248" unitRef="usd">66000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1249" unitRef="usd">691000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1250" unitRef="usd">12677000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1251" unitRef="usd">467000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1252" unitRef="usd">3307000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1253" unitRef="usd">-7601000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1254" unitRef="usd">-13382000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1255" unitRef="usd">-12163000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1256" unitRef="usd">-3946000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1257" unitRef="usd">-1722000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1258" unitRef="usd">-5122000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1259" unitRef="usd">-29000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1260" unitRef="usd">-128000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1261" unitRef="usd">336000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1262" unitRef="usd">-11576000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1263" unitRef="usd">-15232000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1264" unitRef="usd">-16949000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-1" decimals="-3" id="f-1265" unitRef="usd">8000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-14" decimals="-3" id="f-1266" unitRef="usd">4000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-15" decimals="-3" id="f-1267" unitRef="usd">-187000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1268" unitRef="usd">1093000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-14" decimals="-3" id="f-1269" unitRef="usd">-14769000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-15" decimals="-3" id="f-1270" unitRef="usd">-13455000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1271">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between expected income tax expense (benefit) from applying U.S. Federal statutory tax rates to the pre-tax income (loss) and actual income tax expense (benefit) relates primarily to the effect of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;US Federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State taxes, net of Federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-deductible costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Change in state apportionment factors, state and foreign rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and experimentation and charitable credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transfer pricing and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1272" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-14" decimals="3" id="f-1273" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-15" decimals="3" id="f-1274" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1275" unitRef="number">0.048</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-14" decimals="3" id="f-1276" unitRef="number">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-15" decimals="3" id="f-1277" unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1278" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-14" decimals="3" id="f-1279" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-15" decimals="3" id="f-1280" unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-1281" unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-14" decimals="3" id="f-1282" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-15" decimals="3" id="f-1283" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="3" id="f-1284" unitRef="number">0.108</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-14" decimals="3" id="f-1285" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-15" decimals="3" id="f-1286" unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-1287" unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-14" decimals="3" id="f-1288" unitRef="number">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-15" decimals="3" id="f-1289" unitRef="number">-0.008</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes contextRef="c-1" decimals="3" id="f-1290" unitRef="number">-0.118</anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes>
    <anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes contextRef="c-14" decimals="3" id="f-1291" unitRef="number">-0.001</anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes>
    <anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes contextRef="c-15" decimals="3" id="f-1292" unitRef="number">0.055</anip:EffectiveIncomeTaxRateReconciliationStateAndForeignIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1293" unitRef="number">0.190</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-14" decimals="3" id="f-1294" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-15" decimals="3" id="f-1295" unitRef="number">-0.009</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1296" unitRef="number">-0.024</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-14" decimals="3" id="f-1297" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-15" decimals="3" id="f-1298" unitRef="number">-0.029</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1299" unitRef="number">0.055</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-14" decimals="3" id="f-1300" unitRef="number">0.236</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-15" decimals="3" id="f-1301" unitRef="number">0.240</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1302">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of differences between the bases of assets and liabilities for financial reporting and income tax purposes. Deferred income tax assets and liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals and advances&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;9,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for chargebacks and returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;17,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;15,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;33,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitalized research expenditures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;7,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;102,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;91,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(5,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,298)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(10,074)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets, net of deferred tax liabilities and valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;90,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;81,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-6" decimals="-3" id="f-1303" unitRef="usd">12470000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-7" decimals="-3" id="f-1304" unitRef="usd">9233000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-1305" unitRef="usd">6013000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-1306" unitRef="usd">6041000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances contextRef="c-6" decimals="-3" id="f-1307" unitRef="usd">17358000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances contextRef="c-7" decimals="-3" id="f-1308" unitRef="usd">15344000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-6" decimals="-3" id="f-1309" unitRef="usd">4569000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory contextRef="c-7" decimals="-3" id="f-1310" unitRef="usd">5292000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-6" decimals="-3" id="f-1311" unitRef="usd">40193000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-7" decimals="-3" id="f-1312" unitRef="usd">33431000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-1313" unitRef="usd">2900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-1314" unitRef="usd">5994000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-1315" unitRef="usd">11294000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-1316" unitRef="usd">4708000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-1317" unitRef="usd">7450000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-1318" unitRef="usd">11840000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-1319" unitRef="usd">102247000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-1320" unitRef="usd">91883000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-1321" unitRef="usd">5658000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-1322" unitRef="usd">5776000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-6" decimals="-3" id="f-1323" unitRef="usd">5440000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-7" decimals="-3" id="f-1324" unitRef="usd">4298000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-1325" unitRef="usd">11098000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-1326" unitRef="usd">10074000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-1327" unitRef="usd">438000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-1328" unitRef="usd">446000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-1329" unitRef="usd">90711000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-1330" unitRef="usd">81363000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-318" decimals="-5" id="f-1331" unitRef="usd">8000000</us-gaap:OperatingLossCarryforwards>
    <anip:OperatingLossCarryforwardsAnnualLimitationsOnUse contextRef="c-319" decimals="-5" id="f-1332" unitRef="usd">800000</anip:OperatingLossCarryforwardsAnnualLimitationsOnUse>
    <us-gaap:OperatingLossCarryforwards contextRef="c-320" decimals="-5" id="f-1333" unitRef="usd">13000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-316" decimals="-5" id="f-1334" unitRef="usd">1000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c-1" id="f-1335">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All existing leases as of December&#160;31, 2023 are classified as operating leases. As of December&#160;31, 2023, there are 14 operating leases for facilities and office equipment with remaining terms expiring from 2025 through 2028 and a weighted average remaining lease terms of 3.9 years and 2.6 years, as of December 31, 2023 and 2022, respectively. During April 2023, the Company entered into a lease agreement for additional warehouse space in East Windsor, New Jersey. Additionally, during October 2023, the Company entered into an amendment for the Middleton, Wisconsin location which expanded the Company's square footage and also extended the termination date to December 2028. Many of the operating leases have fair value renewal options, none of which are considered certain of being exercised or included in the minimum lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of twelve months or less are not recorded on the balance sheet, and the Company does not separate lease and non-lease components of contracts. The Company&#x2019;s lease agreements do not provide for determination of the interest rate implicit in the lease. Therefore, the Company used a benchmark approach to derive an appropriate incremental borrowing rate. The Company&#x2019;s incremental borrowing rate is the rate of interest that the lessee would have to pay to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. The Company benchmarked itself against other companies of similar credit ratings and comparable quality and derived an incremental borrowing rate, which was used to discount its lease liabilities. The weighted average incremental borrowing rates as of December 31, 2023 and 2022 is 8.12% and 3.99%, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material restrictive covenants. In addition, the Company does not have any finance leases, any sublease arrangements, or any leases where the Company is considered the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense consisted of the following for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;701&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1.37pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;236&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;937&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the lease liabilities recorded on the Consolidated Balance Sheet as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,967&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,610&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,290&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,289&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;506&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,662&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: effects of discounting &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,672&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1361"&gt;Less: current lease liability, included in accrued expenses and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,561)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1363"&gt;Non-current lease liability, included in other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Government Regulation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's products and facilities are subject to regulation by a number of federal and state governmental agencies, such as the Drug Enforcement Administration (&#x201c;DEA&#x201d;), the Food and Drug Administration (&#x201c;FDA&#x201d;), the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;), the Central Drugs Standard Control Organization (&#x201c;CDSCO&#x201d;), The Narcotics Control Bureau (&#x201c;NCB&#x201d;), and India&#x2019;s Ministry of Health and Family Welfare (&#x201c;MoHFW&#x201d;). The FDA, in particular, maintains oversight of the formulation, manufacture, distribution, packaging, and labeling of all of ANI's products. The DEA and NCB maintain oversight over products that are considered controlled substances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Unapproved Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three products, Esterified Estrogen with Methyltestosterone (&#x201c;EEMT&#x201d;), Opium Tincture, Thyroid Tablets, and are marketed without approved NDAs or ANDAs. During the years ended December&#160;31, 2023, 2022, and 2021, net revenues for Esterified Estrogen with Methyltestosterone (&#x201c;EEMT&#x201d;), Opium Tincture and Thyroid Tablets products totaled $22.4 million, $14.2 million, and $16.2 million, respectively. The Company obtained the rights to Hyoscyamine, a product without an approved NDA as of December 27, 2023, which we plan to launch commercially in early 2024 (see further discussion below).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FDA's policy with respect to the continued marketing of unapproved products appears in the FDA's September 2011 Compliance Policy Guide Sec. 440.100 titled &#x201c;Marketed New Drugs without Approved NDAs or ANDAs.&#x201d; Under this policy, the FDA has stated that it will follow a risk-based approach with regard to enforcement against marketing of unapproved products. The FDA evaluates whether to initiate enforcement action on a case-by-case basis, but gives higher priority to enforcement action against products in certain categories, such as those with potential safety risks or that lack evidence of effectiveness. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to believe that, so long as we comply with applicable manufacturing standards, the FDA will continue to operate on a risk-based approach and will not take action against us. However, we can offer no assurance that the FDA will continue to follow this approach or that it will not take a contrary position with any individual product or group of products. If the FDA were to move away from the risk-based approach to enforcement against marketing of unapproved products, we may be required to seek FDA approval for these products or withdraw such products from the market. If we decide to withdraw the products from the market, net revenues for generic pharmaceutical products would decline materially, and if we decide to seek FDA approval, we would face increased expenses and might need to suspend sales of the products until such approval was obtained, and there are no assurances that we would receive such approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One group of products that the Company manufactured on behalf of a contract customer, Hyoscyamine, was marketed by that customer without an approved NDA. Contract manufacturing revenues for Hyoscyamine, for the years ended December&#160;31, 2023, 2022, and 2021 were $1.9 million, $2.6 million, and $2.4 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. On December 27, 2023 the Company purchased the intellectual property and product rights to Hyoscamine from Alvogen, Inc. (Note 10).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Legal proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved, and from time to time may become involved, in various disputes, governmental and/or regulatory inquiries, investigations, government reimbursement related actions and litigation. These matters are complex and subject to significant uncertainties. While we believe that we have valid claims and/or defenses in the litigation and other matters described below, litigation is inherently unpredictable, particularly where the damages sought are substantial or indeterminate or when the proceedings, investigations or inquiries are in the early stages, and the outcome of the proceedings could result in losses, including substantial damages, fines, civil or criminal penalties and injunctive or administrative remedies. We intend to vigorously prosecute and/or defend these matters, as appropriate; however, from time to time, we may settle or otherwise resolve these matters on terms and conditions that we believe are in our best interests. Resolution of any or all claims, investigations, and legal proceedings, individually or in the aggregate, could have a material adverse effect on our results of operations and/or cash flows in any given accounting period or on our overall financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise disclosed, we are unable to predict the outcome of the matter or to provide an estimate of the range of reasonably possible material losses. We record accruals for loss contingencies to the extent we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we are also involved in other pending proceedings for which, in our opinion based upon facts and circumstances known at the time, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to our results, and therefore remain undisclosed. If and when any reasonably possible losses associated with the resolution of such other pending proceedings, in our opinion, become material, we will disclose such matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Furthermore, like many pharmaceutical manufacturers, we are periodically exposed to product liability claims. The prevalence of these claims could limit our coverage under future insurance policies or cause those policies to become more expensive, which could harm our business, financial condition, and operating results. Recent trends in the product liability and director and officer insurance markets is to exclude matters related to certain classes of drugs. Our policies have been subject to such exclusions which place further potential risk of financial loss on us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Legal fees for litigation-related matters are expensed as incurred and included in the consolidated statements of operations under the selling, general, and administrative expense line item. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2020, class action complaints were filed against the Company on behalf of putative classes of direct and indirect purchasers of the drug Bystolic. On December 23, 2020, six individual purchasers of Bystolic, CVS, Rite Aid, Walgreen, Kroger, Albertsons, and H-E-B, filed complaints against the Company. On March 15, 2021, the plaintiffs in these actions filed amended complaints. All amended complaints were substantively identical. The plaintiffs in these actions alleged that, beginning in 2012, Forest Laboratories, the manufacturer of Bystolic, entered into anticompetitive agreements when settling patent litigation related to Bystolic with seven potential manufacturers of a generic version of Bystolic: Hetero, Torrent, Alkem/Indchemie, Glenmark, Amerigen, Watson, and various of their corporate parents, successors, subsidiaries, and affiliates. ANI itself was not a party to patent litigation with Forest concerning Bystolic and did not settle patent litigation with Forest. The plaintiffs named the Company as a defendant based on the Company&#x2019;s January 8, 2020 Asset Purchase Agreement with Amerigen. Under the terms of the 2020 Asset Purchase Agreement, Amerigen agreed to indemnify ANI for certain liabilities relating to Bystolic, including liabilities that arose prior to closing of the asset purchase. The complaints alleged that the 2013 patent litigation settlement agreement between Forest and Amerigen violated federal and state antitrust laws and state consumer protection laws by delaying the market entry of generic versions of Bystolic. Plaintiffs alleged they paid higher prices as a result of delayed generic competition. Plaintiffs sought damages, trebled or otherwise multiplied under applicable law, injunctive relief, litigation costs and attorneys&#x2019; fees. The complaints did not specify the amount of damages sought from the Company or other defendants and the Company. The cases were consolidated in the United States District Court for the Southern District of New York as In re Bystolic Antitrust Litigation, Case No. 20-cv-005735 (LJL). On April 23, 2021, the Company and other defendants filed motions to dismiss the amended complaints. On January 24, 2022, the court dismissed all claims brought by the plaintiffs without prejudice. The court granted the plaintiffs until February 22, 2022 to file amended complaints, which were filed in federal court in the Southern District of New York, on that date. The newly amended complaints contained substantially similar claims. On April 19, 2022, the Company and other defendants filed motions to dismiss the newly amended complaints. After full briefing and oral argument, on February 21, 2023, the court granted the Company and the defendants&#x2019; motion to dismiss all actions with prejudice. Plaintiffs filed an appeal in the Second Circuit.  Oral arguments were held on December 6, 2023 and a decision from the court is pending. ANI continues to dispute any liability in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 24, 2021, Azurity Pharmaceuticals, Inc. (&#x201c;Azurity&#x201d;) filed a complaint in the United States District Court for the District of Minnesota against ANI, asserting that ANI&#x2019;s vancomycin hydrochloride oral solution drug product infringes U.S. Patent No. 10,688,046. The complaint sought injunctive relief, damages, including lost profits and/or royalty, treble damages, and attorneys&#x2019; fee and costs. On February 15, 2022, the Company entered into a settlement agreement with Azurity to resolve all claims related to this action. Under the terms of the agreement, Azurity granted ANI a non-exclusive, non-transferable, non-sublicensable, royalty-bearing license under its patents to sell ANI product in the United States and dismissed the action with prejudice. In exchange, ANI paid Azurity $1.9&#160;million of royalties from past sales and will pay Azurity a royalty equal to 20% of gross margin of sales of the ANI product for a contractually defined term.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 1, 2021, United Therapeutics Corp. and Supernus Pharmaceuticals, Inc. (&#x201c;UTC/Supernus&#x201d;) filed a complaint in the United States District Court for the District of Delaware against ANI, asserting that ANI&#x2019;s proposed Treprostinil extended release drug product, which is subject to ANI&#x2019;s Abbreviated New Drug Application No. 215667, infringes U.S. Patent Nos. 7,417,070, 7,544,713, 8,252,839, 8,349,892, 8,410,169, 8,747,897, 9,050,311, 9,278,901, 9,393,203, 9,422,223, 9,593,066 and 9,604,901 (&#x201c;the Asserted Patents&#x201d;). The complaint sought injunctive relief&lt;/span&gt;&lt;span style="color:#353535;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;attorneys' fee and costs. On May 26, 2022, the parties&#x2019; respective claims and counterclaims were dismissed pursuant to a confidential settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2022, Azurity filed a complaint in the United States District Court for the District of New Jersey against Novitium, seeking a declaratory judgment that Novitium&#x2019;s manufacture, use, sale, importation and/or offer to sell Bionpharma Inc.&#x2019;s (&#x201c;Bionpharma&#x201d;) enalapril maleate oral solution drug product (the &#x201c;Product&#x201d;) would infringe U.S. Patents Nos. 11,040,023 and 11,141,405 (the &#x201c;Novitium Action&#x201d;). The complaint sought injunctive relief, and an award of Azurity&#x2019;s costs and expenses. On October 12, 2022, Bionpharma filed a motion in the New Jersey court to intervene on Novitium&#x2019;s behalf in the litigation and on October 14, 2022, Novitium and Bionpharma jointly moved to transfer venue to the District of Delaware. Transfer was granted on January 20, 2023. On March 27, 2023, the transferred Novitium Action (assigned Delaware Civil Action No. 23-163-MSG) was consolidated with the Delaware Third Wave Suits against Bionpharma (Civil Action Nos. 21-1286-MSG, 21-1455-MSG), which include Azurity&#x2019;s infringement claims against Bionpharma involving the same patents asserted in the Novitium Action, as well as Bionpharma&#x2019;s antitrust claims against Azurity. On August 3, 2023, Azurity filed an amended complaint against Novitium seeking damages for supplying Bionpharma's ANDA product. On November 14, 2023, the court dismissed all of Azurity's claims against Novitium with prejudice and dismissed Novitium as a party from the Delaware Third Wave Suits. Bionpharma has agreed to indemnify Novitium under the terms of its manufacturing and supply agreement for any damages, costs, and expenses relating to actual or alleged infringement of intellectual property rights or sale of the Product by Bionpharma. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 29, 2023, Orphalan SA ("Orphalan") filed a complaint in the United States District Court for the District of Delaware against Novitium, asserting that Novitium's proposed triethylenetetramine tetrachloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218493, infringes U.S. Patent Nos. 10,988,436 and 11,072,577.  The complaint seeks damages, injunctive relief, attorneys' fees and costs. On December 1, 2023, Orphalan voluntarily dismissed the action without prejudice. Novitium disputes any liability in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 21, 2023, Harmony Biosciences, LLC, Bioprojet Societe Civile de Recherche and Bioprojet Pharma SAS filed a compliant in the United States District Court for the District of Delaware against Novitium and certain other defendants named in the complaint, asserting, among other things, that Novitium's proposed pitolisant hydrochloride drug product, which is subject to Novitium's Abbreviated New Drug Application No. 218495, infringes U.S. Patent Nos 8,207,197, 8,354,430 and 8,486,947.  The complaint seeks damages, injunctive relief, attorneys' fees and costs.  Novitium disputes any liability in this matter.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ranitidine Related Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State of New Mexico Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. In July 2020, ANI and Novitium were served with a complaint brought in the First Judicial Court, County of Santa Fe, State of New Mexico by the Office of the Attorney General of the State of New Mexico against manufacturers and sellers of ranitidine products. The complaint asserted a public nuisance claim and a negligence claim against the generic ranitidine manufacturer defendants, including ANI and Novitium. As damages for the nuisance claim, New Mexico asked that the defendants fund this medical monitoring program.  With respect to the nuisance claim, New Mexico asserted that it paid for ranitidine products through state-funded insurance and health-care programs. On April 16, 2021, New Mexico filed an amended complaint in the New Mexico First Judicial District Court in Santa Fe County. It did not name ANI in the amended complaint, effectively voluntarily dismissing ANI from the action. Novitium was named as a defendant in the amended complaint. On September 1, 2023, the court entered an order dismissing Novitium without prejudice.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <anip:NumberOfOperatingLeases
      contextRef="c-6"
      decimals="INF"
      id="f-1336"
      unitRef="operatinglease">14</anip:NumberOfOperatingLeases>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1337">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-7" id="f-1338">P2Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="4" id="f-1339" unitRef="number">0.0812</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-7" decimals="4" id="f-1340" unitRef="number">0.0399</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1341">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease expense consisted of the following for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.676%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.430%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,031&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;701&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;240&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;221&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1.37pt 0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;236&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;48&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,252&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1.37pt 0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;937&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;288&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-1342" unitRef="usd">2031000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-14" decimals="-3" id="f-1343" unitRef="usd">701000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-15" decimals="-3" id="f-1344" unitRef="usd">240000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-1" decimals="-3" id="f-1345" unitRef="usd">221000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-14" decimals="-3" id="f-1346" unitRef="usd">236000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-15" decimals="-3" id="f-1347" unitRef="usd">48000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-1348" unitRef="usd">2252000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-14" decimals="-3" id="f-1349" unitRef="usd">937000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-15" decimals="-3" id="f-1350" unitRef="usd">288000</us-gaap:LeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1351">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the lease liabilities recorded on the Consolidated Balance Sheet as of December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.090%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.597%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.203%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,967&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,610&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,290&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,289&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;506&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,662&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: effects of discounting &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(990)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Present value of future minimum lease payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,672&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1361"&gt;Less: current lease liability, included in accrued expenses and other&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(1,561)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-1363"&gt;Non-current lease liability, included in other non-current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,111&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-1352" unitRef="usd">1967000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-1353" unitRef="usd">1610000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-1354" unitRef="usd">1290000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-1355" unitRef="usd">1289000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-6" decimals="-3" id="f-1356" unitRef="usd">506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-6" decimals="-3" id="f-1357" unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-1358" unitRef="usd">6662000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-1359" unitRef="usd">990000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-1360" unitRef="usd">5672000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-1362" unitRef="usd">1561000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-1364" unitRef="usd">4111000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <anip:NumberOfProductsMarketed
      contextRef="c-6"
      decimals="INF"
      id="f-1365"
      unitRef="product">3</anip:NumberOfProductsMarketed>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-321" decimals="-5" id="f-1366" unitRef="usd">22400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-322" decimals="-5" id="f-1367" unitRef="usd">14200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-323" decimals="-5" id="f-1368" unitRef="usd">16200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-324" decimals="-5" id="f-1369" unitRef="usd">1900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-325" decimals="-5" id="f-1370" unitRef="usd">2600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-326" decimals="-5" id="f-1371" unitRef="usd">2400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LossContingencyNumberOfPlaintiffs
      contextRef="c-327"
      decimals="INF"
      id="f-1372"
      unitRef="plaintiff">6</us-gaap:LossContingencyNumberOfPlaintiffs>
    <anip:LossContingencyNumberOfManufacturers
      contextRef="c-328"
      decimals="0"
      id="f-1373"
      unitRef="manufacturer">7</anip:LossContingencyNumberOfManufacturers>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-329" decimals="-5" id="f-1374" unitRef="usd">1900000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <anip:RoyaltyOnFutureSalesPercent
      contextRef="c-329"
      decimals="2"
      id="f-1375"
      unitRef="number">0.20</anip:RoyaltyOnFutureSalesPercent>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-330"
      decimals="INF"
      id="f-1376"
      unitRef="claim">5</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-330"
      decimals="INF"
      id="f-1377"
      unitRef="claim">5</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-331"
      decimals="INF"
      id="f-1378"
      unitRef="claim">158</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-331"
      decimals="INF"
      id="f-1379"
      unitRef="claim">158</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="c-332"
      decimals="-2"
      id="f-1380"
      unitRef="claim">700</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-333"
      decimals="INF"
      id="f-1381"
      unitRef="claim">6</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-334"
      decimals="INF"
      id="f-1382"
      unitRef="claim">7</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-335"
      decimals="INF"
      id="f-1383"
      unitRef="claim">200</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-336"
      decimals="INF"
      id="f-1384"
      unitRef="claim">28</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-337"
      decimals="INF"
      id="f-1385"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <anip:CortrophinPreLaunchChargesTextBlock contextRef="c-1" id="f-1386">PURIFIED CORTROPHIN GEL PRE-LAUNCH CHARGES&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2016, the Company acquired the right, title and interest in the NDAs for Cortrophin Gel and Cortrophin-Zinc. Subsequently, the Company assembled a Cortrophin Gel re-commercialization team of scientists, executed a long-term supply agreement with a supplier of pig pituitary glands, our primary raw material for corticotrophin API, executed a long-term supply agreement with an API manufacturer, with whom ANI has advanced the manufacture of corticotropin API via manufacture of commercial-scale batches, and executed a long-term commercial supply agreement with a current good manufacturing practice (&#x201c;cGMP&#x201d;) aseptic fill contract manufacturer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the third quarter 2019, all purchases of material, including pig pituitary glands and API, related to the re-commercialization efforts were consumed in research and development activities and recognized as research and development expense in the period in which they were incurred. In the third quarter of 2019, the purchase of materials commenced that were intended to be used commercially in anticipation of FDA approval of Cortrophin Gel and the resultant product launch. The FDA granted approval of the sNDA of this product on October 29, 2021. Prior to FDA approval, under U.S. GAAP, the Company was prohibited from capitalizing these pre-launch purchases of materials as inventory, and accordingly, they were charged to expense in the period in which they were incurred. Subsequent to approval, these purchases are recorded as inventory at net realizable value. During the year ended December 31, 2021, the Company recognized $0.8 million of charges for the purchase of materials. Other charges were incurred directly related to the Cortrophin pre-launch commercialization efforts, including, but not limited to, sales and marketing and consulting expenses. During the year ended December 31, 2021, the Company incurred $14.0 million of these charges, which are included on the consolidated statements of operations as a selling, general, and administrative expense. There were no comparable expenses in 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</anip:CortrophinPreLaunchChargesTextBlock>
    <anip:CortrophinPreLaunchCharges contextRef="c-15" decimals="-5" id="f-1387" unitRef="usd">800000</anip:CortrophinPreLaunchCharges>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-338" decimals="-5" id="f-1388" unitRef="usd">14000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-339" decimals="-5" id="f-1389" unitRef="usd">14000000.0</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-1390">RELATED PARTY TRANSACTIONS&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;8, 2021, the Company entered into an Equity Commitment and Investment Agreement with the PIPE Investor, pursuant to which  25,000 shares were purchased for $1,000 per share and an aggregate purchase price of $25.0 million on November 19, 2021. The Chairman of the Company's board of directors is an operating partner of Ampersand Capital Partners, an affiliate of the PIPE Investor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Novitium, the Company entered into employment agreements with the two executives and founders of Novitium, Muthusamy Shanmugam, Head of R&amp;amp;D and COO of NJ Operations of ANI, and Chad Gassert, Sr. Vice President, Corporate Development and Strategy of ANI. Both serve as executive officers of the Company and Mr. Shanmugam also serves on the Company's board of directors. Mr. Shanmugam holds a minority interest in Scitus Pharma Services (&#x201c;Scitus&#x201d;), which provides clinical research services to Novitium, a majority interest in SS Pharma LLC (&#x201c;SS Pharma&#x201d;), which acquires and supplies API to Novitium, a minority interest in Nuray Chemical Private Limited (&#x201c;Nuray&#x201d;), which manufactures and supplies API to Novitium, and a majority interest in Esjay Pharma LLC (&#x201c;Esjay&#x201d;), which provided research and development and facilities consulting services through September 30, 2022. Mr. Gassert holds a minority interest in Scitus. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of payments to related parties is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scitus Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,075&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SS Pharma LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,235&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,669&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Esjay Pharma LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nuray Chemical Private Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;365&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,955&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;390&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Includes payments during the period from November 19, 2021 to December 31, 2021, subsequent to the acquisition of Novitium. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the outstanding balances due to Scitus and SS Pharma were $0.7&#160;million and $0.6&#160;million, respectively. There was no outstanding balance due to Nuray or Esjay at December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2023, the Company paid $12.5&#160;million of cash consideration to the Company Members of Novitium for the achievement of the "ANDA Filing Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $6.7&#160;million and $1.9&#160;million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.&lt;/span&gt;&lt;/div&gt;On February 22, 2024, the Company paid $12.5 million of cash consideration to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. The Company paid Mr. Shanmugam and Esjay, and Mr. Gassert's company Chali Properties LLC, approximately $6.7&#160;million and $1.9&#160;million, respectively, for their portion of the cash consideration due to them as part of the Novitium acquisition.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="c-340"
      decimals="INF"
      id="f-1391"
      unitRef="shares">25000</anip:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c-341"
      decimals="INF"
      id="f-1392"
      unitRef="usdPerShare">1000</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues contextRef="c-340" decimals="-5" id="f-1393" unitRef="usd">25000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <anip:NumberOfExecutiveFounders
      contextRef="c-6"
      decimals="INF"
      id="f-1394"
      unitRef="founder">2</anip:NumberOfExecutiveFounders>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="c-1" id="f-1395">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of payments to related parties is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021 (1)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Scitus Pharma Services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,646&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,075&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SS Pharma LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,235&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,669&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Esjay Pharma LLC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;101&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nuray Chemical Private Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,110&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;365&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11,881&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6,955&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;390&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:700;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;Includes payments during the period from November 19, 2021 to December 31, 2021, subsequent to the acquisition of Novitium.</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-342" decimals="0" id="f-1396" unitRef="usd">3646000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-343" decimals="0" id="f-1397" unitRef="usd">2075000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-344" decimals="0" id="f-1398" unitRef="usd">0</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-345" decimals="0" id="f-1399" unitRef="usd">8235000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-346" decimals="0" id="f-1400" unitRef="usd">3669000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-347" decimals="0" id="f-1401" unitRef="usd">0</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-348" decimals="0" id="f-1402" unitRef="usd">0</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-349" decimals="0" id="f-1403" unitRef="usd">101000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-350" decimals="0" id="f-1404" unitRef="usd">25000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-351" decimals="0" id="f-1405" unitRef="usd">0</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-352" decimals="0" id="f-1406" unitRef="usd">1110000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-353" decimals="0" id="f-1407" unitRef="usd">365000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-354" decimals="0" id="f-1408" unitRef="usd">11881000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-355" decimals="0" id="f-1409" unitRef="usd">6955000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty contextRef="c-356" decimals="0" id="f-1410" unitRef="usd">390000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableCurrent contextRef="c-357" decimals="-5" id="f-1411" unitRef="usd">700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-358" decimals="-5" id="f-1412" unitRef="usd">600000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-359" decimals="INF" id="f-1413" unitRef="usd">0</us-gaap:AccountsPayableCurrent>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-208" decimals="-5" id="f-1414" unitRef="usd">12500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-360" decimals="-5" id="f-1415" unitRef="usd">6700000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-361" decimals="-5" id="f-1416" unitRef="usd">1900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-209" decimals="-5" id="f-1417" unitRef="usd">12500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-362" decimals="-5" id="f-1418" unitRef="usd">6700000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-363" decimals="-5" id="f-1419" unitRef="usd">1900000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1420">SEGMENT REPORTING&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An operating segment is defined as a component of an entity that engages in business activities from which it may recognize revenues and incur expense, its operating results are regularly reviewed by the entity&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) to make decisions about resources to be allocated to the segment and assess its performance, and its discrete financial information is available. Prior to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, based on this definition, the Company was organized as one operating and reporting segment. Prior period segment disclosures have been recast for the new segment presentation. Effective in the first quarter of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and prospectively, in conjunction with the principal completion of the buildout of infrastructure in the areas of commercialization of rare disease therapies and the launch of Cortrophin Gel, it was determined that the Company has two operating segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Generics, Established Brands, and Other&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Consists of operations related to the development, manufacturing, and marketing of generic and established brand pharmaceuticals, including those sold through traditional channels, contract manufactured products, product development services, royalties, and other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt"&gt;Rare Disease&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; Consists of operations related to the development, manufacturing and marketing of pharmaceuticals used in the treatment of patients with rare conditions. The rare disease segment currently consists of operations related to Cortrophin Gel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The CODM evaluates the performance of the Company as two operating segments based on revenues and EBITDA, exclusive of corporate expenses and other expenses not directly allocated or attributable to an operating segment. These expenses include, but are not limited to, certain management, legal, accounting, human resources, insurance, and information technology expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not manage assets of the Company by operating segment and the CODM does not review asset information by operating segment. Accordingly, the Company does not present total assets by operating segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial information by reportable segment, including historical information that has been retroactively re-cast to reflect two reporting segments, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generics, Established Brands, and Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;374,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,686&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment earnings (loss) before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;) and reconciliation to income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generics, Established Brands, and Other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,418&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate and other unallocated expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before expense (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(62,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.27pt"&gt;Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operations are located in the United States and India. The Company has ceased operations at the Oakville, Ontario, Canada location as of March 31, 2023. The majority of the assets of the Company are located in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table depicts the Company&#x2019;s revenue by geographic operations during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Location of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;312,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211,893&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;565&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table depicts the Company&#x2019;s property and equipment, net according to geographic location as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,343&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,856&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,430&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,047&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,246&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts as of December&#160;31, 2023 and 2022 exclude the land and building at the Canada facility, which are classified as held for sale as of December&#160;31, 2023 and 2022. These assets have a carrying value of $8.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-364"
      decimals="INF"
      id="f-1421"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1422"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1423"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-1424">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial information by reportable segment, including historical information that has been retroactively re-cast to reflect two reporting segments, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generics, Established Brands, and Other&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;374,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;274,699&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;112,117&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;41,686&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total net revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment earnings (loss) before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;) and reconciliation to income (loss) before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generics, Established Brands, and Other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;152,990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;78,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;63,418&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;12,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(18,571)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(59,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(47,252)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="padding-left:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Corporate and other unallocated expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(58,726)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(38,920)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(37,388)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total operating income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;46,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(35,283)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(39,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(26,940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(28,052)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(11,922)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(4,343)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income (loss) before expense (benefit) for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;19,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(62,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(56,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.27pt"&gt;Includes expenses not directly allocated or attributable to a reporting segment, including certain management, legal, accounting, human resources, insurance, and information technology expenses, and are included in selling, general, and administrative expenses in our consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1425"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-365" decimals="-3" id="f-1426" unitRef="usd">374699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-366" decimals="-3" id="f-1427" unitRef="usd">274699000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-367" decimals="-3" id="f-1428" unitRef="usd">216136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-368" decimals="-3" id="f-1429" unitRef="usd">112117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-369" decimals="-3" id="f-1430" unitRef="usd">41686000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-370" decimals="-3" id="f-1431" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1432" unitRef="usd">486816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-1433" unitRef="usd">316385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-1434" unitRef="usd">216136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization contextRef="c-365" decimals="-3" id="f-1435" unitRef="usd">152990000</anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization>
    <anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization contextRef="c-366" decimals="-3" id="f-1436" unitRef="usd">78958000</anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization>
    <anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization contextRef="c-367" decimals="-3" id="f-1437" unitRef="usd">63418000</anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization>
    <anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization contextRef="c-368" decimals="-3" id="f-1438" unitRef="usd">12498000</anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization>
    <anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization contextRef="c-369" decimals="-3" id="f-1439" unitRef="usd">-18348000</anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization>
    <anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization contextRef="c-370" decimals="-3" id="f-1440" unitRef="usd">-18571000</anip:EarningsLossBeforeInterestTaxesDepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-371" decimals="-3" id="f-1441" unitRef="usd">-59791000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-372" decimals="-3" id="f-1442" unitRef="usd">-56973000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-373" decimals="-3" id="f-1443" unitRef="usd">-47252000</us-gaap:DepreciationAndAmortization>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-374" decimals="-3" id="f-1444" unitRef="usd">-58726000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-375" decimals="-3" id="f-1445" unitRef="usd">-38920000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-376" decimals="-3" id="f-1446" unitRef="usd">-37388000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-1447" unitRef="usd">46971000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-14" decimals="-3" id="f-1448" unitRef="usd">-35283000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-15" decimals="-3" id="f-1449" unitRef="usd">-39793000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-1" decimals="-3" id="f-1450" unitRef="usd">-26940000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-14" decimals="-3" id="f-1451" unitRef="usd">-28052000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="c-15" decimals="-3" id="f-1452" unitRef="usd">-11922000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-1453" unitRef="usd">-159000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-14" decimals="-3" id="f-1454" unitRef="usd">670000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-15" decimals="-3" id="f-1455" unitRef="usd">-4343000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1456" unitRef="usd">19872000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-1457" unitRef="usd">-62665000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-1458" unitRef="usd">-56058000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock contextRef="c-1" id="f-1459">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table depicts the Company&#x2019;s revenue by geographic operations during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Location of Operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,251&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;312,427&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;211,893&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;565&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3,958&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4,243&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;486,816&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;316,385&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;216,136&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-377" decimals="-3" id="f-1460" unitRef="usd">486251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-378" decimals="-3" id="f-1461" unitRef="usd">312427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-379" decimals="-3" id="f-1462" unitRef="usd">211893000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-380" decimals="-3" id="f-1463" unitRef="usd">565000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-381" decimals="-3" id="f-1464" unitRef="usd">3958000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-382" decimals="-3" id="f-1465" unitRef="usd">4243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-1466" unitRef="usd">486816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-1467" unitRef="usd">316385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-1468" unitRef="usd">216136000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-1469">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table depicts the Company&#x2019;s property and equipment, net according to geographic location as of:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.113%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;40,343&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Canada&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,856&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;India&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,430&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1.37pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,047&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;44,593&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1.37pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;43,246&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.87pt;font-weight:400;line-height:120%;position:relative;top:-2.62pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts as of December&#160;31, 2023 and 2022 exclude the land and building at the Canada facility, which are classified as held for sale as of December&#160;31, 2023 and 2022. These assets have a carrying value of $8.0 million.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-383" decimals="-3" id="f-1470" unitRef="usd">43163000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-384" decimals="-3" id="f-1471" unitRef="usd">40343000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-65" decimals="-3" id="f-1472" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-64" decimals="-3" id="f-1473" unitRef="usd">1856000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-385" decimals="-3" id="f-1474" unitRef="usd">1430000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-386" decimals="-3" id="f-1475" unitRef="usd">1047000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-1476" unitRef="usd">44593000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-1477" unitRef="usd">43246000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-64" decimals="-5" id="f-1478" unitRef="usd">8000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent contextRef="c-65" decimals="-5" id="f-1479" unitRef="usd">8000000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1480">SUBSEQUENT EVENTS &lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 14, 2024, the Company granted RSA and PSU awards to officers and employees of the Company under the 2022 Plan. The Company granted 525,729 RSAs to employees and officers of the Company. These RSAs vest over four years. The Company granted 73,588 PSUs to employees and officers of the Company (66,433 to officers of the Company). PSU performance will be measured over three years from January 1, 2024 through December 31, 2026 and will cliff-vest contingent upon the achievement of specified performance objectives. PSUs granted to date vest over a three-year performance period. Additionally, on February 15, 2024, the Company granted 13,054 RSAs to new employees of the Company, which will vest over four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 16, 2024, ANI Pharmaceuticals Canada, Inc. and 1540700 Ontario Limited entered into an agreement of purchase and sale for the Oakville, Ontario manufacturing facility for a purchase price of 19.2 million Canadian Dollars, or approximately $14.2 million US Dollars, based on the current exchange rate. The first and second deposits, each amounting to approximately 1.0 million Canadian Dollars or approximately $0.7 million US Dollars, based on the current exchange rate, were received on February 20, 2024, and February 27, 2024, respectively. The remaining balance of the purchase price, less deposits, will be paid upon closing, which is expected to occur by the end of March 2024. The closing of the transaction is subject to customary termination conditions, including the buyer&#x2019;s right to terminate the agreement if the property is materially damaged prior to the closing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 22, 2024, the Company paid $12.5 million to the Company Members of Novitium for the achievement of the "Gross Profit Earn-Out," as defined in the Novitium acquisition agreement, as discussed in Note 2. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2010, ANI, formerly Biosante, entered into an assignment and technology transfer agreement and stock subscription agreement (collectively the "CG Agreement") with CG Oncology, Inc. formerly, Cold Genesys, Inc. (&#x201c;CG Oncology&#x201d;), pursuant to which the Company sold to CG Oncology exclusive, worldwide rights to develop and commercialize BioSante&#x2019;s oncolytic virus technology. The technology includes a replication-competent adenovirus that has completed clinical trials for treatment of superficial bladder cancer. Under the terms of the CG Agreement, the Company receive&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d an equity investment in CG Oncology, an upfront cash payment and the right to receive future royalty payments. Historically, this equity investment was recorded at cost and as of December 31, 2023, this equity investment was valued at zero. On January 24, 2024, CG Oncology completed their Initial Public Offering, at an offering price of $19.00 per share. The Company currently holds 219,925 shares of common stock in CG Oncology. As of February 27, 2024 these shares are valued at approximately $10.2&#160;million. &lt;/span&gt;&lt;/div&gt;On February 28, 2024, CG Oncology disputed the Company's rights to receive royalties. The dispute is unresolved at this time.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-387"
      decimals="0"
      id="f-1481"
      unitRef="shares">525729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-387" id="f-1482">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-388"
      decimals="0"
      id="f-1483"
      unitRef="shares">73588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-389"
      decimals="0"
      id="f-1484"
      unitRef="shares">66433</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-388" id="f-1485">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-388" id="f-1486">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-390"
      decimals="0"
      id="f-1487"
      unitRef="shares">13054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-391" id="f-1488">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-1489" unitRef="cad">19200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-5" decimals="-5" id="f-1490" unitRef="usd">14200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <anip:DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit contextRef="c-5" decimals="-5" id="f-1491" unitRef="cad">1000000</anip:DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit>
    <anip:DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit contextRef="c-5" decimals="-5" id="f-1492" unitRef="usd">700000</anip:DisposalGroupIncludingDiscontinuedOperationConsiderationFirstDeposit>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-209" decimals="-5" id="f-1493" unitRef="usd">12500000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:InvestmentOwnedAtFairValue contextRef="c-392" decimals="INF" id="f-1494" unitRef="usd">0</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:InvestmentOwnedAtCost contextRef="c-392" decimals="0" id="f-1495" unitRef="usd">19</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="c-392"
      decimals="0"
      id="f-1496"
      unitRef="shares">219925</us-gaap:InvestmentOwnedBalanceShares>
    <us-gaap:InvestmentOwnedAtFairValue contextRef="c-393" decimals="-5" id="f-1497" unitRef="usd">10200000</us-gaap:InvestmentOwnedAtFairValue>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-394" id="f-1498">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 27, 2023, Mr. Muthusamy Shanmugam, Head of R&amp;amp;D and COO of NJ Operations, adopted a trading arrangement for the sale of securities of the Company&#x2019;s common stock (a &#x201c;Rule 10b5-1 Trading Plan&#x201d;) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Shanmugam's Rule 10b5-1 Trading Plan, which has a term from March 4, 2024 through November 29, 2024, provides for the sale of up to 400,000 shares of common stock pursuant to the terms of the plan.&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-395" id="f-1499">November 27, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-395" id="f-1500">Mr. Muthusamy Shanmugam</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-395" id="f-1501">Head of R&amp;D and COO</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-395" id="f-1502">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-396"
      decimals="INF"
      id="f-1503"
      unitRef="shares">400000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-397" id="f-1504">On December 12, 2023, Mr. Chad Gassert, Sr. Vice President, Corporate Development and Strategy, adopted a trading arrangement for the sale of securities of the Company&#x2019;s common stock (a &#x201c;Rule 10b5-1 Trading Plan&#x201d;) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Gassert's Rule 10b5-1 Trading Plan, which will terminate September 30, 2024, provides for the sale of up to 100,000 shares of common stock pursuant to the terms of the plan.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrAdoptionDate contextRef="c-398" id="f-1505">December 12, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrIndName contextRef="c-398" id="f-1506">Mr. Chad Gassert</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-398" id="f-1507">Sr. Vice President, Corporate Development and Strategy</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-398" id="f-1508">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-399"
      decimals="INF"
      id="f-1509"
      unitRef="shares">100000</ecd:TrdArrSecuritiesAggAvailAmt>
    <dei:AuditorName contextRef="c-1" id="f-1512">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-1513">Philadelphia, Pennsylvania</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-1514">274</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
